


Risk Evaluation for Trichloroethylene

CASRN: 79-01-6



November 2020

Trial Exhibit

104

Food & Water v. EPA
3:17-cv-02162-EMC

TABLE OF CONTENTS

2	ACKNOWLEDGEMENTS	25
3	ABBREVIATIONS.....	26
4	EXECUTIVE SUMMARY	30
5	1 INTRODUCTION	44
6	1.1 Physical and Chemical Properties	45
7	1.2 Uses and Production Volume	46
8	1.2.1 Data and Information Sources	46
9	1.2.2 Domestic Manufacture of Trichloroethylene.....	47
10	1.3 Regulatory and Assessment History	50
11	1.4 Scope of the Evaluation.....	52
12	1.4.1 Conditions of Use Included in the Risk Evaluation.....	52
13	1.4.2 Exposure Pathways and Risks Addressed by Other EPA-Administered Statutes	62
14	1.4.3 Conceptual Models	69
15	1.5 Systematic Review	73
16	1.5.1 Data and Information Collection	73
17	1.5.2 Data Evaluation	79
18	1.5.3 Data Integration	80
19	2 EXPOSURES	81
20	2.1 Fate and Transport.....	81
21	2.1.1 Fate and Transport Approach and Methodology	82
22	2.1.2 Summary of Fate and Transport	82
23	2.1.3 Assumptions and Key Sources of Uncertainty for Fate and Transport	85
24	2.2 Environmental Exposures	87
25	2.2.1 Environmental Exposures Overview	87
26	2.2.2 Environmental Releases to Water.....	87
27	2.2.2.1 Results for Daily Release Estimate	88
28	2.2.2.2 Approach and Methodology	89
29	2.2.2.2.1 Water Release Estimates.....	89
30	2.2.2.2.2 Estimates of Number of Facilities	90
31	2.2.2.2.3 Estimates of Release Days.....	92
32	2.2.2.3 Assumptions and Key Sources of Uncertainty for Environmental Releases	92
33	2.2.2.3.1 Summary of Overall Confidence in Release Estimates	93
34	2.2.3 Aquatic Exposure Modeling Approach	100
35	2.2.3.1 E-FAST 2014 Equations and Inputs.....	100
36	2.2.4 Surface Water Monitoring Data Gathering Approach.....	103
37	2.2.4.1 Systematic Review of Surface Water Monitoring Data	103
38	2.2.4.2 Surface Water Monitoring Data from WQX/WQP	104
39	2.2.5 Geospatial Analysis Approach	104
40	2.2.6 Environmental Exposure Results.....	105
41	2.2.6.1 Terrestrial Environmental Exposures	105
42	2.2.6.2 Aquatic Environmental Exposures	105
43	2.2.6.2.1 Predicted Surface Water Concentrations: E-FAST 2014 Modeling.....	105
44	2.2.6.2.2 Measured Surface Water Concentrations	108

45	2.2.6.2.3	Geospatial Analysis Comparing Predicted and Measured Surface Water	
46		Concentrations	110
47	2.2.6.3	Assumptions and Key Sources of Uncertainty for Environmental Exposures.....	116
48	2.2.6.4	Confidence in Aquatic Exposure Scenarios	118
49	2.3	Human Exposures	119
50	2.3.1	Occupational Exposures	119
51	2.3.1.1	Results for Occupational Assessment	120
52	2.3.1.2	Approach and Methodology	128
53	2.3.1.2.1	General.....	128
54	2.3.1.2.2	Inhalation Exposure Monitoring Data	129
55	2.3.1.2.3	Inhalation Exposure Modeling.....	129
56	2.3.1.2.4	Acute and Chronic Inhalation Exposure Estimates	131
57	2.3.1.2.5	Dermal Exposure Modeling.....	135
58	2.3.1.2.6	Consideration of Engineering Controls and Personal Protective Equipment	139
59	2.3.1.2.7	Number of Workers and Occupational Non-Users Exposed.....	141
60	2.3.1.3	Assumptions and Key Sources of Uncertainty for Occupational Exposures	145
61	2.3.1.3.1	Number of Workers	145
62	2.3.1.3.2	Analysis of Exposure Monitoring Data	146
63	2.3.1.3.3	Near-Field/Far-Field Model Framework	147
64	2.3.1.3.4	Modeled Dermal Exposures.....	148
65	2.3.1.3.5	Summary of Overall Confidence in Inhalation Exposure Estimates	149
66	2.3.2	Consumer Exposures	155
67	2.3.2.1	Consumer Conditions of Use Evaluated.....	155
68	2.3.2.2	Consumer Exposure Routes Evaluated	157
69	2.3.2.2.1	Inhalation	157
70	2.3.2.2.2	Dermal	157
71	2.3.2.3	Consumer Exposures Approach and Methodology.....	158
72	2.3.2.3.1	Modeling Approach	158
73	2.3.2.4	Consumer Exposure Scenarios and Modeling Inputs.....	161
74	2.3.2.4.1	Consumer Exposure Model Inputs	162
75	2.3.2.5	Consumer Exposure Results.....	171
76	2.3.2.5.1	Characterization of Exposure Results.....	171
77	2.3.2.5.2	Consumer Exposure Estimates	172
78	2.3.2.5.3	Summary of Consumer Exposure Assessment	200
79	2.3.2.6	Assumptions and Key Sources of Uncertainty for Consumer Exposures	201
80	2.3.2.6.1	Modeling Approach Uncertainties.....	202
81	2.3.2.6.2	Data Uncertainties.....	203
82	2.3.2.7	Confidence in Consumer Exposure Scenarios	205
83	2.3.3	Potentially Exposed or Susceptible Subpopulations.....	210
84	3	HAZARDS.....	213
85	3.1	Environmental Hazards	213
86	3.1.1	Approach and Methodology	213
87	3.1.2	Hazard Identification	213
88	3.1.3	Species Sensitivity Distributions (SSDs).....	218
89	3.1.4	Weight of the Scientific Evidence	221
90	3.1.5	Concentrations of Concern	222
91	3.1.6	Summary of Environmental Hazard	224

92	3.1.7 Assumptions and Key Uncertainties for Environmental Hazard Data	224
93	3.2 Human Health Hazards	226
94	3.2.1 Approach and Methodology	226
95	3.2.2 Toxicokinetics.....	228
96	3.2.2.1 Absorption.....	228
97	3.2.2.2 Distribution.....	229
98	3.2.2.3 Metabolism.....	229
99	3.2.2.4 Elimination	231
100	3.2.2.5 Physiologically-Based Pharmacokinetic (PBPK) Modeling Approach	231
101	3.2.3 Hazard Identification	235
102	3.2.3.1 Non-Cancer Hazards	235
103	3.2.3.1.1 Liver toxicity.....	235
104	3.2.3.1.2 Kidney toxicity	236
105	3.2.3.1.3 Neurotoxicity	237
106	3.2.3.1.4 Immunotoxicity.....	238
107	3.2.3.1.5 Reproductive toxicity.....	239
108	3.2.3.1.6 Developmental Toxicity	240
109	3.2.3.1.7 Overt Toxicity Following Acute/Short Term Exposure	243
110	3.2.3.2 Genotoxicity and Cancer Hazards.....	244
111	3.2.3.2.1 Genotoxicity.....	244
112	3.2.3.2.2 Kidney cancer	244
113	3.2.3.2.3 Liver cancer	244
114	3.2.3.2.4 Cancer of the immune system.....	245
115	3.2.3.2.5 Other cancers	245
116	3.2.4 Weight of Scientific Evidence	246
117	3.2.4.1 Non-Cancer Hazards	246
118	3.2.4.1.1 Liver toxicity.....	246
119	3.2.4.1.2 Kidney toxicity	246
120	3.2.4.1.3 Neurotoxicity	246
121	3.2.4.1.4 Immunotoxicity.....	246
122	3.2.4.1.5 Reproductive toxicity.....	247
123	3.2.4.1.6 Developmental Toxicity	247
124	3.2.4.1.7 Overt Toxicity Following Acute/Short Term Exposure	250
125	3.2.4.2 Cancer Hazards.....	250
126	3.2.4.2.1 Meta-Analysis Results	251
127	3.2.4.2.2 Mode of Action.....	252
128	3.2.5 Dose-Response Assessment.....	254
129	3.2.5.1 Selection of Studies for Dose-Response Assessment.....	254
130	3.2.5.1.1 Liver toxicity.....	255
131	3.2.5.1.2 Kidney toxicity	256
132	3.2.5.1.3 Neurotoxicity	256
133	3.2.5.1.4 Immunotoxicity.....	256
134	3.2.5.1.5 Reproductive toxicity.....	256
135	3.2.5.1.6 Developmental toxicity.....	257
136	3.2.5.1.7 Cancer	258
137	3.2.5.2 Potentially Exposed and Susceptible Subpopulations (PESS)	259
138	3.2.5.3 Derivation of Points of Departure (PODs)	260
139	3.2.5.3.1 Non-Cancer PODs for Acute Exposure	261

140	3.2.5.3.2	Non-Cancer PODs for Chronic Exposures	265
141	3.2.5.3.3	Cancer POD for Lifetime Exposures	275
142	3.2.5.4	Selected PODs for Human Health Hazard Domains	277
143	3.2.5.4.1	Best Overall Non-Cancer Endpoints for Risk Conclusions.....	280
144	3.2.6	Assumptions and Key Sources of Uncertainty for Human Health Hazard	282
145	3.2.6.1	Confidence in Hazard Identification and Weight of Evidence.....	282
146	3.2.6.1.1	Uncertainties in Dose-Response Analysis for Select Endpoints	282
147	3.2.6.2	Derivation of PODs, UFs, and PBPK Results.....	283
148	3.2.6.3	Cancer Dose Response	284
149	3.2.6.4	Confidence in Human Health Hazard Data Integration and Best Overall Endpoints ...	285
150	4	RISK CHARACTERIZATION	287
151	4.1	Environmental Risks	287
152	4.1.1	Risk Estimation Approach.....	287
153	4.1.2	Risk Estimation for Aquatic Organisms	288
154	4.1.3	Risk Estimation for Sediment-dwelling Organisms	297
155	4.1.4	Risk Estimation for Terrestrial Organisms	300
156	4.2	Human Health Risks.....	301
157	4.2.1	Risk Estimation Approach.....	301
158	4.2.1.1	Points of Departure Used in Risk Estimation.....	304
159	4.2.2	Risk Estimation for Occupational Exposures by Exposure Scenario.....	305
160	4.2.3	Risk Estimation for Consumer Exposures by Exposure Scenario.....	348
161	4.3	Assumptions and Key Sources of Uncertainty for Risk Characterization	374
162	4.3.1	Environmental Risk Characterization.....	374
163	4.3.2	Human Health Risk Characterization	375
164	4.3.2.1	Occupational Exposure Considerations.....	375
165	4.3.2.2	Consumer/Bystander Exposure Considerations	376
166	4.3.2.3	Dermal Absorption Considerations	377
167	4.3.2.4	Confidence in Risk Estimates.....	377
168	4.4	Other Risk Related Considerations	380
169	4.4.1	Potentially Exposed or Susceptible Populations.....	380
170	4.4.2	Aggregate and Sentinel Exposures	381
171	4.5	Risk Conclusions.....	383
172	4.5.1	Environmental Risk Conclusions	383
173	4.5.2	Human Health Risk Conclusions.....	387
174	4.5.2.1	Summary of Risk Estimates for Workers and ONUs.....	387
175	4.5.2.2	Summary of Risk Estimates for Consumers and Bystanders	402
176	5	UNREASONABLE RISK DETERMINATION.....	407
177	5.1	Overview	407
178	5.1.1	Human Health.....	407
179	5.1.1.1	Non-Cancer Risks Estimates	408
180	5.1.1.2	Cancer Risks Estimates	408
181	5.1.1.3	Determining Unreasonable Risk of Injury to Health.....	409
182	5.1.2	Environment	410
183	5.1.2.1	Determining Unreasonable Risk of Injury to the Environment.....	410
184	5.2	Detailed Unreasonable Risk Determination by Condition of Use	411
185	5.2.1	Human Health.....	415

186	5.2.1.1	Manufacture – Domestic manufacture (Domestic manufacture)	415
187	5.2.1.2	Manufacture – Import (Import)	416
188	5.2.1.3	Processing – Processing as a reactant/intermediate – Intermediate in industrial gas	
189		manufacturing (<i>e.g.</i> , manufacture of fluorinated gases used as refrigerants, foam blowing	
190		agents and solvents) (Processing as a reactant/intermediate).....	417
191	5.2.1.4	Processing – Incorporation into formulation, mixture or reaction product – Solvents (for	
192		cleaning or degreasing); adhesives and sealant chemicals; solvents (which become part	
193		of product formulation or mixture) (<i>e.g.</i> , lubricants and greases, paints and coatings,	
194		other uses) (Processing into a formulation, mixture, or reaction product).....	418
195	5.2.1.5	Processing – Incorporation into articles – Solvents (becomes an integral component of	
196		articles) (Processing into articles)	419
197	5.2.1.6	Processing – Repackaging – Solvents (for cleaning or degreasing) (Repackaging)	420
198	5.2.1.7	Processing – Recycling – Recycling (Recycling)	420
199	5.2.1.8	Distribution in Commerce– Distribution (Distribution in commerce).....	421
200	5.2.1.9	Industrial/Commercial Use – Solvent (for cleaning or degreasing) – Batch vapor	
201		degreaser (open-top) (Solvent for open-top batch vapor degreasing).....	422
202	5.2.1.10	Industrial/Commercial Use – Solvent (for cleaning or degreasing) – Batch vapor	
203		degreaser (closed-loop) (Solvent for closed-loop batch vapor degreasing)	423
204	5.2.1.11	Industrial/Commercial Use – Solvent (for cleaning or degreasing) – In-line vapor	
205		degreaser (conveyorized) (Solvent for in-line conveyorized vapor degreasing).....	424
206	5.2.1.12	Industrial/Commercial Use – Solvent (for cleaning or degreasing) – In-line vapor	
207		degreaser (web cleaner) (Solvent for in-line web cleaner vapor degreasing)	425
208	5.2.1.13	Industrial/Commercial Use – Solvent (for cleaning or degreasing) – Cold cleaners	
209		(Solvent for cold cleaning)	426
210	5.2.1.14	Industrial/Commercial Use – Solvent (for cleaning or degreasing) – Aerosol spray	
211		degreaser/cleaner; mold release (Solvent for aerosol spray degreaser/cleaner and mold	
212		release).....	427
213	5.2.1.15	Industrial/Commercial Use – Lubricants and greases/lubricants and lubricant additives –	
214		Tap and die fluid (Tap and die fluid).....	428
215	5.2.1.16	Industrial/Commercial Use – Lubricants and greases/lubricants and lubricant additives –	
216		Penetrating lubricant (Penetrating lubricant).....	428
217	5.2.1.17	Industrial/Commercial Use – Adhesives and sealants – Solvent-based adhesives and	
218		sealants; tire repair cement/sealer; mirror edge sealant (Adhesives and sealants).....	429
219	5.2.1.18	Industrial/Commercial Use – Functional fluids (closed systems) – Heat exchange fluid	
220		(Functional fluids)	430
221	5.2.1.19	Industrial/Commercial Use – Paints and coatings – Diluent in solvent-based paints and	
222		coatings (Paints and coatings diluent)	431
223	5.2.1.20	Industrial/Commercial Use – Cleaning and furniture care products – Carpet cleaner;	
224		wipe cleaning (Carpet cleaner and wipe cleaning).....	432
225	5.2.1.21	Industrial/Commercial Use – Laundry and dishwashing products – Spot remover (Spot	
226		remover)	433
227	5.2.1.22	Industrial/Commercial Use – Arts, crafts and hobby materials – Fixatives and finishing	
228		spray coatings (Fixatives and finishing spray coatings).....	434
229	5.2.1.23	Industrial/Commercial Use – Corrosion inhibitors and anti-scaling agents (Corrosion	
230		inhibitors and anti-scaling agents).....	434
231	5.2.1.24	Industrial/Commercial Use – Processing aids – Process solvent used in battery	
232		manufacture; process solvent used in polymer fiber spinning, fluoroelastomer	

233	manufacture, and Alcantara manufacture; extraction solvent used in caprolactam	
234	manufacture; precipitant used in beta-cyclodextrin manufacture (Processing aids)	435
235	5.2.1.25 Industrial/Commercial Use – Ink, toner, and colorant products – Toner aid (Toner aid)	
236	436	
237	5.2.1.26 Industrial/Commercial Use – Automotive care products – Brake and parts cleaners	
238	(Brake and parts cleaners)	437
239	5.2.1.27 Industrial/Commercial Use – Apparel and footwear care products – Shoe polish (Shoe	
240	polish)	438
241	5.2.1.28 Industrial/Commercial Use – Hoof polishes; gun scrubber; pepper spray; other	
242	miscellaneous industrial and commercial uses (Other industrial and commercial uses)	
243	439	
244	5.2.1.29 Consumer Use – Solvents (for cleaning or degreasing) – Brake and parts cleaner	
245	(Solvent in brake and parts cleaner)	440
246	5.2.1.30 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol electronic	
247	degreaser/cleaner (Solvent in aerosol electronic degreaser/cleaner).....	440
248	5.2.1.31 Consumer Use – Solvents (for cleaning or degreasing) – Liquid electronic	
249	degreaser/cleaner (Solvent in liquid electronic degreaser/cleaner)	441
250	5.2.1.32 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol spray degreaser/cleaner	
251	(Solvent in aerosol spray degreaser/cleaner).....	442
252	5.2.1.33 Consumer Use – Solvents (for cleaning or degreasing) – Liquid degreaser/cleaner	
253	(Solvent in liquid degreaser/cleaner).....	443
254	5.2.1.34 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol gun scrubber (Solvent	
255	in aerosol gun scrubber)	443
256	5.2.1.35 Consumer Use – Solvents (for cleaning or degreasing) – Liquid gun scrubber (Solvent in	
257	liquid gun scrubber).....	444
258	5.2.1.36 Consumer Use – Solvents (for cleaning or degreasing) – Mold release (Solvent in mold	
259	release).....	445
260	5.2.1.37 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol tire cleaner (Solvent in	
261	aerosol tire cleaner)	446
262	5.2.1.38 Consumer Use – Solvents (for cleaning or degreasing) – Liquid tire cleaner (Solvent in	
263	liquid tire cleaner).....	446
264	5.2.1.39 Consumer Use – Lubricants and greases – Tap and die fluid (Tap and die fluid)	447
265	5.2.1.40 Consumer Use – Lubricants and greases – Penetrating lubricant (Penetrating lubricant)	
266	448	
267	5.2.1.41 Consumer Use – Adhesives and sealants – Solvent-based adhesives and sealants	
268	(Solvent-based adhesives and sealants).....	449
269	5.2.1.42 Consumer Use – Adhesives and sealants – Mirror edge sealant (Mirror edge sealant)	449
270	5.2.1.43 Consumer Use – Adhesives and sealants – Tire repair cement/sealer (Tire repair	
271	cement/sealer).....	450
272	5.2.1.44 Consumer Use – Cleaning and furniture care products – Carpet cleaner (Carpet cleaner)	
273	451	
274	5.2.1.45 Consumer Use – Cleaning and furniture care products – Aerosol spot remover (Aerosol	
275	spot remover).....	452
276	5.2.1.46 Consumer Use – Cleaning and furniture care products – Liquid spot remover (Liquid	
277	spot remover).....	452
278	5.2.1.47 Consumer Use – Arts, crafts, and hobby materials – Fixatives and finishing spray	
279	coatings (Fixatives and finishing spray coatings)	453
280	5.2.1.48 Consumer Use – Apparel and footwear care products – Shoe polish (Shoe polish).....	454

281	5.2.1.49 Consumer Use – Other consumer uses – Fabric spray (Fabric spray)	455
282	5.2.1.50 Consumer Use – Other consumer uses – Film cleaner (Film cleaner)	455
283	5.2.1.51 Consumer Use – Other consumer uses – Hoof polish (hoof polish)	456
284	5.2.1.52 Consumer Use – Other consumer uses – Pepper spray (Pepper spray).....	457
285	5.2.1.53 Consumer Use – Other consumer uses – Toner aid (Toner aid)	457
286	5.2.1.54 Disposal – Disposal – Industrial pre-treatment; Industrial wastewater treatment; Publicly	
287	owned treatment works (POTW) (Disposal).....	458
288	5.2.2 Environment	459
289	5.3 Unreasonable Risk Determination Conclusion	460
290	5.3.1 No Unreasonable Risk Determinations	460
291	5.3.2 Unreasonable Risk Determinations	461
292	REFERENCES.....	463
293	APPENDICES	490
294	Appendix A REGULATORY HISTORY	490
295	A.1 Federal Laws and Regulations	490
296	A.2 State Laws and Regulations	497
297	A.3 International Laws and Regulations.....	498
298	Appendix B LIST OF SUPPLEMENTAL DOCUMENTS.....	500
299	Appendix C ENVIRONMENTAL EXPOSURES.....	503
300	Appendix D CONSUMER EXPOSURES.....	556
301	D.1 Consumer Inhalation Exposure	556
302	D.2 Consumer Dermal Exposure	557
303	D.3 Model Sensitivity	559
304	D.3.1 Continuous Variables.....	560
305	D.3.2 Categorical Variables.....	562
306	D.4 Monitoring Data	562
307	D.4.1 Indoor Air Monitoring.....	562
308	D.4.2 Personal breathing Zone Monitoring Data	564
309	Appendix E ENVIRONMENTAL HAZARDS	566
310	E.1 Species Sensitivity Distribution (SSD) Methodology.....	566
311	E.2 Environmental Risk Quotients (RQs) for Facilities Releasing TCE to Surface Water as	
312	Modeled in E-FAST	581
313	Appendix F WEIGHT OF SCIENTIFIC EVIDENCE FOR CONGENITAL HEART	
314	DEFECTS.....	628
315	F.1 Background	628
316	F.1.1 (Johnson et al., 2003) and (Dawson et al., 1993)	628
317	F.1.2 Updates to the original publications	628
318	F.2 EPA Review of the Charles River (2019) Study.....	629
319	F.2.1 Study Methodology and Results.....	629
320	F.2.2 EPA Review.....	631
321	F.2.2.1 Comparing Results Between Charles River and Johnson Studies.....	631
322	F.2.2.2 Differences in Types of Malformations Observed	632
323	F.2.2.3 Methodology Differences	639

324	F.2.2.4	Adversity of Small VSDs	641
325	F.2.2.5	Conclusions	642
326	F.3	WOE Analysis for Congenital Cardiac Defects	643
327	F.3.1	Methodology	643
328	F.3.2	WOE Results By Study Type	646
329	F.3.3	Mode of Action Discussion	654
330	Appendix G	CONSIDERATIONS FOR BMD MODELING AND APPLICATION OF	
331		UNCERTAINTY FACTORS	656
332	G.1	Selecting the BMD model to use for POD computation	656
333	G.2	Uncertainty Factor Selection	657
334	Appendix H	BENCHMARK DOSE ANALYSIS FOR (Selgrade and Gilmour, 2010)	659
335	H.1	Applied Dose/Concentration	659
336	H.1.1	BMDS Wizard Output Report - Mortality	659
337	H.1.1.1	BMDS Summary of Mortality – BMR 10%	659
338	H.1.1.2	BMDS Summary of Mortality – BMR: 5%	662
339	H.1.1.3	BMDS Summary of Mortality – BMR: 1%	664
340	H.1.2	BMDS Wizard Output Report - Number of Mice Infected	667
341	H.1.2.1	BMDS Summary of Infected at 72 hours – BMR – 10%	667
342	H.2	Internal Dose (TotOxMetabBW34)	668
343	H.2.1	BMDS Wizard Output Summary - Mortality	668
344	H.2.1.1	BMDS Summary of Mortality – BMR 10%	669
345	H.2.1.2	BMDS Summary of Mortality – BMR 5%	670
346	H.2.1.3	BMDS Summary of Mortality – BMR 1%	671
347	Appendix I	BENCHMARK DOSE MODELING UPDATE FOR NESTED FETAL DATA	
348		FROM (Johnson et al., 2003)	673
349	Appendix J	PBPK MODELING UPDATES FOR REPRESENTATIVE ACUTE AND	
350		CHRONIC ENDPOINTS	675
351	J.1	Derivation of Internal Dose Metric Results for (Selgrade and Gilmour, 2010)	675
352	J.1.1	Methods	675
353	J.1.2	Results	675
354	J.2	Derivation of Human Equivalent Concentrations/Doses for Best Overall Acute and Chronic	
355		Non-Cancer Endpoints	676
356	J.2.1	Methods	676
357	J.2.2	Results	677
358	Appendix K	META-ANALYSIS FOR CANCER	679
359	K.1	Study Screening and Selection	679
360	K.1.1	Data Quality and Inclusion/Exclusion Criteria Screening	679
361	K.1.2	Screening results	680
362	K.1.3	Pooled Cohorts	681
363	K.2	Meta-Analysis Methods and Results	682
364	K.2.1	Methods	682
365	K.2.2	Results	684
366	K.2.2.1	Initial Meta-Analyses	684
367	K.2.2.2	Sensitivity analyses	690

368	K.2.3	Selected RR estimates and confidence intervals by study and cancer type.....	698
369	K.2.4	Sample Stata commands for meta-analysis	704
370	Appendix L	APPROACH FOR ESTIMATING WATER RELEASES FROM	
371		MANUFACTURING SITES USING EFFLUENT GUIDELINES	705
372	Appendix M	SAMPLE CALCULATIONS FOR CALCULATING ACUTE AND CHRONIC	
373		(NON-CANCER AND CANCER) INHALATION EXPOSURE	709
374	M.1	Example High-End AC, ADC, and LADC	709
375	M.2	Example Central Tendency AEC, ADC, and LADC	710
376	Appendix N	VAPOR DEGREASING AND COLD CLEANING NEAR-FIELD/FAR-FIELD	
377		INHALATION EXPOSURE MODELS APPROACH AND PARAMETERS	711
378	N.1	Model Design Equations	712
379	N.2	Model Parameters.....	716
380	N.2.1	Far-Field Volume.....	721
381	N.2.2	Air Exchange Rate.....	721
382	N.2.3	Near-Field Indoor Air Speed	721
383	N.2.4	Near-Field Volume	722
384	N.2.5	Exposure Duration.....	722
385	N.2.6	Averaging Time.....	722
386	N.2.7	Vapor Generation Rate	722
387	N.2.8	Operating Hours.....	725
388	Appendix O	BRAKE SERVICING NEAR-FIELD/FAR-FIELD INHALATION EXPOSURE	
389		MODEL APPROACH AND PARAMETERS.....	727
390	O.1	Model Design Equations	727
391	O.2	Model Parameters.....	732
392	O.2.1	Far-Field Volume.....	735
393	O.2.2	Air Exchange Rate.....	735
394	O.2.3	Near-Field Indoor Air Speed	735
395	O.2.4	Near-Field Volume	736
396	O.2.5	Application Time	736
397	O.2.6	Averaging Time	736
398	O.2.7	Trichloroethylene Weight Fraction.....	736
399	O.2.8	Volume of Degreaser Used per Brake Job	737
400	O.2.9	Number of Applications per Brake Job	737
401	O.2.10	Amount of Trichloroethylene Used per Application	738
402	O.2.11	Operating Hours per Week	738
403	O.2.12	Number of Brake Jobs per Work Shift	738
404	Appendix P	SPOT CLEANING NEAR-FIELD/FAR-FIELD INHALATION EXPOSURE	
405		MODEL APPROACH AND PARAMETERS.....	739
406	P.1	Model Design Equations	739
407	P.2	Model Parameters.....	743
408	P.2.1	Far-Field Volume.....	747
409	P.2.2	Near-Field Volume	747
410	P.2.3	Air Exchange Rate.....	747
411	P.2.4	Near-Field Indoor Wind Speed.....	747

412	P.2.5	Averaging Time	748
413	P.2.6	Use Rate	748
414	P.2.7	Vapor Generation Rate	748
415	P.2.8	Operating Hours	748
416	P.2.9	Operating Days	749
417	P.2.10	Fractional Number of Operating Days that a Worker Works	749
418	Appendix Q	OCCUPATIONAL INHALATION EXPOSURE AND WATER RELEASE	
419		ASSESSMENT	750
420	Q.1	Manufacturing	750
421	Q.1.1	Exposure Assessment	750
422	Q.1.2	Water Release Assessment	750
423	Q.2	Processing as a Reactant	753
424	Q.2.1	Exposure Assessment	753
425	Q.2.2	Water Release Assessment	754
426	Q.3	Formulation of Aerosol and Non-Aerosol Products	754
427	Q.3.1	Exposure Assessment	754
428	Q.3.2	Water Release Assessment	755
429	Q.4	Repackaging	755
430	Q.4.1	Exposure Assessment	755
431	Q.4.2	Water Release Assessment	756
432	Q.5	Batch Open Top Vapor Degreasing	757
433	Q.5.1	Exposure Assessment	757
434	Q.5.2	Water Release Assessment	760
435	Q.6	Batch Closed-Loop Vapor Degreasing	764
436	Q.6.1	Exposure Assessment	764
437	Q.6.2	Water Release Assessment	764
438	Q.7	Conveyorized Vapor Degreasing	765
439	Q.7.1	Exposure Assessment	765
440	Q.7.2	Water Release Assessment	767
441	Q.8	Web Vapor Degreasing	767
442	Q.8.1	Exposure Assessment	767
443	Q.8.2	Water Release Assessment	769
444	Q.9	Cold Cleaning	769
445	Q.9.1	Exposure Assessment	769
446	Q.9.2	Water Release Assessment	771
447	Q.10	Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	772
448			
449	Q.10.1	Exposure Assessment	772
450	Q.10.2	Water Release Assessment	773
451	Q.11	Metalworking Fluids	774
452	Q.11.1	Exposure Assessment	774
453	Q.11.2	Water Release Assessment	776
454	Q.12	Adhesives, Sealants, Paints, and Coatings	776
455	Q.12.1	Exposure Assessment	776
456	Q.12.2	Water Release Assessment	777
457	Q.13	Other Industrial Uses	781
458	Q.13.1	Exposure Assessment	781

459	Q.13.2 Water Release Assessment	781
460	Q.14 Spot Cleaning, Wipe Cleaning and Carpet Cleaning	783
461	Q.14.1 Exposure Assessment	783
462	Q.14.2 Water Release Assessment	785
463	Q.15 Industrial Processing Aid	786
464	Q.15.1 Exposure Assessment	786
465	Q.15.2 Water Release Assessment	787
466	Q.16 Commercial Printing and Copying.....	787
467	Q.16.1 Exposure Assessment	787
468	Q.16.2 Water Release Assessment	788
469	Q.17 Other Commercial Uses	789
470	Q.17.1 Exposure Assessment	789
471	Q.17.2 Water Release Assessment	789
472	Q.18 Process Solvent Recycling and Worker Handling of Wastes	790
473	Q.18.1 Exposure Assessment	790
474	Q.18.2 Water Release Assessment	790
475	Q.19 Appendix Q References	790
476	Appendix R MASS BALANCE	799
477	R.1 Approach for Developing the Mass Balance.....	799
478	R.2 Results and Uncertainties in the Mass Balance.....	800
479	Appendix S LEVEL III FUGACITY RESULTS	802
480		

481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528

LIST OF TABLES

Table 1-1. Physical and Chemical Properties of TCE	46
Table 1-2. Assessment History of TCE	51
Table 1-3. Categories and Subcategories of Occupational Conditions of Use and Corresponding Occupational Exposure Scenario	53
Table 1-4. Categories and Subcategories of Consumer Conditions of Use	59
Table 2-1. Environmental Fate Characteristic of TCE	81
Table 2-2. Summary of EPA’s daily water release estimates for each OES and also EPA’s Overall Confidence in these estimates.	88
Table 2-3. Summary of EPA’s estimates for the number of facilities for each OES.	91
Table 2-4. Summary of EPA’s estimates for release days expected for each OES.	92
Table 2-5. Summary of Overall Confidence in Release Estimates by OES	94
Table 2-6. Industry Sector Modeled for Facilities without Site-Specific Flow Data in E-FAST 2014..	103
Table 2-7. Summary of Modeled Surface Water Concentrations by OES for Maximum Days of Release Scenario.....	106
Table 2-8. Summary of Modeled Surface Water Concentrations by OES for 20 Days of Release Scenario for Direct Releases	106
Table 2-9. Summary of Modeled Surface Water Concentrations by OES for 20 Days of Release Scenario for Indirect Releases to a non-POTW WWTP.....	107
Table 2-10. Measured Concentrations of TCE in Surface Water Obtained from the Water Quality Portal: 2013-2017 ¹	108
Table 2-11. Measured Levels of TCE in U.S. Surface Water from Published Literature	109
Table 2-12. A summary for each of the 18 occupational exposure scenarios (OESs).....	123
Table 2-13. Summary of inhalation exposure results for Workers based on monitoring data and exposure modeling for each OES.....	124
Table 2-14. Summary of inhalation exposure results for ONUs based on monitoring data and exposure modeling for each OES.....	125
Table 2-15. A summary of dermal retained dose for Workers based on exposure modeling for each OES	126
Table 2-16: Summary of the total number of workers and ONUs potentially exposed to TCE for each OES	127
Table 2-17. Parameter Values for Calculating Inhalation Exposure Estimates.....	132
Table 2-18. Overview of Average Worker Tenure from U.S. Census SIPP (Age Group 50+).....	134
Table 2-19. Median Year of Tenure with Current Employer by Age Group.	135
Table 2-20. Glove Protection Factors for Different Dermal Protection Strategies.....	137
Table 2-21. EPA grouped dermal exposures associated with the various OESs into four bins.	138
Table 2-22. Assigned Protection Factors for Respirators in OSHA Standard 29 CFR § 1910.134.	140
Table 2-23. SOCs with Worker and ONU Designations for All Conditions of Use Except	142
Table 2-24. SOCs with Worker and ONU Designations for Dry Cleaning Facilities	143
Table 2-25. Estimated Number of Potentially Exposed Workers and ONUs under NAICS 812320....	144
Table 2-26. Summary of overall confidence in inhalation exposure estimates by OES.....	149
Table 2-27. Evaluated Consumer Conditions of Use and Products for TCE.....	155
Table 2-28. Default Modeling Input Parameters	163
Table 2-29. Consumer Product Modeling Scenarios and Varied Input Parameters	165
Table 2-30. Consumer Product Modeling Scenarios and Additional Scenario-Specific Input Parameters	169
Table 2-31. Surface Area and Body Weight Values for Different Consumer and Bystander Subpopulations.....	172

529	Table 2-32. Acute Inhalation Exposure Summary: Brake & Parts Cleaner	172
530	Table 2-33. Acute Dermal Exposure Summary: Brake & Parts Cleaner.....	173
531	Table 2-34. Acute Inhalation Exposure Summary: Aerosol Electronic Degreaser/Cleaner.....	173
532	Table 2-35. Acute Dermal Exposure Summary: Aerosol Electronic Degreaser	174
533	Table 2-36. Acute Inhalation Exposure Summary: Liquid Electronic Degreaser/Cleaner.....	175
534	Table 2-37. Acute Dermal Exposure Summary: Liquid Electronic Degreaser/Cleaner.....	175
535	Table 2-38. Acute Inhalation Exposure Summary: Aerosol Spray Degreaser/Cleaner.....	176
536	Table 2-39. 2014 Acute Inhalation Exposure Summary: Aerosol Spray Degreaser/Cleaner.....	176
537	Table 2-40. Acute Dermal Exposure Summary: Aerosol Spray Degreaser/Cleaner	177
538	Table 2-41. Acute Inhalation Exposure Summary: Liquid Degreaser/Cleaner	177
539	Table 2-42. Acute Dermal Exposure Summary: Liquid Degreaser/Cleaner	178
540	Table 2-43. Acute Inhalation Exposure Summary: Aerosol Gun Scrubber.....	178
541	Table 2-44. Acute Dermal Exposure Summary: Aerosol Gun Scrubber.....	179
542	Table 2-45. Acute Inhalation Exposure Summary: Liquid Gun Scrubber.....	180
543	Table 2-46. Acute Dermal Exposure Summary: Liquid Gun Scrubber.....	180
544	Table 2-47. Acute Inhalation Exposure Summary: Mold Release	181
545	Table 2-48. Acute Dermal Exposure Summary: Mold Release.....	181
546	Table 2-49. Acute Inhalation Exposure Summary: Aerosol Tire Cleaner.....	182
547	Table 2-50. Acute Dermal Exposure Summary: Aerosol Tire Cleaner	182
548	Table 2-51. Acute Inhalation Exposure Summary: Liquid Tire Cleaner.....	183
549	Table 2-52. Acute Dermal Exposure Summary: Liquid Tire Cleaner	183
550	Table 2-53. Acute Inhalation Exposure Summary: Tap & Die Fluid	184
551	Table 2-54. Acute Dermal Exposure Summary: Tap & Die Fluid	184
552	Table 2-55. Acute Inhalation Exposure Summary: Penetrating Lubricant.....	185
553	Table 2-56. Acute Dermal Exposure Summary: Penetrating Lubricant.....	185
554	Table 2-57. Acute Inhalation Exposure Summary: Solvent-based Adhesive & Sealant.....	186
555	Table 2-58. Acute Dermal Exposure Summary: Solvent-based Adhesive & Sealant	186
556	Table 2-59. Acute Inhalation Exposure Summary: Mirror-Edge Sealant.....	187
557	Table 2-60. Acute Dermal Exposure Summary: Mirror-Edge Sealant.....	187
558	Table 2-61. Acute Inhalation Exposure Summary: Tire Repair Cement/Sealer.....	188
559	Table 2-62. Acute Dermal Exposure Summary: Tire Repair Cement/Sealer.....	188
560	Table 2-63. Acute Inhalation Exposure Summary: Carpet Cleaner	189
561	Table 2-64. Acute Dermal Exposure Summary: Carpet Cleaner.....	189
562	Table 2-65. Acute Inhalation Exposure Summary: Aerosol Spot Remover.....	190
563	Table 2-66. Acute Dermal Exposure Summary: Aerosol Spot Remover	190
564	Table 2-67. Acute Inhalation Exposure Summary: Liquid Spot Remover.....	191
565	Table 2-68. Acute Dermal Exposure Summary: Liquid Spot Remover.....	191
566	Table 2-69. Acute Inhalation Exposure Summary: Fixatives & Finishing Spray Coatings	192
567	Table 2-70. 2014 Acute Inhalation Exposure Summary: Fixatives & Finishing Spray Coatings	192
568	Table 2-71. Acute Dermal Exposure Summary: Fixatives & Finishing Spray Coatings	193
569	Table 2-72. Acute Inhalation Exposure Summary: Shoe Polish.....	193
570	Table 2-73. Acute Dermal Exposure Summary: Shoe Polish.....	194
571	Table 2-74. Acute Inhalation Exposure Summary: Fabric Spray	195
572	Table 2-75. Acute Dermal Exposure Summary: Fabric Spray	195
573	Table 2-76. Acute Inhalation Exposure Summary: Film Cleaner.....	196
574	Table 2-77. Acute Dermal Exposure Summary: Film Cleaner.....	196
575	Table 2-78. Acute Inhalation Exposure Summary: Hoof Polish	197
576	Table 2-79. Acute Dermal Exposure Summary: Hoof Polish.....	197

577	Table 2-80. Acute Inhalation Exposure Summary: Pepper Spray	198
578	Table 2-81. Acute Dermal Exposure Summary: Pepper Spray	198
579	Table 2-82. Acute Inhalation Exposure Summary: Toner Aid	199
580	Table 2-83. Acute Dermal Exposure Summary: Toner Aid	199
581	Table 2-84. Evaluated Pathways for Consumer Conditions of Use.....	200
582	Table 2-85. Summary of Consumer Exposure Levels by Category	201
583	Table 2-86. Confidence Ratings for Acute Inhalation Consumer Exposure Modeling Scenarios	206
584	Table 2-87. Confidence Ratings for Acute Dermal Consumer Exposure Modeling Scenarios.....	208
585	Table 2-88. Percentage of Employed Persons by Age, Sex, and Industry Sector	211
586	Table 2-89. Percentage of Employed Adolescent by Detailed Industry Sector.....	212
587	Table 3-1. Ecological Hazard Data used Quantitatively to Characterize TCE Hazard for Aquatic	
588	Organisms	217
589	Table 3-2 Concentrations of Concern (COCs) for Environmental Toxicity.....	224
590	Table 3-3. TCE Metabolites Identified by Pathway	230
591	Table 3-4. Common Metabolites of TCE and Related Compounds	230
592	Table 3-5. List of All of the PBPK-Modeled Dose Metrics Considered in this Risk Evaluation	232
593	Table 3-6. Overall Summary Scores by Line of Evidence for Cardiac Defects from TCE.....	249
594	Table 3-7. Dose-response analysis of selected studies considered for acute exposure scenarios.....	264
595	Table 3-8. Dose-response analysis of selected studies considered for evaluation of liver toxicity	266
596	Table 3-9. Dose-response analysis of selected studies considered for evaluation of kidney toxicity	267
597	Table 3-10. Dose-response analysis of selected studies considered for evaluation of neurological effects	
598	269
599	Table 3-11. Dose-response analysis of selected studies considered for evaluation of immune effects..	271
600	Table 3-12. Dose-response analysis of selected studies considered for evaluation of reproductive effects	
601	274
602	Table 3-13. Dose-response analysis of selected studies considered for acute exposure scenarios.....	278
603	Table 3-14. Dose-response analysis of selected studies considered for chronic exposure scenarios	279
604	Table 3-15. Cancer Points of Departure for Lifetime Exposure Scenarios	280
605	Table 3-16. Occupational PODs for Representative Non-Cancer Endpoints	282
606	Table 4-1. Environmental Risk Quotients for Aquatic Species for Facilities Releasing TCE to Surface	
607	Water as Modeled in E-FAST (RQs \geq 1 in bold)	292
608	Table 4-2. RQs for Aquatic Species Calculated using Monitored Environmental Concentrations from	
609	WQX/WQP	296
610	Table 4-3. RQs for Aquatic Species Calculated using Monitored Environmental Concentrations from	
611	Published Literature	297
612	Table 4-4. Environmental Risk Quotients for Sediment Organisms for Facilities Releasing TCE to	
613	Surface Water as Modeled in E-FAST (RQs \geq 1 in bold)	299
614	Table 4-5. RQs for Sediment Organisms Calculated using Monitored Environmental Concentrations	
615	from WQX/WQP	300
616	Table 4-6. RQs Sediment Organisms Calculated using Monitored Environmental Concentrations from	
617	Published Literature	300
618	Table 4-7. Use Scenarios, Populations of Interest and Toxicological Endpoints Used for Acute and	
619	Chronic Exposures	301
620	Table 4-8. Most Sensitive Endpoints from Each Health Domain for Risk Estimation	304
621	Table 4-9. Inhalation Exposure Data Summary and PPE Use Determination.....	306
622	Table 4-10. Occupational Risk Estimation - Manufacturing	308
623	Table 4-11. Occupational Risk Estimation - Processing as a Reactant	310

624	Table 4-12. Occupational Risk Estimation - Batch Open Top Vapor Degreasing - Inhalation Monitoring	
625	Data	312
626	Table 4-13. Occupational Risk Estimation - Batch Open Top Vapor Degreasing - Inhalation Modeling	
627	Data	313
628	Table 4-14. Occupational Risk Estimation - Batch Closed-Loop Vapor Degreasing	315
629	Table 4-15. Occupational Risk Estimation - Conveyorized Vapor Degreasing - Inhalation Monitoring	
630	Data	317
631	Table 4-16. Occupational Risk Estimation - Conveyorized Vapor Degreasing - Inhalation Modeling	
632	Data	318
633	Table 4-17. Occupational Risk Estimation - Web Vapor Degreasing	320
634	Table 4-18. Occupational Risk Estimation - Cold Cleaning	322
635	Table 4-19. Occupational Risk Estimation - Aerosol Applications	324
636	Table 4-20. Occupational Risk Estimation - Spot Cleaning and Wipe Cleaning (and Other Commercial	
637	Uses) - Inhalation Monitoring Data	326
638	Table 4-21. Occupational Risk Estimation - Spot Cleaning and Wipe Cleaning (and Other Commercial	
639	Uses) - Inhalation Modeling Data	327
640	Table 4-22. Occupational Risk Estimation - Formulation of Aerosol and Non-Aerosol Products	329
641	Table 4-23. Occupational Risk Estimation - Repackaging	331
642	Table 4-24. Occupational Risk Estimation - Metalworking Fluids - Inhalation Monitoring Data	333
643	Table 4-25. Occupational Risk Estimation - Metalworking Fluids - Inhalation Modeling Data	334
644	Table 4-26. Occupational Risk Estimation - Adhesives, Sealants, Paints, and Coatings (Industrial	
645	Setting)	336
646	Table 4-27. Occupational Risk Estimation - Adhesives, Sealants, Paints, and Coatings (Commercial	
647	Setting)	338
648	Table 4-28. Occupational Risk Estimation - Industrial Processing Aid (12 hr)	340
649	Table 4-29. Occupational Risk Estimation - Commercial Printing and Copying	342
650	Table 4-30. Occupational Risk Estimation - Other Industrial Uses	344
651	Table 4-31. Occupational Risk Estimation - Process Solvent Recycling and Worker Handling of Wastes	
652	346
653	Table 4-32. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Brake and Parts	
654	Cleaner	349
655	Table 4-33. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Electronic	
656	Degreaser/Cleaner	350
657	Table 4-34. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid Electronic	
658	Degreaser/Cleaner	351
659	Table 4-35. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Spray	
660	Degreaser/Cleaner	352
661	Table 4-36. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid	
662	Degreaser/Cleaner	353
663	Table 4-37. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Gun Scrubber	
664	354
665	Table 4-38. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid Gun Scrubber	
666	355
667	Table 4-39. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Mold Release	356
668	Table 4-40. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Tire Cleaner	
669	357
670	Table 4-41. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid Tire Cleaner	358
671	Table 4-42. Consumer Risk Estimation - Lubricants and Greases - Tap and Die Fluid	359

672	Table 4-43. Consumer Risk Estimation - Lubricants and Greases - Penetrating Lubricant	360
673	Table 4-44. Consumer Risk Estimation - Adhesives and Sealants - Solvent-Based Adhesive and Sealant	
674	361
675	Table 4-45. Consumer Risk Estimation - Adhesives and Sealants - Mirror Edge Sealant.....	362
676	Table 4-46. Consumer Risk Estimation - Adhesives and Sealants - Tire Repair Cement / Sealer.....	363
677	Table 4-47. Consumer Risk Estimation - Cleaning and Furniture Care Products - Carpet Cleaner.....	364
678	Table 4-48. Consumer Risk Estimation - Cleaning and Furniture Care Products - Aerosol Spot Remover	
679	365
680	Table 4-49. Consumer Risk Estimation - Cleaning and Furniture Care Products - Liquid Spot Remover	
681	366
682	Table 4-50. Consumer Risk Estimation - Arts, Crafts, and Hobby Materials - Fixatives and Finishing	
683	Spray Coatings	367
684	Table 4-51. Consumer Risk Estimation - Apparel and Footwear Care Products - Shoe Polish.....	368
685	Table 4-52. Consumer Risk Estimation - Other Consumer Uses - Fabric Spray	369
686	Table 4-53. Consumer Risk Estimation - Other Consumer Uses - Film Cleaner	370
687	Table 4-54. Consumer Risk Estimation - Other Consumer Uses - Hoof Polish.....	371
688	Table 4-55. Consumer Risk Estimation - Other Consumer Uses - Pepper Spray.....	372
689	Table 4-56. Consumer Risk Estimation - Other Consumer Uses - Toner Aid	373
690	Table 4-57. Facilities with Risk from Acute or Chronic Exposure for Aquatic Organisms (RQs \geq 1 in	
691	bold)	384
692	Table 4-58. Facilities with Risk from Acute or Chronic Exposure for Sediment Organisms (RQs \geq 1 in	
693	bold)	386
694	Table 4-59. Occupational Risk Summary Table.....	389
695	Table 4-60. Consumer Risk Summary Table.....	402
696	Table 5-1. Categories and Subcategories of Conditions of Use Included in the Scope of the Risk	
697	Evaluation	411
698		
699		

700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740

LIST OF FIGURES

Figure 1-1. Total Aggregate TCE Production Volume (lbs.) 2012-2015 ^a	47
Figure 1-2. Percentage of TCE Production Volume by Use.....	48
Figure 1-3. TCE Life Cycle Diagram	61
Figure 1-4. TCE Conceptual Model for Industrial and Commercial Activities and Uses: Potential Exposures and Hazards	70
Figure 1-5. TCE Conceptual Model for Consumer Activities and Uses: Potential Exposures and Hazards	71
Figure 1-6. TCE Conceptual Model for Environmental Releases and Wastes: Potential Exposures and Hazards	72
Figure 1-7. Literature Flow Diagram for Environmental Fate and Transport	75
Figure 1-8. Literature Flow Diagram for Engineering Releases and Occupational Exposure	76
Figure 1-9. Literature Flow Diagram for Consumer and Environmental Exposure Data Sources.....	77
Figure 1-10. Literature Flow Diagram for Environmental Hazard.....	78
Figure 1-11. Literature Flow Diagram for Human Health Hazard	79
Figure 2-1. Environmental transport, partitioning and degradation processes for TCE.....	85
Figure 2-2. An overview of how EPA estimated daily water releases for each OES.....	88
Figure 2-3. Distribution of Active Facility Releases Modeled.....	107
Figure 2-4. TCE Modeled Concentrations from Releasing Facilities (250-365 Days of Release) and Measured Concentrations from WQP: Eastern U.S., 2016.....	111
Figure 2-5. TCE Modeled Concentrations from Releasing Facilities (250-365 Days of Release) and Measured Concentrations from WQP: Western U.S., 2016	112
Figure 2-6. TCE Modeled Concentrations from Releasing Facilities (20 Days of Release) and Measured Concentrations from WQP: Eastern U.S., 2016	113
Figure 2-7. TCE Modeled Concentrations from Releasing Facilities (20 Days of Release) and Measured Concentrations from WQP: Western U.S., 2016	114
Figure 2-8. Co-Location of Modeled Concentrations from Releasing Facilities and Measured Concentrations from WQP (HUC-8) in North Carolina	115
Figure 2-9. Co-Location of Modeled Concentrations from Releasing Facilities and Measured Concentrations from WQP (HUC-8) in New Mexico	116
Figure 2-10. Components of an occupational assessment for each OES.....	120
Figure 2-11. Illustrative applications of the NF/FF model to various exposure scenarios.	130
Figure 3-1. Species Sensitivity Distributions (SSDs) for Acute Hazard Data Using LC _{50s} or EC _{50s} (Etterson, 2020).....	219
Figure 3-2. Species Sensitivity Distribution (SSD) for Algae Species Using EC _{50s} (Etterson, 2020)...	220
Figure 3-3. EPA Approach to Hazard Identification, Data Integration, and Dose-Response Analysis for TCE.....	226
Figure 3-4. Dose-Response Analyses of Rodent Non-Cancer Effects Using.....	234
Figure 3-5. Example of HEC99 Estimation through Interpecies, Intraspecies and	234

741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788

LIST OF APPENDIX TABLES

Table_Apx A-1. Federal Laws and Regulations.....	490
Table_Apx A-2. State Laws and Regulations.....	497
Table_Apx A-3. Regulatory Actions by Other Governments and Tribes	498
Table_Apx C-1. Facility-Specific Aquatic Exposure Modeling Results.....	503
Table_Apx D-1. TCE Residential Indoor Air Concentrations ($\mu\text{g}/\text{m}^3$) in the United States and Canada	563
Table_Apx D-2. Personal Breathing Zone Concentrations ($\mu\text{g}/\text{m}^3$) for TCE in the United States (General/Residential)	565
Table_Apx E-1. Acute Toxicity Data for Aquatic Organisms used in SSD.....	567
Table_Apx E-2. Standard Error for all distributions and fitting methods using TCE’s acute hazard data (Etterson, 2020).....	570
Table_Apx E-3. Algae Toxicity Data used in SSD	573
Table_Apx E-4. Standard Error for all distributions and fitting methods using TCE’s algae hazard data (Etterson, 2020).....	578
Table_Apx E-5. Environmental RQs by Facility (with RQs ≥ 1 in bold)	581
Table_Apx F-1. Strengths and Limitations of (Johnson et al., 2003).....	629
Table_Apx F-2. Experimental Design of (Charles River Laboratories, 2019).....	630
Table_Apx F-3. Summary of Observed Interventricular Defects.....	630
Table_Apx F-4. Incidence of total heart malformations in Johnson and Charles River studies.	631
Table_Apx F-5. Incidence of VSDs in Johnson and Charles River studies.	632
Table_Apx F-6. Heart and Cardiovascular Defects Observed in Select Oral TCE studies	633
Table_Apx F-7. Cardiac Defects Observed in Literature	635
Table_Apx F-8. List of RA Studies Identified in the Literature Search and Observed Defects in Each	635
Table_Apx F-9. Cardiac Defects Observed After Exposure to RA or TCE.....	638
Table_Apx F-10. Weight-of-Evidence Table for Epidemiology Studies	647
Table_Apx F-11. Weight-of-Evidence Table for <i>In Vivo</i> Animal Toxicity Studies.....	649
Table_Apx F-12. Weight-of-Evidence Table for Mechanistic Studies	652
Table_Apx F-13. Overall Weight-of-Evidence Table and Summary Scores	654
Table_Apx H-1. Summary of BMD Modeling Results for Mortality from Applied Dose in Selgrade and Gilmour 2010; BMR = 10% Extra Risk	659
Table_Apx H-2. Summary of BMD Modeling Results for Mortality from Applied Dose in Selgrade and Gilmour 2010; BMR = 5% Extra Risk	662
Table_Apx H-3. Summary of BMD Modeling Results for Mortality from Applied Dose in Selgrade and Gilmour 2010; BMR = 1% Extra Risk	664
Table_Apx H-4. Summary of BMD Modeling Results for Number of Mice Infected at 72 Hours after Infection Following Inhalation Exposure to TCE (Selgrade and Gilmour 2010); BMR = 10% Extra Risk	667
Table_Apx H-5. Study incidence data based on median internal dose metric.	669
Table_Apx H-6. Summary of BMD Modeling Results for Mortality from Internal Dose in Selgrade and Gilmour 2010; BMR = 10% Extra Risk	669
Table_Apx H-7. Summary of BMD Modeling Results for Mortality from Internal Dose in Selgrade and Gilmour 2010; BMR = 5% Extra Risk	670
Table_Apx H-8. Summary of BMD Modeling Results for Mortality from Internal Dose in Selgrade and Gilmour 2010; BMR = 1% Extra Risk	671
Table_Apx I-1. Results for Best-Fitting Model in Comparison to Results	674
Table_Apx J-1. Selected percentiles for TotMetabBW34 and AUCCBld for female mouse simulations	676

789	Table_Apx J-2. Human equivalent concentrations and human equivalent doses for the Selgrade and Keil endpoints under both default and occupational respiratory conditions.	678
790		
791	Table_Apx K-1. Meta-Analysis Inclusion/Exclusion Criteria for Considering Cancer Studies Identified in EPA’s Literature Search	679
792		
793	Table_Apx K-2. Screening Results of Cancer Studies Identified in EPA’s Literature Search Based on Inclusion/Exclusion Criteria	680
794		
795	Table_Apx K-3. Cancer Studies Covering the Same Cohort as Previous Studies from either the 2011 IRIS Assessment or EPA Literature Search.....	681
796		
797	Table_Apx K-4. Analysis of influential studies: NHL	690
798	Table_Apx K-5. Analysis of influential studies: Kidney cancer	690
799	Table_Apx K-6. Analysis of influential studies: Liver cancer	691
800	Table_Apx K-7. Selected RR estimates for NHL associated with TCE exposure (overall effect) from cohort studies published after U.S. EPA (2011).....	698
801		
802	Table_Apx K-8. Selected RR estimates for NHL associated with TCE exposure (overall effect) from case-control studies.....	699
803		
804	Table_Apx K-9. Selected RR estimates for NHL associated with TCE exposure (effect in the highest exposure group) studies	699
805		
806	Table_Apx K-10. Selected RR estimates for kidney cancer associated with TCE exposure (overall effect) from cohort studies	700
807		
808	Table_Apx K-11. Selected RR estimates for kidney cancer associated with TCE exposure (overall effect) from case-control studies published after U.S. EPA (2011)	701
809		
810	Table_Apx K-12. Selected RR estimates for liver cancer associated with TCE exposure (overall effect) from cohort studies	702
811		
812	Table_Apx K-13. Selected RR estimates for liver cancer associated with TCE exposure (overall effect) from case-control studies published after U.S. EPA (2011).....	703
813		
814	Table_Apx L-1. Summary of OCPSF Effluent Guidelines for Trichloroethylene.....	705
815	Table_Apx L-2. Default Parameters for Estimating Water Releases of Trichloroethylene from Manufacturing Sites	706
816		
817	Table_Apx L-3. Summary of Facility Trichloroethylene Production Volumes and Wastewater Flow Rates.....	707
818		
819	Table_Apx N-1. Summary of Parameter Values and Distributions Used in the Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model	717
820		
821	Table_Apx N-2. Summary of Parameter Values and Distributions Used in the ConveyORIZED Degreasing Near-Field/Far-Field Inhalation Exposure Model	718
822		
823	Table_Apx N-3. Summary of Parameter Values and Distributions Used in the Web Degreasing Near-Field/Far-Field Inhalation Exposure Model.....	719
824		
825	Table_Apx N-4. Summary of Parameter Values and Distributions Used in the Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model.....	720
826		
827	Table_Apx N-5. Summary of Trichloroethylene Vapor Degreasing and Cold Cleaning Data from the 2014 NEI.....	722
828		
829	Table_Apx N-6. Distribution of Trichloroethylene Open-Top Vapor Degreasing Unit Emissions.....	723
830	Table_Apx N-7. Distribution of Trichloroethylene ConveyORIZED Degreasing Unit Emissions.....	724
831	Table_Apx N-8. Distribution of Trichloroethylene Web Degreasing Unit Emissions.....	725
832	Table_Apx N-9. Distribution of Trichloroethylene Cold Cleaning Unit Emissions	725
833	Table_Apx N-10. Distribution of Trichloroethylene Open-Top Vapor Degreasing Operating Hours... ..	725
834	Table_Apx N-11. Distribution of Trichloroethylene ConveyORIZED Degreasing Operating Hours.....	725
835	Table_Apx N-12. Distribution of Trichloroethylene Web Degreasing Operating Hours	726
836	Table_Apx N-13. Distribution of Trichloroethylene Cold Cleaning Operating Hours	726

837	Table_Apx O-1. Summary of Parameter Values and Distributions Used in the Brake Servicing Near-	
838	Field/Far-Field Inhalation Exposure Model.....	733
839	Table_Apx O-2. Summary of Trichloroethylene-Based Aerosol Degreaser Formulations	737
840	Table_Apx P-1. Summary of Parameter Values and Distributions Used in the Spot Cleaning	744
841	Table_Apx P-2. Composite Distribution of Dry Cleaning Facility Floor Areas	747
842	Table_Apx Q-1. Summary of Worker Inhalation Exposure Monitoring Data from TCE Manufacturing	
843	750
844	Table_Apx Q-2. Summary of OCPSF Effluent Limitations for Trichloroethylene	751
845	Table_Apx Q-3. Reported Water Releases of Trichloroethylene from Manufacturing Sites Reporting to	
846	2016 TRI	752
847	Table_Apx Q-4. Estimated Water Releases of Trichloroethylene from Manufacturing Sites Not	
848	Reporting to 2016 TRI	753
849	Table_Apx Q-5. Summary of Worker Inhalation Exposure Surrogate Monitoring Data from TCE Use as	
850	a Reactant.....	754
851	Table_Apx Q-6. Water Release Estimates for Sites Using TCE as a Reactant.....	754
852	Table_Apx Q-7. Summary of Worker Inhalation Exposure Monitoring Data for Unloading TCE During	
853	Formulation of Aerosol and Non-Aerosol Products	755
854	Table_Apx Q-8. Summary of Worker Inhalation Exposure Monitoring Data for Unloading/Loading TCE	
855	from Bulk Containers.....	756
856	Table_Apx Q-9. Reported Water Releases of Trichloroethylene from Sites Repackaging TCE.....	757
857	Table_Apx Q-10. Summary of Worker Inhalation Exposure Monitoring Data for Batch Open-Top Vapor	
858	Degreasing	758
859	Table_Apx Q-11. Summary of Exposure Modeling Results for TCE Degreasing in OTVDs.....	760
860	Table_Apx Q-12. Reported Water Releases of Trichloroethylene from Sites Using TCE in Open-Top	
861	Vapor Degreasing	760
862	Table_Apx Q-13. Summary of Worker Inhalation Exposure Monitoring Data for Batch Closed-Loop	
863	Vapor Degreasing	764
864	Table_Apx Q-14. Summary of Worker Inhalation Exposure Monitoring Data for ConveyORIZED Vapor	
865	Degreasing	765
866	Table_Apx Q-15. Summary of Exposure Modeling Results for TCE Degreasing in ConveyORIZED	
867	Degreasers.....	767
868	Table_Apx Q-16. Summary of Exposure Modeling Results for TCE Degreasing in Web Degreasers .	769
869	Table_Apx Q-17. Summary of Exposure Modeling Results for Use of Trichloroethylene in Cold	
870	Cleaning	771
871	Table_Apx Q-18. Summary of Worker and Occupational Non-User Inhalation Exposure Modeling	
872	Results for Aerosol Degreasing	773
873	Table_Apx Q-19. Summary of Worker Inhalation Exposure Monitoring Data for TCE Use in	
874	Metalworking Fluids.....	774
875	Table_Apx Q-20. ESD Exposure Estimates for Metalworking Fluids Based on Monitoring Data	775
876	Table_Apx Q-21. Summary of Exposure Results for Use of TCE in Metalworking Fluids Based on ESD	
877	Estimates	775
878	Table_Apx Q-22. Summary of Worker Inhalation Exposure Monitoring Data for	
879	Adhesives/Paints/Coatings.....	776
880	Table_Apx Q-23. Reported Water Releases of Trichloroethylene from Sites Using TCE in Adhesives,	
881	Sealants, Paints and Coatings	777
882	Table_Apx Q-24. Summary of Occupational Exposure Surrogate Monitoring Data for Unloading TCE	
883	During Other Industrial Uses	781
884	Table_Apx Q-25. Reported Water Releases of Trichloroethylene from Other Industrial Uses.....	782

885	Table_Apx Q-26. Summary of Worker Inhalation Exposure Monitoring Data for Spot Cleaning Using	
886	TCE.....	783
887	Table_Apx Q-27. Summary of Exposure Modeling Results for Spot Cleaning Using TCE	785
888	Table_Apx Q-28. Reported Water Releases of Trichloroethylene from Sites Using TCE Spot Cleaning	
889	785
890	Table_Apx Q-29. Summary of Exposure Monitoring Data for Use as a Processing Aid	786
891	Table_Apx Q-30. Reported Water Releases of Trichloroethylene from Industrial Processing Aid Sites	
892	Using TCE	787
893	Table_Apx Q-31. Summary of Worker Inhalation Exposure Monitoring Data for High Speed Printing	
894	Presses.....	788
895	Table_Apx Q-32. Reported Water Releases of Trichloroethylene from Commercial Printing and	
896	Copying.....	788
897	Table_Apx Q-33. Reported Water Releases of Trichloroethylene from Other Commercial Uses in the	
898	2016 DMR	789
899	Table_Apx Q-34. Estimated Water Releases of Trichloroethylene from Disposal/Recycling of TCE..	790
900		
901		
902		
903		

LIST OF APPENDIX FIGURES

905	Figure_Apx D-1. Elasticities (≥ 0.05) for Parameters Applied in E1.....	560
906	Figure_Apx D-2. Elasticities (≥ 0.05) for Parameters Applied in E3.....	561
907	Figure_Apx D-3. Elasticities (≥ 0.05) for Parameters Applied in P_DER2b.....	562
908	Figure_Apx E-1. SSD Toolbox interface showing HC _{05s} and P values for each distribution and fitting	
909	method using TCE's acute hazard data (Etterson, 2020).....	569
910	Figure_Apx E-2. AIC _c for the five distribution options in the SSD Toolbox for TCE's acute hazard data	
911	(Etterson, 2020).....	570
912	Figure_Apx E-3. All distributions and fitting methods in the SSD Toolbox for TCE's acute hazard data	
913	(Etterson, 2020).....	571
914	Figure_Apx E-4. TCE's acute hazard data fit with the normal, logistic, triangular, Gumbel, and Burr	
915	distributions fit with maximum likelihood in the SSD Toolbox (Etterson, 2020).....	572
916	Figure_Apx E-5. SSD Toolbox interface and list of HC _{05s} for each distribution and fitting method using	
917	TCE's algae hazard data (Etterson, 2020)	577
918	Figure_Apx E-6. AIC _c Table for algae hazard data (Etterson, 2020)	578
919	Figure_Apx E-7. All distributions and fitting methods in the SSD Toolbox for TCE's algae hazard data	
920	(Etterson, 2020).....	579
921	Figure_Apx E-8. TCE algae data fit with all distributions using the maximum likelihood fitting method	
922	(Etterson, 2020).....	580
923	Figure_Apx H-1. Plot of Incidence by Applied Dose (ppm) with Fitted Curve for Log-Probit Model for	
924	Mortality from Introduced Infection in Mice Following Inhalation Exposure to TCE	
925	(Selgrade and Gilmour 2010); BMR = 10% Extra Risk.....	660
926	Figure_Apx H-2. Plot of Incidence by Applied Dose (ppm) with Fitted Curve for Log-Probit Model for	
927	Mortality from Introduced Infection in Mice Following Inhalation Exposure to TCE	
928	(Selgrade and Gilmour 2010); BMR = 5% Extra Risk.....	662
929	Figure_Apx H-3. Plot of Incidence by Applied Dose (ppm) with Fitted Curve for Log-Probit Model for	
930	Mortality from Introduced Infection in Mice Following Inhalation Exposure to TCE	
931	(Selgrade and Gilmour 2010); BMR = 1% Extra Risk.....	665
932	Figure_Apx H-4. Plot of Incidence by Dose (ppm) with Fitted Curve for Probit Model for Number of	
933	Mice Infected at 72 Hours after Infection Following Inhalation Exposure to TCE	
934	(Selgrade and Gilmour 2010); BMR = 10% Extra Risk.....	668
935	Figure_Apx H-5. Plot of Incidence by Internal Dose with Fitted Curve for Log-Probit Model for	
936	Mortality from Selgrade and Gilmour 2010; BMR = 10% Extra Risk.....	670
937	Figure_Apx H-6. Plot of Incidence by Internal Dose with Fitted Curve for Log-Probit Model for	
938	Mortality from Selgrade and Gilmour 2010; BMR = 5% Extra Risk.....	671
939	Figure_Apx H-7. Plot of Incidence by Internal Dose with Fitted Curve for Log-Probit Model for	
940	Mortality from Selgrade and Gilmour 2010; BMR = 1% Extra Risk.....	672
941	Figure_Apx J-1. Distribution of default (resting) respiration rates compared to occupational respiratory	
942	rate.....	677
943	Figure_Apx K-1. Fixed-effects model, overall association of NHL and exposure to TCE.....	684
944	Figure_Apx K-2. Random-effects model, overall association of NHL and exposure to TCE.	685
945	Figure_Apx K-3. Fixed-effects model, association of NHL and high exposure to TCE.....	685
946	Figure_Apx K-4. Random-effects model, association of NHL and high exposure to TCE.	686
947	Figure_Apx K-5. Fixed-effects model, overall association of kidney cancer and.....	687
948	Figure_Apx K-6. Random-effects model, overall association of kidney cancer and.....	687
949	Figure_Apx K-7. Fixed-effects model, overall association of liver cancer and.....	688
950	Figure_Apx K-8. Random-effects model, overall association of liver cancer and.....	689

951	Figure_Apx K-9. Fixed-effects model, overall association of NHL and exposure to TCE, study of	
952	Vlaanderen et al. (2013) omitted.	692
953	Figure_Apx K-10. Fixed-effects model, association of NHL and high exposure to TCE, study of	
954	Vlaanderen et al. (2013) omitted.	692
955	Figure_Apx K-11. Fixed-effects model, overall association of kidney cancer and.....	693
956	Figure_Apx K-12. Fixed-effects model, overall association of liver cancer and	693
957	Figure_Apx K-13. Fixed-effects model, overall association of NHL and.....	694
958	Figure_Apx K-14. Fixed-effects model, overall association of kidney cancer and.....	695
959	Figure_Apx K-15. Fixed-effects model, overall association of liver cancer and	695
960	Figure_Apx K-16. Funnel plots for publication bias.	697
961	Figure_Apx N-1. The Near-Field/Far-Field Model as Applied to the Open-Top Vapor Degreasing Near-	
962	Field/Far-Field Inhalation Exposure Model and the Cold Cleaning Near-Field/Far-Field	
963	Inhalation Exposure Model.....	712
964	Figure_Apx N-2. The Near-Field/Far-Field Model as Applied to the ConveyORIZED Degreasing Near-	
965	Field/Far-Field Inhalation Exposure Model.....	713
966	Figure_Apx N-3. The Near-Field/Far-Field Model as Applied to the Web Degreasing Near-Field/Far-	
967	Field Inhalation Exposure Model.....	713
968	Figure_Apx O-1. The Near-Field/Far-Field Model as Applied to the Brake Servicing Near-Field/Far-	
969	Field Inhalation Exposure Model.....	728
970	Figure_Apx P-1. The Near-Field/Far-Field Model as Applied to the Spot Cleaning Near-Field/Far-Field	
971	Inhalation Exposure Model.....	740
972	Figure_Apx Q-1. Schematic of the Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation	
973	Exposure Model	759
974	Figure_Apx Q-2. Belt/Strip ConveyORIZED Vapor Degreasing Schematic of the ConveyORIZED	
975	Degreasing Near-Field/Far-Field Inhalation Exposure Model	766
976	Figure_Apx Q-3. Schematic of the Web Degreasing Near-Field/Far-Field Inhalation Exposure Model	
977	768
978	Figure_Apx Q-4. Schematic of the Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model..	770
979	Figure_Apx Q-5. Schematic of the Near-Field/Far-Field Model for Aerosol Degreasing	773
980	Figure_Apx Q-6. Schematic of the Near-Field/Far-Field Model for Spot Cleaning	784
981	Figure_Apx R-1. Mass Balance for Trichloroethylene.....	801
982		
983		

984 **ACKNOWLEDGEMENTS**

985 This report was developed by the United States Environmental Protection Agency (EPA), Office of
986 Chemical Safety and Pollution Prevention (OCSPP), Office of Pollution Prevention and Toxics (OPPT).

987

988 **Acknowledgements**

989 The EPA Assessment Team gratefully acknowledges participation and/or input from Intra-agency
990 reviewers that included multiple offices within EPA, Inter-agency reviewers that included multiple
991 Federal agencies, and assistance from EPA contractors: GDIT (Contract No. CIO-SP3,
992 HHSN316201200013W), ERG (Contract No. EP-W-12-006), Versar (Contract No. EP-W-17-006), ICF
993 (Contract No. EPC14001 and 68HERC19D0003), SRC (Contract No. EP-W-12-003 and
994 68HERH19D0022), and Abt Associates (Contract No. EPW-16-009).

995

996 Special acknowledgement is given for PBPK modeling support from EPA Office of Research and
997 Development (ORD), especially Todd Zurlinden for his derivation of internal doses and Human
998 Equivalent Concentrations/Doses for ([Selgrade and Gilmour, 2010](#)) and ([Keil et al., 2009](#)). Additional
999 acknowledgements are provided to Amanda Persad, Audrey Galizia, Barbara Glenn, Channa Keshava,
1000 Nagalakshmi Keshava, Rebecca Nachman and Suryanarayana Vulimiri for study quality evaluation and
1001 systematic review support; George Woodall for exposure response array; and Thomas Bateson for the
1002 cancer meta-analysis.

1003

1004 EPA also acknowledges the contributions of Masashi Ando from the National Institute of Technology
1005 and Evaluation (NITE) in Japan for his contribution to the systematic review of environmental exposure
1006 data.

1007

1008 **Docket**

1009 Supporting information can be found in public docket (Docket: [EPA-HQ-OPPT-2019-0500](#)).

1010

1011 **Disclaimer**

1012 Reference herein to any specific commercial products, process or service by trade name, trademark,
1013 manufacturer or otherwise does not constitute or imply its endorsement, recommendation or favoring by
1014 the United States Government.

1015

1016 **Authors/Contributors**

1017 Sheila Canavan (Division Director), Stan Barone (Deputy Division Director), Nhan Nguyen
1018 (Management Lead), Yvette Selby-Mohamadu (Management Lead), Keith Jacobs (Staff Lead), Rehan
1019 Choudhary (prior Staff co-Lead), Heidi Bethel (prior Staff co-Lead), Stephanie Sarraino, Kara Koehn,
1020 Sheila Xiah Kragie, Franklyn Hall, Wen-Hsiung Lee, Toni Krasnic, Katie McNamara, Niva Kramek,
1021 Lynne Blake-Hedges, Shannon Rebersak, Caitlin Briere, Sue Makris, Sue Euling, Zaida Figueroa, Bryan
1022 Lobar, Matt Etterson, Dave Lynch, Ryan Sullivan, Laura Krnavek, Yashfin Mahid, Mitchell Sumner

1023

1024

ABBREVIATIONS

1025	°C	Degrees Celsius
1026	ϵ_0	Vacuum Permittivity
1027	ACGIH	American Conference of Governmental Industrial Hygienists
1028	AEGL	Acute Exposure Guideline Level
1029	ADD	Average Daily Dose
1030	AF	Assessment Factor
1031	APF	Assigned Protection Factor
1032	AQS	Air Quality System
1033	ATCM	Airborne Toxic Control Measure
1034	atm	Atmosphere(s)
1035	ATSDR	Agency for Toxic Substances and Disease Registries
1036	BAF	Bioaccumulation Factor
1037	BCF	Bioconcentration Factor
1038	BIOWIN	The EPI Suite™ module that predicts biodegradation rates
1039	BW ^{3/4}	body weight ^{3/4}
1040	CAA	Clean Air Act
1041	CARB	California Air Resources Board
1042	CASRN	Chemical Abstracts Service Registry Number
1043	CBI	Confidential Business Information
1044	CCR	California Code of Regulations
1045	CDC	Centers for Disease Control and Prevention
1046	CDR	Chemical Data Reporting
1047	CEHD	Chemical Exposure Health Data
1048	CEM	Consumer Exposure Model
1049	CEPA	Canadian Environmental Protection Act
1050	CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
1051	CFC	Chlorofluorocarbon
1052	CFR	Code of Federal Regulations
1053	CH	Chloral Hydrate
1054	CHD	Congenital Heart Defects
1055	CHIRP	Chemical Risk Information Platform
1056	ChV	Chronic Value
1057	cm ³	Cubic Centimeter(s)
1058	CNS	Central Nervous System
1059	COC	Concentration of Concern
1060	COU	Conditions of Use
1061	CPCat	Chemical and Product Categories
1062	CSCL	Chemical Substances Control Law
1063	CWA	Clean Water Act
1064	CYP	Cytochrome P450
1065	DCA	Dichloroacetic acid
1066	DCE	Dichloroethylene
1067	DCVC	S-dichlorovinyl-L-cysteine
1068	DCVG	S-dichlorovinyl-glutathione
1069	DEVL	Dermal Exposure to Volatile Liquids
1070	DIY	Do-It-Yourself
1071	DMR	Discharge Monitoring Report

1072	EC ₅₀	Effect concentration at which 50% of test organisms exhibit an effect
1073	ECCC	Environment and Climate Change Canada
1074	ECHA	European Chemicals Agency
1075	EDC	Ethylene Dichloride
1076	E-FAST	Exposure and Fate Assessment Screening Tool
1077	EG	Effluent Guidelines
1078	EPA	Environmental Protection Agency
1079	EPCRA	Emergency Planning and Community Right-to-Know Act
1080	EPI Suite™	Estimation Program Interface Suite™
1081	ESD	Emission Scenario Document
1082	EU	European Union
1083	FDA	Food and Drug Administration
1084	FFDCA	Federal Food, Drug, and Cosmetic Act
1085	FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
1086	FR	Federal Register
1087	g	Gram(s)
1088	GACT	Generally Available Control Technology
1089	GS	Generic Scenario
1090	GSH	Glutathione
1091	GST	Glutathione-S-transferase
1092	HAP	Hazardous Air Pollutant
1093	HCFC	Hydrochlorofluorocarbon
1094	HCl	Hydrochloric Acid
1095	HC ₀₅	Hazardous Concentration threshold for 5% of species in a Species Sensitivity Distribution
1096	HEC	Human Equivalent Concentration
1097	HED	Human Equivalent Dose
1098	HFC	Hydrofluorocarbon
1099	HHE	Health Hazard Evaluation
1100	HPV	High Production Volume
1101	Hr	Hour
1102	IARC	International Agency for Research on Cancer
1103	ICIS	Integrated Compliance Information System
1104	IDLH	Immediately Dangerous to Life and Health
1105	IMIS	Integrated Management Information System
1106	IRIS	Integrated Risk Information System
1107	ISHA	Industrial Safety and Health Act
1108	ISOR	Initial Statement of Reasons
1109	IUR	Inhalation Unit Risk
1110	K _{oc}	Soil Organic Carbon-Water Partitioning Coefficient
1111	K _{ow}	Octanol/Water Partition Coefficient
1112	kg	Kilogram(s)
1113	L	Liter(s)
1114	lb	Pound(s)
1115	LC ₅₀	Lethal Concentration at which 50% of test organisms die
1116	LOAEL	Lowest-observed-adverse-effect-level
1117	LOEC	Lowest-observable-effect Concentration
1118	m ³	Cubic Meter(s)
1119	MACT	Maximum Achievable Control Technology

1120	MATC	Maximum Acceptable Toxicant Concentration
1121	MCCEM	Multi-Chamber Concentration and Exposure Model
1122	MCL	Maximum Contaminant Level
1123	MCLG	Maximum Contaminant Level Goal
1124	mg	Milligram(s)
1125	mmHg	Millimeter(s) of Mercury
1126	MOA	Mode of Action
1127	mPa·s	Millipascal(s)-Second
1128	MSDS	Material Safety Data Sheet
1129	MSW	Municipal Solid Waste
1130	NAICS	North American Industry Classification System
1131	NATA	National Scale Air-Toxics Assessment
1132	NCEA	National Center for Environmental Assessment
1133	NICNAS	Australia National Industrial Chemicals Notification and Assessment Scheme
1134	NCI	National Cancer Institute
1135	NCP	National Contingency Plan
1136	NEI	National Emissions Inventory
1137	NESHAP	National Emission Standards for Hazardous Air Pollutants
1138	NHANES	National Health and Nutrition Examination Survey
1139	NICNAS	National Industrial Chemicals Notification and Assessment Scheme
1140	NIH	National Institute of Health
1141	NICNAS	National Industrial Chemicals Notification and Assessment Scheme
1142	NIOSH	National Institute for Occupational Safety and Health
1143	NITE	National Institute of Technology and Evaluation
1144	NOAEL	No-Observed-Adverse-Effect-Level
1145	NOEC	No-observable-effect Concentration
1146	NPDES	National Pollutant Discharge Elimination System
1147	NPDWR	National Primary Drinking Water Regulation
1148	NRC	National Research Council
1149	NTP	National Toxicology Program
1150	NWIS	National Water Information System
1151	OCPSF	Organic Chemicals, Plastics and Synthetic Fibers
1152	OCSPF	Office of Chemical Safety and Pollution Prevention
1153	OECD	Organization for Economic Co-operation and Development
1154	OEHHA	Office of Environmental Health Hazard Assessment
1155	OES	Occupational Exposure Scenario
1156	OEL	Occupational Exposure Limits
1157	ONU	Occupational Non-User
1158	OPPT	Office of Pollution Prevention and Toxics
1159	OR	Odds Ratio
1160	OSH(A)	Occupational Safety and Health (Administration)
1161	OSF	Oral Slope Factor
1162	OST	Office of Science and Technology
1163	OTVD	Open-Top Vapor Degreaser
1164	OW	Office of Water
1165	PBPK	Physiologically-Based Pharmacokinetic
1166	PBZ	Personal Breathing Zone
1167	PCE	Tetrachloroethylene

1168	PF	Protection Factor (for gloves)
1169	PECO	Population, Exposure, Comparator, and Outcome
1170	PEL	Permissible Exposure Limit
1171	PESS	Potentially Exposed or Susceptible Subpopulations
1172	POD	Point of Departure
1173	POTW	Publicly Owned Treatment Works
1174	ppb	Part(s) per Billion
1175	PPE	Personal Protective Equipment
1176	ppm	Part(s) per Million
1177	PSD	Particle Size Distribution
1178	PV	Production Volume
1179	QC	Quality Control
1180	QSAR	Quantitative Structure Activity Relationship
1181	RCRA	Resource Conservation and Recovery Act
1182	REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
1183	REL	Relative Exposure Limit
1184	RR	Relative Risk
1185	RTR	Risk and Technology Review
1186	SDS	Safety Data Sheet
1187	SDWA	Safe Drinking Water Act
1188	SIDS	Screening Information Dataset
1189	SNUN	Significant New Use Notice
1190	SNUR	Significant New Use Rule
1191	SOCMI	Synthetic Organic Chemical Manufacturing Industry
1192	SPARC	SPARC Performs Automated Reasoning in Chemistry
1193	SpERC	Specific Environmental Release Categories
1194	STEL	Short-Term Exposure Limit
1195	STP model	Sewage Treatment Plant model
1196	STORET	STorage and RETrieval
1197	SSD	Species Sensitivity Distribution
1198	TCCR	Transparent, clear, consistent, and reasonable
1199	TCA	Trichloroacetic acid
1200	TCE	Trichloroethylene
1201	TCOH	Trichloroethanol
1202	TCOG	Trichloroethanol, gluuronide conjugate
1203	TNSSS	Targeted National Sewage Sludge Survey
1204	TLV	Threshold Limit Value
1205	TRI	Toxics Release Inventory
1206	TSCA	Toxic Substances Control Act
1207	TWA	Time Weighted Average
1208	UIC	Underground Injection Control
1209	U.S.	United States
1210	UV	Ultraviolet
1211	USGS	United States Geological Survey
1212	VOC	Volatile Organic Compound
1213	VP	Vapor Pressure
1214	Yr	Year(s)
1215		

EXECUTIVE SUMMARY

This Risk Evaluation for trichloroethylene was performed in accordance with the Frank R. Lautenberg Chemical Safety for the 21st Century Act. The Frank R. Lautenberg Chemical Safety for the 21st Century Act amended the Toxic Substances Control Act (TSCA), the Nation’s primary chemicals management law, in June 2016. Under the amended statute, EPA is required, under TSCA Section 6(b), to conduct Risk Evaluations to determine whether a chemical substance presents unreasonable risk of injury to health or the environment, under the conditions of use, without consideration of costs or other non-risk factors, including an unreasonable risk to potentially exposed or susceptible subpopulations, identified as relevant to the Risk Evaluation. Also, as required by TSCA Section (6)(b), EPA established, by rule, a process to conduct these Risk Evaluations: [Procedures for Chemical Risk Evaluation Under the Amended Toxic Substances Control Act \(82 FR 33726\)](#), the “Risk Evaluation Rule.” This Risk Evaluation is in conformance with TSCA Section 6(b), and the Risk Evaluation Rule, and is to be used to inform risk management decisions under TSCA. In accordance with TSCA Section 6(b), if EPA finds unreasonable risk from a chemical substance under its conditions of use in any final Risk Evaluation, the Agency will propose actions to address those risks within the timeframe required by TSCA. However, any proposed or final determination that a chemical substance presents unreasonable risk under TSCA Section 6(b) is not the same as a finding that a chemical substance is “imminently hazardous” under TSCA Section 7. The conclusions, findings, and determinations in this final Risk Evaluation are for the purpose of identifying whether the chemical substance presents unreasonable risk or no unreasonable risk under the conditions of use, in accordance with TSCA Section 6, and are not intended to represent any findings under TSCA Section 7.

TSCA Section 26(h) and (i) require EPA to use scientific information, technical procedures, measures, methods, protocols, methodologies and models consistent with the best available science and to base its decisions on the weight of the scientific evidence (also referred to as WOE).¹ To meet these TSCA Section 26 science standards, EPA used the TSCA systematic review process described in the *Application of Systematic Review in TSCA Risk Evaluations* document ([U.S. EPA, 2018b](#)). The data collection, evaluation, and integration stages of the systematic review process are used to develop the exposure, fate, and hazard assessments for Risk Evaluations under TSCA.

Trichloroethylene has a wide-range of uses in consumer and commercial products and in industry. An estimated 83.6% of TCE’s annual production volume is used as an intermediate in the manufacture of the hydrofluorocarbon, HFC-134a, an alternative to the refrigerant chlorofluorocarbon, CFC-12. Another 14.7% of TCE production volume is used as a degreasing solvent, leaving approximately 1.7% for other uses. The total aggregate production volume decreased from 220.5 to 171.9 million pounds between 2012 and 2015.

EPA evaluated TCE’s occupational conditions of use (COUs), including the following categories: manufacture; import; processing as a reactant/intermediate; incorporation into formulation; mixture or reaction product; incorporated into articles; repackaging; recycling; distribution; solvents for cleaning and degreasing; lubricants and greases; adhesives and sealants; functional fluids in a closed system; paints and coatings; cleaning and furniture care products; laundry and dishwashing products; arts, crafts

¹ Weight of the scientific evidence means a systematic review method, applied in a manner suited to the nature of the evidence or decision, that uses a pre-established protocol to comprehensively, objectively, transparently, and consistently identify and evaluate each stream of evidence, including strengths, limitations, and relevance of each study and to integrate evidence as necessary and appropriate based upon strengths, limitations, and relevance.

1259 and hobby materials; corrosion inhibitors and anti-scaling agents; processing aids; ink, toner, and
1260 colorant products; automotive care products; apparel and footwear care products; other uses; and
1261 disposal. Consumer COU categories are the following: solvents for cleaning and degreasing; lubricants
1262 and greases; adhesives and sealants; cleaning and furniture care products; arts, crafts, and hobby
1263 materials; apparel and footwear care products; and other consumer uses. Consistent with the decision at
1264 the Problem Formulation stage ([U.S. EPA, 2018d](#)), EPA has excluded consumer uses of paint and
1265 coatings from the scope of the evaluation. Trichloroethylene is subject to federal and state regulations
1266 and reporting requirements. Trichloroethylene has been a reportable Toxics Release Inventory (TRI)
1267 chemical under Section 313 of the Emergency Planning and Community Right-to-Know Act (EPCRA)
1268 since 1987. It is designated as a Hazardous Air Pollutant (HAP) under the Clean Air Act (CAA), is a
1269 hazardous substance under the Comprehensive Environmental Response, Compensation and Liability
1270 Act (CERCLA), and is regulated as a hazardous waste under the Resource Conservation and Recovery
1271 Act (RCRA). It is subject to National Primary Drinking Water Regulations (NPDWR) under the Safe
1272 Drinking Water Act (SDWA) and designated as a toxic pollutant under the Clean Water Act (CWA) and
1273 as such is subject to effluent limitations. Under TSCA, EPA previously assessed risks from use of
1274 trichloroethylene in commercial solvent degreasing (aerosol and vapor), consumer use as a spray applied
1275 protective coating for arts and crafts and commercial use as a spot remover at dry cleaning facilities
1276 ([U.S. EPA, 2014b](#)). In this final Risk Evaluation, EPA evaluated the following categories of conditions
1277 of use: manufacturing, processing, distribution in commerce, industrial, commercial and consumer uses
1278 and disposal.²

1279
1280 *Approach*

1281 EPA used reasonably available information (defined in 40 CFR 702.33 in part as “information that
1282 EPA possesses, or can reasonably obtain and synthesize for use in Risk Evaluations, considering the
1283 deadlines . . . for completing the evaluation . . .”), in a fit-for-purpose approach, to develop a Risk
1284 Evaluation that relies on the best available science and is based on the weight of the scientific
1285 evidence. EPA used previous assessments, for example EPA’s IRIS assessment, as a starting point for
1286 identifying key and supporting studies to inform the exposure, fate, and hazard assessments. EPA also
1287 evaluated other studies published since the publication of previous analyses. EPA reviewed the
1288 reasonably available information and evaluated the quality of the methods and reporting of results of
1289 the individual studies using the evaluation strategies described in *Application of Systematic Review in*
1290 *TSCA Risk Evaluations* ([U.S. EPA, 2018b](#)). To satisfy requirements in TSCA section 26(j)(4) and 40
1291 CFR 702.51(e), EPA has provided a list of studies considered in carrying out the Risk Evaluation and
1292 the results of those studies in several supplemental files (Appendix B).

1293
1294 In the Problem Formulation ([U.S. EPA, 2018d](#)), EPA identified the conditions of use within the scope
1295 of the Risk Evaluation and presented three conceptual models and an analysis plan. These have been
1296 carried into the final Risk Evaluation where EPA has evaluated the risk to the environment and human
1297 health, using both monitoring data and modeling approaches, for the conditions of use (identified in
1298 Section 1.4.1 of this Risk Evaluation).³ EPA quantitatively evaluated the risk to aquatic species from

² Although EPA has identified both industrial and commercial uses here, for purposes of distinguishing scenarios in this analysis, the Agency interprets the authority over “any manner or method of commercial use” under TSCA section 6(a)(5) to reach both.

³ EPA did not identify any “legacy uses” (i.e., circumstances associated with activities that do not reflect ongoing or prospective manufacturing, processing, or distribution) or “associated disposal” (i.e., future disposal from legacy uses) of TCE, as those terms are described in EPA’s Risk Evaluation Rule, 82 FR 33726, 33729 (July 20, 2017). Therefore, no such uses or disposals were added to the scope of the Risk Evaluation for TCE following the issuance of the opinion in *Safer Chemicals, Healthy Families v. EPA*, 943 F.3d 397 (9th Cir. 2019). EPA did not evaluate “legacy disposal” (i.e., disposals

1299 exposure to surface water as a result of the manufacturing, processing, use, or disposal of
1300 trichloroethylene. EPA evaluated the risk to workers from inhalation and dermal exposures, and
1301 occupational non-users (ONUs)⁴ from inhalation exposures, by comparing the estimated exposures to
1302 acute and chronic human health hazards (*i.e.*, liver effects, kidney effects, neurological effects,
1303 immunological effects, reproductive effects, developmental effects, and acute overt toxicity). EPA also
1304 evaluated the risk to consumers from inhalation and dermal exposures, and bystanders from inhalation
1305 exposures, by comparing the estimated exposures to acute human health hazards (*i.e.*, immunological
1306 effects and developmental effects).

1307
1308 In this final Risk Evaluation, consistent with the analysis plan from the Problem Formulation, EPA
1309 conducted quantitative analyses for exposure pathways to aquatic organisms via surface water;
1310 sediment-dwelling organisms via sediment; workers and ONUs from industrial/commercial activities;
1311 consumers and bystanders from consumer activities; and workers and ONUs from waste handling,
1312 treatment, and disposal. During Problem Formulation, EPA conducted a qualitative screening-level
1313 analysis for other exposure pathways that were within the scope of the Risk Evaluation, including
1314 exposures to terrestrial and aquatic organisms exposed via soil, and land-applied biosolid pathways and
1315 exposures to terrestrial organisms exposed via surface water. EPA excluded ambient air, drinking water,
1316 land disposal, ambient water, and waste incineration pathways leading to exposures to the general
1317 population and terrestrial organisms from Risk Evaluation since those pathways are under the
1318 jurisdiction of other environmental statutes administered by EPA.

1319
1320 EPA reviewed the environmental hazard data using the data quality review evaluation metrics and the
1321 rating criteria described in the *Application of Systematic Review in TSCA Risk Evaluations* ([U.S. EPA, 2018b](#)). As stated in Section 3.1, the reasonably available environmental hazard data indicate that TCE
1322 presents hazard to aquatic organisms. For acute exposures, aquatic invertebrates are the most sensitive
1323 species with toxicity values ranging from 7.8 mg/L to 33.85 mg/L. For chronic exposures, toxicity
1324 values for fish and aquatic invertebrates are as low as 7.88 mg/L and 9.2 mg/L, respectively. The data
1325 also indicated that TCE presents hazard for aquatic plants, with toxicity values in algae as low as 0.03
1326 mg/L, and a wide range in toxicity between algae species. Algae are cellular organisms which will cycle
1327 through several generations in hours to days; therefore, the data for algae was assessed together
1328 regardless of duration rather than being categorized as acute or chronic. TCE is not expected to
1329 accumulate in aquatic organisms.

1330
1331
1332 EPA evaluated exposures to trichloroethylene in occupational and consumer settings for the conditions
1333 of use included in the scope of the Risk Evaluation, listed in Section 1.4 (Scope of the Evaluation). In
1334 occupational settings, EPA evaluated acute and chronic inhalation exposures to workers and ONUs, and
1335 acute and chronic dermal exposures to workers. EPA used inhalation monitoring data from literature
1336 sources that met data evaluation criteria, where reasonably available. EPA also used modeling
1337 approaches, where reasonably available, to estimate potential inhalation exposures. Dermal doses for
1338 workers were estimated in occupational exposure scenarios since dermal monitoring data were not
1339 reasonably available. In consumer settings, EPA evaluated acute inhalation exposures to both consumers
1340 and bystanders, and acute dermal exposures to consumers. Inhalation exposures and dermal doses for
1341 consumers and bystanders in these scenarios were estimated since inhalation and dermal monitoring data
1342 were not reasonably available. These analyses are described in Section 2.3 of this Risk Evaluation.

that have already occurred) in the Risk Evaluation, because legacy disposal is not a “condition of use” under *Safer Chemicals*, 943 F.3d 397.

⁴ ONUs are workers who do not directly handle trichloroethylene but perform work in an area where trichloroethylene is present.

1343
1344 EPA evaluated reasonably available information for human health hazards and identified hazard
1345 endpoints including acute and chronic toxicity for non-cancer effects and cancer, as described in Section
1346 3.2. EPA used the *Framework for Human Health Risk Assessment to Inform Decision Making* ([U.S.
1347 EPA, 2014a](#)) to evaluate, extract, and integrate trichloroethylene’s human health hazard and dose-
1348 response information. EPA reviewed key and supporting information from previous hazard assessments
1349 [[TSCA Work Plan Chemical Risk Assessment Trichloroethylene: Degreasing, Spot Cleaning and Arts &
1350 Crafts Use](#) ([U.S. EPA, 2014b](#)), [Toxicological Review of Trichloroethylene](#) ([U.S. EPA, 2011e](#)), and other
1351 national and international assessments listed in Table 1-2], however all data sources from prior
1352 assessments were independently reviewed for this Risk Evaluation. EPA also screened and evaluated
1353 relevant studies that were published since these reviews (*i.e.*, from 2010 – 2017, in addition to select
1354 studies published after completion of the literature search). Selected key and supporting studies from
1355 these prior assessments [*List of Key and Supporting Studies for Human Health Hazard. Docket #* [EPA-
1356 HQ-OPPT-2019-0500](#)] were considered together with newer literature for characterization of human
1357 health hazard.

1358
1359 EPA developed a hazard and dose-response analysis using endpoints observed in inhalation and oral
1360 hazard studies, evaluated the weight of the scientific evidence considering EPA and National Research
1361 Council (NRC) risk assessment guidance, and selected the points of departure (POD) for acute, chronic
1362 and non-cancer endpoints, and inhalation unit risk (IUR) and oral slope factors (OSF) for cancer risk
1363 estimates. Health hazards of TCE described and reviewed in this Risk Evaluation include: acute overt
1364 toxicity, liver toxicity, kidney toxicity, neurotoxicity, immunotoxicity (including sensitization),
1365 reproductive toxicity, developmental toxicity, and cancer. Following dose-response analysis,
1366 representative PODs were identified for multiple non-cancer endpoints within the domains of liver
1367 toxicity, kidney toxicity, neurotoxicity, immunotoxicity, reproductive toxicity, and developmental
1368 toxicity. From among these PODs, acute immunosuppression and chronic autoimmunity were identified
1369 as the best overall endpoints for establishing risk conclusions under TSCA in Section 4.5.2. While some
1370 other endpoints present lower PODs (developmental neurotoxicity from [Fredriksson et al., 1993](#);
1371 congenital heart malformations from [Johnson et al., 2003](#)), there is lower confidence in the dose-
1372 response and extrapolation of results from those studies (Section 3.2.6.1.1) resulting in increased
1373 uncertainty surrounding the precision of the derived PODs for those endpoints. Therefore, EPA
1374 concluded that acute immunosuppression and chronic autoimmunity were the best overall non-cancer
1375 endpoints for use in Risk Evaluation under TSCA, based on the best available science and weight of the
1376 scientific evidence. The selection of these endpoints for use in risk conclusions was supported by the
1377 SACC peer review panel (<https://www.regulations.gov/document?D=EPA-HQ-OPPT-2019-0500-0111>).

1378
1379 For cancer, EPA performed meta-analyses in order to statistically evaluate the epidemiological data for
1380 non-Hodgkin Lymphoma (NHL), kidney cancer, and liver cancer. EPA utilized similar methodology as
1381 was employed in the 2011 EPA TCE IRIS Assessment ([U.S. EPA, 2011e](#)) and included sensitivity
1382 analyses, as needed, to partition the results based on both heterogeneity and study quality. See Appendix
1383 J for full details and results. The 2019 meta-analysis of all relevant studies examining kidney cancer,
1384 liver cancer, or NHL (Appendix J) concluded that there is a statistical significant association between
1385 TCE exposure and increased incidence of all three cancers. In accordance with EPA Guidelines for
1386 Carcinogen Risk Assessment ([U.S. EPA, 2005](#)), EPA determined that TCE is “Carcinogenic to
1387 Humans.” For context, this was the same conclusion as the previous EPA meta-analysis in the 2011 IRIS
1388 Assessment ([U.S. EPA, 2011e](#)), which evaluated older literature than the current assessment. Therefore,
1389 EPA utilized the same inhalation unit risk and oral slope factor estimates as were derived in ([U.S. EPA,
1390 2011e](#)) and cited in the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)). A linear

1391 non-threshold assumption was applied to the TCE cancer dose-response analysis because there is
1392 sufficient evidence that TCE-induced kidney cancer likely operates primarily through a mutagenic mode
1393 of action while it cannot be ruled out for the other two cancer types and positive associations were
1394 observed via meta-analysis for all three cancers in epidemiological studies based on low-level,
1395 environmental exposure levels.

1396
1397 Risk Characterization

1398 Environmental Risk: For environmental risk, EPA utilized a risk quotient (RQ) to compare the
1399 environmental concentration to the effect level to characterize the risk to aquatic and sediment-dwelling
1400 organisms. EPA included a qualitative assessment describing trichloroethylene exposure from land-
1401 applied biosolids and soil for terrestrial organisms. Trichloroethylene is not expected to accumulate in
1402 sediments, and is expected to be mobile in soil, and migrate to water or volatilize to air. The results of
1403 the risk characterization are in Section 4.1, including two tables (Table 4-1 and Table 4-4) that
1404 summarize the RQs for acute and chronic risks. Surface water concentrations of TCE were modeled for
1405 214 releases.

1406
1407 EPA identified the expected environmental exposures for aquatic species and sediment-dwelling
1408 species under the conditions of use in the scope of the Risk Evaluation. Estimated releases from
1409 specific facilities result in modeled surface water concentrations that exceed the aquatic benchmark
1410 ($RQ \geq 1$) for either acute, chronic, and/ or algae concentrations of concern (COC) for the following
1411 conditions of use in various locations (see Table 4-1 and Table 4-4): processing as a reactant; open top
1412 vapor degreasing; repackaging; adhesives; sealants; paints and coatings; industrial processing aid;
1413 other industrial uses; other commercial uses; process solvent recycling and worker handling of wastes;
1414 and waste water treatment plants. Details of these estimates are in Section 4.1.2 and 4.1.3.

1415
1416 Qualitative consideration of the physical-chemical and fate characteristics, as well as consideration of
1417 the conditions of use for TCE indicated limited presence in terrestrial environments (Section 4.1.4).
1418 Therefore EPA did not find risks for terrestrial organisms.

1419
1420 Human Health Risks: Risks were estimated following both acute and chronic exposure for the most
1421 sensitive and robust endpoints from every hazard domain.

1422
1423 For workers and ONUs, EPA estimated potential cancer risk from chronic exposures to
1424 trichloroethylene using inhalation unit risk or dermal cancer slope factor values multiplied by the
1425 chronic exposure for each COU. For workers and ONUs, EPA also estimated potential non-cancer
1426 risks resulting from acute and chronic inhalation and dermal exposures using a Margin of Exposure
1427 (MOE) approach. For workers, EPA estimated risks using several occupational exposure scenarios,
1428 with scenario-specific assumptions regarding the expected use of personal protective equipment (PPE)
1429 for respiratory and dermal exposures for workers directly handling trichloroethylene (Table 4-9). More
1430 information on respiratory and dermal protection, including EPA's approach regarding the
1431 occupational exposure scenarios for trichloroethylene, is in Section 2.3.1.

1432
1433 For the majority of exposure scenarios, risks to workers were identified for multiple endpoints in both
1434 acute and chronic exposure scenarios. Based on the most robust and sensitive acute and chronic
1435 endpoints from each hazard domain, acute and chronic non-cancer and cancer risks were indicated for

1436 all exposure scenarios and occupational conditions of use under high-end⁵ inhalation exposure levels.
1437 Non-cancer risks following chronic exposure were also identified for all exposure scenarios at high-end
1438 exposure levels with expected use of respiratory protection up to Assigned Protection Factor (APF) =
1439 50. When only considering the central tendency⁶ inhalation exposure level, risks were not identified for
1440 three out of 18 occupational exposure scenarios. Acute and chronic non-cancer and cancer risks were
1441 indicated for all exposure scenarios and occupational conditions of use under both high-end and central
1442 tendency dermal exposure levels. Risks are still identified for all exposure scenarios (at high-end
1443 exposure levels following acute exposure and at both exposure levels following chronic exposure) when
1444 gloves are worn even when assuming the maximum applicable glove protection factor (either PF 10 or
1445 20).

1446
1447 ONUs are expected to have lower exposure levels than workers in most instances but exposures could
1448 not always be quantified based on reasonably available data and risk estimates for ONUs may be similar
1449 to workers in some settings. Therefore, for those instances where monitoring data or modeling did not
1450 distinguish between worker and far-field ONU inhalation exposure estimates, EPA considered the
1451 worker exposure and risk estimates when determining far-field ONU risk. There is significant
1452 uncertainty in these ONU inhalation risk estimates. While the difference between the exposures of
1453 ONUs and the exposures of workers directly handling TCE generally cannot be quantified, ONU
1454 inhalation exposures are expected to be lower than inhalation exposures for workers directly handling
1455 the chemical. In these instances, EPA considered the ONU exposures to be equal to the central tendency
1456 risk estimates for workers when determining ONU risk attributable to inhalation. While this is likely
1457 health protective as it assumes ONU exposure is as high as it is for the majority of workers (greater
1458 numbers are likely to be exposed near the middle of the distribution), this is uncertain. Dermal exposures
1459 are not expected because ONUs do not typically directly handle TCE, nor are they in the immediate
1460 proximity of TCE.

1461
1462 Based on central-tendency exposure levels, acute and chronic non-cancer risks to ONUs were indicated
1463 for the majority of exposure scenarios. ONUs are not assumed to be using PPE to reduce exposures to
1464 trichloroethylene used in their vicinity. ONUs are not expected to be dermally exposed to
1465 trichloroethylene and therefore dermal risks to ONUs were not assessed. EPA's estimates for ONU risks
1466 for each occupational exposure scenario are presented alongside worker risk estimates in Section 4.2.2
1467 and Table 4-59 in Section 4.5.2.1.

1468
1469 For consumers and bystanders for consumer use, EPA estimated non-cancer risks resulting from acute
1470 inhalation or dermal exposures (applicable to consumers only) that were modeled with a range of user
1471 intensities, described in detail in Section 2.3.2. Bystanders are assumed to not have direct dermal
1472 contact with TCE. Based on reasonably available information, EPA determined that consumers or
1473 bystanders would not use PPE and that all exposures would be acute, rather than chronic (Section
1474 2.3.2.2).

1475
1476 For consumers, risks were identified for multiple acute endpoints at multiple user intensity levels for

⁵ A high-end is assumed to be representative of occupational exposures that occur at probabilities above the 90th percentile but below the exposure of the individual with the highest exposure. EPA provided results at the 95th percentile when available.

⁶ A central tendency is assumed to be representative of occupational exposures in the center of the distribution for a given condition of use. For Risk Evaluation, EPA used the 50th percentile (median), mean (arithmetic or geometric), mode, or midpoint values of a distribution as representative of the central tendency scenario.

1477 all consumer conditions of use except Pepper Spray, which did not indicate risk for the best overall
1478 acute endpoint (immunosuppression). Acute risks were also indicated for most conditions of use for
1479 bystanders at both medium and high-intensity acute inhalation levels. EPA’s estimates for consumer
1480 and bystander risks for each consumer use exposure scenario are presented in Section 4.2.3 and
1481 summarized in Table 4-60 in Section 4.5.2.2.
1482

1483 Uncertainties: Key assumptions and uncertainties in the environmental risk estimation include
1484 uncertainties regarding the hazard data for aquatic and sediment-dwelling species and surface water
1485 concentrations. Additionally the reasonably available environmental monitoring data were limited
1486 temporally and geographically.
1487

1488 For the human health risk estimation, key assumptions and uncertainties are related to data on
1489 exposures, exposure model input parameters, and the estimates for ONU inhalation exposures for COUs
1490 in which monitoring data or probabilistic modeling data were not reasonably available. Additional
1491 sources of uncertainty related to human health hazard include selection of the appropriate
1492 Physiologically-Based Pharmacokinetic (PBPK) dose-metric for each endpoint, the dose-response and
1493 POD derivation for the congenital heart defects ([Johnson et al., 2003](#)) and developmental neurotoxicity
1494 ([Fredriksson et al., 1993](#)) endpoints, and the adjustment of the cancer PODs to account for cancer at
1495 multiple sites. Assumptions and key sources of uncertainty in the risk characterization are detailed in
1496 Section 4.3.
1497

1498 EPA’s assessments, risk estimations, and risk determinations accounted for uncertainties throughout the
1499 Risk Evaluation. EPA used reasonably available information, in a fit-for-purpose approach, to develop a
1500 Risk Evaluation that relies on the best available science and is based on the weight of the scientific
1501 evidence. For instance, systematic review was conducted to identify reasonably available information
1502 related to TCE hazards and exposures. If no applicable monitoring data were identified, exposure
1503 scenarios were assessed using a modeling approach that requires the input of various chemical
1504 parameters and exposure factors. When possible, default model input parameters were modified based
1505 on chemical-specific inputs available in literature databases. The consideration of uncertainties supports
1506 the Agency’s risk determinations, each of which is supported by substantial evidence, as set forth in
1507 detail in later sections of this final Risk Evaluation.
1508

1509 Potentially Exposed or Susceptible Subpopulations (PESS): TSCA Section 6(b)(4) requires that EPA
1510 conduct a Risk Evaluation to “*determine whether a chemical substance presents an unreasonable risk of*
1511 *injury to health or the environment, without consideration of cost or other non-risk factors, including an*
1512 *unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant to the Risk*
1513 *Evaluation by the Administrator, under the conditions of use.*” TSCA Section 3(12) states that “*the term*
1514 *‘potentially exposed or susceptible subpopulation’ means a group of individuals within the general*
1515 *population identified by the Administrator who, due to either greater susceptibility or greater exposure,*
1516 *may be at greater risk than the general population of adverse health effects from exposure to a chemical*
1517 *substance or mixture, such as infants, children, pregnant women, workers, or the elderly.*”
1518

1519 In developing the Risk Evaluation, EPA analyzed the reasonably available information to ascertain
1520 whether some human receptor groups may have greater exposure or greater susceptibility than the
1521 general population to the hazard posed by a chemical. For consideration of the potentially exposed
1522 groups, EPA considered trichloroethylene exposures to be higher among workers and consumer users
1523 using trichloroethylene along with ONUs and consumer bystanders in the vicinity of trichloroethylene
1524 use compared to general population (Section 2.3.3). Risk estimates were also provided separately for
1525 ONUs when sufficient data were reasonably available. EPA was unable to provide separate risk

1526 estimates when insufficient information was reasonably available for quantifying ONU exposure. EPA
1527 considered the central tendency risk estimate when determining ONU risk for those conditions of use for
1528 which ONU exposures were not separately estimated. Consumer risk estimates were provided for low,
1529 medium, and high intensities of use, accounting for differences in duration, weight fraction, and mass
1530 used. Dermal risk estimates were calculated for both average adult workers and women of childbearing
1531 age. See additional discussions in Section 4.4.1. EPA's determinations for unreasonable risk are based
1532 on high-end exposure estimates for workers and high intensity use scenarios for consumers and
1533 bystanders in order to capture individuals who are PESS.
1534

1535 Factors affecting susceptibility examined in the available studies on TCE include lifestage, sex, genetic
1536 polymorphisms, race/ethnicity, preexisting health status, lifestyle factors, and nutrition status. Groups of
1537 individuals for which one or several of these factors apply may be considered PESS (Section 3.2.5.2).
1538 Additionally, based on the hazards identified from the available information, individuals that either have
1539 or are susceptible to kidney, liver, neurological, reproductive, or cancer health conditions are PESS. The
1540 use of the 99th percentile Human Equivalent Concentration/Dose (HEC/HED)₉₉ POD values derived
1541 from relevant (PBPK) dose metrics also account for the vast majority of toxicokinetic variation across
1542 the population. By relying on the 99th percentile output of the PBPK model, these values are expected to
1543 be protective of particularly susceptible subpopulations, including those with genetic polymorphisms
1544 resulting in increased activity of bioactivating enzymes. While there may not be a risk for all endpoints
1545 to all individuals or to an individual at all times, assessment of risks for all relevant endpoints using
1546 toxicokinetic values for the most sensitive 1% of the population is expected to sufficiently cover any
1547 particularly susceptible subpopulations. Inclusion of risk estimates for cardiac malformations accounts
1548 for susceptible mothers ([Jenkins et al., 2007](#)) and their offspring in addition to PESS groups with other
1549 susceptibilities including metabolic sensitivity due to increased enzymatic activity of cytochrome P450
1550 2E1 (CYP2E1) ([Cichocki et al. 2016](#); [U.S. EPA, 2011e](#)).
1551

1552 Aggregate and Sentinel Exposures: Section 2605(b)(4)(F)(ii) of TSCA requires the EPA, as a part of the
1553 Risk Evaluation, to describe whether aggregate or sentinel exposures under the conditions of use were
1554 considered and the basis for their consideration. The EPA has defined aggregate exposure as “*the*
1555 *combined exposures to an individual from a single chemical substance across multiple routes and*
1556 *across multiple pathways* (40 CFR Section 702.33).” Exposures to trichloroethylene were evaluated by
1557 inhalation and dermal routes separately. Inhalation and dermal exposures are assumed to occur
1558 simultaneously for workers and consumers. EPA chose not to employ simple additivity of exposure
1559 pathways at this time within a condition of use because of the uncertainties present in the current
1560 exposure estimation procedures. Without a PBPK model containing a dermal compartment to account
1561 for toxicokinetic processes the true internal dose for any given exposure cannot be determined, and
1562 aggregating exposures by simply adding exposures from multiple routes could inappropriately
1563 overestimate total exposure. Conversely, not aggregating exposures in any manner may potentially
1564 underestimate total exposure for a given individual.
1565

1566 The EPA defines sentinel exposure as “*the exposure to a single chemical substance that represents the*
1567 *plausible upper bound of exposure relative to all other exposures within a broad category of similar or*
1568 *related exposures* (40 CFR Section 702.33).” In this Risk Evaluation, the EPA considered sentinel
1569 exposure the highest exposure given the details of the conditions of use and the potential exposure
1570 scenarios. Sentinel exposures for workers are the high-end no PPE within each OES. EPA considered
1571 sentinel exposures in this Risk Evaluation by considering risks to populations who may have upper
1572 bound (*e.g.*, high-end, high intensities of use) exposures. In cases where sentinel exposures result in
1573 MOEs greater than the benchmark or cancer risk lower than the benchmark (*i.e.*, risks were not

1574 identified), EPA did no further analysis because sentinel exposures represent the worst-case scenario.
1575 EPA's decision for unreasonable risk are based on high-end exposure estimates to capture individuals
1576 with sentinel exposure.

1577
1578 Additional details on how aggregate and sentinel exposures were considered in this Risk Evaluation are
1579 provided in Section 4.4.2.

1580
1581 Unreasonable Risk Determination

1582 In each Risk Evaluation under TSCA Section 6(b), EPA determines whether a chemical substance
1583 presents an unreasonable risk of injury to health or the environment, under the conditions of use. The
1584 determination does not consider costs or other non-risk factors. In making this determination, EPA
1585 considers relevant risk-related factors, including, but not limited to: the effects of the chemical substance
1586 on health and human exposure to such substance under the conditions of use (including cancer and non-
1587 cancer risks); the effects of the chemical substance on the environment and environmental exposure
1588 under the conditions of use; the population exposed (including any potentially exposed or susceptible
1589 subpopulations, as determined by EPA); the severity of hazard (including the nature of the hazard, the
1590 irreversibility of the hazard); and uncertainties. EPA also takes into consideration the Agency's
1591 confidence in the data used in the risk estimate. This includes an evaluation of the strengths, limitations,
1592 and uncertainties associated with the information used to inform the risk estimate and the risk
1593 characterization. The rationale for the risk determination is discussed in Section 5.2. The Agency's risk
1594 determinations are supported by substantial evidence, as set forth in detail in later sections of this final
1595 Risk Evaluation.

1596
1597 Unreasonable Risk of Injury to the Environment: EPA used a screening-level approach to integrate relevant
1598 pathways of environmental exposure with available environmental hazard data to evaluate unreasonable risk to
1599 relevant environmental receptors. EPA assessed environmental exposures derived from predicted and measured
1600 concentrations of TCE in surface water in the U.S. Specifically, the aquatic exposures associated with the
1601 industrial and commercial conditions of use were predicted through modeling, and the aquatic exposure
1602 assessment also includes an analysis of collected measured surface water concentrations from monitoring data.
1603 EPA considered the biological relevance of the species to determine the concentrations of concern for the
1604 location of surface water concentration data to produce risk quotients, as well as frequency and duration of the
1605 exposure. EPA determined that the evaluation does not support an unreasonable risk determination to aquatic
1606 organisms. For sediment-dwelling invertebrates, the toxicity of TCE is similar to the toxicity to aquatic
1607 invertebrates. Therefore, for sediment dwelling organisms the risk estimates, based on the highest ambient
1608 surface water concentration, do not support an unreasonable risk determination to sediment-dwelling organisms
1609 from acute or chronic exposures. TCE exposure to terrestrial organisms is expected to be low since physical-
1610 chemical properties do not support an exposure pathway through water and soil pathways to these organisms.
1611 The risk estimates, the environmental effects of TCE, the exposures, physical chemical properties of TCE, and
1612 consideration of uncertainties support EPA's determination that there is no unreasonable risk to the environment
1613 from all conditions of use of TCE.

1614
1615 Unreasonable Risks of Injury to Health: EPA's determination of unreasonable risk for specific
1616 conditions of use of TCE listed below are based on health risks to workers, occupational non-users,
1617 consumers, or bystanders from consumer use. TCE has a large database of human health toxicity data.
1618 For each hazard domain there are several endpoints, and often a single endpoint was examined by
1619 multiple studies. For acute exposures, EPA evaluated unreasonable risks of non-cancer effects
1620 (developmental toxicity and immunosuppression). For chronic exposures, EPA evaluated unreasonable

1621 risks of non-cancer effects (liver toxicity, kidney toxicity, neurotoxicity, autoimmunity, reproductive
1622 toxicity, and developmental toxicity) as well as cancer (liver, kidney, and non-Hodgkin Lymphoma).
1623 The drivers for EPA’s determination of unreasonable risk are non-cancer effects (immunosuppression)
1624 from acute inhalation and dermal exposures, non-cancer effects (autoimmunity) from chronic inhalation
1625 and dermal exposures, and cancer from chronic inhalation and dermal exposures.

1626
1627 Unreasonable Risk of Injury to Health of the General Population: General population exposures to TCE
1628 may occur from all conditions of use via releases to air, water or land. During the course of the Risk
1629 Evaluation process for TCE, OPPT worked closely with the offices within EPA that administer and
1630 implement regulatory programs under the Clean Air Act (CAA), the Safe Drinking Water Act (SDWA),
1631 the Clean Water Act (CWA), the Comprehensive Environmental Response, Compensation, and Liability
1632 Act (CERCLA), and the Resource Conservation and Recovery Act (RCRA)). Through intra-agency
1633 coordination, EPA found exposures to the general population via surface water, drinking water, ambient
1634 air and sediment pathways are covered under the jurisdiction of other environmental statutes,
1635 administered by EPA, *i.e.*, CAA, SDWA, CWA, CERCLA, and RCRA. As explained in more detail in
1636 Section 1.4.2, EPA believes it is both reasonable and prudent to tailor TSCA Risk Evaluations when
1637 other EPA offices have expertise and experience to address specific environmental media, rather than
1638 attempt to evaluate and regulate potential exposures and risks from those media under TSCA. EPA
1639 believes that coordinated action on exposure pathways and risks addressed by other EPA-administered
1640 statutes and regulatory programs is consistent with the statutory text and legislative history, particularly
1641 as they pertain to TSCA’s function as a “gap-filling” statute, and also furthers EPA aims to efficiently
1642 use Agency resources, avoid duplicating efforts taken pursuant to other Agency programs, and meet the
1643 statutory deadlines for completing Risk Evaluations. EPA has therefore tailored the scope of the Risk
1644 Evaluations for TCE using authorities in TSCA sections 6(b) and 9(b)(1). EPA did not evaluate risk to
1645 the general population from ambient air, water and disposal and pathways for any condition of use, and
1646 the unreasonable risk determinations do not account for exposures to the general population.

1647
1648 Unreasonable Risk of Injury to Health of Workers: EPA evaluated non-cancer effects from acute and
1649 chronic inhalation and dermal occupational exposures and cancer from chronic inhalation and dermal
1650 occupational exposures to determine if there was unreasonable risk of injury to workers’ health. The
1651 drivers for EPA’s determination of unreasonable risk for workers are non-cancer effects from acute
1652 (immunosuppression) and chronic (autoimmunity) inhalation and dermal exposures, and cancer from
1653 chronic inhalation and dermal exposures.

1654
1655 EPA generally assumes compliance with OSHA requirements for protection of workers including the
1656 implementation of the hierarchy of controls. In support of this assumption, EPA used reasonably
1657 available information indicating that some employers, particularly in the industrial setting, are providing
1658 appropriate engineering, administrative controls, or PPE to their employees consistent with OSHA
1659 requirements. EPA does not have reasonable available information to support this assumption for each
1660 condition of use; however, EPA does not believe that the Agency must presume, in the absence of such
1661 information, a lack of compliance with existing regulatory programs and practices. Rather, EPA assumes
1662 there is compliance with worker protection standards unless case-specific facts indicate otherwise, and
1663 therefore existing OSHA regulations for worker protection and hazard communication will result in use
1664 of appropriate PPE in a manner that achieves the stated APF or PF. EPA’s decisions for unreasonable
1665 risk to workers are based on high-end exposure estimates, in order to account for the uncertainties
1666 related to whether or not workers are using PPE. Therefore, EPA’s approach for evaluating risk to
1667 workers and ONUs is to use the reasonably available information and professional judgement to

1668 construct exposure scenarios that reflect the workplace practices involved in the conditions of use of the
1669 chemicals and address uncertainties regarding availability and use of PPE.

1670
1671 For each condition of use of TCE with an identified risk for workers, EPA assumes, as a baseline, the
1672 use of a respirator with an APF of 10 to 50. Similarly, EPA assumes the use of gloves with PF of 10 to
1673 20. However, EPA assumes that for some conditions of use, the use of appropriate respirators is not a
1674 standard industry practice, based on best professional judgement given the burden associated with the
1675 use of respirators, including the expense of the equipment and the necessity of fit-testing and training for
1676 proper use. Similarly, EPA does not assume that it is a standard industry practice that workers in some
1677 small commercial facilities (*e.g.*, those performing spot cleaning, wipe cleaning, shoe polishing, or hoof
1678 polishing; commercial printing and copying) have a respiratory protection program or regularly employ
1679 dermal protection. Therefore, the use of respirators and gloves is unlikely for workers in these facilities.

1680
1681 The unreasonable risk determinations reflect other risk factors, such as the severity of the effects
1682 associated with the occupational exposures to TCE and incorporate consideration of the PPE that EPA
1683 assumes. A full description of EPA's unreasonable risk determination for each condition of use is in
1684 Section 5.2.

1685
1686 Unreasonable Risk of Injury to Health of Occupational Non-Users (ONUs): ONUs are workers who do
1687 not directly handle TCE but perform work in the area where TCE is present. EPA evaluated non-cancer
1688 effects to ONUs from acute and chronic inhalation occupational exposures and cancer from chronic
1689 inhalation occupational exposures to determine if there was unreasonable risk of injury to ONU's health.
1690 The unreasonable risk determinations reflect the severity of the effects associated with occupational
1691 exposures to TCE and the assumed absence of PPE for ONUs, since ONUs do not directly handle the
1692 chemical and are instead doing other tasks in the vicinity. Non-cancer effects and cancer from dermal
1693 occupational exposures to ONUs were not evaluated because ONUs are not dermally exposed to TCE.
1694 For inhalation exposures, when there was reasonably available information, EPA estimated ONUs'
1695 exposures and described the risks separately from workers directly exposed. When the difference
1696 between ONUs' exposures and workers' exposures cannot be quantified, EPA assumed that ONUs'
1697 inhalation exposures are lower than inhalation exposures for workers directly handling the chemical
1698 substance, and EPA considered the central tendency risk estimates when determining ONU risk. A full
1699 description of EPA's unreasonable risk determination for each condition of use is in Section 5.2.

1700
1701 Unreasonable Risk of Injury to Health of Consumers: EPA evaluated non-cancer effects to consumers
1702 from acute inhalation and dermal exposures to determine if there was unreasonable risk of injury to
1703 consumers' health. A full description of EPA's unreasonable risk determination for each condition of
1704 use is in Section 5.2.

1705
1706 Unreasonable Risk of Injury to Health of Bystanders (from Consumer Uses): EPA evaluated non-cancer
1707 effects to bystanders from acute inhalation exposures to determine if there was unreasonable risk of
1708 injury to bystanders' health. EPA did not evaluate non-cancer effects from dermal exposures to
1709 bystanders because bystanders are not dermally exposed to TCE. A full description of EPA's
1710 unreasonable risk determination for each condition of use is in Section 5.2.

1711
1712 Summary of Unreasonable Risk Determinations: In conducting Risk Evaluations, "EPA will determine
1713 whether the chemical substance presents an unreasonable risk of injury to health or the environment
1714 under each condition of use within the scope of the Risk Evaluation..." 40 CFR 702.47. Pursuant to
1715 TSCA section 6(i)(1), a determination of "no unreasonable risk" shall be issued by order and considered

1716 to be final agency action. Under EPA’s implementing regulations, “[a] determination by EPA that the
1717 chemical substance, under one or more of the conditions of use within the scope of the Risk Evaluation,
1718 does not present an unreasonable risk of injury to health or the environment will be issued by order and
1719 considered to be a final Agency action, effective on the date of issuance of the order.” 40 CFR
1720 702.49(d).

1721
1722 EPA has determined that the following conditions of use of TCE do not present an unreasonable risk of
1723 injury to health or the environment. These determinations are considered final agency action and are
1724 being issued by order pursuant to TSCA section 6(i)(1). The details of these determinations are in
1725 Section 5.2, and the TSCA section 6(i)(1) order is contained in Section 5.3.1 of this final Risk
1726 Evaluation.
1727

Conditions of Use that Do Not Present an Unreasonable Risk
<ul style="list-style-type: none">• Distribution in commerce• Consumer use in pepper spray

1728
1729 EPA has determined that the following conditions of use of TCE present an unreasonable risk of injury.
1730 EPA will initiate TSCA section 6(a) risk management actions on these conditions of use as required
1731 under TSCA section 6(c)(1). Pursuant to TSCA section 6(i)(2), the unreasonable risk determinations for
1732 these conditions of use are not considered final agency action. The details of these determinations are in
1733 Section 5.2
1734

Manufacturing that Presents an Unreasonable Risk
<ul style="list-style-type: none">• Manufacturing: domestic manufacture• Manufacturing: import

1735

Processing that Presents an Unreasonable Risk
<ul style="list-style-type: none">• Processing: processing as a reactant/intermediate• Processing: incorporation into a formulation, mixture or reaction product• Processing: incorporation into articles• Processing: repackaging• Processing: recycling

1736

Industrial and Commercial Uses that Present an Unreasonable Risk
<ul style="list-style-type: none">• Industrial and commercial use as a solvent for open-top batch vapor degreasing• Industrial and commercial use as a solvent for closed-loop batch vapor degreasing• Industrial and commercial use as a solvent for in-line conveyORIZED vapor degreasing• Industrial and commercial use as a solvent for in-line web cleaner vapor degreasing• Industrial and commercial use as a solvent for cold cleaning• Industrial and commercial use as a solvent for aerosol spray degreaser/cleaner and mold release

Industrial and Commercial Uses that Present an Unreasonable Risk

- Industrial and commercial use as a lubricant and grease in tap and die fluid
- Industrial and commercial use as a lubricant and grease in penetrating lubricant
- Industrial and commercial use as an adhesive and sealant in solvent-based adhesives and sealants; tire repair cement/sealer; mirror edge sealant
- Industrial and commercial use as a functional fluid in heat exchange fluid
- Industrial and commercial use in paints and coatings as a diluent in solvent-based paints and coatings
- Industrial and commercial use in cleaning and furniture care products in carpet cleaner and wipe cleaning
- Industrial and commercial use in laundry and dishwashing products in spot remover
- Industrial and commercial use in arts, crafts, and hobby materials in fixatives and finishing spray coatings
- Industrial and commercial use in corrosion inhibitors and anti-scaling agents.
- Industrial and commercial use as processing aids in process solvent used in battery manufacture; process solvent used in polymer fiber spinning, fluoroelastomer manufacture and Alcantara manufacture; extraction solvent used in caprolactam manufacture; precipitant used in beta-cyclodextrin manufacture
- Industrial and commercial use as ink, toner and colorant products in toner aid
- Industrial and commercial use in automotive care products in brake parts cleaner
- Industrial and commercial use in apparel and footwear care products in shoe polish
- Industrial and commercial use in hoof polish; gun scrubber; pepper spray; other miscellaneous industrial and commercial uses

1737

Consumer Uses that Present an Unreasonable Risk

- Consumer use as a solvent in brake and parts cleaner
- Consumer use as a solvent in aerosol electronic degreaser/cleaner
- Consumer use as a solvent in liquid electronic degreaser/cleaner
- Consumer use as a solvent in aerosol spray degreaser/cleaner
- Consumer use as a solvent in liquid degreaser/cleaner
- Consumer use as a solvent in aerosol gun scrubber
- Consumer use as a solvent in liquid gun scrubber
- Consumer use as a solvent in mold release
- Consumer use as a solvent in aerosol tire cleaner
- Consumer use as a solvent in liquid tire cleaner
- Consumer use as a lubricant and grease in tap and die fluid
- Consumer use as a lubricant and grease in penetrating lubricant
- Consumer use as an adhesive and sealant in solvent-based adhesives and sealants
- Consumer use as an adhesive and sealant in mirror edge sealant
- Consumer use as an adhesive and sealant in tire repair cement/sealer
- Consumer use as a cleaning and furniture care product in carpet cleaner

Consumer Uses that Present an Unreasonable Risk

- Consumer use as a cleaning and furniture care product in aerosol spot remover
- Consumer use as a cleaning and furniture care product in liquid spot remover
- Consumer use in arts, crafts, and hobby materials in fixative and finishing spray coatings
- Consumer use in apparel and footwear products in shoe polish
- Consumer use in fabric spray
- Consumer use in film cleaner
- Consumer use in hoof polish
- Consumer use in toner aid

1738

Disposal that Presents an Unreasonable Risk

- Disposal

1739

1 INTRODUCTION

This document represents the final Risk Evaluation for trichloroethylene (TCE) under the Frank R. Lautenberg Chemical Safety for the 21st Century Act which amended the Toxic Substances Control Act, the Nation's primary chemicals management law, in June 2016.

The Environmental Protection Agency (EPA) published the scope of the Risk Evaluation for TCE ([U.S. EPA, 2017i](#)) in June 2017, and the Problem Formulation in May, 2018 ([U.S. EPA, 2018d](#)), which represented the analytical phase of Risk Evaluation in which "the purpose for the assessment is articulated, the problem is defined, and a plan for analyzing and characterizing risk is determined" as described in Section 2.2 of the [Framework for Human Health Risk Assessment to Inform Decision Making](#). In this final Risk Evaluation, consistent with the analysis plan from the Problem Formulation, EPA conducted quantitative analyses for exposure pathways to aquatic organisms via surface water; sediment-dwelling organisms via sediment; workers and ONUs from industrial/commercial activities; consumers and bystanders from consumer activities; and workers and ONUs from waste handling, treatment, and disposal. During Problem Formulation, EPA conducted a qualitative screening-level analysis for other exposure pathways that were within the scope of the Risk Evaluation, including exposures to terrestrial and aquatic organisms exposed via soil, and land-applied biosolid pathways and exposures to terrestrial organisms exposed via surface water. EPA excluded ambient air, drinking water, land disposal, ambient water, and waste incineration pathways leading to exposures to the general population and terrestrial organisms from Risk Evaluation since those pathways are under the jurisdiction of other environmental statutes administered by EPA. The conclusions, findings, and determinations in this final Risk Evaluation are for the purpose of identifying whether the chemical substance presents unreasonable risk or no unreasonable risk under the conditions of use, in accordance with TSCA Section 6, and are not intended to represent any findings under TSCA Section 7.

As per EPA's final rule, [Procedures for Chemical Risk Evaluation Under the Amended Toxic Substances Control Act](#) (82 FR 33726 (July 20, 2017)), this Risk Evaluation was subject to both public comment and peer review, which are distinct but related processes. EPA provided 60 days for public comment on any and all aspects of this Risk Evaluation, including the submission of any additional information that might be relevant to the science underlying the Risk Evaluation and the outcome of the systematic review associated with trichloroethylene. This satisfies TSCA (15 U.S.C. 2605(b)(4)(H)), which requires EPA to provide public notice and an opportunity for comment on a draft Risk Evaluation prior to publishing a final Risk Evaluation.

Peer review was conducted in accordance with EPA's regulatory procedures for chemical Risk Evaluations, including using the [EPA Peer Review Handbook](#) and other methods consistent with the science standards laid out in Section 26 of TSCA (*See* 40 CFR 702.45). As explained in the [Risk Evaluation Rule](#) (82 FR 33726 (July 20, 2017)), the purpose of peer review is for the independent review of the science underlying the risk assessment. As such, peer review addressed aspects of the underlying science as outlined in the charge to the peer review panel such as hazard assessment, assessment of dose-response, exposure assessment, and risk characterization.

As EPA explained in the [Risk Evaluation Rule](#) (82 FR 33726 (July 20, 2017)), it is important for peer reviewers to consider how the underlying Risk Evaluation analyses fit together to produce an integrated risk characterization, which forms the basis of an unreasonable risk determination. EPA believed peer reviewers were most effective in this role if they received the benefit of public comments on draft Risk Evaluations prior to peer review. For this reason, and consistent with standard Agency practice, the

1786 public comment period preceded peer review. The final Risk Evaluation changed in response to public
1787 comments received on the draft Risk Evaluation and/or in response to peer review, which itself may be
1788 informed by public comments. EPA responded to public and peer review comments received on the
1789 draft Risk Evaluation and explained changes made in response to those comments in this final Risk
1790 Evaluation and the associated response to comments document.

1791 In this final Risk Evaluation, Section 1.1 presents the basic physical-chemical characteristics of
1792 trichloroethylene, as well as a background on regulatory history, conditions of use, and conceptual
1793 models, with particular emphasis on any changes since the publication of the draft Risk Evaluation. This
1794 section also includes a discussion of the systematic review process utilized in this final Risk Evaluation.
1795 Section 2 provides a discussion and analysis of the exposures, both health and environmental, that can
1796 be expected based on the conditions of use for trichloroethylene. Section 3 discusses environmental and
1797 health hazards of trichloroethylene. Section 4 presents the risk characterization, where EPA integrates
1798 and assesses reasonably available information on health and environmental hazards and exposures, as
1799 required by TSCA (15 U.S.C. 2605(b)(4)(F)). This section also includes a discussion of any
1800 uncertainties and how they impact the draft Risk Evaluation. Section 5 presents EPA's determination of
1801 whether the chemical presents an unreasonable risk under the conditions of use, as required under TSCA
1802 (15 U.S.C. 2605(b)(4)).

1803
1804 EPA also solicited input on the first 10 chemicals as it developed use documents, scope documents, and
1805 Problem Formulations. At each step, EPA has received information and comments specific to individual
1806 chemicals and of a more general nature relating to various aspects of the Risk Evaluation process,
1807 technical issues, and the regulatory and statutory requirements. EPA has considered comments and
1808 information received at each step in the process and factored in the information and comments as the
1809 Agency deemed appropriate and relevant including comments on the published Problem Formulation of
1810 trichloroethylene.

1811 **1.1 Physical and Chemical Properties**

1812 Physical-chemical properties influence the environmental behavior and the toxic properties of a
1813 chemical, thereby informing the potential conditions of use, exposure pathways and routes and hazards
1814 that EPA considered. For scope development, EPA considered the measured or estimated physical-
1815 chemical properties set forth in Table 1-1 and found no additional information during Problem
1816 Formulation or the draft Risk Evaluation that would change these values.

1817
1818 TCE is a colorless liquid with a pleasant, sweet odor resembling that of chloroform. It is considered a
1819 volatile organic compound (VOC) because of its moderate boiling point, 87.2°C, and high vapor
1820 pressure, 73.46 mm Hg at 25°C. TCE is moderately water soluble (1.280 g/L at 25°C) and has a log
1821 octanol/water partition coefficient (Kow) of 2.42. The density of TCE, 1.46 g/m³ at 20°C, is greater than
1822 that of water.
1823

1824
1825

Table 1-1. Physical and Chemical Properties of TCE

Property	Value ^a	References
Molecular Formula	C ₂ HCl ₃	
Molecular Weight	131.39 g/mole	
Physical Form	Colorless, liquid, sweet, pleasant odor, resembles chloroform	(O'Neil et al., 2006)
Melting Point	-84.7°C	(Lide, 2007)
Boiling Point	87.2°C	(Lide, 2007)
Density	1.46 g/cm ³ at 20°C	(ECB, 2000)
Vapor Pressure	73.72 mmHg at 25°C ^b	(Daubert and Danner, 1995)
Vapor Density	4.53	(O'Neil et al., 2006)
Water Solubility	1,280 mg/L at 25°C	(Horvath et al., 1999)
Octanol/Water Partition Coefficient (Log K _{ow})	2.42	(Banerjee et al., 1980)
Henry's Law Constant	9.85E-03 atm·m ³ /mole	(Leighton and Calo, 1981)
Flash Point	90°C (closed cup)	(ECB, 2000)
Auto Flammability	410°C (Estimated)	(WHO, 1985)
Viscosity	0.545 mPa·s at 25°C	(Lide, 2007)
Refractive Index	1.4775 at 20°C	(O'Neil et al., 2001)
Dielectric Constant	3.4 ε ₀ at 16°C	(Weast and Selby, 1966)
Aqueous Permeability Coefficient (Kp)	0.019 cm/hr	(Poet et al., 2000)
Neat Dermal Flux (J _{skin}) ^c	430 nmol/cm ² -min (5.65E-02 mg/cm ² -min)	(Kezic et al. 2001)
^a Measured unless otherwise noted ^b This value was updated based on systematic review re-analysis of original values. The original value of 73.46 mmHg, from (Daubert and Danner, 1989), was used for occupational and consumer modeling of inhalation exposures. The effect of this small difference is expected to be negligible for associated exposure estimates. ^c EPA calculated neat Kp as 0.00232 cm/hr from J _{skin} based on the density of TCE.		

1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839

1.2 Uses and Production Volume

This section contains use and production volume information for TCE.

1.2.1 Data and Information Sources

The summary of use and production volume information for TCE that is presented below is based on research conducted for the *Problem Formulation Document Trichloroethylene* (EPA-740-R1-7014) and any additional information that was learned since the publication of that document. The previous research was based on reasonably available information, including the *Use and Market Profile for Trichloroethylene*, (EPA-HQ-OPPT-2016-0737-0056), public meetings, and meetings with companies, industry groups, chemical users and other stakeholders to aid in identifying conditions of use and verifying conditions of use identified by the EPA. The information and input received from the public, stakeholder meetings and the additional contacts was incorporated into this section to the extent appropriate. Thus, EPA believes the manufacture, processing, distribution, use and disposal activities constitute the conditions of use within the scope of the Risk Evaluation for trichloroethylene, based on reasonably available information.

1.2.2 Domestic Manufacture of Trichloroethylene

A life cycle diagram is provided (Figure 1-3) depicting the conditions of use that are within the scope of the Risk Evaluation during various life cycle stages including manufacturing, processing, use (industrial, commercial, consumer; when distinguishable), distribution and disposal. The information is grouped according to Chemical Data Reporting (CDR) processing codes and use categories (including functional use codes for industrial uses and product categories for industrial, commercial and consumer uses), in combination with other data sources (e.g., published literature and consultation with stakeholders), to provide an overview of conditions of use. The EPA notes that some subcategories of use may be grouped under multiple CDR categories.

For the purposes of this Risk Evaluation, CDR definitions were used. CDR use categories include the following: “industrial use” means use at a site at which one or more chemicals or mixtures are manufactured (including imported) or processed. “Commercial use” means the use of a chemical or a mixture containing a chemical (including as part of an article) in a commercial enterprise providing saleable goods or services. “Consumer use” means the use of a chemical or a mixture containing a chemical (including as part of an article, such as furniture or clothing) when sold to or made available to consumers for their use (U.S. EPA, 2016d).

To understand conditions of use relative to one another and associated potential exposures under those conditions of use, the life cycle diagram includes the production volume associated with each stage of the life cycle, as reported in the 2016 CDR reporting (U.S. EPA, 2016d) when the volume was not claimed confidential business information (CBI). The 2016 CDR reporting data for TCE are provided in Figure 1-1 for TCE from the EPA’s CDR database (U.S. EPA, 2016d). For the 2016 CDR reporting period, non-confidential data indicate a total of 13 manufacturers and importers of TCE in the United States.





Figure 1-1. Total Aggregate TCE Production Volume (lbs.) 2012-2015^a

^aThe CDR data for the 2016 reporting period is available via ChemView (<https://java.epa.gov/chemview>). Because of an ongoing CBI substantiation process required by amended TSCA, the CDR data available in the Risk Evaluation is more specific than currently in ChemView. M = millions of pounds (lbs).

As reported in the Use Document [EPA-HQ-OPPT-2016-0737-0003 (U.S. EPA, 2017c)], as well as in the 2014 TCE risk assessment (U.S. EPA, 2014b), an estimated 83.6% of TCE’s annual production

1874 volume is used as an intermediate in the manufacture of the hydrofluorocarbon, HFC-134a, an
1875 alternative to the refrigerant chlorofluorocarbon, CFC-12. Another 14.7% of TCE production volume is
1876 used as a degreasing solvent, leaving approximately 1.7% for other uses (Figure 1-2). The current status
1877 of the volume of TCE used as an intermediate in the manufacture of HFC-134a, is complicated by
1878 regulatory activity affecting hydrofluorocarbons (HFCs) in general. In 2015, EPA issued a rule under its
1879 Significant New Alternatives Policy (SNAP) program that changed the listings for certain HFCs in
1880 various end-uses in the aerosol, refrigeration and air conditioning, and foam blowing sectors from
1881 acceptable, or acceptable subject to use conditions, to unacceptable, or acceptable subject to narrowed
1882 use limits. The listings were to become effective generally starting in 2016 through 2022, depending on
1883 the use. The SNAP rules, as originally written, would control specific uses of HFCs or HFC blends,
1884 rather than *production*. SNAP continues to list as acceptable several blends of HFCs with other
1885 compounds with lower environmental impact and other small exemptions. Under these listings, a decline
1886 in the use of TCE as an intermediate in the manufacture of HFCs might be expected along with the use
1887 of the HFCs. However, the potential effect is less than clear due to a decision to vacate EPA's rule by
1888 the Court of Appeals for the District of Columbia "to the extent it requires manufacturers to replace
1889 HFCs with a substitute substance." Based on the court's partial vacatur, EPA did not apply the HFC
1890 listings in the 2015 Rule and plans to address the court's remand in a rulemaking which has not yet
1891 occurred. Meanwhile, several states have adopted or are in the process of adopting laws similar to the
1892 2015 SNAP rule and a similar SNAP rule issued in 2016 that also changed the status of certain HFCs
1893 and HFC blends from acceptable to unacceptable. It is important to note that the SNAP rules, as
1894 originally written, would control specific uses of HFCs or HFC blends, rather than *production*. SNAP
1895 continues to list as acceptable several blends of HFCs with other compounds with lower environmental
1896 impact and other small exemptions. Because of uncertainty surrounding the response to EPA's
1897 regulatory activity and the regulatory activity of States with respect to HFCs for certain uses, EPA does
1898 not have a reasonable basis to make assumptions about what the current distribution might be. Also
1899 reflected in the life cycle diagram is the fact that TCE, as a widely used solvent, has numerous
1900 applications across industrial, commercial and consumer settings.
1901



1902 **Figure 1-2. Percentage of TCE Production Volume by Use**

1903 Descriptions of the industrial, commercial and consumer use categories identified from the 2016 CDR
1904 and included in the life cycle diagram (Figure 1-3) are summarized below ([U.S. EPA, 2016d](#)). The
1906

1907 descriptions provide a brief overview of the use category; the [*Environmental Releases and*
1908 *Occupational Exposure Assessment. Docket: [EPA-HQ-OPPT-2019-0500](#)*] contains more detailed
1909 descriptions (e.g., process descriptions, worker activities, process flow diagrams, equipment
1910 illustrations) for each manufacture, processing, use and disposal category. The descriptions provided
1911 below are primarily based on the corresponding industrial function category and/or commercial and
1912 consumer product category descriptions from the 2016 CDR and can be found in the EPA’s [Instructions](#)
1913 [for Reporting 2016 TSCA Chemical Data Reporting \(U.S. EPA, 2016b\)](#).
1914

1915 The following describes several industrial/commercial CDR use categories where TCE has been used;
1916 the [*Environmental Releases and Occupational Exposure Assessment. Docket: [EPA-HQ-OPPT-2019-](#)*
1917 [0500](#))] provides additional process-related information on the remaining categories and life cycle stages.
1918

1919 The “**Solvents for Cleaning and Degreasing**” category encompasses chemical substances used to
1920 dissolve oils, greases and similar materials from a variety of substrates including metal surfaces,
1921 glassware and textiles. This category includes the use of TCE in vapor degreasing, cold cleaning and in
1922 industrial and commercial aerosol degreasing products.
1923

1924 The “**Lubricants and Greases**” category encompasses chemical substances contained in products used
1925 to reduce friction, heat generation and wear between solid surfaces. This category includes the use of
1926 TCE in penetrating lubricants, and tap and die fluids for industrial, commercial and consumer uses.
1927

1928 The “**Adhesives and Sealants**” category encompasses chemical substances contained in adhesive and
1929 sealant products used to fasten other materials together. This category includes the use of TCE in mirror-
1930 edge sealants and other adhesive products.
1931

1932 The “**Functional Fluids (closed system)**” category encompasses liquid or gaseous chemical substances
1933 used for one or more operational properties in a closed system. Examples are heat transfer agents (e.g.,
1934 coolants and refrigerants).
1935

1936 The “**Paints and Coatings**” category encompasses chemical substances contained in paints, lacquers,
1937 varnishes and other coating products that are applied as a thin continuous layer to a surface. Coating
1938 may provide protection to surfaces from a variety of effects such as corrosion and ultraviolet (UV)
1939 degradation; may be purely decorative; or may provide other functions. The EPA anticipates that the
1940 primary subcategory to be the use of TCE in solvent-based coatings. This category covers industrial,
1941 commercial and consumer uses of paints and coatings.
1942

1943 The “**Cleaning and Furniture Care Products**” category encompasses chemical substances contained
1944 in products that are used to remove dirt, grease, stains and foreign matter from furniture and furnishings,
1945 or to cleanse, sanitize, bleach, scour, polish, protect or improve the appearance of surfaces. This
1946 category includes the use of TCE for spot cleaning and carpet cleaning.
1947

1948 The “**Laundry and Dishwashing Products**” category encompasses chemical substances contained in
1949 laundry and dishwashing products and aids formulated as a liquid, granular, powder, gel, cakes, and
1950 flakes that are intended for consumer or commercial use.
1951

1952 The “**Arts, Crafts and Hobby Materials**” category encompasses chemical substances contained in arts,
1953 crafts, and hobby materials that are intended for consumer or commercial use.

1954 **1.3 Regulatory and Assessment History**

1955 The EPA conducted a search of existing domestic and international laws, regulations and assessments
1956 pertaining to TCE. The EPA compiled this summary from data available from federal, state,
1957 international and other government sources, as cited in Appendix A.

1958
1959 ***Federal Laws and Regulations***

1960 TCE is subject to federal statutes or regulations, other than TSCA, that are implemented by other offices
1961 within the EPA and/or other federal agencies/departments. A summary of federal laws, regulations and
1962 implementing authorities is provided in Appendix A.1.

1963
1964 ***State Laws and Regulations***

1965 TCE is subject to state statutes or regulations implemented by state agencies or departments. A summary
1966 of state laws, regulations and implementing authorities is provided in Appendix A.2.

1967
1968 ***Laws and Regulations in Other Countries and International Treaties or Agreements***

1969 TCE is subject to statutes or regulations in countries other than the United States and/or international
1970 treaties and/or agreements. A summary of these laws, regulations, treaties and/or agreements is provided
1971 in Appendix A.3.

1972
1973 EPA has identified assessments conducted by other agency programs and organizations (see Table 1-2).
1974 Depending on the source, these assessments may include information on conditions of use, hazards,
1975 exposures, and potentially exposed or susceptible subpopulations (PESS)—information useful to the
1976 EPA in preparing this Risk Evaluation. Table 1-2 shows the assessments that have been conducted. In
1977 addition to using this information, EPA conducted a full review of the data collected [see
1978 *Trichloroethylene (CASRN 79-01-6) Bibliography: Supplemental File for the TSCA Scope Document,*
1979 [EPA-HQ-OPPT-2016-0737](#)) using the literature search strategy (see *Strategy for Conducting Literature*
1980 *Searches for Trichloroethylene: Supplemental File for the TSCA Scope Document,* [EPA-HQ-OPPT-](#)
1981 [2016-0737](#)] to ensure that the EPA is considering information that has been made available since these
1982 assessments were conducted.

1983
1984 In EPA’s previous TCE Workplan Risk Assessment ([U.S. EPA, 2014b](#)), risks from use of TCE in
1985 commercial and consumer solvent degreasing (aerosol and vapor), consumer use as a spray-applied
1986 protective coating for arts and crafts and commercial use as a spot remover at dry-cleaning facilities
1987 were assessed. The TCE Risk Assessment was used to support two proposed rules under TSCA section
1988 6 ([81 FR 91592](#); December 12, 2016; [82 FR 7432](#); January 19, 2017) to address risks from use of TCE.
1989 Along with other reasonably available information, the EPA used the existing TSCA risk assessments to
1990 inform its development of the TCE Risk Evaluation.

1991

1992
1993

Table 1-2. Assessment History of TCE

Authoring Organization	Assessment
EPA Assessments	
Office of Chemical Safety and Pollution Prevention (OCSPP)/ Office of Pollution Prevention and Toxics (OPPT)	TSCA Work Plan Chemical Risk Assessment Trichloroethylene: Degreasing, Spot Cleaning and Arts & Crafts Use (U.S. EPA, 2014b)
OCSPP/OPPT	Supplemental Occupational Exposure and Risk Reduction Technical Report in Support of Risk Management Options for Trichloroethylene (TCE) Use in Aerosol Degreasing (U.S. EPA, 2016f)
OCSPP/OPPT	Supplemental Exposure and Risk Reduction Technical Report in Support of Risk Management Options for Trichloroethylene (TCE) Use in Consumer Aerosol Degreasing (U.S. EPA, 2016e)
OCSPP/OPPT	Supplemental Occupational Exposure and Risk Reduction Technical Report in Support of Risk Management Options for Trichloroethylene (TCE) Use in Spot Cleaning (U.S. EPA, 2016g)
OCSPP/OPPT	Supplemental Occupational Exposure and Risk Reduction Technical Report in Support of Risk Management Options for Trichloroethylene (TCE) Use in Vapor Degreasing [RIN 2070-AK11] (U.S. EPA, 2016h)
Integrated Risk Information System (IRIS)	Toxicological Review of Trichloroethylene (U.S. EPA, 2011e)
National Center for Environmental Assessment (NCEA)	Sources, Emission and Exposure for Trichloroethylene (TCE) and Related Chemicals (U.S. EPA, 2001)
Office of Water (OW)/ Office of Science and Technology (OST)	Update of Human Health Ambient Water Quality Criteria: Trichloroethylene (TCE) 79-01-6 (U.S. EPA, 2015b)
Other U.S.-Based Organizations	
Agency for Toxic Substances and Disease Registries (ATSDR)	Final Toxicological Profile for Trichloroethylene (ATSDR, 2019)
National Research Council (NRC)	Assessing the Human Health Risks of Trichloroethylene: Key Scientific Issues (NRC, 2006)
Office of Environmental Health Hazard Assessment (OEHHA), Pesticide and Environmental Toxicology Section	Public Health Goal for Trichloroethylene in Drinking Water (CalEPA, 2009)
International	
Institute for Health and Consumer Protection, European Chemicals Bureau	European Union Risk Assessment Report, Trichloroethylene (ECB, 2004)
Australia National Industrial Chemicals Notification and Assessment Scheme (NICNAS)	Trichloroethylene: Priority Existing Chemical Assessment Report No. 8 (NICNAS, 2000)

1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022

1.4 Scope of the Evaluation

1.4.1 Conditions of Use Included in the Risk Evaluation

TSCA Section 3(4) defines the conditions of use (COUs) as “the circumstances, as determined by the Administrator, under which a chemical substance is intended, known, or reasonably foreseen to be manufactured, processed, distributed in commerce, used, or disposed of.” The conditions of use are described below in Table 1-3 and Table 1-4. No additional information was received by the EPA following the publication of the Problem Formulation ([U.S. EPA, 2018d](#)) that would update or otherwise require changes to the life cycle diagram (Figure 1-3) as presented in the Problem Formulation ([U.S. EPA, 2018d](#)). Nonetheless, EPA decided to reorganize the conditions of use for this Risk Evaluation. In this Risk Evaluation, the COUs as described in ([U.S. EPA, 2018d](#)) were evaluated for occupational scenarios based on corresponding occupational exposure scenarios (OES) (Table 1-3). The occupational COUs are also applicable to environmental receptors based on water releases from these activities.

“Lace wig and hair extension glues” have been eliminated as a COU since the publication of the Problem Formulation ([U.S. EPA, 2018d](#)). EPA, after consultation with the FDA, has determined that this use, previously identified in the Problem Formulation as a conditions of use, is not a condition of use because it falls outside the scope of EPA’s jurisdiction. TSCA sec. 3(2) excludes from the definition of “chemical substance” cosmetics as they are defined in the Federal Food, Drug and Cosmetic Act (FFDCA) when manufactured, processed, or distributed in commerce for use as a cosmetic. Because the glue for lace wigs and hair extensions is a cosmetic within section 201(i) of the FFDCA, any TCE used for these purposes is outside the scope of TSCA.

Consumer scenarios were evaluated separately from occupational scenarios, and EPA re-categorized certain COUs based on product function. None of these changes resulted in any difference in how these products are or would have been assessed, they simply reflect a recategorization in order to improve clarity. Additionally, subcategories were added based on availability of differing forms of a product (*e.g.*, aerosol vs liquid). The updated consumer conditions of use and explanations for the changes are presented in Table 1-4.

Table 1-3. Categories and Subcategories of Occupational Conditions of Use and Corresponding Occupational Exposure Scenario

Life Cycle Stage	Category ^a	Subcategory ^b	Occupational Exposure Scenario (OES)	References
Manufacture	Domestic manufacture	Domestic manufacture	Manufacturing	(U.S. EPA, 2016d)
	Import	Import	Repackaging	(U.S. EPA, 2016d)
Processing	Processing as a reactant/intermediate	Intermediate in industrial gas manufacturing (<i>e.g.</i> , manufacture of fluorinated gases used as refrigerants, foam blowing agents and solvents)	Processing as a reactant	(U.S. EPA, 2016d) ; EPA-HQ-OPPT-2016-0737-0013 ; EPA-HQ-OPPT-2016-0737-0013 ; EPA-HQ-OPPT-2016-0737-0026 ; EPA-HQ-OPPT-2016-0737-0027
	Processing - Incorporation into formulation, mixture or reaction product	Solvents (for cleaning or degreasing)	Formulation of Aerosol and Non-Aerosol Products	(U.S. EPA, 2016d)
		Adhesives and sealant chemicals		(U.S. EPA, 2016d)
		Solvents (which become part of product formulation or mixture) (<i>e.g.</i> , lubricants and greases, paints and coatings, other uses)		(U.S. EPA, 2016d) ; EPA-HQ-OPPT-2016-0737-0003 ; EPA-HQ-OPPT-2016-0737-0056
	Processing – incorporated into articles	Solvents (becomes an integral components of articles)		(U.S. EPA, 2016d)
	Repackaging	Solvents (for cleaning or degreasing)	Repackaging	(U.S. EPA, 2016d)
Recycling	Recycling	Process Solvent Recycling and Worker Handling of Wastes	(U.S. EPA, 2017f)	

Life Cycle Stage	Category ^a	Subcategory ^b	Occupational Exposure Scenario (OES)	References
Distribution in commerce	Distribution	Distribution	[Distribution in commerce of TCE is the transportation associated with the moving of TCE in commerce. Exposures and emissions are not expected.]	EPA-HQ-OPPT-2016-0737-0003
Industrial/ commercial use	Solvents (for cleaning or degreasing)	Batch vapor degreaser (<i>e.g.</i> , open-top, closed-loop) ^c	Batch Open-Top Vapor Degreasing; Batch Closed-Loop Vapor Degreasing	EPA-HQ-OPPT-2016-0737-0003 , (U.S. EPA, 2014b), (U.S. EPA, 2016h), EPA-HQ-OPPT-2016-0737-0056
		In-line vapor degreaser (<i>e.g.</i> , conveyORIZED, web cleaner) ^c	Conveyorized Vapor Degreasing; Web Vapor Degreasing	EPA-HQ-OPPT-2016-0737-0003 , (U.S. EPA, 2014b), (U.S. EPA, 2016h), EPA-HQ-OPPT-2016-0737-0056
		Cold cleaner	Cold Cleaning	EPA-HQ-OPPT-2016-0737-0003 ; (U.S. EPA, 2017h); EPA-HQ-OPPT-2016-0737-0056
		Aerosol spray degreaser/ cleaner ^c	Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners,	EPA-HQ-OPPT-2016-0737-0003 , (U.S. EPA, 2014b), (U.S. EPA, 2016f), (U.S. EPA, 2016e), EPA-HQ-OPPT-2016-0737-0056
		Mold release	Penetrating Lubricants, and Mold Releases	EPA-HQ-OPPT-2016-0737-0003 ; EPA-HQ-OPPT-2016-0737-0056
	Lubricants and greases/lubricants and lubricant additives	Tap and die fluid	Metalworking Fluids	(U.S. EPA, 2016d); EPA-HQ-OPPT-2016-0737-0003 ; EPA-HQ-OPPT-2016-0737-0028 , EPA-HQ-OPPT-2016-0737-0056

Life Cycle Stage	Category ^a	Subcategory ^b	Occupational Exposure Scenario (OES)	References
		Penetrating lubricant	Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases; Metalworking Fluids	(U.S. EPA, 2016d) , EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003 ; EPA-HQ-OPPT-2016-0737-0028
	Adhesives and sealants	Solvent-based adhesives and sealants	Adhesives, Sealants, Paints, and Coatings	(U.S. EPA, 2016d) , EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003
Tire repair cement/sealer		(U.S. EPA, 2016d) , EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003		
Mirror edge sealant		EPA-HQ-OPPT-2016-0737-0003 ; (U.S. EPA, 2014b) , EPA-HQ-OPPT-2016-0737-0056		
	Functional fluids (closed systems)	Heat exchange fluid	Other Industrial Uses	(U.S. EPA, 2017h)
	Paints and coatings	Diluent in solvent-based paints and coatings	Adhesives, Sealants, Paints, and Coatings	(U.S. EPA, 2016d) , EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003 ; EPA-HQ-OPPT-2016-0737-0010 ; EPA-HQ-OPPT-2016-0737-0015 ; EPA-HQ-OPPT-2016-0737-0027 ;
	Cleaning and furniture care products	Carpet cleaner	Spot Cleaning, Wipe Cleaning and Carpet Cleaning	EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003

Life Cycle Stage	Category ^a	Subcategory ^b	Occupational Exposure Scenario (OES)	References
		Wipe cleaning ^d		EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003
	Laundry and dishwashing products	Spot remover ^c		EPA-HQ-OPPT-2016-0737-0003 , (U.S. EPA, 2014b), (U.S. EPA, 2016g), EPA-HQ-OPPT-2016-0737-0056
	Arts, crafts and hobby materials	Fixatives and finishing spray coatings ^c	Adhesives, Sealants, Paints, and Coatings	(U.S. EPA, 2014b)
	Corrosion inhibitors and anti-scaling agents	Corrosion inhibitors and anti-scaling agents	Industrial Processing Aid	(U.S. EPA, 2016d)
	Processing aids	Process solvent used in battery manufacture		(U.S. EPA, 2017h)
		Process solvent used in polymer fiber spinning, fluoroelastomer manufacture and Alcantara manufacture		(U.S. EPA, 2017h)
		Extraction solvent used in caprolactam manufacture		(U.S. EPA, 2017h)
		Precipitant used in beta-cyclodextrin manufacture		(U.S. EPA, 2017h)
	Ink, toner and colorant products	Toner aid	Commercial Printing and Copying	EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003

Life Cycle Stage	Category ^a	Subcategory ^b	Occupational Exposure Scenario (OES)	References
	Automotive care products	Brake and parts cleaner	Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003
	Apparel and footwear care products	Shoe polish		(U.S. EPA, 2017h)
	Other uses	Hoof polishes ^e		EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003
		Pepper spray		EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003
		Gun scrubber		EPA-HQ-OPPT-2016-0737-0056 ; EPA-HQ-OPPT-2016-0737-0003
		Other miscellaneous industrial and commercial uses		(U.S. EPA, 2017h)
Disposal	Disposal	Industrial pre-treatment	Process Solvent Recycling and Worker Handling of Wastes	(U.S. EPA, 2017f)
		Industrial wastewater treatment		
		Publicly owned treatment works (POTW)		

Life Cycle Stage	Category ^a	Subcategory ^b	Occupational Exposure Scenario (OES)	References
<p>^a These categories of conditions of use appear in the Life Cycle Diagram, reflect CDR codes, and broadly represent conditions of use of TCE in industrial and/or commercial settings.</p> <p>^b These subcategories reflect more specific uses of TCE.</p> <p>^c This includes uses assessed in the (U.S. EPA, 2014b) risk assessment.</p> <p>^d This condition of use involves wipe cleaning. Note that the Problem Formulation described “cleaning wipes” as a condition of use. This referred to the application of ^a product that is then wiped off, rather than a pre-wet towelette.</p> <p>^e “Hoof polish” would remain within EPA’s jurisdiction unless the article in question was also <i>intended for the diagnosis, cure, mitigation, treatment, of disease or intended to affect the structure or function of the body of animals</i>, as described in the FFDC. EPA identified a single product for hoof polish containing TCE (U.S. EPA, 2017h), and this product is intended for only cosmetic and not medical use. Therefore, “hoof polish” was evaluated as a COU, applicable only to products restricted to cosmetic function.</p>				

2024
2025


Table 1-4. Categories and Subcategories of Consumer Conditions of Use

Life Cycle Stage	Category	Subcategory
Use	Solvents for Cleaning and Degreasing	Brake & Parts Cleaner ²
		Aerosol Electronic Degreaser/Cleaner ¹
		Liquid Electronic Degreaser/Cleaner ¹
		Aerosol Spray Degreaser/Cleaner ¹
		Liquid Degreaser/Cleaner ¹
		Aerosol Gun Scrubber ^{1,3}
		Liquid Gun Scrubber ^{1,3}
		Mold Release
		Aerosol Tire Cleaner ^{1,4}
		Liquid Tire Cleaner ^{1,4}
	Lubricants and Greases	Tap & Die Fluid
		Penetrating Lubricant ⁵
	Adhesives and Sealants	Solvent-based Adhesive & Sealant
		Mirror-edge Sealant
		Tire Repair Cement/Sealer
	Cleaning and Furniture Care Products ¹⁰	Carpet Cleaner
		Aerosol Spot Remover ^{1,6}
		Liquid Spot Remover ^{1,6}
	Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings ⁷
	Apparel and Footwear Care Products	Shoe Polish
	Other Consumer Uses	Fabric Spray ⁸
		Film Cleaner
		Hoof Polish
		Pepper Spray
		Toner Aid ⁹

Life Cycle Stage	Category	Subcategory
<p>¹ Form was determined based on the specific products identified as representative of the associated product subcategories. Distinct subcategories based on differing forms (aerosol and liquid) were not specifically defined in the Problem Formulation. They were added due to product availability based on additional research that helped to differentiate specific product forms (<i>i.e.</i>, liquid or aerosol) and types.</p> <p>² The brake cleaner subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the automotive care products category; however, the same brake cleaning conditions of use are now associated with the broader solvents for cleaning and degreasing category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the brake cleaner product(s) and not a broader category of use.</p> <p>³ The gun scrubber subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the other consumer uses category; however, the same gun scrubber conditions of use are now associated with the broader solvents for cleaning and degreasing category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the gun scrubber product(s) and not a broader category of use.</p> <p>⁴ Tire cleaner products / subcategories of use were not specifically called out in the Problem Formulation; however, such products were identified in the 2017 Use and Market Report (U.S. EPA, 2017f) and Preliminary Information on Manufacturing, Processing, Distribution, Use, and Disposal: TCE (U.S. EPA, 2017c) and fit within the broader Solvents for Cleaning and Degreasing category.</p> <p>⁵ Based on additional research into the specific product(s) associated with the broader lubricants and greases category, the subcategory name was updated from penetrating lubricant to lubricant.</p> <p>⁶ The spot remover subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the laundry and dishwashing products category; however, the same spot remover conditions of use are now associated with the cleaning and furniture care products category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the spot remover product(s) and not a broader category of use.</p> <p>⁷ This subcategory is referred to as “clear protective coating spray” in U.S. EPA (2014b) and as “spray fixative” in the TCE Significant New Use Rule (80 FR 47441).</p> <p>⁸ Fabric spray (specifically an anti-fray spray) was added following Problem Formulation based on identification in the final 2014 TCE Work Plan Chemical Risk Assessment (U.S. EPA, 2014b).</p> <p>⁹ The toner aid subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the Ink, toner, and colorant products category; however, the toner aid use is not like use of a toner or pigment; therefore, the same toner aid condition of use is now associated with the other consumer use category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the toner aid product(s) and not a broader category of use.</p> <p>¹⁰ Problem Formulation described “cleaning wipes” as a condition of use for this category. However, that referred to the application of a product that is then wiped off, rather than a pre-wet towelette. A number of consumer conditions of use involve wipe cleaning and are described in detail in Section 2.3.2.5.2 as leading to dermal contact with impeded evaporation.</p>		

2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040

To help characterize the life cycle of TCE, EPA developed a national mass balance to evaluate how much of the volume of TCE can be accounted for from cradle-to-grave. The inputs into the mass balance included data from the 2016 CDR, 2017 NEI, 2017 TRI, and available market data. The result of the mass balance is provided in Appendix R. The total mass accounted for at the end-of-life stage, which includes wastes from manufacturing, processing, use, waste treatment and disposal facilities, is approximately 101% of the 2015 production volume. The over-accounting of volume is most likely due to incomplete reporting data and comparison of data from different years. There is additional uncertainty arising from the potential to double count TRI volumes reported as transferred off-site for energy recovery, treatment, and recycling that are then received by another TRI site that reports this volume in its on-site waste management activities. Finally, the true export volume is higher than presented in the mass balance as multiple sites reporting to 2016 CDR claimed their export volume as CBI. Additional details on the development of the mass balance can be found in Appendix R.



2041
2042
2043
2044
2045
2046

Figure 1-3. TCE Life Cycle Diagram

The life cycle diagram depicts the conditions of use that are within the scope of the Risk Evaluation during various life cycle stages including manufacturing, processing, use (industrial, commercial, consumer), distribution and disposal. The production volumes shown are for reporting year 2015 from the 2016 CDR reporting period (U.S. EPA, 2016d). A mass balance of TCE throughout the life cycle can be found in Appendix R.

2047 **1.4.2 Exposure Pathways and Risks Addressed by Other EPA-Administered Statutes**

2048 In its TSCA section 6(b) Risk Evaluations, EPA is coordinating action on certain exposure pathways and
2049 risks falling under the jurisdiction of other EPA-administered statutes or regulatory programs. More
2050 specifically, EPA is exercising its TSCA authorities to tailor the scope of its Risk Evaluations, rather
2051 than focusing on environmental exposure pathways addressed under other EPA-administered statutes or
2052 regulatory programs or risks that could be eliminated or reduced to a sufficient extent by actions taken
2053 under other EPA-administered laws. EPA considers this approach to be a reasonable exercise of the
2054 Agency’s TSCA authorities, which include:

- 2055 • TSCA section 6(b)(4)(D): “The Administrator shall, not later than 6 months after the initiation of
2056 a Risk Evaluation, publish the scope of the Risk Evaluation to be conducted, including the
2057 hazards, exposures, conditions of use, and the potentially exposed or susceptible subpopulations
2058 the Administrator expects to consider....”
- 2059 • TSCA section 9(b)(1): “The Administrator shall coordinate actions taken under this chapter with
2060 actions taken under other Federal laws administered in whole or in part by the Administrator. If
2061 the Administrator determines that a risk to health or the environment associated with a chemical
2062 substance or mixture could be eliminated or reduced to a sufficient extent by actions taken under
2063 the authorities contained in such other Federal laws, the Administrator shall use such authorities
2064 to protect against such risk unless the Administrator determines, in the Administrator’s
2065 discretion, that it is in the public interest to protect against such risk by actions taken under this
2066 chapter.”
- 2067 • TSCA section 9(e): “...[I]f the Administrator obtains information related to exposures or releases
2068 of a chemical substance or mixture that may be prevented or reduced under another Federal law,
2069 including a law not administered by the Administrator, the Administrator shall make such
2070 information available to the relevant Federal agency or office of the Environmental Protection
2071 Agency.”
- 2072 • TSCA section 2(c): “It is the intent of Congress that the Administrator shall carry out this chapter
2073 in a reasonable and prudent manner, and that the Administrator shall consider the environmental,
2074 economic, and social impact of any action the Administrator takes or proposes as provided under
2075 this chapter.”
- 2076 • TSCA section 18(d)(1): “Nothing in this chapter, nor any amendment made by the Frank R.
2077 Lautenberg Chemical Safety for the 21st Century Act, nor any rule, standard of performance,
2078 Risk Evaluation, or scientific assessment implemented pursuant to this chapter, shall affect the
2079 right of a State or a political subdivision of a State to adopt or enforce any rule, standard of
2080 performance, Risk Evaluation, scientific assessment, or any other protection for public health or
2081 the environment that— (i) is adopted or authorized under the authority of any other Federal law
2082 or adopted to satisfy or obtain authorization or approval under any other Federal law....”

2084 TSCA authorities supporting tailored Risk Evaluations and intra-agency referrals

2085 TSCA section 6(b)(4)(D) requires EPA, in developing the scope of a Risk Evaluation, to identify the
2086 hazards, exposures, conditions of use, and potentially exposed or susceptible subpopulations the Agency
2087 “expects to consider” in a Risk Evaluation. This language suggests that EPA is not required to consider
2088 all conditions of use, hazards, or exposure pathways in Risk Evaluations.

2089
2090 In the Problem Formulation documents for many of the first 10 chemicals undergoing Risk Evaluation,
2091 EPA applied this authority and rationale to certain exposure pathways, explaining that “EPA is planning
2092 to exercise its discretion under TSCA 6(b)(4)(D) to focus its analytical efforts on exposures that are

likely to present the greatest concern and consequently merit a Risk Evaluation under TSCA, by excluding, on a case-by-case basis, certain exposure pathways that fall under the jurisdiction of other EPA-administered statutes.” This approach is informed by the legislative history of the amended TSCA, which supports the Agency’s exercise of discretion to focus the Risk Evaluation on areas that raise the greatest potential for risk. See June 7, 2016 Cong. Rec., S3519-S3520. Consistent with the approach articulated in the Problem Formulation documents, and as described in more detail below, EPA is exercising its authority under TSCA to tailor the scope of exposures evaluated in TSCA Risk Evaluations, rather than focusing on environmental exposure pathways addressed under other EPA-administered, mediaspecific statutes and regulatory programs.

TSCA section 9(b)(1)

In addition to TSCA section 6(b)(4)(D), the Agency also has discretionary authority under the first sentence of TSCA section 9(b)(1) to “coordinate actions taken under [TSCA] with actions taken under other Federal laws administered in whole or in part by the Administrator.” This broad, freestanding authority provides for intra-agency coordination and cooperation on a range of “actions.” In EPA’s view, the phrase “actions taken under [TSCA]” in the first sentence of section 9(b)(1) is reasonably read to encompass more than just risk management actions, and to include actions taken during Risk Evaluation as well. More specifically, the authority to coordinate intra-agency actions exists regardless of whether the Administrator has first made a definitive finding of risk, formally determined that such risk could be eliminated or reduced to a sufficient extent by actions taken under authorities in other EPA-administered Federal laws, and/or made any associated finding as to whether it is in the public interest to protect against such risk by actions taken under TSCA. TSCA section 9(b)(1) therefore provides EPA authority to coordinate actions with other EPA offices without ever making a risk finding, or following an identification of risk. This includes coordination on tailoring the scope of TSCA Risk Evaluations to focus on areas of greatest concern rather than exposure pathways addressed by other EPA-administered statutes and regulatory programs, which does not involve a risk determination or public interest finding under TSCA section 9(b)(2).

In a narrower application of the broad authority provided by the first sentence of TSCA section 9(b)(1), the remaining provisions of section 9(b)(1) provide EPA authority to identify risks and refer certain of those risks for action by other EPA offices. Under the second sentence of section 9(b)(1), “[i]f the Administrator determines that a risk to health or the environment associated with a chemical substance or mixture could be eliminated or reduced to a sufficient extent by actions taken under the authorities contained in such other Federal laws, the Administrator shall use such authorities to protect against such risk unless the Administrator determines, in the Administrator’s discretion, that it is in the public interest to protect against such risk by actions taken under [TSCA].” Coordination of intra-agency action on risks under TSCA section 9(b)(1) therefore entails both an identification of risk, and a referral of any risk that could be eliminated or reduced to a sufficient extent under other EPA-administered laws to the EPA office(s) responsible for implementing those laws (absent a finding that it is in the public interest to protect against the risk by actions taken under TSCA).

Risk may be identified by OPPT or another EPA office, and the form of the identification may vary. For instance, OPPT may find that one or more conditions of use for a chemical substance present(s) a risk to human or ecological receptors through specific exposure routes and/or pathways. This could involve a quantitative or qualitative assessment of risk based on reasonably available information (which might include, *e.g.*, findings or statements by other EPA offices or other federal agencies). Alternatively, risk could be identified by another EPA office. For example, another EPA office administering non-TSCA authorities may have sufficient monitoring or modeling data to indicate that a particular condition of use presents risk to certain human or ecological receptors, based on expected hazards and exposures. This

2142 risk finding could be informed by information made available to the relevant office under TSCA section
2143 9(e), which supports cooperative actions through coordinated information-sharing.

2144
2145 Following an identification of risk, EPA would determine if that risk could be eliminated or reduced to a
2146 sufficient extent by actions taken under authorities in other EPA-administered laws. If so, TSCA
2147 requires EPA to “use such authorities to protect against such risk,” unless EPA determines that it is in
2148 the public interest to protect against that risk by actions taken under TSCA. In some instances, EPA may
2149 find that a risk could be sufficiently reduced or eliminated by future action taken under non-TSCA
2150 authority. This might include, *e.g.*, action taken under the authority of the Safe Drinking Water Act to
2151 address risk to the general population from a chemical substance in drinking water. This sort of risk
2152 finding and referral could occur during the Risk Evaluation process, thereby enabling EPA to use more a
2153 relevant and appropriate authority administered by another EPA office to protect against hazards or
2154 exposures to affected receptors.

2155
2156 Legislative history on TSCA section 9(b)(1) supports both broad coordination on current intraagency
2157 actions, and narrower coordination when risk is identified and referred to another EPA office for action.
2158 A Conference Report from the time of TSCA’s passage explained that section 9 is intended “to assure
2159 that overlapping or duplicative regulation is avoided while attempting to provide for the greatest
2160 possible measure of protection to health and the environment.” S. Rep. No. 94-1302 at 84. See also H.
2161 Rep. No. 114-176 at 28 (stating that the 2016 TSCA amendments “reinforce TSCA’s original purpose of
2162 filling gaps in Federal law,” and citing new language in section 9(b)(2) intended “to focus the
2163 Administrator's exercise of discretion regarding which statute to apply and to encourage decisions that
2164 avoid confusion, complication, and duplication”). Exercising TSCA section 9(b)(1) authority to
2165 coordinate on tailoring TSCA Risk Evaluations is consistent with this expression of Congressional
2166 intent.

2167
2168 Legislative history also supports a reading of section 9(b)(1) under which EPA coordinates intraagency
2169 action, including information-sharing under TSCA section 9(e), and the appropriately positioned EPA
2170 office is responsible for the identification of risk and actions to protect against such risks. See, *e.g.*,
2171 Senate Report 114-67, 2016 Cong. Rec. S3522 (under TSCA section 9, “if the Administrator finds that
2172 disposal of a chemical substance may pose risks that could be prevented or reduced under the Solid
2173 Waste Disposal Act, the Administrator should ensure that the relevant office of the EPA receives that
2174 information”); H. Rep. No. 114-176 at 28, 2016 Cong. Rec. S3522 (under section 9, “if the
2175 Administrator determines that a risk to health or the environment associated with disposal of a chemical
2176 substance could be eliminated or reduced to a sufficient extent under the Solid Waste Disposal Act, the
2177 Administrator should use those authorities to protect against the risk”). Legislative history on section
2178 9(b)(1) therefore supports coordination with and referral of action to other EPA offices, especially when
2179 statutes and associated regulatory programs administered by those offices could address exposure
2180 pathways or risks associated with conditions of use, hazards, and/or exposure pathways that may
2181 otherwise be within the scope of TSCA Risk Evaluations.

2182 *TSCA sections 2(c) & 18(d)(1)*

2183 Finally, TSCA sections 2(c) and 18(d) support coordinated action on exposure pathways and risks
2184 addressed by other EPA-administered statutes and regulatory programs. Section 2(c) directs EPA to
2185 carry out TSCA in a “reasonable and prudent manner” and to consider “the environmental, economic,
2186 and social impact” of its actions under TSCA. Legislative history from around the time of TSCA’s
2187 passage indicates that Congress intended EPA to consider the context and take into account the impacts
2188 of each action under TSCA. S. Rep. No. 94-698 at 14 (“the intent of Congress as stated in this
2189 subsection should guide each action the Administrator takes under other sections of the bill”).
2190

2191
2192 Section 18(d)(1) specifies that state actions adopted or authorized under any Federal law are not
2193 preempted by an order of no unreasonable risk issued pursuant to TSCA section 6(i)(1) or a rule to
2194 address unreasonable risk issued under TSCA section 6(a). Thus, even if a Risk Evaluation were to
2195 address exposures or risks that are otherwise addressed by other federal laws and, for example,
2196 implemented by states, the state laws implementing those federal requirements would not be preempted.
2197 In such a case, both the other federal and state laws, as well as any TSCA section 6(i)(1) order or TSCA
2198 section 6(a) rule, would apply to the same issue area. See also TSCA section 18(d)(1)(A)(iii). In
2199 legislative history on amended TSCA pertaining to section 18(d), Congress opined that “[t]his approach
2200 is appropriate for the considerable body of law regulating chemical releases to the environment, such as
2201 air and water quality, where the states have traditionally had a significant regulatory role and often have
2202 a uniquely local concern.” Sen. Rep. 114-67 at 26.

2203
2204 EPA’s careful consideration of whether other EPA-administered authorities are available and more
2205 appropriate for addressing certain exposures and risks is consistent with Congress’ intent to maintain
2206 existing federal requirements and the state actions adopted to locally and more specifically implement
2207 those federal requirements, and to carry out TSCA in a reasonable and prudent manner. EPA believes it
2208 is both reasonable and prudent to tailor TSCA Risk Evaluations in a manner reflective of expertise and
2209 experience exercised by other EPA and State offices to address specific environmental media, rather
2210 than attempt to evaluate and regulate potential exposures and risks from those media under TSCA. This
2211 approach furthers Congressional direction and EPA aims to efficiently use Agency resources, avoid
2212 duplicating efforts taken pursuant to other Agency and State programs, and meet the statutory deadline
2213 for completing Risk Evaluations.

2214
2215 EPA-administered statutes and regulatory programs that address specific exposure pathways and/or risks
2216 During the course of the Risk Evaluation process for trichloroethylene, OPPT worked closely with the
2217 offices within EPA that administer and implement regulatory programs under the Clean Air Act (CAA),
2218 the Safe Drinking Water Act (SDWA), the Clean Water Act (CWA), the Comprehensive Environmental
2219 Response, Compensation, and Liability Act (CERCLA), and the Resource Conservation and Recovery
2220 Act (RCRA). Through this intra-agency coordination, EPA determined that specific exposure pathways
2221 are well-regulated by the EPA statutes and regulations described in the following paragraphs.

2222
2223 *Ambient air pathway*

2224 The CAA contains a list of hazardous air pollutants (HAP) and provides EPA with the authority to add
2225 to that list pollutants that present, or may present, a threat of adverse human health effects or adverse
2226 environmental effects. For stationary source categories emitting HAP, the CAA requires issuance of
2227 technology-based standards and, if necessary, additions or revisions to address developments in
2228 practices, processes, and control technologies, and to ensure the standards adequately protect public
2229 health and the environment. The CAA thereby provides EPA with comprehensive authority to regulate
2230 emissions to ambient air of any hazardous air pollutant.

2231
2232 Trichloroethylene is a HAP. See 42 U.S.C. 7412. EPA has issued a number of technologybased
2233 standards for source categories that emit trichloroethylene to ambient air and, as appropriate, has
2234 reviewed, or is in the process of reviewing remaining risks. See 40 CFR part 63; Appendix A. Because
2235 stationary source releases of trichloroethylene to ambient air are addressed under the CAA, EPA is not
2236 evaluating emissions to ambient air from commercial and industrial stationary sources or associated
2237 inhalation exposure of the general population or terrestrial species in this TSCA Risk Evaluation.

2238
2239

2240 *Drinking water pathway*

2241 EPA has regular analytical processes to identify and evaluate drinking water contaminants of potential
2242 regulatory concern for public water systems under the Safe Drinking Water Act (SDWA). Under
2243 SDWA, EPA must also review and revise “as appropriate” existing drinking water regulations every 6
2244 years.

2245
2246 EPA has promulgated National Primary Drinking Water Regulations (NPDWRs) for trichloroethylene
2247 under SDWA. See 40 CFR part 151; Appendix A. EPA has set an enforceable Maximum Contaminant
2248 Level (MCL) as close as feasible to a health based, non-enforceable Maximum Contaminant Level Goal
2249 (MCLG). Feasibility refers to both the ability to treat water to meet the MCL and the ability to monitor
2250 water quality at the MCL, SDWA Section 1412(b)(4)(D), and public water systems are required to
2251 monitor for the regulated chemical based on a standardized monitoring schedule to ensure compliance
2252 with the maximum contaminant level (MCL). Hence, because the drinking water exposure pathway for
2253 trichloroethylene is currently addressed in the SDWA regulatory analytical process for public water
2254 systems, EPA is not evaluating exposures to the general population from the drinking water exposure
2255 pathway in the Risk Evaluation for trichloroethylene under TSCA.
2256

2257 *Ambient water pathway*

2258 EPA develops recommended water quality criteria under section 304(a) of the CWA for pollutants in
2259 surface water that are protective of aquatic life or human health designated uses. EPA develops and
2260 publishes water quality criteria based on priorities of states and others that reflect the latest scientific
2261 knowledge. A subset of these chemicals are identified as “priority pollutants” (103 human health and 27
2262 aquatic life). The CWA requires states adopt numeric criteria for priority pollutants for which EPA has
2263 published recommended criteria under section 304(a), the discharge or presence of which in the affected
2264 waters could reasonably be expected to interfere with designated uses adopted by the state. When states
2265 adopt criteria that EPA approves as part of state’s regulatory water quality standards, exposure is
2266 considered when state permit writers determine if permit limits are needed and at what level for a
2267 specific discharger of a pollutant to ensure protection of the designated uses of the receiving water. Once
2268 states adopt criteria as water quality standards, the CWA requires that National Pollutant Discharge
2269 Elimination System (NPDES) discharge permits include effluent limits as stringent as necessary to meet
2270 standards. CWA section 301(b)(1)(C). This is the process used under the CWA to address risk to human
2271 health and aquatic life from exposure to a pollutant in ambient waters.
2272

2273 EPA has identified trichloroethylene as a priority pollutant and has developed recommended water
2274 quality criteria for protection of human health for trichloroethylene which are available for adoption into
2275 state water quality standards for the protection of human health and are available for use by NPDES
2276 permitting authorities in deriving effluent limits to meet state criteria.⁷ See, e.g., 40 CFR part 423,
2277 Appendix A; 40 CFR 131.11(b)(1); 40 CFR 122.44(d)(1)(vi). As such, EPA is not evaluating exposures
2278 to the general population from the surface water exposure pathway in the Risk Evaluation under TSCA.
2279

2280 *Land application of biosolids and general population exposure*

2281 As wastewater undergoes treatment, some wastewater treatment facilities such as publicly-owned
2282 treatment works (POTWs) use the remaining sludge as biosolids for land application. These biosolids
2283 could have residual trichloroethylene. Trichloroethylene in biosolids that are land applied could be
2284 transported via runoff from rainwater to surface waters. However, surface waters drawn for drinking
2285 water are treated, tested and under the Safe Drinking Water Act, regulated via NPDWRs. EPA
2286 promulgates NPDWRs under SDWA when the Agency concludes a contaminant may have adverse

⁷ See <https://www.epa.gov/wqc/ambient-water-quality-criteria-trichloroethylene>.

2287 health effects, occurs or is substantially likely to occur in public water systems at a level of concern and
2288 that regulation, in the sole judgement of the Administrator, presents a meaningful opportunity for health
2289 risk reduction. For each contaminant with NPDWRs, EPA sets an enforceable MCL as close as feasible
2290 to a health based, non-enforceable MCLG or establishes a treatment technique. The MCL for any
2291 residual levels of trichloroethylene that could result in exposure to the general population is 0.005mg/L.
2292 Residual concentrations of trichloroethylene in surface waters not used for drinking water are covered
2293 by the CWA Ambient Water Quality Criteria for human health consumption of water and organisms (0.4
2294 µg/L). CWA Section 304(a)(1). States and tribal governments may adopt the EPA Clean Water Act
2295 Section 304(a) recommended criteria or may adopt their own criteria that differ from EPA's
2296 recommendations, subject to EPA's approval, using scientifically defensible methods. States are
2297 required to adopt and implement EPA-approved criteria as part of their regulatory water quality
2298 standards, and compliance with these criteria is considered by states in permits and water quality
2299 assessment decisions. Thus, general population exposure via the biosolid pathway is not evaluated under
2300 any of the conditions of use in the final Risk Evaluation.

2301

2302 *Onsite Releases to Land Pathway*

2303 The Comprehensive Environmental Response, Compensation, and Liability Act – otherwise known as
2304 CERCLA or Superfund – provides EPA with broad authority to address uncontrolled or abandoned
2305 hazardous-waste sites as well as accidents, spills, and other releases of hazardous substances, pollutants
2306 and contaminants into the environment. Through CERCLA, EPA is provided authority to conduct a
2307 response action and seek reimbursement of cleanup costs from potentially responsible parties, or in
2308 certain circumstances, order a potentially responsible party to conduct a cleanup.

2309

2310 CERCLA Section 101(14) defines “hazardous substance” by referencing other environmental statutes,
2311 including toxic pollutants listed under CWA Section 307(a); hazardous substances designated pursuant
2312 to CWA Section 311(b)(2)(A); hazardous air pollutants listed under CAA Section 112; imminently
2313 hazardous substances with respect to which EPA has taken action pursuant to TSCA Section 7; and
2314 hazardous wastes having characteristics identified under or listed pursuant to RCRA Section 3001. See
2315 40 CFR 302.4. CERCLA Section 102(a) also authorizes EPA to promulgate regulations designating as
2316 hazardous substances those substances which, when released into the environment, may present
2317 substantial danger to the public health or welfare or the environment. EPA must also promulgate
2318 regulations establishing the quantity of any hazardous substance the release of which must be reported
2319 under Section 103. Section 103 requires persons in charge of vessels or facilities to report to the
2320 National Response Center if they have knowledge of a release of a hazardous substance above the
2321 reportable quantity threshold.

2322

2323 Trichloroethylene is a hazardous substance under CERCLA. Releases of trichloroethylene in excess of
2324 10 pounds within a 24-hour period must be reported (40 CFR 302.4, 302.6). The scope of this EPA
2325 TSCA Risk Evaluation does not include on-site releases to the environment of trichloroethylene at
2326 Superfund sites and subsequent exposure of the general population or non-human species.

2327

2328 *Disposal Pathways*

2329 Trichloroethylene is included on the list of hazardous wastes pursuant to RCRA section 3001 (40 CFR
2330 §§ 261.33) as a listed waste on the F001, F002, K030, and U228 lists. The general standard in RCRA
2331 section 3004(a) for the technical criteria that govern the management (treatment, storage, and disposal)
2332 of hazardous waste are those "necessary to protect human health and the environment," RCRA 3004(a).
2333 The regulatory criteria for identifying “characteristic” hazardous wastes and for “listing” a waste as

2334 hazardous also relate solely to the potential risks to human health or the environment. 40 C.F.R. §§
2335 261.11, 261.21-261.24. RCRA statutory criteria for identifying hazardous wastes require EPA to “tak[e]
2336 into account toxicity, persistence, and degradability in nature, potential for accumulation in tissue, and
2337 other related factors such as flammability, corrosiveness, and other hazardous characteristics.” Subtitle
2338 C controls cover not only hazardous wastes that are landfilled, but also hazardous wastes that are
2339 incinerated (subject to joint control under RCRA Subtitle C and the CAA hazardous waste combustion
2340 MACT) or injected into UIC Class I hazardous waste wells (subject to joint control under Subtitle C and
2341 SDWA).

2342
2343 EPA is not evaluating on-site releases to land from RCRA Subtitle C hazardous waste landfills or
2344 exposures of the general population or terrestrial species from such releases in the TSCA evaluation.
2345 Design standards for Subtitle C landfills require double liner, double leachate collection and removal
2346 systems, leak detection system, run on, runoff, and wind dispersal controls, and a construction quality
2347 assurance program. They are also subject to closure and postclosure care requirements including
2348 installing and maintaining a final cover, continuing operation of the leachate collection and removal
2349 system until leachate is no longer detected, maintaining and monitoring the leak detection and
2350 groundwater monitoring system. Bulk liquids may not be disposed in Subtitle C landfills. Subtitle C
2351 landfill operators are required to implement an analysis and testing program to ensure adequate
2352 knowledge of waste being managed, and to train personnel on routine and emergency operations at the
2353 facility. Hazardous waste being disposed in Subtitle C landfills, including TCE (listed as a hazardous
2354 waste in 40 CFR 261.31, 261.33), must also meet RCRA waste treatment standards before disposal. See
2355 40 CFR part 264; Appendix A.

2356
2357 EPA is not evaluating on-site releases to land from RCRA Subtitle D municipal solid waste (MSW)
2358 landfills or exposures of the general population or terrestrial species from such releases in the TSCA
2359 evaluation. While permitted and managed by the individual states, municipal solid waste landfills are
2360 required by federal regulations to implement some of the same requirements as Subtitle C landfills.
2361 MSW landfills generally must have a liner system with leachate collection and conduct groundwater
2362 monitoring and corrective action when releases are detected. MSW landfills are also subject to closure
2363 and post-closure care requirements, and must have financial assurance for funding of any needed
2364 corrective actions. MSW landfills have also been designed to allow for the small amounts of hazardous
2365 waste generated by households and very small quantity waste generators (less than 220 lbs per month).
2366 Bulk liquids, such as free solvent, may not be disposed of at MSW landfills. See 40 CFR part 258.

2367
2368 EPA is not evaluating on-site releases to land from industrial non-hazardous waste and
2369 construction/demolition waste landfills or associated exposures to the general population or terrestrial
2370 species in the trichloroethylene Risk Evaluation. Industrial non-hazardous and construction/demolition
2371 waste landfills are primarily regulated under authorized state regulatory programs. States must also
2372 implement limited federal regulatory requirements for siting, groundwater monitoring and corrective
2373 action and a prohibition on open dumping and disposal of bulk liquids. States may also establish
2374 additional requirements such as for liners, post-closure and financial assurance, but are not required to
2375 do so. See, *e.g.*, RCRA section 3004(c), 4007; 40 CFR part 257.

2376
2377 EPA is not evaluating emissions to ambient air from municipal and industrial waste incineration and
2378 energy recovery units or associated exposures to the general population or terrestrial species in the Risk
2379 Evaluation, as these emissions are regulated under Section 129 of the Clean Air Act. CAA Section 129
2380 requires EPA to review and, if necessary, add provisions to ensure the standards adequately protect
2381 public health and the environment. Thus, combustion by-products from incineration treatment of

2382 trichloroethylene wastes would be subject to these regulations, as would trichloroethylene burned for
2383 energy recovery. See 40 CFR part 60.

2384
2385 EPA is not evaluating on-site releases to land that go to underground injection or associated exposures to
2386 the general population or terrestrial species in its Risk Evaluation. Environmental disposal of
2387 trichloroethylene injected into Class I hazardous well types are covered under the jurisdiction of RCRA
2388 and SDWA and disposal of trichloroethylene via underground injection is not likely to result in
2389 environmental and general population exposures under any of the conditions of use in this final Risk
2390 Evaluation. See 40 CFR part 144.

2391 **1.4.3 Conceptual Models**

2392 The conceptual models for this final Risk Evaluation are shown in Figure 1-4, Figure 1-5, and Figure
2393 1-6. The EPA considered the potential for hazards to human health and the environment resulting from
2394 exposure pathways outlined in the preliminary conceptual models of the TCE scope document ([U.S.
2395 EPA, 2017d](#)). These conceptual models considered potential exposures resulting from consumer
2396 activities and uses, industrial/ commercial activities, and environmental releases and wastes. The
2397 Problem Formulation documents refined the initial conceptual models and analysis plans that were
2398 provided in the scope documents ([U.S. EPA, 2017d](#)).

2399
2400 For the purpose of this evaluation, EPA considered workers and occupational non-users, which includes
2401 men and women of reproductive age (Figure 1-4). Consumer exposure was assessed for various
2402 pathways for users age 11 and older along with bystanders of all ages (Figure 1-5).

2403
2404 The pathways that were determined to be included in the Risk Evaluation but did not warrant further
2405 analysis in this Risk Evaluation were: exposure to both humans and ecological organisms due to land
2406 application of biosolids following wastewater treatment and exposure to terrestrial organisms. In the
2407 Problem Formulation, the EPA determined that no further evaluation of these pathways is needed due to
2408 the physical/chemical properties associated with TCE (high vapor pressure) and its rapid volatilization
2409 to air from soil and water or rapid migration through soil into groundwater. Due to TCE's fate
2410 properties, a significant portion of TCE would not be available to enter the sediment compartment.

2411
2412 The pathways that were determined to be included in the Risk Evaluation and further analyzed include:

- 2413 • Exposure to aquatic species (*i.e.*, aquatic plants) via contaminated surface water.
- 2414 • Exposure to sediment-dwelling species via sediment.
- 2415 • Inhalation and dermal exposures to workers and consumers, and inhalation exposures to ONUs
2416 and bystanders, from industrial/commercial activities and consumer activities.
- 2417 • Inhalation and dermal exposures to workers and inhalation exposures to ONUs from waste
2418 handling, treatment and disposal.

2419
2420 Review and evaluation of reasonably available information on TCE confirmed the preliminary
2421 conclusions in the Problem Formulation ([U.S. EPA, 2018d](#)). The conceptual models from the Problem
2422 Formulation are shown below in Figure 1-4, Figure 1-5, and Figure 1-6.

2423


**INDUSTRIAL AND COMMERCIAL
ACTIVITIES / USES**

EXPOSURE PATHWAY

EXPOSURE ROUTE

RECEPTORS ^c

HAZARDS



2424

2425

Figure 1-4. TCE Conceptual Model for Industrial and Commercial Activities and Uses: Potential Exposures and Hazards

2426

The conceptual model presents the exposure pathways, exposure routes and hazards to human receptors from industrial and commercial activities and uses of TCE.

2427

^a Some products are used in both commercial and consumer applications. Additional uses of TCE are included in Table 1-3.

2428

^b Fugitive air emissions are those that are not stack emissions, and include fugitive equipment leaks from valves, pump seals, flanges, compressors, sampling connections and open-ended lines; evaporative losses from surface impoundment and spills; and releases from building ventilation systems.

2430

^c Receptors include Potentially Exposed or Susceptible Subpopulations (PESS) including women of childbearing age and their children and genetically susceptible populations.


2432

2433

^d When data and information are reasonably available to support the analysis, EPA also considers the effect that engineering controls and/or personal protective equipment have on occupational exposure levels.

2434

2435



2437
2438

Figure 1-5. TCE Conceptual Model for Consumer Activities and Uses: Potential Exposures and Hazards


The conceptual model presents the exposure pathways, exposure routes and hazards to human receptors from consumer activities and uses of TCE.

^a Some products are used in both commercial and consumer applications. Additional uses of TCE are included in Table 1-3.

^b Exposure may occur through mists that deposit in the upper respiratory tract however, based on physical chemical properties, mists of TCE will likely be rapidly absorbed in the respiratory tract or evaporate and not result in an oral exposure. Although less likely given the physical-chemical properties, oral exposure may also occur from incidental ingestion of residue on hand/body.

^c Receptors include Potentially Exposed or Susceptible Subpopulations (PESS).

2446
2447



2448
2449

Figure 1-6. TCE Conceptual Model for Environmental Releases and Wastes: Potential Exposures and Hazards

The conceptual model presents the exposure pathways, exposure routes and hazards to human and environmental receptors from environmental releases and wastes of TCE.

^a Industrial wastewater or liquid wastes may be treated on-site and then released to surface water (direct discharge), or pre-treated and released to POTW (indirect discharge).

2454
2455

1.5 Systematic Review

TSCA requires the EPA to use scientific information, technical procedures, measures, methods, protocols, methodologies and models consistent with the best available science and base decisions under section 6 on the weight of scientific evidence. Within the TSCA Risk Evaluation context, the weight of the scientific evidence is defined as “a systematic review method, applied in a manner suited to the nature of the evidence or decision, that uses a pre-established protocol to comprehensively, objectively, transparently, and consistently identify and evaluate each stream of evidence, including strengths, limitations, and relevance of each study and to integrate evidence as necessary and appropriate based upon strengths, limitations, and relevance.” (40 CFR 702.33).

To meet the TSCA § 26(h) science standards, EPA used the TSCA systematic review process described in the *Application of Systematic Review in TSCA Risk Evaluations* document ([U.S. EPA, 2018b](#)). The process complements the Risk Evaluation process in that the data collection, data evaluation and data integration stages of the systematic review process are used to develop the exposure and hazard assessments based on reasonably available information. EPA defines “reasonably available information” to mean information that EPA possesses, or can reasonably obtain and synthesize for use in Risk Evaluations, considering the deadlines for completing the evaluation (40 CFR 702.33).

EPA is implementing systematic review methods and approaches within the regulatory context of the amended TSCA. Although EPA will make an effort to adopt as many best practices as practicable from the systematic review community, EPA expects modifications to the process to ensure that the identification, screening, evaluation and integration of data and information can support timely regulatory decision making under the aggressive timelines of the statute.

1.5.1 Data and Information Collection

EPA planned and conducted a comprehensive literature search based on key words related to the different discipline-specific evidence supporting the Risk Evaluation (*e.g.*, environmental fate and transport; engineering releases and occupational exposure; consumers and environmental exposure; and environmental and human health hazard). EPA then developed and applied inclusion and exclusion criteria during the title and abstract screening to identify information potentially relevant for the Risk Evaluation process. The literature and screening strategy as specifically applied to TCE is described in the *Strategy for Conducting Literature Searches for Trichloroethylene (TCE): Supplemental File for the TSCA Scope Document* ([U.S. EPA, 2017e](#)) and the results of the title and abstract screening process were published in the [*Trichloroethylene (CASRN 79-01-6) Bibliography: Supplemental File for the TSCA Scope Document*; ([U.S. EPA, 2017i](#))].

For studies determined to be on-topic (or relevant) after title and abstract screening, EPA conducted a full text screening to further exclude references that were not relevant to the Risk Evaluation. Screening decisions were made based on eligibility criteria documented in the form of the populations, exposures, comparators, and outcomes (PECO) framework or a modified framework.⁸ Data sources that met the criteria were carried forward to the data evaluation stage. The inclusion and exclusion criteria for full text screening for TCE are available in Appendix F of the *Problem Formulation of the Risk Evaluation for Trichloroethylene* ([U.S. EPA, 2018d](#)).

⁸ A PESO statement was used during the full text screening of environmental fate and transport data sources. PESO stands for Pathways and Processes, Exposure, Setting or Scenario, and Outcomes. A RESO statement was used during the full text screening of the engineering and occupational exposure literature. RESO stands for Receptors, Exposure, Setting or Scenario, and Outcomes.

2498 Although EPA conducted a comprehensive search and screening process as described above, EPA made
2499 the decision to leverage the literature published in previous assessments⁹ when identifying relevant key
2500 and supporting data¹⁰ and information for developing the TCE Risk Evaluation. This is discussed in the
2501 *Strategy for Conducting Literature Searches for Trichloroethylene: Supplemental Document to the*
2502 *TSCA Scope Document* (U.S. EPA, 2017e). In general, many of the key and supporting data sources
2503 were identified in the comprehensive *Trichloroethylene (CASRN 79-01-6) Bibliography: Supplemental*
2504 *File for the TSCA Scope Document*; (U.S. EPA, 2017i). However, there were instances in which EPA
2505 missed relevant references that were not captured in the initial categorization of the on-topic references.
2506 EPA found additional relevant data and information using backward reference searching, which was a
2507 technique that will be included in future search strategies. This issue was discussed in Section 4 of the
2508 *Application of Systematic Review for TSCA Risk Evaluations* (U.S. EPA, 2018b). Other relevant key and
2509 supporting references were identified through targeted supplemental searches to support the analytical
2510 approaches and methods in the trichloroethylene Risk Evaluation (e.g., to locate specific information for
2511 exposure modeling) or to identify new data and information published after the date limits of the initial
2512 search.

2513
2514 EPA used previous chemical assessments to quickly identify relevant key and supporting information as
2515 a pragmatic approach to expedite the quality evaluation of the data sources, but many of those data
2516 sources were already captured in the comprehensive literature as explained above. EPA also considered
2517 newer information not taken into account by previous chemical assessments as described in the *Strategy*
2518 *for Conducting Literature Searches for Trichloroethylene: Supplemental Document to the TSCA Scope*
2519 *Document* (U.S. EPA, 2017e). EPA then evaluated the confidence of the key and supporting data
2520 sources as well as newer information instead of evaluating the confidence of all the underlying evidence
2521 ever published on a chemical substance's fate and transport, environmental releases, environmental and
2522 human exposure and hazards. All other literature from previous authoritative assessments were
2523 considered as supplemental information. A comprehensive evaluation of all of the data and information
2524 ever published for a chemical substance would be extremely labor intensive and could not be achieved
2525 considering the deadlines specified in TSCA section 6(b)(4)(G) for completing such evaluation for most
2526 chemical substances especially those that have a data rich database such as TCE. Furthermore, EPA
2527 evaluated how EPA's evaluation of the key and supporting data and information and newer information
2528 would change the previous conclusions presented in the previous assessments.

2529
2530 This pragmatic approach allowed EPA to maximize the scientific and analytical efforts of other
2531 regulatory and non-regulatory agencies by accepting for the most part the relevant scientific knowledge
2532 gathered and analyzed by others except for influential information sources that may have an impact on
2533 the weight of the scientific evidence and ultimately the risk findings. The influential information (i.e.,
2534 key/supporting) came from a smaller pool of sources subject to the rigor of the TSCA systematic review
2535 process to ensure that the Risk Evaluation uses the best available science and the weight of the scientific
2536 evidence.


2537

⁹ Examples of existing assessments are EPA's chemical assessments (e.g., previous work plan risk assessments, Problem Formulation documents), ATSDR's Toxicological Profiles, EPA's IRIS assessments and ECHA's dossiers. This is described in more detail in the *Strategy for Conducting Literature Searches for Trichloroethylene: Supplemental Document to the TSCA Scope Document* (U.S. EPA, 2017e).

¹⁰ Key and supporting data and information are those that support key analyses, arguments, and/or conclusions in the risk evaluation.

2538 Figures 1-5 to 1-9 below depict the literature flow diagrams illustrating the results of this process for
2539 each scientific discipline-specific evidence supporting the final Risk Evaluation. Each diagram provides
2540 the total number of references at the start of each systematic review stage (*i.e.*, data search, data
2541 screening, data evaluation, data extraction/data integration) and those excluded based on criteria guiding
2542 the screening and data quality evaluation decisions.
2543

2544 EPA made the decision to bypass the data screening step for data sources that were highly relevant to the
2545 final Risk Evaluation as described above. These data sources are depicted as “key/supporting data
2546 sources” in the literature flow diagrams. Note that the number of “key/supporting data sources” were
2547 excluded from the total count during the data screening stage and added, for the most part, to the data
2548 evaluation stage depending on the discipline-specific evidence. The exception was the engineering
2549 environmental releases and occupational exposure data sources that were subject to a combined data
2550 extraction and evaluation step (Figure 1-8).
2551



2552

*This is a key and supporting source from existing assessments, the EPI Suite™ set of models, that was highly relevant for the TSCA risk evaluation. This source bypassed the data screening step and moved directly to the data evaluation step.

2553

2554 **Figure 1-7. Literature Flow Diagram for Environmental Fate and Transport**

2555

2556 Note: Literature search results for the environmental fate and transport of TCE yielded 10,040 studies. During Problem
2557 Formulation, following data screening, most environmental exposure pathways were removed from the conceptual models.
2558 As a result, 9,979 studies were deemed off-topic and excluded. One key source ([U.S. EPA, 2012b](#)) and the remaining 61
2559 studies related to environmental exposure pathways retained in the conceptual models entered data evaluation, where 9
2560 studies were deemed unacceptable and 52 moved into data extraction and integration. Note: Data sources identified relevant
2561 to physical-chemical properties were not included in this literature flow diagram. The data quality evaluation of physical-
2562 chemical properties studies can be found in the supplemental document, [*Data Quality Evaluation of Physical-Chemical
2563 Properties Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*] and the extracted data are presented in Table 1-1.
2564
2565





Figure 1-8. Literature Flow Diagram for Engineering Releases and Occupational Exposure

Literature search results for environmental release and occupational exposure yielded 10,132 data sources. Of these data sources, 159 were determined to be relevant for the Risk Evaluation through the data screening process. These relevant data sources were entered into the data extraction/evaluation phase. After data extraction/evaluation, EPA identified several data gaps and performed a supplemental, targeted search to fill these gaps (e.g., to locate information needed for exposure modeling). The supplemental search yielded 8 relevant data sources that bypassed the data screening step [List of Key and Supporting Studies for Environmental Releases and Occupational Exposure. Docket: [EPA-HQ-OPPT-2019-0500](#)] and were evaluated and extracted in accordance with Appendix D: Data Quality Criteria for Occupational Exposure and Release Data of the Application of Systematic Review for TSCA Risk Evaluations document (U.S. EPA, 2018b). Of the 152 sources from which data were extracted and evaluated, 43 sources only contained data that were rated as unacceptable based on serious flaws detected during the evaluation. Of the 124 sources forwarded for data integration, data from 36 sources were integrated, and 73 sources contained data that were not integrated (e.g., lower quality data that were not needed due to the existence of higher quality data, data for release media that were removed from scope after data collection).

*The quality of data in these sources (n=73) were acceptable for risk assessment purposes, but they were ultimately excluded from further consideration based on EPA's integration approach for environmental release and occupational exposure data/information. EPA's approach uses a hierarchy of preferences that guide decisions about what types of data/information are included for further analysis, synthesis and integration into the environmental release and occupational exposure assessments. EPA prefers using data with the highest rated quality among those in the higher level of the hierarchy of preferences (i.e., data > modeling > occupational exposure limits or release limits). If warranted, EPA may use data/information of lower rated quality as supportive evidence in the environmental release and occupational exposure assessments.



*The quality of data in these sources were acceptable for risk assessment purposes and considered for integration. The sources; however, were not extracted for a variety of reasons, such as they contained only secondary source data, duplicate data, or non-extractable data (i.e., charts or figures). Additionally, some data sources were not as relevant to the PECO as other data sources which were extracted.

Figure 1-9. Literature Flow Diagram for Consumer and Environmental Exposure Data Sources

EPA conducted a literature search to determine relevant data sources for assessing exposures for trichloroethylene within the scope of the Risk Evaluation. This search identified 1149 data sources including relevant supplemental documents. Of these, 998 were excluded during the screening of the title, abstract, and/or full text and 151 data sources were recommended for data evaluation across up to five major study types in accordance with *Appendix E: Data Quality Criteria for Studies on Consumer, General Population and Environmental Exposure of the Application of Systematic Review for TSCA Risk Evaluations* document (U.S. EPA, 2018b). Following the evaluation process, 79 references were forwarded for further extraction and data integration. EPA has not developed data quality criteria for all types of exposure information, some of which may be relevant when estimating consumer exposures. This is the case for absorption and permeability data and some product-specific data such as density and weight fraction often reported in Safety Data Sheets. As appropriate, EPA evaluated and summarized these data to determine their utility with supporting the Risk Evaluation.

2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607




Figure 1-10. Literature Flow Diagram for Environmental Hazard

The environmental hazard data sources were identified through literature searches and screening strategies using the ECOTOXicology Knowledgebase System (ECOTOX) Standing Operating Procedures. For studies determined to be on-topic after title and abstract screening, EPA conducted a full text screening to further exclude references that were not relevant to the Risk Evaluation. Screening decisions were made based on eligibility criteria as documented in the ECOTOX User Guide (U.S. EPA, 2018c). Additional details can be found in the *Strategy for Conducting Literature Searches for Trichloroethylene Supplemental Document to the TSCA Scope Document* (U.S. EPA, 2017e).

The “Key/Supporting Studies” box represents data sources cited in an existing assessment (Environment Canada and Health Canada, 1993) that were considered highly relevant for the TSCA Risk Evaluation because they were used as key and supporting information by another regulatory organization to support their chemical hazard and risk assessment. These citations were found independently from the ECOTOX process. These studies bypassed the data screening step and moved directly to the data evaluation step. These two studies were ultimately excluded because they examined hazard to terrestrial species and the relevant exposure pathway of air releases has since been determined to be out of scope.

The literature search process for environmental hazard data found 8,565 citations for TCE. At the title and abstract screening phase, 8,144 citations were excluded as off-topic using ECOTOXicology knowledgebase criteria. The remaining 419 citations underwent a more thorough full text screening using the same criteria to determine which citations should undergo data evaluation. For data evaluation, EPA developed data quality evaluation (DQE) criteria to evaluate the data under TSCA, based on a combination of EPA’s ECOTOXicology knowledgebase (ECOTOX) criteria and the Criteria for Reporting and Evaluating ecotoxicity Data (CRED). There were 71 citations that went to data evaluation for TCE, which included the above-mentioned two additional citations gathered from (Environment Canada and Health Canada, 1993) that were later excluded as out of scope. EPA analyzed each of these studies using the DQE results to determine overall study quality. Twenty-five studies were considered acceptable and were rated high, medium, or low quality during this analysis. The extracted data from these 25 studies were used during data integration for TCE.




Figure 1-11. Literature Flow Diagram for Human Health Hazard

The literature search results for human health hazard of TCE yielded 6,049 studies. This included 95 key and supporting studies identified from previous EPA assessments¹¹. Of the 5,954 new studies screened for relevance, 5,869 were excluded as off topic. The remaining 85 new studies together with the 95 key and supporting studies entered data evaluation. Ten studies were deemed unacceptable based on the evaluation criteria for human health hazard data sources and the remaining 170 studies were carried forward to data extraction/data integration. Additional details can be found in the *Strategy for Conducting Literature Searches for Trichloroethylene Supplemental Document to the TSCA Scope Document* ([U.S. EPA, 2017e](#)).

The “Key/Supporting Studies” box represents data sources cited in an existing assessment ([U.S. EPA, 2011e](#)) that were considered highly relevant for the TSCA Risk Evaluation because they were used as key and supporting information by another regulatory organization to support their chemical hazard and risk assessment. For a list of the key and supporting studies, see *[List of Key and Supporting Studies for Human Health Hazard. Docket # EPA-HQ-OPPT-2019-0500]*.

1.5.2 Data Evaluation

During the data evaluation stage, the EPA assesses the quality of the methods and reporting of results of the individual studies identified during Problem Formulation using the evaluation strategies described in *Application of Systematic Review in TSCA Risk Evaluations* ([U.S. EPA, 2018b](#)). The EPA evaluated the quality of the on-topic TCE study reports identified in *[Trichloroethylene (CASRN 79-01-6) Bibliography: Supplemental File for the TSCA Scope Document; (U.S. EPA, 2017i)]*, and gave all studies an overall high, medium, low or unacceptable confidence rating during data evaluation.

The results of the data quality evaluations for key studies are summarized in Section 2.1 (Fate and Transport), Section **Error! Reference source not found.** (Releases to the Environment), Section 2.2.6 (Environmental Exposures), Section 2.3 (Human Exposures), Section 3.1 (Environmental Hazards) and

¹¹ “Key and supporting studies” for human health are those deemed suitable for consideration for dose-response analysis. This does not include mechanistic or qualitative data, including genotoxicity studies. Data extraction and evaluation results for all relevant genotoxicity studies are presented in *[Data Extraction and Evaluation Tables for Genotoxicity Studies. Docket: EPA-HQ-OPPT-2019-0500]*.

2664 Section 3.2 (Human Health Hazards). Supplemental files¹² also provide details of the data evaluations
2665 including individual metric scores and the overall study score for each data source (Docket: [EPA-HQ-](#)
2666 [OPPT-2019-0500](#)).

2667 **1.5.3 Data Integration**

2668 Data integration includes analysis, synthesis and integration of information for the Risk Evaluation.
2669 During data integration, the EPA considers quality, consistency, relevancy, coherence and biological
2670 plausibility to make final conclusions regarding the weight of the scientific evidence. As stated in
2671 *Application of Systematic Review in TSCA Risk Evaluations* ([U.S. EPA, 2018b](#)), data integration
2672 involves transparently discussing the significant issues, strengths, and limitations as well as the
2673 uncertainties of the reasonably available information and the major points of interpretation ([U.S. EPA,](#)
2674 [2018e](#)). EPA defines “reasonably available information” to mean information that EPA possesses, or can
2675 reasonably obtain and synthesize for use in Risk Evaluations, considering the deadlines for completing
2676 the evaluation (*Procedures for Chemical Risk Evaluation Under the Amended Toxic Substances Control*
2677 *Act* (82 FR 33726).

2678
2679 EPA used previous assessments (see Table 1-2) to identify key and supporting information and then
2680 analyzed and synthesized available evidence regarding TCE’s chemical properties, environmental fate
2681 and transport properties and its potential for exposure and hazard. EPA’s analysis also considered recent
2682 data sources that were not considered in the previous assessments (Section 1.5.1) as well as reasonably
2683 available information on potentially exposed or susceptible subpopulations.

2684
2685 The exposures and hazards sections describe EPA’s analysis of the influential information (*i.e.*, key and
2686 supporting data) that were found acceptable based on the data quality reviews as well as discussion of
2687 other scientific knowledge using the approach described in Section 1.5.1. The exposure section also
2688 describes whether aggregate or sentinel exposures to a chemical substance were considered under the
2689 conditions of use within the scope of the Risk Evaluation, and the basis for that consideration.
2690
2691

¹² See Appendix B for the list of all supplemental files.

2 EXPOSURES

For TSCA exposure assessments, EPA evaluated exposures and releases to the environment resulting from the conditions of use applicable to TCE. Post-release pathways and routes were described to characterize the relationship or connection between the conditions of use for TCE (Section 1.4.1) and the exposure to human receptors, including potentially exposed or susceptible subpopulations (PESS) and ecological receptors. EPA considered, where relevant, the duration, intensity (concentration), frequency and number of exposures in characterizing exposures to TCE.

2.1 Fate and Transport

Environmental fate includes both transport and transformation processes. Environmental transport is the movement of the chemical within and between environmental media. Transformation occurs through the degradation or reaction of the chemical with other species in the environment. Hence, knowledge of the environmental fate of the chemical informs the determination of the specific exposure pathways and potential human and environmental receptors EPA expects to consider in the Risk Evaluation. Table 2-1 presents environmental fate data that EPA identified and considered in the Scoping and Problem Formulation documents as well as additional data extracted from the systematic review process.

Table 2-1. Environmental Fate Characteristic of TCE

Property or Endpoint	Value ^a	References	Data Quality Rating
Indirect photodegradation	1-11 days (atmospheric oxidation based on measured hydroxyl radical oxidation)	(U.S. EPA, 2014b)	High
Hydrolysis half-life	10.7 months (average; decomposition in aerated water in the dark; part of the reaction may have occurred in the vapor phase)	(Dilling et al., 1975)	High
Biodegradation	0% after 3 months (aerobic groundwater)	(Nielsen et al., 1996)	High
	38.9% after 28 days (aerobic OECD 302B Inherent biodegradability test)	(Tobajas et al., 2016)	High
	100% degradation after 20 days (anaerobic serum bottle test with added glucose, phenol, benzoate, acetate, and methanol on incubated shaker table)	(Long et al., 1993)	High
	0% degradation after 40 days (anaerobic groundwater in untreated wells)	(Schmidt and Tiehm, 2008)	High
	100% degradation after 40 days (anaerobic groundwater microcosms with added hydrogen/acetate)	(Schmidt and Tiehm, 2008)	High

Property or Endpoint	Value ^a	References	Data Quality Rating
	TCE removed slowly with a reduction of 40% after 8 weeks (TCE (200 µg/L) incubated with batch bacterial cultures under methanogenic conditions)	(Bouwer and McCarty, 1983)	High
	100% degradation after 20 days (aerobic with Methane culture, aerobic with phenol culture)	(Long et al., 1993)	High
Bioconcentration factor (BCF)	17 (Bluegill)	(Barrows et al., 1980)	High
	18.4 (estimated)	(U.S. EPA, 2012b)	High
Bioaccumulation factor (BAF)	24 (estimated)	(U.S. EPA, 2012b)	High
Organic carbon:water partition coefficient (Log K _{oc})	1.8 (estimated by MCI method)	(U.S. EPA, 2012b)	High
	2.1 (estimated by K _{ow} method)		
^a Measured unless otherwise noted			

19

20

2.1.1 Fate and Transport Approach and Methodology

21 EPA gathered and evaluated environmental fate information according to the process described in the
 22 Application of *Systematic Review in TSCA Risk Evaluations* ([U.S. EPA, 2018b](#)). Reasonable available
 23 environmental fate data, including biotic and abiotic degradation rates, removal during wastewater
 24 treatment, volatilization from lakes and rivers, and organic carbon:water partition coefficient (K_{oc}) were
 25 selected for use in this assessment document.

26

27 Other fate estimates were based on modeling results from EPI (Estimation Programs Interface) Suite™
 28 ([U.S. EPA, 2012b](#); <https://www.epa.gov/tasca-screening-tools/epi-suite™-estimation-program-interface>),
 29 a predictive tool for physical/chemical and environmental fate properties. EPI Suite™ was reviewed by
 30 the EPA Science Advisory Board
 31 (<https://yosemite.epa.gov/sab/sabproduct.nsf/02ad90b136fc21ef85256eba00436459/CCF982BA9F9CF>
 32 [CFA8525735200739805/\\$File/sab-07-011.pdf](https://yosemite.epa.gov/sab/sabproduct.nsf/02ad90b136fc21ef85256eba00436459/CCF982BA9F9CF_CFA8525735200739805/$File/sab-07-011.pdf)) and the individual models have been peer reviewed in
 33 numerous articles published in technical journals. Citations for such articles are available in the EPI
 34 Suite™ help files. Table 2-1 provides environmental fate data that EPA considered while assessing the
 35 fate of TCE.

36

2.1.2 Summary of Fate and Transport

37 The EPI Suite™ ([U.S. EPA, 2012b](#)) STP model was run using default settings (set biodegradation half-
 38 life to 10,000 hours) to evaluate the potential for TCE to volatilize to air or adsorb to sludge during
 39 wastewater treatment. In order to improve the accuracy of the EPI Suite™ estimations, physical and
 40 chemical properties (Log K_{ow}, Boiling point, Melting point, Vapor Pressure, Water solubility, Henry's
 41 Law Constant) from Table 1-1 were entered into EPI Suite along with TCE's SMILES notation entry
 42 (C(=CCL)(CL)CL) before running the module.

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

If TCE is released to the air, TCE does not absorb radiation well at wavelengths that are present in the lower atmosphere (>290 nm) so direct photolysis is not a main degradation process. Degradation by reactants in the atmosphere has a half-life of several days meaning that long range transport is possible.

If TCE is released to water, sediment or soil, the fate of TCE is influenced by volatilization from the water surface or from soil as indicated by its physical chemical properties (e.g., Henry's law constant) and by microbial biodegradation under some conditions. The EPI Suite™ model that estimates volatilization from lakes and rivers ("Volatilization" model) was run using default settings to evaluate the volatilization half-life of TCE in surface water. The volatilization model estimates that the half-life of TCE in a model river is 1.2 hours and the half-life in a model lake is 110 hours. Therefore, the volatilization is likely to be a significant removal process. Although the log K_{oc} indicates that TCE will partition to sediment organic carbon, organic matter typically comprises 25% or less of sediment composition (e.g., <https://pubs.usgs.gov/of/2006/1053/downloads/pdf/of-2006-1053.pdf>) of which approximately 40-60% is organic carbon (Schwarzenbach et al., 2003). Based on these values, and the range of K_{oc} of 1.8 to 2.1 the sediment-water K_d (where K_d = K_{oc} *f_{oc}) is expected to be equal to or less than 9.5 to 19, indicating that at equilibrium, concentrations in sediment would be expected to be less than 19 times higher than in porewater. So, TCE is expected to be present in sediment pore water with concentrations similar to or less than the overlying water. This is due to partitioning to organic matter in sediment and relatively more rapid biodegradation in anaerobic and methanogenic environments compared to aerobic conditions assumed closer to the surface of the water column. In the case of spills or leaks of TCE directly to soil or surface water, TCE may sink as a dense non-aqueous phase liquid (DNAPL). However, such spills and leaks are not considered conditions of use within the scope of the Risk Evaluation.

If TCE is released to wastewater treatment, the removal percentage of TCE is estimated by using the STP model in EPI Suite™ as 81%, including 80% removal via volatilization and 1% removal via adsorption. This value (81%) is used for the calculation of exposure assessment in this document. TCE present in the solids and water portion of biosolids following wastewater treatment and land application would be expected to rapidly volatilize into air. Furthermore, TCE is not anticipated to remain in soil, as it is expected to either volatilize into air or migrate through soil into groundwater.

The partitioning of TCE released to air, water and soil is informed by the use of the level III fugacity model in EPI Suite™. The fugacity model in EPI Suite™ is a level III multimedia fate model which uses environmental parameters and computations identical to those used in (Mackay et al., 1992). The model environment consists of four main compartments: air, water sediment and soil. Mass transport between the compartments via volatilization, diffusion, deposition and runoff are modeled. The level III fugacity model in EPI Suite™ was not used to determine any specific environmental concentrations of TCE. The model was used to qualitatively assess how TCE will behave in specific media (i.e., setting the model to 100% emission to a single medium) in order to inform development of Figure 2-1. EPA also ran the level III fugacity model using emissions from a mass balance developed to account for the amount of TCE entering and leaving all facilities in the United States. For the mass balance EPA attempted to quantify the amount of trichloroethylene associated with each of its life cycle stages from introduction into commerce in the U.S. (from both domestic manufacture and import), processing, use, release, and disposal. The mass balance development and uncertainties are detailed in Appendix R. Physical chemical and environmental fate properties used as input to the model were taken from Table 1-1 and Table 2-1, respectively. The model was run using annual emissions to air and water from the mass balance converted to kilograms per hour. Land disposal, energy recovery and treatment, and off-site recycling were not considered as environmental releases.

92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134

The emissions to air from the mass balance comprise >99% of the total emissions with less than one percent released to water. The model estimates 99.2 percent of TCE will remain in air when release estimates from the mass balance are used. TCE was predicted to continue to partition to air based on its greater fugacities in water and sediment compared to its fugacity in air. The details of the model results are given in Appendix S.

The biodegradation of TCE in the environment is dependent on a variety of factors and thus, a wide range of degradation rates have been reported (ranging from days to years). The BIOWIN module in the EPI Suite™ was run using default settings to estimate biodegradation rates of TCE in soil and sediment. Three out of the four models built in the BIOWIN module (BIOWIN 1, 2, and 5) estimate that TCE will not rapidly biodegrade in aerobic environments, while a fourth (BIOWIN 6) estimates that TCE will rapidly biodegrade in aerobic environments. The weight of the scientific evidence from these estimates suggests that TCE does not biodegrade quickly under aerobic condition. This conclusion is supported by test results in a frequently cited publication ([Rott et al.,1982](#)) which indicates 19% aerobic biodegradation in 28 days (OECD 301D) and 2.4% aerobic biodegradation in 14 days (OECD 301C), respectively. The data were also cited in the 2004 EU TCE Risk Assessment ([ECB, 2004](#)).

During the systematic review process, a high-quality aerobic serum bottle biodegradation study reported that 100% degradation occurred in 20 days in methane and phenol cultures. The result indicates that the aerobic degradation rate with either methane or phenol culture is “fast” and is different from the BIOWIN predictions. However, the “fast” aerobic biodegradation with special cultures cannot represent general environmental conditions, so the “slow aerobic biodegradation” considered in the scoping and Problem Formulation documents was not changed in this Risk Evaluation document.

During the systematic review for fate endpoints, several high-quality anaerobic biodegradation test data were identified and inserted into the original fate table summarized in the Problem Formulation document ([U.S. EPA, 2018c](#)). The added anaerobic biodegradation data suggest that the TCE anaerobic biodegradation rate ranges from slow to rapid and may be dependent on presence of electron donating co-metabolites.

The systematic review did not identify any additional studies for sorption coefficient to soil and sediments, therefore, the log K_{OC} value was estimated with EPI Suite™ as 1.8, which is close to the measured values ranged from 1.86 to 2.17 with different soils in the previous TCE assessments ([U.S. EPA, 2014b](#)). These log K_{OC} values (1.8-2.1) suggest that the sorption of TCE to soil and sediment is low and TCE is mobile in soil and sediment.

The systematic review identified a high quality bioconcentration data with low BCF (BCF=17; [Barrows, 1980](#)). The BAF of TCE is also low (BAF=24) based on EPI Suite™ estimation. Therefore, TCE is not expected to accumulate in aquatic organisms due to low BCF and BAF.

Figure 2-1 summarizes the overall partitioning and degradation expected for TCE.




Figure 2-1. Environmental transport, partitioning and degradation processes for TCE

135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151

In Figure 2-1, transport and partitioning are indicated by green arrows and degradation is indicated by orange arrows. The width of the arrow is a qualitative indication of the likelihood that the indicated partitioning will occur or the rate at which the indicated degradation will occur (*i.e.*, wider arrows indicate more likely partitioning or more rapid degradation). Because transport and partitioning processes (green arrows) can occur in both directions across an interface, the transport and partitioning pathways are illustrated with arrows pointing in both directions. For interfaces where one direction of transport and partitioning is expected to prevail based on release rates and partition coefficients, the primary direction of transport is indicated by a wider arrow. However, the direction of transport in a given locality depends on the site-specific properties of environmental media, weather conditions, TCE release rates, degradation and transformation rates, and TCE concentrations within environmental compartments. The question marks over the aerobic and anaerobic biodegradation arrows indicate uncertainty regarding how quickly TCE will biodegrade. Figure 2-1 considers only transport, partitioning, and degradation within and among environmental media; sources to the environment such as discharge and disposal are not illustrated.

2.1.3 Assumptions and Key Sources of Uncertainty for Fate and Transport

152
153
154
155
156
157
158
159
160
161
162

A range of biodegradation rates have been reported for TCE. The range of degradation rates reported were measured in laboratory studies for biodegradation in water, soil and sediment. These studies are subject to several sources of variability including variability inherent in the methodology, inter-laboratory variability and variability due to factors such as the specific microbial populations used, water, soil and sediment chemistry, oxygen concentration/redox potential, of the collected samples used in the study, temperature and test substance concentration. No single value is universally applicable as it is influenced by these variables and possibly others. However, the weight of evidence shows the aerobic biodegradation of TCE is slow and the anerobic biodegradation in anaerobic condition ranges from slow to rapid. Anaerboic biodegradation results in formation of dichloroethylene (DCE) and which is subsequently degraded to vinyl chloride monomer (VCM) in the same conditions ([Vogel and](#)

163 [McCarty, 1985](#)). But the portion of TCE that is anaerobically biodegraded, thereby forming DCE and
164 VCM, is unknown.

165
166 The range of Log K_{OC} values (1.8-2.1) is supported by the basic principles of environmental chemistry
167 which states that the K_{OC} is typically within one order of magnitude (one log unit) of the octanol:water
168 partition coefficient (K_{ow}).

169 The density of TCE relative to water may result in the formation of free product, or (dense non-aqueous
170 phase liquid) DNAPL under certain conditions. However, under the conditions of use for TCE examined
171 under this Risk Evaluation, it is not expected that TCE DNAPL would be found where dissolved
172 concentrations are less than 1% of its aqueous solubility, or 12,800 ug/L at 25°C ([Horvath et al., 1999](#)).
173 Under conditions in which TCE is present in surface water at concentrations of less than 1% of its
174 solubility, the physical and chemical properties of TCE that lead to TCE's classification as a DNAPL
175 are not likely to increase the residence time in surface water. DNAPL formation in benthic sediments
176 and in subsurface soils and aquifers is not likely to result from the conditions of use described in this
177 final Risk Evaluation.

178 The Volatilization from Water (WVol) model in EPI Suite™ is a screening level model that estimates
179 the rate of volatilization of a chemical from a model river and lake. The estimation method follows a
180 two-film concept for estimating the flux of volatiles across the air-water interface. The program's default
181 parameters for a model river were selected to yield a half-life that may be indicative of relatively fast
182 volatilization from environmental waters due to default current velocity, river depth and wind velocity.
183 The default parameters for the lake yield a much slower volatilization rate. The low wind velocity and
184 current speed are indicative of a pond (or very shallow lake) under relatively calm conditions. These
185 default parameters were selected to specifically model a body of water under calm conditions. Although
186 physical chemical properties of the modeled substance and wind speed, water flow velocity and water
187 depth can be modified by the user, the model does not employ all site specific environmental parameters
188 that effect the rates of volatilization. Therefore, rates of volatilization at a specific location under
189 specific environmental conditions could be over or under estimated by the model.

190
191 Accurate inputs are critical for fugacity modeling. Inputs to the level III fugacity model include half-
192 lives in various media, physical chemical properties, and emissions to air, water and soil. As
193 demonstrated by the change in predicted mass of TCE in each compartment when assumptions regarding
194 emissions (mass released to each environmental compartment) are varied, model results are significantly
195 impacted by emissions assumptions. Thus, for optimal use of the model, complete emissions inventories
196 are needed. EPA developed a mass balance for TCE, however, the uncertainty associated with the mass
197 balance and associated releases to the environment carries over to uncertainty in the results of the
198 fugacity modeling. The results of level III fugacity modeling indicate that TCE released to water will
199 partition to air. However, as noted in the SACC review of the TCE draft Risk Evaluation, release
200 scenarios could exist that, when modeled, indicate movement of TCE from air to water. Under that
201 scenario estimated surface water concentrations could be underpredicted if only direct releases to water
202 are considered.

203
204

205 **2.2 Environmental Exposures**

206 **2.2.1 Environmental Exposures Overview**


207 In this section, EPA presents environmental exposures to TCE for aquatic organisms. Exposure to
208 terrestrial organisms is expected to be low since physical chemical properties do not support an exposure
209 pathway through water and soil pathways to these organisms. To characterize environmental exposure,
210 EPA assessed exposures derived from both predicted and measured concentrations of TCE in surface
211 water in the U.S.

212
213 Aquatic exposures associated with the industrial and commercial conditions of use evaluated were
214 predicted through modeling. Predicted surface water concentrations resulting from facility releases in
215 the EPA Lifecycle Release Analysis were generated for reporting year 2016. Release estimates were
216 based on loading and/or production volume information obtained from TRI, DMR, and CDR (See
217 Section **Error! Reference source not found.**). The surface water modeling was conducted with EPA’s
218 Exposure and Fate Assessment Screening Tool, version 2014 ([U.S. EPA, 2014c](#)), using reported annual
219 release/loading amounts (kg/yr) and estimates of the number of days per year that the annual load is
220 released. The Probabilistic Dilution Model (PDM), a module of E-FAST 2014, was run to predict the
221 number of days per year predicted stream concentrations are expected to exceed the designated chronic
222 aquatic COC value.

223
224 The aquatic exposure assessment also includes an analysis of collected measured surface water
225 concentrations from monitoring data in EPA’s Water Quality Exchange (WQX) using the online Water
226 Quality Portal (WQP) tool and published literature obtained and evaluated through a systematic review
227 process. WQX is the nation’s largest source of water quality monitoring data and includes results from
228 EPA’s STORage and RETrieval (STORET) Data Warehouse, the United States Geological Service
229 (USGS) National Water Information System (NWIS), and other federal, state, and tribal sources. A
230 literature search was also conducted to identify other peer-reviewed or gray sources of measured surface
231 water concentrations in the US. The measured concentrations reflect ambient surface water
232 concentrations at the monitoring sites but cannot be directly attributed to specific industrial or
233 commercial conditions of use. A geospatial analysis at the watershed level was conducted to compare
234 the measured and predicted surface water concentrations and investigate whether modeled facility
235 releases may be located within the same watershed as observed concentrations in surface water.

236 **2.2.2 Environmental Releases to Water**

237 EPA categorized COUs listed in Table 1-3 into 18 OESs. For each OES, a daily water release was
238 estimated based on annual releases, release days, and the number of facilities (Figure 2-2). In this
239 section, EPA describes its approach and methodology for estimating daily water releases, and for each
240 OES, provides a summary of release days, number of facilities, and daily water releases. For detailed
241 facility level results, see Appendix Q of this document and the “Water Release Assessment” section for
242 each OES in [*Environmental Releases and Occupational Exposure Assessment. Docket: [EPA-HQ-
243 OPPT-2019-0500](#)*].



244 **Figure 2-2. An overview of how EPA estimated daily water releases for each OES.**¹³
 245

246 **2.2.2.1 Results for Daily Release Estimate**

247 EPA combined its estimates for annual water releases, release days, and number of facilities to estimate
 248 a range for daily water releases for each OES. A summary of these ranges across facilities is presented
 249 in Table 2-2. See Table 2-5 for more details on deriving the overall confidence score for each OES. For
 250 some OES, EPA was not able to estimate or did not expect water releases. For example:

- 251 • **OES Aerosol Application:** Water releases were not expected due to the volatile nature of TCE;
 252 releases from this OES are expected to be to air.
- 253 • **OES Formulation of Aerosol and Non-Aerosol Products:** All releases reported in TRI were
 254 to off-site land, incineration, or recycling.
 255

256
 257 **Table 2-2. Summary of EPA’s daily water release estimates for each OES and also EPA’s Overall**
 258 **Confidence in these estimates.**

Occupational Exposure Scenario (OES)	Estimated Daily Water Release Range Across Sites (kg/site-day)		Overall Confidence	Source and Notes
	Minimum	Maximum		
Manufacturing	0	1.27	M	From TRI, DMR
Processing as a Reactant	1.7E-03	0.02	M	From TRI, DMR
Formulation of Aerosol and Non-Aerosol Products	-	-	-	No information identified to estimate water releases
Repackaging	6.8E-06	1.1	M	From TRI, DMR
Batch Open-Top Vapor Degreasing	2.53E-07	1.96	M	From TRI, DMR
Batch Closed-Loop Vapor Degreasing	2.53E-07	1.96	M	Same as Batch Open-Top Vapor Degreasing ^a

¹³ TRI = Toxics Release Inventory; DMR = Discharge Monitoring Report; NEI = National Emissions Inventory; CDR = Chemical Data Reporting; ELG = Effluent Limitation Guidelines; ESD = Emission Scenario Document

Occupational Exposure Scenario (OES)	Estimated Daily Water Release Range Across Sites (kg/site-day)		Overall Confidence	Source and Notes
	Minimum	Maximum		
Conveyorized Vapor Degreasing	2.53E-07	1.96	M	Same as Batch Open-Top Vapor Degreasing ^a
Web Vapor Degreasing	2.53E-07	1.96	M	Same as Batch Open-Top Vapor Degreasing ^a
Cold Cleaning	2.53E-07	1.96	M	Same as Batch Open-Top Vapor Degreasing ^a
Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	-	-	H	EPA expects releases of TCE to be to air for this OES
Metalworking Fluids	2.53E-07	1.96	M	Same as Batch Open-Top Vapor Degreasing ^a
Adhesives, Sealants, Paints, and Coatings	3.68E-06	0.30	M	From TRI, DMR
Other Industrial Uses	9.2E-06	1.6	M	From DMR
Spot Cleaning and Wipe Cleaning	2.9E-05	8.0E-05	M	From DMR
Industrial Processing Aid	5.5E-04	0.4	M	From TRI, DMR
Commercial Printing and Copying	2.0E-04	2.0E-04	-	Based on only one reported release in DMR
Other Commercial Uses	1.9E-06	0.013	M	From DMR
Process Solvent Recycling and Worker Handling of Wastes	1.6E-06	24.1	M	From TRI, DMR

259 ^a Water releases from OTVD were repeated for other degreasing operations and for MWF because the releases were
260 estimated using TRI and DMR data. Due to the limited information in these reporting programs, these sites may in fact not
261 operate OTVDs, but may operate other solvent cleaning machines or perform metalworking activities (e.g., closed-loop
262 degreasing, conveyorized degreasing, web cleaning, or cold cleaning) or use of TCE as a metalworking fluid. They are
263 included in the OTVD assessment as EPA expects OTVDs to be the most likely condition of use. EPA assessed annual
264 releases as reported in the 2016 TRI or 2016 DMR and assessed daily releases by assuming 260 days of operation per year, as
265 recommended in the 2017 ESD on Use of Vapor Degreasers, and averaging the annual releases over the operating days.

266 2.2.2.2 Approach and Methodology

267 2.2.2.2.1 Water Release Estimates

268 Where available, EPA used 2016 TRI ([U.S. EPA, 2017g](#)) and 2016 DMR ([U.S. EPA, 2016a](#)) data to
269 provide a basis for estimating releases. Facilities are only required to report to TRI if the facility has 10
270 or more full-time employees, is included in an applicable NAICS code, and manufactures, processes, or
271 uses the chemical in quantities greater than a certain threshold (25,000 pounds for manufacturers and
272 processors of TCE and 10,000 pounds for users of TCE). Due to these limitations, some sites that
273 manufacture, process, or use TCE may not report to TRI and are therefore not included in these datasets.

274
275 For the 2016 DMR ([U.S. EPA, 2016a](#)), EPA used the Water Pollutant Loading Tool within EPA's
276 Enforcement and Compliance History Online (ECHO) to query all TCE point source water discharges in
277 2016. DMR data are submitted by National Pollutant Discharge Elimination System (NPDES) permit
278 holders to states or directly to the EPA according to the monitoring requirements of the facility's permit.
279 States are only required to load major discharger data into DMR and may or may not load minor

280 discharger data. The definition of major vs. minor discharger is set by each state and could be based on
281 discharge volume or facility size. Due to these limitations, some sites that discharge TCE may not be
282 included in the DMR dataset.

283
284 Where releases are expected but TRI and DMR data were not available or where EPA determined TRI
285 and DMR data did not sufficiently represent releases of TCE to water for a condition of use, releases
286 were estimated using data from literature, relevant Emission Scenario Documents (ESDs) or Generic
287 Scenarios (GSs), existing EPA models (*e.g.*, EPA Water Saturation Loss Model), and/or relevant
288 Effluent Limitation Guidelines (ELG). ELG are national regulatory standards set forth by EPA for
289 wastewater discharges to surface water and municipal sewage treatment plants. For more details, please
290 refer to Appendix L.

291 **2.2.2.2.2 Estimates of Number of Facilities**

292 Where available, EPA used 2016 CDR ([U.S. EPA, 2016c](#)), 2016 TRI ([U.S. EPA, 2017g](#)), 2016
293 Discharge Monitoring Report (DMR) ([U.S. EPA, 2016a](#)) and 2014 National Emissions Inventory (NEI)
294 ([U.S. EPA, 2018a](#)) data to provide a basis to estimate the number of sites using TCE within a condition
295 of use. Generally, information for reporting sites in CDR and NEI was sufficient to accurately
296 characterize each reporting site's condition of use. However, information for determining the condition
297 of use for reporting sites in TRI and DMR is typically more limited.

298
299 In TRI, sites submitting a Form R indicate whether they perform a variety of activities related to the
300 chemical including, but not limited to: produce the chemical; import the chemical; use the chemical as a
301 reactant; use the chemical as a chemical processing aid; and ancillary or other use. In TRI, sites
302 submitting Form A are not required to designate an activity. For both Form R and Form A, TRI sites are
303 also required to report the primary North American Industry Classification System (NAICS) code for
304 their site. For each TRI site, EPA used the reported primary NAICS code and activity indicators to
305 determine the condition of use at the site. For instances where EPA could not definitively determine the
306 condition of use because: 1) the reported NAICS codes could include multiple conditions of use; 2) the
307 site reported multiple activities; and/or 3) the site did not report activities due to submitting a Form A,
308 EPA had to make an assumption on the condition of use to avoid double counting the site. For these
309 sites, EPA supplemented the NAICS code and activity information with the following information to
310 determine a "most likely" or "primary" condition of use:

- 311 • Information on known uses of the chemical and market data identifying the most prevalent
312 conditions of use of the chemical.
- 313 • Information obtained from public comments and/or industry meetings with EPA that provided
314 specific information on the site.

315
316 In DMR, the only information reported on condition of use is each site's Standard Industrial
317 Classification (SIC) code. EPA could not determine each reporting site's condition of use based on SIC
318 code alone; therefore, EPA supplemented the SIC code information with the same supplementary
319 information used for the TRI sites (market data, public comments, and industry meetings).

320
321 The National Emissions Inventory (NEI) is a comprehensive and detailed estimate of air emissions of
322 criteria pollutants, criteria precursors, and hazardous air pollutants from air emissions sources. The NEI
323 is released every three years based primarily upon data provided by State, Local, and Tribal air agencies
324 for sources in their jurisdictions and supplemented by data developed by the US EPA. The inventory
325 includes emissions estimates for larger sources that are located at a fixed, stationary location (point
326 sources) and emissions estimates for sources which individually are too small in magnitude to report as
327 point sources (nonpoint sources). In NEI, facilities report on the equipment or process sources for their

328 facility emissions. Based on these reported point sources for TCE emissions, EPA could generally
 329 determine which condition of use the facility fell in.

330
 331 Where the number of sites could not be determined using CDR/TRI/DMR/NEI or where these data
 332 sources were determined to insufficiently capture the number of sites within a condition of use, EPA
 333 supplemented the reasonably available information with U.S. economic data using the following
 334 method:

- 335 • Identify the NAICS codes for the industry sectors associated with these uses.
- 336 • Estimate total number of sites using the U.S. Census' Statistics of US Businesses (SUSB) ([U.S. Census Bureau, 2015](#)) data on total establishments by 6-digit NAICS.
- 337
- 338 • Use market penetration data to estimate the percentage of establishments likely to be using TCE
 339 instead of other chemicals.
- 340 • Combine the data generated in Steps 1 through 3 to produce an estimate of the number of sites
 341 using TCE in each 6-digit NAICS code, and sum across all applicable NAICS codes for the
 342 condition of use to arrive at a total estimate of the number of sites within the condition of use.
- 343
- 344

Table 2-3. Summary of EPA's estimates for the number of facilities for each OES.

Occupational Exposure Scenario (OES)	Number of Facilities	Notes
Manufacturing	5	Based on CDR reporting
Processing as a Reactant	5 to 440 ^a	Based on TRI and DMR reporting, and Census data for NAICS 325120 (Industrial Gas Manufacturing)
Formulation of Aerosol and Non-Aerosol Products	19	Based on TRI reporting
Repackaging	22	Based on TRI and DMR reporting
Batch Open-Top Vapor Degreasing	194	Based on NEI and TRI reporting
Batch Closed-Loop Vapor Degreasing	4	Based on NEI reporting
Conveyorized Vapor Degreasing	8	Based on NEI reporting
Web Vapor Degreasing	1	Based on NEI reporting
Cold Cleaning	13	Based on NEI reporting
Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	4,366	Based on Census data and market penetration estimates based on California Air Resources Board (CARB) survey of automotive maintenance and repair facilities
Metalworking Fluids	-	No information identified to estimate number of facilities
Adhesives, Sealants, Paints, and Coatings	70	Based on NEI, TRI, and DMR reporting
Other Industrial Uses	49	Based on TRI and DMR reporting
Spot Cleaning and Wipe Cleaning	63,748	Based on Census data for NAICS codes 812300, 812320, 561740; assumed 100% market penetration for TCE.
Industrial Processing Aid	18	Based on TRI and DMR reporting
Commercial Printing and Copying	-	No information identified to estimate number of facilities
Other Commercial Uses	-	No information identified to estimate number of facilities
Process Solvent Recycling and Worker Handling of Wastes	30	Based on TRI and DMR reporting

345 ^aThe range provided for the number of sites is a function of known sites for this OES from TRI and DMR data and
 346 integrating it with sites reporting NAICS codes for this type of use.

347 **2.2.2.2.3 Estimates of Release Days**

348 EPA referenced Emission Scenario Documents (ESDs) or needed to make assumptions when estimating
 349 release days for each OES. A summary along with a brief explanation is presented in Table 2-4 below.

350
 351

Table 2-4. Summary of EPA’s estimates for release days expected for each OES.

Occupational Exposure Scenario (OES)	Release Days	Notes
Manufacturing	350	Assumed seven days per week and 50 weeks per year with two weeks per year for shutdown activities.
Processing as a Reactant	350	Assumed seven days per week and 50 weeks per year with two weeks per year for shutdown activities.
Formulation of Aerosol and Non-Aerosol Products	-	Water releases not estimated for this OES.
Repackaging	250	Assumed 5 days per week and 50 weeks per year.
Batch Open-Top Vapor Degreasing	260	2017 ESD on Use of Vapor Degreasing
Batch Closed-Loop Vapor Degreasing	260	2017 ESD on Use of Vapor Degreasing
Conveyorized Vapor Degreasing	260	2017 ESD on Use of Vapor Degreasing
Web Vapor Degreasing	260	2017 ESD on Use of Vapor Degreasing
Cold Cleaning	260	2017 ESD on Use of Vapor Degreasing
Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	-	Water releases not expected from this OES.
Metalworking Fluids	260	2017 ESD on Use of Vapor Degreasing
Adhesives, Sealants, Paints, and Coatings	250	2011 ESD on the Application of Radiation Curable Coatings, Inks, and Adhesives via Spray, Vacuum, Roll and Curtain Coating
Other Industrial Uses	250	Assumed 5 days per week and 50 weeks per year.
Spot Cleaning and Wipe Cleaning	300	Assumed 6 days per week and 50 weeks per year.
Industrial Processing Aid	300	Assumed 6 days per week and 50 weeks per year.
Commercial Printing and Copying	250	Assumed 5 days per week and 50 weeks per year.
Other Commercial Uses	250	Assumed 5 days per week and 50 weeks per year.
Process Solvent Recycling and Worker Handling of Wastes	250	Assumed 5 days per week and 50 weeks per year.

352 **2.2.2.3 Assumptions and Key Sources of Uncertainty for Environmental**
 353 **Releases**

354 EPA estimated water releases using reported discharges from the 2016 TRI and the 2016 DMR. TRI and
 355 DMR data were determined to have a “medium” confidence rating through EPA’s systematic review
 356 process. Due to reporting requirements for TRI and DMR, the number of sites for a given OES may be
 357 underestimated. It is uncertain, the extent to which, sites not captured in these databases discharge
 358 wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-
 359 POTW WWT.

360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403

In addition, information on the use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether the number of facilities estimated for a given OES do in fact represent that specific OES. If sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the release days expected for the different OES.

Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA estimated the release days and averaged the annual releases over these days. There is some uncertainty that all sites for a given OES operate for the assumed duration; therefore, the average daily discharges may be higher if sites have fewer release days or lower if they have greater release days. TRI-reporting facilities are required to submit their “best available data” to EPA for TRI reporting purposes. Some facilities are required to measure or monitor emission or other waste management quantities due to regulations unrelated to the TRI Program (e.g., permitting requirements), or due to company policies. These existing, reasonably available data are often used by facilities for TRI reporting purposes, as they represent the best available data. When monitoring or direct measurement data are not reasonably available, or are known to be non-representative for TRI reporting purposes, the TRI regulations require that facilities determine release and other waste management quantities of TRI-listed chemicals by making reasonable estimates. These reasonable estimates may be obtained through various Release Estimation Techniques, including mass-balance calculations, the use of emission factors, and engineering calculations. There may be greater uncertainty in data resulting from estimates compared to monitoring measurements. However, available monitored data that showed ambient water concentrations were not useful in corroborating the modeling approach because most of them were far downstream from the near-facility modeled concentration estimates.

Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge.

In some cases, the number of facilities for a given OES was estimated using data from the U.S. Census. In such cases, the average daily release calculated from sites reporting to TRI or DMR was applied to the total number of sites reported in ([U.S. Census Bureau, 2015](#)). It is uncertain how accurate this average release is to actual releases at these sites; therefore, releases may be higher or lower than the calculated amount.

The 2014 NEI was also used to estimate the number of facilities for various OES. NEI does not report water release information, therefore, an average release was calculated from the sites reporting water releases to TRI and DMR and applied to sites reported in NEI. It is uncertain how accurate this average release is to actual releases at these sites; therefore, releases may be higher or lower than the calculated amount.

2.2.2.3.1 Summary of Overall Confidence in Release Estimates

Table 2-5 provides a summary of EPA’s overall confidence in its release estimates for each of the Occupational Exposure Scenarios assessed.

Table 2-5. Summary of Overall Confidence in Release Estimates by OES

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
Manufacturing	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI for four sites. TRI data were determined to have a “medium” confidence rating through EPA’s systematic review process. Facilities reporting to TRI only report annual discharges; to assess daily discharges, EPA assumed 350 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites manufacturing TCE will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 350 days/yr or lower if they operate for greater than 350 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. One of the four sites reporting to TRI also reported to DMR. This information was also assessed. The same uncertainties discussed above for TRI releases also apply to the DMR data. Based on this information, EPA has a medium confidence in the wastewater discharge estimates for the four sites in the 2016 TRI and 2016 DMR.</p> <p>Water discharges from the remaining site was estimated using the maximum daily and monthly discharge limits in the OCPSF EG and the estimated volume of wastewater produced per pound of TCE production from the Specific Environmental Release Category (SpERC) developed by the European Solvent Industry Group for the manufacture of a substance. The estimates assume the site operates at the limits set by the EG; actual releases may be lower for sites operating below the limits or higher for sites not in compliance with the OCPSF EG. Based on this information EPA has a medium confidence in the wastewater discharge estimates for this site.</p>
Processing as a Reactant	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, the number of sites in this OES may be underestimated. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are processing TCE as a reactant rather than a different OES. If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 350 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites processing TCE as a reactant will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 350 days/yr or lower if they operate for greater than 350 days/yr. Furthermore,</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
	<p>TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Formulation of Aerosol and Non-Aerosol Products	<p>All sites reporting in TRI show zero water releases; EPA does not expect water releases from this OES.</p>
Repackaging	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, the number of sites in this OES may be underestimated. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are performing repackaging activities rather than a different OES. If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 250 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites repackaging TCE will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 250 days/yr or lower if they operate for greater than 250 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Batch Open-Top Vapor Degreasing	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, EPA does not expect all sites using TCE in OTVD to be captured in the databases. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT; however, the sites may be required to comply with an EG depending on the industry in which the OTVD is being used. Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all of the sites assessed in this section are using TCE in OTVD rather than a different OES (including other vapor degreasing and cold cleaning operations and use of TCE in metalworking fluids). If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however,</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
	<p>average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 260 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites using TCE in OTVDs will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 260 days/yr or lower if they operate for greater than 260 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Batch Closed-Loop Vapor Degreasing	Same as the Open-Top Vapor Degreasing (OTVD) OES.
Conveyorized Vapor Degreasing	Same as the Open-Top Vapor Degreasing (OTVD) OES.
Web Vapor Degreasing	Same as the Open-Top Vapor Degreasing (OTVD) OES.
Cold Cleaning	Same as the Open-Top Vapor Degreasing (OTVD) OES.
Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	<p>EPA assessed no wastewater discharges for this OES. There is some uncertainty as to whether and how much TCE may deposit on shop floors. However, due to the volatility of TCE, EPA expects TCE to evaporate from any such deposit prior to it being discharged; thus, limiting any potential discharges to surface water, POTW, or non-POTW WWT from this source. Based on this information, EPA has a high confidence in the release assessment.</p>
Metalworking Fluids	Same as the Open-Top Vapor Degreasing (OTVD) OES.
Adhesives, Sealants, Paints, and Coatings	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, the number of sites in this OES may be underestimated. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT.</p> <p>Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are performing adhesive, sealant, paint or coating activities rather than a different OES. If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 250 days/yr of operation and averaged the</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
	<p>annual discharges over the operating days. There is some uncertainty that all sites using TCE in adhesives, sealants, paints and coatings will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 250 days/yr or lower if they operate for greater than 250 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge.</p> <p>There is further uncertainty that the number of sites obtained from the 2014 NEI represent the total number of sites using adhesives, sealants, paints or coatings containing TCE. NEI data only covers specific industries which may not capture the entirety of industries using these products and NEI does not include operations that are classified as area sources because area sources are reported at the county level and do not include site-specific information. It is uncertain the extent that sites not captured in this assessment discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Also, NEI do not report water release information, therefore, an average release was calculated from the sites reporting water releases to TRI and DMR and applied to sites reported in NEI. It is uncertain how accurate this average release is to actual releases as these sites; therefore, releases may be higher or lower than the calculated amount. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Other Industrial Uses	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, the number of sites in this OES may be underestimated. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are performing other industrial uses rather than a different OES. If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 250 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites using TCE for other industrial uses will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 250 days/yr or lower if they operate for greater than 250 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
Spot Cleaning and Wipe Cleaning	<p>Wastewater discharges from spot cleaning facilities at industrial launderers are assessed using reported discharges from the 2016 DMR. DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. DMR only contains information for 2 sites. Additional sites may not be in DMR because they may have no water discharges or because they discharge to sewer rather than surface water (sewer discharges not reported in DMR). Facilities reporting to DMR only report annual discharges; to assess daily discharges, EPA assumed annual days of operation and averaged the annual discharges over the operating days. There is some uncertainty that all industrial launderers using TCE will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than the operating days or lower if they operate for greater than the operating days. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates at industrial launderers.</p> <p>There is further uncertainty that the releases estimated for the total number of sites obtained from the U.S. Census’ Bureau for spot, carpet and wipe cleaning accurately reflect releases from these sites. An average release was calculated from the sites reporting water releases to DMR and applied to the total number of sites reported in (U.S. Census Bureau, 2015). It is uncertain how accurate this average release is to actual releases as these sites; therefore, releases may be higher or lower than the calculated amount. It is also uncertain the extent that sites not captured in this assessment discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Industrial Processing Aid	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, the number of sites in this OES may be underestimated. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are using TCE as an industrial processing aid rather than a different OES. If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 300 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites using TCE as an industrial processing aid will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
	<p>than 300 days/yr or lower if they operate for greater than 300 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Commercial Printing and Copying	<p>Wastewater discharges from one commercial printing and copying site was found in the 2016 DMR. DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. However, EPA acknowledges this site does not represent the entirety of commercial printing and copying sites using TCE; data were not reasonably available to estimate water releases from additional sites.</p>
Other Commercial Uses	<p>Wastewater discharges are assessed using reported discharges from the 2016 DMR. DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for DMR, these sites are not expected to capture the entirety of water releases from this OES. It is uncertain the extent that sites not captured in DMR discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Additionally, information on the conditions of use of TCE at facilities in DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are performing other commercial uses rather than a different OES. If the sites were categorized under a different OES, the annual wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to DMR only report annual discharges; to assess daily discharges, EPA assumed 250 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites using TCE in other commercial uses will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 250 days/yr or lower if they operate for greater than 250 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>
Process Solvent Recycling and Worker Handling of Wastes	<p>Wastewater discharges are assessed using reported discharges from the 2016 TRI and the 2016 DMR. TRI and DMR data were determined to have a “medium” confidence rating through EPA’s systematic review process. Due to reporting requirements for TRI and DMR, the number of sites in this OES may be underestimated. It is uncertain the extent that sites not captured in these databases discharge wastewater containing TCE and whether any such discharges would be to surface water, POTW, or non-POTW WWT. Additionally, information on the conditions of use of TCE at facilities in TRI and DMR is limited; therefore, there is some uncertainty as to whether all the sites assessed in this section are recycling/disposing of TCE rather than a different OES. If the sites were categorized under a different OES, the annual</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Release Estimates
	<p>wastewater discharges for each site would remain unchanged; however, average daily discharges may change depending on the number of operating days expected for the OES.</p> <p>Facilities reporting to TRI and DMR only report annual discharges; to assess daily discharges, EPA assumed 250 days/yr of operation and averaged the annual discharges over the operating days. There is some uncertainty that all sites recycling/disposing of TCE will operate for this duration; therefore, the average daily discharges may be higher if sites operate for fewer than 250 days/yr or lower if they operate for greater than 250 days/yr. Furthermore, TCE concentrations in wastewater discharges at each site may vary from day-to-day such that on any given day the actual daily discharges may be higher or lower than the estimated average daily discharge. Based on this information, EPA has a medium confidence in the wastewater discharge estimates.</p>

405 **2.2.3 Aquatic Exposure Modeling Approach**

406 Surface water concentrations resulting from wastewater releases of TCE from facilities that use,
407 manufacture, or process TCE related to the evaluated industrial and commercial conditions of use were
408 modeled using EPA’s Exposure and Fate Assessment Screening Tool, Version 2014 ([U.S. EPA, 2014c](#)).
409 E-FAST 2014 estimates chemical concentrations in surface water resulting from releases to surface
410 water, resulting in exposure estimates at the point of release. Advantages to this model are that it
411 requires minimal input parameters and it has undergone extensive peer review by experts outside of
412 EPA. A brief description of the calculations performed within the tool, as well as a description of
413 required inputs and the methodology to obtain and use inputs specific to this assessment is described
414 below. To obtain more detailed information on the E-FAST 2014 tool from the model documentation
415 ([U.S. EPA, 2007](#)), as well as to download the tool, visit this web address: [https://www.epa.gov/tsca-](https://www.epa.gov/tsca-screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014/)
416 [screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014/](https://www.epa.gov/tsca-screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014/).

417
418 E-FAST 2014 provides estimates of surface water concentration for multiple stream flow parameters. The
419 concentrations reflect predicted levels of TCE in the receiving water body at the point of release and do not
420 incorporate downstream transport or post-release chemical fate processes. For this aquatic exposure
421 assessment, site-specific surface water concentration estimates for free-flowing water bodies are reported for
422 both the 7Q10 and harmonic mean stream flows. The 7Q10 stream flow is the lowest consecutive 7-day
423 average flow during any 10-year period. The harmonic mean stream flow is the inverse mean of
424 reciprocal daily arithmetic mean flow values. Site-specific surface water concentration estimates for still
425 water bodies are reported for calculations using the acute dilution factors. In cases where site-specific
426 flow/dilution data were not reasonably available, the releases were modeled using stream flows of a
427 representative industry sector, as calculated from all facilities assigned to the industry sector in the E-
428 FAST database. Estimates from this calculation method are reported for the 10th percentile harmonic mean
429 and 10th percentile 7Q10 stream flows.

430 **2.2.3.1 E-FAST 2014 Equations and Inputs**

431 ***Estimating Surface Water Concentrations***

432 E-FAST 2014 estimates site-specific surface water concentrations for discharges to both free-flowing
433 water bodies (*i.e.*, rivers and streams) and for still water bodies (*i.e.*, bays, lakes, and estuaries).

434
435 For free-flowing water body assessments, E-FAST 2014 can calculate surface water concentrations for

436 four streamflow conditions using the following equation:

437

438

$$SWC = \frac{WWR \times CF1 \times \left(1 - \frac{WWT}{100}\right)}{SF \times CF2} \quad (\text{Eq. 1})$$

439 where:

440 SWC = Surface water concentration (parts per billion (ppb) or $\mu\text{g/L}$)

441 WWR = Chemical release to wastewater (kg/day)

442 WWT = Removal from wastewater treatment (%)

443 SF = Estimated flow of the receiving stream (MLD)

444 CF1 = Conversion factor ($10^9 \mu\text{g/kg}$)

445 CF2 = Conversion factor (10^6 L/day/MLD)

446

447 The streamflow conditions used to estimate stream concentrations within the model include a mean flow
448 (*i.e.*, the harmonic mean flow) and low flows (30Q5, 7Q10, and 1Q10 flows). The harmonic mean flow
449 is the inverse mean of reciprocal daily arithmetic mean flow values. The 30Q5 flow reflects 30
450 consecutive days of lowest flow over a five-year period. The 7Q10 flow reflects seven consecutive days
451 of lowest flow over a 10-year period. The 1Q10 flow reflects the single day of lowest flow over a 10-
452 year period.

453

454 For still water body assessments, no simple streamflow value represents dilution in these types of water
455 bodies. As such, E-FAST 2014 accounts for dilution by incorporating an acute or chronic dilution factor
456 for the water body of interest instead of streamflows. Dilution factors in E-FAST 2014 are typically 1
457 (representing no dilution) to 200. The following equation is used to calculate surface water
458 concentrations in still water bodies:

459

460

$$SWC = \frac{WWR \times \left(1 - \frac{WWT}{100}\right) \times CF1}{PF \times CF2 \times DF} \quad (\text{Eq. 2})$$

461 where:

462 SWC = Surface water concentration (ppb or $\mu\text{g/L}$)

463 WWR = Chemical release to wastewater (kg/day)

464 WWT = Removal from wastewater treatment (%)

465 PF = Effluent flow of the discharging facility (MLD)

466 DF = Acute or chronic dilution factor used for the water body (typically between 1 and 200)

467 CF1 = Conversion factor ($10^9 \mu\text{g/kg}$)

468 CF2 = Conversion factor (10^6 L/day/MLD)

469

470 ***Estimating Days of COC Exceedance***

471 The Probabilistic Dilution Model (PDM) portion of E-FAST 2014 was also run for free-flowing water
472 bodies, which predicts the number of days per year a chemical's concentration of concern (COC) in an
473 ambient water body will be exceeded. The model is based on a simple mass balance approach presented
474 by ([Di Toro, 1984](#)) that uses probability distributions as inputs to reflect that streams follow a highly
475 variable seasonal flow pattern and there are numerous variables in a manufacturing process that can
476 affect the chemical concentration and flow rate of the effluent. PDM does not estimate exceedances for
477 chemicals discharged to still waters, such as lakes, bays, or estuaries. For these water bodies, the days of
478 exceedance is assumed to be zero unless the predicted surface water concentration exceeds the COC. In
479 these cases, the days of exceedance is set to the number of release days per year (see required inputs
480 below).

481

482 ***Modeling Inputs***

483 Chemical release to wastewater (WWR)

484 Annual wastewater loading estimates (kg/site/year or lb/site/year) were predicted in Section **Error! Reference**
485 **source not found.** and based on reported production loading or production volume estimates. To model these
486 releases within Exposure and Fate Assessment Screening Tool 2014, the annual release is converted to a daily
487 release using an estimated days of release per year, *e.g.*, $WWR \text{ (kg/site/day)} = \text{Annual loading (kg/site/year)} /$
488 $\text{Days released per year (days/year)}$. In cases where the total annual release amount from one facility is
489 discharged via multiple mechanisms (*i.e.*, direct to surface water and/or indirectly through one or more
490 WWTPs), the annual release amount was divided accordingly based on reported information in TRI (Form R).

491
492 Release Days (days/year)

493 The number of days per year that the chemical is discharged is used to calculate a daily release amount from
494 annual loading estimates (see Eq. 3). Current regulations do not require facilities to report the number of days
495 associated with reported releases. Therefore, two release scenarios were modeled for direct discharging facilities
496 to provide a range of surface water concentrations predicted by E-FAST 2014. The two scenarios modeled are a
497 higher release frequency (200 to 365 days) based on release estimates in Section **Error! Reference source not**
498 **found.** and a low-end release frequency of 20 days of release per year as an estimate of releases that could lead
499 to chronic risk for aquatic organisms. The 20-day chronic risk criterion is derived from partial life cycle
500 tests (*e.g.*, daphnid chronic and fish early life stage tests) that typically range from 21 to 28 days in
501 duration. For discharges from water treatment facilities (*e.g.*, POTWs, STPs, WWTPs), only the higher release
502 frequency was modeled because such treatment sites are anticipated to discharge more frequently than non-
503 treatment facilities.

504
505 Removal from wastewater treatment (WWR%)

506 The WWR% is the percentage of the chemical removed from wastewater during treatment before
507 discharge to a body of water. As discussed in Section 2.1.1, the WWR% for TCE is estimated as 81%.
508 The WWR% of 81% was applied, when appropriate, to volumes characterized as being transferred off-
509 site for treatment at a water treatment facility prior to discharge to surface water. A WWR% of zero was
510 used for direct releases to surface water because the release estimates are based on estimated release
511 (post-treatment). In cases where it wasn't clear whether the release was direct or indirect, both possible
512 scenarios were modeled.

513
514 Concentration of Concern

515 Concentrations of Concern (COCs) are threshold concentrations below which adverse effects on aquatic
516 life are expected to be minimal. See Section 3.1.5 for a full discussion of acute and chronic COCs for
517 TCE. For E-FAST modeling, only the chronic COCs are entered for use in PDM runs, which compare
518 estimated stream concentrations calculated based on an annual stream flow distribution to the chronic
519 COCs and output the number of days per year that the selected COCs are exceeded. The COCs used in
520 the PDM module of E-FAST 2014 for TCE were 3, 788, 920, and 14,400 µg/L.

521
522 Facility or Industry Sector

523 The required site-specific stream flow or dilution factor information is contained in the E-FAST 2014
524 database, which is accessed by querying a facility National Pollutant Discharge Elimination System
525 (NPDES) number, facility name, or reach code. For facilities that directly discharge to surface water (*i.e.*,
526 “direct dischargers”), the NPDES of the direct discharger is selected from the database. For facilities that
527 indirectly discharge to surface water (*i.e.*, “indirect dischargers” because the release is sent to a water treatment
528 facility prior to discharge to surface water), the NPDES of the receiving treatment facility is selected. The
529 receiving facility name and location was obtained from the TRI database (Form R), if available. As TRI does not
530 contain the NPDES of receiving facilities, the NPDES was obtained using [EPA’s Envirofacts search tool](#). If a
531 facility NPDES was not available in the E-FAST-2014 database, the release was modeled using water body data
532 for a surrogate NPDES (preferred) or an industry sector, as described below.

533
534
535
536
537
538
539
540
541
542
543
544
545
546

Surrogate NPDES: In cases where the site-specific NPDES was not available in the E-FAST 2014 database, the preferred alternative was to select the NPDES for a nearby facility that discharges to the same waterbody. Nearby facilities were identified using the Chemical Safety Mapper within IGEMS and/or search of the E-FAST 2014 by reach code.

Industry Sector (SIC Code Option): If the NPDES is unknown, no close analog could be identified, or the exact location of a chemical loading is unknown, surface water concentrations were modeled using the “SIC Code Option” within E-FAST 2014. This option uses the 10th and 50th percentile receiving stream flows for dischargers in a given industry sector, as defined by the Standard Industrial Classification (SIC) codes of the industry. Table 2-6 below provides the industrial sectors that were applied as needed for each condition of use category.

Table 2-6. Industry Sector Modeled for Facilities without Site-Specific Flow Data in E-FAST 2014

Condition of Use	Industry Sector in E-FAST 2014 for Stream Flow Data ¹
OES: Adhesives, Sealants, Paints, and Coatings	Adhesives and Sealants Manufacture
OES: Commercial Printing and Copying	Printing
OES: Industrial Processing Aid	POTW ² (Industrial)
OES: Manufacturing	Organic Chemicals Manufacture
OES: N/A Water Treatment Facility	POTW ² (Industrial)
OES: Other Commercial Uses	POTW ² (Industrial)
OES: Other Industrial Uses	POTW ² (Industrial)
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, Cold Cleaning, and Metalworking Fluids)	Primary Metal Forming Manufacture
OES: Process Solvent Recycling and Worker Handling of Wastes	POTW ² (Industrial)
OES: Processing as a Reactant	Organic Chemicals Manufacture
OES: Repackaging	n/a
OES: Spot Cleaning and Carpet Cleaning	n/a

547 ¹ n/a = Not applicable because a NPDES or surrogate NPDES was available in E-FAST 2014 to obtain a site-specific stream
548 flow for all facilities within the OES.

549 ² POTW = Publicly Owned Treatment Works

550 **2.2.4 Surface Water Monitoring Data Gathering Approach**

551 To characterize environmental exposure in ambient water from TCE, EPA used two approaches to
552 obtain measured surface water concentrations.

553 **2.2.4.1 Systematic Review of Surface Water Monitoring Data**

554 EPA conducted a full systematic review of published literature to identify studies reporting
555 concentrations of TCE in surface water in the United States. Studies clearly associated with releases
556 from Superfund sites, improper disposal methods, and landfills were considered not to meet the PECO
557 statement and excluded from data evaluation and extraction. The systematic review process is described
558 in detail in Section 1.5. A total of 28 surface water studies were extracted and the results are summarized
559 in Section 2.2.6.2.2.

2.2.4.2 Surface Water Monitoring Data from WQX/WQP

560
561 For this aquatic exposure assessment, the primary source for data on the occurrence of TCE in surface
562 water is monitoring data retrieved from the Water Quality Portal (WQP), which integrates publicly
563 available US water quality data from multiple databases: 1) the United States Geological Survey
564 National Water Information System (USGS NWIS); 2) EPA's STOrage and RETrieval (STORET); and
565 3) the United States Department of Agriculture Agricultural Research Service (USDA ARS) Sustaining
566 The Earth's Watersheds - Agricultural Research Database System (STEWARDS). NWIS is the Nation's
567 principal repository of water resources data USGS collects from over 1.5 million sites, including sites
568 from the National Water-Quality Assessment (NAWQA). STORET refers to an electronic data system
569 originally created by EPA in the 1960s to compile water quality monitoring data. NWIS and STORET
570 now use common web services, allowing data to be published through the WQP tool. The WQP tool and
571 User Guide is accessed from the following website: (<http://www.waterqualitydata.us/portal.jsp>).

572 Surface water data for TCE were downloaded from the WQP on October 3, 2018. The WQP can be
573 searched through three different search options: Location Parameters, Site Parameters, and Sampling
574 Parameters. Three queries were performed using the Sampling Parameters search. One query obtained
575 STORET data using the Characteristics parameter (selected "Trichlorethylene (STORET)") and two
576 queries obtained NWIS data using the Parameter Codes (34485 for "Trichloroethene, water, filtered,
577 recoverable, micrograms per liter" and 39180 for "Trichloroethene, water, unfiltered, recoverable,
578 micrograms per liter"). Parameters codes were obtained from the USGS website
579 <https://nwis.waterdata.usgs.gov/usa/nwis/pmcodes> using the chemical CASRN. All queries were
580 performed using a Date Range of 01-01-2013 to 12-31-2017. Both the "Site data only" and "Sample
581 results (physical/chemical metadata)" were selected for download in "MS Excel 2007+" format. The
582 "Site data only" file contains monitoring site information (*i.e.*, location in hydrologic cycle, HUC and
583 geographic coordinates); whereas the "Sample result" file contains the sample collection data and
584 analytical results for individual samples.

585
586 The "Site data only" and "Sample results (physical/chemical metadata)" files were linked using the
587 common field "Monitoring Location Identifier" and then filtered to eliminate records not relevant to the
588 scope of the environmental evaluation. Specifically, filtering was applied to select the media of interest
589 (*i.e.*, surface water), eliminate records that were quality control samples (*i.e.*, field blanks) or identified
590 as having analytical quality concerns (*i.e.*, quality control issues, sample contamination, or estimated
591 values), and eliminate records associated with contaminated sites (*i.e.*, Superfund).

592 Following filtering to obtain the final dataset, the domains "ResultDetectionConditionText,"
593 "ResultCommentText," and "MeasureQualifierCode" were examined to identify samples with non-
594 detect concentrations. All non-detect samples were tagged and the concentrations were converted to ½
595 the reported detection limit for summary calculation purposes. If a detection limit was not provided,
596 calculations were performed using the average of the reported detection limits in all samples (calculated
597 as 0.3 µg/L).

2.2.5 Geospatial Analysis Approach

598
599 Using 2016 data, the measured surface water concentrations from the WQP and predicted concentrations
600 from the modeled facility releases were mapped in ArcGIS Version 10.6 to conduct a watershed analysis
601 at the Hydrologic Unit Code (HUC)-8 and HUC-12 level. The purpose of the analysis is to identify
602 whether any the observed surface water concentrations could be associated with the modeled facility
603 releases. In addition, the analysis included a search for Superfund sites within 1 to 5 miles of the surface
604 water monitoring stations. A US-level map was developed to provide a spatial representation of the

605 measured and predicted concentrations. HUCs with co-located monitoring stations and facility releases
606 were identified and examined further.

607
608 The location of the monitoring stations was determined from the geographic coordinates (latitude and
609 longitude) provided in WQP. Releases from facilities were located based on the geographic coordinates
610 for the NPDES, TRI, and/or FRS of the mapped facility, as provided by FRS. For indirect dischargers,
611 the location of the receiving facility was mapped if known. If not known, the location of the indirect
612 discharger was mapped. Superfund sites in 2016 were identified and mapped using geographic
613 coordinates of the “front door,” as reported in the database in Envirofacts.

614 **2.2.6 Environmental Exposure Results**

615 **2.2.6.1 Terrestrial Environmental Exposures**

616 Exposure to terrestrial organisms is expected to be low since physical chemical properties do not support
617 an exposure pathway through water, biosolids, and soil pathways to these organisms. The partition of
618 TCE into sediments is very low. Furthermore, the primary fate of TCE released to surface waters or
619 surface soils is volatilization.

620 **2.2.6.2 Aquatic Environmental Exposures**

621 To characterize environmental exposure, EPA assessed surface water concentrations derived from both
622 predicted concentrations of TCE in surface water (using E-FAST modeling results) and measured
623 concentrations (using monitored data from WQP and the published literature). Generally, the modeled
624 concentrations reflect near-site estimates at the point of release, and the measured concentrations reflect
625 localized ambient water concentrations at the monitoring sites. However, there were several sources in
626 the published literature that represent near facility concentrations and are labeled as such. Facility
627 release data is summarized in Section **Error! Reference source not found.** and full details are provided
628 in Appendix Q.

629 **2.2.6.2.1 Predicted Surface Water Concentrations: E-FAST 2014 Modeling**

630 A summary of the surface water concentration estimates modeled using E-FAST 2014, based on the
631 lifecycle release analysis for the year 2016, is summarized by OES in Table 2-7 through Table 2-9. A
632 break-out of facility-specific modeling results organized per OES, with predicted surface water
633 concentrations and associated days of COC exceedance, are included in Appendix C. These facility-
634 specific modeling results are utilized and discussed in environmental risk characterization presented in
635 Section 4.1.2.

636
637 For the higher release frequency scenarios (250-365 days of release/year), predicted surface water
638 concentrations under 7Q10-flow conditions ranged from 1.27E-5 to 765.63 µg/L (Table 2-7). For the 20-
639 day release/year scenario assumed for direct dischargers, predicted surface water concentrations under
640 7Q10 flow conditions ranged from 0.00019 to 9,937.5 µg/L (Table 2-8). For comparison purposes,
641 indirect releases to non-POTW WWTPs were also modeled assuming 20 days of release, resulting in
642 surface water concentrations of 0.2 to 339.11 µg/L (Table 2-9.).
643

644
645

Table 2-7. Summary of Modeled Surface Water Concentrations by OES for Maximum Days of Release Scenario

OES	No. of Releases Modeled	Surface Water Concentration (7Q10) (µg/L)	
		Min	Max
Manufacturing	6	0.00514	2.77
Processing as a Reactant (low-end # of sites)	3	0.0000518	169
Processing as a Reactant	4	0.18	0.92
Repackaging	4	0.0000189	27.18
OTVD	51	0.0000822	765.63
Adhesives, Sealants, Paints, and Coatings	104	0.000818	10.83
Other Industrial Uses	16	0.0000941	9.5
Spot Cleaning and Carpet Cleaning	1	0.00388	0.00388
Industrial Processing Aid	6	0.000419	9.3
Commercial Printing and Copying	1	0.00292	0.00292
Other Commercial Uses	5	0.00564	9
Process Solvent Recycling and Worker Handling of Wastes	4	0.98	11.76
N/A (WWTP)	9	0.0000127	0.7
Grand Total	214	1.27E-5	765.63

646
647
648

Table 2-8. Summary of Modeled Surface Water Concentrations by OES for 20 Days of Release Scenario for Direct Releases

OES	No. of Releases Modeled	Surface Water Concentration (7Q10) (µg/L)	
		Min	Max
Manufacturing	3	0.0897	49.91
Processing as a Reactant (low-end # of sites)	3	0.000907	3000
Processing as a Reactant	2	16.45	16.45
Repackaging	3	0.000235	89.13
OTVD	51	0.00103	9937.5
Adhesives, Sealants, Paints, and Coatings	52	0.0101	133.33
Other Industrial Uses	16	0.00154	200
Spot Cleaning and Carpet Cleaning	1	0.0485	0.0485
Industrial Processing Aid	3	0.00335	2.2
Commercial Printing and Copying	1	0.0365	0.0365
Other Commercial Uses	5	0.0658	110
Process Solvent Recycling and Worker Handling of Wastes	1	138.24	138.24
N/A (WWTP)	9	0.00019	12.79
Grand Total	150	0.00019	9,937.5

649
650


651 **Table 2-9. Summary of Modeled Surface Water Concentrations by OES for 20 Days of Release**
 652 **Scenario for Indirect Releases to a non-POTW WWTP**

OES	No. of Releases Modeled	Surface Water Concentration (7Q10) (µg/L)	
		Min	Max
Manufacturing	3	9.48	42.14
Processing as a Reactant	1	3.13	3.13
Repackaging	1	339.11	339.11
Industrial Processing Aid	3	0.2	138.34
Process Solvent Recycling and Worker Handling of Wastes	3	11.26	106.75
Grand Total	11	0.2	339.11

653 On a site-specific basis, the modeled surface water concentrations did not exceed the highest COC
 654 (14,400 µg/L) for any facility and only exceeded the COCs of 788 µg/L and 920 µg/L for two releasing
 655 facilities (US Nasa Michoud Assembly Facility in New Orleans, LA and Praxair Technology Center in
 656 Tonawanda, NY). These release scenarios were 20-day scenarios involving release to a still water body,
 657 which applied no additional dilution. There were 102 modeled releases that exceeded the lowest COC of
 658 3 ppb. A detailed summary table by facility is provided in Appendix C.
 659

660
 661 **Characterization of Modeled Releases**

662 As discussed in Section **Error! Reference source not found.**, releases of TCE were estimated for use in
 663 modeling based on data from TRI, DMRs, and CDR (primarily TRI and DMR) for the 2016 calendar
 664 year. Release estimates were generally facility-specific and releasing facilities were assigned to one of
 665 13 occupational exposure scenarios (OES). Overall, modeling was conducted on 157 unique active
 666 releasing facilities plus one OES with sites nationwide (440 unknown sites in OES Processing as a
 667 Reactant). As shown in Figure 2-3., the releases occurred in 39 states. With respect to watersheds, the
 668 releases occurred across 122 HUC-8 areas and 144 HUC-12 areas.
 669



670
 671 **Figure 2-3. Distribution of Active Facility Releases Modeled**
 672

673 Direct and indirect dischargers accounted for 70% and 30% of the total releases modeled, respectively.
 674 Site-specific waterbody flow/dilution data (identified via NPDES) were available in E-FAST 2014 for

675 the majority of the releases (58%); surrogate waterbody flow/dilution data were used in only 15% of the
 676 cases, with the remaining cases (26%) run using a representative industry sector SIC code. For releases
 677 modeled with site-specific receiving waterbody flows or dilution factors, 86% were associated with free-
 678 flowing water bodies and 14% were associated with still water bodies such as lakes, bays, or estuaries.

679 **2.2.6.2.2 Measured Surface Water Concentrations**

680 ***Measured Concentrations of TCE from WQP***

681 A summary of the monitoring data obtained from the WQP is provided in Table 2-10. for the years
 682 2013-2017. Per year, the filtered datasets evaluated contained between 46 and 793 surface water samples
 683 collected from 89 to 193 unique monitoring stations. Detection frequencies were low, ranging from 0 to
 684 8.7%. Concentrations ranged from not detected (ND; <0.022-5) to 0.11 µg/L in 2013, ND (<0.022-5) to
 685 1.86 µg/L in 2014, ND (<0.025-2.4) to 0.011 µg/L in 2015, all ND (<0.025-5) in 2016, and ND (<0.025-
 686 5) to 2.0 µg/L in 2017. Peaks were observed in 2014 and 2017; however, caution should be used in
 687 interpreting trends with these data due to the small number of samples and the lack of samples collected
 688 from the same sites over multiple years. The quantitative environmental assessment used the 2016 data
 689 set only. For the 2016 data, concentrations in all samples were non-detect. No samples in the 2013-2017
 690 dataset had concentrations exceeding the lowest COC of 3 µg/L.

691 **Table 2-10. Measured Concentrations of TCE in Surface Water Obtained from the Water Quality**
 692 **Portal: 2013-2017¹**
 693

Year	Detection Frequency	Concentration (µg/L) in all samples			Concentrations (µg/L) in only samples above the detection limit		
		No. of Samples (No. of Unique Stations)	Range ²	Average (Standard Deviation) ³	No. of Samples (No. of Unique Stations)	Range	Average (Standard Deviation) ³
2013	4.67%	793 (164)	ND (<0.022-<5) to 0.11	0.21 (0.26)	37 (22)	0.008 to 0.11	0.051 (0.016)
2014	3.78%	609 (155)	ND (<0.022-<5) to 1.86	0.33 (0.31)	23 (13)	0.0055 to 1.86	0.17 (0.41)
2015	1.42%	352 (91)	ND (<0.025-<2.4) to 0.011	0.42 (0.16)	5 (2)	0.0075 to 0.011	0.009 (0.001)
2016	0.0%	473 (109)	ND (<0.025-<5)	0.44 (0.27)	0 (0)	NA	NA
2017	8.70%	46 (25)	ND (<0.025-<5) to 2.0	0.47 (0.53)	4 (1)	1.0 to 2.0	1.5 (0.71)
All Years	3.04%	2273 (384)	ND (<0.022-<5) to 2.0	0.33 (0.29)	69 (39)	0.0055 to 2.0	0.13 (0.35)

¹Data were downloaded from the Water Quality Portal (www.waterqualitydata.us) on 10/3/2018. STORET surface water data were obtained by selecting “TCE (STORET)” for the Characteristic. NWIS surface water data were obtained by selecting “34485; 39180” for the Parameter Codes. Samples were filtered for surface water media and locations only. Results were reviewed and cleansed (*i.e.*, samples/sites were eliminated if identified as estimated, quality control, media type other than surface water, Superfund, landfill, failed laboratory quality control, etc.).

²ND = Not Detected. Reported detection limits in all samples ranged from 0.022 to 5 µg/L.

³Calculations were performed using ½ the reported detection limit when results were reported as not detected. If a detection limit was not provided, calculations were performed using the average of the reported detection limits in all samples (0.65 µg/L).

694 The original dataset downloaded contained 31,456 samples for years 2013 through 2017. Following
 695 filtering for relevant media and eliminating records with quality assurance issues or those associated
 696 with superfund sites, only 2,273 (7%) of the samples were retained. The majority of the samples were
 697 excluded because they were an off-topic media (*i.e.*, groundwater, artificial, bulk deposition, leachate,
 698 municipal waste, or stormwater) or location type (*i.e.*, landfill, spring, or well). A smaller number of
 699

700 samples were excluded because they were quality control samples, estimated values, or had other quality
 701 control issues. Samples associated with one Superfund site (Palermo Wellfield Superfund Site) were
 702 also excluded. For the 2016 WQP dataset (473 samples) that is compared with modeled surface water
 703 concentrations in the GIS analysis, observations were made across 10 states (AZ, KS, MN, MO, NJ,
 704 NM, NC, PA, TN, and TX) at 109 unique monitoring sites, with 1 to 13 samples collected per sampling
 705 site.

706 **Measured Concentrations of TCE from Published Literature**

707 Systematic review of published literature yielded a limited amount of surface water monitoring data for
 708 TCE (Table 2-11.). In six U.S. studies encompassing 1,177 surface water samples collected from
 709 between 1979 and 2001, reported concentrations of TCE ranged from below the detection limit (0.0001
 710 to 0.08) to 17.3 µg/L, with reported central tendency values ranging from 0.0002 to 1.17 µg/L. The
 711 maximum concentration was collected from the Charles River in Boston, Massachusetts between 1998
 712 and 2000 (Robinson et al., 2004). The next highest TCE concentration was 2.0 µg/L, collected during a
 713 large nationwide survey of surface water for drinking water sources (rivers and reservoirs) between 1999
 714 and 2000 (USGS, 2003). Robinson et al. (2004) reported the results of sampling conducted between
 715 1996 and 2000 from 26 urban sites nationwide (n=711 samples), as part of the National Water-Quality
 716 Assessment (NAWQA) Program; the median TCE concentration was only 0.09 µg/L (detection
 717 frequency of 41%). One US study (U.S. EPA, 1977) reported much higher concentrations of TCE in
 718 surface water, up to 447 µg/L. These samples were collected in 1976-1977 near facilities producing
 719 and/or using methylchloroform, thus the concentrations reflect historical levels of TCE and are not
 720 considered to be representative of current conditions. Not enough information is reasonably available to
 721 provide a trend analysis of US surface water concentrations identified in published literature.

722
 723 Systematic review also identified data from various other countries and regions, including China, Korea,
 724 United Kingdom, Russia, Portugal, Belgium, Greece, Japan, France, Italy, and Antarctica (see [Data
 725 Extraction Tables for Environmental Monitoring Data. Docket: EPA-HQ-OPPT-2019-0500]).

726
 727 **Table 2-11. Measured Levels of TCE in U.S. Surface Water from Published Literature**


Location Type	Site Information	Dates Sampled	N (Det. Freq.)	Concentration (µg/L)		Source	Data Quality Score
				Range	Central Tendency (Standard Deviation)		
Ambient	Anchorage, AK; Chester Creek (6 urban sampling sites)	1998-2001	11 (0)	All samples ND (<0.08)		(USGS, 2006)	Medium
	Nation-wide; Surface water for drinking water sources (rivers and reservoirs)	1999-2000	375 (0.008)	ND (<0.2) - 2.0	NR	(USGS, 2003)	Medium
	Nation-wide; Urban Rivers (26 sites, as part of the NAWQA Program)	1996-2000	711 (0.41)	NR	Median: 0.09	(Robinson et al., 2004)	Medium
	Boston, MA; Charles Rivers	1998-2000	29 (1)	NR - 17.3	Median: 1.17	(Robinson et al., 2004)	Medium
	Gulf of Mexico, near mouth of the Mississippi River and on the Louisiana Shelf (11 stations in the open ocean and coast representing both	1980	11 (0.27)	ND - 0.05	NR	(Sauer, 1981)	Medium

Location Type	Site Information	Dates Sampled	N (Det. Freq.)	Concentration (µg/L)		Source	Data Quality Score
				Range	Central Tendency (Standard Deviation)		
	unpolluted and anthropogenic influences)						
	Two Bridges, NJ; Passaic River	1996-1998	10 (0.4)	NR	Median: 0.1	(Robinson et al., 2004)	Medium
	Eastern Pacific Ocean (California, US to Valparaiso, Chile)	1979-1981	30 (0.9)	ND (<0.0001) - 0.0007	Mean: 0.3 (0.002); Median: 0.0002	(Singh et al., 1983)	Medium
Near Facility (methyl-chloroform producer or user)	Baton Rouge, LA (Ethyl Corporation); Stream samples (surface) collected upstream and downstream of the outfall.	1976	2 (1.0)	0.4 - 37	NR	(U.S. EPA, 1977)	High
	Freeport, TX (Dow Chemical Plant); Stream samples (bottom and surface) collected from the receiving stream at the plant outfall and upstream and downstream of the outfall.	1976	6 (1.0)	0.9 - 126	NR	(U.S. EPA, 1977)	High
	Geismar, LA (Vulcan Materials Plant); 3 surface water samples collected from the receiving stream at the plant outfall and upstream and downstream of the outfall.	1976	3 (1.0)	5 - 74	NR	(U.S. EPA, 1977)	High
	Lake Charles, LA (PPG Industries); Stream samples (bottom and surface) collected from the receiving stream at the plant outfall and upstream and downstream of the outfall.	1976	5 (1.0)	29 - 447	Mean: 282 (156); Median: 353	(U.S. EPA, 1977)	High
	Auburn, WA (Boeing Company); Stream samples (surface) collected from the receiving stream at outfalls and/or upstream and downstream of the outfall.	1977	5 (1.0)	5 - 30	NR	(U.S. EPA, 1977)	High
NR = Not reported ND = Not detected; detection limit reported in parenthesis if reasonably available							


728 **2.2.6.2.3 Geospatial Analysis Comparing Predicted and Measured Surface Water Concentrations**

729 A geospatial analysis at the watershed level (HUC-8 and HUC-12) was conducted to compare the
 730 measured and predicted surface water concentrations in 2016 and investigate whether any the facility
 731 releases may be associated with the measured concentrations in surface water. A geographic distribution
 732 of the concentrations is shown in Figure 2-4 and Figure 2-5 for the maximum days of release scenario,
 733 and Figure 2-6 and Figure 2-7 for the 20-day release scenario. The surface water concentrations
 734 associated with the monitoring stations and facility releases are denoted on the maps using COCs to

735 determine the concentration thresholds. Overall, there are 39 US states/territories with either a measured
 736 concentration or a predicted concentration; at the watershed level, there are 155 HUC-8 areas and 241
 737 HUC-12 areas with either measured or predicted concentrations. The monitored data, which represents
 738 localized concentrations of TCE in ambient water, generally show lower concentrations than the
 739 modeled surface water concentrations from E-FAST, which represents concentrations near facilities
 740 releasing TCE.
 741




742
 743 **Figure 2-4. TCE Modeled Concentrations from Releasing Facilities (250-365 Days of Release) and**
 744 **Measured Concentrations from WQP: Eastern U.S., 2016**
 745



746
747
748
749


Figure 2-5. TCE Modeled Concentrations from Releasing Facilities (250-365 Days of Release) and Measured Concentrations from WQP: Western U.S., 2016



750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765

Figure 2-6. TCE Modeled Concentrations from Releasing Facilities (20 Days of Release) and Measured Concentrations from WQP: Eastern U.S., 2016


766
767
768



769
770
771
772
773
774
775
776
777
778
779
780
781


Figure 2-7. TCE Modeled Concentrations from Releasing Facilities (20 Days of Release) and Measured Concentrations from WQP: Western U.S., 2016

Co-location of releasing facilities and monitoring sampling locations was examined for their presence in the same watershed (HUC-8 and HUC-12). Co-location does not necessarily indicate there is an upstream/downstream connection between release and sampling sites. The monitoring stations co-located with facilities in the same HUC in the 2016 set were also examined for proximity to Superfund sites, however no Superfund sites were identified within five miles of these sites. The co-occurrence of TCE releasing facilities and monitoring sites is shown in Figure 2-8 and Figure 2-9. These HUC-level maps are only focused on NC and NM states, as those were the only two states with co-located WQP detects and modeled surface water concentrations.



782
783
784
785
786

Figure 2-8. Co-Location of Modeled Concentrations from Releasing Facilities and Measured Concentrations from WQP (HUC-8) in North Carolina



787
788
789

Figure 2-9. Co-Location of Modeled Concentrations from Releasing Facilities and Measured Concentrations from WQP (HUC-8) in New Mexico

790
791

2.2.6.3 Assumptions and Key Sources of Uncertainty for Environmental Exposures

792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809

E-FAST 2014 estimates surface water concentrations at the point of release, without post-release accounting for environmental fate or degradation such as volatilization, biodegradation, photolysis, hydrolysis, or partitioning. Additionally, E-FAST does not estimate stream concentrations based on the potential for downstream transport and dilution. These considerations tend to lead to higher predicted surface water concentrations. Dilution is incorporated, but it is based on the stream flow applied. Therefore, there is uncertainty regarding the level of TCE that would be predicted downstream of a releasing facility or after accounting for potential volatilization from the water surface, which is dependent on the degree of mixing in a receiving water body. Section 4.3.1 discusses the EPISuite modeling done to inform the degree to which volatilization may impact the modeled stream concentrations estimated in E-FAST. Parameters (wind speed, current speed, and water depth) reflective of two releasing sites with the highest predicted surface water concentrations (Praxair Technology Center in Tonawanda, NY and NASA Michoud in New Orleans, LA; see Table 4-1) were used to estimate TCE volatilization half-lives, which varied from one day to more than 10 years. The effect of volatility on estimating instream concentrations is expected to be highly variable and site-specific depending on stream flow and environmental conditions. For discharges to still, shallow water bodies, E-FAST estimates are less likely to overestimate surface water concentrations, as TCE is predicted to have a long half-life in such still water bodies. Despite some sites discharging to or near still water bodies such as lakes or bays, E-FAST does not consider aggregation or accumulation of undegraded

810 chemical. For discharges to faster-flowing, deeper water bodies, E-FAST estimates may inadequately
811 reflect instream volatile losses expected within the timeframe of one day. Given this variation and the
812 predicted half-life of TCE in flowing water bodies, E-FAST surface water concentrations may best
813 represent concentrations found at the point of discharge. Despite these uncertainties, E-FAST is
814 considered an appropriate screening model for near-field environmental concentrations.

815
816 Releases modeled using E-FAST 2014 were predicted based on engineering site-specific estimates, as
817 based on DMR, TRI, and/or CDR databases. These data that form the basis for engineering estimates are
818 self-reported by facilities subject to minimum reporting thresholds; therefore, they may not capture
819 releases from certain facilities not meeting reporting thresholds (*i.e.*, environmental releases may be
820 underestimated).

821
822 The days of release applied in modeling have a direct impact on predicting surface water concentrations.
823 The greater the number of release days assumed, the more the per-day release is diluted (assuming the
824 same overall annual loading estimate). Both the higher release frequency and lower release frequency
825 scenarios were based on estimates and were not based on actual facility reporting. Therefore, there is
826 uncertainty regarding which release scenario is more likely, although the determination was made to
827 consider only the higher release frequency for scenarios involving water treatment facilities.

828
829 Another key parameter in modeling is the applied stream flow distribution, which provides for the
830 immediate dilution of the release estimate. The flow distributions are applied by selecting a facility-
831 specific NPDES code in E-FAST. When site-specific or surrogate site-specific stream flow data were
832 not reasonably available, flow data based on a representative industry sector were used in the
833 assessment. This includes cases where a receiving facility for an indirect release could not be
834 determined. In such cases, it is likely that the stream concentration estimates are higher than they would
835 be if a facility-specific NPDES code was able to be applied, except in certain cases (*e.g.*, NODES
836 associated with low-flow or intermittent streams or bays). Additionally, the stream flow data currently
837 available in E-FAST 2014 are 15 to 30 years old. More recent flow data are available through the
838 National Hydrological Dataset (NHD) but are not available within the E-FAST model.

839
840 With respect to the geospatial comparison of modeled estimates with ambient data obtained from WQX,
841 one limitation is the accuracy of the latitudes and longitudes. The geographic coordinates for facilities
842 were obtained from the FRS Interests geodatabase, which are assigned through various methods
843 including photo-interpretation, address matching, and GPS. These are considered “Best Pick”
844 coordinates. While EPA does assign accuracy values for each record based on the method used, the true
845 accuracy of any individual point is unknown. Also, in some cases the receiving facilities for indirect
846 releases could not be determined. In these cases, the location of the active releaser was mapped. As
847 such, the co-location of facilities and monitoring sites may have been missed. As the number of
848 unknown receiving facilities was small and most monitoring sites had samples with concentrations
849 below the detection limit, this would have minimal impact on the watershed analysis. It is also important
850 to note that only a few USGS-NWIS and STORET monitoring station locations aligned with the
851 watersheds of the TCE -releasing facilities identified under the scope of this assessment, and the two co-
852 located monitoring stations had samples with concentrations below the detection limit; therefore, no
853 direct correlation can be made between them. While these data reflect low levels of trichlorethylene in
854 ambient surface water samples, they cannot be interpreted as reflecting concentrations downstream of
855 direct release sites, which could be higher than reported measured levels.

856
857 The WQP Tool contains data from USGS-NWIS and STORET databases, and is one of the largest
858 environmental monitoring databases in the US; however, comprehensive information needed for data

859 interpretation is not always reasonably available. For example, specific details regarding analytical
860 techniques may be unclear, or not reported at all. As a result, there are uncertainties in the reported data
861 that are difficult to quantify with regard to impacts on exposure estimates. Furthermore, with the high
862 fraction of non-detect (ND) levels, the average may be an overestimate of central tendency while the
863 standard deviation may underestimate variability in the dataset.

864
865 The quality of the data provided in the USGS-NWIS and STORET datasets varies, and some of the
866 information provided is non-quantitative. While many individual sampling results were obtained from
867 these datasets, the monitoring studies used to collect the data were not specifically designed to evaluate
868 TCE distribution across the US. The reasonably available data represent a variety of discrete locations
869 and time periods; therefore, it is unclear whether the data are representative of other locations in the US.
870 While these data reflect low levels of trichlorethylene in ambient surface water samples, they directly
871 reflect sampling done in specific states.

872 **2.2.6.4 Confidence in Aquatic Exposure Scenarios**

873 Confidence ratings for aquatic exposure scenarios are informed by uncertainties surrounding inputs and
874 approaches used in modeling surface water concentrations. In Section 2.2.2.1, confidence ratings are
875 assigned to these estimated daily releases (kg/site-day) on a per occupational exposure scenario (OES)
876 basis and primarily reflect moderate confidence (one OES shows high confidence for this estimate). As
877 these release estimates serve as the key inputs into the exposure mode and are therefore a key
878 component of the overall aquatic exposure scenario confidence.

879
880 Other considerations that impact confidence in the aquatic exposure scenarios include the model used
881 (E-FAST 2014) and its associated default and user-selected values and related uncertainties. As
882 described in Section 2.2.6.3, there are uncertainties related to the ability of E-FAST 2014 to incorporate
883 downstream fate and transport; the likely number of release days from given discharging facilities; and,
884 in some cases (*i.e.*, when the NPDES for the discharging facility cannot be found within the E-FAST
885 database), the applied stream flow distribution. Of note, as stated on the EPA website, “modeled
886 estimates of concentrations and doses are designed to reasonably overestimate exposures, for use in an
887 exposure assessment in the absence of or with reliable monitoring data.”

888
889 There are monitoring data available in surface water that reflect both near-facility and ambient (*i.e.*,
890 background) exposure levels in this media in the United States (see Table 2-10. and Table 2-11.).
891 Samples characterizing background levels in surface water ranged from non-detect (ND) to 17.3 µg/L,
892 from both literature and the Water Quality Portal database. However, based on the modeling approach
893 using site-specific releases and considering that the predicted concentrations reflect near-site
894 concentrations prior to any additional fate and transport processes, these background exposure levels are
895 not as useful in corroborating the modeling approach. Near-facility monitoring data collected between
896 1976 and 1977 show levels of TCE ranging from 0.4 to 447 µg/L, which encompasses the range of the
897 modeled estimates across all OES (with the exception of two sites, which are associated with releases
898 into a still water body) (see [*Aquatic Exposure Modeling Outputs from E-FAST. Docket: [EPA-HQ-
899 OPPT-2019-0500](#)*]). However, these data are not attributable to any of the specific sites modeled, nor are
900 they reflective of ongoing TCE use or release patterns.

901
902 Based on the above considerations, the aquatic exposure assessment scenarios have an overall moderate
903 confidence.

904 2.3 Human Exposures


905 2.3.1 Occupational Exposures

906 EPA categorized the conditions of use (COUs) listed in Table 1-3 into 18 Occupational Exposure
907 Scenarios (OES). In this section, EPA describes its approach and methodology to estimating
908 occupational exposures and provides a summary of results by OES for inhalation and dermal exposure,
909 and also the number of workers and occupational non-users (ONUs) potentially exposed (Figure 2-10).¹⁴
910 For the purpose of the Risk Evaluation, EPA defines ONUs as employees who do not directly handle the
911 chemical but perform work in an area where the chemical is present. The size of this area can vary for
912 each exposure scenario and condition of use, depending on the facility configuration, building and room
913 sizes, presence of vapor barrier, and worker activity pattern. For example, an ONU can be a production
914 employee whose workstation is located on the factory floor where a degreasing unit is installed. Absence
915 of any vapor barrier (e.g., walls) between the degreaser and the rest of the factory, this “area” can be an
916 entire factory floor. Alternatively, the area can be in a specific room of a building where a chemical is
917 handled (e.g., a room in a dry cleaning shop where the dry cleaning machine is installed and where dry
918 cleaned loads are unloaded, pressed, and finished). For detailed occupational exposure results, see
919 Appendix Q of this document and the (i) “Exposure Assessment” section for each OES and (ii) “Dermal
920 Exposure Assessment” section in [*Environmental Releases and Occupational Exposure Assessment*.
921 *Docket: [EPA-HQ-OPPT-2019-0500](#)*]. An occupational exposure assessment includes the following
922 components:

- 923 • **Inhalation Exposure:** Central tendency and high-end estimates of inhalation exposure to
924 workers and occupational non-users by OES.
- 925 • **Dermal Exposure:** Occupational exposure scenarios were grouped into bins based on common
926 characteristics and dermal exposure was estimated for workers for each of these bins.
- 927 • **Number of Workers and Occupational Non-Users:** An estimate of the number of workers and
928 occupational non-users (ONUs) potentially exposed to the chemical for each OES.
929

930 EPA generally does not evaluate occupational exposures through the oral route. Workers may
931 inadvertently transfer chemicals from their hands to their mouths or ingest inhaled particles that deposit
932 in the upper respiratory tract. The frequency and significance of this exposure route are dependent on
933 several factors including the physical-chemical properties of the substance during worker activities, the
934 visibility of the chemicals on the hands while working, workplace training and practices, and personal
935 hygiene that is difficult to predict ([Cherrie et al. 2006](#)). Therefore, it can be difficult to quantitatively
936 evaluate the oral route for occupational exposure scenarios.
937

¹⁴ Occupational exposures from distribution are considered within each condition of use.



938 **Figure 2-10. Components of an occupational assessment for each OES¹⁵.**
 939 Please refer to Section 2.2.2.2 for additional details on the approach and methodology for estimating
 940 number of facilities.

941 **2.3.1.1 Results for Occupational Assessment**

942 In some cases, EPA identified relevant inhalation exposure monitoring data for a given OES. The
 943 quality of the monitoring data was assessed and EPA established an overall confidence for the data when
 944 integrated into the occupational exposure assessment.

945
 946 Where monitoring data were reasonably available, EPA used this data to characterize central tendency
 947 and high end inhalation exposures. Where no inhalation monitoring data were identified, but inhalation
 948 exposure models were reasonably available, EPA estimated central tendency and high end exposures
 949 using only modeling approaches. If both, inhalation monitoring data and exposure models were
 950 reasonably available, where applicable, EPA presented central tendency and high end exposures using
 951 both. EPA did not identify any measured dermal exposure estimates. In all cases, the Dermal Exposure
 952 to Volatile Liquids (DEVL) model was used to estimate high-end and central tendency dermal exposures
 953 for workers in each OES.

954
 955 In Table 2-12, EPA provides a summary for each of the 18 OES by indicating whether monitoring data
 956 were reasonably available, how many data points were identified, the quality of the data, EPA's overall
 957 confidence in the data, whether the data were used to estimate inhalation exposures for workers and
 958 ONUs, and also whether EPA used modeling to estimate inhalation and dermal exposures for workers
 959 and ONUs.

960
 961 In many cases, EPA did not have monitoring data to estimate inhalation exposure for ONUs. In some
 962 cases, this was addressed with the use of exposure models. However, approximately 50% of OESs do

¹⁵ TRI = Toxics Release Inventory; DMR = Discharge Monitoring Report; NEI = National Emissions Inventory; CDR = Chemical Data Reporting; ELG = Effluent Limitation Guidelines; ESD = Emission Scenario Document; BLS = Bureau of Labor Statistics; NIOSH = National Institute of Occupational Safety and Health; OSHA = Occupational Safety and Health Administration; HSIA = Halogenated Solvent Industry Alliance; NF/FF = Near-Field/Far-Field; DEVL = Dermal Exposure to Volatile Liquids.

963 not contain inhalation exposure estimates for ONUs. In addition, EPA expects ONU exposures to be less
964 than worker exposures. Dermal exposure for ONUs was not evaluated because these employees are not
965 expected to be in direct contact with TCE.
966

967 A summary of inhalation exposure results based on monitoring data and exposure modeling for each
968 OES is presented for workers in Table 2-13 and ONUs in Table 2-14. These tables provide a summary
969 of time weighted average (TWA) inhalation exposure estimates as well as Acute Exposure
970 Concentrations (AC), Average Daily Concentrations (ADC), and Lifetime Average Daily
971 Concentrations (LADC). The ADC is used to characterize risks for chronic non-cancer health effects
972 whereas the LADC is used for chronic cancer health effects. Additional details regarding AC, ADC, and
973 LADC calculations are available in section 2.3.1.2.4, while EPA's approach and methodology for
974 modeling inhalation exposure using the Near-Field/Far-Field mass balance model can be found in
975 2.3.1.2.3.
976

977 Table 2-15 includes a summary of central tendency and high-end dermal exposure results based on
978 exposure modeling for workers in each OES. Occluded dermal exposures may occur when liquid
979 becomes trapped between the skin and protective clothing (*e.g.*, gloves). This may result in the liquid
980 being unable to evaporate from the skin surface which may increase the quantity of liquid absorbed.
981 Where applicable, both non-occluded and occluded exposure scenarios are assessed and the impact of
982 various glove protection factors (PFs) are also estimated. EPA estimated the dermal retained dose for
983 workers for each OES. These dose estimates assume one exposure event (applied dose) per work day
984 and that approximately eight to thirteen percent¹⁶ of the applied dose is absorbed through the skin.
985 Central tendency and high-end dermal estimates also factor in ranged values for two variables, the
986 surface area of contact, and the quantity remaining on the skin. Additional information on these
987 variables can be found in section 2.3.1.2.5.
988

989 EPA also estimated central tendency and high-end dermal retained doses for occluded scenarios for
990 OESs where occlusion was reasonably expected to occur. Occluded scenarios are generally expected
991 where workers come into contact with bulk liquid TCE during use in open systems (*e.g.*, during solvent
992 changeout in vapor degreasing) and not expected in closed-type systems (*e.g.*, during connection/
993 disconnection of hoses used in loading of bulk containers in manufacturing).
994

995 Dermal exposure estimates are provided for each OES, where the OESs are "binned" based on the
996 maximum possible exposure concentration (Y_{derm}), the likely level of exposure, and potential for
997 occlusion. The exposure concentration is determined based on EPA's review of currently available
998 products and formulations containing TCE. For example, EPA found that TCE concentration in
999 degreasing formulations such as C-60 Solvent Degreaser can be as high as 100 percent. The calculated
1000 absorbed dose is low for all non-occluded scenarios since TCE evaporates quickly after exposure.
1001 Dermal exposure to liquid is not expected for occupational non-users, since they do not directly handle
1002 TCE. Additional details on EPA's approach and methodology for estimating dermal exposures for
1003 workers can be found in section 2.3.1.2.5.
1004

1005 Table 2-16 provides a summary of EPA's estimates for the total exposed workers and ONUs for each
1006 OES. In order to prepare these estimates, EPA first attempted to identify NAICS codes associated with
1007 each OES. For these NAICS codes, EPA then reviewed Standard Occupational Classification (SOC)
1008 codes from the Bureau of Labor Statistics (BLS) and classified relevant SOC codes as workers or
1009 ONUs. All other SOC codes were assumed to represent occupations where exposure is unlikely.

¹⁶ The absorbed fraction is a function of indoor air speed, which differs for industrial and commercial settings.

1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024

Based on this combination of NAICS and SOC codes, EPA estimated the total number of workers and ONUs potentially exposed for the various OES. EPA also estimated the total number facilities associated with the NAICS codes previously identified based on data from the U.S. Census Bureau.

EPA then estimated the average number of workers and ONUs potentially exposed per site by dividing the total number of workers and ONUs by the total number of facilities. Finally, using EPA's estimates for the number of facilities using TCE, EPA was able to estimate the total number of workers and ONUs potentially exposed to TCE for reach OES.

Additional details on EPA's approach and methodology for estimating the number of facilities using TCE and the number of workers and ONUs potentially exposed to TCE can be found in sections 2.2.2.2.2 and 2.3.1.2.7, respectively.

1025
1026
1027
1028

Table 2-12. A summary for each of the 18 occupational exposure scenarios (OESs).

Where EPA was not able to estimate ONU inhalation exposure from monitoring data or models, this was assumed equivalent to the central tendency experienced by workers for the corresponding OES; dermal exposure for ONUs was not evaluated because they are not expected to be in direct contact with TCE.]

Occupational Exposure Scenario (OES)	Inhalation Exposure									Dermal Exposure Modeling ^c	
	Monitoring					Modeling		Overall Confidence		Worker	ONU
	Monitoring Data	# Data Points	Data Quality Rating	Worker	ONU	Worker	ONU	Worker	ONU		
Manufacturing	✓	50	H	✓	✗	✗	✗	M to H	L	✓	-
Processing as a Reactant	✓	50	M	✓	✗	✗	✗	L to M	L	✓	-
Formulation of Aerosol and Non-Aerosol Products	✓	33	H	✓	✗	✗	✗	M	L	✓	-
Repackaging	✓	33	H	✓	✗	✗	✗	M to H	L	✓	-
Batch Open-Top Vapor Degreasing	✓	123	M	✓	✓	✓	✓	M	M	✓	-
Batch Closed-Loop Vapor Degreasing	✓	19	H	✓	✗	✗	✗	M to H	L	✓	-
Conveyorized Vapor Degreasing	✓	18	M	✓	✗	✓	✓	L to M	L to M	✓	-
Web Vapor Degreasing	✗	-	-	✗	✗	✓	✓	L to M	L to M	✓	-
Cold Cleaning	✗	-	-	✗	✗	✓	✓	L to M	L to M	✓	-
Aerosol Applications ^a	✗	-	-	✗	✗	✓	✓	M	M	✓	-
Metalworking Fluids	✓	3	H	✓	✗	✓	✗	L to M	L	✓	-
Adhesives, Sealants, Paints, and Coatings	✓	24	M to H; M ^b	✓	✓	✗	✗	L to M	L to M	✓	-
Other Industrial Uses	✓	50	M	✓	✗	✗	✗	L to M	L	✓	-
Spot Cleaning and Wipe Cleaning	✓	8	M	✓	✗	✓	✓	M	M	✓	-
Industrial Processing Aid	✓	34	H	✓	✓	✗	✗	M to H	L to M	✓	-
Commercial Printing and Copying	✓	20	M	✓	✗	✗	✗	L to M	L	✓	-
Other Commercial Uses	✓	8	M	✓	✗	✓	✓	M	M	✓	-
Process Solvent Recycling and Worker Handling of Wastes	✓	33	H	✓	✗	✗	✗	M to H	L	✓	-

1029
1030
1031

a. Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases

b. For Workers, data quality is M to H; For ONUs, data quality is M.

c. EPA has a medium level of confidence in its dermal exposure estimates which are based on high-end/central tendency parameters and commercial/industrial settings.

1032

Table 2-13. Summary of inhalation exposure results for Workers based on monitoring data and exposure modeling for each OES.

Occupational Exposure Scenario (OES)	Inhalation Monitoring (Worker, ppm)								Inhalation Modeling (Worker, ppm)							
	TWA		AC		ADC		LADC		TWA		AC		ADC		LADC	
	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT
Manufacturing	2.5	0.12	0.82	3.8E-02	0.56	2.6E-02	0.29	1.0E-02	-	-	-	-	-	-	-	-
Processing as a Reactant	2.5	0.12	0.82	3.8E-02	0.56	2.6E-02	0.29	1.0E-02	-	-	-	-	-	-	-	-
Formulation of Aerosol and Non-Aerosol Products	1.14	4.9E-04	0.38	1.6E-04	0.26	1.1E-04	0.13	4.5E-05	-	-	-	-	-	-	-	-
Repackaging	1.14	4.9E-04	0.38	1.6E-04	0.26	1.1E-04	0.13	4.5E-05	-	-	-	-	-	-	-	-
Batch Open-Top Vapor Degreasing	77.8	13.8	25.9	4.6	17.8	3.2	9.1	1.3	388.0	34.8	129.3	11.6	88.5	8.0	35.3	3.0
Batch Closed-Loop Vapor Degreasing	1.45	0.46	0.48	0.15	0.33	0.10	0.17	4.2E-02	-	-	-	-	-	-	-	-
Conveyorized Vapor Degreasing	48.3	32.4	16.1	10.8	11.0	7.4	5.7	2.9	3043.0	40.8	1014.3	13.6	694.8	9.3	275.2	5.3
Web Vapor Degreasing	-	-	-	-	-	-	-	-	14.1	5.9	4.7	2.0	3.2	1.4	1.3	0.51
Cold Cleaning	-	-	-	-	-	-	-	-	57.2	3.3	19.1	1.1	13.1	0.76	5.2	0.28
Aerosol Applications ^a	-	-	-	-	-	-	-	-	24.0	7.6	8.0	2.5	5.5	1.7	2.2	0.65
Metalworking Fluids	75.4	69.7	25.1	23.2	17.2	15.9	8.8	6.3	0.26	0.07	0.09	0.02	0.06	0.02	0.03	0.01
Adhesives, Sealants, Paints, and Coatings	39.5	4.6	13.2	1.5	9.0	1.1	4.6	0.42	-	-	-	-	-	-	-	-
Other Industrial Uses	2.5	0.12	0.82	3.8E-02	0.56	2.6E-02	0.29	1.0E-02	-	-	-	-	-	-	-	-
Spot Cleaning and Wipe Cleaning	2.9	0.38	0.95	0.13	0.67	0.09	0.34	3.6E-02	2.8	0.96	0.92	0.32	0.65	0.23	0.26	0.08
Industrial Processing Aid ^b	12.8	4.3	6.4	2.13	4.39	1.5	2.2	0.58	-	-	-	-	-	-	-	-
Commercial Printing and Copying	2.1	8.5E-02	0.70	0.03	0.48	0.02	0.25	7.7E-03	-	-	-	-	-	-	-	-
Other Commercial Uses	2.9	0.38	0.95	0.13	0.67	0.09	0.34	3.6E-02	2.8	0.96	0.92	0.32	0.65	0.23	0.26	8.4E-02
Process Solvent Recycling and Worker Handling of Wastes	1.1	4.9E-04	0.38	1.6E-04	0.26	1.1E-04	0.13	4.5E-05	-	-	-	-	-	-	-	-

a. Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases

b. Exposure for this OES is based on a 12 hr TWA; all other exposures based on 8 hr TWAs

1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043

1044
1045
1046

Table 2-14. Summary of inhalation exposure results for ONUs based on monitoring data and exposure modeling for each OES.
[For many cases EPA was not able to estimate inhalation exposure for ONUs, but EPA expects these to be lower than inhalation exposure for Workers.]

Occupational Exposure Scenario (OES)	Inhalation Monitoring (ONU, ppm)								Inhalation Modeling (ONU, ppm)								
	TWA		AC		ADC		LADC		TWA		AC		ADC		LADC		
	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	HE	CT	
Manufacturing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Processing as a Reactant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Formulation of Aerosol and Non-Aerosol Products	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repackaging	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Batch Open-Top Vapor Degreasing	9.1	1.1	3.0	0.37	2.1	0.25	1.06	0.10	237.0	18.1	79.0	6.0	54.0	4.1	21.1	1.5	
Batch Closed-Loop Vapor Degreasing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conveyorized Vapor Degreasing	-	-	-	-	-	-	-	-	1878.0	23.3	626.0	7.8	428.8	5.3	168.3	3.6	
Web Vapor Degreasing	-	-	-	-	-	-	-	-	9.6	3.1	3.2	1.0	2.2	0.71	0.87	0.27	
Cold Cleaning	-	-	-	-	-	-	-	-	34.7	1.8	11.6	0.61	7.9	0.42	3.1	0.15	
Aerosol Applications ^a	-	-	-	-	-	-	-	-	1.0	0.14	0.35	4.7E-02	0.24	3.2E-02	0.09	1.2E-02	
Metalworking Fluids	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Adhesives, Sealants, Paints, and Coatings	1.0	0.94	0.33	0.31	0.23	0.21	0.12	8.5E-02	-	-	-	-	-	-	-	-	
Other Industrial Uses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Spot Cleaning and Wipe Cleaning	-	-	-	-	-	-	-	-	1.8	0.48	0.58	0.16	0.41	0.11	0.16	4.2E-02	
Industrial Processing Aid ^b	2.9	1.3	1.5	0.66	0.99	0.45	0.51	0.18	-	-	-	-	-	-	-	-	
Commercial Printing and Copying	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Other Commercial Uses	-	-	-	-	-	-	-	-	1.8	0.48	0.58	0.16	0.41	0.11	0.16	4.2E-02	
Process Solvent Recycling and Worker Handling of Wastes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

1047
1048
1049
1050
1051
1052
1053
1054

a. Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases

b. Exposure for this OES is based on a 12 hr TWA; all other exposures based on 8 hr TWAs

1055
1056
1057
1058

Table 2-15. A summary of dermal retained dose for Workers based on exposure modeling for each OES

[An explanation of each Bin is provided in Table 2-21; where applicable, both non-occluded and occluded exposure scenarios are assessed and the impact of various glove protection factors (PFs) are also estimated; estimates assume one exposure event per work day and that approximately eight to thirteen percent of the applied dose is absorbed through the skin (see Section 2.3.1.2.5 for additional details).]

Occupational Exposure Scenario (OES)	Bin	Max TCE Weight Fraction (Max Y_{derm})	Non-Occluded Worker Dermal Retained Dose (mg/day)								Occluded Worker Dermal Retained Dose (mg/day)		
			No Gloves (PF = 1)		Protective Gloves (PF = 5)		Protective Gloves (PF = 10)		Protective Gloves (PF = 20)		HE	CT	
			HE	CT	HE	CT	HE	CT	HE	CT			
Manufacturing	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	
Processing as a Reactant	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	
Formulation of Aerosol and Non-Aerosol Products	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	
Repackaging	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	
Batch Open-Top Vapor Degreasing	2	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	2,247	749	
Batch Closed-Loop Vapor Degreasing	2	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	2,247	749	
Conveyorized Vapor Degreasing	2	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	2,247	749	
Web Vapor Degreasing	2	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	2,247	749	
Cold Cleaning	2	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	2,247	749	
Aerosol Applications ^a	3	1.0	184.36	61.45	36.87	12.29	18.44	6.15	-	-	-	-	
Metalworking Fluids	4	0.8	147.49	49.16	29.50	9.83	14.75	4.92	-	-	1,798	599	
Adhesives, Sealants, Paints, and Coatings	Industrial	3	0.9	165.92	55.31	33.18	11.06	16.59	5.53	-	-	-	-
	Commercial	3	0.9	260.50	86.83	52.10	17.37	26.05	8.68	-	-	-	-
Other Industrial Uses	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	
Spot Cleaning and Wipe Cleaning	4	1.0	289.44	96.48	57.89	19.30	28.94	9.65	-	-	2,247	749	
Industrial Processing Aid	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	
Commercial Printing and Copying	4	0.35	101.30	33.77	20.26	6.75	10.13	3.38	-	-	786	262	
Other Commercial Uses	4	1.0	289.44	96.48	57.89	19.30	28.94	9.65	-	-	2,247	749	
Process Solvent Recycling and Worker Handling of Wastes	1	1.0	184.36	61.45	36.87	12.29	18.44	6.15	9.22	3.07	-	-	

a. Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases

1059
1060
1061
1062
1063

1064
1065
1066

Table 2-16: Summary of the total number of workers and ONUs potentially exposed to TCE for each OES

[EPA’s approach and methodology for estimating the number of facilities using TCE and the number of workers and ONUs potentially exposed to TCE can be found in sections 2.2.2.2.2 and 2.3.1.2.7, respectively.]

Occupational Exposure Scenario (OES)	Total Exposed Workers	Total Exposed ONUs	Total Exposed	Number of Facilities ^b	Notes
Manufacturing	350	170	530	5	
Processing as a Reactant	120 to 6,100	55 to 2,900	180 to 9,000	5 to 440	
Formulation of Aerosol and Non-Aerosol Products	306	99	405	19	
Repackaging	36	12	48	22	
Batch Open-Top Vapor Degreasing	4,922	2,889	7,810	194	
Batch Closed-Loop Vapor Degreasing	50	18	68	4	
Conveyorized Vapor Degreasing	92	32	130	8	
Web Vapor Degreasing	-	-	-	1	EPA does not have data to estimate the total workers and ONUs exposed to TCE.
Cold Cleaning	660	400	1,100	13	
Aerosol Applications ^a	14,200	1,690	15,900	4,366	
Metalworking Fluids	-	-	-	-	Based on ESD on the Use of Metalworking Fluids, EPA estimates 46 Workers and 2 ONUs per site; the number of sites that use TCE-based metalworking fluids is unknown to EPA.
Adhesives, Sealants, Paints, and Coatings	3,000	1,400	4,400	70	
Other Industrial Uses	2,300	1,000	3,300	49	
Spot Cleaning and Wipe Cleaning	244,000	25,300	269,000	63,748	Based on assumption of 100% market penetration.
Industrial Processing Aid	310	140	450	18	
Commercial Printing and Copying	-	-	-	-	Based on NIOSH HHE, EPA estimates 44 Workers and 74 ONUs per site; EPA does not have data to estimate total number of sites
Other Commercial Uses	-	-	-	-	EPA does not have data to estimate the total workers and ONUs exposed to TCE
Process Solvent Recycling and Worker Handling of Wastes	380	140	520	30	

1067
1068

a. Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases

b. Please refer to Table 2-3 for notes related to estimates for Number of Facilities using TCE.

1069

2.3.1.2 Approach and Methodology

2.3.1.2.1 General

1071 EPA provided occupational exposure results representative of central tendency conditions and high-end
1072 conditions. A central tendency is assumed to be representative of occupational exposures in the center of
1073 the distribution for a given condition of use. For Risk Evaluation, EPA used the 50th percentile
1074 (median), mean (arithmetic or geometric), mode, or midpoint values of a distribution as representative of
1075 the central tendency scenario. EPA's preference is to provide the 50th percentile of the distribution.
1076 However, if the full distribution is not known, EPA may assume that the mean, mode, or midpoint of the
1077 distribution represents the central tendency depending on the statistics available for the distribution.
1078

1079 A high-end is assumed to be representative of occupational exposures that occur at probabilities above
1080 the 90th percentile but below the exposure of the individual with the highest exposure ([U.S. EPA, 1992](#)).
1081 For Risk Evaluation, EPA provided high-end results at the 95th percentile. If the 95th percentile is not
1082 reasonably available, EPA used a different percentile greater than or equal to the 90th percentile but less
1083 than or equal to the 99.9th percentile, depending on the statistics available for the distribution. If the full
1084 distribution is not known and the preferred statistics are not reasonably available, EPA estimated a
1085 maximum or bounding estimate in lieu of the high-end.
1086

1087 For occupational exposures, EPA used measured or estimated air concentrations to calculate exposure
1088 concentration metrics required for risk assessment, such as average daily concentration (ADC) and
1089 lifetime average daily concentration (LADC). These calculations require additional parameter inputs,
1090 such as years of exposure, exposure duration and frequency, and lifetime years. EPA estimated exposure
1091 concentrations from monitoring data, modeling, or occupational exposure limits.
1092

1093 For the final exposure result metrics, each of the input parameters (*e.g.*, air concentrations, working
1094 years, exposure frequency, lifetime years) may be a point estimate (*i.e.*, a single descriptor or statistic,
1095 such as central tendency or high-end) or a full distribution. EPA considered three general approaches for
1096 estimating the final exposure result metrics:

- 1097 • **Deterministic calculations:** EPA used combinations of point estimates of each parameter to
1098 estimate a central tendency and high-end for each final exposure metric result.
- 1099 • **Probabilistic (stochastic) calculations:** EPA used Monte Carlo simulations using the full
1100 distribution of each parameter to calculate a full distribution of the final exposure metric results
1101 and selecting the 50th and 95th percentiles of this resulting distribution as the central tendency
1102 and high-end, respectively.
- 1103 • **Combination of deterministic and probabilistic calculations:** EPA had full distributions for
1104 some parameters but point estimates of the remaining parameters. For example, EPA used Monte
1105 Carlo modeling to estimate exposure concentrations, but only had point estimates of exposure
1106 duration and frequency, and lifetime years.

1107
1108 EPA follows the following hierarchy in selecting data and approaches for assessing inhalation
1109 exposures:

- 1110 1. Monitoring data:
 - 1111 a. Personal and directly applicable
 - 1112 b. Area and directly applicable
 - 1113 c. Personal and potentially applicable or similar
 - 1114 d. Area and potentially applicable or similar
- 1115 2. Modeling approaches:

- 1116 a. Surrogate monitoring data
- 1117 b. Fundamental modeling approaches
- 1118 c. Statistical regression modeling approaches
- 1119 3. Occupational exposure limits:
- 1120 a. Company-specific OELs (for site-specific exposure assessments, *e.g.*, there is only one
- 1121 manufacturer who provides to EPA their internal OEL but does not provide monitoring data)
- 1122 b. OSHA PEL
- 1123 c. Voluntary limits (ACGIH TLV, NIOSH REL, Occupational Alliance for Risk Science
- 1124 (OARS) workplace environmental exposure level (WEEL) [formerly by AIHA])
- 1125

1126 EPA assessed TCE occupational exposure of the following two receptor categories: male or female
1127 workers who are ≥ 16 years or older; and, female workers of reproductive age (≥ 16 years to less than 50
1128 years).

1129 **2.3.1.2.2 Inhalation Exposure Monitoring Data**

1130 EPA reviewed workplace inhalation monitoring data collected by government agencies such as OSHA
1131 and NIOSH, monitoring data found in published literature (*i.e.*, personal exposure monitoring data and
1132 area monitoring data), and monitoring data submitted via public comments. Studies were evaluated
1133 using the evaluation strategies laid out in the *Application of Systematic Review in TSCA Risk*
1134 *Evaluations* ([U.S. EPA, 2018b](#)).

1135
1136 Exposures are calculated from the datasets provided in the sources depending on the size of the dataset.
1137 For datasets with six or more data points, central tendency and high-end exposures were estimated using
1138 the 50th percentile and 95th percentile. For datasets with three to five data points, central tendency
1139 exposure was calculated using the 50th percentile and the maximum was presented as the high-end
1140 exposure estimate. For datasets with two data points, the midpoint was presented as a midpoint value
1141 and the higher of the two values was presented as a higher value. Finally, data sets with only one data
1142 point presented the value as a what-if exposure. For datasets including exposure data that were reported
1143 as below the limit of detection (LOD), EPA estimated the exposure concentrations for these data,
1144 following EPA's Guidelines for Statistical Analysis of Occupational Exposure Data ([U.S. EPA, 1994a](#))
1145 which recommends using the $LOD/\sqrt{2}$ if the geometric standard deviation of the data is less than 3.0 and
1146 $LOD/2$ if the geometric standard deviation is 3.0 or greater.

1147 **2.3.1.2.3 Inhalation Exposure Modeling**


1148 EPA's inhalation exposure modeling is based on a near-field/far-field approach (NF/FF) ([Nicas, 2009](#)),
1149 where a vapor generation source located inside the near-field diffuses into the surrounding environment.
1150 The NF/FF model has been extensively peer-reviewed, it is extensively used, and results of the model
1151 have been compared with measured data. The comparison indicated that the model and measured values
1152 agreed to within a factor of about three ([U.S. EPA, 2014b](#)).

1153
1154 EPA considers workers at the facility who neither directly perform activities near the TCE source area
1155 nor regularly handle TCE to be occupational non-users (ONU). Workers that are directly handling TCE
1156 and/or perform activities near sources of TCE are in the near field and are called workers throughout this
1157 report. The near-field is reported to be conceptualized as a volume of air within one-meter in any
1158 direction of the worker's head and the far-field comprised the remainder of the room ([Tielemans et al.,](#)
1159 [2008](#)). The source area/exposure zone could be judged by several factors such as the chemical inventory,
1160 ventilation of the facility, vapor pressure and emission potential of the chemical, process temperature,
1161 size of the room, job tasks, and modes of chemical dispersal from activities ([Leblanc et al., 2018](#)).


1162
1163
1164

Esmen et al. (1979) indicated that the assignment of zones is a professional judgment and not a scientific exercise. Applications of the NF/FF model are illustrated in Figure 2-11.


Open-Top Vapor Degreasing and Cold Cleaning




Brake Servicing



ConveyORIZED Degreasing



Web Degreasing



Spot Cleaning




Figure 2-11. Illustrative applications of the NF/FF model to various exposure scenarios.

1165
1166
1167
1168
1169
1170
1171
1172
1173
1174

As the figures show, volatile TCE becomes airborne in the near-field, resulting in worker exposures at a TCE concentration C_{NF} . The concentration is directly proportional to the evaporation rate of TCE, (denoted by G in Figure 2-11), into the near-field, whose volume is denoted by V_{NF} . In the case of brake servicing, there is no evaporation rate. Rather, the aerosol degreaser is assumed to immediately become airborne in the near-field zone upon application, resulting in a sudden rise in the near-field concentration.

The ventilation rate for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-

1175 field, resulting in occupational non-user exposures to TCE at a concentration C_{FF} . V_{FF} denotes the
 1176 volume of the far-field space into which the TCE dissipates out of the near-field. The ventilation rate for
 1177 the surroundings, denoted by Q_{FF} , determines how quickly TCE dissipates out of the surrounding space
 1178 and into the outside air. The NF/FF model design equations are presented below.

1179
 1180 Near-Field Mass Balance

1181
$$V_{NF} \frac{dC_{NF}}{dt} = C_{FF}Q_{NF} - C_{NF}Q_{NF} + G$$

1182
 1183 Far-Field Mass Balance

1184
$$V_{FF} \frac{dC_{FF}}{dt} = C_{NF}Q_{NF} - C_{FF}Q_{NF} - C_{FF}Q_{FF}$$

1185
 1186 Where:

- 1187 V_{NF} = near-field volume;
 1188 V_{FF} = far-field volume;
 1189 Q_{NF} = near-field ventilation rate;
 1190 Q_{FF} = far-field ventilation rate;
 1191 C_{NF} = average near-field concentration;
 1192 C_{FF} = average far-field concentration;
 1193 G = average vapor generation rate; and
 1194 t = elapsed time.

1195
 1196 For details on the modeling approach and model equations, please refer to Appendix N; Appendix O;
 1197 and Appendix P.

1198 **2.3.1.2.4 Acute and Chronic Inhalation Exposure Estimates**

1199 This report assesses TCE exposures to workers in occupational settings, presented as time weighted
 1200 average (TWA). The TWA exposures are then used to calculate acute exposure (AC), average daily
 1201 concentration (ADC) for chronic, non-cancer risks, and lifetime average daily concentration (LADC) for
 1202 chronic, cancer risks.

1203
 1204 Acute workplace exposures are assumed to be equal to the contaminant concentration in air (TWA):

1205
 1206
$$AC = \frac{C \times ED}{AT_{acute}}$$

1207 Where:

- 1208 AC = acute exposure concentration
 1209 C = contaminant concentration in air (TWA)
 1210 ED = exposure duration (hr/day)
 1211 AT_{acute} = acute averaging time (24 hrs)

1212
 1213 ADC and LADC are used to estimate workplace exposures for non-cancer and cancer risks, respectively.
 1214 These exposures are estimated as follows:

1215
 1216
$$ADC \text{ or } LADC = \frac{C \times ED \times EF \times WY}{AT \text{ or } AT_c}$$

1217

1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241

$$AT = WY \times 365 \frac{\text{day}}{\text{yr}} \times 24 \frac{\text{hr}}{\text{day}}$$

$$AT_C = LT \times 365 \frac{\text{day}}{\text{yr}} \times 24 \frac{\text{hr}}{\text{day}}$$

Where:

- ADC = Average daily concentration used for chronic non-cancer risk calculations
- LADC = Lifetime average daily concentration used for chronic cancer risk calculations
- ED = Exposure duration (hr/day)
- EF = Exposure frequency (day/yr)
- WY = Working years per lifetime (yr)
- AT = Averaging time (hr) for chronic, non-cancer risk
- AT_C = Averaging time (hr) for cancer risk
- AWD = Annual working days (day/yr)
- f = Fractional working days with exposure (unitless)
- LT = Lifetime years (yr) for cancer risk

The parameter values in Table 2-17 are used to calculate each of the above acute or chronic exposure estimates. Where exposure is calculated using probabilistic modeling, the AC, ADC, and LADC calculations are integrated into the Monte Carlo simulation. Where multiple values are provided for ED and EF, it indicates that EPA may have used different values for different conditions of use. The rationale for these differences are described below in this section (also see Appendix M for example calculations).

Table 2-17. Parameter Values for Calculating Inhalation Exposure Estimates

Parameter Name	Symbol	Value	Unit
Exposure Duration	ED	8 or 24	hr/day
Exposure Frequency	EF	250	days/yr
Working years	WY	31 (50 th percentile) 40 (95 th percentile)	years
Lifetime Years, cancer	LT	78	years
Averaging Time, non-cancer	AT	271,560 (central tendency) ^a 350,400 (high-end) ^b	hr
Averaging Time, cancer	AT _c	683,280	hr

^a Calculated using the 50th percentile value for working years (WY)

^b Calculated using the 95th percentile value for working years (WY)

Exposure Duration (ED)

EPA generally uses an exposure duration of 8 hours per day for averaging full-shift exposures with an exception of spot-cleaning. Operating hours for spot cleaning were assessed as 2 to 5 hours/day.

Exposure Frequency (EF)

EPA generally uses an exposure frequency of 250 days per year with the following exception: spot cleaning. EPA assumed spot cleaners may operate between five and six days per week and 50 to 52 weeks per year resulting in a range of 250 to 312 annual working days per year (AWD). Taking into

1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252

1253 account fractional days exposed (f) resulted in an exposure frequency (EF) of 249 at the 50th percentile
1254 and 313 at the 95th percentile.

1255
1256 EF is expressed as the number of days per year a worker is exposed to the chemical being assessed. In
1257 some cases, it may be reasonable to assume a worker is exposed to the chemical on each working day. In
1258 other cases, it may be more appropriate to estimate a worker's exposure to the chemical occurs during a
1259 subset of the worker's annual working days. The relationship between exposure frequency and annual
1260 working days can be described mathematically as follows:

1261
1262
$$EF = f \times AWD$$

1263 Where:

1264 EF = exposure frequency, the number of days per year a worker is exposed to the chemical
1265 (day/yr)

1266 f = fractional number of annual working days during which a worker is exposed to the
1267 chemical (unitless)

1268 AWD = annual working days, the number of days per year a worker works (day/yr)

1269
1270 BLS (2016) provides data on the total number of hours worked and total number of employees by each
1271 industry NAICS code. These data are available from the 3- to 6-digit NAICS level (where 3-digit
1272 NAICS are less granular and 6-digit NAICS are the most granular). Dividing the total, annual hours
1273 worked by the number of employees yields the average number of hours worked per employee per year
1274 for each NAICS.

1275
1276 EPA has identified approximately 140 NAICS codes applicable to the multiple conditions of use for the
1277 ten chemicals undergoing Risk Evaluation. For each NAICS code of interest, EPA looked up the
1278 average hours worked per employee per year at the most granular NAICS level available (*i.e.*, 4-digit, 5-
1279 digit, or 6-digit). EPA converted the working hours per employee to working days per year per
1280 employee assuming employees work an average of eight hours per day. The average number of days per
1281 year worked, or AWD, ranges from 169 to 282 days per year, with a 50th percentile value of 250 days
1282 per year. EPA repeated this analysis for all NAICS codes at the 4-digit level. The average AWD for all
1283 4-digit NAICS codes ranges from 111 to 282 days per year, with a 50th percentile value of 228 days per
1284 year. 250 days per year is approximately the 75th percentile. In the absence of industry- and TCE-
1285 specific data, EPA assumes the parameter *f* is equal to one for all conditions of use.

1286
1287 **Working Years (WY)**

1288 EPA has developed a triangular distribution for working years. EPA has defined the parameters of the
1289 triangular distribution as follows:

- 1290
- 1291 • **Minimum value:** BLS CPS tenure data with current employer as a low-end estimate of the
1292 number of lifetime working years: 10.4 years;
 - 1293 • **Mode value:** The 50th percentile tenure data with all employers from SIPP as a mode value for
1294 the number of lifetime working years: 31 years; and
 - 1295 • **Maximum value:** The maximum average tenure data with all employers from SIPP as a high-end
1296 estimate on the number of lifetime working years: 40 years.

1297 This triangular distribution has a 50th percentile value of 31 years and a 95th percentile value of 40 years.
1298 EPA uses these values for central tendency and high-end ADC and LADC calculations, respectively.

1299
1300 The BLS ([U.S. BLS, 2014](#)) provides information on employee tenure with *current employer* obtained

1301 from the Current Population Survey (CPS). CPS is a monthly sample survey of about 60,000 households
 1302 that provides information on the labor force status of the civilian non-institutional population age 16 and
 1303 over; CPS data are released every two years. The data are available by demographics and by generic
 1304 industry sectors but are not available by NAICS codes.

1305
 1306 The U.S. Census' ([U.S. Census Bureau, 2019](#)) Survey of Income and Program Participation (SIPP)
 1307 provides information on lifetime tenure with all employers. SIPP is a household survey that collects data
 1308 on income, labor force participation, social program participation and eligibility, and general
 1309 demographic characteristics through a continuous series of national panel surveys of between 14,000
 1310 and 52,000 households ([U.S. Census Bureau, 2019](#)). EPA analyzed the 2008 SIPP Panel Wave 1, a panel
 1311 that began in 2008 and covers the interview months of September 2008 through December 2008 ([U.S.](#)
 1312 [Census Bureau, 2019](#)). For this panel, lifetime tenure data are available by Census Industry Codes,
 1313 which can be cross-walked with NAICS codes.

1314
 1315 SIPP data include fields for the industry in which each surveyed, employed individual works
 1316 (TJBIND1), worker age (TAGE), and years of work experience *with all employers* over the surveyed
 1317 individual's lifetime.¹⁷ Census household surveys use different industry codes than the NAICS codes
 1318 used in its firm surveys, so these were converted to NAICS using a published crosswalk ([U.S. Census](#)
 1319 [Bureau, 2013](#)). EPA calculated the average tenure for the following age groups: 1) workers age 50 and
 1320 older; 2) workers age 60 and older; and 3) workers of all ages employed at time of survey. EPA used
 1321 tenure data for age group "50 and older" to determine the high-end lifetime working years, because the
 1322 sample size in this age group is often substantially higher than the sample size for age group "60 and
 1323 older." For some industries, the number of workers surveyed, or the *sample size*, was too small to
 1324 provide a reliable representation of the worker tenure in that industry. Therefore, EPA excluded data
 1325 where the sample size is less than five from the analysis.

1326
 1327 Table 2-18 summarizes the average tenure for workers age 50 and older from SIPP data. Although the
 1328 tenure may differ for any given industry sector, there is no significant variability between the 50th and
 1329 95th percentile values of average tenure across manufacturing and non-manufacturing sectors.

1330
 1331 **Table 2-18. Overview of Average Worker Tenure from U.S. Census SIPP (Age Group 50+)**

Industry Sectors	Working Years			
	Average	50 th Percentile	95 th Percentile	Maximum
All industry sectors relevant to the 10 chemicals undergoing Risk Evaluation	35.9	36	39	44
Manufacturing sectors (NAICS 31-33)	35.7	36	39	40
Non-manufacturing sectors (NAICS 42-81)	36.1	36	39	44

1332 Source: ([U.S. Census Bureau, 2019](#))

1333 Note: Industries where sample size is less than five are excluded from this analysis.

1334
 1335 BLS CPS data provides the median years of tenure that wage and salary workers had been with their
 1336 current employer. Table 2-19 presents CPS data for all demographics (men and women) by age group
 1337 from 2008 to 2012. To estimate the low-end value on number of working years, EPA uses the most

¹⁷ To calculate the number of years of work experience EPA took the difference between the year first worked (TMAKMNYR) and the current data year (*i.e.*, 2008). EPA then subtracted any intervening months when not working (ETIMEOFF).

1338 recent (2014) CPS data for workers age 55 to 64 years, which indicates a median tenure of 10.4 years
 1339 with their current employer. The use of this low-end value represents a scenario where workers are only
 1340 exposed to the chemical of interest for a portion of their lifetime working years, as they may change jobs
 1341 or move from one industry to another throughout their career.

1342 **Table 2-19. Median Year of Tenure with Current Employer by Age Group.**

Age	January 2008	January 2010	January 2012	January 2014
16 years and over	4.1	4.4	4.6	4.6
16 to 17 years	0.7	0.7	0.7	0.7
18 to 19 years	0.8	1.0	0.8	0.8
20 to 24 years	1.3	1.5	1.3	1.3
25 years and over	5.1	5.2	5.4	5.5
25 to 34 years	2.7	3.1	3.2	3.0
35 to 44 years	4.9	5.1	5.3	5.2
45 to 54 years	7.6	7.8	7.8	7.9
55 to 64 years	9.9	10.0	10.3	10.4
65 years and over	10.2	9.9	10.3	10.3

1344 Source: ([U.S. BLS, 2014](#)).

1345
 1346 **Lifetime Years (LT)**

1347 EPA assumes a lifetime of 78 years for all worker demographics.

1348 **2.3.1.2.5 Dermal Exposure Modeling**

1349 Dermal exposure data were not reasonably available for the OESs in the assessment. Because TCE is a
 1350 volatile liquid that readily evaporates from the skin, EPA estimated dermal exposures using the Dermal
 1351 Exposure to Volatile Liquids (DEVL) Model. See Appendix H of the [*Environmental Releases and*
 1352 *Occupational Exposure Assessment. Docket: [EPA-HQ-OPPT-2019-0500](#)]* for the development and
 1353 underlying research of this model. This model determines a dermal potential dose rate based on an
 1354 assumed amount of liquid on skin during one contact event per day and the steady-state fractional
 1355 absorption for TCE based on a theoretical framework provided by Kasting ([Kasting and Miller, 2006](#)).
 1356 The amount of liquid on the skin is adjusted by the weight fraction of TCE in the liquid to which the
 1357 worker is exposed.

1358
 1359 The DEVL is used to assess occupational dermal exposure scenarios because the exposure duration is
 1360 typically not known across a wide variety of worker activities, and the model's event-based approach
 1361 allows exposure estimation using the number of exposure events, rather than exposure duration. Further,
 1362 the model can account for the impact of glove use in occupational settings.

1363
 1364 EPA estimated workers' dermal exposure to TCE for the industrial and commercial occupational
 1365 exposure scenarios (OESs) considering evaporation of liquid from the surface of the hands and use with
 1366 and without gloves. The OSHA recommends employers utilize the hierarchy of controls for reducing or
 1367 removing hazardous exposures. The most effective controls are elimination, substitution, or engineering
 1368 controls. Gloves are the last course of worker protection in the hierarchy of controls and should only be

1369 considered when process design and engineering controls cannot reduce workplace exposure to an
1370 acceptable level.

1371
1372 Vapor absorption during dermal exposure requires that TCE be capable of achieving a sufficient
1373 concentration in the media at the temperature and atmospheric pressure of the scenario under
1374 evaluation to provide a significant driving force for skin penetration. Because TCE is a volatile liquid (VP
1375 = 73.46 mmHg and 25°C), the dermal absorption of TCE depends on the type and duration of exposure.
1376 Where exposure is not occluded, only a fraction of TCE that comes into contact with the skin will be
1377 absorbed as the chemical readily evaporates from the skin. Dermal exposure may be significant in cases of
1378 occluded exposure, repeated contacts, or dermal immersion. For example, work activities with a high degree
1379 of splash potential may result in TCE liquids trapped inside the gloves, inhibiting the evaporation of TCE
1380 and increasing the exposure duration. EPA collected and reviewed available SDSs (Safety Data Sheets)
1381 to inform the evaluation of gloves used with TCE in liquid and aerosol form at varying concentrations.

1382
1383 Trichloroethylene in liquid form at 99-100% concentration is expected to be used in both industrial and
1384 commercial settings. For industrial scenarios using this form of TCE, the following OESs are expected;
1385 Manufacture of TCE, Processing as a Reactant, Industrial Processing Aid, Formulation of Aerosol and
1386 Non Aerosol Products, Repackaging, Process Solvent Recycling, Batch Open Top Vapor Degreasing,
1387 Batch Closed-Loop Vapor Degreasing, Conveyorized Vapor Degreasing, and Web Vapor Degreasing.

1388
1389 For trichlorethylene in liquid form at 99-100% concentration an SDS from Mallinckrodt Baker Inc.
1390 recommended neoprene gloves and an SDS from Solvents Australia PTY. LTD. recommended the use
1391 of gloves made from rubber, PVC, or nitrile ([U.S. EPA, 2017c](#)).

1392
1393 Commercial OESs where TCE in liquid form at 99-100% concentration is expected includes Spot
1394 Cleaning, Wipe Cleaning, and Carpet Cleaning. An SDS for an R.R. Street & Co. cleaning agent
1395 recommended wearing Viton® [Butyl-rubber], PVA, or Barrier™ gloves. Two gun wipe cleaning
1396 agent manufacturers A.V.W. Inc. and G.B. Distributors recommend Viton or Neoprene gloves and
1397 polyethylene, neoprene, or PVA gloves, respectively ([U.S. EPA, 2017c](#)).

1398
1399 For Aerosol Degreasing and Aerosol Lubricants applications, TCE is used in a range of concentrations
1400 in aerosol form. An SDS for a 90-100% TCE aerosol degreasing agent from Brownells, Inc.
1401 recommended using PVA gloves and an SDS for a 45-55% TCE aerosol brake parts cleaner from Zep
1402 Manufacturing Co. recommended using Viton® gloves ([U.S. EPA, 2017c](#)).

1403
1404 Metalworking Fluids and Adhesives, Sealants, Paints, and Coatings typically contain a maximum TCE
1405 concentration of 80-90%. An SDS from LPS Laboratories presented a tap and die fluid at 80-90% TCE
1406 concentration and recommended using Viton® [Butyl-rubber], Silver Shield®[PE and EVOH laminate]
1407 and PVA gloves. An SDS for a 75-90% TCE adhesive from Rema Tip Top recommended using
1408 Neoprene, Butyl-rubber, or nitrile rubber ([U.S. EPA, 2017c](#)).

1409
1410 EPA did not find any SDSs with applicable use in commercial printing and copying applications.

1411
1412 To assess exposure, EPA used the *Dermal Exposure to Volatile Liquids Model* to calculate the dermal
1413 retained dose for both non-occluded and occluded scenarios. The equation modifies the *EPA 2-Hand*
1414 *Dermal Exposure to Liquids Model* by incorporating a “fraction absorbed (f_{abs})” parameter to account
1415 for the evaporation of volatile chemicals and a “protection factor (PF)” to account for glove use. Default
1416 PF values, which vary depending on the type of glove used and the presence of employee training
1417 program, are shown in Table 2-20:

1418

1419

$$D_{exp} = S \times \frac{(Q_u \times f_{abs})}{PF} \times Y_{derm} \times FT$$

1420

1421

Where:

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

- S is the surface area of contact: 535 cm² (central tendency) and 1,070 cm² (high end), representing the total surface area of one and two hands, respectively. Note: EPA has no data on actual surface area of contact with liquid and that the value is assumed to represent an adequate proxy for a high-end surface area of contact with liquid that may sometimes include exposures to much of the hands and also beyond the hands, such as wrists, forearms, neck, or other parts of the body, for some scenarios.
- Q_u is the quantity remaining on the skin: 1.4 mg/cm²-event (central tendency) and 2.1 mg/cm²-event (high-end). This is the high-end default value used in the EPA dermal models ([U.S. EPA, 2013a](#)).
- Y_{derm} is the weight fraction of the chemical of interest in the liquid (0 ≤ Y_{derm} ≤ 1)
- FT is the frequency of events (1 event per day)
- f_{abs} is the fraction of applied mass that is absorbed (Default for TCE: 0.08 for industrial facilities and 0.13 for commercial facilities). Note: this value represents the proportion of TCE that remains on the skin after evaporation.
- PF is the glove protection factor (Table 2-20)

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

The steady state fractional absorption (f_{abs}) for TCE is estimated to be 0.08 in industrial facilities with higher indoor wind flows or 0.13 in commercial facilities with lower indoor wind speeds based on a theoretical framework provided by Kasting and Miller (2006) ([Kasting and Miller, 2006](#)), meaning approximately 8 or 13 percent of the applied dose is absorbed through the skin following exposure, from industrial and commercial settings, respectively. However, there is a large standard deviation in the experimental measurement, which is indicative of the difficulty in spreading a small, rapidly evaporating dose of TCE evenly over the skin surface.

Table 2-20. Glove Protection Factors for Different Dermal Protection Strategies.

Dermal Protection Characteristics	Setting	Protection Factor, PF
a. No gloves used, or any glove / gauntlet without permeation data and without employee training	Industrial and Commercial Uses	1
b. Gloves with available permeation data indicating that the material of construction offers good protection for the substance		5
c. Chemically resistant gloves (<i>i.e.</i> , as <i>b</i> above) with “basic” employee training		10
d. Chemically resistant gloves in combination with specific activity training (<i>e.g.</i> , procedure for glove removal and disposal) for tasks where dermal exposure can be expected to occur	Industrial Uses Only	20

1447

Source: ([Marquart et al., 2017](#))

1448

1449

1450

To streamline the dermal exposure assessment, EPA grouped the various OESs based on characteristics known to effect dermal exposure such as the maximum weight fraction of TCE could be present in that

1451 scenario, open or closed system use of TCE, and large or small-scale use. Four different groups or
 1452 “bins” were created based on this analysis (Table 2-21).
 1453
 1454

Table 2-21. EPA grouped dermal exposures associated with the various OESs into four bins.

Bin #	Description
1	<p>Bin 1 covers industrial uses that generally occur in closed systems. For these uses, dermal exposure is likely limited to chemical loading/unloading activities (<i>e.g.</i>, connecting hoses) and taking quality control samples. EPA assesses the following glove use scenarios for Bin 1 conditions of use:</p> <p>No gloves used: Operators in these industrial uses, while working around closed-system equipment, may not wear gloves or may wear gloves for abrasion protection or gripping that are not chemical resistant.</p> <p>Gloves used with a protection factor of 5, 10, and 20: Operators may wear chemical-resistant gloves when taking quality control samples or when connecting and disconnecting hoses during loading/unloading activities. EPA assumes gloves may offer a range of protection, depending on the type of glove and employee training provided.</p> <p>Scenarios not assessed: EPA does not assess occlusion as workers in these industries are not likely to come into contact with bulk liquid TCE that could lead to chemical permeation under the cuff of the glove or excessive liquid contact time leading to chemical permeation through the glove.</p>
2	<p>Bin 2 covers industrial degreasing uses, which are not closed systems. For these uses, there is greater opportunity for dermal exposure during activities such as charging and draining degreasing equipment, drumming waste solvent, and removing waste sludge. EPA assesses the following glove use scenarios for Bin 2 conditions of use:</p> <p>No gloves used: Due to the variety of shop types in these uses the actual use of gloves is uncertain. EPA assumes workers may not wear gloves or may wear gloves for abrasion protection or gripping that are not chemical resistant during routine operations such as adding and removing parts from degreasing equipment.</p> <p>Gloves used with a protection factor of 5, 10, and 20: Workers may wear chemical-resistant gloves when charging and draining degreasing equipment, drumming waste solvent, and removing waste sludge. EPA assumes gloves may offer a range of protection, depending on the type of glove and employee training provided.</p> <p>Occluded Exposure: Occlusion may occur when workers are handling bulk liquid TCE when charging and draining degreasing equipment, drumming waste solvent, and removing waste sludge that could lead to chemical permeation under the cuff of the glove or excessive liquid contact time leading to chemical permeation through the glove.</p>
3	<p>Bin 3 covers aerosol uses, where workers are likely to have direct dermal contact with film applied to substrate and incidental deposition of aerosol to skin. EPA assesses the following glove use scenarios for Bin 3 conditions of use:</p> <p>No gloves used: Actual use of gloves in this use is uncertain. EPA assumes workers may not wear gloves or may wear gloves for abrasion protection or gripping that are not chemical resistant during routine aerosol applications.</p> <p>Gloves used with a protection factor of 5 and 10: Workers may wear chemical-resistant gloves when applying aerosol products. EPA assumes the commercial facilities in Bin 3 do not offer activity-specific training on donning and doffing gloves.</p> <p>Scenarios not assessed: EPA does not assess glove use with protection factors of 20 as EPA assumes chemical-resistant gloves used in these industries would either not be accompanied by training or be accompanied by basic employee training, but not activity-specific training. EPA does not assess occlusion for aerosol applications because TCE formulations are often supplied in an aerosol spray can</p>

Bin #	Description
	and contact with bulk liquid is unlikely. EPA also does not assess occlusion for non-aerosol niche uses because the potential for occlusion is unknown
4	<p>Bin 4 covers commercial activities of similar maximum concentration. Most of these uses are uses as spot cleaners or in wipe cleaning, and/or uses expected to have direct dermal contact with bulk liquids. EPA assesses the following glove use scenarios for Bin 4 conditions of use:</p> <p>No gloves used: Actual use of gloves in this use is uncertain. EPA assumes workers may not wear gloves during routine operations (<i>e.g.</i>, spot cleaning).</p> <p>Gloves used with a protection factor of 5 and 10: Workers may wear chemical-resistant gloves when charging and draining solvent to/from machines, removing and disposing sludge, and maintaining equipment. EPA assumes the commercial facilities in Bin 4 do not offer activity-specific training on donning and doffing gloves.</p> <p>Occluded Exposure: Occlusion may occur when workers are handling bulk liquid TCE when charging and draining solvent to/from machines, removing and disposing sludge, and maintaining equipment that could lead to chemical permeation under the cuff of the glove or excessive liquid contact time leading to chemical permeation through the glove.</p> <p>Scenarios not assessed: EPA does not assess glove use with protection factors of 20 as EPA assumes chemical-resistant gloves used in these industries would either not be accompanied by training or be accompanied by basic employee training, but not activity-specific training.</p>

1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478

2.3.1.2.6 Consideration of Engineering Controls and Personal Protective Equipment

OSHA requires and NIOSH recommends that employers utilize the hierarchy of controls to address hazardous exposures in the workplace ([OSHA, 2016](#), [NIOSH, 2018](#)). The hierarchy of controls strategy outlines, in descending order of priority, the use of elimination, substitution, engineering controls, administrative controls, and lastly personal protective equipment (PPE). The hierarchy of controls prioritizes the most effective measures first which is to eliminate or substitute the harmful chemical (*e.g.*, use a different process, substitute with a less hazardous material), thereby preventing or reducing exposure potential. Following elimination and substitution, the hierarchy recommends engineering controls to isolate employees from the hazard, followed by administrative controls, or changes in work practices to reduce exposure potential (*e.g.*, source enclosure, local exhaust ventilation systems). Administrative controls are policies and procedures instituted and overseen by the employer to protect worker exposures. As the last means of control, the use of personal protective equipment (*e.g.*, respirators, gloves) is recommended, when the other control measures cannot reduce workplace exposure to an acceptable level. The National Institute for Occupational Safety and Health (NIOSH) and the U.S. Department of Labor’s Bureau of Labor Statistics (BLS) conducted a voluntary survey of U.S. employers regarding the use of respiratory protective devices between August 2001 and January 2002 ([NIOSH, 2001](#)). For additional information, please also refer to [*Memorandum_NIOSH_BLS Respirator Usage in Private Sector Firms. Docket # [EPA-HQ-OPPT-2019-0500](#)*].

Respiratory Protection

OSHA’s Respiratory Protection Standard (29 CFR § 1910.134) requires employers in certain industries to address workplace hazards by implementing engineering control measures and, if these are not feasible, provide respirators that are applicable and suitable for the purpose intended.¹⁸ Respirator selection provisions are provided in § 1910.134(d) and require that appropriate respirators are selected

¹⁸ OSHA does not require controls to be used unless a hazard assessment determines that the hazard is significant enough to require mitigation.

1479 based on the respiratory hazard(s) to which the worker will be exposed and workplace and user factors
 1480 that affect respirator performance and reliability. Assigned protection factors (APFs) are provided in
 1481 Table 1 under § 1910.134(d)(3)(i)(A) (see Table 2-22) and refer to the level of respiratory protection
 1482 that a respirator or class of respirators is expected to provide to employees when the employer
 1483 implements a continuing, effective respiratory protection program.

1484
 1485 The United States has several regulatory and non-regulatory exposure limits for TCE: an OSHA PEL of
 1486 100 ppm 8-hour TWA ([OSHA, 2019](#)), a NIOSH Recommended Exposure Limit (REL) of 2 ppm (as a
 1487 60-minute ceiling for TCE usage as an anesthetic) and 25 ppm (as a 10-hour TWA for other exposures)
 1488 ([NIOSH, 2019](#)) and an American Conference of Government Industrial Hygienists (ACGIH) 8-hour
 1489 TLV of 10 ppm and a short-term limit of 25 ppm ([ATSDR, 2019](#)). If respirators are necessary in
 1490 atmospheres that are not immediately dangerous to life or health, workers must use NIOSH-certified air-
 1491 purifying respirators or NIOSH-approved supplied-air respirators with the appropriate APF. Respirators
 1492 that meet these criteria include air-purifying respirators with organic vapor cartridges. Table 2-22 can be
 1493 used as a guide to show the protectiveness of each category of respirator. Based on the APF, inhalation
 1494 exposures may be reduced by a factor of 5 to 10,000, when workers and occupational non-users are
 1495 using respiratory protection.

1496
 1497 The respirators should be used when effective engineering controls are not feasible as per OSHA’s 29
 1498 CFR § 1910.134. The knowledge of the range of respirator APFs is intended to assist employers in
 1499 selecting the appropriate type of respirator that could provide a level of protection needed for a specific
 1500 exposure scenario. Table 2-22 lists the range of APFs for respirators. The complexity and burden of
 1501 wearing respirators increases with increasing APF. The APFs are not to be assumed to be
 1502 interchangeable for any conditions of use, any workplace, or any worker or ONU.

1503
 1504 **Table 2-22. Assigned Protection Factors for Respirators in OSHA Standard 29 CFR § 1910.134.**

Type of Respirator	Quarter Mask	Half Mask	Full Facepiece	Helmet/Hood	Loose-fitting Facepiece
1. Air-Purifying Respirator	5	10	50		
2. Power Air-Purifying Respirator (PAPR)		50	1,000	25/1,000	25
3. Supplied-Air Respirator (SAR) or Airline Respirator					
Demand mode		10	50		
Continuous flow mode		50	1,000	25/1,000	25
Pressure-demand or other positive-pressure mode		50	1,000		
4. Self-Contained Breathing Apparatus (SCBA)					
Demand mode		10	50	50	
Pressure-demand or other positive-pressure mode (<i>e.g.</i> , open/closed circuit)			10,000	10,000	

1505 Source: 29 CFR § 1910.134(d)(3)(i)(A)

1506

1507 **2.3.1.2.7 Number of Workers and Occupational Non-Users Exposed**

1508 This section summarizes the methods that EPA used to estimate the number of workers who are
1509 potentially exposed to TCE in each of its conditions of use. The method consists of the following steps:

- 1510 1. Identify the NAICS codes for the industry sectors associated with each condition of use.
- 1511 2. Estimate total employment by industry/occupation combination using the Bureau of Labor
1512 Statistics' Occupational Employment Statistics data ([U.S. BLS, 2016](#)).
- 1513 3. Refine the estimates based on BLS Occupational Employment Statistics data where they are not
1514 sufficiently granular by using the U.S. Census Statistics of U.S. Businesses (SUSB) ([U.S. Census
1515 Bureau, 2015](#)) data on total employment by 6-digit NAICS.
- 1516 4. Estimate the percentage of employees likely to be using TCE instead of other chemicals (*i.e.*, the
1517 market penetration of TCE in the condition of use).
- 1518 5. Estimate the number of sites and number of potentially exposed employees per site.
- 1519 6. Estimate the number of potentially exposed employees within the condition of use.

1520
1521 **Step 1: Identifying Affected NAICS Codes**

1522 As a first step, EPA identified NAICS industry codes associated with each condition of use. EPA
1523 generally identified NAICS industry codes for a condition of use by:

- 1524 • Querying the [U.S. Census Bureau's NAICS Search tool](#) using keywords associated with each
1525 condition of use to identify NAICS codes with descriptions that match the condition of use.
- 1526 • Referencing EPA Generic Scenarios (GS's) and Organisation for Economic Co-operation and
1527 Development (OECD) Emission Scenario Documents (ESDs) for a condition of use to identify
1528 NAICS codes cited by the GS or ESD.
- 1529 • Reviewing Chemical Data Reporting (CDR) data for the chemical, identifying the industrial
1530 sector codes reported for downstream industrial uses, and matching those industrial sector codes
1531 to NAICS codes using Table D-2 provided in the [CDR reporting instructions](#).

1532
1533 Each condition of use section in the main body of this report identifies the NAICS codes EPA identified
1534 for the respective condition of use.

1535
1536 **Step 2: Estimating Total Employment by Industry and Occupation**

1537 BLS's ([U.S. BLS, 2016](#)) Occupational Employment Statistics data provide employment data for
1538 workers in specific industries and occupations. The industries are classified by NAICS codes (identified
1539 previously), and occupations are classified by Standard Occupational Classification (SOC) codes.

1540
1541 Among the relevant NAICS codes (identified previously), EPA reviewed the occupation description and
1542 identified those occupations (SOC codes) where workers are potentially exposed to TCE. Table 2-23
1543 shows the SOC codes EPA classified as occupations potentially exposed to TCE. These occupations are
1544 classified into workers (W) and occupational non-users (O). All other SOC codes are assumed to
1545 represent occupations where exposure is unlikely.

1546
1547
1548
1549
1550
1551
1552
1553
1554

1555 **Table 2-23. SOC's with Worker and ONU Designations for All Conditions of Use Except**
 1556 **Dry Cleaning**

SOC	Occupation	Designation
11-9020	Construction Managers	O
17-2000	Engineers	O
17-3000	Drafters, Engineering Technicians, and Mapping Technicians	O
19-2031	Chemists	O
19-4000	Life, Physical, and Social Science Technicians	O
47-1000	Supervisors of Construction and Extraction Workers	O
47-2000	Construction Trades Workers	W
49-1000	Supervisors of Installation, Maintenance, and Repair Workers	O
49-2000	Electrical and Electronic Equipment Mechanics, Installers, and Repairers	W
49-3000	Vehicle and Mobile Equipment Mechanics, Installers, and Repairers	W
49-9010	Control and Valve Installers and Repairers	W
49-9020	Heating, Air Conditioning, and Refrigeration Mechanics and Installers	W
49-9040	Industrial Machinery Installation, Repair, and Maintenance Workers	W
49-9060	Precision Instrument and Equipment Repairers	W
49-9070	Maintenance and Repair Workers, General	W
49-9090	Miscellaneous Installation, Maintenance, and Repair Workers	W
51-1000	Supervisors of Production Workers	O
51-2000	Assemblers and Fabricators	W
51-4020	Forming Machine Setters, Operators, and Tenders, Metal and Plastic	W
51-6010	Laundry and Dry-Cleaning Workers	W
51-6020	Pressers, Textile, Garment, and Related Materials	W
51-6030	Sewing Machine Operators	O
51-6040	Shoe and Leather Workers	O
51-6050	Tailors, Dressmakers, and Sewers	O
51-6090	Miscellaneous Textile, Apparel, and Furnishings Workers	O
51-8020	Stationary Engineers and Boiler Operators	W
51-8090	Miscellaneous Plant and System Operators	W
51-9000	Other Production Occupations	W

1557 W = worker designation
 1558 O = ONU designation

1559
 1560 For dry cleaning facilities, due to the unique nature of work expected at these facilities and that different
 1561 workers may be expected to share among activities with higher exposure potential (e.g., unloading the
 1562 dry cleaning machine, pressing/finishing a dry cleaned load), EPA made different SOC code worker and
 1563 ONU assignments for this condition of use. Table 2-24 summarizes the SOC codes with worker and
 1564 ONU designations used for dry cleaning facilities.

1565
 1566
 1567
 1568
 1569
 1570
 1571
 1572
 1573
 1574
 1575
 1576

1577 **Table 2-24. SOCs with Worker and ONU Designations for Dry Cleaning Facilities**

SOC	Occupation	Designation
41-2000	Retail Sales Workers	O
49-9040	Industrial Machinery Installation, Repair, and Maintenance Workers	W
49-9070	Maintenance and Repair Workers, General	W
49-9090	Miscellaneous Installation, Maintenance, and Repair Workers	W
51-6010	Laundry and Dry-Cleaning Workers	W
51-6020	Pressers, Textile, Garment, and Related Materials	W
51-6030	Sewing Machine Operators	O
51-6040	Shoe and Leather Workers	O
51-6050	Tailors, Dressmakers, and Sewers	O
51-6090	Miscellaneous Textile, Apparel, and Furnishings Workers	O

1578 W = worker designation

1579 O = ONU designation

1580

1581 After identifying relevant NAICS and SOC codes, EPA used BLS data to determine total employment
 1582 by industry and by occupation based on the NAICS and SOC combinations. For example, there are
 1583 110,640 employees associated with 4-digit NAICS 8123 (*Drycleaning and Laundry Services*) and SOC
 1584 51-6010 (*Laundry and Dry-Cleaning Workers*).

1585

1586 Using a combination of NAICS and SOC codes to estimate total employment provides more accurate
 1587 estimates for the number of workers than using NAICS codes alone. Using only NAICS codes to
 1588 estimate number of workers typically result in an overestimate, because not all workers employed in that
 1589 industry sector will be exposed. However, in some cases, BLS only provide employment data at the 4-
 1590 digit or 5-digit NAICS level; therefore, further refinement of this approach may be needed (see next
 1591 step).

1592

1593 **Step 3: Refining Employment Estimates to Account for lack of NAICS Granularity**

1594 The third step in EPA’s methodology was to further refine the employment estimates by using total
 1595 employment data in the U.S. Census Bureau’s ([U.S. Census Bureau, 2015](#)) SUSB. In some cases, BLS
 1596 OES’s occupation-specific data are only available at the 4-digit or 5-digit NAICS level, whereas the
 1597 SUSB data are available at the 6-digit level (but are not occupation-specific). Identifying specific 6-digit
 1598 NAICS will ensure that only industries with potential TCE exposure are included. As an example, OES
 1599 data are available for the 4-digit NAICS 8123 *Drycleaning and Laundry Services*, which includes the
 1600 following 6-digit NAICS:

- 1601 • NAICS 812310 Coin-Operated Laundries and Drycleaners;
- 1602 • NAICS 812320 Drycleaning and Laundry Services (except Coin-Operated);
- 1603 • NAICS 812331 Linen Supply; and
- 1604 • NAICS 812332 Industrial Launderers.

1605

1606 In this example, only NAICS 812320 is of interest. The Census data allow EPA to calculate employment
 1607 in the specific 6-digit NAICS of interest as a percentage of employment in the BLS 4-digit NAICS.

1608

1609 The 6-digit NAICS 812320 comprises 46 percent of total employment under the 4-digit NAICS 8123.
 1610 This percentage can be multiplied by the occupation-specific employment estimates given in the BLS
 1611 Occupational Employment Statistics data to further refine our estimates of the number of employees
 1612 with potential exposure.

1613

1614 Table 2-25 illustrates this granularity adjustment for NAICS 812320.

1615

Table 2-25. Estimated Number of Potentially Exposed Workers and ONUs under NAICS 812320.

NAICS	SOC CODE	SOC Description	Occupation Designation	Employment by SOC at 4-digit NAICS level	% of Total Employment	Estimated Employment by SOC at 6-digit NAICS level
8123	41-2000	Retail Sales Workers	O	44,500	46.0%	20,459
8123	49-9040	Industrial Machinery Installation, Repair, and Maintenance Workers	W	1,790	46.0%	823
8123	49-9070	Maintenance and Repair Workers, General	W	3,260	46.0%	1,499
8123	49-9090	Miscellaneous Installation, Maintenance, and Repair Workers	W	1,080	46.0%	497
8123	51-6010	Laundry and Dry-Cleaning Workers	W	110,640	46.0%	50,867
8123	51-6020	Pressers, Textile, Garment, and Related Materials	W	40,250	46.0%	18,505
8123	51-6030	Sewing Machine Operators	O	1,660	46.0%	763
8123	51-6040	Shoe and Leather Workers	O	Not Reported for this NAICS Code		
8123	51-6050	Tailors, Dressmakers, and Sewers	O	2,890	46.0%	1,329
8123	51-6090	Miscellaneous Textile, Apparel, and Furnishings Workers	O	0	46.0%	0
Total Potentially Exposed Employees				206,070		94,740
Total Workers						72,190
Total Occupational Non-Users						22,551

1616

Note: numbers may not sum exactly due to rounding.

1617

W = worker

1618

O = occupational non-user

1619

Source: ([U.S. Census Bureau, 2015](#)); ([U.S. BLS, 2016](#))

1620

1621

Step 4: Estimating the Percentage of Workers Using TCE Instead of Other Chemicals

1622

In the final step, EPA accounted for the market share by applying a factor to the number of workers determined in Step 3. This accounts for the fact that TCE may be only one of multiple chemicals used for the applications of interest. EPA did not identify market penetration data any conditions of use. In the absence of market penetration data for a given condition of use, EPA assumed TCE may be used at up to all sites and by up to all workers calculated in this method as a bounding estimate. This assumes a market penetration of 100%. Market penetration is discussed for each condition of use in the main body of this report.

1628

1629

1630

Step 5: Estimating the Number of Workers per Site

1631

EPA calculated the number of workers and occupational non-users in each industry/occupation combination using the formula below (granularity adjustment is only applicable where SOC data are not available at the 6-digit NAICS level):

1633

$$\text{Number of Workers or ONUs in NAICS/SOC (Step 2)} \times \text{Granularity Adjustment Percentage (Step 3)} =$$

1634

$$\text{Number of Workers or ONUs in the Industry/Occupation Combination}$$

1635

1636

1637

1638 EPA then estimated the total number of establishments by obtaining the number of establishments
1639 reported in the U.S. Census Bureau’s SUSB ([U.S. Census Bureau, 2015](#)) data at the 6-digit NAICS
1640 level.

1641
1642 EPA then summed the number of workers and occupational non-users over all occupations within a
1643 NAICS code and divided these sums by the number of establishments in the NAICS code to calculate
1644 the average number of workers and occupational non-users per site.

1646 **Step 6: Estimating the Number of Workers and Sites for a Condition of Use**

1647 EPA estimated the number of workers and occupational non-users potentially exposed to TCE and the
1648 number of sites that use TCE in a given condition of use through the following steps:

- 1649 1. Obtaining the total number of establishments by:
 - 1650 a. Obtaining the number of establishments from SUSB ([U.S. Census Bureau, 2015](#)) at the 6-
1651 digit NAICS level (Step 5) for each NAICS code in the condition of use and summing these
1652 values; or
 - 1653 b. Obtaining the number of establishments from the Toxics Release Inventory (TRI), Discharge
1654 Monitoring Report (DMR) data, National Emissions Inventory (NEI), or literature for the
1655 condition of use.
- 1656 2. Estimating the number of establishments that use TCE by taking the total number of
1657 establishments from Item 1 and multiplying it by the market penetration factor from Step 4.
- 1658 3. Estimating the number of workers and occupational non-users potentially exposed to TCE by
1659 taking the number of establishments calculated in Item 2 and multiplying it by the average
1660 number of workers and occupational non-users per site from Step 5.

1661 **2.3.1.3 Assumptions and Key Sources of Uncertainty for Occupational** 1662 **Exposures**

1663 **2.3.1.3.1 Number of Workers**

1664 There are a number of uncertainties surrounding the estimated number of workers potentially exposed to
1665 TCE, as outlined below. Most are unlikely to result in a systematic underestimate or overestimate, but
1666 could result in an inaccurate estimate.

1667
1668 CDR data are used to estimate the number of workers associated with manufacturing. There are inherent
1669 limitations to the use of CDR data as they are reported by manufacturers and importers of TCE.
1670 Manufacturers and importers are only required to report if they manufactured or imported TCE in excess
1671 of 25,000 pounds at a single site during any calendar year; as such, CDR may not capture all sites and
1672 workers associated with any given chemical.

1673
1674 There are also uncertainties with BLS data, which are used to estimate the number of workers for the
1675 remaining conditions of use. First, BLS OES employment data for each industry/occupation
1676 combination are only available at the 3-, 4-, or 5-digit NAICS level, rather than the full 6-digit NAICS
1677 level. This lack of granularity could result in an overestimate of the number of exposed workers if some
1678 6-digit NAICS are included in the less granular BLS estimates but are not, in reality, likely to use TCE
1679 for the assessed applications. EPA addressed this issue by refining the OES estimates using total
1680 employment data from the U.S. Census SUSB ([U.S. Census Bureau, 2015](#)). However, this approach
1681 assumes that the distribution of occupation types (SOC codes) in each 6-digit NAICS is equal to the
1682 distribution of occupation types at the parent 5-digit NAICS level. If the distribution of workers in
1683 occupations with TCE exposure differs from the overall distribution of workers in each NAICS, then
1684 this approach will result in inaccuracy.

1685
1686 Second, EPA’s judgments about which industries (represented by NAICS codes) and occupations
1687 (represented by SOC codes) are associated with the uses assessed in this report are based on EPA’s
1688 understanding of how TCE is used in each industry. Designations of which industries and occupations
1689 have potential exposures is nevertheless subjective, and some industries/occupations with few exposures
1690 might erroneously be included, or some industries/occupations with exposures might erroneously be
1691 excluded. This would result in inaccuracy but would be unlikely to systematically either overestimate or
1692 underestimate the count of exposed workers.

1693 **2.3.1.3.2 Analysis of Exposure Monitoring Data**

1694 This report uses existing worker exposure monitoring data to assess exposure to TCE during several
1695 conditions of use. To analyze the exposure data, EPA categorized each PBZ data point as either
1696 “worker” or “occupational non-user”. The categorizations are based on descriptions of worker job
1697 activity as provided in literature and EPA’s judgment. In general, samples for employees that are
1698 expected to have the highest exposure from direct handling of TCE are categorized as “worker” and
1699 samples for employees that are expected to have the lower exposure and do not directly handle TCE are
1700 categorized as “occupational non-user.”

1701
1702 Exposures for occupational non-users can vary substantially. Most data sources do not sufficiently
1703 describe the proximity of these employees to the TCE exposure source. As such, exposure levels for the
1704 “occupational non-user” category will have high variability depending on the specific work activity
1705 performed. It is possible that some employees categorized as “occupational non-user” have exposures
1706 similar to those in the “worker” category depending on their specific work activity pattern.

1707
1708 Some data sources may be inherently biased. For example, bias may be present if exposure monitoring
1709 was conducted to address concerns regarding adverse human health effects reported following exposures
1710 during use or if exposure monitoring results were only provided from industry. Similarly, OSHA CEHD
1711 are obtained from OSHA inspections, which may be the result of worker complaints, and may provide
1712 exposure results that may generally exceed the industry average.

1713
1714 Some scenarios have limited exposure monitoring data in literature, if any. Where there are few data
1715 points available, it is unlikely the results will be representative of worker exposure across the industry.
1716 In cases where there was no exposure monitoring data, EPA may have used monitoring data from
1717 similar conditions of use as surrogate. For example, inhalation monitoring data from manufacturing
1718 facilities were used as surrogate for other conditions of use. The data were chosen as TCE
1719 concentrations for these conditions of use would be comparable to manufacturing, and TCE exposures
1720 during unloading would be comparable in magnitude to TCE loading following manufacture. While
1721 these conditions of use have similar worker activities contributing to exposures, it is unknown that the
1722 results will be fully representative of worker exposure across different conditions of use.

1723
1724 Where sufficient data were reasonably available, the 95th and 50th percentile exposure concentrations
1725 were calculated using reasonably available data. The 95th percentile exposure concentration is intended
1726 to represent a high-end exposure level, while the 50th percentile exposure concentration represents
1727 typical exposure level. The underlying distribution of the data, and the representativeness of the
1728 reasonably available data, are not known. Where discrete data were not reasonably available, EPA used
1729 reported statistics (*e.g.*, median, mean, 90th percentile, etc.). Since EPA could not verify these values,
1730 there is an added level of uncertainty.

1731

1732 EPA calculated ADC and LADC values assuming workers and ONUs are regularly exposed during their
1733 entire working lifetime, which likely results in an overestimate. Individuals may change jobs during the
1734 course of their career such that they are no longer exposed to TCE, and that actual ADC and LADC
1735 values become lower than the estimates presented.

1736 **2.3.1.3.3 Near-Field/Far-Field Model Framework**

1737 The near-field/far-field approach is used as a framework to model inhalation exposure for many
1738 conditions of use. The following describe uncertainties and simplifying assumptions generally
1739 associated with this modeling approach:

- 1740 • There is some degree of uncertainty associated with each model input parameter. In general, the
1741 model inputs were determined based on review of reasonably available literature. Where the
1742 distribution of the input parameter is known, a distribution is assigned to capture uncertainty in
1743 the Monte Carlo analysis. Where the distribution is unknown, a uniform distribution is often
1744 used. The use of a uniform distribution will capture the low-end and high-end values but may not
1745 accurately reflect actual distribution of the input parameters.
- 1746 • The model assumes the near-field and far-field are well mixed, such that each zone can be
1747 approximated by a single, average concentration.
- 1748 • All emissions from the facility are assumed to enter the near-field. This assumption will
1749 overestimate exposures and risks in facilities where some emissions do not enter the airspaces
1750 relevant to worker exposure modeling.
- 1751 • The exposure models estimate airborne concentrations. Exposures are calculated by assuming
1752 workers spend the entire activity duration in their respective exposure zones (*i.e.*, the worker in
1753 the near-field and the occupational non-user in the far-field). Since vapor degreasing and cold
1754 cleaning involve automated processes, a worker may actually walk away from the near-field
1755 during part of the process and return when it is time to unload the degreaser. As such, assuming
1756 the worker is exposed at the near-field concentration for the entire activity duration may
1757 overestimate exposure. Conversely, assuming the occupational non-user is exposed at the far-
1758 field concentration for the entire work day may underestimate exposure as they may not remain
1759 exclusively in the far-field.
- 1760 • For certain TCE applications (*e.g.*, vapor degreasing and cold cleaning), TCE vapor is assumed
1761 to emit continuously while the equipment operates (*i.e.*, constant vapor generation rate). Actual
1762 vapor generation rate may vary with time. However, small time variability in vapor generation is
1763 unlikely to have a large impact in the exposure estimates as exposures are calculated as a time-
1764 weighted average.
- 1765 • The exposure models represent model workplace settings for each TCE condition of use.

1766 Each subsequent item below discusses uncertainties associated with the individual model.
1767

1768 **Vapor Degreasing and Cold Cleaning Models**

1770 The OTVD, conveyORIZED vapor degreasing, and cold cleaning assessments use a near-field/far-field
1771 approach to model worker exposure. In addition to the uncertainties described above, the vapor
1772 degreasing and cold cleaning models have the following uncertainties:

- 1773 • To estimate vapor generation rate for each equipment type, EPA used a distribution of the
1774 emission rates reported in the 2014 NEI for each degreasing/cold cleaning equipment type. NEI
1775 only contains information on major sources not area sources. Therefore, the emission rate
1776 distribution used in modeling may not be representative of degreasing/cold cleaning equipment
1777 emission rates at area sources.

- The emission rate for conveyORIZED vapor degreasing is based on equipment at eight sites. It is uncertain how representative these data are of a “typical” site.
- EPA assumes workers and occupational non-users remove themselves from the contaminated near- and far-field zones at the conclusion of the task, such that they are no longer exposed to any residual TCE in air.

Brake Servicing Model

The aerosol degreasing assessment also uses a near-field/far-field approach to model worker exposure. Specific uncertainties associated with the aerosol degreasing scenario are presented below:

- The model references a CARB study ([CARB, 2000](#)) on brake servicing to estimate use rate and application frequency of the degreasing product. The brake servicing scenario may not be representative of the use rates for other aerosol degreasing applications involving TCE.
- The TCE Use Dossier ([U.S. EPA, 2017c](#)) presented 16 different aerosol degreasing formulations containing TCE. For each Monte Carlo iteration, the model determines the TCE concentration in product by selecting one of 16 possible formulations, assuming the distribution for each formulation is equal to that found in a survey of brake cleaning shops in California. It is uncertain if this distribution is representative of other geographic locations within the U.S.
- Some of the aerosol formulations presented in the TCE Use Dossier ([U.S. EPA, 2017c](#)) were provided as ranges. For each Monte Carlo iteration the model selects a TCE concentration within the range of concentrations using a uniform distribution. In reality, the TCE concentration in the formulation may be more consistent than the range provided.

Spot Cleaning Model

The multi-zone spot cleaning model also uses a near-field/far-field approach. Specific uncertainties associated with the spot cleaning scenario are presented below:

- The model assumes a use rate based on estimates of the amount of TCE-based spot cleaner sold in California and the number of textile cleaning facilities in California ([IRTA, 2007](#)). It is uncertain if this distribution is representative of other geographic locations in the U.S.
- The model assumes a facility floor area based on data from ([CARB, 2006](#)) and King County ([Whittaker and Johanson, 2011](#)). It is unknown how representative the area is of “typical” spot cleaning facilities. Therefore, these assumptions may result in an overestimate or underestimate of worker exposure during spot cleaning.
- Many of the model input parameters were obtained from ([Von Grote et al., 2003](#)), which is a German study. Aspects of the U.S. spot cleaning facilities may differ from German facilities. However, it is not known whether the use of German data will under- or over-estimate exposure.

2.3.1.3.4 Modeled Dermal Exposures

The *Dermal Exposure to Volatile Liquids Model* is used to estimate dermal exposure to TCE in occupational settings. The model assumes a fixed fractional absorption of the applied dose; however, fractional absorption may be dependent on skin loading conditions. The model also assumes a single exposure event per day based on existing framework of the *EPA/OPPT 2-Hand Dermal Exposure to Liquids Model* and does not address variability in exposure duration and frequency. Additionally, the studies used to obtain the underlying values of the quantity remaining on the skin (Q_u) did not take into consideration the fact that liquid retention on the skin may vary with individuals and techniques of application on and removal from the hands. Also the data used were developed from three kinds of oils; therefore, the data may not be applicable to other liquids. Based on the uncertainties described above, EPA has a medium level of confidence in the assessed baseline exposure. See Appendix H of the [*Environmental Releases and Occupational Exposure Assessment. Docket: [EPA-HQ-OPPT-2019-0500](#)*] for the development and underlying research of this model.

1826
1827
1828
1829
1830

2.3.1.3.5 Summary of Overall Confidence in Inhalation Exposure Estimates

Table 2-26 provides a summary of EPA’s overall confidence in its inhalation exposure estimates for each of the Occupational Exposure Scenarios assessed.

Table 2-26. Summary of overall confidence in inhalation exposure estimates by OES.

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
Manufacturing	EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 50 data points from 2 sources, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to high.
Processing as a Reactant	EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of surrogate monitoring data, in the middle of the inhalation approach hierarchy. These monitoring data include 50 data points from 2 sources, and the data quality ratings from systematic review for these data were medium. The primary limitations of these data include the uncertainty of the representativeness of these surrogate data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.
Formulation of Aerosol and Non-Aerosol Products	EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of surrogate monitoring data, in the middle of the inhalation approach hierarchy. These monitoring data include 33 data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these surrogate data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium.
Repackaging	EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 33

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
	<p>data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to high.</p>
<p>Batch Open-Top Vapor Degreasing</p>	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 123 data points from 16 sources, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium.</p> <p>EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Vapor generation rates were derived from TCE unit emissions and operating hours reported in the 2014 National Emissions Inventory. The primary limitations of the air concentration outputs from the model include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties include that the underlying methodologies used to estimate these emissions in the 2014 NEI are unknown. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>
<p>Batch Closed-Loop Vapor Degreasing</p>	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 19 data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to high.</p>
<p>Conveyorized Vapor Degreasing</p>	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
	<p>include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 18 data points from 2 sources, and the data quality ratings from systematic review for these data were medium. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p> <p>EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Vapor generation rates were derived from TCE unit emissions and operating hours reported in the 2014 National Emissions Inventory. The primary limitations of the air concentration outputs from the model include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties include that emissions data available in the 2014 NEI were only found for three total units, and the underlying methodologies used to estimate these emissions are unknown. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>
Web Vapor Degreasing	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of modeling, in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Vapor generation rates were derived from TCE unit emissions and operating hours reported in the 2014 National Emissions Inventory. The primary limitations of the air concentration outputs from the model include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties include that emissions data available in the 2011 NEI were only found for one unit, and the underlying methodologies used to estimate the emission is unknown. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>
Cold Cleaning	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of modeling, in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Vapor generation rates were derived from TCE unit emissions and operating hours reported in the 2014 National Emissions Inventory. The primary limitations of the air concentration outputs from the model include the uncertainty of the</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
	<p>representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties include that emissions data available in the 2014 NEI were only found for ten total units, and the underlying methodologies used to estimate these emissions are unknown. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>
<p>Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases</p>	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of modeling, in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Various model parameters were derived from a CARB brake service study and TCE concentration data for 16 products representative of the OES. The primary limitations of the air concentration outputs from the model include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium.</p>
<p>Metalworking Fluids</p>	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 3 data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include limited dataset (3 data points from 1 site), and the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is low.</p> <p>EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. Data from the 2011 Emission Scenario Document on the Use of Metalworking Fluids was used to estimate inhalation exposures. The primary limitations of the exposure outputs from this model include the uncertainty of the representativeness of these data toward the true distribution of inhalation for all TCE uses for the industries and sites covered by this scenario, and the difference between the modeling data and monitoring data. Added uncertainties include that the underlying TCE concentration used in the metalworking fluid was assumed from one metalworking fluid product. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium.</p>
<p>Adhesives, Sealants, Paints, and Coatings</p>	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
	<p>include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 22 data points from 2 sources, and the data quality ratings from systematic review for these data were medium to high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to medium to low.</p> <p>For the ONU inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 2 data points from 1 source, and the data quality ratings from systematic review for the data point was high. The primary limitations of this data is the limited dataset (two data points from 1 site), and the uncertainty of the representativeness of this data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>
Other Industrial Uses	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of surrogate monitoring data, in the middle of the inhalation approach hierarchy. These monitoring data include 50 data points from 2 sources, and the data quality ratings from systematic review for these data were medium. The primary limitations of these data include the uncertainty of the representativeness of these surrogate data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>
Spot Cleaning and Wipe Cleaning	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 8 data points from 2 sources, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p> <p>EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Various</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
	<p>model parameters were derived from a CARB study. The primary limitations of the air concentration outputs from the model include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties include that the underlying methodologies used to obtain the values in the CARB study, as well as the assumed TCE concentration in the spot cleaning product. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p> <p>Despite these limitations, the modeling and monitoring results match each other very closely. Therefore, the overall confidence is medium.</p>
Industrial Processing Aid	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 12-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 30 data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 12-hr TWA data in this scenario is medium to high.</p> <p>For the ONU inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 4 data points from 1 source, and the data quality ratings from systematic review for the data point was high. The primary limitations of this single data point include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 12-hr TWA data in this scenario is medium to low.</p>
Commercial Printing and Copying	<p>EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 20 data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include a limited dataset, and the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.</p>

Occupational Exposure Scenario (OES)	Overall Confidence in Inhalation Exposure Estimates
Other Commercial Uses	EPA did not identify any inhalation exposure monitoring data related to this OES. EPA assumes the exposure sources, routes, and exposure levels are similar to those for the Spot Cleaning and Wipe Cleaning OES.
Process Solvent Recycling and Worker Handling of Wastes	EPA did not identify any inhalation exposure monitoring data related to waste handling/recycling. EPA assumes the exposure sources, routes, and exposure levels are similar to those for the Repackaging OES.

1831

1832 **2.3.2 Consumer Exposures**

1833 TCE can be found in consumer and commercial products that are available for purchase at common
 1834 retailers and can therefore result in exposures to household consumers (*i.e.*, receptors who use a product
 1835 directly) and bystanders (*i.e.*, receptors who are a non-product users that are incidentally exposed to the
 1836 product or article) ([U.S. EPA, 2017c, h](#)).

1837 **2.3.2.1 Consumer Conditions of Use Evaluated**

1838 Conditions of use associated with consumer exposure were described in the Problem Formulation ([U.S.
 1839 EPA, 2018d](#)). The availability of TCE in consumer products was determined through the development of
 1840 EPA’s 2017 Market and Use Report ([U.S. EPA, 2017h](#)) and Preliminary Information on Manufacturing,
 1841 Processing, Distribution, Use, and Disposal: TCE ([U.S. EPA, 2017c](#)). Following Problem Formulation,
 1842 EPA performed targeted internet searches to confirm TCE concentrations in identified products and to
 1843 identify additional examples of products that may be available to consumers for household use. These
 1844 resources were used to select the most appropriate product-specific inputs (*e.g.*, weight fraction and
 1845 formulation type) associated with each consumer condition of use.

1846

1847 Table 2-27 lays out consumer condition of use categories and associated product subcategories
 1848 evaluated for TCE. Based on additional research, conditions of use may be described in more detail
 1849 (*e.g.*, formulation type, specific product type) when compared to the tables presented in the Problem
 1850 Formulation ([U.S. EPA, 2018d](#)). Any differences between the displayed categories and those presented
 1851 in the Problem Formulation are described in the footnotes.

1852 **Table 2-27. Evaluated Consumer Conditions of Use and Products for TCE**

Life Cycle Stage	Category	Product Subcategory	Form ¹	No. of Products Utilized in Modeling ¹
Use	Solvents for Cleaning and Degreasing	Brake & Parts Cleaner ²	Aerosol	4
		Electronic Degreaser/Cleaner ³	Aerosol	9
		Electronic Degreaser/Cleaner ³	Liquid	1
		Aerosol Spray Degreaser/Cleaner	Aerosol	8
		Liquid Degreaser/Cleaner ³	Liquid	2
		Gun Scrubber ⁴	Aerosol	2
		Gun Scrubber ⁴	Liquid	1
		Mold Release	Aerosol	2

Life Cycle Stage	Category	Product Subcategory	Form ¹	No. of Products Utilized in Modeling ¹
		Tire Cleaner ⁵	Aerosol	2
		Tire Cleaner ⁵	Liquid	1
	Lubricants and Greases	Tap & Die Fluid	Aerosol	1
		Penetrating Lubricant ⁶	Aerosol	5
	Adhesives and Sealants	Solvent-based Adhesive & Sealant	Liquid	3
		Mirror-edge Sealant	Aerosol	1
		Tire Repair Cement/Sealer	Liquid	5
	Cleaning and Furniture Care Products ¹¹	Carpet Cleaner	Liquid	1
		Spot Remover ⁷	Aerosol	1
		Spot Remover ⁷	Liquid	4
	Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings ⁸	Aerosol	1
	Apparel and Footwear Care Products	Shoe Polish	Aerosol	1
	Other Consumer Uses	Fabric Spray ⁹	Aerosol	1
		Film Cleaner	Aerosol	2
		Hoof Polish	Aerosol	1
		Pepper Spray	Aerosol	2
		Toner Aid ¹⁰	Aerosol	1

¹ Form was determined based on the specific products identified as representative of the associated product subcategories. Please see Supplemental File [Consumer Exposure Assessment Model Input Parameters. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full list of representative products.

² The brake cleaner subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the automotive care products category; however, the same brake cleaning conditions of use are now associated with the broader solvents for cleaning and degreasing category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the brake cleaner product(s) and not a broader category of use.

³ Liquid degreaser/cleaner and electronic degreaser/cleaner (aerosol and liquid) were not specifically named in the Problem Formulation as a potential consumer subcategories. They were added due to product availability based on the additional research noted above that helped to differentiate specific product forms (*i.e.*, liquid or aerosol) and types.

⁴ The gun scrubber subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the other consumer uses category; however, the same gun scrubber conditions of use are now associated with the broader solvents for cleaning and degreasing category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the gun scrubber product(s) and not a broader category of use.

⁵ Tire cleaner products / subcategories of use were not specifically called out in the Problem Formulation; however, such products were identified in the 2017 Use and Market Report and Preliminary Information on Manufacturing, Processing, Distribution, Use, and Disposal: TCE ([U.S. EPA, 2017c](#)) and fit within the broader Solvents for Cleaning and Degreasing category.

⁶ Based on additional research into the specific product(s) associated with the broader lubricants and greases category, the subcategory name was updated from penetrating lubricant to lubricant.

⁷ The spot remover subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the laundry and dishwashing products category; however, the same spot remover conditions of use are now associated with the cleaning and furniture care products category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the spot remover product(s) and not a broader category of use.

⁸ Note that this subcategory is referred to as “clear protective coating spray” in U.S. EPA ([2014b](#)) and as “spray fixative” in the TCE Significant New Use Rule (80 FR 47441). This product subcategory is not expected to be a children’s arts, crafts, or hobby use.

⁹ Fabric spray (specifically an anti-fray spray) was added following Problem Formulation based on identification in the final 2014 TCE Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)).

Life Cycle Stage	Category	Product Subcategory	Form ¹	No. of Products Utilized in Modeling ¹
<p>¹⁰ The toner aid subcategory was listed in Table 2-3 of the Problem Formulation as being associated with the Ink, toner, and colorant products category; however, the toner aid use is not like use of a toner or pigment; therefore, the same toner aid condition of use is now associated with the other consumer use category. This change does not impact evaluated conditions of use, as the evaluated product scenarios are based on the toner aid product(s) and not a broader category of use.</p> <p>¹¹ Note that the Problem Formulation described “cleaning wipes” as a condition of use for this category. However, that referred to the application of a product that is then wiped off, rather than a pre-wet towelette. A number of consumer conditions of use involve wipe cleaning and are described in detail in Section 2.3.2.5.2 as leading to dermal contact with impeded evaporation.</p>				

1853 **2.3.2.2 Consumer Exposure Routes Evaluated**

1854 Inhalation and dermal exposures are evaluated for acute exposure scenarios, *i.e.*, those resulting from
1855 short-term or daily exposures. Chronic exposure scenarios resulting from long-term use of household
1856 consumer products were not evaluated. In general, the frequency of product use was considered to be too
1857 low to create chronic risk concerns. Although high-end frequencies of consumer use for a small
1858 percentage of consumers are up to 50 times per year, reasonably available toxicological data is based on
1859 either single or continuous TCE exposure and it is unknown whether these use patterns are expected to
1860 be clustered (*e.g.*, every day for several weeks) or intermittent (*e.g.*, one time per week). There is
1861 uncertainty regarding the extrapolation from continuous studies in animals to the case of repeated,
1862 intermittent human exposures. Therefore, EPA cannot fully rule out that consumers at the high-end
1863 frequency of use could possibly be at risk for chronic hazard effects, however it is expected to be unlikely
1864 based on these considerations.

1865 **2.3.2.2.1 Inhalation**

1866 The acute exposure via inhalation is the most significant route of exposure for consumer exposure
1867 scenarios for users and bystanders. This is in line with EPA’s 2014 TSCA Work Plan Chemical Risk
1868 Assessment, which evaluated acute inhalation exposure to consumers and bystanders from degreasing
1869 and arts & crafts uses ([U.S. EPA, 2014b](#)). EPA evaluated inhalation exposures for consumers and
1870 bystanders for all consumer conditions of use.

1871 Background levels of TCE in indoor and outdoor air are not assessed in this assessment; therefore, there
1872 is a potential for underestimating consumer inhalation exposures, particularly for populations living near
1873 a facility emitting TCE or living in a home with other sources of TCE, such as TCE-containing products
1874 stored in the home. Similarly, inhalation exposures were evaluated on a product-specific basis and are
1875 based on use of a single product type within a day, not multiple products.

1877 **2.3.2.2.2 Dermal**

1878 EPA assessed dermal exposures to TCE from consumer uses. Dermal exposure may occur via contact
1879 with vapor or mist deposition on the skin or via direct liquid contact during use. Exposures to skin
1880 would be expected to evaporate rapidly based on physical chemical properties. Instantaneous exposures
1881 to skin are expected to evaporate before significant dermal absorption occurs based on TCE’s physical
1882 chemical properties which include the vapor pressure, water solubility and log K_{ow} . The log K_{ow}
1883 estimates for instantaneous exposures are 0.8% absorption and 99.2% volatilization and are derived
1884 from IHSkinPerm, a mathematical tool for estimating dermal absorption. Exposure that occurs as a
1885 deposition over time or a repeated exposure that maintains a thin layer of liquid TCE has greater relative
1886 absorption, based on the estimate from IHSkinPerm for an 8-hr exposure of 1.6% absorption and 98.4%
1887 volatilization. Dermal exposures to liquid TCE are expected to be concurrent with inhalation exposures,

1888 which are anticipated to reflect the preponderance of overall exposure from a use or activity for most
1889 consumer exposure scenarios. This agrees with the NIOSH skin notation profile for TCE, which
1890 estimates a low hazard potential by dermal absorption for systemic effects when inhalation and dermal
1891 exposures are concurrent ([Hudson and Dotson, 2017](#)). There may be certain scenarios with higher
1892 dermal exposure potential – where liquid TCE is not able to evaporate readily and volatilization is
1893 inhibited. However, dermal exposures are quantified and presented for all consumer conditions of use.
1894

1895 Generally, individuals that have contact with liquid TCE would be users and not bystanders. Therefore,
1896 dermal exposures to liquid TCE are not expected and inhalation is the primary route of exposure for
1897 bystanders. There is potential for bystanders or users to have indirect dermal contact via contact with a
1898 surface upon which TCE has been applied (*e.g.*, counter, floor). Based on the expectation that TCE
1899 would evaporate from the surface rapidly, with <1% dermal absorption predicted from instantaneous
1900 contact, this route is unlikely to contribute significantly to overall exposure.

1901 **2.3.2.3 Consumer Exposures Approach and Methodology**

1902 Modeling was conducted to estimate exposure from the identified consumer conditions of use.
1903 Exposures via inhalation and dermal contact to TCE-containing consumer products were estimated using
1904 EPA’s Consumer Exposure Model (CEM) Version 2.1 ([U.S. EPA, 2019a](#)), along with consumer
1905 behavioral pattern data (*i.e.*, use patterns) and product-specific characteristics.
1906

1907 Residential indoor air and personal breathing zone data were identified and evaluated during systematic
1908 review. However, measured levels are not attributable to specific consumer products or conditions of use
1909 and were therefore not compared to modeled estimates. For a summary of these data, see Appendix D.4.

1910 **2.3.2.3.1 Modeling Approach**

1911 Consumer Exposure Model (CEM) Version 2.1 was selected for the consumer exposure modeling as the
1912 most appropriate model to use based on the type of input data available for TCE-containing consumer
1913 products. Moreover, EPA did not have the input parameter data (*i.e.*, product-specific chamber emission
1914 data) required to run higher-tier indoor air models. The advantages of using CEM to assess exposures to
1915 consumers and bystanders are the following:

- 1916 • CEM model has been peer-reviewed;
- 1917 • CEM accommodates the distinct inputs available for the products containing TCE; and
- 1918 • CEM uses the same calculation engine to compute indoor air concentrations from a source as the
1919 higher-tier Multi-Chamber Concentration and Exposure Model (MCCEM) but does not require
1920 measured chamber emission values.

1921
1922 For a characterization of model sensitivity, see Appendix D.3.

1923 ***Modeling Air Concentrations and Inhalation Exposure***

1924 CEM predicts indoor air concentrations from consumer product use by implementing a deterministic,
1925 mass-balance calculation utilizing an emission profile determined by implementing appropriate emission
1926 scenarios. The model uses a two-zone representation of the building of use (*e.g.*, residence, school,
1927 office), with Zone 1 representing the room where the consumer product is used (*e.g.*, a utility room) and
1928 zone 2 being the remainder of the building. The product user is placed within Zone 1 for the duration of
1929 use, while a bystander is placed in Zone 2 during product use. Otherwise, product users and bystanders
1930 follow prescribed activity patterns throughout the simulated period. In some instances of product use, a
1931 higher concentration of product is expected very near the product user; CEM addresses this by further
1932 dividing Zone 1 into near-field, with a default volume of 1m³, and far-field, which reflects the remainder
1933 of Zone 1. Each zone is considered well-mixed. Product users are exposed to airborne concentrations
1934

1935 estimated within the near-field during the time of use and otherwise follow their prescribed activity
1936 pattern. Bystanders follow their prescribed activity pattern and are exposed to far-field concentrations
1937 when they are in Zone 1. Background concentrations can be set to a non-zero concentration if desired.
1938

1939 For acute exposure scenarios, emissions from each incidence of product usage are estimated over a
1940 period of 72 hours using the following approach that account for how a product is used or applied, the
1941 total applied mass of the product, the weight fraction of the chemical in the product, and the molecular
1942 weight and vapor pressure of the chemical.
1943

1944 The general steps of the calculation engine within the CEM model include:

- 1945 • Introduction of the chemical (*i.e.*, TCE) into the room of use (Zone 1) through two possible
1946 pathways: (1) overspray of the product or (2) evaporation from a thin film;
- 1947 • Transfer of the chemical to the rest of the house (Zone 2) due to exchange of air between the
1948 different rooms;
- 1949 • Exchange of the house air with outdoor air; and
- 1950 • Compilation of estimated air concentrations in each zone as the modeled occupant (*i.e.*, user or
1951 bystander) moves about the house per prescribed activity patterns

1952
1953 As receptors move between zones in the model, the associated zonal air concentrations at each 30-
1954 second time step were compiled to reflect the air concentrations a user and bystander would be exposed
1955 to throughout the simulation period. Time weighted averages (TWAs) were then computed based on
1956 these user and bystander concentration time series per available human health hazard data. For TCE, 24-
1957 hour TWAs were quantified for use in Risk Evaluation based on alignment relevant to acute human
1958 health hazard endpoints. For additional details on CEM 2.1's underlying emission models, assumptions,
1959 and algorithms, please see the User Guide Section 3: Detailed Descriptions of Models within CEM ([U.S.
1960 EPA, 2019a](#)), also summarized in Appendix D. The emission models used have been compared to other
1961 model results and measured data; see Appendix D: Model Corroboration of the User Guide Appendices
1962 for the results of these analyses ([U.S. EPA, 2019b](#)).
1963

1964 ***Modeling Dermal Exposure***

1965 CEM contains dermal modeling components that estimate absorbed dermal doses resulting from dermal
1966 contact with chemicals found in consumer products: P_DER2a: Dermal Dose from a Product Applied to
1967 Skin, Fraction Absorbed Model and P_DER2b: Dermal Dose from Product Applied to Skin,
1968 Permeability Model. The selection of the appropriate dermal model was based on whether an evaluated
1969 condition of use is expected to involve dermal contact with impeded or unimpeded evaporation. For
1970 scenarios that are more likely to involve dermal contact with impeded evaporation (*e.g.*, wiping or
1971 cleaning with a chemical soaked rag), the permeability model is applied. In contrast, for scenarios less
1972 likely to involve impeded evaporation, the fraction absorbed model is applied. See Appendix D for a
1973 more detailed comparison of these dermal models.
1974

1975 The permeability model estimates the mass of a chemical absorbed and dermal flux based on a
1976 permeability coefficient (K_p) and is based on the ability of a chemical to penetrate the skin layer once
1977 contact occurs. It assumes a constant supply of chemical directly in contact with the skin throughout the
1978 exposure duration. K_p is a measure of the rate of chemical flux through the skin. The parameter can
1979 either be specified by the user (if measured data are reasonably available) or be estimated within CEM
1980 using a chemical's molecular weight and octanol-water partition coefficient (K_{ow}). The permeability
1981 model does not inherently account for evaporative losses (unless the available flux or K_p values are
1982 based on non-occluded, evaporative conditions), which can be considerable for volatile chemicals in

1983 scenarios where evaporation is not impeded. While the permeability model does not explicitly represent
1984 exposures involving such impeded evaporation, the model assumptions make it the preferred model for
1985 such a scenario. For TCE, a measured dermal permeability coefficient (K_p 0.0023 cm/hr) is used, based
1986 on measured dermal flux from a human dermal absorption test with neat TCE ([Kezic et al. 2001](#)). For
1987 additional details on this model, please see Appendix D and the CEM User Guide Section 3: Detailed
1988 Descriptions of Models within CEM ([U.S. EPA, 2019a](#)).

1989
1990 The fraction absorbed model estimates the mass of a chemical absorbed through the application of a
1991 fractional absorption factor to the mass of chemical present on or in the skin following a use event. The
1992 initial dose or amount retained on the skin is determined using a film thickness approach. A fractional
1993 absorption factor is then applied to the initial dose to estimate absorbed dose. The fraction absorbed is
1994 essentially the measure of two competing processes, evaporation of the chemical from the skin surface
1995 and penetration deeper into the skin. It can be estimated using an empirical relationship based on Frasch
1996 and Bunge ([2015](#)). Due to the model's consideration of evaporative processes, it was considered to be
1997 more representative of dermal exposure under unimpeded exposure conditions. For additional details on
1998 this model, please see Appendix D and the CEM User Guide Section 3: Detailed Descriptions of Models
1999 within CEM ([U.S. EPA, 2019a](#)).

2000 2001 **Variation**

2002 To capture a range of potential exposure levels associated with consumer conditions of use, three input
2003 parameters were varied: mass of product used, weight fraction, and duration of use. Aside from these
2004 three parameters, model inputs were held constant across a specific scenario or across all product
2005 scenarios. For example, certain inputs such as the room of use (and associated room/Zone 1 volume),
2006 overspray fraction, and surface area to body weight ratio exposed in dermal exposure scenarios were
2007 held constant across the multiple iterations of a single product scenario but differed across product
2008 scenarios based on their scenario-specific nature. Other parameters such as chemical properties, building
2009 volume, air exchange rate, and user and bystander activity patterns (*i.e.*, movements around the home)
2010 were held constant across all product scenarios and runs. The majority of the non-varied modeling
2011 parameters reflect central tendency inputs (*i.e.*, median or mean values; see Table 2-28); therefore, the
2012 combination of high-end inputs for the three varied parameters do not reflect “worst-case” or bounding
2013 estimates.

2014 2015 Varied Inputs:

2016 Considering the model sensitivity analysis summarized in Appendix D.3 and the availability of high-
2017 quality use-pattern data, EPA varied three input parameters: chemical weight fraction (WF) in a
2018 consumer product; mass of product used per use event; and duration of product use per event.

2019
2020 The low-, mid-, and/or high-end weight fractions were selected principally from MSDS/SDS forms. For
2021 subcategories where there was only one product with a weight fraction range, only one weight fraction
2022 was used for modeling. If there were two or more products with weight fraction ranges, the low-end of
2023 lowest non-zero range and high-end of highest range were the bounding weight fractions. For a central
2024 tendency weight fraction, the mid-point between bounding weight fractions was calculated. In the case
2025 of unknown weight fractions, values were selected from the range of related products. Further detail is
2026 provided in the Supplemental File, [*Consumer Exposure Assessment Model Input Parameters. Docket:*
2027 [EPA-HQ-OPPT-2019-0500](#)].

2028
2029 Mass of product used and duration of use selections define user characteristics (*e.g.*, high-intensity user,
2030 moderate-intensity user, low-intensity user) and are based on the Household Solvent Products: A
2031 National Usage Survey ([U.S. EPA, 1987](#)), referred to as the “Westat survey” or “Westat” herein, and

2032 described further in section 2.3.2.5. The survey was rated as having “high” quality during the data
2033 evaluation phase of systematic review. Weight fraction (*i.e.*, the percentage of TCE in the product
2034 formulation) represents the true range in the market based on manufacturer-developed Safety Data
2035 Sheets (SDSs).

2036
2037 For each parameter varied, up to three distinct inputs were modeled to address known variability across
2038 these three parameters. While this approach resulted in up to 27 distinct exposure results for each
2039 product scenario/condition of use, this was a deterministic assessment and results reflect a range based
2040 on variation of three key parameters, not a distribution. Unlike inhalation modeling, for dermal
2041 modeling, only the weight fraction and duration of product use were varied because mass used is not a
2042 parameter in the dermal exposure models.

2043
2044 In the model sensitivity analysis, summarized in Appendix D.3 and shown in the user guide appendices
2045 ([U.S. EPA, 2019b](#)), additional parameters are identified as highly sensitive, including the air exchange
2046 rate and zone volume. However, the central tendency default modeling values were held constant for
2047 these inputs. The inputs varied included those that characterize actual users and reflect levels of TCE in
2048 actual products.

2049 **2.3.2.4 Consumer Exposure Scenarios and Modeling Inputs**

2050 Exposure modeling scenarios comprise information that characterizes chemical properties, products, and
2051 use patterns, including:

- 2052 • Formulations (*e.g.*, weight fraction, formulation type [aerosol, liquid]);
- 2053 • Chemical or product-specific properties (*e.g.*, product density, vapor pressure, molecular weight
2054 diffusion coefficient, overspray fraction, transfer coefficients, dilution factor);
- 2055 • Use patterns (*e.g.*, frequency, duration, and amount used);
- 2056 • Human exposure factors (*e.g.*, body weight, inhalation rate); and
- 2057 • Environmental conditions (*e.g.*, air exchange rates and room size).

2058
2059 Consumer exposure modeling scenarios for identified conditions of use were based on identified TCE
2060 products that may be available to consumers, including solvents for cleaning and degreasing, lubricants
2061 and greases, adhesives and sealants, and other uses. The subcategories of use (*i.e.*, consumer product
2062 types) cited in Table 2-27 were used to develop distinct consumer exposure modeling scenarios for use
2063 in estimating inhalation and dermal exposure to consumers and bystanders. The availability of TCE in
2064 consumer products was determined through the development of EPA’s 2017 Market and Use Report and
2065 Preliminary Information on Manufacturing, Processing, Distribution, Use, and Disposal: TCE.
2066 Following Problem Formulation, EPA performed targeted internet searches to confirm TCE
2067 concentrations in identified products and to identify additional examples of products that may be
2068 available to consumers for household use. Specific product characteristics obtained from manufacturer
2069 websites and/or Safety Data Sheets (SDSs) such as form/formulation type, weight fraction and density,
2070 were used to select the most appropriate product-specific inputs (*e.g.*, weight fraction and formulation
2071 type) associated with each consumer condition of use. Please see Supplemental File [*Consumer*
2072 *Exposure Assessment Model Input Parameters. Docket: [EPA-HQ-OPPT-2019-0500](#)*]for full product
2073 details, including product-specific formulations, weight fractions, and densities.

2074
2075 CEM requires inputs governing chemical properties, product characteristics, use environment, and user
2076 patterns (*i.e.*, user behavior). These include inputs such as physical chemical properties, weight fraction,
2077 formulation type, duration of product use, mass of product used, and Zone 1 (room of use) volume. To
2078 determine relevance and appropriateness of the consumer use pattern parameters, EPA reviewed the
2079 consumer product categories available in the Westat Survey ([1987](#)). Westat surveyed thousands of

American households via questionnaire or telephone from 4,920 respondents across the United States to gather information on consumer behavior (*i.e.*, use patterns) and product characteristics (*e.g.*, product formulation type) related to product categories that may contain halogenated solvents like TCE. The Westat Survey was rated as a high quality study during data evaluation within the systematic review process. It forms the basis for relevant chapters of EPA's Exposure Factors Handbook ([U.S. EPA, 2011c](#)) and was used to derive certain default parameters in EPA's CEM 2.1. Westat (1987) includes survey response data on 30 distinct product categories and reports the following: numbers of respondents; percentage of respondents reporting use; frequency of use; duration of use; time spent in the room of use; brand of product used; form of product used; amount of product used; and room of use.

The room of use selected for this evaluation is based on the room in which the Westat Survey results reported the highest percentage of respondents that last used a product within the room. When the Westat Survey identified the room of use where the highest percentage of respondents last used the product as "other inside room," the utility room was selected within CEM for modeling. The pre-defined product scenarios within CEM were selected based on a cross-walk to similar product categories within the Westat Survey.

In evaluating Westat survey data for appropriateness, EPA considered the similarity of product category, as well as the similarity of reported product formulation type (*i.e.*, aerosol, liquid). When a direct alignment could not be found between the consumer product and Westat product category, EPA used professional judgement in considering other Westat categories with reasonable ranges for use duration and amount of product used. A crosswalk between TCE consumer use scenarios and Westat Product Categories are listed in Table 2-30 and described in more detail in Section 2.3.2.5.2.

2.3.2.4.1 Consumer Exposure Model Inputs

Chemical-specific inputs required to model consumer inhalation and dermal exposure included physical and chemical properties (Table 1-1), as well as a chemical-specific dermal permeability coefficient, which were held constant across all modeling scenarios and iterations.

The consumer exposure model requires product-specific data based on product characteristics and use patterns. It also requires fixed inputs to define the exposure zones (*e.g.*, room and building volumes, air exchange rates, interzonal ventilation rates); general use patterns defining the amount of time a receptor is likely to be in the home; receptor characteristics (*e.g.*, age, surface area to body weight ratios); and emission characteristics (*e.g.*, background air concentration, emission factor). These default inputs are held constant for a given scenario but may vary across scenarios based on scenario-specific exposure factors or assumptions. As such, these inputs were not altered to capture within-scenario variation. Table 2-28 shows these default parameters.

Table 2-29 displays TCE consumer product modeling scenarios and associated product-specific inputs that were varied to capture within-scenario variation. These varied inputs include: weight fraction, duration of use, and mass of product used. Westat (1987) is the basis for duration of use and mass of product used and product SDSs are the basis for weight fraction and formulation type.

Table 2-30 presents the consumer product modeling scenarios and associated scenario-specific inputs that were not varied within product modeling scenarios but did vary across scenarios. In modeling exposures within and across all scenarios, parameters displayed in both below tables (Table 2-28 and Table 2-29) were utilized, along with the general chemical-specific characteristics and other model defaults. Please see Supplemental File [*Consumer Exposure Assessment Model Input Parameters*].

2127 Docket: [EPA-HQ-OPPT-2019-0500](#)] for a spreadsheet summarizing all of the model inputs and product
 2128 information.

2129
 2130 For all scenarios, the consumer user was assumed to be an adult (age 21+) and two child age groups (16-
 2131 20 years and 11-15 years), while a non-user bystander can include individuals of any age. For the TCE
 2132 products identified, younger children would not be expected to directly use these products. Inhalation
 2133 exposure results are presented as concentrations encountered by users and non-user bystanders and are
 2134 independent of age group. EPA presents all three evaluated user age groups for dermal exposures as reported
 2135 doses are age-group specific.

2136 **Table 2-28. Default Modeling Input Parameters**
 2137

Parameter Type	Modeling Parameter	Default Value Modeled	Value Characterization	Reference
Building Characteristic ¹	Building Volume (m ³)	492	Central Tendency (Mean)	(U.S. EPA, 2011c)
	Air Exchange Rate (hr ⁻¹)	0.45 ²	Central Tendency (Median)	(U.S. EPA, 2011c)
	Interzonal Ventilation Rate (m ³ /hr) ³	Garage: 109 All other rooms modeled: 107	NA	Default (U.S. EPA, 2019a, b)
Emission Characteristics	Background Air Concentration (mg/m ³)	0	Minimum	
	Gas Phase Mass Transfer Coefficient (m/hr)	Based on chemical properties and estimated within CEM		
	Emission Factor (ug/m ² /hr)			
	Saturation Concentration in Air (mg/m ³)	5.18E+05	Based on chemical properties and estimated within CEM	
	Aerosol Fraction (Spray Scenarios Only)	0.06	High-end	
	Product Dilution Fraction	1 (no dilution)	NA	Based on formulation and intended use
Use Patterns and Exposure Factors	Receptor Activity Pattern	Stay at home ⁴	NA	Default (U.S. EPA, 2019a, b)
	Use Start Time	9 AM ⁵	NA	NA
	Frequency of Use	1 event per day	NA	Default (U.S. EPA, 2019a, b)
	Acute Averaging Time	1 day	NA	
	Film Thickness (cm)	0.00655 ⁶		
		Inside of One Hand		

Parameter Type	Modeling Parameter	Default Value Modeled	Value Characterization	Reference	
	Surface Area to Body Weight Ratio	Adult (21+): 3.10	Central tendency (mean)		
		Children (16-20): 2.90			
		Children (11-15): 3.17			
		10% of Hands			Central tendency (mean)
		Adult (21+): 1.24			
		Children (16-20): 1.16			
		Children (11-15): 1.27			
<p>¹ An overall residential building volume of 492 m³ is used to calculate air concentrations in Zone 2 and room volume is used to calculate air concentrations in Zone 1. The volume of the near-field bubble in Zone 1 was assumed to be 1 m³ in all cases, with the remaining volume of Zone 1 comprising the far-field volume.</p> <p>² Air exchange rates differed for two scenarios: pepper spray and hoof polish (see Table 2-30).</p> <p>³ The default interzonal air flows are a function of the overall air exchange rate and volume of the building, as well as the “openness” of the room itself. Kitchens, living rooms, garages, schools, and offices are considered more open to the rest of the home or building of use; bedrooms, bathrooms, laundry rooms, and utility rooms are usually accessed through one door and are considered more closed.</p> <p>⁴ The activity pattern (<i>i.e.</i>, zone location throughout the simulated exposure period) for user and bystander was the default “stay-at-home” resident, which assumes the receptors are primarily in the home (in either Zone 1 or 2) throughout the day. These activity patterns in CEM were developed based on Consolidated Human Activity Database (CHAD) data of activity patterns (Isaacs, 2014).</p> <p>⁵ Product use was assumed to start at 9 AM in the morning; as such, the user was assumed to be in the room of use (Zone 1) at that time, regardless of the default activity pattern placement at 9 AM.</p> <p>⁶ Film thickness of water/ethanol after immersion and no wipe from Table 7-24 from the Exposure Factors Handbook (U.S. EPA, 2011c).</p>					

2138
2139

Table 2-29. Consumer Product Modeling Scenarios and Varied Input Parameters

Consumer Category	Product Sub-Categories	Form (No. of Pdts) ¹	Range of Weight Fraction (% TCE) ²	Weight Fractions Selected for Modeling (% TCE)			Selected Westat Survey Scenario	Duration of Use (min)			Range of Product Density (g/cm ³) ⁴	Mass [Volume] of Product Used (g, [oz])		
				Min ²	Mid	Max		10 th %ile ³	50 th %ile	95 th %ile		10 th %ile	50 th %ile	95 th %ile
Solvents for Cleaning and Degreasing	Brake & Parts Cleaner	Aerosol (4)	0 - 100	20	60	100	Brake Quieters / Cleaners	1	15	120	1.23-1.62	47.9 [1]	191.6 [4]	766.5 [16]
	Electronic Degreaser/ Cleaner	Aerosol (9)	30 - 100	30	65	100	Specialized Electronics Cleaners (for TV, VCR, Razor, etc.)	0.17	2	30	1.25-1.52	1.8 [0.04]	22.5 [0.5]	337.1 [7.5]
	Electronic Degreaser/ Cleaner	Liquid (1)	100	100			Specialized Electronics Cleaners (for TV, VCR, Razor, etc.)	0.17	2	30	1.46	1.7 [0.04]	21.6 [0.5]	323.8 [7.5]
	Spray Degreaser/ Cleaner	Aerosol (8)	60 - 100	60		100	Engine Degreasing ⁵	5	15	120	1.46-1.52	130.8 [2.91]	521.4 [11.6]	2157.4 [48]
	Liquid Degreaser/ Cleaner	Liquid (2)	90 - 100	100			Solvent-Type Cleaning Fluids or Degreasers	2	15	120	1.456	24.1 [0.56]	139.9 [3.25]	1377.7 [32]
	Gun Scrubber	Aerosol (2)	60 - 100 ⁶	60		100	Solvent-Type Cleaning Fluids or Degreasers ⁷	2	15	120	1.36-1.465	NA	0.7 [0.45 mL] ⁸	NA
	Gun Scrubber	Liquid (1)	100 ⁸	100			Solvent-Type Cleaning Fluids or Degreasers ⁷	2	15	120	1.36	NA	0.6 [0.45 mL] ⁸	NA

Consumer Category	Product Sub-Categories	Form (No. of Pdts) ¹	Range of Weight Fraction (% TCE) ²	Weight Fractions Selected for Modeling (% TCE)			Selected Westat Survey Scenario	Duration of Use (min)			Range of Product Density (g/cm ³) ⁴	Mass [Volume] of Product Used (g, [oz])		
				Min ²	Mid	Max		10 th %ile ³	50 th %ile	95 th %ile		10 th %ile	50 th %ile	95 th %ile
	Mold Release	Aerosol (2)	40 - 68.9	40		68.9	Other Lubricants (Excluding Automotive)	0.08	2	30	0.77-1.44	4.3 [0.1]	23.4 [0.55]	212.9 [5]
	Tire Cleaner	Aerosol (2)	70 - 100	70		100	Tire / Hubcap Cleaner	5	15	60	0.67	10.5 [0.53]	52.9 [2.67]	317.0 [16]
	Tire Cleaner	Liquid (1)	80 - 100	100			Tire / Hubcap Cleaner	5	15	60	0.67-1.493	23.4 [0.53]	117.9 [2.67]	706.4 [16]
Lubricants and Greases	Tap & Die Fluid	Aerosol (1)	98	98			Other Lubricants (Excluding Automotive)	0.08	2	30	0.9	2.7 [0.1]	14.8 [0.55]	134.5 [5]
	Penetrating Lubricant	Aerosol (5)	5 - 50	5	27.5	50	Other Lubricants (Excluding Automotive)	0.08	2	30	0.636-1.42	4.2 [0.1]	23.1 [0.55]	209.9 [5]
Adhesives and Sealants	Solvent-based Adhesive & Sealant	Liquid (3)	5 - >90	5	47.5	90	Contact Cement, Super Glues, and Spray Adhesives	0.33	4.25	60	1.33-1.45	1.3 [0.03]	10.7 [0.25]	185.2 [4.32]
	Mirror-edge Sealant	Aerosol (1)	20 - 40	40			Contact Cement, Super Glues, and Spray Adhesives	0.33	4.25	60	0.614	0.5 [0.03]	4.5 [0.25]	78.4 [4.32]
	Tire Repair Cement/ Sealer	Liquid (5)	65 - 95	65	80	95	Contact Cement, Super Glues, and Spray Adhesives	0.33	4.25	60	1.45	1.3 [0.03]	10.7 [0.25]	185.2 [4.32]

Consumer Category	Product Sub-Categories	Form (No. of Pdts) ¹	Range of Weight Fraction (% TCE) ²	Weight Fractions Selected for Modeling (% TCE)			Selected Westat Survey Scenario	Duration of Use (min)			Range of Product Density (g/cm ³) ⁴	Mass [Volume] of Product Used (g, [oz])		
				Min ²	Mid	Max		10 th %ile ³	50 th %ile	95 th %ile		10 th %ile	50 th %ile	95 th %ile
Cleaning and Furniture Care Products	Carpet Cleaner	Liquid (1)	99	99			Spot Removers	0.25	5	30	1.6	11.8 [0.25]	62.9 [1.33]	526.6 [11.13]
	Spot Remover	Aerosol (1)	20 - 30	30			Spot Removers	0.25	5	30	1.562	11.5 [0.25]	61.4 [1.33]	514.1 [11.13]
	Spot Remover	Liquid (4)	<50 - >75	50		75	Spot Removers	0.25	5	30	1.25-1.45	10.7 [0.25]	57.0 [1.33]	477.2 [11.13]
Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings	Aerosol (1)	20 - 30	30			Aerosol Rust Removers ⁹	0.25	5	60	0.704	9.4 [0.45]	45.2 [2.17]	306.0 [14.7]
Apparel and Footwear Care Products	Shoe Polish	Aerosol (1)	10 - 20	20			Spray Shoe Polish	0.5	5	30	0.512	2.9 [0.19]	15.4 [1.02]	151.4 [10]
Other Consumer Uses	Fabric Spray	Aerosol (1)	20 - 40	40			Water Repellents / Protectors (for Suede, Leather, and Cloth)	1.4	10	60	0.614	11.4 [0.63]	49.9 [2.75]	326.8 [18]
	Film Cleaner	Aerosol (2)	80 - 100	100			Aerosol Rust Removers ⁹	0.25	5	60	1.45-1.456	19.4 [0.45]	93.4 [2.17]	632.9 [14.7]
	Hoof Polish	Aerosol (1)	30 ¹⁰	30			Spray Shoe Polish ¹¹	0.5	5	30	0.512-0.704	4.0 [0.19]	21.2 [1.02]	208.2 [10]
	Pepper Spray	Aerosol (2)	91.5	91.5			NA ¹²	NA	0.08 ¹²	NA	1.25	4.0 [0.108]	7.5 [0.27] ₁₂	15 [0.54] ¹²
	Toner Aid	Aerosol (1)	10 - 20	20			Aerosol Rust Removers ⁹	0.25	5	60	1	13.3 [0.45]	64.2 [2.17]	434.7 [14.7]

Consumer Category	Product Sub-Categories	Form (No. of Pdts) ¹	Range of Weight Fraction (% TCE) ²	Weight Fractions Selected for Modeling (% TCE)			Selected Westat Survey Scenario	Duration of Use (min)			Range of Product Density (g/cm ³) ⁴	Mass [Volume] of Product Used (g, [oz])		
				Min ²	Mid	Max		10 th %ile ³	50 th %ile	95 th %ile		10 th %ile	50 th %ile	95 th %ile

¹The number of products identified is based on the product lists in EPA's 2017 Market and Use Report and Preliminary Information on Manufacturing, Processing, Distribution, Use and Disposal: TCE, as well as the 2014 TSCA Work Plan Chemical Risk Assessment for TCE ([U.S. EPA, 2017c, h](#)). Please see Supplemental File [*Consumer Exposure Assessment Model Input Parameters. Docket: EPA-HQ-OPPT-2019-0500*] for the full product list utilized.

²Weight fractions were primarily sourced from product Safety Data Sheets (SDSs) or Material Safety Data Sheets (MSDSs), unless otherwise noted. Please see Supplemental File [*Consumer Exposure Assessment Model Input Parameters. Docket: EPA-HQ-OPPT-2019-0500*] for more detailed information on weight fraction sourcing and ranges. If a single weight fraction was used in modeling, it appears in the "Min" weight fraction column, but does not reflect a minimum.

³Low-end (10th percentile) durations reported by Westat that are less than 0.5 min (30 sec) are modeled as being equal to 0.5 min (smallest time-step modeled).

⁴Product density ranges reflect identified products containing TCE and were sourced from product SDSs or MSDSs. The high end of the range identified was used to convert reported ounces of product used from Westat (1987) to grams of product used, as required for model input.

⁵Two Westat product categories were considered for use (engine degreasing and solvent-type cleaning fluids or degreasers); however, engine degreasing was selected to source duration of use, room of use, and amount used parameters due to the high percentage of respondents (78.9%) reporting aerosol use.

⁶No weight fraction was reasonably available for the aerosol and liquid gun scrubber formulations, so the weight fractions were based on the ranges reflected by the aerosol and liquid degreasing products.

⁷The solvent-type cleaning fluids or degreasers product category from Westat was used as a surrogate for gun scrubbers for the selection of use durations. Product-specific literature was identified and applied for mass of product used.

⁸Based [Eezox Premium Gun Care testing results \(ASTM B117-5 Salt Spray Fog Test\)](#), 0.42-0.45 mL of the product was used to coat the firearm in a very thin film, which is in-line with use directions.

⁹Three modeling scenarios (film cleaner, spray fixative/coating, and toner aid) had no directly-aligned Westat product categories. Therefore, a number of Westat product categories and use pattern data were considered for appropriateness, with a focus on primary formulation type (aerosol or liquid), duration of use, and amount used. The rust remover product category reflects 98% aerosol products and a lower use duration and amount used than many of the other solvent degreasing-type uses.

¹⁰Weight fraction and density were not reasonably available, so were based on the ranges reflected by the spray fixative/coating and aerosol shoe polish products.

¹¹There were no reasonably available data sources for aerosol hoof polish use patterns; the Westat spray shoe polish product category was used for selection of use duration and amount used.

¹²One spray from the most common civilian canister (0.54 oz) is estimated to be approximately 0.0216-0.108 oz (<https://www.sabred.com/pepper-spray-frequently-asked-questions-0>). One spray was assumed for the low-intensity user scenario, while the entire keychain canister (0.54 oz) was assumed for the high-intensity user scenario and a half canister was assumed for the moderate-intensity user scenario. Spraying occurred between 3 and 5 seconds (converted to minutes for use in modeling) before obtaining desired effect ([Bertilsson et al., 2017](#)), but use duration was rounded up to the lowest time step within CEM (30 seconds).

2141
2142
2143
2144
2145

Table 2-30. Consumer Product Modeling Scenarios and Additional Scenario-Specific Input Parameters

Consumer Category	Product Sub-Categories	Form (No. of Pdts) ¹	Zone 1 Room of Use (Volume m ³) ²	CEM Emission Model Applied ³	Air Exchange Rate (hr ⁻¹)	Interzonal Ventilation Rate (m ³ /hr)	CEM Dermal Exposure Model Applied	Dermal Surface Area Exposed
Solvents for Cleaning and Degreasing	Brake & Parts Cleaner	Aerosol (4)	Garage (90)	E3	0.45	109	Permeability	Inside of one hand
	Electronic Degreaser/Cleaner	Aerosol (9)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
	Electronic Degreaser/Cleaner	Liquid (1)	Utility (20)	E1	0.45	107	Permeability	Inside of one hand
	Spray Degreaser/Cleaner	Aerosol (8)	Garage (90)	E3	0.45	109	Permeability	Inside of one hand
	Liquid Degreaser/Cleaner	Liquid (2)	Utility (20)	E1	0.45	107	Permeability	Inside of one hand
	Gun Scrubber	Aerosol (2)	Utility (20)	E3	0.45	107	Permeability	Inside of one hand
	Gun Scrubber	Liquid (1)	Utility (20)	E1	0.45	107	Permeability	Inside of one hand
	Mold Release	Aerosol (2)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
	Tire Cleaner	Aerosol (2)	Garage (90)	E3	0.45	109	Permeability	Inside of one hand
	Tire Cleaner	Liquid (1)	Garage (90)	E1	0.45	109	Permeability	Inside of one hand
Lubricants and Greases	Tap & Die Fluid	Aerosol (1)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
	Penetrating Lubricant	Aerosol (5)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
Adhesives and Sealants	Solvent-based Adhesive & Sealant	Liquid (3)	Utility (20)	E1	0.45	107	Fraction Absorbed	10% of hands
	Mirror-edge Sealant	Aerosol (1)	Bathroom (15)	E3	0.45	107	Fraction Absorbed	10% of hands
	Tire Repair Cement/Sealer	Liquid (5)	Garage (90)	E1	0.45	109	Fraction Absorbed	Inside of one hand
	Carpet Cleaner	Liquid (1)	Bedroom (36)	E1	0.45	107	Permeability	Inside of one hand

Consumer Category	Product Sub-Categories	Form (No. of Pdts) ¹	Zone 1 Room of Use (Volume m ³) ²	CEM Emission Model Applied ³	Air Exchange Rate (hr ⁻¹)	Interzonal Ventilation Rate (m ³ /hr)	CEM Dermal Exposure Model Applied	Dermal Surface Area Exposed
Cleaning and Furniture Care Products	Spot Remover	Aerosol (1)	Utility (20)	E3	0.45	107	Permeability	Inside of one hand
	Spot Remover	Liquid (4)	Utility (20)	E1	0.45	107	Permeability	Inside of one hand
Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings	Aerosol (1)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
Apparel and Footwear care products	Shoe Polish	Aerosol (1)	Utility (20)	E3	0.45	107	Permeability	Inside of one hand
Other Consumer Uses	Fabric Spray	Aerosol (1)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
	Film Cleaner	Aerosol (2)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands
	Hoof Polish	Aerosol (1)	Barn ⁵	E3	4 ⁵	109	Fraction Absorbed	10% of hands
	Pepper Spray	Aerosol (2)	Outside ⁶	E3	100 ⁶	0	Fraction Absorbed	10% of hands
	Toner Aid	Aerosol (1)	Utility (20)	E3	0.45	107	Fraction Absorbed	10% of hands

¹The number of products identified is based on the product lists in EPA's 2017 Market and Use Report and Preliminary Information on Manufacturing, Processing, Distribution, Use and Disposal: TCE ([U.S. EPA, 2017c, h](#)), as well as the 2014 TSCA Work Plan Chemical Risk Assessment for TCE ([U.S. EPA, 2014b](#)). It is possible that specific products and/or formulations identified in those reports and used herein to select appropriate weight fractions, formulation types, and formulation densities for use in modeling no longer contain TCE or are no longer reasonably available to consumers for purchase; however, they were still considered for sourcing such information since they were identified as in these recent EPA publications and therefore represent reasonably-foreseen uses. Please see Supplemental File for the full product list utilized.

² The use environment (room of use) was generally based on the Westat ([1987](#)) survey of consumer behavior patterns, which reported the percentages for the location of last use of product. In cases where the room was identified as "other inside room," the utility room was selected based on professional judgment. Additionally, professional judgment was applied to certain uses, such as those that could reasonably be used in a garage setting.

³Emission models used for TCE include E1 – Emission from Product Applied to a Surface Indoors Incremental Source Model and E3 – Emission from Product Sprayed.

⁵For the purposed of modeling typical aerosol hoof polish consumer exposure, a barn setting was approximated by selecting the garage as the room of use and changing the default air exchange rate from 0.45 to 4 hr⁻¹, which more closely aligns with recommended ventilation levels in a horse barn ([Pennsylvania State University, 2016](#))

⁶The outdoor environment was approximated by selecting the garage as the room of use and increasing the air exchange rate from 0.45 to 100. The "room of use" was also edited to reflect a 16 m³ cloud around user (roughly 6.5-foot dome or cloud surrounding user).

2148 The 2014 TCE TSCA Work Plan Chemical Risk Assessment included two consumer conditions of use:
2149 aerosol degreaser and clear protective coating spray (referred to as “spray fixative” 80 FR 47441) ([U.S.
2150 EPA, 2014b](#)). The inputs included in the 2014 assessment differed from those used in this Risk
2151 Evaluation for similar conditions of use, either due to updated parameter data (*e.g.*, Zone 2 volume), or
2152 professional judgment. The most notable difference between this Risk Evaluation and the 2014 scenarios
2153 related to the parameter selected for mass of product used. In the 2014 assessment, aerosol degreaser
2154 was modeled assuming 24 g (0.85 oz) and clear protecting coating spray was modeled assuming 11g
2155 (0.39 oz). These inputs were not based on user survey data and were described in the 2014 assessment as
2156 “potentially on the low end” when compared against the Westat survey data employed in this RRisk
2157 Evaluation.

2158 **2.3.2.5 Consumer Exposure Results**

2159 Acute inhalation and dermal exposure results are presented below for each consumer condition of use.
2160 These conditions of use are organized by product subcategories and are also referred to as consumer
2161 modeling scenarios. Inhalation estimates are presented in terms of acute indoor air concentrations (ppm)
2162 resulting from a single consumer use event within a one-day exposure period; they are provided for
2163 users and bystanders. Acute dermal exposure estimates are presented as an acute dose (mg/kg/day); they
2164 are provided for users only.

2165 **2.3.2.5.1 Characterization of Exposure Results**

2166 As described in Section 2.3.2.3.1, the consumer exposure modeling approach was deterministic, but a
2167 range of exposure results were estimated based on varying three parameters: weight fraction, mass of
2168 product used, and duration of use/exposure duration. While the exposure results are not reflective of a
2169 probabilistic distribution of all possible exposure levels, the exposure scenarios modeled incorporated
2170 low-end (10th percentile), central tendency (50th percentile), and high-end (95th percentile) inputs from
2171 Westat ([1987](#)) for two of the three varied parameters: mass of product used and exposure duration. Since
2172 these inputs primarily reflect user characterization, results are presented for “high-intensity users,”
2173 “moderate-intensity users,” and “low-intensity users.” For example, the exposure scenario combining
2174 high-end inputs for these three parameters is referred to as a “high-intensity user” scenario. Weight
2175 fraction inputs cannot be described in the same terms, as they reflect the range of actual product weight
2176 fractions, per associated SDSs, and do not reflect a distribution of user survey data.

2177
2178 Other modeling parameters that were not varied (*e.g.*, room volume, air exchange rate, building volume)
2179 reflect central tendency inputs. Therefore, these exposure scenarios and results are not bounding or
2180 “worst-case” and may not capture the maximum or minimum of all possible exposure levels.

2181
2182 For TCE, 24-hr TWA air concentrations are provided for consumers and bystanders based on the
2183 relevant human health hazard metrics. The air concentrations associated with the user are higher than
2184 those associated with the bystander in all scenarios due to the higher concentration of chemical expected
2185 in the room of use (Zone 1) coupled with the greater amount of time a consumer is assumed to be in the
2186 room of use (during and after use event) compared with the bystander. While it is assumed that a
2187 bystander of any age, including pregnant women and children, could be exposed to the reported
2188 concentrations, the concentrations themselves are not unique for specific subpopulations. The
2189 concentrations reported reflect the concentration a consumer or bystander would be exposed to.

2190
2191 Dermal exposure scenarios and results are presented for children and adult age groups, with the children
2192 (age 11-15) resulting in the highest estimates dermal exposures due to surface area to body weight ratio
2193 differences between age groups. Results are not presented specifically for pregnant women or women of
2194 reproductive age; however, the range of results presented for adult and child age groups are expected to

2195 cover dermal exposures for pregnant women as well, with the child (11-15) providing the highest
 2196 surface area to body weight ratio, thereby providing the highest dermal exposure estimate (see below
 2197 table for rationale). All values below in Table 2-31 are sourced and/or derived from EPA's 2011
 2198 Exposure Factors Handbook ([U.S. EPA, 2011c](#)).
 2199

2200 **Table 2-31. Surface Area and Body Weight Values for Different Consumer and Bystander**
 2201 **Subpopulations**

Parameter	Adult	Children (16-21)	Children (11-15)	Pregnant Women	Women (21+)	Women (16-21)
10% of Hands Surface Area (cm ²)	99	83	72	89 ¹	89 ¹	83 ²
Body Weight (kg)	80	71.6	56.8	75 ³	74 ⁴	65.9 ⁵
SA:BW	1.24	1.16	1.27	1.19	1.20	1.26
¹ Surface area based on women 21+ ² Surface area based on combined male/female 16-21 ³ Body weight for all pregnant women ⁴ Body weight for females 21+ ⁵ Body weight for females 16-21						

2202 **2.3.2.5.2 Consumer Exposure Estimates**

2203 ***Solvents for Cleaning and Degreasing***

2204 ***Brake & Parts Cleaner***

2205 Exposure to TCE in brake & parts cleaner products was evaluated based on four aerosol products with
 2206 weight fractions ranging from 0-20% to 90-100% TCE.
 2207

2208 Westat Survey data on brake quieters and cleaners were used as the basis for duration of use and mass of
 2209 product used. Survey responses indicate that 2.6% of respondents have used products in this category;
 2210 65.6% reported use of aerosol formulations. The room of use (Zone 1) was set to the garage (90 m³)
 2211 although the Westat survey data for this category indicate primarily outdoor use.
 2212

2213 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2214 intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for*
 2215 *Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer*
 2216 *Dermal Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all
 2217 iterations of this modeling scenario.
 2218*

2219 **Table 2-32. Acute Inhalation Exposure Summary: Brake & Parts Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (120)	Max (100)	95 th %ile (766.5)	User	5.76E+01
				Bystander	1.67E+01
Moderate-Intensity User	50 th %ile (15)	Mid (60)	50 th %ile (191.6)	User	9.06
				Bystander	2.26
Low-Intensity User	10 th %ile (1)	Min (20)	10 th %ile (47.9)	User	7.09E-01
				Bystander	1.81E-01

2220 ¹Actual product weight fractions were: 0-20%; 45-55%; 97.5%; 90-100%. 60% is a mathematically-derived mid-point (*i.e.*,
 2221 mean) for use in modeling, based on the minimum and maximum inputs.

2222
2223
2224
2225
2226
2227

Dermal exposures for this scenario are based on CEM’s permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

Table 2-33. Acute Dermal Exposure Summary: Brake & Parts Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (120)	Max (100)	Adult (≥21 years)	2.33E+01
			Children (16-20 years)	2.18E+01
			Children (11-15 years)	2.38E+01
Central Tendency	50 th %ile (15)	Mid (60)	Adult (≥21 years)	1.75
			Children (16-20 years)	1.63
			Children (11-15 years)	1.79
Low-Intensity User	10 th %ile (1)	Min (20)	Adult (≥21 years)	3.88E-02
			Children (16-20 years)	3.63E-02
			Children (11-15 years)	3.97E-02

¹Actual product weight fractions were: 0-20%; 45-55%; 97.5%; 90-100%. 60% is a mathematically-derived mid-point (i.e., mean) for use in modeling, based on the minimum and maximum inputs.

2228

Aerosol Electronic Degreaser/Cleaner

2229 Exposure to TCE in aerosol electronic degreasing/cleaning products was evaluated based on nine
2230 aerosol products with weight fractions ranging from 30-100% TCE.

2231

2232 Westat Survey data on specialized electronics cleaners were used as the basis for duration of use and
2233 mass of product used. Survey responses indicate 13.1% of respondents have used products in this
2234 category; 34% reported use of aerosol formulations and 56% reported use of liquid formulations.
2235 Therefore, these Westat data were applied to both aerosol and liquid product scenarios. The room of use
2236 (Zone 1) was set to the utility room (20 m³) although the Westat survey data for this category indicate
2237 living room and other inside room as the top two locations of reported use.

2238

2239 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
2240 intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for
2241 Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based
2242 on all iterations of this modeling scenario.

2243

Table 2-34. Acute Inhalation Exposure Summary: Aerosol Electronic Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	Max (100)	95 th %ile (337.1)	User	3.76E+01
				Bystander	7.56
Moderate-Intensity User	50 th %ile (2)	Mid (65)	50 th %ile (22.5)	User	1.58
				Bystander	2.95E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (30)	10 th %ile (1.8)	User	5.55E-02
				Bystander	1.08E-02

2248 ¹Actual product weight fractions were: 30-50%; 30-60%; 97.2%; 98%; 60-100%; and 90-100%. 65% is a mathematically-
2249 derived mid-point (i.e., mean) for use in modeling, based on the minimum and maximum inputs.

2250
2251
2252
2253
2254
2255
2256

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Dermal exposures for this scenario are based on CEM’s fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

Table 2-35. Acute Dermal Exposure Summary: Aerosol Electronic Degreaser

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	Max (100)	Adult (≥21 years)	3.35
			Children (16-20 years)	3.14
			Children (11-15 years)	3.43
Central Tendency	50 th %ile (2)	Mid (65)	Adult (≥21 years)	2.85E-01
			Children (16-20 years)	2.67E-01
			Children (11-15 years)	2.92E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (30)	Adult (≥21 years)	3.44E-02
			Children (16-20 years)	3.22E-02
			Children (11-15 years)	3.52E-02

2257
2258
2259
2260

¹Actual product weight fractions were: 30-50%; 30-60%; 97.2%; 98%; 60-100%; and 90-100%. 65% is a mathematically-derived mid-point (*i.e.*, mean) for use in modeling, based on the minimum and maximum inputs.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2261

Liquid Electronic Degreaser/Cleaner

2263

Exposure to TCE in liquid electronic degreasing/cleaning products was evaluated based on one liquid product with a weight fraction of 100% TCE.

2264
2265

2266

Westat Survey data on specialized electronics cleaners were used as the basis for duration of use and mass of product used. Survey responses indicate 13.1% of respondents have used products in this category; 34% reported use of aerosol formulations and 56% reported use of liquid formulations.

2267

Therefore, these Westat data were applied to both aerosol and liquid product scenarios. The room of use (Zone 1) was set to the utility room (20 m³) although the Westat survey data for this category indicate living room and other inside room as the top two locations of reported use.

2270
2271
2272

2273

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](https://www.epa.gov/epa-hq-oppt-2019-0500)] for the full range of results based on all iterations of this modeling scenario.

2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285

2286

Table 2-36. Acute Inhalation Exposure Summary: Liquid Electronic Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	(100)	95 th %ile (337.1)	User	3.61E+01
				Bystander	7.26
Moderate-Intensity User	50 th %ile (2)	(100)	50 th %ile (22.5)	User	2.33
				Bystander	4.36E-01
Low-Intensity User	10 th %ile (0.5) ²	(100)	10 th %ile (1.8)	User	1.74E-01
				Bystander	3.41E-02

2287

¹Single weight fraction of 100% available.

2288

²The 10th percentile duration from Westat was < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2289

2290

2291

Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

2292

2293

2294

2295

Table 2-37. Acute Dermal Exposure Summary: Liquid Electronic Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	(100)	Adult (≥21 years)	5.24
			Children (16-20 years)	4.91
			Children (11-15 years)	5.37
Moderate-Intensity User	50 th %ile (2)	(100)	Adult (≥21 years)	3.50E-01
			Children (16-20 years)	3.27E-01
			Children (11-15 years)	3.58E-01
Low-Intensity User	10 th %ile (0.5) ²	(100)	Adult (≥21 years)	8.74E-02
			Children (16-20 years)	8.18E-02
			Children (11-15 years)	8.95E-02

2296

¹Single weight fraction of 100% available.

2297

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2298

2299

2300

Aerosol Spray Degreaser/Cleaner

2301

Exposure to TCE in aerosol spray degreaser/cleaner products was evaluated based on eight aerosol products with weight fractions ranging from 60-100% TCE.

2302

2303

2304

Westat Survey data on engine degreasing were used as the basis for duration of use and mass of product used. Survey responses indicate that 17.2% of respondents have used products in this category; 78.9% reported use of aerosol formulations. The room of use (Zone 1) was set to the garage (90 m³) although the Westat survey data for this category indicate primarily outdoor use.

2305

2306

2307

2308

2309

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all iterations of this modeling scenario.

2310

2311

2312

2313

2314
2315

Table 2-38. Acute Inhalation Exposure Summary: Aerosol Spray Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (120)	Max (100)	95 th %ile (2157.4)	User	1.62E+02
				Bystander	4.71E+01
Moderate-Intensity User	50 th %ile (15)	Max (100)	50 th %ile (521.4)	User	4.11E+01
				Bystander	1.02E+01
Low-Intensity User	10 th %ile (5)	Min (60)	10 th %ile (130.8)	User	6.20
				Bystander	1.50

¹Actual product weight fractions were: 60-100% and 90-100%.

2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330

This condition of use was also assessed in the 2014 TSCA Work Plan Chemical Risk Assessment and refined in the 2016 Supplemental Exposure and Risk Reduction Technical Report in Support of Risk management Options for TCE (TCE) Use in Consumer Aerosol Degreasing. In these prior assessments, different inputs were used for certain modeling parameters including mass used and duration of use. Please see the referenced documents for full details. The amount used (24 g TCE – roughly 27 g product) in the 2014 assessment is much lower than the 10th percentile input obtained from the Westat survey engine degreasing scenario. The lower amount applied in 2014 more closely reflects an aerosol electronic cleaning condition of use, which is characterized by a median mass used of 0.5 oz, or 22.5 g. It is therefore unlikely that the previous assessment captured exposures for consumer involved in larger degreasing efforts such as engine degreasing or brake cleaning. The inputs and associated 24-hr acute air concentrations for users and bystanders from the 2014 assessment are shown below.

Table 2-39. 2014 Acute Inhalation Exposure Summary: Aerosol Spray Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Mass Used (g)	Product User or Bystander	24-hr TWA (ppm)
2014 Work Plan Chemical Risk Assessment	60	90	(24) ¹	User	2.9 ²
				Bystander	0.8

¹ This conversion assumes a formulation density of 1. Actual product densities range from 1.46-1.52 g/cm³. This input is also provided in terms of mass of TCE per use, rather than mass of product per use, which is the actual model input. 24 g of TCE in this 90% formulation would equate to roughly 27 g of product per use.

²This user air concentration was shown in the 2014 assessment as 2 ppm; however, in the 2016 supplemental report, it was corrected to 2.9 ppm due to an earlier rounding error or typo.

2331
2332
2333
2334
2335
2336
2337
2338
2339

Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

2340

Table 2-40. Acute Dermal Exposure Summary: Aerosol Spray Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (120)	Max (100)	Adult (≥21 years)	2.18E+01
			Children (16-20 years)	2.04E+01
			Children (11-15 years)	2.24E+01
Moderate-Intensity User	50 th %ile (15)	Max (100)	Adult (≥21 years)	2.73
			Children (16-20 years)	2.55
			Children (11-15 years)	2.79
Low-Intensity User	10 th %ile (5)	Min (60)	Adult (≥21 years)	5.46E-01
			Children (16-20 years)	5.11E-01
			Children (11-15 years)	5.59E-01

¹Actual product weight fractions were: 60-100% and 90-100%.

2341

2342

2343

Liquid Degreaser/Cleaner

2344

Exposure to TCE in liquid degreasing/cleaning products was evaluated based on two aerosol products with weight fractions ranging from 90-100% TCE.

2345

2346

2347

Westat Survey data on solvent-type cleaning fluids or degreasers were used as the basis for room of use, duration of use, and mass of product used. Survey responses indicate that 28.1% of respondents have used products in this category; 74.4% reported use of liquid formulations. The room of use (Zone 1) was set to the utility room (20 m³).

2348

2349

2350

2351

2352

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all iterations of this modeling scenario.

2353

2354

2355

2356

2357

2358

Table 2-41. Acute Inhalation Exposure Summary: Liquid Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (120)	(100)	95 th %ile (1337.7)	User	1.46E+02
				Bystander	3.61E+01
Moderate-Intensity User	50 th %ile (15)	(100)	50 th %ile (139.9)	User	1.56E+01
				Bystander	2.96
Low-Intensity User	10 th %ile (2)	(100)	10 th %ile (24.1)	User	2.60
				Bystander	4.86E-01

¹Actual product weight fractions were: 90-100% and 100%.

2359

2360

2361

Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

2362

2363

2364

Table 2-42. Acute Dermal Exposure Summary: Liquid Degreaser/Cleaner

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (120)	(100)	Adult (≥21 years)	2.09E+01
			Children (16-20 years)	1.96E+01
			Children (11-15 years)	2.14E+01
Moderate-Intensity User	50 th %ile (15)	(100)	Adult (≥21 years)	2.62
			Children (16-20 years)	2.45
			Children (11-15 years)	2.68
Low-Intensity User	10 th %ile (2)	(100)	Adult (≥21 years)	3.49E-01
			Children (16-20 years)	3.26E-01
			Children (11-15 years)	3.57E-01

¹Actual product weight fractions were: 90-100% and 100%.

2365

2366

2367

Aerosol Gun Scrubber

2368

Exposure to TCE in aerosol gun scrubber/cleaner products was evaluated based on two aerosol products. Only one product had a reported weight fraction (97%), so modeling was based on the full range of aerosol degreasing formulation weight fractions (60-100%).

2369

2370

2371

2372

Westat Survey data on solvent-type cleaning fluids or degreasers were used as the basis for room of use and duration, while manufacturer data on the amount of product required to coat a firearm in a very thin film were used as the basis for the mass of product used. This mass input may not appropriately capture consumers cleaning multiple guns in a day – a scenario that may require a higher mass input. The Westat survey product category selected was not aligned well with this specific use, but the duration data for the selected category was deemed reasonable for use in modeling. The room of use (Zone 1) was set to the utility room (20 m³).

2373

2374

2375

2376

2377

2378

2379

2380

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures* and *Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all iterations of this modeling scenario.

2381

2382

2383

2384

2385

2386

Table 2-43. Acute Inhalation Exposure Summary: Aerosol Gun Scrubber

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (120)	Max (100)	(0.7)	User	7.44E-02
				Bystander	1.83E-02
Moderate-Intensity User	50 th %ile (15)	Max (100)	(0.7)	User	7.83E-02
				Bystander	1.48E-02
Low-Intensity User	10 th %ile (2)	Min (60)	(0.7)	User	4.55E-02
				Bystander	8.47E-03

¹Only one product had a reported weight fraction (97%), so modeling was based on the full range of aerosol degreasing formulation weight fractions (60-100%).

2387

2388

2389

2390 Dermal exposures for this scenario are based on CEM’s permeability model (P_DER2b), as it is
 2391 assumed that the product could be applied in a manner leading to dermal contact with impeded
 2392 evaporation.
 2393

2394 **Table 2-44. Acute Dermal Exposure Summary: Aerosol Gun Scrubber**

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (120)	Max (100)	Adult (≥21 years)	2.11E+01
			Children (16-20 years)	1.97E+01
			Children (11-15 years)	2.15E+01
Moderate-Intensity User	50 th %ile (15)	Max (100)	Adult (≥21 years)	2.63
			Children (16-20 years)	2.46
			Children (11-15 years)	2.69
Low-Intensity User	10 th %ile (2)	Min (60)	Adult (≥21 years)	2.11E-01
			Children (16-20 years)	1.97E-01
			Children (11-15 years)	2.15E-01

2395 ¹Only one product had a reported weight fraction (97%), so modeling was based on the full range of aerosol degreasing
 2396 formulation weight fractions (60-100%).
 2397

2398 Liquid Gun Scrubber

2399 Exposure to TCE in liquid gun scrubber/cleaner products was evaluated based on one liquid product
 2400 with an unreported weight fraction. Modeling was based on the upper-end of the narrow range of liquid
 2401 degreasing formulation weight fractions (90-100%).
 2402

2403 Westat Survey data on solvent-type cleaning fluids or degreasers were used as the basis for room of use
 2404 and duration, while manufacturer data on the amount of product required to coat a firearm in a very thin
 2405 film were used as the basis for the mass of product used. This mass input may not appropriately capture
 2406 consumers cleaning multiple guns in a day – a scenario that may require a higher mass input. The
 2407 Westat survey product category selected was not aligned well with this specific use, but the duration
 2408 data for the selected category was deemed reasonable for use in modeling. The room of use (Zone 1)
 2409 was set to the utility room (20 m³).
 2410

2411 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2412 intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for*
 2413 *Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer*
 2414 *Dermal Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all
 2415 iterations of this modeling scenario.
 2416
 2417
 2418
 2419
 2420
 2421
 2422
 2423
 2424
 2425
 2426*

2427
2428

Table 2-45. Acute Inhalation Exposure Summary: Liquid Gun Scrubber

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (120)	(100)	(0.7)	User	6.37E-02
				Bystander	1.57E-02
Moderate-Intensity User	50 th %ile (15)	(100)	(0.7)	User	6.71E-02
				Bystander	1.27E-02
Low-Intensity User	10 th %ile (2)	(100)	(0.7)	User	6.22E-02
				Bystander	1.22E-02

2429
2430
2431
2432
2433
2434
2435

¹Modeling was based on the upper-end of the narrow range of liquid degreasing formulation weight fractions (90-100%).

Dermal exposures for this scenario are based on CEM’s permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

Table 2-46. Acute Dermal Exposure Summary: Liquid Gun Scrubber

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (120)	(100)	Adult (≥21 years)	1.95E+01
			Children (16-20 years)	1.83E+01
			Children (11-15 years)	2.00E+01
Moderate-Intensity User	50 th %ile (15)	(100)	Adult (≥21 years)	2.44
			Children (16-20 years)	2.29
			Children (11-15 years)	2.50
Low-Intensity User	10 th %ile (2)	(100)	Adult (≥21 years)	3.26E-01
			Children (16-20 years)	3.05E-01
			Children (11-15 years)	3.33E-01

2436
2437
2438

¹Modeling was based on the upper-end of the narrow range of liquid degreasing formulation weight fractions (90-100%).

Mold Release

2439
2440
2441

Exposure to TCE in mold release products was evaluated based on two aerosol products with weight fractions ranging from 40-68.9% TCE.

2442
2443
2444
2445
2446
2447
2448
2449

Westat Survey data on other lubricants (excluding automotive) were used as the basis for room of use, duration of use, and mass of product used. For this product scenario, EPA believes that the selected lubricant Westat scenario, although not a direct match with mold release products, better aligns with the product use pattern when compared against other options, such as solvent-type cleaning fluid, which conveys a much higher use duration and mass used. Survey responses indicate that 34.5% of respondents have used products in this category; 32.5% reported use of aerosol formulations. The room of use (Zone 1) was set to the utility room (20 m³).

2450
2451
2452
2453

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based on all iterations of this modeling scenario.

2454
2455

Table 2-47. Acute Inhalation Exposure Summary: Mold Release

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	Max (68.9)	95 th %ile (212.9)	User	1.64E+01
				Bystander	3.29
Moderate-Intensity User	50 th %ile (2)	Max (68.9)	50 th %ile (23.4)	User	1.75
				Bystander	3.25E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (40)	10 th %ile (4.3)	User	1.77E-01
				Bystander	3.45E-02

2456
2457
2458
2459

¹Actual product weight fractions were: 40-50% and 68.9%.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2460
2461
2462
2463

Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

Table 2-48. Acute Dermal Exposure Summary: Mold Release

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	Max (68.9)	Adult (≥21 years)	2.19
			Children (16-20 years)	2.05
			Children (11-15 years)	2.24
Central Tendency	50 th %ile (2)	Max (68.9)	Adult (≥21 years)	2.87E-01
			Children (16-20 years)	2.68E-01
			Children (11-15 years)	2.93E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (40)	Adult (≥21 years)	4.34E-02
			Children (16-20 years)	4.06E-02
			Children (11-15 years)	4.44E-02

2464
2465
2466
2467

¹Actual product weight fractions were: 40-50% and 68.9%.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2468
2469
2470
2471

Aerosol Tire Cleaner

Exposure to TCE in aerosol tire cleaning products was evaluated based on two aerosol products with weight fractions ranging from 70-100% TCE.

2472
2473
2474
2475
2476
2477
2478

Westat Survey data on tire and hubcap cleaners were used as the basis for duration of use and mass of product used. Survey responses indicate that 15.9% of respondents have used products in this category; 29.5% reported use of aerosol formulations and 70.5% reported use of liquid formulations. Therefore, these Westat data were applied to both aerosol and liquid product scenarios. The room of use (Zone 1) was set to the garage (90 m³) although the Westat survey data for this category indicate primarily outdoor use.

2479
2480
2481

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures* and *Risk Exposure Modeling Results and Risk Estimates for Consumer*

2482 *Dermal Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)* for the full range of results based on all
 2483 iterations of this modeling scenario.

2484 **Table 2-49. Acute Inhalation Exposure Summary: Aerosol Tire Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	Max (100)	95 th %ile (317)	User	1.57E+01
				Bystander	6.84
Moderate-Intensity User	50 th %ile (15)	Max (100)	50 th %ile (52.9)	User	4.17
				Bystander	1.04
Low-Intensity User	10 th %ile (5)	Min (70)	10 th %ile (10.5)	User	5.81E-01
				Bystander	1.40E-01

2486 ¹Actual product weight fractions were: 70-90% and 80-100%.

2487
 2488 Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is
 2489 assumed that the product could be applied in a manner leading to dermal contact with impeded
 2490 evaporation.

2491 **Table 2-50. Acute Dermal Exposure Summary: Aerosol Tire Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	Max (100)	Adult (≥21 years)	4.81
			Children (16-20 years)	4.50
			Children (11-15 years)	4.93
Moderate-Intensity User	50 th %ile (15)	Max (100)	Adult (≥21 years)	1.20E+00
			Children (16-20 years)	1.13E+00
			Children (11-15 years)	1.23E+00
Low-Intensity User	10 th %ile (5)	Min (70)	Adult (≥21 years)	2.81E-01
			Children (16-20 years)	2.63E-01
			Children (11-15 years)	2.87E-01

2493 ¹Actual product weight fractions were: 70-90% and 80-100%.

2494 **Liquid Tire Cleaner**

2495 Exposure to TCE in liquid tire cleaning products was evaluated based on one liquid product with a
 2496 weight fractions ranging of 80-100% TCE.

2497
 2498 Westat Survey data on tire and hubcap cleaners were used as the basis for duration of use and mass of
 2499 product used. Survey responses indicate that 15.9% of respondents have used products in this category;
 2500 29.5% reported use of aerosol formulations and 70.5% reported use of liquid formulations. Therefore,
 2501 these Westat data were applied to both aerosol and liquid product scenarios. The room of use (Zone 1)
 2502 was set to the garage (90 m³) although the Westat survey data for this category indicate primarily
 2503 outdoor use.

2504
 2505 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2506 intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for*
 2507 *Consumer Inhalation Exposures* and *Risk Exposure Modeling Results and Risk Estimates for Consumer*
 2508 *Exposures*]

2509 *Dermal Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)* for the full range of results based on all
 2510 iterations of this modeling scenario.

2511
 2512 **Table 2-51. Acute Inhalation Exposure Summary: Liquid Tire Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	(100)	95 th %ile (706.4)	User	4.76E+01
				Bystander	1.52E+01
Moderate-Intensity User	50 th %ile (15)	(100)	50 th %ile (117.9)	User	9.28
				Bystander	2.32
Low-Intensity User	10 th %ile (5)	(100)	10 th %ile (23.4)	User	1.85
				Bystander	4.47E-01

2513 ¹Single weight fraction of 80-100% available.

2514
 2515 Dermal exposures for this scenario are based on CEM’s permeability model (P_DER2b), as it is
 2516 assumed that the product could be applied in a manner leading to dermal contact with impeded
 2517 evaporation.

2518
 2519 **Table 2-52. Acute Dermal Exposure Summary: Liquid Tire Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	(100)	Adult (≥21 years)	1.07E+01
			Children (16-20 years)	1.00E+01
			Children (11-15 years)	1.10E+01
Moderate-Intensity User	50 th %ile (15)	(100)	Adult (≥21 years)	2.68
			Children (16-20 years)	2.51
			Children (11-15 years)	2.74
Low-Intensity User	10 th %ile (5)	(100)	Adult (≥21 years)	8.94E-01
			Children (16-20 years)	8.37E-01
			Children (11-15 years)	9.15E-01

2520 ¹Single weight fraction of 80-100% available.

2521
 2522 ***Lubricants and Greases***

2523 **Tap & Die Fluid**

2524 Exposure to TCE in tap & die fluid was evaluated based on one aerosol product with a weight fraction
 2525 of 98% TCE.

2526
 2527 Westat Survey data on other lubricants (excluding automotive) were used to select room of use, duration
 2528 of use, and mass of product used. Survey responses indicated that 34.5% of respondents have used
 2529 products in this category; 32.5% reported use of aerosol formulations. The room of use (Zone 1) was set
 2530 to the utility room (20 m³).

2531
 2532 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2533 intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for*
 2534 *Consumer Inhalation Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)*] for the full range of results based
 2535 on all iterations of this modeling scenario.

2536
2537

Table 2-53. Acute Inhalation Exposure Summary: Tap & Die Fluid

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	(98)	95 th %ile (134.5)	User	1.47E+01
				Bystander	2.95
Moderate-Intensity User	50 th %ile (2)	(98)	50 th %ile (14.8)	User	1.57
				Bystander	2.93E-01
Low-Intensity User	10 th %ile (0.5) ²	(98)	10 th %ile (2.7)	User	2.72E-01
				Bystander	5.30E-02

2538
2539
2540
2541
2542
2543
2544
2545

¹Single weight fraction of 98% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Dermal exposures for this scenario are based on CEM’s fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

Table 2-54. Acute Dermal Exposure Summary: Tap & Die Fluid

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	(98)	Adult (≥21 years)	1.97
			Children (16-20 years)	1.84
			Children (11-15 years)	2.01
Central Tendency	50 th %ile (2)	(98)	Adult (≥21 years)	2.58E-01
			Children (16-20 years)	2.41E-01
			Children (11-15 years)	2.64E-01
Low-Intensity User	10 th %ile (0.5) ²	(98)	Adult (≥21 years)	6.72E-02
			Children (16-20 years)	6.29E-02
			Children (11-15 years)	6.88E-02

2546
2547
2548
2549

¹Single weight fraction of 98% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Penetrating Lubricant

Exposure to TCE in lubricant products was evaluated based on five aerosol products with weight fractions ranging from 5-50 % TCE.

2553
2554
2555
2556
2557
2558

Westat Survey data on other lubricants (excluding automotive) were used as the basis for room of use, duration of use, and mass of product used. Survey responses indicate that 34.5% of respondents have used products in this category; 32.5% reported use of aerosol formulations. The room of use (Zone 1) was set to the utility room (20 m³).

2559
2560
2561
2562

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based on all iterations of this modeling scenario.

2563
2564

Table 2-55. Acute Inhalation Exposure Summary: Penetrating Lubricant

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	Max (50)	95 th %ile (209.9)	User	1.17E+01
				Bystander	2.35
Moderate-Intensity User	50 th %ile (2)	Mid (27.5)	50 th %ile (23.1)	User	6.88E-01
				Bystander	1.28E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (5)	10 th %ile (4.2)	User	2.16E-02
				Bystander	4.21E-03

2565
2566
2567
2568
2569

¹Actual product weight fractions were: 5-10%; 10-20%; 30-40%; 48.8%; and 30-50%. 27.5% is a mathematically-derived mid-point (*i.e.*, mean) for use in modeling, based on the minimum and maximum inputs.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2570

Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

2571

2572

2573

Table 2-56. Acute Dermal Exposure Summary: Penetrating Lubricant

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	Max (50)	Adult (≥21 years)	1.57
			Children (16-20 years)	1.47
			Children (11-15 years)	1.60
Central Tendency	50 th %ile (2)	Mid (27.5)	Adult (≥21 years)	1.13E-01
			Children (16-20 years)	1.06E-01
			Children (11-15 years)	1.15E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (5)	Adult (≥21 years)	5.35E-03
			Children (16-20 years)	5.01E-03
			Children (11-15 years)	5.48E-03

2574

¹Actual product weight fractions were: 5-10%; 10-20%; 30-40%; 48.8%; and 30-50%. 27.5% is a mathematically-derived mid-point (*i.e.*, mean) for use in modeling, based on the minimum and maximum inputs.

2575

2576

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2577

2578

2579

Adhesives and Sealants

2580

Solvent-based Adhesive & Sealant

2581

Exposure to TCE in solvent-based adhesive & sealant products was evaluated based on three liquid products with weight fractions ranging from 5->90% TCE.

2582

2583

2584

Westat Survey data on contact cement, superglue, and spray adhesive were used as the basis for room of use, duration of use, and mass of product used. Survey responses indicate that 60.6% of respondents have used products in this category; 97.1% reported use of liquid formulations. The room of use (Zone 1) was set to the utility room (20 m³).

2585

2586

2587

2588

2589

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for*

2590

2591 Consumer Inhalation Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based
 2592 on all iterations of this modeling scenario.

2593
 2594

Table 2-57. Acute Inhalation Exposure Summary: Solvent-based Adhesive & Sealant

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	Max (90)	95 th %ile (185.2)	User	1.69E+01
				Bystander	4.14
Moderate-Intensity User	50 th %ile (4.25)	Mid (47.5)	50 th %ile (10.7)	User	5.55E-01
				Bystander	1.03E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (5)	10 th %ile (1.3)	User	6.64E-03
				Bystander	1.30E-03

2595 ¹Actual product weight fractions were: 5-15%; 40-60; and >90%. 47.5% is a mathematically-derived mid-point (*i.e.*, mean)
 2596 for use in modeling, based on the minimum and maximum inputs.

2597 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2598 timestep in the model run.

2599

2600 Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use
 2601 pattern is not expected to involve dermal contact with impeded evaporation.

2602

2603

Table 2-58. Acute Dermal Exposure Summary: Solvent-based Adhesive & Sealant

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	Max (90)	Adult (≥21 years)	8.53
			Children (16-20 years)	7.98
			Children (11-15 years)	8.72
Central Tendency	50 th %ile (4.25)	Mid (47.5)	Adult (≥21 years)	9.93E-01
			Children (16-20 years)	9.29E-01
			Children (11-15 years)	1.02E+00
Low-Intensity User	10 th %ile (0.5) ²	Min (5)	Adult (≥21 years)	1.37E-02
			Children (16-20 years)	1.28E-02
			Children (11-15 years)	1.40E-02

2604 ¹Actual product weight fractions were: 5-15%; 40-60; and >90%. 47.5% is a mathematically-derived mid-point (*i.e.*, mean)
 2605 for use in modeling, based on the minimum and maximum inputs.

2606 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2607 timestep in the model run.

2608

2609 Mirror-edge Sealant

2610 Exposure to TCE in mirror-edge sealant products was evaluated based on one aerosol product with a
 2611 weight fraction of 20-40% TCE.

2612

2613 Westat Survey data on contact cement, superglue, and spray adhesive were used as the basis for duration
 2614 of use and mass of product used. While there was no Westat scenario that directly aligned with use as a
 2615 mirror-edge sealant, the selected category is believed to be the best fit based on the associated range of
 2616 use duration and mass used. Survey responses indicate that 60.6% of respondents have used products in
 2617 this category; 97.1% reported use of liquid formulations. While the formulation type used by the
 2618 majority of respondents for this category does not reflect the modeled use, which is an aerosol, it

2619 represents the best fit category available. The room of use (Zone 1) was set to the bathroom (15 m³)
 2620 based on the product's apparent use on mirror edging.

2621
 2622 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2623 intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for*
 2624 *Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based
 2625 on all iterations of this modeling scenario.

2626
 2627 **Table 2-59. Acute Inhalation Exposure Summary: Mirror-Edge Sealant**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	(40)	95 th %ile (78.4)	User	3.33
				Bystander	7.84E-01
Moderate-Intensity User	50 th %ile (4.25)	(40)	50 th %ile (4.5)	User	4.98E-01
				Bystander	9.07E-02
Low-Intensity User	10 th %ile (0.5) ²	(40)	10 th %ile (0.5)	User	2.24E-02
				Bystander	4.07E-03

2628 ¹Single weight fraction of 20-40% available.

2629 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2630 timestep in the model run.

2631
 2632 Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use
 2633 pattern is not expected to involve dermal contact with impeded evaporation.

2634
 2635 **Table 2-60. Acute Dermal Exposure Summary: Mirror-Edge Sealant**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	(40)	Adult (≥21 years)	6.42E-01
			Children (16-20 years)	6.01E-01
			Children (11-15 years)	6.57E-01
Central Tendency	50 th %ile (4.25)	(40)	Adult (≥21 years)	1.42E-01
			Children (16-20 years)	1.33E-01
			Children (11-15 years)	1.45E-01
Low-Intensity User	10 th %ile (0.5) ²	(40)	Adult (≥21 years)	1.85E-02
			Children (16-20 years)	1.73E-02
			Children (11-15 years)	1.89E-02

2636 ¹Single weight fraction of 20-40% available.

2637 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2638 timestep in the model run.

2639 **Tire Repair Cement/Sealer**

2640 Exposure to TCE in tire repair products was evaluated based on five liquid products with weight
 2641 fractions ranging from 65-95% TCE.

2642
 2643 Westat Survey data on contact cement, superglue, and spray adhesive were used as the basis for duration
 2644 of use and mass of product used. Survey responses indicate that 60.6% of respondents have used
 2645 products in this category; 97.1% reported use of liquid formulations. The room of use (Zone 1) was set
 2646 to the garage (90 m³) based on the product's apparent use on tires.
 2647

2648
2649
2650
2651
2652
2653
2654

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based on all iterations of this modeling scenario.

Table 2-61. Acute Inhalation Exposure Summary: Tire Repair Cement/Sealer

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	Max (95)	95 th %ile (185.2)	User	1.18E+01
				Bystander	3.80
Moderate-Intensity User	50 th %ile (4.25)	Mid (80)	50 th %ile (10.7)	User	6.64E-01
				Bystander	1.63E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (65)	10 th %ile (1.3)	User	5.97E-02
				Bystander	1.59E-02

2655
2656
2657
2658
2659
2660
2661
2662
2663

¹Actual product weight fractions were: 65-80%; 70-85%; 75-90%; and 80-95%. 80% is a mathematically-derived mid-point (*i.e.*, mean) for use in modeling, based on the minimum and maximum inputs.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Dermal exposures for this scenario are based on CEM’s fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

Table 2-62. Acute Dermal Exposure Summary: Tire Repair Cement/Sealer

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	Max (95)	Adult (≥21 years)	9.00
			Children (16-20 years)	8.42
			Children (11-15 years)	9.21
Central Tendency	50 th %ile (4.25)	Mid (80)	Adult (≥21 years)	1.67
			Children (16-20 years)	1.57
			Children (11-15 years)	1.71
Low-Intensity User	10 th %ile (0.5) ²	Min (65)	Adult (≥21 years)	1.78E-01
			Children (16-20 years)	1.66E-01
			Children (11-15 years)	1.82E-01

2664
2665
2666
2667
2668

¹Actual product weight fractions were: 65-80%; 70-85%; 75-90%; and 80-95%. 80% is a mathematically-derived mid-point (*i.e.*, mean) for use in modeling, based on the minimum and maximum inputs.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Cleaning and Furniture Care Products

Carpet Cleaner

2670
2671
2672
2673
2674
2675
2676

Exposure to TCE in carpet cleaner was evaluated based on a single liquid formulation with a weight fraction of >99% TCE.

Westat Survey data on spot removers were used to select the duration of use and mass of product used. Survey responses indicate that 39.1% of respondents have used products in this category; 43.9% reported use of a liquid formulation. The room of use (Zone 1) was set to the bedroom (36 m³) based on

2677 professional judgement. There are no data in the Westat Survey exactly matching a use as a carpet
 2678 cleaner; therefore, data reflecting spot cleaners were applied.

2679
 2680 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2681 intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for*
 2682 *Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer*
 2683 *Dermal Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all
 2684 iterations of this modeling scenario.*

2685
 2686 **Table 2-63. Acute Inhalation Exposure Summary: Carpet Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	(99)	95 th %ile (526.6)	User	5.26E+01
				Bystander	1.15E+01
Moderate-Intensity User	50 th %ile (5)	(99)	50 th %ile (62.9)	User	6.36
				Bystander	1.26
Low-Intensity User	10 th %ile (0.5) ²	(99)	10 th %ile (11.8)	User	1.10
				Bystander	2.33E-01

2687 ¹Single weight fraction of >99% available.

2688 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2689 timestep in the model run.

2690
 2691 Dermal exposures for this scenario are based on CEM’s permeability model (P_DER2b), as it is
 2692 assumed that the product could be applied in a manner leading to dermal contact with impeded
 2693 evaporation.

2694
 2695 **Table 2-64. Acute Dermal Exposure Summary: Carpet Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	(99)	Adult (≥21 years)	5.69
			Children (16-20 years)	5.32
			Children (11-15 years)	5.82
Central-Tendency	50 th %ile (5)	(99)	Adult (≥21 years)	9.48E-01
			Children (16-20 years)	8.87E-01
			Children (11-15 years)	9.70E-01
Low-Intensity User	10 th %ile (0.5) ²	(99)	Adult (≥21 years)	9.48E-02
			Children (16-20 years)	8.87E-02
			Children (11-15 years)	9.70E-02

2696 ¹Single weight fraction of >99% available.

2697 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the
 2698 model, as it reflects the smallest timestep in the model run.

2699
 2700 **Aerosol Spot Remover**

2701 Exposure to TCE in aerosol spot remover products was evaluated based on one aerosol product with a
 2702 weight fraction of 20-30% TCE.

2703
2704
2705
2706
2707
2708
2709
2710
2711
2712
2713
2714
2715
2716

Westat Survey data on spot removers were used as the basis for room of use, duration of use, and mass of product used. Survey responses indicate that 39.1% of respondents have used products in this category; 43.9% reported use of a liquid formulation and 56.1% reported use of an aerosol formulation. Therefore, these Westat data were applied to both aerosol and liquid product scenarios. The room of use (Zone 1) was set to the utility room (20 m³).

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures* and *Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all iterations of this modeling scenario.

Table 2-65. Acute Inhalation Exposure Summary: Aerosol Spot Remover

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	(30)	95 th %ile (514.1)	User	1.72E+01
				Bystander	3.46
Moderate-Intensity User	50 th %ile (5)	(30)	50 th %ile (61.4)	User	2.04
				Bystander	3.76E-01
Low-Intensity User	10 th %ile (0.5) ²	(30)	10 th %ile (11.15)	User	3.55E-01
				Bystander	6.92E-02

2717
2718
2719
2720
2721
2722
2723
2724
2725

¹Single weight fraction of 20-30% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

Table 2-66. Acute Dermal Exposure Summary: Aerosol Spot Remover

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	(30)	Adult (≥21 years)	1.68
			Children (16-20 years)	1.58
			Children (11-15 years)	1.72
Moderate-Intensity User	50 th %ile (5)	(30)	Adult (≥21 years)	2.81E-01
			Children (16-20 years)	2.63E-01
			Children (11-15 years)	2.87E-01
Low-Intensity User	10 th %ile (0.5) ²	(30)	Adult (≥21 years)	2.81E-02
			Children (16-20 years)	2.63E-02
			Children (11-15 years)	2.87E-02

2726
2727
2728
2729
2730

¹Single weight fraction of 20-30% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2731 Liquid Spot Remover
 2732 Exposure to TCE in liquid spot remover products was evaluated based on four liquid products with
 2733 weight fractions ranging from 50-75%.
 2734

2735 Westat Survey data on spot removers were used as the basis for room of use, duration of use, and mass
 2736 of product used. Survey responses indicate that 39.1% of respondents have used products in this
 2737 category; 43.9% reported use of a liquid formulation and 56.1% reported use of an aerosol formulation.
 2738 Therefore, these Westat data were applied to both aerosol and liquid product scenarios. The room of use
 2739 (Zone 1) was set to the utility room (20 m³).
 2740

2741 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2742 intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for*
 2743 *Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer*
 2744 *Dermal Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)*] for the full range of results based on all
 2745 iterations of this modeling scenario.
 2746
 2747

Table 2-67. Acute Inhalation Exposure Summary: Liquid Spot Remover

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	Max (75)	95 th %ile (477.2)	User	3.99E+01
				Bystander	8.02
Moderate-Intensity User	50 th %ile (5)	Max (75)	50 th %ile (57)	User	4.73
				Bystander	8.72E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (50)	10 th %ile (10.7)	User	5.47E-01
				Bystander	1.07E-01

2748 ¹Actual product weight fractions were: <50%; <75%; and >75%.

2749 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2750 timestep in the model run.
 2751

2752 Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is
 2753 assumed that the product could be applied in a manner leading to dermal contact with impeded
 2754 evaporation.
 2755
 2756

Table 2-68. Acute Dermal Exposure Summary: Liquid Spot Remover

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	Max (75)	Adult (≥21 years)	3.91
			Children (16-20 years)	3.66
			Children (11-15 years)	4.00
Moderate-Intensity User	50 th %ile (5)	Max (75)	Adult (≥21 years)	6.51E-01
			Children (16-20 years)	6.09E-01
			Children (11-15 years)	6.66E-01
Low-Intensity User	10 th %ile (0.5) ²	Min (50)	Adult (≥21 years)	4.34E-02
			Children (16-20 years)	4.06E-02
			Children (11-15 years)	4.44E-02

2757 ¹Actual product weight fractions were: <50%; <75%; and >75%.

2758 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the

model, as it reflects the smallest timestep in the model run.

Arts, Crafts, and Hobby Materials

Fixatives & Finishing Spray Coating

Exposure to TCE in fixatives & finishing spray coating products was evaluated based on one aerosol product with a weight fraction of 20-30% TCE. This particular product subcategory is not expected to be a children’s arts, crafts, or hobby use; therefore, in the dermal exposure scenarios, only children 11 years or greater are included as users, as with other evaluated consumer scenarios.

Westat Survey data on aerosol rust removers were used as the basis for duration of use and mass of product used. This Westat category was selected as a surrogate, as there were no well-aligned product categories for this use. However, survey responses for the selected surrogate category reported 98.3% use of aerosol formulations, which is supportive of its application to the modeled product scenario. Duration of use and mass of product data were considered more reasonable (*i.e.*, lower) than the higher use patterns associated with most of the solvent degreasing or cleaning categories. The room of use (Zone 1) was set to the utility room (20 m³).

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based on all iterations of this modeling scenario.

Table 2-69. Acute Inhalation Exposure Summary: Fixatives & Finishing Spray Coatings

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	(30)	95 th %ile (306)	User	9.31
				Bystander	2.28
Moderate-Intensity User	50 th %ile (5)	(30)	50 th %ile (45.2)	User	1.50
				Bystander	2.77E-01
Low-Intensity User	10 th %ile (0.5) ²	(30)	10 th %ile (9.4)	User	2.90E-01
				Bystander	5.66E-02

¹Single product weight fraction of 20-30% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

This condition of use was also assessed in the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)). In the prior assessment, different inputs were used for certain modeling parameters including mass used and duration of use. The amount of TCE used (11 g – roughly 37 g of product) in the 2014 assessment is roughly equivalent to the 50th percentile input obtained from the Westat survey rust remover surrogate scenario applied in this latest evaluation. These inputs and associated 24-hr acute air concentrations for users and bystanders are included below.

Table 2-70. 2014 Acute Inhalation Exposure Summary: Fixatives & Finishing Spray Coatings

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Mass Used (g)	Product User or Bystander	24-hr TWA (ppm)
2014 Chemical Work Plan Risk Assessment	30	30	11 ¹	User	0.4
				Bystander	0.1

2794
2795
2796
2797
2798
2799
2800
2801
2802

¹Note that this conversion assumes a formulation density of 1. Actual product densities range from 1.46-1.52 g/cm³. This input is also provided in terms of mass of TCE per use, rather than mass of product per use, which is the actual model input. 11 g of TCE in this 30% formulation would equate to roughly 37 g of product per use, which is similar to the central tendency input used in the current evaluation.

Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

Table 2-71. Acute Dermal Exposure Summary: Fixatives & Finishing Spray Coatings

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	(30)	Adult (≥21 years)	5.52E-01
			Children (16-20 years)	5.16E-01
			Children (11-15 years)	5.65E-01
Moderate-Intensity User	50 th %ile (5)	(30)	Adult (≥21 years)	1.40E-01
			Children (16-20 years)	1.31E-01
			Children (11-15 years)	1.44E-01
Low-Intensity User	10 th %ile (0.5) ²	(30)	Adult (≥21 years)	1.59E-02
			Children (16-20 years)	1.49E-02
			Children (11-15 years)	1.63E-02

2803
2804
2805
2806

¹Single product weight fraction of 20-30% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Apparel and Footwear care Products

Shoe Polish

2809
2810

Exposure to TCE in shoe polish products was evaluated based on one aerosol product with a weight fraction of 10-20% TCE.

2811
2812
2813
2814
2815

Westat Survey data on spray shoe polish were used as the basis for room of use, duration of use, and mass of product used. Survey responses indicate that 11.7% of respondents have used products in this category; 97.7% reported use of aerosol formulations. The room of use (Zone 1) was set to the utility room (20 m³).

2816
2817
2818
2819
2820
2821

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures and Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all iterations of this modeling scenario.

2822
2823

Table 2-72. Acute Inhalation Exposure Summary: Shoe Polish

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	(20)	95 th %ile (151.4)	User	2.77
				Bystander	6.79E-01
Moderate-Intensity User	50 th %ile (5)	(20)	50 th %ile (15.4)	User	3.41E-01
				Bystander	6.28E-02

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
Low-Intensity User	10 th %ile (0.5)	(20)	10 th %ile (2.9)	User	5.96E-02
				Bystander	1.16E-02

¹Single weight fraction of 10-20% available.

Dermal exposures for this scenario are based on CEM's permeability model (P_DER2b), as it is assumed that the product could be applied in a manner leading to dermal contact with impeded evaporation.

Table 2-73. Acute Dermal Exposure Summary: Shoe Polish

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	(20)	Adult (≥21 years)	3.68E-01
			Children (16-20 years)	3.44E-01
			Children (11-15 years)	3.76E-01
Moderate-Intensity User	50 th %ile (5)	(20)	Adult (≥21 years)	6.13E-02
			Children (16-20 years)	5.74E-02
			Children (11-15 years)	6.27E-02
Low-Intensity User	10 th %ile (0.5)	(20)	Adult (≥21 years)	6.13E-03
			Children (16-20 years)	5.74E-03
			Children (11-15 years)	6.27E-03

¹Single weight fraction of 10-20% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Other Consumer Uses

Fabric Spray

Exposure to TCE in fabric spray products was evaluated based on one aerosol product with a weight fraction of 20-40% TCE. This use (*i.e.*, no-fray fabric spray) was originally identified in the 2014 TSCA Work Plan Chemical Risk Assessment of TCE ([U.S. EPA, 2014b](#)).

Westat Survey data on water repellents/protectors for suede, leather, and cloth were used as the basis for room of use, duration of use, and mass of product used. Survey responses indicate that 35.5% of respondents have used products in this category; 72.1% reported use of aerosol formulations. The room of use (Zone 1) was set to the utility room (20 m³).

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based on all iterations of this modeling scenario.

2852 **Table 2-74. Acute Inhalation Exposure Summary: Fabric Spray**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	(40)	95 th %ile (326.8)	User	1.33E+01
				Bystander	3.24
Moderate-Intensity User	50 th %ile (10)	(40)	50 th %ile (49.9)	User	2.23
				Bystander	4.15E-01
Low-Intensity User	10 th %ile (1.4)	(40)	10 th %ile (11.4)	User	4.66E-01
				Bystander	9.18E-02

¹Single product weight fraction of 20-40% available.

2853
2854
2855 Dermal exposures for this scenario are based on CEM’s fraction absorbed model (P_DER2a), as this use
2856 pattern is not expected to involve dermal contact with impeded evaporation.
2857

2858 **Table 2-75. Acute Dermal Exposure Summary: Fabric Spray**

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	(40)	Adult (≥21 years)	6.42E-01
			Children (16-20 years)	6.01E-01
			Children (11-15 years)	6.58E-01
Moderate-Intensity User	50 th %ile (10)	(40)	Adult (≥21 years)	2.87E-01
			Children (16-20 years)	2.68E-01
			Children (11-15 years)	2.94E-01
Low-Intensity User	10 th %ile (1.4)	(40)	Adult (≥21 years)	5.05E-02
			Children (16-20 years)	4.73E-02
			Children (11-15 years)	5.18E-02

¹Single product weight fraction of 20-40% available.

2859
2860
2861 Film Cleaner

2862 Exposure to TCE in film cleaner products was evaluated based on two aerosol products with weight
2863 fractions ranging 80-100% TCE.
2864

2865 Westat Survey data on aerosol rust removers were used as the basis for duration of use and mass of
2866 product used. This Westat category was selected as a surrogate, as there were no well-aligned product
2867 categories for this use. However, survey responses for the selected surrogate category reported 98.3%
2868 use of aerosol formulations, which is supportive of its application to the modeled product scenario.
2869 Duration of use and mass of product data were also reviewed for reasonableness and were considered
2870 more reasonable (*i.e.*, lower) than the higher use patterns associated with most of the solvent degreasing
2871 or cleaning categories. The room of use (Zone 1) was set to the utility room (20 m³).
2872

2873 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
2874 intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for*
2875 *Consumer Inhalation Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)*] for the full range of results based
2876 on all iterations of this modeling scenario.
2877
2878
2879

2880 **Table 2-76. Acute Inhalation Exposure Summary: Film Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	(100)	95 th %ile (632.9)	User	6.42E+01
				Bystander	1.57E+01
Moderate-Intensity User	50 th %ile (5)	(100)	50 th %ile (93.4)	User	1.03E+01
				Bystander	1.91
Low-Intensity User	10 th %ile (0.5) ²	(100)	10 th %ile (19.4)	User	1.99
				Bystander	3.89E-01

2881 ¹Actual product weight fractions were: 80-100% and 95%.

2882 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
2883 timestep in the model run.

2884

2885 Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use
2886 pattern is not expected to involve dermal contact with impeded evaporation.

2887

2888 **Table 2-77. Acute Dermal Exposure Summary: Film Cleaner**

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	(100)	Adult (≥21 years)	3.80
			Children (16-20 years)	3.56
			Children (11-15 years)	3.89
Moderate-Intensity User	50 th %ile (5)	(100)	Adult (≥21 years)	9.68E-01
			Children (16-20 years)	9.06E-01
			Children (11-15 years)	9.91E-01
Low-Intensity User	10 th %ile (0.5) ²	(100)	Adult (≥21 years)	1.10E-01
			Children (16-20 years)	1.03E-01
			Children (11-15 years)	1.12E-01

2889 ¹Actual product weight fractions were: 80-100% and 95%.

2890 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
2891 timestep in the model run.

2892

2893 Hoof Polish

2894 Exposure to TCE in hoof polish products was evaluated based on one aerosol product with an
2895 unreported weight fraction. Modeling was based on the upper-end of the narrow range of shoe polish
2896 and spray fixative/coating formulation weight fractions (20-30%).

2897

2898 Westat Survey data on spray shoe polish were used as the basis for duration of use and mass of product
2899 used. This Westat category was selected as a surrogate, as there were no well-aligned product categories
2900 for this use. Survey data indicate that 11.7% of respondents used products in this category; 97.7%
2901 reported use of aerosol formulations. The room of use (Zone 1) was set to approximate a barn
2902 environment. This was done by using a garage (90 m³) but increasing the default air exchange rate of a
2903 residential room from 0.45 to 4 air exchanged per hour, which was based on recommended ventilation
2904 rates for a horse stable ([Pennsylvania State University, 2016](#)).

2905

2906 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
2907 intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for*

2908 Consumer Inhalation Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)] for the full range of results based
 2909 on all iterations of this modeling scenario.

2910
 2911 **Table 2-78. Acute Inhalation Exposure Summary: Hoof Polish**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (30)	(30)	95 th %ile (208.2)	User	2.21
				Bystander	1.10E-02
Moderate-Intensity User	50 th %ile (5)	(30)	50 th %ile (21.2)	User	2.16E-01
				Bystander	4.76E-04
Low-Intensity User	10 th %ile (0.5)	(30)	10 th %ile (4)	User	3.08E-02
				Bystander	7.79E-05

2912 ¹Actual weight fraction is not reported; modeling was based on the upper-end of the narrow range of shoe polish and spray
 2913 fixative/coating formulation weight fractions (20-30%).

2914
 2915 Dermal exposures for this scenario are based on CEM’s fraction absorbed model (P_DER2a), as this use
 2916 pattern is not expected to involve dermal contact with impeded evaporation.

2917
 2918 **Table 2-79. Acute Dermal Exposure Summary: Hoof Polish**

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (30)	(30)	Adult (≥21 years)	4.66E-01
			Children (16-20 years)	4.36E-01
			Children (11-15 years)	4.77E-01
Moderate-Intensity User	50 th %ile (5)	(30)	Adult (≥21 years)	1.40E-01
			Children (16-20 years)	1.31E-01
			Children (11-15 years)	1.44E-01
Low-Intensity User	10 th %ile (0.5) ²	(30)	Adult (≥21 years)	1.59E-02
			Children (16-20 years)	1.49E-02
			Children (11-15 years)	1.63E-02

2919 ¹Actual weight fraction is not reported; modeling was based on the upper-end of the narrow range of shoe polish and spray
 2920 fixative/coating formulation weight fractions (20-30%).

2921 ²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest
 2922 timestep in the model run.

2923
 2924 **Pepper Spray**

2925 Exposure to TCE in pepper spray products was evaluated based on two aerosol products with a single
 2926 reported weight fraction of 91.5% TCE.

2927
 2928 Product research was the basis for duration of use and mass of product used. One spray from the most
 2929 common civilian canister is estimated to be approximately 0.0216-0.108 ounces, based on information
 2930 on a [pepper spray manufacturer’s website](#). One spray was assumed for the low-intensity scenario, while
 2931 use of the entire keychain-sized canister (0.54 oz, 15 g) was assumed for the high-intensity user scenario
 2932 and a half canister was assumed for the moderate-use intensity scenario. Spraying occurred between 3
 2933 and 5 seconds (0.05-0.08 min) before obtaining desired effect ([Bertilsson et al., 2017](#)), but use duration
 2934 was rounded up to the lowest time step within CEM (30 seconds). The room of use (Zone 1) was set to
 2935 approximate a “cloud” around the user (16 m³) in an outdoor environment. This was done by increasing

2936 the default air exchange rate of a residential room from 0.45 to 100 air exchanges per hour. Since the
 2937 interzonal ventilation rate for this “outdoor” scenario is held at 0, there are no bystander exposures
 2938 estimated. Based on the limited parameter data for this scenario, no inputs were varied.
 2939

2940 Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-
 2941 intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for*
 2942 *Consumer Inhalation Exposures. Docket: [EPA-HQ-OPPT-2019-0500](#)*] for the full range of results based
 2943 on all iterations of this modeling scenario.
 2944

2945 **Table 2-80. Acute Inhalation Exposure Summary: Pepper Spray**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	(0.5) ²	(91.5)	(15)	User	6.65E-02
				Bystander	6.65E-02
Moderate -Intensity User	(0.5) ²	(91.5)	(7.5)	User	3.33E-02
				Bystander	3.33E-02
Low-Intensity User	(0.5) ²	(91.5)	(4)	User	1.77E-02
				Bystander	1.77E-02

2946 ¹Single weight fraction of 91.5% available.

2947 ²The selected < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2948 ³Bystander in the home not modeled due to simulated outdoor scenario - can be considered equal to user.
 2949

2950 Dermal exposures for this scenario are based on CEM’s fraction absorbed model (P_DER2a), as this use
 2951 pattern is not expected to involve dermal contact with impeded evaporation. Only a single scenario is
 2952 shown for dermal, as there are only single inputs for duration and weight fraction, which are the only
 2953 two varied parameters utilized in the dermal model.
 2954

2955 **Table 2-81. Acute Dermal Exposure Summary: Pepper Spray**

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Receptor	Acute ADR (mg/kg/day)
Single Scenario	(0.5) ²	(91.5)	Adult (≥21 years)	8.62E-02
			Children (16-20 years)	8.07E-02
			Children (11-15 years)	8.82E-02

2956 ¹Single weight fraction of 91.5% available.

2957 ²The low-end duration is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the
 2958 model run.
 2959

2960 **Toner Aid**

2961 Exposure to TCE in toner aid products was evaluated based on one aerosol product with a weight
 2962 fraction of 10-20% TCE.
 2963

2964 Westat Survey data on aerosol rust removers were used as the basis for duration of use and mass of
 2965 product used. This Westat category was selected as a surrogate, as there were no well-aligned product
 2966 categories for this use. However, survey responses for the selected surrogate category reported 98.3%
 2967 use of aerosol formulations, which is supportive of its application to the modeled product scenario.
 2968 Duration of use and mass of product data were also reviewed for reasonableness and were considered
 2969 more reasonable (*i.e.*, lower) than the higher use patterns associated with most of the solvent degreasing
 2970 or cleaning categories. The room of use (Zone 1) was set to the utility room (20 m³).

2971
2972
2973
2974
2975
2976
2977

Inhalation exposures for users and bystanders are presented below reflecting high-, moderate-, and low-intensity user scenarios. See Supplemental File [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures. Docket: EPA-HQ-OPPT-2019-0500*] for the full range of results based on all iterations of this modeling scenario.

Table 2-82. Acute Inhalation Exposure Summary: Toner Aid

Scenario Description	Duration of Use (min)	Weight Fraction ¹ (%)	Mass Used (g)	Product User or Bystander	24-hr Max TWA (ppm)
High-Intensity User	95 th %ile (60)	(20)	95 th %ile (434.7)	User	8.82
				Bystander	2.16
Moderate-Intensity User	50 th %ile (5)	(20)	50 th %ile (64.2)	User	1.42
				Bystander	2.62E-01
Low-Intensity User	10 th %ile (0.5) ²	(20)	10 th %ile (13.3)	User	2.73E-01
				Bystander	5.34E-02

2978
2979
2980
2981
2982
2983
2984

¹Single weight fraction of 10-20% available.

²The selected < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

Dermal exposures for this scenario are based on CEM's fraction absorbed model (P_DER2a), as this use pattern is not expected to involve dermal contact with impeded evaporation.

Table 2-83. Acute Dermal Exposure Summary: Toner Aid

Scenario Description	Duration of Use (min)	Weight Fraction (%)	Receptor	Acute ADR (mg/kg/day)
High-Intensity User	95 th %ile (60)	(20)	Adult (≥21 years)	5.23E-01
			Children (16-20 years)	4.89E-01
			Children (11-15 years)	5.35E-01
Moderate-Intensity User	50 th %ile (5)	(20)	Adult (≥21 years)	1.33E-01
			Children (16-20 years)	1.24E-01
			Children (11-15 years)	1.36E-01
Low-Intensity User	10 th %ile (0.5) ²	(20)	Adult (≥21 years)	1.51E-02
			Children (16-20 years)	1.41E-02
			Children (11-15 years)	1.54E-02

2985
2986
2987
2988
2989

¹Single weight fraction of 10-20% available.

²The 10th percentile duration from Westat is < 0.5 minutes, but 0.5 minutes was used in the model, as it reflects the smallest timestep in the model run.

2990
2991
2992
2993
2994

2.3.2.5.3 Summary of Consumer Exposure Assessment

Table 2-84 displays the consumer conditions of use evaluated for acute inhalation and/or dermal exposures.

Table 2-84. Evaluated Pathways for Consumer Conditions of Use

Life Cycle Stage	Categories	Product Subcategories	Form	Acute Inhalation Exposure	Acute Dermal Exposure
Use	Solvents for Cleaning and Degreasing	Brake & Parts Cleaner	Aerosol	✓	✓
		Electronic Degreaser/Cleaner	Aerosol	✓	✓
		Electronic Degreaser/Cleaner	Liquid	✓	✓
		Aerosol Spray Degreaser/Cleaner	Aerosol	✓	✓
		Liquid Degreaser/Cleaner	Liquid	✓	✓
		Gun Scrubber	Aerosol	✓	✓
		Gun Scrubber	Liquid	✓	✓
		Mold Release	Aerosol	✓	✓
		Tire Cleaner	Aerosol	✓	✓
		Tire Cleaner	Liquid	✓	✓
	Lubricants and Greases	Tap & Die Fluid	Aerosol	✓	✓
		Penetrating Lubricant	Aerosol	✓	✓
	Adhesives and Sealants	Solvent-based Adhesive & Sealant	Liquid	✓	✓
		Mirror-edge Sealant	Aerosol	✓	✓
		Tire Repair Cement/Sealer	Liquid	✓	✓
	Cleaning and Furniture Care Products	Carpet Cleaner	Liquid	✓	✓
		Spot Remover	Aerosol	✓	✓
		Spot Remover	Liquid	✓	✓
	Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings	Aerosol	✓	✓
	Apparel and Footwear Care Products	Shoe Polish	Aerosol	✓	✓
	Other Consumer Uses	Fabric Spray	Aerosol	✓	✓
		Film Cleaner	Aerosol	✓	✓
		Hoof Polish	Aerosol	✓	✓
		Pepper Spray	Aerosol	✓	✓
		Toner Aid	Aerosol	✓	✓

2995
2996
2997
2998
2999
3000
3001
3002

A range in acute inhalation and acute dermal exposures is provided in Table 2-85., summarized by the consumer category. Ranges provided are based on the presented user scenario descriptions (high-, moderate-, and low-intensity) and may not reflect overall minimum and maximum exposure levels from all iterations of the modeling scenario, which can be seen in the Supplemental Files [*Exposure Modeling Results and Risk Estimates for Consumer Inhalation Exposures* and *Risk Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures*]. Docket: [EPA-HQ-OPPT-2019-0500](#)].

3003 **Table 2-85. Summary of Consumer Exposure Levels by Category**

Consumer Category	Acute Inhalation 24-hr TWA ¹ (ppm)		Acute Dermal ADR ² (mg/kg/d)
Solvents for Cleaning and Degreasing	User	4.55E-02 – 1.62E+02	3.52E-02 – 2.38E+01
	Bystander	8.47E-03 – 4.71E+01	
Lubricants and Greases	User	2.16E-02 – 1.47E+01	5.01E-03 – 2.01
	Bystander	4.21E-03 – 2.95	
Adhesives and Sealants	User	6.64E-03 – 1.69E+01	1.28E-02 – 9.00
	Bystander	1.30E-03 – 4.14	
Cleaning and Furniture Care Products	User	3.55E-01 – 5.26E+01	2.63E-02 – 5.82
	Bystander	6.92E-02 – 1.15E+01	
Arts, Crafts, and Hobby Materials	User	2.90E-01 – 9.31	1.49E-02 – 5.65E-01
	Bystander	5.66E-02 – 2.28	
Apparel and Footwear Care Products	User	5.96E-02 – 2.77	5.74E-03 – 3.76E-01
	Bystander	1.16E-02 – 6.79E-01	
Other Consumer Uses	User	1.77E-02 – 6.42E+01	1.41E-02 – 3.56
	Bystander	7.79E-05 – 1.57E+01	

¹The level of variation displayed in the ranges of consumer categories reflect multiple, specific consumer conditions of use / subcategories and do not reflect the degree of variation present within scenario-specific results. The displayed category ranges therefore reflect a much broader spread of exposure estimates.

²The range in acute dermal ADRs reflect all age groups modeled (children and adult).

3004 **2.3.2.6 Assumptions and Key Sources of Uncertainty for Consumer**
 3005 **Exposures**

3006 EPA’s approach recognizes the need to include uncertainty analysis. One important distinction for such
 3007 an analysis is variability versus uncertainty – both aspects need to be addressed. Variability refers to the
 3008 inherent heterogeneity or diversity of data in an assessment. It is a quantitative description of the range
 3009 or spread of a set of values and is often expressed through statistical metrics, such as variance or
 3010 standard deviation, that reflect the underlying variability of the data. Uncertainty refers to a lack of data
 3011 or an incomplete understanding of the context of the Risk Evaluation decision.

3012
 3013 Variability cannot be reduced, but it can be better characterized. Uncertainty can be reduced by
 3014 collecting more or better data. Quantitative methods to address uncertainty include non-probabilistic
 3015 approaches such as sensitivity analysis and probabilistic or stochastic methods. Uncertainty can also be
 3016 addressed qualitatively, by including a discussion of factors such as data gaps and subjective decisions
 3017 or instances where professional judgment was used.

3018
 3019 Uncertainties associated with approaches and data used in the evaluation of consumer exposures are
 3020 described below.

3021
 3022
 3023

2.3.2.6.1 Modeling Approach Uncertainties

Deterministic vs. Stochastic

With deterministic approaches like the one applied in this evaluation of consumer exposure, the output of the model is fully determined by the choices of parameter values and initial conditions. Stochastic approaches feature inherent randomness, such that a given set of parameter values and initial conditions can lead to an ensemble of different model outputs. The overall approach to the CEM modeling is intended to capture a range of low- to high-intensity User exposure estimates by varying only a limited number of key parameters that represent the range of consumer product and use patterns for each scenario. As previously mentioned the parameters selected were chemical weight fraction, product mass, and duration of use. All other parameters remained constant between model runs. Since not all parameters were varied, there is uncertainty regarding the full range of possible exposure estimates. Although these estimates are thought to reflect the range in exposure estimates for the suite of possible exposures based on the three varied parameters, the scenarios presented are not considered bounding or “worst-case,” as there are unvaried parameters that are also identified as sensitive inputs held constant at a central tendency value. These include the room of use volume, residential building volume, and air exchange rate. Because EPA’s largely deterministic approach involves choices regarding highly influential factors such as mass of product used and weight fraction, it likely captures the range of potential exposure levels although it does not necessarily enable characterization of the full probabilistic distribution of all possible outcomes.

Aggregate Exposure

Dermal and inhalation exposure estimates were not aggregated due to uncertainties associated with the absence of a dermal compartment in the PBPK model. Further, background levels of TCE in indoor and outdoor air are not considered or aggregated in this assessment; therefore, there is a potential for underestimating consumer inhalation exposures, particularly for populations living near a facility emitting TCE or living in a home with other sources of TCE, such as TCE-containing products stored in the home. For example, the indoor air and personal breathing zone monitoring values presented in Appendix D.4 were not considered for aggregation with modeled, use-specific acute air concentrations. Similarly, inhalation exposures were evaluated on a product-specific basis and are based on use of a single product type within a day, not multiple products. See Section 4.4.2 for additional discussion on EPA’s decision to not incorporate aggregate exposure.

Acute Exposure

EPA assumes that a consumer product would be used only once per day. This is a reasonable assumption for most scenarios, but a Do-It-Yourself- (DIY-) type user could potentially use the same product multiple times in one day. Additionally, based on human health hazard considerations and typical use patterns, chronic exposures were not evaluated for TCE-containing consumer products. However, it is possible that there would be concern for chronic exposure effects for use frequencies greater than intermittent. For example, daily or DIY-type uses of consumer products could constitute a short-term chronic exposure scenario or repeated-acute exposure scenario that is not captured in this evaluation. Identified chronic non-cancer and cancer hazard endpoints (Section 3.2) are unlikely to present for these populations based on reasonably available information, however the possibility cannot be ruled out. For the vast majority of the consumer population which are only exposed through short-term, occasional use of TCE products, only acute exposure is applicable.

Dermal Exposure Approach

For dermal exposure scenarios using the permeability model that may involve dermal contact with impeded evaporation based on professional considerations of the formulation type and likely use pattern, there is uncertainty surrounding the assumption that such dermal contact with impeded evaporation

3073 would occur for those scenarios. For example, for aerosol formulations, it is possible that aerosol
3074 degreasing or cleaning products may be sprayed and left to drip or dry from the target surface. It is also
3075 possible users would follow spraying with wiping, which could lead to some duration of dermal contact
3076 with impeded evaporation. There is related uncertainty surrounding the application of exposure
3077 durations for such scenarios. The exposure durations modeled are based on reported durations of product
3078 use and may not reflect reasonable durations of such dermal contact with impeded evaporation. In many
3079 cases, the exposure duration modeled could exceed a reasonable duration of such dermal contact with a
3080 wet rag, for example. Therefore, dermal exposure results based on the higher-end durations (*i.e.*, those
3081 associated with the moderate- and high-intensity user scenarios) may overestimate dermal exposure.
3082

3083 For scenarios using the absorption fraction model that are less likely to involve dermal contact with
3084 impeded evaporation, there is uncertainty surrounding the assumption that the entire mass present in the
3085 thin film is absorbed and retained in the stratum corneum following a use event. The fractional
3086 absorption factor estimated based on on Frasch and Bunge (2015) is intended to be applied to the mass
3087 retained in the stratum corneum after exposure; it does not account for evaporation from the skin surface
3088 during the exposure event. Therefore, the assumption that the entire amount of chemical present in the
3089 thin film on the skin surface is retained in the stratum corneum may lead to uncertainty in the absorbed
3090 dose estimate.
3091

3092 ***Inhalation Modeling for Outdoor Scenarios***

3093 The CEM model does not currently accommodate outdoor scenarios. For products that are intended to
3094 be used outdoors, modifications to the CEM inputs were made to simulate an outdoor scenario by
3095 adjusting Zone 1 parameters (which represents the room of use or use environment). In modeling pepper
3096 spray, the garage was selected as the room of use, but the room volume was changed to 16 m³ to
3097 represent a half-dome chemical cloud around the person using the product. Additionally, the air
3098 exchange rate for Zone 1 was set to 100 to reflect the high rate between the cloud and the rest of outside.
3099 The interzonal ventilation rate was set to 0, which effectively blocks the exchange of air between Zone 1
3100 and the rest of the house. Thus, the concentrations users are exposed to inside the home after product use
3101 is zero. In the outside scenario, bystanders in the home are assumed to have zero exposures. However,
3102 bystanders in the outdoor environment were not modeled, but could potentially be exposed to similar
3103 levels as the user.
3104

3105 ***Bystanders***

3106 Inhalation exposures for bystanders in the home are estimated assuming that they are not present in the
3107 room of use (*i.e.*, Zone 1) during the use event. This is unlike the product user or consumer, who is
3108 assumed to be present in Zone 1 for the duration of the use event. It is possible that bystanders could be
3109 in the room of use, in which case their exposure levels may approach those estimated for the product
3110 users.

3111 **2.3.2.6.2 Data Uncertainties**

3112 ***Product Data***

3113 The products and articles assessed in this Risk Evaluation are largely based on EPA's 2017 Use and
3114 Market Profile for TCE, as well as EPA's Use Report and Preliminary Information on Manufacturing,
3115 Processing, Distribution, Use, and Disposal: TCE, which provide information on commercial and
3116 consumer products available in the US marketplace at that time (U.S. EPA, 2017c, h). While it is
3117 possible that some products may have changed since 2017, EPA believes that the timeframe is recent
3118 enough to represent the ongoing and reasonably foreseen consumer uses. Additional sources of product
3119 information were evaluated, including product databases such as the NIH Household Product Survey
3120 and EPA's Chemical and Products Database (CPDat), and internet searches using CASRNs, chemical

3121 names, and trade names to identify supplier and retail sites for available products, product labels, and
3122 safety data sheets (SDSs). EPA also makes use of communications with companies, industry groups,
3123 environmental organizations, and public comments to supplement the information when possible. There
3124 are limited available product databases and they are not necessarily complete nor consistently updated
3125 and general internet searches cannot guarantee entirely comprehensive product identification. Therefore,
3126 it is possible that the entire universe of products may not have been identified, or that certain changes in
3127 the universe of products may not have been captured, due to market changes or research limitations.

3128
3129 ***Use Patterns***

3130 A comprehensive survey of consumer use patterns in the Westat Survey, was used to parameterize
3131 critical consumer modeling inputs, based on applicable product and use categories. This large survey of
3132 over 4,920 completed questionnaires, obtained through a randomized sampling technique, is highly
3133 relevant because the primary purpose was to provide statistics on the use of solvent-containing consumer
3134 products for the calculation of exposure estimates. The survey focused on 32 different common
3135 household product categories, generally associated with cleaning, painting, lubricating, and automotive
3136 care. Although there is uncertainty due to the age of the use pattern data, as specific products in the
3137 household product categories have likely changed over time, EPA believes that the use pattern data
3138 presented in the Westat survey reflect reasonable estimates for current use patterns of similar product
3139 types.

3140
3141 A crosswalk was completed to select the most appropriate Westat survey category for each consumer
3142 conditions of use in the current Risk Evaluation. Although detailed product descriptions were not
3143 provided in the Westat survey, a list of product brands and formulation type in each category was useful
3144 in pairing the Westat product categories to the scenarios being assessed. In most cases, the product
3145 categories in the Westat survey aligned reasonably well with the products being assessed. Where Westat
3146 survey product categories did not align well with consumer conditions of use, professional judgment
3147 was used to select the most appropriate Westat category. This involved considering the reasonableness
3148 of the duration and mass used, as well as comparing the primary formulation type. For a limited number
3149 of scenarios, technical fact sheets or labels with information on product use amounts were available, and
3150 this information was used in the assessment as needed.

3151
3152 Westat's overall respondent pool of the survey was large, but the number of users in each product
3153 category was varied, with some product categories having a much smaller pool of respondents than
3154 others. Product categories such as spot removers, cleaning fluids, glues and adhesives, lubricants, paints,
3155 paint strippers, fabric water repellents, wood stains, tire cleaners, engine degreasers, carburetor cleaners,
3156 and specialized electronic cleaners had sample sizes ranging from roughly 500 to 2,000 users; whereas,
3157 categories such as shoe polish, adhesive removers, rust removers, primers, outdoor water repellents,
3158 gasket removers and brake cleaners had sample sizes of fewer than 500 users.

3159
3160 Ease of access to products on-line or in big box stores (like home improvement stores), readily
3161 accessible how-to videos, and a consumer movement toward more do-it-yourself projects with products
3162 containing the chemical of concern could impact the representativeness of the consumer use patterns
3163 described within the Westat Survey and may lead to an underestimate of overall consumer exposure. In
3164 addition, patterns of consumer use for certain subpopulations (*e.g.*, tribal communities) may not be
3165 represented in the survey data. Thus, there is a some uncertainty associated with the representativeness
3166 of the consumer use patterns described within the Westat Survey and present day consumer use patterns.

3167
3168

3169 **Emission Rate**

3170 The higher-tier Multi-Chamber Concentration and Exposure Model (MCCEM) was considered by EPA
3171 for use in estimating inhalation exposures from consumer conditions of use; however, key data (*i.e.*,
3172 chamber emission data) were not reasonably available. Therefore, the model used (CEM 2.1) estimates
3173 of emission rate based on chemical properties and emission profiles matching a spray or liquid
3174 application.

3175 **2.3.2.7 Confidence in Consumer Exposure Scenarios**

3176 The considerations and confidence ratings for the acute inhalation consumer exposure scenarios are
3177 displayed in Table 2-86. Overall, there is moderate to high or high confidence in the consumer
3178 inhalation exposure modeling approach and results. This is based on strength of the model employed, as
3179 well as the quality and relevance of the default and user-selected/varied modeling inputs. CEM 2.1 is
3180 peer reviewed, publicly available, and was designed to estimate inhalation and dermal exposures from
3181 household uses of products and articles. CEM 2.1 uses central-tendency default values for sensitive
3182 inputs such as building and room volumes, interzonal ventilation rate, and air exchange rates. These
3183 parameters were not varied by EPA due to EPA having greater confidence in the central tendency inputs
3184 for such factors that are outside of a user's control (unlike, *e.g.*, mass used, use duration). These defaults
3185 are sourced from EPA's exposure factors handbook ([U.S. EPA, 2011c](#)). The one default value with a
3186 high-end input is the overspray fraction, which is used in the aerosol or spray scenarios. It assumes a
3187 certain percentage is immediately available for inhalation. However, due to TCE's physical chemical
3188 properties, this is a not a sensitive parameter. In the 2014 TCE Risk Assessment, this parameter was
3189 varied from 1% to 25% and resulted in almost no difference in the modeled peak air concentration ([U.S.
3190 EPA, 2014b](#)). The default emission rate from a thin film is estimated within the model based on TCE's
3191 molecular weight and vapor pressure, as described in the Chinn equation¹⁹ and is deemed appropriate
3192 given the lack of consumer product chamber emission data. The confidence in the user-selected varied
3193 inputs (*i.e.*, mass used, use duration, and weight fraction) are moderate to high, depending on the
3194 condition of use; the sources of these data include the Westat Survey ([U.S. EPA, 1987](#)) and company-
3195 generated safety data sheets (SDSs). The representativeness of the consumer use patterns (duration of
3196 use, amount used, room of use, etc.) described in the Westat Survey ([U.S. EPA, 1987](#)) is believed to
3197 remain strong when compared to present day consumer use patterns even though some aspects of the use
3198 may have changed. There is some uncertainty associated with the representativeness of the consumer
3199 use patterns described within the Westat Survey and present day consumer use patterns. In some cases,
3200 professional judgment was used in selection of room of use, which sets the volume for modeling zone 1.

3201
3202 The considerations and confidence ratings for the acute dermal consumer exposure scenarios are
3203 displayed in Table 2-87. Overall, there is a moderate confidence in the consumer dermal exposure
3204 modeling approach and results. For scenarios evaluated using the permeability model, there is
3205 uncertainty related to the potential for and duration of dermal contact with impeded evaporation (*i.e.*,
3206 dermal exposure scenarios wherein volatilization from the skin surface is inhibited). For scenarios
3207 evaluated using the fraction absorbed model, there is uncertainty related to the application of the
3208 fractional absorption term to the amount of chemical within the thin film (*i.e.*, amount retained). Neither
3209 approach incorporates any losses of chemical during the exposure event. However, in doing so, the
3210 model assumes that there are no losses throughout the entire use duration. These factors contribute to the
3211 overall lower confidence in dermal exposure estimates.
3212

¹⁹ The value of k is determined from an empirical relationship, developed by ([Chinn, 1981](#)), between the time required for 90% of a pure chemical film to evaporate ($EvapTime$) and the chemical's molecular weight (MW) and vapor pressure (VP): $EvapTime = 145 / (MW \times VP)^{0.9546}$, $k = \ln(10) / (EvapTime \times 60)$, where k = first-order rate constant for emission decline (min⁻¹), MW = molecular weight, VP = vapor pressure.

3213 An additional point of confidence in the consumer modeling approach related to capturing variation and
 3214 estimating results for a range of exposure levels. Although a probabilistic assessment was not employed,
 3215 EPA did use up to three inputs for three key modeling parameters: mass used, use duration, and weight
 3216 fraction. The first two parameters are based on the Westat survey data, which presented a distribution of
 3217 responses. For these parameters, a low-end (10th percentile), central tendency (50th percentile), and high-
 3218 end (95th percentile) was used in modeling. Weight fraction inputs were based on product SDSs, so the
 3219 full range of reported weight fractions was reflected in the modeling inputs using either minimum and
 3220 maximum weight fractions or using minimum and maximum weight fractions along with a mid-point
 3221 weight fraction. For subcategories with only one product, only one weight fraction was used in the
 3222 modeling. Otherwise, these parameters were varied in all possible combinations, resulting in up to 27
 3223 iterations for a given modeling scenario.

3225 Consumer exposure monitoring studies associated with conditions of use are not reasonably available
 3226 for direct comparison with modeled results. Indoor air monitoring data are available but are not
 3227 associated with specific conditions of use or TCE-containing consumer products and are therefore only
 3228 relevant for considerations of background levels of TCE in homes.

3230 While there were certain scenarios that have moderate confidence ratings rather than high confidence for
 3231 user-selected varied inputs, there are not reasonably available alternative inputs that would serve to
 3232 increase confidence in the modeling estimates. For example, in modeling film cleaner, the alternative to
 3233 applying mass used and use duration from the rust remover Westat survey scenario is professional
 3234 judgment, which is unlikely to decrease uncertainty.

Table 2-86. Confidence Ratings for Acute Inhalation Consumer Exposure Modeling Scenarios

Consumer Condition of User			Confidence in Model Used ¹	Confidence in Model Default Values ²	Confidence in User-Selected Varied Inputs				Overall Confidence
Category	Subcategory	Form			Mass Used ³	Use Duration ⁴	Weight Fraction	Room of Use ⁵	
Solvents for Cleaning and Degreasing	Brake & Parts Cleaner	Aerosol	High	High	High	High	High	High	High
Solvents for Cleaning and Degreasing	Electronic Degreaser/Cleaner	Aerosol	High	High	High	High	High	High	High
Solvents for Cleaning and Degreasing	Electronic Degreaser/Cleaner	Liquid	High	High	High	High	High	High	High
Solvents for Cleaning and Degreasing	Spray Degreaser/Cleaner	Aerosol	High	High	High	High	High	High	High
Solvents for Cleaning and Degreasing	Liquid Degreaser/Cleaner	Liquid	High	High	High	High	High	High	High
Solvents for Cleaning and Degreasing	Gun Scrubber	Aerosol	High	High	High	Moderate	High	Moderate	Moderate to High
Solvents for Cleaning	Gun Scrubber	Liquid	High	High	High	Moderate	High	Moderate	Moderate to High

Consumer Condition of User			Confidence in Model Used ¹	Confidence in Model Default Values ²	Confidence in User-Selected Varied Inputs				Overall Confidence
Category	Subcategory	Form			Mass Used ³	Use Duration ⁴	Weight Fraction	Room of Use ⁵	
and Degreasing									
Solvents for Cleaning and Degreasing	Mold Release	Aerosol	High	High	Moderate	High	High	High	Moderate to High
Solvents for Cleaning and Degreasing	Tire Cleaner	Aerosol	High	High	High	High	High	High	High
Solvents for Cleaning and Degreasing	Tire Cleaner	Liquid	High	High	High	High	High	High	High
Lubricants and Greases	Tap & Die Fluid	Aerosol	High	High	High	High	High	High	High
Lubricants and Greases	Penetrating Lubricant	Aerosol	High	High	High	High	High	High	High
Adhesives and Sealants	Solvent-based Adhesive & Sealant	Liquid	High	High	High	High	High	High	High
Adhesives and Sealants	Mirror-edge Sealant	Aerosol	High	High	Moderate	Moderate	High	High	High
Adhesives and Sealants	Tire Repair Cement/ Sealer	Liquid	High	High	High	High	High	High	High
Cleaning and Furniture Care Products	Carpet Cleaner	Liquid	High	High	Moderate	Moderate	High	Moderate	Moderate to High
Cleaning and Furniture Care Products	Spot Remover	Aerosol	High	High	High	High	High	High	High
Cleaning and Furniture Care Products	Spot Remover	Liquid	High	High	High	High	High	High	High
Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings	Aerosol	High	High	Moderate	Moderate	High	Moderate	Moderate to High
Apparel and Footwear Care Products	Shoe Polish	Aerosol	High	High	High	High	High	High	High
Other Consumer Uses	Fabric Spray	Aerosol	High	High	High	High	High	High	High

Consumer Condition of User			Confidence in Model Used ¹	Confidence in Model Default Values ²	Confidence in User-Selected Varied Inputs				Overall Confidence
Category	Subcategory	Form			Mass Used ³	Use Duration ⁴	Weight Fraction	Room of Use ⁵	
Other Consumer Uses	Film Cleaner	Aerosol	High	High	Moderate	Moderate	High	Moderate	Moderate to High
Other Consumer Uses	Hoof Polish	Aerosol	High	NA	Moderate	Moderate	High	High	Moderate to High
Other Consumer Uses	Pepper Spray	Aerosol	High	NA	High	High	High	Moderate	Moderate to High
Other Consumer Uses	Toner Aid	Aerosol	High	High	Moderate	Moderate	High	Moderate	Moderate to High

¹The inhalation models within CEM 2.1 have been peer reviewed, are publicly available, and have been applied in a manner intended – to exposures associated with uses of household products and/or articles.

²These values include inputs such as building and room volumes, interzonal ventilation rates, and air exchange rates. These default values are all central tendency values (*i.e.*, mean or median values) sourced from EPA’s Exposure Factors Handbook ([U.S. EPA, 2011c](#)).

³Mass Used is primarily sourced from the Westat ([1987](#)) survey, which received a high-quality rating during data evaluation and has been applied in previous agency assessments. Two conditions of use had product information that was used instead of Westat (gun scrubber and pepper spray).

⁴Use Duration is primarily sourced from the Westat ([1987](#)) survey, which received a high-quality rating during data evaluation and has been applied in previous agency assessments. One condition of use had product information that was used instead of Westat (pepper spray). Relevance of these inputs from the Westat survey to the specific consumer condition of use they were applied to is considered in the reported confidence ratings.

⁵Room of use (zone 1 in modeling) is informed by responses in the Westat ([1987](#)) survey, which received a high-quality rating during data evaluation, although professional judgment is also applied for some scenarios. The reasonableness of these judgements is considered in the reported confidence ratings.

3237
3238

Table 2-87. Confidence Ratings for Acute Dermal Consumer Exposure Modeling Scenarios

Consumer Condition of User			Confidence in Model Used ¹	Confidence in Model Default Values ²	Confidence in User-Selected Inputs			Overall Confidence
Category	Subcategory	Form			Use Duration ³	Weight Fraction	Kp ⁴	
Solvents for Cleaning and Degreasing	Brake & Parts Cleaner	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Electronic Degreaser/Cleaner	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Electronic Degreaser/Cleaner	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
	Spray Degreaser/Cleaner	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Liquid Degreaser/Cleaner	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
	Gun Scrubber	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Gun Scrubber	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
	Mold Release	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate

Consumer Condition of User			Confidence in Model Used ¹	Confidence in Model Default Values ²	Confidence in User-Selected Inputs			Overall Confidence
Category	Subcategory	Form			Use Duration ³	Weight Fraction	Kp ⁴	
	Tire Cleaner	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Tire Cleaner	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
Lubricants and Greases	Tap & Die Fluid	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Penetrating Lubricant	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
Adhesives and Sealants	Solvent-based Adhesive & Sealant	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
	Mirror-edge Sealant	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Tire Repair Cement/ Sealer	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
Cleaning and Furniture Care Products	Carpet Cleaner	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
	Spot Remover	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Spot Remover	Liquid	Low to Moderate	Moderate	Low	High	High	Moderate
Arts, Crafts, and Hobby Materials	Fixatives & Finishing Spray Coatings	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
Apparel and Footwear Care Products	Shoe Polish	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
Other Consumer Uses	Fabric Spray	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Film Cleaner	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Hoof Polish	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Pepper Spray	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate
	Toner Aid	Aerosol	Low to Moderate	Moderate	Low	High	High	Moderate

¹The dermal models used (permeability and absorption fraction models within CEM 2.1) have been peer reviewed, are publicly available, and have been applied in a manner intended – to estimate exposures associated with uses of household products and/or articles. The low to moderate confidence reflects uncertainties discussed in Section 2.3.2.6.1.

²These values include inputs such as surface area to body weight ratios reflecting dermal contact area and film thickness applied in the absorption fraction model. These values are sourced from EPA’s Exposure Factors Handbook ([U.S. EPA, 2011c](#)).

³The dermal permeability coefficient (K_p) used (0.0023 cm/hr) is derived from the measured flux for TCE (430 nmol/cm²-min [5.65E-02 mg/cm²-min]) for neat TCE on human skin from ([Kezic et al. 2001](#)).

⁴The use duration is primarily sourced from the Westat (1987) survey, which received a high-quality rating during data evaluation and has been applied in previous agency assessments. The dermal modeling receives a “low” confidence for this criterion due to the uncertainty associated with how accurately an exposure event duration reflects dermal contact time.

2.3.3 Potentially Exposed or Susceptible Subpopulations

TSCA requires that a Risk Evaluation “determine whether a chemical substance presents an unreasonable risk of injury to health or the environment, without consideration of cost or other non-risk factors, including an unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant to the Risk Evaluation by the Administrator, under the conditions of use.” TSCA § 3(12) states that “the term ‘*potentially exposed or susceptible subpopulation*’ means a group of individuals within the general population identified by the Administrator who, due to either greater susceptibility or greater exposure, may be at greater risk than the general population of adverse health effects from exposure to a chemical substance or mixture, such as infants, children, pregnant women, workers, or the elderly.”

During Problem Formulation ([U.S. EPA, 2018d](#)), EPA identified potentially exposed or susceptible subpopulations for further analysis during the development and refinement of the life cycle, conceptual models, exposure scenarios, and analysis plan. In this section, EPA addresses the potentially exposed or susceptible subpopulations identified as relevant based on *greater exposure*. EPA addresses the subpopulations identified as relevant based on *greater susceptibility* in Section 3.2.5.2.

In developing the final Risk Evaluation, EPA analyzed the reasonably available information to ascertain whether some human receptor groups may have greater exposure than the general population to the hazard posed by TCE. Exposures of TCE would be expected to be higher amongst groups living near industrial facilities, groups with TCE containing products in their homes, workers who use TCE as part of typical processes, and groups who have greater age- and route-specific intake rates compared to the general population.

Of the human receptors identified in the previous sections, EPA identifies the following as potentially exposed or susceptible subpopulations due to their greater exposure to TCE and considered them in the Risk Evaluation:

Workers and occupational non-users (ONUs). EPA reviewed monitoring data found in published literature including both personal exposure monitoring data (direct exposure) and area monitoring data (indirect exposures) and identified data sources that contain measured monitoring data and or/estimated data for the various conditions of use (including import and processing of TCE). Exposure estimates were developed for employees (males and female workers of reproductive age) exposed to TCE as well as non-users or workers exposed to TCE indirectly by being in the same work area of the building. Also, adolescents and female workers of reproductive age (>16 to less than 50 years old) were also considered as potentially exposed or susceptible subpopulations

Consumers/product users and bystanders associated with consumer use. TCE has been identified as being used in products available to consumers. Sections 2.3.2.1 and 2.3.2.2 provide an overview of exposure pathways considered for the consumer assessment. Furthermore, EPA identified consumers and bystanders associated with use of TCE-containing consumer products as a potentially exposed and susceptible subpopulation due to greater exposure as described in Section 2.3.3. For example, higher-intensity users (*i.e.*, those using consumer products for longer durations and in greater amounts) were considered and evaluated in Section 2.3.2. In addition, consumers are considered to include adults as well as children as young as age 11. Bystanders in the home exposed via inhalation are considered to include any age group from infant (including breast fed infants) to adult (including elderly), including pregnant women and/or women of reproductive age. Younger lifestages are likely exposed to higher internal dose concentrations of TCE than adults due to relative physiological differences in body weight,

3287 breathing rate, and other parameters. However, only some individuals within the general population may
 3288 use these products. Therefore, those who do use these products are a potentially exposed or susceptible
 3289 subpopulation due to greater exposure. Exposures for these subpopulations are considered and/or
 3290 evaluated in Section 2.3.2.5 (Table 2-32 through Table 2-82.).

3291
 3292 Additionally, higher-intensity users (*i.e.*, those using consumer products for longer durations and in
 3293 greater amounts) were considered and evaluated. Exposures and risks for these subpopulations are
 3294 considered and evaluated herein. Receptor categories overlap among highly exposed and potentially
 3295 exposed subpopulations, as individuals may belong to multiple PESS groups.

3296
 3297 In developing dermal exposure scenarios, EPA quantified age and sex-specific differences. For TCE,
 3298 exposure scenarios that involve potentially exposed or susceptible subpopulations considered age-
 3299 specific behaviors, activity patterns, and exposure factors unique to those subpopulations. EPA used the
 3300 Exposure Factors Handbook ([U.S. EPA, 2011c](#)) to inform body weights, intake rates, and body surface
 3301 areas for children and adults. Distinct dermal exposure estimates are provided for adults (including
 3302 women of reproductive age) and children (Section 2.3.2.5.1).

3303
 3304 For occupational exposures, EPA assessed exposures to workers and ONUs from all TCE conditions of
 3305 use. Table 2-88. presents the percentage of employed workers and ONUs who may experience either
 3306 greater exposure or biological susceptibility within select industry sectors relevant to TCE conditions of
 3307 use. The percentages were calculated using Current Population Survey (CPS) data for 2017 ([U.S. BLS,
 3308 2017](#)). CPS is a monthly survey of households conducted by the Bureau of Census for the Bureau of
 3309 Labor Statistics and provides a comprehensive body of data on the labor force characteristics. Statistics
 3310 for the following subpopulations of workers and ONUs are provided: adolescents, men and women of
 3311 reproductive age, and the elderly. For the purpose of this assessment, EPA considers “reproductive age”
 3312 as age >16 to less than 50 years old.

3313
 3314 As shown in Table 2-88., men make up the majority of the workforce in manufacturing sectors. In other
 3315 sectors, women (including those of reproductive age and elderly women) make up nearly half of the
 3316 workforce. Adolescents are generally a small part of the total workforce. Table 2-89. presents further
 3317 breakdown on the percentage of employed adolescents by industry subsectors. As shown in the tables,
 3318 they comprise only 1.2% percent of the manufacturing workforce, and only as high as 3.7% for other
 3319 services such as dry cleaning that fall under a COU for TCE.

3320
 3321 **Table 2-88. Percentage of Employed Persons by Age, Sex, and Industry Sector**

Age group	Sex	Manufacturing	Wholesale and Retail Trade	Professional and Business Services	Other Services
Adolescent (16-19 years)	Male	0.8%	3.0%	0.7%	1.4%
	Female	0.4%	3.2%	0.5%	1.7%
Reproductive age (16-54 years)	Male	52.9%	42.8%	44.4%	35.2%
	Female	22.2%	35.4%	32.8%	38.4%
Elderly (55+)	Male	17.5%	12.3%	13.4%	13.1%
	Female	7.3%	9.6%	9.4%	13.3%

3322 Source: ([U.S. BLS, 2017](#)). While statistics on pregnant women are not reasonably available, CPS provides data on the
 3323 number of employed female workers by age group, which allows for determination of the number of employed women of
 3324 reproductive age. Percentage calculated using CPS Table 14, “Employed persons in nonagricultural industries by age, sex,
 3325 race, and Hispanic or Latino ethnicity.”

3326

3327

Table 2-89. Percentage of Employed Adolescent by Detailed Industry Sector

Sector	Subsector	Adolescent (16-19 years)
Manufacturing	All	1.2%
Wholesale and retail trade	Wholesale trade	1.4%
Professional and business services	Waste management and remediation services	0.9%
Other services	Repair and maintenance	3.1%
	Dry cleaning and laundry services	3.7%

3328 Source: ([U.S. BLS, 2017](#)). Percentage of adolescent calculated using CPS table 18b, “Employed persons by detailed industry
3329 and age.”

3330

3331 The CPS uses 2012 Census industry classification, which was derived from the 2012 NAICS. The
3332 Census classification uses the same basic structure as NAICS but is generally less detailed. TCE
3333 conditions of use fall under the following Census industry sectors:

3334

- 3335 • Manufacturing – The Manufacturing sector comprises establishments engaged in the mechanical,
3336 physical, or chemical transformation of materials, substances, or components into new products.
3337 Establishments in the sector are often described as plants, factories, or mills. For TCE, this sector covers
3338 most conditions of use that occur in an industrial setting, including: Manufacturing, Processing as a
3339 Reactant, Formulation of Aerosol and Non-Aerosol Products, the vast majority of facilities likely
3340 engaged in Vapor Degreasing (all degreaser types), Cold Cleaning, Metalworking Fluids, Adhesives,
3341 Sealants, Paints and Coatings, Other Industrial Uses, Industrial Processing Aids and Printing and
3342 Copying. This sector also covers cement manufacturing facilities that may burn waste containing TCE
3343 for energy recovery. Printing and Copying worker information may also be captured under the
3344 Information sector (see below).
- 3345 • Wholesale and retail trade – The wholesale trade sector comprises establishments engaged in
3346 wholesaling merchandise, generally without transformation, and rendering services incidental to the sale
3347 of merchandise. Wholesalers normally operate from a warehouse or office. This sector likely covers
3348 facilities that are engaged in the repackaging TCE or products and formulations containing TCE. The
3349 retail trade sector comprises establishments engaged in retailing merchandise and rendering services
3350 incidental to the sale of merchandise.
- 3351 • Professional and business services – This sector comprises establishments that specialize in a
3352 wide range of services. This sector covers waste management and remediation services, which includes
3353 establishments that may handle, dispose, treat, and recycle wastes containing TCE.
- 3354 • Other services – This sector comprises establishments engaged in providing services not
3355 specifically provided for elsewhere in the classification system. For TCE, this sector covers the vast
3356 majority of commercial repair and maintenance facilities that are likely to use TCE for Aerosol
3357 Applications (spray degreasing). The sector also covers the use of TCE in spot cleaning.
3358

3359 **3 HAZARDS**

3360 **3.1 Environmental Hazards**

3361 **3.1.1 Approach and Methodology**

3362 During scoping and Problem Formulation ([U.S. EPA, 2018d](#)), EPA reviewed potential environmental
3363 health hazards associated with TCE. EPA identified the following sources of environmental hazard data:
3364 European Chemicals Agency (ECHA) Database ([ECHA, 2017](#)), European Union (EU) environmental
3365 risk assessment on TCE ([ECHA, 2004](#)) EPA Chemical Test Rule Data ([U.S. EPA, 2017a](#)) Environment
3366 and Climate Change Canada (ECCC) Risk Assessment for Trichloroethylene ([Environment Canada and
3367 Health Canada, 1993](#)) and Ecological Hazard Literature Search Results in Trichloroethylene (CASRN
3368 79-01-6) Bibliography: Supplemental File for the TSCA Scope Document ([U.S. EPA, 2017i](#)).

3369
3370 EPA completed the review of environmental hazard data/information sources during Risk Evaluation
3371 using the data quality review evaluation metrics and the rating criteria described in the Application of
3372 Systematic Review in TSCA Risk Evaluations ([U.S. EPA, 2018b](#)). Studies were rated high, medium, or
3373 low for quality. The data quality evaluation results are outlined in the [*Data Quality Evaluation of
3374 Environmental Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*] and indicate that most of the
3375 acceptable studies for TCE were rated high or medium for quality. With the reasonably available data,
3376 EPA used studies rated high or medium for quantitative analysis during data integration, and used
3377 studies rated low qualitatively to characterize the environmental hazards of trichloroethylene. Any study
3378 assigned an overall quality level of unacceptable was not used for data integration. Mechanistic studies
3379 were used qualitatively, because toxicity values measuring a population-level effect (*e.g.*, mortality,
3380 development, growth) were available to use quantitatively.

3381 **3.1.2 Hazard Identification**

3382 ***Toxicity to Aquatic Organisms***

3383 EPA identified 25 acceptable studies that contained aquatic toxicity data, including data for fish,
3384 amphibians, aquatic invertebrates, and algae. Aquatic toxicity studies considered in this assessment are
3385 summarized in the text below, and the data EPA used quantitatively are displayed in Table 3-1. As
3386 stated in Section 2.1, TCE is not expected to accumulate in aquatic organisms due to low measured
3387 BCFs and an estimated BAF.

3388

3389 ***Fish Toxicity***

3390 Acute fish data for TCE were identified in six acceptable studies representing four different species,
3391 including fresh and saltwater species (fathead minnows [*Pimephales promelas*], American flagfish
3392 [*Jordanella floridae*], bluegill [*Lepomis macrochirus*], and sheepshead minnow [*Cyprinodon
3393 variegatus*]). In these studies, all used quantitatively in this assessment, the lethal concentrations at
3394 which 50% of test organisms die (LC₅₀s) ranged from 28.28 mg/L to 66.8 mg/L ([Geiger et al., 1985](#));
3395 ([Broderius et al., 2005](#); [Smith et al., 1991](#); [Ward et al., 1986](#); [Buccafusco et al., 1981](#); [Alexander et al.,
3396 1978](#)). Ward et al. (1986) tested a saltwater species, sheepshead minnow, and derived an LC₅₀ of 52
3397 mg/L. Because this value is within the range of values for freshwater species, and because baseline
3398 narcosis is the expected mode of action for TCE in both freshwater and saltwater fish ([Alexander et al.,
3399 1978](#)); ([Ward et al., 1986](#)); ([Broderius et al., 2005](#)), freshwater and saltwater LC₅₀ values were assessed
3400 together during data integration. EPA calculated a geometric mean of 42 mg/L using LC₅₀s from high
3401 and medium quality studies. Acute fish data for TCE also included a 96-hour EC₅₀ (the concentration at
3402 which 50% of test organisms exhibit an effect) of 21.9 mg/L for loss of equilibrium in a freshwater
3403 species, fathead minnows ([Alexander et al., 1978](#)). This study was rated high for quality.

3404
3405 Subchronic fish data were also identified in two acceptable studies representing two species. Smith et al.
3406 (1991) established a 10-day NOEC of 5.758 mg/L and a LOEC of 21.233 mg/L resulting in a chronic
3407 value (ChV) of 11 mg/L for fry survival in American flagfish (*Jordanella floridae*). Schell (1987)
3408 established a 10-day LC₅₀ of 82 mg/L in Japanese medaka (*Oryzias latipes*) embryos. The author found
3409 that lethality occurred at every stage of development for embryos. Schell also observed lesion
3410 development in the embryos after exposure in a dose-dependent pattern, with higher test concentrations
3411 resulting in earlier formation of lesions. Both abovementioned sub-chronic studies received a high rating
3412 for quality during data evaluation, and EPA used the data quantitatively.

3413
3414 Chronic fish data for TCE were identified in two acceptable studies representing two freshwater species,
3415 American flagfish (*Jordanella floridae*) and fathead minnows (*Pimephales promelas*). In addition to the
3416 subchronic value mentioned above, Smith et al. (1991) established a 28-day NOEC of 10.568 mg/L and
3417 a LOEC of 20.915 mg/L for fry survival in American flagfish. This allowed the authors to establish a
3418 28-day ChV of 14.85 for fry survival. Broderius et al. (2005) established an EC₅₀ for growth of 11.8
3419 mg/L and an EC₂₀ for growth of 7.88 mg/L in a 32-day fathead minnow study. Both studies were rated
3420 high for quality during data evaluation. EPA used the chronic data in these studies quantitatively.

3421
3422 Broderius et al. (2005) reported baseline narcosis as TCE's expected mode of action in fish. This is
3423 corroborated by other studies, including Ward, et al. (1986), which observed signs of narcosis in
3424 sheepshead minnows, a saltwater species, with observations of fish spinning at 357 mg/L. EPA used this
3425 information qualitatively in this assessment. Alexander et al. (1978) reported signs of narcosis in fathead
3426 minnows, a freshwater species, with a 96-hour EC₁₀ of 13.7 mg/L, EC₅₀ of 21.9 mg/L, and EC₉₀ of 34.9
3427 mg/L. The effect reported was loss of equilibrium. EPA used the 96-hour EC₅₀ from Alexander et al.
3428 (1978) quantitatively in this assessment.

3429
3430 Two mechanistic studies were also available for fish. Hayashi et al. (1998) examined genotoxicity in
3431 rose bitterling (*Rhodeus ocellatus*) embryos using a new assay developed by the authors. The authors
3432 found an increase in structural chromosomal aberrations and micronuclei in cells from embryos,
3433 establishing a NOEC of 300 mg/L and a LOEC of 3,000 mg/L. The authors noted the low sensitivity of
3434 the assay and suggested using more embryos in the future. This study was rated medium for quality.
3435 Another *in vitro* study, rated low for quality, derived an EC₅₀ of 11.6 mg/L for the inhibition of total
3436 protein content in a fathead minnow cell line (Dierickx, 1993). Because this cellular effect is not directly
3437 tied to a population effect, and because of the low-quality rating, this study was not used with the other
3438 acute data to calculate a geometric mean of EC₅₀s during data integration; however, the results
3439 contribute to the qualitative description of mechanistic effects of TCE exposure in fish.

3440 3441 *Amphibian Toxicity*

3442 For amphibians, acute data were available from three acceptable studies, representing one species,
3443 African clawed frogs (*Xenopus laevis*). All three studies were rated either high or medium for quality
3444 during data evaluation. The studies included 96-hour LC₅₀ values ranging from 412.0 mg/L to 490.0
3445 mg/L (McDaniel et al., 2004; Fort et al., 2001; Fort et al., 1993; Fort et al., 1991). EPA used these
3446 studies quantitatively, and during data integration, a geometric mean of all LC₅₀s was calculated at 438
3447 mg/L.

3448
3449 Sub-chronic data were also available for amphibians, from four acceptable studies representing five
3450 different species (green frog [*Lithobates clamitans*, formerly *Rana clamitans*], wood frog [*Lithobates*
3451 *sylvatica*, formerly *Rana sylvatica*], African clawed frogs [*Xenopus laevis*], American toad [*Bufo*
3452 *americanus*], and spotted salamander [*Ambystoma maculatum*]). These studies reported 96-hr EC₅₀

3453 values for developmental effects ranging from 22 mg/L to > 85 mg/L ([McDaniel et al., 2004](#); [Fort et al.,](#)
3454 [2001](#); [Fort et al., 1993](#); [Fort et al., 1991](#)). EPA used these data quantitatively, and during data
3455 integration, a geometric mean of all definitive EC₅₀s for developmental effects was calculated at 34
3456 mg/L. These developmental effects are irreversible and would result in effects that last throughout the
3457 animals' lifetime. They could also result in premature death. Developmental effects described included
3458 gut miscoiling and microphthalmia, muscular kinking, incomplete development of the mouth, and severe
3459 hypognathia in African clawed frogs, and edema and dorsal flexure of the tail and notochord in tadpoles
3460 of green frogs, wood frogs, American toads, and spotted salamanders ([McDaniel et al., 2004](#); [Fort et al.,](#)
3461 [1993](#); [Fort et al., 1991](#)). As stated previously, [McDaniel et al. \(2004\)](#) reported signs of narcosis in green
3462 and wood frog tadpoles.

3463
3464 Limited chronic data were also available for amphibians. [McDaniel et al. \(2004\)](#) included a chronic
3465 toxicity test for amphibians on American toad tadpoles. However, chronic toxicity values for deformities
3466 were not established, because more than 25% of control animals exhibited deformities. Mortality,
3467 however, was below 25% in controls, and authors saw no significant difference in mortality between test
3468 concentrations (4 mg/L and 1 mg/L) and controls. This suggests that survival rates for American toad
3469 tadpoles would not be affected by 4 mg/L of TCE. It should be noted that acute exposure data show
3470 American toads are less sensitive to TCE than other amphibian species, so they may also be less
3471 sensitive to chronic exposures. EPA used this information qualitatively.

3472
3473 [McDaniel et al. \(2004\)](#) reported signs of narcosis in green and wood frog tadpoles.

3474 3475 *Aquatic Invertebrate Toxicity*

3476 For aquatic invertebrates, acute data were found in seven acceptable studies representing five different
3477 species, including fresh and saltwater species. Five of these studies included LC₅₀ values or EC₅₀ values
3478 measuring immobilization rated high or medium for quality; these values ranged from 7.75 mg/L to
3479 43.14 mg/L for *Daphnia magna*, *Ceriodaphnia dubia*, and *Mysidopsis bahia* ([Dobaradaran et al., 2012](#);
3480 [Niederlehner et al., 1998](#); [Abernethy et al., 1986](#); [Ward et al., 1986](#); [LeBlanc, 1980](#)). The only saltwater
3481 species tested, *Mysidopsis bahia*, had an LC₅₀ of 14 mg/L, which is within the of the range of values for
3482 freshwater species. EPA used these data quantitatively. Additionally, [Ward et al. \(1986\)](#) and
3483 [Niederlehner et al. \(1998\)](#) reported baseline narcosis as the mode of action for TCE in freshwater and
3484 saltwater invertebrates. Therefore, freshwater and saltwater values were integrated together. The
3485 geometric mean of the EC₅₀ and LC₅₀s from high and medium quality studies is 16 mg/L. EPA used
3486 these data quantitatively. Another study, [Sánchez-Fortún et al. \(1997\)](#), rated low for quality, established
3487 LC₅₀s in *Artemia salina* larvae at three different ages; however, this study was not used quantitatively
3488 during data integration, given that medium and high-quality studies were available for invertebrates.

3489
3490 One subchronic study found an LC₅₀ of 1.7 mg/L in planarian (*Dugesia japonica*) over 7 days ([Yoshioka](#)
3491 [et al., 1986](#)). This study was rated low for quality. Because other higher quality studies were available
3492 for aquatic invertebrates, this study was not used quantitatively during data integration.

3493
3494 Chronic data for aquatic invertebrates were identified in two acceptable studies, both rated high for
3495 quality. One study established toxicity values for reproduction, an effect that is relevant at the
3496 population level. [Niederlehner et al. \(1998\)](#) established a NOEC of 7.1 mg/L and a LOEC of 12 mg/L
3497 for reproduction in *Ceriodaphnia dubia*, resulting in a ChV of 9.2 mg/L. [Niederlehner et al. \(1998\)](#)
3498 established a 7-day reproductive inhibitory concentration (IC₅₀) of 11 mg/L, the concentration at which
3499 the mean number of young decreased by 50%. EPA used these data quantitatively.

3500

3501 Two studies reported baseline narcosis as the mode of action for TCE in invertebrates. Ward et al.
3502 (1986) observed mild intoxication in *Mysidopsis bahia*, a saltwater species, and Niederlehner et al.
3503 (1998) observed behavioral changes, including narcosis and abnormal movement in *Ceriodaphnia*
3504 *dubia*, a freshwater species. EPA used this information qualitatively.

3505
3506 Two studies provided mechanistic data for invertebrates. Vidal et al. (2001), rated high for quality,
3507 examined mechanistic effects of an acute exposure to a freshwater clam species, *Corbicula fluminea*. A
3508 one-time exposure over five days resulted in a significant change in protein activity related to phase I
3509 metabolism. Results indicated a NOEC of 1.2 mg/L and a LOEC of 3.6 mg/L for significantly increasing
3510 cytochrome P-450 levels, and a NOEC of 3.6 mg/L and LOEC of 14 mg/L for significantly decreasing
3511 NADPH cytochrome C reductase activity (Vidal et al., 2001). Houde et al. (2015), also rated high for
3512 quality, examined the effects of TCE on *Daphnia magna* at the cellular and life-stage levels. The authors
3513 found a significant increase in chitinase production over 10 days, with a NOEC of 0.001 mg/L and a
3514 LOEC of 0.01 mg/L. Chitinase is an enzyme involved in molting and therefore development in *Daphnia*
3515 *magna*. While the study did not find a significant change in the total number of molts for the
3516 concentrations tested, the results were very close to significant with a $p = 0.051$ (assuming significance
3517 at $p \leq 0.05$), suggesting more tests are necessary to determine the impact of increased chitinase at the
3518 life-stage level. Because these mechanistic data are not directly linked to a population-level response,
3519 these data were used qualitatively.

3520 3521 *Aquatic Plant Toxicity*

3522 For aquatic plants hazard studies, algae are the common test species. Algae are cellular organisms which
3523 will cycle through several generations in hours to days; therefore the data for algae was assessed
3524 together regardless of duration rather than being categorized as acute or chronic.

3525
3526 There were six acceptable studies that reported data on 11 species of algae, including fresh and saltwater
3527 species, and cyanobacteria and eukaryotes. There was a wide range of toxicity values reported in the
3528 literature for algae exposed to TCE. EC₅₀s measuring growth represent nine species and range from
3529 26.24 mg/L to 820 mg/L (Lukavsky et al., 2011; Labra et al., 2010; Tsai and Chen, 2007; Ando et al.,
3530 2003; Brack and Rottler, 1994; Ward et al., 1986). Ward et al. (1986) reported results on the only
3531 saltwater species found in the acceptable studies, *Skeletonema costatum*, with an EC₅₀ of 95 mg/L. This
3532 value is within the range of values for freshwater species, so saltwater and freshwater species were
3533 integrated together. EPA derived a geometric mean of 242 mg/L from the high and medium quality
3534 EC₅₀s. A 72-hour EC₁₀ of 12.3 mg/L was also established by Brack and Rottler (1994) measuring
3535 biomass (a measure of growth) in *Chlamydomonas reinhardtii*, a freshwater eukaryotic green algae.
3536 Additionally, several NOECs and LOECs were established. Labra et al. (2010) found a 72-hour NOEC
3537 of 0.02 mg/L and a LOEC of 0.05 mg/L for cell count (a measure of growth) in *Raphidocelis*
3538 *subcapitata*. This study also assessed the integrity of algal cell membranes and found a dose-dependent
3539 increase in membrane damage starting at 0.05 mg/L. EPA used the abovementioned algae data
3540 quantitatively.

3541
3542 Ando et al. (2003) measured relative absorbance of chlorophyll *a* (an indirect measure of algal growth)
3543 in three species of algae, *Selenastrum capricornutum*, *Chlorella vulgaris*, and *Volvox steinii*. They
3544 found no significant change in the relative absorbance of chlorophyll *a* for *S. capricornutum* or *C.*
3545 *vulgaris* during the 10-day test; however, they established a 10-day LOEC of 0.003 mg/L for *V. steinii*, a
3546 flagellar algae. The authors attributed the variation in algal species sensitivity to TCE to *V. steinii*'s high
3547 metabolism. For several reasons explained in Section 3.1.4, these data were considered less biologically
3548 relevant than values from other studies and were not used quantitatively during data integration.
3549

3550
3551

Table 3-1. Ecological Hazard Data used Quantitatively to Characterize TCE Hazard for Aquatic Organisms

Duration	Test organism	Endpoint	Hazard value (mg/L) ¹	Geometric Mean ² (mg/L)	Effect Endpoint	Citation (Study Quality)
Acute ³	Fish	LC ₅₀ (freshwater)	28.28 – 66.8	42	Mortality	(Geiger et al., 1985) (high); (Alexander et al., 1978) (high); (Smith et al., 1991) (high); (Broderius et al., 2005) (high); (Buccafusco et al., 1981) (medium)
		LC ₅₀ (saltwater)	52			(Ward et al., 1986) (medium)
		EC ₅₀ (freshwater)	21.9		Immobilization	(Alexander et al., 1978) (high)
	Amphibian	LC ₅₀	412.0 – 490.0	436	Mortality	(Fort et al., 2001) (medium); (Fort et al., 1991) (medium); (Fort et al., 1993) (high)
	Aquatic Invertebrates	EC ₅₀ /LC ₅₀ (freshwater)	7.8 – 33.85	16	Mortality and Immobilization	(LeBlanc, 1980) (high); (Niederlehner et al., 1998) (high); (Abermethy et al., 1986) (medium); (Dobaradaran et al., 2012) (medium)
		LC ₅₀ (saltwater)	14			(Ward et al., 1986) (medium)
Subchronic /Chronic ³	Fish	EC ₂₀	7.88		Growth	(Broderius et al., 2005) (high)
		EC ₅₀	11.8		Growth	
		NOEC LOEC ChV	10.568 20.915 14.87		Fry Survival	(Smith et al., 1991) (high)
		NOEC LOEC ChV (subchronic)	5.758 21.233 11		Fry Survival	
		LC ₅₀ (subchronic)	82		Mortality	(Schell, 1987) (high)
	Amphibians	NOEC	4		Tadpole Survival	(McDaniel et al., 2004) (medium)
		EC ₅₀ (subchronic)	22 – >85	34	Deformities	(Fort et al., 2001) (medium); (Fort et al., 1991) (medium); (Fort et al., 1993) (high); (McDaniel et al., 2004) (high and medium)
	Aquatic invertebrates	NOEC LOEC ChV	7.1 12 9.2		Reproduction	(Niederlehner et al., 1998) (high)
		IC ₅₀	11			
	Algae ⁴	EC ₅₀ (freshwater)	26.24 – 820	242	Growth	(Brack and Rottler, 1994) (high); (Tsai and Chen, 2007) (high); (Labra et al., 2010) (medium); (Ando et al., 2003) (medium); (Lukavsky et al., 2011) (medium)

	EC50 (saltwater)	95			(Ward et al., 1986) (medium)
	EC10	12.3		Growth	(Brack and Rottler, 1994) (high)
	NOEC	0.02		Growth	(Labra et al., 2010) (medium)
	LOEC	0.05			
	ChV	0.03			

3552 ¹Values in the table are presented in the number of significant figures reported by the study authors.

3553 ²Geometric mean of definitive values only (*i.e.*, > 85 mg/L was not used in the calculation).

3554 ³ Acute and chronic hazard data include fish, invertebrates, or amphibian data

3555 ⁴Because algae can cycle through several generations in hours to days, the data for algae was assessed together regardless of duration (*i.e.*, 48-hrs to 96-hrs).


3556 Values in **bold** were used to derive Concentrations of Concern (COC) as described in Section 3.1.5 of this document. All
3557 values are listed individually with study quality in [*Data Quality Evaluation of Environmental Hazard Studies and Data*
3558 *Extraction for Environmental Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)].*

3560 3.1.3 Species Sensitivity Distributions (SSDs)

3561 A Species Sensitivity Distribution (SSD) is a type of probability distribution of toxicity values from
3562 multiple species. It can be used to visualize which species are most sensitive to a toxic chemical
3563 exposure, and to predict a concentration of a toxic chemical that is hazardous to a percentage of test
3564 species. This hazardous concentration is represented as an HC_p, where p is the percent of species. EPA
3565 used an HC₀₅ (a Hazardous Concentration threshold for 5% of species) to estimate a concentration that
3566 would protect 95% of species.

3567 EPA created SSDs using EPA's SSD Toolbox and the acute hazard data for aquatic species, including
3568 fish, amphibians, and invertebrates (Figure 3-1) ([Etterson, 2020](#)). The input data for Figure 3-1 included
3569 acute toxicity values measuring mortality available in the literature representing four species of fish
3570 (LC_{50s}), one species of amphibian (LC_{50s}), and three species of invertebrates (LC_{50s}/EC_{50s}). For
3571 invertebrates EC_{50s} measuring immobilization were used in addition to LC_{50s}, because it is difficult to
3572 distinguish between death and immobilization for aquatic invertebrates. As stated previously, freshwater
3573 and saltwater species were assessed together, because the saltwater values were within the range of
3574 freshwater species in the same taxonomic group. Additionally, for fish and invertebrates, the mode of
3575 action for freshwater and saltwater species is expected to be the same ([Broderius et al., 2005](#); [Ward et](#)
3576 [al., 1986](#); [Alexander et al., 1978](#)).

3577
3578
3579 Using acute hazard data for these aquatic species, EPA derived a model-averaged HC₀₅ from the normal,
3580 logistic, triangular, Gumbel, and Burr distributions (Figure 3-1). The model-averaged HC₀₅ from all five
3581 distributions was 10 mg/L, which estimates a concentration that is hazardous for 5% of aquatic species.
3582 The SSDs showed aquatic invertebrates were the most sensitive species.



3583 **Figure 3-1. Species Sensitivity Distributions (SSDs) for Acute Hazard Data Using LC₅₀s or EC₅₀s**
 3584 **(Etterson, 2020)**

3585 Note: The data in this figure includes LC₅₀s and EC₅₀s measuring mortality and immobilization from medium- or high-quality
 3586 studies. A black dot indicates the toxicity value used for that species. The red diamonds indicate HC₀₅s for the normal,
 3587 logistic, triangular, Gumbel, and Burr distributions using the maximum likelihood fitting method (Appendix E.1).
 3588


3589 This SSD shows that generally, invertebrates are the most sensitive taxonomic group to short-term (48-
 3590 96 hour) exposure to TCE. Amphibians and fish were distributed throughout the center of the
 3591 distribution, with the two frog species being the most sensitive amphibians, and American flagfish
 3592 (*Jordanella floridae*) the most sensitive fish.
 3593

3594 A chronic SSD for aquatic species was not created due to insufficient data.
 3595

3596 As stated previously, there was a wide range of toxicity values reported in the literature for algae
 3597 exposed to TCE. EC₅₀s were as low as 26.24 mg/L and as high as 820 mg/L, representing nine different
 3598 species. With such a wide range of sensitivities, it is helpful to show how TCE could be affecting algae
 3599 species as a whole. Therefore, EPA generated an SSD to help interpret the data. Figure 3-2 shows the
 3600 SSD for algae created using EPA's SSD Toolbox (Etterson, 2020). The data used in the SSD includes
 3601 EC₅₀s measuring growth from freshwater species, a saltwater species, cyanobacteria, eukaryotes, a
 3602 diatom, and a colonizing species. As stated in Section 3.1.2, saltwater and freshwater species were

3603 assessed together, because the only saltwater species, *Skeletonema costatum*, had an EC₅₀ within the
3604 range of values for freshwater species.

3605
3606 Using algae hazard data, EPA derived a model-averaged HC₀₅ from six distributions, the normal,
3607 logistic, triangular, Gumbel, Weibull, and Burr distributions (Figure 3-2). The model-averaged HC₀₅
3608 was 72 mg/L, which estimates a concentration that is hazardous for 5% of aquatic species.



3609 **Figure 3-2. Species Sensitivity Distribution (SSD) for Algae Species Using EC₅₀s (Etterson, 2020)**

3610 Note: The data in this figure includes EC₅₀s measuring growth from medium- or high-quality studies. A black dot indicates
3611 the toxicity value used for that species. The red diamonds indicate HC₀₅s for the normal, logistic, triangular, Gumbel,
3612 Weibull, and Burr distributions using the maximum likelihood fitting method (Appendix E.1).

3613
3614 Given these data, certain algae species may be more sensitive than others; however, there is not enough
3615 data to make definitive conclusions. The three cyanobacteria, *Myrocystis aeruginosa*, *Synechococcus*
3616 *leopoliensis*, and *Synechococcus elongatus*, are distributed throughout the curve and as a group do not
3617 appear to be more or less sensitive than the eukaryotic species. The saltwater species, *Skeletonema*
3618 *costatum*, also the only diatom, is one of the more sensitive species on the distribution. The species that
3619 organizes into colonies, *Myrocystis aeruginosa*, is also one of the more sensitive species represented on
3620 the curve. However, with only one saltwater species, diatom, and colonizing species represented,
3621 generalizations about the sensitivity of these types of algae could not be made.

3622
3623 It is important to note that, for consistency, this distribution only includes EC₅₀s to compare between
3624 studies and species. Therefore, it does not capture some of the lowest toxicity values reported, including
3625 LOECs and NOECs. For example, the ChV of 0.03 mg/L for algae derived from Labra et al. (2010) is
3626 not included in the algae SSD. To account for this uncertainty, EPA used an assessment factor (AF) of 5
3627 when calculating the concentration of concern (COC), which is described in Section 3.1.5.

3.1.4 Weight of the Scientific Evidence

During the data integration stage of systematic review EPA analyzed, synthesized, and integrated the data/information. This involved weighing the scientific evidence for quality and relevance, using a weight-of-evidence approach ([U.S. EPA, 2018b](#)).

During data evaluation, EPA assigned studies an overall quality level of high, medium, or low for quality based on the TSCA criteria described in the *Application of Systematic Review in TSCA Risk Evaluations* ([U.S. EPA, 2018b](#)). While integrating environmental hazard data for TCE, EPA gave more weight to relevant data/information rated high or medium for quality than to data/information rated low. Only data/information rated as high, medium, or low for quality was considered for the environmental risk assessment. Any information rated as unacceptable was not considered. EPA also considered relevance in selecting data/information for this Risk Evaluation, specifically biological, physical/chemical, and environmental relevance ([U.S. EPA, 1998](#)):

- Biological relevance: correspondence among the taxa, life stages, and processes measured or observed and the assessment endpoint.
- Physical/chemical relevance: correspondence between the chemical or physical agent tested and the chemical or physical agent constituting the stressor of concern.
- Environmental relevance: correspondence between test conditions and conditions in the region of concern. ([U.S. EPA, 1998](#))

EPA used this weight-of-evidence approach to assess hazard data and develop concentrations of concern (COCs) and HC_{05s}. Given the reasonably available data, EPA was able to use studies assigned an overall quality level of high or medium to derive COCs or HC_{05s} for each taxonomic group and could avoid studies rated low for quality. EPA integrated data for each trophic level that had comparable toxicity values (*e.g.*, multiple EC_{50s} measuring the same or comparable effects from various species within a trophic level). EPA used probabilistic approaches (*e.g.*, SSDs) when enough data were available and deterministic approaches (*e.g.*, deriving a geometric mean of several comparable values) where more limited data were available. To calculate HC_{05s}, EPA created SSDs for algae species using comparable data (*e.g.*, EC_{50s} measuring growth) and for all other aquatic species (*e.g.*, LC_{50s} for fish and amphibians, and LC_{50s} measuring mortality and EC_{50s} measuring immobilization for aquatic invertebrates). Non-definitive toxicity values (*e.g.*, EC₅₀ >85 mg/L) were not integrated with other data to derive HC_{05s} or geometric means.

To assess aquatic toxicity from acute exposures, data for three taxonomic groups were reasonably available: fish, amphibians, and aquatic invertebrates. For each taxonomic group, data were available for multiple species, and enough acute data were available to create an SSD, which showed that the three most sensitive species in the distribution are aquatic invertebrates. EPA used the SSD to derive a model-averaged HC₀₅ of 10 mg/L. In addition to this probabilistic approach, EPA integrated the data for each taxonomic group by calculating geometric means as shown in Table 3-1. The geometric mean for aquatic invertebrates, 16 mg/L, represented the lowest toxicity value derived from each of the four taxonomic groups. However, EPA has more confidence in the probabilistic approach.

To assess aquatic toxicity from chronic exposures, data for three taxonomic groups were described in the acceptable literature: fish, amphibians, and aquatic invertebrates. However, for amphibians, only a NOEC was established. Therefore, the endpoints for fish and aquatic invertebrates (ChVs, an EC₂₀, and an EC₅₀) were more biologically relevant, because they measured a toxic effect, whereas the NOEC did not. Of the more relevant values, the most sensitive was the EC₂₀ measuring growth in fish at 7.88 mg/L. The EC₂₀ was from a high-quality study, whereas the NOEC of 4 mg/L was from a medium quality

3675 study. Considering the relevance and the quality of each value, EPA had more confidence in the EC₂₀
3676 for fish than in the NOEC for tadpoles.

3677
3678 To assess the toxicity of TCE to algae, data for 11 species were reasonably available from studies rated
3679 high and medium for quality. The most sensitive endpoint reported for algae was a 10-day LOEC of
3680 0.003 mg/L from Ando et al. (2003), rated medium for quality. However, the study did not include
3681 critical details, such as analytical measurement of test concentrations, or chemical substance source or
3682 purity, and the authors were not able to establish a NOEC. Therefore, these data were considered less
3683 biologically relevant than values from other studies, and not used quantitatively during data integration.
3684 The ChV of 0.03 from Labra et al. (2010) was the most sensitive endpoint from the more relevant
3685 studies. Labra et al. (2010) was rated medium for quality. An EC₁₀ of 12.3 mg/L from a high-quality
3686 study, Brack et al. (1994), was also available; however, taking biological relevance into consideration,
3687 EPA used the ChV derived from Labra et al. (2010), because there was a wide range in toxicity values
3688 reported in the literature between algae species. Therefore, EPA used the value from *Raphidocelis*
3689 *subcapitata* (formerly known as *Pseudokirchneriella subcapitata*) from Labra et al. (2010) to represent
3690 the more sensitive algae species in the COCs. (According to the algae SSD, *Raphidocelis subcapitata* is
3691 generally more sensitive to TCE exposure than *Chlamydomonas reinhardtii*, the species used in Brack
3692 et al. (1994).) In addition to this ChV, EPA considered the results from the SSD for algae in assessing
3693 toxicity to algae. The SSD represented toxicity values for nine species of algae and provided an
3694 additional line of evidence for how TCE exposure could affect this taxonomic group. EPA has more
3695 confidence in the probabilistic approach.

3696 **3.1.5 Concentrations of Concern**

3697 The concentrations of concern (COCs) for aquatic species were calculated based on the environmental
3698 hazard data for TCE, using the weight of evidence approach described above and EPA methods (U.S.
3699 EPA, 2016i, 2012c). For TCE, EPA derived an acute COC, a chronic COC, and an algal COC. Algae
3700 was assessed separately and not incorporated into acute or chronic COCs, because durations normally
3701 considered acute for other species (e.g., 48, 72 hours) can encompass several generations of algae.

3702
3703 After weighing the evidence and selecting the appropriate toxicity values from the integrated data to
3704 calculate an acute, chronic, and algal COC, an assessment factor (AF) is applied according to EPA
3705 methods (U.S. EPA, 2016i, 2012c). The application of AFs provides a lower bound effect level that
3706 would likely encompass more sensitive species not specifically represented by the available
3707 experimental data. AFs also account for differences in inter- and intra-species variability, as well as
3708 laboratory-to-field variability. These AFs are dependent on the availability of datasets that can be used
3709 to characterize relative sensitivities across multiple species within a given taxa or species group.
3710 However, they are often standardized in risk assessments conducted under TSCA, since the data
3711 reasonably available for most industrial chemicals are limited. For fish and aquatic invertebrates (e.g.,
3712 daphnia) the acute COC values are divided by an AF of 5. For chronic COCs, an AF of 10 is used (U.S.
3713 EPA 2013, 2012c).

3714
3715 To derive an acute COC for TCE, EPA used acute aquatic species data representing eight species to
3716 produce an SSD, which was used to calculate an HC₀₅ of 10 mg/L. As stated previously, this HC₀₅
3717 estimates a concentration that is hazardous for 5% of species. The HC₀₅ estimates the concentration of
3718 TCE that is expected to protect 95% of algae species. Because the SSD was created using the limited
3719 number of species available across multiple taxa, EPA applied an assessment factor of 5. The HC₀₅, 10
3720 mg/L was divided by an assessment factor of 5, and then multiplied by 1,000 to convert mg/L to µg/L
3721 (or ppb).

3722

3723 Therefore, the acute COC derived from the $HC_{05} = (10 \text{ mg/L}) / \text{AF of } 5 = 2 \times 1,000 = 2,000 \text{ } \mu\text{g/L}$ or
3724 ppb.

3725
3726 The acute COC derived from the HC_{05} for TCE is 2,000 ppb.

3727
3728 Additionally, EPA used the geometric mean of the EC_{50} and LC_{50} s for aquatic invertebrates from five
3729 different studies, all rated high or medium for quality ([Dobaradaran et al., 2012](#); [Niederlehner et al.,](#)
3730 [1998](#); [Abernethy et al., 1986](#); [Ward et al., 1986](#); [LeBlanc, 1980](#)). The geometric mean for aquatic
3731 invertebrates represented the lowest acute value from all four taxonomic groups of aquatic species from
3732 the integrated data for TCE. The data used to calculate the geometric mean represent toxicity data for
3733 three species, *Daphnia magna*, *Ceriodaphnia dubia*, and *Mysidopsis bahia*. EPA derived the geometric
3734 mean, because the hazard values for all three species were similar, and because EPA had more
3735 confidence in a COC derived from a geometric mean for three species than a COC derived from one
3736 value from one species. To calculate an acute COC, the geometric mean, 16 mg/L, was divided by the
3737 AF of 5 for aquatic invertebrates and multiplied by 1,000 to convert mg/L to $\mu\text{g/L}$ (or ppb).

3738
3739 Therefore, the acute COC = $(16 \text{ mg/L}) / \text{AF of } 5 = 3.2 \times 1,000 = 3,200 \text{ } \mu\text{g/L}$ or ppb.

3740
3741 The acute COC derived from the geometric mean for TCE is 3,200 ppb.

3742 To derive a chronic COC, EPA used the lowest chronic toxicity value from the integrated data, an EC_{20}
3743 for growth in fish (fathead minnows) from a study rated high for quality ([Broderius et al., 2005](#)). This
3744 value, 7.88 mg/L was divided by an assessment factor of 10, and then multiplied by 1,000 to convert
3745 from mg/L to $\mu\text{g/L}$ (or ppb).

3746
3747 Therefore, the chronic COC = $(7.88 \text{ mg/L}) / \text{AF of } 10 = 0.788 \times 1,000 = 788 \text{ } \mu\text{g/L}$ or ppb.

3748
3749 The chronic COC for TCE is 788 ppb.

3750 To derive an algal COC, EPA used algae data representing nine species to produce an SSD, which was
3751 used to calculate an HC_{05} of 72 mg/L. As stated previously, this HC_{05} estimates a concentration that is
3752 hazardous for 5% of species. The HC_{05} estimates the concentration of TCE that is expected to protect
3753 95% of algae species. Because the SSD was created using EC_{50} s rather than EC_{10} s or ChVs and because
3754 no higher order plants were represented in the data, EPA applied an assessment factor of 5. The HC_{05} ,
3755 72 mg/L was divided by an assessment factor of 5, and then multiplied by 1,000 to convert mg/L to $\mu\text{g/L}$
3756 (or ppb).

3757
3758 Therefore, the algal COC derived from the $HC_{05} = (72 \text{ mg/L}) / \text{AF of } 5 = 14.4 \times 1,000 = 14,400 \text{ } \mu\text{g/L}$ or
3759 ppb.

3760
3761 The algal COC derived from the HC_{05} for TCE is 14,400 ppb.

3762
3763 Additionally, EPA used a geometric mean of a LOEC and a NOEC for growth in *Raphidocelis*
3764 *subcapitata* ([Labra et al., 2010](#)). This value, 0.03 mg/L was divided by an assessment factor of 10, and
3765 then multiplied by 1,000 to convert mg/L to $\mu\text{g/L}$ (or ppb).

3766
3767 Therefore, the algal COC = $(0.03 \text{ mg/L}) / \text{AF of } 10 = 0.003 \times 1,000 = 3 \text{ } \mu\text{g/L}$ or ppb.

3768
3769 The algal COC derived from geometric mean of the NOEC and LOEC (ChV) for TCE is 3 ppb.

3770 **3.1.6 Summary of Environmental Hazard**

3771 The reasonably available environmental hazard data indicate that TCE presents hazard to aquatic
 3772 organisms. For acute exposures to invertebrates, toxicity values ranged from 7.8 to 33.85 mg/L (LC_{50s}
 3773 and EC_{50s} integrated into a geometric mean of 16 mg/L). For chronic exposures, toxicity values for fish
 3774 and aquatic invertebrates were as low as 7.88 mg/L (EC₂₀ for growth) and 9.2 mg/L (ChV for
 3775 reproduction), respectively. The data also indicated that TCE presents hazard for aquatic plants, with
 3776 toxicity values in algae as low as 0.03 mg/L (geometric mean between a NOEC and a LOEC), and a
 3777 wide range in toxicity between algae species (EC_{50s} ranging from 26.24 – 820 mg/L).

3778 EPA calculated COCs for aquatic organisms, which are summarized in Table 3-2. EPA calculated an
 3779 acute COC from the HC₀₅ of 2,000 ppb for aquatic organisms based on the LC_{50s} (and EC_{50s} measuring
 3780 immobilization for aquatic invertebrates) for eight species, from studies rated medium and high for
 3781 quality. EPA also calculated an acute COC for TCE at 3,200 ppb, based on the geometric mean of LC_{50s}
 3782 and EC_{50s} for aquatic invertebrates, from five studies rated either high or medium for quality
 3783 ([Dobaradaran et al., 2012](#); [Niederlehner et al., 1998](#); [Abernethy et al., 1986](#); [Ward et al., 1986](#); [LeBlanc,
 3784 1980](#)). EPA calculated the chronic COC for TCE at 788 ppb, based on an EC₂₀ for fathead minnows
 3785 from Broderius et al. ([2005](#)), rated high for quality.

3786
 3787 As stated previously, algae were assessed separately from other aquatic organisms, because durations
 3788 normally considered acute for other species (*e.g.*, 96 hours) can encompass several generations of algae.
 3789 EPA calculated a COC from the HC₀₅ of 14,400 ppb for algae based on the EC_{50s} for nine species, from
 3790 studies rated medium and high for quality. EPA also calculated an algal COC for TCE at 3 ppb, based
 3791 on a geometric mean of a LOEC and NOEC for growth in *Raphidocelis subcapitata* from Labra et al.
 3792 ([2010](#)), a study rated medium for quality.

3793 **Table 3-2 Concentrations of Concern (COCs) for Environmental Toxicity**

Environmental Aquatic Toxicity	Hazard Value (µg/L)	Assessment Factor (AF)	Concentration of Concern (µg/L or ppb)
Toxicity from Acute Exposure: Probabilistic Approach (HC ₀₅ from SSD)	10,000	5	2,000
Deterministic Approach (Geometric mean of invertebrate LC _{50s} and EC _{50s} for immobilization)	16,000	5	3,200
Toxicity from Chronic Exposure: Deterministic Approach (fish EC ₂₀ for growth)	7,880	10	788
Deterministic Approach (invertebrate ChV for reproduction)	9,200	10	920
Toxicity for Algae: Probabilistic Approach (HC ₀₅ from SSD)	72,000	5	14,400
Deterministic Approach (ChV)	30	10	3

3795 **3.1.7 Assumptions and Key Uncertainties for Environmental Hazard Data**

3796 After evaluating all available environmental hazard data on TCE, EPA has high confidence in the
 3797 environmental hazard data used to assess the environmental hazard of TCE and high confidence that the
 3798 data incorporates environmentally protective acute and chronic COCs (as described above). Despite the
 3799 high confidence in the data used to assess the environmental hazard of TCE, there are sources of
 3800 uncertainty.

3801
3802 First, assessment factors (AFs) were used to calculate the acute and chronic concentrations of concern
3803 for TCE. As described in Section 3.1.5, AFs account for differences in inter- and intra-species
3804 variability, as well as laboratory-to-field variability and are routinely used within TSCA for assessing
3805 the hazard of new industrial chemicals. Some uncertainty may be associated with the use of the specific
3806 AFs used in the hazard assessment.
3807


3808 Second, there was more acute duration data reasonably available in the literature than chronic duration
3809 data. Therefore, EPA is less certain of chronic hazard values, which are based on a deterministic
3810 approach using one fish species, than the acute hazard values, which are based on a probabilistic
3811 approach using data from multiple species of aquatic invertebrates. However, a few lines of evidence
3812 mitigate the uncertainty in the chronic data. For example, the fish toxicity value on which the chronic
3813 COC is based, is from a high-quality, relevant study. Additionally, the acute data show aquatic
3814 invertebrates are the most sensitive taxonomic group, and they are represented in chronic duration data.
3815 Also, the other chronic fish toxicity values as well as the chronic aquatic invertebrate values were very
3816 close to the fish value used to derive the chronic COC. Therefore, some of the uncertainties associated
3817 with the chronic COC were mitigated.
3818

3819 Third, while the toxicity values for fish, amphibians, and invertebrates are relatively consistent, there
3820 was wide variation in the toxicity values for different species of algae. One study, Lukavsky et al. (2011)
3821 examined several species of algae using standardized methods within the same lab to determine whether
3822 the variation seen in the literature was due to differences in laboratory practices, methodology used, or
3823 species studied. They found that conducting the tests with standard methods in the same lab reduced the
3824 variation seen in toxicity levels between species; however, EC₅₀s were still as low as 130 mg/L and as
3825 high as 820 mg/L for the eight species of algae tested (compared to a range of 26.24 – 820 mg/L from
3826 the entire body of literature), indicating there is in fact a wide range in species sensitivities. Taking this
3827 range of sensitivities into consideration, EPA used two approaches to characterize hazard in algae. EPA
3828 developed an algae COC, using a toxicity value of 0.03 mg/L, which represents one species. The data
3829 show that there are other species that are less sensitive to TCE exposure. To provide more context for
3830 this taxonomic group, EPA also used algae data from nine species to create an SSD and derive an HC₀₅.
3831 EPA considered the HC₀₅ analogous to a COC. However, there are pros and cons to each approach. For
3832 example, the COC incorporates the most sensitive endpoint in a geometric mean of a NOEC and LOEC
3833 for growth, while the HC₀₅ does not consider the most sensitive endpoints reported in the data. However,
3834 the HC₀₅ is derived using data from nine species rather than just one and is therefore representative of a
3835 larger portion of species in the environment. To account for the uncertainty, EPA used an AF of 5 to
3836 calculate the algae COC using the HC₀₅.
3837

3838 **3.2 Human Health Hazards**

3839 **3.2.1 Approach and Methodology**

3840 EPA used the approach described in Section 1.5 to evaluate, extract and integrate TCE’s human health
3841 hazard and dose-response information.
3842



3843
3844 **Figure 3-3. EPA Approach to Hazard Identification, Data Integration, and Dose-Response**
3845 **Analysis for TCE**
3846

3847 Specifically, EPA reviewed key and supporting information from previous hazard assessments as well as
3848 the existing body of knowledge on TCE’s human health hazards. These data sources included an EPA
3849 IRIS Assessment ([U.S. EPA, 2011e](#)) and an ATSDR Toxicological Profile ([ATSDR, 2019](#)), data sources
3850 originally obtained from the 2014 Draft Toxicological Profile); hence, many of the hazards of TCE have
3851 been previously compiled and systematically reviewed. Furthermore, EPA previously reviewed
3852 data/information on health effects endpoints, identified hazards and conducted dose-response analysis in
3853 the 2014 TSCA Work Plan Chemical Risk Assessment for TCE ([U.S. EPA, 2014b](#)) but did not
3854 exclusively rely on this assessment.
3855

3856 All health hazards of TCE previously identified in these reviews were described and reviewed in this
3857 Risk Evaluation, including: acute overt toxicity, liver toxicity, kidney toxicity, neurotoxicity,
3858 immunotoxicity (including sensitization), reproductive toxicity, developmental toxicity, and cancer.
3859 EPA relied heavily on the aforementioned existing reviews along with scientific support from the Office
3860 of Research and Development in preparing this Risk Evaluation. Development of the TCE hazard and
3861 dose-response assessments considered EPA and National Research Council (NRC) risk assessment
3862 guidance.
3863

3864 The new literature was screened against inclusion criteria in the PECO statement and the relevant
3865 studies (e.g., useful for dose-response)²⁰ were further evaluated using the data quality criteria for human,
3866 animal, and *in vitro* studies described in the *Application of Systematic Review in TSCA Risk Evaluations*
3867 ([U.S. EPA, 2018b](#)) (see Section 1.5). EPA skipped the screening step (for relevance to TCE) of the key
3868 and supporting studies [*List of Key and Supporting Studies for Human Health Hazard. Docket # [EPA-](#)*
3869 *[HQ-OPPT-2019-0500](#)*] identified in previous assessments and entered them directly into the data
3870 evaluation step based on their previously identified relevance to the chemical.

3871
3872 EPA considered studies of low, medium, or high confidence for hazard identification and dose-response
3873 analysis. Information from studies that were rated unacceptable were only discussed on a case-by-case
3874 basis for hazard ID and weight-of-scientific-evidence assessment but were not considered for dose-
3875 response analysis.

3876
3877 EPA has not developed data quality criteria for all types of hazard information. This is the case for
3878 toxicokinetics and many types of mechanistic data which EPA typically uses for qualitative support
3879 when synthesizing evidence. As appropriate, EPA evaluated and summarized these data to determine
3880 their utility with supporting the Risk Evaluation.

3881
3882 Following the data quality evaluation, EPA extracted the toxicological information from each relevant
3883 study. In the last step, the strengths and limitations of the data were evaluated for each endpoint and a
3884 weight-of-the-scientific evidence narrative was developed. Data for each selected hazard endpoint
3885 underwent dose-response analysis. Finally, the results were summarized, and the uncertainties were
3886 presented. The process is described in Figure 3-3. The weight of evidence analysis included integrating
3887 information from toxicokinetics, toxicodynamics in relation to the key hazard endpoints: acute overt
3888 toxicity, liver toxicity, kidney toxicity, neurotoxicity, immunotoxicity (including sensitization),
3889 reproductive toxicity, developmental toxicity, and cancer. EPA selected human health studies that were
3890 of high quality and relevance to move forward for dose-response analysis in order to quantitatively
3891 assess each key hazard endpoint.

3892
3893 Tables summarizing all studies considered for this assessment, including the reported no-observed- or
3894 lowest-observed-adverse-effect levels (NOAEL and LOAEL, respectively) for non-cancer health
3895 endpoints by target organ/system and the incidence for cancer endpoints, along with the results of the
3896 data quality evaluation, are provided in [*Data Quality Evaluation of Human Health Hazard Studies and*
3897 *Data Extraction for Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)].*

3898
3899 EPA considered points of departure (POD) from studies that were PECO relevant, scored acceptable in
3900 the data quality evaluation, and contained adequate dose-response information. The POD is a dose or
3901 concentration near the lower end of the observed range without significant extrapolation to lower doses.
3902 It is used as the starting point for subsequent dose-response (or concentration-response) extrapolations
3903 and analyses. PODs can be a no-observed-adverse-effect level (NOAEL), a lowest-observed-adverse-
3904 effect level (LOAEL) for an observed incidence, or change in level of response, or the lower confidence
3905 limit on the dose at the benchmark dose (BMDL).²¹ PODs were adjusted as appropriate to conform to
3906 the specific exposure scenarios evaluated.

3907

²⁰ Some of the studies that were excluded based on the PECO statement were considered later during the systematic review process as needed. For example, EPA reviewed mode of action information to qualitatively support the health hazard assessment.

²¹ The benchmark dose (BMD) is a dose or concentration that produces a predetermined change in response range or rate of an adverse effect (called the benchmark response or BMR) compared to baseline.

3908 Human equivalent concentrations (HECs) and human equivalent doses (HEDs) were obtained via EPA’s
3909 previously published and peer-reviewed Physiologically-Based Pharmacokinetic (PBPK) model ([U.S.
3910 EPA, 2011e](#)), which accounts for both extrapolation from rodents to humans and human variability (see
3911 Section 3.2.2.5 and [*PBPK Model and ReadMe (zipped). Docket: EPA-HQ-OPPT-2019-0500*]). The
3912 PBPK model also allows data-based route-to-route extrapolation between oral and inhalation studies.
3913 For HEC calculations, these values were adjusted based on 24-hr exposure durations unless otherwise
3914 noted. Limited toxicological data are reasonably available by the dermal route for TCE and a PBPK
3915 model that would facilitate route-to-route extrapolation has not been developed for the dermal exposure
3916 route. Therefore, oral HEDs were also utilized for risk estimation following dermal exposure, consistent
3917 with the analysis plan as described in the Problem Formulation ([U.S. EPA, 2018d](#)).
3918

3919 Section 3.2.5 describes the dose-response assessment guiding the selection of PODs for non-cancer
3920 endpoints. The BMD modeling results for pulmonary immunotoxicity ([Selgrade and Gilmour, 2010](#)),
3921 which was not included in the 2014 TCE Risk Assessment ([U.S. EPA, 2014b](#)), are presented in Appendix
3922 F. The full description of the PBPK and BMD model outputs for all other endpoints can be found in ([U.S.
3923 EPA, 2011e](#)).

3924 **3.2.2 Toxicokinetics**

3925 The toxicokinetics and PBPK modeling of TCE were thoroughly discussed in the 2014 Risk Assessment
3926 ([U.S. EPA, 2014b](#)). This discussion is summarized below.

3927 **3.2.2.1 Absorption**

3928 TCE is fat soluble (lipophilic) and easily crosses biological membranes. Due to its relatively low water
3929 solubility and positive log K_{ow} (Table 1-1), it partitions into blood through binding to soluble
3930 components including lipids ([Cichocki et al. 2016](#)). Though there are quantitative differences across
3931 species and routes, TCE is readily absorbed into the body following oral, dermal, or inhalation exposure.
3932 Because of its lipophilicity, TCE can cross the placenta and also passes into breast milk ([U.S. EPA,
3933 2011e](#)).
3934

3935 Absorption following inhalation of TCE is rapid and the inhaled absorbed dose is proportional to the
3936 exposure concentration, duration of exposure, and lung ventilation rate. Therefore, for this Risk
3937 Evaluation absorption of TCE is assumed to be 100% via inhalation, although any more specific
3938 absorption data were incorporated into the PBPK model (Section 3.2.2.5). Likewise, TCE is rapidly
3939 absorbed from the gastrointestinal tract into the systemic circulation (*i.e.*, blood) following oral
3940 ingestion. Oral absorption of TCE has been shown to be influenced by dose of the chemical, the dosing
3941 vehicle and stomach contents. Absorbed TCE is first transported to the liver where it is metabolized for
3942 eventual elimination (*i.e.*, “first-pass effect”) ([U.S. EPA, 2011e](#)).
3943

3944 Rapid absorption through the skin has been shown by both vapor and liquid TCE contact with the skin.
3945 In several human volunteer studies, both TCE liquid and vapors were shown to be well absorbed in
3946 humans via the dermal route. Dermal absorption was rapid following exposures of between 20 and 30
3947 minutes, with peak TCE levels in expired air occurring within 15 minutes (liquid) and 30 minutes
3948 (vapor) ([U.S. EPA, 2011e](#)). Dermal exposure to TCE disrupts the stratum corneum, impacting the
3949 barrier function of skin and promoting its own absorption. Therefore, absorption may increase at a
3950 greater than linear rate due to increasing epidermal disruption over time ([ATSDR, 2019](#)). Based on this
3951 information, this Risk Evaluation assumes that TCE dermal absorption under occluded (or impeded
3952 evaporation) scenarios is 100%. Dermal absorption under non-occluded occupational exposure scenarios
3953 was evaluated by the Dermal Exposure to Volatile Liquids Model in order to account for evaporation of
3954 TCE deposited on skin (Section 2.3.1). For consumer exposures, dermal absorption was evaluated

3955 differently for scenarios that are expected to involve impeded evaporation and those with unimpeded
3956 evaporation. For scenarios involving impeded evaporation, a permeability model was applied. In
3957 contrast, for scenarios less likely to involve impeded evaporation, the fraction absorbed model was
3958 applied (Section 2.3.2.3.1).

3.2.2.2 Distribution

3959
3960 Regardless of the route of exposure, TCE is widely distributed throughout the body and preferentially
3961 partitions into lipid-containing tissues ([Cichocki et al. 2016](#)). TCE levels can be found in many different
3962 human and rodent tissues including: brain, muscle, heart, kidney, lung, liver, and adipose tissues. It can
3963 also be found in human maternal and fetal blood and in the breast milk of lactating women ([U.S. EPA,
3964 2011e](#)). Breast milk ingestion is an exposure pathway specific to infants. In one study detectable levels
3965 of TCE were found in all eight breast milk samples of mothers living in urban areas, however,
3966 concentrations were not provided ([Pellizzari et al., 1982](#)). In a separate study, TCE was detected in 7 of
3967 20 breast milk samples (35%) with a mean concentration of 1.5 ng/mL; concentrations ranged from not
3968 detected to 6 ng/mL milk ([Beamer et al., 2012](#)).

3.2.2.3 Metabolism

3969
3970 The metabolism of TCE has been extensively studied in humans and rodents ([U.S. EPA, 2011e](#)).
3971 Animals and humans metabolize TCE to metabolites to varying degrees. These metabolites are known to
3972 play a key role in causing TCE-associated toxic effects. TCE metabolites are known to target the liver
3973 and kidney. The two major metabolic pathways are (1) oxidative metabolism via the cytochrome P450
3974 (CYP) mixed function oxidase system and (2) glutathione (GSH) conjugation followed by further
3975 biotransformations and processing with other enzymes. Oxidative metabolism is considered to be the
3976 major metabolic pathway relative to conjugative metabolism ([Cichocki et al. 2016](#); [Lash et al. 2014](#)).
3977 This is supported by data showing that production of conjugative metabolites increases in CYP2E1-null
3978 mice ([Luo et al. 2018](#)). That same data also demonstrates that there are various CYPs involved with
3979 oxidative metabolism and some redundancy exists among them, as oxidative metabolism was only
3980 decreased but still active in CYP2E1-null mice ([Luo et al. 2018](#)).

3981
3982 The liver is the major tissue for the oxidative and GSH conjugation metabolic pathways. Both pathways
3983 are saturable, and above the saturable concentration/dose TCE is excreted unchanged in expired air.
3984 Relative metabolism of TCE differs whether absorbed via inhalation or ingestion due to the influence of
3985 first-pass liver metabolism on gastrointestinally-absorbed xenobiotics. Table 3-3 presents the important
3986 metabolites formed following both the CYP (oxidation) and GSH (conjugation) pathways in humans and
3987 animals. The amount and types of metabolites formed are important for understanding the toxicity of
3988 TCE in both animals and humans.

3989
3990 These major TCE metabolites as well as a number of minor metabolites are also observed in the
3991 metabolic pathway of TCE-related compounds (Table 3-4). This may be important in
3992 determining exposures because people may be co-exposed to many of these solvents at the
3993 same time. Concomitant exposures to TCE and its related compounds can affect TCE's metabolism and
3994 increase toxicity by generating higher internal metabolite concentrations than those resulting from TCE
3995 exposure only ([U.S. EPA, 2011e](#)).

3996
3997
3998
3999
4000
4001

4002 **Table 3-3. TCE Metabolites Identified by Pathway**

Oxidative Metabolites	GSH Conjugation Metabolites
Chloral (metabolized to TCOH _a)	DCVG _e (metabolized to DCVC _f isomers)
Trichloroethylene oxide (re-arranged to DCAC _b)	
Trichloroethanol or TCOH (metabolized to TCOG _c)	
Trichloroacetic acid or TCA (may lead to DCA _d)	

Abbreviations: _a TCOH = trichloroethanol; _b DCAC= dichloroacetyl chloride; _c TCOG= trichloroethanol, glucuronide conjugate; _d DCA=dichloroacetic acid; _e DCVG= S-dichlorovinyl-glutathione (collectively, the 1,2- and 2,2- isomers); _f DCVC= S-dichlorovinyl-L-cysteine (collectively, the 1,2- and 2,2- isomers)

4003
4004 A review of *in vitro* metabolism data in the liver suggested that rodents (*i.e.*, especially mice)
4005 have greater capacity to metabolize TCE via the oxidation pathway ([U.S. EPA, 2011e](#)). *In vitro* data
4006 have also reported modest sex- and age-dependent differences in the oxidative TCE metabolism in
4007 humans and animals. Significant variability may exist in human susceptibility to TCE toxicity given the
4008 existence of CYP isoforms and the variability in CYP-mediated TCE oxidation ([U.S. EPA, 2011e](#)).
4009

4010 **Table 3-4. Common Metabolites of TCE and Related Compounds**

Parent ↓ Metabolites	Tetrachloro- ethylene	1,1,2,2,- Tetrachloro- ethane	TCE	1,1,1- Trichloro- ethane	1,2,- Dichloro- ethylene	1,2,- Dichloro-ethane
Oxalic acid		X	X		X	
Chloral	X		X			
Chloral hydrate (CH)	X		X			
Monochloroacetic acid	X	X	X	X	X	X
Dichloroacetic acid (DCA)	X	X	X			X
Dichloroacetic acid (TCA)	X	X	X	X		
Trichloroethanol (TCOH)	X	X	X	X		
Trichloroethanol- glucuronide	X	X	X	X		

Note: Table is the same as Table 2-21 in ([U.S. EPA, 2014b](#)).

4011
4012 Conjugation is a process that generally leads to detoxification. However, this is not the case for TCE and
4013 many other halogenated alkanes and alkenes because they are biotransformed into reactive metabolites.
4014 The eventual metabolite(s) of concern for TCE are formed several steps from the initial GSH conjugate
4015 formed in the liver, which ultimately results in toxicity or carcinogenicity in the kidney ([U.S. EPA,](#)
4016 [2011e](#)).
4017

4018 Compared to the CYP oxidation pathway, there appear to be more significant sex and species
4019 differences in TCE metabolism via the GSH pathway ([U.S. EPA, 2011e](#)). Animal data show that rates of
4020 TCE GSH conjugation in male rats/mice are higher than females. According to some *in vitro* data, the
4021 rates of DCVG production in liver/kidney cytosol are highest in humans, followed by mice, and then
4022 rats. *In vitro* data also suggest that γ -glutamyl transpeptidase (*i.e.*, GGT, an enzyme involved in DCVC
4023 production) activity in kidneys seems to be highest in rats, then humans, and then mice ([U.S. EPA,](#)
4024 [2011e](#)). Furthermore, species-dependent enzymatic activities have been reported for the β -lyase and
4025 FMO3 enzymes ([U.S. EPA, 2011e](#)), with contrasting evidence suggests that metabolic formation of the
4026 reactive conjugative metabolites may be an order of magnitude greater in rats than humans ([Green et al.](#)
4027 [1997b](#); [Lash et al. 1990](#)) based on β -lyase-activity. Overall, the majority of evidence supports faster
4028 metabolism through both oxidative and GSH-conjugative pathways in rodents compared to humans
4029 ([Lash et al. 2014](#)).

4030 **3.2.2.4 Elimination**

4031 The majority of TCE absorbed into the body is eliminated by the metabolic pathways discussed above.
4032 With the exception of unchanged TCE and CO₂, which are excreted by exhalation, most TCE
4033 metabolites (*i.e.*, TCA, TCOH, GSH metabolites) are primarily excreted in urine and feces. Elimination
4034 of TCE metabolites can also occur through the sweat and saliva, but these excretion routes are likely to
4035 be relatively minor ([U.S. EPA, 2011e](#)).

4036 Varying rates of TCE pulmonary excretion in humans have been observed in different studies ([Chiu et](#)
4037 [al., 2007](#); [Opdam, 1989](#); [Sato et al., 1977](#)). The relatively long terminal half-lives observed (up to 44
4038 hours) suggest that the lungs require considerable time to completely eliminate TCE, primarily due to
4039 high partitioning to adipose tissues ([U.S. EPA, 2011e](#)). Various laboratories have studied the urinary
4040 elimination kinetics of TCE and its major metabolites in humans and rodents. Animal studies have
4041 shown that rodents exhibit faster urinary elimination kinetics than humans, with demonstrated
4042 elimination half-lives of just over 50 hours in humans and only approximately 16 hours in rats ([Ikeda](#)
4043 [and Imamura, 1973](#)).

4044 **3.2.2.5 Physiologically-Based Pharmacokinetic (PBPK) Modeling Approach**

4045 Given the complicated metabolic profile of TCE, understanding the relationship between the external
4046 dose/concentration (*i.e.*, exposure) and internal dose at the target organ of interest is critical to
4047 quantifying potential risk(s) because internal dose is more closely associated with toxicity at the target
4048 tissue ([U.S. EPA, 2006](#)). Predictions of internal dose in chemical risk assessments for a given external
4049 applied dose/concentration are achieved by employing PBPK modeling.

4050 PBPK models use a series of mathematical representations to describe the absorption, distribution,
4051 metabolism and excretion (ADME) of a chemical and its metabolites. Because PBPK modeling assumes
4052 that the toxic effects in the target tissue are closely related to the internal dose of the biologically active
4053 form of the chemical, knowledge about the chemical's mode of action guides the selection of the
4054 appropriate dose metric. Traditional risk estimates based on applied dose carry higher uncertainties than
4055 those based on PBPK-derived internal dose metrics because they do not account for the toxicokinetics of
4056 the chemical, which are both dose and time-dependent. This reduction in uncertainty and the versatility
4057 of PBPK approaches have resulted in a growing interest to use these models in risk assessment products
4058 ([U.S. EPA, 2006](#)).

4059 U.S. EPA developed a peer-reviewed comprehensive Bayesian PBPK model-based analysis of TCE and
4060 its metabolites in mice, rats and humans ([U.S. EPA, 2011e](#)). This model is briefly discussed below to
4061 provide clarity on how the PBPK modeling was used to estimate the PBPK-derived HECs. For all PBPK
4062

4066 model files, including inputs and outputs of all model runs, see [*PBPK Model and ReadMe (zipped)*].
 4067 Docket: [EPA-HQ-OPPT-2019-0500](#).
 4068

4069 Physiological, chemical, *in vitro* and *in vivo* data were considered when building the PBPK model,
 4070 including many studies in animals and humans that quantified TCE levels in various tissues following
 4071 oral and inhalation exposures. Some of these studies provided key data/ parameters for the calibration of
 4072 the PBPK model used in the IRIS assessment ([U.S. EPA, 2011e](#)). All of this information was used to
 4073 build a model that was able to predict different dose metrics as measures of potential TCE toxicity. Each
 4074 dose-metric was developed to evaluate a different metabolic pathway/target organ effect based on the
 4075 dose-response analysis and understanding of metabolism (Table 3-5 and Figure 3-4).
 4076

4077 The internal dose-metric for addressing cross-species pharmacokinetics is based on the EPA's cross-
 4078 species scaling methodology. The preferred dose-metric for the parent compound under this
 4079 methodology is equivalent to the daily AUC of the active moiety (parent compound or metabolite). For
 4080 metabolites, in cases where the rate of production, but not the rate of clearance, of the active moiety can
 4081 be estimated, the preferred dose-metric is the rate of metabolism (through the appropriate pathway)
 4082 scaled by body weight to the $\frac{3}{4}$ power. If there are sufficient data to consider the active metabolite
 4083 moiety(ies) reactive and cleared through nonbiological processes, then the preferred dose-metric is the
 4084 rate of metabolism (through the appropriate pathway) scaled by the tissue mass. Finally, if local
 4085 metabolism is thought to be involved, but cannot be estimated with the available data, then the AUC of
 4086 the parent compound in blood is considered an appropriate surrogate and thus the preferred dose-metric.
 4087 In general, an attempt was made to use tissue-specific dose-metrics representing particular pathways or
 4088 metabolites identified from reasonably available data on the role of metabolism in toxicity for each
 4089 endpoint (discussed in more detail below). The selection was limited to dose metrics for which
 4090 uncertainty and variability could be adequately characterized by the PBPK model. For most endpoints,
 4091 sufficient information on the role of metabolites or mode of action was not available to identify likely
 4092 relevant dose metrics, and more upstream metrics representing either parent compound or total
 4093 metabolism had to be used. Both preferred or primary dose metrics and alternative dose metrics were
 4094 selected for each endpoint based on biological support for their involvement in TCE toxicity.
 4095

4096 **Table 3-5. List of All of the PBPK-Modeled Dose Metrics Considered in this Risk Evaluation**

<i>Dose-Metric Identifier</i>	<i>Dose-Metric Definition</i>
ABioactDCVCBW34	Amount of DCVC bioactivated in the kidney per unit adjusted body weight
ABioactDCVCKid	Amount of DCVC bioactivated in the kidney per unit kidney mass
AMetGSHBW34	Amount of TCE conjugated with GSH per unit adjusted body weight
AMetLiv1BW34	Amount of TCE oxidized in liver per unit adjusted body weight
AMetLivOtherBW34	Amount of TCE oxidized to metabolites other than TCA or TCOH per unit adjusted body weight
AMetLivOtherLiv	Amount of TCE oxidized to metabolites other than TCA or TCOH per unit liver weight
AMetLngBW34	Amount of TCE oxidized in respiratory tract per unit adjusted body weight
AMetLngResp	Amount of TCE oxidized in respiratory tract per unit respiratory tract tissue
AUCCBld	Area under the curve of venous blood concentration of TCE
AUCCTCOH	Area under the curve of blood concentration of TCOH
AUCLivTCA	Area under the curve of the liver concentration of TCA
TotMetabBW34	Total amount of TCE metabolized per unit adjusted body weight
TotOxMetabBW34	Total amount of TCE oxidized per unit adjusted body weight
TotTCAInBW	Total amount of TCA produced

4097

4098 For developmental toxicity endpoints, the TCE PBPK model did not incorporate a pregnancy model to
4099 estimate the internal dose of TCE in the developing fetus. In this case, the maternal dose-metric was used
4100 as the surrogate measure of target tissue dose in the developing fetus. This was considered reasonable
4101 because TCE and the major circulating metabolites (TCA and TCOH) appear to cross the placenta and
4102 maternal metabolizing capacity is generally greater than that of the fetus. In the cases where exposure
4103 continues after birth (([Peden-Adams et al., 2006](#)), Section 3.2.5.1.6), no PBPK model-based internal dose
4104 was used. Because of the complicated fetus/neonate dosing that includes transplacental, lactational, and
4105 direct (if dosing continues postweaning) exposure, the maternal internal dose is no more accurate a
4106 surrogate than applied dose in this case. A complete description of the TCE PBPK model, including the
4107 rationale for parameter choices in animals and humans, choice of dose metric, and experimental
4108 information used to calibrate and optimize the model is found in the TCE IRIS assessment ([U.S. EPA,
4109 2011e](#)).

4111 As shown in Figure 3-4 and Figure 3-5, several steps were needed to derive the PBPK-derived HECs
4112 used in this assessment. First, the rodent PBPK model was run to estimate rodent internal doses (for
4113 rodent toxicity studies) for the applied doses in a study based on the selected dose metric (Table 3-5).
4114 The internal dose Point of Departure (idPOD) is then obtained either directly from the internal dose
4115 corresponding to the applied dose LOAEL/NOAEL, or by BMD modeling of responses based on internal
4116 doses. Separately, the human PBPK model was run for a range of continuous exposures from 0.1 to
4117 2,000 ppm or 0.1 to 2,000 mg/kg-bw/day to establish the relationship between human exposure air levels
4118 and internal dose for the same dose-metric evaluated in the rodent PBPK model. This relationship was
4119 used to derive Human Equivalent Concentrations (HECs) and Human Equivalent Doses (HEDs)
4120 corresponding to the idPOD by interpolation. Median values of dose metric estimates were used for
4121 determining rodent internal doses, while both median (50th percentile) and 99th percentile values were
4122 determined for HECs and HEDs ([U.S. EPA, 2011e](#)).




Figure 3-4. Dose-Response Analyses of Rodent Non-Cancer Effects Using the Rodent and Human PBPK Models

Figure adapted from Figure 5-2 (Chapter 5, TCE IRIS assessment) (U.S. EPA, 2011e). Square nodes indicate point values, circle nodes indicate distributions and the inverted triangle indicates a (deterministic) functional relationship.

4123
4124
4125
4126
4127
4128




Figure adapted from Figure 5-3 (Chapter 5, TCE IRIS assessment)

Notes: When using benchmark dose estimates, the idPOD is the modeled BMDL in internal dose units.

Figure 3-5. Example of HEC99 Estimation through Interpecies, Intraspecies and Route-to-Route Extrapolation from a Rodent Study LOAEL/NOAEL

4129
4130
4131
4132

4133 The rodent population model was designed to characterize study-to-study variation and used median
4134 (50th percentile) values of dose-metrics to generate idPODs. The rodent PBPK model did not characterize
4135 variation within studies and assumed that the rodent idPODs were for pharmacokinetically identical
4136 animals. The basis of that assumption was that animals with the same sex/species/strain combination
4137 were considered pharmacokinetically identical and represented by the group average. In practice, the use
4138 of median versus mean internal doses for rodents did not make a substantial difference except when the
4139 uncertainty in the rodent dose-metric was high ([U.S. EPA, 2011e](#)).

4141 On the other hand, the human population model characterizes toxicokinetic uncertainty and individual-
4142 to-individual variation and used median, 95th and 99th percentile values of dose- metrics to general
4143 human idPODs. The 50th, 95th, or 99th percentile of the combined uncertainty and variability distribution
4144 of human internal doses was used to derive the HEC/HED₅₀, HEC/HED₉₅ or HEC/HED₉₉ estimates,
4145 respectively. The HEC₉₅ and HEC₉₉ were interpreted as being the concentrations of TCE in air for which
4146 there is 95% and 99% likelihood, respectively, that a randomly selected individual will have an internal
4147 dose less than or equal to the idPOD derived from the rodent study. HED values represent the same
4148 likelihood for given administered doses of TCE. This Risk Evaluation presents both HEC/HED₅₀ and
4149 HEC/HED₉₉ POD values.

4150 **3.2.3 Hazard Identification**

4151 **3.2.3.1 Non-Cancer Hazards**

4152 EPA previously identified human health hazard for the below endpoints in ([U.S. EPA, 2011e](#)) and ([U.S.](#)
4153 [EPA, 2014b](#)). Key and supporting studies from those publications that were used for derivation of tissue-
4154 specific PODs were reviewed along with any newer studies identified through EPA's updated literature
4155 search beginning with studies published after the TCE IRIS assessment ([U.S. EPA, 2011e](#)). A short
4156 summary of the overall database and short details on any older key studies or relevant new studies are
4157 provided here; details on all reviewed studies can be found in [*Data Extraction for Human Health*
4158 *Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)].*

4159 **3.2.3.1.1 Liver toxicity**

4160 Several studies have demonstrated liver toxicity in both animals and humans exposed to TCE. Specific
4161 effects include the following structural changes: increased liver weight, increase in deoxyribonucleic
4162 acid (DNA) synthesis (transient) and polyploidy, enlarged hepatocytes, enlarged nuclei, and
4163 peroxisome proliferation.

4164
4165 The role of metabolites is important but not well understood. Many investigators have dosed animals
4166 with TCE, as well as with many of its metabolites to determine the role and potency of each in terms
4167 of target organ toxicity. It appears that the oxidation pathway is important for the development of liver
4168 toxicity, but the specific role of each metabolite (*i.e.*, that of TCA, DCA, and chloral hydrate), as well
4169 as the parent TCE, is unclear.

4170
4171 EPA did not identify any new repeat-dose experimental studies in animals or human epidemiological
4172 studies that would contribute significant additional hazard information for this endpoint. Therefore,
4173 EPA relied primarily on conclusions from the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S.](#)
4174 [EPA, 2014b](#)).

4176 Human Data

4177 Several human studies (including those in TCE degreaser operations) reported an association between
4178 TCE exposure and significant changes in serum liver function tests used in diagnosing liver disease,

4179 or changes in plasma or serum bile acids. There was also human evidence for hepatitis accompanying
4180 immune-related generalized skin diseases, jaundice, hepatomegaly, hepatosplenomegaly, and liver
4181 failure in TCE-exposed workers ([U.S. EPA, 2011e](#)). Cohort studies examining cirrhosis and either
4182 TCE exposure or solvent exposure did not generally identify a statistically significant association, but
4183 due to limitations in this database these studies do not rule out an association between TCE and liver
4184 disorders/toxicity ([U.S. EPA, 2011e](#)). A case study published after the 2011 IRIS Assessment reported
4185 TCE hypersensitivity-induced liver damage ([Jung et al., 2012](#)).

4186

4187 Animal Data

4188 The 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) reviewed many oral and
4189 inhalation studies in rats and mice. Studies in animals exposed to TCE reported increased liver weight, a
4190 small, transient increase in DNA synthesis, enlarged hepatocytes, increased size of nuclei of liver cells,
4191 and proliferation of peroxisomes ([U.S. EPA, 2011e](#)). Dose-responsive increases in relative liver weight
4192 (compared to body weight) were observed both following administration of TCE for 6 weeks via
4193 gavage ([Buben and O'Flaherty, 1985](#)) and for up to 120 days via inhalation ([Woolhiser et al., 2006](#);
4194 [Kjellstrand et al., 1983](#)). Hypertrophy, histopathology, cytotoxicity, and altered serum biochemistry
4195 were also observed in mice in ([Buben and O'Flaherty, 1985](#)) with histopathology including
4196 vacuolization and inflammatory cell infiltration observed in ([Kjellstrand et al., 1983](#)). Increased liver
4197 weight was additionally observed in ([Boverhof et al., 2013](#)), identified in the EPA literature search,
4198 following 6 hr/day inhalation exposure to a single concentration level (1000 ppm) of TCE for 4 weeks.

4199 **3.2.3.1.2 Kidney toxicity**

4200 Studies in both humans and animals have shown changes in the proximal tubules of the kidney
4201 following exposure to TCE. DCVC (and to a lesser extent other metabolites) appears to be responsible
4202 for kidney damage and kidney cancer following TCE exposure ([U.S. EPA, 2011e](#)). Toxicokinetic
4203 data suggest that the TCE metabolites derived from GSH conjugation (in particular DCVC) can be
4204 systemically delivered or formed in the kidney. Importantly, DCVC-treated animals showed the same
4205 type of kidney damage as those treated with TCE ([U.S. EPA, 2011e](#)).

4206

4207 EPA did not identify any new repeat-dose experimental studies in animals or human epidemiological
4208 studies that would contribute significant additional hazard information for this endpoint. Therefore,
4209 EPA relied primarily on conclusions from the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S.
4210 EPA, 2014b](#)).

4211

4212 Human Data

4213 Occupational studies showed increased levels of kidney damage (proximal tubules) and end-stage
4214 renal disease in TCE-exposed workers. Human studies reported increased excretion of urinary proteins
4215 among TCE-exposed workers when compared to unexposed controls. While some of these studies
4216 included subjects previously diagnosed with kidney cancer, other studies report similar results in
4217 subjects who are disease free ([U.S. EPA, 2011e](#)).

4218

4219 Animal Data

4220 In animal studies, renal toxicity was evident in both rats and mice following inhalation or gavage
4221 exposures. Maltoni and Cotti ([1986](#)) identified pathological changes in the renal tubule of rats following 1-
4222 2 years of either oral or inhalation exposure. Similar changes were also observed in a chronic gavage study
4223 in female mice conducted by NCI, ([NCI, 1976](#)), however that study scored Unacceptable in EPA data
4224 quality evaluation due to high mortality in control mice and rats as well as long post-exposure period prior
4225 to sacrifice that could have allowed for recovery. The toxicity included damage to the renal tubules (*e.g.*,
4226 both cytomegaly and karyomegaly). In a chronic gavage study, kidney toxicity was observed in almost

4227 100 percent of rodents at high doses ([NTP, 1988](#)). Under inhalation exposure scenarios, male rats were
4228 more susceptible than female rats or mice to kidney toxicity. As noted earlier, this toxicity is likely
4229 caused by DCVC formation through conjugative metabolism ([U.S. EPA, 2011e](#)). Increased relative
4230 kidney weight compared to body weight was also observed in both mice and rats following inhalation
4231 exposure over several weeks to months ([Boverhof et al., 2013](#); [Woolhiser et al., 2006](#); [Kjellstrand et](#)
4232 [al., 1983](#)).

4233 **3.2.3.1.3 Neurotoxicity**

4234 Neurotoxicity has been demonstrated in animal and human studies under both acute and chronic
4235 exposure conditions ([U.S. EPA, 2011e](#)). Due to the effects on the nervous system, TCE was initially
4236 synthesized for use as an anesthetic in humans in the early part of the 20th century. These anesthetic-like
4237 effects occurred at high concentrations. CNS depression has been consistently observed following
4238 acute exposure of humans to TCE (see Section 3.2.3.1.7).

4239
4240 Among newer studies not previously discussed in ([U.S. EPA, 2011e](#)), a single repeat-dose
4241 experimental study in rats ([Liu et al., 2010](#)) along with a few epidemiological studies that identified
4242 specific neurological outcomes were identified in EPA's literature search. These studies only add to
4243 and do not contradict the hazard conclusions from the 2014 TSCA Work Plan Chemical Risk
4244 Assessment ([U.S. EPA, 2014b](#)). Therefore, EPA primarily relied on the previous hazard conclusions.

4245 Human Data

4247 Evaluation of the human studies has reported the following TCE-induced neurotoxic effects:
4248 alterations in trigeminal nerve and vestibular function, auditory effects, changes in vision, alterations
4249 in cognitive function, changes in psychomotor effects, and neurodevelopmental outcomes ([U.S. EPA,](#)
4250 [2011e](#)).

4251
4252 Multiple epidemiological studies in different populations have reported TCE-induced abnormalities in
4253 trigeminal nerve function in humans, with a few studies not reporting any association ([U.S. EPA,](#)
4254 [2011e](#)). The strongest evidence of human neurological hazard is for observed changes in trigeminal
4255 nerve function or morphology and impairment of vestibular function in a High quality study on workers
4256 exposed to TCE for a mean of 16 years ([Ruijten et al., 1991](#)). Fewer and more limited epidemiological
4257 studies are suggestive of TCE exposure being associated with delayed motor function, and changes in
4258 auditory, visual, and cognitive function or performance, and neurodevelopmental abnormalities ([U.S.](#)
4259 [EPA, 2011e](#)).

4260
4261 Human studies have consistently reported vestibular system-related symptoms such as headaches,
4262 dizziness, and nausea following TCE exposure. Although these symptoms are subjective and self-
4263 reported, these effects have been reported extensively in human chamber, occupational, and
4264 geographic-based/drinking water studies ([U.S. EPA, 2011e](#)). Additionally, several newer
4265 epidemiological studies have found an association between TCE exposure and neurodegenerative
4266 disorders such as Amyotrophic Lateral Sclerosis ([Bove et al., 2014a](#)) and Parkinson's disease ([Bove et](#)
4267 [al., 2014b](#); [Goldman et al., 2012](#)).

4269 Animal Data

4270 The 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) reviewed many animal
4271 studies reporting a variety of neurotoxic effects under different exposure conditions. Animal studies
4272 have reported the following TCE-induced neurotoxic effects: morphological changes in the trigeminal
4273 nerve, disruption of the auditory system, visual changes, structural or functional changes in the

4274 hippocampus, sleep disturbances and changes in psychomotor effects ([U.S. EPA, 2011e](#)). Key and
4275 supporting studies considered in this Risk Evaluation identified significant decreases in wakefulness
4276 following 6 weeks of TCE inhalation exposure ([Arito et al., 1994](#)) and demyelination of the
4277 hippocampus following 8 weeks of drinking water exposure ([Isaacson et al., 1990](#)) in rats. Neuronal
4278 degeneration ([Gash et al., 2008](#)) and diminished sciatic nerve regeneration ([Kjellstrand et al., 1987](#))
4279 were also observed following TCE exposure in rodents, however those studies scored Low and
4280 Unacceptable, respectively in data quality evaluation. More recent studies have observed both sedative
4281 ([Wilmer et al., 2014](#)) and stimulatory effects ([Shelton and Nicholson, 2014](#)) of TCE via inhalation at
4282 doses at or above 5000 ppm. Rats administered TCE via gavage for 6 weeks demonstrated loss of
4283 dopaminergic neurons at 500 and 1000 mg/kg-day, with changes in behavior and reduced
4284 mitochondrial activity with increased oxidative stress observed at 1000 mg/kg-day ([Liu et al., 2010](#)).

4285 **3.2.3.1.4 Immunotoxicity**

4286 Immune-related effects following TCE exposures have been observed in both animal and human
4287 studies. In general, these effects were associated with both inducing enhanced immune responses as
4288 well as immunosuppressive effects. These effects may influence a variety of other conditions of
4289 considerable public health importance, such as susceptibility to infection, cancer and atherosclerosis
4290 ([U.S. EPA, 2011e](#)).

4291
4292 EPA's literature search identified a single acute inhalation study in rats that identified a novel endpoint
4293 for impaired response to infection ([Selgrade and Gilmour, 2010](#)). This study was discussed in the TCE
4294 IRIS assessment ([U.S. EPA, 2011e](#)) but was not included in the 2014 TSCA Work Plan Chemical
4295 Risk Assessment ([U.S. EPA, 2014b](#)). All other studies supported the hazard conclusions of the 2014
4296 TCE Risk Assessment ([U.S. EPA, 2014b](#)). Therefore, EPA primarily relied on the previous hazard
4297 conclusions for all other endpoints.
4298

4299 Human Studies

4300 **Autoimmunity/Inappropriate Immune Activation**

4301 Studies have reported a relationship between systemic autoimmune diseases, such as scleroderma, and
4302 occupational exposure to TCE. The TCE IRIS assessment ([U.S. EPA, 2011e](#)) performed a meta-
4303 analysis of a number of human studies evaluating a possible connection between scleroderma and TCE
4304 exposure. Results indicated a significant odds ratio (OR) in men, whereas women showed a lower but
4305 not significant OR. These results may not reflect a true sex difference because the incidence of this
4306 disease is very low in men (approximately one per 100,000 per yr) and somewhat higher in women
4307 (approximately one per 10,000 per yr). In addition, these results may be affected by sex-related
4308 differences in exposure prevalence, the reliability of the exposure assessment, sex-related differences
4309 in susceptibility to TCE toxicity or chance ([U.S. EPA, 2011e](#)).
4310

4311 Increased levels of human inflammatory cytokines have been observed in both workers exposed
4312 occupationally to TCE and infants exposed to TCE via indoor air ([U.S. EPA, 2011e](#)). These findings
4313 were supported by studies in mice (described below) in which short exposures to TCE resulted in
4314 increased levels of inflammatory cytokines.
4315

4316 **Immunosuppression**

4317 The epidemiological database also provides limited evidence of immunosuppression based on
4318 reduced IgG antibody levels in TCE-exposed workers ([Zhang et al., 2013](#)).
4319
4320
4321

4322 Animal Data

4323 **Autoimmunity/Inappropriate Immune Activation**

4324 Numerous studies have shown increased autoimmune responses in autoimmune-prone mice, including
4325 changes in cytokine levels similar to those reported in human studies, with more severe effects, including
4326 autoimmune hepatitis, inflammatory skin lesions, and alopecia, manifesting at longer exposure periods
4327 ([U.S. EPA, 2011e](#)). Key studies identified evidence of autoimmunity from chronic TCE exposure in both
4328 non-autoimmune prone ([Keil et al., 2009](#)) and autoimmune prone ([Wang et al. 2012](#); [Gilbert et al. 2006](#);
4329 [Griffin et al. 2000](#); [Kaneko et al. 2000](#)) mice.

4331 *Sensitization / Hypersensitivity*

4332 Limited epidemiological data do not support an association between TCE exposure and allergic
4333 respiratory sensitization or asthma. However, there have been a large number of case reports and
4334 epidemiological studies ([Kang et al. 2018](#); [Liu 2009](#); [Xu et al. 2009](#); [Nakajima et al. 2003](#);
4335 [Chittasobhaktra et al. 1997](#); [Bond 1996](#)) of TCE-exposed workers developing a severe hypersensitivity
4336 skin disorder, distinct from contact dermatitis, and often accompanied by systemic effects (*e.g.*, hepatitis,
4337 lymph node changes, and other organ effects including cardiac arrest in at least one instance). These
4338 effects appeared after inhalation exposures ranging from less than 9 to greater than 700 ppm TCE.
4339 Similar sensitization/hypersensitivity effects have been observed in guinea pigs and mice following TCE
4340 exposure via drinking water ([U.S. EPA, 2011e](#)), including in the autoimmune-prone MRL+/+ mouse line
4341 ([Griffin et al. 2000](#)).

4343 **Immunosuppression**

4344 Evidence of localized immunosuppression has also been reported in mice and rats ([Boverhof et al.,](#)
4345 [2013](#); [Woolhiser et al., 2006](#); [Sanders et al., 1982](#)). Support for immunotoxicity hazard is further
4346 supported by decreased thymus weight and cellularity in the non-autoimmune prone mice following up
4347 to 30 weeks of drinking water exposure ([Keil et al., 2009](#)).

4349 Inhalation exposure to TCE has been shown to suppress pulmonary host defenses and enhance
4350 susceptibility to respiratory infection in mice co-exposed to aerosolized pathogenic bacteria. Increased
4351 mortality was observed post-infection following exposure to TCE concentrations of 50ppm or greater,
4352 with corresponding dose-dependent effects on bacterial clearance, percentage of infected mice, and
4353 alveolar phagocytosis ([Selgrade and Gilmour, 2010](#)).

4354 **3.2.3.1.5 Reproductive toxicity**

4355 The epidemiological, animal, and mechanistic literature provide suggestive, but limited, evidence of
4356 adverse outcomes to female reproductive toxicity. However, much more extensive evidence exists in
4357 support of an association between TCE exposures and male reproductive toxicity ([U.S. EPA, 2011e](#)).

4359 The reasonably available human data that associate TCE with adverse effects on male reproductive
4360 function are limited in sample size and provide little quantitative dose data. However, the animal data
4361 provide strong and compelling evidence for TCE-related male reproductive toxicity. Strengths of the
4362 animal database include the presence of both functional and structural outcomes, similarities in adverse
4363 treatment-related effects observed in multiple species, and evidence that metabolism of TCE in male
4364 reproductive tract tissues is associated with adverse effects on sperm measures in both humans and
4365 animals. Additionally, some aspects of a putative mode of action (*e.g.*, perturbations in testosterone
4366 biosynthesis) appear to have some commonalities between humans and animals ([U.S. EPA, 2011e](#)).

4368 EPA did not identify any new repeat-dose experimental studies in animals or human epidemiological
4369 studies that would contribute significant additional hazard information for this endpoint. Therefore,

4370 EPA relied primarily on conclusions from the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S.](#)
4371 [EPA, 2014b](#)).

4372

4373 Human Data

4374 Most human studies support an association between TCE exposure and alterations in sperm density
4375 and quality, as well as changes in sexual drive or function and serum endocrine levels. Chia et al.
4376 (1996) observed decreased normal sperm morphology along with hyperzoospermia in male workers
4377 averaging over five years occupational exposure. Fewer epidemiological studies exist linking decreased
4378 incidence of fecundability (time-to-pregnancy) and menstrual cycle disturbances in women with TCE
4379 exposures ([U.S. EPA, 2011e](#)).

4380

4381 Animal Data

4382 Laboratory animal studies provide evidence for similar effects, particularly for male reproductive
4383 toxicity. These animal studies have reported effects on sperm, libido/copulatory behavior, and serum
4384 hormone levels, although some studies that assessed sperm measures did not report treatment-related
4385 alterations ([U.S. EPA, 2011e](#)). Identified key and supporting studies have observed TCE-related
4386 histopathological lesions in the testes or epididymides, altered *in vitro* sperm-oocyte binding, and
4387 increased incidence of irregular sperm in rodents ([Kan et al., 2007](#); [Xu et al., 2004](#); [Kumar et al., 2001](#);
4388 [Kumar et al., 2000](#)). Forkert et al. (2002) also observed effects on the epididymis, however that study
4389 was unacceptable in data quality evaluation. Similarly, decreased *in vitro* fertilization resulted from
4390 exposure of male rats to TCE in drinking water in one study ([Duteaux et al., 2004](#)), however that
4391 study scored a Low in data quality evaluation.

4392

4393 Fewer animal studies are reasonably available for the female reproductive toxicity endpoint. While *in*
4394 *vitro* oocyte fertilizability has been reported to be reduced as a result of TCE exposure in rats, a
4395 number of other laboratory animal studies did not report adverse effects on female reproductive
4396 function effects ([U.S. EPA, 2011e](#)). The key study Narotsky et al. (1995) observed delayed parturition
4397 in female rats. Exposure of either males or females to TCE in feed resulted in reduced successful
4398 copulation and an associated decrease in the number of live pups and litters ([George et al., 1986](#)). A
4399 recent study found that a single high dose of TCE administered orally to rats resulted in reduced fetal
4400 weight and indicators of placental oxidative stress ([Loch-Caruso et al. 2019](#)). A series of studies have
4401 found that the reactive conjugative metabolite DCVC induces oxidative stress and cell death in a
4402 placental cell line ([Elkin et al. 2020](#)), although there is uncertainty relating to the relevance of DCVC
4403 to reproductive toxicity outcomes.

4404 **3.2.3.1.6 Developmental Toxicity**

4405 Developmental toxicity refers to endpoints affecting fetal or neonatal outcomes. An evaluation of the
4406 human and animal developmental toxicity data suggests an association between pre- and/or postnatal
4407 TCE or TCE metabolite exposures and potential developmental adverse outcomes. Heart
4408 malformations observed after developmental TCE exposure in animal studies were identified in the
4409 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) as the most sensitive
4410 developmental toxicity endpoint for dose-response analysis. The developmental toxicity information is
4411 briefly described below, including information from the 2014 TCE TSCA Work Plan Chemical Risk
4412 Assessment and more recent studies.

4413

4414 For developmental toxicity other than congenital heart defects EPA did not identify any new repeat-
4415 dose experimental studies in animals or human epidemiological studies that would contribute
4416 significant novel information for this hazard. Therefore, EPA relied primarily on conclusions from the
4417 2014 TCE TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) for these other endpoints.

4418 For congenital heart defects, EPA evaluated more recent epidemiological studies, mechanistic studies,
4419 and a single experimental animal study that provide conflicting evidence for this endpoint.

4420

4421 Human Data

4422 The 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) evaluated numerous human
4423 studies that examined the possible association of TCE with various developmental outcomes, including
4424 prenatal (*e.g.*, spontaneous abortion and perinatal death, decreased birth weight, and congenital
4425 malformations) and postnatal (*e.g.*, growth, survival, developmental neurotoxicity, developmental
4426 immunotoxicity, and childhood cancers) health outcomes. Most of these were occupational
4427 epidemiology studies. In addition, geographically-based epidemiological studies have been conducted
4428 in various parts of the United States, including Arizona (Tucson Valley), Colorado (Rocky Mountain
4429 Arsenal), Massachusetts, New York (Endicott), Camp Lejeune, North Carolina and Milwaukee,
4430 Wisconsin ([U.S. EPA, 2011e](#)).

4431

4432 **Perinatal death, decreased birth weight, and birth defects**

4433 The Endicott, New York, and the Camp Lejeune studies focused on reproductive and developmental
4434 outcomes. Some of these studies have reported associations between parental exposure to TCE and
4435 spontaneous abortion or perinatal death, and decreased birth weight. However, other occupational and
4436 geographically-based studies have failed to detect a positive association between TCE exposure and
4437 developmental toxicity in humans ([U.S. EPA, 2011e](#)).

4438

4439 ATSDR has conducted studies at Camp Lejeune, North Carolina, where individuals were exposed to
4440 VOC-contaminated drinking water ([Ruckart et al., 2014, 2013](#)). TCE was one of the main contaminants
4441 found in the drinking water. Ruckart et al. found an association between neural tube defects and TCE
4442 exposure above 5 ppb during the first trimester of pregnancy, however null to negative associations
4443 were identified between TCE exposure and other developmental effects (*e.g.*, reduced birth weight, oral
4444 cleft defects). Yauck et al. (2004) observed a strong relative risk estimate for cardiac malformations in
4445 infants from Milwaukee, Wisconsin born to TCE-exposed mothers aged 38 years or older. In addition to
4446 older age, increased risk was also independently associated with other confounders including alcohol
4447 use, hypertension, and diabetes. Forand et al. (2012) (an update for the Endicott, NY community)
4448 reported significant relative risk estimates for low birth weight, small for gestational age, and cardiac
4449 defects. See the below section for further discussion of congenital heart defects.

4450

4451 Other studies have also identified an association between exposure to TCE exposure and
4452 developmental effects. One study reported increased risk of spina bifida to offspring of TCE-exposed
4453 mothers ([Swartz et al., 2015](#)), and both statistically significant and non-significant associations have
4454 been observed between exposure to the TCE metabolites trichloroacetic acid and trichloroethanol with
4455 various outcomes including oral clefts, urinary tract malformations, and limb defects ([Cordier et al.,
4456 2012](#)). In contrast, ([Brender et al., 2014](#)) found no statistically significant association with neural tube
4457 defects, spina bifida, anenocephaly, any oral cleft, cleft palate, cleft lip with or without cleft palate, any
4458 limb deficiency, or longitudinal or transverse limb deficiencies. The study did identify an increased risk
4459 of septal heart defects (see below section), however.

4460

4461 **Developmental neurotoxicity**

4462 As for human developmental neurotoxicity, the available studies collectively suggest that the
4463 developing brain is susceptible to TCE toxicity. These studies have reported an association with TCE
4464 exposure and CNS congenital or postnatal effects such as delayed newborn reflexes, impaired learning
4465 or memory, aggressive behavior, hearing impairment, speech impairment, encephalopathy, impaired
4466 executive and motor function and attention deficit ([U.S. EPA, 2011e](#)).

4467

4468 **Developmental immunotoxicity**

4469 There are very few studies on developmental immunotoxicity associated with human exposure to TCE.
4470 A set of studies published by Lehman et al. (2002; 2001), cited in (U.S. EPA, 2011e) did not find any
4471 statistically significant association with allergic sensitization or change in cytokine-producing T cells
4472 based on measurements of TCE air concentrations in children's bedrooms.
4473

4474

4474 Animal Data

4475 Many of the TCE-related developmental effects reported in humans have been observed in key and
4476 supporting animal studies: increased fetal resorptions (Narotsky et al., 1995), developmental neurotoxicity
4477 (Fredriksson et al., 1993; Taylor et al., 1985), developmental immunotoxicity (Peden-Adams et al., 2006),
4478 and congenital heart defects anomalies ((Johnson et al., 2003; Dawson et al., 1993), further details
4479 below). Healy et al. (1982) observed increased resorptions, skeletal abnormalities, and decreased fetal
4480 weight, but the study scored Unacceptable in data quality evaluation. Some of the observed effects
4481 appear to be strain-specific (U.S. EPA, 2011e). Among newer studies identified in the EPA literature
4482 search, developmental neurotoxicity was indicated by increased locomotor and exploratory activities were
4483 observed following drinking water exposures to mice during nervous system development (Blossom et
4484 al., 2013), however these effects were not consistently dose-responsive. A follow-up study from that
4485 laboratory (Blossom et al. 2016) reported inflammation-mediated cerebellar oxidative stress and
4486 increased locomotor activity following gestational TCE exposure in autoimmune-prone mice, while
4487 another study demonstrated that TCE reduces cell viability and inhibits differentiation of neural
4488 progenitor cells in culture (Salama et al. 2018). In addition to the results from (Blossom et al. 2016),
4489 various indicators of developmental immunotoxicity were also observed in another MRL +/- mice study
4490 (Gilbert et al. 2014).

4491

4492 Congenital Heart Defects

4493 *In vivo* animal studies in rats and chicks have identified an association between TCE exposures and
4494 cardiac defects²² in the developing embryo and/or fetus (U.S. EPA, 2011e). The 2014 TSCA Work
4495 Plan Chemical Risk Assessment (U.S. EPA, 2014b) identified congenital heart defects following TCE
4496 exposure via drinking water as the most sensitive human health endpoint for dose-response analysis
4497 and Risk Evaluation based on data from (Johnson et al., 2003) and (Dawson et al., 1993), despite
4498 public criticisms of insufficient data reporting and other issues in these studies. Mechanistic studies
4499 have also examined various aspects of the induction of cardiac malformations. Human studies have
4500 also identified statistically significant increased risk of developmental cardiac defects following
4501 exposure to TCE (Brender et al., 2014; Forand et al., 2012; Yauck et al., 2004) or metabolites (Wright
4502 et al., 2017), with increased association for older mothers (Yauck et al., 2004; Brender et al., 2014).
4503 The critical window for cardiac development is 1-2 weeks for rodents, 1-2 weeks for chickens, and
4504 from the 3rd to the 8th week for the human fetus.

4505

4506 The scientific literature also has examples of relatively well-conducted studies in rats and mice that did
4507 not observe an increase in TCE-induced cardiac malformations. Most prominent among these include an
4508 inhalation study in rats (Carney et al., 2006) and an oral gavage study in rats (Fisher et al., 2001). Of
4509 note however, while (Fisher et al., 2001) did not report statistically-significant increases in combined
4510 cardiac and cardiovascular effects, there was a very high background incidence of cardiovascular defects

²² “Cardiac” (or “heart”) “defects,” “malformations,” and “abnormalities” are used throughout this Risk Evaluation to refer to adverse findings in the developing heart. These terms, in addition to “congenital heart defects” (CHD), are used in experimental animal, epidemiological, and/or clinical studies to characterize or categorize various morphological cardiovascular outcomes in the fetus or neonate. For the purpose of this Risk Evaluation, they are used interchangeably.

4511 in soybean oil-control rats, and the authors did observe a 19% increase in cardiac-specific defects (per-
4512 litter, statistical significance not calculated) following TCE treatment compared to controls. During the
4513 development of this Risk Evaluation, a study was completed that also did not identify a statistically
4514 significant increase in cardiac defects following TCE exposure via drinking water ([Charles River
4515 Laboratories, 2019](#)). Several epidemiological studies also report either negative ([Lagakos et al., 1986](#)) or
4516 equivocal ([Bove, 1996](#); [Bove et al., 1995](#)) statistical associations between TCE exposure and heart
4517 defects. Gilboa et al. ([2012](#)) identified a statistically significant association of perimembranous
4518 ventricular septal defects with exposure to chlorinated solvents as a class, but not to TCE alone.

4519 **3.2.3.1.7 Overt Toxicity Following Acute/Short Term Exposure**

4520
4521 Acute studies in animals consist of single exposures at high doses specifically designed for assessing
4522 the dose at which lethality occurs or for examining overt toxicity. The interim acute exposure
4523 guideline levels (AEGLs) document for TCE was consulted and used in this assessment to briefly
4524 summarize the acute toxicity data ([NAC/AEGL, 2009](#)). This section describes overt acute toxicity,
4525 representing readily observable clinical effects resulting from short-term exposure (as opposed to
4526 subclinical indications of adversity or delayed/long-term effects).

4527
4528 In humans, TCE odors can be detected at concentrations of ≥ 50 ppm. It was once commonly used as
4529 an anesthetic agent with concentrations ranging from 5,000 to 15,000 ppm for light anesthetic use and
4530 from 3,500 to 5,000 ppm for use as an analgesic. Information on the toxicity of TCE in humans comes
4531 from either case reports in the medical/occupational literature or experimental human inhalation
4532 studies. Lethality data in humans have been reported following accidental exposure to TCE. However,
4533 there is insufficient information about the exposure characterization of these incidents ([NAC/AEGL,
4534 2009](#)).

4535
4536 Human inhalation studies have shown that acute exposure to TCE results in irritation and central
4537 nervous system (CNS) effects in humans. Mild subjective symptoms and nose and throat irritation
4538 were reported by human volunteers exposed to 200 ppm TCE for 7 hrs/day on the first day of exposure
4539 during a 5-day exposure regimen. The study also reported minimal CNS depression following TCE
4540 exposure ([NAC/AEGL, 2009](#)). Laboratory studies have additionally demonstrated acute effects of
4541 TCE on the respiratory tract in the form of both localized irritation and broad fibrosis, likely
4542 dependent on oxidative metabolism. ([U.S. EPA, 2011e](#)).

4543
4544 CNS depression and effects on neurobehavioral functions were seen in human volunteers exposed to
4545 1,000 ppm TCE for a 2-hr period. In the same studies, volunteers were also exposed to 100 or 300
4546 ppm TCE for 2 hrs. Some subjects had similar CNS effects at the middle concentration (300 ppm),
4547 with no such effects observed at the 100 ppm. A different study reported slight to marginal
4548 neurobehavioral effects after exposure to 300 ppm TCE for 2.5 hrs. Cardiac arrhythmias have also
4549 been reported in humans exposed to high concentration of TCE. Several animal studies have reported
4550 neurobehavioral effects and the potential for inducing cardiac sensitization following acute inhalation
4551 exposure to TCE ([NAC/AEGL, 2009](#)).

4552
4553 The NIOSH Skin Notation Profile for TCE ([Hudson and Dotson, 2017](#)) summarizes data providing
4554 evidence for skin irritation and/or corrosion from dermal TCE exposure, with effects including rashes,
4555 blistering, and burning sensations. Eye effects and CNS effects also resulted following simultaneous
4556 vapor inhalation along with percutaneous penetration. Skin irritation potential varied greatly among
4557 individuals in volunteer studies, with some exhibiting extreme pain and others reporting at most only
4558 very mild effects. Studies on both humans and animals demonstrate that TCE is a moderate skin
4559 sensitizer, with hypersensitivity reactions observed following exposure to both TCE and various

4560 metabolites.

4561 **3.2.3.2 Genotoxicity and Cancer Hazards**

4562 **3.2.3.2.1 Genotoxicity**

4563 EPA extracted and all relevant genotoxicity studies for TCE and various important metabolites. Relevant
4564 metabolites were selected based on the species most closely associated with a potential mutagenic mode
4565 of action for cancer target sites (*i.e.*, conjugative metabolites for kidney, CH for liver, see Section
4566 3.2.4.2.2). Results of genotoxicity studies are presented in [*Data Extraction and Evaluation Tables for*
4567 *Genotoxicity Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)]. All identified relevant studies were included
4568 in the data tables for comparison and transparency, including studies that scored Unacceptable or could
4569 not be evaluated. Only acceptable studies were considered in the genotoxicity weight of scientific
4570 evidence and cancer MOA assessment (Section 3.2.4.2.2). There was no overall particular pattern of
4571 excluded studies among positive and negative results, except for GSH conjugation metabolites where all
4572 of the negative studies were deemed unacceptable.*

4573
4574 Overall, TCE genotoxicity was mostly negative in bacterial and yeast systems, although metabolic
4575 activation did induce genotoxicity in a few otherwise negative assays. Results were mixed in
4576 mammalian systems, with positive results observed both with and without metabolic activation across
4577 the database. The metabolite CH was mostly positive across a wide variety of assays both *in vitro* and *in*
4578 *vivo/ex vivo*, however positive results were more consistently observed in *in vitro* systems. GSH
4579 conjugative metabolites such as DCVC were predominantly positive in a variety of assays in both
4580 bacteria and mammalian kidney tissue.

4581 **3.2.3.2.2 Kidney cancer**

4582 The TCE IRIS assessment concluded that TCE is “carcinogenic to humans” based on convincing
4583 evidence of a causal relationship between TCE exposure in humans and kidney cancer. A review of
4584 TCE by the International Agency for Research on Cancer (IARC) also supported this conclusion
4585 ([IARC, 2014](#)). The carcinogenic classification was based on a review of more than 30 human studies,
4586 including studies in TCE degreasing operations, and meta-analyses of the cohort and case- control
4587 studies. Relative risk estimates for increased kidney cancer were consistent across a large number of
4588 epidemiological studies of different designs and populations from different countries and industries
4589 (Appendix C, ([U.S. EPA, 2011b](#))). This strong consistency of the epidemiologic data on TCE and
4590 kidney cancer argues against chance, bias, and confounding as explanations for the elevated kidney
4591 cancer risks ([U.S. EPA, 2011e](#)).

4592
4593 Cancer bioassays with TCE in animals (*i.e.*, both gavage and inhalation exposure routes) did not show
4594 increased kidney tumors in mice, hamsters, or female rats, but did show a slight increase in male rats.
4595 Kidney tumors in rats are relatively rare ([U.S. EPA, 2011e](#)).

4596
4597 The toxicokinetic data and the genotoxicity of DCVC further suggest that a mutagenic mode of action
4598 is involved in TCE-induced kidney tumors, although cytotoxicity followed by compensatory cellular
4599 proliferation cannot be ruled out. As for the mutagenic mode of action, both genetic polymorphisms
4600 (GST pathway) and mutations to tumor suppressor genes have been hypothesized as possible
4601 mechanistic key events in the formation of kidney cancers in humans ([U.S. EPA, 2011e](#)).

4602 **3.2.3.2.3 Liver cancer**

4603 U.S. EPA concluded that TCE exposure causes liver tumors in mice but not rats and the meta-analysis
4604 of human data on liver and gallbladder/biliary passages indicated “...a small, statistically significant

4605 *increase in risk*". Multiple TCE metabolites (*i.e.*, and thus pathways) likely contribute to TCE-induced
4606 liver tumors ([U.S. EPA, 2011e](#)).

4607

4608 Previous meta-analyses of the cohort, case-control, and community (geographic) studies reporting liver
4609 and biliary tract cancer, primary liver cancer, and gallbladder and extra-hepatic bile duct cancer (see
4610 Appendix C in ([U.S. EPA, 2011b](#))) reported a small, statistically significant summary relative risk
4611 (RR_m, overall RR from meta-analysis) for liver and gallbladder/biliary cancer with overall TCE
4612 exposure. However, the meta-analyses reported a lower, nonstatistically significant RR_m for primary
4613 liver cancer when using the highest exposure groups ([U.S. EPA, 2011b](#)).

4614

4615 With respect to liver carcinogenicity, TCE and its oxidative metabolites TCA, DCA, and CH are
4616 clearly carcinogenic in mice, with strain and sex differences in potency. Data in other laboratory animal
4617 species are limited; thus, except for DCA which is carcinogenic in rats, inadequate evidence exists to
4618 evaluate the hepatocarcinogenicity of TCE and its metabolites in rats or hamsters ([U.S. EPA, 2011e](#)).

4619 **3.2.3.2.4 Cancer of the immune system**

4620 Human studies have reported cancers of the immune system resulting from TCE exposure. Lymphoid
4621 tissue neoplasms arise in the immune system and result from events that occur within immature
4622 lymphoid cells in the bone marrow or peripheral blood (leukemias), or more mature cells in the
4623 peripheral organs (non-Hodgkin's lymphoma). The broad category of lymphomas can be divided into
4624 specific types of cancers, including non-Hodgkin's lymphoma, Hodgkin lymphoma, multiple
4625 myeloma, and various types of leukemia (*e.g.*, acute and chronic forms of lymphoblastic and myeloid
4626 leukemia). Leukemia during childhood has been observed in a number of studies in children exposed
4627 to TCE, however this association has not been confirmed ([U.S. EPA, 2011e](#)).

4628

4629 One of the three cancers for which the TCE IRIS assessment based its cancer findings was non-
4630 Hodgkin's lymphoma (NHL) (the other two being kidney and liver cancer) ([U.S. EPA, 2011e](#)). The
4631 human epidemiological database identifies a statistically significant association between TCE exposure
4632 and NHL (Appendix C, ([U.S. EPA, 2011b](#))). Further support comes from animal studies reporting rates
4633 of lymphomas and/or leukemias following TCE exposure ([U.S. EPA, 2011e](#)).

4634 **3.2.3.2.5 Other cancers**

4635 Reproductive System

4636 The effects of TCE on cancers of the reproductive system have been examined for males
4637 and females in both epidemiological and experimental animal studies. The epidemiological
4638 literature includes data on prostate in males and cancers of the breast and cervix in females. The
4639 experimental animal literature includes data on prostate and testes in male rodents; and uterus,
4640 ovary, mammary gland, vulva, and genital tract in female rodents. The evidence for these cancers is
4641 generally not robust ([U.S. EPA, 2011e](#)).

4642

4643 Other cancers

4644 There is limited evidence of increased risk for esophageal cancer following TCE exposure in males only.
4645 The reasonably available evidence is not statistically sensitive enough for informing quantitative
4646 evaluations of esophageal cancer risk from TCE. There is some evidence of association for bladder or
4647 urothelial cancer and high cumulative TCE exposure, however the reasonably available studies examine
4648 multiple sites and do not completely account for potential confounding factors. In several studies
4649 examining the relationship between TCE exposure and cancer of the brain or central nervous system
4650 (CNS), the data does not provide strong evidence in either direction, although there is some association
4651 of TCE exposure with CNS cancers in children ([U.S. EPA, 2011e](#)).

4652

3.2.4 Weight of Scientific Evidence

4653

3.2.4.1 Non-Cancer Hazards

4654 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4655 contributes to or challenges the previously established weight of scientific evidence (WOE) conclusions
4656 for all non-cancer endpoints other than congenital heart defects. For the previous WOE evaluations of all
4657 other endpoints, see the 2011 EPA IRIS Assessment ([U.S. EPA, 2011e](#)) and the 2014 TSCA Work Plan
4658 Chemical Risk Assessment ([U.S. EPA, 2014b](#)).

4659

3.2.4.1.1 Liver toxicity

4660 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4661 contributes to or challenges the previously established weight of evidence (WOE) for this hazard.

4662

4663 Animal data demonstrating increased liver weight, cytotoxicity, hypertrophy, and peroxisome
4664 proliferation is supported by human data demonstrating changes in plasma or bile acid liver enzyme
4665 levels and hypersensitivity-induced liver damage (Section 3.2.3.1.1). Overall, liver toxicity following
4666 TCE exposure is supported by the weight of evidence. Therefore, this hazard was carried forward for
4667 dose-response analysis.

4668

3.2.4.1.2 Kidney toxicity

4669 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4670 contributes to or challenges the previously established weight of evidence (WOE) for this hazard.

4671

4672 The kidney is one of the more sensitive targets of TCE, with toxicity resulting from conjugative
4673 metabolites such as DCVC. Both animal and human studies have observed induction of kidney toxicity
4674 (*e.g.*, damage to renal tubules and nephropathy) and progression of existing kidney disease (Section
4675 3.2.3.1.2). Overall, kidney toxicity following TCE exposure is supported by the weight of evidence.
4676 Therefore, this hazard was carried forward for dose-response analysis.

4677

3.2.4.1.3 Neurotoxicity

4678 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4679 contributes to or challenges the previously established weight of evidence (WOE) for this hazard.

4680

4681 In addition to anesthetic effects at high concentrations, human evidence concludes that TCE exposure
4682 induces abnormalities in trigeminal nerve function, and TCE exposure has also been associated with
4683 neurodegenerative disorders. These effects have been confirmed in animal studies which additionally
4684 demonstrate a variety of neurological effects from TCE exposure (Section 3.2.3.1.3). Overall,
4685 neurotoxicity following TCE exposure is supported by the weight of evidence. Therefore, this hazard
4686 was carried forward for dose-response analysis.

4687

3.2.4.1.4 Immunotoxicity

4688 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4689 contributes to or challenges the previously established weight of evidence (WOE) for this hazard.

4690

4691 Both animal and human studies demonstrate that TCE exposure can result in either autoimmune/immune
4692 enhancement responses or immunosuppression. There is also evidence of both systemic and localized
4693 hypersensitivity resulting in skin sensitization and autoimmune hepatitis (Section 3.2.3.1.4). Selgrade
4694 and Gilmour ([2010](#)), which was not discussed in ([U.S. EPA, 2014b](#)), demonstrated reduced response to
4695 respiratory infection based on a well-established protocol, in agreement with data from an almost identical
4696 study design decades earlier (however *K. pneumoniae* was used in that study ([Aranyi et al. 1986](#)) instead

4697 of *S. zooepidemicus*). This endpoint is also consistent with other chronic data on immunosuppression.
4698 Overall, immunotoxicity in the form of both autoimmunity and immune suppression following TCE
4699 exposure are supported by the weight of evidence. Therefore, this hazard was carried forward for dose-
4700 response analysis.

4701 **3.2.4.1.5 Reproductive toxicity**

4702 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4703 contributes to or challenges the previously established weight of evidence (WOE) for this hazard.

4704
4705 Both human and animal data provide consistent evidence for male reproductive effects from TCE.
4706 Effects observed include effects on sperm, male reproductive organs, hormone levels, and sexual
4707 behavior. There is limited evidence indicating TCE effects on female reproductive toxicity and
4708 mechanistic support for placental effects from metabolites, although the relevance of those studies is
4709 uncertain (Section 3.2.3.1.5). Overall, reproductive toxicity following TCE exposure is supported by the
4710 weight of evidence. Therefore, this hazard was carried forward for dose-response analysis.

4711 **3.2.4.1.6 Developmental Toxicity**

4712 The EPA literature search ([U.S. EPA, 2017i](#)) did not identify any new evidence that significantly
4713 contributes to or challenges the previously established weight of evidence (WOE) conclusions for this
4714 hazard other than for congenital heart defects.

4715
4716 There is substantial evidence from both animal and human studies that TCE exposure is associated with
4717 various developmental outcomes, ranging from decreased birth weight to pre- and postnatal mortality.
4718 Other hazards also present following developmental exposure, including developmental immunotoxicity
4719 and developmental neurotoxicity. While the epidemiological literature does not consistently observe
4720 developmental effects, effects that have been observed in multiple human studies have been
4721 corroborated by animal data (Section 3.2.3.1.6).

4722
4723 Overall, based on suggestive epidemiologic data and fairly consistent laboratory animal data,
4724 developmental toxicity for the above adverse outcomes following TCE exposure is supported by the
4725 weight of evidence. Therefore, this hazard was carried forward for dose-response analysis.

4726
4727 Developmental toxicity endpoints were considered for both acute and chronic scenarios. Although
4728 developmental studies typically involve multiple exposures, they are considered relevant for evaluating
4729 single exposures because evidence indicates that certain developmental effects may result from a single
4730 exposure during a critical window of development ([Davis et al., 2009](#); [Van Raaij et al., 2003](#)). This is
4731 consistent with EPA's *Guidelines for Reproductive Toxicity Risk Assessment* ([U.S. EPA, 1996](#)) and
4732 *Guidelines for Developmental Toxicity Risk Assessment* ([U.S. EPA, 1991](#)), which state that repeated
4733 exposure is not a necessary prerequisite for the manifestation of developmental toxicity. This is a health
4734 protective assumption.

4735 Congenital Heart Defects

4736 The congenital heart defects endpoint for TCE has been widely discussed since the release of the 2011
4737 IRIS Assessment ([U.S. EPA, 2011e](#)). The primary basis for this endpoint was a developmental drinking
4738 water study in rats, ([Johnson et al., 2003](#)), that has been the source of extensive controversy (see
4739 Appendix F.1 for more study details). During the development of this Risk Evaluation, EPA received a
4740 study sponsored by the Halogenated Solvents Industry Alliance (HSIA) ([Charles River Laboratories,](#)
4741 [2019](#)) that attempted to replicate the ([Johnson et al., 2003](#)) study, examining the incidence of
4742 developmental cardiac defects following administration of TCE to rats via drinking water (see Appendix
4743

4744 F.2 for more study details and EPA review). This study was subsequently peer reviewed and published
4745 in the scientific literature.

4746
4747 The results of the Charles River study (2019) appear to contradict the results observed by (Johnson et
4748 al., 2003) and (Dawson et al., 1993), however EPA concluded that the Charles River study methodology
4749 was likely of reduced sensitivity for the full array of defects observed in (Johnson et al., 2003).
4750 Therefore, (Charles River Laboratories, 2019) insufficiently replicates the methodology of (Johnson et
4751 al., 2003), and the results do not entirely contradict the conclusions of Johnson et al. While (Charles
4752 River Laboratories, 2019) was not considered a close enough replication to (Johnson et al., 2003) to
4753 reduce the overall weight of evidence for the endpoint, EPA did consider (Charles River Laboratories,
4754 2019) to be an overall well-conducted study, and it was incorporated into the WOE analysis for the
4755 cardiac defects endpoint along with all other relevant studies identified in the literature.

4756 4757 *WOE Analysis*

4758 EPA previously published weight of evidence (WOE) analyses on the congenital heart defects (CHD)
4759 endpoint both as part of the 2014 TCE Work Plan Chemical Risk Assessment and as a peer-reviewed
4760 journal article (Makris et al., 2016), which concluded that the totality of data demonstrates congenital
4761 heart defects as a human health hazard resulting from exposure to TCE. These WOE analyses utilized
4762 modified Bradford-Hill criteria (Hill, 1965) to evaluate the overall evidence for causality following
4763 study quality review. Recently though, (Wikoff et al., 2018) published a WOE analysis focusing only on
4764 animal and epidemiological data (excluding data from mechanistic studies and TCE metabolites) and
4765 came to the opposite conclusion using a Risk of Bias assessment for internal study validity.

4766
4767 In order to address the conflicting results of the previous WOE assessments (U.S. EPA, 2014b; Makris
4768 et al., 2016; Wikoff et al., 2018), in support of this Risk Evaluation EPA performed another WOE
4769 analysis. This analysis included all relevant primary literature cited in (Makris et al., 2016), the 2014
4770 TCE Work Plan Chemical Risk Assessment (U.S. EPA, 2014b), and any additional on-topic studies
4771 identified in the systematic review literature search (U.S. EPA, 2017i). Additionally, EPA also
4772 incorporated any newer studies published after the end date of the literature search, including an *in vitro*
4773 mechanistic study (Harris et al., 2018) and the recently completed *in vivo* drinking water study (Charles
4774 River Laboratories, 2019), comprising 45 studies in total (42 scoring Acceptable). After reviewing a
4775 sampling of recent literature on systematic approaches to performing weight-of-evidence evaluation,
4776 EPA adopted the methodology described in [*Weight of Evidence in Ecological Assessment. Risk*
4777 *Assessment Forum. EPA/100/R16/00. (U.S. EPA, 2016i)*], which advocates for presenting evidence on a
4778 semiquantitative scale on the basis of three evidence areas: reliability, outcome/strength, and relevance
4779 (see Appendix F.3.1 for more details on selection of approach and methodological details). Summary
4780 scores for individual studies were integrated within each line of evidence (epidemiological, *in vivo*, or
4781 mechanistic) and then finally all lines of evidence were integrated into a single overall score.
4782 Importantly, this WOE assessment also incorporated data on TCE metabolites, which are believed to be
4783 the toxicologically active agent for many of the observed cardiac effects as well as other developmental
4784 outcomes.

4785
4786 The overall WOE for TCE-induced congenital cardiac defects is presented in Table 3-6. The
4787 epidemiology studies as a group provide suggestive evidence for an effect of TCE on cardiac defects in
4788 humans (summary score of +). Even though there are some uncertainties associated with the relevant
4789 epidemiological literature, the observation of a positive association between TCE exposure and CHDs in
4790 multiple exposed human populations increases the plausibility of the positive results from other lines of
4791 evidence (*i.e.*, *in vivo* animal, mechanistic). Oral *in vivo* studies provided ambiguous to weakly positive
4792 (0/+) results for TCE itself, but positive results for its TCA and DCA metabolites (+). Inhalation studies

4793 (which may be most relevant to the majority of human exposure scenarios) contributed negative
 4794 evidence (-). Overall, the *in vivo* animal toxicity studies provided mixed, ambiguous evidence for an
 4795 effect of TCE (summary score of 0). Mechanistic studies provided strong and consistent supporting
 4796 information for effects of TCE and metabolites on cardiac development and precursor effects (summary
 4797 score of +/++) despite lack of support for any particular adverse outcome pathway (AOP).
 4798

4799 The database overall was determined to be both reliable and relevant. Integration of the three lines of
 4800 evidence resulted in an overall summary score of (+), demonstrating positive overall evidence that TCE
 4801 exposure may result in congenital heart defects in humans (based on positive evidence from
 4802 epidemiology studies, mixed evidence from animal toxicity studies, and stronger positive evidence from
 4803 mechanistic studies).
 4804

4805 See Appendix F.3 for the complete WOE narrative and methodology. The complete scoring table and
 4806 detailed evaluation of all studies is presented in [Data Table for Congenital Heart Defects Weight of
 4807 Evidence Analysis. Docket: [EPA-HQ-OPPT-2019-0500](#)].
 4808
 4809

Table 3-6. Overall Summary Scores by Line of Evidence for Cardiac Defects from TCE

Evidence Area	Summary Score
Epidemiology studies	+
<i>In vivo</i> animal toxicity studies	0
Mechanistic studies	+/++
Overall	+

4810
 4811 The differences in observed responses across studies may be partially attributed to experimental design
 4812 differences. These differential responses may also represent varying susceptibility among mammalian
 4813 species, strains, and populations. It is possible that animals showing a greater incidence of defects
 4814 following TCE exposure represent an especially susceptible population, and genetic drift may preclude a
 4815 true replication of previous study conditions (Makris et al., 2016). Functionally, this WOE scoring
 4816 methodology is similar to that used by (Wikoff et al., 2018), although that analysis focused only on data
 4817 quality and reliability through a risk of bias assessment. Importantly, (Wikoff et al., 2018) did not
 4818 evaluate any mechanistic data, which may explain the different overall conclusions between that review
 4819 and this analysis.
 4820

4821 *Mechanistic Evidence/Mode of Action*

4822 The abundance of available mechanistic studies suggest various potential modes of action (MOAs) for
 4823 TCE-related cardiac teratogenicity, however the totality of the data does not consistently support any
 4824 single MOA or AOP. Teratogens may function through a multitude of pathways, often resulting in a
 4825 constellation of effects. Therefore, evidence of a single dominant MOA is not required in order for the
 4826 data to support a plausible mechanism of TCE-induced congenital heart defects. Existing data supports
 4827 potential mechanisms involving endothelial cushion development, alterations in cellular Ca²⁺ flux,
 4828 oxidative stress, epigenetic changes, impaired stem cell differentiation, suppressed endothelial cell
 4829 proliferation, and folate deficiency. Several studies demonstrate non-monotonic and even inverse dose
 4830 responses in gene activation and molecular changes, which may explain the non-monotonic
 4831 polynomial dose-response observed in (Johnson et al., 2003). See Appendix F.3.3 for more discussion
 4832 and details on potential modes of action.
 4833

4834 Overall, an association between increased congenital cardiac defects and TCE exposure is supported by
4835 the weight of evidence, in agreement with previous EPA analyses ([U.S. EPA, 2014b](#); [Makris et al.,](#)
4836 [2016](#)). While the inconsistent observations across studies (especially in animal models) indicate that
4837 TCE-induced CHDs may not be a common occurrence, the endpoint likely remains relevant for
4838 susceptible populations. As described in Section 3.2.5.2, various risk factors may influence the
4839 susceptibility to CHDs and it is possible that experiments using relatively young, healthy, and inbred
4840 laboratory rodent strains may not capture this variability. For instance, epidemiological data indicates
4841 that TCE is strongly associated with CHDs in older mothers ([Brender et al., 2014](#); [Yauck et al., 2004](#)).
4842 Therefore, in order to account for PESS considerations this endpoint was carried forward for dose-
4843 response analysis.

4844 **3.2.4.1.7 Overt Toxicity Following Acute/Short Term Exposure**

4845 There is strong evidence for overt toxicity in humans following acute exposure to high concentrations of
4846 TCE. AEGL guidelines indicate the concentrations at which increasing levels of toxicity are established
4847 following acute inhalation exposure to TCE. High concentrations of TCE have been shown to result in
4848 respiratory and dermal irritation, CNS depression, cardiac arrhythmia, and even death.

4849
4850 While overt toxicity following acute or short term exposure to TCE is supported by the weight of
4851 evidence, studies examining the acute outcomes described above were not selected for assessing acute
4852 risks due to a lack of sufficient dose-response information. EPA considered more sensitive endpoints for
4853 estimation of risks following acute TCE exposure, namely all developmental toxicity endpoints and
4854 reduced response to respiratory infection ([Selgrade and Gilmour, 2010](#)).

4855 **3.2.4.2 Cancer Hazards**

4856 Meta-analyses were performed in the 2011 EPA TCE IRIS Assessment (Appendix C, ([U.S. EPA,](#)
4857 [2011b](#))) in order to statistically evaluate the epidemiological data for NHL, kidney cancer, and liver
4858 cancer. The IRIS Assessment also investigated the association of TCE with lung cancer, primarily as a
4859 means to examine smoking as a potential confounder for the kidney cancer studies (Appendix C, ([U.S.](#)
4860 [EPA, 2011b](#))). In that assessment EPA identified a statistically significant association between TCE
4861 exposure and NHL, kidney cancer, and liver cancer. An association was not identified for lung cancer,
4862 suggesting that there was no confounding from smoking. That assessment concluded that TCE is
4863 carcinogenic to humans by all routes of exposures, most strongly supported by the data on kidney
4864 cancer. The consistency of increased kidney cancer relative risk (RR) estimates across a large number of
4865 independent studies of different designs and populations from different countries and industries provided
4866 compelling evidence given the difficulty, a priori, in detecting effects in epidemiologic studies when the
4867 RRs were modest and the cancers were relatively rare (indicating that individual studies had limited
4868 statistical power). This strong consistency of the epidemiologic data on TCE and kidney cancer argued
4869 against chance, bias, and confounding as explanations for the elevated kidney cancer risks.

4870
4871 The IRIS Toxicological Review of TCE ([U.S. EPA, 2011e](#)) also cited other lines of supporting evidence
4872 for TCE carcinogenicity in humans by all routes of exposure:

4873 *“First, multiple chronic bioassays in rats and mice have reported increased incidences of tumors with*
4874 *TCE treatment via inhalation and gavage, including tumors in the kidney, liver, and lymphoid tissues –*
4875 *target tissues of TCE carcinogenicity also seen in epidemiological studies.”*

4876
4877 *“A second line of supporting evidence for TCE carcinogenicity in humans consists of toxicokinetic data*
4878 *indicating that TCE is well absorbed by all routes of exposure, and that TCE absorption, distribution,*
4879 *metabolism, and excretion are qualitatively similar in humans and rodents.”*

4880

4881 “Finally, available mechanistic data do not suggest a lack of human carcinogenic hazard from TCE
4882 exposure.”
4883

4884 A statistically significant association was not identified for lung cancer and it was not considered as
4885 contributing to the overall oral slope factor or inhalation unit risk. However, the results of the lung
4886 cancer meta-analysis were interpreted to minimize any concern for confounding effects of smoking on
4887 the other cancers.
4888

4889 For this Risk Evaluation, EPA performed new meta-analyses incorporating both the initial group of
4890 studies assessed in the 2011 EPA TCE IRIS Assessment and any newer, on-topic studies of Acceptable
4891 data quality identified in the literature search performed according to the *Application of Systematic
4892 Review in TSCA Risk Evaluations* (U.S. EPA, 2018b). EPA utilized similar methodology as was
4893 employed in the 2011 EPA TCE IRIS Assessment (U.S. EPA, 2011e) while also incorporating
4894 consideration of data quality evaluation as described in (U.S. EPA, 2018b). Additionally, EPA included
4895 sensitivity analyses as needed to partition the results based on both heterogeneity and data quality score.
4896 When more than one report was available for a single study population, only the most recent publication
4897 or the publication reporting the most informative data for TCE was selected for inclusion in the meta-
4898 analysis. While the updated meta-analysis builds off of (U.S. EPA, 2011b), the results presented below
4899 represent a standalone, new analysis. See Appendix J for full details and results.

4900 **3.2.4.2.1 Meta-Analysis Results**

4901 The initial results of meta-analyses for NHL, kidney cancer and liver cancer showed moderate
4902 heterogeneity among studies, due largely to the influence of the study by Vlaanderen et al. (2013).
4903 Random-effects models are consequently preferred to fixed-effects models due to the degree of
4904 heterogeneity. These reduced the influence of the (Vlaanderen et al., 2013) study and demonstrated
4905 stronger positive associations (greater meta-RR value) of all cancers with exposure to TCE, although the
4906 liver cancer meta-RR was not significant. The evidence for an association between TCE exposure and
4907 NHL was further strengthened by a subsequent meta-analysis on studies reporting cohorts categorized as
4908 experiencing “high” exposure to TCE, which demonstrated a greater meta-RR compared to “any”
4909 exposure.
4910

4911 The study of Vlaanderen et al. (2013) carries very large statistical weight due to its large sample size,
4912 but its sensitivity to detect any true effect of TCE is likely to be low. The study is based on a large
4913 general population cohort with exposures estimated by linking job titles recorded in national census data
4914 to a job-exposure matrix. The prevalence and average intensity of TCE exposure are low in the study
4915 population and the indirect method of estimating exposures has significant potential to misclassify
4916 exposure. Further, the study was not scored High for data quality in EPA’s review (it scored Medium).
4917 There was therefore reason to believe that omitting the Vlaanderen et al.(2013) study would improve the
4918 sensitivity of meta-analytic results for all three cancers. In sensitivity analyses omitting the study of
4919 (Vlaanderen et al., 2013), between-study heterogeneity was significantly reduced or eliminated,
4920 demonstrating improved consistency of the data and improved reliability of the meta-analysis results.
4921 Resulting meta-RRs for exposure to TCE were strengthened and were statistically significant for all
4922 three cancers.
4923

4924 Analyses stratified by a data quality score also indicated stronger associations of all cancers with TCE
4925 exposure in studies that scored High for data quality compared to studies that scored Medium or Low;
4926 notably, the latter group included the influential study of (Vlaanderen et al., 2013). Studies that scored
4927 high showed no heterogeneity of effects for NHL and kidney cancer, but moderate heterogeneity
4928 remained for liver cancer.

4929
4930
4931
4932
4933
4934
4935
4936
4937
4938
4939

4940
4941
4942
4943
4944
4945
4946
4947
4948
4949
4950
4951
4952
4953
4954
4955
4956
4957
4958
4959
4960
4961
4962
4963
4964
4965
4966
4967
4968
4969
4970
4971
4972
4973
4974
4975
4976

In summary, meta-analyses accounting for between-study heterogeneity, influential observations, and data quality consistently indicate positive associations of NHL, kidney cancer and liver cancer with exposure to TCE. This conclusion generally agrees with that of other governmental and international organizations. The International Agency for Research on Cancer (IARC) ([IARC, 2014](#)) found sufficient evidence for the carcinogenicity of TCE in humans. IARC definitively stated that TCE causes kidney cancer and determined that a positive association has been identified for NHL and liver cancer. Based on the weight of evidence when accounting for both these authoritative assessments and the results of EPA's meta-analyses and in accordance with EPA Guidelines for Carcinogen Risk Assessment ([U.S. EPA, 2005](#)), EPA determines that TCE is "Carcinogenic to Humans". Cancer was therefore carried forward for dose-response analysis, incorporating extra cancer risk from all three cancer types.

3.2.4.2.2 Mode of Action

Kidney Cancer

Genotoxicity

The predominant mode of action (MOA) for kidney carcinogenicity involves a genotoxic mechanism through formation of reactive GSH metabolites (e.g., DCVC, DCVG). This MOA is well-supported, as toxicokinetic data indicates that these metabolites are present in both human blood and urine, and these metabolites have been shown to be genotoxic both *in vitro* and in animal studies demonstrating kidney-specific genotoxicity ([U.S. EPA, 2011e](#); [Cichocki et al. 2016](#)) and [*Data Extraction and Evaluation Tables for Genotoxicity Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*]. These reactive metabolites may be formed much less in humans than rodents however ([Green et al. 1997b](#); [Lash et al. 1990](#); [Lash et al. 2014](#)), although *in vitro* data suggests that human GSH conjugation activity may actually be higher in humans than rodents in some cases (Table 3-23 and 3-26 of ([U.S. EPA, 2011e](#)) and ([Lash et al., 1999](#); [Lash et al., 1998](#))). Since genotoxicity of parent TCE has not been consistently observed (Section 3.2.3.2.1 and [*Data Extraction and Evaluation Tables for Genotoxicity Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*]), there is some uncertainty as to the true contribution of genotoxicity toward carcinogenesis in humans.

Cytotoxicity and other mechanisms

Observed nephrotoxicity in both human and animal studies, especially at elevated concentrations, provides some evidence of a cytotoxic MOA. Data comparing relative dose-response analysis of nephrotoxicity and kidney cancer incidence suggests that cytotoxicity can occur at doses below those causing carcinogenicity in animal bioassays, however this data also indicates that nephrotoxicity is not sufficient or rate-limiting for renal carcinogenesis. Additionally, studies have not established that TCE-induced proliferation in renal cells is necessary for clonal expansion or cancer. Therefore, a causal or predictive link between cytotoxicity and carcinogenicity cannot be established ([U.S. EPA, 2011e](#)), however cytotoxicity is likely the dominant mechanism of kidney non-cancer toxicity ([Cichocki et al. 2016](#)). There is also inadequate experimental support for other potential MOAs such as peroxisome proliferator activated receptor alpha (PPAR α) induction, α 2 μ -globulin nephropathy, and formic acid-related nephrotoxicity ([U.S. EPA, 2011e](#)).

Conclusion

There is clear evidence of a genotoxic MOA for kidney cancer, either on its own or in combination with other mechanisms. While the kidney is highly sensitive to TCE-induced cytotoxicity, the contribution of cytotoxicity toward kidney carcinogenesis cannot be determined. Renal cytotoxicity may instead serve as a promoter step in tumorigenesis following genotoxic initiation, or it may merely represent an independent pathway of toxicity ([U.S. EPA, 2011e](#)).

4977 **Liver Cancer**

4978 Genotoxicity

4979 The strongest data supporting mutagenic potential of TCE or potential liver metabolites comes from data
4980 on the intermediate metabolite chloral hydrate (CH), which induces a variety of genotoxic effects both *in*
4981 *vitro* and *in vivo* ([U.S. EPA, 2011e](#), [Cichocki et al. 2016](#), and [*Data Extraction and Evaluation Tables*
4982 *for Genotoxicity Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)]). The peak *in vivo* concentrations of CH
4983 in tissue are substantially less than is required for induction of genotoxicity in many *in vitro* assays,
4984 however there is some evidence of *in vivo* genotoxicity at doses comparable to those inducing cancer in
4985 chronic bioassays. Overall, the data are insufficient to conclude that a mutagenic MOA is operating,
4986 however it cannot be ruled out ([U.S. EPA, 2011e](#)). Notably, all of the CH studies performed on human
4987 cells exposed to TCE either *in vitro* or *in vivo* demonstrated positive genotoxic activity ([*Data*
4988 *Extraction and Evaluation Tables for Genotoxicity Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)]).**

4990 PPAR α receptor activation

4991 An MOA through PPAR α is often considered to be less relevant to humans (or at least result in reduced
4992 potency) based on reduced human sensitivity to peroxisome proliferators compared to rodents ([NRC,](#)
4993 [2006](#)). While strong evidence exists for TCA-mediated PPAR α receptor activation (resulting in
4994 downstream perturbation of cell apoptosis and proliferation signaling) based on observed peroxisome
4995 proliferation and increased marker activity in rodents treated with TCE, TCA, or DCA, this appears to
4996 occur at a higher dose than what induces liver tumors in mice. TCE, TCA, and DCA have been found to
4997 be weak peroxisome proliferators, but the overall data suggests that PPAR α activation may not be
4998 sufficient for carcinogenesis. TCA-induced liver tumors in mice occur at lower concentrations than
4999 peroxisome proliferation *in vivo*, however PPAR α occurs at even lower exposure levels. For DCA-
5000 induced tumors, tumorigenesis occurs at much lower doses than either process. Additionally, TCE
5001 induces liver weight increases in PPAR α -null mice and transgene-mediated constitutively active PPAR α
5002 did not induce liver tumors after 11 months in mice. TCE does clearly activate PPAR α and the
5003 reasonably available data supports at least some role of PPAR α activation in liver tumorigenesis, but any
5004 key causal effects are likely mediated by multiple mechanisms and neither causality, sufficiency, or
5005 necessity of PPAR α signaling in liver carcinogenicity can be established. ([U.S. EPA, 2011e](#)).

5007 Polyploidization

5008 TCE induces chromosome duplication in hepatocytes, or polyploidization. Increased DNA content
5009 results in increased gene expression but are also slower dividing and more likely to undergo apoptosis.
5010 Changes in ploidy have been observed in transgenic mouse models that are prone to develop liver
5011 cancer, and there is biological plausibility that polyploidization can contribute to liver carcinogenesis.
5012 However, any potential mechanism of enhancing carcinogenesis is unknown ([U.S. EPA, 2011e](#)) and
5013 available evidence is only correlative. Therefore, it cannot be determined whether polyploidization is
5014 actually contributing to liver tumorigenesis or is merely a biomarker.

5016 Cytotoxicity and regenerative hyperplasia

5017 TCE has been demonstrated to induce liver effects in the form of hypertrophy, histopathology, increased
5018 DNA synthesis, and cirrhosis (Section 3.2.3.1.1), all of which may be indicators of cytotoxicity and
5019 compensatory proliferation leading to hyperplasia. Broad cytotoxicity therefore may play a role in liver
5020 tumorigenesis, however TCE doses relevant to liver carcinogenicity do not result in significant
5021 cytotoxicity. Observed increases in DNA synthesis are likely due to both cellular proliferation and
5022 increased ploidy. Necrosis is not prevalent and is typically minimal to mild. Therefore, it is unlikely that
5023 cytotoxicity and reparative hyperplasia play a significant role in TCE carcinogenicity ([U.S. EPA,](#)
5024 [2011e](#)).

5025

5026
5027
5028
5029
5030
5031
5032
5033
5034
5035
5036
5037
5038
5039
5040
5041
5042
5043
5044
5045
5046
5047
5048
5049
5050
5051
5052
5053
5054
5055
5056
5057

5058

5059
5060
5061
5062
5063
5064
5065
5066
5067
5068
5069
5070
5071
5072

Other mechanisms

There is limited evidence for a tumorigenic role of increased liver weight, negative selection, oxidative stress, and/or glycogen accumulation. Heritable epigenetic changes such as altered DNA methylation patterns, which disrupt the balance of gene expression and may lead to over- or under-expression of various tumor suppressors and promoters, have been associated with liver cancer and other tumors in general. Additionally, TCE has been shown to promote hypomethylation (resulting in increased gene expression) *in vivo* and *ex vivo* in liver tissue. DNA hypomethylation can be sufficient for liver carcinogenesis in other contexts based on choline/methionine deficiency studies, however the applicability of this mechanism to TCE-induced carcinogenesis is unknown as these changes could either be causally or consequentially related to carcinogenicity ([U.S. EPA, 2011e](#)).

Conclusions

The reasonably available data is inadequate to support any singular MOA. The strongest evidence exists for involvement of both genotoxicity and PPAR α activation, however a causal relationship cannot be established because the dose levels required to elicit outcomes through both MOAs are higher than those demonstrating tumorigenic activity ([U.S. EPA, 2011e](#)). The MOA for liver tumors is likely complex and may involve contributions from multiple pathways, while any single mechanism may be insufficient for tumorigenesis on its own.

Non-Hodgkin Lymphoma

There is insufficient data reasonably available for suggesting any particular MOA for NHL.

Overall Conclusions

TCE is carcinogenic by a genotoxic mode of action at least for kidney cancer, while a predominant mode of action cannot be determined for the other tumor types. Per EPA Guidelines for Carcinogen Risk Assessment ([U.S. EPA, 2005](#)), overall, the totality of the reasonably available data/information and the WOE analysis for the cancer endpoint was sufficient to support a linear non-threshold model. The application of a linear non-threshold model is justified based on the likely genotoxic MOA for kidney cancer, the combined relative contributions of multiple tumor types, and the positive associations observed via meta-analysis for all three cancers in epidemiological studies based on low-level, environmental exposure levels (as opposed to relying on extrapolation from high doses in a rodent bioassay).

3.2.5 Dose-Response Assessment

3.2.5.1 Selection of Studies for Dose-Response Assessment

The EPA evaluated data from studies described above (Section 3.2.3.1) to characterize the dose-response relationships of TCE and selected studies and endpoints to quantify risks for specific exposure scenarios. One of the additional considerations was that the selected key studies had adequate information to perform dose-response analysis for the selected PODs. The EPA defines a POD as the dose-response point that marks the beginning of a low-dose extrapolation. This point can be the lower bound in the dose for an estimated incidence, or a change in response level from a dose-response model (*i.e.*, BMD), a NOAEL or a LOAEL for an observed incidence or change in the level of response.

Based on the weight of the evidence evaluation, six health effect domains were selected for non-cancer dose-response analysis: (1) liver; (2) kidney; (3) neurological; (4) immunological; (5) reproductive; and (6) developmental. Additionally, dose-response analysis was performed for cancer based on observed incidences of kidney cancer, liver cancer, and non-Hodgkin lymphoma. These hazards have been carried forward for dose-response analysis. While there is also evidence to support overt toxicity following

5073 acute exposure, endpoints for these effects were not carried forward for dose-response analysis. For a
5074 complete discussion, see Section 3.2.4.1.

5075
5076 Studies that evaluated each of the health effect domains were identified in Section 3.2.3, and are
5077 considered in this section for dose-response analysis. In order to identify studies for dose-response
5078 analysis, several attributes of the studies were reviewed. Preference was given to studies using designs
5079 reasonably expected to detect a dose-related response. Chronic or subchronic studies are generally
5080 preferred over studies of less-than-subchronic duration for deriving chronic and subchronic reference
5081 values. Studies with a broad exposure range and multiple exposure levels are preferred to the extent that
5082 they can provide information about the shape of the exposure-response relationship. Additionally, with
5083 respect to measurement of the endpoint, studies that can reliably measure the magnitude and/or degree
5084 of severity of the effect are preferred.

5085
5086 Experimental animal studies considered for each hazard and effect were evaluated using systematic
5087 review quality considerations discussed in the Systematic Review Methods section. Only studies that
5088 scored an acceptable rating in data evaluation were considered for use in dose-response assessment. In
5089 addition to the data quality score, considerations for choosing from among these studies included study
5090 duration, relevance of study design, and the strength of the toxicological response. Details on these
5091 considerations for each endpoint are provided below.

5092
5093 Given the different TCE exposures scenarios considered (both acute and chronic), different endpoints
5094 were used based on the expected exposure durations. For non-cancer effects and based on a weight-of-
5095 evidence analysis of toxicity studies from rats, risks for developmental effects that may result from a
5096 single exposure were considered for both acute (short-term) and chronic (long-term, continuous)
5097 exposures, whereas risks for other adverse effects (*e.g.*, liver toxicity, kidney toxicity, neurotoxicity,
5098 immunotoxicity, and reproductive toxicity) were only considered for repeated (chronic) exposures to
5099 TCE. Although developmental studies typically involve multiple exposures, they are considered relevant
5100 for evaluating single exposures because evidence indicates that certain developmental effects may result
5101 from a single exposure during a critical window of development ([Davis et al., 2009](#); [Van Raaij et al.,
5102 2003](#); [U.S. EPA, 1991](#)). This is consistent with EPA's Guidelines for Reproductive Toxicity Risk
5103 Assessment ([U.S. EPA, 1996](#)) which state that repeated exposure is not a necessary prerequisite for the
5104 manifestation of developmental toxicity. Consequently, in this Risk Evaluation EPA accepted the
5105 Agency's default assumption and concluded that developmental endpoints are applicable when assessing
5106 acute exposures, where it is assumed that the risk of their occurrence depends on the timing and
5107 magnitude of exposure. This is a health protective approach and assumes that a single acute exposure
5108 could lead to the same effects if that exposure occurs during a critical window within the pregnancy
5109 term. A single acute study examining pulmonary immunotoxicity following 3h TCE inhalation exposure
5110 ([Selgrade and Gilmour, 2010](#)) was also considered for acute exposure scenarios. Overt toxicity studies
5111 (Section 3.2.3.1.7) were not used for the acute POD because they were often only single-dose studies
5112 and the doses at which acute toxic effects or lethality were observed were significantly higher than those
5113 that caused toxic effects in developmental studies.

5114 **3.2.5.1.1 Liver toxicity**

5115 The 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) determined that the studies
5116 of ([Woolhiser et al., 2006](#); [Buben and O'Flaherty, 1985](#); [Kjellstrand et al., 1983](#)) were suitable for the
5117 dose-response assessment of the liver health effects domain. These three studies reported dose-
5118 responsive increases in liver/body weight ratios. ([Buben and O'Flaherty, 1985](#)) and ([Kjellstrand et al.,
5119 1983](#)) also reported cytotoxicity and histopathology in mice. All three of these studies scored Medium
5120 or High in EPA's data quality evaluation [*Data Quality Evaluation of Human Health Hazard Studies*.

5121 Docket: [EPA-HQ-OPPT-2019-0500](#)] and were therefore utilized for dose-response analysis.

5122 **3.2.5.1.2 Kidney toxicity**

5123 The 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) considered five animal
5124 studies reporting kidney toxicity for further non-cancer dose-response analysis. ([Maltoni et al., 1986](#)),
5125 ([NCI, 1976](#)) and ([NTP, 1988](#)) reported histological changes in the kidney, whereas ([Kjellstrand et al.,](#)
5126 [1983](#)) and ([Woolhiser et al., 2006](#)) reported increased kidney/body weight ratios ([U.S. EPA, 2011e](#)).
5127 NCI ([1976](#)) scored Unacceptable in EPA's data quality evaluation [*Data Quality Evaluation of Human*
5128 *Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*] and therefore was excluded from dose-
5129 response analysis. All of the other studies scored Medium in data quality and were therefore utilized for
5130 dose-response analysis.

5131 **3.2.5.1.3 Neurotoxicity**

5132 Among the human studies, ([Ruijten et al., 1991](#)) was the only epidemiological study that the IRIS
5133 program deemed suitable for further evaluation in the TCE's dose-response assessment for
5134 neurotoxicity. Only the following four animal studies were considered suitable for dose-response
5135 analysis for the neurotoxicity endpoint in the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S.](#)
5136 [EPA, 2014b](#)): ([Arito et al., 1994](#)), ([Isaacson et al., 1990](#)), ([Gash et al., 2008](#)), and ([Kjellstrand et al.,](#)
5137 [1987](#)). Kjellstrand ([1987](#)) scored Unacceptable in EPA's data quality evaluation [*Data Quality*
5138 *Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*] and therefore was
5139 excluded from dose-response analysis. Gash et al. ([2008](#)) scored a Low in data evaluation and was also
5140 not carried forward to dose-response analysis given the other, higher quality studies available. Ruijten
5141 et al. ([1991](#)), Arito et al. ([1994](#)), and Isaacson et al. ([1990](#)) all scored Medium or High for data quality
5142 and were therefore utilized for dose-response analysis.

5143 **3.2.5.1.4 Immunotoxicity**

5144 Only the following four animal studies were suitable for the 2014 TSCA Work Plan Chemical Risk
5145 Assessment ([U.S. EPA, 2014b](#)) non-cancer dose-response analysis for the immunotoxicity endpoint:
5146 ([Keil et al., 2009](#)), ([Kaneko et al., 2000](#)), ([Sanders et al., 1982](#)), and ([Woolhiser et al., 2006](#)). For this
5147 Risk Evaluation, EPA also assessed the endpoint of acute immunosuppression observed in ([Selgrade](#)
5148 [and Gilmour, 2010](#)). In Selgrade and Gilmour ([2010](#)), mice were infected via respiration with
5149 aerosolized *S. zooepidemicus* bacteria following 3h TCE exposure. Mortality, bacterial, clearance from
5150 the lung, percent of mice infected, and phagocytic index were assessed following co-exposure. Mortality
5151 was selected as the most statistically sensitive endpoint due to larger numbers of mice per exposure
5152 group and more dose groups, however "percent of mice infected" was also considered for dose-response
5153 analysis (Appendix H.1.2). All of these studies scored Medium or High in EPA's data quality
5154 evaluation [*Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-](#)*
5155 [2019-0500](#)] and were therefore utilized for dose-response analysis.

5156 **3.2.5.1.5 Reproductive toxicity**

5157 Among the human studies, ([Chia et al., 1996](#)) was the only epidemiological study that the 2014 TSCA
5158 Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) deemed suitable for further evaluation in the
5159 TCE's dose-response assessment for reproductive toxicity. Only the following eight reproductive
5160 animal toxicity studies were considered suitable for non-cancer dose-response analysis in the 2014
5161 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)): ([Kumar et al., 2000](#)), ([Kumar et al.,](#)
5162 [2001](#)), ([Kan et al., 2007](#)), ([Xu et al., 2004](#)), ([Narotsky et al., 1995](#)), ([George et al., 1986](#)), ([Duteaux et](#)
5163 [al., 2004](#)), and ([Forkert et al., 2002](#)). Forkert et al. ([2002](#)) scored Unacceptable in EPA's data quality
5164 evaluation and therefore was excluded from dose-response analysis, however it had the same POD as
5165 ([Kan et al., 2007](#)), which scored Medium. Duteaux et al. ([2004](#)) scored a Low for data quality and was

5166 not carried forward to dose-response analysis given the other, higher quality studies available. The
5167 remaining studies all scored Medium or High for data quality [*Data Quality Evaluation of Human*
5168 *Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*] and were therefore utilized for dose-
5169 response analysis.

5170 **3.2.5.1.6 Developmental toxicity**

5171 The 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)) found 5 animal studies that
5172 were suitable for non-cancer dose- response analysis for the following developmental outcomes: pre-
5173 and postnatal mortality; pre- and postnatal growth; developmental neurotoxicity; and congenital heart
5174 malformations (Appendix L of that document).

5175

5176 Developmental Immunotoxicity

5177 Although the focus of the discussion below is on these 5 studies and corresponding endpoints,
5178 developmental immunotoxicity has also been demonstrated in TCE-treated animals. The most sensitive
5179 immune system response was reported by ([Peden-Adams et al., 2006](#)), which observed functional
5180 indications of both immunosuppression and autoimmunity. In this study, B6C3F1 mice were exposed
5181 to TCE via drinking water. Treatment occurred during mating and through gestation to TCE levels of 0,
5182 1.4, or 14 ppm. After delivery, pups were further exposed for either 3 or 8 more weeks at the same
5183 concentration levels that the dams received in drinking water. Suppressed plaque-forming cell (PFC)
5184 response was seen in male pups after 3 and 8 weeks of exposure, whereas female pups showed the
5185 suppression of PFC response and delayed hypersensitivity at 1.4 ppm following 8 weeks. At the higher
5186 concentration (14 ppm), both of these effects were observed again in both males and females following
5187 3 or 8 weeks of postnatal exposure. A LOAEL of 0.37 mg/kg-bw/day served as a POD for the
5188 decreased PFC and increased delayed hypersensitivity responses ([U.S. EPA, 2011e](#)). While this
5189 endpoint exhibits one of the lower PODs among developmental toxicity studies, the study scored a
5190 “Low” in EPA’s data quality evaluation [*Data Quality Evaluation of Human Health Hazard Studies.*
5191 *Docket: [EPA-HQ-OPPT-2019-0500](#)*] due to concerns over statistical reliability and dose precision.
5192 Additionally, it could not be accurately PBPK modeled because exposure occurred *in utero*, through
5193 nursing, and after weaning.

5194

5195 The 2011 IRIS Assessment ([U.S. EPA, 2011e](#)) also included discussion of several studies that reported
5196 evidence of developmental toxicity in autoimmune-prone MRL +/+ mice. These studies ([Blossom et](#)
5197 [al. 2008](#); [Peden-Adams et al. 2008](#); [Blossom and Doss 2007](#)). Similarly to ([Peden-Adams et al., 2006](#)),
5198 these studies demonstrated indications of both immunosuppression and autoimmunity. These studies
5199 also involve uncertainties over dose precision due to exposure covering both pre- and postnatal periods
5200 however, in addition to uncertainty about extrapolation of results in an auto-immune prone strain to
5201 humans. A more recent Medium-quality study in MRL+/+ mice that examined exposure independently
5202 during gestation and early-life periods ([Gilbert et al. 2014](#)) observed various cytokine changes,
5203 evidence of epigenetic changes, increased T-cell activation, and varied effects on thymus cellularity.
5204 The conflicting directionality of cytokine changes and unclear adversity of the other observations make
5205 it difficult to identify any potential POD. Therefore, none of these studies were considered adequate for
5206 for dose-response analysis, although developmental immunotoxicity will still be considered
5207 qualitatively when evaluating PODs for other developmental or immune endpoints.

5208

5209 Pre- and Postnatal Mortality and Growth

5210 The following two studies were considered suitable for non-cancer dose-response analysis for pre- and
5211 postnatal mortality and growth effects in the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S.](#)
5212 [EPA, 2014b](#)): ([Healy et al., 1982](#)), and ([Narotsky et al., 1995](#)). Healy et al. (1982) scored Unacceptable
5213 in EPA’s data quality evaluation [*Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-](#)*

5214 [HQ-OPPT-2019-0500](#)] and therefore was excluded from dose-response analysis. ([Narotsky et al.,](#)
5215 [1995](#)) scored a High and was therefore utilized for dose-response analysis.

5216

5217 Developmental Neurotoxicity

5218 There is evidence of alterations in animal brain development and in behavioral parameters (*e.g.*,
5219 spontaneous motor activity and social behaviors) following TCE exposure during the development of
5220 the nervous system. Among all of the reasonably available studies, there were two oral studies that
5221 reported behavioral changes which were used in the dose-response evaluation for developmental
5222 toxicity: ([Fredriksson et al., 1993](#)) and ([Taylor et al., 1985](#)). ([Taylor et al., 1985](#)) scored a Low in
5223 EPA's data quality evaluation due to the same issues as ([Peden-Adams et al., 2006](#)) and was not
5224 considered further for dose-response assessment. ([Fredriksson et al., 1993](#)) scored a Medium despite
5225 some uncertainty concerning the statistical validity of its sampling methodology [*Data Quality*
5226 *Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)*] and was therefore
5227 utilized for dose-response analysis.

5228

5229 Congenital Heart Defects

5230 The fetal cardiac defects reported in ([Dawson et al., 1993](#)) and ([Johnson et al., 2003](#)) were identified as
5231 the most sensitive endpoint within the developmental toxicity domain and across all of the health effect
5232 domains evaluated in the TCE IRIS assessment. Johnson et al. ([Johnson et al., 2003](#)) reported data
5233 from different experiments over a several-year period in which pregnant Sprague-Dawley rats (9-
5234 13/group; 55 in control group) were exposed to TCE via drinking water. Treatment of pregnant rats
5235 occurred during the entire gestational period (*i.e.*, GD 0 to GD22). The study was a follow-up to
5236 Dawson et al. ([1993](#)), which demonstrated increasing incidence of congenital heart defects at the
5237 highest two dose groups that were later pooled and re-analyzed in ([Johnson et al., 2003](#)).

5238

5239 While the WOE analysis supports a likely association of gestational TCE exposure with induction of
5240 CHDs (Appendix F.3), there is substantial uncertainty in the quantitative dose-response from both
5241 studies and the relevance of these results to the human general population (Appendix F.1, Section
5242 3.2.4.1.6, Section 3.2.5.3.1, and Section 3.2.6.1). Nonetheless, this endpoint is of concern to
5243 susceptible subpopulations (Section 3.2.5.2) and consideration of dose responses from studies that are
5244 more sensitive than the more commonly observed responses observed among relatively young,
5245 healthy, and inbred laboratory rodent strains is important in accounting for human susceptibility.
5246 Therefore, the results from ([Dawson et al., 1993](#)) and ([Johnson et al., 2003](#)) were considered for dose-
5247 response analysis.

5248

5249 Because both studies passed data evaluation with the same score (both scored Medium for data
5250 quality) and statistics were only performed using a pup as the statistical unit for ([Dawson et al., 1993](#)),
5251 EPA decided to utilize the ([Johnson et al., 2003](#)) data for dose-response analysis, which has increased
5252 statistical sensitivity from the additional two dose levels and allowed a nested design for BMD
5253 modeling analysis in order to account for litter effects. Additionally, some defects originally identified
5254 in ([Dawson et al., 1993](#)) were later reclassified or recharacterized in ([Johnson et al., 2003](#)), so
5255 ([Johnson et al., 2003](#)) contains the more updated analysis.

5256 **3.2.5.1.7 Cancer**

5257 The 2019 meta-analysis of all relevant studies examining kidney cancer, liver cancer, or NHL
5258 (Appendix J) came to the same conclusion as the previous EPA meta-analysis in the 2011 IRIS
5259 Assessment ([U.S. EPA, 2011e](#)). Therefore, EPA utilized the same inhalation unit risk and oral slope
5260 factor estimates as were derived in ([U.S. EPA, 2011e](#)) and cited in the 2014 TSCA Work Plan Chemical
5261 Risk Assessment ([U.S. EPA, 2014b](#)). A linear non-threshold assumption was applied to the TCE cancer

5262 dose-response analysis because there is sufficient evidence that TCE-induced kidney cancer operates
5263 primarily through a mutagenic mode of action while it cannot be ruled out for the other two cancer types.
5264

5265 The 2011 IRIS Assessment ([U.S. EPA, 2011e](#)) selected the epidemiological kidney cancer data
5266 Charbotel et al. ([2006](#)) as the best representative dose-response data for derivation of an oral slope factor
5267 and inhalation unit risk value. Charbotel et al. ([2006](#)) was a case-control study with quantitative
5268 cumulative exposure estimates based on a task-exposure matrix based on decades of measurement. The
5269 study received a High score for data quality both overall and for the exposure domain in EPA's data
5270 evaluation [*Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-](#)*
5271 *[0500](#)*]. Therefore, EPA relied on its previous dose-response analysis from this study.

5272 **3.2.5.2 Potentially Exposed and Susceptible Subpopulations (PESS)**

5273 TSCA requires that a Risk Evaluation “determine whether a chemical substance presents an
5274 unreasonable risk of injury to health or the environment, without consideration of cost or other non-risk
5275 factors, including an unreasonable risk to a potentially exposed or susceptible subpopulation identified
5276 as relevant to the Risk Evaluation by the Administrator, under the conditions of use.” TSCA § 3(12)
5277 states that “the term ‘*potentially exposed or susceptible subpopulation*’ means a group of individuals
5278 within the general population identified by the Administrator who, due to either greater susceptibility or
5279 greater exposure, may be at greater risk than the general population of adverse health effects from
5280 exposure to a chemical substance or mixture, such as infants, children, pregnant women, workers, or the
5281 elderly.”
5282

5283 During Problem Formulation ([U.S. EPA, 2018d](#)), EPA identified potentially exposed or susceptible
5284 subpopulations for further analysis during the development and refinement of the life cycle, conceptual
5285 models, exposure scenarios, and analysis plan. In this section, EPA addresses the potentially exposed or
5286 susceptible subpopulations identified as relevant based on *greater susceptibility*. EPA addresses the
5287 subpopulations identified as relevant based on *greater exposure* in Section 2.3.3.
5288

5289 There is some evidence that certain populations may be more biologically susceptible to exposure to
5290 TCE. Factors affecting biological susceptibility examined in the available studies on TCE include
5291 lifestage, sex, genetic polymorphisms, race/ethnicity, preexisting health status, lifestyle factors, and
5292 nutrition status. Factors that affect early lifestage susceptibility include exposures during gestation, such
5293 as transplacental transfer, and during infancy, such as breast milk ingestion (a breastfeeding infant who
5294 is nursing from a mother exposed to the occupational exposure limit for TCE could receive more than
5295 80% of the daily lifetime advisory limit for adults ([Beamer et al., 2012](#))), early lifestage-specific
5296 toxicokinetics, and early lifestage-specific health outcomes including developmental cardiac defects.
5297 Groups of individuals for which one or several of these factors apply may be considered PESS. Sex-
5298 specific differences also exist in toxicokinetics (*e.g.*, cardiac outputs, percent body fat, expression of
5299 metabolizing enzymes) and susceptibility to toxic endpoints (*e.g.*, sex-specific effects on the
5300 reproductive system, sex differences in baseline risks to endpoints such as scleroderma or liver cancer).
5301 Based on the hazards identified from the available information, individuals that either have or are
5302 susceptible to kidney, liver, neurological, reproductive, or cancer health conditions are PESS.
5303

5304 Genetic variation likely has an effect on the toxicokinetics of TCE. Pre-existing diminished health status
5305 (especially diminished function in one of the health domains supported by the weight of the scientific
5306 evidence in Section 3.2.4) may alter the response to TCE exposure. Individuals with increased body
5307 mass or certain conditions such as non-alcoholic fatty liver disease may have an altered toxicokinetic
5308 response due to the increased uptake of TCE into fat. Other conditions that may alter the response to
5309 TCE exposure include diabetes and hypertension, and lifestyle and nutrition factors such as alcohol

5310 consumption, tobacco smoking, nutritional status, physical activity, and socioeconomic status ([U.S.](#)
5311 [EPA, 2011e](#)). Among life stages, the most susceptible is likely to be pregnant women and their
5312 developing fetus based on the hazard findings from reviewing the reasonably available literature for this
5313 assessment, which conclude that developmental toxicity is among the most sensitive acute health effects
5314 associated with TCE exposure. Among pregnant women, older women may be especially susceptible to
5315 TCE-induced cardiac defects in their offspring. Maternal age is known to have a large influence on the
5316 incidence of congenital heart defects, and multiple studies cited in this Risk Evaluation identified a
5317 significantly stronger association of TCE with developmental cardiac defects ([Brender et al., 2014](#);
5318 [Yauck et al., 2004](#)). Additional maternal risk factors for susceptibility to congenital cardiovascular
5319 defects include diabetes, infection status, drug exposure, and stress, among others ([Jenkins et al., 2007](#)).

5320 Significant variability in human susceptibility to TCE toxicity may result from differences in
5321 metabolic potential, given the existence of CYP isoforms and the variability in CYP-mediated TCE
5322 oxidation. Increased enzymatic activity of cytochrome P450 2E1 (CYP2E1) and glutathione-S-
5323 transferase (GST) polymorphisms may influence TCE susceptibility due to effects on the production
5324 of toxic metabolites ([Cichocki et al. 2016](#); [U.S. EPA, 2011e](#)). CYP2E1 expression may be enhanced
5325 by various health conditions including alcoholism, obesity, and diabetes ([NRC, 2006](#)). An
5326 individual may be a member of multiple PESS groups and may exhibit multiple concurrent
5327 susceptibilities.

5328
5329 Animal data show that rates of TCE GSH conjugation in male rats/mice are higher than females
5330 (Section 3.2.2.3), suggesting potential increased susceptibility for kidney effects in males. More
5331 specifically, there appears to be greater susceptibility to TCE-induced kidney cancer in those
5332 individuals that carry an active polymorphism in a gene associated with the GST metabolic
5333 pathway. Particularly, the gene is associated with the β -lyase gene region which is responsible for
5334 converting DCVC to the unstable intermediate DCVT. Also, there are some human studies
5335 suggesting a role for mutations to the tumor suppressor gene, von Hippel Lindau (VHL gene). This
5336 tumor suppressor gene appears to be inactivated in certain TCE-induced kidney cancers ([U.S. EPA,](#)
5337 [2011e](#)). In this Risk Evaluation, EPA performed a population analysis to systematically estimate
5338 uncertainty and variability across several metabolic factors, including human variability related to
5339 oxidative metabolism and glutathione conjugation as a result of GST activity. Integration of these
5340 factors into a probabilistic model resulted in a distribution of human equivalent concentrations/doses
5341 (HECs/HEDs) for each endpoint. HEC₉₉/HED₉₉ values representing the most metabolically
5342 sensitive 1% of the population, a susceptible subpopulation, were used for risk estimation.

5343 **3.2.5.3 Derivation of Points of Departure (PODs)**

5344 Point of departures (PODs) were identified for those studies that had suitable data for dose-response
5345 analysis, described above. PODs can be a NOAEL or LOAEL for an observed incidence, or change in
5346 level of response, or the lower confidence limit on the dose at the benchmark dose (BMDL). PBPK
5347 modeling was used to estimate internal dose PODs (idPOD) and subsequently the human equivalent
5348 concentrations/doses (HECs/HEDs) based on the oral and inhalation PODs identified in earlier steps. The
5349 PBPK modeling integrated internal dose-metrics based on TCE's mode of action and the role of different
5350 TCE metabolites in toxicity ([U.S. EPA, 2011e](#)). Note that the effects within the same health effect
5351 domain were generally assumed to have the same relevant internal dose-metrics, with some exceptions.
5352 Given that the majority of the toxic and carcinogenic responses in many tissues to TCE appears to be
5353 associated with metabolism, the primary dose-metric for systemic effects not associated with a particular
5354 highly metabolic organ (*i.e.*, excluding kidney and liver) or specific metabolite was total metabolism of
5355 TCE scaled by the $\frac{3}{4}$ power of body weight (TotMetabBW^{3/4} [mg/kg^{3/4}/day]). For these endpoints, AUC
5356 of TCE in blood (AUC_{Bld} [mg-hour/L/day]) is the alternative dose-metric. The rationale for the scaling

5357 by body weight to the $\frac{3}{4}$ power is analogous to that for the other metabolism dose-metrics, above.
5358 Compared to the 2014 TSCA Work Plan Chemical Risk Assessment, an additional POD from Selgrade
5359 and Gilmour ([2010](#)) has also been added for acute exposure scenarios.

5360
5361 For this assessment, when an endpoint can be BMD and PBPK modeled, default cumulative acute UF =
5362 10 (UF_A and UF_H both = 3 based only on toxicodynamic uncertainty (UF_{TD}); UF_S and UF_L = 1) and
5363 default cumulative chronic UF = 100 (UF_S = 10 if the study covers less than 10% of lifetime). See
5364 Appendix F for details on the criteria for selection of appropriate BMD models and UFs for each
5365 endpoint.

5366 5367 **POD Selection Metrics**

5368 The below sections present all studies considered for dose-response analysis. From this list, the most
5369 robust and sensitive studies were selected from each health domain /organ system that best
5370 characterized each available endpoint. For some health domains with multiple endpoints this resulted in
5371 multiple studies being selected for consideration in risk estimation. In selecting the most robust and
5372 sensitive studies and PODs, EPA considered the following factors:

- 5373 • Data quality evaluation score
- 5374 • Species (*i.e.*, animal or human)
- 5375 • Exposure duration
- 5376 • Dose range
- 5377 • Cumulative uncertainty factor
- 5378 • Relevance to the endpoint of interest and human exposure scenarios

5379
5380 Dose metric selection is based on a determination of which toxicokinetic measure is most predictive of
5381 localized effects from TCE exposure (Section 3.2.2.5). These factors were evaluated for each
5382 independent endpoint, and EPA considered use of the most health-protective POD only after first
5383 considering each of the above factors. See the 2011 EPA TCE IRIS Assessment ([U.S. EPA, 2011e](#)) for
5384 more details on dose-metric and benchmark response (BMR) determinations for all endpoints except acute
5385 immunosuppression from from Selgrade and Gilmour ([2010](#)). BMD modeling results for ([Selgrade and](#)
5386 [Gilmour, 2010](#)) are presented in Appendix F.

5387 **3.2.5.3.1 Non-Cancer PODs for Acute Exposure**

5388 Acute exposure in humans is defined for occupational settings as exposure over the course of a single
5389 work shift (8 hours) and for consumers as a single 24-hour day. Although developmental studies
5390 typically involve multiple exposures, they are considered relevant for evaluating single exposures
5391 because evidence indicates that certain developmental effects may result from a single exposure during
5392 a critical window of development ([Davis et al., 2009](#); [Van Raaij et al., 2003](#); [U.S. EPA, 1991](#)). This is
5393 consistent with EPA's *Guidelines for Reproductive Toxicity Risk Assessment* ([U.S. EPA, 1996](#)), which
5394 state that repeated exposure is not a necessary prerequisite for the manifestation of developmental
5395 toxicity. Therefore, developmental endpoints were considered relevant for calculating risks associated
5396 with acute occupational or consumer exposure. Single-exposure studies identifying a dose-responsive
5397 specific health outcome were also considered for deriving PODs representative of risks following acute
5398 exposures.

5400 HECs for developmental toxicity were adjusted to reflect a 24-hr value, consistent with both
5401 occupational and consumer exposure values. The POD from Selgrade and Gilmour ([2010](#)), a 3hr acute
5402 inhalation study, was adjusted to a 24hr HEC value for occupational risk estimates due to limited
5403 reasonably available occupational exposure information below 8hr time periods. The 3hr POD was
5404 used without adjustment for estimation of consumer risks due to available exposure estimates for 3hr

5405 time periods.

5406

5407 Developmental Toxicity Endpoints

5408 -- *Prenatal Mortality*

5409 ([Narotsky et al., 1995](#)) was also discussed above in the reproductive toxicity section, but also
5410 identified mortality to the developing fetus following *in utero* TCE exposure. F344 timed-pregnant
5411 rats (8-12 dams/group) were treated with TCE by gavage during GD 6 to 15. The BMDL₀₁ for
5412 increased resorptions was 32.2 mg/kg-bw/day ([U.S. EPA, 2011e](#)).
5413

5414 -- *Developmental Neurotoxicity*

5415 ([Fredriksson et al., 1993](#)) treated male NMRI mouse pups (12/group, selected from 3–4 litters) with
5416 TCE via gavage (0, 50, or 290 mg/kg-bw/day) during postnatal days (PND) 10 to 16. Locomotor
5417 behavior was evaluated at PND 17 and 60. TCE-treated mice showed decreased rearing activity at both
5418 dose levels on PND 60, but not PND 17, resulting in a LOAEL of 50 mg/kg-bw/day as a POD ([U.S.
5419 EPA, 2011e](#)).

5420

5421 -- *Congenital Heart Malformations*

5422 ([Johnson et al., 2003](#)) reported a statistically and biologically significant increase in the formation of
5423 heart defects at the 0.048 mg/kg-bw/day and higher dose levels (concentrations of 0, 0.00045, 0.048,
5424 0.218 or 129 mg/kg-bw/day) measured on both an individual fetus basis and a litter basis. A BMDL₀₁
5425 HEC₉₉ of 0.0037 ppm and HED₉₉ of 0.0052 mg/kg-bw/day were identified as the inhalation and oral
5426 PODs, respectively, for heart malformations in the 2014 TSCA Work Plan Chemical Risk Assessment
5427 ([U.S. EPA, 2014b](#)). EPA quantified the totality of cardiac defects instead of any particular defect, as
5428 cardiac teratogens can result in a diverse constellation of effects (*e.g.*, retinoic acid, see Appendix
5429 F.2.2.2).
5430

5431 The BMR selection from the 2014 TSCA Work Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#))
5432 for ([Johnson et al., 2003](#)) was also reassessed based on the non-monotonic dose-response, decreased
5433 incidence from control at the 2.5ppb dose level, and reduced statistical power due to a less than
5434 recommended number of litters assessed for each dose group. These concerns were discussed as part
5435 of a re-analysis of the 2011 dose-response assessment in ([Makris et al., 2016](#)), which acknowledged
5436 the uncertainty inherent in a selection of a 1% BMR:

5437 *“BMD inference at the 1% extra-risk level is highly uncertain, because BMD and BMDL values vary
5438 by several orders of magnitude depending on the modeling assumptions. This is attributed in part to
5439 the lack of monotonicity at the lowest dose and the apparent supralinearity of the overall exposure-
5440 response relationship. Additional doses would be required to better specify the curve shape in the low-
5441 dose region. More reliable inference can be made for higher BMRs...”*

5442

5443 *There is substantial model and parameter uncertainty at the 1% level of extra risk, although 1% is the
5444 appropriate BMR based on severity of the effect (i.e., cardiac malformations). These uncertainties can
5445 be attributed primarily to having too few data points in the low-dose range, where more data would be
5446 required to adequately characterize the dose-response shape. Uncertainty decreases for higher BMR
5447 levels (5% and 10% extra risk), although 10% exceeds the range of the data for some models.”*

5448

5449 In reevaluating the BMR, EPA considered both biological and statistical factors:

5450

1. The biological severity of the effect

5451

2. The range of observable data relative to the BMR and resulting BMDL

5452

3. The influence of study design and sample size on statistical sensitivity

4. Confidence in the model fit and variance

After considering all these factors, EPA determined that the biological severity of the effect, potentially lethal heart defects, strongly supported a BMR of 1%. For statistical considerations, EPA referred to the nested BMD modeling results from Appendix F.4.2.1 in (U.S. EPA, 2011b). In these results, the BMDL for both a 1% and 5% BMR easily fall within the experimental dose range, increasing confidence in the target BMRs. The observed incidence for the lowest dose in (Johnson et al., 2003) was reduced from controls, adding uncertainty to the modeling estimate, however the difference was not statistically significant. A larger sample size for the treated groups may have increased the statistical sensitivity at lower doses. The BMD model actually displays better visual fit at the lower end of the dose range, near the control, suggesting that a lower BMR may actually represent a more accurate model estimate.

In evaluating model fit, EPA determined that the BMD:BMDL ratio was adequate (3.1), indicating reasonably small variance. To confirm the model fit, EPA updated the BMD analysis on the nested dataset using the latest version of the BMDS software (v3.1.1) due to limitations of the software at the time of the original modeling for the 2011 IRIS Assessment (U.S. EPA, 2011e). These results and discussion of the analysis compared to the 2011 analysis are provided in Appendix I. These results demonstrate strong model fit and agree with the 2011 conclusion that the modeling results for cardiac malformation data are appropriate for reference value derivation.

Based on the above considerations and the improved model fit from the updated BMD modeling run, EPA determined that use of a 1% BMR is most appropriate for risk estimation. The difference between the 1% and 5% BMR POD values is 5.2-fold. Results for both 1% and 5% extra risk BMR options (along with 10%) are presented in Appendix I.

Immunotoxicity

-- Immunosuppression (diminished response to infection)

In addition to the previously described developmental toxicity studies, (Selgrade and Gilmour, 2010) was deemed suitable for dose-response analysis of immunotoxicity based on observed decreased response to infection. In Selgrade and Gilmour (2010), female CD-1 mice were infected via respiration with aerosolized *S. zooepidemicus* bacteria following 3h exposure to 0, 5, 10, 25, 50, 100, or 200 ppm of TCE. Mortality was assessed for all dose groups, with statistically significant and dose-responsive increases observed at 50 ppm and above. Bacterial clearance from the lung, percent of mice infected, and phagocytic index were also assessed for 0, 50, 100, and 200ppm dose groups. This study examined pulmonary immunological responses to respiratory infection following inhalation of TCE and is therefore only applicable to inhalation exposure. The inclusion of the Selgrade and Gilmour (2010) study is an addition to this Risk Evaluation and was not previously evaluated for dose-response analysis in the 2014 TSCA Work Plan Chemical Risk Assessment (U.S. EPA, 2014b). This study was discussed in the 2011 IRIS Assessment (U.S. EPA, 2011e) but was excluded from the 2014 Risk Assessment in an oversight.

For (Selgrade and Gilmour, 2010), BMD modeling was performed on the endpoints of mortality and percentage of mice infected (see [Personal Communication to OPPT. Raw Data Values from Selgrade and Gilmour, 2010. Docket: EPA-HQ-OPPT-2019-0500]). A reliable BMDL could not be obtained from the percentage infected data because BMDs and BMDLs from all models were well below the lowest data point and cannot be considered reliable. For mortality, a BMR of 1% increase was selected due to the severity of the effect. Based on evidence of systemic chronic immunosuppression (Sanders et al.,

5501 [1982; Woolhiser et al., 2006](#)), this acute endpoint was applied to systemic exposure. The BMDL₁ based
 5502 on applied dose is 13.9 ppm (Appendix H.1.1.3).

5503
 5504 The raw data from ([Selgrade and Gilmour, 2010](#)) was input through the PBPK model (described in
 5505 Section 3.2.2.5) to obtain internal doses based on two dose metrics, the total amount of TCE
 5506 metabolized per unit adjusted body weight (TotMetabBW34) and area under the curve venous blood
 5507 concentration of TCE (AUCBld). These two metrics were selected as the primary and alternative dose
 5508 metrics for this endpoint under the assumption that the metabolic contribution to this endpoint matches
 5509 that for other immune endpoints (see ([U.S. EPA, 2011e](#)) and Table 3-11). The internal doses were BMD
 5510 modeled, and HEC/HEC₅₀ and HEC/HED₉₉ were then derived based on default model parameters
 5511 assuming continuous exposure. Full modeling runs and details for both dose metrics are provided in
 5512 [*PBPK Modeling Results for Representative Non-Cancer Endpoints under Continuous and*
 5513 *Occupational Exposure Scenarios and Internal Dose BMD Modeling Results for Selgrade and Gilmour,*
 5514 *2010. Docket: [EPA-HQ-OPPT-2019-0500](#)]. BMD modeling results for applied dose and TotMetabBW34
 5515 dose metric are provided in Appendix F.*

5516
 5517 **Table 3-7. Dose-response analysis of selected studies considered for acute exposure scenarios**

Target Organ/System	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Developmental Effects	Rat (female)	Gestational days 6 to 15	BMDL ₀₁ = 32.2 mg/kg-bw/day	Increased resorptions	TotMetab BW34	57	23	29	28	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Narotsky et al., 1995)	High (1.3)
	Rat (female)	22 days throughout gestation (gestational days 0 to 22)	BMDL ₀₁ = 0.0207 mg/kg-bw/day	Congenital heart defects	TotOx Metab BW34	0.012	0.0037	0.0058	0.0052	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Johnson et al., 2003)	Medium (1.9)
	Rat (male pups)	Postnatal days 10 to 16	LOAEL = 50 mg/kg-bw/day	Decreased rearing activity	TotMetab BW34	8	3	4.2	4.1	UFS=1; UFA= 3; UFH=3; UFL=10; Total UF=100	(Fredriksson et al., 1993)	Medium (1.7)
Immune System	Rat (female)	3hr/day, single dose; followed by respiratory infection	BMDL ₀₁ = 13.9 ppm	Mortality due to immunosuppression	TotMetab BW34	2.84	0.973	1.36	1.34	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Selgrade and Gilmour, 2010)	High (1.6)

¹ POD type can be NOAEL, LOAEL, or BMDL. EPA adjusted all values to continuous exposure.

² UFS=subchronic to chronic UF; UFA=interspecies UF; UFH=intrasppecies UF; UFL=LOAEL to NOAEL UF.

³ See [*Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)]* for full evaluation by metric.

Endpoints within an organ system are separated by double-line borders (=); organ systems are separated by thicker borders (-).

5518
 5519 Table 3-7 presents the derived PODs from all studies considered for dose-response analysis of acute
 5520 exposure scenarios. EPA selected studies representative of the distinct endpoints of prenatal mortality,
 5521 congenital defects, developmental neurotoxicity, and response to infection. Most of the developmental
 5522 toxicity studies utilized the PBPK dose metric of TotMetabBW34, or the total amount TCE metabolized
 5523 per unit adjusted body weight. This dose metric was selected because for these endpoints there is
 5524 insufficient information for site-specific or mechanism-specific determinations of an appropriate dose-
 5525 metric, however in general TCE toxicity is associated with metabolites rather than the parent compound.
 5526 TotOxMetab34, or the total amount TCE oxidized per unit adjusted body weight, was used for deriving
 5527 HEC/HED values for congenital heart defects because evidence demonstrating effects from TCA and
 5528 DCA (see Section 3.2.4.1.6) suggests that oxidative metabolism is important for TCE-induced heart
 5529 malformations.

5530

5531 The LogProbit model was selected for BMD modeling results of ([Selgrade and Gilmour, 2010](#)) data
5532 because it was the model with the lowest AIC, using a BMR of 1% based on the endpoint of mortality
5533 (Appendix F). Data from ([Narotsky et al., 1995](#)) and ([Johnson et al., 2003](#)) were also BMD modeled. A
5534 BMR of 1% ER was selected for ([Johnson et al., 2003](#)) based on the severity of the effect and absence of
5535 a strong statistical justification for raising the value (see discussion above). A BMR of 1% was also
5536 selected for ([Narotsky et al., 1995](#)) because of the severity of the effect (full-litter resorptions) and low
5537 background response. A LOAEL was used as a POD for ([Fredriksson et al., 1993](#)), which was not BMD
5538 modeled. For acute exposures, subchronic-to-chronic UF does not apply, so UFs = 1 for all studies. See
5539 Section 3.2.2.5 and ([U.S. EPA, 2011e](#)) for more details on TCE PBPK modeling, dose metric selection,
5540 and BMR selection.

5541

5542 Differences from standard UF values are explained below:

5543 A U_FA value of 3 was applied to ([Selgrade and Gilmour, 2010](#)) because cross-species scaling based on
5544 blood:air partition coefficient or allometric scaling for body weight was used to adjust the HEC/HED as
5545 necessary. A U_FH of 10 was applied to that study because the data were not subject to PBPK modeling
5546 and therefore a HEC99/HED99 value was not applied which would have accounted for human
5547 toxicokinetic variability.

5548

5549 The selected studies are bold in the table above. The endpoints were each represented by a single study.
5550 While there are some methodological and statistical concerns about ([Johnson et al., 2003](#)) and
5551 ([Fredriksson et al., 1993](#)), based on the WOE for the endpoints and data quality scores of at least
5552 Medium, all four of the studies will be utilized for quantitative risk estimation following acute
5553 exposures. There is also some inherent uncertainty extrapolating from the response to pulmonary
5554 infection observed in ([Selgrade and Gilmour, 2010](#)) to a systemic response across multiple exposure
5555 routes, but an acute systemic response to infection is likely based on the systemic immunosuppression
5556 observed in multiple chronic studies ([Sanders et al., 1982](#); [Woolhiser et al., 2006](#)).

5557 **3.2.5.3.2 Non-Cancer PODs for Chronic Exposures**

5558 Chronic exposure was defined for occupational settings as exposure reflecting a 40-hour work week.
5559 Chronic exposure was not considered relevant to consumers based on expected use patterns (Section
5560 2.3.2.6.1). Non-cancer endpoints selected as most relevant for calculating risks associated with chronic
5561 (repeated) occupational exposures to TCE included effects to the liver, kidney, nervous system, immune
5562 system, reproductive system, and developmental outcomes, with all HECs adjusted to reflect a 24-hr
5563 value, consistent with calculated occupational exposure values.

5564

5565 **Liver toxicity**

5566 -- *Increased liver weight and cytotoxicity/hypertrophy*

5567 ([Kjellstrand et al., 1983](#)) exposed NMRI male mice (10-20/group) with up to nine different TCE
5568 concentrations. These concentrations ranged from 37 to 3,600 ppm and included an air control group.
5569 Exposures were conducted for various durations (1, 2, 4, 8, 16, or 24 hrs/day) and for different time
5570 frames (from 30 to 120 days). Liver weight increased in a dose-responsive matter, with statistical
5571 significance apparent at all exposure groups and durations. EPA calculated a benchmark concentration
5572 lower-bound confidence limit of 21.6 ppm based on the 10% benchmark response (BMDL₁₀) for
5573 increased liver/body weight ratios, with histopathology including vacuolization and inflammatory cell
5574 infiltration also observed at 150ppm and above.

5575

5576 ([Buben and O'Flaherty, 1985](#)) exposed Swiss-Cox male mice (12-15 group) to TCE by gavage. Mice
5577 were exposed to a range of TCE doses (100 to 3,200 mg/kg-bw/day plus control) for 5 days/week for 6
5578 weeks. A BMDL₁₀ of 82 mg/kg-bw/day was identified as the POD for increased liver/body weight

5579 ratios, with cytotoxicity, histopathology, and reduced glucose-6-phosphatase activity also observed.
 5580
 5581 In ([Woolhiser et al., 2006](#)), Sprague-Dawley female rats (16/group) were exposed to TCE via
 5582 inhalation at concentrations of 0, 100, 300, or 1,000 ppm for 6 hrs/day, 5 days/week for 4 weeks. A
 5583 BMDL₁₀ of 25 ppm was estimated for increased liver/body weight ratio.
 5584

5585 **Table 3-8. Dose-response analysis of selected studies considered for evaluation of liver toxicity**

Target Organ System	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Liver	Mouse (male)	Continuous and intermittent exposures, variable time periods for 30-120 days	BMDL₁₀= 21.6 ppm	Increased liver/body weight ratio and cytotoxicity/hypertrophy	AMetLiv1 BW34	25	9.1	9.0	7.9	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Kjellstrand et al., 1983)	Medium (1.8)
	Mouse (male)	6 weeks	BMDL ₁₀ = 82 mg/kg-bw/day		AmetLiv1 BW34	32	11	12	10	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Buben and O'Flaherty, 1985)	High (1.3)
	Rat (female)	6 hr/day, 5 days/week for 4 weeks	BMDL ₁₀ = 25 ppm		AmetLiv1 BW34	53	19	19	16	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Woolhiser et al., 2006)	Medium (2)*

¹ POD type can be NOAEL, LOAEL, or BMDL. EPA adjusted all values to continuous exposure.
² UFS=subchronic to chronic UF; UFA=interspecies UF; UFH=intrasppecies UF; UFL=LOAEL to NOAEL UF.
³ See [Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)] for full evaluation by metric. * Woolhiser et al., 2006 was downgraded from a High, with calculated score = 1.3.
Bold rows indicate studies selected to represent the endpoint within the organ system domain.

5586
 5587 Table 3-8 presents the derived PODs from all studies considered for dose-response analysis. Increased
 5588 liver/body weight ratio was the only endpoint modeled from all studies based on the dose metric
 5589 AMetLiv1BW34, or the amount of TCE oxidized in liver per unit adjusted body weight. This dose metric
 5590 was selected because evidence suggests that hepatic oxidative metabolism is involved in TCE liver
 5591 toxicity (indications of liver toxicity were linearly associated with total urinary (*i.e.*, oxidative)
 5592 metabolites in ([Buben and O'Flaherty, 1985](#))). Additionally, dose-response relationships using this dose
 5593 metric showed greater consistency than other considered metrics. All studies were BMDL modeled. A
 5594 BMR of 10% RD was used to represent a minimal, biologically significant amount of change in relative
 5595 liver weight. See Section 3.2.2.5 and ([U.S. EPA, 2011e](#)) for more details on TCE PBPK modeling, dose
 5596 metric selection, and BMR selection.

5597
 5598 Differences from standard UF values are explained below:

5599 All three studies were assigned UFs = 1 despite shorter exposure duration because although the studies
 5600 were subchronic, hepatomegaly (enlarged liver) occurs rapidly with TCE exposure, and no differences
 5601 were observed in severity of relative liver weight increases between 30 and 120 days in ([Kjellstrand et
 5602 al., 1983](#)).

5603
 5604 The data from ([Kjellstrand et al., 1983](#)) was selected to represent the liver toxicity hazard. ([Woolhiser et
 5605 al., 2006](#)) was excluded from further consideration because additional signs of toxicity were not
 5606 observed, indicating that the increased liver weight was likely merely adaptive. ([Kjellstrand et al., 1983](#))
 5607 was selected over ([Buben and O'Flaherty, 1985](#)) because it covered up to 120 days exposure as opposed
 5608 to only 42 days. Additionally, ([Kjellstrand et al., 1983](#)) utilized the widest dose range of any study,
 5609 imparting more precision in the POD estimate.
 5610

5611 **Kidney toxicity**

5612 -- *Kidney Pathology*

5613 ([Maltoni et al., 1986](#)) exposed Sprague-Dawley male rats (116-124/group) to TCE via inhalation (0,
5614 100, 300, or 600 ppm) for 7 hrs/day, 5 days/week for 104 weeks (and allowed all rats to continue
5615 unexposed until they died). The investigators also conducted an oral (gavage) study that dosed rats
5616 with a range of TCE doses (50 to 250 mg/kg-bw/day) for 4-5 days/week for 52 weeks. BMDL₁₀
5617 values of 40.2 ppm and 34 mg/kg-bw/day were calculated for the inhalation and gavage studies,
5618 respectively, based on renal tubular pathological changes (meganucleocytosis) observed in male rats
5619 ([U.S. EPA, 2011e](#)). These changes included dose-dependent enlargement of tubuli cells (cytomegaly)
5620 and their nuclei (karyomegaly) leading to dysplasia, which may serve as a precursor to cancer and/or
5621 morphological indicators of damaged kidney function ([Maltoni et al., 1986](#)).
5622

5623 In another oral (gavage) study ([NTP, 1988](#)), the National Toxicology Program exposed Marshall female
5624 rats (44-50/group) to TCE (*i.e.*, 0, 500, or 1,000 mg/kg-bw/day) for 5 days/week for 104 weeks. Rats
5625 developed toxic nephropathy following TCE exposure. A BMDL₀₅ of 9.45 mg/kg- bw/day was
5626 calculated for the observed kidney effects ([U.S. EPA, 2011e](#)).
5627

5628 -- *Increased Relative Kidney Weight*

5629 ([Woolhiser et al., 2006](#)) conducted an inhalation study that exposed Sprague-Dawley female rats
5630 (16/group) to 0, 100, 300 or 1,000 ppm TCE for 6 hrs/day for 5 days/weeks for 4 weeks. At the end of
5631 the study, rats exhibited increased kidney/body weight ratios and a BMDL₁₀ of 15.7 ppm was estimated
5632 for these effects ([U.S. EPA, 2011e](#)).
5633

5634 Increased kidney/body weight ratios were also seen in ([Kjellstrand et al., 1983](#)). NMRI male mice (10-
5635 20/group) were exposed to a range of TCE concentrations (37 to 3,600 ppm) for 30 to 120 days on
5636 continuous and intermittent exposure regimens. A BMDL₁₀ of 34.7 ppm was identified as the POD for
5637 increased kidney/body weight ratios ([U.S. EPA, 2011e](#)).
5638

5639 **Table 3-9. Dose-response analysis of selected studies considered for evaluation of kidney toxicity**

Target Organ System	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Kidney	Rat (female)	5 days/week for 104 weeks	BMDL ₀₅ = 9.45 mg/kg-bw/day	Toxic nephropathy	ABioact DCVC BW34	0.042	0.0056	0.033	0.0034	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(NTP, 1988)	Medium (2)*
	Rat (male) - Oral	4-5 days/week for 52 weeks	BMDL ₁₀ = 34 mg/kg-bw/day	Pathology changes in renal tubule	ABioact DCVC BW34	0.19	0.025	0.15	0.015	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Maltoni et al., 1986)	Medium (2)*
	Rat (male) - Inhal.	7 hrs/day, 5 days/week for 2 years	BMDL ₁₀ = 40.2 ppm	Pathology changes in renal tubule	ABioact DCVC BW34	0.28	0.038	0.22	0.023	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Maltoni et al., 1986)	Medium (2)*
	Rat (female)	6 hr/day, 5 days/week for 4 weeks	BMDL ₁₀ = 15.7 ppm	Increased kidney weight/body weight ratio	ABioact DCVC BW34	0.099	0.013	0.078	0.0079	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Woolhiser et al., 2006)	Medium (2)*
	Mouse (male)	Continuous and intermittent exposures for 30-120 days	BMDL ₁₀ = 34.7 ppm	Increased kidney weight/body weight ratio	AMet GSH BW34	0.88	0.12	0.69	0.07	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Kjellstrand et al., 1983)	Medium (1.8)

¹ POD type can be NOAEL, LOAEL, or BMDL. EPA adjusted all values to continuous exposure.

² UFS=subchronic to chronic UF; UFA=interspecies UF; UFH=intraspecies UF; UFL=LOAEL to NOAEL UF.

³ See [Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)] for full evaluation by metric. *NTP 1998 was downgraded from a High, with calculated score = 1.2; Maltoni 1986 was downgraded from a High, with calculated scores = 1.4 (oral) and 1.3 (inhalation); Woolhiser 2006 was downgraded from a High, with calculated score = 1.3.

Bold rows indicate studies selected to represent the endpoint within the organ system domain; endpoints within an organ system are separated by double-line borders (=).

5640

5641 Table 3-9 presents the derived PODs from all studies considered for dose-response analysis. The studies
5642 considered for dose-response analysis identified either indications of kidney pathology or increase
5643 kidney/body weight ratio. All rat studies utilized ABioactDCVCBW34, or the amount of DCVC
5644 bioactivated in the kidney per unit adjusted body weight, because GSH-conjugative bioactivation of
5645 TCE into metabolites such as DCVC in the kidney is expected to be responsible for kidney toxicity,
5646 although there is some uncertainty about their direct connection to kidney toxicity ([Green et al. 1997a](#),
5647 [b](#)). AMetGSHBW34, or the amount of TCE conjugated with GSH per unit adjusted body weight, was
5648 utilized for mice studies because PBPK information on DCVC activation in mice is not reasonably
5649 available. All studies were BMDL modeled. A BMR of 5% ER was used for ([NTP, 1988](#)) because toxic
5650 nephropathy is a severe toxic effect. ([Maltoni et al., 1986](#)) used a BMR of 10% ER because
5651 meganuclocytosis is considered minimally adverse, while both studies examining increased relative
5652 kidney weight used a standard BMR of 10% RD. See Section 3.2.2.5 and ([U.S. EPA, 2011e](#)) for more
5653 details on TCE PBPK modeling, dose metric selection, and BMR selection.

5654

5655 Differences from standard UF values are explained below:

5656 ([Woolhiser et al., 2006](#)) and ([Kjellstrand et al., 1983](#)) were assigned UFs = 1 despite shorter exposure
5657 duration because no differences were observed in severity of relative kidney weight increases between 30
5658 and 120 days in ([Kjellstrand et al., 1983](#)).

5659

5660 EPA determined that kidney pathology was a better indicator of adverse kidney effects than increased
5661 relative organ weight and therefore only that endpoint was selected to represent kidney toxicity. While
5662 there are concerns about the procedure of continuing observation until spontaneous death in ([Maltoni et](#)
5663 [al., 1986](#)) due to the potential for confounding effects from autophagy or infection, there are unlikely to
5664 be significant artifacts from this methodology affecting the interpretation of kidney lesions. There was
5665 random allocation to study groups and kidney lesions were not observed in the control or lowest dose
5666 group. Therefore, background false positives were not an issue and the observed dose-response is
5667 expected to be independent of this confounder. Additionally, a 2011 review of pathology results from
5668 other cancer studies performed in this laboratory (Ramazzini Institute) by the NTP Pathology Working
5669 Group ([Malarkey and Bucher, 2011](#)) found good agreement on the interpretation of most solid tumors
5670 and only identified significant differences among inflammatory cancers of the blood and respiratory
5671 tract.

5672

5673 Both ([Maltoni et al., 1986](#)) and ([NTP, 1988](#)) scored a Medium in data quality, however ([Maltoni et al.,](#)
5674 [1986](#)) tested exposure over a sufficiently similar duration with a more appropriate dose range. The
5675 elevated doses in ([NTP, 1988](#)) resulted in massive nephrotoxicity and introduce large uncertainty in
5676 BMD modeling the effects at low doses well below the tested doses with a BMR well below the
5677 observed effect incidence in the study. Therefore, the BMDL and resulting HEC/HED from ([Maltoni et](#)
5678 [al., 1986](#)) was considered more reliable. Among the inhalation and oral results from ([Maltoni et al.,](#)
5679 [1986](#)), with few other differences among the data the lower resulting oral POD was selected to represent
5680 the endpoint in order to be health-protective. Of note, this represents a change from the 2014 TSCA Work
5681 Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)), which selected the POD from ([NTP, 1988](#)) to
5682 represent kidney toxicity.

5683

5684 **Neurotoxicity**5685 -- *CNS Depression*

5686 ([Arito et al., 1994](#)) exposed Wistar male rats (5/group) to TCE via inhalation to concentrations of 0,
5687 50, 100, or 300 ppm for 8 hrs/day, 5 days/week for 6 weeks. Exposure to all of the TCE concentrations
5688 significantly decreased the amount of time spent in wakefulness during the exposure period. Some
5689 carry over was observed in the 22 hr-post exposure period, with significant decreases in wakefulness
5690 seen at 100 ppm TCE. Significant changes in wakefulness- sleep elicited by the long-term exposure
5691 appeared at lower exposure levels. The LOAEL for sleep changes was 12 ppm (*i.e.*, LOAEL, adjusted
5692 for continuous exposure) ([U.S. EPA, 2011e](#)).

5693

5694 -- *Trigeminal nerve effects*

5695 ([Ruijten et al., 1991](#)) evaluated the TCE exposures and possible health effects of 31 male printing
5696 workers (mean age: 44 yrs) and 28 unexposed control subjects (mean age: 45 yrs). The exposure
5697 duration was expressed as “cumulative exposure” (concentration × time). Using historical monitoring
5698 data, mean exposures were calculated as 704 ppm × number of years worked, where the mean number
5699 of years worked was 16 (range: 160-2,150 ppm x yr) ([U.S. EPA, 2011e](#)). The study measured the
5700 trigeminal nerve function by using the blink reflex, but no abnormal findings were observed. However,
5701 the study found a statistically significant average increase in the latency response time in TCE-exposed
5702 workers on the masseter reflex test, another test commonly used to measure the integrity of the
5703 trigeminal nerve. The POD derived from the dataset was a LOAEL of 14 ppm ([U.S. EPA, 2011e](#)).

5704

5705 -- *Neuronal demyelination*

5706 ([Isaacson et al., 1990](#)) dosed weanling Sprague-Dawley male rats (12/dose group) via the oral route
5707 (drinking water) in an experimental protocol for an 8-week period. The control group had unexposed
5708 rats for 8 weeks. The experimental group #1 exposed rats to 47 mg/kg-bw/day TCE for 4 weeks and
5709 then no TCE exposure for 4 weeks. The experimental group #2 exposed rats to 47 mg/kg-bw/day TCE
5710 for 4 weeks, no TCE exposure for the following 2 weeks, and then 24 mg/kg-bw/day TCE for the final
5711 2 weeks. Rats in group #2 reported a decreased latency to find the platform in the Morris water maze
5712 test. While these results actually suggest increased cognitive performance, all of the TCE-treated groups
5713 exhibited hippocampal demyelination, with effects more severe in the twice-exposed group. The
5714 LOAEL for neurodegenerative effects (*i.e.*, demyelination in the hippocampus) was 47 mg/kg-bw/day
5715 ([U.S. EPA, 2011e](#)).

5716

5717 **Table 3-10. Dose-response analysis of selected studies considered for evaluation of neurological effects**

Target Organ System	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Nervous system	Rat (male)	8 hrs/day, 5 days/weeks for 6 weeks	LOAEL = 12 ppm	Significant decreases in wakefulness	TotMetab BW34	13	4.8	6.6	6.5	UFS=3; UFA= 3; UFH=3; UFL=10; Total UF=300	(Arito et al., 1994)	Medium (2)*
	Human (both sexes)	Mean of 16 years	LOAEL = 14 ppm	Trigeminal nerve effects (increased latency in masseter reflex)	TotMetab BW34	14	5.3	7.4	7.3	UFS=1; UFA= 1; UFH=3; UFL=3; Total UF=10	(Ruijten et al., 1991)	Medium (1.7)
	Rat (male)	8 weeks (intermittent)	LOAEL = 47 mg/kg-bw/day	Demyelination of hippocampus	TotMetab BW34	18	7.1	9.4	9.2	UFS=10; UFA= 3; UFH=3; UFL=10; Total UF=1000	(Isaacson et al., 1990)	Medium (2)*

¹ POD type can be NOAEL, LOAEL, or BMDL. EPA adjusted all values to continuous exposure.

² UFS=subchronic to chronic UF; UFA=interspecies UF; UFH=intrasppecies UF; UFL=LOAEL to NOAEL UF.

³ See [Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)] for full evaluation by metric. *Arito 1994 was downgraded from a High, with calculated score = 1.6; Isaacson 1990 was downgraded from a High, with calculated score = 1.6.

Bold rows indicate studies selected to represent the endpoint within the organ system domain; endpoints within an organ system are separated by double-line borders (=).

5718

5719 Table 3-10 presents the derived PODs from all studies considered for dose-response analysis. The
5720 reasonably available datasets for considering neurotoxicity included single studies for each of the three
5721 endpoints of central nervous system (CNS) depression, trigeminal nerve effects, and neuronal
5722 demyelination. The TotMetabBW34 dose metric, or the total amount TCE metabolized per unit adjusted
5723 body weight, was used for all three studies. This dose metric was selected because for these endpoints
5724 there is insufficient information for site-specific or mechanism-specific determinations of an appropriate
5725 dose-metric, however in general TCE toxicity is associated with metabolites rather than the parent
5726 compound. LOAELs were used as PODs for all studies, and none were BMD modeled. See Section
5727 3.2.2.5 and ([U.S. EPA, 2011e](#)) for more details on TCE PBPK modeling and dose metric selection.

5728

5729 Differences from standard UF values are explained below:

5730 ([Arito et al., 1994](#)) was assigned UFs = 3 (instead of 10) despite being only a 6 week study because
5731 effects observed at 6 weeks exposure were only minimally different than effects at 2 weeks (differences
5732 observed post-exposure).

5733 ([Ruijten et al., 1991](#)) was assigned UFs = 1 because the data were based on a mean of 16 years of human
5734 exposure. UFL = 3 (instead of 10) due to the observed effect being an early marker and representing a
5735 minimal degree of change.

5736

5737 EPA did not select ([Isaacson et al., 1990](#)), demonstrating demyelination of the hippocampus, to
5738 represent the neurotoxicity hazard because dosing during the study was not continuous and the resulting
5739 POD was subject to a large cumulative uncertainty factor (1000). ([Arito et al., 1994](#)) and ([Ruijten et al.,
5740 1991](#)) were both considered for use in quantitative risk estimation as they were relatively well-conducted
5741 studies examining independent endpoints within the hazard of neurological effects.

5742

5743 **Immunotoxicity**

5744 ([Keil et al., 2009](#)) exposed B6C3F1 mice (10/group), a standard test strain not genetically prone to
5745 develop autoimmune disease, to TCE via drinking water for 27 or 30 weeks at concentrations in water
5746 of 0, 1.4, or 14 ppm (0.35 or 3.5 mg/kg-bw/day). The study reported a significant decrease in thymus
5747 weight concentrations at both doses and decreased thymic cellularity at the highest dose. Increased
5748 autoantibodies to ssDNA (single-stranded DNA) and dsDNA (double-stranded DNA) were significantly
5749 increased only at the lowest dose. Activated splenic CD4+/CD44+ T-cells (suggestive of autoimmunity)
5750 were also observed at the highest dose. A LOAEL of 0.35 mg/kg-bw/day was identified as the POD for
5751 the thymic and autoimmune effects ([U.S. EPA, 2011e](#)), although EPA has since determined that the
5752 thymic effects may not be a reliable indicator of autoimmunity and have ambiguous adversity. The
5753 significance of the thymic effects is therefore unclear but may be representative of other immune
5754 outcomes. Increased autoantibodies were not observed in the autoimmune-prone strain (NZBWF1)
5755 tested in parallel. While there was not a consistent dose-response for autoantibodies (responses are
5756 similar or even decreased at the higher dose), this inconsistent dose response is in agreement with
5757 results from autoimmune-prone MRL +/+ mice in ([Griffin et al. 2000](#)).

5758

5759 ([Kaneko et al., 2000](#)) exposed auto-immune prone mice (5/group) to TCE via inhalation at
5760 concentrations of 0, 500, 1,000, or 2,000 ppm for 4 hrs/day, 6 days/week, for 8 weeks. At
5761 concentrations \geq 500 ppm, mice exhibited dose-related liver inflammation, splenomegaly and

5762 hyperplasia of lymphatic follicles. Immunoblastic cell formation in lymphatic follicles was observed in
 5763 mice treated with 1,000 ppm TCE. The LOAEL of 70 ppm (adjusted for continuous 24hr exposure)
 5764 was identified for these effects ([U.S. EPA, 2011e](#)).

5765
 5766 -- *Immunosuppression*

5767 In ([Sanders et al., 1982](#)), male and female CD-1 mice (7-25/group) were given TCE in drinking water
 5768 concentrations of 0, 0.1, 1.0, 2.5, or 5.0 mg/mL (0, 18, 217, 393 or 660 mg/kg-bw/day) for 4 or 6
 5769 months. Female mice showed decreased humoral immunity at 2.5 and 5 mg/mL (393 or 660 mg/kg-
 5770 bw/day), whereas cell-mediated immunity and bone marrow stem cell colonization decreased at all four
 5771 concentrations. Male mice were relatively unaffected after both 4 and 6 months of exposure. A LOAEL
 5772 of 18 mg/kg-bw/day was identified as the POD for immunosuppressive effects ([U.S. EPA, 2011e](#)).

5773
 5774 Another study that was previously discussed for liver and kidney effects ([Woolhiser et al., 2006](#)) also
 5775 reported immunosuppressive effects. Sprague-Dawley female rats (16/group) were treated with 0, 100,
 5776 300 or 1,000 ppm TCE for 6 hrs/day, 5 days/week for 4 weeks. Four days prior to study termination,
 5777 the rats were immunized with sheep red blood cells (SRBC), and within 24 hrs following the last
 5778 exposure to TCE, a plaque-forming cell (PFC) assay was conducted to determine effects on splenic
 5779 anti-SRBC IgM response. At 1,000 ppm, rats demonstrated a 64% decrease in the PFC assay response.
 5780 A BMDL_{1SD} of 24.9 ppm was identified for this immunosuppressive effect ([U.S. EPA, 2011e](#)).

5781
 5782 **Table 3-11. Dose-response analysis of selected studies considered for evaluation of immune effects**

Target Organ System	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Immune System	Mouse (female)	27-30 weeks	LOAEL = 0.35 mg/kg-bw/day	Autoimmunity (increased anti-dsDNA and ssDNA antibodies)	TotMetab BW34	0.092	0.033	0.049	0.048	UF _S =1; UF _A = 3; UF _H =3; UF _L =3; Total UF=30 ⁴	(Keil et al., 2009)	High (1.6)
	Mouse (males; auto-immune prone strain)	4 hrs/day, 6 days/week for 8 weeks	LOAEL = 70 ppm	Autoimmunity (changes in immunoreactive organs)	TotMetab BW34	97	37	44	42	UF _S =10; UF _A = 3; UF _H =1; UF _L =10; Total UF=300	(Kaneko et al., 2000)	High (1.5)
	Mouse (female)	16 or 24 weeks (4 or 6 months)	LOAEL = 18 mg/kg-bw/day	Immuno-suppression	TotMetab BW34	4.8	1.7	2.5	2.5	UF _S =1; UF _A = 3; UF _H =3; UF _L =10; Total UF=100	(Sanders et al., 1982)	High (1.4)
	Rat (female)	6 hrs/day, 5 days/ week for 4 weeks	BMDL _{1SD} = 24.9 ppm	Immuno-suppression	TotMetab BW34	29	11	14	14	UF _S =10; UF _A = 3; UF _H =3; UF _L =1; Total UF=100	(Woolhiser et al., 2006)	High (1.1)

¹ POD type can be NOAEL, LOAEL, or BMDL. The IRIS program adjusted all values to continuous exposure.

² UF_S=subchronic to chronic UF; UF_A=interspecies UF; UF_H=intraspecies UF; UF_L=LOAEL to NOAEL UF.

³ See [Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HQ-OPPT-2019-0500](#)] for full evaluation by metric.

⁴ Two different effects were reported by Keil et al, (2009): decreased thymic weight and cellularity and autoimmunity. A total UF of 100 was used for the thymus toxicity, whereas a total UF of 30 was used for the autoimmune effects. The TCE IRIS assessment allocated different LOAEL-to-NOAEL uncertainty factors (UFL) based on the severity of the effects, which resulted in different total UF ([U.S. EPA, 2011e](#)).

Bold rows indicate studies selected to represent the endpoint within the organ system domain; endpoints within an organ system are separated by double-line borders (=).

5783
 5784 Table 3-11 presents the derived PODs from all studies considered for dose-response analysis. These
 5785 studies covered the endpoints of thyroid effects, autoimmunity, and immunosuppression. The
 5786 TotMetabBW34 dose metric, or the total amount TCE metabolized per unit adjusted body weight, was
 5787 used for all three studies. This dose metric was selected because for these endpoints there is insufficient

5788 information for site-specific or mechanism-specific determinations of an appropriate dose-metric,
5789 however in general TCE toxicity is associated with metabolites rather than the parent compound.
5790 LOAELs were used as PODs for all studies except ([Woolhiser et al., 2006](#)), which was BMD modeled
5791 with a BMR of 1 SD because it was unclear what should constitute the cutoff point for a minimal,
5792 biologically significant change. See Section 3.2.2.5 and ([U.S. EPA, 2011e](#)) for more details on TCE
5793 PBPK modeling, dose metric selection, and BMR selection.

5794

5795 Differences from standard UF values are explained below:

5796 ([Keil et al., 2009](#)) was assigned $UF_L = 3$ (instead of 10). Detection of anti-nuclear antibodies (ANA) is a
5797 long-established clinical marker of autoimmune connective tissue diseases (*e.g.*, lupus). Specificity of
5798 ANA for autoimmune disease states can be low, however anti-dsDNA antibodies have been shown to be
5799 quite specific and are rarely detected at elevated levels in healthy patients ([Kavanaugh et al., 2000](#);
5800 [Wichainun et al., 2013](#)). Therefore, the results from ([Keil et al., 2009](#)) do represent an adequate
5801 biomarker of autoimmunity, and the selection of $UF_L = 3$ is justified due to the observed effect being
5802 considered an early, subclinical or pre-clinical early marker of disease and the non-standard dose-
5803 response observed in the study. An increase in activated T cells, another indicator of autoimmunity, were
5804 observed only at the highest dose, further supporting a reduced UF_L at the lowest dose.

5805

5806 Decreased thymus weight and cellularity as observed in ([Keil et al., 2009](#)) was not considered for use in
5807 dose-response analysis or risk estimation because EPA determined that this effect is insufficiently
5808 adverse compared to the other endpoints and the effects are inconsistent with the indications of
5809 autoimmunity. Of note, elimination of this endpoint and corresponding change in total UF ($UF_L = 10$ was
5810 previously applied to the thymus effects) represents a change from the 2014 TSCA Work Plan Chemical
5811 Risk Assessment ([U.S. EPA, 2014b](#)). The POD from ([Keil et al., 2009](#)) for anti-ssDNA and dsDNA was
5812 selected to represent autoimmunity however, because the study was of longer duration than ([Kaneko et al., 2000](#))
5813 with a smaller cumulative uncertainty factor, and the data from ([Kaneko et al., 2000](#)) was only
5814 on autoimmune-prone mice. ([Sanders et al., 1982](#)) was selected to represent immunosuppression
5815 because the study was of a much longer duration than ([Woolhiser et al., 2006](#)).

5816

5817 **Reproductive toxicity**

5818 -- *Male Reproductive Effects*

5819 ([Chia et al., 1996](#)) examined a cohort of 85 workers in an electronics factory. The workers provided
5820 urine, blood, and sperm samples. The mean urine TCA level was 22.4 mg/g creatinine (range: 0.8–
5821 136.4 mg/g creatinine). In addition, 12 workers provided personal 8-hr air samples, which resulted in a
5822 mean TCE exposure of 29.6 ppm (range: 9–131 ppm). There were no controls in the study. Males
5823 experienced decreased percentage of normal sperm morphology and hyperzoospermia. A $BMDL_{10}$ of
5824 1.4 ppm was identified as the POD for these effects ([U.S. EPA, 2011e](#)).

5825

5826 ([Xu et al., 2004](#)) exposed male CD-1 mice (27/group) to TCE at concentration of 0 or 1,000 ppm for 6
5827 hrs/day, 5 days/week for 6 weeks. Inhalation exposure to TCE did not result in altered body weight,
5828 testis and epididymis weights, sperm count, or sperm morphology or motility.
5829 Percentages of acrosome-intact sperm populations were similar between treated and control animals.
5830 However, decreased *in vitro* sperm-oocyte binding and reduced *in vivo* fertilization were observed in
5831 TCE-treated male mice. A LOAEL of 180 ppm (adjusted for continuous 24hr exposure) was identified
5832 as the POD for these effects ([U.S. EPA, 2011e](#)).

5833

5834 ([Kumar et al., 2000](#)) and ([Kumar et al., 2001](#)) exposed male Wistar rats by inhalation at concentrations
5835 of 0 or 376 ppm TCE. Both study protocols exposed rats for 4 hrs/day, 5 days/week, but had variable
5836 duration scenarios. For instance, ([Kumar et al., 2000](#)) treated rats for the following exposure durations:

5837 2 weeks (to observe the effect on the epididymal sperm maturation phase), 10 weeks (to observe the
5838 effect on the entire spermatogenic cycle), 5 weeks with 2 weeks of rest (to observe the effect on
5839 primary spermatocytes differentiation to sperm), 8 weeks with 5 weeks of rest (to observe effects on an
5840 intermediate stage of spermatogenesis), or 10 weeks with 8 weeks of rest (to observe the effect on
5841 spermatogonial differentiation to sperm). ([Kumar et al., 2001](#)) exposed rats for either 12 or 24 weeks.
5842

5843 ([Kumar et al., 2000](#)) reported altered testicular histopathology, increased sperm abnormalities, and
5844 significantly increased pre- and/or postimplantation loss in litters in the groups with 2 or 10 weeks of
5845 exposure, or 5 weeks of exposure with 2 of weeks rest. Multiple sperm effects were observed in another
5846 study by Kumar ([2001](#)). After 12 weeks of TCE exposure, rats exhibited decreased number of
5847 spermatogenic cells in the seminiferous tubules, fewer spermatids as compared to controls, and the
5848 presence of necrotic spermatogenic cells. Following 24 weeks of exposure, male rates showed reduced
5849 testes weights and epididymal sperm count and motility, testicular atrophy, smaller tubules,
5850 hyperplastic Leydig cells, and a lack of spermatocytes and spermatids in the tubules. Testicular marker
5851 enzymes were altered at both 12 and 24 weeks of exposure. A LOAEL of 45 ppm was identified as the
5852 POD for the sperm and male reproductive effects reported in both studies ([U.S. EPA, 2011e](#)).
5853

5854 ([Kan et al., 2007](#)) also provided evidence for the damage to the epididymis epithelium and sperm.
5855 CD-1 male mice (4/group) were exposed via inhalation to 0 or 1,000-ppm TCE for 6 hrs/day, 5
5856 days/week for 1 to 4 weeks. As early as 1 week after TCE exposure, exposed mice showed
5857 degeneration and sloughing of epithelial cells. These effects increased in severity at 4 weeks of
5858 exposure. A LOAEL of 180 ppm (adjusted for continuous 24hr exposure) was identified as a POD for
5859 the effects in the epididymis epithelium.
5860

5861 -- *Female Reproductive Effects*

5862 ([Narotsky et al., 1995](#)) administered TCE to F344 timed-pregnant rats (8-12 dams/group) by gavage.
5863 Dams were exposed to TCE doses of 0, 10.1, 32, 101, 320, 475, 633, 844 or 1125 mg/kg-bw/day during
5864 gestational days (GD) 6 to 15. The study was a prequel to a complicated protocol with other chemicals
5865 in a mixture study. Delayed parturition was observed at ≥ 475 mg/kg- bw/day. The LOAEL for female
5866 reproductive effects was 475 mg/kg-bw/day ([U.S. EPA, 2011e](#)).
5867

5868 -- *Diminished Reproductive Behavior*

5869 George et al. ([1986](#)) administered TCE to both male and female F344 rats (20 each treated, 40 each
5870 controls) in feed with estimated doses of 0, 72, 186, or 389 mg/kg-bw/day. Breeders were exposed for
5871 one week pre-mating and then for 13 weeks while cohabitating. Pregnant females were subsequently
5872 exposed throughout gestation (an additional 4 weeks). Copulation was reduced equally following
5873 either exposed males or exposed females cohabitating with control mates (only the highest dose
5874 examined). This corresponded with a dose-responsive decrease in the number of litters produced per
5875 breeding pair and the number of live pups per litter.
5876

5877 **Table 3-12. Dose-response analysis of selected studies considered for evaluation of reproductive effects**

Target Organ System	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Reproductive system	Human (male)	Measured values after an 8-hr work shift; mean 5.1 years on the job	BMDL ₁₀ = 1.4 ppm	Hyperzoospermia	TotMetab BW34	1.4	0.5	0.74	0.73	UFS=10; UFA= 1; UFH=3; UFL=1; Total UF=30	(Chia et al., 1996)	Medium (1.8)
	Rat (male)	4 hrs/day, 5 days/week, 2-10 weeks exposed, 2-8 weeks unexposed	LOAEL = 45 ppm	Sperm effects and male reproductive tract effects	TotMetab BW34	32	13	16	16	UFS=10; UFA= 3; UFH=3; UFL=10; Total UF=1000	(Kumar et al., 2000)	Medium (1.7)
		4 hrs/day, 5 days/week for 12 or 24 weeks										
	Mouse (male)	6 hrs/day, 5 days/week for 1-4 weeks	LOAEL = 180 ppm	Effects on epididymis epithelium	TotMetab BW34	190	67	80	73	UFS=10; UFA= 3; UFH=3; UFL=10; Total UF=1000	(Kan et al., 2007)	Medium (2)*
	Mouse (male)	6 hrs/day, 5 days/week for 6 weeks	LOAEL = 180 ppm	Sperm effects (decreased in vitro sperm-oocyte binding and <i>in vivo</i> fertilization)	TotMetab BW34	190	67	80	73	UFS=10; UFA= 3; UFH=3; UFL=10; Total UF=1000	(Xu et al., 2004)	High (1.4)
	Rat (female dams)	9 days (during gestational days 6 to 15)	LOAEL = 475 mg/kg-bw/day	Delayed parturition	TotMetab BW34	98	37	47	44	UFS=1; UFA= 3; UFH=3; UFL=10; Total UF=100	(Narotsky et al., 1995)	High (1.3)
	Rat (male/female)	Breeders exposed 1 week pre-mating and then for 13 weeks cohabitating	LOAEL = 389 mg/kg-bw/day	Decreased copulation; reduced numbers of live litters/pair and pups/litter	TotMetab BW34	204	71	85	77	UFS=1; UFA= 3; UFH=3; UFL=10; UFD=1; Total UF=100	(George et al., 1986)	High (1.1)

¹ POD type can be NOAEL, LOAEL, or BMDL. The IRIS program adjusted all values to continuous exposure.

² UFS=subchronic to chronic UF; UFA=interspecies UF; UFH=intraspecies UF; UFL=LOAEL to NOAEL UF.

³ See [Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HO-OPPT-2019-0500](#)] for full evaluation by metric. *Kan 2007 was downgraded from a High, with calculated score = 1.6.

Bold rows indicate studies selected to represent the endpoint within the organ system domain; endpoints within an organ system are separated by double-line borders (=).

5878

5879 Table 3-12 presents the derived PODs from all studies considered for dose-response analysis. The
 5880 majority of studies identified effects indicative of male reproductive toxicity, with one study
 5881 demonstrating female reproductive toxicity. The TotMetabBW34 dose metric, or the total amount of
 5882 TCE metabolized per unit adjusted body weight, was used for all three studies. This dose metric was
 5883 selected because for these endpoints there is insufficient information for site-specific or mechanism-
 5884 specific determinations of an appropriate dose-metric, however in general TCE toxicity is associated
 5885 with metabolites rather than the parent compound. For (Chia et al., 1996), the 2011 IRIS Assessment
 5886 (U.S. EPA, 2011e) notes some additional uncertainty in the dose estimate because exposure groups were
 5887 defined by ranges and exposure was estimated by conversion of urinary TCA. LOAELs were used as
 5888 PODs for all studies except (Chia et al., 1996), which was BMD modeled with a standard BMR of 10%
 5889 extra risk. The 2011 IRIS Assessment (U.S. EPA, 2011e) indicates some uncertainty in the biological
 5890 significance of this BMR because the study used a lower cutoff to define hyperzoospermia than other
 5891 studies. See Section 3.2.2.5 and (U.S. EPA, 2011e) for more details on TCE PBPK modeling, dose
 5892 metric selection, and BMR selection.

5893

5894 For male reproductive toxicity, ([Chia et al., 1996](#)) was selected over the other studies because it was a
5895 human study over a mean 5.1 year period compared to the other studies which were in mice and all for
5896 only a few weeks except for ([Kumar et al., 2001](#)). Additionally, ([Chia et al., 1996](#)) only has a
5897 cumulative uncertainty factor of 30, compared to 1000 for the other three studies. ([Narotsky et al.,](#)
5898 [1995](#)) received a High in data quality evaluation and was deemed suitable for quantitative assessment
5899 of female reproductive toxicity based on delayed parturition (giving birth). While ([George et al., 1986](#))
5900 received a High in data quality evaluation, it is unclear whether the observed effects are a result of true
5901 reproductive toxicity or merely behavioral changes (*i.e.*, unsuccessful copulation vs. reduced libido).
5902 Effects on copulation are also likely downstream of any specific male or female reproductive
5903 endpoints, which have more sensitive PODs than ([George et al., 1986](#)). Therefore, the POD for
5904 reduced copulation was not selected to represent the reproductive toxicity hazard.

5905

5906 **Developmental toxicity**

5907 As described above in Section 3.2.5.3.1, developmental effects may result from single as well as
5908 repeated exposures at a developmentally critical period; therefore the same endpoints are relevant for
5909 both acute and chronic exposure scenarios. The only difference between acute and chronic exposure
5910 scenarios in evaluating developmental toxicity is the benchmark MOE for ([Fredriksson et al., 1993](#)). The
5911 subchronic-to-chronic UFs = 3 for chronic exposure, because the study only exposed pups during
5912 postnatal days 10-16, suggesting that exposure during a longer period of development may have
5913 exacerbated the observed effects (UFs would not = 10 because neurological development only occurs
5914 over a portion of a lifetime). This results in a cumulative UF and benchmark MOE of 300. See Section
5915 3.2.5.3.1 for a detailed description of the developmental toxicity endpoints.

5916 **3.2.5.3.3 Cancer POD for Lifetime Exposures**

5917 EPA utilized linear low-dose extrapolation for derivation of PODs accounting for all three cancer types.
5918 Regarding low-dose extrapolation, a key consideration in determining what extrapolation approach to
5919 use is the mode(s) of action. However, mode of action data are lacking or limited for each of the cancer
5920 responses associated with TCE exposure, with the exception of the kidney tumors (see Section
5921 3.2.4.2.2). For the other TCE-induced cancers, the mode(s) of action is unknown. When the mode(s) of
5922 action is identified as genotoxic or cannot be clearly defined, EPA generally uses a linear approach to
5923 estimate low-dose risk ([U.S. EPA, 2005](#)), based on the following general principles:

5924

5925 1) A chemical's carcinogenic effects may act additively to ongoing biological processes,
5926 given that diverse human populations are already exposed to other agents and have
5927 substantial background incidences of various cancers.

5928

5929 2) A broadening of the dose-response curve (*i.e.*, less rapid fall-off of response with decreasing dose) in
5930 diverse human populations and, accordingly, a greater potential for risks from low-dose exposures ([Lutz](#)
5931 [et al., 2005](#); [Zeise et al., 1987](#)) is expected for two reasons: First, even if there is a threshold
5932 concentration for effects at the cellular level, that threshold is expected to differ across individuals.
5933 Second, greater variability in response to exposures would be anticipated in heterogeneous populations
5934 than in inbred laboratory species under controlled conditions (due to, *e.g.*, genetic variability, disease
5935 status, age, nutrition, and smoking status).

5936

5937 3) The general use of linear extrapolation provides reasonable upper-bound estimates that
5938 are believed to be health-protective ([U.S. EPA, 2005](#)) and also provides consistency
5939 across assessments.

5940

5941 Dose-response analysis of kidney cancer utilized ABioactDCVCBW34, or the amount of DCVC
5942 bioactivated in the kidney per unit adjusted body weight, for the same rationale as described above for
5943 kidney non-cancer effects. Dose-response modeling for kidney cancer from Charbotel et al. (2006) was
5944 performed by linear regression weighted by the inverse of variances for RR estimates. Consistent with
5945 EPA's Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), the same data and methodology
5946 were also used to estimate the exposure level (EC_x: —effective concentration corresponding to an extra
5947 risk of x%) and the associated 95% lower confidence limit of the effective concentration corresponding
5948 to an extra risk of 1% (LEC_x [lowest effective concentration], x = 0.01). A 1% extra risk level is
5949 commonly used for the determination of the POD for epidemiological data. Use of a 1% extra risk level
5950 for these data is supported by the fact that, based on the actuarial program, the risk ratio (*i.e.*, Rx/Ro) for
5951 an extra risk of 1% for kidney cancer incidence is 1.9, which is in the range of the ORs reported by
5952 Charbotel et al. (ORs range from 1.16 - 2.16 across exposure tertiles). Thus, 1% extra risk was selected
5953 for determination of the POD, and, consistent with EPA's Guidelines for Carcinogen Risk Assessment
5954 (U.S. EPA, 2005), the LEC value corresponding to that risk level was used as the actual POD. For more
5955 details, see Section 5.2.2 in the 2011 IRIS Assessment (U.S. EPA, 2011e). Based on the results of the
5956 meta-analysis (Section 3.2.4.2.1 and Appendix J) confirming a positive association between TCE
5957 exposure and all three cancer sites, the derived PODs will remain the same as for (U.S. EPA, 2011e) and
5958 (U.S. EPA, 2014b).

5959
5960 The inhalation unit risk (IUR) for TCE is defined as a plausible upper bound lifetime extra risk
5961 of cancer from chronic inhalation of TCE per unit of air concentration. The estimate of the inhalation
5962 unit risk for TCE is 2.20×10^{-2} per ppm (2×10^{-2} per ppm [4×10^{-6} per $\mu\text{g}/\text{m}^3$]) rounded to one
5963 significant figure), based on human kidney cancer risks reported by Charbotel et al. (2006) and adjusted
5964 4-fold upward for potential additional risk for NHL and liver cancer. This estimate is based on High-
5965 quality human data, thus avoiding the uncertainties inherent in interspecies extrapolation. This value is
5966 supported by inhalation unit risk estimates demonstrating multisite carcinogenicity in several rodent
5967 bioassays, the most sensitive of which range from 1×10^{-2} to 2×10^{-1} per ppm [2×10^{-6} to 3×10^{-5} per
5968 $\mu\text{g}/\text{m}^3$].

5969
5970 The IUR from Charbotel et al. (2006) (calculated as 5.49×10^{-3} per ppm) was adjusted by a factor of
5971 four to account for estimating risk to all three cancer types combined (*i.e.*, lifetime extra risk for
5972 developing any of the three types of cancer) versus the extra risk for kidney cancer alone. Although only
5973 the Charbotel et al. (2006) study was found adequate for direct estimation of inhalation unit risks, the
5974 available epidemiologic data provide sufficient information for estimating the *relative* potency of TCE
5975 across tumor sites. Section 5.2.2 of the 2011 IRIS Assessment (U.S. EPA, 2011e) describes the process
5976 for this adjustment in more detail. In short, extra lifetime cancer risks were summed across the three
5977 cancer types and the ratio of the sum of the extra risks to the extra risk for kidney alone was derived.
5978 EPA calculated this ratio using two sets of data: the summary RR estimates from the 2011 meta-analyses
5979 for NHL, kidney cancer, and liver cancer, and the SIR estimates for all three cancer types from the
5980 Raaschou-Nielsen et al. (2003) study. The value for the ratio of the sum of the extra risks to the extra
5981 risk for kidney cancer alone was 3.28 from the first calculation (using meta-analysis results) and 4.36
5982 from the second calculation (using (Raaschou-Nielsen et al., 2003) data). The geometric and arithmetic
5983 mean of these two values is 3.8, and EPA decided to round up to 4 based on the imprecision of the
5984 adjustment factor.

5985
5986 The oral slope factor (OSF) for TCE is defined as a plausible upper bound lifetime extra risk of cancer
5987 from chronic ingestion of TCE per mg/kg/day oral dose. The estimate of the oral slope factor is $4.64 \times$
5988 10^{-2} per mg/kg/day (5×10^{-2} per mg/kg/day rounded to one significant figure), resulting from PBPK
5989 model-based route-to-route extrapolation of the inhalation unit risk estimate based on the human kidney

5990 cancer risks reported in Charbotel et al. (2006) and adjusted 5-fold upward for potential risk for NHL
5991 and liver cancer. For this adjustment, individual IUR estimates were first obtained for each site based on
5992 the ratios of extra risk relative to kidney. Those site-specific IUR estimates were then extrapolated to the
5993 equivalent OSFs using site-specific dose metrics,²³ and those individual OSFs were summed to obtain a
5994 ratio of 5.0 relative to kidney cancer alone. Uncertainty in the PBPK model-based route-to-route
5995 extrapolation is relatively low, however variability stemming from the requirement of using distinct
5996 dose-metrics for the different target tissues resulted in a larger 5-fold adjustment, as opposed to the 4-
5997 fold adjustment calculated for the IUR. Extrapolation using different dose-metrics yielded expected
5998 population mean risks within about a two-fold range, and, for any particular dose-metric, the 95% CI for
5999 the extrapolated population mean risks for each site spanned a range of no more than about threefold.
6000 The resulting combined OSF value is supported by oral slope factor estimates from multiple rodent
6001 bioassays, the most sensitive of which range from 3×10^{-2} to 3×10^{-1} per mg/kg/day. The OSF was used
6002 for evaluating dermal risk (dermal absorption was considered in the exposure estimates (Section 2.3.1
6003 and Section 2.3.2.3.1).

6004
6005 EPA decided not to use the IUR or OSF to calculate the theoretical cancer risk associated with a single
6006 (acute) exposure to TCE. NRC (2001) published methodology for extrapolating cancer risks from
6007 chronic to short-term exposures to mutagenic carcinogens, however these methods were published with
6008 the caveat that extrapolation of lifetime theoretical excess cancer risks to single exposures has great
6009 uncertainties. Thus, this Risk Evaluation for TCE does not estimate excess cancer risks for acute
6010 exposures because the relationship between a single short-term exposure to TCE and the induction of
6011 cancer in humans has not been established in the current scientific literature. Risk estimates for cancer
6012 will be based on lifetime exposure durations, represented as Lifetime Average Daily Concentration/Dose
6013 (LADC/LADD).

6014 **3.2.5.4 Selected PODs for Human Health Hazard Domains**

6015 Table 3-13 and Table 3-14 list the studies and corresponding HECs, HEDs, and UFs that EPA is using
6016 in the TCE Risk Evaluation following acute and chronic exposure. Table 3-15 provides the cancer
6017 PODs for evaluating lifetime exposure. Key studies in Table 3-13 and Table 3-14 are briefly described
6018 in Section 3.2.5.1. Presenting PODs for the HEC/HED₅₀ and HEC/HED₉₉ values is intended to provide
6019 a sense of the difference between the median and 99% confidence bound for the combined uncertainty
6020 and variability. Calculations of HEC_{50/99} and HED_{50/99} ratios generally showed a 2-3 fold difference
6021 for the various studies described in Section 3.2.5.3. The exception was for studies reporting kidney
6022 effects, which showed high HEC_{50/99} and HED_{50/99} ratios (7 to 10-fold) due to larger uncertainty in
6023 the rodent internal dose estimates for the GSH metabolism dose metrics (e.g., ABioActDCVCBW34)
6024 (U.S. EPA, 2011e) and greater influence of human variability. Confidence in these metrics was lower
6025 for mouse data due to an absence of GSD-specific in vivo data, and there is some question about how
6026 relevant DCVC formation is for renal toxicity (Green et al. 1997a, b), however sensitivity analyses
6027 demonstrated that model uncertainty was similar as to other metrics for rat and human data (U.S. EPA,
6028 2011e). The HEC/HED₉₉ values represent the PODs that are expected to be protective of sensitive
6029 subpopulations, accounting for the majority of identified toxicokinetic human variability.
6030

²³ Kidney: ABioactDCVCBW34; NHL: TotMetabBW34; Liver: AMetLiv1BW34

6031 **Table 3-13. Dose-response analysis of selected studies considered for acute exposure scenarios**

Target Organ/System	Species	Duration	POD Type (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs)	Reference	Data Quality
Developmental Effects	Rat (female)	Gestational days 6 to 15	BMDL ₀₁ = 32.2 mg/kg-bw/day	Increased resorptions	TotMetab BW34	57	23	29	28	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Narotsky et al., 1995)	High
	Rat (female)	22 days throughout gestation (gestational days 0 to 22)	BMDL ₀₁ = 0.0207 mg/kg-bw/day	Congenital heart defects	TotOx Metab BW34	0.012	0.0037	0.0058	0.0052	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Johnson et al., 2003)	Medium
	Rat (male pups)	Postnatal days 10 to 16	LOAEL = 50 mg/kg-bw/day	Decreased rearing activity	TotMetab BW34	8	3	4.2	4.1	UFS=1; UFA= 3; UFH=3; UFL=10; Total UF=100	(Fredriksson et al., 1993)	Medium
Immune System	Rat (female)	3hr/day, single dose; followed by respiratory infection	BMDL ₀₁ = 13.9 ppm	Mortality due to immunosuppression	TotMetab BW34	2.84	0.973	1.36	1.34	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Selgrade and Gilmour, 2010)	High

6032

Table 3-14. Dose-response analysis of selected studies considered for chronic exposure scenarios

Target Organ System	Species	Duration	POD Type (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs)	Reference	Data Quality
Liver	Mouse (male)	Continuous and intermittent exposures, variable time periods for 30-120 days	BMDL ₁₀ = 21.6 ppm	Increased liver/body weight ratio and cytotoxicity/hypertrophy	AMetLiv1 BW34	25	9.1	9.0	7.9	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Kjellstrand et al., 1983)	Medium
Kidney	Rat (male) - Oral	4-5 days/week for 52 weeks	BMDL ₁₀ = 34 mg/kg-bw/day	Pathology changes in renal tubule	ABioact DCVCBW34	0.19	0.025	0.15	0.015	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Maltoni et al., 1986)	Medium
Nervous System	Rat (male)	8 hrs/day, 5 days/weeks for 6 weeks	LOAEL = 12 ppm	Significant decreases in wakefulness	TotMetab BW34	13	4.8	6.6	6.5	UFS=3; UFA= 3; UFH=3; UFL=10; Total UF=300	(Arito et al., 1994)	Medium
	Human (both sexes)	Mean of 16 years	LOAEL = 14 ppm	Trigeminal nerve effects (increased latency in masseter reflex)	TotMetab BW34	14	5.3	7.4	7.3	UFS=1; UFA= 1; UFH=3; UFL=3; Total UF=10	(Ruijten et al., 1991)	Medium
Immune System	Mouse (female)	27-30 weeks	LOAEL = 0.35 mg/kg-bw/day	Autoimmunity (increased anti-dsDNA and ssDNA antibodies)	TotMetab BW34	0.092	0.033	0.049	0.048	UFS=1; UFA= 3; UFH=3; UFL=3; Total UF=30	(Keil et al., 2009)	High
	Mouse (female)	16 or 24 weeks (4 or 6 months)	LOAEL = 18 mg/kg-bw/day	Immunosuppression	TotMetab BW34	4.8	1.7	2.5	2.5	UFS=1; UFA= 3; UFH=3; UFL=10; Total UF=100	(Sanders et al., 1982)	High
Reproductive System	Human (male)	Measured values after an 8-hr work shift; mean 5.1 years on the job	BMDL ₁₀ = 1.4 ppm	Decreased normal sperm morphology and hyperzoospermia	TotMetab BW34	1.4	0.5	0.74	0.73	UFS=10; UFA= 1; UFH=3; UFL=1; Total UF=30	(Chia et al., 1996)	Medium
	Rat (female dams)	9 days (during gestational days 6-15)	LOAEL = 475 mg/kg-bw/day	Delayed parturition	TotMetab BW34	98	37	47	44	UFS=1; UFA= 3; UFH=3; UFL=10; Total UF=100	(Narotzky et al., 1995)	High
Developmental Effects	Rat (female)	Gestational days 6 to 15	BMDL ₀₁ = 32.2 mg/kg-bw/day	Increased resorptions	TotMetab BW34	57	23	29	28	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Narotzky et al., 1995)	High
	Rat (female)	22 days (gestational days 0-22)	BMDL ₀₁ = 0.0207 mg/kg-bw/day	Congenital heart defects	TotOx Metab BW34	0.012	0.0037	0.0058	0.0052	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Johnson et al., 2003)	Medium
	Rat (male pups)	Postnatal days 10-16	LOAEL = 50 mg/kg-bw/day	Decreased rearing activity	TotMetab BW34	8	3	4.2	4.1	UFS=3; UFA= 3; UFH=3; UFL=10; Total UF=300	(Fredriksson et al., 1993)	Medium

6035 **Table 3-15. Cancer Points of Departure for Lifetime Exposure Scenarios**

POD Type	Oral Slope Factor	Inhalation Unit Risk	Extra Risk Benchmark
POD (extra risk per dose/concentration)	0.0464 per mg/kg	0.022 per ppm	1 x 10 ⁻⁴

6036
 6037 As stated in Section 3.2.5.3.3, these PODs represent the plausible upper bound lifetime extra risk of
 6038 cancer per unit dose or air concentration. The linear non-threshold assumption underlying the derivation
 6039 of these values is appropriate based on the mutagenic mode of action for kidney cancer (with an unclear
 6040 mode of action for the other two cancer types). The PODs are derived from a single High quality kidney
 6041 cancer study ([Charbotel et al., 2006](#)) and the combined estimates account for the additional relative
 6042 contribution from the other two cancers.

6043
 6044 EPA, consistent with 2016 NIOSH guidance ([Whittaker et al., 2016](#)), used 1 x 10⁻⁴ as the benchmark for
 6045 the purposes of this risk determination for individuals in industrial and commercial work environments
 6046 subject to Occupational Safety and Health (OSH) Act requirements. It is important to note that 1x10⁻⁴ is
 6047 not a bright line and EPA has discretion to find unreasonable risks based on other benchmarks as
 6048 appropriate based on analysis. It is important to note that exposure related considerations (duration,
 6049 magnitude, population exposed) can affect EPA’s estimates of the excess lifetime cancer risk (ELCR).
 6050 Cancer assessment is only applicable to evaluation of occupational exposure scenarios, because
 6051 consumer exposures were only evaluated as acute scenarios (Section 2.3.2.2).

6052 **3.2.5.4.1 Best Overall Non-Cancer Endpoints for Risk Conclusions**

6053 From among all the above acute and chronic endpoints presented in Table 3-13 and Table 3-14, EPA
 6054 identified the best overall non-cancer endpoints for risk characterization characterize risk for acute and
 6055 chronic exposure scenarios based on considerations of being both scientifically robust and sufficiently
 6056 sensitive. While some other endpoints present lower PODs (developmental neurotoxicity from
 6057 [Fredriksson et al., 1993](#); congenital heart malformations from [Johnson et al., 2003](#)), there is lower
 6058 confidence in the dose-response and extrapolation of results from those studies (Section 3.2.6.1.1)
 6059 resulting in increased uncertainty surrounding the precision of the derived PODs for those endpoints.
 6060 Therefore, EPA concluded that acute immunosuppression and chronic autoimmunity were the
 6061 best overall non-cancer endpoints for use in Risk Evaluation under TSCA, based on the best available
 6062 science and weight of the scientific evidence, and were used as the basis of risk conclusions in Section
 6063 4.5.2. The selection of these endpoints for use in risk conclusions was supported by the SACC peer
 6064 review panel (<https://www.regulations.gov/document?D=EPA-HQ-OPPT-2019-0500-0111>).
 6065

6066 **Best Overall Acute Non-Cancer Endpoint**

6067 Based on the following considerations, the POD for mortality due to immunosuppression from ([Selgrade
 6068 and Gilmour, 2010](#)) is considered to be the most robust and best overall POD for acute non-cancer
 6069 scenarios. Confidence in the use of this study for evaluating acute exposure scenarios is High.

6070 Considerations for selection of this study and the High confidence rating include the following:

- 6071 1) The study scored a High in data quality evaluation (the only other high quality study
 6072 applicable to acute exposures, ([Narotsky et al., 1995](#)), is >20x less sensitive)
- 6073 2) The study used a broad dose range, with several concentrations above and below the LOAEL
- 6074 3) The response data followed a consistent dose-response curve
- 6075 4) The data is based on an acute exposure study so there is no uncertainty resulting from
 6076 extrapolating from a repeated-dose study
- 6077 5) The study demonstrated multiple assays supporting the apical outcome

6078 6) The endpoint is severe (an important consideration per the [Risk Evaluation Rule](#) (82 FR
6079 33726)

6080 7) The derived POD is very similar to that of the study selected to represent chronic
6081 immunosuppression ([Sanders et al., 1982](#)). In contrast, there are large uncertainties associated
6082 with the dose-response for the other sensitive acute endpoints ([Johnson et al., 2003](#); [Fredriksson](#)
6083 [et al., 1993](#)); see Section 3.2.6.1.1
6084

6085 Best Overall Chronic Non-Cancer Endpoint

6086 Based on the following considerations, the POD for autoimmunity from ([Keil et al., 2009](#)) is considered
6087 to be the most robust and best overall POD for chronic non-cancer scenarios. Confidence in the use of
6088 this study for evaluating acute exposure scenarios is High. Considerations for selection of this study and
6089 the High confidence rating include the following:

6090 1) The study scored a High in data quality evaluation

6091 2) The study was of chronic duration (27-30 weeks) so uncertainty is reduced by not requiring a
6092 subchronic-to-chronic UF

6093 3) The endpoint is associated with sensitive functional immunological markers (increased anti-
6094 self antibodies)

6095 4) The use of an early clinical marker as an endpoint and dose range are expected to account
6096 for susceptibilities of subpopulations in disease progression

6097 5) The POD for this study is also expected to be protective of developmental immunotoxicity.

6098 While EPA did not identify any developmental immunotoxicity studies of sufficient quality for
6099 dose-response analysis, the LOAEL from ([Keil et al., 2009](#)) is almost identical to and even
6100 slightly lower than the LOAEL from ([Peden-Adams et al., 2006](#)), which demonstrated TCE-
6101 induced autoimmunity in neonatal mice.
6102

6103 Derivation of Occupational HEC/HEDs for Best Overall Endpoints

6104 For these two endpoints, EPA performed additional PBPK modeling to present PODs specific to
6105 occupational scenarios. All PODs (including for these two endpoints) were otherwise derived on the
6106 basis of continuous exposure (24 hr/day, 7days/week) as presented in Section 3.2.5.3.
6107

6108 For deriving PODs for occupational scenarios, EPA adjusted model parameters to assume only 8hr/day
6109 exposure (with continued metabolism throughout the day). Additionally, respiratory rate was set at 1.25
6110 m³/hr based on light activity levels (Table 6-43 in ([U.S. EPA, 2011c](#))), a higher rate than the default
6111 median rate of 0.64 m³/hr used in the PBPK model (Appendix J and [[PBPK Model and ReadMe](#)
6112 ([zipped](#)). [Docket: EPA-HQ-OPPT-2019-0500](#)]) based on sedentary activity levels. Occupational
6113 HECs/HEDs based on the primary dose metric of TotMetabBW34 are presented in Table 3-16. They
6114 will be compared to acute and chronic exposure values based on an 8hr duration of daily exposure for
6115 risk estimation.
6116
6117
6118
6119
6120
6121
6122
6123

6124 **Table 3-16. Occupational PODs for Representative Non-Cancer Endpoints**

Exposure Scenario	Species	Duration	POD Type ¹ (applied dose)	Effect	Dose Metric	HEC ₅₀ (ppm)	HEC ₉₉ (ppm)	HED ₅₀ (mg/kg)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs) ²	Reference	Data Quality ³
Acute	Rat (female)	3hr/day, single dose; followed by respiratory infection	BMDL ₀₁ = 13.9 ppm	Mortality due to immunosuppression	TotMetab BW34	4.46 ⁴	2.34 ⁴	1.38	1.34	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Selgrade and Gilmour, 2010)	High (1.6)
Chronic	Mouse (female)	27-30 weeks	LOAEL = 0.35 mg/kg-bw/day	Autoimmunity (increased anti- dsDNA and ssDNA antibodies)	TotMetab BW34	0.153 ⁵	0.083 ⁵	0.049	0.048	UFS=1; UFA= 3; UFH=3; UFL=3; Total UF=30 ⁴	(Keil et al., 2009)	High (1.6)

¹ POD type can be NOAEL, LOAEL, or BMDL. Values presented are for 8hr daily exposure at occupational respiratory rates.
² UFS=subchronic to chronic UF; UFA=interspecies UF; UFH=intrasppecies UF; UFL=LOAEL to NOAEL UF.
³ See [Data Quality Evaluation of Human Health Hazard Studies. Docket: [EPA-HO-OPPT-2019-0500](#)] for full evaluation by metric.
⁴ The HECs represent 8-hr values. Adjusted 12-hr HECs for ([Selgrade and Gilmour, 2010](#)) based on Haber's rule are: HEC₅₀ = 2.97 ppm; HEC₉₉ = 1.56 ppm.

6125 **3.2.6 Assumptions and Key Sources of Uncertainty for Human Health Hazard**

6126 **3.2.6.1 Confidence in Hazard Identification and Weight of Evidence**

6127 There is high confidence in the database for human health hazard. All studies considered for dose-
 6128 response analysis scored either Medium or High in data quality evaluation and were determined to be
 6129 highly relevant to the pertinent health outcome. EPA selected the most robust, sensitive, and relevant
 6130 study for each identified endpoint from among a broad selection of studies, taking into account factors
 6131 such as data quality evaluation score, species, exposure duration, dose range, cumulative uncertainty
 6132 factor, and relevance. The only identified study that examined developmental immunotoxicity ([Peden-
 6133 Adams et al., 2006](#)) scored a Low in data evaluation and a POD could not be sufficiently derived.

6134
 6135 EPA has medium to high confidence in the overall weight of scientific evidence. EPA did not identify
 6136 any information that would question the previous WOE regarding the evaluation of liver, kidney,
 6137 neurological, immunological, reproductive toxicity, and developmental toxicity (other than cardiac
 6138 malformations). For cancer, EPA performed an updated meta-analysis that found positive statistical
 6139 associations between human TCE exposure and cancer of kidney, liver, and NHL types, in agreement
 6140 with the previous meta-analyses performed in 2011 (Appendix C, ([U.S. EPA, 2011b](#))).

6141 **3.2.6.1.1 Uncertainties in Dose-Response Analysis for Select Endpoints**

6142 For congenital heart defects, EPA performed a thorough WOE assessment (Appendix F.3), examining
 6143 all pertinent studies in the reasonably available literature. There is medium confidence in the relevance
 6144 of the endpoint to human toxicity based on the results of the WOE, although uncertainty remains in the
 6145 POD derivation of ([Johnson et al., 2003](#)) and the resulting POD for congenital heart defects and the
 6146 weight of the scientific evidence only provided qualitative support for the CHD endpoint. Unlike the
 6147 immune PODs (Section 3.2.5.4.1), the POD for cardiac defects derived from ([Johnson et al., 2003](#)) is not
 6148 corroborated by results of other animal studies with similar quantitative results. Uncertainty is further
 6149 increased by the non-monotonicity of the dose-response ([Makris et al., 2016](#)) and less than recommended
 6150 sample size (Section 3.2.5.3.1). EPA does not dismiss the results of ([Johnson et al., 2003](#)), however the
 6151 aforementioned uncertainties reduce confidence in that value. Nonetheless, epidemiological, metabolic,
 6152 and mechanistic data suggest that congenital heart defects may be of concern for particular biologically
 6153 susceptible PESS groups such as older mothers (Section 3.2.5.2).

6155 There is also uncertainty in the dose-response for developmental neurotoxicity ([Fredriksson et al., 1993](#))
6156 based on the study design of statistically evaluating neonatal offspring on a per-pup basis, which does
6157 not account for litter effects. The study was also limited in that it only evaluated males instead of both
6158 sexes, as recommended by ([Holson et al., 2008](#)).

6159 **3.2.6.2 Derivation of PODs, UFs, and PBPK Results**

6160 Conceptually, the POD should represent the maximum exposure level at which there is no appreciable
6161 risk for an adverse effect in the study population under study conditions (*i.e.*, the threshold in the dose-
6162 response relationship). In fact, it is not possible to know that exact exposure level even for a laboratory
6163 study because of experimental limitations (*e.g.*, the ability to detect an effect, the doses used and dose
6164 spacing, measurement errors, etc.). The application of UFs is intended to account for this
6165 uncertainty/variability to allow for estimating risk for sensitive human subgroups exposed continuously
6166 for a lifetime. While the selection of UFs is informed by reasonably available data, the true necessary
6167 extent of adjustment most appropriate for capturing all relevant uncertainty and variability is unknown.
6168

6169 BMD modeling for a selected benchmark response can reduce uncertainty surrounding POD
6170 approximations that rely on the particular doses used in the study (*e.g.*, a NOAEL). If a BMDL is used
6171 as the POD, there are uncertainties regarding the appropriate dose-response model to apply to the data,
6172 but these should be minimal if the modeling is in the observable range of the data. There are also
6173 uncertainties about what BMR to use to best approximate the desired exposure level (*i.e.*, threshold, see
6174 above). For continuous endpoints, in particular, it is often difficult to identify the level of change that
6175 constitutes the threshold for an adverse effect. While a 1% BMR is justified for many of the PODs
6176 derived in this assessment based on the severity of the endpoint, it can potentially amplify BMD model
6177 and parameter uncertainty. This is especially of concern for endpoints with greater uncertainties in the
6178 dose-response assessment such as the congenital heart defects endpoint from ([Johnson et al., 2003](#)),
6179 however a reanalysis of the BMR selection for this endpoint concluded that the 1% BMR was in fact
6180 most appropriate (Section 3.2.5.3.1).
6181

6182 For each of these types of PODs, there are additional uncertainties pertaining to adjustments to the
6183 administered exposures (doses). Typically, administered exposures (doses) are converted to equivalent
6184 continuous exposures (daily doses) over the study exposure period under the assumption that the effects
6185 are related to concentration \times time, independent of the daily (or weekly) exposure regimen (*i.e.*, a daily
6186 exposure of 6 hours to 4 ppm is considered equivalent to 24 hours of exposure to 1 ppm). However, the
6187 validity of this assumption is generally unknown, and, if there are dose-rate effects, the assumption of C
6188 $\times t$ equivalence would tend to bias the POD downwards.
6189

6190 For the PBPK analyses in this assessment, the actual administered exposures are taken into account in
6191 the PBPK modeling, and equivalent daily values (averaged over the study exposure period) for the dose-
6192 metrics are obtained. EPA determined that the peer-reviewed PBPK model sufficiently accounted for
6193 any variability and uncertainties in route-to-route extrapolation, and therefore inhalation and oral data
6194 were considered equivalently relevant. Nonetheless, this PBPK model, like any model, does not
6195 incorporate all possible sources of biological uncertainty or variability, and there is likely to be
6196 remaining unaccounted uncertainties associated with route-to-route extrapolation as opposed to relying
6197 on data from the same exposure route as is being assessed.
6198

6199 The PBPK-based POD estimates include uncertainties about the appropriate dose-metric for each effect,
6200 although there was better information about relevant dose-metrics for some effects than for others (see
6201 Section 3.2.5.3). The 2011 TCE IRIS Assessment determined that the PBPK model was most reliable
6202 for dose metrics involving oxidative metabolism flux. There remains substantial uncertainty in the

6203 extrapolation of GSH conjugation from mice to humans due to limitations in the reasonably available
6204 data. This dose metric is specifically applicable to kidney endpoints, which are believed to result from
6205 renal bioactivation through GSH conjugation. In this manner, the HEC/HED₉₉ values (which account for
6206 both modeling uncertainty and interspecies/intraspecies toxicokinetic variability) may potentially over-
6207 estimate kidney toxicity for a proportion of the population, however use of these values are expected to
6208 sufficiently account for the majority of human toxicokinetic variability, including increased biological
6209 susceptibility (see Section 3.2.5.2). Of note, there was significantly less uncertainty for extrapolation of
6210 rat GSH conjugation data, which was used for the selected kidney PODs, compared to data from mice.
6211 There is additional uncertainty in extrapolation to humans based on evidence suggesting that metabolic
6212 formation of the reactive conjugative metabolites may be an order of magnitude greater in rats than
6213 humans ([Green et al. 1997b](#); [Lash et al. 1990](#)) and that renal toxicity may not be directly related to the
6214 rate of DCVC formation ([Green et al. 1997a, b](#)). These metabolites are indeed formed in both rats and
6215 humans however ([Bernauer et al. 1996](#)), and *in vitro* data suggest that human GSH conjugation activity
6216 may actually be higher in humans than rodents in some cases (Table 3-23 and 3-26 of ([U.S. EPA,](#)
6217 [2011e](#)) and ([Lash et al., 1999](#); [Lash et al., 1998](#))). Additionally, the slow elimination kinetics of GSH
6218 metabolites relative to oxidative species indicate that even lower relative concentrations may contribute
6219 to sustained chronic toxicity ([Bernauer et al. 1996](#)). Uncertainty is also elevated for developmental
6220 endpoints based on fetal effects due to the lack of a fetal compartment in the PBPK model, requiring
6221 reliance instead on default adult female parameters.

6222
6223 Despite any limitations of the model, overall uncertainty for the selected PODs is reduced by the use of
6224 a PBPK model. Use of the PBPK model resulted in data-derived HEC/HED₉₉ values replacing default
6225 assumptions and uncertainty factors that would have otherwise been used such as allometric scaling and
6226 a UF_{TK} of 3 in accounting for both interspecies and intraspecies toxicokinetic variability. Data-derived
6227 values are always preferred to default uncertainty adjustments and improve confidence in the adjusted
6228 PODs.

6229
6230 There is additional uncertainty in the precision and appropriateness of a particular POD for representing
6231 the associated endpoint. The POD for immunosuppression in ([Selgrade and Gilmour, 2010](#)) is derived
6232 from mortality data, which may underestimate risk by not capturing more sensitive sublethal effects.
6233 This is likely accounted for in the BMR selection however, whereby a 1% BMR for mortality would be
6234 expected to result in a similar POD as a more sensitive biological endpoint with a higher BMR. In
6235 contrast, the POD for autoimmunity from ([Keil et al., 2009](#)) is an example of a POD based on an early
6236 biomarker that may not be adverse itself. The use of an early biomarker is accounted for by reducing the
6237 UFL from 10 to 3 for that endpoint. Therefore, in both instances EPA assumes that the resulting POD and
6238 benchmark MOEs sufficiently account for the uncertainty associated with endpoint selection.

6239 **3.2.6.3 Cancer Dose Response**

6240 Potential sources of uncertainty associated with Charbotel et al. ([2006](#)) include the modest sample size
6241 of the study and localized population (86 kidney cancer cases, 37 associated with TCE exposure from a
6242 specific region in France), the retrospective estimation of TCE in study subjects, and potential
6243 confounding effects from exposure to other degreasing agents. These uncertainties do not significantly
6244 affect confidence in the study results because Charbotel et al. ([2006](#)) was a well conducted, High quality
6245 study that used a comprehensive exposure assessment with a detailed occupational questionnaire and
6246 sensitivity and regression analyses found no statistical effect on the cancer POD from a sensitivity
6247 analysis adjusting for exposure to other chemicals ([U.S. EPA, 2011e](#)).

6248
6249 The two major sources of uncertainty in quantitative cancer risk estimates are generally interspecies
6250 extrapolation and high-dose to low-dose extrapolation. The unit risk estimate for kidney cancer

6251 incidence derived from the Charbotel et al. (2006) results is not subject to interspecies uncertainty
6252 because it is based on human data. A major uncertainty remains in the extrapolation from occupational
6253 exposures to lower environmental exposures. There was some evidence of a contribution to increased
6254 kidney cancer risk from peak exposures; however, there remained an apparent dose-response
6255 relationship for kidney cancer risk with increasing cumulative exposure without peaks, and the odds
6256 ratio (OR) for exposure with peaks compared to exposure without peaks was not significantly elevated
6257 (Charbotel et al., 2006) Although the actual exposure-response relationship at low exposure levels is
6258 unknown, the conclusion that a mutagenic mode of action is operative for TCE-induced kidney tumors
6259 supports the linear low-dose extrapolation that was used (U.S. EPA, 2005). The weight of evidence also
6260 supports involvement of processes of cytotoxicity and regenerative proliferation in the carcinogenicity
6261 of TCE, although not with the extent of support as for a mutagenic mode of action. In particular, data
6262 linking TCE-induced proliferation to increased mutation or clonal expansion are lacking, as are data
6263 informing the quantitative contribution of cytotoxicity. Because any possible involvement of a
6264 cytotoxicity mode of action would be additional to mutagenicity, the dose-response relationship would
6265 nonetheless be expected to be linear at low doses. Therefore, the additional involvement of a
6266 cytotoxicity mode of action does not provide evidence against the use of linear extrapolation from the
6267 POD.

6268
6269 The upward adjustment of the cancer PODs based on additional contributions from liver and NHL
6270 cancer was based on peer-reviewed methodology as explained in the 2011 IRIS Assessment (U.S. EPA,
6271 2011e). This approach is reasonable, however it is unknown whether these statistical methods resemble
6272 the true combined extra risk from these three cancers. Additionally, the IUR adjustment was rounded up
6273 to 4-fold from a mean of 3.8 and route-to-route extrapolation results in a 5-fold adjustment for the OSF.
6274 When combined with the above factors and the fact that the cancer PODs represent upper-bound values,
6275 these uncertainties may potentially lead to overestimation of risk, but any differences from the true
6276 IUR/OSF values are unlikely to vary by more than ~2-fold.

6277 **3.2.6.4 Confidence in Human Health Hazard Data Integration and Best** 6278 **Overall Endpoints**

6279 Acute Non-Cancer

6280 There is medium overall confidence in the database, weight of evidence, and dose-response for acute
6281 non-cancer endpoints. There are four endpoints relevant to acute exposure scenarios, covering three
6282 distinct endpoints from developmental toxicity studies and an immunological endpoint from an acute co-
6283 infection study. Two of the four studies scored Medium in data quality, while one developmental
6284 endpoint and the acute immunotoxicity study scored High. The PODs cover several orders of magnitude,
6285 with benchmark MOEs of either 10 or 100. Confidence is reduced from a high due to the data quality
6286 scores, the wide range of PODs, and controversy over the most sensitive POD, from (Johnson et al.,
6287 2003). For developmental endpoints, there is some uncertainty extrapolating from chronic
6288 developmental toxicity studies to acute exposure, especially in assuming a consistent dose-response.
6289 This is a health protective assumption consistent with EPA Guidance (U.S. EPA, 1996; U.S. EPA,
6290 1991), however this may possibly result in an overestimation of risk for some scenarios. For the acute
6291 immunotoxicity study (Selgrade and Gilmour, 2010) there is some inherent uncertainty extrapolating
6292 from the observed responses to pulmonary infection to a systemic response across multiple exposure
6293 routes, however an acute systemic response to infection is likely based on the systemic
6294 immunosuppression observed in multiple chronic studies (Sanders et al., 1982; Woolhiser et al., 2006).
6295 Confidence is raised from the robust WOE analysis performed on the congenital heart defects endpoint
6296 (see Appendix I), the presence of a variety of endpoints including a study using acute TCE
6297 administration, and reduced uncertainty factors due to the use of a PBPK model or allometric scaling. As

6298 stated in Section 3.2.5.4.1, there is High confidence in the POD for the best overall acute endpoint of
6299 immunosuppression from ([Selgrade and Gilmour, 2010](#)).

6300

6301 Chronic Non-Cancer

6302 There is high overall confidence in the database, weight of evidence, and dose-response for chronic non-
6303 cancer endpoints. There are eleven endpoints relevant to chronic exposure scenarios across six health
6304 domains. Seven of the studies scored Medium in data quality, while the other four scored High. The
6305 PODs cover several orders of magnitude with benchmark MOEs ranging from 10 to 300. Confidence is
6306 high because there is strong WOE in support of all health effects, the PODs for three most sensitive
6307 endpoints differ by within an order of magnitude from each other, and the majority of PODs and have
6308 reduced uncertainty factors due to the use of a PBPK model. As stated in Section 3.2.5.4.1, there is High
6309 confidence in the POD for the best overall chronic endpoint of immunosuppression autoimmunity from
6310 ([Keil et al., 2009](#)).

6311

6312 Cancer

6313 There is medium to high overall confidence in the database, weight of evidence, and dose-response for
6314 cancer. Meta-analyses on the full database of relevant epidemiological studies confirm a statistically
6315 significant association between human exposure to TCE and the incidence of kidney cancer, liver
6316 cancer, or NHL. The IUR/OSF is derived from a High quality study ([Charbotel et al., 2006](#)) on kidney
6317 cancer, with the PODs adjusted upward to account for the additional two cancer sites. Confidence is
6318 slightly reduced due to some uncertainty over the precision of the dose-response estimate in accounting
6319 for all three cancer sites and in the GSH metabolism dose metrics but remains medium-high due to
6320 strong evidence for a mutagenic mode of action.

4 RISK CHARACTERIZATION

4.1 Environmental Risks

EPA took fate, exposure, and environmental hazard into consideration to characterize the environmental risk of TCE. EPA determined that no further analysis beyond what was presented in the Problem Formulation document would be done for environmental exposure pathways for terrestrial organisms, or land application of biosolids, water, or soil pathways for terrestrial organisms, in this Risk Evaluation. As stated in Section 2.1 Fate and Transport, TCE is not expected to accumulate in wastewater biosolids, soil, sediment, or biota. TCE is expected to volatilize from the water surface or from moist soil as indicated by its physical chemical properties (*e.g.*, Henry's law constant) and by microbial biodegradation under some conditions. The EPI Suite™ volatilization module estimates that the half-life of TCE in a model river will be 1.2 hours and the half-life in a model lake will be 110 hours. Biodegradation of TCE in the environment is dependent on a variety of factors and thus, a wide range of degradation rates have been reported (ranging from days to years). TCE is not expected to accumulate in aquatic organisms due to low measured BCFs and estimated BAF.

Environmental exposure pathways for surface water for aquatic and sediment organisms are assessed and presented in this Risk Evaluation. As stated in Section 2.2 Environmental Exposures, modeled surface water concentrations of TCE ranged from 1.27E-5 ppb to 9,937.5 ppb from facilities releasing the chemical to surface water. Measured surface water concentrations near facilities range from 0.4 ppb to 447 ppb from published literature (1976-1977). Measured surface water concentrations in ambient water range from below the detection limit to 2.0 ppb in the Water Quality Portal (2013-2017) and from below the detection limit to 17 ppb in the published literature (1996-2001).

As stated in Section 3.1 Environmental Hazards, the reasonably available environmental hazard data indicate that TCE presents hazard to aquatic organisms. For acute exposures to invertebrates, toxicity values ranged from 7.8 to 33.85 mg/L (integrated into a geometric mean of 16 mg/L). For chronic exposures, toxicity values for fish and aquatic invertebrates were as low as 7.88 mg/L and 9.2 mg/L, respectively. These data also indicated that TCE presents hazard for aquatic plants, with toxicity values in algae as low as 0.03 mg/L (geometric mean between a NOEC and a LOEC), and a wide range in toxicity between algae species (EC₅₀s ranging from 26.24 – 820 mg/L).

A total of 25 aquatic environmental hazard studies were identified for TCE as acceptable. They were given mostly high and medium quality ratings during data evaluation (See [*Data Quality Evaluation of Environmental Hazard Studies* and *Environmental Hazard Data Extraction Table*. Docket: [EPA-HQ-OPPT-2019-0500](#)]). The [*Data Quality Evaluation of Environmental Hazard Studies*. Docket: [EPA-HQ-OPPT-2019-0500](#)] document presents details of the data evaluations for each study, including scores for each metric and the overall study score.

Given TCE's conditions of use under TSCA outlined in the Problem Formulation ([U.S. EPA, 2018d](#)), EPA determined that environmental exposures are expected for aquatic species, and risk estimation is discussed in Section 4.1.2 Risk Estimation for Aquatic.

4.1.1 Risk Estimation Approach

EPA used modeled exposure data from E-FAST, as well as monitored data from the Water Quality Portal (www.waterqualitydata.us) and reasonably available literature, to characterize the risk of TCE to

45 aquatic species. Risk quotients (RQs) were calculated using modeled surface water concentrations from
46 E-FAST, monitored data, reasonably available literature, and the COCs calculated in the hazard section
47 of this document (Section 3.1.5). An RQ is defined as:

$$48 \text{RQ} = \text{Predicted Environmental Concentration} / \text{Effect Level or COC}$$

50
51 An RQ equal to 1 indicates that environmental exposures are the same as the COC. If the RQ is above 1,
52 the exposure is greater than the COC. If the RQ is below 1, the exposure is less than the COC. The
53 COCs for aquatic organisms shown in Table 3-2 and the environmental concentrations shown in Section
54 2.2.6.2 were used to calculate RQs. ([U.S. EPA, 1998](#))

55
56 EPA considered the biological relevance of the species that the COCs were based on when integrating
57 the COCs with surface water concentration data to produce RQs. For example, certain biological factors
58 affect the potential for adverse effects in aquatic organisms. Life-history and the habitat of aquatic
59 organisms influences the likelihood of exposure above the hazard benchmark in an aquatic environment.

60
61 Frequency and duration of exposure also affect potential for adverse effects in aquatic organisms,
62 especially for chronic exposures. Therefore, the number of days that a COC was exceeded was also
63 calculated using E-FAST. The days of exceedance modeled in E-FAST are not necessarily consecutive
64 and could occur sporadically throughout the year. For TCE, EPA assumed continuous aquatic exposure
65 for the longer exposure scenarios (*i.e.*, 117-365 days per year of exceedance of a COC), and more of an
66 interval or pulse exposure for shorter exposure scenarios (*i.e.*, 1-40 days per year of exceedances of a
67 COC). Due to the volatile properties of TCE, it is more likely that a chronic exposure duration will occur
68 when there are long-term consecutive days of release versus an interval or pulse exposure which would
69 more likely result in an acute exposure duration.

70 **4.1.2 Risk Estimation for Aquatic Organisms**

71 To characterize potential risk due to TCE exposure, RQs were calculated based on modeled data from E-
72 FAST for sites that had surface water discharges of TCE according to TRI and DMR data (see Table
73 4-1). Surface water concentrations of TCE were modeled for 214 releases. Direct releases from facilities
74 (releases from an active facility directly to surface water) were modeled with two scenarios based on
75 high-end and low-end days of release. Indirect facilities (transfer of wastewater from an active facility to
76 a receiving POTW or non-POTW WWTP) were modeled with a high-end days of releases scenario. As
77 stated in Section 2.2.3, the maximum releases frequency (200 to 365 days) is based on release estimates
78 specific to the facility's condition of use and the low-end releases frequency (20 days) is an estimate of
79 releases that could lead to chronic risk for aquatic organisms.

80
81 These facilities were modeled in E-FAST and all RQs are listed in Appendix E.2. As stated previously,
82 the frequency and duration of exposure affects potential for adverse effects in aquatic organisms.
83 Therefore, the number of days a COC was exceeded was also calculated using E-FAST. Facilities with
84 RQs and days of exceedance that indicate risk for aquatic organisms (facilities with an acute $RQ \geq 1$, or
85 a chronic $RQ \geq 1$ and 20 days or more of exceedance for the chronic COC) are presented in Table 4-1.
86 All facilities were below these thresholds for manufacturing, spot cleaning and carpet cleaning, and
87 commercial printing and copying; therefore, EPA did not identify risks to aquatic organisms for these
88 conditions of use.

89 **Processing as a Reactant:**

90
91 Of the 443 facilities processing TCE as a reactant (including 440 unknown sites modeled in E-FAST),
92 one facility had acute $RQs \geq 1$, or chronic or algae $RQs \geq 1$ with 20 days or more of exceedances.

93 Assuming 20 days of releases, Praxair Technology Center in Tonawanda, NY had an acute RQ of 1.50,
94 a chronic RQ of 3.81 with 20 days of exceedance, and an algae RQ representing the most sensitive
95 species of algae of 1,000 with 20 days of exceedance. In other words, the surface water concentration
96 modeled for this facility was 1.5 times higher than the COC for acute exposures, 3.81 times higher than
97 the COC for chronic exposures, and 1,000 times higher than the COC for the most sensitive species of
98 algae. Assuming 260 days of releases from the facility, the algae RQ representing the most sensitive
99 species was 56.33 with 350 days of exceedance. However, for algae species as a whole, RQs for this site
100 were 0.06 assuming 20 days of release and 0.00 assuming 350 days of release, meaning the
101 concentration did not exceed the COC of 14,400 ppb which represents nine different species of algae.
102 *Therefore, there may be risk for some of the most sensitive species of algae at this site, but EPA did not*
103 *identify risks for algae species as a whole. Risks were identified at this site for other aquatic organisms*
104 *for acute exposures with a surface water concentration 1.50 times higher than the acute COC, and*
105 *chronic exposures, with a surface water concentration 3.81 times higher than the chronic COC and 20*
106 *days of exceedance.*

107 108 **Repackaging:**

109 Of the six facilities repackaging TCE, one had algae RQs ≥ 1 with 20 days or more of exceedances.
110 Assuming 20 days of release per year, Hubbard-Hall Inc in Waterbury, CT had an RQ for the most
111 sensitive species of algae as high as 113.04 with 20 days of exceedance. Assuming this facility released
112 TCE for 250 days per year, the RQ is 9.06 with 194 days of exceedance. However, for algae species as a
113 whole, RQs for this site were 0.01 for 20 days of releases, and 0.00 for 250 days, meaning the
114 concentration did not exceed the COC of 14,400 ppb which represents nine different species of algae.
115 *Therefore, there may be risk for some of the most sensitive species of algae at these sites, but EPA did*
116 *not identify risks for algae species as a whole. EPA did not identify risks for other aquatic organisms in*
117 *this condition of use.*

118 119 **Open-Top Vapor Degreasing:**

120 Of the 64 open-top vapor degreasing facilities, three sites had acute RQs ≥ 1 , or chronic or algae RQs \geq
121 1 with 20 days or more of exceedances. Assuming 20 days of releases, US Nasa Michoud Assembly
122 Facility in New Orleans, LA had acute RQs of 4.97, a chronic RQs of 12.61 with 20 days of exceedance,
123 and an algae RQ representing the most sensitive species of algae of 3,312.50 with 20 days of
124 exceedance. Assuming 260 days of release from the facility, the algae RQ representing the most
125 sensitive species was 255.21 with 260 days of exceedance. However, for algae species as a whole, RQs
126 for this site were 0.05 assuming 260 days of release, and 0.69 assuming 20 days of release, meaning the
127 concentration did not exceed the COC of 14,400 ppb which represents nine different species of algae.
128 *Therefore, there may be risk for some of the most sensitive species of algae at this site, but EPA did not*
129 *identify risks for algae species as a whole. Risks were identified at this site for other aquatic organisms*
130 *for acute and chronic exposures, with a surface water concentration 4.97 times higher than the acute*
131 *COC and 12.61 times higher than the chronic COC and 20 days of exceedance.*

132
133 GM Components Holdings LLC in Lockport, NY had an RQ for the most sensitive species of algae of
134 3.66 with 117 days of exceedance, assuming 260 days of release per year. Assuming 20 days of release,
135 this site has an RQ for the most sensitive species of algae of 48.16 with 20 days of exceedance.
136 However, for algae species as a whole, RQs for this facility were 0.00 assuming 260 days or release and
137 0.01 assuming 20 days of release for this site, meaning the concentration did not exceed the COC of
138 14,400 ppb which represents nine different species of algae. *Therefore, there may be risk for some of the*
139 *most sensitive species of algae at this site, but EPA did not identify risks for algae species as a whole.*

140

141 Akebono Elizabethtown Plant in Elizabethtown, KY had an RQ for the most sensitive species of algae
142 of 1.62 with 27 days of exceedance, assuming 260 days of release per year. However, for algae species
143 as a whole, RQs for this facility were 0.00 for this site, meaning the concentration did not exceed the
144 COC of 14,400 ppb which represents nine different species of algae. *Therefore, there may be risk for*
145 *some of the most sensitive species of algae at this site, but EPA did not identify risks for algae species as*
146 *a whole.*

147

148 **Adhesives, Sealants, Paints, and Coatings:**

149 Of the 54 facilities using TCE as adhesives, sealants, paints, and coatings, one site had algae RQs ≥ 1
150 with 20 days or more of exceedances. Raytheon Company in Portsmouth, RI had an RQ for the most
151 sensitive species of algae as high as 44.44, assuming 20 days of release per year. In other words, the
152 surface water concentration modeled for this facility was 44.44 times higher than the COC for the most
153 sensitive species of algae (3 ppb). Additionally, this COC was exceeded for 20 days. Assuming this
154 facility released TCE for 250 days per year, the RQ is 3.61 with 250 days of exceedance. However, for
155 algae species as a whole, RQs for this facility were 0.00 assuming 250 days or release and 0.01
156 assuming 20 days of release, meaning the concentration did not exceed the COC of 14,400 ppb which
157 represents nine different species of algae. *Therefore, there may be risk for some of the most sensitive*
158 *species of algae at this site, but not for algae species as a whole. EPA did not identify risks for other*
159 *aquatic organisms for this condition of use.*

160

161 **Other Industrial Uses:**

162 Of the 21 facilities with other industrial uses of TCE, three sites had algae RQs ≥ 1 with 20 days or more
163 of exceedances. Eli Lilly And Company-Lilly Tech Ctr in Indianapolis, IN had an RQ for the most
164 sensitive species of algae of 3.01, assuming 250 days of release per year. In other words, the surface
165 water concentration modeled for this facility was 3.01 times higher than the COC for the most sensitive
166 species of algae (3 ppb). Additionally, this COC was exceeded for 35 days. Washington Penn Plastics in
167 Frankfort, KY had an RQ for the most sensitive species of algae of 2.51, assuming 250 days of release
168 per year. Additionally, this COC was exceeded for 22 days. Keeshan and Bost Chemical Co., Inc. in
169 Manvel, TX had an RQ for the most sensitive species of algae of 66.67 with 20 days of exceedance,
170 assuming 20 days of release per year. Assuming 350 days of release, this site has an RQ for the most
171 sensitive species of algae of 3.17 with 350 days of exceedance. However, for algae species as a whole,
172 RQs for these facilities were 0.00 or 0.01, meaning the concentration did not exceed the COC of 14,400
173 ppb which represents nine different species of algae. *Therefore, there may be risk for some of the most*
174 *sensitive species of algae at these sites, but not for algae species as a whole. EPA did not identify risks*
175 *for other aquatic organisms for this condition of use.*

176

177 **Industrial Processing Aid:**

178 Of the six industrial processing aid facilities, one site had algae RQs ≥ 1 with 20 days or more of
179 exceedances. Entek International LLC in Lebanon, OR had an RQ for the most sensitive species of algae
180 as high as 46.11, assuming 20 days of release per year. In other words, the surface water concentration
181 modeled for this facility was 46.11 times higher than the COC for the most sensitive species of algae (3
182 ppb). Additionally, this COC was exceeded for 20 days. Assuming this facility released TCE for 300
183 days per year, the RQ is 3.10 with 140 days of exceedance. However, for algae species as a whole, RQs
184 for this facility were 0.00 or 0.01, meaning the concentration did not exceed the COC of 14,400 ppb
185 which represents nine different species of algae. *Therefore, there may be risk for some of the most*
186 *sensitive species of algae at this site, but EPA did not identify risks for algae species as a whole. EPA*
187 *did not identify risks for other aquatic organisms for this condition of use.*

188

189 **Other Commercial Uses:**

190 Of the nine facilities with other commercial uses of TCE, one site had algae RQs ≥ 1 with 20 days or
191 more of exceedances. Park Place Mixed Use Development in Annapolis, MD had an RQ for the most
192 sensitive species of algae as high as 36.67, assuming 20 days of release per year. In other words, the
193 surface water concentration modeled for this facility was 36.67 times higher than the COC for the most
194 sensitive species of algae (3 ppb). Additionally, this COC was exceeded for 20 days. Assuming this
195 facility released TCE for 250 days per year, the RQ is 3.00 with 250 days of exceedance. However, for
196 algae species as a whole, RQs for this facility were 0.00 or 0.01, meaning the concentration did not
197 exceed the COC of 14,400 ppb which represents nine different species of algae. *Therefore, there may be*
198 *risk for some of the most sensitive species of algae at this site, but EPA did not identify risks for algae*
199 *species as a whole. EPA did not identify risks for other aquatic organisms in this condition of use.*
200

201 **Process Solvent Recycling and Worker Handling of Wastes:**

202 Of the five facilities with other commercial uses of TCE, three sites had algae RQs ≥ 1 with 20 days or
203 more of exceedances. Assuming 20 days of release per year, Clean Water Of New York Inc in Staten
204 Island, NY had an RQ for the most sensitive species of algae as high as 46.08 with 20 days of
205 exceedance. Assuming this facility released TCE for 250 days per year, the RQ is 3.92 with 250 days of
206 exceedance. Assuming 20 days of release, Veolia Es Technical Solutions LLC in Middlesex, NJ had an
207 RQ for the most sensitive species of algae of 11.91 with 20 days of exceedance. And assuming 250 days
208 of releases, Clean Harbors Deer Park LLC in La Porte, TX had an RQ for the most sensitive species of
209 algae of 2.86 with 110 days of exceedance. However, for algae species as a whole, RQs for at all three
210 facilities were 0.00 or 0.01, meaning the concentration did not exceed the COC of 14,400 ppb which
211 represents nine different species of algae. *Therefore, there may be risk for some of the most sensitive*
212 *species of algae at these sites, but EPA did not identify risks for algae species as a whole. EPA did not*
213 *identify risks for other aquatic organisms in this condition of use.*
214

215 **Wastewater Treatment Plants (WWTPs):**

216 Of the nine WWTPs, one site had algae RQs ≥ 1 with 20 days or more of exceedances. New Rochelle
217 STP in New Rochelle, NY had an RQ for the most sensitive species of algae of 4.26, assuming 20 days
218 of release per year. This means that the surface water concentration modeled for this facility was 4.26
219 times higher than the COC for the most sensitive species of algae (3 ppb). Additionally, this COC was
220 exceeded for 20 days. Assuming this facility released TCE for 365 days per year, the RQ is only 0.23
221 with 0 days of exceedance. A WWTP is likely to be operating at greater than 20 days of release,
222 therefore the RQ associated with the high-end days of release scenario (365 days) is likely more
223 representative of actual conditions. *Therefore, EPA did not identify risks to aquatic species for this*
224 *facility or condition of use.*
225

226 **Table 4-1. Environmental Risk Quotients for Aquatic Species for Facilities Releasing TCE to Surface Water as Modeled in E-FAST**
 227 (RQs ≥ 1 in bold)

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient
OES: Processing as a Reactant										
Praxair Technology Center, Tonawanda, NY NPDES: NY0000281	Surface Water	NPDES NY0000281	Still body	350	0.00169	169	Acute (HC ₀₅)	2,000	NA	0.08
							Chronic	788	0	0.21
							Algae (ChV)	3	350	56.33
				20	0.03	3000	Algae (HC ₀₅)	14,400	0	0.01
							Acute (HC ₀₅)	2,000	NA	1.50
							Chronic	788	20	3.81
Algae (ChV)	3	20	1,000.00							
Algae (HC ₀₅)	14,400	0	0.21							
OES: Repackaging										
Hubbard-Hall Inc, Waterbury, CT NPDES: Unknown	Off-site Waste-water Treatment	Receiving Facility: Recycle Inc.; POTW (Ind.)	Surface water	250	1.108	27.18	Acute (HC ₀₅)	2,000	NA	0.02
							Chronic	788	0	0.03
							Algae (ChV)	3	194	9.06
				20	13.85	339.11	Algae (HC ₀₅)	14,400	0	0.00
							Acute (HC ₀₅)	2,000	NA	0.17
							Chronic	788	1	0.43
Algae (ChV)	3	20	113.04							
Algae (HC ₀₅)	14,400	0	0.01							
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, and Metalworking Fluids)										
US Nasa Michoud Assembly Facility, New Orleans, LA NPDES: LA0052256	Surface Water	Surrogate NPDES LA0003280	Still body	260	1.96	765.63	Acute (HC ₀₅)	2,000	NA	0.38
							Chronic	788	0	0.97
							Algae (ChV)	3	260	255.21
				20	25.44	9937.5	Algae (HC ₀₅)	14,400	0	0.05
							Acute (HC ₀₅)	2,000	NA	4.97
							Chronic	788	20	12.61
Algae (ChV)	3	20	3,312.50							
Algae (HC ₀₅)	14,400	0	0.69							
GM Components Holdings LLC, Lockport, NY NPDES: NY0000558	Surface Water	NPDES NY0000558	Surface water	260	0.13	10.97	Acute (HC ₀₅)	2,000	NA	0.01
							Chronic	788	0	0.01
							Algae (ChV)	3	117	3.66
				20	1.71	144.47	Algae (HC ₀₅)	14,400	0	0.00
							Acute (HC ₀₅)	2,000	NA	0.07
							Chronic	788	0	0.18
Algae (ChV)	3	20	48.16							

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient				
							Algae (HC ₀₅)	14,400	0	0.01				
Akebono Elizabethtown Plant, Elizabethtown, KY NPDES: KY0089672	Surface Water	Surrogate NPDES KY0022039	Surface water	260	0.07	4.87	Acute (HC ₀₅)	2,000	NA	0.00				
							Chronic	788	0	0.01				
							Algae (ChV)	3	27	1.62				
								20	0.897	62.38	Algae (HC ₀₅)	14,400	0	0.00
											Acute (HC ₀₅)	2,000	NA	0.03
								Chronic	788	0	0.08			
								Algae (ChV)	3	16	20.79			
							Algae (HC ₀₅)	14,400	0	0.00				
OES: Adhesives, Sealants, Paints, and Coatings														
Raytheon Company, Portsmouth, RI NPDES: RI0000281	Surface Water	NPDES RI0000281	Still body	250	0.013	10.83	Acute (HC ₀₅)	2,000	NA	0.01				
							Chronic	788	0	0.01				
							Algae (ChV)	3	250	3.61				
				20	0.160	133.33	Algae (HC ₀₅)	14,400	0	0.00				
							Acute (HC ₀₅)	2,000	NA	0.07				
							Chronic	788	0	0.17				
	250	0.013	0.32	Algae (ChV)	3	20	44.44							
				Algae (HC ₀₅)	14,400	0	0.01							
				Acute (HC ₀₅)	2,000	NA	0.00							
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.						Chronic	788	0	0.00			
Algae (ChV)								3	0	0.11				
Algae (HC ₀₅)								14,400	0	0.00				
OES: Other Industrial Uses														
Eli Lilly And Company- Lilly Tech Ctr, Indianapolis, IN NPDES: IN0003310	Surface Water	NPDES IN0003310	Surface water	250	1.553	9.03	Acute (HC ₀₅)	2,000	NA	0.00				
							Chronic	788	0	0.01				
							Algae (ChV)	3	35	3.01				
				20	19.410	113.09	Algae (HC ₀₅)	14,400	0	0.00				
							Acute (HC ₀₅)	2,000	NA	0.06				
							Chronic	788	0	0.14				
							Algae (ChV)	3	17	37.70				
							Algae (HC ₀₅)	14,400	0	0.01				
Washington Penn Plastics, Frankfort, KY NPDES: KY0097497	Surface Water	Surrogate NPDES KY0028410	Surface water	250	0.032	7.53	Acute (HC ₀₅)	2,000	NA	0.00				
							Chronic	788	0	0.01				
							Algae (ChV)	3	22	2.51				
				20	0.399	94.12	Algae (HC ₀₅)	14,400	0	0.00				
							Acute (HC ₀₅)	2,000	NA	0.05				
							Chronic	788	0	0.12				

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient
Keeshan and Bost Chemical Co., Inc., Manvel, TX NPDES: TX0072168	Surface Water	NPDES TX0072168	Still body	350	0.000095	9.50	Algae (ChV)	3	13	31.37
							Algae (HC ₀₅)	14,400	0	0.01
							Chronic	788	0	0.01
							Algae (ChV)	3	350	3.17
				20	0.002	200.00	Algae (HC ₀₅)	14,400	0	0.00
							Chronic	788	0	0.10
							Algae (ChV)	3	20	66.67
							Algae (HC ₀₅)	14,400	0	0.01
OES: Industrial Processing Aid										
Entek International LLC, Lebanon, OR NPDES: N/A	Off-site Waste-water Treatment	No info on receiving facility; POTW (Ind.)	Surface water	300	0.38	9.3	Acute (HC ₀₅)	2,000	NA	0.00
							Chronic	788	0	0.01
							Algae (ChV)	3	140	3.10
							Algae (HC ₀₅)	14,400	0	0.00
				20	5.65	138.34	Acute (HC ₀₅)	2,000	0	0.07
							Chronic	788	0	0.18
							Algae (ChV)	3	20	46.11
							Algae (HC ₀₅)	14,400	0	0.01
OES: Other Commercial Uses										
Park Place Mixed Use Development, Annapolis, MD NPDES: MD0068861	Surface Water	Surrogate NPDES MD0052868	Still body	250	0.00027	9	Acute (HC ₀₅)	2,000	NA	0.00
							Chronic	788	0	0.01
							Algae (ChV)	3	250	3.00
							Algae (HC ₀₅)	14,400	0	0.00
				20	0.00334	110	Acute (HC ₀₅)	2,000	NA	0.06
							Chronic	788	0	0.14
							Algae (ChV)	3	20	36.67
							Algae (HC ₀₅)	14,400	0	0.01
OES: Process Solvent Recycling and Worker Handling of Wastes										
Clean Water Of New York Inc, Staten Island, NY NPDES: NY0200484	Surface Water	Surrogate NPDES NJ0000019	Still body	250	0.004	11.76	Acute (HC ₀₅)	2,000	NA	0.01
							Chronic	788	0	0.01
							Algae (ChV)	3	250	3.92
							Algae (HC ₀₅)	14,400	0	0.00
				20	0.047	138.24	Acute (HC ₀₅)	2,000	NA	0.07
							Chronic	788	0	0.18
							Algae (ChV)	3	20	46.08
							Algae (HC ₀₅)	14,400	0	0.01

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient				
Veolia Es Technical Solutions LLC, Middlesex, NJ NPDES: NJ0020141	Off-site Wastewater Treatment	Receiving Facility: Middlesex Cnty UA; NPDES NJ0020141	Still body	250	24.1	2.85	Acute (HC ₀₅)	2,000	NA	0.00				
							Chronic	788	0	0.00				
							Algae (ChV)	3	0	0.95				
								20	301.78	35.72	Algae (HC ₀₅)	14,400	0	0.00
											Acute (HC ₀₅)	2,000	NA	0.02
											Chronic	788	0	0.05
Clean Harbors Deer Park LLC, La Porte, TX NPDES: TX0005941	Off-site Wastewater Treatment	POTW (Ind.)	Surface water	250	0.35	8.57	Algae (ChV)	3	20	11.91				
							Algae (HC ₀₅)	14,400	0	0.00				
							Acute (HC ₀₅)	2,000	NA	0.00				
								20	4.36	106.75	Chronic	788	0	0.01
											Algae (ChV)	3	110	2.86
											Algae (HC ₀₅)	14,400	0	0.00
OES: Wastewater Treatment Plants (WWTP)														
New Rochelle STP, New Rochelle, NY NPDES: NY0026697	Surface Water	NPDES NY0026697	Still body	365	0.043	0.7	Acute (HC ₀₅)	2,000	NA	0.00				
							Chronic	788	0	0.00				
							Algae (ChV)	3	0	0.23				
								20	0.786	12.79	Algae (HC ₀₅)	14,400	0	0.00
											Acute (HC ₀₅)	2,000	NA	0.01
											Chronic	788	0	0.02
							Algae (ChV)	3	20	4.26				
							Algae (HC ₀₅)	14,400	0	0.00				

- a. Facilities actively releasing trichloroethylene were identified via DMR, TRI, and CDR databases for the 2016 reporting year.
- b. Release media are either direct (release from active facility directly to surface water) or indirect (transfer of wastewater from active facility to a receiving POTW or non-POTW WWTP facility). A wastewater treatment removal rate of 81% is applied to all indirect releases, *i.e.*, volumes characterized as being transferred off-site for treatment at a water treatment facility prior to discharge to surface water.
- c. If a valid NPDES of the direct or indirect releaser was not available in EFAST, the release was modeled using either a surrogate representative facility in EFAST (based on location) or a representative generic industry sector. The name of the indirect releaser is provided, as reported in TRI.
- d. EFAST uses either the “surface water” model, for rivers and streams, or the “still water” model, for lakes, bays, and oceans.
- e. Modeling was conducted with the maximum days of release per year expected. For direct releasing facilities, a minimum of 20 days was also modeled.
- f. The daily release amount was calculated from the reported annual release amount divided by the number of release days per year.
- g. For releases discharging to lakes, bays, estuaries, and oceans, the acute scenario mixing zone water concentration was reported in place of the 7Q10 SWC.
- h. To determine the PDM days of exceedance for still bodies of water, the release days provided by the EPA Engineers should become the days of exceedance only if the predicted surface water concentration exceeds the COC. Otherwise, the days of exceedance can be assumed to be zero.

229 EPA also used surface water monitoring data from the Water Quality Portal (WQP) and from the
 230 published literature to characterize the risk of TCE to aquatic organisms. For the most part these
 231 monitored surface water concentrations reflect concentrations of TCE in ambient water. There was one
 232 U.S. study ([U.S. EPA, 1977](#)) that had measurements reflecting near-facility monitoring data. The other
 233 monitored data collected in the US reflect ambient concentrations.

234
 235 Monitored data from one U.S. study ([U.S. EPA, 1977](#)) in the published literature reporting near-facility
 236 concentrations of TCE collected between 1976 and 1977 ranging from 0.4 to 447 µg/L. While these data
 237 reflect historical levels of TCE, they are helpful to compare measured near-facility concentrations to the
 238 modeled near-facility concentrations from E-FAST. The measured concentrations in this study
 239 encompasses the range of the modeled estimates across all OES with the exception of two sites that
 240 release to still water bodies.

241
 242 EPA also had monitored data reflecting ambient water concentrations. EPA’s Storage and Retrieval
 243 (STORET) data and USGS’s National Water Information System (NWIS) data were extracted on Oct
 244 3rd, 2018 from the WQX/WQP. These data show an average concentration for TCE of 0.33 ± 0.29 µg/L
 245 or ppb in surface water from 2,273 measurements taken throughout the US between 2013 and 2017. The
 246 highest value recorded during these years was 2 µg/L or ppb, which was measured in 2017. Table 4-2
 247 shows that none of the RQs for aquatic species are greater than or equal to 1. The RQs for algae range
 248 from 0 to 0.67. Acute and chronic RQs for other aquatic species are all very close to 0.

249
 250 **Table 4-2. RQs for Aquatic Species Calculated using Monitored Environmental Concentrations**
 251 **from WQX/WQP**

Monitored Surface Water Concentrations (ppb) from 2013-2017	Algae RQ		RQ using Acute COC of 2,000 ppb	RQ using Chronic COC of 788 ppb
	using COC of 3 ppb	using HC ₀₅ of 52,000 ppb		
Mean (Standard Deviation): 0.33 (0.29) ppb	0.11	0.0	0.0	0.0
Maximum: 2 ppb	0.67	0.0	0.0	0.0

252
 253 The published literature show monitored data in six U.S. studies encompassing 1,177 surface water
 254 samples collected from river and oceans throughout the nation between 1979 and 2001. Reported
 255 concentrations of TCE ranged from below the detection limit (0.0001 to 0.08) to 17.3 µg/L or ppb, with
 256 reported central tendency values ranging from 0.0002 to 1.17 µg/L ([USGS, 2006](#); [Sauer, 1981](#); [Singh et al., 1983](#); [USGS, 2003](#); [Robinson et al., 2004](#)). The maximum concentration was collected from the
 257 Charles River in Boston, Massachusetts (an urban area) between 1998 and 2000 ([Robinson et al., 2004](#)).
 258 The next highest TCE concentration was 2.0 µg/L, collected during a large nationwide survey of surface
 259 water for drinking water sources (rivers and reservoirs) between 1999 and 2000 ([USGS, 2003](#)). Table
 260 4-3 shows that RQs for algae range from 0 to 5.77 using monitored surface water concentrations from
 261 the published literature. Acute RQs for other aquatic organisms range from 0 to 0.01, and chronic RQs
 262 range from 0 to 0.02.
 263
 264

265
266

Table 4-3. RQs for Aquatic Species Calculated using Monitored Environmental Concentrations from Published Literature

Monitored Surface Water Concentrations (ppb) from 2013-2017	Algae RQ		RQ using Acute COC of 2,000 ppb	RQ using Chronic COC of 788 ppb
	using COC of 3 ppb	using HC ₀₅ of 52,000 ppb		
Central tendency values: 0.0002 – 1.17 ppb	0.00 – 0.39	0.00	0.00	0.00
Maximum: 17.3 ppb	5.77	0.00	0.01	0.02

267
268
269
270
271
272
273
274
275
276
277
278

To compare the modeled data with the monitored data, EPA conducted a watershed analysis by combining monitored data from WQX/WQP with predicted concentrations from E-FAST modeled facility releases, using the geospatial analysis outlined in Section 2.2. A geographic distribution of the concentrations is shown in Figure 2-4 and Figure 2-5 (east and west US) for the maximum days of release scenario, and in Figure 2-6 and Figure 2-7 (east and west US) for the 20-days of release scenario. The co-location of TCE releasing facilities and monitoring stations in a HUC is shown in Figure 2-8 for HUCs in North Carolina and in Figure 2-9 for the HUC in New Mexico. The modeled estimates are only shown in Figure 2-8 and Figure 2-9 for the higher release frequency scenarios, which are associated with lower predicted surface water concentrations. The surface water concentrations were compared to the COCs in these maps.

279
280
281
282
283
284
285
286

Figure 2-4 to Figure 2-9 in Section 2.2.6 compare WQX Monitoring Stations from 2016 to TCE-releasing facilities modeled in E-FAST. The figures show that while some facilities releasing TCE to surface water were co-located with monitoring locations in WQX, none were downstream from facilities. The monitored data, which represents localized concentrations of TCE in ambient water, generally show lower concentrations than the modeled surface water concentrations from E-FAST, which represents concentrations near facilities releasing TCE. The modeled and monitored data together indicate that risk to aquatic organisms from TCE exposure is more likely in areas near the facilities, rather than in ambient water; however the monitored data were limited geographically and temporally.

287

4.1.3 Risk Estimation for Sediment-dwelling Organisms

288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303

EPA also quantitatively analyzed exposure to sediment organisms. While no ecotoxicity studies were available for sediment-dwelling organisms (*e.g.*, *Lumbriculus variegatus*, *Hyalella azteca*, *Chironomus riparius*), aquatic invertebrates were used as a surrogate species. EPA is uncertain whether TCE is more or less toxic to daphnia than sediment-dwelling species. However, because TCE is not expected to sorb to sediment and will instead remain in pore water, daphnia which feed through the entire water column were deemed to be an acceptable surrogate species for sediment invertebrates. EPA calculated an acute aquatic invertebrate COC of 2,000 ppb, and a chronic aquatic invertebrate COC of 920 ppb to address hazards to sediment organisms. TCE is expected to be in sediment and pore water with concentrations similar to or less than the overlying water due to its water solubility (>1280 mg/L), low partitioning to organic matter (log K_{oc} = 1.8-2.17), and biodegradability in anaerobic environments. Thus, TCE concentrations in sediment and pore water are expected to be similar to or less than the concentrations in the overlying water, and concentrations of TCE in the deeper part of sediment, where anaerobic conditions prevail, are expected to be lower.

Therefore, EPA used modeled surface water concentrations to estimate the concentration of TCE in pore water near facilities. EPA also used monitored data to estimate the concentration of TCE in pore water

304 based on ambient surface water. Comparing aquatic invertebrate data to these exposure numbers, the
305 data showed that there is risk to sediment dwelling organisms near two facilities due to acute and
306 chronic exposure. Table 4-4 shows an RQ from acute exposure near Praxair Technology Center at RQ =
307 1.5 and an RQ from chronic exposure at 3.26 with 20 days of exceedance for aquatic invertebrates.
308 Table 4-4 also shows an RQ from acute exposure near US Nasa Michoud Assembly Facility at RQ =
309 4.97 and an RQ from chronic exposure at 10.8 with 20 days of exceedance for aquatic invertebrates
310 (Table 4-4).

311
312 However, in ambient surface water, for both acute and chronic exposures to TCE, the RQs are 0.00 and
313 0.02, based on the highest ambient surface water concentration of 17.3 ppb, indicating exposures are less
314 than the COC (RQs < 0) to sediment organisms from acute or chronic exposures (Table 4-5 and Table
315 4-6).

316 **Table 4-4. Environmental Risk Quotients for Sediment Organisms for Facilities Releasing TCE to Surface Water as Modeled in E-**
 317 **FAST (RQs \geq 1 in bold)**

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient
OES: Processing as a Reactant										
Praxair Technology Center, Tonawanda, NY NPDES: NY0000281	Surface Water	NPDES NY0000281	Still body	350	0.00169	169	Acute (HC ₀₅)	2,000	NA	0.08
							Chronic (ChV)	920	0	0.18
				20	0.03	3000	Acute (HC ₀₅)	2,000	NA	1.50
							Chronic (ChV)	920	20	3.26
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, and Metalworking Fluids)										
US Nasa Michoud Assembly Facility, New Orleans, LA NPDES: LA0052256	Surface Water	Surrogate NPDES LA0003280	Still body	260	1.96	765.63	Acute (HC ₀₅)	2,000	NA	0.38
							Chronic (ChV)	920	0	0.83
				20	25.44	9937.5	Acute (HC ₀₅)	2,000	NA	4.97
							Chronic (ChV)	920	20	10.8
<p>a. Facilities actively releasing trichloroethylene were identified via DMR, TRI, and CDR databases for the 2016 reporting year.</p> <p>b. Release media are either direct (release from active facility directly to surface water) or indirect (transfer of wastewater from active facility to a receiving POTW or non-POTW WWTP facility). A wastewater treatment removal rate of 81% is applied to all indirect releases, <i>i.e.</i>, volumes characterized as being transferred off-site for treatment at a water treatment facility prior to discharge to surface water.</p> <p>c. If a valid NPDES of the direct or indirect releaser was not available in EFAST, the release was modeled using either a surrogate representative facility in EFAST (based on location) or a representative generic industry sector. The name of the indirect releaser is provided, as reported in TRI.</p> <p>d. EFAST uses either the “surface water” model, for rivers and streams, or the “still water” model, for lakes, bays, and oceans.</p> <p>e. Modeling was conducted with the maximum days of release per year expected. For direct releasing facilities, a minimum of 20 days was also modeled.</p> <p>f. The daily release amount was calculated from the reported annual release amount divided by the number of release days per year.</p> <p>g. For releases discharging to lakes, bays, estuaries, and oceans, the acute scenario mixing zone water concentration was reported in place of the 7Q10 SWC.</p> <p>h. To determine the PDM days of exceedance for still bodies of water, the release days provided by the EPA Engineers should become the days of exceedance only if the predicted surface water concentration exceeds the COC. Otherwise, the days of exceedance can be assumed to be zero</p>										

318

319 **Table 4-5. RQs for Sediment Organisms Calculated using Monitored Environmental**
 320 **Concentrations from WQX/WQP**

Monitored Surface Water Concentrations (ppb) from 2013-2017	RQ using Acute COC of 2,000 ppb	RQ using Chronic COC of 920 ppb
Mean (Standard Deviation): 0.33 (0.29) ppb	0.0	0.0
Maximum: 2 ppb	0.0	0.0

321
 322 **Table 4-6. RQs Sediment Organisms Calculated using Monitored Environmental Concentrations**
 323 **from Published Literature**

Monitored Surface Water Concentrations (ppb) from 2013-2017	RQ using Acute COC of 2,000 ppb	RQ using Chronic COC of 920 ppb
Central tendency values: 0.0002 – 1.17 ppb	0.00	0.00
Maximum: 17.3 ppb	0.01	0.02

324

325 **4.1.4 Risk Estimation for Terrestrial Organisms**

326 EPA did not quantitatively assess exposure to terrestrial organisms through soil, water, or biosolids.
 327 TCE is not expected to partition to soil but is expected to volatilize to air, based on its physical-chemical
 328 properties. Review of hazard data for terrestrial organisms shows potential hazard; however, physical-
 329 chemical properties do not support an exposure pathway through water and soil pathways to terrestrial
 330 organisms.

331

332 For terrestrial organisms, during Problem Formulation exposure pathways to these organisms through
 333 water and biosolids were within scope but not further analyzed, because physical chemical properties do
 334 not support these pathways. TCE is not anticipated to partition to biosolids during wastewater treatment.
 335 TCE has a predicted 81% wastewater treatment removal efficiency, predominately due to volatilization
 336 during aeration. Any TCE present in the water portion of biosolids following wastewater treatment and
 337 land application would be expected to rapidly volatilize into air. Furthermore, TCE is not anticipated to
 338 remain in soil, as it is expected to either volatilize into air or migrate through soil into groundwater. And
 339 the air exposure pathway from biosolids and surface water are insignificant. Based on the Guidance for
 340 Ecological Soil Screening Levels ([U.S. EPA, 2003a](#); [U.S. EPA, 2003b](#)) document, for terrestrial
 341 wildlife, relative exposures associated with inhalation and dermal exposure pathways are insignificant,
 342 even for volatile substances, compared to direct ingestion and ingestion of food (by approximately
 343 1,000-fold). Therefore, volatilization from surface water and biosolids to air of TCE is not a concern for
 344 wildlife. TCE is not expected to bioaccumulate in tissues, and concentrations will not increase from prey
 345 to predator in either aquatic or terrestrial food webs.

346

347 TCE is expected to volatilize to air, based on physicochemical properties. However, the emission
 348 pathways to ambient air from commercial and industrial stationary sources or associated inhalation
 349 exposure of terrestrial species were out of the scope of the Risk Evaluation because stationary source
 350 releases of TCE to ambient air are covered under the jurisdiction of the Clean Air Act (CAA).

351 **4.2 Human Health Risks**

352 **4.2.1 Risk Estimation Approach**

353 The use scenarios, populations of interest and toxicological endpoints used for acute and chronic
 354 exposures are presented in Table 4-7.

355
 356 **Table 4-7. Use Scenarios, Populations of Interest and Toxicological Endpoints Used for Acute and**
 357 **Chronic Exposures**

<p>Population of Interest and Exposure Scenario</p>	<p>Workers: ¹ <u>Acute</u>- Adolescent (≥16 years old to <21 years old) and adult workers exposed to TCE for a single 8-hr exposure <u>Chronic</u>- Adolescent (≥16 years old to <21 years old) and adult workers exposed to TCE for the entire 8-hr workday for 260 days per year for 40 working years</p> <p>Occupational Non-User: <u>Acute or Chronic</u>- Adolescent (≥16 years old to <21 years old) and adult worker exposed to TCE indirectly by being in the same work area of the building</p> <p>Consumers ² <u>Acute</u>- Children (≥11 years old to <21 years old) and adult consumers exposed to TCE for a short period of time during use ³</p> <p>Bystanders: <u>Acute</u>- Individuals of all ages exposed to TCE through consumer use of another individual.</p>
<p>Health Effects, Concentration and Time Duration</p>	<p>Non-Cancer Point of Departures (POD): <u>HEC</u>- ppm; POD HECs represent 24hr values based on continuous exposure and resting respiratory rate. Exposure concentrations have been adjusted to match the time duration for inhalation exposure. HECs for the best overall acute (immunosuppression) and chronic (autoimmunity) non-cancer endpoints were also derived for occupational scenarios based on 8hr daily exposure and increased respiratory rate (Section 3.2.5.4.1). <u>HED</u>- mg/kg; for dermal risk estimates</p> <p>Non-Cancer Health Effects: ⁴ <u>Acute</u>- Developmental effects and immunotoxicity</p> <p><u>Chronic</u>- Liver effects, kidney effects, neurological effects, immune effects, reproductive effects, and developmental effects</p>
<p>Uncertainty Factors (UF) used in Non-Cancer Margin of Exposure (MOE) calculations</p>	<p>Benchmark MOEs: Vary by endpoint; Benchmark MOE = 10 for best overall acute endpoint (immunosuppression), 30 for best overall chronic endpoint (autoimmunity) Benchmark MOE = (UF_S) x (UF_A) x (UF_H) x (UF_L)⁵</p>

¹Adult workers (>16 years old to <21 years old) include both female and male workers.

²EPA believes that the users of these products are generally adults, but young teenagers and even younger children may be users or be in the same room with the user while engaging in various conditions of use. Since there are not survey data for consumer behavior patterns or a way to create varying behavior patterns for different age groups, the indoor air concentrations shown in Table 4-7. Use could be extended to all users.

³EPA believes that the users of these products are generally adults, but young teenagers and even younger children may be users or be in the same room with the user while engaging in various conditions of use. Since there are not survey data for consumer behavior patterns or a way to create varying behavior patterns for different age groups, the indoor air concentrations could be extended to all users.

⁴Female workers of childbearing age are the population of interest for reproductive and developmental effects. For other health effects (e.g., liver, kidney, etc.), healthy female or male workers were assumed to be the population of interest.

⁵UF_S=subchronic to chronic UF; UF_A=interspecies UF; UF_H=intraspecies UF; UF_L=LOAEL to NOAEL UF

358

359 The EPA uses a Margin of Exposure (MOE) approach to assess non-cancer risk. The MOE is the ratio of
360 the point of departure (POD) dose divided by the human exposure dose. The MOE is compared to the
361 benchmark MOE. If the MOE exceeds the benchmark MOE, this indicates the potential for risk to
362 human health.

363

364 Acute or chronic MOEs (MOE_{acute} or MOE_{chronic}) were used in this assessment to estimate non- cancer
365 risks using Equation 4-1.

366

367 **Equation 4-1. Equation to Calculate Non-Cancer Risks Following Acute or Chronic Exposures**
368 **Using Margin of Exposures**

369

370
$$\text{MOE}_{\text{acute or chronic}} = \frac{\text{Non - cancer Hazard value (POD)}}{\text{Human Exposure}}$$

371

372 Where:

MOE = Margin of exposure (unitless)
Hazard Value (POD) = HEC (ppm) or HED (mg/kg)
Human Exposure = Exposure estimate (in ppm or mg/kg) from occupational exposure assessment
= Exposure estimate (in ppm or mg/kg) from consumer exposure assessment

373

374 Acute Concentrations (ACs) in ppm and acute Average Daily Doses (ADDs) were used to calculate
375 occupational non-cancer risks following acute inhalation or dermal exposure, respectively. Average
376 Daily Concentrations (ADC) and non-cancer chronic ADDs were used for calculating occupational non-
377 cancer risks following inhalation or dermal chronic exposure, respectively. ADD values accounted for
378 modeled evaporation, representing an estimated absorbed dose. Lifetime Average Daily Concentrations
379 (LADC) and cancer Chronic Retained Doses (CRDs) were used for calculating occupational cancer
380 risks. See Appendix M for more details on the derivation of chronic exposure values from acute
381 concentrations/doses.

382

383 Consumer risks via inhalation were calculated based on maximum Time-Weighted Average (TWAs) for
384 24h periods and consumer risks via dermal exposure were calculated based on Acute Dose Rate (ADR).
385 See Section 2.3.1.3.1 for more details on consumer exposure.

386

387

388 EPA used margin of exposures (MOEs) to estimate acute or chronic risks for non-cancer based on the
389 following:

- 390 • the HECs/HEDs from robust and sensitive studies that best represent each endpoint;
- 391 • the endpoint/study-specific UFs applied to the HECs/HEDs per EPA RfD/RfC Guidance ([U.S. EPA, 2002](#)); and
- 392 • the exposure estimates calculated for TCE uses examined in this risk assessment (see Section 2.3 -
393 Human Exposures).

395
396 MOEs allow for the presentation of a range of risk estimates. The occupational exposure scenarios
397 considered both acute and chronic exposures, while consumer exposure scenarios considered only acute
398 exposures. In general, the frequency of product use was considered to be too low to create chronic risk
399 concerns. Although Westat ([1987](#)) survey data indicate that use frequencies for a small percentage of
400 high-end product users (*i.e.*, those reflecting 95th percentile annual use frequencies) may use products up
401 to 50 times per year, available toxicological data is based on either single or continuous TCE exposure
402 and it is unknown whether these use patterns are expected to be clustered (*e.g.*, every day for several
403 weeks) or intermittent (*e.g.*, one time per week). There is uncertainty regarding the extrapolation from
404 continuous studies in animals to the case of repeated intermittent human exposures. Therefore, EPA
405 cannot fully rule out that consumers at the high-end frequency of use could possibly be at risk for chronic
406 hazard effects (Section 3.2), however it is expected to be unlikely based on these considerations.

407
408 Different adverse endpoints were used based on the expected exposure durations. For non-cancer
409 effects, risks for developmental effects were evaluated for acute (short-term) exposures, whereas risks
410 for other adverse effects (liver toxicity, kidney toxicity, neurotoxicity, immunotoxicity, reproductive
411 effects, and developmental effects) were evaluated for repeated (chronic) exposures to TCE.

412
413 The total UF for each non-cancer POD was the benchmark MOE used to interpret the MOE risk
414 estimates for each use scenario. The MOE estimate was interpreted as human health risk if the MOE
415 estimate was less than the benchmark MOE (*i.e.*, the total cumulative UF). On the other hand, the MOE
416 estimate indicated negligible concerns for adverse human health effects if the MOE estimate exceeded
417 the benchmark MOE. Typically, the larger the MOE relative to the benchmark MOE for that endpoint,
418 the more unlikely it is that a non-cancer adverse effect would occur.

419
420 Extra cancer risks for chronic exposures to TCE were estimated using Equation 4-2. Estimates of extra
421 cancer risks should be interpreted as the incremental probability of an individual developing cancer over
422 a lifetime as a result of exposure to the potential carcinogen (*i.e.*, incremental or extra individual lifetime
423 cancer risk). For purposes of this Risk Evaluation, EPA considers extra risk of 1×10^{-4} (or 1E-4 in
424 shorthand) to be the benchmark for occupational risk estimation.

425
426 **Equation 4-2. Equation to Calculate Extra Cancer Risks**

$$427 \quad \text{Risk} = \text{Human Exposure (LADC)} \times \text{POD (IUR or OSF)}$$

428
429
430 Where:

431 **Risk** = Extra cancer risk (unitless)

432 **Human exposure** = Exposure estimate (ppm or mg/kg/day) from occupational exposure
433 assessment

434 **POD** = Inhalation unit risk (0.022 per ppm) or oral slope factor (0.0464 per mg/kg-day)

435

436 Risk estimates were calculated for all of the studies per health effects domain that EPA considered
 437 suitable for the Risk Evaluation of acute and chronic exposure scenarios in this Risk Evaluation for
 438 TCE. EPA used a previously developed peer-reviewed PBPK model in order to obtain both HECs and
 439 HEDs from animal toxicological studies involving either oral or inhalation administration of TCE. The
 440 PBPK model does not account for dermal exposure, so EPA relied on traditional route-to-route
 441 extrapolation from oral HED values. EPA conservatively assumes 100% absorption through all routes
 442 based on reasonably available toxicokinetic data. EPA did not evaluate TCE exposure through the oral
 443 route because the route is out of scope for this evaluation ([U.S. EPA, 2017d](#)). The volatile properties of
 444 TCE suggest that the majority of dermally deposited TCE would quickly evaporate except in occluded
 445 scenarios. Therefore, inhalation is expected to be the predominant route of human exposure for most
 446 conditions of use. Dermal exposure was considered for occupational scenarios while accounting for
 447 evaporation according to modeling from ([Kasting and Miller, 2006](#)) (see Section 2.3.1.2.5). For
 448 consumers, dermal exposure was only considered for scenarios resulting in dermal contact with impeded
 449 evaporation (See Section 2.3.2.2.2).

450 **4.2.1.1 Points of Departure Used in Risk Estimation**

451 All PODs listed in Table 3-13 will be used for risk estimation of acute exposure scenarios. For chronic
 452 exposure scenarios, due to the large number of relevant endpoints, risks will be assessed using a single
 453 endpoint representative of each health domain. EPA considers all of the endpoints identified in Table
 454 3-14 to be similarly relevant to human health hazard from TCE exposure. Therefore risk estimates for
 455 chronic exposure scenarios will be presented for only those endpoints representing the most sensitive and
 456 robust data within each health domain, with the presumption that evaluation of risks for these endpoints
 457 would also account for all other less sensitive yet relevant endpoints. These PODs are presented in Table
 458 4-8. For complete MOE tables displaying risk estimates for all chronic endpoints, see [*Risk Calculator*
 459 *for Occupational Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)].

460
 461 As described in Section 3.2.5.4.1, EPA considers the POD for mortality due to immunosuppression from
 462 ([Selgrade and Gilmour, 2010](#)) (referred to as simply immunosuppression in the risk tables) to be the best
 463 overall endpoint for acute scenarios and autoimmunity from ([Keil et al., 2009](#)) to be the best overall non-
 464 cancer endpoint for chronic scenarios. However, EPA presents risk estimates for all acute endpoints and
 465 chronic health domains in Section 4.2.2 and 4.2.3 in order to more accurately describe the range of risk
 466 associated with TCE exposure.

467
 468 **Table 4-8. Most Sensitive Endpoints from Each Health Domain for Risk Estimation**
 469 **of Chronic Exposure Scenarios**

Target Organ / System	POD Type	Effect	HEC ₉₉ (ppm)	HED ₉₉ (mg/kg)	Uncertainty Factors (UFs)	Reference	Data Quality
Developmental Effects	BMDL ₀₁ = 0.0207mg/kg-bw/day	Congenital heart defects	0.0037	0.0052	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Johnson et al., 2003)	Medium
Kidney	BMDL ₁₀ = 34 mg/kg-bw/day	Pathology changes in renal tubule	0.025	0.015	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Maltoni et al., 1986)	Medium
Immune System	LOAEL = 0.35 mg/kg-bw/day	Autoimmunity (increased anti-dsDNA and -ssDNA antibodies)	0.033	0.048	UFS=1; UFA= 3; UFH=3; UFL=3; Total UF=30	(Keil et al., 2009)	High
Reproductive System	BMDL ₁₀ = 1.4 ppm	Decreased normal sperm morphology and hyperzoospermia	0.5	0.73	UFS=10; UFA= 1; UFH=3; UFL=1; Total UF=30	(Chia et al., 1996)	Medium

Nervous System	LOAEL = 12 ppm	Significant decreases in wakefulness	4.8	6.5	UFS=3; UFA= 3; UFH=3; UFL=10; Total UF=300	(Arito et al., 1994)	Medium
Liver	BMDL ₁₀ = 21.6 ppm	Increased liver/body weight ratio and cytotoxicity/hypertrophy	9.1	7.9	UFS=1; UFA= 3; UFH=3; UFL=1; Total UF=10	(Kjellstrand et al., 1983)	Medium

470
471
472
473
474
475

HEC/HED₉₉ values will be used for risk estimation. These upper-end outputs from the PBPK model are expected to be protective of susceptible subpopulations, accounting for the majority of identified toxicokinetic human variability. The toxicokinetic metric of the interspecies and intraspecies uncertainty factors has been eliminated based on the use of these data-derived values, resulting in a reduced U_FA and U_FH of 3.

476

4.2.2 Risk Estimation for Occupational Exposures by Exposure Scenario

477
478
479
480
481
482
483
484
485

Risk estimates via inhalation and dermal exposure are provided below for workers and ONUs following acute (single day), chronic (40-year), or lifetime (78 year) TCE exposure. Inhalation risk estimates are based on monitoring and/or modeling exposure data. Both are presented for exposure scenarios where both data types were reasonably available. Non-cancer endpoints were applied to acute and chronic exposures while cancer risk estimates are provided for adjusted lifetime exposure. For most endpoints, HECs based on default PBPK parameters of continuous exposure and resting respiratory rate were used for occupational risk estimates. For the best overall non-cancer endpoints of acute immunosuppression and chronic autoimmunity however, risk estimates are based on derived occupational HECs (presented in Table 3-16).

486
487
488
489
490
491
492
493
494

Although generally ONU exposures are expected to be less than workers, when sufficient data were not reasonably available for quantifying ONU exposures EPA provided risk estimates for ONUs based on assuming that ONU exposure may be comparable to worker central-tendency values. This is a health-protective assumption. When reasonably available, inhalation risk estimates are presented based on both monitoring and modeling data. Otherwise, risk estimates are presented for the type of inhalation exposure data that was reasonably available. All dermal risk estimates are based on modeling data as discussed in Section 2.3.1.2.5. For details on the exposure estimates for each exposure scenario, see Section 2.3.1.

495
496
497
498
499
500
501
502
503
504
505
506

For occupational scenarios, EPA evaluated the impact of potential respirator use based on respirator APF of 10 and 50 in the below tables. The calculated non-cancer MOE or extra cancer risk with respirator use is then compared to the benchmark MOE to determine the level of APF required to mitigate risk for all health domains. EPA does not evaluate respirator use for occupational non-users because they do not directly handle TCE and EPA assumes that they are unlikely to consistently wear respirators. In addition, EPA believes small commercial facilities performing spot cleaning, wipe cleaning, and other related commercial uses as well as commercial printing and copying are unlikely to have a respiratory protection program. For dermal protection, EPA evaluated the impact of glove use up to the maximum possible PF of 20 for industrial scenarios and PF of 10 for commercial scenarios (see Table 2-20). For complete MOE tables displaying risk estimates for all endpoints and all PPE options, see [*Risk Calculator for Occupational Exposures*. Docket: [EPA-HQ-OPPT-2019-0500](#)].

507
508
509
510
511
512

EPA considered the reasonably available data for estimating exposures for each OES. EPA also determined whether air-supplied respirator use up to APF = 50 was plausible for those OES based on expert judgement and reasonably available information. Table 4-9 presents this information below, which is considered in the risk characterization for each OES in the following sections.

513 EPA did not assume respirator or glove use for the following occupational scenarios:
 514 • **Dry Cleaning; Spot Cleaner, Stain Remover:** Many dry cleaning shops are small, family -owned
 515 businesses and are unlikely to have a respiratory protection program or regularly employ dermal
 516 protection.
 517 • **Commercial Copying and Printing:** Many copying and printing shops are small, family -owned
 518 businesses and are unlikely to have a respiratory protection program or regularly employ dermal
 519 protection.
 520 • **Other Commercial Uses:** Due to unknown facilities and operations and the likelihood that
 521 commercial operations will be family-owned businesses, EPA believes these facilities are unlikely to
 522 have a respiratory protection program or regularly employ dermal protection.
 523
 524

Table 4-9. Inhalation Exposure Data Summary and PPE Use Determination

Occupational Exposure Scenario	Inhalation Exposure Approach	Number of Data Points	Model Used	Approach for ONUs	Respirator/ Glove Use	Industrial or Commercial OES
Domestic Manufacture	Monitoring Data	50 (8-hr TWA)	N/A – monitoring data only	None Established	Assumed	Industrial
Processing as a Reactant	Surrogate Monitoring Data	50 (8-hr TWA)	N/A – monitoring data only	None Established	Assumed	Industrial
Batch Open Top Vapor Degreasing	Monitoring Data and Modeling	108 (8-hr TWA), 1 (12-hr TWA)	Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model	Monitoring Data and Modeling	Assumed	Industrial/ Commercial
Batch Closed-Loop Vapor Degreasing	Monitoring Data	19 (8-hr TWA)	N/A – monitoring data only	None Established	Assumed	Industrial
Conveyorized Vapor Degreasing	Monitoring Data and Modeling	18 (8-hr TWA)	Conveyorized Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model	Far-field model results	Assumed	Industrial
Web Vapor Degreasing	Modeling	N/A – model only	Web Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model	Far-field model results	Assumed	Industrial
Cold Cleaning	Modeling	N/A – model only	Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model	Far-field model results	Assumed	Industrial
Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases	Modeling	N/A – model only	Brake Servicing Near-field/Far-field Exposure Model	Far-field model results	Assumed	Commercial

Occupational Exposure Scenario	Inhalation Exposure Approach	Number of Data Points	Model Used	Approach for ONUs	Respirator/ Glove Use	Industrial or Commercial OES
Spot Cleaning, Wipe Cleaning and Carpet Cleaning	Monitoring Data and Modeling	8 (8-hr TWA), 1 (12-hr TWA)	Spot Cleaning Near-Field/Far-Field Inhalation Exposure Model	Far-field model results	Not expected	Commercial
Formulation of Aerosol and Non-Aerosol Products	Surrogate Monitoring Data	33 (8-hr TWA)	N/A – monitoring data only	None Established	Assumed	Industrial
Repackaging	Monitoring Data	33 (8-hr TWA)	N/A – monitoring data only	None Established	Assumed	Industrial
Metalworking Fluids	Monitoring Data and Modeling	3 (8-hour TWA)	2011 ESD on Use of Metalworking Fluids	None Established	Assumed	Industrial
Adhesives, Sealants, Paints, and Coatings (Commercial)	Surrogate Monitoring Data	22 (8-hr TWA), 2 (8-hr TWA, ONU)	N/A – monitoring data only	Monitoring Data	Assumed	Commercial
Adhesives, Sealants, Paints, and Coatings (Industrial)	Monitoring Data	22 (8-hr TWA), 2 (8-hr TWA, ONU)	N/A – monitoring data only	Monitoring Data	Assumed	Industrial
Industrial Processing Aid	Monitoring Data	30 (12-hr TWA), 4 (12-hr TWA, ONU)	N/A – monitoring data only	Monitoring Data	Assumed	Industrial
Commercial Printing and Copying	Monitoring Data	20 (8-hr TWA)	N/A – monitoring data only	Monitoring Data	Not expected	Commercial
Other Industrial Uses	Surrogate Monitoring Data	50 (8-hr TWA)	N/A – monitoring data only	Monitoring Data	Assumed	Industrial
Other Commercial Uses	Monitoring Data and Modeling	8 (8-hr TWA), 1 (12-hr TWA)	Spot Cleaning Near-Field/Far-Field Inhalation Exposure Model	Far-field model results	Not expected	Commercial
Process Solvent Recycling and Worker Handling of Wastes	Surrogate Monitoring Data	33 (8-hr TWA)	N/A – monitoring data only	None Established	Assumed	Industrial

526 Table 4-10. Occupational Risk Estimation - Manufacturing

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	4.5E-03	4.5E-02	0.23	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	9.7E-02	0.97	4.8	9.7E-02	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	3.7	36.6	183.0	-	1.8	8.9	17.8	35.6
		Central Tendency	78.3	782.6	3,913.0	78.3	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	28.1	280.6	1,403.0	-	12.2	60.8	121.5	243.0
		Central Tendency	600.0	6,000.0	30,000.0	600.0	36.5	182.3	364.5	729.0
Immunotoxicity – Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.95	9.5	47.6	-	0.58	2.9	5.8	11.6
		Central Tendency	20.3	203.5	1,017.4	20.3	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	16.2	162.1	810.5	-	5.0	25.0	50.1	100.1
		Central Tendency	346.6	3,465.9	17,329.6	346.6	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	4.5E-02	0.45	2.2	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	0.95	9.5	47.6	0.95	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	8.5	85.5	427.5	-	4.1	20.6	41.2	82.4
		Central Tendency	182.8	1,828.2	9,140.9	182.8	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.89	8.9	44.5	-	0.46	2.3	4.6	9.2
		Central Tendency	19.0	190.4	952.2	19.0	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	6.6E-03	6.6E-02	0.33	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	0.14	1.4	7.0	0.14	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	4.9E-02	0.49	2.5	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	1.1	10.5	52.7	1.1	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	6.3E-03	6.3E-04	1.3E-04	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	2.3E-04	2.3E-05	4.6E-06	2.3E-04	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are considered plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550

MOE results for *Manufacturing* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-10.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for congenital heart defects at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for multiple endpoints at high-end inhalation exposure and for multiple endpoints at both high-end and central tendency inhalation exposure even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for multiple endpoints at both dermal exposure levels even when assuming the highest plausible glove PF.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates remained above the benchmark for cancer at high-end inhalation exposure even when assuming the highest plausible APF. Risk estimates remained above the benchmark for multiple endpoints at both dermal exposure levels even when assuming the highest plausible glove PF.

551 Table 4-11. Occupational Risk Estimation - Processing as a Reactant

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	4.5E-03	4.5E-02	0.23	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	9.7E-02	0.97	4.8	9.7E-02	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	3.7	36.6	183.0	-	1.8	8.9	17.8	35.6
		Central Tendency	78.3	782.6	3,913.0	78.3	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	28.1	280.6	1,403.0	-	12.2	60.8	121.5	243.0
		Central Tendency	600.0	6,000.0	30,000.0	600.0	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.95	9.5	47.6	-	0.58	2.9	5.8	11.6
		Central Tendency	20.3	203.5	1,017.4	20.3	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	16.2	162.1	810.5	-	5.0	25.0	50.1	100.1
		Central Tendency	346.6	3,465.9	17,329.6	346.6	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	4.5E-02	0.45	2.2	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	0.95	9.5	47.6	0.95	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	8.5	85.5	427.5	-	4.1	20.6	41.2	82.4
		Central Tendency	182.8	1,828.2	9,140.9	182.8	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.89	8.9	44.5	-	0.46	2.3	4.6	9.2
		Central Tendency	19.0	190.4	952.2	19.0	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	6.6E-03	6.6E-02	0.33	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	0.14	1.4	7.0	0.14	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	4.9E-02	0.49	2.5	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	1.1	10.5	52.7	1.1	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	6.3E-03	6.3E-04	1.3E-04	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	2.3E-04	2.3E-05	4.6E-06	2.3E-04	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are considered plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

552

553 MOE results for *Processing as a Reactant* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table
554 4-11.

555

556 Acute Non-Cancer Risk Estimates:

557 MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both
558 inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates
559 were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for congenital heart defects at both
560 exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

561

562 Chronic Non-Cancer Risk Estimates:

563 MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both
564 inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates
565 were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for multiple endpoints at high-end
566 inhalation exposure and for multiple endpoints at both high-end and central tendency inhalation exposure even when assuming the highest
567 plausible APF. MOEs remained below the benchmark MOE for multiple endpoints at both dermal exposure levels even when assuming the
568 highest plausible glove PF.

569

570 Cancer Risk Estimates:

571 Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both
572 inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates
573 were applied as an approximation of likely ONU exposures. Risk estimates remained above the benchmark for cancer at high-end inhalation
574 exposure even when assuming the highest plausible APF. Risk estimates remained above the benchmark for multiple endpoints at both dermal
575 exposure levels even when assuming the highest plausible glove PF.

576

577 Table 4-12. Occupational Risk Estimation - Batch Open Top Vapor Degreasing - Inhalation Monitoring Data

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	1.4E-04	1.4E-03	7.1E-03	1.2E-03	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	8.0E-04	8.0E-03	4.0E-02	1.0E-02	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.12	1.2	5.8	0.99	1.8	8.9	17.8	35.6
		Central Tendency	0.65	6.5	32.6	8.1	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	0.89	8.9	44.4	7.6	12.2	60.8	121.5	243.0
		Central Tendency	5.0	50.0	250.0	62.3	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	3.0E-02	0.30	1.5	0.26	0.58	2.9	5.8	11.6
		Central Tendency	0.17	1.7	8.5	2.1	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	0.51	5.1	25.6	4.4	5.0	25.0	50.1	100.1
		Central Tendency	2.9	28.9	144.4	36.0	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	1.4E-03	1.4E-02	7.0E-02	1.2E-02	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	7.9E-03	7.9E-02	0.40	9.9E-02	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	0.27	2.7	13.5	2.3	4.1	20.6	41.2	82.4
		Central Tendency	1.5	15.2	76.2	19.0	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	2.8E-02	0.28	1.4	0.24	0.46	2.3	4.6	9.2
		Central Tendency	0.16	1.6	7.9	2.0	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	2.1E-04	2.1E-03	1.0E-02	1.8E-03	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	1.2E-03	1.2E-02	5.9E-02	1.5E-02	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	1.6E-03	1.6E-02	7.8E-02	1.3E-02	3.0E-02	0.15	0.30	0.61
		Central Tendency	8.8E-03	8.8E-02	0.44	0.11	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.20	2.0E-02	4.0E-03	2.3E-02	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	2.8E-02	2.8E-03	5.5E-04	2.2E-03	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

578 Table 4-13. Occupational Risk Estimation - Batch Open Top Vapor Degreasing - Inhalation Modeling Data

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	2.9E-05	2.9E-04	1.4E-03	4.7E-05	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	3.2E-04	3.2E-03	1.6E-02	6.1E-04	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	2.3E-02	0.23	1.2	3.8E-02	1.8	8.9	17.8	35.6
		Central Tendency	0.26	2.6	12.9	0.50	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	0.18	1.8	8.9	0.29	12.2	60.8	121.5	243.0
		Central Tendency	2.0	19.8	99.1	3.8	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	6.0E-03	6.0E-02	0.30	9.9E-03	0.58	2.9	5.8	11.6
		Central Tendency	6.7E-02	0.67	3.4	0.13	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	0.10	1.0	5.1	0.17	5.0	25.0	50.1	100.1
		Central Tendency	1.1	11.4	57.2	2.2	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	2.8E-04	2.8E-03	1.4E-02	4.6E-04	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	3.1E-03	3.1E-02	0.16	6.0E-03	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	5.4E-02	0.54	2.7	8.9E-02	4.1	20.6	41.2	82.4
		Central Tendency	0.60	6.0	30.2	1.2	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	5.6E-03	5.6E-02	0.28	9.3E-03	0.46	2.3	4.6	9.2
		Central Tendency	6.3E-02	0.63	3.1	0.12	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	4.2E-05	4.2E-04	2.1E-03	6.9E-05	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	4.6E-04	4.6E-03	2.3E-02	8.9E-04	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	3.1E-04	3.1E-03	1.6E-02	5.1E-04	3.0E-02	0.15	0.30	0.61
		Central Tendency	3.5E-03	3.5E-02	0.17	6.7E-03	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.78	7.8E-02	1.6E-02	0.46	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	6.5E-02	6.5E-03	1.3E-03	3.4E-02	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are considered plausible for this exposure scenario.

580

581 MOE results for *Batch Open Top Vapor Degreasing* utilized both monitoring and modeling inhalation exposure data (with dermal modeling).
582 Results are presented in Table 4-12 and Table 4-13.

583

584 Acute Non-Cancer Risk Estimates:

585 Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for all endpoints at both high-end and
586 central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple
587 endpoints based on monitoring and for all endpoints based on modeling at both high-end and central tendency inhalation exposure levels.
588 Based on both monitoring and modeling data, MOEs remained below the benchmark MOE for multiple endpoints at both inhalation exposure
589 levels even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both
590 dermal exposure levels even when assuming the highest plausible glove PF protection.

591

592 Chronic Non-Cancer Risk Estimates:

593 Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for all endpoints at both high-end and
594 central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple
595 endpoints based on monitoring and for all endpoints based on modeling at both high-end and central tendency inhalation exposure levels.
596 Based on both monitoring and modeling data, MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via
597 dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

598

599 Cancer Risk Estimates:

600 Based on both monitoring and modeling data, extra risk estimates for workers were above the benchmark level for cancer at both high-end
601 and central tendency exposure levels via both inhalation and dermal routes. Based on both monitoring and modeling data, risk estimates for
602 ONUs were also above the benchmark for cancer at both high-end and central tendency inhalation exposure levels. Based on both monitoring
603 and modeling data, risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even
604 when assuming the highest plausible APF and glove PF protection.

605

606 OSHA PEL considerations

607 The OSHA PEL for TCE is 100 ppm (8hr TWA). The monitoring dataset for this OES included some data points above the PEL value. In an
608 alternative approach, EPA calculated central tendency and high end values for the measurements lower than the PEL. This resulted in a
609 reduction of the high-end acute exposure estimate from 25.9 ppm to 19.2 ppm and the central tendency acute exposure estimate from 4.6 ppm
610 to 4.3 ppm. Chronic high-end and central tendency exposures are reduced from 17.8 ppm and 3.2 ppm to 13.17 ppm and 2.92 ppm,
611 respectively. Lifetime exposures are reduced from 9.1 ppm and 1.23 ppm to 6.8 ppm and 1.2 ppm, respectively. The reduced exposures do not
612 significantly affect the risk estimates, since exposures were only reduced by up to ~30%. Based on PEL-capped exposure estimates, the
613 central tendency MOE for the acute immunosuppression endpoint (with benchmark MOE = 10) is 0.18 and the central tendency MOE for the
614 chronic autoimmunity endpoint (with benchmark MOE = 30) is 9.5E-03. The central tendency cancer extra risk (benchmark = 1E-04) is 2.6E-
615 02. Therefore, the MOEs remain orders of magnitude below the benchmark MOE (or above the benchmark for cancer risk) when using only
616 PEL-capped exposure estimates. Risks also remain at these endpoints for ONUs. Full details are provided in [*Occupational Risk Estimate*
617 *Calculator. Docket # [EPA-HQ-OPPT-2019-0500](#)].*

618 Table 4-14. Occupational Risk Estimation - Batch Closed-Loop Vapor Degreasing

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	7.6E-03	7.6E-02	0.38	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	2.4E-02	0.24	1.2	2.4E-02	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	6.2	61.9	309.5	-	1.8	8.9	17.8	35.6
		Central Tendency	19.7	196.6	983.0	19.7	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	47.5	474.5	2,372.5	-	12.2	60.8	121.5	243.0
		Central Tendency	150.7	1,507.3	7,536.5	150.7	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	1.6	16.1	80.5	-	0.58	2.9	5.8	11.6
		Central Tendency	5.1	51.1	255.6	5.1	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	27.4	274.1	1,370.5	-	5.0	25.0	50.1	100.1
		Central Tendency	87.1	870.7	4,353.5	87.1	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	7.5E-02	0.75	3.8	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	0.24	2.4	12.0	0.24	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	14.5	144.6	722.9	-	4.1	20.6	41.2	82.4
		Central Tendency	45.9	459.3	2,296.3	45.9	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	1.5	15.1	75.3	-	0.46	2.3	4.6	9.2
		Central Tendency	4.8	47.8	239.2	4.8	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	1.1E-02	0.11	0.56	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	3.5E-02	0.35	1.8	3.5E-02	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	8.3E-02	0.83	4.2	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	0.26	2.6	13.2	0.26	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	3.7E-03	3.7E-04	7.5E-05	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	9.1E-04	9.1E-05	1.8E-05	9.1E-04	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645

MOE results for *Batch Closed-Loop Vapor Degreasing* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-14.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for congenital heart defects at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for multiple endpoints at high-end inhalation exposure and for immunotoxicity at both high-end and central tendency inhalation exposure even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for multiple endpoints at both dermal exposure levels even when assuming the highest plausible glove PF.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates were not above the benchmark for high-end inhalation exposure when assuming APF = 50 or for central tendency inhalation exposure when assuming APF = 10. Risk estimates remained above the benchmark for multiple endpoints at both dermal exposure levels even when assuming the highest plausible glove PF.

646 Table 4-15. Occupational Risk Estimation - Conveyorized Vapor Degreasing - Inhalation Monitoring Data

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	2.3E-04	2.3E-03	1.1E-02	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	3.4E-04	3.4E-03	1.7E-02	3.4E-04	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.19	1.9	9.3	-	1.8	8.9	17.8	35.6
		Central Tendency	0.28	2.8	13.9	0.28	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	1.4	14.3	71.4	-	12.2	60.8	121.5	243.0
		Central Tendency	2.1	21.3	106.5	2.1	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	4.8E-02	0.48	2.4	-	0.58	2.9	5.8	11.6
		Central Tendency	7.2E-02	0.72	3.6	7.2E-02	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	0.83	8.3	41.3	-	5.0	25.0	50.1	100.1
		Central Tendency	1.2	12.3	61.5	1.2	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	2.3E-03	2.3E-02	0.11	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	3.4E-03	3.4E-02	0.17	3.4E-03	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	0.44	4.4	21.8	-	4.1	20.6	41.2	82.4
		Central Tendency	0.65	6.5	32.5	0.65	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	4.5E-02	0.45	2.3	-	0.46	2.3	4.6	9.2
		Central Tendency	6.8E-02	0.68	3.4	6.8E-02	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	3.4E-04	3.4E-03	1.7E-02	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	5.0E-04	5.0E-03	2.5E-02	5.0E-04	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	2.5E-03	2.5E-02	0.13	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	3.7E-03	3.7E-02	0.19	3.7E-03	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.12	1.2E-02	2.5E-03	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	6.5E-02	6.5E-03	1.3E-03	6.5E-02	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

647 Table 4-16. Occupational Risk Estimation - Conveyorized Vapor Degreasing - Inhalation Modeling Data

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	3.6E-06	3.6E-05	1.8E-04	5.9E-06	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	2.7E-04	2.7E-03	1.4E-02	4.8E-04	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	3.0E-03	3.0E-02	0.15	4.8E-03	1.8	8.9	17.8	35.6
		Central Tendency	0.22	2.2	11.0	0.39	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	2.3E-02	0.23	1.1	3.7E-02	12.2	60.8	121.5	243.0
		Central Tendency	1.7	16.9	84.6	3.0	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	7.7E-04	7.7E-03	3.8E-02	1.2E-03	0.58	2.9	5.8	11.6
		Central Tendency	5.7E-02	0.57	2.9	0.10	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	1.3E-02	0.13	0.65	2.1E-02	5.0	25.0	50.1	100.1
		Central Tendency	0.98	9.8	48.8	1.7	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	3.6E-05	3.6E-04	1.8E-03	5.8E-05	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	2.7E-03	2.7E-02	0.13	4.7E-03	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	6.9E-03	6.9E-02	0.35	1.1E-02	4.1	20.6	41.2	82.4
		Central Tendency	0.52	5.2	25.8	0.90	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	7.2E-04	7.2E-03	3.6E-02	1.2E-03	0.46	2.3	4.6	9.2
		Central Tendency	5.4E-02	0.54	2.7	9.4E-02	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	5.3E-06	5.3E-05	2.7E-04	8.6E-06	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	4.0E-04	4.0E-03	2.0E-02	6.9E-04	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	4.0E-05	4.0E-04	2.0E-03	6.5E-05	3.0E-02	0.15	0.30	0.61
		Central Tendency	3.0E-03	3.0E-02	0.15	5.2E-03	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	6.1	0.61	0.12	3.7	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	0.12	1.2E-02	2.3E-03	7.9E-02	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680

MOE results for *Conveyorized Vapor Degreasing* utilized both monitoring and modeling inhalation exposure data (with dermal modeling). Results are presented in Table 4-15 and Table 4-16.

Acute Non-Cancer Risk Estimates:

Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via inhalation and for most endpoints via the dermal route. EPA is unable to estimate ONU exposures separately from workers based on monitoring data, central tendency worker estimates were applied as an approximation of likely ONU exposures. ONU risk estimates were below the benchmark MOE for all endpoints at both high-end and central tendency inhalation exposure levels based on modeling data. Based on both monitoring and modeling data, MOEs remained below the benchmark MOE for multiple endpoints at both inhalation exposure levels even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers based on monitoring data, central tendency worker estimates were applied as an approximation of likely ONU exposures. ONU risk estimates were below the benchmark MOE for all endpoints at both high-end and central tendency inhalation exposure levels based on modeling data. Based on both monitoring and modeling data, MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Based on both monitoring and modeling data, extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers based on monitoring data, central tendency worker estimates were applied as an approximation of likely ONU exposures. ONU risk estimates were above the benchmark at both high-end and central tendency inhalation exposure levels based on modeling data. Based on both monitoring and modeling data, risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

681 Table 4-17. Occupational Risk Estimation - Web Vapor Degreasing

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	7.9E-04	7.9E-03	3.9E-02	1.2E-03	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	1.9E-03	1.9E-02	9.3E-02	3.5E-03	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.64	6.4	31.8	0.94	1.8	8.9	17.8	35.6
		Central Tendency	1.5	15.1	75.7	2.9	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	4.9	48.8	244.0	7.2	12.2	60.8	121.5	243.0
		Central Tendency	11.6	116.1	580.4	22.1	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.17	1.7	8.3	0.24	0.58	2.9	5.8	11.6
		Central Tendency	0.39	3.9	19.7	0.75	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	2.8	28.2	140.9	4.2	5.0	25.0	50.1	100.1
		Central Tendency	6.7	67.1	335.3	12.7	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	7.7E-03	7.7E-02	0.39	1.1E-02	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	1.8E-02	0.18	0.92	3.5E-02	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	1.5	14.9	74.3	2.2	4.1	20.6	41.2	82.4
		Central Tendency	3.5	35.4	176.8	6.7	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.15	1.5	7.7	0.23	0.46	2.3	4.6	9.2
		Central Tendency	0.37	3.7	18.4	0.70	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	1.1E-03	1.1E-02	5.7E-02	1.7E-03	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	2.7E-03	2.7E-02	0.14	5.2E-02	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	8.6E-03	8.6E-02	0.43	1.3E-02	3.0E-02	0.15	0.30	0.61
		Central Tendency	2.0E-02	0.20	1.0	3.9E-02	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	2.9E-02	2.9E-03	5.8E-04	1.9E-02	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	1.1E-02	1.1E-03	2.3E-04	5.9E-03	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708

MOE results for *Web Vapor Degreasing* utilized modeling inhalation exposure data (with dermal modeling) and are presented in Table 4-17.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for most endpoints at both high-end and central tendency exposure levels via inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at the central tendency inhalation exposure level. MOEs remained below the benchmark MOE for multiple endpoints at both inhalation exposure levels even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at the central tendency inhalation exposure level. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Risk estimates for ONUs were also above the benchmark for cancer at the central tendency inhalation exposure level. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

709 Table 4-18. Occupational Risk Estimation - Cold Cleaning

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	1.9E-04	1.9E-03	9.7E-03	3.2E-04	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	3.3E-03	3.3E-02	0.17	6.0E-03	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.16	1.6	7.9	0.26	1.8	8.9	17.8	35.6
		Central Tendency	2.7	27.0	135.1	4.9	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	1.2	12.1	60.3	2.0	12.2	60.8	121.5	243.0
		Central Tendency	20.7	207.2	1,036.0	37.5	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	4.1E-02	0.41	2.0	6.7E-02	0.58	2.9	5.8	11.6
		Central Tendency	0.70	7.0	35.1	1.3	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	0.69	6.9	34.7	1.2	5.0	25.0	50.1	100.1
		Central Tendency	12.0	119.7	598.7	21.7	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	1.9E-03	1.9E-02	9.5E-02	3.2E-03	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	3.3E-02	0.33	1.6	6.0E-02	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	0.37	3.7	18.3	0.61	4.1	20.6	41.2	82.4
		Central Tendency	6.3	63.2	315.8	11.4	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	3.8E-02	0.38	1.9	6.3E-02	0.46	2.3	4.6	9.2
		Central Tendency	0.66	6.6	32.9	1.2	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	2.8E-04	2.8E-03	1.4E-02	4.7E-04	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	4.9E-03	4.9E-02	0.24	8.8E-03	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	2.1E-03	2.1E-02	0.11	3.5E-03	3.0E-02	0.15	0.30	0.61
		Central Tendency	3.6E-02	0.36	1.8	6.6E-02	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.11	1.1E-02	2.3E-03	6.9E-02	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	6.2E-03	6.2E-04	1.2E-04	3.3E-03	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732

MOE results for *Cold Cleaning* utilized modeling inhalation exposure data (with dermal modeling) and are presented in Table 4-18.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for most endpoints at both high-end and central tendency exposure levels via inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for congenital heart defects at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for most endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Risk estimates for ONUs were also above the benchmark for cancer at both high-end and central tendency inhalation exposure levels. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

733 Table 4-19. Occupational Risk Estimation - Aerosol Applications

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	4.6E-04	4.6E-03	2.3E-02	1.1E-02	1.4E-03	7.2E-03	1.4E-02	2.9E-02
		Central Tendency	1.5E-03	1.5E-02	7.3E-02	7.9E-02	4.3E-03	2.2E-02	4.3E-02	8.6E-02
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.38	3.8	18.8	8.7	1.1	5.7	11.3	22.7
		Central Tendency	1.2	11.8	59.0	64.3	3.4	17.0	34.0	68.0
Developmental - Mortality (Narotsky et al., 1995)	10	High End	2.9	28.8	143.9	66.3	7.7	38.7	77.4	154.8
		Central Tendency	9.0	90.4	452.2	492.9	23.2	116.1	232.2	464.3
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	9.8E-02	0.98	4.9	2.3	0.37	1.9	3.7	7.4
		Central Tendency	0.31	3.1	15.3	16.7	1.1	5.6	11.1	22.2
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	1.7	16.6	83.1	38.2	3.2	15.9	31.9	63.8
		Central Tendency	5.2	52.3	261.3	284.4	9.6	47.8	95.6	191.3
Kidney (Maltoni et al., 1986)	10	High End	4.6E-03	4.6E-02	0.23	0.11	6.1E-03	3.0E-02	6.1E-02	0.12
		Central Tendency	1.4E-02	0.14	0.72	0.78	1.8E-02	9.1E-02	0.18	0.36
Neurotoxicity (Arito et al., 1994)	300	High End	0.88	8.8	43.8	20.2	2.6	13.1	26.2	52.5
		Central Tendency	2.8	27.6	137.9	150.0	7.9	39.3	78.7	157.4
Reproductive Toxicity (Chia et al., 1996)	30	High End	9.1E-02	0.91	4.6	2.1	0.29	1.5	2.9	5.9
		Central Tendency	0.29	2.9	14.4	15.6	0.88	4.4	8.8	17.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	6.8E-04	6.8E-03	3.4E-02	1.6E-02	2.1E-03	1.0E-02	2.1E-02	4.2E-02
		Central Tendency	2.1E-03	2.1E-02	0.11	0.12	6.3E-03	3.1E-02	6.3E-02	0.13
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	5.1E-03	5.1E-02	0.25	0.12	1.9E-02	9.7E-02	0.19	0.39
		Central Tendency	1.6E-02	0.16	0.79	0.87	5.8E-02	0.29	0.58	1.2
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	4.9E-02	4.9E-03	9.7E-04	2.0E-03	5.9E-02	1.2E-02	5.9E-03	2.9E-03
		Central Tendency	1.4E-02	1.4E-03	2.9E-04	2.6E-04	1.5E-02	3.0E-03	1.5E-03	7.6E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755

MOE results for *Aerosol Applications* utilized modeling inhalation exposure data (with dermal modeling) and are presented in Table 4-19.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for most endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Risk estimates for ONUs were also above the benchmark for cancer at both high-end and central tendency inhalation exposure levels. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

756 **Table 4-20. Occupational Risk Estimation - Spot Cleaning and Wipe Cleaning (and Other Commercial Uses) - Inhalation Monitoring Data**

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)				
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE	
ACUTE NON-CANCER											
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	3.9E-03	3.9E-02	0.19	-	1.4E-03	7.2E-03	1.4E-02	N/A ²	
		Central Tendency	2.9E-02	0.29	1.4	2.9E-02	4.3E-03	2.2E-02	4.3E-02		
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	3.2	31.6	157.8	-	1.1	5.7	11.3		
		Central Tendency	23.5	235.1	1,175.3	23.5	3.4	17.0	34.0		
Developmental - Mortality (Narotsky et al., 1995)	10	High End	24.2	242.0	1,210.1	-	7.7	38.7	77.4		
		Central Tendency	180.2	1,802.2	9,010.9	180.2	23.2	116.1	232.2		
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.82	8.2	41.0	-	0.37	1.9	3.7		
		Central Tendency	6.1	61.1	305.6	6.1	1.1	5.6	11.1		
CHRONIC NON-CANCER											
Liver (Kjellstrand et al., 1983)	10	High End	13.5	135.5	677.3	-	2.7	13.6	27.2		N/A ²
		Central Tendency	100.9	1,008.7	5,043.7	100.9	9.3	46.3	92.7		
Kidney (Maltoni et al., 1986)	10	High End	3.7E-02	0.37	1.9	-	5.2E-03	2.6E-02	5.2E-02		
		Central Tendency	0.28	2.8	13.9	0.28	1.8E-02	8.8E-02	0.18		
Neurotoxicity (Arito et al., 1994)	300	High End	7.1	71.5	357.3	-	2.2	11.2	22.4		
		Central Tendency	53.2	532.1	2,660.4	53.2	7.6	38.1	76.3		
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.74	7.4	37.2	-	0.25	1.3	2.5		
		Central Tendency	5.5	55.4	277.1	5.5	0.86	4.3	8.6		
Developmental Toxicity (Johnson et al., 2003)	10	High End	5.5E-03	5.5E-02	0.28	-	1.8E-03	9.0E-03	1.8E-02		
		Central Tendency	4.1E-02	0.41	2.1	4.1E-02	6.1E-03	3.1E-02	6.1E-02		
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	4.1E-02	0.41	2.1	-	1.7E-02	8.3E-02	0.17		
		Central Tendency	0.31	3.1	15.3	0.31	5.6E-02	0.28	0.56		
LIFETIME CANCER RISK											
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	7.6E-03	7.6E-04	1.5E-04	-	6.9E-02	1.4E-02	6.9E-03	N/A ²	
		Central Tendency	7.9E-04	7.9E-05	1.6E-05	7.9E-04	1.6E-02	3.1E-03	1.6E-03		

Bold text/pink shading indicates MOE < benchmark MOE. Consistent PPE usage is not expected for this scenario and is only included as a “what-if” analysis for comparison purposes.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

² Glove PF =20 is only applicable to industrial settings (See Section 2.3.1).

757 **Table 4-21. Occupational Risk Estimation - Spot Cleaning and Wipe Cleaning (and Other Commercial Uses) - Inhalation Modeling Data**

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)				
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE	
ACUTE NON-CANCER											
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	4.0E-03	4.0E-02	0.20	6.3E-03	1.4E-03	7.2E-03	1.4E-02	N/A ¹	
		Central Tendency	1.2E-02	0.12	0.58	2.3E-02	4.3E-03	2.2E-02	4.3E-02		
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	3.2	32.5	162.5	5.1	1.1	5.7	11.3		
		Central Tendency	9.4	93.7	468.3	18.8	3.4	17.0	34.0		
Developmental - Mortality (Narotsky et al., 1995)	10	High End	24.9	249.1	1,245.5	39.4	7.7	38.7	77.4		
		Central Tendency	71.8	718.0	3,590.0	144.1	23.2	116.1	232.2		
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.85	8.5	42.5	1.3	0.37	1.9	3.7		
		Central Tendency	2.4	24.3	121.6	4.9	1.1	5.6	11.1		
CHRONIC NON-CANCER											
Liver (Kjellstrand et al., 1983)	10	High End	14.0	139.6	697.9	22.1	2.7	13.6	27.2		N/A ¹
		Central Tendency	40.3	402.7	2,013.3	80.5	9.3	46.3	92.7		
Kidney (Maltoni et al., 1986)	10	High End	3.8E-02	0.38	1.9	6.1E-02	5.2E-03	2.6E-02	5.2E-02		
		Central Tendency	0.11	1.1	5.5	0.22	1.8E-02	8.8E-02	0.18		
Neurotoxicity (Arito et al., 1994)	300	High End	7.4	73.6	368.1	11.7	2.2	11.2	22.4		
		Central Tendency	21.2	212.4	1,061.9	42.5	7.6	38.1	76.3		
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.77	7.7	38.3	1.2	0.25	1.3	2.5		
		Central Tendency	2.2	22.1	110.6	4.4	0.86	4.3	8.6		
Developmental Toxicity (Johnson et al., 2003)	10	High End	5.7E-03	5.7E-02	0.28	9.0E-03	1.8E-03	9.0E-03	1.8E-02		
		Central Tendency	1.6E-02	0.16	0.82	3.3E-02	6.1E-03	3.1E-02	6.1E-02		
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	4.3E-02	0.43	2.1	6.7E-02	1.7E-02	8.3E-02	0.17		
		Central Tendency	0.12	1.2	6.1	0.25	5.6E-02	0.28	0.56		
LIFETIME CANCER RISK											
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	5.8E-03	5.8E-04	1.2E-04	3.6E-03	6.9E-02	1.4E-02	6.9E-03	N/A ¹	
		Central Tendency	1.8E-03	1.8E-04	3.7E-05	9.2E-04	1.6E-02	3.1E-03	1.6E-03		

Bold text/pink shading indicates MOE < benchmark MOE. Consistent PPE usage is not expected for this scenario and is only included as a “what-if” analysis for comparison purposes.

¹ Glove PF =20 is only applicable to industrial settings (See Section 2.3.1).

759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794

MOE calculations for *Spot Cleaning and Wipe Cleaning* utilized both monitoring and modeling inhalation exposure data (with dermal modeling). This data also applies to the exposure scenario of *Other Commercial Uses*. Results are presented in Table 4-20 and Table 4-21.

Acute Non-Cancer Risk Estimates:

Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers based on monitoring data, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. ONU risk estimates were below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels based on modeling data. Based on both monitoring and modeling data, MOEs remained below the benchmark MOE for congenital heart defects at both exposure levels via inhalation and for multiple endpoints via the dermal route even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers based on monitoring data, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. ONU risk estimates were below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels based on modeling data. Based on both monitoring and modeling data, MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via both inhalation and dermal routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Based on both monitoring and modeling data, extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers based on monitoring data, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. ONU risk estimates were above the benchmark at both high-end and central tendency inhalation exposure levels based on modeling data. Based on both monitoring and modeling data, risk estimates remained above the benchmark for cancer at high-end inhalation exposure levels and both dermal exposure levels even when assuming the highest plausible APF and glove PF protection. Risk estimates were not above the benchmark for central tendency inhalation exposure when assuming APF = 10 based on monitoring data or when assuming APF = 50 based on modeling data.

PPE Considerations

EPA is presenting risk estimates for respiratory protection up to APF = 50 as a what-if scenario, however EPA believes that small commercial facilities performing spot cleaning, wipe cleaning, and other related commercial uses are unlikely to have a respiratory protection program or regularly employ dermal protection. Therefore, the use of respirators or gloves is unlikely for workers in these facilities.

795 Table 4-22. Occupational Risk Estimation - Formulation of Aerosol and Non-Aerosol Products

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	9.7E-03	9.7E-02	0.49	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	22.4	224.3	1,121.3	22.4	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	7.9	78.9	394.7	-	1.8	8.9	17.8	35.6
		Central Tendency	18,182.7	181,827.5	909,137.3	18,182.7	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	60.5	605.3	3,026.3	-	12.2	60.8	121.5	243.0
		Central Tendency	139,401.1	1,394,010.5	6,970,052.6	139,401.1	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	2.1	20.5	102.6	-	0.58	2.9	5.8	11.6
		Central Tendency	4,727.5	47,275.1	236,375.7	4727.5	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	35.0	349.6	1,748.2	-	5.0	25.0	50.1	100.1
		Central Tendency	80,525.3	805,253.2	4,026,266.0	80,525.3	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	9.6E-02	0.96	4.8	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	221.2	2,212.2	11,061.2	221.2	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	18.4	184.4	922.1	-	4.1	20.6	41.2	82.4
		Central Tendency	42,474.9	424,748.9	2,123,744.7	42,474.9	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	1.9	19.2	96.1	-	0.46	2.3	4.6	9.2
		Central Tendency	4,424.5	44,244.7	221,223.4	4,424.5	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	1.4E-02	0.14	0.71	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	32.7	327.4	1,637.1	32.7	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	0.11	1.1	5.3	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	244.8	2,448.2	12,241.0	244.8	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	2.9E-03	2.9E-04	5.9E-05	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	9.9E-07	9.9E-08	2.0E-08	9.9E-07	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826

MOE results for *Formulation of Aerosol and Non-Aerosol Products* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-22.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at high-end inhalation exposures, but MOEs were above the benchmark MOE for all endpoints at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs were below the benchmark MOE for multiple endpoints at both dermal exposure levels. MOEs remained below the benchmark MOE for congenital heart defects at high-end inhalation exposure even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels and for multiple endpoints at high-end dermal exposures even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at high-end inhalation exposures, but MOEs were above the benchmark MOE for all endpoints at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs were below the benchmark MOE for multiple endpoints at both dermal exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at high-end inhalation exposure and at both dermal exposure levels even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at at high-end inhalation exposures, but risk estimates were below the benchmark for cancer at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates were above the benchmark at both dermal exposure levels. Risk estimates were not above the benchmark for high-end inhalation exposure when assuming APF = 50. Risk estimates remained above the benchmark for cancer at both dermal exposure levels even when assuming the highest plausible glove PF protection.

827 Table 4-23. Occupational Risk Estimation - Repackaging

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	9.7E-03	9.7E-02	0.49	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	22.4	224.3	1,121.3	22.4	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	7.9	78.9	394.7	-	1.8	8.9	17.8	35.6
		Central Tendency	18,182.7	181,827.5	909,137.3	18,182.7	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	60.5	605.3	3,026.3	-	12.2	60.8	121.5	243.0
		Central Tendency	139,401.1	1,394,010.5	6,970,052.6	139,401.1	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	2.1	20.5	102.6	-	0.58	2.9	5.8	11.6
		Central Tendency	4,727.5	47,275.1	236,375.7	4,727.5	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	35.0	349.6	1,748.2	-	5.0	25.0	50.1	100.1
		Central Tendency	80,525.3	805,253.2	4,026,266.0	80,525.3	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	9.6E-02	0.96	4.8	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	221.2	2,212.2	11,061.2	221.2	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	18.4	184.4	922.1	-	4.1	20.6	41.2	82.4
		Central Tendency	42,474.9	424,748.9	2,123,744.7	42,474.9	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	1.9	19.2	96.1	-	0.46	2.3	4.6	9.2
		Central Tendency	4,424.5	44,244.7	221,223.4	4,424.5	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	1.4E-02	0.14	0.71	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	32.7	327.4	1,637.1	32.7	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	0.11	1.1	5.3	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	244.8	2,448.2	12,241.0	244.8	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	2.9E-03	2.9E-04	5.9E-05	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	9.9E-07	9.9E-08	2.0E-08	9.9E-07	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865

MOE results for *Repackaging* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-23.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at high-end inhalation exposures, but MOEs were above the benchmark MOE for all endpoints at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs were below the benchmark MOE for multiple endpoints at both dermal exposure levels. MOEs remained below the benchmark MOE for congenital heart defects at high-end inhalation exposure even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels and for multiple endpoints at high-end dermal exposures even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at high-end inhalation exposures, but MOEs were above the benchmark MOE for all endpoints at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs were below the benchmark MOE for multiple endpoints at both dermal exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at high-end inhalation exposure and at both dermal exposure levels even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at at high-end inhalation exposures, but risk estimates were below the benchmark for cancer at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates were above the benchmark at both dermal exposure levels. Risk estimates were not above the benchmark for high-end inhalation exposure when assuming APF = 50. Risk estimates remained above the benchmark for cancer at both dermal exposure levels even when assuming the highest plausible glove PF protection.

866 Table 4-24. Occupational Risk Estimation - Metalworking Fluids - Inhalation Monitoring Data

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	1.5E-04	1.5E-03	7.4E-03	-	2.8E-03	1.4E-02	2.8E-02	5.6E-02
		Central Tendency	1.6E-04	1.6E-03	8.0E-03	1.6E-04	8.5E-03	4.2E-02	8.5E-02	0.17
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.12	1.2	6.0	-	2.2	11.1	22.2	44.5
		Central Tendency	0.13	1.3	6.5	0.13	6.7	33.4	66.7	133.4
Developmental - Mortality (Narotsky et al., 1995)	10	High End	0.92	9.2	45.8	-	15.2	75.9	151.9	303.8
		Central Tendency	0.99	9.9	49.5	0.99	45.6	227.8	455.6	911.3
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	3.1E-02	0.31	1.6	-	0.73	3.6	7.3	14.5
		Central Tendency	3.4E-02	0.34	1.7	3.4E-02	2.2	10.9	21.8	43.6
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	0.53	5.3	26.4	-	6.3	31.3	62.6	125.1
		Central Tendency	0.57	5.7	28.6	0.57	18.8	93.8	187.7	375.4
Kidney (Maltoni et al., 1986)	10	High End	1.5E-03	1.5E-02	7.3E-02	-	1.2E-02	5.9E-02	0.12	0.24
		Central Tendency	1.6E-03	1.6E-02	7.9E-02	1.6E-03	3.6E-02	0.18	0.36	0.71
Neurotoxicity (Arito et al., 1994)	300	High End	0.28	2.8	13.9	-	5.1	25.7	51.5	103.0
		Central Tendency	0.30	3.0	15.1	0.30	15.4	77.2	154.4	308.9
Reproductive Toxicity (Chia et al., 1996)	30	High End	2.9E-02	0.29	1.5	-	0.58	2.9	5.8	11.6
		Central Tendency	3.1E-02	0.31	1.6	3.1E-02	1.7	8.7	17.3	34.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	2.2E-04	2.2E-03	1.1E-02	-	4.1E-03	2.1E-02	4.1E-02	8.2E-02
		Central Tendency	2.3E-04	2.3E-03	1.2E-02	2.3E-04	1.2E-02	6.2E-02	0.12	0.25
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	1.6E-03	1.6E-02	8.0E-02	-	3.8E-02	0.19	0.38	0.76
		Central Tendency	1.7E-03	1.7E-02	8.7E-02	1.7E-03	0.11	0.57	1.1	2.3
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.19	1.9E-02	3.9E-03	-	3.0E-02	6.0E-03	3.0E-03	1.5E-03
		Central Tendency	0.14	1.4E-02	2.8E-03	0.14	7.8E-03	1.6E-03	7.8E-04	3.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

867 **Table 4-25. Occupational Risk Estimation - Metalworking Fluids - Inhalation Modeling Data**

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Modeling)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	4.3E-02	0.43	2.1	-	2.8E-03	1.4E-02	2.8E-02	5.6E-02
		Central Tendency	0.16	1.6	7.9	0.16	8.5E-03	4.2E-02	8.5E-02	0.17
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	34.6	346.2	1,730.8	-	2.2	11.1	22.2	44.5
		Central Tendency	128.6	1,285.7	6,428.6	128.6	6.7	33.4	66.7	133.4
Developmental - Mortality (Narotsky et al., 1995)	10	High End	265.4	2,653.8	13,269.2	-	15.2	75.9	151.9	303.8
		Central Tendency	985.7	9,857.1	49,285.7	985.7	45.6	227.8	455.6	911.3
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	9.0	90.0	450.0	-	0.73	3.6	7.3	14.5
		Central Tendency	33.4	334.3	1,671.4	33.4	2.2	10.9	21.8	43.6
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	151.7	1,516.7	7,583.3	-	6.3	31.3	62.6	125.1
		Central Tendency	568.8	5,687.5	28,437.5	568.8	18.8	93.8	187.7	375.4
Kidney (Maltoni et al., 1986)	10	High End	0.42	4.2	20.8	-	1.2E-02	5.9E-02	0.12	0.24
		Central Tendency	1.6	15.6	78.1	1.6	3.6E-02	0.18	0.36	0.71
Neurotoxicity (Arito et al., 1994)	300	High End	80.0	800.0	4,000.0	-	5.1	25.7	51.5	103.0
		Central Tendency	300.0	3,000.0	15,000.0	300.0	15.4	77.2	154.4	308.9
Reproductive Toxicity (Chia et al., 1996)	30	High End	8.3	83.3	416.7	-	0.58	2.9	5.8	11.6
		Central Tendency	31.3	312.5	1,562.5	31.3	1.7	8.7	17.3	34.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	6.2E-02	0.62	3.1	-	4.1E-03	2.1E-02	4.1E-02	8.2E-02
		Central Tendency	0.23	2.3	11.6	0.23	1.2E-02	6.2E-02	0.12	0.25
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	0.47	4.7	23.3	-	3.8E-02	0.19	0.38	0.76
		Central Tendency	1.7	17.3	86.6	1.7	0.11	0.57	1.1	2.3
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	6.6E-04	6.6E-05	1.3E-05	-	3.0E-02	6.0E-03	3.0E-03	1.5E-03
		Central Tendency	1.3E-04	1.3E-05	2.6E-06	1.3E-04	7.8E-03	1.6E-03	7.8E-04	3.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901

MOE calculations for *Metalworking Fluids* utilized both monitoring and modeling inhalation exposure data (with dermal modeling). Results are presented in Table 4-24 and Table 4-25.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints based on monitoring and for congenital heart defects based on modeling at both high-end and central tendency exposure levels via inhalation. Based on both monitoring and modeling data, EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for multiple endpoints via dermal exposure. MOEs remained below the benchmark MOE for multiple endpoints based on monitoring and for congenital heart defects based on modeling at both exposure levels via inhalation and for congenital heart defects at both dermal exposure levels even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints based on monitoring and for multiple endpoints based on modeling at both high-end and central tendency exposure levels via inhalation. Based on both monitoring and modeling data, EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Based on both monitoring and modeling data, MOEs for workers were below the benchmark MOE for all endpoints via dermal exposure. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection based on monitoring data. For modeling data, MOEs were not below the benchmark MOE at central tendency exposure level when assuming APF = 50, although MOEs were below the benchmark MOE for multiple endpoints via the dermal route even when assuming the highest plausible glove PF protection.

Cancer Risk Estimates:

Based on both monitoring and modeling data, extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Based on both monitoring and modeling data, EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection based on monitoring data. For modeling data, risk estimates were not above the benchmark at either inhalation exposure level when assuming APF = 10, although risk estimates were above the benchmark via the dermal route even when assuming the highest plausible glove PF protection.

902 Table 4-26. Occupational Risk Estimation - Adhesives, Sealants, Paints, and Coatings (Industrial Setting)

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	2.8E-04	2.8E-03	1.4E-02	1.1E-02	2.5E-03	1.3E-02	2.5E-02	5.0E-02
		Central Tendency	2.4E-03	2.4E-02	0.12	1.2E-02	7.5E-03	3.8E-02	7.5E-02	0.15
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.23	2.3	11.4	9.0	2.0	9.9	19.8	39.5
		Central Tendency	1.9	19.4	97.1	9.6	5.9	29.7	59.3	118.6
Developmental - Mortality (Narotsky et al., 1995)	10	High End	1.7	17.5	87.4	69.0	13.5	67.5	135.0	270.0
		Central Tendency	14.9	148.8	744.1	73.3	40.5	202.5	405.0	810.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	5.9E-02	0.59	3.0	2.3	0.65	3.2	6.5	12.9
		Central Tendency	0.50	5.0	25.2	2.5	1.9	9.7	19.4	38.8
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	1.0	10.1	50.5	39.9	5.6	27.8	55.6	111.2
		Central Tendency	8.6	86.0	429.9	42.4	16.7	83.4	166.8	333.7
Kidney (Maltoni et al., 1986)	10	High End	2.8E-03	2.8E-02	0.14	0.11	1.1E-02	5.3E-02	0.11	0.21
		Central Tendency	2.4E-02	0.24	1.2	0.12	3.2E-02	0.16	0.32	0.63
Neurotoxicity (Arito et al., 1994)	300	High End	0.53	5.3	26.6	21.0	4.6	22.9	45.8	91.5
		Central Tendency	4.5	45.3	226.7	22.3	13.7	68.6	137.3	274.5
Reproductive Toxicity (Chia et al., 1996)	30	High End	5.5E-02	0.55	2.8	2.2	0.51	2.6	5.1	10.3
		Central Tendency	0.47	4.7	23.6	2.3	1.5	7.7	15.4	30.8
Developmental Toxicity (Johnson et al., 2003)	10	High End	4.1E-04	4.1E-03	2.1E-02	1.6E-02	3.7E-03	1.8E-02	3.7E-02	7.3E-02
		Central Tendency	3.5E-03	3.5E-02	0.17	1.7E-02	1.1E-02	5.5E-02	0.11	0.22
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	3.1E-03	3.1E-02	0.15	0.12	3.4E-02	0.17	0.34	0.68
		Central Tendency	2.6E-02	0.26	1.3	0.13	0.10	0.51	1.0	2.0
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.10	1.0E-02	2.0E-03	2.6E-03	3.4E-02	6.8E-03	3.4E-03	1.7E-03
		Central Tendency	9.3E-03	9.3E-04	1.9E-04	1.9E-03	8.7E-03	1.7E-03	8.7E-04	4.4E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928

MOE results for *Adhesives, Sealants, Paints, and Coatings (Industrial Setting)* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-26. Inhalation exposures are estimated to be identical for industrial and commercial workers.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for most endpoints at both high-end and central tendency exposure levels via inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both inhalation exposure levels even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels and for multiple endpoints at high-end dermal exposures even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Risk estimates for ONUs were also above the benchmark for cancer at both high-end and central tendency inhalation exposure levels. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

929 **Table 4-27. Occupational Risk Estimation - Adhesives, Sealants, Paints, and Coatings (Commercial Setting)**

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)				
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE	
ACUTE NON-CANCER											
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	2.8E-04	2.8E-03	1.4E-02	1.1E-02	1.6E-03	8.0E-03	1.6E-02	N/A ¹	
		Central Tendency	2.4E-03	2.4E-02	0.12	1.2E-02	4.8E-03	2.4E-02	4.8E-02		
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.23	2.3	11.4	9.0	1.3	6.3	12.6		
		Central Tendency	1.9	19.4	97.1	9.6	3.8	18.9	37.8		
Developmental - Mortality (Narotsky et al., 1995)	10	High End	1.7	17.5	87.4	69.0	8.6	43.0	86.0		
		Central Tendency	14.9	148.8	744.1	73.3	25.8	129.0	258.0		
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	5.9E-02	0.59	3.0	2.3	0.41	2.1	4.1		
		Central Tendency	0.50	5.0	25.2	2.5	1.2	6.2	12.3		
CHRONIC NON-CANCER											
Liver (Kjellstrand et al., 1983)	10	High End	1.0	10.1	50.5	39.9	3.5	17.7	35.4		N/A ¹
		Central Tendency	8.6	86.0	429.9	42.4	10.6	53.1	106.3		
Kidney (Maltoni et al., 1986)	10	High End	2.8E-03	2.8E-02	0.14	0.11	6.7E-03	3.4E-02	6.7E-02		
		Central Tendency	2.4E-02	0.24	1.2	0.12	2.0E-02	0.10	0.20		
Neurotoxicity (Arito et al., 1994)	300	High End	0.53	5.3	26.6	21.0	2.9	14.6	29.1		
		Central Tendency	4.5	45.3	226.7	22.3	8.7	43.7	87.4		
Reproductive Toxicity (Chia et al., 1996)	30	High End	5.5E-02	0.55	2.8	2.2	0.33	1.6	3.3		
		Central Tendency	0.47	4.7	23.6	2.3	0.98	4.9	9.8		
Developmental Toxicity (Johnson et al., 2003)	10	High End	4.1E-04	4.1E-03	2.1E-02	1.6E-02	2.3E-03	1.2E-02	2.3E-02		
		Central Tendency	3.5E-03	3.5E-02	0.17	1.7E-02	7.0E-03	3.5E-02	7.0E-02		
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	3.1E-03	3.1E-02	0.15	0.12	2.2E-02	0.11	0.22		
		Central Tendency	2.6E-02	0.26	1.3	0.13	6.5E-02	0.32	0.65		
LIFETIME CANCER RISK											
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	0.10	1.0E-02	2.0E-03	2.6E-03	5.3E-02	1.1E-02	5.3E-03	N/A ¹	
		Central Tendency	9.3E-03	9.3E-04	1.9E-04	1.9E-03	1.4E-02	2.7E-03	1.4E-03		

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ Glove PF =20 is only applicable to industrial settings (See Section 2.3.1).

931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955

MOE results for *Adhesives, Sealants, Paints, and Coatings (Commercial Setting)* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-27. Inhalation exposures are estimated to be identical for industrial and commercial settings.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Risk estimates for ONUs were also above the benchmark for cancer at both high-end and central tendency inhalation exposure levels. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

956 Table 4-28. Occupational Risk Estimation - Industrial Processing Aid (12 hr)

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	5.8E-04	5.8E-03	2.9E-02	2.5E-03	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	1.7E-03	1.7E-02	8.7E-02	5.6E-03	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	0.47	4.7	23.4	2.1	1.8	8.9	17.8	35.6
		Central Tendency	1.4	14.1	70.6	4.6	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	3.6	35.9	179.6	15.8	12.2	60.8	121.5	243.0
		Central Tendency	10.8	108.2	540.9	35.1	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.12	1.2	6.1	0.54	0.58	2.9	5.8	11.6
		Central Tendency	0.37	3.7	18.3	1.2	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	2.1	20.7	103.7	9.2	5.0	25.0	50.1	100.1
		Central Tendency	6.2	62.5	312.5	20.3	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	5.7E-03	5.7E-02	0.28	2.5E-02	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	1.7E-02	0.17	0.86	5.6E-02	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	1.1	10.9	54.7	4.8	4.1	20.6	41.2	82.4
		Central Tendency	3.3	33.0	164.8	10.7	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.11	1.1	5.7	0.50	0.46	2.3	4.6	9.2
		Central Tendency	0.34	3.4	17.2	1.1	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	8.4E-04	8.4E-03	4.2E-02	3.7E-03	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	2.5E-03	2.5E-02	0.13	8.2E-03	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	6.3E-03	6.3E-02	0.31	2.8E-02	3.0E-02	0.15	0.30	0.61
		Central Tendency	1.9E-02	0.19	0.94	6.1E-02	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	4.9E-02	4.9E-03	9.9E-04	1.1E-02	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	1.3E-02	1.3E-03	2.5E-04	3.9E-03	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986

MOE results for *Industrial Processing Aid* utilized 12hr monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-28.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for most endpoints at both high-end and central tendency exposure levels via inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both inhalation exposure levels even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels and for multiple endpoints at high-end dermal exposures even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for all endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. MOEs for ONUs were also below the benchmark MOE for multiple endpoints at both high-end and central tendency inhalation exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. Risk estimates for ONUs were also above the benchmark for cancer at both high-end and central tendency inhalation exposure levels. Risk estimates remained above the benchmark for cancer at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

987 **Table 4-29. Occupational Risk Estimation - Commercial Printing and Copying**

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)				
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE	
ACUTE NON-CANCER											
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	5.3E-03	5.3E-02	0.26	-	4.1E-03	2.1E-02	4.1E-02	NA ²	
		Central Tendency	0.13	1.3	6.5	0.13	1.2E-02	6.2E-02	0.12		
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	4.3	42.9	214.7	-	3.2	16.2	32.4		
		Central Tendency	105.9	1,058.8	5,294.1	105.9	9.7	48.6	97.1		
Developmental - Mortality (Narotsky et al., 1995)	10	High End	32.9	329.3	1,646.4	-	22.1	110.6	221.1		
		Central Tendency	811.8	8,117.6	40,588.2	811.8	66.3	331.7	663.4		
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	1.1	11.2	55.8	-	1.1	5.3	10.6		
		Central Tendency	27.5	275.3	1,376.5	27.5	3.2	15.9	31.7		
CHRONIC NON-CANCER											
Liver (Kjellstrand et al., 1983)	10	High End	19.0	190.2	951.0	-	9.1	45.5	91.1		NA ²
		Central Tendency	468.9	4,689.2	23,445.9	468.9	27.3	136.6	273.3		
Kidney (Maltoni et al., 1986)	10	High End	5.2E-02	0.52	2.6	-	1.7E-02	8.6E-02	0.17		
		Central Tendency	1.3	12.9	64.4	1.3	5.2E-02	0.26	0.52		
Neurotoxicity (Arito et al., 1994)	300	High End	10.0	100.3	501.6	-	7.5	37.5	74.9		
		Central Tendency	247.3	2,473.4	12,367.1	247.3	22.5	112.4	224.8		
Reproductive Toxicity (Chia et al., 1996)	30	High End	1.0	10.5	52.3	-	0.84	4.2	8.4		
		Central Tendency	25.8	257.6	1,288.2	25.8	2.5	12.6	25.2		
Developmental Toxicity (Johnson et al., 2003)	10	High End	7.7E-03	7.7E-02	0.39	-	6.0E-03	3.0E-02	6.0E-02		
		Central Tendency	0.19	1.9	9.5	0.19	1.8E-02	9.0E-02	0.18		
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	5.8E-02	0.58	2.9	-	5.5E-02	0.28	0.55		
		Central Tendency	1.4	14.3	71.3	1.4	0.17	0.83	1.7		
LIFETIME CANCER RISK											
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	5.4E-03	5.4E-04	1.1E-04	-	2.1E-02	4.1E-03	2.1E-03	NA ²	
		Central Tendency	1.7E-04	1.7E-05	3.4E-06	1.7E-04	5.3E-03	1.1E-03	5.3E-04		

Bold text/pink shading indicates MOE < benchmark MOE. Consistent PPE usage is not expected for this scenario and is only included as a “what-if” analysis for comparison purposes.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

² Glove PF =20 is only applicable to industrial settings (See Section 2.3.1).

989
990 MOE results for *Commercial Printing and Copying* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in
991 Table 4-29.

992
993 Acute Non-Cancer Risk Estimates:

994 MOEs for workers were below the benchmark MOE congenital heart defects at both high-end and central tendency exposure levels via both
995 inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates
996 were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for congenital heart defects via
997 inhalation and for multiple endpoints via dermal exposure at both exposure levels even when assuming the highest plausible APF and glove
998 PF protection.

999
1000 Chronic Non-Cancer Risk Estimates:

1001 MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via
1002 inhalation and for all endpoints via the dermal route. EPA is unable to estimate ONU exposures separately from workers, therefore central
1003 tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for
1004 congenital heart defects via inhalation and for multiple endpoints via dermal exposure at both exposure levels even when assuming the
1005 highest plausible APF and glove PF protection.

1006
1007 Cancer Risk Estimates:

1008 Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both
1009 inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates
1010 were applied as an approximation of likely ONU exposures. Risk estimates remained above the benchmark at high-end inhalation exposure
1011 but were not above the benchmark at central tendency inhalation exposure when assuming APF = 10. Risk estimates remained above the
1012 benchmark at both dermal exposure levels even when assuming the highest plausible glove PF protection.

1013
1014 PPE Considerations

1015 EPA is presenting risk estimates for respiratory protection up to APF = 50 as a what-if scenario, however EPA believes that small commercial
1016 facilities performing commercial printing and copying are unlikely to have a respiratory protection program. Therefore, the use of respirators is
1017 unlikely for workers in these facilities.

1018
1019

1020 Table 4-30. Occupational Risk Estimation - Other Industrial Uses

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	4.5E-03	4.5E-02	0.23	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	9.7E-02	0.97	4.8	9.7E-02	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	3.7	36.6	183.0	-	1.8	8.9	17.8	35.6
		Central Tendency	78.3	782.6	3,913.0	78.3	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	28.1	280.6	1,403.0	-	12.2	60.8	121.5	243.0
		Central Tendency	600.0	6,000.0	30,000.0	600.0	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	0.95	9.5	47.6	-	0.58	2.9	5.8	11.6
		Central Tendency	20.3	203.5	1,017.4	20.3	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	16.2	162.1	810.5	-	5.0	25.0	50.1	100.1
		Central Tendency	346.6	3,465.9	17,329.6	346.6	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	4.5E-02	0.45	2.2	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	0.95	9.5	47.6	0.95	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	8.5	85.5	427.5	-	4.1	20.6	41.2	82.4
		Central Tendency	182.8	1,828.2	9,140.9	182.8	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	0.89	8.9	44.5	-	0.46	2.3	4.6	9.2
		Central Tendency	19.0	190.4	952.2	19.0	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	6.6E-03	6.6E-02	0.33	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	0.14	1.4	7.0	0.14	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	4.9E-02	0.49	2.5	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	1.1	10.5	52.7	1.1	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	6.7E-03	6.7E-04	1.3E-04	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	7.5E-04	7.5E-05	1.5E-05	7.5E-04	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers; central tendency worker estimates were applied as an approximation of likely ONU exposures.

1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044

MOE results for *Other Industrial Uses* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-30.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for congenital heart defects at both exposure levels via dermal and inhalation routes even when assuming the highest plausible APF and glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs remained below the benchmark MOE for multiple endpoints at high-end inhalation exposure and for multiple endpoints at both high-end and central tendency inhalation exposure even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for multiple endpoints at both dermal exposure levels even when assuming the highest plausible glove PF.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at both high-end and central tendency exposure levels via both inhalation and dermal routes. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates remained above the benchmark for cancer at high-end inhalation exposure even when assuming the highest plausible APF. Risk estimates remained above the benchmark for multiple endpoints at both dermal exposure levels even when assuming the highest plausible glove PF.

1045 Table 4-31. Occupational Risk Estimation - Process Solvent Recycling and Worker Handling of Wastes

Endpoint	Benchmark MOE	Exposure Level	Inhalation (Monitoring)				Dermal (Modeling)			
			No PPE Worker MOE	APF = 10 Worker MOE	APF = 50 Worker MOE	No PPE ONU MOE ¹	No PPE Worker MOE	Glove PF=5 Worker MOE	Glove PF=10 Worker MOE	Glove PF=20 Worker MOE
ACUTE NON-CANCER										
Developmental - Congenital Heart Defects (Johnson et al., 2003)	10	High End	9.7E-03	9.7E-02	0.49	-	2.3E-03	1.1E-02	2.3E-02	4.5E-02
		Central Tendency	22.4	224.3	1,121.3	22.4	6.8E-03	3.4E-02	6.8E-02	0.14
Developmental - Neurotoxicity (Fredriksson et al., 1993)	100	High End	7.9	78.9	394.7	-	1.8	8.9	17.8	35.6
		Central Tendency	18,182.7	181,827.5	909,137.3	18,182.7	5.3	26.7	53.4	106.7
Developmental - Mortality (Narotsky et al., 1995)	10	High End	60.5	605.3	3,026.3	-	12.2	60.8	121.5	243.0
		Central Tendency	139,401.1	1,394,010.5	6,970,052.6	139,401.1	36.5	182.3	364.5	729.0
Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)	10	High End	2.1	20.5	102.6	-	0.58	2.9	5.8	11.6
		Central Tendency	4,727.5	47,275.1	236,375.7	4,727.5	1.7	8.7	17.4	34.9
CHRONIC NON-CANCER										
Liver (Kjellstrand et al., 1983)	10	High End	35.0	349.6	1,748.2	-	5.0	25.0	50.1	100.1
		Central Tendency	80,525.3	805,253.2	4,026,266.0	80,525.3	15.0	75.1	150.2	300.3
Kidney (Maltoni et al., 1986)	10	High End	9.6E-02	0.96	4.8	-	9.5E-03	4.8E-02	9.5E-02	0.19
		Central Tendency	221.2	2,212.2	11,061.2	221.2	2.9E-02	0.14	0.29	0.57
Neurotoxicity (Arito et al., 1994)	300	High End	18.4	184.4	922.1	-	4.1	20.6	41.2	82.4
		Central Tendency	42,474.9	424,748.9	2,123,744.7	42,474.9	12.4	61.8	123.5	247.1
Reproductive Toxicity (Chia et al., 1996)	30	High End	1.9	19.2	96.1	-	0.46	2.3	4.6	9.2
		Central Tendency	4,424.5	44,244.7	221,223.4	4,424.5	1.4	6.9	13.9	27.7
Developmental Toxicity (Johnson et al., 2003)	10	High End	1.4E-02	0.14	0.71	-	3.3E-03	1.6E-02	3.3E-02	6.6E-02
		Central Tendency	32.7	327.4	1,637.1	32.7	9.9E-03	4.9E-02	9.9E-02	0.20
Immunotoxicity - Autoimmunity (Keil et al., 2009)	30	High End	0.11	1.1	5.3	-	3.0E-02	0.15	0.30	0.61
		Central Tendency	244.8	2,448.2	12,241.0	244.82	9.1E-02	0.46	0.91	1.8
LIFETIME CANCER RISK										
Combined Cancer Risk - Kidney, NHL, Liver	1 x 10 ⁻⁴	High End	2.9E-03	2.9E-04	5.9E-05	-	3.8E-02	7.5E-03	3.8E-03	1.9E-03
		Central Tendency	9.9E-07	9.9E-08	2.0E-08	9.9E-07	9.7E-03	1.9E-03	9.7E-04	4.9E-04

Bold text/pink shading indicates MOE < benchmark MOE. The highest PPE scenarios displayed are plausible for this exposure scenario.

¹ EPA is unable to estimate ONU exposures separately from workers.

1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078

MOE results for *Process Solvent Recycling and Worker Handling of Wastes* utilized monitoring inhalation exposure data (with dermal modeling) and are presented in Table 4-31.

Acute Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at high-end inhalation exposures, but MOEs were above the benchmark MOE for all endpoints at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs were below the benchmark MOE for multiple endpoints at both dermal exposure levels. MOEs remained below the benchmark MOE for congenital heart defects at high-end inhalation exposure even when assuming the highest plausible APF. MOEs remained below the benchmark MOE for congenital heart defects at both dermal exposure levels and for multiple endpoints at high-end dermal exposures even when assuming the highest plausible glove PF protection.

Chronic Non-Cancer Risk Estimates:

MOEs for workers were below the benchmark MOE for multiple endpoints at high-end inhalation exposures, but MOEs were above the benchmark MOE for all endpoints at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. MOEs were below the benchmark MOE for multiple endpoints at both dermal exposure levels. MOEs remained below the benchmark MOE for multiple endpoints at high-end inhalation exposure and at both dermal exposure levels even when assuming the highest plausible APF and glove PF protection.

Cancer Risk Estimates:

Extra risk estimates for workers were above the benchmark level for cancer at at high-end inhalation exposures, but risk estimates were below the benchmark for cancer at central tendency inhalation exposures. EPA is unable to estimate ONU exposures separately from workers, therefore central tendency worker estimates were applied as an approximation of likely ONU exposures. Risk estimates were above the benchmark at both dermal exposure levels. Risk estimates were not above the benchmark for high-end inhalation exposure when assuming APF = 50. Risk estimates remained above the benchmark for cancer at both dermal exposure levels even when assuming the highest plausible glove PF protection.

1079 **4.2.3 Risk Estimation for Consumer Exposures by Exposure Scenario**

1080 Risk estimates via inhalation and dermal routes are provided below for consumers and bystanders
1081 following acute exposure. Risk estimates were presented for differing exposure assumptions,
1082 categorized as high, moderate, or low intensity users based on variation in weight fraction, mass of
1083 product used, and duration of use/exposure duration. Risk estimates primarily utilized central tendency
1084 values for other modeling parameters (*e.g.*, room volume, air exchange rate, building volume) and
1085 therefore do not necessarily represent an upper bound of possible exposures. See Section 2.3.2.5.1 for
1086 more details on the characterization of consumer exposure and [*CEM Modeling Results and Risk*
1087 *Estimates. Docket # [EPA-HQ-OPPT-2019-0500](#)*] for MOE estimates of all modeled scenarios.
1088

1089 As discussed in Section 2.3.2.2, in general, the frequency of product use was considered to be too low to
1090 create chronic risk concerns. Although high-end frequencies of consumer use for a small percentage of
1091 consumers are up to 50 times per year, available toxicological data is based on either single or
1092 continuous TCE exposure and it is unknown whether these use patterns are expected to be clustered
1093 (*e.g.*, every day for several weeks) or intermittent (*e.g.*, one time per week). There is uncertainty
1094 regarding the extrapolation from continuous studies in animals to the case of repeated, intermittent human
1095 exposures. Therefore, EPA cannot fully rule out that consumers at the high-end frequency of use could
1096 possibly be at risk for chronic hazard effects, however it is expected to be unlikely based on the above
1097 considerations. Therefore, based on reasonably available information, EPA did not develop risk estimates
1098 for this population.
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126

1127 **Table 4-32. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Brake and Parts**
 1128 **Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	6.4E-05	5.2E-02	0.40	3.7E-02
	Bystander	2.2E-04	1.8E-01	1.4	5.8E-02
Moderate-Intensity User	User	4.1E-04	0.33	2.5	0.11
	Bystander	1.6E-03	1.3	10 ^a	0.43
Low-Intensity User	User	5.2E-03	4.2	32	1.4
	Bystander	2.0E-02	17	127	5.4
Dermal Exposure (permeability method)					
High-Intensity User	Adult (≥21 years)	2.2E-04	0.18	1.20	5.8E-02
	Children (16-20 years)	2.4E-04	0.19	1.29	6.2E-02
	Children (11-15 years)	2.2E-04	0.17	1.18	5.6E-02
Moderate-Intensity User	Adult (≥21 years)	3.0E-03	2.3	16	0.77
	Children (16-20 years)	3.2E-03	2.5	17	0.82
	Children (11-15 years)	2.9E-03	2.3	16	0.75
Low-Intensity User	Adult (≥21 years)	0.13	106	722	35
	Children (16-20 years)	0.14	113	771	37
	Children (11-15 years)	0.13	103	705	34

^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.

1129
 1130 MOE results for *Brake and Parts Cleaner* are presented in Table 4-32.
 1131
 1132 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1133 low-intensity inhalation exposure levels. Dermal MOEs were below the benchmark MOE for multiple
 1134 endpoints and all age groups at both moderate and high-intensity exposure levels. MOEs for bystanders
 1135 were below the benchmark MOE for multiple endpoints at high, medium, and low-intensity user
 1136 inhalation exposure levels.

1137 **Table 4-33. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol**
 1138 **Electronic Degreaser/Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	9.8E-05	8.0E-02	0.61	2.6E-02
	Bystander	4.9E-04	0.40	3.0	0.13
Moderate-Intensity User	User	2.3E-03	1.9	15	0.61
	Bystander	1.3E-02	10	78	3.3
Low-Intensity User	User	6.7E-02	54	414	18
	Bystander	0.34	277	2123	90
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	1.6E-03	1.2	8.3	0.40
	Children (16-20 years)	1.7E-03	1.3	8.9	0.43
	Children (11-15 years)	1.5E-03	1.2	8.2	0.39
Moderate-Intensity User	Adult (≥21 years)	1.8E-02	14	98	4.7
	Children (16-20 years)	1.9E-02	15	105	5.0
	Children (11-15 years)	1.8E-02	14	96	4.6
Low-Intensity User	Adult (≥21 years)	0.15	119	814	39
	Children (16-20 years)	0.16	127	870	42
	Children (11-15 years)	0.15	117	796	38

1139
 1140 MOE results for *Aerosol Electronic Degreaser/Cleaner* are presented in Table 4-33.

1141
 1142 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1143 low-intensity inhalation exposure levels. Dermal MOEs were below the benchmark MOE for multiple
 1144 endpoints and all age groups at both moderate and high-intensity exposure levels. MOEs for bystanders
 1145 were below the benchmark MOE for multiple endpoints at high and medium-intensity exposure levels.

1146
 1147
 1148
 1149
 1150

1151 **Table 4-34. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid Electronic**
 1152 **Degreaser/Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	1.0E-04	8.3E-02	0.64	2.7E-02
	Bystander	5.1E-04	0.41	3.2	0.13
Moderate-Intensity User	User	1.6E-03	1.3	9.9	0.42
	Bystander	8.5E-03	6.9	53	2.2
Low-Intensity User	User	2.1E-02	17	132	5.6
	Bystander	0.11	88	674	29
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	9.9E-04	0.78	5.3	0.26
	Children (16-20 years)	1.1E-03	0.84	5.7	0.27
	Children (11-15 years)	9.7E-04	0.76	5.2	0.25
Moderate-Intensity User	Adult (≥21 years)	1.5E-02	12	80	3.8
	Children (16-20 years)	1.6E-02	13	86	4.1
	Children (11-15 years)	1.5E-02	11	78	3.7
Low-Intensity User	Adult (≥21 years)	5.9E-02	47	320	15
	Children (16-20 years)	6.4E-02	50	342	16
	Children (11-15 years)	5.8E-02	46	313	15

1153

1154 MOE results for *Liquid Electronic Degreaser/Cleaner* are presented in Table 4-34.

1155

1156 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1157 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1158 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1159 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1160 levels.

1161

1162 **Table 4-35. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Spray**
 1163 **Degreaser/Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.3E-05	1.8E-02	0.14	6.0E-02
	Bystander	7.9E-05	6.4E-02	0.49	2.1E-02
Moderate-Intensity User	User	9.0E-05	7.3E-02	0.56	2.4E-02
	Bystander	3.6E-04	0.29	2.2	9.5E-02
Low-Intensity User	User	6.0E-04	0.48	3.7	0.16
	Bystander	2.5E-03	2.0	15	0.65
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	2.4E-04	0.19	1.3	6.1E-02
	Children (16-20 years)	2.5E-04	0.20	1.4	6.6E-02
	Children (11-15 years)	2.3E-04	0.18	1.3	6.0E-02
Moderate-Intensity User	Adult (≥21 years)	1.9E-03	1.5	10 ^a	0.49
	Children (16-20 years)	2.0E-03	1.6	11	0.52
	Children (11-15 years)	1.9E-03	1.5	10 ^a	0.48
Low-Intensity User	Adult (≥21 years)	9.5E-03	7.5	51	2.5
	Children (16-20 years)	1.0E-02	8.0	55	2.6
	Children (11-15 years)	9.3E-03	7.3	50	2.4
^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.					

1164
 1165 MOE results for *Aerosol Spray Degreaser/Cleaner* are presented in Table 4-35.
 1166
 1167 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1168 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1169 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1170 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1171 levels.
 1172

1173 **Table 4-36. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid**
 1174 **Degreaser/Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.5E-05	2.0E-02	0.16	6.6E-03
	Bystander	1.0E-04	8.3E-02	0.64	2.7E-02
Moderate-Intensity User	User	2.4E-04	0.19	1.5	6.2E-02
	Bystander	1.2E-03	1.0	7.8	0.33
Low-Intensity User	User	1.4E-03	1.2	8.8	0.37
	Bystander	7.6E-03	6.2	47	2.0
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	2.5E-04	0.20	1.3	6.4E-02
	Children (16-20 years)	2.7E-04	0.21	1.4	6.8E-02
	Children (11-15 years)	2.4E-04	0.19	1.3	6.3E-02
Moderate-Intensity User	Adult (≥21 years)	2.0E-03	1.6	11	0.51
	Children (16-20 years)	2.1E-03	1.7	11	0.55
	Children (11-15 years)	1.9E-03	1.5	10 ^a	0.50
Low-Intensity User	Adult (≥21 years)	1.5E-02	12	80	3.8
	Children (16-20 years)	1.6E-02	13	86	4.1
	Children (11-15 years)	1.5E-02	11	78	3.8
^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.					

1175
 1176 MOE results for *Liquid Degreaser/Cleaner* are presented in Table 4-36.

1177
 1178 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1179 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1180 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1181 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1182 levels.

1183

1184 **Table 4-37. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Gun**
 1185 **Scrubber**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	5.0E-02	40	309	13
	Bystander	0.20	164	1255	53
Moderate-Intensity User	User	4.7E-02	38	294	12
	Bystander	0.25	202	1551	66
Low-Intensity User	User	8.1E-02	66	506	21
	Bystander	0.44	354	2715	115
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	2.5E-04	0.19	1.3	6.4E-02
	Children (16-20 years)	2.6E-04	0.21	1.4	6.8E-02
	Children (11-15 years)	2.4E-04	0.19	1.3	6.2E-02
Moderate-Intensity User	Adult (≥21 years)	2.0E-03	1.6	11	0.51
	Children (16-20 years)	2.1E-03	1.7	11	0.54
	Children (11-15 years)	1.9E-03	1.5	10 ^a	0.50
Low-Intensity User	Adult (≥21 years)	2.5E-02	19	133	6.4
	Children (16-20 years)	2.6E-02	21	142	6.8
	Children (11-15 years)	2.4E-02	19	130	6.2

^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.

1186
 1187 MOE results for *Aerosol Gun Scrubber* are presented in Table 4-37.
 1188

1189 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1190 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1191 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1192 benchmark MOE for congenital heart defects at high, medium, and low-intensity user inhalation
 1193 exposure levels.

1194 **Table 4-38. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid Gun**
 1195 **Scrubber**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	5.8E-02	47	361	15
	Bystander	0.24	191	1465	62
Moderate-Intensity User	User	5.5E-02	45	343	14
	Bystander	0.29	236	1809	77
Low-Intensity User	User	5.9E-02	48	370	16
	Bystander	0.30	247	1893	80
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	2.7E-04	0.21	1.4	6.9E-02
	Children (16-20 years)	2.8E-04	0.22	1.5	7.3E-02
	Children (11-15 years)	2.6E-04	0.21	1.4	6.7E-02
Moderate-Intensity User	Adult (≥21 years)	2.1E-03	1.7	11	0.55
	Children (16-20 years)	2.3E-03	1.8	12	0.59
	Children (11-15 years)	2.1E-03	1.6	11	0.54
Low-Intensity User	Adult (≥21 years)	1.6E-02	13	86	4.1
	Children (16-20 years)	1.7E-02	13	92	4.4
	Children (11-15 years)	1.6E-02	12	84	4.0

1196
 1197 MOE results for *Liquid Gun Scrubber* are presented in Table 4-38.
 1198

1199 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1200 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1201 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1202 benchmark MOE for congenital heart defects at high, medium, and low-intensity user inhalation
 1203 exposure levels.

1204
 1205
 1206

1207 **Table 4-39. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Mold Release**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.3E-04	0.18	1.4	5.9E-02
	Bystander	1.1E-03	0.91	7.0	0.30
Moderate-Intensity User	User	2.1E-03	1.7	13	0.56
	Bystander	1.1E-02	9.2	71	3.0
Low-Intensity User	User	2.1E-02	17	130	5.5
	Bystander	0.11	87	667	28
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	2.4E-03	1.9	13	6.1E-01
	Children (16-20 years)	2.5E-03	2.0	14	6.5E-01
	Children (11-15 years)	2.3E-03	1.8	12	6.0E-01
Moderate-Intensity User	Adult (≥21 years)	1.8E-02	14	98	4.7
	Children (16-20 years)	1.9E-02	15	104	5.0
	Children (11-15 years)	1.8E-02	14	96	4.6
Low-Intensity User	Adult (≥21 years)	0.12	94	645	31
	Children (16-20 years)	0.13	101	689	33
	Children (11-15 years)	0.12	92	630	30

1208
 1209 MOE results for *Mold Release* are presented in Table 4-39.

1210
 1211 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1212 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1213 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1214 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1215 levels.

1216
 1217

1218 **Table 4-40. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Aerosol Tire**
 1219 **Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.4E-04	0.19	1.5	6.2E-02
	Bystander	5.4E-04	0.44	3.4	1.4E-02
Moderate-Intensity User	User	8.9E-04	0.72	5.5	0.23
	Bystander	3.6E-03	2.9	22	0.94
Low-Intensity User	User	6.4E-03	5.2	40	1.7
	Bystander	2.6E-02	21	164	6.9
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	1.1E-03	8.5E-01	5.8	2.8E-01
	Children (16-20 years)	1.2E-03	9.1E-01	6.2	3.0E-01
	Children (11-15 years)	1.1E-03	8.3E-01	5.7	2.7E-01
Moderate-Intensity User	Adult (≥21 years)	4.3E-03	3.4	23	1.1
	Children (16-20 years)	4.6E-03	3.6	25	1.2
	Children (11-15 years)	4.2E-03	3.3	23	1.1
Low-Intensity User	Adult (≥21 years)	1.9E-02	15	100	4.8
	Children (16-20 years)	2.0E-02	16	107	5.1
	Children (11-15 years)	1.8E-02	14	97	4.7

1220
 1221 MOE results for *Aerosol Tire Cleaner* are presented in Table 4-40.
 1222

1223 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1224 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1225 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1226 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1227 levels.
 1228

1229 **Table 4-41. Consumer Risk Estimation - Solvents for Cleaning and Degreasing - Liquid Tire**
 1230 **Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	7.8E-05	6.3E-02	0.48	2.0E-02
	Bystander	2.4E-04	0.20	1.5	6.4E-02
Moderate-Intensity User	User	4.0E-04	0.32	2.5	0.10
	Bystander	1.6E-03	1.3	9.9	0.42
Low-Intensity User	User	2.0E-03	1.6	12	0.53
	Bystander	8.3E-03	6.7	51	2.2
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	4.8E-04	0.38	2.6	0.12
	Children (16-20 years)	5.2E-04	0.41	2.8	0.13
	Children (11-15 years)	4.7E-04	0.37	2.6	0.12
Moderate-Intensity User	Adult (≥21 years)	1.9E-03	1.5	10 ^a	0.50
	Children (16-20 years)	2.1E-03	1.6	11	0.53
	Children (11-15 years)	1.9E-03	1.5	10 ^a	0.49
Low-Intensity User	Adult (≥21 years)	5.8E-03	4.6	31	1.5
	Children (16-20 years)	6.2E-03	4.9	33	1.6
	Children (11-15 years)	5.7E-03	4.5	31	1.5
^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.					

1231
 1232 MOE results for *Liquid Tire Cleaner* are presented in Table 4-41.
 1233
 1234 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1235 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1236 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1237 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1238 levels.
 1239

1240 **Table 4-42. Consumer Risk Estimation - Lubricants and Greases - Tap and Die Fluid**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.5E-04	0.20	1.6	6.6E-02
	Bystander	1.3E-03	1.0	7.8	3.3E-01
Moderate-Intensity User	User	2.4E-03	1.9	15	0.62
	Bystander	1.3E-02	10	79	3.3
Low-Intensity User	User	1.4E-02	11	85	3.6
	Bystander	7.0E-02	57	434	18
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	2.6E-03	2.1	14	0.68
	Children (16-20 years)	2.8E-03	2.2	15	0.73
	Children (11-15 years)	2.6E-03	2.0	14	0.67
Moderate-Intensity User	Adult (≥21 years)	2.0E-02	16	109	5.2
	Children (16-20 years)	2.2E-02	17	116	5.6
	Children (11-15 years)	2.0E-02	16	106	5.1
Low-Intensity User	Adult (≥21 years)	7.7E-02	61	416	20
	Children (16-20 years)	8.3E-02	65	445	21
	Children (11-15 years)	7.6E-02	60	407	19

1241
 1242 MOE results for *Tap and Die Fluid* are presented in Table 4-42.

1243
 1244 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1245 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1246 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1247 benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation exposure
 1248 levels.

1249

1250 **Table 4-43. Consumer Risk Estimation - Lubricants and Greases - Penetrating Lubricant**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	3.2E-04	0.26	2.0	8.3E-02
	Bystander	1.6E-03	1.3	9.8	4.1E-01
Moderate-Intensity User	User	5.4E-03	4.4	33	1.4
	Bystander	2.9E-02	23	179	7.6
Low-Intensity User	User	0.17	139	1065	45
	Bystander	0.88	712	5460	231
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	3.3E-03	2.6	18	0.86
	Children (16-20 years)	3.5E-03	2.8	19	0.91
	Children (11-15 years)	3.2E-03	2.6	17	0.84
Moderate-Intensity User	Adult (≥21 years)	4.6E-02	36	248	12
	Children (16-20 years)	4.9E-02	39	265	13
	Children (11-15 years)	4.5E-02	36	243	12
Low-Intensity User	Adult (≥21 years)	0.97	766	5230	250
	Children (16-20 years)	1.0	818	5589	267
	Children (11-15 years)	0.95	748	5111	245

1251
 1252 MOE results for *Penetrating Lubricant* are presented in Table 4-43.

1253
 1254 MOEs for consumer users were below the benchmark MOE for for multiple endpoints at high and
 1255 medium-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1256 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1257 benchmark MOE for multiple endpoints at high and medium-intensity inhalation exposure levels.

1258
 1259

1260 **Table 4-44. Consumer Risk Estimation - Adhesives and Sealants - Solvent-Based Adhesive and**
 1261 **Sealant**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.2E-04	1.8E-01	1.4	5.8E-02
	Bystander	8.9E-04	7.3E-01	5.6	0.24
Moderate-Intensity User	User	6.7E-03	5.4	41	1.8
	Bystander	3.6E-02	29	222	9.4
Low-Intensity User	User	0.56	452	3462	146
	Bystander	2.8	2300	17636	746
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	6.1E-04	0.48	3.3	0.16
	Children (16-20 years)	6.5E-04	0.51	3.5	0.17
	Children (11-15 years)	6.0E-04	0.47	3.2	0.15
Moderate-Intensity User	Adult (≥21 years)	5.2E-03	4.1	28	1.3
	Children (16-20 years)	5.6E-03	4.4	30	1.4
	Children (11-15 years)	5.1E-03	4.0	28	1.3
Low-Intensity User	Adult (≥21 years)	0.38	300	2049	98
	Children (16-20 years)	0.41	321	2189	105
	Children (11-15 years)	0.37	293	2002	96

1262
 1263 MOE results for *Solvent-Based Adhesive and Sealant* are presented in Table 4-44.
 1264

1265 MOEs for consumer users were below the benchmark MOE for for multiple endpoints at high and
 1266 medium-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1267 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1268 benchmark MOE for multiple endpoints at high and medium-intensity inhalation exposure levels.
 1269

1270 **Table 4-45. Consumer Risk Estimation - Adhesives and Sealants - Mirror Edge Sealant**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	1.1E-03	0.90	6.9	0.29
	Bystander	4.7E-03	3.8	29	1.2
Moderate-Intensity User	User	7.4E-03	6.0	46	2.0
	Bystander	4.1E-02	33	254	11
Low-Intensity User	User	0.17	134	1028	43
	Bystander	0.91	737	5651	239
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	8.1E-03	6.4	44	2.1
	Children (16-20 years)	8.7E-03	6.8	47	2.2
	Children (11-15 years)	7.9E-03	6.2	43	2.0
Moderate-Intensity User	Adult (≥21 years)	3.7E-02	29	198	9.5
	Children (16-20 years)	3.9E-02	31	211	10
	Children (11-15 years)	3.6E-02	28	193	9.2
Low-Intensity User	Adult (≥21 years)	2.8E-01	221	1512	72
	Children (16-20 years)	3.0E-01	237	1616	77
	Children (11-15 years)	2.7E-01	216	1478	71

1271
 1272 MOE results for *Mirror Edge Sealant* are presented in Table 4-45.
 1273

1274 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high and medium-
 1275 intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1276 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1277 benchmark MOE for multiple endpoints at high and medium-intensity inhalation exposure levels.
 1278

1279 **Table 4-46. Consumer Risk Estimation - Adhesives and Sealants - Tire Repair Cement / Sealer**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	3.1E-04	0.25	1.9	8.2E-02
	Bystander	9.7E-04	0.79	6.1	2.6E-01
Moderate-Intensity User	User	5.6E-03	4.5	35	1.5
	Bystander	2.3E-02	18	141	6
Low-Intensity User	User	6.2E-02	50	385	16
	Bystander	0.23	188	1444	61
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	5.8E-04	0.46	3.1	0.15
	Children (16-20 years)	6.2E-04	0.49	3.3	0.16
	Children (11-15 years)	5.6E-04	0.45	3.0	0.15
Moderate-Intensity User	Adult (≥21 years)	3.1E-03	2.5	17	0.80
	Children (16-20 years)	3.3E-03	2.6	18	0.86
	Children (11-15 years)	3.0E-03	2.4	16	0.78
Low-Intensity User	Adult (≥21 years)	2.9E-02	23	158	7.5
	Children (16-20 years)	3.1E-02	25	168	8.1
	Children (11-15 years)	2.9E-02	23	154	7.4

1280
 1281 MOE results for *Tire Repair Cement/Sealer* are presented in Table 4-46.

1282
 1283 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high and medium-
 1284 intensity exposure levels via both inhalation and at all exposure levels via dermal routes. Dermal MOEs
 1285 were below the benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were
 1286 below the benchmark MOE for multiple endpoints at high and medium-intensity inhalation exposure
 1287 levels.

1288
 1289

1290 **Table 4-47. Consumer Risk Estimation - Cleaning and Furniture Care Products - Carpet Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	7.0E-05	5.7E-02	0.44	1.8E-02
	Bystander	3.2E-04	0.26	2.0	8.4E-02
Moderate-Intensity User	User	5.8E-04	0.47	3.6	0.15
	Bystander	2.9E-03	2.4	18	0.77
Low-Intensity User	User	3.4E-03	2.7	21	0.89
	Bystander	1.6E-02	13	99	4.2
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	9.1E-04	0.72	4.9	0.24
	Children (16-20 years)	9.8E-04	0.77	5.3	0.25
	Children (11-15 years)	8.9E-04	0.70	4.8	0.23
Moderate-Intensity User	Adult (≥21 years)	5.5E-03	4.3	30	1.4
	Children (16-20 years)	5.9E-03	4.6	32	1.5
	Children (11-15 years)	5.4E-03	4.2	29	1.4
Low-Intensity User	Adult (≥21 years)	5.5E-02	43	295	14
	Children (16-20 years)	5.9E-02	46	315	15
	Children (11-15 years)	5.4E-02	42	289	14

1291
 1292 MOE results for *Carpet Cleaner* are presented in Table 4-47.

1293
 1294 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1295 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1296 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1297 benchmark MOE for multiple endpoints at high, medium, and low-intensity inhalation exposure levels.
 1298

1299 **Table 4-48. Consumer Risk Estimation - Cleaning and Furniture Care Products - Aerosol Spot**
 1300 **Remover**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.2E-04	0.17	1.3	5.7E-02
	Bystander	1.1E-03	0.87	6.7	0.28
Moderate-Intensity User	User	1.8E-03	1.5	11	0.48
	Bystander	9.8E-03	8.0	61	2.6
Low-Intensity User	User	1.0E-02	8.5	65	2.7
	Bystander	5.3E-02	43	332	14
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	3.1E-03	2.4	17	0.80
	Children (16-20 years)	3.3E-03	2.6	18	0.85
	Children (11-15 years)	3.0E-03	2.4	16	0.78
Moderate-Intensity User	Adult (≥21 years)	1.9E-02	15	100	4.8
	Children (16-20 years)	2.0E-02	16	107	5.1
	Children (11-15 years)	1.8E-02	14	98	4.7
Low-Intensity User	Adult (≥21 years)	0.19	146	998	48
	Children (16-20 years)	0.20	156	1066	51
	Children (11-15 years)	0.18	143	975	47

1301
 1302 MOE results for *Aerosol Spot Remover* are presented in Table 4-48.
 1303

1304 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1305 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1306 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1307 benchmark MOE for multiple endpoints at high, medium, and low-intensity inhalation exposure levels.
 1308

1309 **Table 4-49. Consumer Risk Estimation - Cleaning and Furniture Care Products - Liquid Spot**
 1310 **Remover**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	9.3E-05	7.5E-02	0.58	2.4E-02
	Bystander	4.6E-04	0.37	2.9	0.12
Moderate-Intensity User	User	7.8E-04	0.63	4.9	0.21
	Bystander	4.2E-03	3.4	26	1.1
Low-Intensity User	User	6.8E-03	5.5	42	1.8
	Bystander	3.4E-02	28	214	9.1
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	1.3E-03	1.0	7.2	0.34
	Children (16-20 years)	1.4E-03	1.1	7.7	0.37
	Children (11-15 years)	1.3E-03	1.0	7.0	0.34
Moderate-Intensity User	Adult (≥21 years)	8.0E-03	6.3	43	2.1
	Children (16-20 years)	8.5E-03	6.7	46	2.2
	Children (11-15 years)	7.8E-03	6.2	42	2.0
Low-Intensity User	Adult (≥21 years)	0.12	94	645	31
	Children (16-20 years)	0.13	101	689	33
	Children (11-15 years)	0.12	92	630	30

1311
 1312 MOE results for *Liquid Spot Remover* are presented in Table 4-49.

1313
 1314 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1315 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1316 benchmark MOE for multiple endpoints and all age groups at high and medium-intensity exposure
 1317 levels and for multiple age groups at all exposure levels. MOEs for bystanders were below the
 1318 benchmark MOE for multiple endpoints at high, medium, and low-intensity inhalation exposure levels.
 1319

1320 **Table 4-50. Consumer Risk Estimation - Arts, Crafts, and Hobby Materials - Fixatives and**
 1321 **Finishing Spray Coatings**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	4.0E-04	0.32	2.5	0.10
	Bystander	1.6E-03	1.3	10 ^a	0.43
Moderate-Intensity User	User	2.5E-03	2.0	15	0.65
	Bystander	1.3E-02	11	83	3.5
Low-Intensity User	User	1.3E-02	10	79	3.4
	Bystander	6.5E-02	53	407	17
Dermal Exposure (Fraction Absorbed Method)					
High-Intensity User	Adult (≥21 years)	9.4E-03	7.4	51	2.4
	Children (16-20 years)	1.0E-02	7.9	54	2.6
	Children (11-15 years)	9.2E-03	7.3	50	2.4
Moderate-Intensity User	Adult (≥21 years)	3.7E-02	29	199	9.5
	Children (16-20 years)	4.0E-02	31	213	10 ^a
	Children (11-15 years)	3.6E-02	29	195	9.3
Low-Intensity User	Adult (≥21 years)	0.33	257	1758	84
	Children (16-20 years)	0.35	275	1879	90
	Children (11-15 years)	0.32	252	1718	82
^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.					

1322

1323 MOE results for *Fixatives and Finishing Spray Coatings* are presented in Table 4-50.

1324

1325 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1326 low-intensity inhalation exposure levels. Dermal MOEs were below the benchmark MOE for multiple
 1327 endpoints and all age groups at high and medium-intensity exposure levels. MOEs for bystanders were
 1328 below the benchmark MOE for multiple endpoints at high, medium, and low-intensity user inhalation
 1329 exposure levels.

1330

1331 **Table 4-51. Consumer Risk Estimation - Apparel and Footwear Care Products - Shoe Polish**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	1.3E-03	1.1	8.3	0.35
	Bystander	5.5E-03	4.4	34	1.4
Moderate-Intensity User	User	1.1E-02	8.8	67	2.9
	Bystander	5.9E-02	48	366	15
Low-Intensity User	User	6.2E-02	50	386	16
	Bystander	3.2E-01	258	1977	84
Dermal Exposure (Permeability Method)					
High-Intensity User	Adult (≥21 years)	1.4E-02	11	76	3.6
	Children (16-20 years)	1.5E-02	12	81	3.9
	Children (11-15 years)	1.4E-02	11	74	3.6
Moderate-Intensity User	Adult (≥21 years)	8.5E-02	67	457	22
	Children (16-20 years)	9.1E-02	71	488	23
	Children (11-15 years)	8.3E-02	65	446	21
Low-Intensity User	Adult (≥21 years)	0.85	669	4567	219
	Children (16-20 years)	0.91	715	4880	234
	Children (11-15 years)	0.83	654	4463	214

1332
 1333 MOE results for *Shoe Polish* are presented in Table 4-51.

1334
 1335 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1336 low-intensity inhalation exposure levels. Dermal MOEs were below the benchmark MOE for multiple
 1337 endpoints and all age groups at high and medium-intensity exposure levels. MOEs for bystanders were
 1338 below the benchmark MOE for multiple endpoints for high and medium-intensity inhalation exposure
 1339 levels.

1340

1341 **Table 4-52. Consumer Risk Estimation - Other Consumer Uses - Fabric Spray**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	2.8E-04	0.23	1.7	7.3E-02
	Bystander	1.1E-03	0.92	7.1	0.30
Moderate-Intensity User	User	1.7E-03	1.3	10 ^a	0.44
	Bystander	8.9E-03	7.2	55	2.3
Low-Intensity User	User	7.9E-03	6.4	49	2.1
	Bystander	4.0E-02	33	251	11
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	8.1E-03	6.4	44	2.1
	Children (16-20 years)	8.7E-03	6.8	47	2.2
	Children (11-15 years)	7.9E-03	6.2	43	2.0
Moderate-Intensity User	Adult (≥21 years)	1.8E-02	14	98	4.7
	Children (16-20 years)	1.9E-02	15	104	5.0
	Children (11-15 years)	1.8E-02	14	95	4.6
Low-Intensity User	Adult (≥21 years)	0.10	81	554	27
	Children (16-20 years)	0.11	87	592	28
	Children (11-15 years)	0.10	79	541	26

^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.

1342
 1343 MOE results for *Fabric Spray* are presented in Table 4-52.
 1344
 1345 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1346 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1347 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1348 benchmark MOE for multiple endpoints at high, medium, and low-intensity inhalation exposure levels.
 1349

1350 **Table 4-53. Consumer Risk Estimation - Other Consumer Uses - Film Cleaner**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	5.8E-05	4.7E-02	0.36	1.5E-02
	Bystander	2.4E-04	0.19	1.5	6.2E-02
Moderate-Intensity User	User	3.6E-04	0.29	2.2	9.4E-02
	Bystander	1.9E-03	1.6	12	0.51
Low-Intensity User	User	1.9E-03	1.5	12	0.49
	Bystander	9.5E-03	7.7	59	2.5
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	1.4E-03	1.1	7.4	0.35
	Children (16-20 years)	1.5E-03	1.2	7.9	0.38
	Children (11-15 years)	1.3E-03	1.1	7.2	0.34
Moderate-Intensity User	Adult (≥21 years)	5.4E-03	4.2	29	1.4
	Children (16-20 years)	5.7E-03	4.5	31	1.5
	Children (11-15 years)	5.2E-03	4.1	28	1.4
Low-Intensity User	Adult (≥21 years)	4.7E-02	37	255	12
	Children (16-20 years)	5.1E-02	40	273	13
	Children (11-15 years)	4.6E-02	36	249	12

1351
 1352 MOE results for *Film Cleaner* are presented in Table 4-53.

1353
 1354 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1355 low-intensity exposure levels via both inhalation and dermal routes. Dermal MOEs were below the
 1356 benchmark MOE for multiple endpoints and all age groups. MOEs for bystanders were below the
 1357 benchmark MOE for multiple endpoints at high, medium, and low-intensity inhalation exposure levels.

1358

1359 **Table 4-54. Consumer Risk Estimation - Other Consumer Uses - Hoof Polish**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	1.7E-03	1.4	10	0.44
	Bystander	0.34	272	2084	88
Moderate-Intensity User	User	1.7E-02	14	106	4.5
	Bystander	7.8	6307	48351	2045
Low-Intensity User	User	0.12	97	747	32
	Bystander	48	38519	295309	12493
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	1.1E-02	8.8	60	2.9
	Children (16-20 years)	1.2E-02	9.4	64	3.1
	Children (11-15 years)	1.1E-02	8.6	59	2.8
Moderate-Intensity User	Adult (≥21 years)	3.7E-02	29	199	9.5
	Children (16-20 years)	4.0E-02	31	213	10 ^a
	Children (11-15 years)	3.6E-02	29	195	9.3
Low-Intensity User	Adult (≥21 years)	0.33	257	1758	84
	Children (16-20 years)	0.35	275	1879	90
	Children (11-15 years)	0.32	252	1718	82

^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.

1360
 1361 MOE results for *Hoof Polish* are presented in Table 4-54.
 1362
 1363 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1364 low-intensity inhalation exposure levels. Dermal MOEs were below the benchmark MOE for multiple
 1365 endpoints and all age groups at high and medium-intensity exposure levels. MOEs for bystanders were
 1366 below the benchmark MOE for multiple endpoints at high and medium-intensity inhalation exposure
 1367 levels. MOEs for bystanders were not below the benchmark MOE for any endpoint at low-intensity
 1368 inhalation exposure levels.
 1369

1370 **Table 4-55. Consumer Risk Estimation - Other Consumer Uses - Pepper Spray**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Immunosuppression (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	5.6E-02	45	346	15
	Bystander	Not modeled due to simulated outdoor scenario - can be considered equal to user.			
Moderate-Intensity User	User	0.11	90	692	29
	Bystander	Not modeled due to simulated outdoor scenario - can be considered equal to user.			
Low-Intensity User	User	0.21	169	1297	55
	Bystander	Not modeled due to simulated outdoor scenario - can be considered equal to user.			
Dermal Exposure (Absorption Fraction Method)					
Single Scenario	Adult (≥21 years)	6.0E-02	48	325	16
	Children (16-20 years)	6.4E-02	51	347	17
	Children (11-15 years)	5.9E-02	46	317	15

1371
 1372 MOE results for *Pepper Spray* are presented in Table 4-55.

1373
 1374 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high and medium-
 1375 intensity inhalation exposure levels, however MOEs were not below the benchmark for the best overall
 1376 endpoint of acute immunotoxicity. Dermal MOEs were below the benchmark MOE for multiple
 1377 endpoints and all age groups for the single scenario assessed, however MOEs were not below the
 1378 benchmark for the best overall endpoint of acute immunotoxicity. MOEs for bystanders were not
 1379 modeled because bystander exposure is considered equivalent to user exposure.

1380
 1381
 1382
 1383
 1384
 1385

1386 **Table 4-56. Consumer Risk Estimation - Other Consumer Uses - Toner Aid**

Scenario	Consumer Receptor	Benchmark			
		10	100	10	10
		Developmental Effects - Congenital Heart Defects (Johnson et al., 2003)	Developmental Effects - Developmental Neurotoxicity (Fredriksson et al., 1993)	Developmental Effects - Increased Resorptions (Narotsky et al., 1995)	Acute Immunotoxicity - Response to Infection (Selgrade and Gilmour, 2010)
Inhalation Exposure					
High-Intensity User	User	4.2E-04	0.34	2.6	0.11
	Bystander	1.7E-03	1.4	11	0.45
Moderate-Intensity User	User	2.6E-03	2.1	16	0.68
	Bystander	1.4E-02	11	88	3.7
Low-Intensity User	User	1.4E-02	11	84	3.6
	Bystander	6.9E-02	56	431	18
Dermal Exposure (Absorption Fraction Method)					
High-Intensity User	Adult (≥21 years)	9.9E-03	7.8	54	2.6
	Children (16-20 years)	1.1E-02	8.4	57	2.7
	Children (11-15 years)	9.7E-03	7.7	52	2.5
Moderate-Intensity User	Adult (≥21 years)	3.9E-02	31	211	10 ^a
	Children (16-20 years)	4.2E-02	33	225	11
	Children (11-15 years)	3.8E-02	30	206	9.8
Low-Intensity User	Adult (≥21 years)	0.34	272	1857	89
	Children (16-20 years)	0.37	291	1984	95
	Children (11-15 years)	0.34	266	1815	87

^a If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.

1387

1388 MOE results for *Toner Aid* are presented in Table 4-56.

1389

1390 MOEs for consumer users were below the benchmark MOE for multiple endpoints at high, medium, and
 1391 low-intensity inhalation exposure levels. Dermal MOEs were below the benchmark MOE for multiple
 1392 endpoints and all age groups at high and medium-intensity exposure levels. MOEs for bystanders were
 1393 below the benchmark MOE for multiple endpoints at high, medium, and low-intensity inhalation
 1394 exposure levels.

1395 **4.3 Assumptions and Key Sources of Uncertainty for Risk Characterization**

1396 **4.3.1 Environmental Risk Characterization**

1397 There were some uncertainties related to environmental risk for TCE, with some leading to potentially
1398 underestimating risk and some leading to potentially overestimating risk. As mentioned in Section 3.1.7,
1399 there were uncertainties regarding the hazard data for aquatic species; however, some of the uncertainty
1400 was mitigated by the use of multiple lines of evidence supporting the assessment of hazard.

1401
1402 There were also uncertainties around surface water concentrations used to determine the environmental
1403 risk. EPA used E-FAST, monitored data, and data from reasonably available literature to characterize
1404 acute and chronic exposures of TCE to aquatic organisms. E-FAST estimates may underestimate
1405 exposure to some degree, because release data used in E-FAST to estimate surface water concentrations
1406 are based primarily on TRI and DMR reporting data. TRI does not include smaller facilities with fewer
1407 than 10 full time employees, nor does it cover certain sectors, which may lead to underestimates in total
1408 TCE releases to the environment. DMR data are submitted by NPDES permit holders to states or
1409 directly to the EPA according to the monitoring requirements of the facility's permit. States are only
1410 required to load major discharger data into DMR and may or may not load minor discharger data. The
1411 definition of major vs. minor discharger is set by each state and could be based on discharge volume or
1412 facility size. Due to these limitations, some sites that discharge may not be included in the DMR dataset.

1413
1414 E-FAST may also overestimate exposure to aquatic species, because TCE is a volatile chemical, and E-
1415 FAST doesn't take volatilization or other post-release fate processes or downstream transport into
1416 consideration; and, for static water bodies, E-FAST uses a dilution factor as low as one. This may have
1417 led to an over estimation of surface water concentrations for the two facilities with environmental risks,
1418 as both release to still water bodies. Additionally, both facilities with risk showed 20 days of exceeding
1419 the chronic COC (The 20-day chronic risk criterion is derived from partial life cycle tests [*e.g.*, daphnid
1420 chronic and fish early life stage tests] that typically range from 21 to 28 days in duration). However,
1421 there is uncertainty about whether those 20 days would be consecutive, because the days of exceedance
1422 modeled in E-FAST occur sporadically throughout the year. Because TCE is a volatile chemical, it is
1423 more likely that a chronic exposure duration will occur when there are more days of exceedances.

1424
1425 Since E-FAST does not incorporate volatilization into its stream concentration estimates, volatilization
1426 half-lives of TCE were estimated using EPISuite's Water Volatilization Program (WVOLWIN™) using
1427 water depths, water velocities, and wind speeds representative of the two sites that showed exceedances
1428 of the 788 and 920 µg/L COCs (Praxair Technology Center in Tonawanda, NY and NASA Michoud in
1429 New Orleans, LA; see Table 4-1). For the NY site, a 6-m depth, 0.9 m/s current velocity, and a 5 m/s
1430 wind speed were applied. For the LA site, a 1.5-m depth, 3.09E-05 m/s current velocity, and 3.5 m/s
1431 wind speed were applied; the current velocity for this site is based on the EPA/Office of Pesticides Index
1432 Reservoir, which has a depth of 2.74 m, width of 82.2 m and flow of 25.01 m³/hr (Jones et al., 1998).
1433 Results predicted a half-life of about one day (26 hours) for the NY site's receiving water body and a
1434 half-life exceeding 10 years for the LA site.

1435
1436 While the inability to consider fate or hydrologic transport characteristics is a limitation of the E-FAST
1437 model, the effect of volatility on estimating instream concentrations is expected to be highly variable
1438 and site-specific depending on stream flow and environmental conditions. For discharges to still,
1439 shallow water bodies, E-FAST estimates are less likely to overestimate surface water concentrations, as
1440 TCE is predicted to have a long half-life in such still water bodies. For discharges to faster-flowing,

1441 deeper water bodies, E-FAST estimates may inadequately reflect instream volatile losses expected
1442 within the timeframe of one day. Therefore, the estimated concentrations provided are within the bounds
1443 of variability and a reasonable estimation of actual instream concentrations, particularly for still or slow-
1444 moving and shallow water bodies. Given this variation and the predicted half-life of TCE in flowing
1445 water bodies, E-FAST surface water concentrations may best represent concentrations found at the point
1446 of discharge. The farther from the facility, the more uncertainty, and the lower the confidence EPA has
1447 in the concentration.

1448
1449 The reasonably available monitored data were limited temporally and geographically. Aquatic
1450 environmental conditions such as temperature and composition (*i.e.*, total organic carbon, water
1451 hardness, dissolve oxygen, and pH) can fluctuate with the seasons, which could affect TCE
1452 concentrations in water and sediment pore water. In addition, TCE monitoring data were collected only
1453 in certain areas, and within a limited number of states in the U.S. There were no measurements
1454 reasonably available immediately downstream from facilities releasing TCE to surface water; these data
1455 are only a limited representation of ambient water.

1456 **4.3.2 Human Health Risk Characterization**

1457 **4.3.2.1 Occupational Exposure Considerations**

1458 Air concentrations. In most scenarios where data were reasonably available, EPA did not find enough
1459 reasonably available data to determine complete statistical distributions of actual air concentrations for
1460 the workers exposed to TCE. Ideally, EPA would like to know 50th and 95th percentiles for each
1461 exposed population. In the absence of percentile data for monitoring, the air concentration means and
1462 medians (means are preferred over medians) of the data sets served as substitutes for 50th percentiles
1463 (central tendencies) of the actual distributions, whereas high ends of ranges served as substitutes for 95th
1464 percentiles of the actual distributions. However, these substitutes are uncertain and are not as reliable as
1465 the true percentiles. For instance, in the few cases where enough data were found to determine statistical
1466 means and 95th percentiles, the associated substitutes (*i.e.*, medians and high ends of ranges) were
1467 shown to overestimate exposures, sometimes significantly. While most air concentration data represent
1468 real exposure levels, EPA cannot determine whether these concentrations are representative of the
1469 statistical distributions of actual air concentrations to which workers are exposed. It is unknown whether
1470 these uncertainties overestimate or underestimate exposures. The range of air concentration estimates
1471 from central tendency to high-end was generally not large (*e.g.*, less than 20-fold for most exposure
1472 scenarios). Because of this the results of risk characterization were generally not sensitive to the
1473 individual estimates of the central tendency and high-end separately but rather were based on
1474 considering both central tendency and high-end exposure estimates which increase the overall
1475 confidence in the risk characterization.

1476
1477 Exposures for ONUs can vary substantially. EPA notes that ONUs are likely a heterogeneous population
1478 of workers, and some could be exposed more than just occasionally to high concentrations. Most data
1479 sources do not sufficiently describe the proximity of these employees to the exposure source. As such,
1480 exposure levels for the “occupational non-user” category will have high variability depending on the
1481 specific work activity performed. It is possible that some employees categorized as “occupational non-
1482 user” have exposures similar to those in the “worker” category depending on their specific work activity
1483 pattern. Therefore, in the absence of specific monitoring or modeling data, worker risk estimates were
1484 applied to ONUs. In many instances, this is likely to overestimate exposures, although the central
1485 tendency worker values may be a reasonable approximation of ONU estimates.

1486

1487 Additionally, some data sources may be inherently biased. For example, bias may be present if exposure
1488 monitoring was conducted to address concerns regarding adverse human health effects reported
1489 following exposures during use. These sources may cause exposures to be overestimated.
1490

1491 Where data were not reasonably available, the modeling approaches used to estimate air concentrations
1492 also involve uncertainties. Model parameter values did not all contain distributions known to represent
1493 the modeled scenario. It is also uncertain whether the model equations generate results that represent
1494 actual workplace air concentrations. It is unknown whether these uncertainties overestimate or
1495 underestimate exposures.
1496

1497 Averaging Times. EPA cannot determine how accurately the assumptions of exposure frequencies
1498 (days/yr exposed) and exposed working years may represent actual exposure frequencies and exposed
1499 working years. For example, tenure is used to represent exposed working years, but many workers may
1500 not be exposed during their entire tenure. It is unknown whether these uncertainties overestimate or
1501 underestimate exposures, although the high-end values may result in overestimates when used in
1502 combination with high-end values of other parameters.

1503 See Section 2.3.1.3 for more details on uncertainties and assumptions underlying the occupational
1504 exposure assessment.

1505 Occluded Dermal Exposure

1506 Occluded exposures were presented as a what-if scenario in Appendix H of [*Environmental Releases*
1507 *and Occupational Exposure Assessment*. Docket: [EPA-HQ-OPPT-2019-0500](#)]. Risks were not
1508 calculated for these scenarios however because EPA does not know the likelihood or frequency of these
1509 scenarios in the workplace. Occluded dermal exposures are likely to increase risks for workers
1510 compared to “no-glove” scenarios as evaluated in this Risk Evaluation.

1511 4.3.2.2 Consumer/Bystander Exposure Considerations

1512 Inhalation and dermal exposures are evaluated for acute exposure scenarios, *i.e.*, those resulting from
1513 short-term or daily exposures. Chronic exposure scenarios resulting from long-term use of household
1514 consumer products are not evaluated because as discussed in Section 2.3.2.2, in general the frequency of
1515 product use was considered to be too low to create chronic risk concerns. Although high-end frequencies
1516 of consumer use for a small percentage of consumers are up to 50 times per year, reasonably available
1517 toxicological data is based on either single or continuous TCE exposure and it is unknown whether these
1518 use patterns are expected to be clustered (*e.g.*, every day for several weeks) or intermittent (*e.g.*, one
1519 time per week). There is uncertainty regarding the extrapolation from continuous studies in animals to
1520 the case of repeated, intermittent human exposures. Therefore, EPA cannot fully rule out that consumers
1521 at the high-end frequency of use could possibly be at risk for chronic hazard effects, however it is
1522 expected to be unlikely based on these considerations. As discussed in Section 2.3.2.2.1, EPA also did
1523 not assess background levels of TCE in indoor and outdoor air and may therefore be underestimating
1524 consumer inhalation risks. However, these background exposures are likely significantly lower than the
1525 assessed exposure estimates for each exposure scenario and would therefore be unlikely to drive risk
1526 conclusions
1527

1528 The output of the consumer exposure model is fully determined by the choices of parameter values and
1529 initial conditions. Stochastic approaches feature inherent randomness, such that a given set of parameter
1530 values and initial conditions can lead to an ensemble of different model outputs. Because EPA’s largely
1531 deterministic approach involves choices regarding low, medium, and high values for highly influential
1532 factors such as chemical mass and frequency/duration of product use, it likely captures the range of

1533 potential exposure levels although it does not necessarily enable characterization of the full probabilistic
1534 distribution of all possible outcomes.

1535
1536 Certain inputs to which model outputs are sensitive, such as zone volumes and airflow rates, were not
1537 varied across product-use scenarios. As a result, model outcomes for extreme circumstances such as a
1538 relatively large chemical mass in a relatively low-volume environment likely are not represented among
1539 the model outcomes. Such extreme outcomes are believed to lie near the upper end (*e.g.*, at or above the
1540 90th percentile) of the exposure distribution.

1541 EPA calculated inhalation risk estimates based on ambient air concentrations and did not derive
1542 lifestage-specific internal doses. As stated in Section 4.4.1, EPA expects that the PBPK model and UF_H
1543 at least partially account for lifestage specific differences, however younger lifestages are likely exposed
1544 to several fold higher internal dose of TCE compared to adults. Therefore, using air concentrations
1545 across all lifestages may underestimate risk, especially for infant bystanders.

1546 See Section 2.3.2.6 for more details on uncertainties and assumptions underlying the consumer exposure
1547 assessment.

1548 **4.3.2.3 Dermal Absorption Considerations**

1549 The occupational and consumer assessment approaches utilize different models for estimating dermal
1550 absorption. As discussed in Section 2.3.2.4.1, the occupational exposure assessment used a fractional
1551 absorption model that accounts for evaporation of volatile chemicals such as TCE. In contrast, the
1552 consumer assessment model varied based on whether unimpeded evaporation was expected. A
1553 permeability/flux model was used for impeded evaporation and a fraction absorbed model was used
1554 when evaporation was expected (Section 2.3.2.3.1). There are several parameters that must be estimated
1555 for each of the respective models, including quantity deposited on skin, surface area of contact,
1556 evaporative flux, film thickness, and exposure duration. Many of these are likely to vary not only by
1557 condition of use but also the particulars of the individual activity patterns on a daily basis. Therefore,
1558 these parameters can only be approximated and the absorption estimates may either underestimate or
1559 overestimate the actual exposure of any particular worker or consumer on a given day, however they
1560 serve as a reasonable generalized approximation if not a higher-end bound.

1561
1562 The choice of one model over the other is primarily driven by the exposure scenario that needs to be
1563 assessed and the information that is reasonably available. For example, EPA does not know the exact
1564 duration of exposure for occupational loading and unloading hence EPA used the engineering model for
1565 occupational exposure assessment since it is event based and does not require a duration input. In
1566 contrast, for consumer applications there is reasonably available information for duration of use, hence
1567 the CEM permeability model or the fraction absorbed model can be used for these exposure scenarios
1568 with greater confidence. Overall, the models are considered appropriate for their respective uses based
1569 on the reasonably available information.

1570 **4.3.2.4 Confidence in Risk Estimates**

1571 Occupational Exposure Scenarios

1572 There is varying confidence in inhalation exposure estimates from different occupational risk scenarios,
1573 ranging from low-to-medium to medium-to-high (see Table 2-12). Despite some OES with low to
1574 medium overall confidence, many of these are further supported by the availability of both monitoring
1575 and modeling data, despite the uncertainties within each (see Table 2-26). Additionally, the data quality
1576 scores for monitoring data ranged from medium to high, and the inhalation modeling approach was peer
1577 reviewed during the 2014 TCE risk assessment process ([U.S. EPA, 2014b](#)) (for a subset of COUs).

1578 EPA acknowledges the uncertainty and lower confidence in applying worker estimates to represent
1579 ONUs in the absence of reasonably available ONU data for certain OES. Therefore, EPA has low
1580 confidence in risk estimates for ONUs based on this assumption. There is medium confidence in the
1581 occupational dermal modeling approach, which was developed from a peer-reviewed publication
1582 ([Kasting and Miller, 2006](#)).

1583 1584 Consumer Exposure Scenarios

1585 There is medium to high confidence in consumer inhalation exposure modeling (see Section 2.3.2.7),
1586 however there is low to medium confidence in consumer dermal exposure modeling due to uncertainties
1587 related to absorption (as discussed above) and assumptions regarding impeded vs unimpeded
1588 evaporation for particular conditions of use.

1589 1590 Human Health Hazard

1591 The human health database covers a wide range of endpoints, with most health effects supported by
1592 animal, epidemiological, and mechanistic evidence. There is medium confidence in the integration of
1593 human health data for acute non-cancer, medium to high confidence for cancer, and high confidence for
1594 chronic non-cancer endpoints, although there is additional uncertainty in the dose-response analysis for
1595 the congenital heart defects endpoint (see Section 3.2.6 for more details).

1596 1597 Risk Conclusions

1598 For all exposure scenarios, the confidence in the risk estimates is raised due to the presence of both
1599 central tendency and high end estimates for occupational scenarios and low-, moderate-, and high-
1600 intensity user estimates for consumer scenarios. Any reduced confidence in individual exposure
1601 estimates is mitigated by the use of a range of exposure estimates, which cover a variety of different
1602 assumptions to account for any uncertainty and variability. Therefore, while there is lower confidence in
1603 various occupational inhalation estimates and for consumer dermal exposure estimates, there is high
1604 confidence in the overall approach and it is unlikely that any refinement of risk estimates would result in
1605 variation of more than a few fold in either direction.

1606
1607 In considering risk estimates relative to the benchmark MOE/extra risk, identified risks are typically
1608 present for multiple endpoints, at both high-end and central tendency (or high and medium-intensity user
1609 scenarios for consumers) exposure levels, for both inhalation and dermal exposure, and based on both
1610 monitoring and modeling data, when available (Sections 4.5.2.1 and 4.5.2.2). In accounting for the
1611 totality of uncertainties, including confidence levels for each exposure scenario/COU, strength of the
1612 human health hazard information, and range of risk estimates provided for the different aspects of the
1613 Risk Evaluation relative to the benchmark, confidence in the risk estimates for each of the receptors and
1614 exposure durations is as follows:

1615 1616 Occupational

1617 **Acute Non-Cancer Inhalation Occupational Risk (workers):** Medium

1618 **Acute Non-Cancer Dermal Occupational Risk (workers):** Medium

1619 **Acute Non-Cancer Inhalation Occupational Risk (ONUs):** Medium (Low²⁴ when based on central
1620 tendency of workers without ONU-specific data)

1621
1622

²⁴ EPA notes that while there is low confidence in the accuracy of the risk estimates due to low confidence in the exposure estimates in these instances, the risk conclusions (*i.e.*, risk estimate below or above benchmark) do not change if ONU chronic exposure values are varied by 10x in either direction.

1623 **Chronic Inhalation Non-Cancer Occupational Risk (workers):** High
1624 **Chronic Dermal Non-Cancer Occupational Risk (workers):** Medium-High
1625 **Chronic Inhalation Non-Cancer Occupational Risk (ONUs):** Medium-High (Low²⁴ when based on
1626 central tendency of workers without ONU-specific data)
1627
1628 **Lifetime Cancer Inhalation Occupational Risk (workers):** Medium-High
1629 **Lifetime Cancer Dermal Occupational Risk (workers):** Medium-High
1630 **Lifetime Cancer Inhalation Occupational Risk (ONUs):** Medium-High (Low²⁴ when based on central
1631 tendency of workers without ONU-specific data)
1632
1633 Consumer
1634 **Acute Non-Cancer Inhalation Consumer Risk (users):** Medium-High
1635 **Acute Non-Cancer Dermal Consumer Risk (users):** Low-Medium
1636 **Acute Non-Cancer Inhalation Consumer Risk (bystanders):** Medium-High
1637
1638

4.4 Other Risk Related Considerations

1640

4.4.1 Potentially Exposed or Susceptible Populations

1641

EPA identified workers, ONUs, consumers, and bystanders as potentially exposed populations. EPA provided risk estimates for workers and ONUs at both central tendency and high-end exposure levels for all COUs. Consumer and bystander risk estimates were provided for low, medium, and high intensities of use, accounting for differences in duration, weight fraction, and mass used. Dermal risk estimates were calculated for both average workers and women of childbearing age [*Occupational Risk Estimate Calculator. Docket: EPA-HQ-OPPT-2019-0500*] based on differences in delivered dose accounting for differing body weight and hand size. Exposures differ by only ~10% between these groups, so this difference is relatively insignificant considering the magnitude of risk estimates relative to the benchmark MOE. Accordingly, the risk characterization section only presents dermal risk estimates for average adult workers (Section 4.2.2). Similarly, risk estimates were provided for each of the three lifestages that are expected to potentially be directly exposed through consumer use, namely 11-15 year olds, 16-20 year olds, and adults 21 and over (Section 4.2.3). These risk estimates also only varied by a small percentage relative to the magnitude of risk estimates relative to the benchmark MOE. EPA determined that bystanders may include lifestages of any age.

1655

1656

For inhalation exposures, risk estimates did not differ between sexes or across lifestages because both exposures and inhalation hazard values are expressed as an air concentration. EPA expects that variability in human physiological factors (*e.g.*, breathing rate, body weight, tidal volume) which may affect internal delivered concentration or dose is sufficiently accounted for in the PBPK model, although some differences among lifestages may not have been accounted for (Section 4.3.2.2). In order to address increased internal dose among workers and ONUs compared to at-rest individuals due to increased breathing rate, EPA used the PBPK model to derive occupational HECs for the best overall acute and chronic non-cancer endpoints (Section 3.2.5.4.1). The use of HEC/HED₉₉ values is expected to account for the vast majority of physiological differences among individuals. The PBPK model does not contain a fetal compartment (Section 3.2.2.5), therefore EPA conservatively assumed that maternal internal dose was directly applicable to fetal exposure. While EPA did not assess risk for breast feeding infants, evaluating developmental effects based on maternal internal dose would be protective of this subpopulation.

1668

1669

1670

EPA identified lifestage, sex, genetic polymorphisms, race/ethnicity, preexisting health status, and lifestyle factors and nutrition status as factors affecting biological susceptibility. The use of HEC/HED₉₉ POD values derived from relevant PBPK dose metrics accounts for the vast majority of toxicokinetic variation across the population. By relying on the 99th percentile output of the PBPK model, these values are expected to be protective of particularly susceptible subpopulations, including those with genetic polymorphisms resulting in increased activity of bioactivating enzymes. Additionally, risk estimates were provided for three developmental endpoints in order to account for the PESS group of pregnant mothers and women of childbearing age. The (Selgrade and Gilmour, 2010) study accounts for pre-existing infection concurrent with TCE exposure, representing a susceptible status that applies intermittently to the entire population. Cardiac malformations are most strongly associated with offspring of older mothers (Brender et al., 2014; Yauck et al., 2004). While there are inconsistencies in the data on cardiac malformations (Appendix F.3) and reduced confidence in the dose-response and POD derivation for (Johnson et al., 2003), EPA inclusion of risk estimates for cardiac malformations accounts for susceptible mothers (Jenkins et al., 2007) and their offspring in addition to PESS groups with other susceptibilities (*e.g.*, diabetes, infection status, drug exposure, stress (Jenkins et al., 2007), and metabolic sensitivity due to increased enzymatic activity of cytochrome P450 2E1 (CYP2E1)

1685

1686 ([Cichocki et al. 2016](#); [U.S. EPA, 2011e](#)). An individual may be a member of multiple PESS groups
1687 (perhaps including both exposure and biological susceptibility considerations) and may exhibit multiple
1688 concurrent susceptibilities.

1689
1690 EPA acknowledges that it was unable to directly account for all possible PESS considerations and
1691 subpopulations in the risk estimates. It is unknown whether the HEC/HED₉₉ and remaining 3x UF_H for
1692 toxicodynamic variability sufficiently accounts for the full breadth of human responses, and
1693 subpopulations with particular disease states or genetic predispositions may fall outside of the range
1694 covered by this UF. Additionally, EPA was unable to precisely model developmental effects due to the
1695 lack of a fetal compartment in the model, requiring the use of default adult female parameters as a
1696 surrogate. As previously discussed, EPA also only considered acute effects from consumer exposure.
1697 While typical use patterns are unlikely to result in any chronic effects for the vast majority of
1698 consumers, EPA cannot rule out that consumers at very high frequencies of use may be at risk for
1699 chronic hazards, especially if those consumers also exhibit biological susceptibilities. EPA also cannot
1700 rule out that certain subpopulations, whether due to very elevated exposure or biological susceptibility,
1701 may be at risk for hazards that were not fully supported by the weight of evidence or could not be
1702 quantified. However, in these circumstances EPA assumes that these effects are likely to occur at a
1703 higher dose than more sensitive endpoints that were accounted for by risk estimates. In order to account
1704 for these uncertainties, EPA's decisions for unreasonable risk are based on high-end exposure estimates
1705 (see below in Section 4.4.2).

1706 **4.4.2 Aggregate and Sentinel Exposures**

1707 Section 2605(b)(4)(F)(ii) of TSCA requires the EPA, as a part of the Risk Evaluation, to describe
1708 whether aggregate or sentinel exposures under the conditions of use were considered and the basis for
1709 their consideration. The EPA has defined aggregate exposure as “*the combined exposures to an*
1710 *individual from a single chemical substance across multiple routes and across multiple pathways*” (40
1711 CFR Section 702.33). In this Risk Evaluation, EPA determined that aggregating dermal and inhalation
1712 exposure for risk characterization was not appropriate due to uncertainties in quantifying the relative
1713 contribution of dermal vs inhalation exposure, since dermally applied dose could evaporate and then be
1714 inhaled. Additionally, without a PBPK model containing a dermal compartment to account for
1715 toxicokinetic processes the true internal dose for any given exposure cannot be determined. Aggregating
1716 exposures could inappropriately overestimate total exposure, as simply adding exposures from different
1717 routes without an available PBPK model for those routes would compound uncertainties. It is unknown
1718 whether exposures from multiple routes would act in an additive fashion, and saturation of metabolic
1719 processes at elevated exposures may result in a steady-state that hampers subsequent absorption relative
1720 to excretive processes. Conversely, not aggregating exposures in any manner may potentially
1721 underestimate total exposure for a given individual. EPA also did not consider aggregate exposure
1722 among individuals who may be exposed both in an occupational and consumer context or incorporate
1723 background general population exposures because there is insufficient information reasonably available
1724 as to the likelihood of this scenario or the relative distribution of exposures from each pathway. Risk is
1725 likely to be elevated for individuals who experience TCE exposure in multiple contexts.

1726
1727 EPA defines sentinel exposure as “*the exposure to a single chemical substance that represents the*
1728 *plausible upper bound of exposure relative to all other exposures within a broad category of similar or*
1729 *related exposures*” (40 CFR Section 702.33). In this Risk Evaluation, EPA considered sentinel
1730 exposures by considering risks to populations who may have upper bound exposures – for example,
1731 workers and ONUs who perform activities with higher exposure potential, or consumers who have
1732 higher exposure potential (*e.g.*, those involved with do-it-yourself projects) or certain physical factors
1733 like body weight or skin surface area exposed. In an attempt to assess “upper bound” exposures, EPA

1734 characterized high-end exposures in evaluating exposure using both monitoring data and modeling
1735 approaches. As stated in [*Environmental Releases and Occupational Exposure Assessment. Docket:*
1736 [EPA-HQ-OPPT-2019-0500](#)], a high-end is assumed to be representative of occupational exposures that
1737 occur at probabilities above the 90th percentile but below the exposure of the individual with the highest
1738 exposure. For Risk Evaluation, EPA provided high-end results at the 95th percentile. If the 95th
1739 percentile is not available, EPA used a different percentile greater than or equal to the 90th percentile
1740 but less than or equal to the 99.9th percentile, depending on the statistics available for the distribution. If
1741 the full distribution is not known and the preferred statistics are not available, EPA estimated a
1742 maximum or bounding estimate in lieu of the high-end. For consumer and bystander exposures, EPA
1743 characterized sentinel exposure through a “high-intensity use” category based on both product and user-
1744 specific factors. In cases where sentinel exposures result in MOEs greater than the benchmark or cancer
1745 risk lower than the benchmark (*i.e.*, risks were not identified), EPA did no further analysis because
1746 sentinel exposures represent the worst-case scenario. EPA’s decisions for unreasonable risk are based on
1747 high-end exposure estimates to capture individuals with sentinel exposure. In this Risk Evaluation, the
1748 EPA considered sentinel exposure in the form of a high-end scenarios for occupational exposure
1749 resulting from dermal and inhalation exposures, as these exposure routes are the most likely to result in
1750 the highest exposure given the details of the manufacturing process and the potential exposure scenarios
1751 discussed above. The calculation for dermal exposure is especially conservative given that it assumes
1752 full contact/immersion.
1753

1754 4.5 Risk Conclusions

1755 4.5.1 Environmental Risk Conclusions

1756 Risks to aquatic organisms, like fish and invertebrates were identified near one open-top vapor
1757 degreasing facility and one facility that processes TCE as a reactant (See Table 4-57). These facilities
1758 had an acute RQ ≥ 1 , or a chronic RQ ≥ 1 and 20 days or more of exceedance for the chronic COC.
1759 Risk to the most sensitive species of algae were identified near 15 facilities with 20 days or more of
1760 exceedances (10 of these facilities had 100 days or more of exceedances); however, as a taxonomic
1761 group, results do not indicate risk for 95% of algae species. In other words, these facilities had RQs ≥ 1
1762 using the algae COC of 3 ppb but RQs < 1 using the algae HC₀₅ of 14,400 ppb. These facilities are not
1763 included in Table 4-57 in this section, but are in Table 4-1 for reference.

1764
1765 EPA did not identify risks to aquatic organisms like fish and invertebrates in the ambient water where
1766 monitored data were reasonably available. Monitored data from the Water Quality Portal and the
1767 reasonably available literature show no exceedances of the acute COC or chronic COC in ambient water.
1768 Monitored data from literature showed some exceedances of the algae COC of 3 ppb in ambient water;
1769 however, the data show no exceedances of the algae COC of 14,400 ppb.

1770
1771 Near-facility monitoring data report levels of TCE ranging from 0.4 to 447 $\mu\text{g/L}$ ([U.S. EPA, 1977](#)).
1772 These data show that measured, near-facility concentrations compare to the modeled near-facility
1773 concentrations from E-FAST. With the exception of two sites, the measured concentrations in this study
1774 encompass the range of the modeled estimates across all OES from E-FAST.

1775 1776 **Processing as a Reactant:**

1777 One out of 443 facilities (including 440 unknown sites modeled in E-FAST) that process TCE as a
1778 reactant had releases of TCE to surface water that indicate risk to aquatic organisms like fish and
1779 invertebrates. Praxair Technology Center in Tonawanda, NY had an acute RQ of 1.50 and a chronic
1780 RQs of 3.81 with 20 days of exceedance. In other words, the surface water concentration modeled for
1781 this facility was 1.5 times higher than the COC for acute exposures and 3.81 times higher than the COC
1782 for chronic exposures. *Therefore, EPA identified risk to aquatic organisms at this site for acute and*
1783 *chronic exposures to TCE.*

1784 1785 **Open-top Vapor Degreasing:**

1786 One out of 64 open-top vapor degreasing facilities had releases of TCE to surface water that indicate
1787 risk to aquatic organisms. U.S. NASA Michoud Assembly Facility in New Orleans, LA had an acute RQ
1788 ≥ 1 (RQ = 4.97). In other words, the surface water concentration modeled for this facility was 4.97 times
1789 higher than the acute COC of 2,000 ppb, indicating risk to aquatic organisms from acute exposures. The
1790 facility also had a chronic RQ of 12.61 with 20 days of exceedance. This means the surface water
1791 concentration was 12.61 higher than the COC of 788 for 20 days. *Therefore, EPA identified risk to*
1792 *aquatic organisms at this site for acute and chronic exposures to TCE.*
1793

Table 4-57. Facilities with Risk from Acute or Chronic Exposure for Aquatic Organisms (RQs ≥ 1 in bold)

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient
OES: Processing as a Reactant										
Praxair Technology Center, Tonawanda, NY NPDES: NY0000281	Surface Water	NPDES NY0000281	Still body	350	0.00169	169	Acute	2,000	NA	0.08
							Chronic	788	0	0.21
							Algae	3	350	56.33
				20	0.03	3000	Algae (HC ₀₅)	14,400	0	0.01
							Acute	2,000	NA	1.50
							Chronic	788	20	3.81
							Algae	3	20	1,000.00
Algae (HC ₀₅)	14,400	0	0.21							
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, and Metalworking Fluids)										
US Nasa Michoud Assembly Facility, New Orleans, LA NPDES: LA0052256	Surface Water	Surrogate NPDES LA0003280	Still body	260	1.96	765.63	Acute	2,000	NA	0.38
							Chronic	788	0	0.97
							Algae (COC)	3	260	255.21
				20	25.44	9937.5	Algae (HC ₀₅)	14,400	0	0.05
							Acute	2,000	NA	4.97
							Chronic	788	20	12.61
							Algae	3	20	3,312.50
Algae (HC ₀₅)	14,400	0	0.69							
<p>a. Facilities actively releasing trichloroethylene were identified via DMR, TRI, and CDR databases for the 2016 reporting year.</p> <p>b. Release media are either direct (release from active facility directly to surface water) or indirect (transfer of wastewater from active facility to a receiving POTW or non-POTW WWTP facility). A wastewater treatment removal rate of 81% is applied to all indirect releases, <i>i.e.</i>, volumes characterized as being transferred off-site for treatment at a water treatment facility prior to discharge to surface water.</p> <p>c. If a valid NPDES of the direct or indirect releaser was not reasonably available in EFAST, the release was modeled using either a surrogate representative facility in EFAST (based on location) or a representative generic industry sector. The name of the indirect releaser is provided, as reported in TRI.</p> <p>d. EFAST uses either the “surface water” model, for rivers and streams, or the “still water” model, for lakes, bays, and oceans.</p> <p>e. Modeling was conducted with the maximum days of release per year expected. For direct releasing facilities, a minimum of 20 days was also modeled.</p> <p>f. The daily release amount was calculated from the reported annual release amount divided by the number of release days per year.</p> <p>g. For releases discharging to lakes, bays, estuaries, and oceans, the acute scenario mixing zone water concentration was reported in place of the 7Q10 SWC.</p> <p>h. To determine the PDM days of exceedance for still bodies of water, the release days provided by the EPA Engineers should become the days of exceedance only if the predicted surface water concentration exceeds the COC. Otherwise, the days of exceedance can be assumed to be zero</p>										

1796 EPA identified risks to sediment organisms near the same two facilities, one open-top vapor degreasing
1797 facility and one facility that processes TCE as a reactant. Table 4-58 shows an RQ from acute exposure
1798 near Praxair Technology Center at 1.5 and an RQ from chronic exposure at 3.26 with 20 days of
1799 exceedance for aquatic invertebrates. Table 4-58 also shows an RQ from acute exposure near US NASA
1800 Michoud Assembly Facility at 4.97 and an RQ from chronic exposure at 10.8 with 20 days of
1801 exceedance for aquatic invertebrates (Table 4-58).

1802
1803 As stated in Section 4.1.3, in ambient water, both acute and chronic exposures to TCE are less than the
1804 COC (RQs < 0). More specifically, RQs for sediment organisms are between 0.00 and 0.02 based on the
1805 highest ambient surface water concentration of 17.3 ppb from acute or chronic exposures.

1806 **Table 4-58. Facilities with Risk from Acute or Chronic Exposure for Sediment Organisms (RQs \geq 1 in bold)**

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	COC Type	COC (ppb)	Days of Exceedance (days/year) ^h	Risk Quotient
OES: Processing as a Reactant										
Praxair Technology Center, Tonawanda, NY NPDES: NY0000281	Surface Water	NPDES NY0000281	Still body	350	0.00169	169	Acute (HC ₀₅)	2,000	NA	0.08
							Chronic (ChV)	920	0	0.18
				20	0.03	3000	Acute (HC ₀₅)	2,000	NA	1.50
							Chronic (ChV)	920	20	3.26
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, and Metalworking Fluids)										
US Nasa Michoud Assembly Facility, New Orleans, LA NPDES: LA0052256	Surface Water	Surrogate NPDES LA0003280	Still body	260	1.96	765.63	Acute (HC ₀₅)	2,000	NA	0.38
							Chronic (ChV)	920	0	0.83
				20	25.44	9937.5	Acute (HC ₀₅)	2,000	NA	4.97
							Chronic	920	20	10.8
<p>a. Facilities actively releasing trichloroethylene were identified via DMR, TRI, and CDR databases for the 2016 reporting year.</p> <p>b. Release media are either direct (release from active facility directly to surface water) or indirect (transfer of wastewater from active facility to a receiving POTW or non-POTW WWTP facility). A wastewater treatment removal rate of 81% is applied to all indirect releases, <i>i.e.</i>, volumes characterized as being transferred off-site for treatment at a water treatment facility prior to discharge to surface water.</p> <p>c. If a valid NPDES of the direct or indirect releaser was not available in EFAST, the release was modeled using either a surrogate representative facility in EFAST (based on location) or a representative generic industry sector. The name of the indirect releaser is provided, as reported in TRI.</p> <p>d. EFAST uses either the “surface water” model, for rivers and streams, or the “still water” model, for lakes, bays, and oceans.</p> <p>e. Modeling was conducted with the maximum days of release per year expected. For direct releasing facilities, a minimum of 20 days was also modeled.</p> <p>f. The daily release amount was calculated from the reported annual release amount divided by the number of release days per year.</p> <p>g. For releases discharging to lakes, bays, estuaries, and oceans, the acute scenario mixing zone water concentration was reported in place of the 7Q10 SWC.</p> <p>h. To determine the PDM days of exceedance for still bodies of water, the release days provided by the EPA Engineers should become the days of exceedance only if the predicted surface water concentration exceeds the COC. Otherwise, the days of exceedance can be assumed to be zero.</p>										

1807

1808

4.5.2 Human Health Risk Conclusions

1809

4.5.2.1 Summary of Risk Estimates for Workers and ONUs

1810

Table 4-59 summarizes the representative risk estimates for inhalation and dermal exposures for all occupational exposure scenarios. Risk estimates that exceed the benchmark (*i.e.*, MOEs less than the benchmark MOE or cancer risks greater than the cancer risk benchmark) are highlighted by bolding the number and shading the cell in gray. When both monitoring and modeling inhalation exposures were available, EPA presented the most reliable data source in the table. The occupational exposure assessment and risk characterization are described in more detail in Sections 2.3.1 and 4.2.2, respectively. Specific links to the relevant risk characterization sections are listed in Table 4-59 in the Occupational Exposure Scenario column.

1818

1819

The risk summary below is based on the most robust and well-supported PODs selected from among the most sensitive acute and chronic non-cancer endpoints, as well as cancer. EPA selected immunosuppression ([Selgrade and Gilmour, 2010](#)) as the best overall representative acute endpoint, and autoimmunity from the immunotoxicity domain ([Keil et al., 2009](#)) was selected to best represent chronic exposure based on being both robust and sensitive. While some other endpoints present lower PODs (developmental neurotoxicity from [Fredriksson et al., 1993](#); congenital heart malformations from [Johnson et al., 2003](#)), there is lower confidence in the dose-response and extrapolation of results from those studies (Section 3.2.6.1.1) resulting in increased uncertainty surrounding the precision of the derived PODs for those endpoints. Therefore, EPA concluded that these were the best overall non-cancer endpoints for use in Risk Evaluation under TSCA, based on the best available science and weight of scientific evidence (Section 3.2.5.4.1). Occupational-adjusted PODs for these endpoints (Table 3-16) were used in estimating occupational risks. For the majority of exposure scenarios, risks were identified for multiple endpoints in both acute and chronic exposure scenarios, however risk estimates are only summarized for these particular endpoints. Risk estimates are also presented considering PPE up to respirator APF 50 and glove PF 10 or 20. When risks did not exceed the benchmark, the lowest protection factor that results in no risk is shown (*i.e.*, if risks do not exceed the benchmark for APF 10 and above, the risk estimate for APF 10 is shown).

1836

1837

Inhalation Exposure

1838

For acute and chronic exposures via inhalation without PPE (*i.e.*, no respirators) there are risks for workers relative to the benchmarks for all the OES at the high-end exposure level for non-cancer effects from both acute and chronic exposure durations as well as for cancer. Occupational non-users (ONUs) are expected to have lower exposure levels than workers in most instances but exposures could not always be quantified. Therefore, when separate ONU exposure estimates were not reasonably available, EPA provided risk estimates for ONUs based on worker values (without PPE). These instances are indicated in Table 4-59 with “worker estimate” added to the ONU cell in the Population column. Risks to ONUs were indicated at high-end exposure levels for all OES following chronic exposure and for most OES following acute exposure, although central-tendency exposure levels are considered more representative for ONUs.

1848

1849

When only considering central tendency inhalation exposure level, risks for any endpoint were not identified to workers or ONUs for the following exposure scenarios:

1851

- Formulation of Aerosol and Non-Aerosol Products
- Repackaging
- Process Solvent Recycling and Worker Handling of Wastes

1852

1853

1854

1855 When respirators are worn (either APF 10 or 50) there are risks relative to the benchmarks for non-
1856 cancer effects and for cancer for workers (ONUs are assumed to not consistently wear respirators) from
1857 both acute and chronic exposure durations at high-end exposure levels for the majority of OES (risks
1858 remain with respirator use for all exposure scenarios following chronic exposure). Risks for any
1859 endpoint were not identified when assuming the maximum plausible APF (up to APF =50) and central
1860 tendency exposure levels for the same exposure scenarios that did not demonstrate risk without PPE:

- 1861 • Formulation of Aerosol and Non-Aerosol Products
- 1862 • Repackaging
- 1863 • Process Solvent Recycling and Worker Handling of Wastes

1864

1865 Dermal Exposure

1866 For acute and chronic exposures via dermal contact without PPE (*i.e.*, no gloves) there are risks to
1867 workers for both non-cancer effects and cancer (ONUs are assumed to not have direct dermal contact
1868 with TCE) at both high-end and central-tendency exposure levels for all OES. Risks are still identified
1869 for all exposure scenarios (at high-end exposure levels following acute exposure and at both exposure
1870 levels following chronic exposure) when gloves are worn even when assuming the maximum applicable
1871 glove protection (either PF 10 or 20).

1872 Table 4-59. Occupational Risk Summary Table

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
Manufacture - Domestic manufacture	Domestic manufacture	Manufacturing - Table 4-10	Worker	Inhalation	High-End	0.95	4.9E-02	6.3E-03	47.6 (APF 50)	2.5 (APF 50)	1.3E-04 (APF 50)
					Central Tendency	20.3	1.1	2.3E-04	203.5 (APF 10)	52.7 (APF 50)	4.6E-06 (APF 10)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	20.3	1.1	2.3E-04	N/A		
Manufacture - Import	Import	Repackaging - Table 4-23	Worker	Inhalation	High-End	2.1	0.11	2.9E-03	20.5 (APF 10)	5.3 (APF 50)	5.9E-05 (APF 50)
					Central Tendency	4728	245	9.9E-07	47275 (APF 10)	2448 (APF 10)	9.9E-08 (APF 10)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	4728	245	9.9E-07	N/A		
Processing - Processing as a reactant/ intermediate	Intermediate in industrial gas manufacturing (e.g., manufacture of fluorinated gases used as	Processing as a Reactant - Table 4-11	Worker	Inhalation	High-End	0.95	4.9E-02	6.3E-03	47.6 (APF 50)	2.5 (APF 50)	1.3E-04 (APF 50)
					Central Tendency	20.3	1.1	2.3E-04	203.5 (APF 10)	52.7 (APF 50)	4.6E-06 (APF 10)

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE					
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)			
	refrigerants, foam blowing agents and solvents)			Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)			
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)			
				ONU (worker estimate)	Inhalation	High-End	-	-	-	-				
						Central Tendency	20.3	1.1	2.3E-04	N/A				
			Processing - Incorporation into formulation, mixture or reaction product	Solvents (for cleaning or degreasing)	Formulation of Aerosol and Non-Aerosol Products - Table 4-22	Worker	Inhalation	High-End	2.1	0.11	2.9E-03	20.5 (APF 10)	5.3 (APF 50)	5.9E-05 (APF 50)
								Central Tendency	4728	245	9.9E-07	47275 (APF 10)	2448 (APF 10)	9.9E-08 (APF 10)
Adhesives and sealant chemicals	Dermal	High-End		0.58			3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)			
		Central Tendency		1.7			9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)			
Solvents (which become part of product formulation or mixture) (e.g., lubricants and greases, paints and coatings, other uses)	ONU (worker estimate)	Inhalation		High-End		-	-	-	-					
				Central Tendency		4728	245	9.9E-07	N/A					
Processing - incorporated into articles	Solvents (becomes an integral component of articles)	Formulation of Aerosol and Non-Aerosol Products - Table 4-22	Worker	Inhalation	High-End	2.1	0.11	2.9E-03	20.5 (APF 10)	5.3 (APF 50)	5.9E-05 (APF 50)			
					Central Tendency	4728	245	9.9E-07	47275 (APF 10)	2448 (APF 10)	9.9E-08 (APF 10)			
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)			
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)			

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	4728	245	9.9E-07	N/A		
Processing - Repackaging	Solvents (for cleaning or degreasing)	Repackaging - Table 4-23	Worker	Inhalation	High-End	6.2	0.11	2.9E-03	61.6 (APF 10)	5.3 (APF 50)	5.9E-05 (APF 50)
					Central Tendency	14182	245	9.9E-07	141825 (APF 10)	2448 (APF 10)	9.9E-08 (APF 10)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	14182	245	9.9E-07	N/A		
Processing - Recycling	Recycling	Process Solvent Recycling and Worker Handling of Wastes - Table 4-31	Workers	Inhalation	High-End	2.1	0.11	2.9E-03	20.5 (APF 10)	5.3 (APF 50)	5.9E-05 (APF 50)
					Central Tendency	4728	245	9.9E-07	47275 (APF 10)	2448 (APF 10)	9.9E-08 (APF 10)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	4728	245	9.9E-07	N/A		

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
Distribution in commerce - Distribution	Distribution	Distribution	Distribution in commerce of TCE is the transportation associated with the moving of TCE in commerce. Exposures and emissions are not expected.								
Industrial/commercial use Solvents (for cleaning or degreasing)	Batch vapor degreaser (e.g., open-top, closed-loop)	Batch Open-Top Vapor Degreasing - Table 4-12	Workers	Inhalation (Monitoring Data) ^a	High-End	3.0E-02	1.6E-03	0.20	1.5 (APF 50)	7.8E-02 (APF 50)	4.0E-03 (APF 50)
					Central Tendency	0.17	8.8E-03	2.8E-02	8.5 (APF 50)	0.44 (APF 50)	5.5E-04 (APF 50)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU	Inhalation (Monitoring Data) ^a	High-End	0.26	1.3E-02	2.3E-02	N/A		
					Central Tendency	2.1	0.11	2.2E-03	N/A		
		Batch Closed-Loop Vapor Degreasing - Table 4-14	Workers	Inhalation	High-End	1.6	8.3E-02	3.7E-03	16.1 (APF 10)	4.2 (APF 50)	7.5E-05 (APF 50)
					Central Tendency	5.1	0.26	9.1E-04	51.1 (APF 10)	13.2 (APF 50)	9.1E-05 (APF 10)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	5.1	0.32	9.1E-04	N/A		

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
Industrial/ commercial use - Solvents (for cleaning or degreasing)	In-line vapor degreaser (e.g., conveyORIZED, web cleaner)	Conveyorized Vapor Degreasing - Table 4-15	Workers	Inhalation (Monitoring Data) ^a	High-End	4.8E-02	2.5E-03	0.12	2.4 (APF 50)	0.13 (APF 50)	2.5E-03 (APF 50)
					Central Tendency	7.2E-02	3.7E-03	6.5E-02	3.6 (APF 50)	0.19 (APF 50)	1.3E-03 (APF 50)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
		ONU (worker estimate)	Inhalation (Monitoring Data) ^a	High-End	-	-	-	-			
				Central Tendency	7.2E-02	3.7E-03	6.5E-02	N/A			
		Web Vapor Degreasing - Table 4-17	Workers	Inhalation	High-End	0.17	8.6E-03	2.9E-02	8.3 (APF 50)	1.3E-02 (APF 50)	5.8E-04 (APF 50)
					Central Tendency	0.39	2.0E-02	1.1E-02	19.7 (APF 50)	3.9E-02 (APF 50)	2.3E-04 (APF 50)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
	ONU		Inhalation	High-End	0.24	1.3E-02	1.9E-02	N/A			
				Central Tendency	0.75	3.9E-02	5.9E-03	N/A			
	Cold cleaner	Cold Cleaning - Table 4-18	Worker	Inhalation	High-End	4.1E-02	2.1E-03	0.11	2.0 (APF 50)	0.11 (APF 50)	2.3E-03 (APF 50)
					Central Tendency	0.70	3.6E-02	6.2E-03	35.1 (APF 50)	1.8 (APF 50)	1.2E-04 (APF 50)

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
Industrial/ commercial use Solvents (for cleaning or degreasing)	Cold cleaner	Cold Cleaning - Table 4-18	ONU	Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU	Inhalation	High-End	6.7E-02	3.5E-03	6.9E-02	N/A		
					Central Tendency	1.3	6.6E-02	3.3E-03	N/A		
	Aerosol spray degreaser/cleaner	Aerosol Applications - Table 4-19	Worker	Inhalation	High-End	9.8E-02	5.1E-03	4.9E-02	4.9 (APF 50)	0.25 (APF 50)	9.7E-04 (APF 50)
					Central Tendency	0.31	1.6E-02	1.4E-02	15.3 (APF 50)	0.79 (APF 50)	2.9E-04 (APF 50)
				Dermal	High-End	0.37	1.9E-02	5.9E-02	7.4 (PF 20)	0.39 (PF 20)	2.9E-03 (PF 20)
					Central Tendency	1.1	5.8E-02	1.5E-02	11.1 (PF 10)	1.2 (PF 20)	7.6E-04 (PF 20)
	Mold release	ONU	Inhalation	High-End	2.3	0.12	2.0E-03	N/A			
				Central Tendency	16.7	0.87	2.6E-04	N/A			
Industrial/ commercial use - Lubricants and greases/ lubricants and lubricant additives	Tap and die fluid	Metalworking Fluids - Table 4-25	Worker	Inhalation (Modeling Data) ^b	High-End	9.0	0.47	6.6E-04	90.0 (APF 10)	23.3 (APF 50)	1.3E-05 (APF 50)
					Central Tendency	33.4	1.7	1.3E-04	334.3 (APF 10)	86.6 (APF 50)	2.6E-06 (APF 50)
				Dermal	High-End	0.73	3.8E-02	3.0E-02	14.5 (PF 20)	0.76 (PF 20)	1.5E-03 (PF 20)
					Central Tendency	2.2	0.11	7.8E-03	10.9 (PF 5)	2.3 (PF 20)	3.9E-04 (PF 20)

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE				
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)		
Industrial/ commercial use - Lubricants and greases/ lubricants and lubricant additives	Penetrating lubricant	Aerosol Applications - Table 4-19	ONU (worker estimate)	Inhalation	High-End	-	-	-	-				
					Central Tendency	33.4	1.7	1.3E-04	N/A				
	Worker		Inhalation	High-End	9.8E-02	5.1E-03	4.9E-02	4.9 (APF 50)	0.25 (APF 50)	9.7E-04 (APF 50)			
				Central Tendency	0.31	1.6E-02	1.4E-02	15.3 (APF 50)	0.79 (APF 50)	2.9E-04 (APF 50)			
			Dermal	High-End	0.37	1.9E-02	5.9E-02	7.4 (PF 20)	0.39 (PF 20)	2.9E-03 (PF 20)			
				Central Tendency	1.1	5.8E-02	1.5E-02	11.1 (PF 10)	1.2 (PF 20)	7.6E-04 (PF 20)			
	ONU		Inhalation	High-End	2.3	0.12	2.0E-03	N/A					
				Central Tendency	16.7	0.87	2.6E-04	N/A					
	Industrial/ commercial use - Adhesives and sealants		Solvent-based adhesives and sealants	Adhesives, Sealants, Paints, and Coatings - Table 4-26 and Table 4-27	Worker	Inhalation	High-End	5.9E-02	3.1E-03	0.10	3.0 (APF 50)	0.15 (APF 50)	2.0E-03 (APF 50)
			Central Tendency				0.50	2.6E-02	9.3E-03	25.2 (APF 50)	1.3 (APF 50)	1.9E-04 (APF 50)	
Dermal (Industrial)		High-End	0.65			3.4E-02	3.4E-02	12.9 (PF 20)	0.68 (PF 20)	1.7E-03 (PF 20)			
		Central Tendency	1.9			0.10	8.7E-03	19.4 (PF 10)	2.0 (PF 20)	4.4E-04 (PF 20)			
Tire repair cement/ Sealer		Dermal (Commercial)	High-End			0.41	2.2E-02	5.3E-02	4.1 (PF 10)	0.22 (PF 10)	5.3E-03 (PF 10)		
			Central Tendency			1.2	6.5E-02	1.4E-02	12.3 (PF 10)	0.65 (PF 10)	1.4E-03 (PF 10)		

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
						Mirror edge sealant	ONU	Inhalation	High-End	2.3	0.12
				Central Tendency	2.5	0.13	1.9E-03	N/A			
Industrial/commercial use - Functional fluids (closed systems)	Heat exchange fluid	Other Industrial Uses - Table 4-30	Worker	Inhalation	High-End	0.95	4.9E-02	6.3E-03	47.6 (APF 50)	2.5 (APF 50)	1.3E-04 (APF 50)
					Central Tendency	20.3	1.1	2.3E-04	203.5 (APF 10)	52.7 (APF 50)	2.3E-05 (APF 10)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU (worker estimate)	Inhalation	High-End	-	-	-	-		
					Central Tendency	20.3	1.1	2.3E-04	N/A		
Industrial/commercial use - Paints and coatings	Diluent in solvent-based paints and coatings	Adhesives, Sealants, Paints, and Coatings - Table 4-26 and Table 4-27	Worker	Inhalation	High-End	5.9E-02	3.1E-03	0.10	3.0 (APF 50)	0.15 (APF 50)	2.0E-03 (APF 50)
					Central Tendency	0.50	2.6E-02	9.3E-03	25.2 (APF 50)	1.3 (APF 50)	1.9E-04 (APF 50)
				Dermal (Industrial)	High-End	0.65	3.4E-02	3.4E-02	12.9 (PF 20)	0.68 (PF 20)	1.7E-03 (PF 20)
					Central Tendency	1.9	0.10	8.7E-03	19.4 (PF 10)	2.0 (PF 20)	4.4E-04 (PF 20)
				Dermal (Commercial)	High-End	0.41	2.2E-02	5.3E-02	4.1 (PF 10)	0.22 (PF 10)	5.3E-03 (PF 10)
					Central Tendency	1.2	6.5E-02	1.4E-02	12.3 (PF 10)	0.65 (PF 10)	1.4E-03 (PF 10)

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
			ONU	Inhalation	High-End	2.3	0.12	2.6E-03	N/A		
					Central Tendency	2.5	0.13	1.9E-03	N/A		
Industrial/commercial use - Cleaning and furniture care products	Carpet cleaner	Spot Cleaning and Wipe Cleaning ^c - Table 4-21	Worker	Inhalation (Modeling Data) ^b	High-End	0.85	4.3E-02	5.8E-03	42.5 (APF 50) ^c	2.1 (APF 50) ^c	1.2E-04 (APF 50) ^c
					Central Tendency	2.4	0.12	1.8E-03	24.3 (APF 10) ^c	6.1 (APF 50) ^c	3.7E-05 (APF 10) ^c
				Dermal	High-End	0.37	1.7E-02	6.9E-02	3.7 (PF 10) ^c	0.17 (PF 10) ^c	6.9E-03 (PF 10) ^c
	Central Tendency		1.1		5.6E-02	1.6E-02	11.1 (PF 10) ^c	0.56 (PF 10) ^c	1.6E-03 (PF 10) ^c		
	Wipe cleaning		ONU	Inhalation (Modeling Data) ^b	High-End	1.3	6.7E-02	3.6E-03	N/A		
					Central Tendency	4.9	0.25	9.3E-04	N/A		
Industrial/commercial use Laundry and dishwashing products	Spot remover	Spot Cleaning and Wipe Cleaning ^c - Table 4-21	Worker	Inhalation (Modeling Data) ^b	High-End	0.85	4.3E-02	5.8E-03	42.5 (APF 50) ^c	2.1 (APF 50) ^c	1.2E-04 (APF 50) ^c
					Central Tendency	2.4	0.12	1.8E-03	24.3 (APF 10) ^c	6.1 (APF 50) ^c	3.7E-05 (APF 10) ^c
				Dermal	High-End	0.37	1.7E-02	6.9E-02	3.7 (PF 10) ^c	0.17 (PF 10) ^c	6.9E-03 (PF 10) ^c
			Central Tendency		1.1	5.6E-02	1.6E-02	11.1 (PF 10) ^c	0.56 (PF 10) ^c	1.6E-03 (PF 10) ^c	
			ONU	Inhalation (Modeling Data) ^b	High-End	1.3	6.7E-02	3.6E-03	N/A		
					Central Tendency	4.9	0.25	9.3E-04	N/A		

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
Industrial/ commercial use - Arts, crafts and hobby materials	Fixatives and finishing spray coatings	Adhesives, Sealants, Paints, and Coatings - Table 4-26 and Table 4-27	Worker	Inhalation	High-End	5.9E-02	3.1E-03	0.10	3.0 (APF 50)	0.15 (APF 50)	2.0E-03 (APF 50)
					Central Tendency	0.50	2.6E-02	9.3E-03	25.2 (APF 50)	1.3 (APF 50)	1.9E-04 (APF 50)
				Dermal (Industrial)	High-End	0.65	3.4E-02	3.4E-02	12.9 (PF 20)	0.68 (PF 20)	1.7E-03 (PF 20)
					Central Tendency	1.9	0.10	8.7E-03	19.4 (PF 10)	2.0 (PF 20)	4.4E-04 (PF 20)
				Dermal (Commercial)	High-End	0.41	2.2E-02	5.3E-02	4.1 (PF 10)	0.22 (PF 10)	5.3E-03 (PF 10)
					Central Tendency	1.2	6.5E-02	1.4E-02	12.3 (PF 10)	0.65 (PF 10)	1.4E-03 (PF 10)
			ONU	Inhalation	High-End	2.3	0.12	2.6E-03	N/A		
					Central Tendency	2.5	0.13	1.9E-03	N/A		
Industrial/ commercial use - Corrosion inhibitors and anti-scaling agents	Corrosion inhibitors and anti-scaling agents	Industrial Processing Aid - Table 4-28	Worker	Inhalation	High-End	0.12	6.3E-03	4.9E-02	6.1 (APF 50)	0.31 (APF 50)	9.9E-04 (APF 50)
					Central Tendency	0.37	1.9E-02	1.3E-02	18.3 (APF 50)	0.94 (APF 50)	2.5E-04 (APF 50)
				Dermal	High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)
					Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)
			ONU	Inhalation	High-End	0.54	2.8E-02	1.1E-02	N/A		
					Central Tendency	1.2	6.1E-02	3.9E-03	N/A		

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
Industrial/ commercial use - Processing aids	Process solvent used in battery manufacture	Industrial Processing Aid - Table 4-28	Worker	Inhalation	High-End	0.12	6.3E-03	4.9E-02	6.1 (APF 50)	0.31 (APF 50)	9.9E-04 (APF 50)
					Central Tendency	0.37	1.9E-02	1.3E-02	18.3 (APF 50)	0.94 (APF 50)	2.5E-04 (APF 50)
	Dermal			High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)	
				Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)	
	Extraction solvent used in caprolactam manufacture		ONU	Inhalation	High-End	0.54	2.8E-02	1.1E-02	N/A		
					Central Tendency	1.2	6.1E-02	3.9E-03	N/A		
Precipitant used in beta-cyclodextrin manufacture											
Industrial/ commercial use - Ink, toner and colorant products	Toner aid	Commercial Printing and Copying ^c - Table 4-29	Workers	Inhalation	High-End	1.1	5.8E-02	5.4E-03	11.2 (APF 10) ^c	2.9 (APF 50) ^c	1.1E-04 (APF 50) ^c
					Central Tendency	27.5	1.4	1.7E-04	275.3 (APF 10) ^c	71.3 (APF 50) ^c	1.7E-05 (APF 10) ^c
				Dermal	High-End	1.1	5.5E-02	2.1E-02	10.6 (PF 10) ^c	0.55 (PF 10) ^c	2.1E-03 (PF 10) ^c
					Central Tendency	3.2	0.17	5.3E-03	15.9 (PF 5) ^c	1.7 (PF 10) ^c	5.3E-04 (PF 10) ^c
			ONU (upper limit)	Inhalation	High-End	-	-	-	-		
					Central Tendency	27.5	1.4	1.7E-04	N/A		
Industrial/ commercial use - Automotive care products	Brake and parts cleaner	Aerosol Applications - Table 4-19	Workers	Inhalation	High-End	9.8E-02	5.1E-03	4.9E-02	4.9 (APF 50)	0.25 (APF 50)	9.7E-04 (APF 50)
					Central Tendency	0.31	1.6E-02	1.4E-02	15.3 (APF 50)	0.79 (APF 50)	2.9E-04 (APF 50)

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE					
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)			
				Dermal	High-End	0.37	1.9E-02	5.9E-02	7.4 (PF 20)	0.39 (PF 20)	2.9E-03 (PF 20)			
					Central Tendency	1.1	5.8E-02	1.5E-02	11.1 (PF 10)	1.2 (PF 20)	7.6E-04 (PF 20)			
				ONU	Inhalation	High-End	2.3	0.12	2.0E-03	N/A				
						Central Tendency	16.7	0.87	2.6E-04	N/A				
			Industrial/commercial use - Apparel and footwear care products	Shoe polish	Other Commercial Uses (Spot Cleaning and Wipe Cleaning) ^c - Table 4-21	Worker	Inhalation (Modeling Data) ^b	High-End	0.85	4.3E-02	5.8E-03	42.5 (APF 50) ^c	2.1 (APF 50) ^c	1.2E-04 (APF 50) ^c
								Central Tendency	2.4	0.12	1.8E-03	24.3 (APF 10) ^c	6.1 (APF 50) ^c	3.7E-05 (APF 10) ^c
Dermal	High-End	0.37					1.7E-02	6.9E-02	3.7 (PF 10) ^c	0.17 (PF 10) ^c	6.9E-03 (PF 10) ^c			
	Central Tendency	1.1					5.6E-02	1.6E-02	11.1 (PF 10) ^c	0.56 (PF 10) ^c	1.6E-03 (PF 10) ^c			
ONU	Inhalation (Modeling Data) ^b	High-End				1.3	6.7E-02	3.6E-03	N/A					
		Central Tendency				4.9	0.25	9.3E-04	N/A					
Industrial/commercial use - Other uses	Hoof polishes	Other Commercial Uses (Spot Cleaning and Wipe Cleaning) ^c - Table 4-21	Worker	Inhalation (Modeling Data) ^b	High-End	0.85	4.3E-02	5.8E-03	42.5 (APF 50) ^c	2.1 (APF 50) ^c	1.2E-04 (APF 50) ^c			
	Central Tendency				2.4	0.12	1.8E-03	24.3 (APF 10) ^c	6.1 (APF 50) ^c	3.7E-05 (APF 10) ^c				
	Pepper spray			Dermal	High-End	0.37	1.7E-02	6.9E-02	3.7 (PF 10) ^c	0.17 (PF 10) ^c	6.9E-03 (PF 10) ^c			
					Central Tendency	1.1	5.6E-02	1.6E-02	11.1 (PF 10) ^c	0.56 (PF 10) ^c	1.6E-03 (PF 10) ^c			

Life Cycle Stage/ Category	Subcategory	Occupational Exposure Scenario	Population	Exposure Route and Duration	Exposure Level	Risk Estimates for No PPE			Risk Estimates with PPE		
						Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)	Acute Non-Cancer (benchmark MOE = 10)	Chronic Non-Cancer (benchmark MOE = 30)	Cancer (benchmark = 10 ⁻⁴)
	Other miscellaneous industrial and commercial uses		ONU	Inhalation (Modeling Data) ^b	High-End	1.3	6.7E-02	3.6E-03	N/A		
					Central Tendency	4.9	0.25	9.3E-04	N/A		
Disposal	Industrial pre-treatment	Process Solvent Recycling and Worker Handling of Wastes - Table 4-31	Workers	Inhalation	High-End	2.1	0.11	2.9E-03	20.5 (APF 10)	5.3 (APF 50)	5.9E-05 (APF 50)
					Central Tendency	4728	245	9.9E-07	47275 (APF 10)	2448 (APF 10)	9.9E-08 (APF 10)
	Dermal			High-End	0.58	3.0E-02	3.8E-02	11.6 (PF 20)	0.61 (PF 20)	1.9E-03 (PF 20)	
				Central Tendency	1.7	9.1E-02	9.7E-03	17.4 (PF 10)	1.8 (PF 20)	4.9E-04 (PF 20)	
	Publicly owned treatment works (POTW)		ONU (upper limit)	Inhalation	High-End	-	-	-	-		
					Central Tendency	4728	245	9.9E-07	N/A		

^a Monitoring data were selected as most representative based on the EPA data hierarchy where high-quality monitoring data is preferred over modeling results or exposure limits.

^b Modeling data were selected as most representative because the monitoring dataset contained a very low number of datapoints.

^c EPA believes that small commercial facilities performing spot cleaning, wipe cleaning, and other related commercial uses as well as commercial printing and copying are unlikely to have a respiratory protection program or regularly employ dermal protection. Therefore, the use of respirators and gloves is unlikely for workers in these facilities. Consistent PPE usage is not expected for this scenario and is only included as a “what-if” analysis for comparison purposes.

N/A = Not Applicable. ONUs are assumed to not wear respiratory protection.

4.5.2.2 Summary of Risk Estimates for Consumers and Bystanders

Table 4-60 summarizes the risk estimates for CNS effects from acute inhalation and dermal exposures for all consumer exposure scenarios. Risk estimates that exceed the benchmark (*i.e.*, MOEs less than the benchmark MOE) are highlighted by bolding the number and shading the cell in gray. The consumer exposure assessment and risk characterization are described in more detail in Sections 2.3.2 and 4.2.3, respectively. Specific links to the relevant risk characterization sections are listed in Table 4-60 in the Consumer Condition of Use Scenario column.

The risk summary below is based on the most robust and well-supported PODs selected from among the most sensitive acute non-cancer endpoints. EPA selected immunosuppression ([Selgrade and Gilmour, 2010](#)) as the best overall acute endpoint based on being both robust and sensitive. While some other endpoints present lower PODs (developmental neurotoxicity from [Fredriksson et al., 1993](#); congenital heart malformations from [Johnson et al., 2003](#)), there is lower confidence in the dose-response and extrapolation of results from those studies (Section 3.2.6.1.1) resulting in increased uncertainty surrounding the precision of the derived PODs for those endpoints. Therefore, EPA concluded that immunosuppression from ([Selgrade and Gilmour, 2010](#)) was the best overall endpoint for use in evaluation of acute risks under TSCA, based on the best available science and weight of scientific evidence (Section 3.2.5.4.1). For the majority of exposure scenarios, risks were identified for multiple endpoints, however risk estimates are only summarized for this particular endpoint.

Inhalation

For acute inhalation exposures there are risks for non-cancer effects for consumer users relative to the benchmarks for all COUs except Pepper Spray and for bystanders for most COUs at both medium and high-intensity user exposure levels.

Dermal

For acute dermal exposures there are risks for non-cancer effects for consumer users (bystanders are assumed to not have direct dermal contact with TCE) relative to the benchmarks for all COUs except for Pepper Spray at both medium and high-intensity user exposure levels (and for most COUs at low-intensity).

Table 4-60. Consumer Risk Summary Table

Life Cycle Stage/ Category	Subcategory/ Consumer Condition of Use Scenario	Population	Exposure Route and Duration	Age Group ^a	Acute Non-Cancer (benchmark MOE = 10)		
					High-Intensity User	Moderate-Intensity User	Low-Intensity User
Consumer Use - Solvents (for cleaning or degreasing)	Brake and Parts Cleaner - Table 4-32	User	Inhalation	All	3.7E-02	0.11	1.4
			Dermal	21+	5.8E-02	0.77	35
		16-20		6.2E-02	0.82	37	
		11-15		5.6E-02	0.75	34	
	Bystander	Inhalation	All	5.8E-02	0.43	5.4	
	Aerosol electronic degreaser/cleaner - Table 4-33	User	Inhalation	All	2.6E-02	0.61	18
Dermal			21+	0.40	4.7	39	
			16-20	0.43	5.0	42	

Life Cycle Stage/ Category	Subcategory/ Consumer Condition of Use Scenario	Population	Exposure Route and Duration	Age Group ^a	Acute Non-Cancer (benchmark MOE = 10)		
					High-Intensity User	Moderate-Intensity User	Low-Intensity User
				11-15	0.39	4.6	38
		Bystander	Inhalation	All	0.13	3.3	90
	Liquid electronic degreaser/cleaner - Table 4-34	User	Inhalation	All	2.7E-02	0.42	5.6
Dermal			21+	0.26	3.8	15	
			16-20	0.27	4.1	16	
			11-15	0.25	3.7	15	
Bystander		Inhalation	All	0.13	2.2	29	
	Aerosol spray degreaser/cleaner - Table 4-35	User	Inhalation	All	6.0E-02	2.4E-02	0.16
Dermal			21+	6.1E-02	0.49	2.5	
			16-20	6.6E-02	0.52	2.6	
			11-15	6.0E-02	0.48	2.4	
Bystander		Inhalation	All	2.1E-02	9.5E-02	0.65	
	Liquid degreaser/cleaner - Table 4-36	User	Inhalation	All	6.6E-03	6.2E-02	0.37
Dermal			21+	6.4E-02	0.51	3.8	
			16-20	6.8E-02	0.55	4.1	
			11-15	6.3E-02	0.50	3.8	
Bystander		Inhalation	All	2.7E-02	0.33	2.0	
	Aerosol gun scrubber - Table 4-37	User	Inhalation	All	13	12	21
Dermal			21+	6.4E-02	0.51	6.4	
			16-20	6.8E-02	0.54	6.8	
			11-15	6.2E-02	0.50	6.2	
Bystander		Inhalation	All	53	66	115	
	Liquid gun scrubber - Table 4-38	User	Inhalation	All	15	14	16
Dermal			21+	6.9E-02	0.55	4.1	
			16-20	7.3E-02	0.59	4.4	
			11-15	6.7E-02	0.54	4.0	
Bystander		Inhalation	All	62	77	80	
	Mold Release - Table 4-39	User	Inhalation	All	5.9E-02	0.56	5.5
Dermal			21+	6.1E-01	4.7	31	
			16-20	6.5E-01	5.0	33	
			11-15	6.0E-01	4.6	30	
Bystander		Inhalation	All	0.30	3.0	28	
	Aerosol Tire Cleaner - Table 4-40	User	Inhalation	All	6.2E-02	0.23	1.7
Dermal			21+	2.8E-01	1.1	4.8	

Life Cycle Stage/ Category	Subcategory/ Consumer Condition of Use Scenario	Population	Exposure Route and Duration	Age Group ^a	Acute Non-Cancer (benchmark MOE = 10)			
					High-Intensity User	Moderate-Intensity User	Low-Intensity User	
					16-20	21+	11-15	
		Bystander	Inhalation	All	1.4E-02	0.94	6.9	
			User	Inhalation	All	2.0E-02	0.10	0.53
				Dermal	21+	0.12	0.50	1.5
	16-20	0.13	0.53		1.6			
	11-15	0.12	0.49		1.5			
	Liquid Tire Cleaner - Table 4-41	Bystander	Inhalation	All	6.4E-02	0.42	2.2	
		Consumer Use - Lubricants and greases	Tap and Die Fluid - Table 4-42	User	Inhalation	All	6.6E-02	0.62
	Dermal				21+	0.68	5.2	20
				16-20	0.73	5.6	21	
				11-15	0.67	5.1	19	
Bystander	Inhalation		All	3.3E-01	3.3	18		
Penetrating lubricant - Table 4-43	User		Inhalation	All	8.3E-02	1.4	45	
				Dermal	21+	0.86	12	250
			16-20		0.91	13	267	
	11-15		0.84		12	245		
Bystander	Inhalation		All	4.1E-01	7.6	231		
Consumer Use - Adhesives and sealants	Solvent-based adhesives and sealants - Table 4-44	User	Inhalation	All	5.8E-02	1.8	146	
				21+	0.16	1.3	98	
			Dermal	16-20	0.17	1.4	105	
				11-15	0.15	1.3	96	
		Bystander	Inhalation	All	0.24	9.4	746	
	Mirror edge sealant - Table 4-45	User	Inhalation	All	0.29	2.0	43	
				21+	2.1	9.5	72	
			Dermal	16-20	2.2	10^b	77	
				11-15	2.0	9.2	71	
		Bystander	Inhalation	All	1.2	11	239	
	Tire repair cement/ sealer - Table 4-46	User	Inhalation	All	8.2E-02	1.5	16	
				21+	0.15	0.80	7.5	
			Dermal	16-20	0.16	0.86	8.1	
				11-15	0.15	0.78	7.4	
		Bystander	Inhalation	All	2.6E-01	13	133	
	Carpet cleaner -	User	Inhalation	All	1.8E-02	0.15	0.89	

Life Cycle Stage/ Category	Subcategory/ Consumer Condition of Use Scenario Table 4-47	Population	Exposure Route and Duration	Age Group ^a	Acute Non-Cancer (benchmark MOE = 10)		
					High-Intensity User	Moderate-Intensity User	Low-Intensity User
Consumer use - Cleaning and furniture care products		Dermal	21+	0.24	1.4	14	
			16-20	0.25	1.5	15	
			11-15	0.23	1.4	14	
		Bystander	Inhalation	All	8.4E-02	0.77	4.2
	Aerosol Spot Remover - Table 4-48	User	Inhalation	All	5.7E-02	0.48	2.7
			Dermal	21+	0.80	4.8	48
				16-20	0.85	5.1	51
		11-15		0.78	4.7	47	
	Bystander	Inhalation	All	0.28	2.6	14	
	Liquid Spot Remover - Table 4-49	User	Inhalation	All	2.4E-02	0.21	1.8
			Dermal	21+	0.34	2.1	31
				16-20	0.37	2.2	33
		11-15		0.34	2.0	30	
	Bystander	Inhalation	All	0.12	1.1	9.1	
	Consumer use - Arts, crafts, and hobby materials		User	Inhalation	All	0.10	0.65
Dermal				21+	2.4	9.5	84
				16-20	2.6	10 ^b	90
			11-15	2.4	9.3	82	
Bystander	Inhalation	All	0.43	3.5	17		
Consumer use - Apparel and footwear care products	Shoe polish - Table 4-51	User	Inhalation	All	0.35	2.9	16
			Dermal	21+	3.6	22	219
				16-20	3.9	23	234
		11-15		3.6	21	214	
Bystander	Inhalation	All	1.4	15	84		
Consumer use - Other consumer uses	Fabric spray - Table 4-52	User	Inhalation	All	7.3E-02	0.44	2.1
			Dermal	21+	2.1	4.7	27
				16-20	2.2	5.0	28
		11-15		2.0	4.6	26	
	Bystander	Inhalation	All	0.30	2.3	11	
	Film cleaner - Table 4-53	User	Inhalation	All	1.5E-02	9.4E-02	0.49
			Dermal	21+	0.35	1.4	12
				16-20	0.38	1.5	13
11-15		0.34		1.4	12		
Bystander	Inhalation	All	6.2E-02	0.51	2.5		

Life Cycle Stage/ Category	Subcategory/ Consumer Condition of Use Scenario	Population	Exposure Route and Duration	Age Group ^a	Acute Non-Cancer (benchmark MOE = 10)		
					High-Intensity User	Moderate-Intensity User	Low-Intensity User
	Hoof polish - Table 4-54	User	Inhalation	All	0.44	2045	12493
			Dermal	21+	2.9	9.5	84
				16-20	3.1	10 ^b	90
				11-15	2.8	9.3	82
		Bystander	Inhalation	All	88	3653	22309
	Pepper spray - Table 4-55	User	Inhalation	All	15	29	55
			Dermal	21+	16		
				16-20	17		
				11-15	15		
		Bystander	Not modeled - can be considered equal to user.				
	Toner aid - Table 4-56	User	Inhalation	All	0.11	0.68	3.6
			Dermal	21+	2.6	10 ^b	89
				16-20	2.7	11	95
11-15				2.5	9.8	87	
Bystander		Inhalation	All	0.45	3.7	18	

^a Inhalation exposures are based on a 2-zone model of air concentrations (Section 2.3.2.3.1) that are independent of any age-specific exposure factors.

^b If an MOE equal to the benchmark is not highlighted, the unrounded MOE is greater than the benchmark.

5 UNREASONABLE RISK DETERMINATION

5.1 Overview

In each Risk Evaluation under TSCA section 6(b), EPA determines whether a chemical substance presents an unreasonable risk of injury to health or the environment, under the conditions of use. These determinations do not consider costs or other non-risk factors. In making these determinations, EPA considers relevant risk-related factors, including, but not limited to: the effects of the chemical substance on health and human exposure to such substance under the conditions of use (including cancer and non-cancer risks); the effects of the chemical substance on the environment and environmental exposure under the conditions of use; the population exposed (including any potentially exposed or susceptible subpopulations (PESS)); the severity of hazard (including the nature of the hazard, the irreversibility of the hazard); and uncertainties. EPA also takes into consideration the Agency's confidence in the data used in the risk estimate. This includes an evaluation of the strengths, limitations and uncertainties associated with the information used to inform the risk estimate and the risk characterization. This approach is in keeping with the Agency's final rule, *Procedures for Chemical Risk Evaluation Under the Amended Toxic Substances Control Act* (82 FR 33726).²⁵

This section describes the final unreasonable risk determinations for the conditions of use in the scope of the Risk Evaluation. The final unreasonable risk determinations are based on the risk estimates and consideration of other risk-related factors in the final Risk Evaluation, which may differ from the draft Risk Evaluation due to peer review and public comments. The relevant risk-related factors for TCE are further explained in Section 5.1.1 below and in Section 4.3 and 4.4 of the risk characterization. In Section 5.1.1, the relevant risk-related factors are identified for each condition of use, such as the health effects considered, the use of high-end risk estimates to address PESS and other uncertainties relevant to each condition of use. Therefore, the final unreasonable risk determinations of some conditions of use may differ from those in the draft Risk Evaluation.

5.1.1 Human Health

EPA's Risk Evaluation identified non-cancer adverse effects from acute (immunosuppression) and chronic (autoimmunity) inhalation and dermal exposures to TCE, and cancer from chronic inhalation and dermal exposures to TCE. The health risk estimates for all conditions of use are in Section 4.5 (Table 4-59 and Table 4-60).

For the TCE Risk Evaluation, EPA identified as Potentially Exposed or Susceptible Subpopulations: workers and ONUs, including men and women of reproductive age, adolescents, and biologically susceptible subpopulations; and consumer users (age 11 and older) and bystanders (of any age group, including infants, toddlers, children, and elderly), including biologically susceptible subpopulations.

EPA evaluated exposures to workers, ONUs, consumer users, and bystanders using reasonably available monitoring and modeling data for inhalation and dermal exposures, as applicable. For example, EPA assumed that ONUs and bystanders do not have direct contact with TCE; therefore, non-cancer effects and cancer from dermal exposures to TCE are not expected and were not evaluated. Additionally, EPA did not evaluate chronic

²⁵ This risk determination is being issued under TSCA section 6(b) and the terms used, such as unreasonable risk, and the considerations discussed are specific to TSCA. Other statutes have different authorities and mandates and may involve risk considerations other than those discussed here.

41 exposures for consumer users and bystanders because EPA considered the frequency of consumer product use
42 to be too low to create chronic risk concerns. The description of the data used for human health exposure is in
43 Section 2.3. Uncertainties in the analysis are discussed in Section 4.3 and considered in the unreasonable risk
44 determination for each condition of use presented below in Section 5.2, including the fact that the dermal model
45 used does not address variability in exposure duration and frequency.

46

47 EPA did not evaluate risks to the general population, and as such the unreasonable risk determinations for
48 relevant conditions of use do not account for any risk to the general population. Additional details regarding the
49 general population are in Section 2.3.3.

50 **5.1.1.1 Non-Cancer Risks Estimates**

51 The risk estimates of non-cancer effects (MOEs) refer to adverse health effects associated with health endpoints
52 other than cancer, including to the body's organ systems, such as reproductive/developmental effects, cardiac
53 and lung effects, and kidney and liver effects. The MOE is the point of departure (POD) (an approximation of
54 the no-observed adverse effect level (NOAEL) or benchmark dose level (BMDL)) for a specific health endpoint
55 divided by the exposure concentration for the specific scenario of concern. Section 3.2.5 presents the PODs for
56 non-cancer effects for TCE and Section 4.2 presents the MOEs for non-cancer effects.

57

58 The MOEs are compared to a benchmark MOE. The benchmark MOE accounts for the total uncertainty in a
59 POD, including, as appropriate: (1) the variation in sensitivity among the members of the human population
60 (*i.e.*, intrahuman/intraspecies variability); (2) the uncertainty in extrapolating animal data to humans (*i.e.*,
61 interspecies variability); (3) the uncertainty in extrapolating from data obtained in a study with less-than-
62 lifetime exposure to lifetime exposure (*i.e.*, extrapolating from subchronic to chronic exposure); and (4) the
63 uncertainty in extrapolating from a lowest observed adverse effect level (LOAEL) rather than from a NOAEL.
64 A lower benchmark MOE (*e.g.*, 30) indicates greater certainty in the data (because fewer of the default UFs
65 relevant to a given POD as described above were applied). A higher benchmark MOE (*e.g.*, 1000) would
66 indicate more uncertainty for specific endpoints and scenarios. However, these are often not the only
67 uncertainties in a Risk Evaluation. The benchmark MOE for acute non-cancer risks for TCE is 10, and the
68 benchmark MOE for chronic non-cancer risks for TCE is 30. Additional information regarding the benchmark
69 MOE is in Section 4.2.1.

70 **5.1.1.2 Cancer Risks Estimates**

71 Cancer risk estimates represent the incremental increase in probability of an individual in an exposed
72 population developing cancer over a lifetime (excess lifetime cancer risk (ELCR)) following exposure to
73 the chemical. Standard cancer benchmarks used by EPA and other regulatory agencies are an increased
74 cancer risk above benchmarks ranging from 1 in 1,000,000 to 1 in 10,000 (*i.e.*, 1×10^{-6} to 1×10^{-4})
75 depending on the subpopulation exposed.²⁶

76

²⁶ As an example, when EPA's Office of Water in 2017 updated the Human Health Benchmarks for Pesticides, the benchmark for a "theoretical upper-bound excess lifetime cancer risk" from pesticides in drinking water was identified as 1 in 1,000,000 to 1 in 10,000 over a lifetime of exposure (EPA. Human Health Benchmarks for Pesticides: Updated 2017 Technical Document (pp.5). (EPA 822-R -17 -001). Washington, DC: U.S. Environmental Protection Agency, Office of Water. January 2017. <https://www.epa.gov/sites/production/files/2015-10/documents/hh-benchmarks-techdoc.pdf>). Similarly, EPA's approach under the Clean Air Act to evaluate residual risk and to develop standards is a two-step approach that "includes a presumptive limit on maximum individual lifetime [cancer] risk (MIR) of approximately 1 in 10 thousand" and consideration of whether emissions standards provide an ample margin of safety to protect public health "in consideration of all health information, including the number of persons at risk levels higher than approximately 1 in 1 million, as well as other relevant factors" (54 FR 38044, 38045, September 14, 1989).

77 EPA, consistent with 2017 NIOSH guidance,²⁷ used 1×10^{-4} as the benchmark for the purposes of this
78 unreasonable risk determination for individuals in industrial and commercial work environments. The 1×10^{-4} is
79 not a bright line and EPA has discretion to make unreasonable risk determinations based on other benchmarks
80 as appropriate.

81 **5.1.1.3 Determining Unreasonable Risk of Injury to Health**

82 Calculated risk estimates (MOEs or cancer risk estimates) can provide a risk profile by presenting a range of
83 estimates for different health effects for different conditions of use. A calculated MOE that is less than the
84 benchmark MOE supports a determination of unreasonable risk of injury to health, based on non-cancer effects.
85 Similarly, a calculated cancer risk estimate that is greater than the cancer benchmark supports a determination
86 of unreasonable risk of injury to health from cancer. Whether EPA makes a determination of unreasonable risk
87 depends upon other risk-related factors, such as the endpoint under consideration, the reversibility of effect,
88 exposure-related considerations (*e.g.*, duration, magnitude, or frequency of exposure, or population exposed),
89 and the confidence in the information used to inform the hazard and exposure values. A calculated MOE greater
90 than the benchmark MOE or a calculated cancer risk estimate less than the cancer benchmark, alone do not
91 support a determination of unreasonable risk, since EPA may consider other risk-based factors when making an
92 unreasonable risk determination.

93
94 When making an unreasonable risk determination based on injury to health of workers (who are one example of
95 PESS), EPA also makes assumptions regarding workplace practices and the implementation of the required
96 hierarchy of controls from OSHA. EPA assumes that feasible exposure controls, including engineering controls,
97 or use of personal protective equipment (PPE) are implemented in the workplace. EPA's decisions for
98 unreasonable risk to workers are based on high-end exposure estimates, in order to capture not only exposures
99 for PESS but also to account for the uncertainties related to whether or not workers are using PPE. However,
100 EPA does not assume that ONUs use PPE. For each condition of use, depending on the information available
101 and professional judgement, EPA assumes the use of appropriate respirators with APFs ranging from 10 to 50,
102 and gloves with a PF of 10 to 20. However, EPA assumes that for some conditions of use, the use of respirators
103 is not a standard industry practice, based on professional judgement given the burden associated with the use of
104 respirators, including the expense of the equipment and the necessity of fit-testing and training for proper use.
105 Similarly, EPA does not assume that it is a standard industry practice that workers in some small commercial
106 facilities (*e.g.*, those performing spot cleaning, wipe cleaning, shoe polishing, or hoof polishing; commercial
107 printing and copying) have a respiratory protection program or regularly employ dermal protection. Therefore,
108 the use of respirators and gloves is unlikely for workers in these facilities. Section 4.2.2 explains how EPA
109 considers the use of PPE for each occupational exposure scenario of the Risk Evaluation, and Table 4-9
110 summarizes the information. Once EPA has applied the appropriate PPE assumption for a particular condition
111 of use in each unreasonable risk determination, in those instances when EPA assumes PPE is used, EPA also
112 assumes that the PPE is used in a manner that achieves the stated APF or PF.

113
114 EPA identified several acute and chronic endpoints for non-cancer effects of TCE (*e.g.*, developmental toxicity,
115 reproductive toxicity, liver toxicity, kidney toxicity, neurotoxicity, and immunotoxicity). In Section 3.2.5.4.1
116 EPA identified the best overall non-cancer endpoints to be immunosuppression effects for acute inhalation and
117 dermal exposures, and autoimmunity effects for chronic inhalation and dermal exposures. EPA determined that
118 these were the best overall endpoints for Risk Evaluation under TSCA, based on the best available science,
119 weight of the scientific evidence, and confidence in the POD, and were used as the basis of risk conclusions in

²⁷ NIOSH Current intelligence bulletin 68: NIOSH chemical carcinogen policy (Whittaker et al. 2016).

120 Section 4.5.2 and risk determinations in Section 0. As described in EPA’s framework rule for Risk Evaluations
121 [82 FR 33726], weight of the scientific evidence includes consideration of the “strengths, limitations and
122 relevance of the information.” Neither the statute nor the framework rule requires that EPA choose the lowest
123 number and EPA believes that public health is best served when EPA relies upon the highest quality
124 information for which EPA has the greatest confidence.

125
126 Consistent with EPA guidance as indicated in the 2011 EPA TCE IRIS Assessment, in this Risk Evaluation
127 EPA concluded that TCE is carcinogenic to workers and ONUs by all routes of exposure. This is most strongly
128 supported by the data on kidney cancer. The cancer hazard analysis is described in Section 3.2.4.2. EPA
129 considered cancer risk estimates from chronic inhalation or dermal exposures in the unreasonable risk
130 determination.

131
132 When making a determination of unreasonable risk, the Agency has a higher degree of confidence where
133 uncertainty is low. Similarly, EPA has high confidence in the hazard and exposure characterizations when, for
134 example, the basis for characterizations is measured or monitoring data or a robust model and the hazards
135 identified for risk estimation are relevant for conditions of use. Where EPA has made assumptions in the
136 scientific evaluation, whether or not those assumptions are protective is also a consideration. Additionally, EPA
137 considers the central tendency and high-end exposure levels when determining the unreasonable risk. High-end
138 risk estimates (*e.g.*, 95th percentile) are generally intended to cover individuals or sub-populations with greater
139 exposure (PESS) as well as to capture individuals with sentinel exposure, and central tendency risk estimates
140 are generally estimates of average or typical exposure.

141
142 EPA may make a determination of no unreasonable risk for conditions of use where the substance’s hazard and
143 exposure potential, or where the risk-related factors described previously, lead the Agency to determine that the
144 risks are not unreasonable.

145 **5.1.2 Environment**

146 EPA calculated a risk quotient (RQ) to compare environmental concentrations against an effect level.
147 The environmental concentration is determined based on the levels of the chemical released to the
148 environment (*e.g.*, surface water, sediment, soil, biota) under the conditions of use, based on the fate
149 properties, release potential, and reasonably available environmental monitoring data. The effect level is
150 calculated using concentrations of concern that represent hazard data for aquatic, sediment-dwelling, and
151 terrestrial organisms. Section 4.1 provides more detail regarding the risk quotients for TCE.

152 **5.1.2.1 Determining Unreasonable Risk of Injury to the Environment**

153 An RQ equal to 1 indicates that the exposures are the same as the concentration that causes effects. An RQ less
154 than 1, when the exposure is less than the effect concentration, supports a determination that there is no
155 unreasonable risk of injury to the environment. An RQ greater than 1, when the exposure is greater than the
156 effect concentration, supports a determination that there is unreasonable risk of injury to the environment.
157 Consistent with EPA’s human health evaluations, other risk-based factors may be considered (*e.g.*, confidence
158 in the hazard and exposure characterization, duration, magnitude, uncertainty) for purposes of making an
159 unreasonable risk determination. Due to the volatile properties of TCE, EPA also considered when it was more
160 likely for acute or chronic exposure durations to occur.

161

162 EPA considered the effects on aquatic, sediment-dwelling, and terrestrial organisms. EPA provides estimates
 163 for environmental risk in Section 4.1 and Table 4-1, while the details for determining whether there is
 164 unreasonable risk to the environment are discussed in Section 5.2.2.

165 **5.2 Detailed Unreasonable Risk Determination by Condition of Use**

Table 5-1. Categories and Subcategories of Conditions of Use Included in the Scope of the Risk Evaluation

Life Cycle Stage	Category ^a	Subcategory ^b	Unreasonable Risk	Detailed Risk Determination
Manufacture	Domestic manufacture	Domestic manufacture	Yes	Sections 5.2.1.1, and 5.2.2
	Import	Import	Yes	Sections 5.2.1.2 and 5.2.2
Processing	Processing as a reactant/ intermediate	Processing as a reactant/intermediate in industrial gas manufacturing (<i>e.g.</i> , manufacture of fluorinated gases used as refrigerants, foam blowing agents and solvents)	Yes	Sections 5.2.1.3 and 5.2.2
	Processing - incorporation into formulation, mixture or reaction product	Solvents (for cleaning or degreasing); adhesives and sealant chemicals; solvents (which become part of product formulation or mixture) (<i>e.g.</i> , lubricants and greases, paints and coatings, other uses)	Yes	Sections 5.2.1.4 and 5.2.2
	Processing - incorporation into articles	Solvents (becomes an integral components of articles)	Yes	Sections 5.2.1.5 and 5.2.2
	Repackaging	Solvents (for cleaning or degreasing)	Yes	Sections 5.2.1.6 and 5.2.2
	Recycling	Recycling	Yes	Sections 5.2.1.7 and 5.2.2
Distribution in commerce	Distribution	Distribution	No	Sections 5.2.1.8 and 5.2.2
Industrial/commercial use	Solvent (for cleaning or degreasing)	Batch vapor degreaser (open-top)	Yes	Sections 5.2.1.9 and 5.2.2

Table 5-1. Categories and Subcategories of Conditions of Use Included in the Scope of the Risk Evaluation

Life Cycle Stage	Category ^a	Subcategory ^b	Unreasonable Risk	Detailed Risk Determination
		Batch vapor degreaser (closed-loop)	Yes	Sections 5.2.1.10 and 5.2.2
		In-line vapor degreaser (conveyorized)	Yes	Sections 5.2.1.11 and 5.2.2
		In-line vapor degreaser (web cleaner)	Yes	Sections 5.2.1.12 and 5.2.2
		Cold cleaner	Yes	Sections 5.2.1.13 and 5.2.2
		Aerosol spray degreaser/cleaner; mold release	Yes	Sections 5.2.1.14 and 5.2.2
	Lubricants and greases/lubricants and lubricant additives	Tap and die fluid	Yes	Sections 5.2.1.15 and 5.2.2
		Penetrating lubricant	Yes	Sections 5.2.1.16 and 5.2.2
	Adhesives and sealants	Solvent-based adhesives and sealants; tire repair cement/sealer; mirror edge sealant	Yes	Sections 5.2.1.17 and 5.2.2
	Functional fluids (closed systems)	Heat exchange fluid	Yes	Sections 5.2.1.18 and 5.2.2
	Paints and coatings	Diluent in solvent-based paints and coatings	Yes	Sections 5.2.1.19 and 5.2.2
	Cleaning and furniture care products	Carpet cleaner; wipe cleaner ^c	Yes	Sections 5.2.1.20 and 5.2.2.
	Laundry and dishwashing products	Spot remover ^d	Yes	Sections 5.2.1.21 5.2.2
	Arts, crafts and hobby materials	Fixatives and finishing spray coatings	Yes	Sections 5.2.1.22 and 5.2.2
	Corrosion inhibitors and anti-scaling agents	Corrosion inhibitors and anti-scaling agents	Yes	Sections 5.2.1.23 and 5.2.2
	Processing aids	Process solvent used in battery manufacture; process solvent used in polymer fiber spinning, fluoroelastomer manufacture, and	Yes	Sections 5.2.1.24 and 5.2.2

Table 5-1. Categories and Subcategories of Conditions of Use Included in the Scope of the Risk Evaluation

Life Cycle Stage	Category ^a	Subcategory ^b	Unreasonable Risk	Detailed Risk Determination
		Alcantara manufacture; extraction solvent used in caprolactam manufacture; precipitant used in beta-cyclodextrin manufacture		
	Ink, toner and colorant products	Toner aid	Yes	Sections 5.2.1.25 and 5.2.2
	Automotive care products	Brake and parts cleaners	Yes	Sections 5.2.1.26 , and 5.2.2
	Apparel and footwear care products	Shoe polish	Yes	Sections 5.2.1.27 and 5.2.2
	Other commercial uses	Hoof polishes; gun scrubber; pepper spray; other miscellaneous industrial and commercial uses	Yes	Sections 5.2.1.28 and 5.2.2
Consumer uses	Solvent (cleaning or degreasing)	Brake and parts cleaner	Yes	Sections 5.2.1.29 and 5.2.2
		Aerosol electronic degreaser/cleaner	Yes	Sections 5.2.1.30 and 5.2.2
		Liquid electronic degreaser/cleaner	Yes	Sections 5.2.1.31 and 5.2.2
		Aerosol spray degreaser/cleaner	Yes	Sections 5.2.1.32 and 5.2.2
		Liquid degreaser/cleaner	Yes	Sections 5.2.1.33 and 5.2.2
		Aerosol gun scrubber	Yes	Sections 5.2.1.34 and 5.2.2
		Liquid gun scrubber	Yes	Sections 5.2.1.35 and 5.2.2
		Mold release	Yes	Sections 5.2.1.36 and 5.2.2
		Aerosol tire cleaner	Yes	Sections 5.2.1.37 and 5.2.2
		Liquid tire cleaner	Yes	Sections 5.2.1.38 and 5.2.2

Table 5-1. Categories and Subcategories of Conditions of Use Included in the Scope of the Risk Evaluation

Life Cycle Stage	Category ^a	Subcategory ^b	Unreasonable Risk	Detailed Risk Determination
	Lubricants and greases	Tap and die fluid	Yes	Sections 5.2.1.39 and 5.2.2
		Penetrating lubricant	Yes	Sections 5.2.1.40 and 5.2.2
	Adhesives and sealants	Solvent-based adhesives and sealants	Yes	Sections 5.2.1.41 and 5.2.2
		Mirror edge sealant	Yes	Sections 5.2.1.42 and 5.2.2
		Tire repair cement/sealer	Yes	Sections 0 and 5.2.2
	Cleaning and furniture care products	Carpet cleaner	Yes	Sections 5.2.1.44 and 5.2.2
		Aerosol spot remover	Yes	Sections 5.2.1.45 and 5.2.2
		Liquid spot remover	Yes	Sections 5.2.1.46 and 5.2.2
	Arts, crafts, and hobby materials	Fixatives and finishing spray coatings	Yes	Sections 5.2.1.47 and 5.2.2
	Apparel and footwear care products	Shoe polish	Yes	Sections 5.2.1.48 and 5.2.2
	Other consumer uses	Fabric spray	Yes	Sections 5.2.1.49 and 5.2.2
		Film cleaner	Yes	Sections 5.2.1.50 and 5.2.2
		Hoof polish ^e	Yes	Sections 5.2.1.51 and 5.2.2
		Pepper spray	No	Sections 5.2.1.52 and 5.2.2
		Toner aid	Yes	Sections 5.2.1.53 and 5.2.2
Disposal	Disposal	Industrial pre-treatment	Yes	Sections 5.2.1.54 and 5.2.2
		Industrial wastewater treatment		
		Publicly owned treatment works (POTW)		

166 ^aThese categories of conditions of use appear in the Life Cycle Diagram, reflect CDR codes, and broadly
167 represent additional information regarding all conditions of use of TCE.
168 ^bThese subcategories reflect more specific information regarding the conditions of use of TCE.
169 ^cThis condition of use involves wipe cleaning. Note that the Problem Formulation described “cleaning wipes” as
170 a condition of use. This referred to the application of a product that is then wiped off, rather than a pre-wet
171 towelette.
172 ^dThis includes uses assessed in the (U.S. EPA, 2014b) risk assessment.
173 ^e“Hoof polish” is in EPA’s jurisdiction unless the article in question was also *intended for the diagnosis, cure,*
174 *mitigation, treatment, of disease or intended to affect the structure or function of the body of animals,* as described
175 in the FFDCA. EPA identified a single product for hoof polish containing TCE (U.S. EPA, 2017h), and this
176 product is intended for only cosmetic and not medical use. Therefore, “hoof polish” was evaluated as a COU,
177 applicable only to products restricted to cosmetic function.
178 *Although EPA has identified both industrial and commercial uses here for purposes of distinguishing scenarios
179 in this document, the Agency interprets the authority over “any manner or method of commercial use” under
180 TSCA section 6(a)(5) to reach both.
181

182 5.2.1 Human Health

183 5.2.1.1 Manufacture – Domestic manufacture (Domestic manufacture)

184
185 **Section 6(b)(4)(A) unreasonable risk determination for the domestic manufacture of TCE: Presents an**
186 **unreasonable risk of injury to health (workers and ONUs).**
187

188 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
189 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
190 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
191 **was unreasonable risk of cancer from chronic inhalation exposures at the high-end and dermal**
192 **exposures at the central tendency and high-end, even when assuming use of PPE. For ONUs, EPA**
193 **found that there was unreasonable risk of non-cancer effects (autoimmunity) from chronic**
194 **inhalation exposures at the central tendency, and of cancer from chronic inhalation exposures at**
195 **the central tendency.**
196

197 EPA’s determination that the domestic manufacturing of TCE presents an unreasonable risk is based on the
198 comparison of the risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As
199 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures from the condition of
200 use, and the uncertainties in the analysis (Section 4.3), including uncertainties related to the exposures for
201 ONUs:

- 202 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
203 estimates of non-cancer effects and cancer from chronic inhalation at the high-end, and the risk
204 estimates of non-cancer effects and cancer from chronic dermal exposures at the central tendency and
205 high-end support an unreasonable risk determination.
- 206 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
207 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
208 support an unreasonable risk determination.
- 209 • For ONUs, the risk estimates of non-cancer effects from acute inhalation exposures do not support an
210 unreasonable risk determination.
- 211 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
212 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers

- 213 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
214 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
215 • Inhalation exposures were assessed during manufacturing using monitoring data submitted by the
216 Halogenated Solvents Industry Alliance (HSIA) ([Halogenated Solvents Industry Alliance, 2018](#)) and
217 Arkema, Inc. ([Arkema, 2020](#)).
218 • Dermal exposures were assessed using modeled data.

219 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
220 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
221 domestic manufacturing of TCE.
222

223 5.2.1.2 Manufacture – Import (Import)

224
225 Section 6(b)(4)(A) unreasonable risk determination for the import of TCE: Presents an unreasonable
226 risk of injury to health (workers); does not present an unreasonable risk of injury to health (ONUs).
227

228 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
229 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
230 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
231 **was unreasonable risk of cancer from chronic dermal exposures at the central tendency and high-**
232 **end, even when assuming use of PPE.** For ONUs, EPA found that there was no unreasonable risk of
233 non-cancer effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at
234 the central tendency or of cancer from chronic inhalation exposures at the central tendency.
235

236 EPA’s determination that the import of TCE presents an unreasonable risk is based on the comparison of the
237 risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1,
238 EPA also considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
239 the analysis (Section 4.3), including uncertainties related to the exposures for ONUs:

- 240 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
241 effects from chronic inhalation exposures at the high-end support an unreasonable risk determination.
242 Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-cancer effects and
243 cancer from chronic dermal exposures at the central tendency and high-end support an unreasonable risk
244 determination.
245 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
246 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
247 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
248 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
249 support an unreasonable risk determination.
250 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
251 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
252 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
253 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
254 • Inhalation exposures were assessed based on monitoring data using the repackaging occupational
255 exposure scenario.
256 • Dermal exposures were assessed using modeled data.

257 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
258 support EPA’s determination that there is unreasonable risk of injury to health (workers) from the import of
259 TCE.
260

261 **5.2.1.3 Processing – Processing as a reactant/intermediate – Intermediate in**
262 **industrial gas manufacturing (e.g., manufacture of fluorinated gases used as**
263 **refrigerants, foam blowing agents and solvents) (Processing as a**
264 **reactant/intermediate)**

265
266 Section 6(b)(4)(A) unreasonable risk determination for the processing of TCE as a reactant/intermediate:
267 **Presents an unreasonable risk of injury to health (workers and ONUs).**
268

269 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
270 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
271 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
272 **was unreasonable risk of cancer from chronic inhalation exposures at the high-end and dermal**
273 **exposures at the central tendency and high-end, even when assuming use of PPE. For ONUs, EPA**
274 **found that there was unreasonable risk of non-cancer effects (autoimmunity) from chronic**
275 **inhalation exposures at the central tendency, and of cancer from chronic inhalation exposures at**
276 **the central tendency.**
277

278 EPA’s determination that the processing of TCE as a reactant/intermediate presents an unreasonable risk is
279 based on the comparison of the risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59).
280 As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures from the condition of
281 use, and the uncertainties in the analysis (Section 4.3), including uncertainties related to the exposures for
282 ONUs:

- 283 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
284 estimates of non-cancer effects and cancer from chronic inhalation at the high-end, and the risk
285 estimates of non-cancer effects and cancer from chronic dermal exposures at the central tendency and
286 high-end support an unreasonable risk determination.
- 287 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
288 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
289 support an unreasonable risk determination.
- 290 • For ONUs, the risk estimates of non-cancer effects from acute inhalation exposures do not support an
291 unreasonable risk determination.
- 292 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
293 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
294 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
295 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
- 296 • Inhalation exposures were assessed using monitoring data from the manufacture of TCE as surrogate
297 data for the processing condition of use. EPA did not identify inhalation exposure monitoring data
298 related to processing TCE as a reactant. EPA believes the handling and TCE concentrations for both
299 conditions of use to be similar.
- 300 • Dermal exposures were assessed using modeled data.

301 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
302 support EPA's determination that there is unreasonable risk of injury to health (workers and ONUs) from the
303 processing of TCE as a reactant/intermediate.
304

305 **5.2.1.4 Processing – Incorporation into formulation, mixture or reaction**
306 **product – Solvents (for cleaning or degreasing); adhesives and sealant chemicals;**
307 **solvents (which become part of product formulation or mixture) (e.g., lubricants**
308 **and greases, paints and coatings, other uses) (Processing into a formulation,**
309 **mixture, or reaction product)**

310
311 Section 6(b)(4)(A) unreasonable risk determination for the processing of TCE into a formulation,
312 mixture, or reaction product: Presents an unreasonable risk of injury to health (workers); does not
313 present an unreasonable risk of injury to health (ONUs).
314

315 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
316 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
317 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
318 **was unreasonable risk of cancer from chronic dermal exposures at the central tendency and high-**
319 **end, even when assuming use of PPE.** For ONUs, EPA found that there was no unreasonable risk of
320 non-cancer effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at
321 the central tendency or of cancer from chronic inhalation exposures at the central tendency.
322

323 EPA's determination that the processing of TCE into formulation, mixture, or reaction product presents an
324 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to the
325 benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of TCE, the
326 exposures from the condition of use, and the uncertainties in the analysis (Section 4.3), including uncertainties
327 related to the exposures for ONUs:

- 328 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
329 effects from chronic inhalation exposures at the high-end support an unreasonable risk determination.
330 Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-cancer effects and
331 cancer from chronic dermal exposures at the central tendency and high-end support an unreasonable risk
332 determination.
- 333 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
334 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
- 335 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
336 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
337 support an unreasonable risk determination.
- 338 • Based on EPA's analysis, the data for worker and ONU inhalation exposures could not be distinguished;
339 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
340 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers'
341 central tendency risk estimates from inhalation exposures when determining ONUs' unreasonable risk.
- 342 • Inhalation exposures were assessed using monitoring data from repackaging as a surrogate. EPA did not
343 identify inhalation exposure monitoring data related to using TCE when formulating aerosol and non-
344 aerosol products.
- 345 • Dermal exposures were assessed using modeled data.

346 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
347 support EPA's determination that there is unreasonable risk of injury to health (workers) from the processing of
348 TCE into formulation, mixture, or reaction product.
349

350 **5.2.1.5 Processing – Incorporation into articles – Solvents (becomes an** 351 **integral component of articles) (Processing into articles)**

352
353 Section 6(b)(4)(A) unreasonable risk determination for the processing of TCE into articles: **Presents an**
354 **unreasonable risk of injury to health (workers);** does not present an unreasonable risk of injury to
355 health (ONUs).
356

357 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
358 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
359 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
360 **was unreasonable risk of cancer from chronic dermal exposures at the central tendency and high-**
361 **end, even when assuming use of PPE.** For ONUs, EPA found that there was no unreasonable risk of
362 non-cancer effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at
363 the central tendency or of cancer from chronic inhalation exposures at the central tendency.
364

365 EPA's determination that the processing of TCE into articles presents an unreasonable risk is based on the
366 comparison of the risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As
367 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures from the condition of
368 use, and the uncertainties in the analysis (Section 4.3), including uncertainties related to the exposures for
369 ONUs:

- 370 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
371 effects from chronic inhalation exposures at the high-end support an unreasonable risk determination.
372 Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-cancer effects and
373 cancer from chronic dermal exposures at the central tendency and high-end support an unreasonable risk
374 determination.
- 375 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
376 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
- 377 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
378 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
379 support an unreasonable risk determination.
- 380 • Based on EPA's analysis, the data for worker and ONU inhalation exposures could not be distinguished;
381 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
382 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers'
383 central tendency risk estimates from inhalation exposures when determining ONUs' unreasonable risk.
- 384 • Inhalation exposures were assessed using monitoring data from repackaging as a surrogate. EPA did not
385 identify inhalation exposure monitoring data related to using TCE when formulating aerosol and non-
386 aerosol products.
- 387 • Dermal exposures were assessed using modeled data.

388 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
389 support EPA's determination that there is unreasonable risk of injury to health (workers) from the processing of
390 TCE into articles.

391 **5.2.1.6 Processing – Repackaging – Solvents (for cleaning or degreasing)**
392 **(Repackaging)**

393
394 Section 6(b)(4)(A) unreasonable risk determination for the repackaging of TCE: Presents an
395 **unreasonable risk of injury to health (workers);** does not present an unreasonable risk of injury to
396 health (ONUs).

397
398 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
399 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
400 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
401 **was unreasonable risk of cancer from chronic dermal exposures at the central tendency and high-**
402 **end, even when assuming use of PPE.** For ONUs, EPA found that there was no unreasonable risk of
403 non-cancer effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at
404 the central tendency or of cancer from chronic inhalation exposures at the central tendency.

405
406 EPA's determination that the repackaging of TCE presents an unreasonable risk is based on the comparison of
407 the risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section
408 5.1, EPA also considered the health effects of TCE, the exposures from the condition of use, and the
409 uncertainties in the analysis (Section 4.3), including uncertainties related to the exposures for ONUs:

- 410 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
411 effects from chronic inhalation exposures at the high-end support an unreasonable risk determination.
412 Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-cancer effects and
413 cancer from chronic dermal exposures at the central tendency and high-end support an unreasonable risk
414 determination.
- 415 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
416 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
- 417 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
418 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
419 support an unreasonable risk determination.
- 420 • Based on EPA's analysis, the data for worker and ONU inhalation exposures could not be distinguished;
421 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
422 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers'
423 central tendency risk estimates from inhalation exposures when determining ONUs' unreasonable risk.
- 424 • Inhalation exposures were assessed based on monitoring data using the repackaging occupational
425 exposure scenario.
- 426 • Dermal exposures were assessed using modeled data.

427 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
428 support EPA's determination that there is unreasonable risk of injury to health (workers) from the repackaging
429 of TCE.

431 **5.2.1.7 Processing – Recycling – Recycling (Recycling)**

432
433 Section 6(b)(4)(A) unreasonable risk determination for the recycling of TCE: Presents an
434 **unreasonable risk of injury to health (workers);** does not present an unreasonable risk of injury to
435 health (ONUs).

436

437 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
438 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
439 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
440 **was unreasonable risk of cancer from chronic dermal exposures at the central tendency and high-**
441 **end, even when assuming use of PPE.** For ONUs, EPA found that there was no unreasonable risk of
442 non-cancer effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at
443 the central tendency or of cancer from chronic inhalation exposures at the central tendency.
444

445 EPA's determination that the recycling of TCE presents an unreasonable risk is based on the comparison of the
446 risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1,
447 EPA also considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
448 the analysis (Section 4.3), including uncertainties related to the exposures for ONUs:

- 449 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
450 effects from chronic inhalation exposures at the high-end support an unreasonable risk determination.
451 Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-cancer effects and
452 cancer from chronic dermal exposures at the central tendency and high-end support an unreasonable risk
453 determination.
- 454 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
455 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
- 456 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
457 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
458 support an unreasonable risk determination.
- 459 • Based on EPA's analysis, the data for worker and ONU inhalation exposures could not be distinguished;
460 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
461 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers'
462 central tendency risk estimates from inhalation exposures when determining ONUs' unreasonable risk.
- 463 • Inhalation exposures were assessed using monitoring data from repackaging as a surrogate for recycling.
- 464 • Dermal exposures were assessed using modeled data.

465 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
466 support EPA's determination that there is unreasonable risk of injury to health (workers) from the recycling of
467 TCE.
468

469 **5.2.1.8 Distribution in Commerce– Distribution (Distribution in commerce)**

470
471 Section 6(b)(4)(A) unreasonable risk determination for distribution of TCE: Does not present an
472 unreasonable risk of injury to health (workers and ONUs).
473

474 For the purposes of the unreasonable risk determination, distribution in commerce of TCE is the
475 transportation associated with the moving of TCE in commerce. EPA is assuming that workers and
476 ONUs will not be handling TCE because the loading and unloading activities are associated with other
477 conditions of use and EPA assumes transportation of TCE is in compliance with existing regulations for
478 the transportation of hazardous materials ([49 CFR 172](#)). Emissions are therefore minimal during
479 transportation, so there is limited exposure (with the exception of spills and leaks, which are outside the
480 scope of the Risk Evaluation). Based on the limited emissions and exposures from the transportation of

481 chemicals, EPA determined there is no unreasonable risk of injury to health (workers and ONUs) from
482 the distribution in commerce of TCE.
483

484 **5.2.1.9 Industrial/Commercial Use – Solvent (for cleaning or degreasing) –**
485 **Batch vapor degreaser (open-top) (Solvent for open-top batch vapor degreasing)**
486

487 Section 6(b)(4)(A) unreasonable risk determination for the industrial and commercial use of TCE as a
488 solvent for open-top batch vapor degreasing: Presents an unreasonable risk of injury to health
489 (workers and ONUs).
490

491 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
492 **(immunosuppression) inhalation exposures and from chronic (autoimmunity) inhalation and**
493 **dermal exposures at the central tendency and high-end, even when assuming use of PPE. In**
494 **addition, for workers, EPA found that there was unreasonable risk of cancer from chronic**
495 **inhalation and dermal exposures at the central tendency and high-end, even when assuming use of**
496 **PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from acute**
497 **(immunosuppression) and chronic (autoimmunity) inhalation exposures at the central tendency**
498 **and high-end, and of cancer from chronic inhalation exposures at the central tendency and high-**
499 **end.**
500

501 EPA’s determination that the industrial and commercial use of TCE as a solvent for open-top batch
502 vapor degreasing presents an unreasonable risk is based on the comparison of the risk estimates for non-
503 cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also
504 considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
505 the analysis (Section 4.3):

- 506 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
507 effects from acute and chronic inhalation exposures, and of cancer from chronic inhalation exposures at
508 the central tendency and high-end support an unreasonable risk determination. Similarly, when assuming
509 use of gloves with PF of 20, the risk estimates of non-cancer effects and cancer from chronic dermal
510 exposures at the central tendency and high-end support an unreasonable risk determination.
- 511 • For workers, when assuming the use of gloves with PF of 20, the risk estimates of non-cancer effects
512 from acute dermal exposure at the high-end do not support an unreasonable risk determination.
- 513 • Inhalation exposures for workers and ONUs were assessed using monitoring data from NIOSH
514 investigations at twelve sites using TCE as a degreasing solvent in OTVDs. Due to the large variety in
515 shop types that may use TCE as a vapor degreasing solvent, it is unclear how representative these data
516 are of a “typical” shop. Therefore, EPA supplemented the identified monitoring data using the Open-
517 Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model. EPA’s inhalation exposure
518 modeling is based on a near-field/far-field approach, where a vapor generation source located inside the
519 near-field diffuses into the surrounding environment. Near-field exposure represents exposure
520 concentrations for workers who directly operate the vapor degreasing equipment, whereas far-field
521 exposure represents exposure concentrations for occupational non-users (*i.e.*, workers in the surrounding
522 area who do not handle the degreasing equipment). Assumptions and key sources of uncertainty for
523 occupational exposures, including the near-field/ far-field framework are described in Section 2.3.1.3.
524 These estimates were used for determining worker and ONU risks.
- 525 • Dermal exposures were assessed using modeled data.

526 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
527 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
528 industrial and commercial use of TCE as a solvent for open-top batch vapor degreasing.
529

530 **5.2.1.10 Industrial/Commercial Use – Solvent (for cleaning or degreasing) –**
531 **Batch vapor degreaser (closed-loop) (Solvent for closed-loop batch vapor**
532 **degreasing)**

534 Section 6(b)(4)(A) unreasonable risk determination for the industrial and commercial use of TCE as a
535 solvent for closed-loop batch vapor degreasing: Presents an unreasonable risk of injury to health
536 (workers and ONUs).
537

538 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
539 **from chronic inhalation and dermal exposures at the central tendency and high-end, even when**
540 **assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of**
541 **cancer from chronic dermal exposures at the central tendency and high-end, even when assuming**
542 **use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from**
543 **acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the central**
544 **tendency, and of cancer from chronic inhalation exposures at the central tendency.**
545

546 EPA’s determination that the industrial and commercial use of TCE as a solvent for closed-loop batch
547 vapor degreasing presents an unreasonable risk is based on the comparison of the risk estimates for non-
548 cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also
549 considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
550 the analysis (Section 4.3), including uncertainties related to the exposures for ONUs:

- 551 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
552 effects from chronic inhalation exposures at the central tendency and high-end support an unreasonable
553 risk determination. Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-
554 cancer effects and cancer from chronic dermal exposures at the central tendency and high-end support
555 an unreasonable risk determination.
- 556 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
557 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
558 support an unreasonable risk determination.
- 559 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
560 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
- 561 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
562 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
563 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
564 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
- 565 • Inhalation exposures were assessed using exposure monitoring data from a Chemical Safety report
566 where TCE is used in closed degreasing operations. EPA assumed these reasonably available data are of
567 a “typical” batch closed-loop degreasing shop.
- 568 • Dermal exposures were assessed using modeled data.

569 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
570 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
571 industrial and commercial use of TCE as a solvent for closed-loop batch vapor degreasing.
572

573 **5.2.1.11 Industrial/Commercial Use – Solvent (for cleaning or degreasing) –**
574 **In-line vapor degreaser (conveyorized) (Solvent for in-line conveyorized vapor**
575 **degreasing)**

576
577 Section 6(b)(4)(A) unreasonable risk determination for the industrial and commercial use of TCE as a
578 solvent for in-line conveyorized vapor degreasing: Presents an unreasonable risk of injury to health
579 (workers and ONUs).
580

581 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
582 **(immunosuppression) inhalation exposures and from chronic (autoimmunity) inhalation and**
583 **dermal exposures at the central tendency and high-end, even when assuming use of PPE. In**
584 **addition, for workers, EPA found that there was unreasonable risk of cancer from chronic**
585 **inhalation and dermal exposures at the central tendency and high-end, even when assuming use of**
586 **PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from acute**
587 **(immunosuppression) and chronic (autoimmunity) inhalation exposures at the central tendency,**
588 **and of cancer from chronic inhalation exposures at the central tendency.**
589

590 EPA’s determination that the industrial and commercial use of TCE as a solvent for in-line conveyorized
591 vapor degreasing presents an unreasonable risk is based on the comparison of the risk estimates for non-
592 cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also
593 considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
594 the analysis (Section 4.3), including uncertainties related to the exposures for ONUs:

- 595 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
596 effects from acute and chronic inhalation exposures, and of cancer from chronic inhalation exposures at
597 the central tendency and high-end support an unreasonable risk determination. Similarly, when assuming
598 use of gloves with PF of 20, the risk estimates of non-cancer effects and cancer from chronic dermal
599 exposures at the central tendency and high-end support an unreasonable risk determination.
- 600 • For workers, when assuming the use of gloves with PF of 20, the risk estimates of non-cancer effects
601 from acute dermal exposure at the high-end do not support an unreasonable risk determination.
- 602 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
603 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
604 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
605 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
- 606 • Inhalation exposures for workers were assessed using monitoring data from NIOSH investigations at
607 two sites using TCE in conveyorized vapor degreasing. Due to the large variety in shop types that may
608 use TCE as a vapor degreasing solvent, it is unclear how representative these data are of a “typical”
609 shop. Therefore, EPA supplemented the identified monitoring data using the Conveyorized Degreasing
610 Near-Field/Far-Field Inhalation Exposure Model. Near-field exposure represents exposure
611 concentrations for workers who directly operate the vapor degreasing equipment, whereas far-field
612 exposure represents exposure concentrations for occupational non-users (*i.e.*, workers in the surrounding
613 area who do not handle the degreasing equipment).
- 614 • Dermal exposures were assessed using modeled data.

615 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
616 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
617 industrial and commercial use of TCE as a solvent for in-line conveyORIZED vapor degreasing.
618

619 **5.2.1.12 Industrial/Commercial Use – Solvent (for cleaning or degreasing) –**
620 **In-line vapor degreaser (web cleaner) (Solvent for in-line web cleaner vapor**
621 **degreasing)**
622

623 Section 6(b)(4)(A) unreasonable risk determination for the industrial and commercial use of TCE as a
624 solvent for in-line web cleaner vapor degreasing: Presents an unreasonable risk of injury to health
625 (workers and ONUs).
626

627 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
628 **(immunosuppression) inhalation exposures at the high-end and from chronic (autoimmunity)**
629 **inhalation and dermal exposures at the central tendency and high-end, even when assuming use of**
630 **PPE. In addition, for workers, EPA found that there was unreasonable risk of cancer from**
631 **chronic inhalation and dermal exposures at the central tendency and high-end, even when**
632 **assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
633 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the**
634 **central tendency and high-end, and of cancer from chronic inhalation exposures at the central**
635 **tendency and high-end.**
636

637 EPA’s determination that the industrial and commercial use of TCE as a solvent for in-line web cleaner
638 vapor degreasing presents an unreasonable risk is based on the comparison of the risk estimates for non-
639 cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also
640 considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
641 the analysis (Section 4.3):

- 642 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
643 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from
644 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
645 determination. Similarly, when assuming the use of gloves with PF of 20, the risk estimates of non-
646 cancer effects and cancer from chronic dermal exposures support an unreasonable risk determination.
- 647 • For workers, when assuming the use of gloves with PF of 20, the risk estimates of non-cancer effects
648 from acute dermal exposure at the high-end do not support an unreasonable risk determination.
- 649 • Inhalation exposures for workers and ONUs were assessed using the Web Degreasing Near-Field/Far-
650 Field Inhalation Exposure Model. EPA did not identify any inhalation exposure monitoring data related
651 to the use of TCE in web degreasing. EPA’s inhalation exposure modeling is based on a near-field/far-
652 field approach, where a vapor generation source located inside the near-field diffuses into the
653 surrounding environment. Near-field exposure represents exposure concentrations for workers who
654 directly operate the vapor degreasing equipment, whereas far-field exposure represents exposure
655 concentrations for occupational non-users (*i.e.*, workers in the surrounding area who do not handle the
656 degreasing equipment). Assumptions and key sources of uncertainty for occupational exposures,
657 including the near-field/ far-field framework, are described in Section 2.3.1.3. These estimates were
658 used for determining worker and ONU risks.
- 659 • Dermal exposures were assessed using modeled data.
660

661 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
662 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
663 industrial and commercial use of TCE as a solvent for in-line web cleaner vapor degreasing.
664

665 **5.2.1.13 Industrial/Commercial Use – Solvent (for cleaning or degreasing) –**
666 **Cold cleaners (Solvent for cold cleaning)**

667 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE as a
668 solvent for cold cleaning: Presents an unreasonable risk of injury to health (workers and ONUs).
669

670
671 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
672 **(immunosuppression) inhalation exposures at the high-end and from chronic (autoimmunity)**
673 **inhalation and dermal exposures at the central tendency and high-end, even when assuming use of**
674 **PPE. In addition, for workers, EPA found that there was unreasonable risk of cancer from**
675 **chronic inhalation and dermal exposures at the central tendency and high-end, even when**
676 **assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
677 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the**
678 **central tendency and high-end, and of cancer from chronic inhalation exposures at the central**
679 **tendency and high-end.**

680
681 EPA’s determination that the industrial and commercial use of TCE as a solvent for cold cleaning
682 presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and
683 cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health
684 effects of TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section
685 4.3):

- 686 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
687 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from
688 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
689 determination. Similarly, when assuming the use of glove with PF of 20, the risk estimates of non-
690 cancer effects and cancer from chronic dermal exposures at the central tendency and high-end support
691 an unreasonable risk determination.
- 692 • For workers, when assuming the use of gloves with PF of 20, the risk estimates of non-cancer effects
693 from acute dermal exposure at the high-end do not support an unreasonable risk determination.
- 694 • Inhalation exposures for workers and ONUs were assessed using the Cold Cleaning Near-Field/Far-
695 Field Inhalation Exposure Model. EPA did not identify inhalation exposure monitoring data for the Cold
696 Cleaning condition of use. EPA’s inhalation exposure modeling is based on a near-field/far-field
697 approach, where a vapor generation source located inside the near-field diffuses into the surrounding
698 environment. Near-field exposure represents exposure concentrations for workers who directly operate
699 the vapor degreasing equipment, whereas far-field exposure represents exposure concentrations for
700 occupational non-users (*i.e.*, workers in the surrounding area who do not handle the degreasing
701 equipment). Assumptions and key sources of uncertainty for occupational exposures, including the near-
702 field/ far-field framework are described in Section 2.3.1.3. These estimates were used for determining
703 worker and ONU risks.
- 704 • Dermal exposures were assessed using modeled data.

705 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
706 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
707 industrial and commercial use of TCE as a solvent for cold cleaning.
708

709 **5.2.1.14 Industrial/Commercial Use – Solvent (for cleaning or degreasing) –**
710 **Aerosol spray degreaser/cleaner; mold release (Solvent for aerosol spray**
711 **degreaser/cleaner and mold release)**

712
713 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE as a
714 solvent for aerosol spray degreaser/cleaner and mold release: **Presents an unreasonable risk of injury**
715 **to health (workers and ONUs).**
716

717 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
718 **(immunosuppression) inhalation and dermal exposures at the high-end, and from chronic**
719 **(autoimmunity) inhalation and dermal exposures at the central tendency and high-end, even when**
720 **assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of**
721 **cancer from chronic inhalation and dermal exposures at the central tendency and high-end, even**
722 **when assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
723 **effects from acute (immunosuppression) inhalation exposures at the high-end, from chronic**
724 **(autoimmunity) inhalation exposures at the central tendency and high-end, and of cancer from**
725 **chronic inhalation exposures at the central tendency and high-end.**
726

727 EPA’s determination that the industrial and commercial use of TCE as a solvent for aerosol spray
728 degreaser/cleaner and mold release presents an unreasonable risk is based on the comparison of the risk
729 estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1,
730 EPA also considered the health effects of TCE, the exposures from the condition of use, and the
731 uncertainties in the analysis (Section 4.3):

- 732 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
733 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end, and the risk
734 estimates of non-cancer effects and cancer from chronic inhalation and dermal exposures at the central
735 tendency and high-end support an unreasonable risk determination.
- 736 • Inhalation exposures for workers and ONUs were assessed using the Brake Servicing Near-field/Far-
737 field Exposure Model. EPA did not identify inhalation exposure monitoring data related to the use of
738 TCE in aerosol degreasers, and used the brake servicing model as a representative scenario for this
739 condition of use. EPA’s inhalation exposure modeling is based on a near-field/far-field approach, where
740 a vapor generation source located inside the near-field diffuses into the surrounding environment. Near-
741 field exposure represents exposure concentrations for workers who directly operate the vapor degreasing
742 equipment, whereas far-field exposure represents exposure concentrations for occupational non-users
743 (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment). Assumptions and
744 key sources of uncertainty for occupational exposures, including the near-field/ far-field framework are
745 described in Section 2.3.1.3. These estimates were used for determining worker and ONU risks.
- 746 • Dermal exposures were assessed using modeled data.
747

748 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
749 support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the
750 industrial and commercial use of TCE as a solvent for aerosol spray degreaser/cleaner and mold release.

751 **5.2.1.15 Industrial/Commercial Use – Lubricants and greases/lubricants and**
752 **lubricant additives – Tap and die fluid (Tap and die fluid)**
753

754 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in tap and
755 die fluid: Presents an unreasonable risk of injury to health (workers and ONUs).
756

757 **For workers, EPA found that there was unreasonable risk of non-cancer effects from chronic**
758 **(autoimmunity) inhalation exposures at the high-end and dermal exposures at the central**
759 **tendency and high-end, even when assuming use of PPE. In addition, for workers, EPA found that**
760 **there was unreasonable risk of cancer from chronic dermal exposures at the central tendency and**
761 **high-end, even when assuming use of PPE. For ONUs, EPA found that there was unreasonable**
762 **risk of non-cancer effects from chronic (autoimmunity) inhalation exposures at the central**
763 **tendency, and of cancer from chronic inhalation exposures at the central tendency.**
764

765 EPA's determination that the industrial and commercial use of TCE in tap and die fluid presents an
766 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to
767 the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
768 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3),
769 including uncertainties related to the exposures for ONUs:

- 770 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
771 effects from chronic inhalation at the high-end support an unreasonable risk determination. Similarly,
772 when assuming the use of gloves with PF of 20 the risk estimates of non-cancer effects and cancer from
773 chronic dermal exposures at the central tendency and high-end support an unreasonable risk
774 determination.
- 775 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
776 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
777 support an unreasonable risk determination, and when assuming the use of respirators with APF of 50,
778 the risk estimates of cancer from chronic inhalation exposures at the high-end do not support an
779 unreasonable risk determination.
- 780 • Based on EPA's analysis, the data for worker and ONU inhalation exposures could not be distinguished;
781 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
782 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers'
783 central tendency risk estimates from inhalation exposures when determining ONUs' unreasonable risk.
- 784 • Inhalation exposures were assessed using monitoring data from OSHA facility inspections at two sites
785 using TCE in metalworking fluids.
- 786 • Dermal exposures were assessed using modeled data.

787 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
788 support EPA's determination that there is unreasonable risk of injury to health (workers and ONUs) from the
789 industrial and commercial use of TCE in tap and die fluid.
790

791 **5.2.1.16 Industrial/Commercial Use – Lubricants and greases/lubricants and**
792 **lubricant additives – Penetrating lubricant (Penetrating lubricant)**
793

794 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in
795 penetrating lubricant: Presents an unreasonable risk of injury to health (workers and ONUs).

796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841

For workers, EPA found that there was unreasonable risk of non-cancer effects from acute (immunosuppression) inhalation and dermal exposures at the high-end, and from chronic (autoimmunity) inhalation and dermal exposures at the central tendency and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of cancer from chronic inhalation and dermal exposures at the central tendency and high-end, even when assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from acute (immunosuppression) inhalation exposures at the high-end, from chronic (autoimmunity) inhalation exposures at the central tendency and high-end, and of cancer from chronic inhalation exposures at the central tendency and high-end.

EPA’s determination that the industrial and commercial use of TCE in penetrating lubricant presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3):

- For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end, and the risk estimates of non-cancer effects and cancer from chronic inhalation and dermal exposures at the central tendency and high-end support an unreasonable risk determination.
- Inhalation exposures for workers and ONUs were assessed using the Brake Servicing Near-field/Far-field Exposure Model. EPA did not identify inhalation exposure monitoring data related to this use of TCE, and used the brake servicing model as a representative scenario for this condition of use. EPA’s inhalation exposure modeling is based on a near-field/far-field approach, where a vapor generation source located inside the near-field diffuses into the surrounding environment. Near-field exposure represents exposure concentrations for workers who directly operate the vapor degreasing equipment, whereas far-field exposure represents exposure concentrations for occupational non-users (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment). Assumptions and key sources of uncertainty for occupational exposures, including the near-field/ far-field framework are described in Section 2.3.1.3. These estimates were used for determining worker and ONU risks.
- Dermal exposures were assessed using modeled data.

In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers and ONUs) from the industrial and commercial use of TCE in penetrating lubricant.

5.2.1.17 Industrial/Commercial Use – Adhesives and sealants – Solvent-based adhesives and sealants; tire repair cement/sealer; mirror edge sealant (Adhesives and sealants)

Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in an adhesives and sealants: Presents an unreasonable risk of injury to health (workers and ONUs).

For workers, EPA found that there was unreasonable risk of non-cancer effects from acute (immunosuppression) inhalation and dermal exposures at the high-end, and from chronic (autoimmunity) inhalation and dermal exposures at the central tendency and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of

842 **cancer from chronic inhalation and dermal exposures at the central tendency and high-end, even**
843 **when assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
844 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the**
845 **central tendency and high-end, and of cancer from chronic inhalation exposures at the central**
846 **tendency and high-end.**

847
848 EPA’s determination that the industrial and commercial use of TCE in adhesives and sealants presents
849 an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer
850 to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
851 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3):

- 852 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
853 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from
854 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
855 determination. Similarly, when assuming the use of gloves with PF of 10 for commercial scenarios, the
856 risk estimates of non-cancer effects from acute dermal exposures at the high-end, and of non-cancer
857 effects and cancer from chronic dermal exposures at the central tendency and high-end support an
858 unreasonable risk determination. When assuming the use of gloves with PF of 20 for industrial
859 scenarios, the risk estimates of non-cancer effects and cancer from chronic dermal exposures at the
860 central tendency and high-end support an unreasonable risk determination.
- 861 • Inhalation exposures for workers and ONUs were assessed using monitoring data from a NIOSH Health
862 Hazard Evaluation report ([Chrostek, 1981](#)) using TCE in coating applications and from OSHA facility
863 inspections ([OSHA, 2017](#)) at three sites using TCE in adhesives and coatings. The OSHA data also
864 provided two data points where the worker job description was “foreman.” EPA assumed this data is
865 applicable to ONU exposure.
- 866 • Dermal exposures were assessed using modeled data.

867 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
868 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
869 and ONUs) from the industrial and commercial use of TCE in adhesives and sealants.
870

871 **5.2.1.18 Industrial/Commercial Use – Functional fluids (closed systems) – Heat** 872 **exchange fluid (Functional fluids)**

873
874 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in
875 functional fluids: Presents an unreasonable risk of injury to health (workers and ONUs).

876
877 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
878 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
879 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
880 **was unreasonable risk of cancer from chronic inhalation exposures at the high-end and dermal**
881 **exposures at the central tendency and high-end, even when assuming use of PPE. For ONUs, EPA**
882 **found that there was unreasonable risk of non-cancer effects (autoimmunity) from chronic**
883 **inhalation exposures at the central tendency, and of cancer from chronic inhalation exposures at**
884 **the central tendency.**

885
886 EPA’s determination that the industrial and commercial use of TCE in functional fluids presents an
887 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to

888 the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
889 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3),
890 including uncertainties related to the exposures for ONUs:

- 891 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
892 estimates of non-cancer effects and cancer from chronic inhalation at the high-end, and the risk
893 estimates of non-cancer effects and cancer from chronic dermal exposures at the central tendency and
894 high-end support an unreasonable risk determination.
- 895 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
896 estimates of non-cancer effects from acute inhalation and dermal exposures do not support an
897 unreasonable risk determination.
- 898 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
899 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
900 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
901 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
- 902 • Inhalation exposures were assessed using monitoring data from loading/unloading TCE during
903 manufacturing as a surrogate for this condition of use. EPA did not identify inhalation exposure
904 monitoring data related to using TCE for other industrial uses.
- 905 • Dermal exposures were assessed using modeled data.

906 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
907 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
908 and ONUs) from the industrial and commercial use of TCE in functional fluids.
909

910 **5.2.1.19 Industrial/Commercial Use – Paints and coatings – Diluent in solvent-** 911 **based paints and coatings (Paints and coatings diluent)**

913 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in paints
914 and coatings diluent: Presents an unreasonable risk of injury to health (workers and ONUs).

916 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
917 **(immunosuppression) inhalation and dermal exposures at the high-end, and from chronic**
918 **(autoimmunity) inhalation and dermal exposures at the central tendency and high-end, even when**
919 **assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of**
920 **cancer from chronic inhalation and dermal exposures at the central tendency and high-end, even**
921 **when assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
922 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the**
923 **central tendency and high-end, and of cancer from chronic inhalation exposures at the central**
924 **tendency and high-end.**

926 EPA’s determination that the industrial and commercial use of TCE in paints and coatings diluent
927 presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and
928 cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health
929 effects of TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section
930 4.3):

- 931 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
932 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from

- 933 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
934 determination. Similarly, when assuming the use of gloves with PF of 10, the risk estimates of non-
935 cancer effects from acute dermal exposures at the high-end, and of non-cancer effects and cancer from
936 chronic dermal exposures at the central tendency and high-end support an unreasonable risk
937 determination.
- 938 • Inhalation exposures for workers and ONUs were assessed using monitoring data from a NIOSH Health
939 Hazard Evaluation report ([Chrostek, 1981](#)) using TCE in coating applications and from OSHA facility
940 inspections ([OSHA, 2017](#)) at three sites using TCE in adhesives and coatings. The OSHA data also
941 provided two data points where the worker job description was “foreman.” EPA assumed this data is
942 applicable to ONU exposure.
 - 943 • Dermal exposures were assessed using modeled data.

944 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
945 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
946 and ONUs) from the industrial and commercial use of TCE in paints and coatings diluent.
947

948 **5.2.1.20 Industrial/Commercial Use – Cleaning and furniture care products –** 949 **Carpet cleaner; wipe cleaning (Carpet cleaner and wipe cleaning)**

950 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in carpet
951 cleaner and wipe cleaning: Presents an unreasonable risk of injury to health (workers and ONUs).
952

953 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
954 **(immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
955 **chronic inhalation exposures at the central tendency and high-end, without assuming use of**
956 **respirators. In addition, for workers, EPA found that there was unreasonable risk of non-cancer**
957 **effects from acute (immunosuppression) and chronic (autoimmunity) dermal exposures, and of**
958 **cancer from chronic dermal exposures at the central tendency and high-end, without assuming use**
959 **of gloves. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from**
960 **acute (immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
961 **chronic inhalation exposures at the central tendency and high-end.**
962

963 EPA’s determination that the industrial and commercial use of TCE in carpet cleaner and wipe cleaning
964 presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and
965 cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health
966 effects of TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section
967 4.3):
968

- 969 • Based on professional judgment regarding practices at small commercial facilities performing carpet
970 cleaning and wipe cleaning, EPA assumes workers are unlikely to wear respiratory protection or
971 regularly employ dermal protection for this condition of use.
- 972 • EPA identified minimal inhalation exposure monitoring data related to the spot cleaning using TCE.
973 Therefore, EPA supplemented the identified monitoring data using the Near-field/Far-field Exposure
974 Model. EPA’s inhalation exposure modeling is based on a near-field/far-field approach, where a vapor
975 generation source located inside the near-field diffuses into the surrounding environment. Near-field
976 exposure represents exposure concentrations for workers who directly operate the vapor degreasing
977 equipment, whereas far-field exposure represents exposure concentrations for occupational non-users

978 (i.e., workers in the surrounding area who do not handle the degreasing equipment). Assumptions and
979 key sources of uncertainty for occupational exposures, including the near-field/ far-field framework are
980 described in Section 2.3.1.3. These estimates were used for determining worker and ONU risks.
981

- Dermal exposures were assessed using modeled data.

982 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
983 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
984 and ONUs) from the industrial and commercial use of TCE in carpet cleaner and wipe cleaning.
985

986 **5.2.1.21 Industrial/Commercial Use – Laundry and dishwashing products –** 987 **Spot remover (Spot remover)**

988

989 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in spot
990 remover: Presents an unreasonable risk of injury to health (workers and ONUs).

991

992 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
993 **(immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
994 **chronic inhalation exposures at the central tendency and high-end, without assuming use of**
995 **respirators. In addition, for workers, EPA found that there was unreasonable risk of non-cancer**
996 **effects from acute (immunosuppression) and chronic (autoimmunity) dermal exposures, and of**
997 **cancer from chronic dermal exposures at the central tendency and high-end, without assuming use**
998 **of gloves. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from**
999 **acute (immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
1000 **chronic inhalation exposures at the central tendency and high-end.**

1001

1002 EPA’s determination that the industrial and commercial use of TCE in spot remover presents an
1003 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to
1004 the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
1005 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3):

1006

- Based on professional judgement regarding practices at small commercial facilities performing spot cleaning, EPA assumes workers are unlikely to wear respiratory protection or regularly employ dermal protection for this condition of use.
- EPA identified minimal inhalation exposure monitoring data related to the spot cleaning use of TCE. Therefore, EPA supplemented the identified monitoring data using the Near-field/Far-field Exposure Model. EPA’s inhalation exposure modeling is based on a near-field/far-field approach, where a vapor generation source located inside the near-field diffuses into the surrounding environment. Near-field exposure represents exposure concentrations for workers who directly operate the vapor degreasing equipment, whereas far-field exposure represents exposure concentrations for occupational non-users (i.e., workers in the surrounding area who do not handle the degreasing equipment). Assumptions and key sources of uncertainty for occupational exposures, including the near-field/ far-field framework are described in Section 2.3.1.3. These estimates were used for determining worker and ONU risks.
- Dermal exposures were assessed using modeled data.

1009

1020 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1021 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
1022 and ONUs) from the industrial and commercial use of TCE in spot remover.

1023 **5.2.1.22 Industrial/Commercial Use – Arts, crafts and hobby materials –**
1024 **Fixatives and finishing spray coatings (Fixatives and finishing spray coatings)**
1025

1026 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in fixatives
1027 and finishing spray coatings: Presents an unreasonable risk of injury to health (workers and ONUs).
1028

1029 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1030 **(immunosuppression) inhalation and dermal exposures at the high-end, and from chronic**
1031 **(autoimmunity) inhalation and dermal exposures at the central tendency and high-end, even when**
1032 **assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of**
1033 **cancer from chronic inhalation and dermal exposures at the central tendency and high-end, even**
1034 **when assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
1035 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures, and of**
1036 **cancer from chronic inhalation exposures at the central tendency and high-end.**
1037

1038 EPA's determination that the industrial and commercial use of TCE in fixatives and finishing spray
1039 coatings presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer
1040 effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the
1041 health effects of TCE, the exposures from the condition of use, and the uncertainties in the analysis
1042 (Section 4.3):

- 1043 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
1044 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from
1045 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
1046 determination. Similarly, when assuming the use of gloves with PF of 10, the risk estimates of non-
1047 cancer effects from acute dermal exposures at the high-end, and of non-cancer effects and cancer from
1048 chronic dermal exposures at the central tendency and high-end support an unreasonable risk
1049 determination.
- 1050 • Inhalation exposures for workers and ONUs were assessed using monitoring data from a NIOSH Health
1051 Hazard Evaluation report ([Chrostek, 1981](#)) using TCE in coating applications and from OSHA facility
1052 inspections ([OSHA, 2017](#)) at three sites using TCE in adhesives and coatings. The OSHA data also
1053 provided two data points where the worker job description was "foreman." EPA assumed this data is
1054 applicable to ONU exposure.
- 1055 • Dermal exposures were assessed using modeled data.

1056 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1057 uncertainties support EPA's determination that there is unreasonable risk of injury to health (workers
1058 and ONUs) from the industrial and commercial use of TCE in fixatives and finishing spray coatings.
1059

1060 **5.2.1.23 Industrial/Commercial Use – Corrosion inhibitors and anti-scaling**
1061 **agents (Corrosion inhibitors and anti-scaling agents)**
1062

1063 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in
1064 corrosion inhibitor, and anti-scaling agent: Presents an unreasonable risk of injury to health
1065 (workers and ONUs).
1066

1067 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1068 **(immunosuppression) inhalation exposures at the high-end, and from chronic (autoimmunity)**

1069 **inhalation and dermal exposures at the central tendency and high-end, even when assuming use of**
1070 **PPE. In addition, for workers, EPA found that there was unreasonable risk of cancer from**
1071 **chronic inhalation and dermal exposures at the central tendency and high-end, even when**
1072 **assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
1073 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the**
1074 **central tendency and high-end, and of cancer from chronic inhalation exposures at the central**
1075 **tendency and high-end.**

1076
1077 EPA's determination that the industrial and commercial use of TCE in corrosion inhibitors and anti-
1078 scaling agents presents an unreasonable risk is based on the comparison of the risk estimates for non-
1079 cancer effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also
1080 considered the health effects of TCE, the exposures from the condition of use, and the uncertainties in
1081 the analysis (Section 4.3):

- 1082 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
1083 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from
1084 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
1085 determination. Similarly, when assuming the use of gloves with PF of 20, the risk estimates of non-
1086 cancer effects and cancer from chronic dermal exposures at the central tendency and high-end support
1087 an unreasonable risk determination.
- 1088 • For workers, when assuming the use of gloves with PF of 20, the risk estimates of non-cancer effects
1089 from acute dermal exposures at the high-end do not support an unreasonable risk determination.
- 1090 • Inhalation exposures for workers and ONUs were assessed using monitoring data for the use of TCE as
1091 a processing aid from a European Commission (EC) Technical Report ([EC, 2014](#)). The data were
1092 supplied to the EC as supporting documentation in an application for continued use of TCE under the
1093 REACH Regulation. Because of the limited data set, EPA is unsure of the representativeness of these
1094 data toward actual exposures to TCE for all sites covered by this condition of use.
- 1095 • Dermal exposures were assessed using modeled data.

1096 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1097 uncertainties support EPA's determination that there is unreasonable risk of injury to health (workers
1098 and ONUs) from the industrial and commercial use of TCE in corrosion inhibitors and anti-scaling
1099 agents.

1100
1101 **5.2.1.24 Industrial/Commercial Use – Processing aids – Process solvent used in**
1102 **battery manufacture; process solvent used in polymer fiber spinning,**
1103 **fluoroelastomer manufacture, and Alcantara manufacture; extraction solvent used**
1104 **in caprolactam manufacture; precipitant used in beta-cyclodextrin manufacture**
1105 **(Processing aids)**

1106
1107 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in
1108 processing aids: Presents an unreasonable risk of injury to health (workers and ONUs).

1109
1110 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1111 **(immunosuppression) inhalation exposures at the high-end, and from chronic (autoimmunity)**
1112 **inhalation and dermal exposures at the central tendency and high-end, even when assuming use of**
1113 **PPE. In addition, for workers, EPA found that there was unreasonable risk of cancer from**
1114 **chronic inhalation and dermal exposures at the central tendency and high-end, even when**

1115 **assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
1116 **effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at the**
1117 **central tendency and high-end, and of cancer from chronic inhalation exposures at the central**
1118 **tendency and high-end.**

1120 EPA's determination that the industrial and commercial use of TCE in processing aids presents an
1121 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to
1122 the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
1123 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1124 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
1125 effects from acute inhalation exposures at the high-end, and of non-cancer effects and cancer from
1126 chronic inhalation exposures at the central tendency and high-end support an unreasonable risk
1127 determination. Similarly, when assuming the use of gloves with PF of 20, the risk estimates of non-
1128 cancer effects and cancer from chronic dermal exposures at the central tendency and high-end support
1129 an unreasonable risk determination.
- 1130 • For workers, when assuming the use of gloves with PF of 20, the risk estimates of non-cancer effects
1131 from acute dermal exposures at the high-end do not support an unreasonable risk determination.
- 1132 • Inhalation exposures for workers and ONUs were assessed using monitoring data for the use of TCE as
1133 a processing aid from a European Commission (EC) Technical Report ([EC, 2014](#)). The data were
1134 supplied to the EC as supporting documentation in an application for continued use of TCE under the
1135 REACH Regulation. Because of the limited data set, EPA is unsure of the representativeness of these
1136 data toward actual exposures to TCE for all sites covered by this condition of use.
- 1137 • Dermal exposures were assessed using modeled data.

1138 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1139 uncertainties support EPA's determination that there is unreasonable risk of injury to health (workers
1140 and ONUs) from the industrial and commercial use of TCE in processing aids.

1142 **5.2.1.25 Industrial/Commercial Use – Ink, toner, and colorant products –** 1143 **Toner aid (Toner aid)**

1144 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in toner
1145 aid: Presents an unreasonable risk of injury to health (workers and ONUs).

1148 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1149 **(immunosuppression) inhalation exposures at the high-end, and from chronic (autoimmunity)**
1150 **inhalation exposures at the central tendency and high-end, and of cancer from chronic inhalation**
1151 **exposures at the central tendency and high-end, without assuming use of respirators. In addition,**
1152 **for workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1153 **(immunosuppression) and chronic (autoimmunity) dermal exposures, and of cancer from chronic**
1154 **dermal exposures at the central tendency and high-end, without assuming use of gloves. For**
1155 **ONUs, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity) and**
1156 **cancer from chronic inhalation exposures at the central tendency.**

1157
1158 EPA's determination that the industrial and commercial use of TCE in toner aid presents an
1159 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to
1160 the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of

1161 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3),
1162 including uncertainties related to the exposures for ONUs:

- 1163 • Based on professional judgement regarding practices at small commercial facilities using toner aid for
1164 commercial printing and copying, EPA assumes workers are unlikely to wear respiratory protection or
1165 regularly employ dermal protection for this condition of use.
- 1166 • Based on EPA’s analysis, the data for worker and ONU inhalation exposures could not be distinguished;
1167 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
1168 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers’
1169 central tendency risk estimates from inhalation exposures when determining ONUs’ unreasonable risk.
- 1170 • Inhalation exposures were assessed using monitoring data from a NIOSH Health Hazard Evaluation
1171 (HHE) report ([Finely and Page, 2005](#)) using TCE in high speed printing presses.
- 1172 • Dermal exposures were assessed using modeled data.

1173 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1174 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
1175 and ONUs) from the industrial and commercial use of TCE in toner aid.
1176

1177 **5.2.1.26 Industrial/Commercial Use – Automotive care products – Brake and** 1178 **parts cleaners (Brake and parts cleaners)**

1179
1180 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in brake
1181 and parts cleaners: Presents an unreasonable risk of injury to health (workers and ONUs).
1182

1183 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1184 **(immunosuppression) inhalation and dermal exposures at the high-end, and from chronic**
1185 **(autoimmunity) inhalation and dermal exposures at the central tendency and high-end, even when**
1186 **assuming use of PPE. In addition, for workers, EPA found that there was unreasonable risk of**
1187 **cancer from chronic inhalation and dermal exposures at the central tendency and high-end, even**
1188 **when assuming use of PPE. For ONUs, EPA found that there was unreasonable risk of non-cancer**
1189 **effects from acute (immunosuppression) inhalation exposures at the high-end, from chronic**
1190 **(autoimmunity) inhalation exposures at the central tendency and high-end, and of cancer from**
1191 **chronic inhalation exposures at the central tendency and high-end.**
1192

1193 EPA’s determination that the industrial and commercial use of TCE in brake and parts cleaners presents
1194 an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer
1195 to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
1196 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1197 • For workers, when assuming the use of respirators with APF of 50 and gloves with PF of 20, the risk
1198 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end, and the risk
1199 estimates of non-cancer effects and cancer from chronic inhalation and dermal exposures at the central
1200 tendency and high-end support an unreasonable risk determination.
- 1201 • Inhalation exposures for workers and ONUs were assessed using the Brake Servicing Near-field/Far-field
1202 Exposure Model. EPA did not identify inhalation exposure monitoring data related to this use of TCE,
1203 and used the brake servicing model as a representative scenario for this condition of use. EPA’s
1204 inhalation exposure modeling is based on a near-field/far-field approach, where a vapor generation
1205 source located inside the near-field diffuses into the surrounding environment. Near-field exposure

1206 represents exposure concentrations for workers who directly operate the vapor degreasing equipment,
1207 whereas far-field exposure represents exposure concentrations for occupational non-users (*i.e.*, workers
1208 in the surrounding area who do not handle the degreasing equipment). Assumptions and key sources of
1209 uncertainty for occupational exposures, including the near-field/ far-field framework are described in
1210 Section 2.3.1.3. These estimates were used for determining worker and ONU risks.

- 1211 • Dermal exposures were assessed using modeled data.

1212 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1213 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
1214 and ONUs) from the industrial and commercial use of TCE in brake and parts cleaners.
1215

1216 **5.2.1.27 Industrial/Commercial Use – Apparel and footwear care products –** 1217 **Shoe polish (Shoe polish)**

1218 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in shoe
1219 polish: Presents an unreasonable risk of injury to health (workers and ONUs).
1220

1221
1222 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1223 **(immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
1224 **chronic inhalation exposures at the central tendency and high-end, without assuming use of**
1225 **respirators. In addition, for workers, EPA found that there was unreasonable risk of non-cancer**
1226 **effects from acute (immunosuppression) and chronic (autoimmunity) dermal exposures, and of**
1227 **cancer from chronic dermal exposures at the central tendency and high-end, without assuming use**
1228 **of gloves. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from**
1229 **acute (immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
1230 **chronic inhalation exposures at the central tendency and high-end.**
1231

1232 EPA’s determination that the industrial and commercial use of TCE in shoe polish presents an
1233 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects and cancer to
1234 the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the health effects of
1235 TCE, the exposures from the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1236 • Based on professional judgement regarding practices at small commercial facilities using shoe polish,
1237 EPA assumes workers are unlikely to wear respiratory protection or regularly employ dermal protection
1238 for this condition of use.
- 1239 • EPA identified minimal inhalation exposure monitoring data related to the spot cleaning using TCE.
1240 Therefore, EPA supplemented the identified monitoring data using the Near-field/Far-field Exposure
1241 Model. EPA’s inhalation exposure modeling is based on a near-field/far-field approach, where a vapor
1242 generation source located inside the near-field diffuses into the surrounding environment. Near-field
1243 exposure represents exposure concentrations for workers who directly operate the vapor degreasing
1244 equipment, whereas far-field exposure represents exposure concentrations for occupational non-users
1245 (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment). Assumptions and
1246 key sources of uncertainty for occupational exposures, including the near-field/ far-field framework are
1247 described in Section 2.3.1.3. These estimates were used for determining worker and ONU risks.
- 1248 • Dermal exposures were assessed using modeled data.
1249

1250 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1251 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
1252 and ONUs) from the industrial and commercial use of TCE in shoe polish.
1253

1254 **5.2.1.28 Industrial/Commercial Use – Hoof polishes; gun scrubber; pepper**
1255 **spray; other miscellaneous industrial and commercial uses (Other industrial and**
1256 **commercial uses)**

1257 Section 6(b)(4)(A) unreasonable risk determination for the industrial/commercial use of TCE in other
1258 industrial and commercial uses: Presents an unreasonable risk of injury to health (workers and
1259 ONUs).
1260

1261
1262 **For workers, EPA found that there was unreasonable risk of non-cancer effects from acute**
1263 **(immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
1264 **chronic inhalation exposures at the central tendency and high-end, without assuming use of**
1265 **respirators. In addition, for workers, EPA found that there was unreasonable risk of non-cancer**
1266 **effects from acute (immunosuppression) and chronic (autoimmunity) dermal exposures, and of**
1267 **cancer from chronic dermal exposures at the central tendency and high-end, without assuming use**
1268 **of gloves. For ONUs, EPA found that there was unreasonable risk of non-cancer effects from**
1269 **acute (immunosuppression) and chronic (autoimmunity) inhalation exposures, and of cancer from**
1270 **chronic inhalation exposures at the central tendency and high-end.**
1271

1272 EPA’s determination that the industrial and commercial use of TCE in other industrial and commercial
1273 uses presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer
1274 effects and cancer to the benchmarks (Table 4-59). As explained in Section 5.1, EPA also considered the
1275 health effects of TCE, the exposures from the condition of use, and the uncertainties in the analysis
1276 (Section 4.3):

- 1277 • Based on professional judgement regarding practices at small commercial facilities using miscellaneous
1278 commercial uses, EPA assumes workers are unlikely to wear respiratory protection or regularly employ
1279 dermal protection for this condition of use.
- 1280 • EPA identified minimal inhalation exposure monitoring data related to the spot cleaning using TCE.
1281 Therefore, EPA supplemented the identified monitoring data using the Near-field/Far-field Exposure
1282 Model. EPA’s inhalation exposure modeling is based on a near-field/far-field approach, where a vapor
1283 generation source located inside the near-field diffuses into the surrounding environment. Near-field
1284 exposure represents exposure concentrations for workers who directly operate the vapor degreasing
1285 equipment, whereas far-field exposure represents exposure concentrations for occupational non-users
1286 (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment). Assumptions and
1287 key sources of uncertainty for occupational exposures, including the near-field/ far-field framework are
1288 described in Section 2.3.1.3. These estimates were used for determining worker and ONU risks.
- 1289 • Dermal exposures were assessed using modeled data.

1290
1291 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1292 uncertainties support EPA’s determination that there is unreasonable risk of injury to health (workers
1293 and ONUs) from the industrial and commercial use of TCE in other industrial and commercial uses.
1294

1295 **5.2.1.29 Consumer Use – Solvents (for cleaning or degreasing) – Brake and**
1296 **parts cleaner (Solvent in brake and parts cleaner)**

1297
1298 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in brake
1299 and parts cleaners: Presents an unreasonable risk of injury to health (consumers and bystanders).

1300
1301 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1302 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1303 **use, and from acute dermal exposures at the moderate and high intensity use. For bystanders,**
1304 **EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1305 **exposures at the low, moderate, and high intensity use.**

1306
1307 EPA's determination that the consumer use of TCE as a solvent in brake and parts cleaner presents an
1308 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1309 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1310 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1311 • Risk estimates for the consumer use of TCE as a solvent in brake and parts cleaner were based on
1312 modeled risk estimates of four aerosol products.
- 1313 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1314 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1315 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1316 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1317 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1318 consumers result from dermal contact involving impeded evaporation while using the product. The
1319 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1320 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1321 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1322 high vapor pressure.

1323
1324 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1325 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1326 the consumer use of TCE as a solvent in brake and parts cleaner.

1327
1328 **5.2.1.30 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol**
1329 **electronic degreaser/cleaner (Solvent in aerosol electronic degreaser/cleaner)**

1330
1331 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in aerosol
1332 electronic degreaser/cleaner: Presents an unreasonable risk of injury to health (consumers and
1333 bystanders).

1334
1335 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1336 **(immunosuppression) from acute inhalation and dermal exposures at the moderate and high**
1337 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1338 **(immunosuppression) from acute inhalation exposures at the moderate and high intensity use.**

1340 EPA's determination that the consumer use of TCE as a solvent in aerosol electronic degreaser/cleaner
1341 presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to
1342 the benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of
1343 TCE, the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1344 • Risk estimates for the consumer use of TCE as a solvent in aerosol electronic degreaser/cleaner were
1345 based on modeled risk estimates of nine aerosol products.
- 1346 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1347 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1348 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1349 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1350 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
1351 to consumers result from dermal contact not involving impeded evaporation while using the product.
1352 The magnitude of dermal exposures depends on several factors, including skin surface area, film
1353 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1354 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1355 chemical properties of TCE, such as high vapor pressure.

1356
1357 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1358 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1359 the consumer use of TCE as a solvent in aerosol electronic degreaser/cleaner.
1360

1361 **5.2.1.31 Consumer Use – Solvents (for cleaning or degreasing) – Liquid** 1362 **electronic degreaser/cleaner (Solvent in liquid electronic degreaser/cleaner)**

1363
1364 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in liquid
1365 electronic degreaser/cleaner: Presents an unreasonable risk of injury to health (consumers and
1366 bystanders).
1367

1368 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1369 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1370 **use, and from acute dermal exposures at the moderate and high intensity use. For bystanders,**
1371 **EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1372 **exposures at the moderate and high intensity use.**
1373

1374 EPA's determination that the consumer use of TCE as a solvent in liquid electronic degreaser/cleaner
1375 presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to
1376 the benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of
1377 TCE, the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1378 • Risk estimates for the consumer use of TCE as a solvent for liquid electronic degreaser/cleaner were
1379 based on modeled risk estimates of one liquid product.
- 1380 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1381 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1382 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1383 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1384 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1385 consumers result from dermal contact involving impeded evaporation while using the product. The

1386 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1387 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1388 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1389 high vapor pressure.

1391 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1392 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1393 the consumer use of TCE as a solvent in liquid electronic degreaser/cleaner.

1395 **5.2.1.32 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol spray**
1396 **degreaser/cleaner (Solvent in aerosol spray degreaser/cleaner)**

1398 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in aerosol
1399 spray degreaser/cleaner: Presents an unreasonable risk of injury to health (consumers and
1400 bystanders).

1401 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1402 **(immunosuppression) from acute inhalation and dermal exposures at the low, moderate, and high**
1403 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1404 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1405 **use.**

1406
1407
1408 EPA's determination that the consumer use of TCE as a solvent in aerosol spray degreaser/cleaner
1409 presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to
1410 the benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of
1411 TCE, the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1412 • Risk estimates for the consumer use of TCE as a solvent for aerosol spray degreaser/cleaner were based
1413 on modeled risk estimates of eight aerosol products.
- 1414 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1415 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1416 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1417 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1418 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1419 consumers result from dermal contact involving impeded evaporation while using the product. The
1420 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1421 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1422 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1423 high vapor pressure.

1424
1425 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1426 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1427 the consumer use of TCE as a solvent in aerosol spray degreaser/cleaner.

1429 **5.2.1.33 Consumer Use – Solvents (for cleaning or degreasing) – Liquid**
1430 **degreaser/cleaner (Solvent in liquid degreaser/cleaner)**

1431
1432 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in liquid
1433 degreaser/cleaner: Presents an unreasonable risk of injury to health (consumers and bystanders).
1434

1435 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1436 **(immunosuppression) from acute inhalation and dermal exposures at the low, moderate, and high**
1437 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1438 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1439 **use.**

1440
1441 EPA's determination that the consumer use of TCE as a solvent in liquid degreaser/cleaner presents an
1442 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1443 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1444 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1445 • Risk estimates for the consumer use of TCE as a solvent for liquid degreaser/cleaner were based on
1446 modeled risk estimates of two aerosol products.
- 1447 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1448 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1449 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1450 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1451 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1452 consumers result from dermal contact involving impeded evaporation while using the product. The
1453 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1454 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1455 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1456 high vapor pressure.

1457
1458 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1459 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1460 the consumer use of TCE as a solvent in liquid degreaser/cleaner.
1461

1462 **5.2.1.34 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol gun**
1463 **scrubber (Solvent in aerosol gun scrubber)**

1464
1465 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in aerosol
1466 gun scrubber: Presents an unreasonable risk of injury to health (consumers); does not present an
1467 unreasonable risk of injury to health (bystanders).
1468

1469 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1470 **(immunosuppression) from acute dermal exposures at the low, moderate, and high intensity use.**
1471 **For bystanders, EPA found no unreasonable risk of non-cancer effects (immunosuppression) from acute**
1472 **inhalation exposures at the low, moderate, and high intensity use.**
1473

1474 EPA's determination that the consumer use of TCE as a solvent in aerosol gun scrubber presents an
1475 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1476 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1477 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1478 • For consumers, the risk estimates of non-cancer effects from acute inhalation exposures do not support
1479 an unreasonable risk determination.
- 1480 • Risk estimates for the consumer use of TCE as a solvent for aerosol gun scrubber were based on
1481 modeled risk estimates of two aerosol products.
- 1482 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1483 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1484 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1485 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1486 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1487 consumers result from dermal contact involving impeded evaporation while using the product. The
1488 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1489 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1490 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1491 high vapor pressure.

1492
1493 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1494 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers)
1495 from the consumer use of TCE as a solvent in aerosol gun scrubber.
1496

1497 **5.2.1.35 Consumer Use – Solvents (for cleaning or degreasing) – Liquid gun** 1498 **scrubber (Solvent in liquid gun scrubber)**

1499
1500 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in liquid
1501 gun scrubber: Presents an unreasonable risk of injury to health (consumers); does not present an
1502 unreasonable risk of injury to health (bystanders).
1503

1504 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1505 **(immunosuppression) from acute dermal exposures at the low, moderate, and high intensity use.**
1506 For bystanders, EPA found no unreasonable risk of non-cancer effects (immunosuppression) from acute
1507 inhalation exposures at the low, moderate, and high intensity use.
1508

1509 EPA's determination that the consumer use of TCE as a solvent in liquid gun scrubber presents an
1510 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1511 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1512 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1513 • For consumers, the risk estimates of non-cancer effects from acute inhalation exposures do not support
1514 an unreasonable risk determination.
- 1515 • Risk estimates for the consumer use of TCE as a solvent for liquid gun scrubber were based on modeled
1516 risk estimates of one liquid product.
- 1517 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1518 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on

several factors, including the concentration of TCE in products used, use patterns (including frequency, duration, amount of product used, room of use, and local ventilation), and application methods.

- Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to consumers result from dermal contact involving impeded evaporation while using the product. The magnitude of dermal exposures depends on several factors, including skin surface area, concentration of TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as high vapor pressure.

In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties support EPA’s determination that there is unreasonable risk of injury to health (consumers) from the consumer use of TCE as a solvent in liquid gun scrubber.

5.2.1.36 Consumer Use – Solvents (for cleaning or degreasing) – Mold release (Solvent in mold release)

Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in mold release: Presents an unreasonable risk of injury to health (consumers and bystanders).

For consumers, EPA found there was unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity use, and from acute dermal exposures at the moderate and high intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the moderate and high intensity use.

EPA’s determination that the consumer use of TCE as a solvent in mold release presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- Risk estimates for the consumer use of TCE as a solvent for mold release were based on modeled risk estimates of two aerosol products.
- Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on several factors, including the concentration of TCE in products used, use patterns (including frequency, duration, amount of product used, room of use, and local ventilation), and application methods.
- Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures to consumers result from dermal contact not involving impeded evaporation while using the product. The magnitude of dermal exposures depends on several factors, including skin surface area, film thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional absorption. The potential for dermal exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as high vapor pressure.

In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties support EPA’s determination that there is unreasonable risk of injury to health (consumers and bystanders) from the consumer use of TCE as a solvent in mold release.

1564 **5.2.1.37 Consumer Use – Solvents (for cleaning or degreasing) – Aerosol tire**
1565 **cleaner (Solvent in aerosol tire cleaner)**

1566
1567 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in aerosol
1568 tire cleaner: Presents an unreasonable risk of injury to health (consumers and bystanders).
1569

1570 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1571 **(immunosuppression) from acute inhalation and dermal exposures at the low, moderate, and high**
1572 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1573 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1574 **use.**
1575

1576 EPA's determination that the consumer use of TCE as a solvent in aerosol tire cleaner presents an
1577 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1578 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1579 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1580 • Risk estimates for the consumer use of TCE as a solvent for aerosol tire cleaner were based on modeled
1581 risk estimates of two aerosol products.
- 1582 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1583 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1584 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1585 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1586 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1587 consumers result from dermal contact involving impeded evaporation while using the product. The
1588 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1589 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1590 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1591 high vapor pressure.

1592
1593 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1594 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1595 the consumer use of TCE as a solvent in aerosol tire cleaner.
1596

1597 **5.2.1.38 Consumer Use – Solvents (for cleaning or degreasing) – Liquid tire**
1598 **cleaner (Solvent in liquid tire cleaner)**

1600 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE as a solvent in liquid
1601 tire cleaner: Presents an unreasonable risk of injury to health (consumers and bystanders).
1602

1603 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1604 **(immunosuppression) from acute inhalation and dermal exposures at the low, moderate, and high**
1605 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1606 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1607 **use.**
1608

1609 EPA's determination that the consumer use of TCE as a solvent in liquid tire cleaner presents an
1610 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1611 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1612 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1613 • Risk estimates for the consumer use of TCE as a solvent for liquid tire cleaner were based on modeled
1614 risk estimates of one liquid product.
- 1615 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1616 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1617 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1618 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1619 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1620 consumers result from dermal contact involving impeded evaporation while using the product. The
1621 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1622 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1623 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1624 high vapor pressure.

1625
1626 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1627 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1628 the consumer use of TCE as a solvent in liquid tire cleaner.
1629

1630 **5.2.1.39 Consumer Use – Lubricants and greases – Tap and die fluid (Tap and** 1631 **die fluid)**

1632
1633 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in tap and die fluid:
1634 **Presents an unreasonable risk of injury to health (consumers and bystanders).**
1635

1636 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1637 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1638 **use, and from acute dermal exposures at the moderate and high intensity use. For bystanders,**
1639 **EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1640 **exposures at the moderate, and high intensity use.**
1641

1642 EPA's determination that the consumer use of TCE in tap and die fluid presents an unreasonable risk is
1643 based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As
1644 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
1645 of use, and the uncertainties in the analysis (Section 4.3):

- 1646 • Risk estimates for the consumer use of TCE as a lubricant and grease in tap and die fluid were based on
1647 modeled risk estimates of one aerosol product.
- 1648 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1649 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1650 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1651 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1652 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
1653 to consumers result from dermal contact not involving impeded evaporation while using the product.

1654 The magnitude of dermal exposures depends on several factors, including skin surface area, film
1655 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1656 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1657 chemical properties of TCE, such as high vapor pressure.

1659 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1660 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1661 and bystanders) from the consumer use of TCE in tap and die fluid.

1663 **5.2.1.40 Consumer Use – Lubricants and greases – Penetrating lubricant** 1664 **(Penetrating lubricant)**

1666 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in a penetrating
1667 lubricant: Presents an unreasonable risk of injury to health (consumers and bystanders).

1669 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1670 **(immunosuppression) from acute inhalation exposures at the moderate and high intensity use, and**
1671 **from acute dermal exposures at the high intensity use. For bystanders, EPA found unreasonable**
1672 **risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the moderate**
1673 **and high intensity use.**

1674
1675 EPA's determination that the consumer use of TCE in a penetrating lubricant presents an unreasonable
1676 risk is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table
1677 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the
1678 condition of use, and the uncertainties in the analysis (Section 4.3):

- 1679 • Risk estimates for the consumer use of TCE as a penetrating lubricant were based on modeled risk
1680 estimates of five aerosol products.
- 1681 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1682 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1683 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1684 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1685 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
1686 to consumers result from dermal contact not involving impeded evaporation while using the product.
1687 The magnitude of dermal exposures depends on several factors, including skin surface area, film
1688 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1689 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1690 chemical properties of TCE, such as high vapor pressure.

1691
1692 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1693 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1694 and bystanders) from the consumer use of TCE in penetrating lubricant.

1697 **5.2.1.41 Consumer Use – Adhesives and sealants – Solvent-based adhesives**
1698 **and sealants (Solvent-based adhesives and sealants)**

1700 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in solvent-based
1701 adhesives and sealants: Presents an unreasonable risk of injury to health (consumers and
1702 bystanders).

1704 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1705 **(immunosuppression) from acute inhalation and dermal exposures at the moderate and high**
1706 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1707 **(immunosuppression) from acute inhalation exposures at the moderate and high intensity use.**

1709 EPA's determination that the consumer use of TCE in solvent-based adhesives and sealants presents an
1710 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1711 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1712 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1713 • Risk estimates for the consumer use of TCE in adhesives and sealants as solvent-based adhesive and
1714 sealant were based on modeled risk estimates of three liquid products.
- 1715 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1716 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1717 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1718 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1719 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
1720 to consumers result from dermal contact not involving impeded evaporation while using the product.
1721 The magnitude of dermal exposures depends on several factors, including skin surface area, film
1722 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1723 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1724 chemical properties of TCE, such as high vapor pressure.

1726 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1727 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1728 and bystanders) from the consumer use of TCE in solvent-based adhesives and sealants.

1730 **5.2.1.42 Consumer Use – Adhesives and sealants – Mirror edge sealant**
1731 **(Mirror edge sealant)**

1733 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in mirror edge sealant:
1734 Presents an unreasonable risk of injury to health (consumers and bystanders).

1736 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1737 **(immunosuppression) from acute inhalation and dermal exposures at the moderate and high**
1738 **intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects**
1739 **(immunosuppression) from acute inhalation exposures at the high intensity use.**

1741 EPA's determination that the consumer use of TCE in mirror edge sealant presents an unreasonable risk
1742 is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60).

As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- Risk estimates for the consumer use of TCE in adhesives and sealants as mirror edge sealant were based on modeled risk estimates of one aerosol product.
- Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on several factors, including the concentration of TCE in products used, use patterns (including frequency, duration, amount of product used, room of use, and local ventilation), and application methods.
- Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures to consumers result from dermal contact not involving impeded evaporation while using the product. The magnitude of dermal exposures depends on several factors, including skin surface area, film thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional absorption. The potential for dermal exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as high vapor pressure.

In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from the consumer use of TCE in mirror edge sealant.

5.2.1.43 Consumer Use – Adhesives and sealants – Tire repair cement/sealer (Tire repair cement/sealer)

Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in tire repair cement/sealer: Presents an unreasonable risk of injury to health (consumers and bystanders).

For consumers, EPA found there was unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the moderate and high intensity use, and from acute dermal exposures at the low, moderate, and high intensity use. For bystanders, EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the moderate and high intensity use.

EPA's determination that the consumer use of TCE in tire repair cement/sealer presents an unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- Risk estimates for the consumer use of TCE in adhesives and sealants as tire repair cement/sealer were based on modeled risk estimates of five liquid products.
- Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on several factors, including the concentration of TCE in products used, use patterns (including frequency, duration, amount of product used, room of use, and local ventilation), and application methods.
- Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures to consumers result from dermal contact not involving impeded evaporation while using the product. The magnitude of dermal exposures depends on several factors, including skin surface area, film

1789 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1790 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1791 chemical properties of TCE, such as high vapor pressure.
1792

1793 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1794 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1795 and bystanders) from the consumer use of TCE in tire repair cement/sealer.
1796

1797 **5.2.1.44 Consumer Use – Cleaning and furniture care products – Carpet** 1798 **cleaner (Carpet cleaner)**

1800 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in carpet cleaner:
1801 **Presents an unreasonable risk of injury to health (consumers and bystanders).**
1802

1803 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1804 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1805 **use, and from acute dermal exposures at the moderate and high intensity use. For bystanders,**
1806 **EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1807 **exposures at the low, moderate, and high intensity use.**
1808

1809 EPA's determination that the consumer use of TCE in carpet cleaner presents an unreasonable risk is
1810 based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As
1811 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
1812 of use, and the uncertainties in the analysis (Section 4.3):

- 1813 • Risk estimates for the consumer use of TCE in cleaning and furniture care products as carpet cleaner
1814 were based on modeled risk estimates of one liquid formulation.
- 1815 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1816 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1817 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1818 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1819 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1820 consumers result from dermal contact involving impeded evaporation while using the product. The
1821 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1822 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1823 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1824 high vapor pressure.
1825

1826 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1827 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1828 the consumer use of TCE in carpet cleaner.
1829
1830
1831

1832 **5.2.1.45 Consumer Use – Cleaning and furniture care products – Aerosol spot**
1833 **remover (Aerosol spot remover)**

1834
1835 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in aerosol spot
1836 remover: Presents an unreasonable risk of injury to health (consumers and bystanders).

1837
1838 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1839 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1840 **use and from acute dermal exposures at the moderate and high intensity use. For bystanders, EPA**
1841 **found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1842 **exposures at the moderate and high intensity use.**

1843
1844 EPA's determination that the consumer use of TCE in aerosol spot remover presents an unreasonable
1845 risk is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table
1846 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the
1847 condition of use, and the uncertainties in the analysis (Section 4.3):

- 1848 • Risk estimates for the consumer use of TCE in cleaning and furniture care products as aerosol spot
1849 remover were based on modeled risk estimates of one aerosol product.
- 1850 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1851 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1852 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1853 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1854 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1855 consumers result from dermal contact involving impeded evaporation while using the product. The
1856 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1857 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1858 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1859 high vapor pressure.

1860
1861 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1862 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1863 the consumer use of TCE in as aerosol spot remover.

1864
1865 **5.2.1.46 Consumer Use – Cleaning and furniture care products – Liquid spot**
1866 **remover (Liquid spot remover)**

1867
1868 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in liquid spot remover:
1869 Presents an unreasonable risk of injury to health (consumers and bystanders).

1870
1871 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1872 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1873 **use and from acute dermal exposures at the moderate and high intensity use. For bystanders, EPA**
1874 **found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1875 **exposures at the low, moderate, and high intensity use.**

1877 EPA's determination that the consumer use of TCE in liquid spot remover presents an unreasonable risk
1878 is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60).
1879 As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the
1880 condition of use, and the uncertainties in the analysis (Section 4.3):

- 1881 • Risk estimates for the consumer use of TCE in cleaning and furniture care products as liquid spot
1882 remover were based on modeled risk estimates of four liquid products.
- 1883 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1884 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1885 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1886 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1887 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1888 consumers result from dermal contact involving impeded evaporation while using the product. The
1889 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1890 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1891 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1892 high vapor pressure.

1893
1894 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of uncertainties
1895 support EPA's determination that there is unreasonable risk of injury to health (consumers and bystanders) from
1896 the consumer use of TCE in liquid spot remover.

1897

1898 **5.2.1.47 Consumer Use – Arts, crafts, and hobby materials – Fixatives and**
1899 **finishing spray coatings (Fixatives and finishing spray coatings)**

1900

1901 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in fixative and
1902 finishing spray coating: Presents an unreasonable risk of injury to health (consumers and
1903 bystanders).

1904

1905 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1906 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
1907 **use, and from acute dermal exposures at the moderate and high intensity use. For bystanders,**
1908 **EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
1909 **exposures at the moderate and high intensity use.**

1910

1911 EPA's determination that the consumer use of TCE in as fixative and finishing spray coating presents an
1912 unreasonable risk is based on the comparison of the risk estimates for non-cancer effects to the
1913 benchmarks (Table 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE,
1914 the exposures for the condition of use, and the uncertainties in the analysis (Section 4.3):

- 1915 • Risk estimates for the consumer use of TCE in arts, crafts, and hobby materials as fixative and
1916 finishing spray coating were based on modeled risk estimates of one aerosol product.
- 1917 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1918 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1919 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1920 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1921 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
1922 to consumers result from dermal contact not involving impeded evaporation while using the product.

1923 The magnitude of dermal exposures depends on several factors, including skin surface area, film
1924 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1925 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1926 chemical properties of TCE, such as high vapor pressure.

1927
1928 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1929 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1930 and bystanders) from the consumer use of TCE in fixative and finishing spray coating.
1931

1932 **5.2.1.48 Consumer Use – Apparel and footwear care products – Shoe polish** 1933 **(Shoe polish)**

1934
1935 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in shoe polish:
1936 **Presents an unreasonable risk of injury to health (consumers and bystanders).**

1937
1938 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
1939 **(immunosuppression) from acute inhalation exposures at the moderate and high intensity use and**
1940 **from acute dermal exposures at the high intensity use. For bystanders, EPA found unreasonable**
1941 **risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the high**
1942 **intensity use.**

1943
1944 EPA's determination that the consumer use of TCE in shoe polish presents an unreasonable risk is based
1945 on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As
1946 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
1947 of use, and the uncertainties in the analysis (Section 4.3):

- 1948 • Risk estimates for the consumer use of TCE in apparel and footwear care products in shoe polish were
1949 based on modeled risk estimates of one aerosol product.
- 1950 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1951 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1952 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1953 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1954 • Dermal exposures to consumers were evaluated with the CEM (Permeability). Dermal exposures to
1955 consumers result from dermal contact involving impeded evaporation while using the product. The
1956 magnitude of dermal exposures depends on several factors, including skin surface area, concentration of
1957 TCE in product used, permeability coefficient, and dermal exposure duration. The potential for dermal
1958 exposures to TCE is limited by several factors including physical-chemical properties of TCE, such as
1959 high vapor pressure.

1960
1961 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1962 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1963 and bystanders) from the consumer use of TCE in shoe polish.
1964
1965
1966

1967 **5.2.1.49 Consumer Use – Other consumer uses – Fabric spray (Fabric spray)**
1968

1969 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in fabric spray:
1970 **Presents an unreasonable risk of injury to health (consumers and bystanders).**

1971
1972 **For consumers, EPA found there was unreasonable risk of non-cancer effects (immuno-**
1973 **suppression) from acute inhalation exposures at the low, moderate, and high intensity use, and**
1974 **from acute dermal exposures at the moderate and high intensity use. For bystanders, EPA found**
1975 **unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at**
1976 **the moderate and high intensity use.**

1977
1978 EPA's determination that the consumer use of TCE in fabric spray presents an unreasonable risk is
1979 based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As
1980 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
1981 of use, and the uncertainties in the analysis (Section 4.3):

- 1982 • Risk estimates for the consumer use of TCE in fabric spray were based on modeled risk estimates of one
1983 aerosol product.
- 1984 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
1985 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
1986 several factors, including the concentration of TCE in products used, use patterns (including frequency,
1987 duration, amount of product used, room of use, and local ventilation), and application methods.
- 1988 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
1989 to consumers result from dermal contact not involving impeded evaporation while using the product.
1990 The magnitude of dermal exposures depends on several factors, including skin surface area, film
1991 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
1992 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
1993 chemical properties of TCE, such as high vapor pressure.

1994
1995 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
1996 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
1997 and bystanders) from the consumer use of TCE in fabric spray.
1998

1999 **5.2.1.50 Consumer Use – Other consumer uses – Film cleaner (Film cleaner)**
2000

2001 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in film cleaner:
2002 **Presents an unreasonable risk of injury to health (consumers and bystanders).**

2003
2004 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
2005 **(immunosuppression) from acute inhalation exposures at the low, moderate, and high intensity**
2006 **use, and from acute dermal exposures at the moderate and high intensity use. For bystanders,**
2007 **EPA found unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation**
2008 **exposures at the low, moderate, and high intensity use.**

2009
2010 EPA's determination that the consumer use of TCE in film cleaner presents an unreasonable risk is
2011 based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As

2012 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
2013 of use, and the uncertainties in the analysis (Section 4.3):

- 2014 • Risk estimates for the consumer use of TCE in film cleaner were based on modeled risk estimates of two
2015 aerosol products.
- 2016 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
2017 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
2018 several factors, including the concentration of TCE in products used, use patterns (including frequency,
2019 duration, amount of product used, room of use, and local ventilation), and application methods.
- 2020 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
2021 to consumers result from dermal contact not involving impeded evaporation while using the product.
2022 The magnitude of dermal exposures depends on several factors, including skin surface area, film
2023 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
2024 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
2025 chemical properties of TCE, such as high vapor pressure.

2026
2027 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
2028 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
2029 and bystanders) from the consumer use of TCE in film cleaner.
2030

2031 **5.2.1.51 Consumer Use – Other consumer uses – Hoof polish (hoof polish)**

2032
2033 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in hoof polish:
2034 **Presents an unreasonable risk of injury to health (consumers);** does not present an unreasonable risk
2035 of injury to health (bystanders).
2036

2037 **For consumers, EPA found there was unreasonable risk of non-cancer effects**
2038 **(immunosuppression) from acute inhalation exposures at the high intensity use, and from acute**
2039 **dermal exposures at the moderate and high intensity use.** For bystanders, EPA found no
2040 unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at the
2041 low, moderate, and high intensity use.
2042

2043 EPA's determination that the consumer use of TCE in hoof polish presents an unreasonable risk is based
2044 on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As
2045 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
2046 of use, and the uncertainties in the analysis (Section 4.3):

- 2047 • Risk estimates for the consumer use of TCE in hoof polish were based on modeled risk estimates of one
2048 aerosol product and shoe polish and spray/coating formulations.
- 2049 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
2050 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
2051 several factors, including the concentration of TCE in products used, use patterns (including frequency,
2052 duration, amount of product used, room of use, and local ventilation), and application methods.
- 2053 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
2054 to consumers result from dermal contact not involving impeded evaporation while using the product.
2055 The magnitude of dermal exposures depends on several factors, including skin surface area, film
2056 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional

2057 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
2058 chemical properties of TCE, such as high vapor pressure.

2059
2060 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
2061 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers)
2062 from the consumer use of TCE in hoof polish.
2063

2064 5.2.1.52 Consumer Use – Other consumer uses – Pepper spray (Pepper spray)

2065
2066 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in pepper spray: Does
2067 not present an unreasonable risk of injury to health (consumers and bystanders).
2068

2069 For consumers, EPA found there was no unreasonable risk of non-cancer effects (immunosuppression)
2070 from acute inhalation and dermal exposures at the low, moderate, and high intensity use. For bystanders,
2071 EPA found no unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation
2072 exposures at the low, moderate, and high intensity use.
2073

2074 EPA's determination that the consumer use of TCE in pepper spray does not present an unreasonable
2075 risk is based on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table
2076 4-60). As explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the
2077 condition of use, and the uncertainties in the analysis (Section 4.3):

- 2078 • Risk estimates for the consumer use of TCE in pepper spray were based on modeled risk estimates of
2079 two aerosol products.
- 2080 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
2081 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
2082 several factors, including the concentration of TCE in products used, use patterns (including frequency,
2083 duration, amount of product used, room of use, and local ventilation), and application methods.
- 2084 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
2085 to consumers result from dermal contact not involving impeded evaporation while using the product.
2086 The magnitude of dermal exposures depends on several factors, including skin surface area, film
2087 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
2088 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
2089 chemical properties of TCE, such as high vapor pressure.
2090

2091 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
2092 uncertainties support EPA's determination that there is no unreasonable risk of injury to health
2093 (consumers and bystanders) from the consumer use of TCE in pepper spray.
2094

2095 5.2.1.53 Consumer Use – Other consumer uses – Toner aid (Toner aid)

2096
2097 Section 6(b)(4)(A) unreasonable risk determination for the consumer use of TCE in toner aid: Presents
2098 an unreasonable risk of injury to health (consumers and bystanders).
2099

2100 **For consumers, EPA found there was unreasonable risk of non-cancer effects (immuno-**
2101 **suppression) from acute inhalation exposures at the low, moderate, and high intensity use, and**
2102 **from acute dermal exposures at the moderate and high intensity use. For bystanders, EPA found**

2103 **unreasonable risk of non-cancer effects (immunosuppression) from acute inhalation exposures at**
2104 **the moderate and high intensity use.**

2105
2106 EPA's determination that the consumer use of TCE in toner aid presents an unreasonable risk is based
2107 on the comparison of the risk estimates for non-cancer effects to the benchmarks (Table 4-60). As
2108 explained in Section 5.1, EPA also considered the health effects of TCE, the exposures for the condition
2109 of use, and the uncertainties in the analysis (Section 4.3):

- 2110 • Risk estimates for the consumer use of TCE in toner aid were based on modeled risk estimates of
2111 one aerosol product.
- 2112 • Inhalation exposures to consumers and bystanders were evaluated with the Consumer Exposure Model
2113 Version 2.1 (CEM 2.1). The magnitude of inhalation exposures to consumers and bystanders depends on
2114 several factors, including the concentration of TCE in products used, use patterns (including frequency,
2115 duration, amount of product used, room of use, and local ventilation), and application methods.
- 2116 • Dermal exposures to consumers were evaluated with the CEM (Fraction Absorbed). Dermal exposures
2117 to consumers result from dermal contact not involving impeded evaporation while using the product.
2118 The magnitude of dermal exposures depends on several factors, including skin surface area, film
2119 thickness, concentration of TCE in product used, dermal exposure duration, and estimated fractional
2120 absorption. The potential for dermal exposures to TCE is limited by several factors including physical-
2121 chemical properties of TCE, such as high vapor pressure.

2122
2123 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
2124 uncertainties support EPA's determination that there is unreasonable risk of injury to health (consumers
2125 and bystanders) from the consumer use of TCE in toner aid.

2127 **5.2.1.54 Disposal – Disposal – Industrial pre-treatment; Industrial wastewater**
2128 **treatment; Publicly owned treatment works (POTW) (Disposal)**

2129
2130 Section 6(b)(4)(A) unreasonable risk determination for the disposal of TCE: Presents an unreasonable
2131 **risk of injury to health (workers);** does not present an unreasonable risk of injury to health (ONUs).

2132
2133 **For workers, EPA found that there was unreasonable risk of non-cancer effects (autoimmunity)**
2134 **from chronic inhalation exposures at the high-end and dermal exposures at the central tendency**
2135 **and high-end, even when assuming use of PPE. In addition, for workers, EPA found that there**
2136 **was unreasonable risk of cancer from chronic dermal exposures at the central tendency and high-**
2137 **end, even when assuming use of PPE.** For ONUs, EPA found that there was no unreasonable risk of
2138 non-cancer effects from acute (immunosuppression) and chronic (autoimmunity) inhalation exposures at
2139 the central tendency, or of cancer from chronic inhalation exposures at the central tendency.

2140
2141 EPA's determination that the disposal of TCE presents an unreasonable risk is based on the comparison
2142 of the risk estimates for non-cancer effects and cancer to the benchmarks (Table 4-59). As explained in
2143 Section 5.1, EPA also considered the health effects of TCE, the exposures from the condition of use, and
2144 the uncertainties in the analysis (Section 4.3), including uncertainties related to the exposure for ONUs:

- 2145 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of non-cancer
2146 effects from chronic inhalation exposures at the high-end support an unreasonable risk determination.
2147 Similarly, when assuming use of gloves with PF of 20, the risk estimates of non-cancer effects and

2148 cancer from chronic dermal exposures at the central tendency and high-end support an unreasonable risk
2149 determination.

- 2150 • For workers, when assuming the use of respirators with APF of 50, the risk estimates of cancer from
2151 chronic inhalation exposures at the high-end do not support an unreasonable risk determination.
- 2152 • For workers, when assuming the use of respirators with APF of 10 and gloves with PF of 20, the risk
2153 estimates of non-cancer effects from acute inhalation and dermal exposures at the high-end do not
2154 support an unreasonable risk determination.
- 2155 • Based on EPA's analysis, the data for worker and ONU inhalation exposures could not be distinguished;
2156 however, ONU inhalation exposures are assumed to be lower than inhalation exposures for workers
2157 directly handling the chemical substance. To account for this uncertainty, EPA considered the workers'
2158 central tendency risk estimates from inhalation exposures when determining ONUs' unreasonable risk.
- 2159 • Inhalation exposures were assessed using monitoring data from repackaging as a surrogate for disposal.
- 2160 • Dermal exposures were assessed using modeled data.

2161 In summary, the risk estimates, the health effects of TCE, the exposures, and consideration of
2162 uncertainties support EPA's determination that there is unreasonable risk of injury to health (workers)
2163 from disposal of TCE.
2164

2165 **5.2.2 Environment**

2166 Section 6(b)(4)(A) unreasonable risk determination for all conditions of use of TCE: Does not present an
2167 unreasonable risk of injury **to the environment** (aquatic, sediment-dwelling, and terrestrial organisms).
2168

2169 For all conditions of use, for aquatic organisms, the RQ values (Table 4-57 and Table 4-58) do not support an
2170 unreasonable risk determination in water for acute and chronic exposures of TCE. To characterize the exposure
2171 to TCE by aquatic organisms, EPA used modeled data to represent surface water concentrations near facilities
2172 actively releasing TCE to surface water, and monitored concentrations to represent ambient water
2173 concentrations of TCE. EPA considered the biological relevance of the species to determine the concentrations
2174 of concern for the location of surface water concentration data to produce RQs, as well as frequency and
2175 duration of the exposure. Some site-specific RQs that were calculated from modeled release data were greater
2176 than or equal to one. Facilities with RQs ≥ 1 and duration of the exceedance are presented in Table 4-1.
2177 Uncertainties related to these particular estimates are discussed in Section 4.3.1. Uncertainties in the modeled
2178 concentrations include underestimating exposure due to limitations in data reported through TRI and DMR, and
2179 some sites may not be included in the data analyzed. However, the modeled concentrations also overestimates
2180 exposures because it does not take volatilization of TCE into consideration; furthermore, the model does not
2181 indicate if the 20 days of exceedance of the chronic COC are consecutive or could occur sporadically
2182 throughout the year. Since TCE is a volatile chemical, it is more likely that a chronic exposure duration will
2183 occur when there are more days of exceedances. As an additional uncertainty, the model may not consider
2184 dilution in static water bodies. The monitoring data did not reflect conditions downstream from facilities and
2185 was limited temporally and geographically.
2186

2187 For sediment-dwelling invertebrates, the toxicity of TCE is similar to the toxicity to aquatic
2188 invertebrates. TCE is expected to remain in aqueous phases and not adsorb to sediment due to its water
2189 solubility and low partitioning to organic matter. TCE has relatively low partitioning to organic matter
2190 and biodegrades slowly, so TCE concentrations in sediment pore water are expected to be similar to the
2191 concentrations in the overlying water or lower in the deeper part of sediment where anaerobic condition

2192 prevails. Thus, the TCE detected in sediments is likely from the pore water. Therefore, for sediment-
2193 dwelling organisms, the risk estimates, based on the highest ambient surface water concentration, do not
2194 support an unreasonable risk determination to sediment-dwelling organisms from acute or chronic
2195 exposures. There is uncertainty due to the lack of ecotoxicity studies specifically for sediment-dwelling
2196 organisms and limited sediment monitoring data.

2197
2198 For terrestrial organisms, TCE exposure is expected to be low since physical-chemical properties do not support
2199 an exposure pathway through water and soil pathways to these organisms.

2200
2201 In summary, the risk estimates, the environmental effects of TCE, the exposures, physical-chemical properties
2202 of TCE, and consideration of uncertainties support EPA’s determination that there is no unreasonable risk to the
2203 environment from all conditions of use of TCE.

2204

2205 **5.3 Unreasonable Risk Determination Conclusion**

2206 **5.3.1 No Unreasonable Risk Determinations**

2207

2208 TSCA section 6(b)(4) requires EPA to conduct Risk Evaluations to determine whether chemical
2209 substances present unreasonable risk under their conditions of use. In conducting Risk Evaluations,
2210 “EPA will determine whether the chemical substance presents an unreasonable risk of injury to health or
2211 the environment under each condition of use within the scope of the Risk Evaluation...” 40 CFR
2212 702.47. Pursuant to TSCA section 6(i)(1), a determination of “no unreasonable risk” shall be issued by
2213 order and considered to be final agency action. Under EPA’s implementing regulations, “[a]
2214 determination made by EPA that the chemical substance, under one or more of the conditions of use
2215 within the scope of the Risk Evaluations, does not present an unreasonable risk of injury to health or the
2216 environment will be issued by order and considered to be a final Agency action, effective on the date of
2217 issuance of the order.” 40 CFR 702.49(d).

2218

2219 EPA has determined that the following conditions of use of TCE do not present an unreasonable risk of
2220 injury to health or the environment:

- 2221 • Distribution in commerce (Section 5.2.1.8, Section 5.2.2, Section 4, and Section 3)
- 2222 • Consumer use in pepper spray (Section 5.2.1.52, Section 5.2.2, Section 4, and Section 3)

2223 This subsection of the final Risk Evaluation therefore constitutes the order required under TSCA section
2224 6(i)(1), and the “no unreasonable risk” determinations in this subsection are considered to be final
2225 agency action effective on the date of issuance of this order. All assumptions that went into reaching the
2226 determinations of no unreasonable risk for these conditions of use, including any considerations
2227 excluded for these conditions of use, are incorporated into this order.

2228

2229 The support for each determination of “no unreasonable risk” is set forth in Section 5.2 of the final Risk
2230 Evaluation, “Detailed Unreasonable Risk Determinations by Condition of Use.” This subsection also
2231 constitutes the statement of basis and purpose required by TSCA section 26(f).

2232

5.3.2 Unreasonable Risk Determinations

EPA has determined that the following conditions of use of TCE present an unreasonable risk of injury to health:

- Manufacturing: domestic manufacture
- Manufacturing: import
- Processing: processing as a reactant/intermediate
- Processing: incorporation into a formulation, mixture or reaction product
- Processing: incorporation into articles
- Processing: repackaging
- Processing: recycling
- Industrial and commercial use as a solvent for open-top batch vapor degreasing
- Industrial and commercial use as a solvent for closed-loop batch vapor degreasing
- Industrial and commercial use as a solvent for in-line conveyORIZED vapor degreasing
- Industrial and commercial use as a solvent for in-line web cleaner vapor degreasing
- Industrial and commercial use as a solvent for cold cleaning
- Industrial and commercial use as a solvent for aerosol spray degreaser/cleaner and mold release
- Industrial and commercial use as a lubricant and grease in tap and die fluid
- Industrial and commercial use as a lubricant and grease in penetrating lubricant
- Industrial and commercial use as an adhesive and sealant in solvent-based adhesives and sealants; tire repair cement/sealer; mirror edge sealant
- Industrial and commercial use as a functional fluid in heat exchange fluid
- Industrial and commercial use in paints and coatings as a diluent in solvent-based paints and coatings
- Industrial and commercial use in cleaning and furniture care products in carpet cleaner and wipe cleaning
- Industrial and commercial use in laundry and dishwashing products in spot remover
- Industrial and commercial use in arts, crafts, and hobby materials in fixatives and finishing spray coatings
- Industrial and commercial use in corrosion inhibitors and anti-scaling agents.
- Industrial and commercial use as processing aids in process solvent used in battery manufacture; process solvent used in polymer fiber spinning, fluoroelastomer manufacture and Alcantara manufacture; extraction solvent used in caprolactam manufacture; precipitant used in beta-cyclodextrin manufacture
- Industrial and commercial use as ink, toner and colorant products in toner aid
- Industrial and commercial use in automotive care products in brake parts cleaner
- Industrial and commercial use in apparel and footwear care products in shoe polish
- Industrial and commercial use in hoof polish; gun scrubber; pepper spray; other miscellaneous industrial and commercial uses
- Consumer use as a solvent in brake and parts cleaner
- Consumer use as a solvent in aerosol electronic degreaser/cleaner
- Consumer use as a solvent in liquid electronic degreaser/cleaner
- Consumer use as a solvent in aerosol spray degreaser/cleaner

- 2276 • Consumer use as a solvent in liquid degreaser/cleaner
- 2277 • Consumer use as a solvent in aerosol gun scrubber
- 2278 • Consumer use as a solvent in liquid gun scrubber
- 2279 • Consumer use as a solvent in mold release
- 2280 • Consumer use as a solvent in aerosol tire cleaner
- 2281 • Consumer use as a solvent in liquid tire cleaner
- 2282 • Consumer use as a lubricant and grease in tap and die fluid
- 2283 • Consumer use as a lubricant and grease in penetrating lubricant
- 2284 • Consumer use as an adhesive and sealant in solvent-based adhesive and sealant
- 2285 • Consumer use as an adhesive and sealant in mirror edge sealant
- 2286 • Consumer use as an adhesive and sealant in tire repair cement/sealer
- 2287 • Consumer use as a cleaning and furniture care product in carpet cleaner
- 2288 • Consumer use as a cleaning and furniture care product in aerosol spot remover
- 2289 • Consumer use as a cleaning and furniture care product in liquid spot remover
- 2290 • Consumer use in arts, crafts, and hobby materials in fixative and finishing spray coatings
- 2291 • Consumer use in apparel and footwear products in shoe polish
- 2292 • Consumer use in fabric spray
- 2293 • Consumer use in film cleaner
- 2294 • Consumer use in hoof polish
- 2295 • Consumer use in toner aid
- 2296 • Disposal

2297 EPA will initiate TSCA section 6(a) risk management actions on these conditions of use as required
2298 under TSCA section 6(c)(1). Pursuant to TSCA section 6(i)(2), the “unreasonable risk”
2299 determinations for these conditions of use are not considered final agency action.
2300

2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348

REFERENCES

- [Abernethy, S; Bobra, AM; Shiu, WY; Wells, PG; Mackay, D.](#) (1986). Acute lethal toxicity of hydrocarbons and chlorinated hydrocarbons to two planktonic crustaceans the key role of organism-water partitioning. *Aquat Toxicol AMST*: 163-174.
- [Adgate, JL; Church, TR; Ryan, AD; Ramachandran, G; Fredrickson, AL; Stock, TH; Morandi, MT; Sexton, K.](#) (2004). Outdoor, indoor, and personal exposure to VOCs in children. *Environ Health Perspect* 112: 1386-1392. <http://dx.doi.org/10.1289/ehp.7107>
- [AIHA.](#) (2009). Mathematical models for estimating occupational exposure to chemicals. In CB Keil; CE Simmons; TR Anthony (Eds.), (2nd ed.). Fairfax, VA: AIHA Press.
- [Alanee, S; Clemons, J; Zahnd, W; Sadowski, D; Dynda, D.](#) (2015). Trichloroethylene Is Associated with Kidney Cancer Mortality: A Population-based Analysis. *Anticancer Res* 35: 4009-4013.
- [Alexander, HC; McCarty, WM; Bartlett, EA.](#) (1978). Toxicity of perchloroethylene, trichloroethylene, 1,1,1-trichloroethane, and methylene chloride to fathead minnows. *Bull Environ Contam Toxicol* 20: 344-352. <http://dx.doi.org/10.1007/BF01683531>
- [Ando, T; Otsuka, S; Nishiyama, M; Senoo, K; Watanabe, MM; Matsumoto, S.](#) (2003). Toxic Effects of Dichloromethane and Trichloroethylene on the Growth of Planktonic Green Algae, *Chlorella vulgaris* NIES227, *Selenastrum capricornutum* NIES35, and *Volvox steinii* NIES545. *18*: 43-46.
- [Anttila, A; Pukkala, E; Sallmen, M; Hernberg, S; Hemminki, K.](#) (1995). Cancer incidence among Finnish workers exposed to halogenated hydrocarbons. *J Occup Environ Med* 37: 797-806.
- [Aranyi, C; O'Shea, WJ; Graham, JA; Miller, FJ.](#) (1986). The effects of inhalation of organic chemical air contaminants on murine lung host defenses. *Fundam Appl Toxicol* 6: 713-720. [http://dx.doi.org/10.1016/0272-0590\(86\)90184-3](http://dx.doi.org/10.1016/0272-0590(86)90184-3).
- [Arito, H; Takahashi, M; Ishikawa, T.](#) (1994). Effect of subchronic inhalation exposure to low-level trichloroethylene on heart rate and wakefulness-sleep in freely moving rats. *Sangyo Igaku* 36: 1-8.
- [ATSDR.](#) (2019). Toxicological Profile for Trichloroethylene: CAS # 79-01-6. Atlanta, GA. <https://www.atsdr.cdc.gov/ToxProfiles/tp19.pdf>
- [Axelson, O; Seldén, A; Andersson, K; Hogstedt, C.](#) (1994). Updated and expanded Swedish cohort study on trichloroethylene and cancer risk. *J Occup Med* 36: 556-562.
- [Bahr, DE; Aldrich, TE; Seidu, D; Brion, GM; Tollerud, DJ; Plant, PGD.](#) (2011). OCCUPATIONAL EXPOSURE TO TRICHLOROETHYLENE AND CANCER RISK FOR WORKERS AT THE PADUCAH GASEOUS DIFFUSION PLANT. *Int J Occup Med Environ Health* 24: 67-77. <http://dx.doi.org/10.2478/s13382-011-0007-1>
- [Baldwin, PE; Maynard, AD.](#) (1998a). A survey of wind speed in indoor workplaces. *Ann Occup Hyg* 42: 303-313. [http://dx.doi.org/10.1016/S0003-4878\(98\)00031-3](http://dx.doi.org/10.1016/S0003-4878(98)00031-3)
- [Banerjee, S; Yalkowsky, SH; Valvani, SC.](#) (1980). Water solubility and octanol-water partition-coefficients of organics - limitations of the solubility-partition coefficient correlation. *Environ Sci Technol* 14: 1227-1229. <http://dx.doi.org/10.1021/es60170a013>
- [Baraka, A; Mikhail, M; Guemei, A; El Ghotny, S.](#) (2009). Effect of targeting mitogen-activated protein kinase on cardiac remodeling in rats. *J Cardiovasc Pharmacol Ther* 14: 339-346. <http://dx.doi.org/10.1177/1074248409349620>
- [Barrows, ME; Petrocelli, SR; Macek, KJ; Carroll, JJ.](#) (1980). Bioconcentration and elimination of selected water pollutants by bluegill sunfish (*Lepomis macrochirus*). In R Haque (Ed.), Dynamics, exposure and hazard assessment of toxic chemicals (pp. 379-392). Ann Arbor, MI: Ann Arbor Science.
- [Bassig, BA; Zhang, L; Vermeulen, R; Tang, X; Li, G; Hu, W, ei; Guo, W; Purdue, MP; Yin, S; Rappaport, SM; Shen, M, in; Ji, Z; Qiu, C; Ge, Y; Hosgood, HD; Reiss, B; Wu, B; Xie, Y; Li, L;](#)

2349 [Yue, F, ei; Freeman, LEB; Blair, A; Hayes, RB; Huang, H; Smith, MT; Rothman, N; Lan, Q.](#)
2350 (2016). Comparison of hematological alterations and markers of B-cell activation in workers
2351 exposed to benzene, formaldehyde and trichloroethylene. *Carcinogenesis* 37: 692-700.
2352 <http://dx.doi.org/10.1093/carcin/bgw053>
2353 [Beamer, PI; Luik, CE; Abrell, L; Campos, S; Martinez, ME; Sáez, AE.](#) (2012). Concentration of
2354 trichloroethylene in breast milk and household water from Nogales, Arizona. *Environ Sci*
2355 *Technol* 46: 9055-9061. <http://dx.doi.org/10.1021/es301380d>
2356 [Beliles, RP; Brusick, DJ; Mecler, FJ.](#) (1980). Teratogenic-mutagenic risk of workplace contaminants:
2357 trichloroethylene, perchloroethylene, and carbon disulfide. (210-77-0047). Cincinnati, OH:
2358 National Institute for Occupation Safety and Health.
2359 [Bernauer, U; Birner, G; Dekant, W; Henschler, D.](#) (1996). Biotransformation of trichloroethene: Dose-
2360 dependent excretion of 2,2,2-trichloro-metabolites and mercapturic acids in rats and humans
2361 after inhalation. *Arch Toxicol* 70: 338-346. <http://dx.doi.org/10.1007/s002040050283>.
2362 [Bertilsson, J; Petersson, U; Fredriksson, PJ; Magnusson, M; Fransson, PA.](#) (2017). Use of pepper spray
2363 in policing: retrospective study of situational characteristics and implications for violent
2364 situations. *18*: 391-406. <http://dx.doi.org/10.1080/15614263.2017.1288119>
2365 [Blossom, SJ; Cooney, CA; Melnyk, SB; Rau, JL; Swearingen, CJ; Wessinger, WD.](#) (2013). Metabolic
2366 changes and DNA hypomethylation in cerebellum are associated with behavioral alterations in
2367 mice exposed to trichloroethylene postnatally. *Toxicol Appl Pharmacol* 269: 263-269.
2368 <http://dx.doi.org/10.1016/j.taap.2013.03.025>
2369 [Blossom, SJ; Doss, JC.](#) (2007). Trichloroethylene alters central and peripheral immune function in
2370 autoimmune-prone MRL(+/+) mice following continuous developmental and early life exposure.
2371 *J Immunotoxicol* 4: 129-141. <http://dx.doi.org/10.1080/15476910701337035>.
2372 [Blossom, SJ; Doss, JC; Hennings, LJ; Jernigan, S; Melnyk, S; James, SJ.](#) (2008). Developmental
2373 exposure to trichloroethylene promotes CD4+ T cell differentiation and hyperactivity in
2374 association with oxidative stress and neurobehavioral deficits in MRL+/+ mice. *Toxicol Appl*
2375 *Pharmacol* 231: 344-353. <http://dx.doi.org/10.1016/j.taap.2008.05.009>.
2376 [Blossom, SJ; Melnyk, SB; Li, M; Wessinger, WD; Cooney, CA.](#) (2016). Inflammatory and oxidative
2377 stress-related effects associated with neurotoxicity are maintained after exclusively prenatal
2378 trichloroethylene exposure. *Neurotoxicology* 59: 164-174.
2379 <http://dx.doi.org/10.1016/j.neuro.2016.01.002>.
2380 [Boice, JD, Jr; Marano, D; Fryzek, J; Sadler, C; McLaughlin, JK.](#) (1999). Mortality among aircraft
2381 manufacturing workers. *Occup Environ Med* 56: 581-597.
2382 <http://dx.doi.org/10.1136/oem.56.9.581>
2383 [Boice, JD; Marano, DE; Cohen, SS; Mumma, MT; Blot, WJ; Brill, AB; Fryzek, JP; Henderson, BE;](#)
2384 [McLaughlin, JK.](#) (2006). Mortality among Rocketdyne workers who tested rocket engines, 1948-
2385 1999. *J Occup Environ Med* 48: 1070-1092.
2386 <http://dx.doi.org/10.1097/01.jom.0000240661.33413.b5>
2387 [Bond, GR.](#) (1996). Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report
2388 and speculation on mechanistic similarity to halothane induced hepatitis [Review]. *Clin Toxicol*
2389 34: 461-466.
2390 [Bouman, HG; Broekhuizen, ML; Baasten, AM; Gittenberger-De Groot, AC; Wenink, AC.](#) (1998).
2391 Diminished growth of atrioventricular cushion tissue in stage 24 retinoic acid-treated chicken
2392 embryos. *Dev Dyn* 213: 50-58. [http://dx.doi.org/10.1002/\(SICI\)1097-0177\(199809\)213:1<50::AID-AJA5>3.0.CO;2-X](http://dx.doi.org/10.1002/(SICI)1097-0177(199809)213:1<50::AID-AJA5>3.0.CO;2-X)
2393 [Bouman, HGA; Broekhuizen, MLA; Baasten, AMJ; Gittenberger-De Groot, AC; Wenink, ACG.](#) (1995).
2394 Spectrum of looping disturbances in stage 34 chicken hearts after retinoic acid treatment. *Anat*
2395 *Rec* 243: 101-108. <http://dx.doi.org/10.1002/ar.1092430112>
2396

2397 [Bouwer, EJ; McCarty, PL.](#) (1983). Transformations of 1- and 2-carbon halogenated aliphatic organic
2398 compounds under methanogenic conditions. *Appl Environ Microbiol* 45: 1286-1294.

2399 [Bove, FJ.](#) (1996). Public drinking water contamination and birthweight, prematurity, fetal deaths, and
2400 birth defects. *Toxicol Ind Health* 12: 255-266.

2401 [Bove, FJ; Fulcomer, MC; Klotz, JB; Esmart, J; Dufficy, EM; Savrin, JE.](#) (1995). Public drinking water
2402 contamination and birth outcomes. *Am J Epidemiol* 141: 850-862.

2403 [Bove, FJ; Ruckart, PZ; Maslia, M; Larson, TC.](#) (2014a). Evaluation of mortality among marines and
2404 navy personnel exposed to contaminated drinking water at USMC base Camp Lejeune: a
2405 retrospective cohort study. *Environ Health* 13: 10. <http://dx.doi.org/10.1186/1476-069X-13-10>

2406 [Bove, FJ; Ruckart, PZ; Maslia, M; Larson, TC.](#) (2014b). Mortality study of civilian employees exposed
2407 to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study.
2408 *Environ Health* 13: 68. <http://dx.doi.org/10.1186/1476-069X-13-68>

2409 [Boverhof, DR; Krieger, SM; Hotchkiss, J; Stebbins, KE; Thomas, J; Woolhiser, MR.](#) (2013).
2410 Assessment of the immunotoxic potential of trichloroethylene and perchloroethylene in rats
2411 following inhalation exposure. *J Immunotoxicol* 10: 311-320.
2412 <http://dx.doi.org/10.3109/1547691X.2012.735275>

2413 [Boyer, A; Finch, W; Runyan, R.](#) (2000). Trichloroethylene inhibits development of embryonic heart
2414 valve precursors in vitro. *Toxicol Sci* 53: 109-117. <http://dx.doi.org/10.1093/toxsci/53.1.109>

2415 [Brack, W; Rottler, H.](#) (1994). Toxicity testing of highly volatile chemicals with green algae: A new
2416 assay. *Environ Sci Pollut Res Int* 1: 223-228.

2417 [Brender, JD; Shinde, MU; Zhan, FB; Gong, X; Langlois, PH.](#) (2014). Maternal residential proximity to
2418 chlorinated solvent emissions and birth defects in offspring: a case-control study. *Environ Health*
2419 13: 96. <http://dx.doi.org/10.1186/1476-069X-13-96>

2420 [Bridges, J; Sauer, UG; Buesen, R; Deferme, L; Tollefsen, KE; Tralau, T; van Ravenzwaay, B; Poole, A;
2421 Pemberton, M.](#) (2017). Framework for the quantitative weight-of-evidence analysis of 'omics
2422 data for regulatory purposes. *Regul Toxicol Pharmacol* 91: S46-S60.
2423 <http://dx.doi.org/10.1016/j.yrtph.2017.10.010>

2424 [Bridges, J; Solomon, KR.](#) (2016). Quantitative weight-of-evidence analysis of the persistence,
2425 bioaccumulation, toxicity, and potential for long-range transport of the cyclic volatile methyl
2426 siloxanes [Review]. *J Toxicol Environ Health B Crit Rev* 19: 345-379.
2427 <http://dx.doi.org/10.1080/10937404.2016.1200505>

2428 [Broderius, SJ; Kahl, MD; Elonen, GE; Hammermeister, DE; Hoglund, MD.](#) (2005). A Comparison of
2429 the Lethal and Sublethal Toxicity of Organic Chemical Mixtures to the Fathead Minnow
2430 (*Pimphales promelas*). 24: 3117-3127.

2431 [Broekhuizen M, LA; Gittenberger-De Groot, AC; Baasten, MJ; Wladimiroff, JW; Poelmann, RE.](#)
2432 (1998). Disturbed vagal nerve distribution in embryonic chick hearts after treatment with all-
2433 trans retinoic acid. *Anat Embryol* 197: 391-397. <http://dx.doi.org/10.1007/s004290050150>

2434 [Broekhuizen, ML; Bouman, HG; Mast, F; Mulder, PG; Gittenberger-De Groot, AC; Wladimiroff, JW.](#)
2435 (1995). Hemodynamic changes in HH stage 34 chick embryos after treatment with all-trans-
2436 retinoic acid. *Pediatr Res* 38: 342-348. <http://dx.doi.org/10.1203/00006450-199509000-00012>

2437 [Bross, G; Difrancesco, D; Desmond, ME.](#) (1983). The effects of low dosages of trichloroethylene on
2438 chick development. *Toxicology* 28: 283-294. [http://dx.doi.org/10.1016/0300-483X\(83\)90002-1](http://dx.doi.org/10.1016/0300-483X(83)90002-1)

2439 [Brüning, T; Pesch, B; Wiesenhütter, B; Rabstein, S; Lammert, M; Baumüller, A; Bolt, H.](#) (2003). Renal
2440 cell cancer risk and occupational exposure to trichloroethylene: Results of a consecutive case-
2441 control study in Arnsberg, Germany. *Am J Ind Med* 43: 274-285.
2442 <http://dx.doi.org/10.1002/ajim.10185>

2443 [Brus, R; Szkilnik, R; Nowak, P; Popieluch, I; Kasperska, A; Ostadalova Vvana, TP; Ostadal, B; Kolar,
2444 F.](#) (1995). Inotropic effect of increasing concentration of Ca-2+ in the fetal rat heart with retinoic

2445 acid-induced malformations. *Pediatr Res* 38: 892-895. [http://dx.doi.org/10.1203/00006450-](http://dx.doi.org/10.1203/00006450-199512000-00011)
2446 [199512000-00011](http://dx.doi.org/10.1203/00006450-199512000-00011)

2447 [Buben, JA; O'Flaherty, EJ.](#) (1985). Delineation of the role of metabolism in the hepatotoxicity of
2448 trichloroethylene and perchloroethylene: A dose-effect study. *Toxicol Appl Pharmacol* 78: 105-
2449 122.

2450 [Buccafusco, RJ; Ells, SJ; LeBlanc, GA.](#) (1981). Acute toxicity of priority pollutants to bluegill (*Lepomis*
2451 *macrochirus*). *Bull Environ Contam Toxicol* 26: 446-452. <http://dx.doi.org/10.1007/BF01622118>

2452 [Buhagen, M; Grønskag, A; Ragde, SF; Hilt, B.](#) (2016). Association between kidney cancer and
2453 occupational exposure to trichloroethylene. *J Occup Environ Med* 58: 957-959.
2454 <http://dx.doi.org/10.1097/JOM.0000000000000838>

2455 [Burnham, KP; Anderson, DR.](#) (2002). Model selection and multimodel inference: a practical
2456 information-theoretic approach (2nd ed.). New York: Springer.
2457 <http://www.springer.com/statistics/statistical+theory+and+methods/book/978-0-387-95364-9>

2458 [Caldwell, PT; Thorne, PA; Johnson, PD; Boitano, S; Runyan, RB; Selmin, O.](#) (2008). Trichloroethylene
2459 disrupts cardiac gene expression and calcium homeostasis in rat myocytes. *Toxicol Sci* 104: 135-
2460 143. <http://dx.doi.org/10.1093/toxsci/kfn078>

2461 [CalEPA.](#) (2009). Public health goals for chemicals in drinking water: Trichloroethylene. Sacramento,
2462 CA. https://oehha.ca.gov/media/downloads/water/chemicals/phg/tcephg070909_0.pdf

2463 [CARB.](#) (2000). Initial statement of reasons for the proposed airborne toxic control measure for
2464 emissions of chlorinated toxic air contaminants from automotive maintenance and repair
2465 activities. California Air Resources Board.

2466 [CARB.](#) (2006). California Dry Cleaning Industry Technical Assessment Report. Stationary Source
2467 Division, Emissions Assessment Branch.
2468 <https://www.arb.ca.gov/toxics/dryclean/finaldrycleantechreport.pdf>

2469 [Carney, EW; Thorsrud, BA; Dugard, PH; Zablony, CL.](#) (2006). Developmental toxicity studies in
2470 Crl:CD (SD) rats following inhalation exposure to trichloroethylene and perchloroethylene. *Birth*
2471 *Defects Res B Dev Reprod Toxicol* 77: 405-412. <http://dx.doi.org/10.1002/bdrb.20091>

2472 [Chan, CC; Vainer, L; Martin, JW; Williams, DT.](#) (1990). Determination of organic contaminants in
2473 residential indoor air using an adsorption-thermal desorption technique. *J Air Waste Manag*
2474 *Assoc* 40: 62-67.

2475 [Charbotel, B; Fevotte, J; Hours, M; Martin, JL; Bergeret, A.](#) (2006). Case-control study on renal cell
2476 cancer and occupational exposure to trichloroethylene. Part II: Epidemiological aspects. *Ann*
2477 *Occup Hyg* 50: 777-787. <http://dx.doi.org/10.1093/annhyg/mel039>

2478 [Charles River Laboratories.](#) (2019). An oral (drinking water) study of the effects of trichloroethylene
2479 (TCE) on fetal heart development in Sprague Dawley rats: Laboratory Project ID 00459506.
2480 (EPA-HQ-OPPT-2016-0737-0120).

2481 [Cherrie, JW; Semple, S; Christopher, Y; Saleem, A; Hughson, GW; Phillips, A.](#) (2006). How important
2482 is inadvertent ingestion of hazardous substances at work? *Ann Occup Hyg* 50: 693-704.
2483 <http://dx.doi.org/10.1093/annhyg/mel035>.

2484 [Chia, SE; Ong, CN; Tsakok, MF; Ho, A.](#) (1996). Semen parameters in workers exposed to
2485 trichloroethylene. *Reprod Toxicol* 10: 295-299. [http://dx.doi.org/10.1016/0890-6238\(96\)00058-5](http://dx.doi.org/10.1016/0890-6238(96)00058-5)

2486 [Chin, JY; Godwin, C; Parker, E; Robins, T; Lewis, T; Harbin, P; Batterman, S.](#) (2014). Levels and
2487 sources of volatile organic compounds in homes of children with asthma. *Indoor Air* 24: 403-
2488 415. <http://dx.doi.org/10.1111/ina.12086>

2489 Chinn, KSK. (1981). A simple model for predicting chemical agent evaporation. Alexandria, VA: U.S.
2490 Department of Defense, Defense Technical Information Center, Cameron Station.
2491 http://www.epa.gov/opptintr/exposure/presentations/efast/chinn_1981_a_simple_method_for_pr
2492 [edicting.pdf](http://www.epa.gov/opptintr/exposure/presentations/efast/chinn_1981_a_simple_method_for_pr)

2493 [Chittasobhaktra, T; Wannanukul, W; Wattanakrai, P; Pramoolsinsap, C; Sohonslitsuk, A; Nitiyanant,](#)
2494 [P.](#) (1997). Fever, skin rash, jaundice and lymphadenopathy after trichloroethylene exposure: A
2495 case report. (BIOSIS/98/04989). Volume 80; Suppl. 1.
2496 [Chiu, WA; Micallef, S; Monster, AC; Bois, FY.](#) (2007). Toxicokinetics of inhaled trichloroethylene and
2497 tetrachloroethylene in humans at 1 ppm: Empirical results and comparisons with previous
2498 studies. *Toxicol Sci* 95: 23-36. <http://dx.doi.org/10.1093/toxsci/kfl129>
2499 [Christensen, KY; Vizcaya, D; Richardson, H; Lavoué, J; Aronson, K; Siemiatycki, J.](#) (2013). Risk of
2500 selected cancers due to occupational exposure to chlorinated solvents in a case-control study in
2501 Montreal. *J Occup Environ Med* 55: 198-208. <http://dx.doi.org/10.1097/JOM.0b013e3182728eab>
2502 [Cichocki, JA; Guyton, KZ; Guha, N; Chiu, WA; Rusyn, I; Lash, LH.](#) (2016). Target Organ Metabolism,
2503 Toxicity, and Mechanisms of Trichloroethylene and Perchloroethylene: Key Similarities,
2504 Differences, and Data Gaps [Review]. *J Pharmacol Exp Ther* 359: 110-123.
2505 <http://dx.doi.org/10.1124/jpet.116.232629>.
2506 [Clayton, CA; Pellizzari, ED; Whitmore, RW; Perritt, RL; Quackenboss, JJ.](#) (1999). National Human
2507 Exposure Assessment Survey (NHEXAS): Distributions and associations of lead, arsenic, and
2508 volatile organic compounds in EPA Region 5. *J Expo Anal Environ Epidemiol* 9: 381-392.
2509 <http://dx.doi.org/10.1038/sj.jea.7500055>
2510 [Cocco, P; T'Mannetje, A; Fadda, D; Melis, M; Becker, N; de Sanjosé, S; Foretova, L; Mareckova, J;](#)
2511 [Staines, A; Kleefeld, S; Maynadié, M; Nieters, A; Brennan, P; Boffetta, P.](#) (2010). Occupational
2512 exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control
2513 study. *Occup Environ Med* 67: 341-347. <http://dx.doi.org/10.1136/oem.2009.046839>
2514 [Cocco, P; Vermeulen, R; Flore, V; Nonne, T; Campagna, M; Purdue, M; Blair, A; Monnereau, A; Orsi,](#)
2515 [L; Clavel, J; Becker, N; de Sanjosé, S; Foretova, L; Staines, A; Maynadié, M; Nieters, A; Miligi,](#)
2516 [L; T Mannetje, A; Krickler, A; Brennan, P; Boffetta, P; Lan, Q; Rothman, N.](#) (2013).
2517 Occupational exposure to trichloroethylene and risk of non-Hodgkin lymphoma and its major
2518 subtypes: a pooled interLymph analysis. *Occup Environ Med* 70: 795-802.
2519 <http://dx.doi.org/10.1136/oemed-2013-101551>
2520 [Collier, JM; Selmin, O; Johnson, PD; Runyan, RB.](#) (2003). Trichloroethylene effects on gene expression
2521 during cardiac development. *Birth Defects Res A Clin Mol Teratol* 67: 488-495.
2522 <http://dx.doi.org/10.1002/bdra.10073>
2523 [Cordier, S; Garlantézec, R; Labat, L; Rouget, F; Monfort, C; Bonvallot, N; Roig, B; Pulkkinen, J;](#)
2524 [Chevrier, C; Multigner, L, uc.](#) (2012). Exposure during pregnancy to glycol ethers and
2525 chlorinated solvents and the risk of congenital malformations. *Epidemiology* 23: 806-812.
2526 <http://dx.doi.org/10.1097/EDE.0b013e31826c2bd8>
2527 [Cosby, NC; Dukelow, WR.](#) (1992). Toxicology of maternally ingested trichloroethylene (TCE) on
2528 embryonal and fetal development in mice and of TCE metabolites on in vitro fertilization.
2529 *Fundam Appl Toxicol* 19: 268-274.
2530 [Daubert, TE; Danner, RP.](#) (1989). Physical and thermodynamic properties of pure chemicals: Data
2531 compilation. Washington, DC: Taylor & Francis.
2532 [Daubert, TE; Danner, RP.](#) (1995). Physical and thermodynamic properties of pure chemicals: Data
2533 compilation. Washington DC: Taylor and Francis.
2534 [Davis, A; Gift, JS; Woodall, GM; Narotsky, MG; Fourman, GL.](#) (2009). The role of developmental
2535 toxicity studies in acute exposure assessments: analysis of single-day vs. multiple-day exposure
2536 regimens. *Regul Toxicol Pharmacol* 54: 134-142. <http://dx.doi.org/10.1016/j.yrtph.2009.03.006>
2537 [Davis, LA; Sadler, TW.](#) (1981). Effects of vitamin A on endocardial cushion development in the mouse
2538 heart. *Teratology* 24: 139-148. <http://dx.doi.org/10.1002/tera.1420240205>
2539 [Dawson, B; Johnson, P; Goldberg, S; Ulreich, J.](#) (1990). Cardiac teratogenesis of trichloroethylene and
2540 dichloroethylene in a mammalian model. *J Am Coll Cardiol* 16: 1304-1309.

2541 [Dawson, B; Johnson, P; Goldberg, S; Ulreich, J.](#) (1993). Cardiac teratogenesis of halogenated
2542 hydrocarbon-contaminated drinking water. *J Am Coll Cardiol* 21: 1466-1472.
2543 [http://dx.doi.org/10.1016/0735-1097\(93\)90325-U](http://dx.doi.org/10.1016/0735-1097(93)90325-U)
2544 [Dekant, W; Bridges, J.](#) (2016). Assessment of reproductive and developmental effects of DINP, DnHP
2545 and DCHP using quantitative weight of evidence. *Regul Toxicol Pharmacol* 81: 397-406.
2546 <http://dx.doi.org/10.1016/j.yrtph.2016.09.032>
2547 [Demou, E; Hellweg, S; Wilson, MP; Hammond, SK; McKone, TE.](#) (2009). Evaluating indoor exposure
2548 modeling alternatives for LCA: A case study in the vehicle repair industry. *Environ Sci Technol*
2549 43: 5804-5810. <http://dx.doi.org/10.1021/es803551y>
2550 [Di Toro, DM.](#) (1984). Probability Model of Stream Quality Due to Runoff. *ASCE. J Environ Eng* 110:
2551 607-628.
2552 [Dickman, ED; Smith, SM.](#) (1996). Selective regulation of cardiomyocyte gene expression and cardiac
2553 morphogenesis by retinoic acid. *Dev Dyn* 206: 39-48. [http://dx.doi.org/10.1002/\(SICI\)1097-0177\(199605\)206:1<39::AID-AJA4>3.0.CO;2-1](http://dx.doi.org/10.1002/(SICI)1097-0177(199605)206:1<39::AID-AJA4>3.0.CO;2-1).
2554 [Dierickx, PJ.](#) (1993). Comparison between fish lethality data and the in vitro cytotoxicity of lipophilic
2555 solvents to cultured fish cells in a two-compartment model. *Chemosphere* 27: 1511-1518.
2556 [Dilling, WL; Tefertiller, NB; Kallos, GJ.](#) (1975). Evaporation rates and reactivities of methylene
2557 chloride, chloroform, 1,1,1-trichloroethane, trichloroethylene, tetrachloroethylene, and other
2558 chlorinated compounds in dilute aqueous solutions. *Environ Sci Technol* 9: 833-838.
2559 <http://dx.doi.org/10.1021/es60107a008>
2560 [Dobaradaran, S; Mahvi, AH; Nabizadeh, R; Ramavandi, B; Nazmara, S; Zarei, S.](#) (2012). BIOASSAY
2561 COMPARISON OF TRICHLOROETHYLENE (TCE) TOXICITY ON DAPHNIA MAGNA
2562 (D. MAGNA) BEFORE AND AFTER ULTRASOUND AND PHOTOLYSIS PROCESSES.
2563 *Fresen Environ Bull* 21: 1533-1538.
2564 [Dodson, RE; Levy, JI; Spengler, JD; Shine, JP; Bennett, DH.](#) (2008). Influence of basements, garages,
2565 and common hallways on indoor residential volatile organic compound concentrations. *Atmos*
2566 *Environ* 42: 1569-1581. <http://dx.doi.org/10.1016/j.atmosenv.2007.10.088>
2567 [Dorfmueller, MA; Henne, SP; York, RG; Bornschein, RL; Manson, JM.](#) (1979). Evaluation of
2568 teratogenicity and behavioral toxicity with inhalation exposure of maternal rats to
2569 trichloroethylene. *Toxicology* 14: 153-166. [http://dx.doi.org/10.1016/0300-483X\(79\)90061-1](http://dx.doi.org/10.1016/0300-483X(79)90061-1)
2570 [Dosemeci, M; Cocco, P; Chow, WH.](#) (1999). Gender differences in risk of renal cell carcinoma and
2571 occupational exposures to chlorinated aliphatic hydrocarbons. *Am J Ind Med* 36: 54-59.
2572 [http://dx.doi.org/10.1002/\(SICI\)1097-0274\(199907\)36:1<54::AID-AJIM8>3.0.CO;2-0](http://dx.doi.org/10.1002/(SICI)1097-0274(199907)36:1<54::AID-AJIM8>3.0.CO;2-0)
2573 [Dow, J; Green, T.](#) (2000). Trichloroethylene induced vitamin B(12) and folate deficiency leads to
2574 increased formic acid excretion in the rat. *Toxicology* 146: 123-136.
2575 [http://dx.doi.org/10.1016/S0300-483X\(00\)00156-6](http://dx.doi.org/10.1016/S0300-483X(00)00156-6)
2576 [Drake, V; Koprowski, S; Lough, J; Hu, N; Smith, S.](#) (2006a). Trichloroethylene exposure during cardiac
2577 valvuloseptal morphogenesis alters cushion formation and cardiac hemodynamics in the avian
2578 embryo. *Environ Health Perspect* 114: 842-847. <http://dx.doi.org/10.1289/ehp.8781>
2579 [Drake, VJ; Koprowski, SL; Hu, N; Smith, SM; Lough, J.](#) (2006b). Cardiogenic effects of
2580 trichloroethylene and trichloroacetic acid following exposure during heart specification of avian
2581 development. *Toxicol Sci* 94: 153-162. <http://dx.doi.org/10.1093/toxsci/kfl083>
2582 [Duteaux, SB; Berger, T; Hess, RA; Sartini, BL; Miller, MG.](#) (2004). Male reproductive toxicity of
2583 trichloroethylene: Sperm protein oxidation and decreased fertilizing ability. *Biol Reprod* 70:
2584 1518-1526. <http://dx.doi.org/10.1095/biolreprod.103.022210>
2585 [EC.](#) (2018). Memorandum on weight of evidence and uncertainties. Revision 2018. Scientific
2586 Committee on Health, Environmental and Emerging Risks (SCHEER).
2587 https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_014.pdf
2588

2589 [ECB](#). (2000). IUCLID dataset: CAS No. 79-01-6: Trichloroethylene. Ispra, Italy: European Chemicals
2590 Bureau, European Commission. Retrieved from [https://echa.europa.eu/substance-information/-](https://echa.europa.eu/substance-information/-/substanceinfo/100.001.062)
2591 [/substanceinfo/100.001.062](#)
2592 [ECB](#). (2004). European Union risk assessment report: Trichloroethylene (pp. 1-348). (EUR 21057 EN).
2593 European Commission. [https://echa.europa.eu/documents/10162/83f0c99f-f687-4cdf-a64b-](https://echa.europa.eu/documents/10162/83f0c99f-f687-4cdf-a64b-514f1e26fdc0)
2594 [514f1e26fdc0](#)
2595 [ECHA](#). (2004). Summary risk assessment report: Trichloroethylene. (I.04.29). Ispra, Italy: European
2596 Commission Joint Research Centre, Institute for Health and Consumer Protection, European
2597 Chemicals Bureau. [https://echa.europa.eu/documents/10162/d30e53cc-89e7-4d1c-89c0-](https://echa.europa.eu/documents/10162/d30e53cc-89e7-4d1c-89c0-7ec216f84d48)
2598 [7ec216f84d48](#)
2599 [ECHA](#). (2017). Registration dossier: Trichloroethylene. Reasonably available online at
2600 <https://echa.europa.eu/el/registration-dossier/-/registered-dossier/14485> (accessed October 1,
2601 2018).
2602 [EFSA](#). (2017). Guidance on the use of the weight of evidence approach in scientific assessments. EFSA
2603 J 15: 1-69. <http://dx.doi.org/10.2903/j.efsa.2017.4971>
2604 [Elkin, ER; Bridges, D; Harris, SM; Loch-Carusio, RK](#). (2020). Exposure to trichloroethylene metabolite
2605 S-(1,2-dichlorovinyl)-L-cysteine causes compensatory changes to macronutrient utilization and
2606 energy metabolism in placental HTR-8/SVneo cells. Chem Res Toxicol 33: 1339-1355.
2607 <http://dx.doi.org/10.1021/acs.chemrestox.9b00356>.
2608 [Elovaara, E; Hemminki, K; Vainio, H](#). (1979). Effects of methylene chloride, trichloroethane,
2609 trichloroethylene, tetrachloroethylene and toluene on the development of chick embryos.
2610 Toxicology 12: 111-119. [http://dx.doi.org/10.1016/0300-483X\(79\)90037-4](http://dx.doi.org/10.1016/0300-483X(79)90037-4)
2611 [Engineers, USACo](#). (2018). Weight-of-Evidence Concepts: Introduction and Application to Sediment
2612 Management. <https://apps.dtic.mil/dtic/tr/fulltext/u2/1048843.pdf>
2613 [Environment Canada and Health Canada](#). (1993). Canadian Environmental protection act priority
2614 substances list assessment report trichloroethylene. Ottawa Canada.
2615 [Epstein, DL; Nolen, GA; Randall, JL; Christ, SA; Read, EJ; Stober, JA; Smith, MK](#). (1992).
2616 Cardiopathic effects of dichloroacetate in the fetal Long-Evans rat. Teratology 46: 225-235.
2617 <http://dx.doi.org/10.1002/tera.1420460306>
2618 [Esmen, N; Corn, M; Hammad, Y; Whittier, D; Kotsko, N](#). (1979). Summary of measurements of
2619 employee exposure to airborne dust and fiber in sixteen facilities producing man-made mineral
2620 fibers. Am Ind Hyg Assoc J 40: 108-117.
2621 [Etterson, M](#). (2020). Species Sensitivity Distribution (SSD) Toolbox. Duluth, MN: US Environmental
2622 Protection Agency.
2623 [European Solvents Industry Group \(ESIG\)](#). (2012). SPERC fact sheet: Manufacture of substance -
2624 industrial (solvent-borne). Brussels, Belgium. <https://www.esig.org/reach-ges/environment/>
2625 [Fisher, J; Channel, S; Eggers, J; Johnson, P; Macmahon, K; Goodyear, C; Sudberry, G; Warren, D;](#)
2626 [Latendresse, J; Graeter, L](#). (2001). Trichloroethylene, trichloroacetic acid, and dichloroacetic
2627 acid: Do they affect fetal rat heart development. Int J Toxicol 20: 257-267.
2628 <http://dx.doi.org/10.1080/109158101753252992>
2629 [Fleeman, TL; Cappon, GD; Hurtt, ME](#). (2004). Postnatal closure of membranous ventricular septal
2630 defects in Sprague-Dawley rat pups after maternal exposure with trimethadione. Birth Defects
2631 Res B Dev Reprod Toxicol 71: 185-190. <http://dx.doi.org/10.1002/bdrb.20011>
2632 [Forand, SP; Lewis-Michl, EL; Gomez, MI](#). (2012). Adverse birth outcomes and maternal exposure to
2633 trichloroethylene and tetrachloroethylene through soil vapor intrusion in New York State.
2634 Environ Health Perspect 120: 616-621. <http://dx.doi.org/10.1289/ehp.1103884>
2635 [Forkert, P; Lash, L; Nadeau, V; Tardif, R; Simmonds, A](#). (2002). Metabolism and toxicity of
2636 trichloroethylene in epididymis and testis. Toxicol Appl Pharmacol 182: 244-254.

2637 [Fort, D; Rayburn, J; Deyoung, D; Bantle, J.](#) (1991). Assessing the efficacy of an Aroclor 1254-induced
2638 exogenous metabolic activation system for FETAX. *Drug Chem Toxicol* 14: 143-160.
2639 <http://dx.doi.org/10.3109/01480549109017873>
2640 [Fort, D; Rogers, R; Stover, E; Finch, R.](#) (2001). Optimization of an exogenous metabolic activation
2641 system for FETAX. I. Post-isolation rat liver microsome mixtures. *Drug Chem Toxicol* 24: 103-
2642 115. <http://dx.doi.org/10.1081/DCT-100102604>
2643 [Fort, DJ; Stover, EL; Rayburn, JR; Hull, M; Bantle, JA.](#) (1993). Evaluation of the developmental
2644 toxicity of trichloroethylene and detoxification metabolites using *Xenopus*. *Birth Defects Res B*
2645 *Dev Reprod Toxicol* 13: 35-45.
2646 [Fredriksson, A; Danielsson, BRG; Eriksson, P.](#) (1993). Altered behaviour in adult mice orally exposed
2647 to tri- and tetrachloroethylene as neonates. *Toxicol Lett* 66: 13-19.
2648 [http://dx.doi.org/10.1016/0378-4274\(93\)90074-8](http://dx.doi.org/10.1016/0378-4274(93)90074-8)
2649 [Gangwal, S; Reif, DM; Mosher, S; Egeghy, PP; Wambaugh, JF; Judson, RS; Hubal, EA.](#) (2012).
2650 Incorporating exposure information into the toxicological prioritization index decision support
2651 framework. *Sci Total Environ* 435-436: 316-325.
2652 <http://dx.doi.org/10.1016/j.scitotenv.2012.06.086>
2653 [Gash, D; Rutland, K; Hudson, N; Sullivan, P; Bing, G; Cass, W; Pandya, J; Liu, M; Choi, D; Hunter, R;](#)
2654 [Gerhardt, G; Smith, C; Slevin, J; Prince, T.](#) (2008). Trichloroethylene: Parkinsonism and
2655 complex 1 mitochondrial neurotoxicity. *Ann Neurol* 63: 184-192.
2656 <http://dx.doi.org/10.1002/ana.21288>
2657 [Geiger, DL; Northcott, CE; Call, DJ; Brooke, LT.](#) (1985). Acute toxicities of organic chemicals to
2658 fathead minnows (*Pimephales promelas*): Volume II. Superior, WI: University of Wisconsin-
2659 Superior, Center for Lake Superior Environmental Studies.
2660 [George, JD; Reel, J. R.; Myers, CB; Lawton, AD; Lamb, JC.](#) (1986). Trichloroethylene: Reproduction
2661 and fertility assessment in F344 rats when administered in the feed (pp. 312 PP). (NTP-86-085).
2662 Research Triangle Park, NC: National Institute of Environmental Health Sciences, National
2663 Toxicology Program.
2664 [Gilbert, K; Pumford, N; Blossom, S.](#) (2006). Environmental contaminant trichloroethylene promotes
2665 autoimmune disease and inhibits T-cell apoptosis in MRL(+/+) mice. *J Immunotoxicol* 3: 263-
2666 267. <http://dx.doi.org/10.1080/15476910601023578>.
2667 [Gilbert, KM; Woodruff, W; Blossom, SJ.](#) (2014). Differential immunotoxicity induced by two different
2668 windows of developmental trichloroethylene exposure. 2014: 982073.
2669 <http://dx.doi.org/10.1155/2014/982073>.
2670 [Gilboa, SM; Desrosiers, TA; Lawson, C; Lupo, PJ; Riehle-Colarusso, TJ; Stewart, PA; van](#)
2671 [Wijngaarden, E; Waters, MA; Correa, A; Stud, NBDP.](#) (2012). Association between maternal
2672 occupational exposure to organic solvents and congenital heart defects, National Birth Defects
2673 Prevention Study, 1997-2002. *Occup Environ Med* 69: 628-635.
2674 <http://dx.doi.org/10.1136/oemed-2011-100536>
2675 [Goldberg, SJ; Lebowitz, MD; Graver, EJ; Hicks, S.](#) (1990). An association of human congenital cardiac
2676 malformations and drinking water contaminants. *J Am Coll Cardiol* 16: 155-164.
2677 [Goldman, SM; Quinlan, PJ; Ross, GW; Marras, C; Meng, C; Bhudhikanok, GS; Comyns, K; Korell, M;](#)
2678 [Chade, AR; Kasten, M; Priestley, B; Chou, KL; Fernandez, HH; Cambi, F; Langston, JW;](#)
2679 [Tanner, CM.](#) (2012). Solvent exposures and parkinson disease risk in twins. *Ann Neurol* 71: 776-
2680 784. <http://dx.doi.org/10.1002/ana.22629>
2681 [Golsteijn, L; Huizer, D; Hauck, M; van Zelm, R; Huijbregts, MA.](#) (2014). Including exposure variability
2682 in the life cycle impact assessment of indoor chemical emissions: the case of metal degreasing.
2683 *Environ Int* 71: 36-45. <http://dx.doi.org/10.1016/j.envint.2014.06.003>

2684 [Gough, D.](#) (2007). Weight of Evidence: a framework for the appraisal of the quality and relevance of
2685 evidence. 22: 213-228. <http://dx.doi.org/10.1080/02671520701296189>

2686 [Green, T; Dow, J; Ellis, MK; Foster, JR; Odum, J.](#) (1997a). The Role of Glutathione Conjugation in the
2687 Development of Kidney Tumors in Rats Exposed to Trichloroethylene (pp. 99-117).
2688 (NIOSH/00239675). Green, T; Dow, J; Ellis, MK; Foster, JR; Odum, J.

2689 [Green, T; Dow, J; Ellis, MK; Foster, JR; Odum, J.](#) (1997b). The role of glutathione conjugation in the
2690 development of kidney tumours in rats exposed to trichloroethylene. Chem Biol Interact 105: 99-
2691 117.

2692 [Green, T; Dow, J; Ong, C; Ng, V; Ong, H; Zhuang, Z; Yang, X; Bloemen, L.](#) (2004). Biological
2693 monitoring of kidney function among workers occupationally exposed to trichloroethylene.
2694 Occup Environ Med 61: 312-317. <http://dx.doi.org/10.1136/oem.2003.007153>

2695 [Greenland, S; Salvan, A; Wegman, DH; Hallock, MF; Smith, TJ.](#) (1994). A case-control study of cancer
2696 mortality at a transformer-assembly facility. Int Arch Occup Environ Health 66: 49-54.
2697 <http://dx.doi.org/10.1007/BF00386579>

2698 [Griffin, JM; Gilbert, KM; Lamps, LW; Pumford, NR.](#) (2000). CD4+ T-cell activation and induction of
2699 autoimmune hepatitis following trichloroethylene treatment in MRL+/+ mice. Toxicol Sci 57:
2700 345-352.

2701 [Haga, S; Uji, S; Suzuki, T.](#) (2008). Evaluation of the effects of retinoids and carotenoids on egg quality
2702 using a microinjection system. Aquaculture 282: 111-116.
2703 <http://dx.doi.org/10.1016/j.aquaculture.2008.06.031>

2704 [Hansen, J; Raaschou-Nielsen, O; Christensen, JM; Johansen, I; McLaughlin, JK; Lipworth, L; Blot, WJ;
2705 Olsen, JH.](#) (2001). Cancer incidence among Danish workers exposed to trichloroethylene. J
2706 Occup Environ Med 43: 133-139.

2707 [Hansen, J; Sallmen, M; Selden, AI; Anttila, A; Pukkala, E; Andersson, K; Bryngelsson, I; Raaschou-
2708 Nielsen, O, le; Olsen, JH; McLaughlin, JK.](#) (2013). Risk of Cancer Among Workers Exposed to
2709 Trichloroethylene: Analysis of Three Nordic Cohort Studies. J Natl Cancer Inst 105: 869-877.
2710 <http://dx.doi.org/10.1093/jnci/djt107>

2711 [Hardell, L; Eriksson, M; Degerman, A.](#) (1994). Exposure to phenoxyacetic acids, chlorophenols, or
2712 organic solvents in relation to histopathology, stage, and anatomical localization of non-
2713 Hodgkin's lymphoma. Cancer Res 54: 2386-2389.

2714 [Hardin, BD; Bond, GP; Sikov, MR; Andrew, FD; Beliles, RP; Niemeier, RW.](#) (1981). Testing of
2715 selected workplace chemicals for teratogenic potential. Scand J Work Environ Health 7: 66-75.

2716 [Harris, AP; Ismail, KA; Nunez, M; Martopullo, I; Lencinas, A; Selmin, OI; Runyan, RB.](#) (2018).
2717 Trichloroethylene perturbs HNF4a expression and activity in the developing chick heart. Toxicol
2718 Lett 285: 113-120. <http://dx.doi.org/10.1016/j.toxlet.2017.12.027>

2719 [Hassoun, E; Kariya, C; Williams, F.](#) (2005). Dichloroacetate-induced developmental toxicity and
2720 production of reactive oxygen species in zebrafish embryos. J Biochem Mol Toxicol 19: 52-58.
2721 <http://dx.doi.org/10.1002/jbt.20051>

2722 [Hayashi, M; Ueda, T; Uyeno, K; Wada, K; Kinae, N; Saotome, K; Tanaka, N; Takai, A; Sasaki, YF;
2723 Asano, N; Sofuni, T; Ojima, Y.](#) (1998). Development of genotoxicity assay systems that use
2724 aquatic organisms. Mutat Res 399: 125-133.

2725 [Healy, TEJ; Poole, TR; Hopper, A.](#) (1982). Rat fetal development and maternal exposure to
2726 trichloroethylene 100 ppm. Br J Anaesth 54: 337-341.

2727 [Heavner, DL; Morgan, WT; Ogden, MW.](#) (1995). Determination of volatile organic compounds and
2728 ETS apportionment in 49 homes. Environ Int 21: 3-21. [http://dx.doi.org/10.1016/0160-
4120\(94\)00018-3](http://dx.doi.org/10.1016/0160-
2729 4120(94)00018-3)

2730 [Hellweg, S; Demou, E; Bruzzi, R; Meijer, A; Rosenbaum, RK; Huijbregts, MA; Mckone, TE.](#) (2009).
2731 Integrating human indoor air pollutant exposure within Life Cycle Impact Assessment [Review].
2732 Environ Sci Technol 43: 1670-1679. <http://dx.doi.org/10.1021/es8018176>
2733 [Higgins, JP; Thompson, SG; Deeks, JJ; Altman, DG.](#) (2003). Measuring inconsistency in meta-analyses
2734 [Review]. BMJ 327: 557-560. <http://dx.doi.org/10.1136/bmj.327.7414.557>
2735 [Hill, AB.](#) (1965). The environment and disease: Association or causation? Proc R Soc Med 58: 295-300.
2736 [Holson, RR; Freshwater, Le; Maurissen, JPJ; Moser, VC; Phang, W.](#) (2008). Statistical issues and
2737 techniques appropriate for developmental neurotoxicity testing - A report from the ILSI Research
2738 Foundation/Risk Science Institute expert working group on neurodevelopmental endpoints
2739 [Review]. Neurotoxicol Teratol 30: 326-348. <http://dx.doi.org/10.1016/j.ntt.2007.06.001>
2740 [Horvath, AL; Getzen, FW; Maczynska, Z.](#) (1999). IUPAC-NIST Solubility data series 67: Halogenated
2741 ethanes and ethenes with water. J Phys Chem Ref Data 28: 395-627.
2742 <http://dx.doi.org/10.1063/1.556039>
2743 [Houde, M; Douville, M; Gagnon, P; Sproull, J; Cloutier, F.](#) (2015). Exposure of Daphnia magna to
2744 trichloroethylene (TCE) and vinyl chloride (VC): evaluation of gene transcription, cellular
2745 activity, and life-history parameters. Ecotoxicol Environ Saf 116: 10-18.
2746 <http://dx.doi.org/10.1016/j.ecoenv.2015.02.031>
2747 [Hudson, NL; Dotson, GS.](#) (2017). NIOSH Skin Notation (SK) Profile: Trichloroethylene (TCE) (CAS
2748 No. 79-01-6).
2749 [Hunter, E; Rogers, E; Schmid, J; Richard, A.](#) (1996). Comparative effects of haloacetic acids in whole
2750 embryo culture. Teratology 54: 57-64. [http://dx.doi.org/10.1002/\(SICI\)1096-
2751 9926\(199606\)54:2<57::AID-TERA1>3.0.CO;2-1](http://dx.doi.org/10.1002/(SICI)1096-9926(199606)54:2<57::AID-TERA1>3.0.CO;2-1)
2752 [IARC.](#) (2014). IARC Monographs on the evaluation of carcinogenic risks to humans: Trichloroethylene,
2753 tetrachloroethylene, and some other chlorinated agents. Geneva, Switzerland: World Health
2754 Organization, International Agency for Research on Cancer.
2755 <http://monographs.iarc.fr/ENG/Monographs/PDFs/index.php>
2756 [Ikeda, M; Imamura, T.](#) (1973). Biological half-life of trichloroethylene and tetrachloroethylene in human
2757 subjects [Review]. Int Arch Occup Environ Health 31: 209-224.
2758 <http://dx.doi.org/10.1007/BF00539241>
2759 [IRTA.](#) (2007). Spotting chemicals: Alternatives to perchloroethylene and trichloroethylene in the textile
2760 cleaning industry. Prepared for: Cal/EPA's Department of Toxic Substances Control and U.S.
2761 Environmental Protection Agency Region IX.
2762 <http://www.irta.us/reports/DTSC%20Spotting%20Chemical%20for%20Web.pdf>
2763 [Isaacs, K.](#) (2014). The consolidated human activity database - master version (CHAD-Master) technical
2764 memorandum. Washington, DC: U.S. Environmental Protection Agency, National Exposure
2765 Research Laboratory. [https://www.epa.gov/sites/production/files/2015-
2766 02/documents/chadmaster_091814_1.pdf](https://www.epa.gov/sites/production/files/2015-02/documents/chadmaster_091814_1.pdf)
2767 [Isaacson, LG; Spohler, SA; Taylor, DH.](#) (1990). Trichloroethylene affects learning and decreases myelin
2768 in the rat hippocampus. Neurotoxicol Teratol 12: 375-381. [http://dx.doi.org/10.1016/0892-
2769 0362\(90\)90057-J](http://dx.doi.org/10.1016/0892-0362(90)90057-J)
2770 [Iwase, T; Ohyama, N; Inazawa, K; Watanabe, T; Yamamoto, M; Arishima, K; Eguchi, Y.](#) (1998).
2771 Dysmorphogenic effects of synthetic retinoids, Am80 and Ch55 on cultured rat embryos
2772 [Abstract]. Teratology 57: 14-16, A-08.
2773 [Jayjock, MA.](#) (2012). Engineering case report: Estimating overspray exposure potential from aerosol
2774 sprayed products onto surfaces. J Occup Environ Hyg 9: D155-D160.
2775 <http://dx.doi.org/10.1080/15459624.2012.700191>
2776 [Jenkins, KJ; Correa, A; Feinstein, JA; Botto, L; Britt, AE; Daniels, SR; Elixson, M; Warnes, CA; Webb,
2777 CL.](#) (2007). Noninherited risk factors and congenital cardiovascular defects: Current knowledge:

2778 A scientific statement from the American Heart Association Council on cardiovascular disease in
2779 the young. *Circulation* 115: 2995-3014.
2780 <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.183216>
2781 [Jia, C; Batterman, S; Godwin, C.](#) (2008a). VOCs in industrial, urban and suburban neighborhoods, Part
2782 1: Indoor and outdoor concentrations, variation, and risk drivers. *Atmos Environ* 42: 2083-2100.
2783 <http://dx.doi.org/10.1016/j.atmosenv.2007.11.055>
2784 [Jia, CR; D'Souza, J; Batterman, S.](#) (2008b). Distributions of personal VOC exposures: A population-
2785 based analysis. *Environ Int* 34: 922-931. <http://dx.doi.org/10.1016/j.envint.2008.02.002>
2786 [Jiang, Y; Wang, D; Zhang, G; Wang, G; Tong, J; Chen, T.](#) (2015). Disruption of cardiogenesis in human
2787 embryonic stem cells exposed to trichloroethylene. *Environ Toxicol* 31: 1372-1380.
2788 <http://dx.doi.org/10.1002/tox.22142>
2789 [Johnson, P.](#) (2008). Personal communication from Paula Johnson, University of Arizona, to Susan
2790 Makris, U.S. EPA, 26 August 2008 [Personal Communication].
2791 [Johnson, P.](#) (2014). [Personal communication from Paula Johnson, University of Arizona, to Susan
2792 Makris, U.S. EPA, 21 February 2014] [Personal Communication].
2793 [Johnson, PD; Dawson, BV; Goldberg, SJ.](#) (1998). Cardiac teratogenicity of trichloroethylene
2794 metabolites. *J Am Coll Cardiol* 32: 540-545. [http://dx.doi.org/10.1016/S0735-1097\(98\)00232-0](http://dx.doi.org/10.1016/S0735-1097(98)00232-0)
2795 [Johnson, PD; Goldberg, SJ; Mays, MZ; Dawson, BV.](#) (2003). Threshold of trichloroethylene
2796 contamination in maternal drinking waters affecting fetal heart development in the rat. *Environ*
2797 *Health Perspect* 111: 289-292. <http://dx.doi.org/10.1289/ehp.5125>
2798 [Johnson, PD; Goldberg, SJ; Mays, MZ; Dawson, BV.](#) (2005). Erratum: Threshold of trichloroethylene
2799 contamination in maternal drinking waters affecting fetal heart development in the rat ” (Johnson
2800 et al. 2003) [Erratum]. *Environ Health Perspect* 113: A18.
2801 [Johnson, PD; Goldberg, SJ; Mays, MZ; Dawson, BV.](#) (2014). Erratum: Erratum for Johnson et al.
2802 [Environ Health Perspect 113:A18 (2005)] [Erratum]. *Environ Health Perspect* 122: A94.
2803 <http://dx.doi.org/10.1289/ehp.122-A94>
2804 [Jones, DR; Abel, S; Effland, W; Matzner, R; Parker, R.](#) (1998). An Index Reservoir for Use in Assessing
2805 Drinking Water Exposure: Chapter IV in Proposed Methods for Basin-Scale Estimation of
2806 Pesticide Concentrations in Flowing Water and Reservoirs for Tolerance Reassessment.
2807 Presented to the FIFRA Science Advisory Panel on July 29,1998. Jones, D.R.; Abel, S.; Effland,
2808 W.; Matzner, R.; Parker, R. <https://www.epa.gov/sap/fifra-scientific-advisory-panel-meetings>
2809 [Jung, H; Kim, H; Song, B; Kim, E.](#) (2012). Trichloroethylene Hypersensitivity Syndrome: A Disease of
2810 Fatal Outcome. *Yonsei Med J* 53: 231-235. <http://dx.doi.org/10.3349/ymj.2012.53.1.231>
2811 [Kan, FW; Forkert, PG; Wade, MG.](#) (2007). Trichloroethylene exposure elicits damage in epididymal
2812 epithelium and spermatozoa in mice. *Histol Histopathol* 22: 977-988.
2813 <http://dx.doi.org/10.14670/HH-22.977>
2814 [Kaneko, T; Saegusa, M; Tasaka, K; Sato, A.](#) (2000). Immunotoxicity of trichloroethylene: A study with
2815 MRL-lpr/lpr mice. *J Appl Toxicol* 20: 471-475. [http://dx.doi.org/10.1002/1099-1263\(200011/12\)20:6](http://dx.doi.org/10.1002/1099-1263(200011/12)20:6)
2816 [Kang, YJ; Lee, J; Ahn, J; Park, S; Shin, MY; Lee, HW.](#) (2018). Trichloroethylene hypersensitivity
2817 syndrome: Should be considered when diagnosing DRESS syndrome. *J Korean Med Sci* 33: 1-6.
2818 <http://dx.doi.org/10.3346/jkms.2018.33.e106>.
2819 [Kasting, BG; Miller, MA.](#) (2006). Kinetics of finite dose absorption through skin 2: Volatile
2820 compounds. *J Pharm Sci* 95: 268-280. <http://dx.doi.org/10.1002/jps.20497>
2821 [Kavanaugh, A; Tomar, R; Reveille, J; Solomon, DH; Homburger, HA.](#) (2000). Guidelines for clinical
2822 use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens.
2823 American College of Pathologists. *Arch Pathol Lab Med* 124: 71-81.
2824 [http://dx.doi.org/10.1043/0003-9985\(2000\)124<0071:GFCUOT>2.0.CO;2](http://dx.doi.org/10.1043/0003-9985(2000)124<0071:GFCUOT>2.0.CO;2)
2825

2826 [Keil, DE; Peden-Adams, MM; Wallace, S; Ruiz, P; Gilkeson, GS.](#) (2009). Assessment of
2827 trichloroethylene (TCE) exposure in murine strains genetically-prone and non-prone to develop
2828 autoimmune disease. *J Environ Sci Health A Tox Hazard Subst Environ Eng* 44: 443-453.
2829 <http://dx.doi.org/10.1080/10934520902719738>.

2830 [Kezic, S; Monster, AC; van de Gevel, I; Krüse, J; Opdam, JG; Verberk, MM.](#) (2001). Dermal absorption
2831 of neat liquid solvents on brief exposures in volunteers. *Am Ind Hyg Assoc J* 62: 12-18.
2832 <http://dx.doi.org/10.1080/15298660108984604>.

2833 [Kim, JS; Seo, JW; Lee, YM; Chi, JG.](#) (1999). Cardiac laterality and ventricular looping in retinoic acid-
2834 treated rat embryos. *J Korean Med Sci* 14: 138-146.
2835 <http://dx.doi.org/10.3346/jkms.1999.14.2.138>

2836 [Kim, SH; Son, CS; Lee, JW; Tockgo, YC; Chun, YH.](#) (1995). Visceral heterotaxy syndrome induced by
2837 retinoids in mouse embryo. *J Korean Med Sci* 10: 250-257.
2838 <http://dx.doi.org/10.3346/jkms.1995.10.4.250>

2839 [Kjellstrand, P; Holmquist, B; Alm, P; Kanje, M; Romare, S; Jonsson, I; Månsson, L; Bjerkemo, M.](#)
2840 (1983). Trichloroethylene: Further studies of the effects on body and organ weights and plasma
2841 butyrylcholinesterase activity in mice. *Acta Pharmacol Toxicol* 53: 375-384.
2842 <http://dx.doi.org/10.1111/j.1600-0773.1983.tb03438.x>.

2843 [Kjellstrand, P; Kanje, M; Bjerkemo, M.](#) (1987). Regeneration of the sciatic nerve in mice and rats
2844 exposed to trichloroethylene. *Toxicol Lett* 38: 187-191. [http://dx.doi.org/10.1016/0378-](http://dx.doi.org/10.1016/0378-4274(87)90127-5)
2845 [4274\(87\)90127-5](http://dx.doi.org/10.1016/0378-4274(87)90127-5)

2846 [Klein, P; Kurz, J.](#) (1994a). [Reduction of Solvent Concentrations in Surroundings of Dry-Cleaning
2847 Shops]. Bonningheim, Germany: Hohenstein Physiological Institute on Clothing.

2848 [Klimisch, HJ; Andreae, M; Tillmann, U.](#) (1997). A systematic approach for evaluating the quality of
2849 experimental toxicological and ecotoxicological data. *Regul Toxicol Pharmacol* 25: 1-5.
2850 <http://dx.doi.org/10.1006/rtph.1996.1076>

2851 [Kołodzińska, A; Heleniak, A; Ratajska, A.](#) (2013). Retinoic acid-induced ventricular non-compacted
2852 cardiomyopathy in mice. *Kardiol Pol* 71: 447-452. <http://dx.doi.org/10.5603/KP.2013.0090>

2853 [Kraft, JC; Willhite, CC; Juchau, MR.](#) (1994). Embryogenesis in cultured whole rat embryos after
2854 combined exposures to 3,3',5-triiodo-L-thyronine (T3) plus all-trans-retinoic acid and to T3 plus
2855 9-cis-retinoic acid. *J Craniofac Genet Dev Biol* 14: 75-86.

2856 [Kumar, P; Prasad, A; Mani, U; Maji, B; Dutta, K.](#) (2001). Trichloroethylene induced testicular toxicity
2857 in rats exposed by inhalation. *Hum Exp Toxicol* 20: 585-589.
2858 <http://dx.doi.org/10.1191/096032701718620882>

2859 [Kumar, P; Prasad, AK; Saxena, DK; Manu, U; Maji, BK; Dutta, KK.](#) (2000). Fertility and general
2860 reproduction studies in trichloroethylene exposed rats. *Indian Journal of Occupational Health* 43:
2861 117-126.

2862 [Laborde, JB; Pipkin, JL; Hinson, WG; Anson, JF; Sheehan, DM; Young, JF; Hansen, DK.](#) (1995).
2863 Retinoic acid-induced stress protein-synthesis in the mouse. *Life Sci* 56: 1767-1778.
2864 [http://dx.doi.org/10.1016/0024-3205\(95\)00148-Y](http://dx.doi.org/10.1016/0024-3205(95)00148-Y)

2865 [Labra, M; Mattia, F; Bernasconi, M; Bertacchi, D; Grassi, F; Bruni, I; Citterio, S.](#) (2010). The Combined
2866 Toxic and Genotoxic Effects of Chromium and Volatile Organic Contaminants to
2867 *Pseudokirchneriella subcapitata*. *Water Air Soil Pollut* 213: 57-70.
2868 <http://dx.doi.org/10.1007/s11270-010-0367-3>

2869 [Lagakos, SW; Wessen, BJ; Zelen, M.](#) (1986). An analysis of contaminated well water and health effects
2870 in Woburn, Massachusetts. *J Am Stat Assoc* 81: 583-596. <http://dx.doi.org/10.2307/2288982>

2871 [Lash, LH; Nelson, RM; Van Dyke, RA; Anders, MW.](#) (1990). Purification and characterization of
2872 human kidney cytosolic cysteine conjugate beta-lyase activity. *Drug Metab Dispos* 18: 50-54.

2873 [Lash, LH; Chiu, WA; Guyton, KZ; Rusyn, I.](#) (2014). Trichloroethylene biotransformation and its role in
2874 mutagenicity, carcinogenicity and target organ toxicity [Review]. *Mutat Res Rev Mutat Res* 762:
2875 22-36. <http://dx.doi.org/10.1016/j.mrrev.2014.04.003>.
2876 [LeBlanc, GA.](#) (1980). Acute toxicity of priority pollutants to water flea (*Daphnia magna*). *Bull Environ*
2877 *Contam Toxicol* 24: 684-691. <http://dx.doi.org/10.1007/BF01608174>
2878 [Lee, Yo; Kim, JSu; Han, SY; Park, Ku; Jang, SJa; Seo, JW.](#) (1998). Abnormal ventricular looping and
2879 abnormal laterality of the atrial chambers are the main morphogenetic mechanisms of cardiac
2880 lesions in cultured rat embryos treated with retinoic acid. *J Korean Med Sci* 13: 117-122.
2881 [Leblanc, M; Allen, JG; Herrick, RF; Stewart, JH.](#) (2018). Comparison of the near field/far field model
2882 and the advanced reach tool (ART) model V1.5: exposure estimates to benzene during parts
2883 washing with mineral spirits. *Int J Hyg Environ Health* 221: 231-238.
2884 <http://dx.doi.org/10.1016/j.ijheh.2017.10.016>
2885 [Lehmann, I; Rehwagen, M; Diez, U; Seiffart, A; Rolle-Kampczyk, U; Richter, M; Wetzig, H; Borte, M;](#)
2886 [Herbarth, O.](#) (2001). Enhanced in vivo IgE production and T cell polarization toward the type 2
2887 phenotype in association with indoor exposure to VOC: Results of the LARS study. *Int J Hyg*
2888 *Environ Health* 204: 211-221. <http://dx.doi.org/10.1078/1438-4639-00100>.
2889 [Lehmann, I; Thoelke, A; Rehwagen, M; Rolle-Kampczyk, U; Schlink, U; Schulz, R; Borte, M; Diez, U;](#)
2890 [Herbarth, O.](#) (2002). The influence of maternal exposure to volatile organic compounds on the
2891 cytokine secretion profile of neonatal T cells. *Environ Toxicol* 17: 203-210.
2892 <http://dx.doi.org/10.1002/tox.10055>.
2893 [Leighton, DT, Jr; Calo, JM.](#) (1981). Distribution coefficients of chlorinated hydrocarbons in dilute air-
2894 water systems for groundwater contamination applications. *Journal of Chemical and Engineering*
2895 *Data* 26: 382-585. <http://dx.doi.org/10.1021/je00026a010>
2896 [Lide, DR.](#) (2007). CRC handbook of chemistry and physics: A ready-reference book of chemical and
2897 physical data. In DR Lide (Ed.), (88th ed.). Boca Raton, FL: CRC Press.
2898 [Lindstrom, AB; Proffitt, D; Fortune, CR.](#) (1995). Effects of modified residential construction on indoor
2899 air quality. *Indoor Air* 5: 258-269. <http://dx.doi.org/10.1111/j.1600-0668.1995.00005.x>
2900 [Linkov, I; Massey, O; Keisler, J; Rusyn, I; Hartung, T.](#) (2015). From "Weight of Evidence" to
2901 Quantitative Data Integration using Multicriteria Decision Analysis and Bayesian Methods.
2902 *ALTEX* 32: 3-8. <http://dx.doi.org/10.14573/altex.1412231>
2903 [Lipworth, L; Sonderman, JS; Mumma, MT; Tarone, RE; Marano, DE; Boice, JD; McLaughlin, JK.](#)
2904 (2011). Cancer mortality among aircraft manufacturing workers: an extended follow-up. *J Occup*
2905 *Environ Med* 53: 992-1007. <http://dx.doi.org/10.1097/JOM.0b013e31822e0940>
2906 [Liu, J.](#) (2009). Clinical Analysis of Seven Cases of Trichloroethylene Medicamentose-like Dermatitis.
2907 *Ind Health* 47: 685-688.
2908 [Liu, M, ei; Choi, DY; Hunter, RL; Pandya, JD; Cass, WA; Sullivan, PG; Kim, HC; Gash, D; Bing, G.](#)
2909 (2010). Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats. *J*
2910 *Neurochem* 112: 773-783. <http://dx.doi.org/10.1111/j.1471-4159.2009.06497.x>
2911 [Loch-Caruso, R; Hassan, I; Harris, SM; Kumar, A; Bjork, F; Lash, LH.](#) (2019). Trichloroethylene
2912 exposure in mid-pregnancy decreased fetal weight and increased placental markers of oxidative
2913 stress in rats. *Reprod Toxicol* 83: 38-45. <http://dx.doi.org/10.1016/j.reprotox.2018.11.002>.
2914 [Loeber, C; Hendrix, M; Diez De Pinos, S; Goldberg, S.](#) (1988). Trichloroethylene: A cardiac teratogen
2915 in developing chick embryos. *Pediatr Res* 24: 740-744. [http://dx.doi.org/10.1203/00006450-](http://dx.doi.org/10.1203/00006450-198812000-00018)
2916 [198812000-00018](http://dx.doi.org/10.1203/00006450-198812000-00018)
2917 [Long, JL; Stensel, HD; Ferguson, JF; Strand, SE; Ongerth, JE.](#) (1993). Anaerobic and aerobic treatment
2918 of chlorinated aliphatic compounds. *J Environ Eng* 119: 300-320.

2919 [Lukavsky, J; Furnadzhieva, S; Ditttr, F.](#) (2011). Toxicity of Trichloroethylene (TCE) on Some Algae
2920 and Cyanobacteria. *Bull Environ Contam Toxicol* 86: 226-231.
2921 <http://dx.doi.org/10.1007/s00128-011-0195-1>

2922 [Luo, YS; Furuya, S; Soldatov, VY; Kosyk, O; Yoo, HS; Fukushima, H; Lewis, L; Iwata, Y; Rusyn, I.](#)
2923 (2018). Metabolism and Toxicity of Trichloroethylene and Tetrachloroethylene in Cytochrome
2924 P450 2E1 Knockout and Humanized Transgenic Mice. *Toxicol Sci* 164: 489-500.
2925 <http://dx.doi.org/10.1093/toxsci/kfy099>.

2926 [Lutz, WK; Gaylor, DW; Conolly, RB; Lutz, RW.](#) (2005). Nonlinearity and thresholds in dose-response
2927 relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small
2928 differences in individual susceptibility [Review]. *Toxicol Appl Pharmacol* 207: S565-S569.
2929 <http://dx.doi.org/10.1016/j.taap.2005.01.038>

2930 [Mackay, D; Paterson, S; Shiu, WY.](#) (1992). Generic models for evaluating the regional fate of
2931 chemicals. *Chemosphere* 24: 695-717.

2932 [Makris, SL; Scott, CS; Fox, J; Knudsen, TB; Hotchkiss, AK; Arzuaga, X; Euling, SY; Powers, CM;](#)
2933 [Jinot, J; Hogan, KA; Abbott, BD; Hunter, ES; Narotsky, MG.](#) (2016). A systematic evaluation of
2934 the potential effects of trichloroethylene exposure on cardiac development [Review]. *Reprod*
2935 *Toxicol* 65: 321-358. <http://dx.doi.org/10.1016/j.reprotox.2016.08.014>

2936 [Makwana, O; Ahles, L; Lencinas, A; Selmin, OI; Runyan, RB.](#) (2013). Low-dose trichloroethylene
2937 alters cytochrome P450-2C subfamily expression in the developing chick heart. *Cardiovasc*
2938 *Toxicol* 13: 77-84. <http://dx.doi.org/10.1007/s12012-012-9180-0>

2939 [Makwana, O; King, NM; Ahles, L; Selmin, O; Granzier, HL; Runyan, RB.](#) (2010). Exposure to low-
2940 dose trichloroethylene alters shear stress gene expression and function in the developing chick
2941 heart. *Cardiovasc Toxicol* 10: 100-107. <http://dx.doi.org/10.1007/s12012-010-9066-y>

2942 [Malarkey, DE; Bucher, JR.](#) (2011). Summary report of the National Toxicology Program and
2943 Environmental Protection Agency-sponsored review of pathology materials from selected
2944 Ramazzini Institute rodent cancer bioassays [NTP]. Research Triangle Park: National
2945 Toxicology Program.
2946 http://ntp.niehs.nih.gov/ntp/about_ntp/partnerships/international/summarypwg_report_ri_bioassa
2947 [ys.pdf](#)

2948 [Maltoni, C; Lefemine, G; Cotti, G.](#) (1986). Experimental research on trichloroethylene carcinogenesis.
2949 In *Experimental research on trichloroethylene carcinogenesis*. Princeton, NJ: Princeton Scientific
2950 Publishing.

2951 [Mao, B; Qiu, J; Zhao, N; Shao, Y; Dai, W; He, W; Cui, H; Lin, X; Lv, L; Tang, Z; Xu, S; Huang, H;](#)
2952 [Zhou, M; Xu, X; Qiu, W; Liu, Q; Zhang, Y.](#) (2017). Maternal folic acid supplementation and
2953 dietary folate intake and congenital heart defects. *PLoS ONE* 1: 1-14.
2954 <http://dx.doi.org/10.1371/journal.pone.0187996>

2955 [Marquart, H; Franken, R; Goede, H; Fransman, W; Schinkel, J.](#) (2017). Validation of the dermal
2956 exposure model in ECETOC TRA. *Annals of Work Exposures and Health* 61: 854-871.
2957 <http://dx.doi.org/10.1093/annweh/wxx059>

2958 [McDaniel, T; Martin, P; Ross, N; Brown, S; Lesage, S; Pauli, B.](#) (2004). Effects of chlorinated solvents
2959 on four species of North American amphibians. *Arch Environ Contam Toxicol* 47: 101-109.

2960 [Miligi, L; Costantini, AS; Benvenuti, A; Kriebel, D; Bolejack, V; Tumino, R; Ramazzotti, V; Rodella,](#)
2961 [S; Stagnaro, E; Crosignani, P; Amadori, D; Mirabelli, D; Sommani, L; Belletti, I; Troschel, L;](#)
2962 [Romeo, L; Miceli, G; Tozzi, GA; Mendico, I; Vineis, P.](#) (2006). Occupational exposure to
2963 solvents and the risk of lymphomas. *Epidemiology* 17: 552-561.
2964 <http://dx.doi.org/10.1097/01.ede.0000231279.30988.4d>

2965 [Mishima, N; Hoffman, S; Hill, EG; Krug, EL.](#) (2006). Chick embryos exposed to trichloroethylene in an
2966 ex ovo culture model show selective defects in early endocardial cushion tissue formation. Birth
2967 Defects Res A Clin Mol Teratol 76: 517-527. <http://dx.doi.org/10.1002/bdra.20283>
2968 [Miura, S; Miyagawa, S; Morishima, M; Ando, M; Takao, A.](#) (1990). Retinoic acid-induced viscerotrial
2969 heterotaxy syndrome in rat embryos. In EB Clark; A Takao (Eds.), (pp. 467-484). Mount Kisco,
2970 NY: Futura Publishing Company.
2971 [Moore, LE; Boffetta, P; Karami, S; Brennan, P; Stewart, PS; Hung, R; Zaridze, D; Matveev, V; Janout,](#)
2972 [V; Kollarova, H; Bencko, V; Navratilova, M; Szeszenia-Dabrowska, N; Mates, D; Gromiec, J;](#)
2973 [Holcatova, I; Merino, M; Chanock, S; Chow, WH; Rothman, N.](#) (2010). Occupational
2974 trichloroethylene exposure and renal carcinoma risk: Evidence of genetic susceptibility by
2975 reductive metabolism gene variants. Cancer Res 70: 6527-6536. <http://dx.doi.org/10.1158/0008->
2976 [5472.CAN-09-4167](#)
2977 [Morgan, RW; Kelsh, MA; Zhao, K; Heringer, S.](#) (1998). Mortality of aerospace workers exposed to
2978 trichloroethylene. Epidemiology 9: 424-431.
2979 [Morris, M; Wolf, K.](#) (2005). Evaluation of New and Emerging Technologies for Textile Cleaning.
2980 Institute for Research and Technical Assistance (IRTA).
2981 http://wsppn.org/pdf/irta/Emerging_Technologies_Textile_%20Clea.pdf
2982 [NAC/AEGL.](#) (2009). Trichloroethylene (CAS reg. no. 79-01-6): Interim acute exposure guidelines
2983 levels (AEGLs) [AEGL]. Washington, DC: National Advisory Committee for Acute Exposure
2984 Guideline Levels. <https://www.epa.gov/sites/production/files/2014->
2985 [08/documents/trichloroethylene_interim_dec_2008_v1.pdf](#)
2986 [Nakajima, T; Yamanoshita, O; Kamijima, M; Kishi, R; Ichihara, G.](#) (2003). Generalized skin reactions
2987 in relation to trichloroethylene exposure: a review from the viewpoint of drug-metabolizing
2988 enzymes [Review]. J Occup Health 45: 8-14.
2989 [Nakajima, Y; Hiruma, T; Nakazawa, M; Morishima, M.](#) (1996). Hypoplasia of cushion ridges in the
2990 proximal outflow tract elicits formation of a right ventricle-to-aortic route in retinoic acid-
2991 induced complete transposition of the great arteries in the mouse: scanning electron microscopic
2992 observations of corrosion cast models. Anat Rec 245: 76-82.
2993 [http://dx.doi.org/10.1002/\(SICI\)1097-0185\(199605\)245:1<76::AID-AR12>3.0.CO;2-6](http://dx.doi.org/10.1002/(SICI)1097-0185(199605)245:1<76::AID-AR12>3.0.CO;2-6)
2994 [Narematsu, M; Kamimura, T; Yamagishi, T; Fukui, M; Nakajima, Y.](#) (2015). Impaired development of
2995 left anterior heart field by ectopic retinoic acid causes transposition of the great arteries. J Am
2996 Heart Assoc 4: e001889. <http://dx.doi.org/10.1161/JAHA.115.001889>
2997 [Narotsky, MG; Kavlock, RJ.](#) (1995). A multidisciplinary approach to toxicological screening: II.
2998 Developmental toxicity. J Toxicol Environ Health 45: 145-171.
2999 <http://dx.doi.org/10.1080/15287399509531987>
3000 [Narotsky, MG; Weller, EA; Chinchilli, VM; Kavlock, RJ.](#) (1995). Nonadditive developmental toxicity
3001 in mixtures of trichloroethylene, di(2-ethylhexyl) phthalate, and heptachlor in a 5 x 5 x 5 design.
3002 Fundam Appl Toxicol 27: 203-216. <http://dx.doi.org/10.1093/toxsci/27.2.203>
3003 [NCI.](#) (1976). Carcinogenesis bioassay of trichloroethylene. (NCI-CG-TR-2). Bethesda, MD: U.S.
3004 Department of Health, Education, and Welfare, Public Health Service, National Institutes of
3005 Health. http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr002.pdf
3006 [Nicas, M.](#) (2009). The near field/far field (two-box) model with a constant contamination emission rate.
3007 In CB Keil; CE Simmons; TR Anthony (Eds.), (2nd ed., pp. 47-52). Fairfax, VA: AIHA Press.
3008 [NICNAS.](#) (2000). Trichloroethylene: Priority existing chemical assessment report no. 8. (8). Sydney,
3009 Australia. <http://www.nicnas.gov.au/Publications/CAR/PEC/PEC8.asp>
3010 [Niederlehner, B; Cairns, J; Smith, E.](#) (1998). Modeling acute and chronic toxicity of nonpolar narcotic
3011 chemicals and mixtures to Ceriodaphnia dubia. Ecotoxicol Environ Saf 39: 136-146.
3012 <http://dx.doi.org/10.1006/eesa.1997.1621>

3013 [Nielsen, PH; Bjerg, PL; Nielsen, P; Smith, P; Christensen, TH.](#) (1996). In situ and laboratory determined
3014 first-order degradation rate constants of specific organic compounds in an aerobic aquifer.
3015 *Environ Sci Technol* 30: 31-37. <http://dx.doi.org/10.1021/es940722o>
3016 [NIOSH.](#) (2001). Respirator Usage in Private Sector Firms. Washington D.C.: United States Department
3017 of Labor, Bureau of Labor Statistics and National Institute for Occupational Safety and Health.
3018 <https://www.cdc.gov/niosh/docs/respsurv/>
3019 [Nordström, M; Hardell, L; Magnuson, A; Hagberg, H; Rask-Andersen, A.](#) (1998). Occupational
3020 exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a
3021 case-control study. *Br J Cancer* 77: 2048-2052.
3022 [NRC.](#) (2001). Standing Operating Procedures for Developing Acute Exposure Guideline Levels for
3023 Hazardous Chemicals. http://www.nap.edu/catalog.php?record_id=10122
3024 [NRC.](#) (2006). Assessing the human health risks of trichloroethylene: Key scientific issues. Washington,
3025 DC: The National Academies Press. http://www.nap.edu/catalog.php?record_id=11707
3026 [NTP.](#) (1988). Toxicology and carcinogenesis studies of trichloroethylene (CAS No. 79-01-6) in four
3027 strains of rats (ACI, August, Marshall, Osborne-Mendel) (gavage studies). Research Triangle
3028 Park, NC: U.S. Department of Health and Human Services, Public Health Service, National
3029 Institutes of Health. http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr273.pdf
3030 [NTP.](#) (2015). Handbook for conducting a literature-based health assessment using OHAT approach for
3031 systematic review and evidence integration. U.S. Dept. of Health and Human Services, National
3032 Toxicology Program. https://ntp.niehs.nih.gov/ntp/ohat/pubs/handbookjan2015_508.pdf
3033 [Oku, S; Tanaka, Y; Kaname, T; Matsuda, Y; Miyata, K.](#) (1995). Cardiac malformations induced by all-
3034 trans retinoic acid (RA) in Wistar rats [Abstract]. *Congenit Anom* 35: 388-389.
3035 [O'Neil, MJ; Heckelman, PE; Koch, CB.](#) (2006). The Merck index: An encyclopedia of chemicals, drugs,
3036 and biologicals (14th ed.). Whitehouse Station, NJ: Merck & Co.
3037 [O'Neil, MJ; Smith, A; Heckelman, PE.](#) (2001). Trichloroethylene. In Merck Index. Whitehouse Station,
3038 NJ: Merck & Co., Inc.
3039 [Opdam, JJ.](#) (1989). Intra and interindividual variability in the kinetics of a poorly and highly
3040 metabolising solvent. *Br J Ind Med* 46: 831-845. <http://dx.doi.org/10.1136/oem.46.12.831>
3041 [Ostádalová, I; Pexieder, T; Ostádal, B; Kolár, F.](#) (1995). Inotropic effect of increasing concentration of
3042 Ca²⁺ in the fetal rat heart with retinoic acid-induced malformations. *Pediatr Res* 38: 892-895.
3043 <http://dx.doi.org/10.1203/00006450-199512000-00011>
3044 [Ou, J; Ou, Z; Mccarver, D; Hines, R; Oldham, K; Ackerman, A; Pritchard, K.](#) (2003). Trichloroethylene
3045 decreases heat shock protein 90 interactions with endothelial nitric oxide synthase: implications
3046 for endothelial cell proliferation. *Toxicol Sci* 73: 90-97. <http://dx.doi.org/10.1093/toxsci/kfg062>
3047 [Palbykin, B; Borg, J; Caldwell, PT; Rowles, J; Papoutsis, AJ; Romagnolo, DF; Selmin, OI.](#) (2011).
3048 Trichloroethylene Induces Methylation of the Serca2 Promoter in H9c2 Cells and Embryonic
3049 Heart. *Cardiovasc Toxicol* 11: 204-214. <http://dx.doi.org/10.1007/s12012-011-9113-3>
3050 [Pan, J; Baker, KM.](#) (2007). Retinoic acid and the heart [Review]. *Vitam Horm* 75: 257-283.
3051 [http://dx.doi.org/10.1016/S0083-6729\(06\)75010-5](http://dx.doi.org/10.1016/S0083-6729(06)75010-5)
3052 [Peden-Adams, MM; Eudaly, JG; Heesemann, LM; Smythe, J; Miller, J; Gilkeson, GS; Keil, DE.](#) (2006).
3053 Developmental immunotoxicity of trichloroethylene (TCE): Studies in B6C3F1 mice. *J Environ*
3054 *Sci Health A Tox Hazard Subst Environ Eng* 41: 249-271.
3055 <http://dx.doi.org/10.1080/10934520500455289>.
3056 [Peden-Adams, MM; Eudaly, JG; Lee, AM; Miller, J; Keil, DE; Gilkeson, GS.](#) (2008). Lifetime exposure
3057 to trichloroethylene (TCE) does not accelerate autoimmune disease in MRL +/+ mice. *J Environ*
3058 *Sci Health A Tox Hazard Subst Environ Eng* 43: 1402-1409.
3059 <http://dx.doi.org/10.1080/10934520802232063>.

3060 [Pellizzari, ED; Hartwell, TD; Harris, BS, III; Waddell, RD; Whitaker, DA; Erickson, MD.](#) (1982).
3061 Purgeable organic compounds in mother's milk. *Bull Environ Contam Toxicol* 28: 322-328.
3062 <http://dx.doi.org/10.1007/BF01608515>
3063 [Pennsylvania State University.](#) (2016). Horse Stable Ventilation. [https://extension.psu.edu/horse-stable-](https://extension.psu.edu/horse-stable-ventilation)
3064 [ventilation.](#)
3065 [Persson, B; Fredrikson, M.](#) (1999). Some risk factors for non-Hodgkin's lymphoma. *Int J Occup Med*
3066 *Environ Health* 12: 135-142.
3067 [Pesch, B; Haerting, J; Ranft, U; Klimpel, A; Oelschlägel, B; Schill, W.](#) (2000). Occupational risk factors
3068 for renal cell carcinoma: Agent-specific results from a case-control study in Germany. *Int J*
3069 *Epidemiol* 29: 1014-1024. <http://dx.doi.org/10.1093/ije/29.6.1014>
3070 [Pexieder, T; Pffizenmaier Rousseil, M; Frutos, JC; Prados Frutos, JC.](#) (1990). Spectrum of cardiac and
3071 extracardiac anomalies induced by retinoic acid in rats [Abstract]. *Teratology* 41: 584-585, P125.
3072 [Poet, TS; Corley, RA; Thrall, KD; Edwards, JA; Tanojo, H; Weitz, KK; Hui, X; Maibach, HI; Wester,](#)
3073 [RC.](#) (2000). Assessment of the percutaneous absorption of trichloroethylene in rats and humans
3074 using MS/MS real-time breath analysis and physiologically based pharmacokinetic modeling.
3075 *Toxicol Sci* 56: 61-72. <http://dx.doi.org/10.1093/toxsci/56.1.61>
3076 [Poole, C; Greenland, S.](#) (1999). Random-effects meta-analyses are not always conservative. *Am J*
3077 *Epidemiol* 150: 469-475. <http://dx.doi.org/10.1093/oxfordjournals.aje.a010035>
3078 [Purdue, MP; Bakke, B; Stewart, P; De Roos, AJ; Schenk, M; Lynch, CF; Bernstein, L; Morton, LM;](#)
3079 [Cerhan, JR; Severson, RK; Cozen, W; Davis, S; Rothman, N; Hartge, P; Colt, JS.](#) (2011). A
3080 case-control study of occupational exposure to trichloroethylene and non-Hodgkin lymphoma.
3081 *Environ Health Perspect* 119: 232-238. <http://dx.doi.org/10.1289/ehp.1002106>
3082 [Purdue, MP; Stewart, PA; Friesen, MC; Colt, JS; Locke, SJ; Hein, MJ; Waters, MA; Graubard, BI;](#)
3083 [Davis, F; Ruterbusch, J; Schwartz, K; Chow, WH; Rothman, N; Hofmann, JN.](#) (2016).
3084 Occupational exposure to chlorinated solvents and kidney cancer: a case-control study. *Occup*
3085 *Environ Med* 74: 268-274. <http://dx.doi.org/10.1136/oemed-2016-103849>
3086 [Raaschou-Nielsen, O; Hansen, J; McLaughlin, JK; Kolstad, H; Christensen, JM; Tarone, RE; Olsen, JH.](#)
3087 (2003). Cancer risk among workers at Danish companies using trichloroethylene: A cohort study.
3088 *Am J Epidemiol* 158: 1182-1192. <http://dx.doi.org/10.1093/aje/kwg282>
3089 [Radican, L; Blair, A; Stewart, P; Wartenberg, D.](#) (2008). Mortality of aircraft maintenance workers
3090 exposed to trichloroethylene and other hydrocarbons and chemicals: Extended follow-up. *J*
3091 *Occup Environ Med* 50: 1306-1319. <http://dx.doi.org/10.1097/JOM.0b013e3181845f7f>
3092 [Ratajska, A; Cizek, B; Zajackowska, A; Jabłońska, A; Juszyński, M.](#) (2009). Angioarchitecture of the
3093 venous and capillary system in heart defects induced by retinoic acid in mice. *Birth Defects Res*
3094 *A Clin Mol Teratol* 85: 599-610. <http://dx.doi.org/10.1002/bdra.20578>
3095 [Ratajska, A; Złotorowicz, R; Błazejczyk, M; Wasiutyński, A.](#) (2005). Coronary artery embryogenesis in
3096 cardiac defects induced by retinoic acid in mice. *Birth Defects Res A Clin Mol Teratol* 73: 966-
3097 979. <http://dx.doi.org/10.1002/bdra.20200>
3098 [Reif, DM; Sypa, M; Lock, EF; Wright, FA; Wilson, A; Cathey, T; Judson, RR; Rusyn, I.](#) (2013). ToxPi
3099 GUI: an interactive visualization tool for transparent integration of data from diverse sources of
3100 evidence. *Bioinformatics* 29: 402-403. <http://dx.doi.org/10.1093/bioinformatics/bts686>
3101 [Rhombert, LR; Goodman, JE; Bailey, LA; Prueitt, RL; Beck, NB; Bevan, C; Honeycutt, M; Kaminski,](#)
3102 [NE; Paoli, G; Pottenger, LH; Scherer, RW; Wise, KC; Becker, RA.](#) (2013). A survey of
3103 frameworks for best practices in weight-of-evidence analyses [Review]. *Crit Rev Toxicol* 43:
3104 753-784. <http://dx.doi.org/10.3109/10408444.2013.832727>
3105 [Roberts, C; Ivins, S; Cook, AC; Baldini, A; Scambler, PJ.](#) (2006). Cyp26 genes a1, b1 and c1 are down-
3106 regulated in Tbx1 null mice and inhibition of Cyp26 enzyme function produces a phenocopy of

3107 DiGeorge Syndrome in the chick. *Hum Mol Genet* 15: 3394-3410.
3108 <http://dx.doi.org/10.1093/hmg/ddl416>

3109 [Robinson, KW; Flanagan, SM; Ayotte, JD; Campo, KW; Chalmers, A.](#) (2004). Water Quality in the
3110 New England Coastal Basins, Maine, New Hampshire, Massachusetts, and Rhode Island, 1999-
3111 2001. (NTIS/02928874). Robinson, KW; Flanagan, SM; Ayotte, JD; Campo, KW; Chalmers, A.
3112 [Rooney, AA; Boyles, AL; Wolfe, MS; Bucher, JR; Thayer, KA.](#) (2014). Systematic review and evidence
3113 integration for literature-based environmental health science assessments. *Environ Health*
3114 *Perspect* 122: 711-718. <http://dx.doi.org/10.1289/ehp.1307972>

3115 [Rott, B; Viswanathan, R; Freitag, D; Korte, F.](#) (1982). Vergleichende Untersuchung der Anwendbarkeit
3116 verschiedener Tests zur Überprüfung der Abbaubarkeit von Umweltchemikalien. *Chemosphere*
3117 11: 531-538. [http://dx.doi.org/10.1016/0045-6535\(82\)90186-2](http://dx.doi.org/10.1016/0045-6535(82)90186-2)

3118 [Ruckart, PZ; Bove, FJ; Maslia, M.](#) (2013). Evaluation of exposure to contaminated drinking water and
3119 specific birth defects and childhood cancers at Marine Corps Base Camp Lejeune, North
3120 Carolina: a case--control study. *Environ Health* 12: 104. <http://dx.doi.org/10.1186/1476-069X-12-104>

3122 [Ruckart, PZ; Bove, FJ; Maslia, M.](#) (2014). Evaluation of contaminated drinking water and preterm birth,
3123 small for gestational age, and birth weight at Marine Corps Base Camp Lejeune, North Carolina:
3124 a cross-sectional study. *Environ Health* 13: 99. <http://dx.doi.org/10.1186/1476-069X-13-99>

3125 [Rufer, ES; Hacker, TA; Flentke, GR; Drake, VJ; Brody, MJ; Lough, J; Smith, SM.](#) (2010). Altered
3126 cardiac function and ventricular septal defect in avian embryos exposed to low-dose
3127 trichloroethylene. *Toxicol Sci* 113: 444-452. <http://dx.doi.org/10.1093/toxsci/kfp269>

3128 [Ruijten, MW; Verberk, MM; Sallé, HJ.](#) (1991). Nerve function in workers with long term exposure to
3129 trichloroethene. *Br J Ind Med* 48: 87-92.

3130 [Saillenfait, AM; Langonne, I; Sabate, JP.](#) (1995). Developmental toxicity of trichloroethylene,
3131 tetrachloroethylene and four of their metabolites in rat whole embryo culture. *Arch Toxicol* 70:
3132 71-82. <http://dx.doi.org/10.1007/BF02733666>.

3133 [Salama, MM; El-Naggar, DA; Abdel-Rahman, RH; Elhak, SAG.](#) (2018). Toxic Effects of
3134 Trichloroethylene on Rat Neuroprogenitor Cells. 9: 741.
3135 <http://dx.doi.org/10.3389/fphar.2018.00741>.

3136 [Sanchez-Fortun, S; Sanz, F; Santa-Maria, A; Ros, JM; De Vicente, ML; Encinas, MT; Vinagre, E;](#)
3137 [Barahona, MV.](#) (1997). Acute sensitivity of three age classes of *Artemia salina* larvae to seven
3138 chlorinated solvents. *Bull Environ Contam Toxicol* 59: 445-451.
3139 <http://dx.doi.org/10.1007/s001289900498>

3140 [Sanders, VM; Tucker, AN; White, KL, Jr; Kauffmann, BM; Hallett, P; Carchman, RA; Borzelleca, JF;](#)
3141 [Munson, AE.](#) (1982). Humoral and cell-mediated immune status in mice exposed to
3142 trichloroethylene in the drinking water. *Toxicol Appl Pharmacol* 62: 358-368.
3143 [http://dx.doi.org/10.1016/0041-008X\(82\)90138-7](http://dx.doi.org/10.1016/0041-008X(82)90138-7)

3144 [Sato, A; Nakajima, T; Fujiwara, Y; Murayama, N.](#) (1977). A pharmacokinetic model to study the
3145 excretion of trichloroethylene and its metabolites after an inhalation exposure. *Br J Ind Med* 34:
3146 56-63.

3147 [Sauer, TC.](#) (1981). Volatile organic compounds in open ocean and coastal surface waters. *Organic*
3148 *Geochemistry* 3: 91-101.

3149 [Sax, SN; Bennett, DH; Chillrud, SN; Kinney, PL; Spengler, JD.](#) (2004). Differences in source emission
3150 rates of volatile organic compounds in inner-city residences of New York City and Los Angeles.
3151 *J Expo Anal Environ Epidemiol* 14: S95-109. <http://dx.doi.org/10.1038/sj.jea.7500364>

3152 [Schell, JD, Jr.](#) (1987) Interactions of halogenated hydrocarbon mixtures in the embryo of the Japanese
3153 medaka (*Oryzias latipes*). (Doctoral Dissertation). Rutgers University, New Brunswick, NJ.

3154 [Schmidt, KR; Tiehm, A.](#) (2008). Natural attenuation of chloroethenes: identification of sequential
3155 reductive/oxidative biodegradation by microcosm studies. *Water Sci Technol* 58: 1137-1145.
3156 <http://dx.doi.org/10.2166/wst.2008.729>
3157 [Schwarzenbach, RP; Gschwend, PM; Imboden, DM.](#) (2003). *Environmental Organic Chemistry* (2 ed.).
3158 Hoboken, New Jersey: John Wiley & Sons.
3159 [Schwetz, BA; Leong, BKJ; Gehring, PJ.](#) (1975). The effect of maternally inhaled trichloroethylene,
3160 perchloroethylene, methyl chloroform, and methylene chloride on embryonal and fetal
3161 development in mice and rats. *Toxicol Appl Pharmacol* 32: 84-96.
3162 [http://dx.doi.org/10.1016/0041-008X\(75\)90197-0](http://dx.doi.org/10.1016/0041-008X(75)90197-0)
3163 [Selgrade, MK; Gilmour, MI.](#) (2010). Suppression of pulmonary host defenses and enhanced
3164 susceptibility to respiratory bacterial infection in mice following inhalation exposure to
3165 trichloroethylene and chloroform. *J Immunotoxicol* 7: 350-356.
3166 <http://dx.doi.org/10.3109/1547691X.2010.520139>
3167 [Selmin, OI; Thorne, PA; Caldwell, PT; Taylor, MR.](#) (2008). Trichloroethylene and trichloroacetic acid
3168 regulate calcium signaling pathways in murine embryonal carcinoma cells p19. *Cardiovasc*
3169 *Toxicol* 8: 47-56. <http://dx.doi.org/10.1007/s12012-008-9014-2>
3170 [Sexton, K; Mongin, SJ; Adgate, JL; Pratt, GC; Ramachandran, G; Stock, TH; Morandi, MT.](#) (2007).
3171 Estimating volatile organic compound concentrations in selected microenvironments using time-
3172 activity and personal exposure data. *J Toxicol Environ Health A* 70: 465-476.
3173 <http://dx.doi.org/10.1080/15287390600870858>
3174 [Shelton, KL; Nicholson, KL.](#) (2014). Pharmacological classification of the abuse-related discriminative
3175 stimulus effects of trichloroethylene vapor. 3: 235839. <http://dx.doi.org/10.4303/jdar/235839>
3176 [Siemiatycki, J.](#) (1991). Risk factors for cancer in the workplace. In J Siemiatycki (Ed.). Boca Raton,
3177 FL: CRC Press.
3178 [Silver, SR; Pinkerton, LE; Fleming, DA; Jones, JH; Allee, S; Luo, L; Bertke, SJ.](#) (2014). Retrospective
3179 Cohort Study of a Microelectronics and Business Machine Facility. *Am J Ind Med* 57: 412-424.
3180 <http://dx.doi.org/10.1002/ajim.22288>
3181 [Singh, HB; Salas, LJ; Stiles, RE.](#) (1983). Selected man-made halogenated chemicals in the air and
3182 oceanic environment. *J Geophys Res* 88: 3675-3683.
3183 [Sinning, AR.](#) (1998). Role of vitamin A in the formation of congenital heart defects [Review]. *Anat Rec*
3184 253: 147-153. [http://dx.doi.org/10.1002/\(SICI\)1097-0185\(199810\)253:5<147::AID-AR8>3.0.CO;2-0](http://dx.doi.org/10.1002/(SICI)1097-0185(199810)253:5<147::AID-AR8>3.0.CO;2-0)
3185
3186 [Siu, BL; Alonzo, MR; Vargo, TA; Fenrich, AL.](#) (2002). Transient dilated cardiomyopathy in a newborn
3187 exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of
3188 pregnancy. *Int J Gynecol Cancer* 12: 399-402.
3189 [Smith, AD; Bharath, A; Mallard, C; Orr, D; Smith, K; Sutton, JA; Vukmanich, J; McCarty, LS; Ozburn,](#)
3190 [GW.](#) (1991). The acute and chronic toxicity of ten chlorinated organic compounds to the
3191 American flagfish (*Jordanella floridae*). *Arch Environ Contam Toxicol* 20: 94-102.
3192 <http://dx.doi.org/10.1007/BF01065334>
3193 [Smith, EP; Lipkovich, I; Ye, K.](#) (2002). Weight-of-Evidence (WOE): Quantitative Estimation of
3194 Probability of Impairment for Individual and Multiple Lines of Evidence. *Hum Ecol Risk Assess*
3195 8: 1585-1596.
3196 [Smith, MK; Randall, JL; Read, EJ; Stober, JA.](#) (1989). Teratogenic activity of trichloroacetic acid in the
3197 rat. *Teratology* 40: 445-451. <http://dx.doi.org/10.1002/tera.1420400506>
3198 [Smith, MK; Randall, JL; Read, EJ; Stober, JA.](#) (1992). Developmental toxicity of dichloroacetate in the
3199 rat. *Teratology* 46: 217-223. <http://dx.doi.org/10.1002/tera.1420460305>

3200 [Smith, SM; Dickman, ED.](#) (1997). New insights into retinoid signaling in cardiac development and
3201 physiology. *Trends Cardiovasc Med* 7: 324-329. <http://dx.doi.org/10.1016/S1050->
3202 [1738\(97\)00096-0](#)

3203 [Stefanovic, S; Zaffran, S.](#) (2017). Mechanisms of retinoic acid signaling during cardiogenesis [Review].
3204 *Mech Dev* 143: 9-19. <http://dx.doi.org/10.1016/j.mod.2016.12.002>

3205 [Stuckhardt, JL; Poppe, SM.](#) (1984). Fresh visceral examination of rat and rabbit fetuses used in
3206 teratogenicity testing. *Teratog Carcinog Mutagen* 4: 181-188.
3207 <http://dx.doi.org/10.1002/tcm.1770040203>

3208 [Su, FC; Mukherjee, B; Batterman, S.](#) (2013). Determinants of personal, indoor and outdoor VOC
3209 concentrations: An analysis of the RIOPA data. *Environ Res* 126: 192-203.
3210 <http://dx.doi.org/10.1016/j.envres.2013.08.005>

3211 [Swartz, MD; Cai, Y; Chan, W; Symanski, E; Mitchell, LE; Danysh, HE; Langlois, PH; Lupo, PJ.](#)
3212 (2015). Air toxics and birth defects: a Bayesian hierarchical approach to evaluate multiple
3213 pollutants and spina bifida. *Environ Health* 14: 16. <http://dx.doi.org/10.1186/1476-069X-14-16>

3214 [Taylor, DH; Lagory, KE; Zaccaro, DJ; Pfohl, RJ; Laurie, RD.](#) (1985). Effect of trichloroethylene on the
3215 exploratory and locomotor activity of rats exposed during development. *Sci Total Environ* 47:
3216 415-420. [http://dx.doi.org/10.1016/0048-9697\(85\)90345-6](http://dx.doi.org/10.1016/0048-9697(85)90345-6)

3217 [Taylor, IM; Wiley, MJ; Agur, A.](#) (1980). Retinoic acid-induced heart malformations in the hamster.
3218 *Teratology* 21: 193-197. <http://dx.doi.org/10.1002/tera.1420210210>

3219 [Tielemans, E; Schneider, T; Goede, H; Tischer, M; Warren, N; Kromhout, H; Van Tongeren, M; Van](#)
3220 [Hemmen, J; Cherrie, JW.](#) (2008). Conceptual model for assessment of inhalation exposure:
3221 Defining modifying factors. *Ann Occup Hyg* 52: 577-586.
3222 <http://dx.doi.org/10.1093/annhyg/men059>

3223 [Tobajas, M; Verdugo, V; Polo, AM; Rodriguez, JJ; Mohedano, AF.](#) (2016). Assessment of toxicity and
3224 biodegradability on activated sludge of priority and emerging pollutants. *Environ Technol* 37:
3225 713-721. <http://dx.doi.org/10.1080/09593330.2015.1079264>

3226 [Tsai, KP; Chen, CY.](#) (2007). An algal toxicity database of organic toxicants derived by a closed-system
3227 technique. *Environ Toxicol Chem* 26: 1931-1939. <http://dx.doi.org/10.1897/06-612R.1>

3228 [Turton, JA; Willars, GB; Haselden, JN; Ward, SJ; Steele, CE; Hicks, RM.](#) (1992). COMPARATIVE
3229 TERATOGENICITY OF 9 RETINOIDS IN THE RAT. *Int J Exp Pathol* 73: 551-563.

3230 [U.S. BLS.](#) (2014). Employee Tenure News Release.
3231 http://www.bls.gov/news.release/archives/tenure_09182014.htm

3232 [U.S. BLS.](#) (2016). May 2016 Occupational Employment and Wage Estimates: National Industry-
3233 Specific Estimates [Website]. <http://www.bls.gov/oes/tables.htm>

3234 [U.S. Census Bureau.](#) (2013). Census 2012 Detailed Industry Code List [Database].
3235 <https://www.census.gov/topics/employment/industry-occupation/guidance/code-lists.html>

3236 [U.S. Census Bureau.](#) (2015). Statistics of U.S. Businesses (SUSB).
3237 <https://www.census.gov/data/tables/2015/econ/susb/2015-susb-annual.html>

3238 [U.S. Census Bureau.](#) (2019). Survey of Income and Program Participation data [Website].
3239 <https://www.census.gov/programs-surveys/sipp/data/datasets/2008-panel/wave-1.html>

3240 [U.S. EPA.](#) (1977). Environmental monitoring near industrial sites methylchloroform [EPA Report].
3241 (EPA-560/5-77-025). Washington, DC.

3242 [U.S. EPA.](#) (1987). Household solvent products: A national usage survey. (EPA-OTS 560/5-87-005).
3243 Washington, DC: Office of Toxic Substances, Office of Pesticides and Toxic Substances.
3244 <https://ntrl.ntis.gov/NTRL/dashboard/searchResults.xhtml?searchQuery=PB88132881>

3245 [U.S. EPA.](#) (1988). Recommendations for and documentation of biological values for use in risk
3246 assessment [EPA Report] (pp. 1-395). (EPA/600/6-87/008). Cincinnati, OH: U.S. Environmental

3247 Protection Agency, Office of Research and Development, Office of Health and Environmental
3248 Assessment. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855>
3249 U.S. EPA. (1991). Guidelines for developmental toxicity risk assessment (pp. 1-71). (EPA/600/FR-
3250 91/001). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
3251 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=23162>
3252 U.S. EPA. (1992). Guidelines for exposure assessment. Federal Register 57(104):22888-22938 [EPA
3253 Report]. (EPA/600/Z-92/001). Washington, DC.
3254 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=15263>
3255 U.S. EPA. (1994a). Guidelines for Statistical Analysis of Occupational Exposure Data: Final. United
3256 States Environmental Protection Agency :: U.S. EPA.
3257 U.S. EPA. (1994b). Methods for derivation of inhalation reference concentrations and application of
3258 inhalation dosimetry [EPA Report]. (EPA/600/8-90/066F). Research Triangle Park, NC: U.S.
3259 Environmental Protection Agency, Office of Research and Development, Office of Health and
3260 Environmental Assessment, Environmental Criteria and Assessment Office.
3261 [https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=71993&CFID=51174829&CFTOKEN=2](https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=71993&CFID=51174829&CFTOKEN=25006317)
3262 [5006317](https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=71993&CFID=51174829&CFTOKEN=25006317)
3263 U.S. EPA. (1996). Guidelines for reproductive toxicity risk assessment (pp. 1-143). (EPA/630/R-
3264 96/009). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
3265 https://www.epa.gov/sites/production/files/2014-11/documents/guidelines_repro_toxicity.pdf
3266 U.S. EPA. (1998). Guidelines for ecological risk assessment [EPA Report]. (EPA/630/R-95/002F).
3267 Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
3268 <https://www.epa.gov/risk/guidelines-ecological-risk-assessment>
3269 U.S. EPA. (2001). Sources, emission and exposure for trichloroethylene (TCE) and related chemicals
3270 [EPA Report]. In Govt Reports Announcements & Index (pp. 138). (EPA/600/R-00/099).
3271 Washington, DC. <https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=21006>
3272 U.S. EPA. (2002). A review of the reference dose and reference concentration processes (pp. 1-192).
3273 (EPA/630/P-02/002F). Washington, DC: U.S. Environmental Protection Agency, Risk
3274 Assessment Forum. [http://www.epa.gov/osa/review-reference-dose-and-reference-concentration-](http://www.epa.gov/osa/review-reference-dose-and-reference-concentration-processes)
3275 [processes](http://www.epa.gov/osa/review-reference-dose-and-reference-concentration-processes)
3276 U.S. EPA. (2003a). Attachment 1-3 Guidance for Developing Ecological Soil Screening Levels (Eco-
3277 SSLs): Evaluation of Dermal Contact and Inhalation Exposure Pathways for the Purpose of
3278 Setting Eco-SSLs. (OSWER9285755E). Washington, DC: .S. Environmental Protection Agency,
3279 Office of Solid Waste and Emergency Response.
3280 https://www.epa.gov/sites/production/files/2015-09/documents/ecossl_attachment_1-3.pdf
3281 U.S. EPA. (2003b). Guidance for developing ecological soil screening levels (Eco-SSLs): Review of
3282 background concentration for metals - Attachment 1-4 [EPA Report]. (OSWER Directive 92857-
3283 55). Washington, DC.
3284 U.S. EPA. (2005). Guidelines for carcinogen risk assessment [EPA Report] (pp. 1-166). (EPA/630/P-
3285 03/001F). Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
3286 <http://www2.epa.gov/osa/guidelines-carcinogen-risk-assessment>
3287 U.S. EPA. (2006). Approaches for the application of physiologically based pharmacokinetic (PBPK)
3288 models and supporting data in risk assessment (Final Report) [EPA Report] (pp. 1-123).
3289 (EPA/600/R-05/043F). Washington, DC: U.S. Environmental Protection Agency, Office of
3290 Research and Development, National Center for Environmental Assessment.
3291 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=157668>
3292 U.S. EPA. (2007). Exposure and fate assessment screening tool (E-FAST): Version 2.0, documentation
3293 manual [EPA Report]. (EPA Contract No. EP-W-04-035). Springfield, VA.
3294 <http://www.epa.gov/opptintr/exposure/pubs/efast2man.pdf>

3295 [U.S. EPA](#). (2011b). Appendices for the Toxicological review of trichloroethylene (CAS No. 79-01-6) in
3296 support of summary information on the Integrated Risk Information System (IRIS) [EPA
3297 Report]. (EPA/635/R-09/011F). Washington, DC.
3298 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100CB6V.txt>
3299 [U.S. EPA](#). (2011c). Exposure factors handbook: 2011 edition (final) [EPA Report]. (EPA/600/R-
3300 090/052F). Washington, DC: U.S. Environmental Protection Agency, Office of Research and
3301 Development, National Center for Environmental Assessment.
3302 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=236252>
3303 [U.S. EPA](#). (2011d). Recommended use of body weight 3/4 as the default method in derivation of the
3304 oral reference dose (pp. 1-50). (EPA/100/R11/0001). Washington, DC: U.S. Environmental
3305 Protection Agency, Risk Assessment Forum, Office of the Science Advisor.
3306 [https://www.epa.gov/risk/recommended-use-body-weight-34-default-method-derivation-oral-
3307 reference-dose](https://www.epa.gov/risk/recommended-use-body-weight-34-default-method-derivation-oral-reference-dose)
3308 [U.S. EPA](#). (2011e). Toxicological review of trichloroethylene (CASRN 79-01-6) in support of summary
3309 information on the Integrated Risk Information System (IRIS) [EPA Report]. (EPA/635/R-
3310 09/011F). Washington, DC.
3311 https://cfpub.epa.gov/ncea/iris/iris_documents/documents/toxreviews/0106tr.pdf
3312 [U.S. EPA](#). (2012a). Benchmark dose technical guidance. (EPA/100/R-12/001). Washington, DC: U.S.
3313 Environmental Protection Agency, Risk Assessment Forum.
3314 <https://www.epa.gov/risk/benchmark-dose-technical-guidance>
3315 [U.S. EPA](#). (2012b). Estimation Programs Interface Suite™ for Microsoft® Windows, v 4.11 [Computer
3316 Program]. Washington, DC. Retrieved from [https://www.epa.gov/tsca-screening-tools/epi-
3317 suitetm-estimation-program-interface](https://www.epa.gov/tsca-screening-tools/epi-suitetm-estimation-program-interface)
3318 [U.S. EPA](#). (2012c). Sustainable futures P2 framework manual [EPA Report]. (EPA-748-B12-001).
3319 Washington DC. [http://www.epa.gov/sustainable-futures/sustainable-futures-p2-framework-
3320 manual](http://www.epa.gov/sustainable-futures/sustainable-futures-p2-framework-manual)
3321 [U.S. EPA](#). (2013a). Final peer review comments for the OPPT trichloroethylene (TCE) draft risk
3322 assessment [Website]. [https://www.epa.gov/sites/production/files/2017-
3323 06/documents/tce_consolidated_peer_review_comments_september_5_2013.pdf](https://www.epa.gov/sites/production/files/2017-06/documents/tce_consolidated_peer_review_comments_september_5_2013.pdf)
3324 [U.S. EPA](#). (2013b). Interpretive assistance document for assessment of discrete organic chemicals.
3325 Sustainable futures summary assessment [EPA Report]. Washington, DC.
3326 http://www.epa.gov/sites/production/files/2015-05/documents/05-iad_discretes_june2013.pdf
3327 [U.S. EPA](#). (2014a). Framework for human health risk assessment to inform decision making. Final
3328 [EPA Report]. (EPA/100/R-14/001). Washington, DC: U.S. Environmental Protection, Risk
3329 Assessment Forum. [https://www.epa.gov/risk/framework-human-health-risk-assessment-inform-
3330 decision-making](https://www.epa.gov/risk/framework-human-health-risk-assessment-inform-decision-making)
3331 [U.S. EPA](#). (2014b). TSCA work plan chemical risk assessment. Trichloroethylene: Degreasing, spot
3332 cleaning and arts & crafts uses. (740-R1-4002). Washington, DC: Environmental Protection
3333 Agency, Office of Chemical Safety and Pollution Prevention.
3334 [http://www2.epa.gov/sites/production/files/2015-
3335 09/documents/tce_opptworkplanchemra_final_062414.pdf](http://www2.epa.gov/sites/production/files/2015-09/documents/tce_opptworkplanchemra_final_062414.pdf)
3336 [U.S. EPA](#). (2014c). Exposure and Fate Assessment Screening Tool Version 2014 (E-FAST 2014).
3337 Washington, DC: Office of Pollution Prevention and Toxics. [https://www.epa.gov/tsca-
3338 screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014](https://www.epa.gov/tsca-screening-tools/e-fast-exposure-and-fate-assessment-screening-tool-version-2014)
3339 [U.S. EPA](#). (2015a). EDSP: Weight of Evidence Analysis of Potential Interaction with the Estrogen,
3340 Androgen or Thyroid Pathways. Chemical: Glyphosate. Office of Pesticide Programs.
3341 [https://www.epa.gov/endocrine-disruption/endocrine-disruptor-screening-program-tier-1-
3342 screening-determinations-and](https://www.epa.gov/endocrine-disruption/endocrine-disruptor-screening-program-tier-1-screening-determinations-and)

3343 [U.S. EPA.](#) (2015b). Update of human health ambient water quality criteria: Trichloroethylene (TCE) 79-
3344 01-6. (EPA 820-R-15-066). Washington D.C.: Office of Water, Office of Science and
3345 Technology. <https://www.regulations.gov/document?D=EPA-HQ-OW-2014-0135-0173>
3346 [U.S. EPA.](#) (2016b). Instructions for reporting 2016 TSCA chemical data reporting. Washington, DC:
3347 Office of Pollution Prevention and Toxics. [https://www.epa.gov/chemical-data-](https://www.epa.gov/chemical-data-reporting/instructions-reporting-2016-tsca-chemical-data-reporting)
3348 [reporting/instructions-reporting-2016-tsca-chemical-data-reporting](https://www.epa.gov/chemical-data-reporting/instructions-reporting-2016-tsca-chemical-data-reporting)
3349 [U.S. EPA.](#) (2016c). Non-confidential 2016 Chemical Data Reporting (CDR) Database [Website].
3350 <http://www.epa.gov/cdr/>
3351 [U.S. EPA.](#) (2016d). Public database 2016 chemical data reporting (May 2017 release). Washington, DC:
3352 US Environmental Protection Agency, Office of Pollution Prevention and Toxics. Retrieved
3353 from <https://www.epa.gov/chemical-data-reporting>
3354 [U.S. EPA.](#) (2016e). Supplemental exposure and risk reduction technical report in support of risk
3355 management options for trichloroethylene (TCE) use in consumer aerosol degreasing.
3356 Washington D.C.: Office of Chemical Safety and Pollution Prevention.
3357 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0163-0023>
3358 [U.S. EPA.](#) (2016f). Supplemental occupational exposure and risk reduction technical report in support of
3359 risk management options for trichloroethylene (TCE) use in aerosol degreasing. (RIN 2070-
3360 AK03). Washington D.C.: Office of Chemical Safety and Pollution Prevention.
3361 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0163-0021>
3362 [U.S. EPA.](#) (2016g). Supplemental occupational exposure and risk reduction technical report in support
3363 of risk management options for trichloroethylene (TCE) use in spot cleaning. (RIN 2070-AK03).
3364 Washington D.C.: Office of Chemical Safety and Pollution Prevention.
3365 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0163-0024>
3366 [U.S. EPA.](#) (2016h). Supplemental occupational exposure and risk reduction technical report in support
3367 of risk management options for trichloroethylene (TCE) use in vapor degreasing. (RIN 2070-
3368 AK11). Washington D.C.: Office of Chemical Safety and Pollution Prevention.
3369 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0387-0126>
3370 [U.S. EPA.](#) (2016i). Weight of evidence in ecological assessment [EPA Report]. (EPA100R16001).
3371 Washington, DC: Office of the Science Advisor.
3372 https://cfpub.epa.gov/si/si_public_record_report.cfm?dirEntryId=335523
3373 [U.S. EPA.](#) (2017a). Chemical test rule data: Trichloroethylene. Washington, DC. Retrieved from
3374 <http://java.epa.gov/chemview>
3375 [U.S. EPA.](#) (2017b). Consumer Exposure Model (CEM) version 2.0: User guide. U.S. Environmental
3376 Protection Agency, Office of Pollution Prevention and Toxics.
3377 https://www.epa.gov/sites/production/files/2017-06/documents/cem_2.0_user_guide.pdf
3378 [U.S. EPA.](#) (2017c). Preliminary information on manufacturing, processing, distribution, use, and
3379 disposal: Trichloroethylene [Comment]. (EPA-HQ-OPPT-2016-0737-003). Washington, DC:
3380 Office of Chemical Safety and Pollution Prevention.
3381 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0737-0003>
3382 [U.S. EPA.](#) (2017d). Scope of the Risk Evaluation for trichloroethylene. CASRN: 79 - 01 - 6 [EPA
3383 Report]. (EPA-740-R1-7004). [https://www.epa.gov/sites/production/files/2017-](https://www.epa.gov/sites/production/files/2017-06/documents/tce_scope_06-22-17.pdf)
3384 [06/documents/tce_scope_06-22-17.pdf](https://www.epa.gov/sites/production/files/2017-06/documents/tce_scope_06-22-17.pdf)
3385 [U.S. EPA.](#) (2017e). Strategy for conducting literature searches for trichloroethylene (TCE):
3386 Supplemental document to the TSCA Scope Document. CASRN: 79-01-6 [EPA Report].
3387 [https://www.epa.gov/sites/production/files/2017-](https://www.epa.gov/sites/production/files/2017-06/documents/tce_lit_search_strategy_053017_0.pdf)
3388 [06/documents/tce_lit_search_strategy_053017_0.pdf](https://www.epa.gov/sites/production/files/2017-06/documents/tce_lit_search_strategy_053017_0.pdf)
3389 [U.S. EPA.](#) (2017f). Toxics Release Inventory (TRI), reporting year 2015. Retrieved from
3390 <https://www.epa.gov/toxics-release-inventory-tri-program/tri-data-and-tools>

3391 [U.S. EPA.](#) (2017h). Trichloroethylene market and use report. Washington, DC: U.S. Environmental
3392 Protection Agency, Office of Chemical Safety and Pollution Prevention, Chemistry, Economics,
3393 and Sustainable Strategies Division. [https://www.epa.gov/sites/production/files/2016-](https://www.epa.gov/sites/production/files/2016-05/documents/instructions_for_reporting_2016_tasca_cdr_13may2016.pdf)
3394 [05/documents/instructions_for_reporting_2016_tasca_cdr_13may2016.pdf](https://www.epa.gov/sites/production/files/2016-05/documents/instructions_for_reporting_2016_tasca_cdr_13may2016.pdf)
3395 [U.S. EPA.](#) (2017i). Trichloroethylene (79 - 01 - 6) bibliography: Supplemental file for the TSCA
3396 Scope Document [EPA Report]. [https://www.epa.gov/sites/production/files/2017-](https://www.epa.gov/sites/production/files/2017-06/documents/tce_comp_bib.pdf)
3397 [06/documents/tce_comp_bib.pdf](https://www.epa.gov/sites/production/files/2017-06/documents/tce_comp_bib.pdf)
3398 [U.S. EPA.](#) (2018a). 2014 National Emissions Inventory (NEI) data (2 ed.). Washington, DC.
3399 <https://www.epa.gov/air-emissions-inventories/2014-national-emissions-inventory-nei-data>
3400 [U.S. EPA.](#) (2018b). Application of systematic review in TSCA Risk Evaluations. (740-P1-8001).
3401 Washington, DC: U.S. Environmental Protection Agency, Office of Chemical Safety and
3402 Pollution Prevention. [https://www.epa.gov/sites/production/files/2018-](https://www.epa.gov/sites/production/files/2018-06/documents/final_application_of_sr_in_tasca_05-31-18.pdf)
3403 [06/documents/final_application_of_sr_in_tasca_05-31-18.pdf](https://www.epa.gov/sites/production/files/2018-06/documents/final_application_of_sr_in_tasca_05-31-18.pdf)
3404 [U.S. EPA.](#) (2018c). ECOTOX user guide: ECOTOXicology database system. Version 5.0.
3405 <https://cfpub.epa.gov/ecotox/>
3406 [U.S. EPA.](#) (2018d). Problem Formulation of the Risk Evaluation for Trichloroethylene. (EPA-740-R1-
3407 7014). Washington, DC: Office of Chemical Safety and Pollution Prevention, United States
3408 Environmental Protection Agency. [https://www.epa.gov/sites/production/files/2018-](https://www.epa.gov/sites/production/files/2018-06/documents/tce_problem_formulation_05-31-31.pdf)
3409 [06/documents/tce_problem_formulation_05-31-31.pdf](https://www.epa.gov/sites/production/files/2018-06/documents/tce_problem_formulation_05-31-31.pdf)
3410 [U.S. EPA.](#) (2018e). Strategy for assessing data quality in TSCA Risk Evaluations. Washington DC: U.S.
3411 Environmental Protection Agency, Office of Pollution Prevention and Toxics.
3412 [U.S. EPA.](#) (2019a). Consumer Exposure Model (CEM) 2.1 User Guide. (EPA Contract # EP-W-12-
3413 010). Washington, DC.
3414 [U.S. EPA.](#) (2019b). Consumer Exposure Model (CEM) 2.1 User Guide - Appendices. (EPA Contract #
3415 EP-W-12-010). Washington, DC.
3416 [U.S. EPA.](#) (2019c). Organic chemicals, plastics, and synthetic fibers. (40 CFR Part 414). Washington,
3417 D.C. [https://www.ecfr.gov/cgi-bin/text-](https://www.ecfr.gov/cgi-bin/text-idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.414&rgn=div5)
3418 [idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.414&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.414&rgn=div5)
3419 [U.S. EPA.](#) (2019d). Biennial Review of 40 CFR Part 503 As Required Under the Clean Water Act
3420 Section 405(d)(2)(C). [https://www.epa.gov/sites/production/files/2019-06/documents/2016-](https://www.epa.gov/sites/production/files/2019-06/documents/2016-2017-biosolids-biennial-review.pdf)
3421 [2017-biosolids-biennial-review.pdf](https://www.epa.gov/sites/production/files/2019-06/documents/2016-2017-biosolids-biennial-review.pdf)
3422 [U.S. EPA.](#) (2020a). 2017 National Emissions Inventory complete release: technical support document.
3423 [https://www.epa.gov/air-emissions-inventories/2017-national-emissions-inventory-nei-technical-](https://www.epa.gov/air-emissions-inventories/2017-national-emissions-inventory-nei-technical-support-document-tsd)
3424 [support-document-tsd](https://www.epa.gov/air-emissions-inventories/2017-national-emissions-inventory-nei-technical-support-document-tsd)
3425 [U.S. EPA.](#) (2020b). 2017 Toxics Release Inventory (TRI) data. Washington, DC: US Environmental
3426 Protection Agency. <https://www.epa.gov/toxics-release-inventory-tri-program/tri-data-and-tools>
3427 [USGS.](#) (2003). A national survey of methyl tert-butyl ether and other volatile organic compounds in
3428 drinking-water sources: Results of the random survey. Reston, VA: U.S. Department of the
3429 Interior, U.S. Geological Survey. <https://pubs.er.usgs.gov/publication/wri024079>
3430 [USGS.](#) (2006). Water-quality conditions of Chester Creek, Anchorage, Alaska, 1998-2001. Reston, VA:
3431 U.S. Department of the Interior, U.S. Geological Survey.
3432 <https://pubs.er.usgs.gov/publication/sir20065229>
3433 [Van Maldergem, L; Jauniaux, E; Gillerot, Y.](#) (1992). Morphological features of a case of retinoic acid
3434 embryopathy. *Prenat Diagn* 12: 699-701. <http://dx.doi.org/10.1002/pd.1970120812>
3435 [Van Raaij, MTM; Janssen, PAH; Piersma, AH.](#) (2003). The relevance of developmental toxicity
3436 endpoints for acute limits settings (pp. 1-88). (RIVM Report 601900004). Netherlands:
3437 Netherlands National Institute for Public Health and the Environment.
3438 <http://www2.epa.gov/sites/production/files/2014-04/documents/mtg35b.pdf>

3439 [Vidal, M; Bassères, A; Narbonne, J.](#) (2001). Potential biomarkers of trichloroethylene and toluene
3440 exposure in *Corbicula fluminea*. *Environ Toxicol Pharmacol* 9: 87-97.
3441 [http://dx.doi.org/10.1016/S1382-6689\(00\)00068-5](http://dx.doi.org/10.1016/S1382-6689(00)00068-5)
3442 [Vlaanderen, J; Straif, K; Pukkala, E; Kauppinen, T; Kyyronen, P; Martinsen, J; Kjaerheim, K;](#)
3443 [Tryggvadottir, L; Hansen, J; Sparen, P, ar; Weiderpass, E.](#) (2013). Occupational exposure to
3444 trichloroethylene and perchloroethylene and the risk of lymphoma, liver, and kidney cancer in
3445 four Nordic countries. *Occup Environ Med* 70: 393-401. [http://dx.doi.org/10.1136/oemed-2012-](http://dx.doi.org/10.1136/oemed-2012-101188)
3446 [101188](http://dx.doi.org/10.1136/oemed-2012-101188)
3447 [Vogel, TM; McCarty, PL.](#) (1985). Biotransformation of tetrachloroethylene to trichloroethylene,
3448 dichloroethylene, vinyl chloride, and carbon dioxide under methanogenic conditions. *Appl*
3449 *Environ Microbiol* 49: 1080-1083.
3450 [von Grote, J; Hürlimann, C; Scheringer, M; Hungerbühler, K.](#) (2006). Assessing occupational exposure
3451 to perchloroethylene in dry cleaning. *J Occup Environ Hyg* 3: 606-619.
3452 <http://dx.doi.org/10.1080/15459620600912173>
3453 [Von Grote, J; Hurlimann, JC; Scheringer, M; Hungerbuhler, K.](#) (2003). Reduction of Occupational
3454 Exposure to Perchloroethylene and Trichloroethylene in Metal Degreasing over the Last 30
3455 years: Influence of Technology Innovation and Legislation. *J Expo Anal Environ Epidemiol* 13:
3456 325-340. <http://dx.doi.org/10.1038/sj.jea.7500288>
3457 [Wallace, LA.](#) (1987). The total exposure assessment methodology (TEAM) study: Summary and
3458 analysis: Volume I [EPA Report]. (EPA/600/6-87/002a). Washington, DC: U.S. Environmental
3459 Protection Agency; Office of Acid Deposition, Environmental Monitoring, and Quality
3460 Assurance.
3461 [Wang, R; Zhang, Y; Lan, Q; Holford, TR; Leaderer, B; Zahm, SH; Boyle, P; Dosemeci, M; Rothman,](#)
3462 [N; Zhu, Y; Qin, Q; Zheng, T.](#) (2009). Occupational exposure to solvents and risk of non-
3463 Hodgkin lymphoma in Connecticut women. *Am J Epidemiol* 169: 176-185.
3464 <http://dx.doi.org/10.1093/aje/kwn300>
3465 [Wang, G; Wang, J; Fan, X; Ansari, GAS; Khan, MF.](#) (2012). Protein adducts of malondialdehyde and 4-
3466 hydroxynonenal contribute to trichloroethene-mediated autoimmunity via activating Th17 cells:
3467 dose- and time-response studies in female MRL+/+ mice. *Toxicology* 292: 113-122.
3468 <http://dx.doi.org/10.1016/j.tox.2011.12.001>.
3469 [Ward, GS; Tolmsoff, AJ; Petrocelli, SR.](#) (1986). ACUTE TOXICITY OF TRICHLOROETHYLENE
3470 TO SALTWATER ORGANISMS. *Bull Environ Contam Toxicol* 37: 830-836.
3471 [Weast, RC; Selby, SM.](#) (1966). Ethene, trichloro. In *CRC handbook of chemistry and physics*.
3472 Cleveland, OH: The Chemical Rubber Co.
3473 [Weed, DL.](#) (2005). Weight of evidence: A review of concept and methods [Review]. *Risk Anal* 25:
3474 1545-1557. <http://dx.doi.org/10.1111/j.1539-6924.2005.00699.x>
3475 [Whittaker, C; Rice, F; McKernan, L; Dankovic, D; Lentz, T; Macmahon, K; Kuempel, E; Zumwalde, R;](#)
3476 [Schulte, P.](#) (2016). Current Intelligence Bulletin 68: NIOSH Chemical Carcinogen Policy.
3477 Whittaker, C; Rice, F; Mckernan, L; Dankovic, D; Lentz, T; Macmahon, K; Kuempel, E;
3478 Zumwalde, R; Schulte, P.
3479 [Whittaker, SG; Johanson, CA.](#) (2011). A profile of the dry cleaning industry in King County,
3480 Washington: Final report. (LHWMP 0048). Seattle, WA: Local Hazardous Waste Management
3481 Program in King County.
3482 [http://www.hazwastehelp.org/publications/publications_detail.aspx?DocID=Oh73%2fQilg9Q%3](http://www.hazwastehelp.org/publications/publications_detail.aspx?DocID=Oh73%2fQilg9Q%3d)
3483 [d](http://www.hazwastehelp.org/publications/publications_detail.aspx?DocID=Oh73%2fQilg9Q%3d)
3484 [Wichainun, R; Kasitanon, N; Wangkaew, S; Hongsongkiat, S; Sukitawut, W; Louthrenoo, W.](#) (2013).
3485 Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus
3486 erythematosus: a comparison using control sera obtained from healthy individuals and patients

3487 with multiple medical problems. *Asian Pac J Allergy Immunol* 31: 292-298.
3488 <http://dx.doi.org/10.12932/AP0272.31.4.2013>
3489 [WHO](#). (1985). Environmental health criteria: Trichloroethylene. Geneva, Switzerland.
3490 [Wikoff, D; Urban, JD; Harvey, S; Haws, LC](#). (2018). Role of Risk of Bias in Systematic Review for
3491 Chemical Risk Assessment: A Case Study in Understanding the Relationship Between
3492 Congenital Heart Defects and Exposures to Trichloroethylene. *Int J Toxicol* 37: 125-143.
3493 <http://dx.doi.org/10.1177/1091581818754330>
3494 [Williams, FE; Sickelbaugh, TJ; Hassoun, E](#). (2006). Modulation by ellagic acid of DCA-induced
3495 developmental toxicity in the zebrafish (*Danio rerio*). *J Biochem Mol Toxicol* 20: 183-190.
3496 <http://dx.doi.org/10.1002/jbt.20135>
3497 [Wilmer, JW; Spencer, PJ; Ball, N; Bus, JS](#). (2014). Assessment of the genotoxicity of trichloroethylene
3498 in the in vivo micronucleus assay by inhalation exposure. *Mutagenesis* 29: 209-214.
3499 <http://dx.doi.org/10.1093/mutage/geu006>
3500 [Wirbisky, SE; Damayanti, N; Mahapatra, CT; Sepulveda, MS; Irudayaraj, J; Freeman, JL](#). (2016).
3501 Mitochondrial Dysfunction, Disruption of F-Actin Polymerization, and Transcriptomic
3502 Alterations in Zebrafish Larvae Exposed to Trichloroethylene. *Chem Res Toxicol* 29: 169-179.
3503 <http://dx.doi.org/10.1021/acs.chemrestox.5b00402>
3504 [Woolhiser, MR; Krieger, SM; Thomas, J; Hotchkiss, JA](#). (2006). Trichloroethylene (TCE):
3505 Immunotoxicity potential in CD rats following a 4-week vapor inhalation exposure. (031020).
3506 Midland, MI: Dow Chemical Company.
3507 [Wright, JM; Evans, A; Kaufman, JA; Rivera-Núñez, Z; Narotsky, MG](#). (2017). Disinfection by-product
3508 exposures and the risk of specific cardiac birth defects. *Environ Health Perspect* 125: 269-277.
3509 <http://dx.doi.org/10.1289/EHP103>
3510 [Xavier-Neto, J; Neville, CM; Shapiro, MD; Houghton, L; Wang, GF; Nikovits, W; Stockdale, FE;](#)
3511 [Rosenthal, N](#). (1999). A retinoic acid-inducible transgenic marker of sino-atrial development in
3512 the mouse heart. *Development* 126: 2677-2687.
3513 [Xu, H; Tanphaichitr, N; Forkert, PG; Anupriwan, A; Weerachayanukul, W; Vincent, R; Leader, A;](#)
3514 [Wade, MG](#). (2004). Exposure to trichloroethylene and its metabolites causes impairment of
3515 sperm fertilizing ability in mice. *Toxicol Sci* 82: 590-597.
3516 <http://dx.doi.org/10.1093/toxsci/kfh277>
3517 [Xu, X; Yang, R; Wu, N; Zhong, P; Ke, Y; Zhou, L; Yuan, J; Li, G; Huang, H; Wu, B](#). (2009). Severe
3518 hypersensitivity dermatitis and liver dysfunction induced by occupational exposure to
3519 trichloroethylene. *Ind Health* 47: 107-112.
3520 [Yasui, H; Morishima, M; Nakazawa, M; Ando, M; Aikawa, E](#). (1999). Developmental spectrum of
3521 cardiac outflow tract anomalies encompassing transposition of the great arteries and
3522 dextroposition of the aorta: pathogenic effect of extrinsic retinoic acid in the mouse embryo.
3523 *Anat Rec* 254: 253-260. [http://dx.doi.org/10.1002/\(SICI\)1097-0185\(19990201\)254:2<253::AID-AR11>3.0.CO;2-4](http://dx.doi.org/10.1002/(SICI)1097-0185(19990201)254:2<253::AID-AR11>3.0.CO;2-4)
3524
3525 [Yauck, JS; Malloy, ME; Blair, K; Simpson, PM; Mccarver, DG](#). (2004). Proximity of residence to
3526 trichloroethylene-emitting sites and increased risk of offspring congenital heart defects among
3527 older women. *Birth Defects Res A Clin Mol Teratol* 70: 808-814.
3528 <http://dx.doi.org/10.1002/bdra.20060>
3529 [Yoshioka, Y; Ose, Y; Sato, T](#). (1986). Correlation of the five test methods to assess chemical toxicity
3530 and relation to physical properties. *Ecotoxicol Environ Saf* 12: 15-21.
3531 [Zeise, L; Wilson, R; Crouch, EA](#). (1987). Dose-response relationships for carcinogens: A review
3532 [Review]. *Environ Health Perspect* 73: 259-306.
3533 [Zhang, J](#). (2015). A review of spontaneous closure of ventricular septal defects. *28*: 516-520.

3534 [Zhang, L; Bassig, BA; Mora, JL; Vermeulen, R; Ge, Y; Curry, JD; Hu, W; Shen, M; Qiu, C; Ji, Z;](#)
3535 [Reiss, B; Mchale, CM; Liu, S; Guo, W; Purdue, MP; Yue, F; Li, L; Smith, MT; Huang, H; Tang,](#)
3536 [X; Rothman, N; Lan, Q.](#) (2013). Alterations in serum immunoglobulin levels in workers
3537 occupationally exposed to trichloroethylene. Carcinogenesis.
3538 <http://dx.doi.org/10.1093/carcin/bgs403>
3539 [Zhao, Y; Krishnadasan, A; Kennedy, N; Morgenstern, H; Ritz, B.](#) (2005). Estimated effects of solvents
3540 and mineral oils on cancer incidence and mortality in a cohort of aerospace workers. Am J Ind
3541 Med 48: 249-258. <http://dx.doi.org/10.1002/ajim.20216>
3542

APPENDICES

Appendix A REGULATORY HISTORY

A.1 Federal Laws and Regulations

Table Apx A-1. Federal Laws and Regulations

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
EPA Regulations		
Toxics Substances Control Act (TSCA) - Section 6(a)	Provides EPA with the authority to prohibit or limit the manufacture (including import), processing, distribution in commerce, use or disposal of a chemical if EPA evaluates the risk and concludes that the chemical presents an unreasonable risk to human health or the environment.	Proposed rule under section 6 of TSCA to address the unreasonable risks presented by TCE use in vapor degreasing (82 FR 7432 ; January 19, 2017).
TSCA - Section 6(a)	Provides EPA with the authority to prohibit or limit the manufacture (including import), processing, distribution in commerce, use or disposal of a chemical if EPA evaluates the risk and concludes that the chemical presents an unreasonable risk to human health or the environment	Proposed rule under section 6 of TSCA to address the unreasonable risks presented by TCE use in commercial and consumer aerosol degreasing and for spot cleaning at dry cleaning facilities (81 FR 91592 ; December 16, 2016).
TSCA - Section 6(b)	Directs EPA to promulgate regulations to establish processes for prioritizing chemicals and conducting Risk Evaluations on priority chemicals. In the meantime, EPA is directed to identify and begin Risk Evaluations on 10 chemical substances drawn from the 2014 update of the TSCA Work Plan for Chemical Assessments.	TCE is on the initial list of chemicals to be evaluated for unreasonable risks under TSCA (81 FR 91927 , December 19, 2016).
TSCA - Section 5(a)	Once EPA determines that a use of a chemical substance is a significant new use under TSCA section 5(a), persons are required to submit a significant new use notice (SNUN) to EPA at least 90 days before they manufacture (including import) or process the chemical substance for that use.	Significant New Use Rule (SNUR) (81 FR 20535 ; April 8, 2016). TCE is subject to reporting under the SNUR for manufacture (including import) or processing of TCE for use in a consumer product except for use in cleaners and solvent degreasers, film cleaners, hoof polishes, lubricants, mirror

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
		edge sealants and pepper spray. This SNUR ensures that EPA will have the opportunity to review any new consumer uses of TCE and, if appropriate, take action to prohibit or limit those uses.
TSCA - Section 8(a)	The TSCA section 8(a) CDR rule requires manufacturers (including importers) to give EPA basic exposure-related information on the types, quantities and uses of chemical substances produced domestically and imported into the United States.	TCE manufacturing (including importing), processing and use information is reported under the CDR rule (76 FR 50816 , August 16, 2011).
TSCA - Section 8(b)	EPA must compile, keep current and publish a list (the TSCA Inventory) of each chemical substance manufactured, processed or imported in the United States.	TCE was on the initial TSCA Inventory and was therefore not subject to EPA's new chemicals review process (60 FR 16309 , March 29, 1995).
TSCA - Section 8(e)	Manufacturers (including importers), processors and distributors must immediately notify EPA if they obtain information that supports the conclusion that a chemical substance or mixture presents a substantial risk of injury to health or the environment.	28 substantial risk notifications received for TCE (U.S. EPA, ChemView. Accessed April 13, 2017).
TSCA - Section 4	Provides EPA with authority to issue rules and orders requiring manufacturers (including importers) and processors to test chemical substances and mixtures.	Seven studies received for TCE (U.S. EPA, ChemView. Accessed April 13, 2017).
Emergency Planning and Community Right-to-Know Act (EPCRA) - Section 313	Requires annual reporting from facilities in specific industry sectors that employ 10 or more full time equivalent employees and that manufacture, process, or otherwise use a Toxics Release Inventory (TRI)-listed chemical in quantities above threshold levels. A facility that meets reporting requirements must submit a reporting form for each chemical for which it triggered reporting, providing data across a variety of categories, including activities and uses of the chemical, releases and other waste management (e.g., quantities recycled, treated, combusted) and pollution	TCE is a listed substance subject to reporting requirements under 40 CFR 372.65 effective as of January 1, 1987.

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
	prevention activities (under section 6607 of the Pollution Prevention Act). These data include on- and off-site data as well as multimedia data (<i>i.e.</i> , air, land and water).	
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) – Sections 3 and 6	FIFRA governs the sale, distribution and use of pesticides. Section 3 of FIFRA generally requires that pesticide products be registered by EPA prior to distribution or sale. Pesticides may only be registered if, among other things, they do not cause “unreasonable adverse effects on the environment.” Section 6 of FIFRA provides EPA with the authority to cancel pesticide registrations if either: (1) the pesticide, labeling, or other material does not comply with FIFRA or (2) when used in accordance with widespread and commonly recognized practice, the pesticide generally causes unreasonable adverse effects on the environment.	TCE is no longer used as an inert ingredient in pesticide products.
Clean Air Act (CAA) - Section 112(b)	Defines the original list of CAA hazardous air pollutants (HAPs). Under 112(c) of the CAA, EPA must identify and list source categories that emit HAPs and then set emission standards for those listed source categories under CAA section 112(d). CAA section 112(b)(3)(A) specifies that any person may petition the Administrator to modify the list of HAPs by adding or deleting a substance.	Lists TCE as a HAP (42 U.S.C. 7412(b)(1)).
CAA - Section 112(d)	Directs EPA to establish, by rule, National Emission Standards for Hazardous Air Pollutants (NESHAP) for each category or subcategory of listed major sources and area sources of HAPs (listed pursuant to Section 112(c)). The standards must require the maximum degree of emission reduction that the EPA determines to be achievable by each particular source category. This is generally referred to as maximum achievable control technology (MACT). For area sources, the standards must	EPA has promulgated a number of NESHAP regulating industrial source categories that emit trichloroethylene and other HAPs. These include, for example, the NESHAP for Halogenated Solvent Cleaning (59 FR 61801 ; December 2, 1994), among others.

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
	require generally achievable control technology (GACT) though may require MACT.	
CAA - Sections 112(d) and 112 (f)	Risk and technology review (RTR) of section 112(d) MACT standards. Section 112(f)(2) requires EPA to conduct risk assessments for each source category subject to section 112(d) MACT standards, and to determine if additional standards are needed to reduce remaining risks. Section 112(d)(6) requires EPA to review and revise the MACT standards, as necessary, taking into account developments in practices, processes and control technologies.	EPA has promulgated a number of RTR NESHAP (<i>e.g.</i> , the RTR NESHAP for Halogenated Solvent Cleaning (72 FR 25138 ; May 3, 2007) and will do so, as required, for the remaining source categories with NESHAP.
Clean Water Act (CWA) – Sections 301(b), 304(b), 306, and 307(b)	Requires establishment of Effluent Limitations Guidelines and Standards for conventional, toxic, and non-conventional pollutants. For toxic and non-conventional pollutants, EPA identifies the best available technology that is economically achievable for that industry after considering statutorily prescribed factors and sets regulatory requirements based on the performance of that technology. Regulations apply to existing and new sources.	TCE is designated as a toxic pollutant under section 307(a)(1) of the CWA and as such, is subject to effluent limitations.
CWA - Section 307(a)	Establishes a list of toxic pollutants or combination of pollutants under the CWA. The statute specifies a list of families of toxic pollutants also listed in 40 CFR 401.15. The “priority pollutants” specified by those families are listed in 40 CFR part 423, Appendix A. These are pollutants for which best available technology effluent limitations must be established on either a national basis through rules (Section 301(b), 304(b), 307(b), 306) or on a case-by-case best professional judgement basis in National Pollutant Discharge Elimination System (NPDES) permits, see Section 4029a)(1)(B).	

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
Safe Drinking Water Act (SDWA) - Section 1412	Requires EPA to publish a non-enforceable maximum contaminant level goals (MCLGs) for contaminants which 1. may have an adverse effect on the health of persons; 2. are known to occur or there is a substantial likelihood that the contaminant will occur in public water systems with a frequency and at levels of public health concern; and 3. in the sole judgement of the Administrator, regulation of the contaminant presents a meaningful opportunity for health risk reductions for persons served by public water systems. When EPA publishes an MCLG, EPA must also promulgate a National Primary Drinking Water Regulation (NPDWR) which includes either an enforceable maximum contaminant level (MCL), or a required treatment technique. Public water systems are required to comply with NPDWRs.	TCE is subject to NPDWR under the SDWA with a MCLG of zero and an enforceable MCL of 0.005 mg/L (52 FR 25690, July 8, 1987).
Resource Conservation and Recovery Act (RCRA) - Section 3001	Directs EPA to develop and promulgate criteria for identifying the characteristics of hazardous waste, and for listing hazardous waste, taking into account toxicity, persistence, and degradability in nature, potential for accumulation in tissue and other related factors such as flammability, corrosiveness, and other hazardous characteristics.	TCE is included on the list of commercial chemical products, manufacturing chemical intermediates or off-specification commercial chemical products or manufacturing chemical intermediates that, when disposed (or when formulations containing any one of these as a sole active ingredient are disposed) unused, become hazardous wastes pursuant to RCRA 3001. RCRA Hazardous Waste Status: D040 at 0.5 mg/L; F001, F002; U228
Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) - Section 102(a) and 103	Authorizes EPA to promulgate regulations designating as hazardous substances those substances which, when released into the environment, may present substantial danger to the public health or welfare or the environment. EPA must also promulgate regulations establishing the quantity of any hazardous substance the release of which must be reported under Section 103.	TCE is a hazardous substance with a reportable quantity pursuant to section 102(a) of CERCLA (40 CFR 302.4) and EPA is actively overseeing cleanup of sites contaminated with TCE pursuant to the National Contingency Plan (NCP) (40 CFR 751).

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
	<p>Section 103 requires persons in charge of vessels or facilities to report to the National Response Center if they have knowledge of a release of a hazardous substance above the reportable quantity threshold.</p>	
Other Federal Regulations		
<p>Occupational Safety and Health Act (OSH Act)</p>	<p>Requires employers to provide their workers with a place of employment free from recognized hazards to safety and health, such as exposure to toxic chemicals, excessive noise levels, mechanical dangers, heat or cold stress or unsanitary conditions (29 U.S.C. section 651 et seq.).</p> <p>Under the Act, OSHA can issue occupational safety and health standards including such provisions as Permissible Exposure Limits (PELs), exposure monitoring, engineering and administrative controls, and respiratory protection.</p>	<p>In 1971, OSHA issued occupational safety and health standards for TCE that included a PEL of 100 ppm as an 8-hr TWA with an acceptable ceiling concentration of 200 ppm. An acceptable maximum peak above the acceptable ceiling concentration for an 8 hour shift is 300 ppm, based on the maximum duration of 5 minutes in any 2 hours (29 CFR 1910.1000).</p> <p>While OSHA has established a PEL for TCE, OSHA has recognized that many of its PELs are outdated and inadequate for ensuring protection of worker health. Most of OSHA’s PELs were issued shortly after adoption of the Occupational Safety and Health (OSH) Act in 1970, and have not been updated since that time. Section 6(a) of the OSH Act granted the Agency the authority to adopt existing Federal standards or national consensus standards as enforceable OSHA standards. “OSHA recommends that employers consider using the alternative occupational exposure limits because the Agency believes that exposures above some of these alternative occupational exposure levels are in compliance with the relevant PELs.” For TCE, the alternative occupational exposure limits are the NIOSH</p>

Statutes/Regulations	Description of Authority/Regulation	Description of Regulation
		REL of 2 ppm (as a 60-minute ceiling) during the usage of TCE as an anesthetic agent and 25 ppm (as a 10-hour TWA) during all other exposures. https://www.osha.gov/dsg/annotated-pels/
Atomic Energy Act	The Atomic Energy Act authorizes the Department of Energy to regulate the health and safety of its contractor employees	10 CFR 851.23, Worker Safety and Health Program, requires the use of the ACGIH TLVs if they are more protective than the OSHA PEL. The 2012 TLV for TCE is 10 ppm and the short-term limit is 25 ppm (ATSDR, 2019).
Federal Food, Drug, and Cosmetic Act (FFDCA)	Provides the FDA with authority to oversee the safety of food, drugs and cosmetics.	Tolerances are established for residues of TCE resulting from its use as a solvent in the manufacture of decaffeinated coffee and spice oleoresins (21 CFR 173.290).
Federal Hazardous Material Transportation Act	Section 5103 of the Act directs the Secretary of Transportation to: Designate material (including an explosive, radioactive material, infectious substance, flammable or combustible liquid, solid or gas, toxic, oxidizing or corrosive material and compressed gas) as hazardous when the Secretary determines that transporting the material in commerce may pose an unreasonable risk to health and safety or property. Issue regulations for the safe transportation, including security, of hazardous material in intrastate, interstate and foreign commerce.	The Department of Transportation (DOT) has designated TCE as a hazardous material, and there are special requirements for marking, labeling and transporting it (49 CFR Part 171, 49 CFR 172, 40 CFR § 173.202 and 40 CFR § 173.242).

7
8
9
10
11
12
13
14
15

16
17
18

A.2 State Laws and Regulations

Table_Apx A-2. State Laws and Regulations

State Actions	Description of Action
California Code of Regulations (CCR), Title 17, Section 94509(a)	Lists standards for VOCs for consumer products sold, supplied, offered for sale or manufactured for use in California. As part of that regulation, use of consumer general purpose degreaser products that contain TCE are banned in California and safer substitutes are in use (17 CCR, Section 94509(a)).
State Permissible Exposure Limits (PELs)	Most states have set PELs identical to the OSHA 100 ppm 8-hour TWA PEL. Nine states have PELs of 50 ppm. California's PEL of 25 ppm is the most stringent (CCR, Title 8, Table AC-1).
VOC regulations for consumer products	Many states regulate TCE as a VOC. These regulations may set VOC limits for consumer products and/or ban the sale of certain consumer products as an ingredient and/or impurity. Regulated products vary from state to state, and could include contact and aerosol adhesives, aerosols, electronic cleaners, footwear or leather care products and general degreasers, among other products. California (Title 17, California Code of Regulations, Division 3, Chapter 1, Subchapter 8.5, Articles 1, 2, 3 and 4), Connecticut (R.C.S.A Sections 22a-174-40, 22a-174-41, and 22a-174-44), Delaware (Adm. Code Title 7, 1141), District of Columbia (Rules 20-720, 20-721, 20-735, 20-736, 20-737), Illinois (35 Adm Code 223), Indiana (326 IAC 8-15), Maine (Chapter 152 of the Maine Department of Environmental Protection Regulations), Maryland (COMAR 26.11.32.00 to 26.11.32.26), Michigan (R 336.1660 and R 336. 1661), New Hampshire (Env-A 4100) New Jersey (Title 7, Chapter 27, Subchapter 24), New York (6 CRR-NY III A 235), Rhode Island (Air Pollution Control Regulation No. 31) and Virginia (9VAC5 Chapter 45) all have VOC regulations or limits for consumer products. Some of these states also require emissions reporting.
Bans	Beginning June 1, 2022, an owner or operator of a facility required to have an air emissions permit issued by the Pollution Control Agency may not use TCE at its permitted facility, including in any manufacturing, processing, or cleaning processes, except for few uses (Minn. Stat. 116.385)
Other	TCE is on California Proposition 65 List of chemicals known to cause cancer in 1988 or birth defects or other reproductive harm in 2014 (CCR Title 27, section 27001). TCE is on California's Safer Consumer Products Regulations Candidate List of chemicals that exhibit a hazard trait and are on an authoritative list (CCR Title 22, Chapter 55).

19
20
21
22

23
24
25

A.3 International Laws and Regulations

Table_Apx A-3. Regulatory Actions by Other Governments and Tribes

Country/ Organization	Requirements and Restrictions
Canada	<p>TCE is on the Canadian List of Toxic Substances (CEPA 1999 Schedule 1). TCE is also regulated for use and sale for solvent degreasing under <i>Solvent Degreasing Regulations (SOR/2003-283)</i> (<i>Canada Gazette</i>, Part II on August 13, 2003). The purpose of the regulation is to reduce releases of TCE into the environment from solvent degreasing facilities using more than 1000 kilograms of TCE per year. The regulation includes a market intervention by establishing tradable allowances for the use of TCE in solvent degreasing operations that exceed the 1000 kilograms threshold per year.</p>
European Union	<p>In 2011, TCE was added to Annex XIV (Authorisation list) of regulation (EC) No 1907/2006 - REACH (Registration, Evaluation, Authorization and Restriction of Chemicals). Entities that would like to use TCE needed to apply for authorization by October 2014, and those entities without an authorization must stop using TCE by April 2016. The European Chemicals Agency (ECHA) received 19 applications for authorization from entities interested in using TCE beyond April 2016.</p> <p>TCE is classified as a carcinogen category 1B, and was added to the EU REACH restriction of substances classified as carcinogen category 1A or 1B under the EU Classification and Labeling regulation (among other characteristics) in 2009. The restriction bans the placing on the market or use of TCE as substance, as constituent of other substances, or, in mixtures for supply to the general public when the individual concentration in the substance or mixture is equal to or greater than 0.1 % w/w (Regulation (EC) No 1907/2006 - REACH (Registration, Evaluation, Authorization and Restriction of Chemicals)). Previous regulations, such as the Solvent Emissions Directive (Directive 1999/13/EC) introduced stringent emission controls of TCE.</p>
Australia	<p>In 2000, TCE was assessed (National Industrial Chemicals Notification and Assessment Scheme, NICNAS (2000), <i>Trichloroethylene</i>. Accessed April, 18 2017).</p>
Japan Chemical Substances Control Law	<p>TCE is regulated in Japan under the following legislation:</p>

	<ul style="list-style-type: none"> -Act on the Evaluation of Chemical Substances and Regulation of Their Manufacture, etc. (Chemical Substances Control Law; CSCL) -Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof -Industrial Safety and Health Act (ISHA) -Air Pollution Control Law -Water Pollution Control Law -Soil Contamination Countermeasures Act -Law for the Control of Household Products Containing Harmful Substances <p>(National Institute of Technology and Evaluation (NITE) Chemical Risk Information Platform (CHIRP), Accessed April 18, 2017).</p>
<p>Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Japan, Latvia, New Zealand, People's Republic of China, Poland, Singapore, South Korea, Spain, Sweden, Switzerland, United Kingdom</p>	<p>Occupational exposure limits for TCE (GESTIS International limit values for chemical agents (Occupational exposure limits, OELs) database. Accessed April 18, 2017).</p>

26
27
28

29 **Appendix B LIST OF SUPPLEMENTAL DOCUMENTS**

30 List of supplemental documents (see Docket: [EPA-HQ-OPPT-2019-0500](#) for access to all files):

31
32 Associated **Systematic Review Data Quality Evaluation and Data Extraction** Documents –
33 Provides additional detail and information on individual study evaluations and data extractions
34 including criteria and scoring results:
35

36 Physical/Chemical Properties, Fate and Transport

- 37 a. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
38 *Evaluation of Physical-Chemical Properties Studies*
- 39
- 40 b. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
41 *Evaluation of Environmental Fate and Transport Studies*
- 42
- 43 c. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Extraction*
44 *for Environmental Fate and Transport Studies*

45 Occupational Exposures and Releases

- 46
- 47 d. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
48 *Evaluation of Environmental Releases and Occupational Exposure Data*
- 49
- 50 e. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
51 *Evaluation of Environmental Releases and Occupational Exposure Common Sources*
- 52
- 53 f. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: List of Key and*
54 *Supporting Studies for Environmental Releases and Occupational Exposure*

55 Consumer and Environmental Exposures

- 56
- 57 g. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
58 *Evaluation for Data Sources on Consumer and Environmental Exposure*
- 59
- 60 h. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Extraction*
61 *Tables for Environmental Monitoring Data*
- 62
- 63 i. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Extraction*
64 *for Biomonitoring Data*

65 Environmental Hazard

- 66
- 67 j. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
68 *Evaluation of Environmental Hazard Studies*
- 69
- 70 k. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Extraction*
71 *for Environmental Hazard Studies*

72 Human Health Hazard

- 73
- 74 l. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
75 *Evaluation of Human Health Hazard Studies - Animal and Mechanistic Data*

76

- 77 m. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Quality*
78 *Evaluation of Human Health Hazard Studies - Epidemiological Data*
79
80 n. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Updates to the*
81 *Data Quality Criteria for Epidemiological Studies*
82
83 o. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Extraction*
84 *for Human Health Hazard Studies*
85
86 p. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: Data Extraction*
87 *and Evaluation Tables for Genotoxicity Studies*
88
89 q. *Risk Evaluation for Trichloroethylene, Systematic Review Supplemental File: List of Key and*
90 *Supporting Studies for Human Health Hazard Assessment*
91

92 Associated **Supplemental Information Documents** – Provides additional details and information
93 on exposure, hazard and risk assessments:
94

95 Occupational Exposures and Releases

- 96 r. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Environmental*
97 *Releases and Occupational Exposure Assessment*
98
99 s. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Risk Calculator for*
100 *Occupational Exposures*
101
102 t. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Memorandum on*
103 *Respirator Usage in Private Sector Firms*
104

105 Consumer and Environmental Exposures

- 106 u. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Aquatic Exposure*
107 *Modeling Outputs from E-FAST*
108
109 v. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Consumer Exposure*
110 *Assessment Model Input Parameters*
111
112 w. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Exposure Modeling*
113 *Results and Risk Estimates for Consumer Inhalation Exposures*
114
115 x. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Exposure Modeling*
116 *Results and Risk Estimates for Consumer Dermal Exposures*
117

118 Human Health

- 119 y. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Data Table for*
120 *Congenital Heart Defects Weight of Evidence Analysis*
121
122 z. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Personal*
123 *Communication to OPPT. Raw Data Values from Selgrade and Gilmour, 2010*
124

125
126
127
128
129
130
131
132

- aa. *Risk Evaluation for Trichloroethylene, Supplemental Information File: PBPK Model and ReadMe (zipped)*
- bb. *Risk Evaluation for Trichloroethylene, Supplemental Information File: Internal Dose BMD Modeling Results for Selgrade and Gilmour, 2010*

133 **Appendix C ENVIRONMENTAL EXPOSURES**

134 A break-out of facility-specific modeling results organized per OES, with predicted surface water concentrations and associated days of COC
 135 exceedance, are included in Table_Apx C-1. These facility-specific modeling results are utilized and discussed in environmental risk
 136 characterization presented in Section 4.1.2.

137 **Table_Apx C-1. Facility-Specific Aquatic Exposure Modeling Results**

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
OES: Manufacturing									
Axiall Corporation, Westlake, LA NPDES: LA0007129	Surface Water	NPDES LA0007129	Surface water	350	1.266	0.00156	0.0051	3	0
								788	0
								920	0
								14,400	0
				20	22.150	0.0273	0.0897	3	0
								788	0
								920	0
								14,400	0
Olin Blue Cube, Freeport, TX NPDES: Not available	Off-site Waste-water Treatment	Organic Chemicals Manuf.	Surface water	350	0.069	0.26	2.42	3	37
								788	0
								920	0
								14,400	0
				20	1.200	4.51	42.14	3	11
								788	0
								920	0
								14,400	0
Solvents & Chemicals, Pearland, TX NPDES: Not available	Off-site Waste-water Treatment	Organic Chemicals Manuf.	Surface water	350	0.015	0.0564	0.53	3	17
								788	0
								920	0
								14,400	0
				20	0.265	1.01	9.48	3	5
								788	0
								920	0
								14,400	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
	Surface Water	Organic Chemicals Manuf.	Surface water	350	0.015	0.30	2.77	3	40
								788	0
								920	0
								14,400	0
				20	0.265	5.34	49.91	3	12
								788	0
								920	0
								14,400	0
OES: Processing as a Reactant									
440 unknown sites ⁸ NPDES: Not applicable	Off-site Waste-water Treatment	Organic Chemicals Manufacture	Surface water	350	0.005	0.0188	0.18	3	5
								788	0
								920	0
								14,400	0
				20	0.089	0.33	3.13	3	2
								788	0
								920	0
								14,400	0
	Surface Water	Organic Chemicals Manufacture	Surface water	350	0.005	0.0989	0.92	3	23
								788	0
								920	0
								14,400	0
				20	0.089	1.76	16.45	3	7
								788	0
								920	0
								14,400	0
Arkema Inc. Calvert City, KY NPDES: KY0003603	Surface Water	NPDES KY0003603	Surface water	350	0.017	0.000197	0.00073 7	3	0
								788	0
								920	0
								14,400	0
				20	0.295	0.00342	0.128	3	0
								788	0
								920	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								14,400	0
Honeywell International - Geismar Complex, Geismar, LA NPDES: LA0006181	Surface Water	NPDES LA0006181	Surface water	350	0.0128	0.0000158	0.0000518	3	0
								788	0
								920	0
								14,400	0
				20	0.224	0.000276	0.000907	3	0
								788	0
								920	0
								14,400	0
Praxair Technology Center, Tonawanda, NY NPDES: NY0000281	Surface Water	NPDES NY0000281	Still body	350	0.00169	n/a	169.00	3	350
								788	0
								920	0
								14,400	0
				20	0.030	n/a	3000.00	3	20
								788	20
								920	20
								14,400	0
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, and Metalworking Fluids)									
Texas Instruments, Inc., Attleboro, MA NPDES: MA0001791	Surface Water	NPDES MA0001791	Surface water	260	0.005	0.00502	0.0188	3	0
								788	0
								920	0
								14,400	0
				20	0.067	0.0673	0.25	3	0
								788	0
								920	0
								14,400	0
Accellent Inc/Collegetown, Collegetown, PA NPDES: PA0042617	Surface Water	NPDES PA0042617	Surface water	260	0.002	0.00711	0.0425	3	0
								788	0
								920	0
								14,400	0
				20	0.029	0.10	0.62	3	0
								788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								920	0
								14,400	0
Ametek Inc. U.S. Gauge Div., Sellersville, PA NPDES: PA0056014	Surface Water	Surrogate NPDES PA0020460	Surface water	260	0.001	0.0113	0.0619	3	0
								788	0
								920	0
								14,400	0
				20	0.011	0.12	0.68	3	0
								788	0
								920	0
								14,400	0
Atk-Allegany Ballistics Lab (Nirop), Keyser, WV NPDES: WV0020371	Surface Water	NPDES WV0020371	Surface water	260	0.0005	0.000669	0.00311	3	0
								788	0
								920	0
								14,400	0
				20	0.0061	0.00803	0.0373	3	0
								788	0
								920	0
								14,400	0
Handy & Harman Tube Co/East Norriton, Norristown, PA NPDES: PA0011436	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
US Nasa Michoud Assembly Facility, New Orleans, LA NPDES: LA0052256	Surface Water	Surrogate NPDES LA0003280	Still body	260	1.96	n/a	765.63	3	260
								788	0
								920	0
								14,400	0
				20	25.44	n/a	9937.50	3	20
								788	20
								920	20
								14,400	0
GM Components Holdings LLC, Lockport, NY	Surface Water	NPDES NY0000558	Surface water	260	0.13	3.14	10.97	3	117
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: NY0000558				20	1.71	41.38	144.47	14,400	0
								3	20
								788	0
								920	0
								14,400	0
Akebono Elizabethtown Plant, Elizabethtown, KY NPDES: KY0089672	Surface Water	Surrogate NPDES KY0022039	Surface water	260	0.07	1.15	4.87	3	27
								788	0
								920	0
								14,400	0
				20	0.897	14.77	62.38	3	16
								788	0
								920	0
								14,400	0
Delphi Harrison Thermal Systems, Dayton, OH NPDES: OH0009431	Surface Water	NPDES OH0009431	Surface water	260	0.04	0.0175	0.0752	3	0
								788	0
								920	0
								14,400	0
				20	0.465	0.20	0.87	3	0
								788	0
								920	0
								14,400	0
Chemours Company Fc LLC, Washington, WV NPDES: WV0001279	Surface Water	NPDES WV0001279	Surface water	260	0.03	0.000631	0.00301	3	0
								788	0
								920	0
								14,400	0
				20	0.334	0.00703	0.0335	3	0
								788	0
								920	0
								14,400	0
Equistar Chemicals Lp, La Porte, TX NPDES: TX0119792	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.02	0.46	2.22	3	38
								788	1
								920	1

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.218	5.06	24.44	14,400	0
								3	12
								788	1
								920	1
GE Aviation, Lynn, MA NPDES: MA0003905	Surface Water	NPDES MA0003905	Still water	260	0.01	n/a	0.0425	14,400	0
								3	0
								788	0
								920	0
				20	0.128	n/a	0.54	14,400	0
								3	0
								788	0
								920	0
Certa Vandalia LLC, Vandalia, OH NPDES: OH0122751	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.01	0.23	1.11	14,400	0
								3	28
								788	0
								920	0
				20	0.107	2.46	11.89	14,400	0
								3	9
								788	1
								920	1
GM Components Holdings LLC Kokomo Ops, Kokomo, IN NPDES: IN0001830	Surface Water	NPDES IN0001830	Surface water	260	0.01	0.0387	0.20	14,400	0
								3	0
								788	0
								920	0
				20	0.086	0.33	1.73	14,400	0
								3	0
								788	0
								920	0
Amphenol Corp-Aerospace Operations, Sidney, NY	Surface Water	NPDES NY0003824	Surface water	260	0.01	0.00882	0.0486	14,400	0
								3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: NY0003824				20	0.082	0.0723	0.40	14,400	0
								3	0
								788	0
								920	0
								14,400	0
Emerson Power Trans Corp, Maysville, KY NPDES: KY0100196	Surface Water	Surrogate NPDES KY0020257	Surface water	260	0.01	0.000076	0.0004	3	3
								788	3
								920	3
								14,400	3
				20	0.081	0.000995	0.00522	3	0
								788	0
								920	0
								14,400	0
Olean Advanced Products, Olean, NY NPDES: NY0073547	Surface Water	Surrogate NPDES NY0027162	Surface water	260	0.01	0.00462	0.0188	3	0
								788	0
								920	0
								14,400	0
				20	0.068	0.0314	0.13	3	0
								788	0
								920	0
								14,400	0
Hollingsworth Saco Lowell, Easley, SC NPDES: SC0046396	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.00469	0.11	0.52	3	24
								788	0
								920	0
								14,400	0
				20	0.061	1.40	6.78	3	6
								788	1
								920	0
								14,400	0
Trelleborg YSH Incorporated Sandusky Plant, Sandusky, MI	Surface Water	NPDES MI0028142	Surface water	260	0.00360	0.21	1.76	3	1
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: MI0028142				20	0.047	2.69	23.04	14,400	0
								3	4
								788	0
								920	0
Timken Us Corp Honea Path, Honea Path, SC NPDES: SC0047520	Surface Water	Surrogate NPDES SC0000698	Surface water	260	0.00355	0.20	1.06	3	2
								788	0
								920	0
								14,400	0
				20	0.0462	2.63	13.77	3	5
								788	0
								920	0
								14,400	0
Johnson Controls Incorporated, Wichita, KS NPDES: KS0000850	Surface Water	NPDES KS0000850	Surface water	260	0.00228	0.0068	0.0548	3	0
								788	0
								920	0
								14,400	0
				20	0.0296	0.0898	0.72	3	0
								788	0
								920	0
								14,400	0
National Railroad Passenger Corporation (Amtrak) Wilmington Maintenance Facility, Wilmington, DE NPDES: DE0050962	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.00203	0.0467	0.230	3	21
								788	0
								920	0
								14,400	0
				20	0.026	0.60	2.89	3	3
								788	0
								920	0
								14,400	0
Electrolux Home Products (Formerly Frigidaire), Greenville, MI	Surface Water	NPDES MI0002135	Surface water	260	0.00201	0.00644	0.0171	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: MI0002135				20	0.026	0.0834	0.22	14,400	0
								3	0
								788	0
								920	0
								14,400	0
Rex Heat Treat Lansdale Inc, Lansdale, PA NPDES: PA0052965	Surface Water	Surrogate NPDES PA0026182	Surface water	260	0.00194	0.00896	0.0523	3	0
								788	0
								920	0
								14,400	0
				20	0.025	0.12	0.67	3	0
								788	0
								920	0
								14,400	0
Carrier Corporation, Syracuse, NY NPDES: NY0001163	Surface Water	NPDES NY0001163	Still water	260	0.00177	n/a	0.220	3	0
								788	0
								920	0
								14,400	0
				20	0.023	n/a	2.84	3	0
								788	0
								920	0
								14,400	0
Cascade Corp (0812100207), Springfield, OH NPDES: OH0085715	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.00117	0.0269	0.130	3	18
								788	0
								920	0
								14,400	0
				20	0.015	0.35	1.67	3	3
								788	0
								920	0
								14,400	0
USAF-Wurtsmith Afb, Oscoda, MI NPDES: MI0042285	Surface Water	Surrogate NPDES MI0028282	Surface water	260	0.00115	0.000320	0.00075 3	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.015	0.00417	0.00983	14,400	0
								3	0
								788	0
								920	0
								14,400	0
AAR Mobility Systems, Cadillac, MI NPDES: MI0002640	Surface Water	Surrogate NPDES MI0020257	Surface water	260	0.00112	0.00413	0.00916	3	0
								788	0
								920	0
								14,400	0
				20	0.014	0.0517	0.11	3	0
								788	0
								920	0
								14,400	0
Eaton Mdh Company Inc, Kearney, NE NPDES: NE0114405	Surface Water	Surrogate NPDES NE0052647	Still water	260	0.00107	n/a	0.130	3	0
								788	0
								920	0
								14,400	0
				20	0.014	n/a	1.69	3	0
								788	0
								920	0
								14,400	0
Lake Region Medical, Trappe, PA NPDES: PA0042617	Surface Water	NPDES PA0042617	Surface water	260	0.000500	0.00178	0.0106	3	0
								788	0
								920	0
								14,400	0
				20	0.007	0.0249	0.15	3	0
								788	0
								920	0
								14,400	0
Motor Components L L C, Elmira, NY NPDES: NY0004081	Surface Water	NPDES NY0004081	Surface water	260	0.00096	0.0143	0.0618	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.0125	0.19	0.83	14,400	0
								3	0
								788	0
								920	0
								14,400	0
Salem Tube Mfg, Greenville, PA NPDES: PA0221244	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000897	0.0206	0.0997	3	17
								788	0
								920	0
								14,400	0
				20	0.012	0.28	1.33	3	2
								788	0
								920	0
								14,400	0
GE (Greenville) Gas Turbines LLC, Greenville, SC NPDES: SC0003484	Surface Water	NPDES SC0003484	Surface water	260	0.000806	0.0378	0.0821	3	0
								788	0
								920	0
								14,400	0
				20	0.010	0.47	1.02	3	0
								788	0
								920	0
								14,400	0
Parker Hannifin Corporation, Waverly, OH NPDES: OH0104132	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000747	0.0172	0.0830	3	16
								788	0
								920	0
								14,400	0
				20	0.010	0.23	1.11	3	2
								788	0
								920	0
								14,400	0
Mahle Engine Components Usa Inc, Muskegon, MI	Surface Water	NPDES MI0004057	Surface water	260	0.000742	0.00808	0.0336	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: MI0004057				20	0.010	0.11	0.45	14,400	0
								3	0
								788	0
								920	0
								14,400	0
General Electric Company - Waynesboro, VA NPDES: VA0002402	Surface Water	NPDES VA0002402	Surface water	260	0.000733	0.00241	0.00705	3	0
								788	0
								920	0
								14,400	0
				20	0.010	0.0329	0.0962	3	0
								788	0
								920	0
								14,400	0
Globe Engineering Co Inc, Wichita, KS NPDES: KS0086703	Surface Water	Surrogate NPDES KS0043036	Surface water	260	0.00173	0.00175	0.00853	3	0
								788	0
								920	0
								14,400	0
				20	0.023	0.0232	0.110	3	0
								788	0
								920	0
								14,400	0
Gayston Corp, Dayton, OH NPDES: OH0127043	Surface Water	Surrogate NPDES OH0024881	Surface water	260	0.000643	0.000281	0.00121	3	0
								788	0
								920	0
								14,400	0
				20	0.008	0.0035	0.0150	3	0
								788	0
								920	0
								14,400	0
Styrolution America LLC, Channahon, IL NPDES: IL0001619	Surface Water	NPDES IL0001619	Surface water	260	0.000637	0.0000845	0.00021	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.008	0.00106	0.00278	14,400	0
								3	0
								788	0
								920	0
Remington Arms Co Inc, Ilion, NY NPDES: NY0005282	Surface Water	NPDES NY0005282	Surface water	260	0.000612	0.000291	0.000799	3	0
								788	0
								920	0
								14,400	0
				20	0.008	0.00380	0.0104	3	0
								788	0
								920	0
								14,400	0
United Technologies Corporation, Pratt And Whitney Division, East Hartford, CT NPDES: CT0001376	Surface Water	NPDES CT0001376	Surface water	260	0.000480	0.0000218	0.0000822	3	0
								788	0
								920	0
								14,400	0
				20	0.006	0.000273	0.00103	3	0
								788	0
								920	0
								14,400	0
Atk-Allegany Ballistics Lab (Nirop), Keyser, WV NPDES: WV0020371	Surface Water	NPDES WV0020371	Surface water	260	0.000470	0.000629	0.00292	3	0
								788	0
								920	0
								14,400	0
				20	0.006	0.00803	0.0373	3	0
								788	0
								920	0
								14,400	0
Sperry & Rice Manufacturing Co LLC, Brookville, IN	Surface Water	NPDES IN0001473	Surface water	260	0.000328	0.00117	0.00569	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: IN0001473				20	0.004	0.0143	0.0694	14,400	0
								3	0
								788	0
								920	0
								14,400	0
Owt Industries, Pickens, SC NPDES: SC0026492	Surface Water	NPDES SC0026492	Surface water	260	0.000314	0.000820	0.00213	3	0
								788	0
								920	0
								14,400	0
				20	0.004	0.0104	0.0272	3	0
								788	0
								920	0
								14,400	0
Boler Company, Hillsdale, MI NPDES: MI0053651	Surface Water	Surrogate NPDES MI0022136	Surface water	260	0.000269	0.00461	0.0204	3	0
								788	0
								920	0
								14,400	0
				20	0.003	0.0514	0.23	3	0
								788	0
								920	0
								14,400	0
Mccanna Inc., Carpentersville, IL NPDES: IL0071340	Surface Water	Surrogate NPDES IL0027944	Surface water	260	0.000268	0.000260	0.00091 1	3	0
								788	0
								920	0
								14,400	0
				20	0.003	0.00291	0.0102	3	0
								788	0
								920	0
								14,400	0
Cutler Hammer, Horseheads, NY NPDES: NY0246174	Surface Water	Surrogate NPDES NY0004081	Surface water	260	0.000238	0.00352	0.0153	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.003	0.0443	0.19	14,400	0
								3	0
								788	0
								920	0
								14,400	0
US Air Force Offutt Afb Ne, Offutt A F B, NE NPDES: NE0121789	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000159	0.00366	0.0177	3	5
								788	0
								920	0
								14,400	0
				20	0.002	0.0460	0.22	3	2
								788	0
								920	0
								14,400	0
Troxel Company, Moscow, TN NPDES: TN0000451	Surface Water	NPDES TN0000451	Surface water	260	0.000134	0.000254	0.000741	3	0
								788	0
								920	0
								14,400	0
				20	0.002	0.00379	0.0111	3	0
								788	0
								920	0
								14,400	0
Austin Tube Prod, Baldwin, MI NPDES: MI0054224	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000114	0.00262	0.0127	3	3
								788	0
								920	0
								14,400	0
				20	0.001	0.023	0.11	3	1
								788	0
								920	0
								14,400	0
LS Starrett Precision Tools, Athol, MA NPDES: MA0001350	Surface Water	NPDES MA0001350	Surface water	260	0.000102	0.000339	0.00153	3	0
								788	0
								920	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.001	0.00333	0.015	14,400	0
								3	0
								788	0
								920	0
								14,400	0
Avx Corp, Raleigh, NC NPDES: NC0089494	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.0000883	0.00203	0.00981	3	2
								788	0
								920	0
								14,400	0
				20	0.001	0.023	0.11	3	1
								788	0
								920	0
								14,400	0
Indian Head Division, Naval Surface Warfare Center, Indian Head, MD NPDES: MD0003158	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
General Dynamics Ordnance Tactical Systems, Red Lion, PA NPDES: PA0043672	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Trane Residential Solutions - Fort Smith, Fort Smith, AR NPDES: AR0052477	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Lexmark International Inc., Lexington, KY NPDES: KY0097624	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Alliant Techsystems Operations LLC, Elkton, MD NPDES: MD0000078	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Daikin Applied America, Inc. (Formally Mcquay International),	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Scottsboro, AL NPDES: AL0069701									
Beechcraft Corporation, Wichita, KS NPDES: KS0000183	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Federal-Mogul Corp, Scottsville, KY NPDES: KY0106585	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Cessna Aircraft Co (Pawnee Facility), Wichita, KS NPDES: KS0000647	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
N.G.I, Parkersburg, WV NPDES: WV0003204	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Hyster-Yale Group, Inc, Sulligent, AL NPDES: AL0069787	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Hitachi Electronic Devices (Usa), Inc., Greenville, SC NPDES: SC0048411	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
OES: Spot Cleaning and Carpet Cleaning									
Boise State University, Boise, ID NPDES: IDG911006	Surface Water	Surrogate NPDES ID0023981	Surface water	300	0.00008	0.000205	0.00388	3	0
								788	0
								920	0
								14,400	0
				20	0.001	0.00256	0.0485	3	0
								788	0
								920	0
								14,400	0
Venetian Hotel And Casino, Las Vegas, NV NPDES: NV0022888	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
63,746 unknown sites NPDES: All POTW SIC	Surface Water or POTW	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
OES: Repackaging									
Hubbard-Hall Inc, Waterbury, CT NPDES: Unknown	Off-site Waste-water Treatment	Receiving Facility: Recycle Inc.; POTW (Ind.)	Surface water	250	1.108	5.33	27.18	3	194
								788	0
								920	0
								14,400	0
				20	13.85	66.45	339.11	3	20
								788	1
920	1								
14,400	0								
Oiltanking Houston Inc, Houston, TX NPDES: TX0091855	Surface Water	Surrogate NPDES TX0065943	Surface water	250	0.003	0.32	6.52	3	2
								788	0
								920	0
								14,400	0
				20	0.041	4.36	89.13	3	4
								788	0
920	0								
14,400	0								
St. Gabriel Terminal, Saint Gabriel, LA NPDES: LA0005487	Surface Water	NPDES LA0005487	Surface water	250	0.00550	0.00000677	0.00002 23	3	0
								788	0
								920	0
								14,400	0
				20	0.069	0.0000850	0.00027 9	3	0
								788	0
920	0								
14,400	0								
Vopak Terminal Westwego Inc, Westwego, LA NPDES: LA0124583	Surface Water	Surrogate NPDES LA0042064	Surface water	250	0.00468	0.00000576	0.00001 89	3	0
								788	0
								920	0
								14,400	0
				20	0.058	0.0000714		3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
							0.000235	788 920 14,400	0 0 0
Research Solutions Group Inc, Pelham, AL NPDES: AL0074276	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Carlisle Engineered Products Inc, Middlefield, OH NPDES: OH0052370	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
OES: Process Solvent Recycling and Worker Handling of Wastes									
Clean Water Of New York Inc, Staten Island, NY NPDES: NY0200484	Surface Water	Surrogate NPDES NJ0000019	Still body	250	0.004	n/a	11.76	3	250
								788	0
								920	0
				20	0.047	n/a	138.24	14,400	0
								3	20
								788	0
920	0								
14,400	0								
Reserve Environmental Services, Ashtabula, OH NPDES: OH0098540	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Veolia Es Technical Solutions LLC, Middlesex, NJ NPDES: NJ0020141	Off-site Waste-water Treatment	Receiving Facility: Middlesex Cnty UA; NPDES NJ0020141	Still body	250	24.1	n/a	2.85	3	0
								788	0
								920	0
				20	301.78	n/a	35.72	14,400	0
								3	20
								788	0
920	0								
14,400	0								
Clean Harbors Deer Park LLC, La Porte, TX NPDES: TX0005941	Off-site Waste-water Treatment	POTW (Ind.)	Surface water	250	0.35	1.68	8.57	3	110
								788	0
								920	0
								14,400	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	4.36	20.92	106.75	3	19
								788	0
								920	0
								14,400	0
Clean Harbors El Dorado LLC, El Dorado, AR NPDES: AR0037800	Off-site Waste-water Treatment	POTW (Ind.)	Surface water	250	0.04	0.19	0.98	3	6
								788	0
								920	0
								14,400	0
				20	0.455	2.21	11.26	3	11
								788	0
								920	0
								14,400	0
OES: Adhesives, Sealants, Paints, and Coatings									
Able Electropolishing Co Inc, Chicago, IL NPDES: Not available	POTW	Adhesives and Sealants Manuf.	Surface water	250	0.298	0.86	7.28	3	8
								788	0
								920	0
								14,400	0
Garlock Sealing Technologies, Palmyra, NY NPDES: NY0000078	Surface Water	NPDES NY0000078	Surface water	250	0.00033	0.00252	0.00716	3	0
								788	0
								920	0
								14,400	0
				20	0.00407	0.0312	0.0889	3	0
								788	0
								920	0
								14,400	0
Ls Starrett Co, Athol, MA NPDES: MAR05B615	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Aerojet Rocketdyne ⁸ , Inc., East Camden, AR	Surface Water		Surface water	250	0.013	0.20	1.67	3	0
								788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)	
NPDES: AR0051071, ARR00A521, ARR00A520		Adhesives and Sealants Manuf.		20	0.160	2.42	20.57	920	0	
								14,400	0	
								3	3	
								788	0	
								920	0	
	14,400	0								
	POTW				250	0.013	0.0374	0.32	3	0
									788	0
									920	0
									14,400	0
Best One Tire & Service ⁸ , Nashville, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	
	POTW				20	0.160	2.42	20.57	3	3
									788	0
									920	0
									14,400	0
POTW				250	0.013	0.0374	0.32	3	0	
								788	0	
								920	0	
								14,400	0	
Bridgestone Aircraft Tire (Usa), Inc. 8, Mayodan, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	
				20	0.160	2.42	20.57	3	3	
								788	0	

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
	POTW			250	0.013	0.0374	0.32	920	0
								14,400	0
								3	0
								788	0
								920	0
Clayton Homes Inc8, Oxford, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			250	0.013	0.0374	0.32	3	3
								788	0
								920	0
								14,400	0
								3	0
								788	0
Cmh Manufacturing, Inc. Db a Schult Homes - Plant 9588, Richfield, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			250	0.013	0.0374	0.32	3	3
								788	0
								920	0
								14,400	0
								3	0
								788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)	
								920	0	
								14,400	0	
Delphi Thermal Systems ⁸ , Lockport, NY NPDES: NY0000558	Surface Water	NPDES NY0000558	Surface water	250	0.013	0.31	1.10	3	2	
								788	0	
								920	0	
								14,400	0	
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.		250	0.160	3.87	13.50	3	11	
								788	0	
								920	0	
								14,400	0	
	Green Bay Packaging Inc - Coon Rapids ⁸ , Coon Rapids, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
									788	0
									920	0
									14,400	0
POTW		250			0.160	2.42	20.57	3	3	
								788	0	
								920	0	
								14,400	0	
Mastercraft Boat Company ⁸ ,				250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Vonore, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	20	0.160	2.42	20.57	788	0
								920	0
								14,400	0
								3	3
								788	0
								920	0
	14,400	0							
	POTW	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.0374	0.32	3	0
								788	0
								920	0
14,400								0	
Michelin Aircraft Tire Company ⁸ , Norwood, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
								3	3
								788	0
	920	0							
	14,400	0							
	POTW	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.0374	0.32	3	0
								788	0
920								0	
14,400								0	
M-Tek, Inc ⁸ , Manchester, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)			
								788	0			
								920	0			
								14,400	0			
	POTW						250	0.013	0.0374	0.32	3	0
											788	0
											920	0
											14,400	0
Olin Corp ⁸ , East Alton, IL NPDES: IL0000230	Surface Water	NPDES IL0000230	Surface water	250	0.013	0.08	0.18	3	0			
								788	0			
								920	0			
								14,400	0			
				20	0.160	1.03	2.26	3	7			
								788	0			
	920							0				
	14,400							0				
	POTW			No info on receiving facility; Adhesives and Sealants Manuf.			250	0.013	0.0374	0.32	3	0
											788	0
											920	0
											14,400	0
Parker Hannifin Corp – Paraflex Division ⁸ , Manitowoc, WI NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0			
								788	0			
								920	0			
								14,400	0			
				20	0.160	2.42	20.57	3	3			
								788	0			
								920	0			
								14,400	0			

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)			
	POTW			250	0.013	0.0374	0.32	3	0			
								788	0			
								920	0			
								14,400	0			
Parrish Tire Company ⁸ , Yadkinville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0			
								788	0			
								920	0			
								14,400	0			
	POTW			250	0.013	0.0374	0.32	3	3			
								788	0			
								920	0			
								14,400	0			
	Republic Doors And Frames ⁸ , Mckenzie, TN NPDES: Not available			Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
											788	0
											920	0
											14,400	0
POTW		250	0.013	0.0374			0.32	3	3			
								788	0			
								920	0			
								14,400	0			

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Ro-Lab Rubber Company Inc.8, Tracy, CA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0
	POTW	250	0.013	0.0374	0.32	3	0		
						788	0		
						920	0		
						14,400	0		
Royale Comfort Seating, Inc. 8 - Plant No. 1, Taylorsville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0
	POTW	250	0.013	0.0374	0.32	3	0		
						788	0		
						920	0		
						14,400	0		
Snider Tire, Inc. 8, Statesville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
				20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0
	POTW			250	0.013	0.0374	0.32	3	0
								788	0
								920	0
								14,400	0
Snyder Paper Corporation ⁸ , Hickory, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0
POTW	250	0.013	0.0374	0.32	3	0			
					788	0			
					920	0			
					14,400	0			
Stellana Us ⁸ , Lake Geneva, WI NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)			
	POTW			250	0.013	0.0374	0.32	3	0			
								788	0			
								920	0			
								14,400	0			
Thomas Built Buses - Courtesy Road8, High Point, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0			
								788	0			
								920	0			
								14,400	0			
	POTW			250	0.013	0.0374	0.32	3	3			
								788	0			
								920	0			
								14,400	0			
	Unicel Corp8, Escondido, CA NPDES: Not available			Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
											788	0
											920	0
											14,400	0
POTW		250	0.013	0.0374			0.32	3	3			
								788	0			
								920	0			
								14,400	0			

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Acme Finishing Co Llc8, Elk Grove Village, IL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0
	14,400	0	0	0	0	0			
							POTW	250	0.013
	788	0							
	920	0							
	14,400	0							
	Aerojet Rocketdyne, Inc. 8, Rancho Cordova, CA NPDES: CA0004111	Surface Water	NPDES CA0004111	Surface water	250	0.013	0.000295	0.000818	3
788									0
920									0
14,400									0
20					0.160	0.00363	0.0101	3	0
								788	0
14,400		0	0	0	0	0			
							POTW	250	0.013
788		0							
920		0							
14,400		0							
Allegheny Cnty Airport Auth/ Pgh Intl Airport8, Coraopolis Pittsburgh, PA NPDES: Not available		Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3
	788								0
	920								0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)			
								14,400	0			
								3	3			
								788	0			
								920	0			
	POTW						250	0.013	0.0374	0.32	14,400	0
											3	0
											788	0
											920	0
Amphenol Corp – Aerospace Operations8, Sidney, NY NPDES: NY0003824	Surface Water	NPDES NY0003824	Surface water	250	0.013	0.0115	0.0631	3	0			
								788	0			
								920	0			
								14,400	0			
	POTW			No info on receiving facility; Adhesives and Sealants Manuf.			250	0.013	0.03740	0.3200	3	0
											788	0
											920	0
											14,400	0
	Aprotech Powertrain8, Asheville, NC NPDES: Not available			Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
											788	0
											920	0
											14,400	0
							20	0.160	2.42	20.57	3	3
											788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
	POTW			250	0.013	0.0374	0.32	920	0
								14,400	0
								3	0
								788	0
								920	0
Coating & Converting Tech Corp/ Adhesive Coatings ⁸ , Philadelphia, PA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			250	0.013	0.0374	0.32	3	3
								788	0
								920	0
								14,400	0
								3	0
								788	0
Corpus Christi Army Depot ⁸ , Corpus Christi, TX NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			250	0.013	0.0374	0.32	3	3
								788	0
								920	0
								14,400	0
								3	0
								788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)	
								920	0	
								14,400	0	
Electronic Data Systems Camp Pendleton ⁸ , Camp Pendleton, CA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	
	POTW			20	0.160	2.42	20.57	3	3	
								788	0	
								920	0	
								14,400	0	
	Florida Production Engineering, Inc. 8, Ormond Beach, FL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
									788	0
									920	0
									14,400	0
POTW		20			0.160	2.42	20.57	3	3	
								788	0	
								920	0	
								14,400	0	
Goodrich Corporation ⁸ , Jacksonville, FL	Surface Water		Surface water	250	0.013	0.20	1.67	3	0	
								788	0	

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
NPDES: Not available		Adhesives and Sealants Manuf.		20	0.160	2.42	20.57	920	0
								14,400	0
								3	3
								788	0
								920	0
	14,400	0							
	POTW	250	0.013	0.0374	0.32	3	0		
						788	0		
						920	0		
						14,400	0		
Kasai North America Inc ⁸ , Madison Plant, Madison, MS NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW	20	0.160	2.42	20.57	3	3		
						788	0		
						920	0		
						14,400	0		
POTW	250	0.013	0.0374	0.32	3	0			
					788	0			
					920	0			
					14,400	0			
Kirtland Air Force Base ⁸ , Albuquerque, NM NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)								
	POTW			250	0.013	0.0374	0.32	920	0								
								14,400	0								
								3	0								
								788	0								
								920	0								
Marvin Windows & Doors8, Warroad, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0								
								788	0								
								920	0								
								14,400	0								
	POTW			250	0.013	0.0374	0.32	3	3								
								788	0								
								920	0								
								14,400	0								
								Mcneilus Truck & Manufacturing Inc8, Dodge Center, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
																788	0
920	0																
14,400	0																
POTW	250	0.013	0.0374	0.32	3	3											
					788	0											
					920	0											
					14,400	0											
									250			0.013	0.20	1.67	3	0	
															788	0	
920	0																
14,400	0																
				250	0.013	0.0374			0.32	3	0						
										788	0						

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								920	0
								14,400	0
Metal Finishing Co. 8 – Wichita (S Mclean Blvd), Wichita, KS NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0
	POTW	250	0.013	0.0374	0.32	3	0		
						788	0		
						920	0		
						14,400	0		
Murakami Manufacturing Usa Inc8, Campbellsville, KY NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
	POTW			20	0.160	2.42	20.57	3	3
								788	0
								920	0
								14,400	0
	POTW	250	0.013	0.0374	0.32	3	0		
						788	0		
						920	0		
						14,400	0		
Peterbilt Motors Denton Facility8,	Surface Water		Surface water	250	0.013	0.20	1.67	3	0
								788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)	
Denton, TX NPDES: Not available		Adhesives and Sealants Manuf.		20	0.160	2.42	20.57	920	0	
								14,400	0	
								3	3	
								788	0	
								920	0	
	14,400	0								
	POTW				250	0.013	0.0374	0.32	3	0
									788	0
									920	0
									14,400	0
Portsmouth Naval Shipyard ⁸ , Kittery, ME NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	
	POTW				20	0.160	2.42	20.57	3	3
									788	0
									920	0
									14,400	0
R.D. Henry & Co. 8, Wichita, KS NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	
					20	0.160	2.42	20.57	3	3
									788	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)	
	POTW			250	0.013	0.0374	0.32	920	0	
								14,400	0	
								3	0	
								788	0	
								920	0	
14,400	0									
Raytheon Company ⁸ , Portsmouth, RI NPDES: RI0000281	Surface Water	NPDES RI0000281	Still body	250	0.013	n/a	10.83	3	250	
								788	0	
								920	0	
								14,400	0	
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.			20	0.160	n/a	133.33	3	20
									788	0
									920	0
									14,400	0
	POTW				250	0.013	0.03740	0.32	3	0
									788	0
									920	0
									14,400	0
Rehau Inc ⁸ , Cullman, AL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0	
								788	0	
								920	0	
								14,400	0	
	POTW				20	0.160	2.42	20.57	3	3
									788	0
									920	0
									14,400	0
POTW				250	0.013	0.0374	0.32	3	0	

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)			
								788	0			
								920	0			
								14,400	0			
Rotochopper Inc8, Saint Martin, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0			
								788	0			
								920	0			
								14,400	0			
	POTW			250	0.013	0.0374	0.32	3	3			
								788	0			
								920	0			
								14,400	0			
	Rubber Applications8, Mulberry, FL NPDES: Not available			Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
											788	0
											920	0
											14,400	0
POTW		250	0.013	0.0374			0.32	3	3			
								788	0			
								920	0			
								14,400	0			
							250	0.013	0.20	1.67	3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)	
Sapa Precision Tubing Rockledge, Llc8, Rockledge, FL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water					788	0	
								920	0	
								14,400	0	
				20	0.160	2.42	20.57	3	3	
								788	0	
								920	0	
	14,400		0							
	POTW		250	0.013	0.0374	0.32	3	0		
							788	0		
							920	0		
			14,400	0						
			Thomas & Betts8, Albuquerque, NM NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67
788		0								
920	0									
14,400	0									
20	0.160	2.42					20.57	3	3	
								788	0	
				920		0				
14,400	0									
POTW	250	0.013		0.0374		0.32	3	0		
							788	0		
							920	0		
	14,400	0								
	Thomas Built Buses - Fairfield Road8, High Point, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
									788	0
920									0	
14,400					0					
20					0.160	2.42	20.57	3	3	

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								788	0
								920	0
								14,400	0
								3	0
	POTW			250	0.013	0.0374	0.32	788	0
								920	0
								14,400	0
								3	0
Timco, DbA Haeco Americas Airframe Services ⁸ , Greensboro, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0
	920							0	
	14,400							0	
	POTW			250	0.013	0.0374	0.32	3	0
								788	0
								920	0
								14,400	0
Trelleborg Coated Systems Us, Inc ⁸ – Grace Advanced Materials, Rutherfordton, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	3	0
								788	0
								920	0
								14,400	0
				20	0.160	2.42	20.57	3	3
								788	0
	920							0	
	14,400							0	
	POTW			250	0.013	0.0374	0.32	3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
U.S. Coast Guard Yard - Curtis Bay ⁸ , Curtis Bay, MD NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	788	0
								920	0
								14,400	0
								3	0
	POTW			20	0.160	2.42	20.57	788	0
								920	0
								14,400	0
								3	3
				250	0.013	0.0374	0.32	788	0
								920	0
								14,400	0
								3	0
Viracon Inc ⁸ , Owatonna, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	0.20	1.67	788	0
								920	0
								14,400	0
								3	3
	POTW			20	0.160	2.42	20.57	788	0
								920	0
								14,400	0
								3	0
				250	0.013	0.0374	0.32	788	0
								920	0
								14,400	0
								3	0

OES: Industrial Processing Aid

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Occidental Chemical Corp Niagara Plant, Niagara Falls, NY NPDES: NY0003336	Surface Water	NPDES NY0003336	Still body	300	0.019	n/a	0.14	3	0
								788	0
								920	0
								14,400	0
				20	0.292	n/a	2.200	3	0
								788	0
								920	0
								14,400	0
Stepan Co Millsdale Road, Elwood, IL NPDES: IL0002453	Surface Water	NPDES IL0002453	Surface water	300	0.001	0.00016	0.000419	3	0
								788	0
								920	0
								14,400	0
				20	0.008	0.00128	0.00335	3	0
								788	0
								920	0
								14,400	0
Entek International LLC, Lebanon, OR NPDES: N/A	Off-site Waste-water Treatment	No info on receiving facility; POTW (Ind.)	Surface water	300	0.38	1.82	9.30	3	140
								788	0
								920	0
								14,400	0
				20	5.65	27.11	138.34	3	20
								788	0
								920	0
								14,400	0
National Electrical Carbon Products Dba Morgan Adv Materials, Fostoria, OH NPDES: OH0052744	Off-site Waste-water Treatment	Receiving Facility: City of Fostoria; NPDES OH0052744	Surface water	300	0.008	0.0336	0.15	3	0
								788	0
								920	0
								14,400	0
				20	0.115	0.50	2.32	3	1
								788	0
								920	0
								14,400	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
PPG Industries Inc Barberton, Barberton, OH NPDES: OH0024007	Off-site Waste-water Treatment	Receiving Facility: City of Barberton; NPDES OH0024007	Surface water	300	0.005	0.00478	0.0141	3	0
								788	0
								920	0
								14,400	0
				20	0.070	0.067	0.20	3	0
								788	0
								920	0
								14,400	0
Daramic LLC, Corydon, IN NPDES: IN0020893	Surface Water	NPDES IN0020893	Surface water	300	0.008	0.00572	0.0206	3	0
								788	0
								920	0
								14,400	0
				20	0.114	0.0816	0.29	3	0
								788	0
								920	0
								14,400	0
OES: Commercial Printing and Copying									
Printing And Pub Sys Div, Weatherford, OK NPDES: OK0041785	Surface Water	Printing	Surface water	250	0.00020	0.000662	0.00292	3	0
								788	0
								920	0
								14,400	0
				20	0.00250	0.00827	0.0365	3	0
								788	0
								920	0
								14,400	0
OES: Other Industrial Uses									
Eli Lilly And Company- Lilly Tech Ctr, Indianapolis, IN NPDES: IN0003310	Surface Water	NPDES IN0003310	Surface water	250	1.553	1.63	9.03	3	35
								788	0
								920	0
								14,400	0
				20	19.410	20.47	113.09	3	17

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								788	0
								920	0
								14,400	0
Oxy Vinyls LP - Deer Park Pvc, Deer Park, TX NPDES: TX0007412	Surface Water	NPDES TX0007412	Surface water	250	0.148	0.13	0.49	3	1
								788	0
								920	0
				20	1.854	1.58	5.98	14,400	0
								3	9
								788	0
920	0								
14,400	0								
Washington Penn Plastics, Frankfort, KY NPDES: KY0097497	Surface Water	Surrogate NPDES KY0028410	Surface water	250	0.032	1.25	7.53	3	22
								788	0
								920	0
				20	0.399	15.62	94.12	14,400	0
								3	13
								788	0
920	0								
14,400	0								
Natrium Plant, New Martinsville, WV NPDES: WV0004359	Surface Water	NPDES WV0004359	Surface water	250	0.022	0.000566	0.00262	3	0
								788	0
								920	0
				20	0.274	0.00695	0.0322	14,400	0
								3	0
								788	0
920	0								
14,400	0								
Leroy Quarry, Leroy, NY NPDES: NY0247189	Surface Water	Surrogate NPDES NY0030546	Surface water	250	0.019	0.16	0.71	3	0
								788	0
								920	0
				20	0.242	2.05	8.91	14,400	0
								3	3

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								788	0
								920	0
								14,400	0
George C Marshall Space Flight Center, Huntsville, AL NPDES: AL0000221	Surface Water	Surrogate NPDES AL0025585	Surface water	250	0.010	0.0738	0.20	3	0
								788	0
								920	0
				20	0.128	0.96	2.63	14,400	0
								3	8
								788	0
920	0								
14,400	0								
Whelan Energy Center Power Plant, Hastings, NE NPDES: NE0113506	Surface Water	NPDES NE0113506	Surface water	250	0.009	0.67	2.92	3	30
								788	0
								920	0
				20	0.118	8.95	38.96	14,400	0
								3	13
								788	0
920	0								
14,400	0								
Army Cold Regions Research & Engineering Lab, Hanover, NH NPDES: NH0001619	Surface Water	Surrogate NPDES NH0100099	Surface water	250	0.0002	0.0000266	0.000103	3	0
								788	0
								920	0
				20	0.0029	0.000398	0.00154	14,400	0
								3	0
								788	0
920	0								
14,400	0								
Corning - Canton Plant, Canton, NY NPDES: NY0085006	Surface Water	Surrogate NPDES NY0034762	Surface water	250	0.0002	0.000101	0.000340	3	0
								788	0
								920	0
				20	0.0028	0.00152	0.00510	14,400	0
								3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								788	0
								920	0
								14,400	0
Ames Rubber Corp Plant #1, Hamburg Boro, NJ NPDES: NJ0000141	Surface Water	Surrogate NPDES NJ0000141i	Surface water	250	0.00011	0.00258	0.0149	3	53i
								788	50i
								920	50i
								14,400	50i
				20	0.00133	0.0304	0.18	3	6
								788	4
								920	4
								14,400	4
Gorham, Providence, RI NPDES: RIG85E004	Surface Water	POTW (Ind.)	Surface water	250	0.0001	0.00253	0.0129	3	0
								788	0
								920	0
								14,400	0
				20	0.0012	0.0253	0.13	3	0
								788	0
								920	0
								14,400	0
Solvay - Houston Plant, Houston, TX NPDES: TX0007072	Surface Water	NPDES TX0007072	Surface water	350	0.024	0.22	4.44	3	3
								788	0
								920	0
								14,400	0
				20	0.414	3.72	75.93	3	5
								788	0
								920	0
								14,400	0
Akzo Nobel Surface Chemistry LLC, Morris, IL NPDES: IL0026069	Surface Water	NPDES IL0026069	Surface water	350	0.000329	0.000300	0.000688	3	0
								788	0
								920	0
								14,400	0
				20	0.006	0.00546	0.0125	3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
								788	0
								920	0
								14,400	0
Solutia Nitro Site, Nitro, WV NPDES: WV0116181	Surface Water	Surrogate NPDES WV0023229	Surface water	350	0.000318	0.0000214	0.0000941	3	0
								788	0
								920	0
				20	0.006	0.000401	0.00176	14,400	0
								3	0
								788	0
920	0								
14,400	0								
Amphenol Corporation - Columbia, SC NPDES: SC0046264	Surface Water	Organic Chemicals Manufacture	Surface water	350	0.000202	0.00395	0.037	3	0
								788	0
								920	0
				20	0.004	0.0791	0.74	14,400	0
								3	1
								788	0
920	0								
14,400	0								
Keeshan and Bost Chemical Co., Inc., Manvel, TX NPDES: TX0072168	Surface Water	NPDES TX0072168	Still body	350	0.000095	n/a	9.50	3	350
								788	0
								920	0
				20	0.002	n/a	200.00	14,400	0
								3	20
								788	0
920	0								
14,400	0								
Chemtura North and South Plants, Morgantown, WV NPDES: WV0004740	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Indorama Ventures Olefins, LLC,	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Sulphur, LA NPDES: LA0069850									
Emerson Power Transmission, Ithaca, NY NPDES: NY0002933	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
William E. Warne Power Plant, Los Angeles County, CA NPDES: CA0059188	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
Raytheon Aircraft Co(Was Beech Aircraft), Boulder, CO NPDES: COG315176	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.							
OES: Other Commercial Uses									
Corning Hospital, Corning, NY NPDES: NY0246701	Surface Water	Surrogate NPDES NY0025721	Surface water	250	0.013	0.00597	0.0271	3	0
								788	0
								920	0
								14,400	0
				20	0.159	0.0735	0.33	3	0
								788	0
								920	0
								14,400	0
Water Street Commercial Bldg, Dayton, OH NPDES: OH0141496	Surface Water	Surrogate NPDES OH0009521	Surface water	250	0.003	0.00131	0.00564	3	0
								788	0
								920	0
								14,400	0
				20	0.035	0.0153	0.0658	3	0
								788	0
								920	0
								14,400	0
Union Station North Wing Office Building, Denver, CO NPDES: COG315293	Surface Water	Surrogate NPDES CO00200959	Surface water	250	0.00040	0.0196	0.0881	3	213 ⁹
								788	213 ⁹
								920	213 ⁹
								14,400	213 ⁹
				20	0.00499	0.24	1.10	3	18

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)				
								788	17				
								920	17				
								14,400	17				
Confluence Park Apartments, Denver, CO NPDES: COG315339	Surface Water	Surrogate NPDES CO002009510	Surface water	250	0.00028	0.0137	0.0617	3	213 ¹⁰				
								788	213 ¹⁰				
								920	213 ¹⁰				
								20	0.00354	0.17	0.77	14,400	213 ¹⁰
				3	17								
				788	17								
								920	17				
								14,400	17				
Park Place Mixed Use Development, Annapolis, MD NPDES: MD0068861	Surface Water	Surrogate NPDES MD0052868	Still body	250	0.00027	n/a	9.00	3	250				
								788	0				
								920	0				
								20	0.00334	n/a	110.00	14,400	0
				3	20								
				788	0								
								920	0				
								14,400	0				
Tree Top Inc Wenatchee Plant, Wenatchee, WA NPDES: WA0051527	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.											
Wynkoop Denver LLC St, Denver, CO NPDES: COG603115	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.											
Greer Family Llc, South Burlington, VT NPDES: VT0001376	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.											
John Marshall III Site, Mclean, VA NPDES: VA0090093	Surface Water	Annual releases estimated to be <0.02 kg/year were not modeled, as they were determined to be unlikely to exceed the most sensitive COC using the most conservative input assumptions.											
OES: N/A (WWTP)													
New Rochelle STP,			Still body	365	0.043	n/a	0.70	3	0				

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
New Rochelle, NY NPDES: NY0026697	Surface Water	NPDES NY0026697						788	0
								920	0
								14,400	0
				20	0.786	n/a	12.79	3	20
								788	0
								920	0
							14,400	0	
Everett Water Pollution Control Facility, Everett, WA NPDES: WA0024490	Surface Water	NPDES WA0024490	Surface water	365	0.016	0.13	0.17	3	0
								788	0
								920	0
				20	0.299	2.37	3.11	14,400	0
								3	7
								788	0
							920	0	
							14,400	0	
Sullivan WWTP, Sullivan, MO NPDES: MO0104736	Surface Water	NPDES MO0104736	Surface water	365	0.010	0.16	0.61	3	2
								788	0
								920	0
				20	0.176	2.81	10.97	14,400	0
								3	7
								788	0
							920	0	
							14,400	0	
Sunnyside STP, Sunnyside, WA NPDES: WA0020991	Surface Water	NPDES WA0020991	Surface water	365	0.005	0.00146	0.00673	3	0
								788	0
								920	0
				20	0.083	0.0242	0.110	14,400	0
								3	0
								788	0
							920	0	
							14,400	0	
		POTW (Ind.)		365	0.002	0.0505	0.26	3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Port Of Sunnyside Industrial WWTF, Sunnyside, WA NPDES: WA0052426	Surface Water		Surface water					788	0
								920	0
								14,400	0
				20	0.035	0.88	4.51	3	5
								788	0
								920	0
14,400	0								
U.S. Air Force Shaw AFB SC, Shaw AFB, SC NPDES: SC0024970	Surface Water	POTW (Ind.)	Surface water	365	0.002	0.0505	0.26	3	0
								788	0
								920	0
				20	0.032	0.81	4.12	14,400	0
								3	4
								788	0
920	0								
14,400	0								
Gnf-A Wilmington-Castle Hayne WWTP, Wilmington, NC NPDES: NC0001228	Surface Water	NPDES NC0001228	Surface water	365	0.0004	0.000304	0.00194	3	0
								788	0
								920	0
				20	0.0067	0.00533	0.0340	14,400	0
								3	0
								788	0
920	0								
14,400	0								
Cameron Trading Post WWTP, Cameron, AZ NPDES: NN0021610	Surface Water	POTW (Ind.)	Surface water	365	0.0003	0.00758	0.0387	3	0
								788	0
								920	0
				20	0.0047	0.13	0.64	14,400	0
								3	0
								788	0
920	0								
14,400	0								
Coal Grove WWTP,				365	0.0002	0.00000250		3	0

Name, Location, and ID of Active Releaser Facility	Release Media ¹	Modeled Facility or Industry Sector in EFAST ²	EFAST Waterbody Type ³	Days of Release ⁴	Release ⁵ (kg/day)	Harmonic Mean SWC (µg/L)	7Q10 SWC ⁶ (µg/L)	COC (µg/L)	Days of Exceedance ⁷ (days/yr)
Coal Grove, OH NPDES: OH0104558	Surface Water	NPDES OH0029432	Surface water				0.0000127	788	0
								920	0
								14,400	0
				20	0.0031	0.0000375	0.00019	3	0
								788	0
								920	0
								14,400	0

¹ Release media are either direct (release from facility directly to surface water) or indirect (transfer of wastewater from active facility to a receiving POTW or non-POTW WWTP facility). A wastewater treatment removal rate of 81% is applied to all indirect releases, *i.e.*, volumes characterized as being transferred off-site for treatment at a water treatment facility prior to discharge to surface water.

² If a valid NPDES of facility was not available in EFAST, the release was modeled using either a surrogate representative facility in EFAST (based on location discharging into the same water body) or a representative generic industry sector.

³ EFAST uses either the “surface water” model, for rivers and streams, or the “still water” model, for lakes, bays, and oceans.

⁴ Modeling was conducted with the maximum days of release per year expected. For direct releasing facilities, a minimum of 20 days was also modeled.

⁵ The daily release amount was calculated from the reported annual release amount divided by the number of release days per year.

⁶ For releases discharging to lakes, bays, estuaries, and oceans, the acute scenario mixing zone water concentration was reported in place of the 7Q10 SWC.

⁷ To determine the PDM days of exceedance for still bodies of water, the release days provided by the EPA Engineers is equal to the days of exceedance only if the predicted surface water concentration exceeds the COC. Otherwise, the days of exceedance can be assumed to be zero.

⁸ Predicted water releases for the indicated sites changed slightly between modeling and publication of the Risk Evaluation. For the 440 unknown sites in the Processing as a Reactant OES changed from 1.75 kg/yr to 2.2 kg/yr. For the sites listed under the Adhesives, Sealants, Paints, and Coatings OES, annual release predictions changed from 3.25 kg/yr to 4.4 kg/yr. These slight differences (*i.e.*, between 0.5 to 1.2 kg/yr) are unlikely to impact risk characterization.

⁹ The predicted days of exceedance are presented although the estimated 7Q10 never approaches the lowest COC due to the fact that the EFAST database has minimum stream flow of 0 MLD and a mean stream flow of 2.69 MLD for this site. Therefore, these days of exceedances were not considered in environmental risk characterization.

¹⁰ The predicted days of exceedance are presented although the estimated 7Q10 never approaches the lowest COC due to the fact that the EFAST database has minimum stream flow of 0 MLD and a mean stream flow of 0 MLD for this site. Therefore, these days of exceedances were not considered in environmental risk characterization.

139
140
141
142

143 **Appendix D CONSUMER EXPOSURES**

144 For additional consumer modeling support files, please see the following supplemental documents: 24.
145 *Final Risk Evaluation for Trichloroethylene Supplemental Information File Consumer Exposure*
146 *Assessment Model Input Parameters.xlsx*; 25. *Final Risk Evaluation for Trichloroethylene Supplemental*
147 *Information File Exposure Modeling Results and Risk Estimates for Consumer Inhalation*
148 *Exposures.xlsx*; 26. *Final Risk Evaluation for Trichloroethylene Supplemental Information File*
149 *Exposure Modeling Results and Risk Estimates for Consumer Dermal Exposures.xlsx*.

150 **D.1 Consumer Inhalation Exposure**

151 CEM predicts indoor air concentrations from consumer product use by implementing a deterministic,
152 mass-balance calculation utilizing an emission profile determined by implementing appropriate emission
153 scenarios. The model uses a two-zone representation of the building of use (*e.g.*, residence, school,
154 office), with Zone 1 representing the room where the consumer product is used (*e.g.*, a utility room) and
155 zone 2 being the remainder of the building. The product user is placed within Zone 1 for the duration of
156 use, while a bystander is placed in Zone 2 during product use. Otherwise, product users and bystanders
157 follow prescribed activity patterns throughout the simulated period. In some instances of product use, a
158 higher concentration of product is expected very near the product user; CEM addresses this by further
159 dividing Zone 1 into near-field, with a default volume of 1m³, and far-field, which reflects the remainder
160 of Zone 1. Each zone is considered well-mixed. Product users are exposed to airborne concentrations
161 estimated within the near-field during the time of use and otherwise follow their prescribed activity
162 pattern. Bystanders follow their prescribed activity pattern and are exposed to far-field concentrations
163 when they are in Zone 1. Background concentrations can be set to a non-zero concentration if desired.
164

165 For acute exposure scenarios, emissions from each incidence of product usage are estimated over a
166 period of 72 hours using the following approach that account for how a product is used or applied, the
167 total applied mass of the product, the weight fraction of the chemical in the product, and the molecular
168 weight and vapor pressure of the chemical.
169

170 The general steps of the calculation engine within the CEM model include:

- 171 • Introduction of the chemical (*i.e.*, TCE) into the room of use (Zone 1) through two possible
172 pathways: (1) overspray of the product or (2) evaporation from a thin film;
- 173 • Transfer of the chemical to the rest of the house (Zone 2) due to exchange of air between the
174 different rooms;
- 175 • Exchange of the house air with outdoor air; and
- 176 • Compilation of estimated air concentrations in each zone as the modeled occupant (*i.e.*, user
177 or bystander) moves about the house per prescribed activity patterns.

178
179 As receptors move between zones in the model, the associated zonal air concentrations at each 30-
180 second time step were compiled to reflect the air concentrations a user and bystander would be exposed
181 to throughout the simulation period. Time weighted averages (TWAs) were then computed based on
182 these user and bystander concentration time series per available human health hazard data. For TCE, 3-
183 and 24-hour TWAs were quantified for use in Risk Evaluation based on alignment relevant acute human
184 health hazard endpoints.
185
186

187 **Emission Models**

188 Based on the suite of product scenarios developed to evaluate the TCE consumer conditions of use, the
189 specific emission models applied for the purposes of modeling TCE products include: E1: Emission
190 from Product Applied to a Surface Indoors Incremental Source Model and E3: Emission from Product
191 Sprayed.

192
193 E1 assumes a constant application rate over a user-specified duration of use and an emission rate that
194 declines exponentially over time, at a rate that depends on the chemical molecular weight and vapor
195 pressure. This emission model is generally applicable to liquid products applied to surfaces that
196 evaporate from those surfaces, such as cleaners. E1 was applied for all liquid formulations in the
197 modeling of TCE consumer inhalation exposures. E3 assumes a small percentage of product becomes
198 airborne rather than contacting the target surface and therefore immediately available for uptake via
199 inhalation. This is called “overspray” and is not well characterized, though default parameters ranging
200 from 4.5 to 6% overspray are based on a combination of modeled and empirical data from Jayjock
201 (2012) and are said to reflect reasonable worst-case overspray potential (U.S. EPA, 2017b). The
202 remainder of chemical is assumed to contact the target surface and volatilize at a rate that depends on the
203 chemical molecular weight and vapor pressure. The aerosolized portion is treated using a constant
204 emission rate model while the non-aerosolized mass is treated in the same manner as liquid products
205 applied to a surface, combining a constant application rate with an exponentially declining rate. In U.S.
206 EPA (2014b), modeled scenarios were found not to be sensitive to this parameter, with overspray
207 fractions of 1 and 25% producing nearly identical peak concentrations for TCE. Both E1 and E3 have a
208 near-field model option that is selected to capture the higher concentration in the breathing zone of a
209 product user during use.

210
211 For additional details on CEM 2.1’s underlying emission models, assumptions, and algorithms, please
212 see the User Guide Section 3: Detailed Descriptions of Models within CEM (U.S. EPA, 2019a). The
213 emission models used have been compared to other model results and measured data; see Appendix D:
214 Model Corroboration of the User Guide Appendices for the results of these analyses (U.S. EPA, 2019b).

215 **D.2 Consumer Dermal Exposure**

216 Two models were used to evaluate consumer dermal exposures, the Fraction Absorbed model (P_DE2a
217 within CEM) and the Permeability model (P_DER2b within CEM). A brief comparison of these two
218 dermal models through the calculation of acute dose rates (ADRs) is provided below. They have been
219 applied to distinct exposure conditions, with the permeability model applied to scenarios likely to
220 involve occluded dermal contact where evaporation may be inhibited and the fraction absorbed model
221 applied to scenarios less likely to involve occluded dermal contact.

222
223 The dermal models described below were run for all consumer conditions of use to provide a
224 comparison between the two results while recognizing each model is unique in its approach to
225 estimating dermal exposure and may not be directly comparable. Keeping these limitations in mind, the
226 full suite of exposure results from both models is shown for all conditions of use in 26. *Final Risk
227 Evaluation for Trichloroethylene Supplemental Information File Exposure Modeling Results and Risk
228 Estimates for Consumer Dermal Exposures.xlsx*.

229
230 Because neither model considers the mass of chemical as an input in the absorbed dose equations, both
231 have the potential to overestimate the dermal absorption by modeling a mass which is larger than the
232 mass used in a scenario. Therefore, when utilizing either of the CEM models for dermal exposure

233 estimations, a mass check is necessary outside of the CEM model to make sure the mass absorbed does
234 not exceed the typical mass used for a given scenario.

235

236 ***CEM Absorption Fraction Model (P_DER2a)***

237 The fraction absorbed model estimates the mass of a chemical absorbed through the application of a
238 fractional absorption factor to the mass of chemical present on or in the skin following a use event. The
239 initial dose or amount retained on the skin is determined using a film thickness approach. A fractional
240 absorption factor is then applied to the initial dose to estimate absorbed dose. The fraction absorbed is
241 essentially the measure of two competing processes, evaporation of the chemical from the skin surface
242 and penetration deeper into the skin. It can be estimated using an empirical relationship based on Frisch
243 and Bunge (2015). Due to the model's consideration of evaporative processes, it was considered to be
244 more representative of dermal exposure under unimpeded exposure conditions. For additional details on
245 this model, please see Appendix D and the CEM User Guide Section 3: Detailed Descriptions of Models
246 within CEM (U.S. EPA, 2019a).

247

$$248 \quad ADR = \frac{AR \times F_{abs} \times \frac{SA}{BW} \times FQ_{ac} \times Dil \times WF \times ED_{ac} \times CF_1}{AT_{ac}}$$

249

250 Where:

- 251 ADR = Acute daily dose rate (mg/kg-day)
252 AR = Amount retained in the skin (g/cm², film thickness [cm] multiplied by product density)
253 F_{abs} = Absorption fraction (see below)
254 D_{ac} = Duration of use (min/event)
255 SA/BW = Surface area to body weight ratio (cm²/kg)
256 FQ_{ac} = Frequency of use (events/day, 1 for acute exposure scenarios)
257 Dil = Product dilution fraction (unitless, 1 [no dilution] for all TCE scenarios)
258 WF = Weight fraction of chemical in product (unitless)
259 ED_{ac} = Exposure duration (1 day for acute exposure scenarios)
260 CF₁ = Conversion factor (1,000 mg/g)
261 AT_{cr} = Averaging time (1 day for acute exposure scenarios)

262

263 The fraction absorbed (F_{abs}) term is estimated using the ratio of evaporation from the stratum corneum to
264 the dermal absorption rate through the stratum corneum, as informed by gas phase mass transfer
265 coefficient, vapor pressure, molecular weight, water solubility, real gas constant, and permeability
266 coefficient.

267

$$268 \quad FR_{abs} = \frac{3 + \chi \left[1 - \exp\left(-a \frac{D_{ac}}{t_{lag} \chi CF_1}\right) \right]}{3(1 + \chi)}$$

269

270 Where:

- 271 χ = Ratio of the evaporation rate from the stratum corneum (SC) to the dermal absorption rate
272 α = Constant (2.906)
273 D_{ac} = Duration of use (min/event)
274 t_{lag} = Lag time for chemical transport through SC (hr)
275 CF₁ = Conversion factor (60 min/hr)

276

277 ***CEM Permeability Model (P_DER2b)***

278 The permeability model estimates the mass of a chemical absorbed and dermal flux based on a
279 permeability coefficient (K_p) and is based on the ability of a chemical to penetrate the skin layer once
280 contact occurs. It assumes a constant supply of chemical directly in contact with the skin throughout the

281 exposure duration. K_p is a measure of the rate of chemical flux through the skin. The parameter can
 282 either be specified by the user (if measured data are reasonably available) or be estimated within CEM
 283 using a chemical's molecular weight and octanol-water partition coefficient (K_{ow}). The permeability
 284 model does not inherently account for evaporative losses (unless the available flux or K_p values are
 285 based on non-occluded, evaporative conditions), which can be considerable for volatile chemicals in
 286 scenarios where evaporation is not impeded. While the permeability model does not explicitly represent
 287 exposures involving such impeded evaporation, the model assumptions make it the preferred model for
 288 an such a scenario. For TCE, a measured dermal permeability coefficient (K_p 0.0023 cm/hr) is used,
 289 based on measured dermal flux from a human dermal absorption test with neat TCE ([Kezic et al. 2001](#)).
 290 For additional details on this model, please see Appendix D and the CEM User Guide Section 3:
 291 Detailed Descriptions of Models within CEM ([U.S. EPA, 2019a](#)).

292
 293 The acute form of the dermal permeability model is given below:
 294

$$295 \quad ADR = \frac{K_p \times D_{ac} \times \rho \times \frac{SA}{BW} \times FQ_{ac} \times Dil \times WF \times ED_{ac} \times CF_1}{AT_{ac} \times CF_2}$$

296
 297 Where:

- 298 ADR = Potential acute dose rate (mg/kg-day)
- 299 K_p = Permeability coefficient (cm/hr)
- 300 D_{ac} = Duration of use (min/event)
- 301 ρ = Density of formulation (g/cm³)
- 302 SA/BW = Surface area to body weight ratio (cm²/kg)
- 303 FQ_{ac} = Frequency of use (events/day, 1 for acute exposure scenarios)
- 304 Dil = Product dilution fraction (unitless, 1 [no dilution] for all TCE scenarios)
- 305 WF = Weight fraction of chemical in product (unitless)
- 306 ED_{ac} = Exposure duration (1 day for acute exposure scenarios)
- 307 CF1 = Conversion factor (1,000 mg/g)
- 308 CF2 = Conversion factor (60 min/hr)
- 309 AT_{ac} = Averaging time (1 day for acute exposure scenarios)

311 **D.3 Model Sensitivity**

312 The CEM developers conducted a detailed sensitivity analysis for CEM, as described in Appendix C of
 313 the CEM User Guide ([U.S. EPA, 2019b](#)). The CEM developers included results of model corroboration
 314 analysis in Appendix D of the CEM User Guide ([U.S. EPA, 2019b](#)).

315
 316 In brief, the analysis was conducted on continuous variables and categorical variables that were used in
 317 CEM emission or dermal models. A base run of different CEM models using various product or article
 318 categories, along with CEM defaults, was used. Individual variables were modified, one at a time, and
 319 the resulting Acute Dose Rate (ADR) and Chronic Average Daily Dose (CADD) were compared to the
 320 corresponding results for the base run. Benzyl alcohol, a VOC, was used as an example for product
 321 models such as those applied in this evaluation of TCE.


322
 323 The tested model parameters were increased by 10%. The measure of sensitivity for continuous
 324 variables such as mass of product used, weight fraction, and air exchange rate was "elasticity," defined
 325 as the ratio of percent change in each result to the corresponding percent change in model input. A
 326 positive elasticity indicates that an increase in the model parameter resulted in an increase in the model
 327 output, whereas a parameter with negative elasticity is associated with a decrease in the model output.

328 For categorical variables such as receptor activity pattern (*i.e.*, work schedule) and room of use, the
329 percent difference in model outputs for different category pairs was used as the measure of sensitivity.

330
331 The results are summarized below for the inhalation and dermal models used to evaluate consumer
332 exposures to TCE (*i.e.*, emission models E1 and E3 and the dermal permeability model P_DER2b. For
333 full results and additional background, refer to Appendix C of the CEM User Guide ([U.S. EPA, 2017b](#)).


334 D.3.1 Continuous Variables

335 For acute exposures generated from emission model E1, WF (weight fraction) and M_acute (mass of
336 product used) have the greatest positive elasticities of the tested parameters (see Figure_Apx D-1). The
337 next most sensitive parameters demonstrate negative elasticity and include: Vol_Building (building
338 volume); AER_Zone2 (air exchange rate in Zone 2); AER_Zone1 (air exchange rate in Zone 1);
339 Vol_Zone1 (room of use, or Zone 1 volume). Inhalation exposures from liquid consumer product
340 formulations were modeled using E1 and the two most sensitive variables identified in this analysis were
341 varied to estimate a range of exposures.
342



343
344 **Figure_Apx D-1. Elasticities (≥ 0.05) for Parameters Applied in E1**

345
346 For acute exposures generated from emission model E3, WF (weight fraction) and M_acute (mass of
347 product used) have the greatest positive elasticities of the tested parameters (see Figure_Apx D-2). The
348 next most sensitive parameters demonstrate negative elasticity and include: Vol_Building (building
349 volume); AER_Zone2 (air exchange rate in Zone 2); MW (molecular weight); VP (vapor pressure);
350 AER_Zone1 (air exchange rate in Zone 1); Vol_Zone1 (room of use, or Zone 1 volume). Inhalation
351 exposures from aerosol or spray consumer product formulations were modeled using E3 and the two
352 most sensitive variables identified in this analysis were varied to estimate a range of exposures.
353




354

355 **Figure_Apx D-2. Elasticities (≥ 0.05) for Parameters Applied in E3**

356

357 For acute exposures generated from the dermal permeability model, the chemical properties that inform
 358 absorption rate, or absorption rate estimates, have the greatest elasticities (see Figure_Apx D-3). For
 359 TCE, dermal exposures from consumer product formulations were modeled using a measured Kp
 360 (permeability coefficient). Therefore, LogKow (octanol/water partition coefficient) and MW (molecular
 361 weight) were not used to estimate skin penetration.
 362



363

364 **Figure_Apx D-3. Elasticities (≥ 0.05) for Parameters Applied in P_DER2b**

365 **D.3.2 Categorical Variables**

366 For categorical variables there were multiple parameters that affected other model inputs. For example,
 367 varying the room type changed the ventilation rates, volume size and the amount of time per day that a
 368 person spent in the room. Thus, each modeling result was calculated as the percent difference from the
 369 base run. For continuous variables, each modeling result was calculated as elasticity.

370

371 Among the categorical variables, the most sensitive parameters included receptor type (adult vs. child),
 372 room of use (Zone 1) selection, and application of the near-field bubble within Zone 1. However, these
 373 types of variables were held constant within a given product modeling scenario and were applied using
 374 consistent assumptions across all modeling scenarios.

375 **D.4 Monitoring Data**

376 **D.4.1 Indoor Air Monitoring**

377 Systematic review identified indoor air monitoring studies reporting levels of TCE in residential indoor
 378 air samples. The air concentrations reported in these studies are not used to evaluate risk to consumers
 379 since measurements are not attributable to consumer conditions of use. The full suite of extracted data
 380 (including residential, commercial) and associated data evaluation forms are found in [*Data Extraction*
 381 *Tables for Environmental Monitoring Data. Docket: EPA-HQ-OPPT-2019-0500*].

382

383 Concentrations of TCE in residential indoor air in the United States and Canada collected from nine
 384 studies identified during Systematic Review are summarized in Table_Apx D-1. Overall, more than
 385 1,800 samples were collected between 1986 and 2010 in eleven US states (CA, CO, IL, IN, MA, MI,
 386 MN, NJ, NY, OH, and TX) and Canada (exact location not reported). Concentrations ranged from non-
 387 detect (detection limits varied) to $42 \mu\text{g}/\text{m}^3$. The highest concentrations were observed in residential
 388 garages and apartment hallways. Measures of central tendency (mean or median) across all studies were
 389 generally less than $1 \mu\text{g}/\text{m}^3$, with a couple central tendency measurements above $3 \mu\text{g}/\text{m}^3$.

390

391 Data extracted for residential indoor air samples from studies conducted outside of North America, as
 392 well as studies conducted in schools and commercial establishments in the US and other countries, are

393 provided in [Data Extraction Tables for Environmental Monitoring Data. Docket: EPA-HQ-OPPT-
 394 2019-0500].

395

396 **Table_Apx D-1. TCE Residential Indoor Air Concentrations ($\mu\text{g}/\text{m}^3$) in the United States and**
 397 **Canada**

Study Info	Site Description	LOQ	Min.	Mean	Median	Max.	Variance	Data Eval. Score
(Chin et al., 2014) US, 2009-2010 (n=126; DF = 0.06)	Detroit, MI area; Homes (n=126) with children with asthma	0.09	ND	0.07	0.04	1.48	0.14 (SD)	High
(Dodson et al., 2008) ^a US, 2004-2005 (n=83; DF = 0.93)	Boston, MA; Interior room of residences	0.04	ND	0.6	0.2	2.2 (95th)	1.7 (SD)	High
(Dodson et al., 2008) ^a US, 2004-2005 (n=52; DF = 0.75)	Boston, MA; Basement of residences	0.04	ND	0.4	0.1	1.4 (95th)	1.1 (SD)	High
(Dodson et al., 2008) ^a US, 2004-2005 (n=10; DF = 0.9)	Boston, MA; Apartment hallway of residences	0.04	ND	3.7	0.3	23 (95th)	7.3 (SD)	High
(Dodson et al., 2008) ^a US, 2004-2005 (n=16; DF = 0.63)	Boston, MA; Garage of residences	0.04	ND	3.3	0.1	42 (95th)	10 (SD)	High
(Jia et al., 2008a) US, 2004-2005 (n=252; DF = 0.56)	Ann Arbor, Ypsilanti, and Dearborn MI; Residences (n=159) in industrial, urban, and suburban cities over two seasons	0.008	ND	0.06	0.03	2.01	--	Medium
(Adgate et al., 2004) US, 2000 (n=113; DF = 0.828)	Minneapolis, MN; Inside home, during the winter. Sampling from room where child spent the most time.	--	ND (10 th 0.1)	--	0.3	--	--	Medium
(Adgate et al., 2004) US, 2000 (n=113; DF = 0.737)	Minneapolis, MN; Inside home, during the spring. Sampling from room where child spent the most time.	--	ND (10 th 0.1)	--	0.2	--	--	Medium
(Sax et al., 2004) US, 2000 (n=32; DF = 0.47)	Los Angeles, CA; Homes (n=35) in inner-city neighborhood, sampled in the fall	0.13	ND	0.2	0.1	0.8	0.2 (SD)	High
(Sax et al., 2004) US, 2000 (n=40; DF = 0.68)	Los Angeles, CA; Homes (n=40) in inner-city neighborhood, sampled in the winter	0.13	ND	0.2	0.2	1.2	0.3 (SD)	High
(Sax et al., 2004) US, 1999 (n=36; DF = 0.92)	New York, NY; Homes (n=38) in inner-city neighborhood, sampled in the winter	0.13	ND	1.1	0.4	19	3.2 (SD)	High
(Sax et al., 2004) US, 1999 (n=30; DF = 0.44)	New York, NY; Homes (n=41) in inner-city neighborhood, sampled in the summer	0.13	ND	0.3	0.1	2.6	0.5 (SD)	High

Study Info	Site Description	LOQ	Min.	Mean	Median	Max.	Variance	Data Eval. Score
(Su et al., 2013) ^b US, 1999-2001 (n=539; DF = NR)	Elizabeth, NJ; Houston, TX; and Los Angeles, CA; Non-smoking households (n=310)	--	--	0.99	0.22	1.74 (95th)	7.29 (SD)	Medium
(Clayton et al., 1999) ^c US, 1995-1997 (n=402; DF = 0.361)	IL, IN, OH, MI, MN, WI (Great Lakes Region); Non-institutionalized persons residing in households in six states	--	ND	3.84	0.56	2.28 (90th)	--	High
(Lindstrom et al., 1995) US, 1994 (n=9; DF = 0.56)	Denver, CO; Homes, occupied (n=9)	0.12	ND	0.64	0.61	--	0.66 (SD)	Medium
(Chan et al., 1990) CA, 1987 (n=6; DF = 0.83)	Homes (n=6), main floor	--	ND	1.6	--	5	--	Medium
(Chan et al., 1990) CA, 1986 (n=12; DF = 0.42)	Homes (n=12), main floor	--	ND	0.5	--	2	--	Medium

Study Info: The information provided includes the citation; country and year samples collected; number of samples and detection frequency.
Abbreviations: If a value was not reported, it is shown in this table as "--". ND = not detected at the reported detection limit. GSD = geometric standard deviation. DF = detection frequency. NR = Not reported. US = United States. CA = Canada
Parameters: All statistics are shown as reported in the study. Some reported statistics may be less than the detection limit; the method of handling non-detects varied by study. All minimum values determined to be less than the detection limit are shown in this table as "ND." If a maximum value was not provided, the highest percentile available is shown (as indicated in parentheses); if a minimum value was not provided, the lowest percentile available is shown (as indicated in parentheses).
^a Samples from this study were collected as part of the BEAMS study.
^b Samples from this study were collected as part of the RIOPA study.
^c Samples from this study were collected as part of the NHEXAS Phase 1 field study.

398

399 D.4.2 Personal breathing Zone Monitoring Data

400 Concentrations of TCE (TCE) in the personal breathing zones of residents in the United States collected
401 from seven studies identified during Systematic Review are summarized in Table_Apx D-2. Overall, the
402 measured concentration dataset contains approximately 2,750 samples that were collected between 1981
403 and 2001, and represents time spent in various microenvironments (*i.e.*, home, school, work, transit)
404 during the monitoring period. Only the 3-hr samples from Heavner et al. ([1995](#)) represent time inside the
405 home only. Concentrations ranged from non-detect (limits varied) to 327.3 µg/m³. The highest
406 concentration was observed in samples collected in 2000 as part of the NHANES 1999-2000 study ([Jia
407 et al., 2008b](#)). The study states that the top ten highest concentrations exceeded 300 µg/m³, which they
408 suggest may indicate exposure from immediate contact with solvents. The 95th percentile concentration
409 in this study is 7.4 µg/m³. All other studies showed maximum concentrations less than 10 µg/m³.
410 Median concentrations ranged from ND to 1.05 µg/m³; and average concentrations ranged from 0.66 to
411 13 µg/m³.

412

413 Data extracted for residential/general personal breathing zones studies conducted outside of North
414 America, as well as studies conducted in schools and commercial establishments in the US and other
415 countries, is provided in [*Data Extraction Tables for Environmental Monitoring Data. Docket: EPA-
416 HQ-OPPT-2019-0500*].

417

418 **Table_Apx D-2. Personal Breathing Zone Concentrations ($\mu\text{g}/\text{m}^3$) for TCE in the United States**
 419 **(General/Residential)**

Study Info	Type	Site Description	LOD	Min.	Mean	Median	Max	Variance	Data Eval. Score
(Su et al., 2013) ^a US, 1999-2001 (n=544; DF = 0.23)	48-hr	Elizabeth, NJ; Houston, TX; and Los Angeles, CA; Adults (n=309) and children (n=118) from 310 non-smoking households.	--	ND	1.44	0.22	2.37 (95th)	10.74 (SD)	Medium
(Jia et al., 2008b) ^b US, 1999-2000 (n=665; DF = 0.229)	48-to 72-hr	Nation-wide; Adults (ages 20–59 years) in NHANES study	0.44	ND	0.4 (GM)	ND	327.3 (7.4 - 95 th)	3.4 (GSD)	High
(Sexton et al., 2007) US, 1999 (n=333; DF = 0.925)	48-hr	Minneapolis -St. Paul, MN; Adults, non-smoking (n=70) living in three neighborhoods: (inner-city, blue-collar/near manufacturing plants, and affluent)	--	ND	1	0.2	1.8 (90th)	--	High
(Clayton et al., 1999) ^c US, 1995-1997 (n=386; DF = 0.394)	6-day	IL, IN, OH, MI, MN, WI (Great Lakes Region); Non-institutionalized persons	--	ND	5.27	0.63	5.98 (90th)	--	High
(Heavner et al., 1995) US, 1991 (n=24; DF = NR)	3-hrs (in home only)	Columbus, OH; Non-smoking women (n=24) with non-smoking husbands	--	ND	1.84	1.05	9.08	2.39	Medium
(Heavner et al., 1995) US, 1991 (n=25; DF = NR)	3-hrs (in home only)	Columbus, OH; Non-smoking (n=25) women with smoking husbands	--	ND	0.66	ND	3.41	1.04	Medium
(Wallace, 1987) ^d US, 1981-1984 (n=772; DF = 0-0.97)	12-hrs	Elizabeth and Bayonne, NJ, Los Angeles, CA, and Contra Costa, CA; Adults in industrial/ chemical manufacturing and /or petroleum refining regions of the US.	--	--	3.8 to 13	--	--	--	High

Abbreviations: If a value was not reported, it is shown in this table as "--". LOD = level of detection. ND = not detected at the reported detection limit. GM = geometric mean. GSD = geometric standard deviation. DF = detection frequency. NR = Not reported. US = United States.

Parameters: All statistics are shown as reported in the study. Some reported statistics may be less than the detection limit; the method of handling non-detects varied by study. All minimum values determined to be less than the detection limit are shown in this table as "ND." If a maximum value was not provided, the highest percentile available is shown (as indicated in parentheses); if a minimum value was not provided, the lowest percentile available is shown (as indicated in parentheses).

^a Samples from this study were collected as part of the RIOPA study.

^b Samples from this study were collected as part of the NHANES 1999-2000. The top ten highest concentrations exceeded 300 $\mu\text{g}/\text{m}^3$, which the authors suggest may be from immediate contact with solvents.

^c Samples from this study were collected as part of the NHEXAS Phase 1 field study.

^d Samples from this study were collected as part of the TEAMS study.

421 **Appendix E ENVIRONMENTAL HAZARDS**

422

423 **E.1 Species Sensitivity Distribution (SSD) Methodology**

424 The SSD Toolbox is a resource created by EPA's Office of Research and Development (ORD) that can
425 fit SSDs to environmental hazard data ([Etterson, 2020](#)). It runs on Matlab 2018b (9.5) for Windows 64
426 bit. For this TCE Risk Evaluation, EPA created two SSDs with the SSD Toolbox, one using only algae
427 hazard data and the other using acute hazard data for all other aquatic species. This appendix outlines the
428 methodology used to create each.

429

430 For the acute SSD, acute hazard data for fish, amphibians, and invertebrates were curated to prioritize
431 study quality and to assure comparability between toxicity values. For example, the dataset included
432 only LC_{50s} for fish and amphibians, and EC_{50s} or LC_{50s} that measured immobilization and mortality for
433 aquatic invertebrates. The dataset included both saltwater and freshwater species, because the toxicity
434 values for saltwater species value were within the range of values reported for freshwater species in the
435 same taxonomic group. Additionally, for fish and invertebrates, the mode of action for freshwater and
436 saltwater species expected to be the same. Table_Apx E-1 shows the data that was used in the algae
437 SSD, as well as data that was not included in the SSD and why.

438

439 With this dataset, the Toolbox was used to apply a variety of algorithms to fit and visualize SSDs with
440 different distributions. Figure_Apx E-1 shows the Toolbox interface after each distribution and fitting
441 method was fit to the data. An HC₀₅ is calculated for each.

Table_Apx E-1. Acute Toxicity Data for Aquatic Organisms used in SSD

Species	LC ₅₀ (mg/L)*	Source (quality rating)	Used in SSD
Amphibians			
African clawed frogs (Xenopus laevis)	434.0	(Fort et al., 1993) (high)	Yes
African clawed frogs (Xenopus laevis)	434 (geometric mean)	(Fort et al., 1991) (medium)	Yes, used a geometric mean of two values for LC ₅₀ s in the study
African clawed frogs (Xenopus laevis)	441 (geometric mean)	(Fort et al., 2001) (medium)	Yes, used a geometric mean of three values for LC ₅₀ s in the study
Fish			
Fathead minnow (Pimephales promelas)	44.1	(Geiger et al., 1985) (high)	Yes
Fathead minnow (Pimephales promelas)	40.7	(Alexander et al., 1978) (high)	Yes
Fathead minnow (Pimephales promelas)	66.8	(Alexander et al., 1978) (medium)	No, because this value from a static study was rated medium for quality and a high-quality flow through value from the same study was available
American flagfish (Jordanella floridae)	28.28	(Smith et al., 1991) (high)	Yes
American flagfish (Jordanella floridae)	31.00	(Smith et al., 1991) (medium)	No, because this value from a static study was rated medium for quality and a high-quality flow through value from the same study was available
Fathead minnow (Pimephales promelas)	46.7 (geometric mean)	(Broderius et al., 2005) (high)	Yes, used a geometric mean of three values for LC ₅₀ s in the study
Bluegill (Lepomis macrochirus)	45	(Buccafusco et al., 1981) (medium)	Yes
Sheepshead minnows (Cyprinodon variegatus)	52	(Ward et al., 1986) (medium)	Yes


Species	LC ₅₀ (mg/L)*	Source (quality rating)	Used in SSD
Sheepshead minnows (Cyprinodon variegatus)	99	(Ward et al., 1986) (medium)	No, because this LC ₅₀ measured initial TCE concentrations and the average concentrations were available in the same study
Invertebrates			
Daphnia magna	18	(LeBlanc, 1980) (high)	Yes
Daphnia magna	22	(LeBlanc, 1980) (high)	No, because a 48-hour value was available in the same paper
Daphnia magna	7.75	(Abernethy et al., 1986) (medium)	Yes
Daphnia magna	33.85	(Dobaradaran et al., 2012) (medium)	Yes
Daphnia magna	43.14	(Dobaradaran et al., 2012) (medium)	No, because a 48-hour value was available in the same paper
Daphnia magna	28.39	(Dobaradaran et al., 2012) (medium)	No, because a 48-hour value was available in the same paper
Daphnia magna	26.55	(Dobaradaran et al., 2012) (medium)	No, because a 48-hour value was available in the same paper
Mysidopsis bahia (Mysid shrimp)	14	(Ward et al., 1986) (medium)	Yes
Ceriodaphnia dubia	17.08	(Niederlehner et al., 1998) (high)	Yes

443
444

*EC₅₀s measuring immobilization were also used for invertebrates, because it is difficult to distinguish between death and immobilization for aquatic invertebrates.

445
446

Figure_Apx E-1. SSD Toolbox interface showing HC₀₅ and P values for each distribution and fitting method using TCE’s acute hazard data (Etterson, 2020)




447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462

The SSD Toolbox’s output contained several methods for choosing an appropriate distribution and fitting method, including goodness-of-fit, standard error, and sample-size corrected Akaike Information Criterion (AIC_c, [Burnham and Anderson, 2002]). However, choosing the distribution with the best fit was challenging with a small dataset (*e.g.*, hazard data for 8 algae species). Most P values for goodness-of-fit were above 0.05, showing no evidence for lack of fit. However for the Weibull distribution, the maximum likelihood and graphical methods fitting methods had P values for goodness-of-fit below 0.05 showing lack of fit, so they were eliminated. For all other distributions P values for goodness-of-fit were > 0.05 (Figure_Apx E-1). Standard error was mixed across fitting methods for some distributions but generally the lowest for the burr distribution (Table_Apx E-2) shows that the Gumbel distribution has the lowest AIC_c, indicating it may be the best distribution for this data though the relative AIC support compared to other distributions is weak. Because the ability for these measures to distinguish between distributions was limited, visual inspection of the distributions was also used; however, no distributions could be eliminated through this method either (Figure_Apx E-3).

463 **Table_Apx E-2. Standard Error for all distributions and fitting methods using TCE's acute**
 464 **hazard data (Etterson, 2020)**

	Normal Distribution				Logistic Distribution				Triangular Distribution				Gumbel Distribution				Weibull Distribution	Burr Distribution	
	ML	MO	GR	MH	ML	MO	GR	MH	ML	MO	GR	MH	ML	MO	GR	MH	MH	ML	MH
Standard Error for HC ₀₅ (mg/L)	5.5	5.4	4.6	3.7	5.3	5.5	4.0	3.5	6.7	5.0	4.1	4.0	4.2	4.7	4.2	4.0	2.8	5.5	0.4


465 **Figure_Apx E-2. AIC_c for the five distribution options in the SSD Toolbox for TCE's acute hazard**
 466 **data (Etterson, 2020)**
 467



468

469
470


Figure_Apx E-3. All distributions and fitting methods in the SSD Toolbox for TCE's acute hazard data (Etterson, 2020)



471
472
473
474
475
476
477
478
479

Because there was no obvious distribution that was the best fit using goodness-of-fit, standard error, and sample-size corrected AIC_c, EPA used five distributions to calculate an HC₀₅, including normal, logistic, triangular, Gumbel, and Burr distributions using the maximum likelihood fitting method. EPA did not use the Weibull distribution because the maximum likelihood fitting method for Weibull was eliminated because its P value for goodness-of-fit was ≤ 5 . The model-averaged HC₀₅ from all five distributions was 10 mg/L or 10,000 μ g/L, and the SSDs showed aquatic invertebrates were the most sensitive species (Figure_Apx E-4).

480 **Figure_Apx E-4. TCE's acute hazard data fit with the normal, logistic, triangular, Gumbel, and**
481 **Burr distributions fit with maximum likelihood in the SSD Toolbox (Etterson, 2020)**



482
483

484 For the algae SSD, algae hazard data were curated to prioritize study quality and to assure comparability
485 between toxicity values (e.g., comparing EC₅₀s to EC₅₀s). The dataset included both saltwater and
486 freshwater species, because the only saltwater species value was within the range of values reported for
487 freshwater species. Table_Apx E-3 shows the data that was used in the algae SSD, as well as data that
488 was not included in the SSD and why.

489

490 With this dataset, the Toolbox was used to apply a variety of algorithms to fit and visualize SSDs with
491 different distributions. Figure_Apx E-5 shows the Toolbox interface after each distribution and fitting
492 method was fit to the data. A hazardous concentration for 5% of species (HC₀₅) is calculated for each.

Table_Apx E-3. Algae Toxicity Data used in SSD

Species	EC ₅₀ for growth (mg/L)	Source (quality rating)	Used in SSD
Saltwater			
Skeletonema costatum	95	(Ward et al., 1986) (medium)	Yes
Freshwater			
Chlamydomonas reinhardtii	36.5	(Brack and Rottler, 1994) (high)	Yes
Chlamydomonas reinhardtii	520	(Lukavsky et al., 2011) (medium)	Yes
Chlorella kessleri	321, geometric mean of two population growth rate values	(Lukavsky et al., 2011) (medium)	Yes
Desmodesmus quadricauda	447, geometric mean of two population growth rate values	(Lukavsky et al., 2011) (medium)	Yes
Desmodesmus subspicatus	536, geometric mean of two population growth rate values	(Lukavsky et al., 2011) (medium)	Yes
Mycrocystis aeruginosa	130	(Lukavsky et al., 2011) (medium)	Yes
Raphidocelis subcapitata	26.24	(Tsai and Chen, 2007) (high)	Yes
Raphidocelis subcapitata	315, geometric mean of two population growth rate values	(Lukavsky et al., 2011) (medium)	Yes
Synechococcus elongatus	800	(Lukavsky et al., 2011) (medium)	Yes
Synechococcus leopoliensis	424, geometric mean of two population growth rate values	(Lukavsky et al., 2011) (medium)	Yes
Chlamydomonas reinhardtii	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Chlamydomonas reinhardtii	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a

Species	EC ₅₀ for growth (mg/L)	Source (quality rating)	Used in SSD
			more biologically relevant effect than photosynthesis.
Chlorella kessleri	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Chlorella kessleri	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Raphidocelis subcapitata	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Raphidocelis subcapitata	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Desmodesmus quadricauda	500	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Desmodesmus quadricauda	600	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a


Species	EC ₅₀ for growth (mg/L)	Source (quality rating)	Used in SSD
			more biologically relevant effect than photosynthesis.
Desmodesmus subspicatus	400	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Desmodesmus subspicatus	400	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Synechococcus elongatus	600	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Synechococcus elongatus	700	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Synechococcus leopoliensis	480	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Synechococcus leopoliensis	450	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a

Species	EC ₅₀ for growth (mg/L)	Source (quality rating)	Used in SSD
			more biologically relevant effect than photosynthesis.
Microcystis aeruginosa	100	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.
Microcystis aeruginosa	250	(Lukavsky et al., 2011) (medium)	No, because an EC ₅₀ measuring population growth rate was available in the same study for this species and that was considered a more biologically relevant effect than photosynthesis.

494

495
496

Figure_Apx E-5. SSD Toolbox interface and list of HC₀₅s for each distribution and fitting method using TCE’s algae hazard data (Etterson, 2020)




497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512

The SSD Toolbox’s output contained several methods for choosing an appropriate distribution and fitting method, including goodness-of-fit, standard error, and sample-size corrected Akaike Information Criterion (AIC_c, [Burnham and Anderson, 2002]). However, choosing the distribution with the best fit was challenging with a small dataset (e.g., hazard data for 9 algae species). Most P values for goodness-of-fit were above 0.05, showing no evidence for lack of fit. However for the Gumbel distribution, the moment estimator fitting method had a P value for goodness-of-fit below 0.05 showing lack of fit, so it was eliminated. For all other distributions P values for goodness-of-fit were > 0.05, providing no help in discriminating among distributions (Figure_Apx E-5). Standard error was lowest across fitting methods for the Gumbel and Burr distributions (Table_Apx E-4). And the AIC_c Table (Figure_Apx E-6) showed that triangular, normal, and Weibull distributions may be the best fit. Because the ability for these measures to distinguish between distributions was limited, visual inspection of the distributions was used; however, no distributions could be eliminated through this method either (Figure_Apx E-7).

513 **Table_Apx E-4. Standard Error for all distributions and fitting methods using TCE's algae**
 514 **hazard data (Etterson, 2020)**

	Normal Distribution				Logistic Distribution				Triangular Distribution				Gumbel Distribution				Weibull Distribution			Burr Distribution	
	ML	MO	GR	MH	ML	MO	GR	MH	ML	MO	GR	MH	ML	MO	GR	MH	ML	GR	MH	ML	MH
Standard Error for HC ₀₅ (mg/L)	34	32	26	27	34	37	28	28	32	29	30	29	25	27	27	24	40	33	32	30	1.3


515
 516 **Figure_Apx E-6. AICc Table for algae hazard data (Etterson, 2020)**



517

518
519

Figure_Apx E-7. All distributions and fitting methods in the SSD Toolbox for TCE's algae hazard data (Etterson, 2020)




520
521
522
523
524
525

Because there was no obvious distribution that was the best fit using goodness-of-fit, standard error, and sample-size corrected AIC_c, EPA used all six distributions to calculate an HC₀₅. Using the normal, logistic, triangular, Gumbel, Weibull, and Burr distributions, EPA calculated a modeled average HC₀₅ of 72 mg/L or 72,000 µg/L.

526
527

Figure_Apx E-8. TCE algae data fit with all distributions using the maximum likelihood fitting method (Etterson, 2020)



528
529

530

E.2 Environmental Risk Quotients (RQs) for Facilities Releasing TCE to Surface Water as Modeled in E-FAST

Table_Apx E-5. Environmental RQs by Facility (with RQs ≥ 1 in bold)

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
OES: Adhesives, Sealants, Paints, and Coatings											
Able Electropolishing Co Inc, Chicago, IL NPDES: Not available	POTW	Adhesives and Sealants Manuf.	Surface water	250	0.298	7.28	0.00	0.01	0.01	2.43	0.00
Garlock Sealing Technologies, Palmyra, NY, NPDES: NY0000078	Surface Water	NPDES NY0000078	Surface water	250	0.00033	0.00716	0.00	0.00	0.00	0.00	0.00
				20	0.00407	0.0889	0.00	0.00	0.00	0.03	0.00
Ls Starrett Co, Athol, MA NPDES: MAR05B615	Surface Water	Not assessed (below the min risk level).									
Aerojet Rocketdyne, Inc., East Camden, AR NPDES: AR0051071, ARR00A521, ARR00A520	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Best One Tire & Service, Nashville, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Bridgestone Aircraft Tire (Usa), Inc., Mayodan, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Clayton Homes Inc, Oxford, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Cmh Manufacturing, Inc. Db a Schult Homes - Plant 958, Richfield, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Delphi Thermal Systems, Lockport, NY NPDES: NY0000558	Surface Water	NPDES NY0000558	Surface water	250	0.013	1.1	0.00	0.00	0.00	0.37	0.00
				20	0.16	13.5	0.01	0.01	0.02	4.50	0.00
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.		250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
				250	0.013	1.67	0.00	0.00	0.00	0.56	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Green Bay Packaging Inc - Coon Rapids, Coon Rapids, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Mastercraft Boat Company, Vonore, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Michelin Aircraft Tire Company, Norwood, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
M-Tek, Inc, Manchester, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Olin Corp, East Alton, IL NPDES: IL0000230	Surface Water	NPDES IL0000230	Surface water	250	0.013	0.18	0.00	0.00	0.00	0.06	0.00
				20	0.16	2.26	0.00	0.00	0.00	0.75	0.00
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.		250	0.013	0.32	0.00	0.00	0.00	0.11	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Parker Hannifin Corp – Paraflex Division, Manitowoc, WI NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Parrish Tire Company, Yadkinville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Republic Doors And Frames, Mckenzie, TN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Ro-Lab Rubber Company Inc., Tracy, CA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Royale Comfort Seating, Inc. - Plant No. 1, Taylorsville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Snider Tire, Inc., Statesville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Snyder Paper Corporation, Hickory, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Stellana Us, Lake Geneva, WI NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Thomas Built Buses - Courtesy Road, High Point, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Unicel Corp, Escondido, CA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Acme Finishing Co Llc, Elk Grove Village, IL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Aerojet Rocketdyne, Inc., Rancho Cordova, CA NPDES: CA0004111	Surface Water	NPDES CA0004111	Surface water	250	0.013	0.000818	0.00	0.00	0.00	0.00	0.00
				20	0.16	0.0101	0.00	0.00	0.00	0.00	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Allegheny Cnty Airport Auth/ Pgh Intl Airport, Coroapolis Pittsburgh, PA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Amphenol Corp – Aerospace Operations, Sidney, NY NPDES: NY0003824	Surface Water	NPDES NY0003824	Surface water	250	0.013	0.0631	0.00	0.00	0.00	0.02	0.00
				20	0.16	0.78	0.00	0.00	0.00	0.26	0.00
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.		250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Aprotech Powertrain, Asheville, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW				250	0.013	0.32	0.00	0.00	0.00	0.11
Coating & Converting Tech Corp/ Adhesive Coatings, Philadelphia, PA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Corpus Christi Army Depot, Corpus Christi, TX NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Electronic Data Systems Camp Pendleton, Camp Pendleton, CA NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Florida Production Engineering, Inc., Ormond Beach, FL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Goodrich Corporation, Jacksonville, FL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Kasai North America Inc, Madison Plant, Madison, MS NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Kirtland Air Force Base, Albuquerque, NM NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Marvin Windows & Doors, Warroad, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Mcneilus Truck & Manufacturing Inc, Dodge Center, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Metal Finishing Co. – Wichita (S Mclean Blvd), Wichita, KS NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Murakami Manufacturing Usa Inc, Campbellsville, KY NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Peterbilt Motors Denton Facility, Denton, TX NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Portsmouth Naval Shipyard, Kittery, ME NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
R.D. Henry & Co., Wichita, KS NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Raytheon Company, Portsmouth, RI NPDES: RI0000281	Surface Water	NPDES RI0000281	Still body	250	0.013	10.83	0.01	0.01	0.01	3.61	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.16	133.33	0.07	0.14	0.17	44.44	0.01
	POTW	No info on receiving facility; Adhesives and Sealants Manuf.		250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Rehau Inc, Cullman, AL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Rotochopper Inc, Saint Martin, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Rubber Applications, Mulberry, FL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Sapa Precision Tubing Rockledge, Llc, Rockledge, FL NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Thomas & Betts, Albuquerque, NM NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Thomas Built Buses - Fairfield Road, High Point, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Timco, Dba Haeco Americas Airframe Services, Greensboro, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Trelleborg Coated Systems Us, Inc – Grace Advanced Materials, Rutherfordton, NC NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
U.S. Coast Guard Yard - Curtis Bay, Curtis Bay, MD NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
Viracon Inc, Owatonna, MN NPDES: Not available	Surface Water	Adhesives and Sealants Manuf.	Surface water	250	0.013	1.67	0.00	0.00	0.00	0.56	0.00
				20	0.16	20.57	0.01	0.02	0.03	6.86	0.00
	POTW			250	0.013	0.32	0.00	0.00	0.00	0.11	0.00
OES: Commercial Printing and Copying											
Printing And Pub Sys Div, Weatherford, OK NPDES: OK0041785	Surface Water	Printing	Surface water	250	0.0002	0.00292	0.00	0.00	0.00	0.00	0.00
				20	0.0025	0.0365	0.00	0.00	0.00	0.01	0.00
OES: Industrial Processing Aid											

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Occidental Chemical Corp Niagara Plant, Niagara Falls, NY NPDES: NY0003336	Surface Water	NPDES NY0003336	Still body	300	0.019	0.14	0.00	0.00	0.00	0.05	0.00
				20	0.292	2.2	0.00	0.00	0.00	0.73	0.00
Stepan Co Millsdale Road, Elwood, IL NPDES: IL0002453	Surface Water	NPDES IL0002453	Surface water	300	0.001	0.000419	0.00	0.00	0.00	0.00	0.00
				20	0.008	0.00335	0.00	0.00	0.00	0.00	0.00
Entek International LLC, Lebanon, OR NPDES: N/A	Off-site Waste-water Treatment	No info on receiving facility; POTW (Ind.)	Surface water	300	0.38	9.3	0.00	0.01	0.01	3.10	0.00
				20	5.65	138.34	0.07	0.15	0.18	46.11	0.01
National Electrical Carbon Products DbA Morgan Adv Materials, Fostoria, OH NPDES: OH0052744	Off-site Waste-water Treatment	Receiving Facility: City of Fostoria; NPDES OH0052744	Surface water	300	0.008	0.15	0.00	0.00	0.00	0.05	0.00
				20	0.115	2.32	0.00	0.00	0.00	0.77	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
PPG Industries Inc Barberton, Barberton, OH NPDES: OH0024007	Off-site Waste-water Treatment	Receiving Facility: City of Barberton; NPDES OH0024007	Surface water	300	0.005	0.0141	0.00	0.00	0.00	0.00	0.00
				20	0.07	0.2	0.00	0.00	0.00	0.07	0.00
Daramic LLC, Corydon, IN NPDES: IN0020893	Surface Water	NPDES IN0020893	Surface water	300	0.008	0.0206	0.00	0.00	0.00	0.01	0.00
				20	0.114	0.29	0.00	0.00	0.00	0.10	0.00
OES: Manufacturing											
Axiall Corporation, Westlake, LA NPDES: LA0007129	Surface Water	NPDES LA0007129	Surface water	350	1.266	0.0051	0.00	0.00	0.00	0.00	0.00
				20	22.15	0.0897	0.00	0.00	0.00	0.03	0.00
Olin Blue Cube, Freeport, TX NPDES: Not available	Off-site Waste-water Treatment	Organic Chemicals Manuf.	Surface water	350	0.069	2.42	0.00	0.00	0.00	0.81	0.00
				20	1.2	42.14	0.02	0.05	0.05	14.05	0.00
Solvents & Chemicals, Pearland, TX NPDES: Not available	Off-site Waste-water Treatment	Organic Chemicals Manuf.	Surface water	350	0.015	0.53	0.00	0.00	0.00	0.18	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
	Surface Water	Organic Chemicals Manuf.	Surface water	20	0.265	9.48	0.00	0.01	0.01	3.16	0.00
				350	0.015	2.77	0.00	0.00	0.00	0.92	0.00
				20	0.265	49.91	0.02	0.05	0.06	16.64	0.00
OES: Waste Water Treatment Plant (WWTP)											
New Rochelle STP, New Rochelle, NY NPDES: NY0026697	Surface Water	NPDES NY0026697	Still body	365	0.043	0.7	0.00	0.00	0.00	0.23	0.00
				20	0.786	12.79	0.01	0.01	0.02	4.26	0.00
Everett Water Pollution Control Facility, Everett, WA NPDES: WA0024490	Surface Water	NPDES WA0024490	Surface water	365	0.016	0.17	0.00	0.00	0.00	0.06	0.00
				20	0.299	3.11	0.00	0.00	0.00	1.04	0.00
Sullivan WWTP, Sullivan, MO NPDES: MO0104736	Surface Water	NPDES MO0104736	Surface water	365	0.01	0.61	0.00	0.00	0.00	0.20	0.00
				20	0.176	10.97	0.01	0.01	0.01	3.66	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Sunnyside STP, Sunnyside, WA NPDES: WA0020991	Surface Water	NPDES WA0020991	Surface water	365	0.005	0.00673	0.00	0.00	0.00	0.00	0.00
				20	0.083	0.11	0.00	0.00	0.00	0.04	0.00
Port Of Sunnyside Industrial WWTF, Sunnyside, WA NPDES: WA0052426	Surface Water	POTW (Ind.)	Surface water	365	0.002	0.26	0.00	0.00	0.00	0.09	0.00
				20	0.035	4.51	0.00	0.00	0.01	1.50	0.00
U.S. Air Force Shaw AFB SC, Shaw AFB, SC NPDES: SC0024970	Surface Water	POTW (Ind.)	Surface water	365	0.002	0.26	0.00	0.00	0.00	0.09	0.00
				20	0.032	4.12	0.00	0.00	0.01	1.37	0.00
Gnf-A Wilmington-Castle Hayne WWTP, Wilmington, NC NPDES: NC0001228	Surface Water	NPDES NC0001228	Surface water	365	0.0004	0.00194	0.00	0.00	0.00	0.00	0.00
				20	0.0067	0.034	0.00	0.00	0.00	0.01	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Cameron Trading Post WWTP, Cameron, AZ NPDES: NN0021610	Surface Water	POTW (Ind.)	Surface water	365	0.0003	0.0387	0.00	0.00	0.00	0.01	0.00
				20	0.0047	0.64	0.00	0.00	0.00	0.21	0.00
Coal Grove WWTP, Coal Grove, OH NPDES: OH0104558	Surface Water	NPDES OH0029432	Surface water	365	0.0002	0.0000127	0.00	0.00	0.00	0.00	0.00
				20	0.0031	0.00019	0.00	0.00	0.00	0.00	0.00
OES: Other Commercial Uses											
Corning Hospital, Corning, NY NPDES: NY0246701	Surface Water	Surrogate NPDES NY0025721	Surface water	250	0.013	0.0271	0.00	0.00	0.00	0.01	0.00
				20	0.159	0.33	0.00	0.00	0.00	0.11	0.00
Water Street Commercial Bldg, Dayton, OH NPDES: OH0141496	Surface Water	Surrogate NPDES OH0009521	Surface water	250	0.003	0.00564	0.00	0.00	0.00	0.00	0.00
				20	0.035	0.0658	0.00	0.00	0.00	0.02	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Union Station North Wing Office Building, Denver, CO NPDES: COG315293	Surface Water	Surrogate NPDES CO0020095	Surface water	250	0.0004	0.0881	0.00	0.00	0.00	0.03	0.00
				20	0.00499	1.1	0.00	0.00	0.00	0.37	0.00
Confluence Park Apartments, Denver, CO NPDES: COG315339	Surface Water	Surrogate NPDES CO0020095	Surface water	250	0.00028	0.0617	0.00	0.00	0.00	0.02	0.00
				20	0.00354	0.77	0.00	0.00	0.00	0.26	0.00
Park Place Mixed Use Development, Annapolis, MD NPDES: MD0068861	Surface Water	Surrogate NPDES MD0052868	Still body	250	0.00027	9	0.00	0.01	0.01	3.00	0.00
				20	0.00334	110	0.06	0.12	0.14	36.67	0.01
Tree Top Inc Wenatchee Plant, Wenatchee, WA NPDES: WA0051527	Surface Water	Not assessed (below the min risk level).									
Wynkoop Denver LLCP St, Denver, CO NPDES: COG603115	Surface Water	Not assessed (below the min risk level).									

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Greer Family Llc, South Burlington, VT NPDES: VT0001376	Surface Water	Not assessed (below the min risk level).									
John Marshall III Site, Mclean, VA NPDES: VA0090093	Surface Water	Not assessed (below the min risk level).									
OES: Other Industrial Uses											
Eli Lilly And Company- Lilly Tech Ctr, Indianapolis, IN NPDES: IN0003310	Surface Water	NPDES IN0003310	Surface water	250	1.553	9.03	0.00	0.01	0.01	3.01	0.00
				20	19.41	113.09	0.06	0.12	0.14	37.70	0.01
Oxy Vinyls LP - Deer Park Pvc, Deer Park, TX NPDES: TX0007412	Surface Water	NPDES TX0007412	Surface water	250	0.148	0.49	0.00	0.00	0.00	0.16	0.00
				20	1.854	5.98	0.00	0.01	0.01	1.99	0.00
Washington Penn Plastics, Frankfort, KY NPDES: KY0097497	Surface Water	Surrogate NPDES KY0028410	Surface water	250	0.032	7.53	0.00	0.01	0.01	2.51	0.00
				20	0.399	94.12	0.05	0.10	0.12	31.37	0.01

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Natrium Plant, New Martinsville, WV NPDES: WV0004359	Surface Water	NPDES WV0004359	Surface water	250	0.022	0.00262	0.00	0.00	0.00	0.00	0.00
				20	0.274	0.0322	0.00	0.00	0.00	0.01	0.00
Leroy Quarry, Leroy, NY NPDES: NY0247189	Surface Water	Surrogate NPDES NY0030546	Surface water	250	0.019	0.71	0.00	0.00	0.00	0.24	0.00
				20	0.242	8.91	0.00	0.01	0.01	2.97	0.00
George C Marshall Space Flight Center, Huntsville, AL NPDES: AL0000221	Surface Water	Surrogate NPDES AL0025585	Surface water	250	0.01	0.2	0.00	0.00	0.00	0.07	0.00
				20	0.128	2.63	0.00	0.00	0.00	0.88	0.00
Whelan Energy Center Power Plant, Hastings, NE NPDES: NE0113506	Surface Water	NPDES NE0113506	Surface water	250	0.009	2.92	0.00	0.00	0.00	0.97	0.00
				20	0.118	38.96	0.02	0.04	0.05	12.99	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Army Cold Regions Research & Engineering Lab, Hanover, NH NPDES: NH0001619	Surface Water	Surrogate NPDES NH0100099	Surface water	250	0.0002	0.000103	0.00	0.00	0.00	0.00	0.00
				20	0.0029	0.00154	0.00	0.00	0.00	0.00	0.00
Corning - Canton Plant, Canton, NY NPDES: NY0085006	Surface Water	Surrogate NPDES NY0034762	Surface water	250	0.0002	0.00034	0.00	0.00	0.00	0.00	0.00
				20	0.0028	0.0051	0.00	0.00	0.00	0.00	0.00
Ames Rubber Corp Plant #1, Hamburg Boro, NJ NPDES: NJG000141	Surface Water	Surrogate NPDES NJ0000141	Surface water	250	0.00011	0.0149	0.00	0.00	0.00	0.00	0.00
				20	0.00133	0.18	0.00	0.00	0.00	0.06	0.00
Gorham, Providence, RI NPDES: RIG85E004	Surface Water	POTW (Ind.)	Surface water	250	0.0001	0.0129	0.00	0.00	0.00	0.00	0.00
				20	0.0012	0.13	0.00	0.00	0.00	0.04	0.00
Emerson Power Transmission, Ithaca, NY	Surface Water	Not assessed (below the min risk level).									

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
NPDES: NY0002933											
William E. Warne Power Plant, Los Angeles County, CA NPDES: CA0059188	Surface Water	Not assessed (below the min risk level).									
Raytheon Aircraft Co(Was Beech Aircraft), Boulder, CO NPDES: COG315176	Surface Water	Not assessed (below the min risk level).									
OES: OTVD (Includes releases for Closed-Loop Degreasing, Conveyorized Degreasing, Web Degreasing, and Metalworking Fluids)											
Texas Instruments, Inc., Attleboro, MA NPDES: MA0001791	Surface Water	NPDES MA0001791	Surface water	260	0.005	0.0188	0.00	0.00	0.00	0.01	0.00
				20	0.067	0.25	0.00	0.00	0.00	0.08	0.00
Accellent Inc/Collegeville Microcoax, Collegeville, PA NPDES: PA0042617	Surface Water	NPDES PA0042617	Surface water	260	0.002	0.0425	0.00	0.00	0.00	0.01	0.00
				20	0.029	0.62	0.00	0.00	0.00	0.21	0.00
Ametek Inc. U.S. Gauge Div., Sellersville, PA NPDES: PA0056014	Surface Water	Surrogate NPDES PA0020460	Surface water	260	0.001	0.0619	0.00	0.00	0.00	0.02	0.00
				20	0.011	0.68	0.00	0.00	0.00	0.23	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Atk-Allegany Ballistics Lab (Nirop), Keyser, WV NPDES: WV0020371	Surface Water	NPDES WV0020371	Surface water	260	0.0005	0.00311	0.00	0.00	0.00	0.00	0.00
				20	0.0061	0.0373	0.00	0.00	0.00	0.01	0.00
Handy & Harman Tube Co/East Norriton, Norristown, PA NPDES: PA0011436	Surface Water	Not assessed (below the min risk level).									
US Nasa Michoud Assembly Facility, New Orleans, LA NPDES: LA0052256	Surface Water	Surrogate NPDES LA0003280	Still body	260	1.96	765.63	0.38	0.83	0.97	255.21	0.05
				20	25.44	9937.5	4.97	10.80	12.61	3312.50	0.69
GM Components Holdings LLC, Lockport, NY NPDES: NY0000558	Surface Water	NPDES NY0000558	Surface water	260	0.13	10.97	0.01	0.01	0.01	3.66	0.00
				20	1.71	144.47	0.07	0.16	0.18	48.16	0.01
Akebono Elizabethtown Plant, Elizabethtown, KY NPDES: KY0089672	Surface Water	Surrogate NPDES KY0022039	Surface water	260	0.07	4.87	0.00	0.01	0.01	1.62	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.897	62.38	0.03	0.07	0.08	20.79	0.00
Delphi Harrison Thermal Systems, Dayton, OH NPDES: OH0009431	Surface Water	NPDES OH0009431	Surface water	260	0.04	0.0752	0.00	0.00	0.00	0.03	0.00
				20	0.465	0.87	0.00	0.00	0.00	0.29	0.00
Chemours Company Fc LLC, Washington, WV NPDES: WV0001279	Surface Water	NPDES WV0001279	Surface water	260	0.03	0.00301	0.00	0.00	0.00	0.00	0.00
				20	0.334	0.0335	0.00	0.00	0.00	0.01	0.00
Equistar Chemicals Lp, La Porte, TX NPDES: TX0119792	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.02	2.22	0.00	0.00	0.00	0.74	0.00
				20	0.218	24.44	0.01	0.03	0.03	8.15	0.00
GE Aviation, Lynn, MA NPDES: MA0003905	Surface Water	NPDES MA0003905	Still water	260	0.01	0.0425	0.00	0.00	0.00	0.01	0.00
				20	0.128	0.54	0.00	0.00	0.00	0.18	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Certa Vandalia LLC, Vandalia, OH NPDES: OH0122751	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.01	1.11	0.00	0.00	0.00	0.37	0.00
				20	0.107	11.89	0.01	0.01	0.02	3.96	0.00
GM Components Holdings LLC Kokomo Ops, Kokomo, IN NPDES: IN0001830	Surface Water	NPDES IN0001830	Surface water	260	0.01	0.2	0.00	0.00	0.00	0.07	0.00
				20	0.086	1.73	0.00	0.00	0.00	0.58	0.00
Amphenol Corp- Aerospace Operations, Sidney, NY NPDES: NY0003824	Surface Water	NPDES NY0003824	Surface water	260	0.01	0.0486	0.00	0.00	0.00	0.02	0.00
				20	0.082	0.4	0.00	0.00	0.00	0.13	0.00
Emerson Power Trans Corp, Maysville, KY NPDES: KY0100196	Surface Water	Surrogate NPDES KY0020257	Surface water	260	0.01	0.0004	0.00	0.00	0.00	0.00	0.00
				20	0.081	0.00522	0.00	0.00	0.00	0.00	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Olean Advanced Products, Olean, NY NPDES: NY0073547	Surface Water	Surrogate NPDES NY0027162	Surface water	260	0.01	0.0188	0.00	0.00	0.00	0.01	0.00
				20	0.068	0.13	0.00	0.00	0.00	0.04	0.00
Hollingsworth Saco Lowell, Easley, SC NPDES: SC0046396	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.00469	0.52	0.00	0.00	0.00	0.17	0.00
				20	0.061	6.78	0.00	0.01	0.01	2.26	0.00
Trelleborg YSH Incorporated Sandusky Plant, Sandusky, MI NPDES: MI0028142	Surface Water	NPDES MI0028142	Surface water	260	0.0036	1.76	0.00	0.00	0.00	0.59	0.00
				20	0.047	23.04	0.01	0.03	0.03	7.68	0.00
Timken Us Corp Honea Path, Honea Path, SC NPDES: SC0047520	Surface Water	Surrogate NPDES SC0000698	Surface water	260	0.00355	1.06	0.00	0.00	0.00	0.35	0.00
				20	0.0462	13.77	0.01	0.01	0.02	4.59	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Johnson Controls Incorporated, Wichita, KS NPDES: KS0000850	Surface Water	NPDES KS0000850	Surface water	260	0.00228	0.0548	0.00	0.00	0.00	0.02	0.00
				20	0.0296	0.72	0.00	0.00	0.00	0.24	0.00
National Railroad Passenger Corporation (Amtrak) Wilmington Maintenance Facility, Wilmington, DE NPDES: DE0050962	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.00203	0.23	0.00	0.00	0.00	0.08	0.00
				20	0.026	2.89	0.00	0.00	0.00	0.96	0.00
Electrolux Home Products (Formerly Frigidaire), Greenville, MI NPDES: MI0002135	Surface Water	NPDES MI0002135	Surface water	260	0.00201	0.0171	0.00	0.00	0.00	0.01	0.00
				20	0.026	0.22	0.00	0.00	0.00	0.07	0.00
Rex Heat Treat Lansdale Inc, Lansdale, PA NPDES: PA0052965	Surface Water	Surrogate NPDES PA0026182	Surface water	260	0.00194	0.0523	0.00	0.00	0.00	0.02	0.00
				20	0.025	0.67	0.00	0.00	0.00	0.22	0.00
Carrier Corporation, Syracuse, NY NPDES: NY0001163	Surface Water	NPDES NY0001163	Still water	260	0.00177	0.22	0.00	0.00	0.00	0.07	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.023	2.84	0.00	0.00	0.00	0.95	0.00
Cascade Corp (0812100207), Springfield, OH NPDES: OH0085715	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.00117	0.13	0.00	0.00	0.00	0.04	0.00
				20	0.015	1.67	0.00	0.00	0.00	0.56	0.00
USAF-Wurtsmith Afb, Oscoda, MI NPDES: MI0042285	Surface Water	Surrogate NPDES MI0028282	Surface water	260	0.00115	0.000753	0.00	0.00	0.00	0.00	0.00
				20	0.015	0.00983	0.00	0.00	0.00	0.00	0.00
AAR Mobility Systems, Cadillac, MI NPDES: MI0002640	Surface Water	Surrogate NPDES MI0020257	Surface water	260	0.00112	0.00916	0.00	0.00	0.00	0.00	0.00
				20	0.014	0.11	0.00	0.00	0.00	0.04	0.00
Eaton Mdh Company Inc, Kearney, NE NPDES: NE0114405	Surface Water	Surrogate NPDES NE0052647	Still water	260	0.00107	0.13	0.00	0.00	0.00	0.04	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.014	1.69	0.00	0.00	0.00	0.56	0.00
Lake Region Medical, Trappe, PA NPDES: PA0042617	Surface Water	NPDES PA0042617	Surface water	260	0.0005	0.0106	0.00	0.00	0.00	0.00	0.00
				20	0.007	0.15	0.00	0.00	0.00	0.05	0.00
Motor Components L L C, Elmira, NY NPDES: NY0004081	Surface Water	NPDES NY0004081	Surface water	260	0.00096	0.0618	0.00	0.00	0.00	0.02	0.00
				20	0.0125	0.83	0.00	0.00	0.00	0.28	0.00
Salem Tube Mfg, Greenville, PA NPDES: PA0221244	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000897	0.0997	0.00	0.00	0.00	0.03	0.00
				20	0.012	1.33	0.00	0.00	0.00	0.44	0.00
GE (Greenville) Gas Turbines LLC, Greenville, SC NPDES: SC0003484	Surface Water	NPDES SC0003484	Surface water	260	0.000806	0.0821	0.00	0.00	0.00	0.03	0.00
				20	0.01	1.02	0.00	0.00	0.00	0.34	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Parker Hannifin Corporation, Waverly, OH NPDES: OH0104132	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000747	0.083	0.00	0.00	0.00	0.03	0.00
				20	0.01	1.11	0.00	0.00	0.00	0.37	0.00
Mahle Engine Components Usa Inc, Muskegon, MI NPDES: MI0004057	Surface Water	NPDES MI0004057	Surface water	260	0.000742	0.0336	0.00	0.00	0.00	0.01	0.00
				20	0.01	0.45	0.00	0.00	0.00	0.15	0.00
General Electric Company - Waynesboro, Waynesboro, VA NPDES: VA0002402	Surface Water	NPDES VA0002402	Surface water	260	0.000733	0.00705	0.00	0.00	0.00	0.00	0.00
				20	0.01	0.0962	0.00	0.00	0.00	0.03	0.00
Globe Engineering Co Inc, Wichita, KS NPDES: KS0086703	Surface Water	Surrogate NPDES KS0043036	Surface water	260	0.00173	0.00853	0.00	0.00	0.00	0.00	0.00
				20	0.023	0.11	0.00	0.00	0.00	0.04	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Gayston Corp, Dayton, OH NPDES: OH0127043	Surface Water	Surrogate NPDES OH0024881	Surface water	260	0.000643	0.00121	0.00	0.00	0.00	0.00	0.00
				20	0.008	0.015	0.00	0.00	0.00	0.01	0.00
Styrolution America LLC, Channahon, IL NPDES: IL0001619	Surface Water	NPDES IL0001619	Surface water	260	0.000637	0.000221	0.00	0.00	0.00	0.00	0.00
				20	0.008	0.00278	0.00	0.00	0.00	0.00	0.00
Remington Arms Co Inc, Ilion, NY NPDES: NY0005282	Surface Water	NPDES NY0005282	Surface water	260	0.000612	0.000799	0.00	0.00	0.00	0.00	0.00
				20	0.008	0.0104	0.00	0.00	0.00	0.00	0.00
United Technologies Corporation, Pratt And Whitney Division, East Hartford, CT NPDES: CT0001376	Surface Water	NPDES CT0001376	Surface water	260	0.00048	0.0000822	0.00	0.00	0.00	0.00	0.00
				20	0.006	0.00103	0.00	0.00	0.00	0.00	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Atk-Allegany Ballistics Lab (Nirop), Keyser, WV NPDES: WV0020371	Surface Water	NPDES WV0020371	Surface water	260	0.00047	0.00292	0.00	0.00	0.00	0.00	0.00
				20	0.006	0.0373	0.00	0.00	0.00	0.01	0.00
Sperry & Rice Manufacturing Co LLC, Brookville, IN NPDES: IN0001473	Surface Water	NPDES IN0001473	Surface water	260	0.000328	0.00569	0.00	0.00	0.00	0.00	0.00
				20	0.004	0.0694	0.00	0.00	0.00	0.02	0.00
Owt Industries, Pickens, SC NPDES: SC0026492	Surface Water	NPDES SC0026492	Surface water	260	0.000314	0.00213	0.00	0.00	0.00	0.00	0.00
				20	0.004	0.0272	0.00	0.00	0.00	0.01	0.00
Boler Company, Hillsdale, MI NPDES: MI0053651	Surface Water	Surrogate NPDES MI0022136	Surface water	260	0.000269	0.0204	0.00	0.00	0.00	0.01	0.00
				20	0.003	0.23	0.00	0.00	0.00	0.08	0.00
Mccanna Inc., Carpentersville, IL NPDES: IL0071340	Surface Water	Surrogate NPDES IL0027944	Surface water	260	0.000268	0.000911	0.00	0.00	0.00	0.00	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
				20	0.003	0.0102	0.00	0.00	0.00	0.00	0.00
Cutler Hammer, Horseheads, NY NPDES: NY0246174	Surface Water	Surrogate NPDES NY0004081	Surface water	260	0.000238	0.0153	0.00	0.00	0.00	0.01	0.00
				20	0.003	0.19	0.00	0.00	0.00	0.06	0.00
US Air Force Offutt Afb Ne, Offutt A F B, NE NPDES: NE0121789	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000159	0.0177	0.00	0.00	0.00	0.01	0.00
				20	0.002	0.22	0.00	0.00	0.00	0.07	0.00
Troxel Company, Moscow, TN NPDES: TN0000451	Surface Water	NPDES TN0000451	Surface water	260	0.000134	0.000741	0.00	0.00	0.00	0.00	0.00
				20	0.002	0.0111	0.00	0.00	0.00	0.00	0.00
Austin Tube Prod, Baldwin, MI NPDES: MI0054224	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.000114	0.0127	0.00	0.00	0.00	0.00	0.00
				20	0.001	0.11	0.00	0.00	0.00	0.04	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
LS Starrett Precision Tools, Athol, MA NPDES: MA0001350	Surface Water	NPDES MA0001350	Surface water	260	0.000102	0.00153	0.00	0.00	0.00	0.00	0.00
				20	0.001	0.015	0.00	0.00	0.00	0.01	0.00
Avx Corp, Raleigh, NC NPDES: NC0089494	Surface Water	Primary Metal Forming Manuf.	Surface water	260	0.0000883	0.00981	0.00	0.00	0.00	0.00	0.00
				20	0.001	0.11	0.00	0.00	0.00	0.04	0.00
Indian Head Division, Naval Surface Warfare Center, Indian Head, MD NPDES: MD0003158	Surface Water	Not assessed (below the min risk level).									
General Dynamics Ordnance Tactical Systems, Red Lion, PA NPDES: PA0043672	Surface Water	Not assessed (below the min risk level).									
Trane Residential Solutions - Fort Smith, Fort Smith, AR NPDES: AR0052477	Surface Water	Not assessed (below the min risk level).									
Lexmark International Inc., Lexington, KY NPDES: KY0097624	Surface Water	Not assessed (below the min risk level).									

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Alliant Techsystems Operations LLC, Elkton, MD NPDES: MD0000078	Surface Water	Not assessed (below the min risk level).									
Daikin Applied America, Inc. (Formally Mcquay International), Scottsboro, AL NPDES: AL0069701	Surface Water	Not assessed (below the min risk level).									
Beechcraft Corporation, Wichita, KS NPDES: KS0000183	Surface Water	Not assessed (below the min risk level).									
Federal-Mogul Corp, Scottsville, KY NPDES: KY0106585	Surface Water	Not assessed (below the min risk level).									
Cessna Aircraft Co (Pawnee Facility), Wichita, KS NPDES: KS0000647	Surface Water	Not assessed (below the min risk level).									
N.G.I, Parkersburg, WV NPDES: WV0003204	Surface Water	Not assessed (below the min risk level).									
Hyster-Yale Group, Inc, Sulligent, AL NPDES: AL0069787	Surface Water	Not assessed (below the min risk level).									
Hitachi Electronic Devices (Usa), Inc., Greenville, SC NPDES: SC0048411	Surface Water	Not assessed (below the min risk level).									

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
OES: Process Solvent Recycling and Worker Handling of Wastes											
Clean Water Of New York Inc, Staten Island, NY NPDES: NY0200484	Surface Water	Surrogate NPDES NJ0000019	Still body	250	0.004	11.76	0.01	0.01	0.01	3.92	0.00
				20	0.047	138.24	0.07	0.15	0.18	46.08	0.01
Reserve Environmental Services, Ashtabula, OH NPDES: OH0098540	Surface Water						0.00	0.00	0.00	0.00	0.00
Veolia Es Technical Solutions LLC, Middlesex, NJ NPDES: NJ0020141	Off-site Waste-water Treatment	Receiving Facility: Middlesex Cnty UA; NPDES NJ0020141	Still body	250	24.1	2.85	0.00	0.00	0.00	0.95	0.00
				20	301.78	35.72	0.02	0.04	0.05	11.91	0.00
Clean Harbors Deer Park LLC, La Porte, TX NPDES: TX0005941	Off-site Waste-water Treatment	POTW (Ind.)	Surface water	250	0.35	8.57	0.00	0.01	0.01	2.86	0.00
				20	4.36	106.75	0.05	0.12	0.14	35.58	0.01

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Clean Harbors El Dorado LLC, El Dorado, AR NPDES: AR0037800	Off-site Waste-water Treatment	POTW (Ind.)	Surface water	250	0.04	0.98	0.00	0.00	0.00	0.33	0.00
				20	0.455	11.26	0.01	0.01	0.01	3.75	0.00
OES: Processing as a Reactant											
440 unknown sites NPDES: Not applicable	Off-site Waste-water Treatment	Organic Chemicals Manufacture	Surface water	350	0.005	0.18	0.00	0.00	0.00	0.06	0.00
				20	0.089	3.13	0.00	0.00	0.00	1.04	0.00
	Surface Water	Organic Chemicals Manufacture	Surface water	350	0.005	0.92	0.00	0.00	0.00	0.31	0.00
				20	0.089	16.45	0.01	0.02	0.02	5.48	0.00
Arkema Inc. Calvert City, KY NPDES: KY0003603	Surface Water	NPDES KY0003603	Surface water	350	0.017	0.000737	0.00	0.00	0.00	0.00	0.00
				20	0.295	0.128	0.00	0.00	0.00	0.04	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
US DOE Paducah Site, Kevil, KY NPDES: KY0102083	Surface Water	Not assessed (below the min risk level).									
GNF-A Wilmington-Castle Hayne, Wilmington NC NPDES: NC0001228	Surface Water	Not assessed (below the min risk level).									
Solvay - Houston Plant, Houston, TX NPDES: TX0007072	Surface Water	NPDES TX0007072	Surface water	350	0.024	4.44	0.00	0.00	0.01	1.48	0.00
				20	0.414	75.93	0.04	0.08	0.10	25.31	0.01
Honeywell International - Geismar Complex, Geismar, LA NPDES: LA0006181	Surface Water	NPDES LA0006181	Surface water	350	0.0128	0.0000518	0.00	0.00	0.00	0.00	0.00
				20	0.224	0.000907	0.00	0.00	0.00	0.00	0.00
Praxair Technology Center, Tonawanda, NY NPDES: NY0000281	Surface Water	NPDES NY0000281	Still body	350	0.00169	169	0.08	0.18	0.21	56.33	0.01
				20	0.03	3000	1.50	3.26	3.81	1000.00	0.21

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
US DOE Paducah Site, Kevil, KY NPDES: KY0102083	Surface Water	Not assessed (below the min risk level).									
GNF-A Wilmington-Castle Hayne, Wilmington NC NPDES: NC0001228	Surface Water	Not assessed (below the min risk level).									
Akzo Nobel Surface Chemistry LLC, Morris, IL NPDES: IL0026069	Surface Water	NPDES IL0026069	Surface water	350	0.000329	0.000688	0.00	0.00	0.00	0.00	0.00
				20	0.006	0.0125	0.00	0.00	0.00	0.00	0.00
Solutia Nitro Site, Nitro, WV NPDES: WV0116181	Surface Water	Surrogate NPDES WV0023229	Surface water	350	0.000318	0.0000941	0.00	0.00	0.00	0.00	0.00
				20	0.006	0.00176	0.00	0.00	0.00	0.00	0.00
Amphenol Corporation - Columbia, Columbia, SC NPDES: SC0046264	Surface Water	Organic Chemicals Manufacture	Surface water	350	0.000202	0.037	0.00	0.00	0.00	0.01	0.00
				20	0.004	0.74	0.00	0.00	0.00	0.25	0.00
Keeshan and Bost Chemical Co., Inc.,	Surface Water	NPDES TX0072168	Still body	350	0.000095	9.5	0.00	0.01	0.01	3.17	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
Manvel, TX NPDES: TX0072168				20	0.002	200	0.10	0.22	0.25	66.67	0.01
Chemtura North and South Plants, Morgantown, WV NPDES: WV0004740	Surface Water	Not assessed (below the min risk level).									
Indorama Ventures Olefins, LLC, Sulphur, LA NPDES: LA0069850	Surface Water	Not assessed (below the min risk level).									
OES: Repackaging											
Hubbard-Hall Inc, Waterbury, CT NPDES: Unknown	Off-site Waste-water Treatment	Receiving Facility: Recycle Inc.; POTW (Ind.)	Surface water	250	1.108	27.18	0.01	0.03	0.03	9.06	0.00
				20	13.85	339.11	0.17	0.37	0.43	113.04	0.02
Oiltanking Houston Inc, Houston, TX NPDES: TX0091855	Surface Water	Surrogate NPDES TX0065943	Surface water	250	0.003	6.52	0.00	0.01	0.01	2.17	0.00
				20	0.041	89.13	0.04	0.10	0.11	29.71	0.01
St. Gabriel Terminal, Saint Gabriel, LA NPDES: LA0005487	Surface Water	NPDES LA0005487	Surface water	250	0.0055	0.0000223	0.00	0.00	0.00	0.00	0.00
				20	0.069	0.000279	0.00	0.00	0.00	0.00	0.00
Vopak Terminal Westwego Inc, Westwego, LA	Surface Water	Surrogate NPDES LA0042064	Surface water	250	0.00468	0.0000189	0.00	0.00	0.00	0.00	0.00

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
NPDES: LA0124583				20	0.058	0.000235	0.00	0.00	0.00	0.00	0.00
Research Solutions Group Inc, Pelham, AL NPDES: AL0074276	Surface Water	Not assessed (below the min risk level).									
Carlisle Engineered Products Inc, Middlefield, OH NPDES: OH0052370	Surface Water	Not assessed (below the min risk level).									
OES: Spot Cleaning and Carpet Cleaning											
Boise State University, Boise, ID NPDES: IDG911006	Surface Water	Surrogate NPDES ID0023981	Surface water	300	0.00008	0.00388	0.00	0.00	0.00	0.00	0.00
				20	0.001	0.0485	0.00	0.00	0.00	0.02	0.00
Venetian Hotel And Casino, Las Vegas, NV NPDES: NV0022888	Surface Water	Not assessed (below the min risk level).									
63,746 unknown sites NPDES: All POTW SIC	Surface Water or POTW	Not assessed (below the min risk level).									
<p>a. Facilities actively releasing trichloroethylene were identified via DMR, TRI, and CDR databases for the 2016 reporting year.</p> <p>b. Release media are either direct (release from active facility directly to surface water) or indirect (transfer of wastewater from active facility to a receiving POTW or non-POTW WWTP facility). A wastewater treatment removal rate of 81% is applied to all indirect releases, <i>i.e.</i>, volumes characterized as being transferred off-site for treatment at a water treatment facility prior to discharge to surface water.</p> <p>c. If a valid NPDES of the direct or indirect releaser was not available in EFAST, the release was modeled using either a surrogate representative facility in EFAST (based on location) or a representative generic industry sector. The name of the indirect releaser is provided, as reported in TRI.</p> <p>d. EFAST uses either the “surface water” model, for rivers and streams, or the “still water” model, for lakes, bays, and oceans.</p> <p>e. Modeling was conducted with the maximum days of release per year expected. For direct releasing facilities, a minimum of 20 days was also modeled.</p> <p>f. The daily release amount was calculated from the reported annual release amount divided by the number of release days per year.</p> <p>g. For releases discharging to lakes, bays, estuaries, and oceans, the acute scenario mixing zone water concentration was reported in place of the 7Q10 SWC.</p>											

Name, Location, and ID of Active Releaser Facility ^a	Release Media ^b	Modeled Facility or Industry Sector in EFAST ^c	EFAST Waterbody Type ^d	Days of Release ^e	Release (kg/day) ^f	7Q10 SWC (ppb) ^g	Acute Risk Quotients (using COC of 2,000 ppb)	Chronic Risk Quotients (using invertebrate COC of 920 ppb)	Chronic Risk Quotients (using fish COC of 788 ppb)	Algae Quotients (using COC of 3 ppb)	Algae Quotients (using COC of 14,400 ppb)
h. To determine the PDM days of exceedance for still bodies of water, the release days provided by the EPA Engineers should become the days of exceedance only if the predicted surface water concentration exceeds the COC. Otherwise, the days of exceedance can be assumed to be zero.											

535

536 **Appendix F WEIGHT OF SCIENTIFIC EVIDENCE FOR**
537 **CONGENITAL HEART DEFECTS**

538 **F.1 Background**

539 **F.1.1 ([Johnson et al., 2003](#)) and ([Dawson et al., 1993](#))**

540 The congenital heart defects endpoint for TCE has been widely discussed since the release of the 2011
541 IRIS Assessment ([U.S. EPA, 2011e](#)). The primary basis for this endpoint was a developmental drinking
542 water study in rats, ([Johnson et al., 2003](#)), that has been the source of extensive controversy. The study
543 administered 0 ppb, 2.5 ppb, 250 ppb, 1.5 ppm, and 1100 ppm to pregnant Sprague-Dawley rats via
544 drinking water for the entire duration of pregnancy. On the last day of pregnancy, dams were
545 euthanized, and the heart and great vessels of fetuses were examined for abnormalities. The study
546 reported statistically significant increases in variety of cardiac defects at multiple dose levels in the
547 incidence of a broad array of cardiac defects. EPA considered the constellation of observed effects in
548 totality, as opposed to any particular individual defects.

549
550 The authors reported in followup errata ([Johnson et al., 2005](#)) that the study data were derived from a 6-
551 year academic research program and consolidated data from several cohorts. Control data were
552 combined from 6 independent cohort experiments; the data from the highest two TCE doses had been
553 previously published by the laboratory ([Dawson et al., 1993](#)). Although study methods were generally
554 consistent throughout the research program, there are potential concerns of genetic drift due to the TCE
555 dose groups being administered up to 6 years apart, and the control vehicle used in the Dawson et al.,
556 1993 study was filtered tap water while distilled water was used in all subsequent study cohorts. Both
557 ([Dawson et al., 1993](#)) and ([Johnson et al., 2003](#)) were deficient in adequate reporting of methods and
558 raw scoring data; however, many of those concerns have been alleviated by subsequent communications
559 to EPA ([Johnson, 2014, 2008](#)). The positive findings reported in ([Dawson et al., 1993](#)) and ([Johnson et](#)
560 [al., 2003](#)) have not been confirmed by another laboratory, so controversy over the results remains.

561 **F.1.2 Updates to the original publications**

562 Much of the controversy surrounding the reliability of the ([Johnson et al., 2003](#)) study relates to the
563 pooling of control animals and data across several years, including the use of different vehicles (tap
564 water vs distilled water). EPA therefore compared the data from ([Johnson et al., 2003](#)) and from
565 ([Dawson et al., 1993](#)), the earlier study comprising the highest two doses of the ([Johnson et al., 2003](#))
566 study in which data were not pooled and only a single vehicle was used. Unfortunately, EPA was
567 unable to use a nested benchmark dose (BMD) model because individual pup data could not be easily
568 tracked to a particular dam, so this data is less statistically reliable. Both studies scored a “Medium” in
569 in EPA’s data quality evaluation [*Data Quality Evaluation of Human Health Hazard Studies. Docket:*
570 [EPA-HQ-OPPT-2019-0500](#)], which incorporated all available information on the two studies,
571 including subsequent errata and communications to EPA ([Johnson et al., 2014; Johnson, 2014, 2008;](#)
572 [Johnson et al., 2005](#)). While the original publications had extensive data and methodology reporting
573 issues, many of the data quality concerns from the original study were mitigated by the information
574 provided in these updates. These updates provided the following information which was lacking in the
575 initial publications:

- 576 1) Individual fetal cardiac malformation data for each litter
577 2) Individual maternal terminal body weight data
578 3) Detailed description of fetal evaluation procedures including:
579 - methods used to blind fetal examiners to treatment group

- 580 - protocol for unanimous confirmation of any observed cardiac defects by the three
- 581 principle investigators
- 582 3) Additional information on animal husbandry and randomized group assignment of dams to
- 583 study group
- 584 4) Transparency regarding experimental variables across the dates of the experiments
- 585
- 586

587 The ([Johnson et al., 2003](#)) / ([Dawson et al., 1993](#)) publications had several important limitations,
 588 however these updates also highlighted several strengths of the research. These are presented in
 589 Table_Apx F-1.

591 **Table_Apx F-1. Strengths and Limitations of ([Johnson et al., 2003](#))**

Strengths	Limitations
Positive findings required unanimous agreement among experts	Tap water was used for earlier testing; distilled water was used later
Methods, supplier, and investigators remained consistent across time	Study took place over 6 years with a few years in-between examining the highest and lowest two dose groups
Details of dissection, preservation, and examination methods were provided	Individual fetus data could not be tied to a particular dam
Dams were randomly assigned to control or treatment groups	Control animals were pooled from multiple studies that did not all occur at the same time as the treated animal studies
Fully blinded examination	Details for the dates of individual animal measurements are not available, precluding more granular analysis

592
 593 The results of ([Johnson et al., 2003](#)) have not been confirmed in any other publications. Subsequent rat
 594 studies administering TCE via oral gavage ([Fisher et al., 2001](#)) or inhalation ([Carney et al., 2006](#)) did
 595 not find any statistically significant increase in congenital heart defects. Therefore, ([Charles River](#)
 596 [Laboratories, 2019](#)) attempted to replicate the ([Johnson et al., 2003](#)) utilizing the same administration
 597 route and study design.

599 **F.2 EPA Review of the Charles River ([2019](#)) Study**

600 **F.2.1 Study Methodology and Results**

601 In a study sponsored by the Halogenated Solvents Industry Alliance (HSIA), Charles River Laboratories
 602 Ashland, LLC performed “An Oral (Drinking Water) Study of the Effects of Trichloroethylene (TCE)
 603 on Fetal Heart Development in Sprague Dawley Rats”. The study was based on general accordance with
 604 OPPTS 870.3700 and OECD Test Guideline 414 according to principles of Good Laboratory Practice
 605 with the stated purpose of replicating the findings of ([Dawson et al., 1993](#)) and ([Johnson et al., 2003](#)),
 606 which observed increased cardiac malformations in the fetuses of pregnant female Sprague Dawley rats
 607 administered TCE in drinking water.

608

609 The study utilized 6 test groups, including negative and positive controls. Retinoic acid (RA) served as a
 610 positive control and was administered daily via gavage. TCE was administered via drinking water. See
 611 details in Table_Apx F-2, which is adapted from Text Table 4 in the study.
 612

613 **Table_Apx F-2. Experimental Design of (Charles River Laboratories, 2019)**

Group	Treatment	Target Concentration	Route of Administration	Number of Females (Dams)
1	Vehicle (water)	0 ppm	Drinking Water	25
2	Retinoic Acid	3 mg/ml	Gavage	25
3	TCE	0.25 ppm	Drinking Water	25
4	TCE	1.5 ppm	Drinking Water	25
5	TCE	500 ppm	Drinking Water	25
6	TCE	1000 ppm	Drinking Water	25

614
 615 In order to reduce TCE loss due to evaporation, drinking water formulations were prepared at volumes
 616 large enough to minimize headspace and a connected nitrogen source was used to backfill headspace
 617 during dosing. Despite this effort, 24-hour loss monitoring indicated that 30% to 49% of average
 618 measured TCE concentration was lost over the course of a day.
 619

620 Interventricular septal defects (VSDs) were the only cardiac malformation observed in TCE-treated
 621 groups. Additional types of defects were observed in the positive control RA-treated group, including
 622 malformations of the aorta and arteries, small ventricle, and situs inversus (transposition of the heart and
 623 great/major vessels). Situs inversus was also observed in a single vehicle control fetus. The study
 624 authors did not observe a statistically significant increase in VSDs among TCE-treated fetuses compared
 625 to vehicle. Additionally, all VSDs observed in TCE-exposed fetuses were smaller than 1mm, in contrast
 626 with vehicle and RA-treated groups. Results are shown in Table_Apx F-3 below, which is adapted from
 627 Text Table 14 in the study, with a few small edits. The Charles River study described the statistical
 628 estimate used as “summation per group (%)”, which appears to be the sum of viable fetuses affected per
 629 litter (%) / number of litters per group”. EPA determined that while this method is appropriate, the
 630 description is unclear and would be better described as “Mean % Affected / Litter per Group”. EPA
 631 therefore replaced the descriptor “% per litter” with the above descriptor. EPA also identified that the
 632 RA-treated group actually had 41.2% affected, as opposed to 42.2% as was presented in Text Table 14
 633 of the study.
 634

635 **Table_Apx F-3. Summary of Observed Interventricular Defects**

Dosage:	0 ppm (Vehicle)	15 mg/kg-day RA	0.25 ppm TCE	1.5 ppm TCE	500 ppm TCE	1000 ppm TCE
# Affected Fetuses (Litters)	7 (5)	112 (23)	4 (4)	5 (3)	13 (8)	12 (6)
Mean % Affected / Litter per Group	2.4%	41.2% (p < 0.01)	1.4%	1.5%	3.8%	3.7%

Dosage:	0 ppm (Vehicle)	15 mg/kg-day RA	0.25 ppm TCE	1.5 ppm TCE	500 ppm TCE	1000 ppm TCE
Size of Opening (Number of Fetuses)	<1mm (6) 1mm (1)	<1mm (103) 1mm (8) >2mm (1)	<1mm (All)	<1mm (All)	<1mm (All)	<1mm (All)
Defect Location	Membranous	Membranous (111); Muscular (1)	Membranous	Membranous	Membranous	Membranous

636

637

638

639

640

641

VSDs were not statistically significantly increased in TCE-treated groups compared to vehicle control, while RA treatment resulted in a substantially increased incidence of cardiac defects. The authors additionally highlighted the fact that all identified VSDs in TCE-treated groups were smaller than 1mm. The study states that these would be expected to resolve postnatally and are therefore unlikely to be adverse.

642

F.2.2 EPA Review

643

F.2.2.1 Comparing Results Between Charles River and Johnson Studies

644

645

646

647

648

649

650

651

The Charles River study calculated observed defects differently than was done for the Dawson and Johnson studies. The calculation for mean % affected / litter per group results in different values than the “% fetuses affected” and “% litters affected” metrics used in the Dawson and Johnson studies, which simply divided the amount of affected fetuses or litters by the total (multiplied by 100 to create a percentage). For comparison, Table_Apx F-4 below presents the data from both the Johnson and Charles River studies calculated as the % fetuses and % litters affected.

Table_Apx F-4. Incidence of total heart malformations in Johnson and Charles River studies.

Dose	Johnson 2003			Charles River 2019		
	% fetuses affected	% litters affected	Source	% fetuses affected	% litters affected	Source/Notes
0 ppm	13/606 (2.2%)	9/55 (16.4%)	(Johnson et al., 2003)	8/308 (2.5%)	6/24 (25.0%)	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
2.5 ppb	0/44 (0.0%)	0/12 (0.0%)	(Johnson et al., 2003)	N/A	N/A	N/A
0.25 ppm	5/110 (4.5%)	4/9 (44.4)	(Johnson et al., 2003)	4/275 (1.4%)	4/22 (18.2%)	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
1.5 ppm	9/181 (5.0%)	5/13 (38.5%)	(Johnson et al., 2003)	5/321 (1.5%)	3/24 (12.5%)	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
500 ppm	N/A	N/A	N/A	13/330 (3.9%)	8/24 (33.3%)	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
1000 (Charles River) or 1100 (Johnson) ppm	11/105 (10.5%)	6/9 (66.7%)	(Johnson et al., 2003)	12/342 (3.5%)	6/24 (25.0%)	(Charles River Laboratories, 2019), Table 15

652
653
654
655
656
657
658
659
660
661
662
663

The Johnson study clearly shows greater incidences of cardiac defects at 0.25 ppm, 1.5 ppm, and 1100 ppm compared to the same or similar doses (1000 ppm in Charles River). Of note however, VSDs, and specifically only membranous VSDs, were the only type of heart malformation identified by the Charles River study in TCE-treated fetuses. In contrast, the Johnson study identified a broad variety of defects in exposed fetuses. The Johnson study observed VSDs at only a slightly greater incidence per fetus than by Charles River at higher doses, while (peri)membranous VSDs were observed at a similar or lower incidence than by Charles River. Additionally, Charles River observed substantially higher incidences of VSDs in the control and 0.25 ppm groups. The data comparing the incidence of VSDs only is presented in Table_Apx F-5, with the incidence of membranous VSDs displayed in parentheses.

Table_Apx F-5. Incidence of VSDs in Johnson and Charles River studies.

Dose	Johnson 2003		Charles River 2019	
	% fetuses affected (mem. only)	Source	% fetuses affected	Source/Notes
0 ppm	0.66% (0.33%)	(Johnson et al., 2003), Table 2	2.5%	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
2.5 ppb	0%	(Johnson et al., 2003), Table 2	N/A	N/A
0.25 ppm	0%	(Johnson et al., 2003), Table 2	1.4%	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
1.5 ppm	2.21% (1.66%)	(Johnson et al., 2003), Table 2	1.5%	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
500 ppm	N/A	N/A	3.9%	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86
1000 (Charles River) or 1100 (Johnson) ppm	3.81% (2.86%)	(Johnson et al., 2003), Table 2	3.5%	(Charles River Laboratories, 2019), Table 15 (soft tissue), p. 86

664

665 **F.2.2.2 Differences in Types of Malformations Observed**

666 The majority of cardiac malformations observed in the Johnson study were not VSDs (see Table 2 in
667 ([Johnson et al., 2003](#)), while the Charles River study only identified VSDs in controls and TCE-treated
668 offspring. Of note, two major categories of heart malformations identified in the Johnson study that are
669 absent from even the positive control group of the Charles River study are atrial septal defects and valve
670 defects. The Charles River study methodology appeared to be focused primarily on identification of VSDs
671 over other heart defects, which may explain the observed positive bias toward detection of VSDs in
672 vehicle control and low-dose fetuses as compared to both the Johnson study and historical control data.
673 Table_Apx F-6 compares the heart defects observed across all *in vivo* oral studies. Fisher et al. ([2001](#)), a

674 gavage study that also did not find a statistically significant association of TCE exposure with congenital
 675 cardiac defects, is also included for comparison. Of note, the (Fisher et al., 2001) study utilized the same
 676 dissection and evaluation methodology as the (Johnson et al., 2003) studies. There is substantial overlap in
 677 the many type of defects identified in the three studies, while only membranous VSDs were observed in
 678 TCE-treated animals in (Charles River Laboratories, 2019) (great blood vessel variation was identified in a
 679 few TCE-treated pups but was considered incidental by the study authors). When comparing the results
 680 from (Fisher et al., 2001) and (Charles River Laboratories, 2019), EPA acknowledges that differences in
 681 dosing method, vehicle volume, and other variables may also contribute to any observed differences.

682

683

Table_Apx F-6. Heart and Cardiovascular Defects Observed in Select Oral TCE studies

Trichloroethylene (TCE)			Retinoic Acid (RA)	
Johnson et al. (2003) ^a	Charles River (2019)	Fisher et al. (2001)	Charles River (2019)	Fisher et al. (2001)
Septal defects				
Ventricular septal defect (VSD) (perimembranous, subaortic, muscular)	Ventricular septal defect (VSD) (membranous)		Ventricular septal defect (VSD) (membranous, subaortic, muscular)	Ventricular septal defect (VSD) (membranous, aortic, muscular)
Atrial septal defect (ASD)		Atrial septal defect (ASD)		Atrial septal defect (ASD)
Valve defects				
Mitral valve defect		Mitral valve defect		Mitral valve defect
Tricuspid valve defect		Tricuspid valve defect		Tricuspid valve defect
Pulmonary valve defect				Pulmonary valve defect
Aortic valve defects (multiple)			Aortic stenosis	Aortic stenosis
Atrium, ventricle, and miscellaneous structural abnormalities				
Atrioventricular septal defect (endocardial cushion defects)		Endocardial cushion defects		
		Right ventricle enlarged		Right ventricle enlarged
		Left ventricle aneurysm dissecting	Heart ventricle, small	Left atrial hypertrophy
				Cleft, apex of heart
Great vessel structural abnormalities				
			Transposition of the great vessels	Transposition of the great vessels
			Aortic arch effects	Aortic arch effects
			Major blood vessel variation	Major blood vessel variation
Pulmonary artery hypoplasia				Pulmonary artery hypoplasia
Aortic hypoplasia				
		Innominate artery short		Innominate artery effect

Trichloroethylene (TCE)			Retinoic Acid (RA)	
Coronary artery/sinus			Stenotic carotid	Truncus dilated
Positional abnormalities of the heart and great vessels				
		Situs inversus	Situs inversus	Dextrocardia
Abnormal looping				Overriding aorta
^a Includes data from Dawson et al. (1993). Bold text indicates defects observed across multiple studies (both TCE and RA treatment). Red bold text indicates defects only observed with RA treatment across multiple studies.				

684

685 EPA's conclusion that the Charles River study insufficiently sensitive to non-VSD defects was supported
686 by the limited variety of malformations observed in the RA positive control based on a compiled literature
687 search:

- 688 1. EPA searched HERO and PubMed for studies investigating heart defects and malformations that
689 occur during prenatal exposure to all-trans retinoic acid (RA). Of the 37 studies reviewed, 12
690 studies were excluded from analysis because they were abstracts, book chapters, reviews, or
691 studies that did not expose animals to all-trans RA. Thus, EPA reviewed 25 studies and
692 compared the results of these studies to those reported by the Charles River and Johnson studies.
- 693 2. In all species examined, a total of 35 heart defects were associated with prenatal exposure to RA
694 in the identified literature.
- 695 3. The Charles River study reported 10 types of heart defects in animals exposed to RA.
- 696 4. Heart defects associated with TCE exposure partially overlap defects associated with RA
697 exposure. The Johnson study identified 10 types of cardiac defects in TCE-exposed fetuses.
698 Charles River only identified one defect (membranous VSDs) associated with TCE exposure
699 (major blood vessel variation was observed in 1-2 TCE-treated fetuses, but this effect was not
700 considered treatment-related).
- 701 5. All 35 defects associated with RA exposure were observed in rodents in the literature review. If
702 we limit the analysis to studies examining only rats, 31 of the total 35 defects were observed.
703 Only 6 of the 35 defects were noted in chickens, and 2 of the 35 were noted in zebrafish.
704 Therefore, the differences between defects captured in the Charles River study and the general
705 literature cannot be explained simply by inclusion of additional experimental species in the
706 general literature.

707

708 EPA therefore concludes that Charles River did not capture the entirety of cardiac defects that were
709 expected upon exposure to RA.

710

711 EPA searched HERO using the following keywords:

- 712 • Retinoic Acid
- 713 • Retinoic Acid + Cardiac

714 EPA also searched PubMed using the following keywords:

- 715 • retinoic acid (RA)-induced cardiac defects
- 716 • retinoic acid AND (cardiac defects OR cardiac malformations OR heart defects OR heart
717 malformations OR cardiac teratogenesis OR aorta OR ventricle OR endocardial cushion OR
718 pulmonary valve OR mitral valve OR aortic valve OR ventricular septum OR atrial septum OR
719 tricuspid valve OR aneurysm).

720

721 Table_Apx F-7 presents all of the cardiac defects found in the literature search and Table_Apx F-8
 722 provides the full list of identified studies and observed defects. Table_Apx F-9 compares the types of
 723 defects observed across the Johnson and Charles River studies with those identified in the literature
 724 search. Several defects associated with TCE exposure as well as several RA-induced defects in the
 725 Charles River study were not associated with RA exposure in the literature. Overall, the spectrum of
 726 heart defects observed upon RA exposure in the literature largely, but not entirely, overlaps with heart
 727 defects associated with TCE exposure. Of note, atrial septal defects, which were the most common type
 728 of malformation identified in the Johnson study, were identified in 5 other RA studies but not in the
 729 Charles River study, including a human study ([Siu et al., 2002](#)).

730
 731 **Table_Apx F-7. Cardiac Defects Observed in Literature**

Cardiac Defect *	Number of Studies
VSD	12
ASD	5
Tetralogy_Fallot	1
Hypoplastic_Left_Heart_Syndrome	1
Tricuspid_Atresia	1
Aortic_Valve_Stenosis	1
Pulmonary_Trunk_Stenosis	3
Right_Ventricular_Hypertrophy	2
Left_Ventricular_Hypertrophy	1
Right_Atrial_Hypertrophy	2
Left_Atrial_Hypertrophy	1
CAVC	1
Situs_Inversus	2
Dextrocardia	5
d_Transposition	12
I_Transposition	1
Cleft_Apex	1
CoA	1
ARSA	2
IAA	1
Left_Circumflex_Aorta	1
Right aortic arch defect (RAA)	4
Double_Aortic_Arch	1
Cervical_Aortic_Arch	1
Hypoplastic_Aortic_Arch	1
Truncus_Arteriosus	7
PDA	1
Innominate_Artery_Absent	1
Innominate_Artery_Short	1
Right_Carotid_Off_Aorta	1
Right_Subclavian_Artery_Absent	1
DORV	10
Endocardial_Cushion_Defect	3
Abnormal_Heart_Looping	7
Other	14

* Abbreviations defined in Table_Apx F-9

732
 733 **Table_Apx F-8. List of RA Studies Identified in the Literature Search and Observed Defects in Each**

Study	Inclusion?	Species	Strain (if applicable/reported)	Defects observed
(Siu et al., 2002)	Yes	human	N/A	ASD, right ventricular hypertrophy, right atrial hypertrophy, PDA
(Broekhuizen M et al., 1998)	Yes	chicken	White Leghorn	DORV, other (abnormal branching)
(Broekhuizen et al., 1995)	Yes	chicken	White Leghorn	VSD, d-transposition
(Ratajska et al., 2009)	Yes	mouse	Balb/c inbred and F1 cross of B57BL/6xCBA	d-transposition, DORV, other (abnormal conal vein, right ventricle hypoplasia, aortic hypoplasia, other non-specified)
(Yasui et al., 1999)	Yes	mouse	Jcl:ICR	VSD, dextrocardia, DORV, other (hypoplasia/dysplasia)
(Kim et al., 1995)	Yes	mouse	DDY	VSD, dextrocardia, d-transposition, IAA, left circumflex aorta, RAA, DORV, other (right subclavian artery)
(Kołodzińska et al., 2013)	Yes	mouse	F1 cross of C57BL/6 and CBA mouse inbred strains	VSD, tetralogy of Fallot, d-transposition, truncus arteriosus, DORV, other (noncompaction)
(Kraft et al., 1994)	Yes	rat	Sprague -Dawley described as Wistar derived	No defects observed; fetuses/conceptuses exposed <i>ex vivo</i> only
(Laborde et al., 1995)	Yes	mouse	CD-1	No cardiac defects observed
(Narematsu et al., 2015)	Yes	chicken	Not reported	d-transposition
(Ratajska et al., 2005)	Yes	mouse	CFW/LL and MIZZ	VSD, ASD, hypoplastic left heart syndrome, d-transposition, RAA, hypoplastic aortic arch, truncus arteriosus, DORV, other (dicuspid aortic valve, hypomorphic semilunar valve, great vessel spiraling)
(Taylor et al., 1980)	Yes	hamster	golden Syrian	VSD, ASD, tricuspid atresia, pulmonary trunk stenosis, d-transposition, RAA, truncus arteriosus, DORV, abnormal hear looping, other (overriding aorta complex, mitral-aortic continuity, aortic hypoplasia, left ventricular hypoplasia, univentricular heart, atrioventricularis)
(Fisher et al., 2001)	Yes	rat	Sprague-Dawley CrI:CDR (SD) BR	VSD, ASD, aortic valve stenosis, right ventricular hypertrophy, right atrial hypertrophy, left atrial hypertrophy, situs invertus, dextrocardia, d-transposition, cleft apex, ARSA, RAA, truncus arteriosus, innominate artery absent, immomina artery short, right carotid off aorta, right subclavian artery absent, other (pulmonary artery hypoplasia, right subclavian artery defect)
(Brus et al., 1995)	Yes	rat	Wistar	VSD, pulmonary trunk stenosis
(Dickman and Smith, 1996)	Yes	chicken	Not reported	Situs inversus, abnormal heart looping, other (cardia bafia, clustered heart tissue)
(Yu et al., 2003)	Yes	rat	Sprague Dawley	VSD, ASD, ARSA, CoA, double aortic arch, cervical aortic arch, truncus arteriosus, DORV
(Davis and Sadler, 1981)	Yes	mouse	ICR	VSD, d-transposition, truncus arteriosus, DORV, endocardial cushion defect

Study	Inclusion?	Species	Strain (if applicable/reported)	Defects observed
(Bouman et al., 1998)	Yes	chicken	Not reported	Abnormal heart looping
(Bouman et al., 1995)	Yes	chicken	Not reported	VSD, abnormal heart looping
(Xavier-Neto et al., 1999)	Yes	Chicken; zebrafish	Transgenic mice on FVB background	Other (hearts with marked atrial dominance)
(Nakajima et al., 1996)	Yes	mouse	ICR	Endocardial cushion defect, other (hypoplasticity of the proximal parietal and septal ridges in the outflow tract – develop from endocardial cushion)
(Lee et al., 1998)	Yes	rat	Wistar	Left ventricle hypertrophy, dextrocardia, d-transposition, l-transposition, abnormal heart looping
(Kim et al., 1999)	Yes	rat	Wistar	CAVC, dextrocardia, endocardial cushion defects, abnormal heart looping
(Ostádalová et al., 1995)	Yes	rat	Wistar	VSD, pulmonary trunk stenosis, DORV
(Haga et al., 2008)	Yes	zebrafish	Danio rerio	Abnormal heart looping, other (pericardial edema)
(Baraka et al., 2009)	No. RA not used to induce defects.	N/A	N/A	N/A
(Turton et al., 1992)	No. No effects at lower dosage and no fetuses available at higher doses.	N/A	N/A	N/A
(Miura et al., 1990)	No. Not RA, study on 13-cis-RA	N/A	N/A	N/A
(Pan and Baker, 2007)	No. Review only.	N/A	N/A	N/A
(Roberts et al., 2006)	No. No RA exposure.	N/A	N/A	N/A
(Sinning, 1998)	No. Review only.	N/A	N/A	N/A
(Smith and Dickman, 1997)	No. Review only.	N/A	N/A	N/A
(Stefanovic and Zaffran, 2017)	No. Review only.	N/A	N/A	N/A
(Pexieder et al., 1990)	No. Abstract only.	N/A	N/A	N/A
(Van Maldergem et al., 1992)	No. Exposure is to isotretinoin.	N/A	N/A	N/A
(Oku et al., 1995)	No. Abstract only.	N/A	N/A	N/A
(Iwase et al., 1998)	No. Abstract only.	N/A	N/A	N/A

Table_Apx F-9. Cardiac Defects Observed After Exposure to RA or TCE

Chemical:		TCE	TCE	RA	RA	RA
Malformation Class	Malformation Name	Charles River 2019	Johnson 2003	Charles River 2019	Other Literature (No. Studies)	Other Literature Species ¹
Atrium, Ventricle and Valve Defects	Ventricular Septal Defect (VSD) ²	√	√	√	√ (12)	C, H, M, R
Atrium, Ventricle and Valve Defects	Atrial Septal Defect (ASD)		√		√ (5)	Hu, H, R
Atrium, Ventricle and Valve Defects	Double outlet ventricle (DORV)				√ (10)	C, H, M, R
Atrium, Ventricle and Valve Defects	Tetralogy of Fallot				√ (1)	M
Atrium, Ventricle and Valve Defects	Hypoplastic Left Heart Syndrome				√ (1)	R
Atrium, Ventricle and Valve Defects	Tricuspid defects		√		√ (1)	H
Atrium, Ventricle and Valve Defects	Aortic valve defects		√ ³		√ (1)	R
Atrium, Ventricle and Valve Defects	Mitral valve defects		√			
Atrium, Ventricle and Valve Defects	Right ventricular hypertrophy				√ (2)	R
Atrium, Ventricle and Valve Defects	Left ventricular hypertrophy				√ (1)	R
Atrium, Ventricle and Valve Defects	Right atrial hypertrophy				√ (2)	R
Atrium, Ventricle and Valve Defects	Left atrial hypertrophy				√ (1)	R
Atrium, Ventricle and Valve Defects	Small ventricle			√		
Atrium, Ventricle and Valve Defects	Complete Atrioventricular Canal defect (CAVC)		√		√ (1)	R
Symmetry	Situs Inversus			√	√ (2)	C, R
Symmetry	Dextrocardia				√ (5)	M, R
Symmetry	d-Transposition of the great arteries			√	√ (12)	C, H, M, R
Symmetry	l-Transposition of the Great Arteries				√ (1)	R
Symmetry	Cleft, apex of heart				√ (1)	R
Aortic Arch Defects	Coarctation of the Aorta (CoA)			√	√ (1)	R
Aortic Arch Defects	Left aortic arch with aberrant right subclavian artery (ARSA)			√ ⁴	√ (2)	R
Aortic Arch Defects	left circumflex aorta				√ (1)	M
Aortic Arch Defects	Right aortic arch defects (RAA)		√		√ (4)	H, M, R
Aortic Arch Defects	Double aortic arch				√ (1)	R
Aortic Arch Defects	Cervical aortic arch				√ (1)	R
Aortic Arch Defects	Interruption of the aortic arch (IAA)			√	√ (1)	M

Chemical:		TCE	TCE	RA	RA	RA
Malformation Class	Malformation Name	Charles River 2019	Johnson 2003	Charles River 2019	Other Literature (No. Studies)	Other Literature Species ¹
Aortic Arch Defects	Hypoplastic aortic arch				√ (1)	R
Aortic Arch Defects	Stenotic aortic arch			√		
Other vessel defects	Pulmonary trunk stenosis				√ (3)	H, R
Other vessel defects	Truncus Arteriosus (dilated truncus)				√ (7)	H, M, R
Other vessel defects: incomplete postnatal development	Patent Ductus Arteriosus (PDA)				√ (1)	R
Other vessel defects	Innominate artery absent				√ (1)	R
Other vessel defects	Innominate artery short				√ (1)	R
Other vessel defects	Right carotid off aorta				√ (1)	R
Other vessel defects	Stenotic carotid			√		
Other vessel defects	Right subclavian artery absent				√ (1)	R
Other vessel defects	Pulmonary artery hypoplasia		√			
Other vessel defects	Coronary artery/sinus defects		√			
Other early developmental defect	Endocardial cushion defects				√ (3)	M, R
Other early developmental defect	Abnormal heart looping		√		√ (7)	C, H, R, Z
Other⁵				√ ⁷	√ (14)	C, H, M, R, Z

¹ Human (Hu), Chicken (C), Hamster, (H), Mouse (M), Rat (R), Zebrafish (Z).

² Most studies reviewed did not specify among perimembranous, muscular or subarterial VSDs, so these were included all as "VSDs" for the literature review comparison.

³ Aortic valve defects included aortic valve defect with fenestrated leaflets and aortic valve stenosis described as aortic valve defect with fused leaflets creating aortic valvular stenosis.

⁴ Chicken (C), Hamster, (H), Mouse (M), Rat (R), Zebrafish (Z).

⁴ Retroesophageal aortic arch described in Charles River study was tagged as ARSA defect.

⁵ Major blood vessel variation (right carotid and subclavian arteries arose independently from the aortic arch [no brachiocephalic trunk] or right subclavian artery coursed retroesophageal and joined the aortic arch adjacent to ductus arteriosus [no brachiocephalic trunk]) tagged to RAA defects.

⁵ If EPA was unsure of the general malformation class, the defect was categorized as "other".

⁶ "Other" defect in HSIA study (RA exposure groups) was a major blood vessel variation (an elongated brachiocephalic trunk or a missing brachiocephalic trunk due to right carotid and right subclavian arising independently from the aortic arch, or due to a retroesophageal right subclavian; or (right carotid and subclavian arteries arose independently from the aortic arch [no brachiocephalic trunk] or right subclavian artery coursed retroesophageal and joined the aortic arch adjacent to ductus arteriosus [no brachiocephalic trunk]).

737

F.2.2.3 Methodology Differences

738

There are likely several contributing factors explaining why the Charles River study did not identify atrial or valve defects. In the Johnson study, the materials and methods section described examination of the internal structure of the heart for all fetuses. The dissection methodology allows detailed examination of the atrial septum. In contrast, the Charles River study states that the fetal evaluation methods were conducted according to Stuckhardt and Poppe (1984), which does not include examination of atrial septal defects. Therefore, the methodology used by the Charles River study was likely to miss this important category of cardiac malformations. As shown in Table_Apx F-9, five other studies were identified in the literature that observed atrial septal defects following RA exposure, while none were observed in the Charles River study.

746

747

748 The Stuckhardt and Poppe method ([1984](#)) does includes visualization of the valves (the tricuspid, mitral,
749 aortic, and pulmonary valves) but the methods as described in the Johnson study and supporting
750 information are more likely to reveal valvular defects as compared to the Stuckhardt and Poppe
751 methodology. The Stuckhardt and Poppe method specifies that two cuts are made in the fresh fetal heart.
752 This allows visualization of the tricuspid valve, between the right atrium and right ventricle, the three
753 cusps of the semilunar valve of the pulmonary artery, and the interventricular septum. In comparison,
754 the Johnson study clearly specified that the fetal hearts were to be examined in situ for external defects
755 and then excised, preserved with glutaraldehyde, and dissected. The examination of the internal structure
756 of the heart for all fetuses specifically included removing tissue to expose the pulmonary, aortic,
757 tricuspid, and mitral valves. The location of the coronary ostium was noted, each valve was probed for
758 patency, and the formation of each valve leaflet was examined.

759
760 EPA believes that there is a certain amount of tissue elasticity in fresh fetal hearts that can obscure the
761 detection of valvular defects during fetal morphological evaluation. Because the Johnson study evaluated
762 the internal structure of the fetal hearts post-fixation, examination of the valvular structures would have
763 been facilitated. Additionally, valve defects may be overlooked during examination unless the technician
764 is directly focusing on evaluating the cardiac valves in all fetuses (not just those, for example, in which
765 external cardiac morphological differences, such as a collapsed ventricle, might suggest a potential valve
766 problem). No indication is given in the Charles River report whether a directed effort was made to
767 identify valvular abnormalities.

768
769 Other identified differences and uncertainties in the methodology between the two studies may or may
770 not have contributed to the differences in results. These factors could potentially make either the Johnson
771 or the Charles River data more precise. These include the following:

- 772 1. Variations in TCE loss over time. While the Charles River study made extensive efforts to
773 minimize TCE loss, the 24-hour loss monitoring indicated that average loss across all
774 measurements was actually greater than that in the Johnson study (42% vs 35%). The Johnson
775 study did not provide analytical measurements for close comparison, but it is possible that on
776 average the delivered dose was greater in the Johnson study.
- 777 2. Possible differences in criteria for fetuses selected for examination. In the Johnson study, it is not
778 explicitly stated whether all or only viable fetuses were examined. The Charles River study
779 indicates that only viable fetuses were examined. For the Charles River study, this is a moot
780 point as there were no dead fetuses in the entire study. However, this aspect of study design is
781 not documented in the Dawson or Johnson studies.
- 782 3. Randomization methods. Differences in incidences at the litter level could potentially result from
783 non-randomized groups of animals at different dose levels. Different randomization strategies
784 were used in Johnson 2003 compared to the HSIA study. Dam assignments to exposure groups
785 was randomized in Johnson 2003, whereas the HSIA study used stratified randomization. Details
786 of the stratified randomization strategy were not presented, except to indicate that the goal was to
787 achieve similar group mean body weights. Given that there were six treatment groups and many
788 racks have six cages per row, it raises the possibility that treatment group was confounded with
789 cage position, *i.e.*, Group 1 in one column, Group 2 in the next column, etc. The Dawson and
790 Johnson methods of randomization did not include consideration of, or stratification by, body
791 weight.
- 792 4. Husbandry differences. the Charles River study individually housed the pregnant females,
793 whereas the Dawson and Johnson studies group-housed the females, so several dams were
794 consuming treated drinking water from the same bottle. Thus, there would be greater precision in
795 the Charles River dose calculations.

- 796 5. Source and strain of rats. The rats used in all the studies conducted as part of the TCE research
797 program at the University of Arizona that included ([Dawson et al., 1993](#)) and ([Johnson et al.,](#)
798 [2003](#)) were Harlan Sprague-Dawley rats purchased from Harlan Laboratories Inc., Indianapolis,
799 IN. The Charles River rats were Crl:CD(SD) Sprague-Dawley rats from Charles River
800 Laboratories in Raleigh, NC. It is unknown what influence the source or strain differences might
801 have had on the response to treatment with TCE. Additional information from both groups of
802 researchers would be needed to ascertain whether the source, sub strain or genetic drift of the test
803 animals influenced the incidences of cardiac malformations.
- 804 6. Technical confirmation of diagnosis. The Charles River report did not specify whether cardiac
805 abnormalities were confirmed by other technical staff or the Study Director. There is no
806 opportunity to re-examine fetuses because the report states that all carcasses were discarded
807 following completion of the internal examination of the fetuses. In comparison, the three
808 principle authors of the Dawson and Johnson studies (P. Johnson, S. Goldberg, and B. Dawson),
809 each examined every identified fetal cardiac anomaly, and they only included findings for which
810 there was unanimous agreement on diagnosis (as described in ([Makris et al., 2016](#))). Therefore,
811 there is high confidence in the determination of observed defects in the Dawson and Johnson
812 studies. Of note, neither study was designed to confirm diagnoses of normal fetal morphology.

813 **F.2.2.4 Adversity of Small VSDs**

814 In addition to the lack of a statistically significant increase in cardiac defects, the Charles River study
815 claims that the <1mm VSDs induced by TCE are non-adverse because "...similar to humans, small
816 spontaneous interventricular septal defects in rats close postnatally and hence should not be considered
817 adverse. Based on these data, the interventricular septal defects observed in the TCE-treated groups were
818 considered to be spontaneous background occurrences and unrelated to TCE exposure." This claim is
819 confounding and internally inconsistent however, because the vast majority (92%) of VSDs observed in
820 the RA-treated positive control group were also <1mm. If VSDs <1mm are truly non-adverse, then this
821 positive control data provides additional indication that the study is insufficiently sensitive for detecting
822 adverse cardiac defects.

823
824 The Charles River study cites ([Fleeman et al., 2004](#)), which based on results of trimethadione exposure
825 concluded: "...some treatment-induced membranous VSD will close during postnatal development
826 similar to spontaneously occurring membranous VSD." The authors then state that "small, isolated VSD
827 do not seem to impact postnatal viability and growth; however, large VSD are likely to affect postnatal
828 survival." Importantly, the presence of a VSD was associated with reduced survival, so observing
829 reduced incidence of VSDs postnatally may be selecting for those pups that were less adversely affected.
830 Nonetheless, the data does demonstrate that some, but not all, VSDs are compatible with postnatal life.
831 However, as there is no information provided in this paper to characterize the size range of VSD in those
832 pups that died compared to the size of the VSD in those that survive, one cannot rule out the possibility
833 that any VSD may be a potential adverse effect of chemical exposure.

834
835 A review of the literature on spontaneous closure of VSDs ([Zhang, 2015](#)) summarized that both defect
836 size and location can influence the likelihood of postnatal closure. The author reports that studies have
837 found defects <3-6mm are more likely to close but acknowledges the controversy over the significance
838 of defect size. More significantly, the study concluded that muscular VSDs are much more likely to
839 close spontaneously than membranous VSDs (which were the only VSD type associated with TCE
840 exposure in the Charles River study). The incidence in humans of spontaneous closure in cited studies
841 examining only muscular VSDs ranges from 22% to 84%, while for studies examining only
842 membranous or perimembranous VSDs the incidence ranges from only 4% to 47%. Additionally, the
843 morphological characterization of closure of the membranous VSD seems to most commonly involve

844 the use of a leaflet of the tricuspid valve, which would be expected to impact the functional ability of
845 that heart valve. Therefore, even if a membranous VSD is able to spontaneously close, there are likely
846 functional impacts of that closer, resulting in an adverse health effect.

847

848 Overall, it is impossible to speculate whether the specific VSDs identified in these studies would have
849 closed during lactation. Congenital heart defects of any kind are considered to be an adverse medical
850 event in humans, whether they eventually close naturally or need to be surgically repaired. When
851 considering the uncertainty over the likelihood of VSD closure and the preponderance of additional
852 types of defects observed in other studies, this consideration is not relevant to the significance of this
853 endpoint.

854

F.2.2.5 Conclusions

855 In short, the methodology and positive control data indicate that the Charles River study (2019) was
856 primarily focused on ventricular septal defects (VSDs) and therefore did not sufficiently examine the
857 complete range of potential cardiac defects. The Johnson study (2003) specifically described assessment
858 of valves and observed both valve and atrial septal defects using their laboratory dissection and
859 examination methodology. In contrast, while the Stuckhardt and Poppe dissection method (1984) used by
860 the Charles River study should allow visualization of valves, the Charles River study did not report valve
861 defects in any TCE group or the RA positive control group even though many other published reports
862 have identified valve defects following administration of TCE or RA. Additionally, the Stuckhardt and
863 Poppe method (1984) does not include examination of the heart for atrial septal defects, and the Charles
864 River study did not report any atrial septal defects in either the RA positive control group or the TCE
865 groups. In fact, the Charles River study (2019) observed a similar percentage of VSDs as (Johnson et al.,
866 2003). Considering total VSDs, 3.5% of fetuses showed a VSD in Charles River vs 3.8% in Johnson at
867 the highest dose, with 1.5% in Charles River vs 2.2% in Johnson at 1.5ppm. When considering only
868 membranous VSDs (the only type observed in the Charles River study), observed incidences were
869 actually higher in Charles River at the highest dose (3.5% vs 2.86%). Meanwhile, a substantial
870 percentage of the total cardiac defects observed in (Johnson et al., 2003) were valvular or atrial.

871

872 As further indication of the potentially narrowed sensitivity of (Charles River Laboratories, 2019), the
873 defects observed from exposure to the retinoic acid (RA) positive control were also somewhat limited
874 compared to the broader RA literature (which did identify atrial septal defects). Additionally, the other
875 oral TCE study (Fisher et al., 2001), which did not identify a statistically significant increase in cardiac
876 defects following TCE administration at a high dose via gavage, identified a significant number of
877 additional defects that match those identified in (Johnson et al., 2003) and (Dawson et al., 1993)
878 (including atrial septal and valve defects). Therefore, (Charles River Laboratories, 2019) insufficiently
879 replicates the methodology of (Johnson et al., 2003), and the results do not entirely contradict the
880 conclusions of that study. Based on these considerations along with some data reporting errors, (Charles
881 River Laboratories, 2019) received a Medium in data quality evaluation, the same as (Dawson et al.,
882 1993) and (Johnson et al., 2003).

883

884 While (Charles River Laboratories, 2019) was not considered a close enough replication to (Johnson et
885 al., 2003) to sway the weight of evidence for the endpoint on it's own, EPA did consider (Charles River
886 Laboratories, 2019) to be an overall well-conducted study, and it was incorporated into the WOE
887 analysis for the cardiac defects endpoint along with all other relevant studies identified in the literature.

888

F.3 WOE Analysis for Congenital Cardiac Defects

890

F.3.1 Methodology

891

- 1) EPA identified, collected and reviewed a sampling of recent literature on systematic approaches to performing weight-of-evidence evaluation. Relevant articles were identified by simple Google searches and by tree searching references listed in these publications. References included the following:

895

a. Weed. 2005. Weight of Evidence: A Review of Concept and Methods. *Risk Anal* 25(6): 1545-1557 ([Weed, 2005](#)).

896

897

b. Gough. 2007. Weight of Evidence: A Framework for the Appraisal of the Quality and Relevance of Evidence. *Research Papers in Education* 22(2): 213-228 ([Gough, 2007](#)).

898

899

c. Rhomberg et al. 2013. A survey of frameworks for best practices in weight-of-evidence analyses. *Crit Rev Toxicol* 43(9): 753–784 ([Rhomberg et al., 2013](#)).

900

901

d. Rooney et al. 2014. Systematic Review and Evidence Integration for Literature-Based Environmental Health Science Assessments. *Env Health Perspect* 122 (7): 711-718

902

903

([Rooney et al., 2014](#)).

904

e. NTP. 2015. Handbook for Conducting a Literature-Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration ([NTP, 2015](#)).

905

906

f. EPA. 2016. Weight of Evidence in Ecological Assessment. *Risk Assessment Forum*. EPA/100/R16/001 ([U.S. EPA, 2016i](#)).

907

908

g. EPA. 2015. EDSP: Weight of Evidence Analysis of Potential Interaction with the Estrogen, Androgen or Thyroid Pathways. Chemical: Glyphosate. Office of Pesticide Programs ([U.S. EPA, 2015a](#)).

909

910

h. US Army Corps of Engineers. 2018. Weight-of-Evidence Concepts: Introduction and Application to Sediment Management ([Engineers, 2018](#)).

911

912

i. European Commission. 2018. Memorandum on weight of evidence and uncertainties. Revision 2018. Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) ([EC, 2018](#)).

913

914

915

j. EFSA. 2017. Guidance on the use of the weight of evidence approach in scientific assessments. *EFSA Journal* 15(8): 4971 (1-69) ([EFSA, 2017](#)).

916

917

k. Linkov et al. 2015. From "Weight of Evidence" to Quantitative Data Integration using Multicriteria Decision Analysis and Bayesian Methods. *Altex* 32(1): 3-8 ([Linkov et al., 2015](#)).

918

919

920

l. Smith et al. 2002. Weight of Evidence (WOE): Quantitative Estimation of Probability of Impact. Manuscript ([Smith et al., 2002](#)).

921

922

m. Bridges et al. 2017. Framework for the quantitative weight-of-evidence analysis of 'omics data for regulatory purposes. *Reg Tox Pharm* 91: S46-S60 ([Bridges et al., 2017](#)).

923

924

n. Dekant and Bridges. 2016. Assessment of reproductive and developmental effects of DINP, DnHP and DCHP using quantitative weight of evidence. *Reg Tox Pharm* 81: 397-406 ([Dekant and Bridges, 2016](#)).

925

926

927

o. Bridges and Solomon. 2016. Quantitative weight-of-evidence analysis of the persistence, bioaccumulation, toxicity, and potential for long-range transport of the cyclic volatile methyl siloxanes. *J Toxicol Environ Health Part B* 19(8): 345-379 ([Bridges and Solomon, 2016](#)).

928

929

930

p. Gangwal et al. 2012. Incorporating exposure information into the toxicological prioritization index decision support framework. *Sci Total Environ* 435-436: 316-325 ([Gangwal et al., 2012](#)).

931

932

933

934

- 935 q. Reif et al. 2013. ToxPi GUI: an interactive visualization tool for transparent integration
936 of data from diverse sources of evidence. *Bioinformatics* 29(3): 402-403 ([Reif et al.,](#)
937 [2013](#)).
- 938 r. Klimisch et al. 1997. A Systematic Approach for Evaluating the Quality of Experimental
939 Toxicological and Ecotoxicological Data. *Reg Tox Pharm* 25: 1-5 ([Klimisch et al., 1997](#)).
- 940
- 941 2) Upon review of the various weight-of-evidence approaches that have been proposed, EPA chose
942 to adopt the method presented by EPA Risk Assessment Forum ([U.S. EPA, 2016i](#)). This method
943 was originally designed for ecological assessment and offers some flexibility in its
944 recommendations, so it has been adapted as fit-for-purpose to perform the weight-of-evidence
945 analysis for TCE cardiac defects. Benefits of this method are as follows:
- 946 a. The distinguishing feature of this method is that pieces of evidence are scored not just for
947 reliability (quality) and relevance, as in most methods reviewed, but also strength of the
948 evidence. EPA concurs with ([U.S. EPA, 2016i](#)) that explicitly scoring the strength of the
949 individual pieces of evidence (*e.g.*, magnitude, dose-response, etc.) is crucial to
950 performing a weight-of-evidence assessment.
- 951 b. The scoring system presented is qualitative and uses intuitive and easily understood
952 symbols to convey both the implication of a piece of evidence (+, -, 0 for positive,
953 negative, none, or supports, weakens, neutral/ambiguous) and the weight attached to it (+,
954 ++, +++ or -, --, --- for low, medium and high). EPA believes that symbols are preferable
955 to numerical scores because their use correctly implies that they cannot be numerically
956 combined. They simply signify semi-quantitative levels of confidence, strength, and
957 directionality of the results for the different qualitative properties.
- 958 c. Assessment results are presented as weight-of evidence tables that show a visual picture
959 of the findings. The tables capture nuances in the evidence being weighed and yet remain
960 understandable. Seeing patterns in the frequencies of +, - and 0 symbols that indicate the
961 weight of evidence is easier than if words or numbers are used to score evidence.
- 962 d. The method is flexible. Although developed for use in ecological assessment, it is easily
963 adaptable to use in human health assessment and to different approaches (*e.g.*, individual
964 pieces of evidence can be assessed and weighed for a line or type of evidence based on
965 source, such as inhalation toxicity studies, or for a line of evidence for a particular
966 property (*e.g.*, temporal association or other Hill consideration).
- 967
- 968 3) For our implementation of the ([U.S. EPA, 2016i](#)) weight-of-evidence method, EPA developed an
969 Excel spreadsheet [*EPA, 2019. Data Table for Congenital Heart Defects Weight of Evidence*
970 *Analysis. Docket: EPA-HQ-OPPT-2019-0500*], as follows:
- 971 a. The pieces of evidence are studies (or distinct experiments within studies). They are
972 organized into lines of evidence based on study type: epidemiological, *in vivo* animal),
973 and mechanistic. Within each line of evidence, pieces of evidence are further organized
974 into subsets based on route of exposure (oral, inhalation, other) and test material (TCE or
975 metabolite) for toxicological studies or vertebrate class of tissue, embryo or animal
976 studied (mammalian, avian, fish) for mechanistic studies. WOE determinations are made
977 in succession, first for subsets of a line of evidence, then for the full lines of evidence,
978 and then for the overall database, each building on the assessments that came before.
- 979 b. Each piece of evidence (study) was graded in 3 areas: reliability (quality),
980 outcome/strength, and relevance. The rationale for each grade was recorded.
- 981 i. Reliability is defined in ([U.S. EPA, 2016i](#)) as inherent properties that make
982 evidence convincing. For our implementation, because each piece of evidence is

983 a study, this refers primarily to aspects of study design, execution, and
984 transparency.

- 985 1. Possible scores for reliability were 0, +, ++, or +++ for unusable, low,
986 medium and high.
- 987 2. In contrast to the study quality evaluations performed in Distiller, which
988 included >20 specific quality criteria for each study, here each study was
989 given only a single overall grade. We considered the same issues, but we
990 did not formally go through and assign grades on each one individually.
991 Instead, focus was on key attributes. Noteworthy deficiencies were
992 recorded and grades were assigned based on the number and nature of the
993 specific deficiencies identified.

994 ii. Outcome/strength is defined in ([U.S. EPA, 2016i](#)) as degree of differentiation
995 from control, reference, or randomness. This is based on study results and may be
996 influenced by magnitude, dose-response, number of related elements changed
997 (*e.g.*, consistent changes in histopathology and serum chemistry), temporal
998 concordance, etc.

- 999 1. Possible scores for outcome/strength were ---, --, -, 0, +, ++, or +++ for
1000 results ranging from strongly negative to no effect/ambiguous to strongly
1001 positive.

1002 iii. Relevance is defined in ([U.S. EPA, 2016i](#)) as degree of correspondence between
1003 the evidence and the assessment endpoint. This can be thought of as the degree of
1004 extrapolation that would be needed to use the data in question for developing a
1005 toxicity value.

- 1006 1. Possible scores for relevance were 0, +, ++, or +++ for none, low, medium
1007 and high.
- 1008 2. Maximum values based on study type were +++ for epidemiology studies,
1009 ++ for in vivo animal studies by natural route of exposure, and + for in
1010 vivo animal studies by other route of exposure and in vitro studies.
1011 Starting from these maximum scores, deductions were made for issues
1012 such as testing of TCE metabolites rather than TCE for in vivo animal
1013 studies and poorly defined exposures in epidemiology studies.

1014 iv. The grades for reliability, outcome/strength, and relevance for each piece of
1015 evidence (study) were integrated across each area (horizontally) into an overall
1016 grade for that study. In deriving the overall grade, low area scores were
1017 considered to have more weight than higher scores, as per ([U.S. EPA, 2016i](#)). In
1018 other words, if any one of the three grading areas was low, then even if other
1019 aspects of the study were rated highly, the study still contributed lower weight
1020 overall to the WOE analysis (*e.g.*, a great study with a compelling result
1021 performed using DCA rather than TCE). Based on this methodology, overall
1022 grades for each study were always in the same direction as the strength score (*i.e.*,
1023 + vs -) at a value defined by the lowest amplitude (+ vs ++ vs +++) of the three
1024 factors. Rationale for the overall grade was provided, as it was for the individual
1025 area grades.

1026 c. When integrating overall study scores from all studies within a line of evidence (or subset
1027 of a line of evidence) or across lines of evidence (vertically), overall summary scores
1028 were determined as a the best semi-quantitative representation of all overall study grades
1029 within that line of evidence, with considerations given to both the amplitude of the
1030 overall study grades along with the consistency of the strength direction across studies.

- 1031 When results were mixed, overall summary scores for a line of evidence gave greater
1032 weight to overall study grades of greater amplitude (e.g., ++ vs +). Similarly, studies with
1033 non-ambiguous results (not a strength score of 0) were considered more informative than
1034 ambiguous studies. Additionally, consistent overall study grades of lower amplitude (e.g.,
1035 all +) may have resulted in a summary score of a higher amplitude (++)). In this way,
1036 WOE determination was most influenced by studies with the strongest, clearest effects
1037 and/or lines of evidence with the most consistent results. This differs from how the
1038 individual area grades were combined into overall study grades (See Section b(iv),
1039 above), where the lowest amplitude value determined the overall weight.
- d. Evidence areas were also integrated as a mathematical average (e.g., ++ = 2, 0/- = -0.5),
1040 in order to summarize the evidence areas for all studies. In contrast with the overall
1041 summary score however, for individual evidence areas, the integrated area scores
1042 represented a true average and were not adjusted upward for consistency or in order to
1043 favor non-ambiguous results (which was specific to strength score). Of note, these are
1044 included for presentation purposes only and were not used to determine the overall
1045 summary score for a line of evidence. The overall summary scores were determined by
1046 integrating the overall grades for each study, in the manner as described in Section c.
1047 Because of these different methodologies and the fact that overall study grades are
1048 defined by the lowest amplitude evidence area, the overall summary score may differ
1049 from the integrated area scores.
1050

1051
1052 **Note:** This analysis was performed in parallel with the systematic review data evaluation of the
1053 individual studies. The WOE analysis had a greater focus on relevance to the specific endpoint while the
1054 data evaluation metrics aimed to evaluate the utility of a study for dose-response analysis. Therefore, the
1055 conclusions of the WOE analysis for individual studies occasionally differed from the results of the
1056 systematic review data evaluation. The results of both are presented together in [EPA, 2019. *Data Table*
1057 *for Congenital Heart Defects Weight of Evidence Analysis*. Docket: [EPA-HQ-OPPT-2019-0500](#)]. Of
1058 note, studies that scored Unacceptable in data quality evaluation were not considered in the WOE
1059 analysis. Their evaluation is included for reference, but their scores had no impact on the overall grades
1060 for each line of evidence or subset. Unacceptable studies are indicated by **red text** in the below tables
1061 and the supplemental data table.
1062

1063 This analysis included all relevant primary literature cited in ([Makris et al., 2016](#)), the 2014 TCE Work
1064 Plan Chemical Risk Assessment ([U.S. EPA, 2014b](#)), and any additional on-topic studies identified in the
1065 systematic review literature search ([U.S. EPA, 2017i](#)). Additionally, EPA also incorporated any newer
1066 studies published after the end date of the literature search, including an *in vitro* mechanistic study
1067 ([Harris et al., 2018](#)) and the recently completed *in vivo* drinking water study ([Charles River](#)
1068 [Laboratories, 2019](#)), comprising 45 studies in total (42 scoring Acceptable). Several studies cited in
1069 previous reviews were screened out as off-topic because the study reports did not indicate direct
1070 assessment of cardiac defects, cardiovascular effects, or any related outcomes. These studies were:
1071 ([Beliles et al., 1980](#); [Bross et al., 1983](#); [Cosby and Dukelow, 1992](#); [Dorfmueller et al., 1979](#); [Elovaara et](#)
1072 [al., 1979](#); [Narotsky and Kavlock, 1995](#); [Narotsky et al., 1995](#)). Additional studies were initially included
1073 but were determined to be not rated (NR) after thorough evaluation through the WOE criteria ([Ruckart](#)
1074 [et al., 2013](#); [Palbykin et al., 2011](#), see below). These two studies are indicated by **blue text** in the
1075 supplemental data table, however they are not included in the tables below.

1076 **F.3.2 WOE Results By Study Type**

1077 Data evaluated to assess the weight-of-evidence for congenital heart defects from exposure to TCE
1078 include studies from three lines of evidence: epidemiology studies, *in vivo* animal toxicity studies, and

1079 mechanistic studies. For this analysis, the three lines of evidence will be considered both individually
 1080 and collectively.

1081
 1082 Table_Apx F-10 shows the weight-of-evidence for the various epidemiology studies that were
 1083 considered in this review. Ruckart et al. (2013) was identified in previous reviews but was graded as
 1084 NR (not relevant) and dropped from the analysis because the study did not include cardiac defects as an
 1085 assessed endpoint. All of the other TCE studies were considered to be of (++) relevance scores because
 1086 they examined associations of TCE exposure in humans, however quantitative exposure to TCE was
 1087 assessed indirectly in all of them. One study that examined exposure to TCE degradants (Wright et al.,
 1088 2017) scored only (+) for relevance because the degradants may also have originated from a different
 1089 source. The high potential for misclassification of exposure was a limiting factor for all of these studies,
 1090 which were otherwise generally adequate ecological or case-control studies (reliability rated as + for all
 1091 studies). Of the relevant studies, four reported results suggestive of a positive association between
 1092 maternal TCE exposure and congenital cardiac defects in offspring, one reported a lack of an
 1093 association, and two reported ambiguous results. Of the three studies with a positive association,
 1094 (Goldberg et al., 1990) was rated Unacceptable in data quality evaluation and therefore did not
 1095 contribute to the WOE. The Bove reports (1996; 1995) (considered here as a single study because the
 1096 two papers contain the same data on cardiac defects) reported elevated but nonsignificant increases in
 1097 odds ratios. Yauck et al. (2004) reported a positive association between congenital heart defects and
 1098 TCE exposure only in older mothers, while younger mothers and the overall population had a null
 1099 association. The finding of a negative association in the study by (Lagakos et al., 1986) has some
 1100 ambiguity because it was based on a very small number of cases, exposure was not classified based on
 1101 TCE specifically, and there was atypical directionality of confounder effects. Gilboa et al. (2012) did not
 1102 find any positive association with TCE exposure in a large but limited study. Three studies showing
 1103 positive associations of varying strength (Brender et al., 2014; Forand et al., 2012; Wright et al., 2017)
 1104 also had some limitations but collectively provide suggestive evidence for an association between
 1105 maternal TCE exposure and cardiac defects in offspring. In evaluating all studies and giving greater
 1106 weight to studies with non-ambiguous results, the resulting overall summary score for epidemiology is
 1107 (+), indicating a positive association between TCE exposure and congenital cardiac defects.
 1108
 1109

Table_Apx F-10. Weight-of-Evidence Table for Epidemiology Studies

Evidence Area	Reliability	Strength	Relevance	Overall Grade
TCE				
(Lagakos et al., 1986)	+	0/-	++	0/-
(Bove, 1996; Bove et al., 1995)	+	0	++	0
(Yauck et al., 2004)	+	0/+	++	0/+
(Forand et al., 2012)	+	++	++	+
(Gilboa et al., 2012)	+ / ++	-	++	-
(Brender et al., 2014)	+	+	++	+
(Goldberg et al., 1990)	0	+	++	0
METABOLITES (TCA, DCA)				
(Wright et al., 2017)	++	+	+	+

Evidence Area	Reliability	Strength	Relevance	Overall Grade
Integrated Area Scores (all epidemiology)	+	0/+	++	
Summary Score (all epidemiology)				+
<p>Possible scores for reliability and relevance were 0, +, ++, or +++ for unusable, low, medium and high. Possible scores for strength and overall weight were ---, --, -, 0, +, ++, or +++, with ranges inbetween, for results ranging from strongly negative to ambiguous to strongly positive. Red text identifies studies that scored Unacceptable in data quality evaluation and a 0 for reliability. The WOE scores are provided for reference but were not incorporated into the overall score for the line of evidence.</p>				

1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147

Table_Apx F-11 shows the weight-of-evidence for the various *in vivo* animal studies that were considered in this review. The four TCE oral studies were considered of (++) relevance because they used a natural route of exposure (drinking water or gavage) in a mammalian study. Dawson et al. (1993) and the Charles River Laboratories study (2019) were rated as (++) reliability, while Fisher et al. (2001) and Johnson et al. (2003) were rated as (+) reliability. The score was downgraded for (Fisher et al., 2001) because only a single dose group was used and the negative control for TCE demonstrated a very elevated prevalence of heart and cardiovascular defects. Johnson et al. (2003) was rated as lower reliability due to the small group sizes, poor data reporting (somewhat mitigated by subsequent errata and personal communications), and the pooling of data from multiple trials into a single experiment. Increased incidence of cardiac defects were observed in pups from the (Dawson et al., 1993) and (Johnson et al., 2003) studies. The Strength scores for these studies were characterized as (++) for (Johnson et al., 2003) and (+) for (Dawson et al., 1993), influenced by the low magnitude of effect in the high dose groups and uncertainty surrounding the precision of estimated doses. The incidence of cardiac defects were not increased by TCE oral gavage in the (Fisher et al., 2001) study; however, this study used only a single dose group and the incidence of heart defects was elevated in the soybean oil controls compared to drinking water controls, therefore the strength score was (0/-). The recent study by Charles River Laboratories (2019) also did not find any statistically significant increase in developmental cardiac defects following TCE administration in drinking water, however this study appeared to be of reduced sensitivity in its ability to detect all types of cardiac defects (see Appendix F.1). It therefore also scored (0/-) for Strength. The overall summary for the TCE oral studies was characterized as ambiguous to weakly positive (0/+) due to conflicting study results, with a lean toward positive based on the ambiguity of the negative studies.

Six oral experiments using TCE metabolites (TCA or DCA) were rated as lower relevance (+), because a metabolite was administered (not TCE) and the relevance of these effects to humans likely dependent upon individual toxicokinetic variability and the administered dose. These studies were considered mostly reliable with ratings of (+++) (Smith et al., 1989) and (++) (Fisher et al., 2001; Epstein et al., 1992). Only (Johnson et al., 1998) received a lower reliability score (0/+) due to concerns about source of the test substance and sharing of bottles among animals. Both TCA and DCA were convincingly shown to produce strong dose-related cardiac defects (strength score of ++) in the (Smith et al., 1992, 1989) studies (downgraded for use of relatively high doses that produced other embryo/fetotoxic effects or even maternal effects), with weaker positive strength scores (+) in the (Johnson et al., 1998) and (Epstein et al., 1992) studies. The (Fisher et al., 2001) study (also reviewed separately for TCE administration) only showed a small, non-statistically significant increase in cardiac defects for both TCA and DCA, but only a single dose level was used. The overall summary score for the oral metabolite studies was (+).

1148 Three inhalation studies using TCE were considered relevant (natural exposure route) and reliable.
 1149 Reliability ratings were reduced for studies with a single exposure group and poor reporting (+,
 1150 ([Schwetz et al., 1975](#))) in addition to small group sizes and high negative control responses with a lack
 1151 of dose-responsiveness (0/+, ([Dorfmueller et al., 1979](#))). These studies were also reduced in relevancy
 1152 score (+) because they were general teratology studies and the focus on cardiac effects was unclear. Two
 1153 studies scored an Unacceptable in data quality and a 0 in reliability for limited reporting of study details
 1154 ([Hardin et al., 1981](#)) and use of a nonstandard exposure duration with insufficient details on exposure
 1155 method ([Healy et al., 1982](#)). These studies did not contribute to the WOE. Among acceptable inhalation
 1156 studies, the results were consistently negative, however with varying scores in the three evidence areas.
 1157 Carney et al. (2006) was the best inhalation study, scoring the maximum (+++) for reliability and
 1158 showing a strong negative response (--). Based on these results, the summary score for the inhalation
 1159 studies was (-), primarily driven by the weight of the ([Carney et al., 2006](#)) data but reduced by the
 1160 weaknesses of the other studies and the limited number of acceptable studies with non-ambiguous
 1161 results.

1163 As for other exposure routes, Dawson et al. (1990) administered TCE via intrauterine instillation in rats.
 1164 This relevance of this study was rated as lower (+) due to the unnatural exposure route and the study
 1165 reliability was low (0/+), because of sampling inadequacy, small group sizes, and poor reporting. The
 1166 strength of this study was (+) due to several factors, including the use of fetuses (not litters) as the
 1167 experimental unit, the small magnitude of the response seen in the high dose group only (which was a
 1168 very high dose considering the exposure route). The overall summary score for animal studies across all
 1169 exposure routes suggests an unclear/ambiguous relationship between TCE exposure during gestation and
 1170 the incidence of cardiac defects in offspring. This ambiguity is based on weakly positive evidence from
 1171 oral or intrauterine TCE administration, positive evidence from oral TCE metabolites, and a negative
 1172 evidence with TCE inhalation. The WOE from *in vivo* animal toxicity studies therefore does not either
 1173 support or refute the association of TCE exposure with developmental cardiac defects.

1174 **Table_Apx F-11. Weight-of-Evidence Table for *In Vivo* Animal Toxicity Studies**

Evidence Area	Reliability	Strength	Relevance	Overall Grade
ORAL				
TCE				
(Dawson et al., 1993)	++	+	++	+
(Johnson et al., 2003)	+	++	++	+
(Fisher et al., 2001)	+	0/-	++	0/-
(Charles River Laboratories, 2019)	++	0/-	++	0/-
Integrated Area Scores	+ / ++	0 / +	++	
Summary Score (TCE)				0 / +
METABOLITES (TCA, DCA)				
(Smith et al., 1989)	+++	++	+	+
(Smith et al., 1992)	+++	++	+	+
(Johnson et al., 1998)	0 / +	+	+	0 / +
(Fisher et al., 2001)	++	-	+	-

Evidence Area	Reliability	Strength	Relevance	Overall Grade
(Epstein et al., 1992)	++	+	+	+
Integrated Area Scores	++	+	+	
Summary Score (Metabolites)				+
Integrated Area Scores (all oral studies)	++	+	++	
Summary Score (all oral studies)				+
INHALATION				
TCE				
(Schwetz et al., 1975)	+	0/-	+	0/-
(Dorfmueller et al., 1979)	0/+	0/-	+	0/-
(Carney et al., 2006)	+++	--	++	--
(Hardin et al., 1981)	0	-	++	0
(Healy et al., 1982)	0	-	++	0
Integrated Area Scores (all inhalation studies)	+ / ++	-	+ / ++	
Summary Score (all inhalation studies)				-
OTHER ROUTES (Uterine Infusion)				
(Dawson et al., 1990)	0/+	+	+	0/+
Integrated Area Scores (<i>in vivo</i> - all routes)	+ / ++	0/+	+ / ++	
Summary Score (<i>in vivo</i> - all routes)				0
Possible scores for reliability and relevance were 0, +, ++, or +++, with ranges inbetween, for unusable, low, medium and high. Possible scores for strength and overall weight were ---, --, -, 0, +, ++, or +++, with ranges inbetween, for results ranging from strongly negative to ambiguous to strongly positive. Red text identifies studies that scored Unacceptable in data quality evaluation. The WOE scores are provided for reference but were not incorporated into the overall score for the line of evidence.				

1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189

Mechanistic studies that inform the weight-of-evidence for developmental heart defects include evaluations of cardiac structure and function in chick and rodent embryos and mode-of-action or key event data focused on processes and pathways that contribute to the observed valvulo-septal defects (e.g., altered calcium flux, inhibition of stem cell differentiation and endothelial cell proliferation) as well as altered expression of oxidative metabolism enzymes. A mechanistic study from Palbykin et al. (2011) was graded as not relevant and was dropped from the analysis because it merely examined molecular mechanisms underlying the results observed in (Caldwell et al., 2008) without contributing any additional WOE to the endpoint. The remaining mechanistic studies in mammalian cells/tissues, chick embryos and zebrafish embryos were generally rated as lower relevance in comparison to human studies and *in vivo* animal studies using a natural route of administration except for studies on *ex vivo* whole rat embryos or *in vivo* data from rodents or humans, which were assigned a relevance score of (+/++). All other studies were rated as (+) relevance.

1190 Mechanistic studies in mammalian systems included an occupational worker study ([Green et al., 2004](#)),
1191 *in vivo* rat studies ([Collier et al., 2003](#); [Dow and Green, 2000](#)), studies using rat and mouse whole
1192 embryo cultures ([Hunter et al., 1996](#); [Saillenfait et al., 1995](#)) and *in vitro* studies using cell lines ([Jiang et](#)
1193 [al., 2015](#); [Caldwell et al., 2008](#); [Selmin et al., 2008](#); [Ou et al., 2003](#)). Ou et al. (2003) and Jiang et al.
1194 (2015) were rated as highly reliable (+++) because they were well-designed and well-conducted studies
1195 with a full reporting of the results. Most of the remaining mammalian studies were rated as (++) for
1196 reliability, because there were minor deficiencies noted in study design, performance or reporting. Dow
1197 and Green (2000) was rated as low (0/+) for reliability, with flaws including pooling of experiments,
1198 poor data reporting, and insufficient justification of dose selection. In mammalian systems, higher
1199 strength (++) was ascribed to studies that demonstrated structural changes in the embryonic heart
1200 ([Hunter et al., 1996](#)), suppression of endothelial cell proliferation in cell culture ([Ou et al., 2003](#)), and
1201 inhibition of cardiac differentiation from embryonic stem cells ([Jiang et al., 2015](#)). Studies that
1202 demonstrated precursor events that contribute to altered cardiac development (*i.e.*, changes in gene
1203 expression, altered calcium flux, folate deficiency) were rated as weakly positive (+) for strength. These
1204 included changes in gene expression relating to cardiac development and calcium flux ([Jiang et al.,](#)
1205 [2015](#); [Caldwell et al., 2008](#); [Selmin et al., 2008](#); [Collier et al., 2003](#)) and *in vivo* folate deficiency ([Green](#)
1206 [et al., 2004](#); [Dow and Green, 2000](#)) (which has been associated with congenital heart defects in humans
1207 ([Mao et al., 2017](#))). Saillenfait et al. (1995) did not observe morphological cardiac changes in whole rat
1208 embryos exposed to TCE in culture, although only morphological features were examined and the
1209 results were not explicitly discussed in the text. This study was rated as moderately negative (-/-) for
1210 strength.

1211
1212 With the exception of the Saillenfait study (which did not describe its procedure for evaluation of
1213 malformations in whole rat embryos), the other mammalian mechanistic studies all reported positive
1214 results. Several of these studies demonstrated a clear dose-response, although in others the results were
1215 less clear (*e.g.*, suggestive of a biphasic dose-response, with change at the lower doses but not the higher
1216 doses, see discussion in Section 3.2.4.1.6). The overall summary score for mammalian mechanistic
1217 studies was (+).

1218
1219 The chick embryo is a valid model system for studying embryonic development, and in particular,
1220 cardiac development. Eight studies investigated development of cardiac defects and associated effects
1221 in chick embryos exposed to TCE and metabolites. These were all generally well-designed, conducted
1222 and reported. All chick embryo studies received a (++) rating for reliability except for ([Loeber et al.,](#)
1223 [1988](#)), which was downgraded slightly to (+/++) due to missing reporting details and a potentially
1224 insensitive evaluation procedure. Two studies reported significant increases in incidences of a variety of
1225 cardiac defects ([Rufer et al., 2010](#); [Loeber et al., 1988](#)), resulting in a strength rating of (++) . The
1226 remaining studies showed various mechanistic changes thought to be involved in cardiac development
1227 or function and scored less positive for strength, (+). The only study that did not produce a clear
1228 positive result featured an earlier exposure window than the others and obtained ambiguous results with
1229 mixed results on endocardioyte proliferation and no changes in cardiac output was rated as (0) for
1230 strength ([Drake et al., 2006b](#)). The overall summary score for chick embryo studies was (++) based on
1231 the relatively large number of studies demonstrating consistently positive effects.

1232
1233 The zebrafish embryo is also a valid model for evaluating cardiac development. Two of the three
1234 zebrafish embryo studies were well designed and well documented with few notable limitations (rated as
1235 highly reliable, +++). The reliability rating for ([Williams et al., 2006](#)) was reduced to (++) due to the use
1236 of a single exposure level. All three studies gave positive results indicating the potential for TCE (or its
1237 metabolite DCA) to effect cardiac development in zebrafish. The study by Wirbisky et al. (2016) was

1238 the most comprehensive study of the three (rated as +++ for strength), identifying multiple dose-
 1239 responsive cardiovascular effects as well as associated gene changes. The other two studies received a
 1240 (++) for strength because of observed severe changes in heart rate but at concentrations associated with
 1241 other toxicities ([Hassoun et al., 2005](#)) or because only a single, elevated dose was used ([Williams et al.,
 1242 2006](#)). The overall summary score for zebrafish embryo studies was (+). The overall summary score for
 1243 mechanistic studies across all species and study designs was (+/+++), with the overall score increased due
 1244 to consistent positive outcomes observed in all study types. The WOE from mechanistic studies
 1245 therefore provides stronger positive evidence of an association between TCE exposure and congenital
 1246 cardiac defects.

1247
 1248 **Table_Apx F-12. Weight-of-Evidence Table for Mechanistic Studies**

Evidence Area	Reliability	Strength	Relevance	Overall Grade
MAMMALIAN CELLS/TISSUE				
TCE				
(Saillenfait et al., 1995)	++	-/--	+/+++	-/--
(Collier et al., 2003)	++	+	+	+
(Selmin et al., 2008)	++	+	+	+
(Caldwell et al., 2008)	++	+	+	+
(Ou et al., 2003)	+++	++	+	+
(Jiang et al., 2015)	+++	++	+	+
(Dow and Green, 2000)	0/+	+	+/+++	0/+
(Green et al., 2004)	++	+	+/+++	+
METABOLITES (TCA, DCA, Trichloroethanol, Chloral)				
(Saillenfait et al., 1995)	++	-/--	+/+++	-/--
(Collier et al., 2003)	++	+	+/+++	+
(Hunter et al., 1996)	++	++	+/+++	+
(Selmin et al., 2008)	++	+	+	+
(Dow and Green, 2000)	++	+	+	+
Integrated Area Scores	++	+	+	
Summary Score (all mammalian tissue studies)				+
CHICK EMBRYO				
TCE				
(Loeber et al., 1988)	+/+++	++	+	+
(Boyer et al., 2000)	++	+	+	+
(Mishima et al., 2006)	++	+	+	+
(Drake et al., 2006a)	++	+	+	+
(Drake et al., 2006b)	++	0	+	0

Evidence Area	Reliability	Strength	Relevance	Overall Grade
(Rufer et al., 2010)	++	++	+	+
(Makwana et al., 2010)	++	+	+	+
(Makwana et al., 2013)	++	+	+	+
METABOLITES (TCA)				
(Harris et al., 2018)	++	+	+	+
(Drake et al., 2006a)	++	+	+	+
(Drake et al., 2006b)	++	0	+	0
Integrated Area Scores	++	+	+	
Summary Score (all chick studies)				+ / ++
ZEBRAFISH EMBRYO				
TCE				
(Wirbisky et al., 2016)	+++	+++	+	+
METABOLITES (DCA)				
(Hassoun et al., 2005)	+++	++	+	+
(Williams et al., 2006)	++	++	+	+
Integrated Area Scores	+++	++ / +++	+	
Summary Score (all zebrafish studies)				+
Integrated Area Scores (all mechanistic studies)	+++	+ / ++	+	
Summary Score (all mechanistic studies)				+ / ++
Possible scores for reliability and relevance were 0, +, ++, or +++, with ranges inbetween, for unusable, low, medium and high. Possible scores for strength and overall weight were ---, --, -, 0, +, ++, or +++, with ranges inbetween, for results ranging from strongly negative to ambiguous to strongly positive.				

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

In summary, the database contains a large and diverse set of studies pertinent to assessing congenital heart defects from TCE exposure (overall relevance was rated as ++). Well-designed, conducted and reported studies were located for all categories, although the epidemiology studies were limited to ecological or case-control study designs with potential for misclassification of exposure and many of the *in vivo* animal studies contained at least one major limitation (overall reliability rating of + / ++). The integrated strength area score was (+), indicating a suggestive positive association of TCE with congenital cardiac defects. The epidemiology studies as a group provide suggestive evidence for an effect of TCE on cardiac defects in humans (summary score of +). Even though there are some uncertainties associated with the relevant epidemiological literature, the observation of a positive association between TCE exposure and CHDs in multiple exposed human populations increases the plausibility of the positive results from other evidence areas. Oral *in vivo* studies provided ambiguous to weakly positive (0 / +) results for TCE itself, but positive results for its TCA and DCA metabolites (+), while inhalation studies (which may be most relevant to the majority of human exposure scenarios) contributed negative evidence (-). Mechanistic studies provided solid, consistent supporting information for effects of TCE and metabolites on cardiac development and precursor effects (summary score of

1265 +/++) despite lack of support for any particular adverse outcome pathway (AOP). Overall, the database
 1266 is both reliable and relevant and provides positive overall evidence that TCE may produce cardiac
 1267 defects in humans (based on positive evidence from epidemiology studies, ambiguous evidence from
 1268 animal toxicity studies, and stronger positive evidence from mechanistic studies).

1269 **Table_Apx F-13. Overall Weight-of-Evidence Table and Summary Scores**

Evidence Area	Reliability	Strength	Relevance	Summary Score
Epidemiology studies	+	+	++	+
<i>In vivo</i> animal toxicity studies	+ / ++	0 / +	+ / ++	0
Mechanistic studies	+++	+ / ++	+	+ / ++
Integrated Area Scores	++	+	++	+

Possible scores for reliability and relevance were 0, +, ++, or +++, with ranges inbetween, for unusable, low, medium and high. Possible scores for strength and overall weight were ---, --, -, 0, +, ++, or +++, with ranges inbetween, for results ranging from strongly negative to ambiguous to strongly positive.

1271

1272 **F.3.3 Mode of Action Discussion**

1273 A number of studies have been conducted to elucidate the mode of action for TCE-related cardiac
 1274 teratogenicity. During early cardiac morphogenesis, outflow tract and atrioventricular endothelial cells
 1275 differentiate into mesenchymal cells. These mesenchymal cells have characteristics of smooth muscle-
 1276 like myofibroblasts and form endocardial cushion tissue, which is the primordia of septa and valves in
 1277 the adult heart. Many of the cardiac defects observed in humans and laboratory species involved septal
 1278 and valvular structures. Thus, a major research area has focused on the disruptions in cardiac valve
 1279 formation in avian *in ovo* and *in vitro* studies following TCE treatment. These mechanistic studies
 1280 have revealed TCE's ability to alter the endothelial cushion development, which could be a possible
 1281 mode of action underlying the cardiac defects involving septal and valvular morphogenesis in rodents
 1282 and chickens. Other modes of actions may also be involved in the induction of cardiac malformation
 1283 following TCE exposure. For example, studies have reported TCE-related alterations in cellular Ca²⁺
 1284 fluxes during cardiac development ([Caldwell et al., 2008](#); [Selmin et al., 2008](#); [Collier et al., 2003](#)).
 1285 Other studies have demonstrated structural changes in the embryonic heart ([Hunter et al., 1996](#)),
 1286 suppression of endothelial cell proliferation in cell culture ([Ou et al., 2003](#)), and inhibition of cardiac
 1287 differentiation from embryonic stem cells ([Jiang et al., 2015](#)). TCE exposure in both in rats ([Dow and](#)
 1288 [Green, 2000](#)) and humans ([Green et al., 2004](#)) is also associated with folate deficiency, a known
 1289 susceptibility factor for CHDs ([Mao et al., 2017](#)).

1290

1291 Early stages of cardiac development are quite similar across various species ([Makris et al., 2016](#)), and
 1292 these mechanistic data provide support to the plausibility of TCE-related cardiac effects in humans
 1293 ([U.S. EPA, 2011e](#)). Teratogens may function through a multitude of pathways, often resulting in a
 1294 constellation of effects. Therefore, evidence of a single dominant MOA is not required in order for the
 1295 data to support a plausible mechanism of TCE-induced congenital heart defects.

1296

1297 Several *in vitro* studies have observed non-monotonic dose responses in gene activation and other
 1298 molecular changes following TCE exposure at varying concentrations ([Palbykin et al., 2011](#); [Makwana](#)
 1299 [et al., 2010](#)). Specifically, TCE exposure induced expression of oxidative stress genes ([Makwana et al.,](#)

1300 [2010](#)) and increased DNA hypermethylation of a calcium-ATP pump promoter in developing cardiac
1301 tissue ([Palbykin et al., 2011](#)) only at lower and not higher doses, resulting in multimodal calcium
1302 responses ([Caldwell et al., 2008](#)). TCE also increased significantly increased gene expression of the
1303 oxidative metabolism enzyme CYP2H1 specifically in cardiac tissue only at the lower dose (([Makwana](#)
1304 [et al., 2013](#))). In ([Harris et al., 2018](#)), expression of genes involved in cardiac development and
1305 metabolism were either reduced (low dose) or increased (high dose), depending on the administered
1306 concentration. These results may explain the non-monotonic polynomial dose-response observed in
1307 ([Johnson et al., 2003](#)), whereby toxicological outcomes present at different doses equating to either
1308 inhibition or activation of particular gene expression ([Harris et al., 2018](#)). This differential gene
1309 expression would in turn lead to dose-specific downstream metabolic and phenotypic effects.

1310

Appendix G CONSIDERATIONS FOR BMD MODELING AND APPLICATION OF UNCERTAINTY FACTORS

A set of dose-response models were applied to empirically model the dose-response relationship in the range of the observed data. The models in EPA’s Benchmark Dose Software were applied. Consistent with EPA’s *Benchmark Dose Technical Guidance Document* (U.S. EPA, 2012a), the benchmark dose (BMD) and 95% lower confidence limit on the BMD (BMDL) were estimated using a benchmark response (BMR) to represent a minimal, biologically significant level of change, when possible. The BMR is represented by a specified percentage change, or relative deviation (RD), for continuous data. The BMR for dichotomous data is represented by a specified incidence, or extra risk (ER). In the absence of information regarding the level of change that was considered biologically significant, a BMR of 1 standard deviation (SD) from the control mean for continuous data or a BMR of 10% ER for dichotomous data were used to estimate the BMD and BMDL, and to facilitate a consistent basis of comparison across endpoints, studies, and assessments. According to (U.S. EPA, 2012a), smaller BMRs can be used to account for more severe (or “frank”) effects, and standard EPA practice applies a BMR of 1-5% for developmental and mortality endpoints. Where modeling was feasible, the estimated BMDLs were used as points of departure (PODs). Further details, including the modeling output and graphical results for the model selected for each endpoint, can be found in the 2011 EPA IRIS Assessment (U.S. EPA, 2011e) and Appendix I (for (Selgrade and Gilmour, 2010)). A comparison of results from updated BMDL modeling runs with results from (U.S. EPA, 2011e) for (Johnson et al., 2003) are provided in Appendix I. Where dose-response modeling was not feasible, NOAELs or LOAELs were also identified and are summarized.

G.1 Selecting the BMD model to use for POD computation

The following approach is recommended for selecting the model(s) to use for computing the BMDL to serve as the POD for a specific dataset according to EPA Benchmark Dose Guidance (U.S. EPA, 2012a).

- 1) Assess goodness-of-fit, using a value of $\alpha = 0.1$ to determine a critical value (or $\alpha = 0.05$ or $\alpha = 0.01$) if there is reason to use a specific model(s) rather than fitting a suite of models.
- 2) Further reject models that apparently do not adequately describe the relevant low- dose portion of the dose-response relationship, examining residuals and graphs of models and data.
- 3) As the remaining models have met the recommended default statistical criteria for adequacy and visually fit the data, any of them theoretically could be used for determining the BMDL. The remaining criteria for selecting the BMDL are necessarily somewhat arbitrary and are suggested as defaults.
- 4) If the BMDL estimates from the remaining models are sufficiently close (given the needs of the assessment), reflecting no particular influence of the individual models, then the model with the lowest Akaike’s Information Criteria (AIC)²⁸ may be used to calculate the BMDL for the POD. This criterion is intended to help arrive at a single BMDL value in an objective, reproducible manner. If two or more models share the lowest AIC, the simple average or geometric mean of the BMDLs with the lowest AIC may be used. Note that this is not the same as “model averaging”, which involves weighing a fuller set of adequately fitting models. In addition, such an average has drawbacks, including the fact that it is not

²⁸ Akaike’s Information Criteria—a measure of information loss from a dose-response model that can be used to compare a set of models. Among a specified set of models, the model with the lowest AIC is considered the best. If two or more models share the lowest AIC, an average of the BMDLs could be used, but averaging was not used in this assessment because for the one occasion in which models shared the lowest AIC, a selection was made based on visual fit.

1354 a 95% lower bound (on the average BMD); it is just the average of the particular BMDLs under
1355 consideration (*i.e.*, the average loses the statistical properties of the individual estimates).
1356
1357 5) If the BMDL estimates from the remaining models are not sufficiently close, some model dependence
1358 of the estimate can be assumed. Expert statistical judgment may help at this point to judge whether
1359 model uncertainty is too great to rely on some or all of the results. If the range of results is judged to be
1360 reasonable, there is no clear remaining biological or statistical basis on which to choose among them,
1361 and the lowest BMDL may be selected as a reasonable conservative estimate. Additional analysis and
1362 discussion might include consideration of additional models, the examination of the parameter values for
1363 the models used, or an evaluation of the BMDs to determine if the same pattern exists as for the
1364 BMDLs. Discussion of the decision procedure should always be provided.

1365 6) In some cases, modeling attempts may not yield useful results. When this occurs and the most
1366 biologically relevant effect is from a study considered adequate but not amenable to modeling, the
1367 NOAEL (or LOAEL) could be used as the POD. The modeling issues that arose should be discussed in
1368 the assessment, along with the impacts of any related data limitations on the results from the alternate
1369 NOAEL/LOAEL approach.

1370 **G.2 Uncertainty Factor Selection**

1371 After the PODs were determined for each study/endpoint, uncertainty factors (UFs) were used to derive
1372 acceptable benchmark margins of exposure (MOEs). UFs are used to address differences between study
1373 conditions and conditions of human environmental exposure. These include:
1374

1375 (a) *Extrapolating from laboratory animals to humans (UF_A):*

1376 If a POD is derived from experimental animal data, it is divided by an UF to reflect pharmacokinetic and
1377 pharmacodynamic differences that may make humans more sensitive than laboratory animals. For oral
1378 exposures, the standard value for the interspecies UF is 10, which breaks down (approximately) to a
1379 factor of 3 for pharmacokinetic differences (which is removed if the PBPK model is used) and a factor
1380 of 3 for pharmacodynamic differences. For inhalation exposures, ppm equivalence across species is
1381 generally assumed or other cross-species scaling is performed, in accordance with U.S. EPA inhalation
1382 dosimetry guidance ([U.S. EPA, 1994b](#)), in which case, residual pharmacokinetic differences are
1383 considered to be negligible. Therefore, the standard value used for the interspecies UF is 3, which is
1384 ascribed to pharmacodynamic differences. These standard values were used for all of the PODs based on
1385 laboratory animal data in this assessment.
1386

1387 (b) *Human (intraspecies) variability (UF_H):*

1388 Sensitive humans could be adversely affected at lower exposures than a general study
1389 population; consequently, PODs from general-population studies are divided by an UF to address
1390 sensitive humans. Similarly, the animals used in most laboratory animal studies are considered to be
1391 typical or average responders, and the human (intraspecies) variability UF is also applied to PODs from
1392 such studies to address sensitive subgroups. The standard value for the human variability UF is 10,
1393 which breaks down (approximately) to a factor of 3 for pharmacokinetic variability (which is removed if
1394 the PBPK model is used) and a factor of 3 for pharmacodynamic variability. This standard value was
1395 used for all of the PODs in this assessment.
1396

1397 (c) *Uncertainty in extrapolating from subchronic to chronic exposures (UF_S):*²⁹

²⁹ Chronic exposure covers > 10% of expected lifetime. Rodent studies exceeding 90 days of exposure are considered chronic, and rodent studies covering from 4 weeks to 90 days of exposure are considered subchronic. For human studies, chronic exposure exceeds 7-8years, on average ([U.S. EPA, 1994b](#)).

1398 Chronic risk estimates apply to long-term exposure over decades, but sometimes the best (or only)
1399 reasonably available data come from less-than-lifetime studies. Lifetime exposure can induce effects
1400 that may not be apparent or as large in magnitude in a shorter study; consequently, a dose that elicits a
1401 specific level of response from a lifetime exposure may be less than the dose eliciting the same level of
1402 response from a shorter exposure period. Thus, PODs based on subchronic exposure data are generally
1403 divided by a subchronic-to-chronic UF, which has a standard value of 10. If there is evidence suggesting
1404 that exposure for longer time periods does not increase the magnitude of an effect, a lower value of 3 or
1405 one might be used. For some reproductive and developmental effects, chronic exposure is that which
1406 covers a specific window of exposure that is relevant for eliciting the effect, and subchronic exposure
1407 would correspond to an exposure that is notably less than the full window of exposure.
1408

1409 (d) *Uncertainty in extrapolating from LOAELs to NOAELs (UF_L):*

1410 PODs are intended to be estimates of exposure levels without appreciable risk under the study
1411 conditions so that, after the application of appropriate UFs for interspecies extrapolation, human
1412 variability, and/or duration extrapolation, the absence of appreciable risk is conveyed. Under the
1413 NOAEL/LOAEL approach to determining a POD, however, adverse effects are sometimes observed at
1414 all study doses. If the POD is a LOAEL, then it is divided by an UF to better estimate a NOAEL. The
1415 standard value for the LOAEL-to-NOAEL UF is 10, although a value of 3 is sometimes used if the
1416 effect is considered minimally adverse at the response level observed at the LOAEL or is an early
1417 marker for an adverse effect. For NOAEL or BMDL values, the UF_L is 1.
1418

Appendix H BENCHMARK DOSE ANALYSIS FOR ([Selgrade and Gilmour, 2010](#))

H.1 Applied Dose/Concentration

H.1.1 BMDS Wizard Output Report - Mortality

The benchmark dose (BMD) modeling of dichotomous data were conducted with the EPA’s BMD software (BMDS (version 2.7) via BMDS Wizard (version 1.11). All reasonably available dichotomous models (Gamma, Logistic, Dichotomous-Hill, Logistic, Log-Logistic, Probit, Log-Probit, Weibull, Multistage, and Quantal Linear) were fit to the incidence data for mortality due to introduced infection in mice following inhalation exposure to TCE. BMRs of 1%, 5%, and 10% extra risk were used in the BMD modeling, per technical direction. Adequacy of model fit was judged based on the χ^2 goodness-of-fit p -value ($p > 0.1$), magnitude of scaled residuals, and visual inspection of the model fit.

All models except for the Probit and Logistic provided adequate overall fit to the data, based on the χ^2 goodness-of-fit p -value ($p > 0.1$). Among the remaining models, the Quantal Linear, Multistage, Weibull, Gamma and Log-Logistic models all showed poor fit at the 25 ppm data point, based on scaled residuals ranging from $> |1.5|$ to $> |2|$. This was the data point closest to the BMD for the Quantal Linear at BMR = 10% and for the rest of these models at BMR = 5%. Regardless of whether the models with poor fit at 25 ppm are included or not, the BMDLs at BMR = 10% or 5% are sufficiently close (within 3-fold), so that the model with the lowest AIC was selected; this is the Log-Probit. At BMR = 1%, however, the BMDLs are no longer within 3-fold; the results at this BMR show model-dependence. This reflects the lack of information reasonably available for the models to use in the data for the low-dose region of the dose-response curve (responses were similar in the control, 5, 10 and 25 ppm groups) and signifies increased uncertainty in selecting an appropriate BMDL at this BMR. Excluding the models with high scaled residuals at 25 ppm as less reliable leaves the Log-Probit and Dichotomous-Hill models. BMDLs for these models are sufficiently close, so the model with the lower AIC, the Log-Probit, was selected.

H.1.1.1 BMDS Summary of Mortality – BMR 10%

Table_Apx H-1. Summary of BMD Modeling Results for Mortality from Applied Dose in Selgrade and Gilmour 2010; BMR = 10% Extra Risk

Model ^a	Goodness of fit		BMD _{10Pct} (ppm)	BMDL _{10Pct} (ppm)	Basis for model selection
	p -value	AIC			
Gamma	0.292	342.35	43.5	31.2	All models provided adequate overall fit to the data except for the Probit and Logistic models (based on the χ^2 goodness-of-fit p -value). Although the Quantal Linear model provided adequate overall fit, the scaled residual nearest the BMD was $> 2 $, indicating poor fit in that part of the curve. With or without the Quantal Linear, the BMDLs are sufficiently close (< 3 fold), so the model with the lowest AIC was selected (Log-Probit).
Dichotomous-Hill	0.563	340.91	44.7	36.2	
Logistic	0.0074	351.35	66.2	57.6	
LogLogistic	0.370	341.62	43.3	31.6	
Probit	0.0211	348.55	61.1	53.3	
LogProbit	0.582	338.72	46.6	39.6	
Weibull	0.259	342.81	42.5	30.3	
Multistage 2 ^{ob}	0.177	344.14	39.9	27.9	
Multistage 3 ^{oc}	0.177	344.14	39.9	27.9	
Multistage 4 ^{od}					

Multistage 5 ^{oe}					
Multistage 6 ^{of}					
Quantal-Linear	0.230	343.25	33.0	26.6	

^a Selected model in bold; scaled residuals for selected model for doses 0, 5, 10, 25, 50, 100, and 200 ppm were 0.38, -0.08, -0.18, -1.16, 1.08, 0.22, -1.02, respectively.

^b The Multistage 2^o model may appear equivalent to the Multistage 3^o model, however differences exist in digits not displayed in the table. This also applies to the Multistage 4^o model. This also applies to the Multistage 5^o model. This also applies to the Multistage 6^o model.

^c The Multistage 3^o model may appear equivalent to the Multistage 2^o model, however differences exist in digits not displayed in the table.

^d For the Multistage 4^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 3^o model.

^e For the Multistage 5^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 4^o model.

^f For the Multistage 6^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 5^o model.




Figure Apx H-1. Plot of Incidence by Applied Dose (ppm) with Fitted Curve for Log-Probit Model for Mortality from Introduced Infection in Mice Following Inhalation Exposure to TCE (Selgrade and Gilmour 2010); BMR = 10% Extra Risk

Probit Model. (Version: 3.4; Date: 5/21/2017)

The form of the probability function is: $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$, where $\text{CumNorm}(\cdot)$ is the cumulative normal distribution function

Slope parameter is restricted as slope ≥ 1

Benchmark Dose Computation.

BMR = 10% Extra risk

BMD = 46.6299

BMDL at the 95% confidence level = 39.5537

Parameter Estimates

Variable	Estimate	Default Initial Parameter Values
background	0.0281182	0.0338983
intercept	-5.1238E+00	-5.2930E+00
slope	1	1

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	p-value
Full model	-165.36	7			
Fitted model	-167.36	2	4.00401	5	0.55
Reduced model	-208.64	1	86.5627	6	<.0001

AIC: = 338.719

Goodness of Fit Table

Dose	Est. Prob.	Expected	Observed	Size	Scaled Resid
0	0.0281	3.318	4	118	0.38
5	0.0283	1.077	1	38	-0.08
10	0.0304	1.187	1	39	-0.18
25	0.0557	4.346	2	78	-1.16
50	0.1377	15.979	20	116	1.08
100	0.3216	25.088	26	78	0.22
200	0.5814	22.093	19	38	-1.02

Chi² = 3.78 d.f = 5 P-value = 0.5818

H.1.1.2 BMDs Summary of Mortality – BMR: 5%

Table_Apx H-2. Summary of BMD Modeling Results for Mortality from Applied Dose in Selgrade and Gilmour 2010; BMR = 5% Extra Risk

Model ^a	Goodness of fit		BMD _{5Pct} (ppm)	BMDL _{5Pct} (ppm)	Basis for model selection
	p-value	AIC			
Gamma	0.292	342.35	26.2	15.7	All models provided adequate overall fit to the data except for the Probit and Logistic models (based on the χ^2 goodness-of-fit p-value). However, The Quantal Linear, Multistage, Weibull, Gamma and Log-Logistic models all showed poor fit at the 25 ppm data point, based on scaled residuals ranging from $> 1.5 $ to $> 2 $. This was the data point closest to the BMD for all of these models except the Quantal Linear. With or without these models, the BMDLs are sufficiently close (< 3 fold), so the model with the lowest AIC was selected (Log-Probit).
Dichotomous-Hill	0.563	340.91	33.9	22.5	
Logistic	0.0074	351.35	40.3	34.4	
LogLogistic	0.370	341.62	26.8	17.0	
Probit	0.0211	348.55	36.6	31.4	
LogProbit	0.582	338.72	32.4	27.5	
Weibull	0.259	342.81	24.5	14.9	
Multistage 2 ^o Multistage 3 ^{ob} Multistage 4 ^{oc} Multistage 5 ^{od} Multistage 6 ^{oe}	0.177	344.14	20.6	13.6	
Quantal-Linear	0.230	343.25	16.0	12.9	


^a Selected model in bold; scaled residuals for selected model for doses 0, 5, 10, 25, 50, 100, and 200 ppm were 0.38, -0.08, -0.18, -1.16, 1.08, 0.22, -1.02, respectively.

^b For the Multistage 3^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 2^o model.

^c For the Multistage 4^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 3^o model.

^d For the Multistage 5^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 4^o model.

^e For the Multistage 6^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 5^o model.



Figure_Apx H-2. Plot of Incidence by Applied Dose (ppm) with Fitted Curve for Log-Probit Model for Mortality from Introduced Infection in Mice Following Inhalation Exposure to TCE (Selgrade and Gilmour 2010); BMR = 5% Extra Risk

Probit Model. (Version: 3.4; Date: 5/21/2017)

The form of the probability function is: $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$, where $\text{CumNorm}(\cdot)$ is the cumulative normal distribution function

Slope parameter is restricted as $\text{slope} \geq 1$

Benchmark Dose Computation.

BMR = 5% Extra risk

BMD = 32.4253

BMDL at the 95% confidence level = 27.5047

Parameter Estimates

Variable	Estimate	Default Initial Parameter Values
background	0.0281182	0.0338983
intercept	-5.1238E+00	-5.2930E+00
slope	1	1

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	p-value
Full model	-165.36	7			
Fitted model	-167.36	2	4.00401	5	0.55
Reduced model	-208.64	1	86.5627	6	<.0001

AIC: = 338.719

Goodness of Fit Table

Dose	Est. Prob.	Expected	Observed	Size	Scaled Resid
0	0.0281	3.318	4	118	0.38
5	0.0283	1.077	1	38	-0.08
10	0.0304	1.187	1	39	-0.18
25	0.0557	4.346	2	78	-1.16
50	0.1377	15.979	20	116	1.08
100	0.3216	25.088	26	78	0.22
200	0.5814	22.093	19	38	-1.02

$\chi^2 = 3.78$ d.f = 5 P-value = 0.5818

H.1.1.3 BMDS Summary of Mortality – BMR: 1%

Table_Apx H-3. Summary of BMD Modeling Results for Mortality from Applied Dose in Selgrade and Gilmour 2010; BMR = 1% Extra Risk

Model ^a	Goodness of fit		BMD _{1Pct} (ppm)	BMDL _{1Pct} (ppm)	Basis for model selection
	p-value	AIC			
Gamma	0.292	342.35	8.52	3.22	All models provided adequate overall fit to the data except for the Probit and Logistic models (based on the χ^2 goodness-of-fit p-value). However, The Quantal Linear, Multistage, Weibull, Gamma and Log-Logistic models all showed poor fit at the 25 ppm data point, based on scaled residuals ranging from $> 1.5 $ to $> 2 $. If all models are included, the BMDLs are not sufficiently close (> 3 -fold). For this reason, the BMDS Wizard recommended selection of the Quantal Linear model, which had the lowest BMDL. The > 3 -fold range of BMDLs is indicative of model dependence and signifies increased uncertainty in selecting an appropriate BMDL at this BMR. Excluding the models with high scaled residuals at 25 ppm as less reliable leaves the Log-Probit and Dichotomous-Hill models. BMDLs for these models are sufficiently close, so the model with the lower AIC, the Log-Probit, was selected.
Dichotomous-Hill	0.563	340.91	19.1	7.62	
Logistic	0.0074	351.35	10.2	8.35	
LogLogistic	0.370	341.62	9.29	4.17	
Probit	0.0211	348.55	9.14	7.52	
LogProbit	0.582	338.72	16.4	13.9	
Weibull	0.259	342.81	7.05	2.93	
Multistage 2 ^{ob}	0.177	344.14	4.27	2.66	
Multistage 3 ^{oc}	0.177	344.14	4.27	2.66	
Multistage 4 ^{od}					
Multistage 5 ^{oe}					
Multistage 6 ^{of}					
Quantal-Linear	0.230	343.25	3.14	2.53	

^a Selected model in bold; scaled residuals for selected model for doses 0, 5, 10, 25, 50, 100, and 200 ppm were 0.38, -0.08, -0.18, -1.16, 1.08, 0.22, -1.02, respectively.


^b The Multistage 2^o model may appear equivalent to the Multistage 3^o model, however differences exist in digits not displayed in the table. This also applies to the Multistage 4^o model. This also applies to the Multistage 5^o model. This also applies to the Multistage 6^o model.

^c The Multistage 3^o model may appear equivalent to the Multistage 2^o model, however differences exist in digits not displayed in the table.

^d For the Multistage 4^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 3^o model.

^e For the Multistage 5^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 4^o model.

^f For the Multistage 6^o model, the beta coefficient estimates were 0 (boundary of parameters space). The models in this row reduced to the Multistage 5^o model.



Figure_Apx H-3. Plot of Incidence by Applied Dose (ppm) with Fitted Curve for Log-Probit Model for Mortality from Introduced Infection in Mice Following Inhalation Exposure to TCE (Selgrade and Gilmour 2010); BMR = 1% Extra Risk

Probit Model. (Version: 3.4; Date: 5/21/2017)

The form of the probability function is: $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$, where $\text{CumNorm}(\cdot)$ is the cumulative normal distribution function

Slope parameter is restricted as $\text{slope} \geq 1$

Benchmark Dose Computation.

BMR = 1% Extra risk

BMD = 16.4027

BMDL at the 95% confidence level = 13.9135

Parameter Estimates

Variable	Estimate	Default Initial Parameter Values
background	0.0281182	0.0338983
intercept	-5.1238E+00	-5.2930E+00
slope	1	1

Analysis of Deviance Table

Model	Log(likelihood)	# Param's	Deviance	Test d.f.	p-value
Full model	-165.36	7			
Fitted model	-167.36	2	4.00401	5	0.55
Reduced model	-208.64	1	86.5627	6	<.0001

AIC: = 338.719

Goodness of Fit Table

Dose	Est. Prob.	Expected	Observed	Size	Scaled Resid
0	0.0281	3.318	4	118	0.38
5	0.0283	1.077	1	38	-0.08
10	0.0304	1.187	1	39	-0.18
25	0.0557	4.346	2	78	-1.16
50	0.1377	15.979	20	116	1.08
100	0.3216	25.088	26	78	0.22
200	0.5814	22.093	19	38	-1.02

Chi² = 3.78 d.f = 5 P-value = 0.5818

H.1.2 BMDS Wizard Output Report - Number of Mice Infected

The benchmark dose (BMD) modeling of dichotomous data were conducted with the EPA's BMD software (BMDS (version 2.7) via BMDS Wizard (version 1.11). All reasonably available dichotomous models (Gamma, Logistic, Dichotomous-Hill, Logistic, Log-Logistic, Probit, Log-Probit, Weibull, Multistage, and Quantal Linear) were fit to the incidence data for mortality due to introduced infection in mice following inhalation exposure to TCE. BMRs of 1%, 5%, and 10% extra risk were used in the BMD modeling, per technical direction. Adequacy of model fit was judged based on the χ^2 goodness-of-fit p -value ($p > 0.1$), magnitude of scaled residuals, and visual inspection of the model fit.

All models except for the Probit and Logistic provided adequate overall fit to the data, based on the χ^2 goodness-of-fit p -value ($p > 0.1$). Among the remaining models, the Quantal Linear, Multistage, Weibull, Gamma and Log-Logistic models all showed poor fit at the 25 ppm data point, based on scaled residuals ranging from $> |1.5|$ to $> |2|$. This was the data point closest to the BMD for the Quantal Linear at BMR = 10% and for the rest of these models at BMR = 5%. Regardless of whether the models with poor fit at 25 ppm are included or not, the BMDLs at BMR = 10% or 5% are sufficiently close (within 3-fold), so that the model with the lowest AIC was selected; this is the Log-Probit. At BMR = 1%, however, the BMDLs are no longer within 3-fold; the results at this BMR show model-dependence. This reflects the lack of information reasonably available for the models to use in the data for the low-dose region of the dose-response curve (responses were similar in the control, 5, 10 and 25 ppm groups) and signifies increased uncertainty in selecting an appropriate BMDL at this BMR. Excluding the models with high scaled residuals at 25 ppm as less reliable leaves the Log-Probit and Dichotomous-Hill models. BMDLs for these models are sufficiently close, so the model with the lower AIC, the Log-Probit, was selected.

H.1.2.1 BMDS Summary of Infected at 72 hours – BMR – 10%

Table_Apx H-4. Summary of BMD Modeling Results for Number of Mice Infected at 72 Hours after Infection Following Inhalation Exposure to TCE (Selgrade and Gilmour 2010); BMR = 10% Extra Risk

Model ^a	Goodness of fit		BMD _{10Pct} (ppm)	BMDL _{10Pct} (ppm)	Basis for model selection
	p -value	AIC			
Gamma	0.190	23.637	9.77	4.24	All models provided adequate fit to the data (based on the χ^2 goodness-of-fit p -value), although a BMDL could not be calculated for the Dichotomous-Hill model. The BMDS Wizard recommended the Probit model because it had the lowest AIC. BMDs and BMDLs from all models are well below the lowest data point and cannot be considered reliable.
Dichotomous-Hill	0.164	23.965	12.7	error^b	
Logistic	0.428	21.584	15.6	8.36	
LogLogistic	0.164	23.965	12.7	1.13	
Probit	0.448	21.445	15.7	9.11	
LogProbit	0.383	21.877	15.6	6.86	
Weibull	0.189	23.606	14.3	4.25	
Multistage 2°	0.202	23.480	13.6	4.32	
Multistage 3°	0.228	23.267	13.8	4.43	
Quantal-Linear	0.425	21.639	8.56	4.24	

^a Selected model in bold; scaled residuals for selected model for doses 0, 50, 100, and 200 ppm were -0.23, 0.86, -0.82, 0.38, respectively.

^b BMD or BMDL computation failed for this model.




Figure Apx H-4. Plot of Incidence by Dose (ppm) with Fitted Curve for Probit Model for Number of Mice Infected at 72 Hours after Infection Following Inhalation Exposure to TCE (Selgrade and Gilmour 2010); BMR = 10% Extra Risk

H.2 Internal Dose (TotOxMetabBW34)

Benchmark dose (BMD) modeling was conducted with the newest version of EPA’s BMD software (BMDS version 3.1.2) using the internal dose metric median TotMetabBW34 (see [*Internal Dose BMD Modeling Results for Selgrade and Gilmour, 2010. Docket: EPA-HQ-OPPT-2019-0500*] for full results including data for the AUCBld dose metric). All available dichotomous models (Dichotomous Hill, Gamma, Logistic, Log-Logistic, Probit, Log-Probit, Weibull, and Multistage) were fit to the incidence data for mortality due to introduced infection in mice following inhalation exposure to TCE (Selgrade and Gilmour 2010). BMRs of 1%, 5%, and 10% extra risk were used in the BMD modeling, per technical direction. All models were run using the default parameter restrictions implemented in BMDS v3.1.2, *i.e.*, Weibull, Gamma – α (power) ≥ 1 ; Log Logistic, Dichotomous Hill – slope ≥ 1 ; Multistage – $\beta \geq 0$; Logistic, Probit, Log-Probit – unrestricted. Adequacy of model fit was judged based on the χ^2 goodness-of-fit p -value ($p > 0.1$), magnitude of scaled residuals, and visual inspection of the model fit.

All models except for the 1-degree Multistage and Logistic models provided adequate overall fit to the data, based on the χ^2 goodness-of-fit p -value ($p > 0.1$). The models with adequate overall fit also showed adequate fit near the predicted BMD, based on scaled residuals ($< |2|$). BMDLs for the adequately fit models at BMR = 10%, 5%, and 1% were sufficiently close (within 3-fold), so the model with the lowest AIC, the Log-Probit, was selected. Using the Log-Probit model, BMD/BMDLs at BMR = 10%, 5%, and 1% were 15.19/12.13, 11.22/8.19, and 6.35/3.84 for median TotMetabBW34, respectively.

H.2.1 BMDS Wizard Output Summary - Mortality

BMD modeling was performed based on the incidence data from (Selgrade and Gilmour, 2010) after translating the applied dose/concentration into the internal dose metric of TotMetabBW34 as described in Appendix J.

Table_Apx H-5. Study incidence data based on median internal dose metric.


Applied dose (ppm)	TotMetabBW34	N	Incidence
0	0	118	4
5	2.127	38	1
10	4.143	39	1
25	9.536	78	2
50	16.839	116	20
100	28.842	78	26
200	47.241	38	19

H.2.1.1 BMDS Summary of Mortality – BMR 10%

Table_Apx H-6. Summary of BMD Modeling Results for Mortality from Internal Dose in Selgrade and Gilmour 2010; BMR = 10% Extra Risk

Model ^a	Restriction	BMD	BMDL	Goodness of fit		BMDS Recommendation	BMDS Recommendation Notes
				p-value	AIC		
Dichotomous Hill	Restricted	15.4	12.7	0.6	340.8	Viable - Alternate	
Gamma	Restricted	15.2	11.8	0.4	341.2	Viable - Alternate	
Log-Logistic	Restricted	15.1	11.8	0.5	340.9	Viable - Alternate	
Multistage Degree 6	Restricted	15.6	11.4	0.3	342.6	Viable - Alternate	
Multistage Degree 5	Restricted	15.6	11.4	0.3	342.6	Viable - Alternate	
Multistage Degree 4	Restricted	15.6	11.4	0.3	342.6	Viable - Alternate	
Multistage Degree 3	Restricted	15.6	11.4	0.3	342.6	Viable - Alternate	
Multistage Degree 2	Restricted	15.6	11.4	0.3	342.6	Viable - Alternate	
Multistage Degree 1	Restricted	9.8	7.9	0.1	348.1	Questionable	Goodness of fit p-value < 0.1 Residual for Dose Group Near BMD > 2
Weibull	Restricted	14.9	11.4	0.3	341.9	Viable - Alternate	
Logistic	Unrestricted	17.6	15.6	0.1	344.8	Questionable	Goodness of fit p-value < 0.1
Log-Probit	Unrestricted	15.2	12.1	0.6	339.8	Viable - Recommended	Lowest AIC
Probit	Unrestricted	16.4	14.5	0.2	342.9	Viable - Alternate	

^a Selected model in bold: scaled residuals for selected model for the dose group near BMD and control dose group were 0.77 and 0.46, respectively.




Figure_Apx H-5. Plot of Incidence by Internal Dose with Fitted Curve for Log-Probit Model for Mortality from Selgrade and Gilmour 2010; BMR = 10% Extra Risk

H.2.1.2 BMDS Summary of Mortality – BMR 5%

Table_Apx H-7. Summary of BMD Modeling Results for Mortality from Internal Dose in Selgrade and Gilmour 2010; BMR = 5% Extra Risk

Model ^a	Restriction	BMD	BMDL	Goodness of fit		BMDS Recommendation	BMDS Recommendation Notes
				<i>p</i> -value	AIC		
Dichotomous Hill	Restricted	12.3	8.8	0.6	340.8	Viable - Alternate	
Gamma	Restricted	10.5	7.2	0.4	341.2	Viable - Alternate	
Log-Logistic	Restricted	10.5	7.3	0.5	340.9	Viable - Alternate	
Multistage Degree 6	Restricted	10.4	6.2	0.3	342.6	Viable - Alternate	
Multistage Degree 5	Restricted	10.4	6.2	0.3	342.6	Viable - Alternate	
Multistage Degree 4	Restricted	10.4	6.2	0.3	342.6	Viable - Alternate	
Multistage Degree 3	Restricted	10.4	6.2	0.3	342.6	Viable - Alternate	
Multistage Degree 2	Restricted	10.4	6.2	0.3	342.6	Viable - Alternate	
Multistage Degree 1	Restricted	4.8	3.9	0.1	348.1	Questionable	Goodness of fit <i>p</i> -value < 0.1 Residual for Dose Group Near BMD > 2
Weibull	Restricted	9.8	6.6	0.3	341.9	Viable - Alternate	
Logistic	Unrestricted	11.2	9.6	0.1	344.8	Questionable	Goodness of fit <i>p</i> -value < 0.1
Log-Probit	Unrestricted	11.2	8.2	0.6	339.8	Viable - Recommended	Lowest AIC
Probit	Unrestricted	10.3	8.8	0.2	342.9	Viable - Alternate	

^a Selected model in bold: scaled residuals for selected model for the dose group near BMD and control dose group were -1.25 and 0.46, respectively.




Figure_Apx H-6. Plot of Incidence by Internal Dose with Fitted Curve for Log-Probit Model for Mortality from Selgrade and Gilmour 2010; BMR = 5% Extra Risk

H.2.1.3 BMDS Summary of Mortality – BMR 1%

Table_Apx H-8. Summary of BMD Modeling Results for Mortality from Internal Dose in Selgrade and Gilmour 2010; BMR = 1% Extra Risk

Model ^a	Restriction	BMD	BMDL	Goodness of fit		BMDS Recommendation	BMDS Recommendation Notes
				p-value	AIC		
Dichotomous Hill	Restricted	7.8	3.6	0.6	340.8	Viable - Alternate	
Gamma	Restricted	4.8	2.3	0.4	341.2	Viable - Alternate	
Log-Logistic	Restricted	4.7	2.5	0.5	340.9	Viable - Alternate	
Multistage Degree 6	Restricted	3.8	1.3	0.3	342.6	Viable - Alternate	
Multistage Degree 5	Restricted	3.8	1.3	0.3	342.6	Viable - Alternate	
Multistage Degree 4	Restricted	3.8	1.3	0.3	342.6	Viable - Alternate	
Multistage Degree 3	Restricted	3.8	1.3	0.3	342.6	Viable - Alternate	
Multistage Degree 2	Restricted	3.8	1.3	0.3	342.6	Viable - Alternate	
Multistage Degree 1	Restricted	0.9	0.8	0.1	348.1	Questionable	Goodness of fit p-value < 0.1 Residual for Dose Group Near BMD > 2
Weibull	Restricted	3.8	1.9	0.3	341.9	Viable - Alternate	
Logistic	Unrestricted	3.0	2.5	0.1	344.8	Questionable	Goodness of fit p-value < 0.1
Log-Probit	Unrestricted	6.4	3.8	0.6	339.8	Viable - Recommended	Lowest AIC
Probit	Unrestricted	2.8	2.2	0.2	342.9	Viable - Alternate	

^a Selected model in bold: scaled residuals for selected model for the dose group near BMD and control dose group were -0.13 and 0.46, respectively.



Figure_Apx H-7. Plot of Incidence by Internal Dose with Fitted Curve for Log-Probit Model for Mortality from Selgrade and Gilmour 2010; BMR = 1% Extra Risk

Appendix I **BENCHMARK DOSE MODELING UPDATE FOR NESTED FETAL DATA FROM ([Johnson et al., 2003](#))**

BMD modeling of the nested fetal data for cardiac defects from ([Johnson et al., 2003](#)) was done to verify the BMD modeling results reported in Appendix F.4.2.1 of the EPA 2011 IRIS Toxicological Review for TCE Appendices ([U.S. EPA, 2011b](#)).

- 1) BMD modeling was performed using the nested logistic model in BMDS (v3.1.1) with and without a litter specific covariate to account for intra-litter similarity (litter effects) based on pre-treatment condition and with and without modeling of intra-litter correlation to account for intra-litter similarity based on effects during treatment. IRIS also used the nested logistic model with and without litter specific covariate and intra-litter correlation. Previous modeling from ([U.S. EPA, 2011b](#)) was performed with and without the high dose group dropped, however the model based on dropping the highest dose was used in the assessment because it had smaller scaled residuals and predicted expected response values were closer to observed. Therefore, current modeling was performed without the high dose group. Modeling in ([U.S. EPA, 2011b](#)) was performed using applied dose and two alternative internal dose metrics based on PBPK modeling (avg amount of TCE metabolized by oxidation/kg^{3/4}-day and AUC for TCE in blood). The same 3 sets of doses were modeled for the current effort. BMRs used for both the IRIS and current modeling were 10%, 5% and 1% extra risk.
- 2) Total weight gain during pregnancy (TWtGn) was used as the litter specific covariate in the modeling performed for the IRIS assessment. The individual animal data reasonably available for the current effort included TWtGn for the treated groups, but not for the control group. Based on the data available, litter size was used as the covariate for the current modeling effort instead of TWtGn.
- 3) P-values reported by an older version of the BMDS software as presented in Table F-6 of the 2011 IRIS Assessment Appendices ([U.S. EPA, 2011b](#)) for the nested models are incorrect, apparently due to a problem with the software used at that time. These results suggested that the models did not have adequate fit to the data ($p = 0.0128$). The re-analysis exercise reported in Appendix F.4.2.1.2 of ([U.S. EPA, 2011b](#)) was performed to show that the p-values were much higher than indicated in the raw modeling results and that model fit was acceptable. This approach still relied on the subgrouping of individual litter results but regrouped the litter data 100 times and reported the percentage of times the estimated p-value indicated appropriate model fit. Calculation of p-values for the nested models in the current version of BMDS follows a bootstrap methodology similar to that described in Appendix F.4.2.1.2. of the IRIS appendices. Because the original p-values in presented in ([U.S. EPA, 2011b](#)) were incorrect, comparisons of current modeling results to IRIS were only made for AIC, BMD and BMDL. The p-values from the updated BMD modeling runs are presented for context.
- 4) In the previous BMD modeling, the best fitting model as determined by lowest AIC was the model without litter-specific covariate but with intra-litter correlation. This was true for the current modeling as well.
- 5) Results from the models without litter-specific covariate, including the best-fitting model, closely matched the results from the IRIS assessment (see Table_Apx I-1).
- 6) Results for the models that included the litter-specific covariate differed from the IRIS results, because a different covariate was used (litter size rather than TWtGn, due to missing data).

- 7) Model fits (AICs) and BMD/BMDL values are identical (within rounding error) between the updated modeling results and those reported in ([U.S. EPA, 2011b](#)).

Table_Apx I-1. Results for Best-Fitting Model in Comparison to Results Reported in IRIS ([U.S. EPA, 2011b](#), Highlighted)

Model	Covariate	Intra-litter Correlation	Dose Metric	BMR	AIC	p-value ^d	BMD	BMDL
Nested Logistic	Not Used	Modeled	Applied Dose ^a	0.10	243.815	0.665	0.71114	0.227675
					243.815	NR	0.71114	0.227675
				0.05	243.815	0.641	0.336856	0.107846
					243.815	NR	0.336856	0.107846
				0.01	243.815	0.661	0.064649	0.020698
					243.815	NR	0.064649	0.020698
			TotOxMetabBW34 ^b	0.10	243.816	0.642	0.489388	0.156646
					243.815	NR	0.489442	0.156698
				0.05	243.816	0.642	0.231816	0.074201
					ND	NR	ND	ND
				0.01	243.816	0.636	0.04449	0.014241
					243.815	NR	0.0444948	0.0142453
			AUCCBld ^c	0.10	243.816	0.656	0.022279	0.00713
					243.816	NR	0.0222789	0.00712997
				0.05	243.816	0.656	0.010553	0.003377
					ND	NR	ND	ND
				0.01	243.816	0.656	0.002025	0.000648
					243.816	NR	0.00202535	.000648179

^a0, 0.00045, 0.048, 0.218 mg/kg-day

^bTotal oxidative metabolism scaled by body weight to the ³/₄-power: 0, 0.00031, 0.033, 0.15

^cAUC of TCE in blood: 0, 0.0000141, 0.00150254, 0.00682727

^d p-values from the 2011 IRIS Assessment are not reported because the original values were incorrect.

ND = no data

NR = not relevant; original p-values as calculated by BMDS software in 2011 were incorrect (e.g., p = 0.0129 for 1% BMR without litter-specific covariate and with intra-litter correlation).

The resulting BMDLs and AICs (a measure of model fit, see Appendix I) agreed with results in the 2011 IRIS Assessment ([U.S. EPA, 2011b](#)). However, the p-value of = 0.661 from the updated BMDS nested model run is significantly improved on the improperly calculated p values from ([U.S. EPA, 2011b](#)), confirming strong model fit.

Appendix J PBPK MODELING UPDATES FOR REPRESENTATIVE ACUTE AND CHRONIC ENDPOINTS

J.1 Derivation of Internal Dose Metric Results for ([Selgrade and Gilmour, 2010](#))

J.1.1 Methods

MCSim (v5.6.6) was used to sample from the joint posterior distributions for the PBPK model [*PBPK Model and ReadMe (zipped)*]. Docket: [EPA-HQ-OPPT-2019-0500](#)] parameters and Python (v3.6.5) was used for all post processing and analysis of MCSim output. For each exposure simulation, desired percentiles were reported for each internal dose metric: *TotMetabBW34* and *AUCCBld*.

The PBPK model translated the external applied concentration (ppm) from ([Selgrade and Gilmour, 2010](#)) to a corresponding internal dose metric (*TotMetabBW34* and *AUCCBld*). These two metrics were selected as the primary and alternative dose metrics for this endpoint under the assumption that the metabolic contribution to this endpoint matches that for other immune endpoints (see ([U.S. EPA, 2011e](#)) and Table 3-11). Internal dose metric values were output as predicted 1st, 5th, 10th, 50th, 90th, 95th, and 99th percentiles for mouse. The median (50th percentil values) were then subject to BMD modeling (Appendix H.2 and [*Internal Dose BMD Modeling Results for Selgrade and Gilmour, 2010*]. Docket: [EPA-HQ-OPPT-2019-0500](#)]).

Exposure parameters:

- Inhalation exposure
- Dose concentrations (ppm): [5, 10, 25, 500, 200]
- Inhalation duration: 3 hours
- Sex: Female
- Species: Mouse
- Body weight: 0.025 kg (average Female CD1 mouse at 5-6 weeks)
- Internal dose metrics: *TotMetabBW34* and *AUCCBld*

J.1.2 Results

The modeling results for the analysis of cumulative mortality following exposure to TCE and *S. zooepidemicus* infection in ([Selgrade and Gilmour, 2010](#)) are described in this section below.

- Predictions of mouse internal dose metrics utilized the female mouse-specific joint posterior parameter distributions from the TCE PBPK model.

In ([Selgrade and Gilmour, 2010](#)), individual mice were exposed to increasing concentrations of TCE through inhalation and subsequently infected with *S. zooepidemicus*. Selgrade and Gilmour observed a dose-dependent effect on cumulative mortality following exposure to TCE. Therefore, EPA utilized study-matched exposure variables and the mouse-specific parameters of the TCE PBPK model to predict the corresponding internal dose metrics for each exposure reported in the study.

Table_Apx J-1. Selected percentiles for TotMetabBW34 and AUCCBld for female mouse simulations

Internal Dose Metric	Route	Dose (ppm)	mean	SD	1.00%	25.00%	50.00%	75.00%	99.00%
TotMetabBW34_1.1	Inhalation	5	2.294231	1.032454	0.655835	1.528783	2.126685	2.865015	5.503253
TotMetabBW34_2.1	Inhalation	10	4.437913	2.033409	1.22793	2.93177	4.143145	5.56502	10.89413
TotMetabBW34_3.1	Inhalation	25	10.24195	4.90276	2.641508	6.67256	9.535745	12.81168	25.25738
TotMetabBW34_4.1	Inhalation	50	19.99376	9.430442	5.518223	11.73308	18.2659	23.6544	49.59246
TotMetabBW34_5.1	Inhalation	100	32.563	17.17391	7.451471	19.9501	28.8424	41.81023	85.19594
TotMetabBW34_6.1	Inhalation	200	54.27246	29.99192	12.51255	32.71683	47.2414	68.7213	148.7853
AUCCBld_1.1	Inhalation	5	0.310672	0.108683	0.13889	0.234156	0.288099	0.367049	0.63204
AUCCBld_2.1	Inhalation	10	0.636832	0.22911	0.278085	0.474244	0.589897	0.757263	1.31563
AUCCBld_3.1	Inhalation	25	1.681136	0.63107	0.700461	1.221415	1.55746	2.01261	3.574621
AUCCBld_4.1	Inhalation	50	4.118071	1.633029	1.667898	2.56827	3.79901	4.284455	9.310272
AUCCBld_5.1	Inhalation	100	7.710392	3.010024	2.946904	5.549918	7.21414	9.32249	16.86953
AUCCBld_6.1	Inhalation	200	17.05727	6.84398	6.371642	12.23283	15.8771	20.6827	38.34951
Median (50 th percentile) values were used for BMD modeling; SD = Standard Deviation									

J.2 Derivation of Human Equivalent Concentrations/Doses for Best Overall Acute and Chronic Non-Cancer Endpoints

EPA utilized the PBPK model to obtain Human Equivalent Concentrations (HECs) and Human Equivalent Doses (HEDs) for ([Selgrade and Gilmour, 2010](#)) in the same manner as they were derived for other endpoints in ([U.S. EPA, 2011e](#)). Additionally, EPA utilized the PBPK model to derive PODs specific to occupational scenarios for the best overall acute and chronic non-cancer endpoints from ([Selgrade and Gilmour, 2010](#)) and ([Keil et al., 2009](#)), respectively (Section 3.2.5.4.1).

J.2.1 Methods

BMD modeling results for the mouse (Appendix H.2 and [*Internal Dose BMD Modeling Results for Selgrade and Gilmour, 2010. Docket: EPA-HQ-OPPT-2019-0500*]) were used to predict human equivalent concentrations (HEC) and human equivalent doses (HED) based on the internal dose point-of-departure (PoD) derived during the BMD modeling step. HEC/HED calculations occurred for multiple exposure scenarios and idPODs as outlined below:

- Acute (single dose) and chronic (repeat dosing for 100 weeks)
- idPOD for ([Selgrade and Gilmour, 2010](#)) endpoints (TotMetabBW34 and AUCCBld)
- idPOD for ([Keil et al., 2009](#)) endpoints (TotMetabBW34)
- Respiratory rates (QM) assuming default and occupational (1.25 m³/hr) respiration


Setpoint simulations of the human-specific joint posterior parameter distributions were run spanning a large range of possible inhalation concentrations and doses. For the Selgrade idPOD's, we assumed an acute exposure and calculated the HEC/HEDs following a 24-hour simulation. The average daily HEC/HED for the Keil idPOD was determined using a 100-week (700 day) simulation. Using interpolation, the HEC and HED were determined from the simulated 99th and 50th percentile for each internal dose metric.

Determination of Occupational Respiration Rate

EPA assumes a respiration rate of 1.25 m³/hr for occupational scenarios based on light activity levels from Table 6-43 in (U.S. EPA, 2011c). The TCE PBPK model assumes a respiratory dead volume of 30%. In order to translate respiration rate (QM) to alveolar ventilation rate (QP) the following equation was used:

$$QP = QM * 0.7$$

Using this transformation, the ‘QP_{meas}’ input to the model for occupational alveolar ventilation was 0.875 m³/hr or 875 L/hr. Figure_Apx J-1 illustrates the difference between the default respiration rate probability distribution (median value of 0.64 m³/hr) vs. the single value (1.25 m³/hr) for occupational respiration rate. The absence of variability in the respiration rate for the occupational scenario reduced the overall uncertainty in the HEC/HED calculations. At higher HEC percentiles, the default respiratory rate approaches the occupational rate, resulting in reduced differences among HEC values.



Figure_Apx J-1. Distribution of default (resting) respiration rates compared to occupational respiration rate.

J.2.2 Results

Using the internal dose point-of-departure (idPOD) for (Selgrade and Gilmour, 2010), EPA first calculated the HECs and HEDs for the 99th and 50th percentile outputs for each dose metric’s idPOD at default parameters of resting respiration rate and continuous exposure. EPA also calculated the corresponding HECs and HEDs for occupational scenarios using the occupational respiration rate for and 8hr/day exposure duration. For the (Keil et al., 2009) chronic endpoint, EPA compared the HEC_{50/99} and HED_{50/99} results across default and occupational input parameters conditions following both 8 hours and 24 hours of exposure. Below is a summary of the idPODs used in this section of the analysis:

(Selgrade and Gilmour, 2010) **TotMetabBW34**: 3.84 mg TCE metabolized/d/kg^{3/4}

(Selgrade and Gilmour, 2010) **AUCCBld**: 0.3853 mg TCE-hr/L

(Keil et al., 2009) **TotMetabBW34**: 0.139 mg TCE metabolized/d/kg^{3/4}

Table_Apx J-2 presents the tabulated HEDs and HECs for each endpoint.

Table_Apx J-2. Human equivalent concentrations and human equivalent doses for the Selgrade and Keil endpoints under both default and occupational respiratory conditions.

Study	Selgrade and Gilmour, 2010								Keil et al., 2009			
Exposure scenario	Acute								Chronic			
Dose metric used	TotMetabBW34				AUCBld				TotMetabBW34			
idPOD Exposure duration	3.840				0.3853				0.139			
	8h single-day		24h single-day		8h single-day		24h single-day		8h repeated		24h repeated	
Respiration	Default	Occupational	Default	Occupational	Default	Occupational	Default	Occupational	Default	Occupational	Default ¹	Occupational
HEC ₉₉ (ppm)	2.959	2.343	0.973	0.792	1.735	1.663	0.617	0.585	0.100	0.083	0.033	0.027
HEC ₅₀ (ppm)	8.242	4.458	2.841	1.535	2.936	2.648	1.032	0.926	0.276	0.153	0.092	0.051
HED ₉₉ (mg/kg/d)	1.331	1.335	1.336	1.338	1.145	1.282	1.236	1.357	0.048	0.048	0.048	0.048
HED ₅₀ (mg/kg/d)	1.355	1.380	1.362	1.385	9.066	9.024	12.134	11.794	0.048	0.049	0.048	0.049

¹Values presented in ([U.S. EPA, 2011e](#)) and Section 3.2.5.3.2. They are presented here for comparison to occupational values.

1 Appendix K META-ANALYSIS FOR CANCER

2 K.1 Study Screening and Selection

3 All epidemiologic studies included in the U.S. EPA 2011 IRIS assessment of TCE (Appendix C, [U.S. EPA, 2011b](#)) were considered to be informative and carried forward for meta-analysis. Informative
4 epidemiologic studies of non-Hodgkin lymphoma (NHL), kidney cancer or liver cancer and exposure to
5 TCE published since the 2011 IRIS assessment were identified through a systematic literature search.
6 Studies examining only other cancer types were excluded from consideration.
7

8 K.1.1 Data Quality and Inclusion/Exclusion Criteria Screening

9 Relevant studies were evaluated for data quality and were additionally screened through
10 inclusion/exclusion criteria developed based on the criteria established in the 2011 IRIS assessment
11 (Appendix C, [U.S. EPA, 2011b](#)), as described in Table_Apx K-1. Results of this criteria screening are
12 presented in Table_Apx K-2.
13

14 **Table_Apx K-1. Meta-Analysis Inclusion/Exclusion Criteria for Considering Cancer Studies**
15 **Identified in EPA’s Literature Search**

Inclusion Criteria	Exclusion Criteria
<i>Study Design</i>	
Cohort and case control studies.	Geographic-based, ecological, or proportionate mortality ratio (PMR) study design.
<i>Participant Selection</i>	
Adequate selection in cohort studies of exposure and control groups and of cases and controls in case-control studies.	Inadequate selection in cohort studies (exposed and control groups were not similar, and differences were not controlled for in the statistical analysis). Controls were drawn from a very dissimilar population than cases or recruited within very different time frames (case control studies).
<i>Exposure</i>	
TCE exposure potential inferred to each subject and quantitative assessment of TCE exposure for each subject by reference to industrial hygiene records indicating a high probability of TCE use, individual biomarkers, job exposure matrices (JEMs), water distribution models, or obtained from subjects using questionnaire (case-control studies).	TCE exposure potential not assigned to individual subjects using JEM, individual biomarkers, water distribution models, or industrial hygiene data indicating a high probability of TCE use (cohort studies).
Reports as least 2 levels of exposure (<i>e.g.</i> , exposed/unexposed).	The range and distribution of exposure are not adequate to determine an exposure-response relationship. No description is provided on the levels or range of exposure.
<i>Outcome Assessment</i>	
Evaluation of incidence or mortality from kidney cancer, liver cancer, or NHL. RR estimates and corresponding CIs (or information to allow calculation).	Data for non-cancer health outcomes or incidence or mortality reported for cancers other than kidney, liver, or NHL. All hemato- and lymphopoietic cancer reported as broad category.
<i>Statistical Power (sensitivity)</i>	
The number of participants or cases and controls are adequate to detect an effect in the exposed population and/or subgroups of the total population.	The number of participants or cases and controls are inadequate to detect an effect in the exposed population and/or subgroups of the total population.

16
17
18

Table_Apx K-2. Screening Results of Cancer Studies Identified in EPA’s Literature Search Based on Inclusion/Exclusion Criteria

Studies recommended for inclusion in quantitative meta-analysis:	
Studies	Primary reason(s)
(Bove et al., 2014a) (Bove et al., 2014b) (Buhagen et al., 2016) (Christensen et al., 2013) (Cocco et al., 2013) (Hansen et al., 2013) (Lipworth et al., 2011) (Purdue et al., 2016) (Silver et al., 2014) (Vlaanderen et al., 2013)	Analytical study designs of cohort or case-control; evaluation of incidence or mortality; adequate selection in cohort studies of exposure and control groups and of cases and controls in case-control studies; TCE exposure potential inferred to each subject and quantitative assessment of TCE exposure assessment for each subject by reference to industrial hygiene records indicating a high probability of TCE use, individual biomarkers, JEMs, water distribution models, or obtained from subjects using questionnaire (case-control studies); RR estimates for kidney cancer, liver cancer, or NHL with confidence intervals

Studies NOT recommended for inclusion in quantitative meta-analysis:	
Studies	Primary reason(s)
(Alanee et al., 2015)	Weakness with respect to analytical study design (<i>i.e.</i> , geographic-based, ecological or PMR design).
(Alanee et al., 2015)	TCE exposure potential not assigned to individual subjects using JEM, individual biomarkers, water distribution models, or industrial hygiene data from other process indicating a high probability of TCE use (cohort studies).
(Bassig et al., 2016) (Ruckart et al., 2013)	Examined noncancer health outcomes or cancer incidence or mortality for cancers other than kidney, liver, or NHL. All hemato- and lymphopoietic cancer reported as broad category.
(Bahr et al., 2011)	EPA reviewer scored the study as Unacceptable (Rationale: Repeated examples of poor quality, study design and execution and ignorance of potential biases that went unmentioned even in the discussion indicate inexperience and poor quality control).

19

K.1.2 Screening results

20 Data quality and inclusion/exclusion criteria screening identified ten studies suitable for use in meta-
 21 analysis. Of these, there were nine new studies with suitable informative data on the association of
 22 exposure to TCE and NHL ([Bove et al., 2014a](#); [Bove et al., 2014b](#); [Christensen et al., 2013](#); [Cocco et al.,](#)
 23 [2013](#); [Hansen et al., 2013](#); [Lipworth et al., 2011](#); [Purdue et al., 2016](#); [Silver et al., 2014](#); [Vlaanderen et](#)
 24 [al., 2013](#)), eight new studies with informative data for kidney cancer ([Bove et al., 2014a](#); [Buhagen et al.,](#)
 25 [2016](#); [Christensen et al., 2013](#); [Hansen et al., 2013](#); [Lipworth et al., 2011](#); [Purdue et al., 2016](#); [Silver et](#)
 26 [al., 2014](#); [Vlaanderen et al., 2013](#)), and six new studies with informative data for liver cancer ([Bove et](#)
 27 [al., 2014a](#); [Christensen et al., 2013](#); [Hansen et al., 2013](#); [Lipworth et al., 2011](#); [Silver et al., 2014](#);
 28 [Vlaanderen et al., 2013](#)). All of these studies scored Acceptable for data quality except ([Bahr et al.,](#)
 29 [2011](#)), which was excluded for scoring Unacceptable. Every study scored at least a Medium except for
 30 ([Buhagen et al., 2016](#)), which scored a Low but was recommended for inclusion by inclusion/exclusion
 31 criteria. The respective data quality scores were considered in sensitivity analyses of the meta-analyses
 32 results (see Appendix K.2.2.2).

33

34 All studies from the 2011 IRIS meta-analysis were Acceptable in data quality and scored at least a
 35 Medium. Therefore, data from the ten new studies that passed the criteria screening were extracted along

36 with results from previous studies identified in the 2011 IRIS assessment ([U.S. EPA, 2011e](#)). When
 37 more than one report was available for a single study population, only the most recent publication or the
 38 publication reporting the most informative data for TCE was selected for inclusion in the meta-analysis
 39 (see Table_Apx K-3). This resulted in a smaller set of data included in the meta-analysis as compared to
 40 the total list of studies.

41 **K.1.3 Pooled Cohorts**

42 Two of the new papers pooled data from earlier studies included in the 2011 IRIS meta-analysis.
 43 ([Hansen et al., 2013](#)) pooled and updated three Nordic national cohort studies of workers biologically
 44 monitored for exposure to TCE ([Anttila et al., 1995](#); [Axelson et al., 1994](#); [Hansen et al., 2001](#)).
 45 Similarly, ([Cocco et al., 2013](#)) pooled earlier case-control studies of NHL including ([Cocco et al., 2010](#)),
 46 ([Miligi et al., 2006](#)), and ([Purdue et al., 2011](#)). Two other new studies provided updated data on
 47 populations included in the U.S. EPA 2011 IRIS assessment: ([Lipworth et al., 2011](#)) updated a cohort
 48 study of aircraft workers ([Boice et al., 1999](#)) and ([Christensen et al., 2013](#)) updated an earlier
 49 population-based case-control study ([Siemiatycki, 1991](#)). After removing these overlapping and
 50 superseded studies, a total of 18 studies of NHL, 18 studies of kidney cancer, and 11 studies of liver
 51 cancer were available for meta-analysis.

52
 53 Among the included studies, up to about 800 of the approximately 40,000 Danish workers studied by
 54 ([Raaschou-Nielsen et al., 2003](#)) may have also been included in the Nordic pooled study of 5553
 55 biomonitored workers ([Hansen et al., 2013](#)). However, both studies were retained in the analysis because
 56 any overlap would have been minor. There was also minor overlap between the cohorts studied by
 57 ([Zhao et al., 2005](#)) and ([Boice et al., 2006](#)), but those papers reported data for different outcomes. These
 58 results are summarized in Table_Apx K-3.

59
 60 **Table_Apx K-3. Cancer Studies Covering the Same Cohort as Previous Studies from either the**
 61 **2011 IRIS Assessment or EPA Literature Search**

Study reviewed	Other assessed studies with participants from the same cohort
2011 IRIS Assessment	
(Anttila et al., 1995) (Finland only)	Included in (Hansen et al., 2013)
(Axelson et al., 1994) (Sweden only)	Included in (Hansen et al., 2013)
(Boice et al., 1999)	Updated in (Lipworth et al., 2011)
(Boice et al., 2006)	(Zhao et al., 2005) (partial)
(Brüning et al., 2003)	None
(Charbotel et al., 2006)	None
(Cocco et al., 2010)	Included in (Cocco et al., 2013)
(Dosemeci et al., 1999)	None
(Greenland et al., 1994)	None
(Hansen et al., 2001) (Denmark only)	(Raaschou-Nielsen et al., 2003) (partial); Included in (Hansen et al., 2013)
(Hardell et al., 1994)	None
(Miligi et al., 2006)	Included in (Cocco et al., 2013)
(Moore et al., 2010)	None

Study reviewed	Other assessed studies with participants from the same cohort
(Morgan et al., 1998)	None
(Nordström et al., 1998)	None
(Persson and Fredrikson, 1999)	None
(Pesch et al., 2000)	None
(Purdue et al., 2011)	Included in (Cocco et al., 2013)
(Raaschou-Nielsen et al., 2003)	Partial overlap with (Hansen et al., 2001)
(Radican et al., 2008)	None
(Siemiatycki, 1991)	Updated in (Christensen et al., 2013)
(Wang et al., 2009)	None
(Zhao et al., 2005)	(Boice et al., 2006) (partial)
New Studies Identified in EPA Literature Search	
(Bove et al., 2014a)	None
(Bove et al., 2014b)	None
(Buhagen et al., 2016)	None
(Cocco et al., 2013)	(Cocco et al., 2010); (Miligi et al., 2006); (Purdue et al., 2011)
(Christensen et al., 2013)	(Siemiatycki, 1991)
(Hansen et al., 2013)	(Hansen et al., 2001); (Anttila et al., 1995); (Raaschou-Nielsen et al., 2003) (partial)
(Lipworth et al., 2011)	(Boice et al., 1999)
(Purdue et al., 2016)	None
(Silver et al., 2014)	None
(Vlaanderen et al., 2013)	None

62 **K.2 Meta-Analysis Methods and Results**

63 **K.2.1 Methods**

64 **Data abstraction**

65 Data for each pertinent study identified, including measures of the association (including rate ratio (RR),
66 odds ratio (OR), hazard ratio (HR), etc.) of each cancer of interest with exposure to TCE, their
67 confidence intervals (CI) and if reasonably available, standard errors, identification of the type of
68 measure (RR, OR, etc), the study design and the exposure metric (ever/never exposed, cumulative
69 exposure, duration of exposure, etc.) were abstracted for meta-analysis. All types of epidemiologic ratio
70 measures of association, including RR, OR, HR and standardized mortality or incidence ratios (SMR,
71 SIR), were considered to be equivalent and are collectively referred to below as RRs. The preferred
72 estimates of association for meta-analysis were based on contrasts within the study population and were
73 either 1) comparisons of groups exposed and not exposed to trichloroethylene or 2) comparisons of
74 groups with the highest and lowest level of exposure to trichloroethylene, in that order. For NHL,
75 estimates of association for the most highly exposed group were also abstracted, when they were
76 reasonably available. For each comparison, the most fully adjusted risk estimate was selected.

77 Estimates of association based on cumulative exposure were preferred to those based on other exposure
78 metrics.

79
80 Data for studies included in the U.S. EPA 2011 IRIS assessment ([U.S. EPA, 2011e](#)) were abstracted
81 from tables in Appendix C of that assessment. The measures of association, confidence limits and
82 estimates of SE listed in those tables were utilized for consistency with the previous assessment.

83
84 For newer studies not included in the IRIS assessment, log-relative risks and their standard errors were
85 estimated from the extracted data; the data for the newer studies are provided in tables in Section K.2.3.
86 If the standard error (SE) of RR was reported in the publication, the standard error of $\ln(\text{RR})$ was taken
87 as $\ln(\text{SE})$. If SE was not reported and the CI was reasonably symmetric around the point estimate ($< 5\%$
88 difference between upper and lower half CI), it was approximated as $(\ln(\text{upper bound CI}) - \ln(\text{lower}$
89 $\text{bound CI}))/3.92$. Different approaches in the event of more substantial CI asymmetry. If the measure
90 of RR was a SMR or SIR, SE was approximated by $(1/O)^{1/2}$, where O is the observed number of cases
91 (Greenland & O'Rourke, 2008). If RR was 1 or >1 , SE was estimated from the upper half CI, as
92 $(\ln(\text{upper bound CI}) - \ln(\text{RR}))/1.96$. For $\text{RR} < 1$, SE was estimated from the lower half CI in an
93 equivalent manner. Despite these varying approaches, differences in the method of estimating SE are
94 unlikely to substantially affect the point estimate or CI of a meta-RR.

95 96 **Data analysis**

97 Meta-analyses were performed using the metan procedure in Stata (Stata Corp, College Station TX).
98 The metan procedure also provides options for utilizing a user-provided estimate of SE or estimating SE
99 from input confidence intervals assuming approximate symmetry.

100
101 For each cancer type of interest, the initial analysis included all of the selected studies in a fixed-effects
102 model. Models were specified using the logs of RR and SE as input parameters, allowing the software
103 to estimate study-specific and overall 95% CIs. Heterogeneity was assessed using the I^2 statistic
104 ([Higgins et al., 2003](#)) and visual inspection of the plots. If no important heterogeneity was indicated, the
105 fixed-effects meta-estimate was taken as the measure of overall association. Fixed effects models are
106 preferred for this purpose, as they are generally unbiased ([Poole and Greenland, 1999](#)). Where notable
107 heterogeneity was indicated, a random-effects model using the DerSimonian-Laird estimators was
108 applied to estimate the overall association. EPA's preferred approach is to estimate SE according to the
109 methods described above. With this procedure, the study-specific CIs displayed on forest plots were
110 estimated by the software and may differ slightly from those reported in the original publications.

111
112 The influence of individual studies was assessed in a "leave one out" meta-analysis using the metainf
113 procedure in Stata. Each study was omitted in turn and the meta-estimate was re-calculated without that
114 study to gauge its effect on the overall association. Meta-analyses stratified by the quality score
115 assigned in the initial reviewer were carried out to assess whether effects differed in high versus
116 medium- or low-quality studies.

117
118 The potential for publication bias was assessed by visual inspection of funnel plots.

119
120 Sample Stata commands are provided in Section K.2.4.

121


K.2.2.1 Initial Meta-Analyses

Non-Hodgkin lymphoma


In the fixed-effects model for NHL (Figure_Apx K-1), the meta-RR for overall exposure to TCE was 1.02 (95% CI 0.97-1.08) with moderate heterogeneity between studies (I^2 38.4%, p 0.05). The large study by Vlaanderen et al. (2013) was heavily weighted in the fixed-effects model. Fitting a random-effects model (Figure_Apx K-2) to the same set of studies reduced the weight of the (Vlaanderen et al., 2013) study and gave a meta-estimate of 1.14 (95% CI 1.00-1.30).

In the 2011 TCE meta-analysis of NHL, there was some indication of heterogeneity (I^2 -value was 26%, suggesting low-to-moderate heterogeneity). Little to no heterogeneity was found for kidney or renal cancers. Additional analyses focused on the studies with the highest exposure, because if TCE exposure increases the risk of NHL, the effects should be more apparent in the highest exposure groups. Analysis showed that the summary effect estimate of the highest exposed groups was stronger, a finding that lent support to the conclusion that TCE exposure increased the risk of NHL. Since moderate heterogeneity (greater than in 2011) was identified for the overall set of studies, EPA additionally analyzed results from populations identified as receiving “high exposure” to TCE in order to parallel the analyses performed in the 2011 IRIS Assessment. Fixed- and random-effects models comparing the highest to lowest exposure groups in each study also weighted the (Vlaanderen et al., 2013) study heavily and produced meta-RRs of 1.03 (95% CI 0.93-1.15) and 1.33 (95% CI 0.98-1.80), respectively (Figure_Apx K-3 and Figure_Apx K-4). Extracted RR estimates and confidence intervals from each NHL study are presented in Table_Apx K-7, Table_Apx K-8, and Table_Apx K-9.

Figure_Apx K-1. Fixed-effects model, overall association of NHL and exposure to TCE.




149 **Figure_Apx K-2. Random-effects model, overall association of NHL and exposure to TCE.**




150
151
152

Figure_Apx K-3. Fixed-effects model, association of NHL and high exposure to TCE.



153
154

Figure_Apx K-4. Random-effects model, association of NHL and high exposure to TCE.



156

157

158

159

160

161

Kidney Cancer

162

163

164

165


166

167

For kidney cancer, the fixed effects model (Figure_Apx K-5) gave a meta-RR of 1.06 (95% CI 1.00-1.11) for overall exposure, with moderate, statistically-significant heterogeneity (I^2 41.1%, p 0.04). As for NHL, the study of (Vlaanderen et al., 2013) was heavily weighted. In the random-effects model (Figure_Apx K-6), the meta-RR was 1.22 (95% CI 1.07-1.38). Extracted RR estimates and confidence intervals from each kidney cancer study are presented in Table_Apx K-10 and Table_Apx K-11.


168
169

Figure_Apx K-5. Fixed-effects model, overall association of kidney cancer and exposure to TCE.



170
171
172
173
174

Figure_Apx K-6. Random-effects model, overall association of kidney cancer and exposure to TCE.




175
176
177

178 **Liver cancer**

179 Fixed- and random-effects models for liver cancer showed a similar pattern of results, with meta-RRs of
 180 1.08 (95% CI 0.99-1.18) and 1.18 (95% CI 0.98-1.43), respectively (Figure_Apx K-7 and Figure_Apx
 181 K-8). Heterogeneity was moderate and not statistically significant (I^2 36.5%, p 0.107). Extracted RR
 182 estimates and confidence intervals from each liver cancer study are presented in Table_Apx K-12 and
 183 Table_Apx K-13.

184
 185
 186
 187


Figure_Apx K-7. Fixed-effects model, overall association of liver cancer and exposure to TCE.



188
 189

190
191

Figure_Apx K-8. Random-effects model, overall association of liver cancer and exposure to TCE.



192
193

194
195
196
197
198
199
200

K.2.2.2 Sensitivity analyses

Removal of Vlaanderen et al. (2013)

In analyses of influential observations, the study of (Vlaanderen et al., 2013) strongly influenced the meta-RRs for all three cancers (Table_Apx K-4, Table_Apx K-5, and Table_Apx K-6). No other single study had an appreciable impact on the overall association. Further meta-analyses were conducted to characterize the sensitivity of the results to the influence of that study.

Table_Apx K-4. Analysis of influential studies: NHL

Study omitted	Estimate	95% CI	
Bove et al. 2014a	1.02	0.97	1.08
Bove et al. 2014b	1.03	0.97	1.09
Hansen et al. 2013	1.02	0.96	1.08
Lipworth et al. 2011	1.02	0.97	1.09
Silver et al. 2014	1.03	0.97	1.09
Vlaanderen et al. 2013	1.20	1.07	1.34
Christensen et al. 2013	1.02	0.97	1.08
Cocco et al. 2013	1.02	0.96	1.08
Greenland et al. 1994	1.02	0.97	1.09
Morgan et al. 1998	1.02	0.97	1.09
Raaschou-Nielsen 2003	1.01	0.95	1.07
Radican et al. 2008	1.02	0.96	1.08
Zhao et al. 2005	1.02	0.96	1.08
Hardell et al. 1994	1.02	0.96	1.08
Nordstrom et al. 1998	1.02	0.96	1.08
Persson and Fredrikson 1999	1.02	0.97	1.08
Purdue et al. 2011	1.02	0.96	1.08
Wang et al. 2009	1.02	0.96	1.08

201

Table_Apx K-5. Analysis of influential studies: Kidney cancer

Study omitted	Estimate	95% CI	
Bove et al. 2014a	1.06	1.00	1.11
Buhagen et al. 2016	1.05	1.00	1.11
Hansen et al. 2013	1.06	1.00	1.11
Lipworth et al. 2011	1.06	1.01	1.11
Silver et al. 2014	1.05	1.00	1.11
Vlaanderen et al. 2013	1.26	1.14	1.40
Christensen et al. 2013	1.06	1.01	1.11
Purdue et al. 2016	1.06	1.01	1.12
Greenland et al. 1994	1.06	1.00	1.11
Morgan et al. 1998	1.06	1.00	1.11
Radican et al. 2008	1.06	1.00	1.11
Zhao et al. 2005	1.06	1.00	1.11
Brüning et al. 2003	1.05	1.00	1.11

Table_Apx K-5. Analysis of influential studies: Kidney cancer

Study omitted	Estimate	95% CI	
Charbotel et al. 2006	1.05	1.00	1.11
Dosemeci et al. 1999	1.05	1.00	1.11
Moore et al. 2010	1.05	1.00	1.11
Pesch et al. 2000	1.04	0.99	1.10
Raaschou-Nielsen et al. 2003	1.05	1.00	1.11

Table_Apx K-6. Analysis of influential studies: Liver cancer

Study omitted	Estimate	95% CI	
Bove et al. 2014a	1.09	0.99	1.19
Hansen et al. 2013	1.04	0.95	1.14
Lipworth et al. 2011	1.09	0.99	1.19
Silver et al. 2014	1.08	0.99	1.19
Vlaanderen et al. 2013	1.34	1.13	1.59
Christensen et al. 2013	1.08	0.99	1.18
Boice et al. 2006	1.08	0.99	1.18
Greenland et al. 1994	1.08	0.99	1.19
Morgan et al. 1998	1.08	0.99	1.18
Radican et al. 2008	1.08	0.99	1.19
Raaschou-Nielsen et al. 2003	1.05	0.95	1.16

202

203

204 Meta-RRs for each cancer were re-estimated by omitting that study from the fixed-effects model. For
 205 NHL, omitting the study of ([Vlaanderen et al., 2013](#)) from the analysis of overall exposure to TCE
 206 (Figure_Apx K-9) substantially reduced between-study heterogeneity (I^2 9.7%, p 0.34) and yielded a
 207 meta-RR of 1.20 (95% CI 1.07-1.34). In the model for NHL using only the high exposure groups
 208 (Figure_Apx K-10), no heterogeneity remained when the ([Vlaanderen et al., 2013](#)) study was omitted (I^2
 209 0.0%, p 0.56); the meta-RR for high exposure was 1.53 (95% CI 1.19-1.97). Omitting the study of
 210 ([Vlaanderen et al., 2013](#)) from the model for kidney cancer (Figure_Apx K-11), gave a meta-RR of 1.26
 211 (95% CI 1.14-1.40) with no indication of heterogeneity (I^2 0.0%, p 0.57). Dropping that study from the
 212 analysis of liver cancer (

213


214 Figure_Apx **K-12**) similarly eliminated the heterogeneity among studies (I^2 0.0%, p 0.56) and gave a
 215 meta-RR of 1.34 (95% CI 1.13-1.59). Meta-RR values for all three tissues increased without the
 216 ([Vlaanderen et al., 2013](#)) study and achieved statistical significance.

217

218


219
220

Figure_Apx K-9. Fixed-effects model, overall association of NHL and exposure to TCE, study of Vlaanderen et al. (2013) omitted.



221
222
223
224
225


Figure_Apx K-10. Fixed-effects model, association of NHL and high exposure to TCE, study of Vlaanderen et al. (2013) omitted.



226
227
228
229


230
231

Figure_Apx K-11. Fixed-effects model, overall association of kidney cancer and exposure to TCE, study of Vlaanderen et al. (2013) omitted.



232
233
234
235
236
237

Figure_Apx K-12. Fixed-effects model, overall association of liver cancer and exposure to TCE, study of Vlaanderen et al. (2013) omitted.




238
239

240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262

Stratification by Data Quality

Fixed-effects meta-analyses for each cancer were also stratified by the study quality score assigned in EPA’s review to assess whether the strength of association varied between highest- and lower-quality studies. In this manner, the meta-RR was compared among studies scoring High in data quality to those scoring Medium or Low. For NHL (Figure_Apx K-13), there was no heterogeneity among studies scored as high quality (I^2 0.0%, p 0.78) and the meta-RR was 1.29 (95% CI 1.04-1.59), while among studies scored medium or low the meta-RR was 1.01 (95% CI 0.95-1.07) with moderate heterogeneity (I^2 40.0%, p 0.06). Studies of kidney cancer (Figure_Apx K-14) that scored high for data quality gave a meta-RR of 1.14 (95% CI 0.85-1.53) with no indicated heterogeneity (I^2 0.0% p 0.45), whereas lower-ranked studies gave a meta-RR of 1.06 (95% CI 1.00-1.11) with significant heterogeneity (I^2 50.0% p 0.02). In contrast, moderate, non-significant heterogeneity (I^2 36.0% p 0.21), remained among the three studies of liver cancer (Figure_Apx K-15) scored high for data quality; the meta-RR among those studies was 1.59 (95% CI 1.17-2.16). Lower scoring studies showed no heterogeneity (I^2 0.0% p 0.56) and a meta-RR of 1.04 (95% CI 0.95-1.15). Fitting a random-effects model reduced the meta-RR for highly scored studies to 1.42 (95% CI 0.88-2.30) but did not change the estimate for lower-scored studies. For all three tissues, the meta-RR was greater among the high quality studies compared to medium or low quality studies. Statistical significance was not always achieved due to the low number of studies scored High, however this stratification demonstrates stronger associations of cancer with TCE exposure among higher-quality data.


Figure_Apx K-13. Fixed-effects model, overall association of NHL and exposure to TCE stratified by study quality score.



263
264
265
266
267


268
269

Figure_Apx K-14. Fixed-effects model, overall association of kidney cancer and exposure to TCE stratified by study quality score.



270
271
272
273

Figure_Apx K-15. Fixed-effects model, overall association of liver cancer and exposure to TCE stratified by study quality score.



274
275
276
277

278 **Assessment of Publication Bias**


279 Funnel plots can be used to assess publication bias, a systematic error that occurs if statistically
280 significant studies are more likely to be submitted and published than nonsignificant studies. One feature
281 of publication bias is that smaller studies tend to have larger effect sizes than larger studies, since
282 smaller studies need larger effect sizes in order to be statistically significant. To measure this, funnel
283 plots plot standard error (SE) vs natural log of the RR (LnEst) to compare study size and effect size. If
284 there is no relationship, the studies should be symmetrically distributed around the summary RR
285 estimate (the vertical line), while publication bias is indicated by the points veering towards higher RR
286 estimates with increasing SEs (*i.e.*, toward the lower right).

287
288 Funnel plots including all studies (Figure_Apx K-16, a-c) were consistent with modest publication bias,
289 with a possible tendency toward omission of moderate-sized studies with weak or null associations.
290 With the ([Vlaanderen et al., 2013](#)) study omitted, however, the plots became more symmetrical,
291 consistent with an absence of publication bias among the remaining studies (Figure_Apx K-16, d-f).
292


293
294
295
296
297

Figure_Apx K-16. Funnel plots for publication bias.
All studies: a. NHL; b. kidney cancer; c. liver cancer;
Omitting Vlaanderen et al. (2013): d. NHL; e. kidney cancer; f. liver cancer.

a.




b.




298
299

c.




d.




300
301

e.



f.



302
303

304
305
306

K.2.3 Selected RR estimates and confidence intervals by study and cancer type

Table_Apx K-7. Selected RR estimates for NHL associated with TCE exposure (overall effect) from cohort studies published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	RR type	ln RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Bove et al. (2014a) (2799547)	1.15	0.56	2.34	HR	0.140	0.37	None	Adjusted hazard ratio for males and females; cumulative exposure for high exposure in enlisted personnel; reference group had no exposure to TCE; 10-year lag time; specific ICD codes were not reported.
Bove et al. (2014b) (2800329)	0.32	0.05	2.10	HR	-1.1	0.45	None	Adjusted hazard ratio for males and females, Camp Lejeune cohort; cumulative exposure to TCE, >median vs <median (referent group); 10-year lag time; specific ICD codes not reported.
Hansen et al. (2013) (2128005)	1.21	0.83	1.71	SIR	0.191	0.18	1.11 (0.68-1.72) SIR for 20-year lag time; 1.26 (0.89-1.73) SIR for no lag	ICD-7 200 + 202; standard incidence ratio for males and females in three populations (Denmark, Sweden, and Finland); 10-year lag time; study also reports hazard rate ratios for NHL based on urinary TCE metabolite
Lipworth et al. (2011) (1235276)	1.02	0.55	1.90	RR	0.020	0.32	1.10 (0.59-2.04) RR for 1-4 yr exposure; 0.84 (0.48-1.47) RR for <1 yr exposure; 1.31 (0.97-1.73) SMR for routine and intermittent exposure for at least 1 yr (compared with general population)	ICD-9 200 + 202; relative risk for sex and race combined; ≥5 yr exposure in workers, routine and intermittent exposure; referent category was nonexposed factory workers
Silver et al. (2014) (2799800)	0.87	0.57	1.35	HR	-0.14	0.22	None	Hazard ratio at 5 modified exposure years for males and females; cumulative exposure; adjusted for sex and paycode; 10-year lag time; specific ICD codes not reported.

Study	RR	95% LCL	95% UCL	RR type	ln RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Vlaanderen et al. (2013) 2128436	0.97	0.91	1.04	HR	-0.030	0.034	0.95 (0.84-1.06) HR for men and women; cumulative exposure for high exposure groups only (n=353 cases)	ICD-7 200 + 202; hazard ratio for men and women; third tertile of cumulative exposure (n=1211 cases); occupationally unexposed individuals were used as the reference group; unlagged exposure (up to 20 years of lag time had a negligible impact on HR)

307

308

Table_Apx K-8. Selected RR estimates for NHL associated with TCE exposure (overall effect) from case-control studies

309

published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	ln RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Christensen et al. (2013) (2127914)	1.2	0.5	2.9	0.18	0.45	1.0 (0.3–3.5) OR for substantial exposure	ICD-9 200 + 202; odds ratio for males and females; any exposure; adjusted by age, census tract median income, educational attainment (years), ethnicity, questionnaire respondent (self vs. proxy) and, smoking using population and cancer controls weighting proportionately
Cocco et al. (2013) (2129584)	1.4	0.9	2.1	0.34	0.22	1.0 (0.8-1.2); any vs no exposure in all subjects	Specific ICD codes not reported; odds ratio for males and females; all study subjects with high probability of exposure ; adjusted by age, sex, and contributing study (50 cases, 38 controls).

310

311

312

Table_Apx K-9. Selected RR estimates for NHL associated with TCE exposure (effect in the highest exposure group) studies

313

published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	log RR	SE (log RR)	Alternate RR estimates (95% CI)	Comments
Cohort Studies							

Hansen et al. (2013) (2128005)	0.66	0.21	2.03	HRR	-0.42	0.50	None
Vlaanderen et al. (2013) 2128436 Nested Case-control	0.95	0.84	1.06	HR	-0.051	0.059	0.96 (0.84-1.09) HR for men and women; intensity x prevalence for high exposure groups only (n=269 cases); occupationally unexposed individuals were used as the reference group; unlagged exposure
Case-Control Studies							
Christensen et al. (2013) (2127914)	1.0	0.3	3.5	0.00	0.63	NA	ICD-9 200 + 202; odds ratio for males and females; substantial exposure; adjusted by age, census tract median income, educational attainment (years), ethnicity, questionnaire respondent (self vs. proxy) and, smoking using population and cancer controls weighting proportionately.
Cocco et al. (2013) (2129584)	2.2	0.7	6.7	0.79	0.58	1.4 (1.0-2.1) OR for >150 ppm intensity level among all subjects.	Specific ICD codes were not reported; odds ratio for males and females; >75 ppm intensity level for study subjects with high probability of exposure (9 cases, 5 controls); adjusted by age, sex, and study.

314
315
316

Table_Apx K-10. Selected RR estimates for kidney cancer associated with TCE exposure (overall effect) from cohort studies published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	RR type	ln RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Bove et al. (2014a) (2799547)	1.52	0.64	3.61	HR	0.419	0.44	None	Adjusted hazard ratio for males and females; cumulative exposure for high exposure in enlisted personnel; reference group had no exposure to TCE; 10-year lag time
Buhagen et al. (2016) 3502047	1.7	1.0	3.0	SIR	0.53	0.30	None	14 cases had confirmed occupational exposure to TCE.
Hansen et al. (2013) (2128005)	1.04	0.71	1.50	SIR	0.039	0.18	1.11 (0.67-1.73) SIR for 20-year lag time; 1.01 (0.70-1.42) SIR for no lag	Standard incidence ratio for males and females in three populations (Denmark, Sweden, and Finland); 10-year lag time; study also reports hazard rate ratios for kidney cancer based on urinary TCE metabolite

Study	RR	95% LCL	95% UCL	RR type	ln RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Lipworth et al. (2011) (1235276)	0.85	0.33	2.19	RR	-0.16	0.48	0.42 (0.13-1.42) RR for 1-4 yr exposure; 0.52 (0.21-1.30) RR for <1 yr exposure; 0.66 (0.38-1.07) SMR for routine and intermittent exposure for at least 1 yr (compared with general population)	Relative risk; sex and race combined; ≥5 yr exposure in workers, routine and intermittent exposure; referent category was nonexposed factory workers
Silver et al. (2014) (2799800)	1.24	0.87	1.77	HR	0.215	0.18	None	Hazard ratio at 5 modified exposure years for males and females; cumulative exposure; adjusted for sex and paycode; 10-year lag time
Vlaanderen et al. (2013) (2128436)	1.00	0.95	1.07	HR	0.00	0.030	0.86 (0.75-0.98) HR for men and women; cumulative exposure for high exposure groups only (n=251 cases)	Hazard ratio for males and females; third tertile of cumulative exposure (n=1372 cases); occupationally unexposed individuals were used as the reference group; unlagged exposure (up to 20 years of lag time had a negligible impact on HR)

317
318
319

Table_Apx K-11. Selected RR estimates for kidney cancer associated with TCE exposure (overall effect) from case-control studies published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	ln RR	SE (ln RR)	Alternate RR estimate (95% CI)	Comments
Christensen et al. (2013) (2127914)	0.9	0.4	2.4	-0.11	0.46	0.6 (0.1-2.8) OR for substantial exposure	Odds ratio for males and females; any exposure, adjusted by age, census tract median income, educational attainment (years), ethnicity, questionnaire respondent (self vs. proxy), smoking, and coffee, beer, wine, and spirit intake using population and cancer controls weighting proportionately

Purdue et al. (2016) (3482059)	0.8	0.4	1.5	-0.22	0.34	OR 0.9 (0.5 – 1.9) for third tertile of cumulative hours exposed, any exposure intensity (23 cases, 19 controls).	Odds ratio for kidney cancer in group with highest probability of exposure ($\geq 90\%$; 32 cases, 32 controls); adjusted for age, sex, race, study center, education level, smoking status, BMI and history of hypertension
--------------------------------	-----	-----	-----	-------	------	---	--

320

321

322

Table_Apx K-12. Selected RR estimates for liver cancer associated with TCE exposure (overall effect) from cohort studies published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	RR type	ln RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Bove et al. (2014a) (2799547)	0.86	0.37	1.97	HR	-0.15	0.43	None	Adjusted hazard ratio for males and females; cumulative exposure for high exposure in enlisted personnel; reference group had no exposure to TCE; 10-year lag time
Hansen et al. (2013) (2128005)	1.83	1.24	2.56	SIR	0.604	0.177	2.09 (1.34-3.11) SIR for 20-year lag time; 1.77 (1.24-2.45) SIR for no lag	Liver and biliary passages; standard incidence ratio for males and females in three populations (Denmark, Sweden, and Finland); 10-year lag time; study also reports hazard rate ratios for liver and biliary passages cancer based on urinary TCE metabolite
Lipworth et al. (2011) (1235276)	0.83	0.36	1.91	RR	-0.19	0.43	0.69 (0.28-1.71) RR for 1-4 yr exposure; 0.67 (0.32-1.42) RR for <1 yr exposure 0.89 (0.57-1.33) SMR for routine and intermittent exposure for at least 1 yr (compared with general population)	Liver and biliary passages; relative risk; sex and race combined; ≥ 5 yr exposure in workers, routine and intermittent exposure; referent category was nonexposed factory workers
Silver et al. (2014) (2799800)	0.99	0.50	1.95	HR	-0.010	0.35	None	Liver, biliary passages, and gallbladder; hazard ratio at 5 modified exposure years for males and females; cumulative exposure; adjusted for sex and paycode; 10-year lag time

Study	RR	95% LCL	95% UCL	RR type	In RR	SE (ln RR)	Alternate RR estimates (95% CI)	Comments
Vlaanderen et al. (2013) 2128436	1.00	0.90	1.11	HR	0.00	0.054	1.02 (0.82-1.25) HR for men and women; cumulative exposure for high exposure groups only (n=106 cases)	Hazard ratio for males and females; third tertile of cumulative exposure (n=422 cases); occupationally unexposed individuals were used as the reference group; unlagged exposure (up to 20 years of lag time had a negligible impact on HR)

323
324
325

Table_Apx K-13. Selected RR estimates for liver cancer associated with TCE exposure (overall effect) from case-control studies published after U.S. EPA (2011)

Study	RR	95% LCL	95% UCL	ln RR	SE (ln RR)	Alternate RR estimate (95% CI)	Comments
Christensen et al. (2013) (2127914)	1.1	0.1	8.5	0.095	1.1	2.1 (0.2-18) OR for substantial exposure	Odds ratio for males and females; any exposure, adjusted by age, census tract median income, educational attainment (years), ethnicity, questionnaire respondent (self vs. proxy), smoking, and beer, wine, and spirit intake using population and cancer controls weighting proportionately

326

327 **K.2.4 Sample Stata commands for meta-analysis**

328 Notes: the variables LnEst and SE are the natural log(RR) and its estimated standard error,
329 respectively; Author_date labels studies on forest plots.
330

331 Basic fixed-effects analysis with axis labels:
332 metan LnEst SE, eform label(namevar=Author_date) effect(RR) xlabel(0.1, 0.2, 0.5, 1.0,
333 2.0,5.0,10)
334

335 Basic random-effects analysis with axis labels:
336 metan LnEst SE random, eform label(namevar=Author_date) effect(RR) xlabel(0.1, 0.2, 0.5, 1.0,
337 2.0,5.0,10)
338

339 Basic fixed-effects model omitting one study (indicated by NAME):
340 metan LnEst SE if Author!="NAME", eform label(namevar=Author_date) effect(RR) xlabel(0.1,
341 0.2, 0.5, 1.0, 2.0,5.0,10)
342

343 Fixed-effects model stratifying by quality score (HiQ):
344 metan LnEst SE, eform label(namevar=Author_date) effect(RR) xlabel(0.1, 0.2, 0.5, 1.0,
345 2.0,5.0,10) by(HiQ)
346

347 Basic “leave one out” analysis of influence:
348 metaninf LnEst SE, eform label(namevar=Author_date) effect(RR)
349

350 Basic funnel plot:
351 metafunnel LnEst SE
352

353 **Appendix L APPROACH FOR ESTIMATING WATER**
 354 **RELEASES FROM MANUFACTURING SITES**
 355 **USING EFFLUENT GUIDELINES**

356 This appendix presents a methodology for estimating water releases of TCE from manufacturing
 357 sites using effluent guidelines (EGs). This method uses the maximum daily and maximum
 358 average monthly concentrations allowed under the Organic Chemicals, Plastics and Synthetic
 359 Fibers (OCPSF) Effluent Guidelines and Standards ([U.S. EPA](#)). EGs are national regulatory
 360 standards set forth by EPA for wastewater discharges to surface water and municipal sewage
 361 treatment plants. The OCPSF EG applies to facilities classified under the following SIC codes:

- 362
- 363 • 2821—Plastic Materials, Synthetic Resins, and Nonvulcanizable Elastomers;
- 364 • 2823—Cellulosic Man-Made Fibers;
- 365 • 2865—Cyclic Crudes and Intermediates, Dyes, and Organic Pigments; and
- 366 • 2869—Industrial Organic Chemicals, Not Elsewhere Classified.
- 367

368 Manufacturers of TCE would typically be classified under SIC code 2869; therefore, the
 369 requirements of the OCPSF EG are assumed to apply to manufacturing sites. Subparts I, J, and K
 370 of the OCPSF EG set limits for the concentration of TCE in wastewater effluent for industrial
 371 facilities that are direct discharge point sources using end-of-pipe biological treatment, direct
 372 discharge point sources that do not use end-of-pipe biological treatment, and indirect discharge
 373 point sources, respectively ([U.S. EPA, 2019c](#)). Direct dischargers are facilities that discharge
 374 effluent directly to surface waters and indirect dischargers are facilities that discharge effluent to
 375 publicly-owned treatment works (POTW). The OCPSF limits for TCE in each of the Subparts
 376 are provided in Table_Apx L-1.

377 **Table_Apx L-1. Summary of OCPSF Effluent Guidelines for Trichloroethylene**
 378

OCPSF Subpart	Maximum for Any One Day (µg/L)	Maximum for Any Monthly Average (µg/L)	Basis
Subpart I – Direct Discharge Point Sources That Use End-of-Pipe Biological Treatment	54	21	BAT effluent limitations and NSPS
Subpart J – Direct Discharge Point Sources That Do Not Use End-of-Pipe Biological Treatment	69	26	BAT effluent limitations and NSPS
Subpart K – Indirect Discharge Point Sources	69	26	Pretreatment Standards for Existing Sources (PSES) and Pretreatment Standards for New Sources (PSNS)

379 BAT = Best Available Technology Economically Achievable; NSPS = New Source Performance Standards; PSES =
 380 Pretreatment Standards for Existing Sources; PSNS = Pretreatment Standards for New Sources.
 381 Source: ([U.S. EPA](#))

382
 383 To estimate daily releases from the EG, EPA used Equation I-1 to estimate daily releases and
 384 Equation D-2 to estimate annual releases using the parameters in Table_Apx L-2. The prevalence
 385 of end-of-pipe biological treatment is unknown; therefore, EPA used the discharge limits for
 386 direct discharge point sources that do not use end-of-pipe biological treatment (Subpart J) and
 387 indirect discharge point sources (Subpart K). EPA estimated a central tendency daily release
 388 using the limit for the maximum monthly average (26 µg/L) from Subparts J and K, a high-end
 389 daily release using the limit for the maximum for any one day (69 µg/L) from Subparts J and K,
 390 and an annual release using the maximum monthly average from Subparts J and K.

391
 392 **Equation L-1**

$$DR = \frac{DL \times PW \times PV}{1,000,000,000 \times OD}$$

393
 394
 395 **Equation L-2**

$$AR = \frac{DL \times PW \times PV}{1,000,000,000}$$

396
 397
 398 **Table_Apx L-2. Default Parameters for Estimating Water Releases of Trichloroethylene**
 399 **from Manufacturing Sites**

Parameter	Parameter Description	Default Value	Unit
DR	Daily release rate	Calculated from equation	kg/site-day
DL	Discharge limit ^a	Max Daily: 69 Average Daily: 26 Annual: 26	µg/L
PW	Produced water ^b	10	L/kg
PV	Annual TCE production volume	Site-specific	kg/site-yr
OD	Operating Days ^c	350	days/yr
AR	Annual release rate	Calculated from equation	kg/site-yr

400 ^a Discharge limits are based on the maximum discharge limits allowed in the OCPSF EG, which correspond to the
 401 discharge limits for direct discharge point sources with no biological end-of-pipe treatment (Subpart J) and indirect
 402 discharge points sources (Subpart K) (citation for 40 C.F.R. 414). There is no “average” daily discharge limit set by
 403 the EGs; therefore, EPA assumed that the average daily discharge concentration would be equal to the maximum
 404 monthly average discharge limit.

405 ^b The amount of produced water per kilogram of TCE produced is based on the SpERC developed by the European
 406 Solvent Industry Group for the manufacture of a substance, which estimates 10 m³ of wastewater generated per
 407 metric ton of substance produced and converted to 10 L/kg ([European Solvents Industry Group \(ESIG\), 2012](#)).

408
 409 ^c Due to large throughput, manufacturing sites are assumed to operate seven days per week and 50 weeks per year
 410 with two weeks per year for shutdown activities.

411
 412 EPA did not identify TCE-specific information on the amount of wastewater produced per day.
 413 The Specific Environmental Release Category (SpERC) developed by the European Solvent
 414 Industry Group for the manufacture of a substance estimates 10 m³ of wastewater generated per
 415 metric ton of substance produced (equivalent to 10 L water/kg of substance produced) ([European](#)
 416 [Solvents Industry Group \(ESIG\), 2012](#)). In lieu of TCE-specific information, EPA estimated
 417 wastewater flow using the SpERC specified wastewater production volume and the annual TCE
 418 production rates for each facility. Table_Apx L-3 provides estimated daily production volume
 419 and wastewater flow for each facility that EPA used the EG to assess water releases.
 420

421 **Table_Apx L-3. Summary of Facility Trichloroethylene Production Volumes and**
 422 **Wastewater Flow Rates**

Site	Annual Production Volume (kg/site-yr)	Annual Operating Days (days/yr)	Daily Production Volume (kg/site-day)	Daily Wastewater Flow (L/site-day)
Solvents & Chemicals, Pearland, TX ^a	20,382,094	350	58,234	582,345

423 ^a The 2015 annual production volumes in the 2016 CDR for this site was either claimed as CBI or withheld. EPA
 424 estimated the production volume by subtracting known site production volumes from the national production
 425 volume and averaging the result over all the sites with CBI or withheld production volumes and converting from
 426 pounds to kilograms.
 427

428 EPA estimated both a maximum daily release and an average daily release using the OCPSF EG
 429 limits for TCE for maximum on any one day and maximum for any monthly average,
 430 respectively. Prevalence of end-of-pipe biological treatment at TCE manufacturing sites is
 431 unknown; therefore, EPA used limits for direct discharges with no end-of-pipe biological
 432 treatment and indirect dischargers as conservative. EPA estimated annual releases from the
 433 average daily release and assuming 350 days/yr of operation.
 434

435 Example max daily, average daily, and annual water release calculations for TCE at
 436 manufacturing sites based on the estimated production volume for Solvents & Chemicals
 437 (44,934,862 lbs/yr or 20,382,094 kg/yr):³⁰
 438

$$439 \quad \text{Max DR} = \frac{69 \frac{\mu\text{g}}{\text{L}} \times 10 \frac{\text{L}}{\text{kg}} \times 20,382,094 \frac{\text{kg}}{\text{yr}}}{1,000,000,000 \frac{\mu\text{g}}{\text{kg}} \times 350 \frac{\text{days}}{\text{yr}}} = 0.04 \frac{\text{kg}}{\text{day}}$$

440

³⁰ This estimated production volume is equal to the estimated production volume assessed for all manufacturing sites.

441
$$\text{Average DR} = \frac{26 \frac{\mu\text{g}}{\text{L}} \times 10 \frac{\text{L}}{\text{kg}} \times 20,382,094 \frac{\text{kg}}{\text{yr}}}{1,000,000,000 \frac{\mu\text{g}}{\text{kg}} \times 350 \frac{\text{days}}{\text{yr}}} = 0.015 \frac{\text{kg}}{\text{day}}$$

442

443
$$\text{AR} = \frac{26 \frac{\mu\text{g}}{\text{L}} \times 10 \frac{\text{L}}{\text{kg}} \times 20,382,094 \frac{\text{kg}}{\text{yr}}}{1,000,000,000 \frac{\mu\text{g}}{\text{kg}}} = 5.3 \frac{\text{kg}}{\text{yr}}$$

444

445 **Appendix M SAMPLE CALCULATIONS FOR**
446 **CALCULATING ACUTE AND CHRONIC (NON-**
447 **CANCER AND CANCER) INHALATION**
448 **EXPOSURE**

449 Sample calculations for high-end and central tendency acute and chronic exposure
450 concentrations for one setting, Manufacturing, are demonstrated below. The explanation of the
451 equations and parameters used is provided in [*Environmental Releases and Occupational*
452 *Exposure Assessment. Docket: [EPA-HQ-OPPT-2019-0500](#)]. The final values will have two
453 significant figures since they are based on values from modeling.
454*

455 **M.1 Example High-End AC, ADC, and LADC**

456 Calculate AC_{HE} :

$$459 \quad AC_{HE} = \frac{C_{HE} \times ED}{AT_{acute}}$$

$$461 \quad AC_{HE} = \frac{2.6 \text{ ppm} \times 8 \text{ hr/day}}{24 \text{ hr/day}} = 0.87 \text{ ppm}$$

462 Calculate ADC_{HE} :

$$464 \quad ADC_{HE} = \frac{C_{HE} \times ED \times EF \times EWY}{AT}$$

$$466 \quad ADC_{HE} = \frac{2.6 \text{ ppm} \times 8 \frac{\text{hr}}{\text{day}} \times 250 \frac{\text{days}}{\text{year}} \times 40 \text{ years}}{\left(40 \text{ years} \times 365 \frac{\text{days}}{\text{year}} \times 24 \frac{\text{hours}}{\text{day}}\right)} = 0.59 \text{ ppm}$$

467 Calculate $LADC_{HE}$:

$$470 \quad LADC_{HE} = \frac{C_{HE} \times ED \times EF \times EWY}{AT_{LADC}}$$

$$472 \quad LADC_{HE} = \frac{2.6 \text{ ppm} \times 8 \frac{\text{hr}}{\text{day}} \times 250 \frac{\text{days}}{\text{year}} \times 40 \text{ years}}{\left(78 \text{ years} \times 365 \frac{\text{days}}{\text{year}} \times 24 \frac{\text{hours}}{\text{day}}\right)} = 0.30 \text{ ppm}$$

M.2 Example Central Tendency AEC, ADC, and LADC

475

476

477 Calculate AC_{CT}:

478

$$AC_{CT} = \frac{C_{CT} \times ED}{AT_{acute}}$$

479

480

$$AC_{CT} = \frac{0.03 \text{ ppm} \times 8 \text{ hr/day}}{24 \text{ hr/day}} = 0.01 \text{ ppm}$$

481

482 Calculate ADC_{CT}:

483

$$ADC_{CT} = \frac{C_{CT} \times ED \times EF \times WY}{AT}$$

484

485

$$ADC_{CT} = \frac{0.03 \text{ ppm} \times 8 \frac{\text{hr}}{\text{day}} \times 250 \frac{\text{days}}{\text{year}} \times 31 \text{ years}}{31 \text{ years} \times 365 \frac{\text{days}}{\text{yr}} \times 24 \frac{\text{hr}}{\text{day}}} = 0.01 \text{ ppm}$$

486

487 Calculate LADC_{CT}:

488

$$LADC_{CT} = \frac{C_{CT} \times ED \times EF \times WY}{AT_c}$$

489

490

$$LADC_{CT} = \frac{0.03 \text{ ppm} \times 8 \frac{\text{hr}}{\text{day}} \times 250 \frac{\text{days}}{\text{year}} \times 31 \text{ years}}{78 \text{ years} \times 365 \frac{\text{days}}{\text{year}} \times 24 \text{ hr/day}} = 2.8 \times 10^{-3} \text{ ppm}$$

491 **Appendix N VAPOR DEGREASING AND COLD CLEANING**
492 **NEAR-FIELD/FAR-FIELD INHALATION EXPOSURE**
493 **MODELS APPROACH AND PARAMETERS**

494
495 This appendix presents the modeling approach and model equations used in the following models:
496

- 497 • Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model;
- 498 • Conveyorized Degreasing Near-Field/Far-Field Inhalation Exposure Model;
- 499 • Web Degreasing Near-Field/Far-Field Inhalation Exposure Model; and
- 500 • Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model.

501
502 The models were developed through review of the literature and consideration of existing EPA exposure
503 models. These models use a near-field/far-field approach (Nicas, 2009), where a vapor generation source
504 located inside the near-field diffuses into the surrounding environment. Workers are assumed to be
505 exposed to TCE vapor concentrations in the near-field, while occupational non-users are exposed at
506 concentrations in the far-field.

507
508 The model uses the following parameters to estimate exposure concentrations in the near-field and far-
509 field:

- 510 • Far-field size;
- 511 • Near-field size;
- 512 • Air exchange rate;
- 513 • Indoor air speed;
- 514 • Exposure duration;
- 515 • Vapor generation rate; and
- 516 • Operating hours per day.

517
518
519 An individual model input parameter could either have a discrete value or a distribution of values. EPA
520 assigned statistical distributions based on reasonably available literature data. A Monte Carlo simulation
521 (a type of stochastic simulation) was conducted to capture variability in the model input parameters. The
522 simulation was conducted using the Latin hypercube sampling method in @Risk Industrial Edition,
523 Version 7.0.0. The Latin hypercube sampling method is a statistical method for generating a sample of
524 possible values from a multi-dimensional distribution. Latin hypercube sampling is a stratified method,
525 meaning it guarantees that its generated samples are representative of the probability density function
526 (variability) defined in the model. EPA performed the model at 100,000 iterations to capture the range of
527 possible input values (*i.e.*, including values with low probability of occurrence).

528
529 Model results from the Monte Carlo simulation are presented as 95th and 50th percentile values. The
530 statistics were calculated directly in @Risk. The 95th percentile value was selected to represent high-end
531 exposure level, whereas the 50th percentile value was selected to represent typical exposure level. The
532 following subsections detail the model design equations and parameters for vapor degreasing and cold
533 cleaning models.
534

535

N.1 Model Design Equations

536

537

538

539

540

541


542

543

544

545

Figure_Apx N-1 through Figure_Apx N-3 illustrate the near-field/far-field modeling approach as it was applied by EPA to each vapor degreasing and cold cleaning model. As the figures show, volatile TCE vapors evaporate into the near-field, resulting in worker exposures at a TCE concentration C_{NF} . The concentration is directly proportional to the evaporation rate of TCE, (denoted by “G” in Figure 2-7), into the near-field, whose volume is denoted by V_{NF} . The ventilation rate for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field, resulting in occupational non-user exposures to TCE at a concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the TCE dissipates out of the near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly TCE dissipates out of the surrounding space and into the outside air.



546


547

548

549


550

Figure_Apx N-1. The Near-Field/Far-Field Model as Applied to the Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model and the Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model



551
552
553
554

Figure_Apx N-2. The Near-Field/Far-Field Model as Applied to the Conveyorized Degreasing Near-Field/Far-Field Inhalation Exposure Model



555
556
557
558
559
560
561

Figure_Apx N-3. The Near-Field/Far-Field Model as Applied to the Web Degreasing Near-Field/Far-Field Inhalation Exposure Model

The model design equations are presented below in Equation K-1 through Equation K-18. Note the design equations are the same for each of the models discussed in this appendix.

562 Near-Field Mass Balance

563 **Equation K-1**

564
$$V_{NF} \frac{dC_{NF}}{dt} = C_{FF}Q_{NF} - C_{NF}Q_{NF} + G$$

565 Far-Field Mass Balance

566 **Equation K-2**

567
$$V_{FF} \frac{dC_{FF}}{dt} = C_{NF}Q_{NF} - C_{FF}Q_{NF} - C_{FF}Q_{FF}$$

568 Where:

- 569 V_{NF} = near-field volume;
570 V_{FF} = far-field volume;
571 Q_{NF} = near-field ventilation rate;
572 Q_{FF} = far-field ventilation rate;
573 C_{NF} = average near-field concentration;
574 C_{FF} = average far-field concentration;
575 G = average vapor generation rate; and
576 t = elapsed time.

577

578 Both of the previous equations can be solved for the time-varying concentrations in the near-field and
579 far-field as follows ([Nicas, 2009](#)):

580

581 **Equation K-3**

582
$$C_{NF} = G(k_1 + k_2e^{\lambda_1 t} - k_3e^{\lambda_2 t})$$

583

584 **Equation K-4**

585
$$C_{FF} = G\left(\frac{1}{Q_{FF}} + k_4e^{\lambda_1 t} - k_5e^{\lambda_2 t}\right)$$

586 Where:

587 **Equation K-5**

588
$$k_1 = \frac{1}{\left(\frac{Q_{NF}}{Q_{NF} + Q_{FF}}\right) Q_{FF}}$$

589

590 **Equation K-6**

591
$$k_2 = \frac{Q_{NF}Q_{FF} + \lambda_2 V_{NF}(Q_{NF} + Q_{FF})}{Q_{NF}Q_{FF}V_{NF}(\lambda_1 - \lambda_2)}$$

592

593 **Equation K-7**

594
$$k_3 = \frac{Q_{NF}Q_{FF} + \lambda_1 V_{NF}(Q_{NF} + Q_{FF})}{Q_{NF}Q_{FF}V_{NF}(\lambda_1 - \lambda_2)}$$

595

596 **Equation K-8**

597
$$k_4 = \left(\frac{\lambda_1 V_{NF} + Q_{NF}}{Q_{NF}}\right) k_2$$

598

599 **Equation K-9**

600
$$k_5 = \left(\frac{\lambda_2 V_{NF} + Q_{NF}}{Q_{NF}}\right) k_3$$

601
602

Equation K-10

$$\lambda_1 = 0.5 \left[- \left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right) + \sqrt{\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right)^2 - 4 \left(\frac{Q_{NF}Q_{FF}}{V_{NF}V_{FF}} \right)} \right]$$

604
605

Equation K-11

$$\lambda_2 = 0.5 \left[- \left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right) - \sqrt{\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right)^2 - 4 \left(\frac{Q_{NF}Q_{FF}}{V_{NF}V_{FF}} \right)} \right]$$

607

608 EPA calculated the hourly TWA concentrations in the near-field and far-field using Equation M-1221
609 and Equation M-13, respectively. Note that the numerator and denominator of Equation M-1221 and
610 Equation M-132 use two different sets of time parameters. The numerator is based on operating times
611 for the scenario (e.g., two or eight hours for OTVDs, 8 to 24 hours for conveyORIZED degreasers, 8 hours
612 for web degreasers, and 3 to 8 hours for cold cleaning, see Appendix P.2) while the denominator is fixed
613 to an average time span, t_{avg} , of eight hours (since EPA is interested in calculating 8-hr TWA
614 exposures). Mathematically, the numerator and denominator must reflect the same amount of time. This
615 is indeed the case since the numerator assumes exposures are zero for any hours not within the operating
616 time. Therefore, mathematically speaking, both the numerator and the denominator reflect eight hours
617 regardless of the values selected for t_1 and t_2 .

618
619

Equation K-12

$$C_{NF,TWA} = \frac{\int_{t_1}^{t_2} C_{NF} dt}{\int_0^{t_{avg}} dt} = \frac{\int_{t_1}^{t_2} G(k_1 + k_2 e^{\lambda_1 t} - k_3 e^{\lambda_2 t}) dt}{t_{avg}} =$$

$$\frac{G \left(k_1 t_2 + \frac{k_2 e^{\lambda_1 t_2}}{\lambda_1} - \frac{k_3 e^{\lambda_2 t_2}}{\lambda_2} \right) - G \left(k_1 t_1 + \frac{k_2 e^{\lambda_1 t_1}}{\lambda_1} - \frac{k_3 e^{\lambda_2 t_1}}{\lambda_2} \right)}{t_{avg}}$$

623
624

Equation K-13

$$C_{FF,TWA} = \frac{\int_{t_1}^{t_2} C_{FF} dt}{\int_0^{t_{avg}} dt} = \frac{\int_{t_1}^{t_2} G \left(\frac{1}{Q_{FF}} + k_4 e^{\lambda_1 t} - k_5 e^{\lambda_2 t} \right) dt}{t_{avg}} =$$

$$\frac{G \left(\frac{t_2}{Q_{FF}} + \frac{k_4 e^{\lambda_1 t_2}}{\lambda_1} - \frac{k_5 e^{\lambda_2 t_2}}{\lambda_2} \right) - G \left(\frac{t_1}{Q_{FF}} + \frac{k_4 e^{\lambda_1 t_1}}{\lambda_1} - \frac{k_5 e^{\lambda_2 t_1}}{\lambda_2} \right)}{t_{avg}}$$

628
629
630
631
632
633

To calculate the mass transfer to and from the near-field, the free surface area, FSA, is defined to be the surface area through which mass transfer can occur. Note that the FSA is not equal to the surface area of the entire near-field. EPA defined the near-field zone to be a rectangular box resting on the floor; therefore, no mass transfer can occur through the near-field box's floor. FSA is calculated in Equation M-23, below:

634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660

Equation K-14

$$FSA = 2(L_{NF}H_{NF}) + 2(W_{NF}H_{NF}) + (L_{NF}W_{NF})$$

Where: L_{NF} , W_{NF} , and H_{NF} are the length, width, and height of the near-field, respectively. The near-field ventilation rate, Q_{NF} , is calculated in Equation M-154 from the near-field indoor wind speed, v_{NF} , and FSA, assuming half of FSA is available for mass transfer into the near-field and half of FSA is available for mass transfer out of the near-field:

Equation K-15

$$Q_{NF} = \frac{1}{2}v_{NF}FSA$$

The far-field volume, V_{FF} , and the air exchange rate, AER, is used to calculate the far-field ventilation rate, Q_{FF} , as given by Equation M-25:

Equation K-16

$$Q_{FF} = V_{FF}AER$$

Using the model inputs described in Appendix E.2, EPA estimated TCE inhalation exposures for workers in the near-field and for occupational non-users in the far-field. EPA then conducted the Monte Carlo simulations using @Risk (Version 7.0.0). The simulations applied 100,000 iterations and the Latin Hypercube sampling method for each model.

N.2 Model Parameters

Table_Apx N-1 through Table_Apx N-4 summarize the model parameters and their values for each of the models discussed in this Appendix. Each parameter is discussed in detail in the following subsections.

661
662
663

Table_Apx N-1. Summary of Parameter Values and Distributions Used in the Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model

Input Parameter	Symbol	Unit	Deterministic Values		Uncertainty Analysis Distribution Parameters				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Far-field volume	V _{FF}	ft ³	10,594	Midpoint	10,594	70,629	17,657	Triangular	See Section N.2.1
Air exchange rate	AER	hr ⁻¹	2	Mode	2	20	3.5	Triangular	See Section N.2.2
Near-field indoor wind speed	V _{NF}	ft/hr	1,181	50th percentile	154	23,882	—	—	See Section N.2.3
		cm/s	10	50th percentile	1.3	202.2	—	—	
Near-field length	L _{NF}	ft	10	—	—	—	—	Constant Value	See Section N.2.4
Near-field width	W _{NF}	ft	10	—	—	—	—	Constant Value	
Near-field height	H _{NF}	ft	6	—	—	—	—	Constant Value	
Starting time	t ₁	hr	0	—	—	—	—	Constant Value	Constant.
Exposure Duration	t ₂	hr	8	—	2	8	—	--	See Section N.2.5
Averaging Time	t _{avg}	hr	8	—	—	—	—	Constant Value	See Section N.2.6
Vapor generation rate	G	mg/hr	2.34E+07	Average	4.54E+02	4.67E+07	—	Discrete	See Section N.2.7
		lb/hr	51.50	Average	0.001	103.00	—	Discrete	
Operating hours per day	OH	hr/day	8	—	—	—	—	Discrete	See Section E.2.8

664
665**Table_Apx N-2. Summary of Parameter Values and Distributions Used in the Conveyorized Degreasing Near-Field/Far-Field Inhalation Exposure Model**

Input Parameter	Symbol	Unit	Deterministic Values		Uncertainty Analysis Distribution Parameters				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Far-field volume	V _{FF}	ft ³	10,594	Midpoint	10,594	70,629	17,657	Triangular	See Section N.2.1
Air exchange rate	AER	hr ⁻¹	2	Mode	2	20	3.5	Triangular	See Section N.2.2
Near-field indoor wind speed	V _{NF}	ft/hr	1,181	50th percentile	154	23,882	—	—	See Section N.2.3
		cm/s	10	50th percentile	1.3	202.2	—	—	
Near-field length	L _{NF}	ft	10	—	—	—	—	Constant Value	See Section N.2.4
Near-field width	W _{NF}	ft	10	—	—	—	—	Constant Value	
Near-field height	H _{NF}	ft	6	—	—	—	—	Constant Value	
Starting time	t ₁	hr	0	—	—	—	—	Constant Value	Constant.
Exposure Duration	t ₂	hr	24	—	24	8	—	Constant Value	See Section N.2.5
Averaging Time	t _{avg}	hr	8	—	—	—	—	Constant Value	See Section N.2.6
Vapor generation rate	G	mg/hr	1.6E+07	Average	3.63E+05	3.29E+07	—	Discrete	See Section N.2.7
		lb/hr	36.6	Average	0.80	72.5	—	Discrete	
Operating hours per day	OH	hr/day	24	—	—	—	—	Constant	See Section E.2.8

666
667**Table_Apx N-3. Summary of Parameter Values and Distributions Used in the Web Degreasing Near-Field/Far-Field Inhalation Exposure Model**

Input Parameter	Symbol	Unit	Deterministic Values		Uncertainty Analysis Distribution Parameters				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Far-field volume	V _{FF}	ft ³	10,594	Midpoint	10,594	70,629	17,657	Triangular	See Section N.2.1
Air exchange rate	AER	hr ⁻¹	2	Mode	2	20	3.5	Triangular	See Section N.2.2
Near-field indoor wind speed	V _{NF}	ft/hr	1,181	50th percentile	154	23,882	—	—	See Section N.2.3
		cm/s	10	50th percentile	1.3	202.2	—	—	
Near-field length	L _{NF}	ft	10	—	—	—	—	Constant Value	See Section N.2.4
Near-field width	W _{NF}	ft	10	—	—	—	—	Constant Value	
Near-field height	H _{NF}	ft	6	—	—	—	—	Constant Value	
Starting time	t ₁	hr	0	—	—	—	—	Constant Value	Constant.
Exposure Duration	t ₂	hr	8	—	8	8	—	Constant Value	See Section N.2.5
Averaging Time	t _{avg}	hr	8	—	—	—	—	Constant Value	See Section N.2.6
Vapor generation rate	G	mg/hr	—	—	1.12E+05	1.12E+05	—	Discrete	See Section N.2.7; Single Data Point
Operating hours per day	OH	hr/day	24	—	—	—	—	Constant	See Section P.2.8

668
669**Table_Apx N-4. Summary of Parameter Values and Distributions Used in the Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model**

Input Parameter	Symbol	Unit	Deterministic Values		Uncertainty Analysis Distribution Parameters				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Far-field volume	V _{FF}	ft ³	10,594	Midpoint	10,594	70,629	17,657	Triangular	See Section N.2.1
Air exchange rate	AER	hr ⁻¹	2	Mode	2	20	3.5	Triangular	See Section N.2.2
Near-field indoor wind speed	V _{NF}	ft/hr	1,181	50th percentile	154	23,882	—	—	See Section N.2.3
		cm/s	10	50th percentile	1.3	202.2	—	—	
Near-field length	L _{NF}	ft	10	—	—	—	—	Constant Value	See Section N.2.4
Near-field width	W _{NF}	ft	10	—	—	—	—	Constant Value	
Near-field height	H _{NF}	ft	6	—	—	—	—	Constant Value	
Starting time	t ₁	hr	0	—	—	—	—	Constant Value	Constant.
Exposure Duration	t ₂	hr	—	—	3	8	—	Discrete	See Section N.2.5
Averaging Time	t _{avg}	hr	8	—	—	—	—	Constant Value	See Section N.2.6
Vapor generation rate	G	mg/hr	5.14E+05	Average	6.28E+02	1.02E+06	—	Discrete	See Section N.2.7
		lb/hr	1.13	Average	0.001	2.26	—	Discrete	
Operating hours per day	OH	hr/day	—	—	—	—	—	—	See Section P.2.8

670

671 **N.2.1 Far-Field Volume**

672 EPA used the same far-field volume distribution for each of the models discussed. The far-field volume
673 is based on information obtained from ([Von Grote et al., 2003](#)) that indicated volumes at German metal
674 degreasing facilities can vary from 300 to several thousand cubic meters. They noted that smaller
675 volumes are more typical and assumed 400 and 600 m³ (14,126 and 21,189 ft³) in their exposure models
676 ([Von Grote et al., 2003](#)). These are the highest and lowest values EPA identified in the literature;
677 therefore, EPA assumes a triangular distribution bound from 300 m³ (10,594 ft³) to 2,000 m³ (70,629 ft³)
678 with a mode of 500 m³ (the midpoint of 400 and 600 m³) (17,657 ft³).

679 **N.2.2 Air Exchange Rate**

680 EPA used the same air exchange rate distribution for each of the models discussed. The air exchange
681 rate is based on data from ([Hellweg et al., 2009](#)) and information received from a peer reviewer during
682 the development of the 2014 *TSCA Work Plan Chemical Risk Assessment Trichloroethylene:
683 Degreasing, Spot Cleaning and Arts & Crafts Uses* ([U.S. EPA, 2013a](#)). ([Hellweg et al., 2009](#)) reported
684 that average air exchange rates for occupational settings using mechanical ventilation systems vary from
685 3 to 20 hr⁻¹. The risk assessment peer reviewer comments indicated that values around 2 to 5 hr⁻¹ are
686 likely ([U.S. EPA, 2013a](#)), in agreement with the low end reported by ([Hellweg et al., 2009](#)). Therefore,
687 EPA used a triangular distribution with the mode equal to 3.5 hr⁻¹, the midpoint of the range provided by
688 the risk assessment peer reviewer (3.5 is the midpoint of the range 2 to 5 hr⁻¹), with a minimum of 2 hr⁻¹,
689 per the risk assessment peer reviewer ([U.S. EPA, 2013a](#)) and a maximum of 20 hr⁻¹ per ([Hellweg et al.,
690 2009](#)).

691 **N.2.3 Near-Field Indoor Air Speed**

692 ([Baldwin and Maynard, 1998a](#)) measured indoor air speeds across a variety of occupational settings in
693 the United Kingdom. Fifty-five work areas were surveyed across a variety of workplaces.

694
695 EPA analyzed the air speed data from ([Baldwin and Maynard, 1998a](#)) and categorized the air speed
696 surveys into settings representative of industrial facilities and representative of commercial facilities.
697 EPA fit separate distributions for these industrial and commercial settings and used the industrial
698 distribution for facilities performing vapor degreasing and/or cold cleaning.

699
700 EPA fit a lognormal distribution for both data sets as consistent with the authors observations that the air
701 speed measurements within a surveyed location were lognormally distributed and the population of the
702 mean air speeds among all surveys were lognormally distributed. Since lognormal distributions are
703 bound by zero and positive infinity, EPA truncated the distribution at the largest observed value among
704 all of the survey mean air speeds from ([Baldwin and Maynard, 1998a](#)) (1998).

705
706 EPA fit the air speed surveys representative of industrial facilities to a lognormal distribution with the
707 following parameter values: mean of 22.414 cm/s and standard deviation of 19.958 cm/s. In the model,
708 the lognormal distribution is truncated at a maximum allowed value of 202.2 cm/s (largest surveyed
709 mean air speed observed in ([Baldwin and Maynard, 1998a](#)) (1998)) to prevent the model from sampling
710 values that approach infinity or are otherwise unrealistically large.

711
712 ([Baldwin and Maynard, 1998a](#)) only presented the mean air speed of each survey. The authors did not
713 present the individual measurements within each survey. Therefore, these distributions represent a
714 distribution of mean air speeds and not a distribution of spatially variable air speeds within a single
715 workplace setting. However, a mean air speed (averaged over a work area) is the required input for the
716 model.

717 **N.2.4 Near-Field Volume**

718 EPA assumed a near-field of constant dimensions of 10 ft x 10 ft x 6 ft resulting in a total volume of 600
719 ft³.

720 **N.2.5 Exposure Duration**

721 EPA assumed the maximum exposure duration for each model is equal to the entire work-shift (eight
722 hours). Therefore, if the degreaser/cold cleaning machine operating time was greater than eight hours,
723 then exposure duration was set equal to eight hours. If the operating time was less than eight hours, then
724 exposure duration was set equal to the degreaser/cold cleaning machine operating time (see Appendix
725 E.2.8 for discussion of operating hours).

726 **N.2.6 Averaging Time**

727 EPA was interested in estimating 8-hr TWAs for use in risk calculations; therefore, a constant averaging
728 time of eight hours was used for each of the models.

729 **N.2.7 Vapor Generation Rate**

730 For the vapor generation rate from each machine type (OTVD, conveyORIZED and cold), EPA used a
731 discrete distribution based on the annual unit emission rates reported in the ([U.S. EPA, 2018a](#)). No web
732 degreasers were reported in the 2014 NEI, therefore, ([U.S. EPA, 2011a](#)) data were used for web
733 degreasers. Annual unit emission rates were converted to hourly unit emission rates by dividing the
734 annual reported emissions by the reported annual operating hours (see Appendix E.2.8). Reported annual
735 emissions in NEI without accompanying reported annual operating hours were not included in the
736 analysis. Emission rates reported as zero were also excluded as it is unclear if this is before or after
737 vapor controls used by the site and if the vapor controls used would control emissions into the work area
738 (thus reducing exposure) or only control emissions to the environment (which would not affect worker
739 exposures). Table_Apx N-5 summarizes the data available in the 2014 NEI.

741 **Table_Apx N-5. Summary of Trichloroethylene Vapor Degreasing and Cold Cleaning Data from**
742 **the 2014 NEI**

Unit Type	Total Units	Units with Zero Emissions	Units without Accompanying Operating Hours	Units Used in Analysis ^a
Open-Top Vapor Degreasers	149	29	62	76
ConveyORIZED Degreasers	8	0	5	3
Web Degreasers ^b	1	0	0	1
Cold Cleaning Machines	17	1	6	10

743 a – Some units with zero emissions also did not include accompanying operating hours; therefore, subtracting the units with
744 zero emissions and the units without operating hours from the total units does not equal the units in the analysis due to double
745 counting.

746 b – No web degreasers reported in the 2014 NEI. One web degreaser reported in the ([U.S. EPA, 2011a](#)) was used in this
747 analysis.

748 Source: ([U.S. EPA, 2018a](#)); ([U.S. EPA, 2011a](#))

749
750
751 Table_Apx N-6 through Table_Apx N-9 summarize the distribution of hourly unit emissions for each
752 machine type calculated from the annual emission in the 2014 NEI.

753

Table_Apx N-6. Distribution of Trichloroethylene Open-Top Vapor Degreasing Unit Emissions

Count of Units	Unit Emissions (lb/unit-hr)	Fractional Probability
1	103.00	0.0132
1	63.95	0.0132
1	19.04	0.0132
1	13.20	0.0132
1	12.18	0.0132
1	9.47	0.0132
1	9.21	0.0132
1	8.14	0.0132
1	7.30	0.0132
1	6.93	0.0132
1	6.64	0.0132
1	6.61	0.0132
1	6.44	0.0132
1	6.40	0.0132
1	6.32	0.0132
1	5.10	0.0132
1	5.06	0.0132
1	4.89	0.0132
1	4.85	0.0132
1	4.14	0.0132
1	3.96	0.0132
1	3.82	0.0132
1	3.77	0.0132
1	3.68	0.0132
2	3.66	0.0263
1	3.64	0.0132
1	3.43	0.0132
1	3.40	0.0132
1	2.88	0.0132
1	2.79	0.0132
1	2.64	0.0132
1	2.61	0.0132
1	2.48	0.0132
1	2.37	0.0132
1	2.20	0.0132
1	1.97	0.0132
1	1.96	0.0132
1	1.73	0.0132
1	1.62	0.0132
1	1.59	0.0132

Count of Units	Unit Emissions (lb/unit-hr)	Fractional Probability
1	1.44	0.0132
1	1.33	0.0132
1	1.22	0.0132
1	1.09	0.0132
2	0.93	0.0263
1	0.90	0.0132
2	0.84	0.0263
1	0.83	0.0132
1	0.79	0.0132
3	0.79	0.0395
1	0.70	0.0132
1	0.62	0.0132
1	0.60	0.0132
1	0.43	0.0132
1	0.42	0.0132
1	0.39	0.0132
1	0.38	0.0132
1	0.38	0.0132
1	0.35	0.0132
1	0.23	0.0132
1	0.18	0.0132
1	0.15	0.0132
1	0.15	0.0132
1	0.14	0.0132
1	0.11	0.0132
1	0.10	0.0132
2	0.10	0.0263
1	0.07	0.0132
1	0.03	0.0132
1	0.001	0.0132

755

756

Table_Apx N-7. Distribution of Trichloroethylene Conveyorized Degreasing Unit Emissions

Count of Units	Unit Emissions (lb/unit-hr)	Fractional Probability
1	72.48	0.3333
1	1.51	0.3333
1	0.80	0.3333

757

758 **Table_Apx N-8. Distribution of Trichloroethylene Web Degreasing Unit Emissions**

Count of Units	Unit Emissions (lb/unit-hr)	Fractional Probability
—	0.247	1.00

759
760 **Table_Apx N-9. Distribution of Trichloroethylene Cold Cleaning Unit Emissions**

Count of Units	Unit Emissions (lb/unit-hr)	Fractional Probability
1.00	2.26	0.1000
1.00	0.83	0.1000
1.00	0.83	0.1000
1.00	0.83	0.1000
1.00	0.83	0.1000
1.00	0.05	0.1000
1.00	0.01	0.1000
1.00	0.01	0.1000
1.00	0.01	0.1000
1.00	0.00	0.1000

761

762 **N.2.8 Operating Hours**

763 For the operating hours of each machine type (OTVD, conveyORIZED, web, and cold), EPA used a
764 discrete distribution based on the daily operating hours reported in the 2014 NEI. It should be noted that
765 not all units had an accompanying reported daily operating hours; therefore, the distribution for the
766 operating hours per day is based on a subset of the reported units. Table_Apx N-10 through Table_Apx
767 N-13 summarize the distribution of operating hours per day for each machine type.

768

769 **Table_Apx N-10. Distribution of Trichloroethylene Open-Top Vapor Degreasing Operating Hours**

Count of Occurrences	Operating Hours (hr/day)	Fractional Probability
—	24	0.4048
—	16	0.0952
—	8	0.2381
—	6	0.0476
—	4	0.0714
—	2	0.1429

770

771 **Table_Apx N-11. Distribution of Trichloroethylene ConveyORIZED Degreasing Operating Hours**

Count of Occurrences	Operating Hours (hr/day)	Fractional Probability
—	24	1.0000

772

773 **Table_Apx N-12. Distribution of Trichloroethylene Web Degreasing Operating Hours**

Count of Occurrences	Operating Hours (hr/day)	Fractional Probability
—	24	1.0000

774

775 **Table_Apx N-13. Distribution of Trichloroethylene Cold Cleaning Operating Hours**

Count of Occurrences	Operating Hours (hr/day)	Fractional Probability
—	24	0.4000
—	8	0.5000
—	3	0.1000

776

777

779 **Appendix O BRAKE SERVICING NEAR-FIELD/FAR-FIELD**
 780 **INHALATION EXPOSURE MODEL APPROACH AND**
 781 **PARAMETERS**

782 This appendix presents the modeling approach and model equations used in the Brake Servicing Near-
 783 Field/Far-Field Inhalation Exposure Model. The model was developed through review of the literature
 784 and consideration of existing EPA exposure models. This model uses a near-field/far-field approach
 785 ([Nicas, 2009](#)), where an aerosol application located inside the near-field generates a mist of droplets, and
 786 indoor air movements lead to the convection of the droplets between the near-field and far-field.
 787 Workers are assumed to be exposed to TCE droplet concentrations in the near-field, while occupational
 788 non-users are exposed at concentrations in the far-field.

789
 790 The model uses the following parameters to estimate exposure concentrations in the near-field and far-
 791 field:

- 792
- 793 • Far-field size;
- 794 • Near-field size;
- 795 • Air exchange rate;
- 796 • Indoor air speed;
- 797 • Concentration of TCE in the aerosol formulation;
- 798 • Amount of degreaser used per brake job;
- 799 • Number of degreaser applications per brake job;
- 800 • Time duration of brake job;
- 801 • Operating hours per week; and
- 802 • Number of jobs per work shift.

803
 804 An individual model input parameter could either have a discrete value or a distribution of values. EPA
 805 assigned statistical distributions based on reasonably available literature data. A Monte Carlo simulation
 806 (a type of stochastic simulation) was conducted to capture variability in the model input parameters. The
 807 simulation was conducted using the Latin hypercube sampling method in [@Risk](#) Industrial Edition,
 808 Version 7.0.0. The Latin hypercube sampling method is a statistical method for generating a sample of
 809 possible values from a multi-dimensional distribution. Latin hypercube sampling is a stratified method,
 810 meaning it guarantees that its generated samples are representative of the probability density function
 811 (variability) defined in the model. EPA performed the model at 100,000 iterations to capture the range of
 812 possible input values (*i.e.*, including values with low probability of occurrence).


813
 814 Model results from the Monte Carlo simulation are presented as 95th and 50th percentile values. The
 815 statistics were calculated directly in [@Risk](#). The 95th percentile value was selected to represent high-end
 816 exposure level, whereas the 50th percentile value was selected to represent central tendency exposure
 817 level. The following subsections detail the model design equations and parameters for the brake
 818 servicing model.

819
 820 **O.1 Model Design Equations**

821 In brake servicing, the vehicle is raised on an automobile lift to a comfortable working height to allow
 822 the worker (mechanic) to remove the wheel and access the brake system. Brake servicing can include

823 inspections, adjustments, brake pad replacements, and rotor resurfacing. These service types often
824 involve disassembly, replacement or repair, and reassembly of the brake system. Automotive brake
825 cleaners are used to remove oil, grease, brake fluid, brake pad dust, or dirt. Mechanics may occasionally
826 use brake cleaners, engine degreasers, carburetor cleaners, and general purpose degreasers
827 interchangeably (CARB, 2000). Automotive brake cleaners can come in aerosol or liquid form (CARB,
828 2000): this model estimates exposures from aerosol brake cleaners (degreasers).
829

830 Figure_Apx O-1 illustrates the near-field/far-field modeling approach as it was applied by EPA to brake
831 servicing using an aerosol degreaser. The application of the aerosol degreaser immediately generates a
832 mist of droplets in the near-field, resulting in worker exposures at a TCE concentration C_{NF} . The
833 concentration is directly proportional to the amount of aerosol degreaser applied by the worker, who is
834 standing in the near-field-zone (*i.e.*, the working zone). The volume of this zone is denoted by V_{NF} . The
835 ventilation rate for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field
836 (*i.e.*, the facility space surrounding the near-field), resulting in occupational non-user exposures to TCE
837 at a concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the TCE dissipates out
838 of the near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly
839 TCE dissipates out of the surrounding space and into the outside air.
840



841 **Figure_Apx O-1. The Near-Field/Far-Field Model as Applied to the Brake Servicing Near-**
842 **Field/Far-Field Inhalation Exposure Model**
843
844

845 In brake servicing using an aerosol degreaser, aerosol degreaser droplets enter the near-field in non-
846 steady “bursts,” where each burst results in a sudden rise in the near-field concentration. The near-field
847 and far-field concentrations then decay with time until the next burst causes a new rise in near-field
848 concentration. Based on site data from automotive maintenance and repair shops obtained by CARB
849 (CARB, 2000) for brake cleaning activities and as explained in Sections O.2.5 and O.2.9 below, the
850 model assumes a worker will perform an average of 11 applications of the degreaser product per brake
851 job with five minutes between each application and that a worker may perform one to four brake jobs
852 per day each taking one hour to complete. EPA modeled two scenarios: one where the brake jobs
853 occurred back-to-back and one where brake jobs occurred one hour apart. In both scenarios, EPA

854 assumed the worker does not perform a brake job, and does not use the aerosol degreaser, during the
855 first hour of the day.

856
857 EPA denoted the top of each five-minute period for each hour of the day (e.g., 8:00 am, 8:05 am, 8:10
858 am, etc.) as $t_{m,n}$. Here, m has the values of 0, 1, 2, 3, 4, 5, 6, and 7 to indicate the top of each hour of the
859 day (e.g., 8 am, 9 am, etc.) and n has the values of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 to indicate the top
860 of each five-minute period within the hour. No aerosol degreaser is used, and no exposures occur, during
861 the first hour of the day, $t_{0,0}$ to $t_{0,11}$ (e.g., 8 am to 9 am). Then, in both scenarios, the worker begins the
862 first brake job during the second hour, $t_{1,0}$ (e.g., 9 am to 10 am). The worker applies the aerosol
863 degreaser at the top of the second 5-minute period and each subsequent 5-minute period during the hour-
864 long brake job (e.g., 9:05 am, 9:10 am, ... 9:55 am). In the first scenario, the brake jobs are performed
865 back-to-back, if performing more than one brake job on the given day. Therefore, the second brake job
866 begins at the top of the third hour (e.g., 10 am), and the worker applies the aerosol degreaser at the top
867 of the second 5-minute period and each subsequent 5-minute period (e.g., 10:05 am, 10:10 am, ... 10:55
868 am). In the second scenario, the brake jobs are performed every other hour, if performing more than one
869 brake job on the given day. Therefore, the second brake job begins at the top of the fourth hour (e.g., 11
870 am), and the worker applies the aerosol degreaser at the top of the second 5-minute period and each
871 subsequent 5-minute period (e.g., 11:05 am, 11:10 am, ... 11:55 am).

872
873 In the first scenario, after the worker performs the last brake job, the workers and occupational non-users
874 (ONUs) continue to be exposed as the airborne concentrations decay during the final three to six hours
875 until the end of the day (e.g., 4 pm). In the second scenario, after the worker performs each brake job,
876 the workers and ONUs continue to be exposed as the airborne concentrations decay during the time in
877 which no brake jobs are occurring and then again when the next brake job is initiated. In both scenarios,
878 the workers and ONUs are no longer exposed once they leave work.

879
880 Based on data from CARB ([CARB, 2000](#)), EPA assumes each brake job requires one 14.4-oz can of
881 aerosol brake cleaner as described in further detail below. The model determines the application rate of
882 TCE using the weight fraction of TCE in the aerosol product. EPA uses a uniform distribution of weight
883 fractions for TCE based on facility data for the aerosol products in use ([CARB, 2000](#)).

884
885 The model design equations are presented below.

886
887 Near-Field Mass Balance

888 **Equation L-1**

889
$$V_{NF} \frac{dC_{NF}}{dt} = C_{FF}Q_{NF} - C_{NF}Q_{NF}$$

890 Far-Field Mass Balance

891 **Equation L-2**

892
$$V_{FF} \frac{dC_{FF}}{dt} = C_{NF}Q_{NF} - C_{FF}Q_{NF} - C_{FF}Q_{FF}$$

893 Where:

- 894 V_{NF} = near-field volume;
895 V_{FF} = far-field volume;
896 Q_{NF} = near-field ventilation rate;
897 Q_{FF} = far-field ventilation rate;
898 C_{NF} = average near-field concentration;
899 C_{FF} = average far-field concentration; and
900 t = elapsed time.

901
 902 Solving the above equations in terms of the time-varying concentrations in the near-field and far-field
 903 yields Equation L-3 and Equation L-4, which EPA applied to each of the 12 five-minute increments
 904 during each hour of the day. For each five-minute increment, EPA calculated the initial near-field
 905 concentration at the top of the period ($t_{m,n}$), accounting for both the burst of TCE from the degreaser
 906 application (if the five-minute increment is during a brake job) and the residual near-field concentration
 907 remaining after the previous five-minute increment ($t_{m,n-1}$; except during the first hour and $t_{m,0}$ of the first
 908 brake job, in which case there would be no residual TCE from a previous application). The initial far-
 909 field concentration is equal to the residual far-field concentration remaining after the previous five-
 910 minute increment. EPA then calculated the decayed concentration in the near-field and far-field at the
 911 end of the five-minute period, just before the degreaser application at the top of the next period ($t_{m,n+1}$).
 912 EPA then calculated a 5-minute TWA exposure for the near-field and far-field, representative of the
 913 worker's and ONUs' exposures to the airborne concentrations during each five-minute increment using
 914 Equation L-13 and Equation L-14. The k coefficients (Equation L-5 through Equation L-8) are a
 915 function of the initial near-field and far-field concentrations, and therefore are re-calculated at the top of
 916 each five-minute period. In the equations below, where the subscript "m, n-1" is used, if the value of n-1
 917 is less than zero, the value at "m-1, 11" is used and where the subscript "m, n+1" is used, if the value of
 918 n+1 is greater than 11, the value at "m+1, 0" is used.

919
 920 **Equation L-3**

$$C_{NF,t_{m,n+1}} = (k_{1,t_{m,n}} e^{\lambda_1 t} + k_{2,t_{m,n}} e^{\lambda_2 t})$$

922
 923 **Equation L-4**

$$C_{FF,t_{m,n+1}} = (k_{3,t_{m,n}} e^{\lambda_1 t} - k_{4,t_{m,n}} e^{\lambda_2 t})$$

924
 925
 926 Where:

927 **Equation L-5**

$$k_{1,t_{m,n}} = \frac{Q_{NF} (C_{FF,0}(t_{m,n}) - C_{NF,0}(t_{m,n})) - \lambda_2 V_{NF} C_{NF,0}(t_{m,n})}{V_{NF} (\lambda_1 - \lambda_2)}$$

929
 930 **Equation L-6**

$$k_{2,t_{m,n}} = \frac{Q_{NF} (C_{NF,0}(t_{m,n}) - C_{FF,0}(t_{m,n})) + \lambda_1 V_{NF} C_{NF,0}(t_{m,n})}{V_{NF} (\lambda_1 - \lambda_2)}$$

932
 933 **Equation L-7**

$$k_{3,t_{m,n}} = \frac{(Q_{NF} + \lambda_1 V_{NF})(Q_{NF} (C_{FF,0}(t_{m,n}) - C_{NF,0}(t_{m,n})) - \lambda_2 V_{NF} C_{NF,0}(t_{m,n}))}{Q_{NF} V_{NF} (\lambda_1 - \lambda_2)}$$

935
 936 **Equation L-8**

$$k_{4,t_{m,n}} = \frac{(Q_{NF} + \lambda_2 V_{NF})(Q_{NF} (C_{NF,0}(t_{m,n}) - C_{FF,0}(t_{m,n})) + \lambda_1 V_{NF} C_{NF,0}(t_{m,n}))}{Q_{NF} V_{NF} (\lambda_1 - \lambda_2)}$$

939 **Equation L-9**

$$940 \quad \lambda_1 = 0.5 \left[- \left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right) + \sqrt{\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right)^2 - 4 \left(\frac{Q_{NF}Q_{FF}}{V_{NF}V_{FF}} \right)} \right]$$

941
942 **Equation L-10**

$$943 \quad \lambda_2 = 0.5 \left[- \left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right) - \sqrt{\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}} \right)^2 - 4 \left(\frac{Q_{NF}Q_{FF}}{V_{NF}V_{FF}} \right)} \right]$$

944
945 **Equation L-11**

$$946 \quad C_{NF,o}(t_{m,n}) = \begin{cases} 0, & m = 0 \\ \frac{Amt}{V_{NF}} \left(1,000 \frac{mg}{g} \right) + C_{NF}(t_{m,n-1}), & n > 0 \text{ for all } m \text{ where brake job occurs} \end{cases}$$

947
948 **Equation L-12**

$$949 \quad C_{FF,o}(t_{m,n}) = \begin{cases} 0, & m = 0 \\ C_{FF}(t_{m,n-1}), & \text{for all } n \text{ where } m > 0 \end{cases}$$

950
951 **Equation L-13**

$$952 \quad C_{NF, 5\text{-min TWA}, t_{m,n}} = \frac{\left(\frac{k_{1,t_{m,n-1}}}{\lambda_1} e^{\lambda_1 t_2} + \frac{k_{2,t_{m,n-1}}}{\lambda_2} e^{\lambda_2 t_2} \right) - \left(\frac{k_{1,t_{m,n-1}}}{\lambda_1} e^{\lambda_1 t_1} + \frac{k_{2,t_{m,n-1}}}{\lambda_2} e^{\lambda_2 t_1} \right)}{t_2 - t_1}$$

953
954 **Equation L-14**

$$955 \quad C_{FF, 5\text{-min TWA}, t_{m,n}} = \frac{\left(\frac{k_{3,t_{m,n-1}}}{\lambda_1} e^{\lambda_1 t_2} + \frac{k_{4,t_{m,n-1}}}{\lambda_2} e^{\lambda_2 t_2} \right) - \left(\frac{k_{3,t_{m,n-1}}}{\lambda_1} e^{\lambda_1 t_1} + \frac{k_{4,t_{m,n-1}}}{\lambda_2} e^{\lambda_2 t_1} \right)}{t_2 - t_1}$$

956
957 After calculating all near-field/far-field 5-minute TWA exposures (*i.e.*, $C_{NF, 5\text{-min TWA}, t_{m,n}}$ and
958 $C_{FF, 5\text{-min TWA}, t_{m,n}}$) for each five-minute period of the work day, EPA calculated the near-field/far-field
959 8-hour TWA concentration and 1-hour TWA concentrations following the equations below:

960
961 **Equation L-15**

$$962 \quad C_{NF, 8\text{-hr TWA}} = \frac{\sum_{m=0}^7 \sum_{n=0}^{11} [C_{NF, 5\text{-min TWA}, t_{m,n}} \times 0.0833 \text{ hr}]}{8 \text{ hr}}$$

963
964 **Equation L-16**

$$965 \quad C_{NF, 8\text{-hr TWA}} = \frac{\sum_{m=0}^7 \sum_{n=0}^{11} [C_{FF, 5\text{-min TWA}, t_{m,n}} \times 0.0833 \text{ hr}]}{8 \text{ hr}}$$

966

967 **Equation L-17**

968
$$C_{NF,1\text{-hr TWA}} = \frac{\sum_{n=0}^{11} [C_{NF,5\text{-min TWA},t_{m,n}} \times 0.0833 \text{ hr}]}{1 \text{ hr}}$$

969
970 **Equation L-18**

971
$$C_{FF,1\text{-hr TWA}} = \frac{\sum_{n=0}^{11} [C_{FF,5\text{-min TWA},t_{m,n}} \times 0.0833 \text{ hr}]}{1 \text{ hr}}$$

972
973 EPA calculated rolling 1-hour TWA's throughout the workday and the model reports the maximum
974 calculated 1-hour TWA.

975
976 To calculate the mass transfer to and from the near-field, the free surface area (FSA) is defined to be the
977 surface area through which mass transfer can occur. The FSA is not equal to the surface area of the
978 entire near-field. EPA defined the near-field zone to be a hemisphere with its major axis oriented
979 vertically, against the vehicle, and aligned through the center of the wheel (see Figure_Apx O-1). The
980 top half of the circular cross-section rests against, and is blocked by, the vehicle and is not available for
981 mass transfer. The FSA is calculated as the entire surface area of the hemisphere's curved surface and
982 half of the hemisphere's circular surface per Equation L-19, below:

983
984 **Equation L-19**

985
$$FSA = \left(\frac{1}{2} \times 4\pi R_{NF}^2 \right) + \left(\frac{1}{2} \times \pi R_{NF}^2 \right)$$

986
987 Where: R_{NF} is the radius of the near-field

988
989 The near-field ventilation rate, Q_{NF} , is calculated in Equation M-1520 from the indoor wind speed, v_{NF} ,
990 and FSA, assuming half of the FSA is available for mass transfer into the near-field and half of the FSA
991 is available for mass transfer out of the near-field:

992
993 **Equation L-20**

994
$$Q_{NF} = \frac{1}{2} v_{NF} FSA$$

995
996 The far-field volume, V_{FF} , and the air exchange rate, AER, is used to calculate the far-field ventilation
997 rate, Q_{FF} , as given by Equation M-21:

998
999 **Equation L-21**

1000
$$Q_{FF} = V_{FF} AER$$

1001
1002 Using the model inputs described in Appendix F.2, EPA estimated TCE inhalation exposures for
1003 workers in the near-field and for occupational non-users in the far-field. EPA then conducted the Monte
1004 Carlo simulations using @Risk (Version 7.0.0). The simulations applied 100,000 iterations and the Latin
1005 Hypercube sampling method.

1006
1007 **O.2 Model Parameters**

1008 Table_Apx O-1 summarizes the model parameters and their values for the Brake Servicing Near-Field/
1009 Far-Field Inhalation Exposure Model. Each parameter is discussed in detail in the following subsections.

1010
1011
1012

Table_Apx O-1. Summary of Parameter Values and Distributions Used in the Brake Servicing Near-Field/Far-Field Inhalation Exposure Model

Input Parameter	Symbol	Unit	Constant Model Parameter Values		Variable Model Parameter Values				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Far-field volume	V _{FF}	m ³	—	—	206	70,679	3,769	Triangular	Distribution based on data collected by CARB (CARB, 2000).
Air exchange rate	AER	hr ⁻¹	—	—	1	20	3.5	Triangular	(Demou et al., 2009) identifies typical AERs of 1 hr ⁻¹ and 3 to 20 hr ⁻¹ for occupational settings without and with mechanical ventilation systems, respectively. (Hellweg et al., 2009) identifies average AERs for occupational settings utilizing mechanical ventilation systems to be between 3 and 20 hr ⁻¹ . (Golsteijn et al., 2014) indicates a characteristic AER of 4 hr ⁻¹ . Peer reviewers of EPA's 2013 TCE draft risk assessment commented that values around 2 to 5 hr ⁻¹ may be more likely (U.S. EPA, 2013a), in agreement with (Golsteijn et al., 2014). A triangular distribution is used with the mode equal to the midpoint of the range provided by the peer reviewer (3.5 is the midpoint of the range 2 to 5 hr ⁻¹).
Near-field indoor wind speed	V _{NF}	ft/hr	—	—	0	23,882	—	Lognormal	Lognormal distribution fit to commercial-type workplace data from (Baldwin and Maynard, 1998a).
		cm/s	—	—	0	202.2	—	Lognormal	
Near-field radius	R _{NF}	m	1.5	—	—	—	—	Constant Value	Constant.
Starting time for each application period	t ₁	hr	0	—	—	—	—	Constant Value	Constant.

Input Parameter	Symbol	Unit	Constant Model Parameter Values		Variable Model Parameter Values				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
End time for each application period	t ₂	hr	0.0833	—	—	—	—	Constant Value	Assumes aerosol degreaser is applied in 5-minute increments during brake job.
Averaging Time	t _{avg}	hr	8	—	—	—	—	Constant Value	Constant.
TCE weight fraction	wfrac	wt frac	—	—	0.40	1.00	—	Discrete	Discrete distribution of TCE-based aerosol product formulations based on products identified in EPA's Preliminary Information on Manufacturing, Processing, Distribution, Use, and Disposal for TCE (U.S. EPA, 2017c). Where the weight fraction of TCE in the formulation was given as a range, EPA assumed a uniform distribution within the reported range for the TCE concentration in the product.
Degreaser Used per Brake Job	W _d	oz/ job	14.4	—	—	—	—	Constant Value	Based on data from CARB (CARB, 2000).
Number of Applications per Job	N _A	Applications/ job	11	—	—	—	—	Constant Value	Calculated from the average of the number of applications per brake and number of brakes per job.
Amount Used per Application	Amt	g TCE/ application	—	—	14.8	37.1	—	Calculated	Calculated from wfrac, W _d , and N _A .
Operating hours per week	OHpW	hr/week	—	—	40	122.5	—	Lognormal	Lognormal distribution fit to the operating hours per week observed in CARB (CARB, 2000) site visits.
Number of Brake Jobs per Work Shift	N _J	jobs/site-shift	—	—	1	4	—	—	Calculated from the average number of brake jobs per site per year, OHpW, and assuming 52 operating weeks per year and 8 hours per work shift.

O.2.1 Far-Field Volume

The far-field volume is based on information obtained from (CARB, 2000) from site visits of 137 automotive maintenance and repair shops in California. (CARB, 2000) indicated that shop volumes at the visited sites ranged from 200 to 70,679 m³ with an average shop volume of 3,769 m³. Based on this data EPA assumed a triangular distribution bound from 200 m³ to 70,679 m³ with a mode of 3,769 m³ (the average of the data from (CARB, 2000)).

CARB measured the physical dimensions of the portion of the facility where brake service work was performed at the visited facilities. CARB did not consider other areas of the facility, such as customer waiting areas and adjacent storage rooms, if they were separated by a normally closed door. If the door was normally open, then CARB did consider those areas as part of the measured portion where brake servicing emissions could occur (CARB, 2000). CARB's methodology for measuring the physical dimensions of the visited facilities provides the appropriate physical dimensions needed to represent the far-field volume in EPA's model. Therefore, CARB's reported facility volume data are appropriate for EPA's modeling purposes.

O.2.2 Air Exchange Rate

The air exchange rate (AER) is based on data from (Demou et al., 2009), (Hellweg et al., 2009), (Golsteijn et al., 2014), and information received from a peer reviewer during the development of the 2014 TSCA Work Plan Chemical Risk Assessment Trichloroethylene: Degreasing, Spot Cleaning and Arts & Crafts Uses (U.S. EPA, 2013a). (Demou et al., 2009) identifies typical AERs of 1 hr⁻¹ and 3 to 20 hr⁻¹ for occupational settings without and with mechanical ventilation systems, respectively. Similarly, (Hellweg et al., 2009) identifies average AERs for occupational settings using mechanical ventilation systems to vary from 3 to 20 hr⁻¹. (Golsteijn et al., 2014) indicates a characteristic AER of 4 hr⁻¹. The risk assessment peer reviewer comments indicated that values around 2 to 5 hr⁻¹ are likely (U.S. EPA, 2013a), in agreement with (Golsteijn et al., 2014) and the low end reported by (Demou et al., 2009) and (Hellweg et al., 2009). Therefore, EPA used a triangular distribution with the mode equal to 3.5 hr⁻¹, the midpoint of the range provided by the risk assessment peer reviewer (3.5 is the midpoint of the range 2 to 5 hr⁻¹), with a minimum of 1 hr⁻¹, per (Demou et al., 2009) and a maximum of 20 hr⁻¹ per (Demou et al., 2009) and (Hellweg et al., 2009)).

O.2.3 Near-Field Indoor Air Speed

(Baldwin and Maynard, 1998a) measured indoor air speeds across a variety of occupational settings in the United Kingdom. Fifty-five work areas were surveyed across a variety of workplaces.

EPA analyzed the air speed data from (Baldwin and Maynard, 1998a) and categorized the air speed surveys into settings representative of industrial facilities and representative of commercial facilities. EPA fit separate distributions for these industrial and commercial settings and used the commercial distribution for facilities performing aerosol degreasing or other aerosol applications.

EPA fit a lognormal distribution for both data sets as consistent with the authors observations that the air speed measurements within a surveyed location were lognormally distributed and the population of the mean air speeds among all surveys were lognormally distributed. Since lognormal distributions are bound by zero and positive infinity, EPA truncated the distribution at the largest observed value among all of the survey mean air speeds from (Baldwin and Maynard, 1998a).

EPA fit the air speed surveys representative of commercial facilities to a lognormal distribution with the following parameter values: mean of 10.853 cm/s and standard deviation of 7.883 cm/s. In the model, the lognormal distribution is truncated at a maximum allowed value of 202.2 cm/s (largest surveyed

1061 mean air speed observed in ([Baldwin and Maynard, 1998a](#)) to prevent the model from sampling values
1062 that approach infinity or are otherwise unrealistically large.
1063
1064 ([Baldwin and Maynard, 1998a](#)) only presented the mean air speed of each survey. The authors did not
1065 present the individual measurements within each survey. Therefore, these distributions represent a
1066 distribution of mean air speeds and not a distribution of spatially-variable air speeds within a single
1067 workplace setting. However, a mean air speed (averaged over a work area) is the required input for the
1068 model.

1069 **O.2.4 Near-Field Volume**

1070 EPA defined the near-field zone to be a hemisphere with its major axis oriented vertically, against the
1071 vehicle, and aligned through the center of the wheel (see Figure_Apx O-1). The near-field volume is
1072 calculated per Equation L-22. EPA defined a near-field radius (R_{NF}) of 1.5 meters, approximately 4.9
1073 feet, as an estimate of the working height of the wheel, as measured from the floor to the center of the
1074 wheel.

1075 **Equation L-22**

$$1076 \quad V_{NF} = \frac{1}{2} \times \frac{4}{3} \pi R_{NF}^3$$

1078 **O.2.5 Application Time**

1079 EPA assumed an average of 11 brake cleaner applications per brake job (see Section F.2.9). CARB
1080 observed, from their site visits, that the visited facilities did not perform more than one brake job in any
1081 given hour ([CARB, 2000](#)). Therefore, EPA assumed a brake job takes one hour to perform. Using an
1082 assumed average of 11 brake cleaner applications per brake job and one hour to perform a brake job,
1083 EPA calculates an average brake cleaner application frequency of once every five minutes (0.0833 hr).
1084 EPA models an average brake job of having no brake cleaner application during its first five minutes
1085 and then one brake cleaner application per each subsequent 5-minute period during the one-hour brake
1086 job.

1087 **O.2.6 Averaging Time**

1088 EPA was interested in estimating 8-hr TWAs for use in risk calculations; therefore, a constant averaging
1089 time of eight hours was used.

1090 **O.2.7 Trichloroethylene Weight Fraction**

1091 EPA reviewed the *Preliminary Information on Manufacturing, Processing, Distribution, Use, and*
1092 *Disposal: Trichloroethylene* report ([U.S. EPA, 2017c](#)) for aerosol degreasers that contain TCE. EPA
1093 (2017) identifies 16 aerosol degreaser products that overall range in TCE content from 40 to 100 weight
1094 percent. The identified aerosol degreasers include a brake cleaner as well as general purpose degreasers,
1095 machine cleaners, electronic/electrical parts cleaners, and a mold cleaner. EPA includes all of these
1096 aerosol degreasers in the estimation of TCE content as: 1) automotive maintenance and repair facilities
1097 may use different degreaser products interchangeably as observed by ([CARB, 2000](#)); and 2) EPA uses
1098 this brake servicing model as an exposure scenario representative of all commercial-type aerosol
1099 degreaser applications.

1100
1101 EPA used a discrete distribution to model the TCE weight fraction based on the number of occurrences
1102 of each product type. In some instances, the concentration of TCE was reported as a range. For these
1103 product types, EPA used a uniform distribution to model the TCE weight fraction within the product
1104 type. Table_Apx O-2 provides a summary of the reported TCE content reported in the safety data sheets

1105 identified in ([U.S. EPA, 2017c](#)), the number of occurrences of each product type, and the fractional
 1106 probability of each product type.

1107
 1108

Table_Apx O-2. Summary of Trichloroethylene-Based Aerosol Degreaser Formulations

Name of Aerosol Degreaser Product Identified in (U.S. EPA, 2017c)	Trichloroethylene Weight Percent	Number of Occurrences	Fractional Probability
C-60 Solvent Degreaser	90-100%	1	0.063
Fusing Machine Cleaner	40-60%	1	0.063
Solvent Degreaser	> 90%	1	0.063
Electro Blast	90-100%	1	0.063
Electro Solv	90-100%	1	0.063
Pro Tools NF Solvent Degreaser	60-100%	1	0.063
Aerosolve II	>90%	1	0.063
Power Solv II	90-100%	1	0.063
Zep 45	40-50%	1	0.063
Super Solv	90-100%	1	0.063
Parts Cleaner	45-55%	1	0.063
Electronic Contact Cleaner & Protectant - Aerosol	97%	1	0.063
Flash Free Electrical Degreaser	98%	1	0.063
Chlorinated Brake & Parts Cleaner – Aerosol	98%	1	0.063
MR 351 - Mold Cleaner	69%	1	0.063
C-60 Solvent [TCE Cleaner] Degreaser	90-100%	1	0.063
Total		16	1.000

1109

O.2.8 Volume of Degreaser Used per Brake Job

1110

1111 ([CARB, 2000](#)) assumed that brake jobs require 14.4 oz of aerosol product. EPA did not identify other
 1112 information to estimate the volume of aerosol product per job; therefore, EPA used a constant volume of
 1113 14.4 oz per brake job based on ([CARB, 2000](#)).

O.2.9 Number of Applications per Brake Job

1114

1115 Workers typically apply the brake cleaner before, during, and after brake disassembly. Workers may
 1116 also apply the brake cleaner after brake reassembly as a final cleaning process ([CARB, 2000](#)).
 1117 Therefore, EPA assumed a worker applies a brake cleaner three or four times per wheel. Since a brake
 1118 job can be performed on either one axle or two axles ([CARB, 2000](#)), EPA assumed a brake job may
 1119 involve either two or four wheels. Therefore, the number of brake cleaner (aerosol degreaser)
 1120 applications per brake job can range from six (3 applications/brake x 2 brakes) to 16 (4
 1121 applications/brake x 4 brakes). EPA assumed a constant number of applications per brake job based on
 1122 the midpoint of this range of 11 applications per brake job.

1123 **O.2.10 Amount of Trichloroethylene Used per Application**

1124 EPA calculated the amount of Trichloroethylene used per application using Equation L-23. The
1125 calculated mass of Trichloroethylene used per application ranges from 14.8 to 37.1 grams.

1126
1127 **Equation L-23**

$$1128 \quad Amt = \frac{W_d \times wtfrac \times 28.3495 \frac{g}{oz}}{N_A}$$

1129 Where:

- 1130 Amt = Amount of TCE used per application (g/application);
1131 W_d = Weight of degreaser used per brake job (oz/job);
1132 $Wtfrac$ = Weight fraction of TCE in aerosol degreaser (unitless); and
1133 N_A = Number of degreaser applications per brake job (applications/job).
1134

1135 **O.2.11 Operating Hours per Week**

1136 (CARB, 2000) collected weekly operating hour data for 54 automotive maintenance and repair facilities.
1137 The surveyed facilities included service stations (fuel retail stations), general automotive shops, car
1138 dealerships, brake repair shops, and vehicle fleet maintenance facilities. The weekly operating hours of
1139 the surveyed facilities ranged from 40 to 122.5 hr/week. EPA fit a lognormal distribution to the surveyed
1140 weekly operating hour data. The resulting lognormal distribution has a mean of 16.943 and standard
1141 deviation of 13.813, which set the shape of the lognormal distribution. EPA shifted the distribution to
1142 the right such that its minimum value is 40 hr/week and set a truncation of 122.5 hr/week (the truncation
1143 is set as 82.5 hr/week relative to the left shift of 40 hr/week).

1144 **O.2.12 Number of Brake Jobs per Work Shift**

1145 (CARB, 2000) visited 137 automotive maintenance and repair shops and collected data on the number of
1146 brake jobs performed annually at each facility. CARB calculated an average of 936 brake jobs
1147 performed per facility per year. EPA calculated the number of brake jobs per work shift using the
1148 average number of jobs per site per year, the operating hours per week, and assuming 52 weeks of
1149 operation per year and eight hours per work shift using Equation L-24 and rounding to the nearest
1150 integer. The calculated number of brake jobs per work shift ranges from one to four.

1151
1152 **Equation L-24**

$$1153 \quad N_j = \frac{936 \frac{jobs}{site-year} \times 8 \frac{hours}{shift}}{52 \frac{weeks}{yr} \times OHpW}$$

1154 Where:

- 1155 N_j = Number of brake jobs per work shift (jobs/site-shift); and
1156 $OHpW$ = Operating hours per week (hr/week).

1157 **Appendix P SPOT CLEANING NEAR-FIELD/FAR-FIELD**
1158 **INHALATION EXPOSURE MODEL APPROACH AND**
1159 **PARAMETERS**

1160 This appendix presents the modeling approach and model equations used in the Spot Cleaning Near-
1161 Field/Far-Field Inhalation Exposure Model. The model was developed through review of relevant
1162 literature and consideration of existing EPA exposure models. The model uses a near-field/far-field
1163 approach ([AIHA, 2009](#)), where a vapor generation source located inside the near-field leads to the
1164 evaporation of vapors into the near-field, and indoor air movements lead to the convection of vapors
1165 between the near-field and far-field. Workers are assumed to be exposed to TCE vapor concentrations in
1166 the near-field, while occupational non-users are exposed at concentrations in the far-field.

1167
1168 The model uses the following parameters to estimate exposure concentrations in the near-field and far-
1169 field:

- 1170
- 1171 • Far-field size;
- 1172 • Near-field size;
- 1173 • Air exchange rate;
- 1174 • Indoor air speed;
- 1175 • Spot cleaner use rate;
- 1176 • Vapor generation rate;
- 1177 • Weight fraction of TCE in the spot cleaner; and
- 1178 • Operating hours per day.
- 1179


1180 An individual model input parameter could either have a discrete value or a distribution of values. EPA
1181 assigned statistical distributions based on reasonably available literature data. A Monte Carlo simulation
1182 (a type of stochastic simulation) was conducted to capture variability in the model input parameters. The
1183 simulation was conducted using the Latin hypercube sampling method in [@Risk](#) Industrial Edition,
1184 Version 7.0.0. The Latin hypercube sampling method is a statistical method for generating a sample of
1185 possible values from a multi-dimensional distribution. Latin hypercube sampling is a stratified method,
1186 meaning it guarantees that its generated samples are representative of the probability density function
1187 (variability) defined in the model. EPA performed the model at 100,000 iterations to capture the range of
1188 possible input values (*i.e.*, including values with low probability of occurrence).

1189 Model results from the Monte Carlo simulation are presented as 95th and 50th percentile values. The
1190 statistics were calculated directly in [@Risk](#). The 95th percentile value was selected to represent a high-
1191 end exposure, whereas the 50th percentile value was selected to represent a central tendency exposure
1192 level. The following subsections detail the model design equations and parameters for the spot cleaning
1193 model.

1194 1195 **P.1 Model Design Equations**

1196 Figure_Apx P-1 illustrates the near-field/far-field modeling approach as it was applied by EPA to spot
1197 cleaning facilities. As the figure shows, TCE vapors evaporate into the near-field (at evaporation rate G),
1198 resulting in near-field exposures to workers at a concentration C_{NF} . The concentration is directly
1199 proportional to the amount of spot cleaner applied by the worker, who is standing in the near-field-zone
1200 (*i.e.*, the working zone). The volume of this zone is denoted by V_{NF} . The ventilation rate for the near-

1201 field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field (*i.e.*, the facility space
 1202 surrounding the near-field), resulting in occupational non-user exposures to TCE at a concentration C_{FF} .
 1203 V_{FF} denotes the volume of the far-field space into which the TCE dissipates out of the near-field. The
 1204 ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly TCE dissipates out of the
 1205 surrounding space and into the outdoor air.
 1206



1207
 1208 **Figure_Apx P-1. The Near-Field/Far-Field Model as Applied to the Spot Cleaning Near-Field/Far-**
 1209 **Field Inhalation Exposure Model**

1210
 1211
 1212 The model design equations are presented below in Equation M-1 through Equation M-16.

1213
 1214 Near-Field Mass Balance

1215 **Equation M-1**

1216
$$V_{NF} \frac{dC_{NF}}{dt} = C_{FF}Q_{NF} - C_{NF}Q_{NF} + G$$

1217 Far-Field Mass Balance

1218 **Equation M-2**

1219
$$V_{FF} \frac{dC_{FF}}{dt} = C_{NF}Q_{NF} - C_{FF}Q_{NF} - C_{FF}Q_{FF}$$

1220 Where:

- 1221 V_{NF} = near-field volume;
 1222 V_{FF} = far-field volume;
 1223 Q_{NF} = near-field ventilation rate;
 1224 Q_{FF} = far-field ventilation rate;
 1225 C_{NF} = average near-field concentration;
 1226 C_{FF} = average far-field concentration;
 1227 G = average vapor generation rate; and
 1228 t = elapsed time.

1229

1230 Both of the previous equations can be solved for the time-varying concentrations in the near-field and
1231 far-field as follows ([AIHA, 2009](#)):

1232

1233 **Equation M-3**

1234

$$C_{NF} = G(k_1 + k_2e^{\lambda_1 t} - k_3e^{\lambda_2 t})$$

1235

1236 **Equation M-4**

1237

$$C_{FF} = G\left(\frac{1}{Q_{FF}} + k_4e^{\lambda_1 t} - k_5e^{\lambda_2 t}\right)$$

1238 Where:

1239 **Equation M-5**

1240

$$k_1 = \frac{1}{\left(\frac{Q_{NF}}{Q_{NF} + Q_{FF}}\right) Q_{FF}}$$

1241

1242 **Equation M-6**

1243

$$k_2 = \frac{Q_{NF}Q_{FF} + \lambda_2V_{NF}(Q_{NF} + Q_{FF})}{Q_{NF}Q_{FF}V_{NF}(\lambda_1 - \lambda_2)}$$

1244

1245 **Equation M-7**

1246

$$k_3 = \frac{Q_{NF}Q_{FF} + \lambda_1V_{NF}(Q_{NF} + Q_{FF})}{Q_{NF}Q_{FF}V_{NF}(\lambda_1 - \lambda_2)}$$

1247

1248 **Equation M-8**

1249

$$k_4 = \left(\frac{\lambda_1V_{NF} + Q_{NF}}{Q_{NF}}\right) k_2$$

1250

1251 **Equation M-9**

1252

$$k_5 = \left(\frac{\lambda_2V_{NF} + Q_{NF}}{Q_{NF}}\right) k_3$$

1253

1254 **Equation M-10**

1255

$$\lambda_1 = 0.5 \left[-\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}}\right) + \sqrt{\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}}\right)^2 - 4\left(\frac{Q_{NF}Q_{FF}}{V_{NF}V_{FF}}\right)} \right]$$

1256

1257 **Equation M-11**

1258

$$\lambda_2 = 0.5 \left[-\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}}\right) - \sqrt{\left(\frac{Q_{NF}V_{FF} + V_{NF}(Q_{NF} + Q_{FF})}{V_{NF}V_{FF}}\right)^2 - 4\left(\frac{Q_{NF}Q_{FF}}{V_{NF}V_{FF}}\right)} \right]$$

1259

1260 EPA calculated the hourly TWA concentrations in the near-field and far-field using the following
1261 equations. Note that the numerator and denominator of Equation M-12 and Equation M-1313, use two

different sets of time parameters. The numerator is based on the operating hours for the scenario while the denominator is fixed to an averaging time span, t_{avg} , of 8 hours (since EPA is interested in calculating 8-hr TWA exposures). Mathematically, the numerator and denominator must reflect the same amount of time. This is indeed the case: although the spot cleaning operating hours ranges from two to five hours (as discussed in Section A.2.8), EPA assumes exposures are equal to zero outside of the operating hours, such that the integral over the balance of the eight hours (three to six hours) is equal to zero in the numerator. Therefore, the numerator inherently includes an integral over the balance of the eight hours equal to zero that is summed to the integral from t_1 to t_2 .

Equation M-12

$$C_{NF,TWA} = \frac{\int_{t_1}^{t_2} C_{NF} dt}{\int_0^{t_{avg}} dt} = \frac{\int_{t_1}^{t_2} G(k_1 + k_2 e^{\lambda_1 t} - k_3 e^{\lambda_2 t}) dt}{t_{avg}} =$$

$$\frac{G\left(k_1 t_2 + \frac{k_2 e^{\lambda_1 t_2}}{\lambda_1} - \frac{k_3 e^{\lambda_2 t_2}}{\lambda_2}\right) - G\left(k_1 t_1 + \frac{k_2 e^{\lambda_1 t_1}}{\lambda_1} - \frac{k_3 e^{\lambda_2 t_1}}{\lambda_2}\right)}{t_{avg}}$$

Equation M-13

$$C_{FF,TWA} = \frac{\int_{t_1}^{t_2} C_{FF} dt}{\int_0^{t_{avg}} dt} = \frac{\int_{t_1}^{t_2} G\left(\frac{1}{Q_{FF}} + k_4 e^{\lambda_1 t} - k_5 e^{\lambda_2 t}\right) dt}{t_{avg}} =$$

$$\frac{G\left(\frac{t_2}{Q_{FF}} + \frac{k_4 e^{\lambda_1 t_2}}{\lambda_1} - \frac{k_5 e^{\lambda_2 t_2}}{\lambda_2}\right) - G\left(\frac{t_1}{Q_{FF}} + \frac{k_4 e^{\lambda_1 t_1}}{\lambda_1} - \frac{k_5 e^{\lambda_2 t_1}}{\lambda_2}\right)}{t_{avg}}$$

To calculate the mass transfer to and from the near-field, the Free Surface Area, FSA, is defined to be the surface area through which mass transfer can occur. Note that the FSA is not equal to the surface area of the entire near-field. EPA defined the near-field zone to be a rectangular box resting on the floor; therefore, no mass transfer can occur through the near-field box's floor. FSA is calculated in Equation M-14, below:

Equation M-14

$$FSA = 2(L_{NF}H_{NF}) + 2(W_{NF}H_{NF}) + (L_{NF}W_{NF})$$

Where: L_{NF} , W_{NF} , and H_{NF} are the length, width, and height of the near-field, respectively. The near-field ventilation rate, Q_{NF} , is calculated in Equation M-15 from the near-field indoor wind speed, v_{NF} , and FSA, assuming half of FSA is available for mass transfer into the near-field and half of FSA is available for mass transfer out of the near-field:

Equation M-15

$$Q_{NF} = \frac{1}{2} v_{NF} FSA$$

The far-field volume, V_{FF} , and the air exchange rate, AER, is used to calculate the far-field ventilation rate, Q_{FF} , as given by Equation M-:

1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311

Equation M-16

$$Q_{FF} = V_{FF}AER$$

Using the model inputs in Table H-1, EPA estimated TCE inhalation exposures for workers in the near-field and for occupational non-user in the far-field. EPA then conducted the Monte Carlo simulations using @Risk (Version 7.0.0). The simulations applied 100,000 iterations and the Latin hypercube sampling method.

P.2 Model Parameters

Table_Apx P-1 summarizes the model parameters and their values for the Spot Cleaning Near-Field/Far-Field Exposure Model. Each parameter is discussed in detail in the following subsections.

1312
1313
1314

Table_Apx P-1. Summary of Parameter Values and Distributions Used in the Spot Cleaning Near-Field/Far-Field Inhalation Exposure Model

Input Parameter	Symbol	Unit	Constant Model Parameter Values		Variable Model Parameter Values				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Floor Area	A	ft ²	—	—	500	20,000	—	Beta	Facility floor area is based on data from the (CARB, 2006) and King County (Whittaker and Johanson, 2011) study. ERG fit a beta function to this distribution with parameters: $\alpha_1 = 6.655$, $\alpha_2 = 108.22$, min = 500 ft ² , max = 20,000 ft ² .
Far-field volume	V _{FF}	ft ³	—	—	6,000	240,000	—	—	Floor area multiplied by height. Facility height is 12 ft (median value per (CARB, 2006) study).
Near-field length	L _{NF}	ft	10	—	—	—	—	—	EPA assumed a constant near-field volume.
Near-field width	W _{NF}	ft	10	—	—	—	—	—	
Near-field height	H _{NF}	ft	6	—	—	—	—	—	
Air exchange rate	AER	hr ⁻¹	—	—	1	19	3.5	Triangular	Values based on (von Grote et al., 2006), and (U.S. EPA, 2013a). The mode represents the midpoint of the range reported in (U.S. EPA, 2013a).
Near-field indoor wind speed	V _{NF}	cm/s	—	—	0	202.2	—	Lognormal	Lognormal distribution fit to the data presented in (Baldwin and Maynard, 1998a).
		ft/hr	—	—	0	23,882	—	Lognormal	
Starting time	t ₁	hr	0	—	—	—	—	—	Constant value.
Exposure Duration	t ₂	hr	—	—	2	5	—	Uniform	Equal to operating hours per day.
Averaging time	t _{avg}	hr	8	—	—	—	—	—	Constant value.

Input Parameter	Symbol	Unit	Constant Model Parameter Values		Variable Model Parameter Values				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Use rate	UR	gal/yr	8.4	—	—	—	—	—	(IRTA, 2007) used estimates of the amount of TCE-based spot cleaner sold in California and the number of textile cleaning facilities in California to calculate a use rate value.
Vapor generation rate	G	mg/hr	—	—	2.97E+03	9.32E+04	—	Calculated	G is calculated based on UR and assumes 100% volatilization and accounts for the weight fraction of TCE.
		g/min	—	—	0.05	1.55	—	Calculated	
TCE weight fraction	wtfrac	wt frac	—	—	0.1	1	—	Uniform	(IRTA, 2007) observed TCE-based spotting agents contain 10% to 100% TCE.
Operating hours per day	OH	hr/day	—	—	2	5	—	Uniform	Determined from a California survey performed by (Morris and Wolf, 2005) and an analysis of two model plants constructed by the researchers
Operating days per year	OD	days/yr	—	—	249	313	300	Triangular	Operating days/yr distribution assumed as triangular distribution with min of 250, max of 312, and mode of 300.

Input Parameter	Symbol	Unit	Constant Model Parameter Values		Variable Model Parameter Values				Comments
			Value	Basis	Lower Bound	Upper Bound	Mode	Distribution Type	
Fractional number of operating days that a worker works	f	Dimensionless	1	—	0.8	1.0	—	Uniform	<p>In BLS/Census data, the weighted average worked hours per year and per worker in the dry cleaning sector is approximately 1,600 (<i>i.e.</i>, 200 day/yr at 8 hr/day).</p> <p>The BLS/Census data weighted average of 200 day/yr falls outside the triangular distribution of operating days and to account for lower exposure frequencies and part-time workers, EPA defines f as a uniform distribution ranging from 0.8 to 1.0. The 0.8 value was derived from the observation that the weighted average of 200 day/yr worked (from BLS/Census) is 80% of the standard assumption that a full-time worker works 250 day/yr. The maximum of 1.0 is appropriate as dry cleaners may be family owned and operated and some workers may work as much as every operating day.</p>

1315

1316 **P.2.1 Far-Field Volume**

1317 EPA calculated the far-field volume by setting a distribution for the facility floor area and multiplying
1318 the floor area by a facility height of 12 ft (median value per (CARB, 2006) study) as discussed in more
1319 detail below.

1320
1321 The 2006 CARB *California Dry Cleaning Industry Technical Assessment Report* (CARB, 2006) and the
1322 Local Hazardous Waste Management Program in King County *A Profile of the Dry Cleaning Industry in*
1323 *King County, Washington* (Whittaker and Johanson, 2011) provide survey data on dry cleaning facility
1324 floor area. The CARB (2006) study also provides survey data on facility height. Using survey results
1325 from both studies, EPA composed the following distribution of floor area. To calculate facility volume,
1326 EPA used the median facility height from the CARB (2006) study. The facility height distribution in the
1327 CARB (2006) study has a low level of variability, so the median height value of 12 ft presents a simple
1328 but reasonable approach to calculate facility volume combined with the floor area distribution. Results
1329 are provided in Table_Apx P-2

1330
1331 **Table_Apx P-2. Composite Distribution of Dry Cleaning Facility Floor Areas**

Floor Area Value (ft ²)	Percentile (as fraction)	Source
20,000	1	King County
3,000	0.96	King County
2,000	0.84	King County
1,600	0.5	CARB 2006
1,100	0.1	CARB 2006
500	0	CARB 2006

1332
1333 EPA fit a beta function to this distribution with parameters: $\alpha_1 = 6.655$, $\alpha_2 = 108.22$, min = 500 ft², max
1334 = 20,000 ft².

1335 **P.2.2 Near-Field Volume**

1336 EPA assumed a near-field of constant dimensions of 10 ft wide by 10 ft long by 6 ft high resulting in a
1337 total volume of 600 ft³.

1338 **P.2.3 Air Exchange Rate**

1339 (von Grote et al., 2006) indicated typical air exchange rates (AERs) of 5 to 19 hr⁻¹ for dry cleaning
1340 facilities in Germany. (Klein and Kurz, 1994a) indicated AERs of 1 to 19 hr⁻¹, with a mean of 8 hr⁻¹ for
1341 dry cleaning facilities in Germany. During the 2013 peer review of EPA's 2013 draft risk assessment of
1342 TCE, a peer reviewer indicated that air exchange rate values around 2 to 5 hr⁻¹ are likely (U.S. EPA,
1343 2013a), in agreement with the low end of the ranges reported by von Grote et al. and (Klein and Kurz,
1344 1994a). A triangular distribution is used with the mode equal to the midpoint of the range provided by
1345 the peer reviewer (3.5 is the midpoint of the range 2 to 5 hr⁻¹).

1346 **P.2.4 Near-Field Indoor Wind Speed**

1347 (Baldwin and Maynard, 1998a) measured indoor air speeds across a variety of occupational settings in
1348 the United Kingdom. Fifty-five work areas were surveyed across a variety of workplaces.

1349
1350 EPA analyzed the air speed data from (Baldwin and Maynard, 1998a) and categorizing the air speed
1351 surveys into settings representative of industrial facilities and representative of commercial facilities.

1352 EPA fit separate distributions for these industrial and commercial settings and used the commercial
1353 distribution for dry cleaners (including other textile cleaning facilities that conduct spot cleaning).
1354
1355 EPA fit a lognormal distribution for both data sets as consistent with the authors observations that the air
1356 speed measurements within a surveyed location were lognormally distributed and the population of the
1357 mean air speeds among all surveys were lognormally distributed. Since lognormal distributions are
1358 bound by zero and positive infinity, EPA truncated the distribution at the largest observed value among
1359 all of the survey mean air speeds from ([Baldwin and Maynard, 1998a](#)).

1360
1361 The air speed surveys representative of commercial facilities were fit to a lognormal distribution with
1362 the following parameter values: mean of 10.853 cm/s and standard deviation of 7.883 cm/s. In the
1363 model, the lognormal distribution is truncated at a maximum allowed value of 202.2 cm/s (largest
1364 surveyed mean air speed observed in ([Baldwin and Maynard, 1998a](#)) to prevent the model from
1365 sampling values that approach infinity or are otherwise unrealistically large.

1366
1367 ([Baldwin and Maynard, 1998a](#)) only presented the mean air speed of each survey. The authors did not
1368 present the individual measurements within each survey. Therefore, these distributions represent a
1369 distribution of mean air speeds and not a distribution of spatially-variable air speeds within a single
1370 workplace setting. However, a mean air speed (averaged over a work area) is the required input for the
1371 model.

1372 **P.2.5 Averaging Time**

1373 EPA is interested in estimating 8-hr TWAs for use in risk calculations; therefore, a constant averaging
1374 time of eight hours was used.

1375 **P.2.6 Use Rate**

1376 EPA used a top-down approach to estimate use rate based on the volume of TCE-based spotting agent
1377 sold in California and the number of textile cleaning facilities in California.

1378
1379 ([IRTA, 2007](#)) estimated 42,000 gal of TCE-based spotting agents are sold in California annually and
1380 there are approximately 5,000 textile cleaning facilities in California. This results in an average use rate
1381 of 8.4 gal/site-year of TCE-based spotting agents.

1382
1383 The study authors' review of safety data sheets identified TCE-based spotting agents contain 10% to
1384 100% TCE.

1385 **P.2.7 Vapor Generation Rate**

1386 EPA set the vapor generation rate for spot cleaning (G) equal to the use rate of TCE with appropriate
1387 unit conversions. EPA multiplied the spotting agent use rate by the weight fraction of TCE (which
1388 ranges from 0.1 to 1) and assumed all TCE applied to the garment evaporates. EPA used a density of
1389 1.46 g/cm³ ([U.S. EPA, 2018d](#)). To calculate an hourly vapor generation rate, EPA divided the annual use
1390 rate by the number of operating days and the number of operating hours selected from their respective
1391 distributions for each iteration.

1392 **P.2.8 Operating Hours**

1393 ([Morris and Wolf, 2005](#)) surveyed dry cleaners in California, including their spotting labor. The authors
1394 developed two model plants: a small PERC dry cleaner that cleans 40,000 lb of clothes annually; and a
1395 large PERC dry cleaner that cleans 100,000 lb of clothes annually. The authors modeled the small dry

1396 cleaner with a spotting labor of 2.46 hr/day and the large dry cleaner with a spotting labor of 5 hr/day.
1397 EPA models a uniform distribution of spotting labor varying from 2 to 5 hr/day.

1398 **P.2.9 Operating Days**

1399 EPA modeled the operating days per year using a triangular distribution from 250 to 312 days per year
1400 with a mode of 300 days per year.³¹ The low-end operating days per year is based on the assumption that
1401 at a minimum the dry cleaner operates five days per week and 50 weeks per year. The mode of 300 days
1402 per year is based on an assumption that most dry cleaners will operate six days per week and 50 weeks
1403 per year. The high-end value is based on the assumption that the dry cleaner would operate at most six
1404 days per week and 52 weeks per year, assuming the dry cleaner is open year-round.

1405 **P.2.10 Fractional Number of Operating Days that a Worker Works**

1406 To account for lower exposure frequencies and part-time workers, EPA defines a fractional days of
1407 exposure as a uniform distribution ranging from 0.8 to 1.0. EPA expects a worker's annual working days
1408 may be less than the operating days based on BLS/Census data that showed the weighted average
1409 worked hours per year and per worker in the dry cleaning sector is approximately 1,600 (*i.e.*, 200 day/yr
1410 at 8 hr/day) which falls outside the range of operating days per year used in the model (250 to 312
1411 day/yr with mode of 300 day/yr).

1412
1413 The low end of the range, 0.8, was derived from the observation that the weighted average of 200 day/yr
1414 worked (from BLS/Census) is 80% of the standard assumption that a full-time worker works 250 day/yr.
1415 The maximum of 1.0 is appropriate as dry cleaners may be family owned and operated and some
1416 workers may work as much as every operating day. EPA defines the exposure frequency as the number
1417 of operating days (250 to 312 day/yr) multiplied by the fractional days of exposure (0.8 to 1.0).
1418

³¹ For modeling purposes, the minimum value was set to 249 days per year and the maximum to 313 days per year; however, these values have a probability of zero; therefore, the true range is from 250 to 312 days per year.

Appendix Q OCCUPATIONAL INHALATION EXPOSURE AND WATER RELEASE ASSESSMENT

Q.1 Manufacturing

Q.1.1 Exposure Assessment

EPA assessed inhalation exposures during manufacturing using identified inhalation exposure monitoring data. Table_Apx Q-1 summarizes 8-hr TWA samples obtained from data submitted by Arkema, Inc., a TCE manufacturer ([Arkema, 2020](#)), and by the Halogenated Solvents Industry Alliance (HSIA) ([Halogenated Solvents Industry Alliance, 2018](#)) via public comment for one company listed as “Company B”. HSIA also provided “General 12-hr” full-shift exposure data from “Company A”. However, “Company A” data points were listed as “Not detected ≤ 0.062 ppm. Two additional studies with monitoring data for manufacturing were identified; however, the data from these studies were not used as the data were from China and almost 30 years old and are unlikely to be representative of current conditions at U.S. manufacturing sites. No data were found to estimate ONU exposures during TCE manufacturing. EPA estimates that ONU exposures are lower than worker exposures, since ONUs do not typically directly handle the chemical.

EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 50 data points from 2 sources, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to high.

Table_Apx Q-1. Summary of Worker Inhalation Exposure Monitoring Data from TCE Manufacturing

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	2.46	0.82	0.56	0.29	50	High
Central Tendency	0.12	$3.8E^{-2}$	$2.6E^{-2}$	$1.0E^{-2}$		

AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration. Source: ([Halogenated Solvents Industry Alliance, 2018 5176415](#))

Q.1.2 Water Release Assessment

In general, potential sources of water releases in the chemical industry may include the following: equipment cleaning operations, aqueous wastes from scrubbers/decanter, reaction water, process water from washing intermediate products, and trace water settled in storage tanks ([OECD, 2019](#)). Based on the process for manufacturing TCE, EPA expects the sources of water releases to be from aqueous wastes from decanters used to separate catalyst fines, caustic neutralizer column, and caustic scrubbers; and water removed from the TCE product in drying columns ([Most, 1989](#)). Additional water releases

1457 may occur if a site uses water to clean process equipment; however, EPA does not expect this to be a
 1458 primary source of water releases from manufacturing sites as equipment cleaning is not expected to
 1459 occur daily and manufacturers would likely use an organic solvent to clean process equipment.
 1460

1461 Of the five manufacturing sites assessed, three reported in the 2016 TRI (one of these three sites
 1462 reported zero water releases to TRI). Additionally, one of these sites also reported to 2016 DMR. For the
 1463 sites that reported water releases, EPA assessed water releases as reported in the 2016 TRI and 2016
 1464 DMR. For the remaining two sites, EPA assessed water releases at the maximum daily and maximum
 1465 average monthly concentrations allowed under the Organic Chemicals, Plastics and Synthetic Fibers
 1466 (OCPSF) Effluent Guidelines (EG) and Standards (40 C.F.R. Part 414) ([U.S. EPA, 2019g](#)). The OCPSF
 1467 EG applies to facilities classified under the following SIC codes:
 1468

- 1469 • 2821—Plastic Materials, Synthetic Resins, and Nonvulcanizable Elastomers;
- 1470 • 2823—Cellulosic Man-Made Fibers;
- 1471 • 2865—Cyclic Crudes and Intermediates, Dyes, and Organic Pigments; and
- 1472 • 2869—Industrial Organic Chemicals, Not Elsewhere Classified.

1473 Manufacturers of TCE would typically be classified under SIC code 2869; therefore, the requirements of
 1474 the OCPSF EG apply to these sites. Subparts I, J, and K of the OCPSF EG set limits for the
 1475 concentration of TCE in wastewater effluents for industrial facilities that are direct discharge point
 1476 sources using end-of-pipe biological treatment, direct discharge point sources that do not use end-of-
 1477 pipe biological treatment, and indirect discharge point sources, respectively 40 C.F.R. Part 414 ([U.S.
 1478 EPA, 2019g](#)). Direct dischargers are facilities that discharge effluents directly to surface waters and
 1479 indirect dischargers are facilities that discharge effluents to publicly-owned treatment works (POTW).
 1480 The OCPSF limits for TCE are provided in Table_Apx Q-2.
 1481

1482 **Table_Apx Q-2. Summary of OCPSF Effluent Limitations for Trichloroethylene**

OCPSF Subpart	Maximum for Any One Day (µg/L)	Maximum for Any Monthly Average (µg/L)	Basis
Subpart I – Direct Discharge Point Sources That Use End-of-Pipe Biological Treatment	54	21	BAT effluent limitations and NSPS
Subpart J – Direct Discharge Point Sources That Do Not Use End-of-Pipe Biological Treatment	69	26	BAT effluent limitations and NSPS
Subpart K – Indirect Discharge Point Sources	69	26	Pretreatment Standards for Existing Sources (PSES) and Pretreatment Standards for New Sources (PSNS)

1483 BAT = Best Available Technology Economically Achievable; NSPS = New Source Performance Standards; PSES =
 1484 Pretreatment Standards for Existing Sources; PSNS = Pretreatment Standards for New Sources.
 1485 Source: ([U.S. EPA, 2019g](#))
 1486

1487 EPA did not identify TCE-specific information on the amount of wastewater produced per day. The
 1488 Specific Environmental Release Category (SpERC) developed by the European Solvent Industry Group

1489 for the manufacture of a substance estimates 10 m³ of wastewater generated per metric ton of substance
 1490 produced ([ESIG, 2012](#)). In lieu of TCE-specific information, EPA estimated water releases using the
 1491 SpERC specified wastewater production volume and the annual TCE production rates from each facility.
 1492

1493 EPA estimated both a maximum daily release and an average daily release using the OCPSF EG
 1494 limitations for TCE for maximum on any one day, and maximum for any monthly average, respectively.
 1495 Prevalence of end-of-pipe biological treatment at TCE manufacturing sites is unknown; therefore, EPA
 1496 used limitations for direct discharges with no end-of-pipe biological treatment and indirect dischargers
 1497 to address the uncertainty at these sites. EPA estimated annual releases from the average daily release
 1498 and assuming 350 days/yr of operation.³²
 1499

1500 Table_Apx Q-3 summarizes water releases from the manufacturing process for sites reporting to TRI
 1501 and Table_Apx Q-4 summarizes water releases from sites not reporting to TRI. The estimated total
 1502 annual release across all sites is 79.2 – 472.3 kg/yr discharged to surface water or POTWs.
 1503

1504 **Table_Apx Q-3. Reported Water Releases of Trichloroethylene from Manufacturing Sites**
 1505 **Reporting to 2016 TRI**

Site	Annual Release ^a (kg/site-yr)	Annual Release Days (days/yr)	Average Daily Release ^a (kg/site-day)	NPDES Code	Release Media
Olin Blue Cube, Freeport, TX	24	350	0.07	TX0059447	non-POTW WWT
Geon Oxy Vinyl Laporte Plant, Laporte, TX	0	N/A	0	TX0070416	N/A
Occidental Chemical Corp. Wichita, KS	0	N/A	0	Not available	N/A
Axiall Corporation dba Eagle US 2 LLC, Westlake, LA ^b	49.9-443 ^c	350	0.14-1.27	LA0000761 ^d	Surface Water

1506 POTW = Publicly-Owned Treatment Works; WWT = Wastewater Treatment; N/A = Not applicable
 1507 ^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual
 1508 release rate and assuming 300 days of operation per year.
 1509 ^b Axiall was purchased by Westlake Chemical in 2016. The site at 1300 PPG Drive Westlake, LA dba Eagle US 2 LLC.
 1510 ^cFirst value based on 2016 TRI, second value based on 2016 DMR data ([U.S. EPA, 2016a](#)).
 1511 ^dBased on Eagle US 2 LLC NPDES Permit provided in DMR Data ([U.S. EPA, 2016a](#)).
 1512
 1513
 1514
 1515
 1516
 1517
 1518
 1519
 1520

³² Due to large throughput, manufacturing sites are assumed to operate seven days per week and 50 weeks per year with two weeks per year for shutdown activities.

1521
1522

Table_Apx Q-4. Estimated Water Releases of Trichloroethylene from Manufacturing Sites Not Reporting to 2016 TRI

Site	Annual Operating Days (days/yr)	Daily Production Volume ^a (kg/site-day)	Daily Wastewater Flow ^b (L/site-day)	Maximum Daily Release ^c (kg/site-day)	Average Daily Release ^d (kg/site-day)	Average Annual Release ^e (kg/site-yr)	NPDES Code	Release Media
Solvents & Chemicals, Pearland, TX	350	58,234	582,345	0.04	0.02	5.3	Not available	Surface Water or POTW

1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535

POTW = Publicly-Owned Treatment Works

^a Daily production volume calculated using the annual production volume and dividing by the annual operating days per year (300 days/yr).

^b The estimated wastewater flow rate is calculated assuming 10 m³ of wastewater is produced per metric ton of TCE produced (equivalent to 10 L wastewater/kg of TCE) based on the SpERC for the manufacture of a substance ([ESIG, 2012](#)).

^c The maximum daily release is calculated using the maximum daily concentration from the OCPSF EG, 26 µg/L, and multiplying by the daily wastewater flow.

^d The average daily release is calculated using the maximum monthly average concentration from the OCPSF EG, 69 µg/L, and multiplying by the daily wastewater flow.

^e The average annual release is calculated as the maximum monthly average concentration multiplied by the daily wastewater production, and 350 operating days/year.

Q.2 Processing as a Reactant

Q.2.1 Exposure Assessment

EPA did not identify inhalation exposure monitoring data related processing TCE as a reactant. Therefore, EPA used monitoring data from the manufacture of TCE as surrogate. EPA believes the handling and TCE concentrations for both conditions of use to be similar. However, EPA is unsure of the representativeness of these surrogate data toward actual exposures to TCE at all sites covered by this condition of use.

EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of surrogate monitoring data, in the middle of the inhalation approach hierarchy. These monitoring data include 50 data points from 2 sources, and the data quality ratings from systematic review for these data were medium. The primary limitations of these data include the uncertainty of the representativeness of these surrogate data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.

The surrogate data were obtained from (HSIA) via public comment ([Halogenated Solvents Industry Alliance, 2018](#)) and from the TCE manufacturer Arkema ([Arkema, 2020](#)), presented in Table_Apx Q-5 below. No data were found to estimate ONU exposures during use of TCE as a reactant. EPA estimates

1556 that ONU exposures are lower than worker exposures, since ONUs do not typically directly handle the
 1557 chemical.

1558
 1559 **Table_Apx Q-5. Summary of Worker Inhalation Exposure Surrogate Monitoring Data from TCE**
 1560 **Use as a Reactant**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Associated Air Concentration Data
High-End	2.46	0.82	0.56	0.29	50	Medium
Central Tendency	0.12	3.8E ⁻²	2.6E ⁻²	1.0E ⁻²		

1561 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

1562 **Q.2.2 Water Release Assessment**

1563 In general, potential sources of water releases in the chemical industry may include the following:
 1564 equipment cleaning operations, aqueous wastes from scrubbers/decanter, reaction water, process water
 1565 from washing intermediate products, and trace water settled in storage tanks (OECD, 2019). Based on
 1566 the use as a reactant, EPA expects minimal sources of TCE release to water.

1567
 1568 Two of the three sites reporting to TRI did not report any water releases of TCE; the other TRI site
 1569 reported 13 lb/yr (5.9 kg/yr) released to water. For the two sites found through DMR data, total water
 1570 releases were calculated to be approximately 11 lb/yr (5 kg/yr). Based on the information for these 5
 1571 sites, an average annual release of approximately 2.2 kg/site-yr was calculated. Using this estimate, and
 1572 assuming 440 sites as a high-end estimate, the total TCE water discharge from these 440 sites equal
 1573 approximately 968 kg/yr. Table_Apx Q-6 summarizes the low and high end water release estimates.
 1574

1575 **Table_Apx Q-6. Water Release Estimates for Sites Using TCE as a Reactant**

Number of Sites	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day)	NPDES Code	Release Media
<i>Low End Number of Sites</i>					
Arkema Inc., Calvert City, KY	5.9	350	0.02	KY0003603	Surface Water
Honeywell International - Geismar Complex, Geismar, LA	4.5	350	0.01	LA0006181	Surface Water
Praxair Technology Center, Tonawanda, NY	0.6	350	1.7E-03	NY0000281	Surface Water
<i>High End Number of Sites</i>					
440 unknown sites	2.2 ^a	350	6.3E-03	N/A	Surface Water or POTW

1576 ^a Calculated from the total yearly water releases of TCE from DMR and TRI data, and dividing by the number of reporting sites
 1577 (5 sites). Mexichem Fluor Inc. and Halocarbon Products Corp reported no water releases to TRI.
 1578

1579 **Q.3 Formulation of Aerosol and Non-Aerosol Products**

1580 **Q.3.1 Exposure Assessment**

1581 EPA did not identify inhalation exposure monitoring data related using TCE when formulating aerosol
 1582 and non-aerosol products. Therefore, EPA used monitoring data from repackaging as a surrogate, as
 1583 EPA believes the handling and TCE concentrations for both conditions of use to be similar. However,

1584 EPA is unsure of the representativeness of these surrogate data toward actual exposures to TCE at all
1585 sites covered by this condition of use.

1586
1587 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
1588 to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths
1589 include the assessment approach, which is the use of surrogate monitoring data, in the middle of the
1590 inhalation approach hierarchy. These monitoring data include 33 data points from 1 source, and the data
1591 quality ratings from systematic review for these data were high. The primary limitations of these data
1592 include the uncertainty of the representativeness of these surrogate data toward the true distribution of
1593 inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths
1594 and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data
1595 in this scenario is medium.

1596
1597 Table_Apx Q-7 summarizes the 8-hr TWA from monitoring data from unloading/loading TCE from
1598 bulk containers. The data were obtained from a Chemical Safety Report ([DOW Deutschland, 2014b](#)).
1599 No data were found to estimate ONU exposures during formulation of aerosol and non-aerosol products.
1600 EPA estimates that ONU exposures are lower than worker exposures, since ONUs do not typically
1601 directly handle the chemical.

1602
1603 **Table_Apx Q-7. Summary of Worker Inhalation Exposure Monitoring Data for Unloading TCE**
1604 **During Formulation of Aerosol and Non-Aerosol Products**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	1.1	0.4	0.3	0.1	33	Medium
Central Tendency	4.9E-4	1.6E-4	1.1E-4	4.5E-5		

1605 AC= Acute Exposure and ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

1606 **Q.3.2 Water Release Assessment**

1607 In general, potential sources of water releases in the chemical industry may include the following:
1608 equipment cleaning operations, aqueous wastes from scrubbers/decanter, reaction water, process water
1609 from washing intermediate products, and trace water settled in storage tanks ([OECD, 2019](#)). Based on
1610 the use in formulations and the amount of TCE used for this condition of use, EPA expects minimal
1611 sources of TCE release to water.

1612
1613 None of the sites reporting to TRI reported any water releases of TCE. All releases were to off-site land,
1614 incineration or recycling. Based on this information, EPA does not have enough information to estimate
1615 water releases of TCE for this condition of use.

1616 **Q.4 Repackaging**

1617 **Q.4.1 Exposure Assessment**

1618 EPA identified inhalation exposure monitoring data related unloading/loading TCE into/from bulk
1619 transport containers. Table_Apx Q-8 summarizes the 8-hr TWA from monitoring data from
1620 unloading/loading TCE from bulk containers. The data were obtained from a Chemical Safety Report
1621

1622 ([DOW Deutschland, 2014b](#)). It should be noted that this study indicates that the filling system uses a
 1623 “largely automated process” ([DOW Deutschland, 2014b](#)). Therefore, EPA is unsure of the
 1624 representativeness of these data toward actual exposures to TCE for all sites covered by this condition of
 1625 use.

1626
 1627 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
 1628 to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the
 1629 primary strengths include the assessment approach, which is the use of monitoring data, the highest of
 1630 the inhalation approach hierarchy. These monitoring data include 33 data points from 1 source, and the
 1631 data quality ratings from systematic review for these data were high. The primary limitations of these
 1632 data include the uncertainty of the representativeness of these data toward the true distribution of
 1633 inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths
 1634 and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data
 1635 in this scenario is medium to high.

1636
 1637 No data were found to estimate ONU exposures during formulation of aerosol and non-aerosol products.
 1638 EPA estimates that ONU exposures are lower than worker exposures, since ONUs do not typically
 1639 directly handle the chemical.

1640
 1641 **Table_Apx Q-8. Summary of Worker Inhalation Exposure Monitoring Data for**
 1642 **Unloading/Loading TCE from Bulk Containers**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	1.1	0.4	0.26	0.1	33	Medium to High
Central Tendency	4.9E-4	1.6E-4	1.1E-4	4.5E-5		

1643 AC= Acute Exposure and ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

1644 **Q.4.2 Water Release Assessment**

1645 EPA expects the primary source of water releases from repackaging activities to be from the use of
 1646 water or steam to clean bulk containers used to transport TCE or products containing TCE. EPA expects
 1647 the use of water/steam for cleaning containers to be limited at repackaging sites as TCE is an organic
 1648 substance and classified as a hazardous waste under RCRA. EPA expects the majority of sites to use
 1649 organic cleaning solvents which would be disposed of as hazardous waste (incineration or landfill) over
 1650 water or steam.

1651
 1652 Water releases during repackaging were assessed using data reported in the 2016 DMR and 2016 TRI.
 1653 One of the 20 sites reporting to TRI reported water releases of TCE to off-site wastewater treatment. All
 1654 other sites reporting to TRI reported releases to off-site land or incineration. EPA assessed annual
 1655 releases as reported in the 2016 DMR and assessed daily releases by assuming 250 days of operation per
 1656 year. A summary of the water releases reported to the 2016 DMR and TRI can be found in Table_Apx
 1657 Q-9.

1658

16659

Table_Apx Q-9. Reported Water Releases of Trichloroethylene from Sites Repackaging TCE

Site Identity	Annual Release (kg/site-yr) ^a	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Hubbard-Hall Inc, Waterbury, CT	277	250	1.1	Not available	Non-POTW WWT
St. Gabriel Terminal, Saint Gabriel, LA	1.4	250	5.5E-03	LA0052353	Surface Water
Vopak Terminal Westwego Inc, Westwego, LA	1.2	250	4.7E-03	LA0124583	Surface Water
Oiltanking Houston Inc, Houston, TX	0.8	250	3.3E-03	TX0091855	Surface Water
Research Solutions Group Inc, Pelham, AL	0.01	250	3.3E-05	AL0074276	Surface Water
Carlisle Engineered Products Inc, Middlefield, OH	1.7E-3	250	6.8E-06	OH0052370	Surface Water

^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual release rate and assuming 250 days of operation per year.

Sources: ([U.S. EPA, 2016a](#)) and ([U.S. EPA, 2017c](#))

Q.5 Batch Open Top Vapor Degreasing

Q.5.1 Exposure Assessment

EPA identified inhalation exposure monitoring data from NIOSH investigations at twelve sites using TCE as a degreasing solvent in OTVDs. Due to the large variety in shop types that may use TCE as a vapor degreasing solvent, it is unclear how representative these data are of a “typical” shop. Therefore, EPA supplemented the identified monitoring data using the Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model. The following subsections detail the results of EPA’s occupational exposure assessment for batch open-top vapor degreasing based on inhalation exposure monitoring data and modeling.

Table_Apx Q-10 summarizes the 8-hr TWA monitoring data for the use of TCE in OTVDs. The data were obtained from NIOSH Health Hazard Evaluation reports (HHEs). NIOSH HHEs are conducted at the request of employees, employers, or union officials, and provide information on existing and potential hazards present in the workplaces evaluated ([Daniels et al., 1988](#)), ([Ruhe et al., 1981](#)), ([Barsan, 1991](#)), ([Ruhe, 1982](#)), ([Rosensteel and Lucas, 1975](#)), ([Seitz and Driscoll, 1989](#)), ([Gorman et al., 1984](#)), ([Gilles et al., 1977](#)), ([Vandervort and Polakoff, 1973](#)), and ([Lewis, 1980](#)).

Data from these sources cover exposures at several industries including metal tube production, valve manufacturing, jet and rocket engine manufacture, air conditioning prep and assembly, and AC motor parts ([Ruhe et al., 1981](#)), ([Barsan, 1991](#)), ([Rosensteel and Lucas, 1975](#)), ([Gorman et al., 1984](#)), ([Vandervort and Polakoff, 1973](#)), and ([Lewis, 1980](#)). Except for one site, sample times ranged from approximately five to eight hours ([Ruhe et al., 1981](#)), ([Barsan, 1991](#)), ([Rosensteel and Lucas, 1975](#)), ([Gorman et al., 1984](#)), and ([Lewis, 1980](#)). The majority of samples taken at the other site were taken for 2 hours or less ([Vandervort and Polakoff, 1973](#)). Where sample times were less than eight hours, EPA converted to an 8-hr TWA assuming exposure outside the sample time was zero. For sample times greater than eight hours, EPA left the measured concentration as is. It should be noted that additional sources for degreasing were identified but were not used in EPA’s analysis as they either: 1) did not specify the machine type in use; or 2) only provided a statistical summary of worker exposure monitoring.

1693
1694
1695

Table_Apx Q-10. Summary of Worker Inhalation Exposure Monitoring Data for Batch Open-Top Vapor Degreasing

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
<i>Workers</i>						
High-End	77.8	25.9	17.8	9.1	113	Medium
Central Tendency	13.8	4.6	3.2	1.3		
<i>Occupational non-users</i>						
High-End	9.1	3.0	2.1	1.1	10	Medium
Central Tendency	1.1	0.4	0.3	0.1		

1696 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

1697

1698 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
1699 to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the
1700 primary strengths include the assessment approach, which is the use of monitoring data, the highest of
1701 the inhalation approach hierarchy. These monitoring data include 123 data points from 16 sources, and
1702 the data quality ratings from systematic review for these data were medium. The primary limitations of
1703 these data include the uncertainty of the representativeness of these data toward the true distribution of
1704 inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths
1705 and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data
1706 in this scenario is medium.


1707

1708 EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. A
1709 Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input
1710 parameters. Vapor generation rates were derived from TCE unit emissions and operating hours reported
1711 in the 2014 National Emissions Inventory. The primary limitations of the air concentration outputs from
1712 the model include the uncertainty of the representativeness of these data toward the true distribution of
1713 inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties
1714 include that the underlying methodologies used to estimate these emissions in the 2014 NEI are
1715 unknown. Based on these strengths and limitations of the air concentrations, the overall confidence for
1716 these 8-hr TWA data in this scenario is medium to low.

1717

1718 Figure_Apx Q-1 illustrates the near-field/far-field model that can be applied to open-top vapor
1719 degreasing (AIHA, 2009). As the figure shows, volatile TCE vapors evaporate into the near-field,
1720 resulting in worker exposures at a concentration C_{NF} . The concentration is directly proportional to the
1721 evaporation rate of TCE, G , into the near-field, whose volume is denoted by V_{NF} . The ventilation rate
1722 for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field, resulting in
1723 occupational non-user exposures to TCE at a concentration C_{FF} . V_{FF} denotes the volume of the far-field
1724 space into which the TCE dissipates out of the near-field. The ventilation rate for the surroundings,
1725 denoted by Q_{FF} , determines how quickly TCE dissipates out of the surrounding space and into the
1726 outside air.

1727



Figure_Apx Q-1. Schematic of the Open-Top Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model

To estimate the TCE vapor generation rate, the model developed a distribution from the reported annual emission rates and annual operating times reported in the 2014 NEI. NEI records where the annual operating time was not reported were excluded from the distribution.

Batch degreasers are assumed to operate between two and 24 hours per day, based on NEI data on the reported operating hours for OTVD using TCE. EPA performed a Monte Carlo simulation with 100,000 iterations and the Latin Hypercube sampling method in @Risk to calculate 8-hour TWA near-field and far-field exposure concentrations. Near-field exposure represents exposure concentrations for workers who directly operate the vapor degreasing equipment, whereas far-field exposure represents exposure concentrations for occupational non-users (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment).

Table_Apx Q-11 presents a statistical summary of the exposure modeling results. These exposure estimates represent modeled exposures for the workers and occupational non-users. For workers, the 50th percentile exposure is 34.8 ppm 8-hr TWA, with a 95th percentile of 388 ppm 8-hr TWA.

Both of these values are an order of magnitude higher than identified in the monitoring data. This may be due to the limited number of sites from which the monitoring data were taken whereas the model is meant to capture a broader range of scenarios. It is also uncertain of the underlying methodologies used to estimate emissions in the 2014 NEI data.

1759

Table_Apx Q-11. Summary of Exposure Modeling Results for TCE Degreasing in OTVDs

Percentile	8-hr TWA (ppm)	AC ^a (ppm)	ADC (ppm)	LADC (ppm)	Confidence Rating of Air Concentration Data
<i>Workers (Near-field)</i>					
High-End	388	129.3	88.5	35.3	N/A – Modeled Data
Central Tendency	34.8	79.0	8.0	3.0	
<i>Occupational non-users (Far-Field)</i>					
High-End	237	79.0	54.0	21.1	N/A – Modeled Data
Central Tendency	18.1	6.0	4.1	1.5	

1760

AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

1761

^a Acute exposures calculated as a 24-hr TWA.

1762

Q.5.2 Water Release Assessment

1763

The primary source of water releases from OTVDs is wastewater from the water separator. Water in the OTVD may come from two sources: 1) Moisture in the atmosphere that condenses into the solvent when exposed to the condensation coils on the OTVD; and/or 2) steam used to regenerate carbon adsorbers used to control solvent emissions on OTVDs with enclosures ([Durkee, 2014](#); [Kanegsberg and Kanegsberg, 2011](#); [NIOSH, 2002a, b, c, d](#)). The water is removed in a gravity separator and sent for disposal ([NIOSH, 2002a, b, c, d](#)). The current disposal practices of the wastewater are unknown; however, a 1982 EPA ([Gilbert et al., 1982](#)) report estimated 20% of water releases from metal cleaning (including batch systems, conveyORIZED systems, and vapor and cold systems) were direct discharges to surface water and 80% of water releases were discharged indirectly to a POTW.

1766

1767

1768

1769

1770

1771

1772

1773

1774

1775

1776

1777

1778

1779

1780

1781

1782

1783

Table_Apx Q-12. Reported Water Releases of Trichloroethylene from Sites Using TCE in Open-Top Vapor Degreasing

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day)	NPDES Code	Release Media
US Nasa Michoud Assembly Facility, New Orleans, LA	509	260	1.96	LA0052256	Surface Water
GM Components Holdings LLC, Lockport, NY	34.2	260	0.13	NY0000558	Surface Water
Akebono Elizabethtown Plant, Elizabethtown, KY	17.9	260	0.07	KY0089672	Surface Water
Delphi Harrison Thermal Systems, Dayton, OH	9.3	260	0.04	OH0009431	Surface Water

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day)	NPDES Code	Release Media
Chemours Company Fc LLC, Washington, WV	6.7	260	0.03	WV0001279	Surface Water
Equistar Chemicals LP, La Porte, TX	4.4	260	0.02	TX0119792	Surface Water
GE Aviation, Lynn, MA	2.6	260	0.01	MA0003905	Surface Water
Certa Vandalia LLC, Vandalia, OH	2.1	260	0.01	OH0122751	Surface Water
GM Components Holdings LLC Kokomo Ops, Kokomo, IN	1.7	260	0.01	IN0001830	Surface Water
Amphenol Corp-Aerospace Operations, Sidney, NY	1.6	260	0.01	NY0003824	Surface Water
Emerson Power Trans Corp, Maysville, KY	1.6	260	0.01	KY0100196	Surface Water
Olean Advanced Products, Olean, NY	1.4	260	0.01	NY0073547	Surface Water
Texas Instruments, Inc., Attleboro, MA	1.3	260	5.18E-03	MA0001791	Surface Water
Hollingsworth Saco Lowell, Easley, SC	1.2	260	4.69E-03	SC0046396	Surface Water
Trelleborg YSH Incorporated Sandusky Plant, Sandusky, MI	0.9	260	3.60E-03	MI0028142	Surface Water
Timken Us Corp Honea Path, Honea Path, SC	0.9	260	3.55E-03	SC0047520	Surface Water
Johnson Controls Incorporated, Wichita, KS	0.6	260	2.28E-03	KS0000850	Surface Water
Accellent Inc/Collegeville Microcoax, Collegeville, PA	0.6	260	2.22E-03	PA0042617	Surface Water
National Railroad Passenger Corporation (Amtrak) Wilmington Maintenance Facility, Wilmington, DE	0.5	260	2.03E-03	DE0050962	Surface Water
Electrolux Home Products (Formerly Frigidaire), Greenville, MI	0.5	260	2.01E-03	MI0002135	Surface Water
Rex Heat Treat Lansdale Inc, Lansdale, PA	0.5	260	1.94E-03	PA0052965	Surface Water
Carrier Corporation, Syracuse, NY	0.5	260	1.77E-03	NY0001163	Surface Water
Globe Engineering Co Inc, Wichita, KS	0.5	260	1.74E-03	KS0086703	Surface Water
Cascade Corp (0812100207), Springfield, OH	0.3	260	1.17E-03	OH0085715	Surface Water
USAF-Wurtsmith AFB, Oscoda, MI	0.3	260	1.15E-03	MI0042285	Surface Water
AAR Mobility Systems, Cadillac, MI	0.3	260	1.12E-03	MI0002640	Surface Water
Eaton Mdh Company Inc, Kearney, NE	0.3	260	1.07E-03	NE0114405	Surface Water
Motor Components L C, Elmira, NY	0.3	260	9.64E-04	NY0004081	Surface Water
Salem Tube Mfg, Greenville, PA	0.233	260	8.97E-04	PA0221244	Surface Water
Ametek Inc. U.S. Gauge Div., Sellersville, PA	0.227	260	8.72E-04	PA0056014	Surface Water

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day)	NPDES Code	Release Media
GE (Greenville) Gas Turbines LLC, Greenville, SC	0.210	260	8.06E-04	SC0003484	Surface Water
Parker Hannifin Corporation, Waverly, OH	0.194	260	7.47E-04	OH0104132	Surface Water
Mahle Enginecomponents USA Inc, Muskegon, MI	0.193	260	7.42E-04	MI0004057	Surface Water
General Electric Company - Waynesboro, Waynesboro, VA	0.191	260	7.33E-04	VA0002402	Surface Water
Gayston Corp, Dayton, OH	0.167	260	6.43E-04	OH0127043	Surface Water
Styrolution America LLC, Channahon, IL	0.166	260	6.37E-04	IL0001619	Surface Water
Remington Arms Co Inc, Ilion, NY	0.159	260	6.12E-04	NY0005282	Surface Water
Lake Region Medical, Trappe, PA	0.1	260	5.06E-04	Not available	Surface Water
United Technologies Corporation, Pratt And Whitney Division, East Hartford, CT	0.1	260	4.80E-04	CT0001376	Surface Water
Atk-Allegany Ballistics Lab (Nirop), Keyser, WV	0.1	260	4.70E-04	WV0020371	Surface Water
Techalloy Co Inc, Union, IL	0.1	260	4.27E-04	IL0070408	Surface Water
Owt Industries, Pickens, SC	0.1	260	3.14E-04	SC0026492	Surface Water
Boler Company, Hillsdale, MI	0.1	260	2.69E-04	MI0053651	Surface Water
Mccanna Inc., Carpentersville, IL	0.1	260	2.68E-04	IL0071340	Surface Water
Cutler Hammer, Horseheads, NY	0.1	260	2.38E-04	NY0246174	Surface Water
Sperry & Rice Manufacturing Co LLC, Brookville, IN	8.54E-02	260	3.28E-04	IN0001473	Surface Water
US Air Force Offutt Afb Ne, Offutt A F B, NE	4.14E-02	260	1.59E-04	NE0121789	Surface Water
Troxel Company, Moscow, TN	3.49E-02	260	1.34E-04	TN0000451	Surface Water
Austin Tube Prod, Baldwin, MI	2.96E-02	260	1.14E-04	MI0054224	Surface Water
LS Starrett Precision Tools, Athol, MA	2.65E-02	260	1.02E-04	MA0001350	Surface Water
Avx Corp, Raleigh, NC	2.30E-02	260	8.83E-05	NC0089494	Surface Water
Handy & Harman Tube Co/East Norriton, Norristown, PA	1.61E-02	260	6.17E-05	PA0011436	Surface Water
Indian Head Division, Naval Surface Warfare Center, Indian Head, MD	1.08E-02	260	4.16E-05	MD0003158	Surface Water
General Dynamics Ordnance Tactical Systems, Red Lion, PA	6.34E-03	260	2.44E-05	PA0043672	Surface Water
Trane Residential Solutions - Fort Smith, Fort Smith, AR	3.46E-03	260	1.33E-05	AR0052477	Surface Water
Lexmark International Inc., Lexington, KY	3.23E-03	260	1.24E-05	KY0097624	Surface Water
Alliant Techsystems Operations LLC, Elkton, MD	3.02E-03	260	1.16E-05	MD0000078	Surface Water
Daikin Applied America, Inc. (Formally Mcquay International), Scottsboro, AL	2.15E-03	260	8.26E-06	AL0069701	Surface Water

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day)	NPDES Code	Release Media
Beechcraft Corporation, Wichita, KS	2.04E-03	260	7.86E-06	KS0000183	Surface Water
Federal-Mogul Corp, Scottsville, KY	1.50E-03	260	5.78E-06	KY0106585	Surface Water
Cessna Aircraft Co (Pawnee Facility), Wichita, KS	1.36E-03	260	5.24E-06	KS0000647	Surface Water
N.G.I, Parkersburg, WV	3.43E-04	260	1.32E-06	WV0003204	Surface Water
Hyster-Yale Group, Inc, Sulligent, AL	2.35E-04	260	9.03E-07	AL0069787	Surface Water
Hitachi Electronic Devices (USA), Inc., Greenville, SC	6.58E-05	260	2.53E-07	SC0048411	Surface Water

WWT = Wastewater Treatment

^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual release rate and assuming 260 days of operation per year.

Sources: 2016 TRI ([U.S. EPA, 2017c](#)); 2016 DMR ([U.S. EPA, 2016a](#))

Data from TRI and DMR may not represent the entirety of sites using TCE in OTVDs. EPA did not identify other data sources to estimate water releases from sites not reporting to TRI or DMR. However, sites operating degreasers are regulated by the following national ELGs:

- Electroplating Point Source Category Subparts A, B, D, E, F, G, and H ([U.S. EPA, 2019d](#));³³
- Iron and Steel Manufacturing Point Source Category Subpart J ([U.S. EPA, 2019e](#));
- Metal Finishing Point Source Category Subpart A ([U.S. EPA, 2019f](#));³⁴
- Coil Coating Point Source Category Subpart D ([U.S. EPA, 2019b](#));
- Aluminum Forming Point Source Category Subparts A, B, C, D, E, and F ([U.S. EPA, 2019a](#)); and
- Electrical and Electronic Components Point Source Category Subparts A and B ([U.S. EPA, 2019c](#)).

All above ELGs set discharges limits based on the total toxic organics (TTO) concentration in the wastewater stream and not a specific TCE limit. TTO is the summation of the concentrations for a specified list of pollutants which may be different for each promulgated ELG and includes TCE for the above referenced ELGs. Therefore, the concentration of TCE in the effluent is expected to be less than the TTO limit.

The operation of the water separator via gravity separation is such that the maximum concentration of TCE leaving the OTVD is equal to the solubility of TCE in water, 1,280 mg/L ([Durkee, 2014](#)). In cases where this concentration exceeds the limit set by the applicable ELGs, EPA expects sites will perform some form of wastewater treatment for the effluent stream leaving the OTVD to ensure compliance with the ELG prior to discharge. EPA did not identify information on the amount of wastewater generated from OTVDs to estimate releases from sites not reporting to TRI or DMR.

³³ The Electroplating ELG applies only to sites that discharge to POTW (indirect discharge) that were in operation before July 15, 1983. Processes that began operating after July 15, 1983 and direct dischargers are subject to the Metal Finishing ELG (40 C.F.R Part 433).

³⁴ The Metal Finishing ELG do not apply when wastewater discharges from metal finishing operations are already regulated by the Iron and Steel, Coil Coating, Aluminum Forming, or Electrical and Electronic Components ELGs.

1814

Q.6 Batch Closed-Loop Vapor Degreasing

1815

Q.6.1 Exposure Assessment

1816 EPA identified inhalation exposure monitoring data from a European Chemical Safety report using TCE
1817 in closed degreasing operations. However, it is unclear how representative these data are of a “typical”
1818 batch closed-loop degreasing shop. Table_Apx Q-13 summarizes the 8-hr TWA monitoring data for the
1819 use of TCE in vapor degreasers. The data were obtained from a Chemical Safety Report ([DOW](#)
1820 [Deutschland, 2014a](#)).

1821

1822 Data from these sources cover exposures at several industries where industrial parts cleaning occurred
1823 using vapor degreasing in closed systems. It should be noted that additional sources for degreasing were
1824 identified but were not used in EPA’s analysis as they either: 1) did not specify the machine type in use;
1825 or 2) only provided a statistical summary of worker exposure monitoring.

1826

1827 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
1828 to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the
1829 primary strengths include the assessment approach, which is the use of monitoring data, the highest of
1830 the inhalation approach hierarchy. These monitoring data include 19 data points from 1 source, and the
1831 data quality ratings from systematic review for these data were high. The primary limitations of these
1832 data include the uncertainty of the representativeness of these data toward the true distribution of
1833 inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths
1834 and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data
1835 in this scenario is medium to high.

1836

1837 **Table_Apx Q-13. Summary of Worker Inhalation Exposure Monitoring Data for Batch Closed-**
1838 **Loop Vapor Degreasing**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	1.4	0.5	0.3	0.2	19	High
Central Tendency	0.5	0.2	0.1	0.04		

1839

AC = Acute Concentration, ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

1840

Q.6.2 Water Release Assessment

1841 Similar to OTVDs, the primary source of water releases from closed-loop systems is wastewater from
1842 the water separator. However, unlike OTVDs, no water is expected to enter the system through
1843 condensation ([Durkee, 2014](#)). The reason for this is that enclosed systems flush the work chamber with
1844 water-free vapor (typically nitrogen gas) after the parts to be cleaned are added to the chamber and the
1845 chamber is sealed but before the solvent enters ([Durkee, 2014](#)). Multiple flushes can be performed to
1846 reduce the concentration of water to acceptable levels prior to solvent cleaning ([Durkee, 2014](#)).
1847 Therefore, the primary source of water in closed-loop systems is from steam used to regenerate carbon
1848 adsorbers ([Durkee, 2014](#); [Kanegsberg and Kanegsberg, 2011](#); [NIOSH, 2002a, b, c, d](#)). Similar to
1849 OTVDs, the water is removed in a gravity separator and sent for disposal ([NIOSH, 2002a, b, c, d](#)). As
1850 indicated in the OTVD assessment, current disposal practices of the wastewater are unknown with the
1851 latest available data from a 1982 EPA ([Gilbert et al., 1982](#)) report estimating 20% of water releases were
1852 direct discharges to surface water and 80% of water releases were discharged indirectly to a POTW.

1853

1854 EPA assumes the TRI and DMR data cover all water discharges of TCE from closed-loop vapor
1855 degreasing. However, EPA cannot distinguish between degreaser types in TRI and DMR data; therefore,
1856 a single set of water release for all degreasing operations is used for OTVDs.
1857

1858 **Q.7 ConveyORIZED Vapor Degreasing**

1859 **Q.7.1 Exposure Assessment**

1860 EPA identified inhalation exposure monitoring data from NIOSH investigations at two sites using TCE
1861 in conveyORIZED degreasing. Due to the large variety in shop types that may use TCE as a vapor
1862 degreasing solvent, it is unclear how representative these data are of a “typical” shop. Therefore, EPA
1863 supplemented the identified monitoring data using the ConveyORIZED Degreasing Near-Field/Far-Field
1864 Inhalation Exposure Model. The following subsections detail the results of EPA’s occupational
1865 exposure assessment for batch open-top vapor degreasing based on inhalation exposure monitoring data
1866 and modeling.
1867

1868 Table_Apx Q-14 summarizes the 8-hr TWA monitoring data for the use of TCE in conveyORIZED
1869 degreasing. The data were obtained from two NIOSH Health Hazard Evaluation reports (HHEs)
1870 ([Crandall and Albrecht, 1989](#)), ([Kinnes, 1998](#)).
1871

1872 **Table_Apx Q-14. Summary of Worker Inhalation Exposure Monitoring Data for ConveyORIZED**
1873 **Vapor Degreasing**


Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	48.3	16.1	11.0	5.6	18	Medium
Central Tendency	32.4	10.8	7.4	2.9		

1874 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.
1875

1876 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
1877 to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the
1878 primary strengths include the assessment approach, which is the use of monitoring data, the highest of
1879 the inhalation approach hierarchy. These monitoring data include 18 data points from 2 sources, and the
1880 data quality ratings from systematic review for these data were medium. The primary limitations of
1881 these data include the uncertainty of the representativeness of these data toward the true distribution of
1882 inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths
1883 and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data
1884 in this scenario is medium to low.
1885

1886 EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. A
1887 Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input
1888 parameters. Vapor generation rates were derived from TCE unit emissions and operating hours reported
1889 in the 2014 National Emissions Inventory. The primary limitations of the air concentration outputs from
1890 the model include the uncertainty of the representativeness of these data toward the true distribution of
1891 inhalation concentrations for the industries and sites covered by this scenario. Added uncertainties
1892 include that emissions data available in the 2014 NEI were only found for three total units, and the
1893 underlying methodologies used to estimate these emissions are unknown. Based on these strengths and
1894 limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is
1895 medium to low.
1896

1897 Figure_Apx Q-2 illustrates the near-field/far-field model that can be applied to conveyORIZED vapor
1898 degreasing. As the figure shows, TCE vapors evaporate into the near-field (at evaporation rate G),
1899 resulting in near-field exposures to workers at a concentration C_{NF} . The concentration is directly
1900 proportional to the evaporation rate of TCE, G , into the near-field, whose volume is denoted by V_{NF} .
1901 The ventilation rate for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-
1902 field (*i.e.*, the facility space surrounding the near-field), resulting in occupational non-user exposures to
1903 TCE at a concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the TCE dissipates
1904 out of the near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly
1905 TCE dissipates out of the surrounding space and into the outdoor air.
1906



1907
1908 **Figure_Apx Q-2. Belt/Strip ConveyORIZED Vapor Degreasing Schematic of the ConveyORIZED**
1909 **Degreasing Near-Field/Far-Field Inhalation Exposure Model**
1910

1911 To estimate the TCE vapor generation rate, the model uses the annual emission rate and annual
1912 operating time from the single conveyORIZED degreasing unit reported in the 2014 NEI. Because the
1913 vapor generation rate is based a limited data set, it is unknown how representative the model is of a
1914 “typical” conveyORIZED degreasing site.
1915

1916 EPA performed a Monte Carlo simulation with 100,000 iterations and the Latin Hypercube sampling
1917 method in @Risk to calculate 8-hour TWA near-field and far-field exposure concentrations. Near-field
1918 exposure represents exposure concentrations for workers who directly operate the vapor degreasing
1919 equipment, whereas far-field exposure represents exposure concentrations for occupational non-users
1920 (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment).
1921

1922 Table_Apx Q-15 presents a statistical summary of the exposure modeling results. These exposure
1923 estimates represent modeled exposures for the workers and occupational non-users. For workers, the
1924 50th percentile exposure is 40.8 ppm 8-hr TWA, with a 95th percentile of 3,043 ppm 8-hr TWA.
1925

1926 The high-end value is two orders of magnitude higher than identified in the monitoring data, but the
1927 central tendency is comparable to the monitoring data. This may be due to the limited number of sites

1928 from which the monitoring data were taken or that limited data for conveyORIZED degreaser were
 1929 reported to the 2014 NEI data (data were only found for three total units). It is also uncertain of the
 1930 underlying methodologies used to estimate emissions in the 2014 NEI data.
 1931

1932 **Table_Apx Q-15. Summary of Exposure Modeling Results for TCE Degreasing in ConveyORIZED**
 1933 **Degreasers**

Scenario	8-hr TWA (ppm)	AC ^a (ppm)	ADC (ppm)	LADC (ppm)	Data Quality Rating of Associated Air Concentration Data
<i>Workers (Near-field)</i>					
High-End	3,043	1,014.4	694.8	275.2	N/A – Modeled Data
Central Tendency	40.8	13.6	9.3	5.3	
<i>Occupational non-users (Far-Field)</i>					
High-End	1,878	626	428.8	168.3	N/A – Modeled Data
Central Tendency	23.3	7.8	5.3	3.6	

1934 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

1935 ^a Acute exposures calculated as a 24-hr TWA.

1936 **Q.7.2 Water Release Assessment**

1937 Similar to OTVDs, the primary source of water releases from conveyORIZED systems is expected to be
 1938 from wastewater from the water separator with the primary sources of water being: 1) Moisture in the
 1939 atmosphere that condenses into the solvent when exposed to the condensation coils on the system;
 1940 and/or 2) steam used to regenerate carbon adsorbers used to control solvent emissions ([Durkee, 2014](#);
 1941 [Kanegsberg and Kanegsberg, 2011](#); [NIOSH, 2002a, b, c, d](#)). The current disposal practices of the
 1942 wastewater are unknown; however, a 1982 EPA ([Gilbert et al., 1982](#)) report estimated 20% of water
 1943 releases from metal cleaning (including batch systems, conveyORIZED systems, and vapor and cold
 1944 systems) were direct discharges to surface water and 80% of water releases were discharged indirectly to
 1945 a POTW.

1946 EPA assumes the TRI and DMR data cover all water discharges of TCE from conveyORIZED degreasing.
 1947 However, EPA cannot distinguish between degreaser types in TRI and DMR data; therefore, a single set
 1948 of water release for all degreasing operations is presented in Section Q.5.2 for OTVDs.
 1949


1950 **Q.8 Web Vapor Degreasing**

1951 **Q.8.1 Exposure Assessment**

1952 EPA did not identify inhalation exposure monitoring data related to the use of TCE in web degreasing.
 1953 Therefore, EPA used the Near-Field/Far-Field Model to estimate exposures to workers and ONUs. The
 1954 following details the results of EPA’s occupational exposure assessment for use in web degreasers based
 1955 on inhalation exposure modeling.
 1956

1957 Figure_Apx Q-3 illustrates the near-field/far-field model that can be applied to web degreasing. As the
 1958 figure shows, TCE vapors evaporate into the near-field (at evaporation rate G), resulting in near-field
 1959 exposures to workers at a concentration C_{NF}. The concentration is directly proportional to the
 1960

1961 evaporation rate of TCE, G , into the near-field, whose volume is denoted by V_{NF} . The ventilation rate
1962 for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field (*i.e.*, the facility
1963 space surrounding the near-field), resulting in occupational non-user exposures to TCE at a
1964 concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the TCE dissipates out of the
1965 near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly TCE
1966 dissipates out of the surrounding space and into the outdoor air.
1967



1968
1969 **Figure_Apx Q-3. Schematic of the Web Degreasing Near-Field/Far-Field Inhalation Exposure**
1970 **Model**
1971

1972 To estimate the TCE vapor generation rate, the model uses the annual emission rate and annual
1973 operating time from the single web degreasing unit reported in the ([U.S. EPA, 2011](#)). Because the vapor
1974 generation rate is based a limited data set, it is unknown how representative the model is of a “typical”
1975 web degreasing site.
1976

1977 EPA performed a Monte Carlo simulation with 100,000 iterations and the Latin Hypercube sampling
1978 method in @Risk to calculate 8-hour TWA near-field and far-field exposure concentrations. Near-field
1979 exposure represents exposure concentrations for workers who directly operate the vapor degreasing
1980 equipment, whereas far-field exposure represents exposure concentrations for occupational non-users
1981 (*i.e.*, workers in the surrounding area who do not handle the degreasing equipment).
1982

1983 Table_Apx Q-16 presents a statistical summary of the exposure modeling results. These exposure
1984 estimates represent modeled exposures for the workers and occupational non-users. For workers, the
1985 50th percentile exposure is 5.9 ppm 8-hr TWA, with a 95th percentile of 14.1 ppm 8-hr TWA.
1986

1987 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
1988 to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths
1989 include the assessment approach, which is the use of modeling, in the middle of the inhalation approach
1990 hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential
1991 input parameters. Vapor generation rates were derived from TCE unit emissions and operating hours
1992 reported in the 2014 National Emissions Inventory. The primary limitations of the air concentration
1993 outputs from the model include the uncertainty of the representativeness of these data toward the true

1994 distribution of inhalation concentrations for the industries and sites covered by this scenario. Added
 1995 uncertainties include that emissions data available in the 2011 NEI were only found for one unit, and the
 1996 underlying methodologies used to estimate the emission is unknown. Based on these strengths and
 1997 limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is
 1998 medium to low.

1999
 2000
 2001

Table_Apx Q-16. Summary of Exposure Modeling Results for TCE Degreasing in Web Degreasers

Scenario	8-hr TWA (ppm)	AC ^a (ppm)	ADC (ppm)	LADC (ppm)	Confidence Rating of Air Concentration Data
<i>Workers (Near-field)</i>					
High-End	14.1	4.7	3.2	1.4	N/A – Modeled Data
Central Tendency	5.9	2.0	1.4	0.5	
<i>Occupational non-users (Far-Field)</i>					
High-End	9.6	3.2	2.2	0.9	N/A – Modeled Data
Central Tendency	3.1	1.0	0.7	0.3	

2002 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.
 2003 ^a Acute exposures calculated as a 24-hr TWA.

2004 **Q.8.2 Water Release Assessment**

2005 Similar to OTVDs, the primary source of water releases from web systems is expected to be from
 2006 wastewater from the water separator with the primary sources of water being: 1) Moisture in the
 2007 atmosphere that condenses into the solvent when exposed to the condensation coils on the system;
 2008 and/or 2) steam used to regenerate carbon adsorbers used to control solvent emissions ([Durkee, 2014](#);
 2009 [Kanegsberg and Kanegsberg, 2011](#); [NIOSH, 2002a, b, c, d](#)). The current disposal practices of the
 2010 wastewater are unknown; however, a 1982 EPA ([Gilbert et al., 1982](#)) report estimated 20% of water
 2011 releases from metal cleaning (including batch systems, conveyORIZED systems, and vapor and cold
 2012 systems) were direct discharges to surface water and 80% of water releases were discharged indirectly to
 2013 a POTW.

2014
 2015 EPA assumes the TRI and DMR data cover all water discharges of TCE from web vapor degreasing.
 2016 However, EPA cannot distinguish between degreaser types in TRI and DMR data; therefore, a single set
 2017 of water release for all degreasing operations is used for OTVDs.

2018
 2019


Q.9 Cold Cleaning

2020 **Q.9.1 Exposure Assessment**

2021 EPA did not identify inhalation exposure monitoring data for the Cold Cleaning condition of use.
 2022 Therefore, EPA used the Cold Cleaning Near-Field/Far-Field Inhalation Exposure Model to estimate
 2023 exposures to workers and ONUs. The following details the results of EPA’s occupational exposure
 2024 assessment for cold cleaning based on modeling.

2025

2026 Figure_Apx Q-4 illustrates the near-field/far-field model that can be applied to cold cleaning. As the
 2027 figure shows, TCE vapors evaporate into the near-field (at evaporation rate G), resulting in near-field
 2028 exposures to workers at a concentration C_{NF} . The concentration is directly proportional to the
 2029 evaporation rate of TCE, G , into the near-field, whose volume is denoted by V_{NF} . The ventilation rate
 2030 for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field (*i.e.*, the facility
 2031 space surrounding the near-field), resulting in occupational non-user exposures to TCE at a
 2032 concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the TCE dissipates out of the
 2033 near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly TCE
 2034 dissipates out of the surrounding space and into the outdoor air.
 2035



2036
 2037 **Figure_Apx Q-4. Schematic of the Cold Cleaning Near-Field/Far-Field Inhalation Exposure**
 2038 **Model**
 2039

2040 To estimate the TCE vapor generation rate, the model developed a distribution from the reported annual
 2041 emission rates and annual operating times reported in the 2014 NEI ([U.S. EPA, 2018a](#)). NEI records
 2042 where the annual operating time was not reported were excluded from the distribution. Because the
 2043 vapor generation rate is based a limited data set (ten total units), it is unknown how representative the
 2044 model is of a “typical” cold cleaning site.
 2045

2046 Cold cleaners are assumed to operate between 3 to 24 hours per day, based on NEI data on the reported
 2047 operating hours for cold cleaners using TCE. EPA performed a Monte Carlo simulation with 100,000
 2048 iterations and the Latin Hypercube sampling method in @Risk to calculate 8-hour TWA near-field and
 2049 far-field exposure concentrations. Near-field exposure represents exposure concentrations for workers
 2050 who directly operate the vapor degreasing equipment, whereas far-field exposure represents exposure
 2051 concentrations for occupational non-users (*i.e.*, workers in the surrounding area who do not handle the
 2052 cold cleaning equipment).
 2053

2054 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
 2055 to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths
 2056 include the assessment approach, which is the use of modeling, in the middle of the inhalation approach
 2057 hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential

2058 input parameters. Vapor generation rates were derived from TCE unit emissions and operating hours
 2059 reported in the 2014 National Emissions Inventory. The primary limitations of the air concentration
 2060 outputs from the model include the uncertainty of the representativeness of these data toward the true
 2061 distribution of inhalation concentrations for the industries and sites covered by this scenario. Added
 2062 uncertainties include that emissions data available in the 2014 NEI were only found for ten total units,
 2063 and the underlying methodologies used to estimate these emissions are unknown. Based on these
 2064 strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this
 2065 scenario is medium to low.

2066
 2067 Table_Apx Q-17 presents a statistical summary of the exposure modeling results. Estimates of AC,
 2068 ADC, and LADC for use in assessing risk were made using the approach and equations described in
 2069 Appendix B. These exposure estimates represent modeled exposures for the workers and occupational
 2070 non-users. For workers, the 50th percentile exposure is 3.33 ppm 8-hr TWA, with a 95th percentile of
 2071 57.2 ppm 8-hr TWA.

2072
 2073 **Table_Apx Q-17. Summary of Exposure Modeling Results for Use of Trichloroethylene in Cold**
 2074 **Cleaning**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Confidence Rating of Air Concentration Data
<i>Workers (Near-field)</i>					
High-End	57.2	19.1	13.1	5.2	N/A – Modeled Data
Central Tendency	3.33	1.11	0.8	0.3	
<i>Occupational non-users (Far-Field)</i>					
High-End	34.7	11.6	7.9	3.1	N/A – Modeled Data
Central Tendency	1.8	0.6	0.4	0.2	

2075 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

2076 **Q.9.2 Water Release Assessment**

2077 Similar to OTVDs, the primary source of water releases from cold cleaners is expected to be from
 2078 wastewater from the water separator with the primary source of water expected to be from moisture in
 2079 the atmosphere that condenses into the solvent. Water may also enter vapor degreasers via steam used to
 2080 regenerate carbon adsorbers; however, it is unclear if carbon adsorbers would be used in conjunction
 2081 with cold cleaning equipment. The current disposal practices of the wastewater are unknown; however, a
 2082 1982 EPA ([Gilbert et al., 1982](#)) report estimated 20% of water releases from metal cleaning (including
 2083 batch systems, conveyORIZED systems, and vapor and cold systems) were direct discharges to surface
 2084 water and 80% of water releases were discharged indirectly to a POTW.

2085
 2086 EPA assesses water release using TRI and DMR data. However, EPA cannot distinguish between
 2087 degreasers and cold cleaners in TRI and DMR data; therefore, a single set of water release for all
 2088 degreasing and cold cleaning operations is used for OTVDs.

2089

Q.10 Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners, Penetrating Lubricants, and Mold Releases

Q.10.1 Exposure Assessment

EPA did not identify inhalation exposure monitoring data related to the use of TCE in aerosol degreasers. Therefore, EPA estimated inhalation exposures using the Brake Servicing Near-field/Far-field Exposure Model. EPA used the brake servicing model as a representative scenario for this condition of use as there was ample data describing the brake servicing use and it is a significant use of TCE-based aerosol products. The following details the results of EPA's occupational exposure assessment for aerosol degreasing and aerosol lubricants based on modeling.


EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths include the assessment approach, which is the use of modeling, in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input parameters. Various model parameters were derived from a CARB brake service study and TCE concentration data for 16 products representative of the condition of use. The primary limitations of the air concentration outputs from the model include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is medium.

Figure_Apx Q-5 illustrates the near-field/far-field for the aerosol degreasing scenario. As the figure shows, TCE in aerosolized droplets immediately volatilizes into the near-field, resulting in worker exposures at a concentration C_{NF} . The concentration is directly proportional to the amount of aerosol degreaser applied by the worker, who is standing in the near-field-zone (*i.e.*, the working zone). The volume of this zone is denoted by V_{NF} . The ventilation rate for the near-field zone (Q_{NF}) determines how quickly TCE dissipates into the far-field (*i.e.*, the facility space surrounding the near-field), resulting in occupational non-user exposures to TCE at a concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the TCE dissipates out of the near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines how quickly TCE dissipates out of the surrounding space and into the outside air.

In this scenario, TCE mists enter the near-field in non-steady "bursts," where each burst results in a sudden rise in the near-field concentration, followed by a more gradual rise in the far-field concentration. The near-field and far-field concentrations then decay with time until the next burst causes a new rise in near-field concentration.

Based on site data from maintenance and auto repair shops obtained by CARB (CARB, 2000) for brake cleaning activities, the model assumes a worker will perform 11 applications of the degreaser product per brake job with five minutes between each application and that a worker may perform one to four brake jobs per day each taking one hour to complete. EPA modeled two scenarios, one where the brake cleaning jobs occurred back-to-back and one where braking cleaning jobs occurred one hour apart. Based on data from CARB (CARB, 2000), EPA assumes each brake job requires 14.4 oz of aerosol brake cleaner. The model determines the application rate of TCE using the weight fraction of TCE in the aerosol product. EPA uses uniform distribution of weight fractions for TCE based on facility data for the

2136 aerosol products in use (CARB, 2000). It is uncertain whether the use rate and weight fractions for brake
 2137 cleaning are representative of other aerosol degreasing and lubricant applications.



2138 **Figure_Apx Q-5. Schematic of the Near-Field/Far-Field Model for Aerosol Degreasing**

2139 EPA performed a Monte Carlo simulation with 1,000,000 iterations and the Latin hypercube sampling
 2140 method to model near-field and far-field exposure concentrations in the aerosol degreasing scenario. The
 2141 model calculates both 8-hr TWA exposure concentrations and acute 24-hr TWA exposure
 2142 concentrations. Table_Apx Q-18 presents a statistical summary of the exposure modeling results.
 2143
 2144

2145 For workers, the exposures are 7.63 ppm 8-hr TWA at the 50th percentile and 23.98 ppm 8-hr TWA at
 2146 the 95th percentile. For occupational non-users, the model exposures are 0.14 ppm 8-hr TWA at the 50th
 2147 percentile and 1.04 ppm 8-hr TWA at the 95th percentile.
 2148
 2149

2150 **Table_Apx Q-18. Summary of Worker and Occupational Non-User Inhalation Exposure**
 2151 **Modeling Results for Aerosol Degreasing**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Confidence Rating of Air Concentration Data
<i>Workers (Near-field)</i>					
High-End	24.0	8.0	5.5	2.2	N/A – Modeled Data
Central Tendency	7.6	2.5	1.7	0.6	
<i>Occupational non-users (Far-Field)</i>					
High-End	1.0	0.4	0.2	0.1	N/A – Modeled Data
Central Tendency	0.1	0.05	0.03	0.01	

2152 AC = Acute Concentration; ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

2153 **Q.10.2 Water Release Assessment**

2154 EPA does not expect releases of TCE to water from the use of aerosol products. Due to the volatility of
 2155 TCE the majority of releases from the use of aerosol products will likely be to air as TCE evaporates

2156 from the aerosolized mist and the substrate surface. There is a potential that TCE that deposits on shop
 2157 floors during the application process could possibly end up in a floor drain (if the shop has one) or could
 2158 runoff outdoors if garage doors are open. However, EPA expects the potential release to water from this
 2159 to be minimal as there would be time for TCE to evaporate before entering one of these pathways. This
 2160 is consistent with estimates from the International Association for Soaps, Detergents and Maintenance
 2161 Products (AISE) SpERC for Wide Dispersive Use of Cleaning and Maintenance Products, which
 2162 estimates 100% of volatiles are released to air ([Products, 2012](#)). EPA expects residuals in the aerosol
 2163 containers to be disposed of with shop trash that is either picked up by local waste management or by a
 2164 waste handler that disposes shop wastes as hazardous waste.
 2165

2166 **Q.11 Metalworking Fluids**

2167 **Q.11.1 Exposure Assessment**

2168 EPA identified inhalation exposure monitoring data from OSHA facility inspections ([OSHA, 2017](#)) at
 2169 two sites using TCE in metalworking fluids. Due to small sample sizes, it is unclear how representative
 2170 these data are of “typical” MWF use. Therefore, EPA supplemented the identified monitoring data with
 2171 an assessment of inhalation exposures using the ESD on the Use of Metalworking Fluids ([OECD,
 2172 2011b](#)). The following subsections detail the results of EPA’s occupational exposure assessment for
 2173 TCE use in MWFs based on inhalation exposure monitoring data and modeling.
 2174

2175 Table_Apx Q-19 summarizes the 8-hr TWA monitoring data for the use of TCE in MWFs. No data were
 2176 found to estimate ONU exposures from use in metalworking fluids. Data from this source covers
 2177 exposures at a facility that produces various electrical resistors ([Gilles and Philbin, 1976](#)). The data were
 2178 provided as full-shift TWAs.
 2179

2180 **Table_Apx Q-19. Summary of Worker Inhalation Exposure Monitoring Data for TCE Use in**
 2181 **Metalworking Fluids**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	75.4	25.1	17.2	8.8	3	High
Central Tendency	69.7	23.2	15.9	6.3		

2182 AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.
 2183

2184 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
 2185 to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths
 2186 include the assessment approach, which is the use of monitoring data, the highest of the inhalation
 2187 approach hierarchy. These monitoring data include 3 data points from 1 source, and the data quality
 2188 ratings from systematic review for these data were high. The primary limitations of these data include
 2189 limited dataset (3 data points from 1 site), and the uncertainty of the representativeness of these data
 2190 toward the true distribution of inhalation concentrations for the industries and sites covered by this
 2191 scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall
 2192 confidence for these 8-hr TWA data in this scenario is low.
 2193

2194 EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy.
 2195 Data from the 2011 Emission Scenario Document on the Use of Metalworking Fluids was used to

2196 estimate inhalation exposures. The primary limitations of the exposure outputs from this model include
 2197 the uncertainty of the representativeness of these data toward the true distribution of inhalation for all
 2198 TCE uses for the industries and sites covered by this scenario, and the difference between the modeling
 2199 data and monitoring data. Added uncertainties include that the underlying TCE concentration used in the
 2200 metalworking fluid was assumed from one metalworking fluid product. Based on these strengths and
 2201 limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this scenario is
 2202 medium.

2204 The ESD estimates typical and high-end exposures for different types of metalworking fluids. These
 2205 estimates are provided in Table_Apx Q-20 and are based on a NIOSH study of 79 small metalworking
 2206 facilities ([OECD, 2011b](#)). The concentrations for these estimates are for the solvent-extractable portion
 2207 and do not include water contributions ([OECD, 2011b](#)). The “typical” mist concentration is the
 2208 geometric mean of the data and the “high-end” is the 90th percentile of the data ([OECD, 2011b](#)).
 2209

2210 **Table_Apx Q-20. ESD Exposure Estimates for Metalworking Fluids Based on Monitoring Data**

Type of Metalworking Fluid	Typical Mist Concentration (mg/m ³) ^a	High-End Mist Concentration (mg/m ³) ^b
Conventional Soluble	0.19	0.87
Semi-Synthetic	0.20	0.88
Synthetic	0.24	1.10
Straight Oil	0.39	1.42

2211 ^a The typical mist concentration is the geometric mean of the data ([OECD, 2011b](#))

2212 ^b The high-end mist concentration is the 90th percentile of the data ([OECD, 2011b](#))

2213 Source: ([OECD, 2011b](#))

2214
 2215 The recommended use of the TCE-based metalworking fluid is an oil-based cutting and tapping fluid;
 2216 therefore, EPA assesses exposure to the TCE-based metalworking fluids using the straight oil mist
 2217 concentrations and the max concentration of TCE in the metalworking fluid. Straight oils are not diluted;
 2218 therefore, the concentration of TCE specified in the SDS (98%) ([U.S. EPA, 2017b](#)) is equal to the
 2219 concentration of TCE in the mist. Table_Apx Q-21 presents the exposure estimates for the use of TCE-
 2220 based metalworking fluids. The ESD estimates an exposure duration of eight hours per day; therefore,
 2221 results are presented as 8-hr TWA exposure values. It should be noted that these estimates may
 2222 underestimate exposures to TCE during use of metalworking fluids as they do not account for exposure
 2223 to TCE that evaporates from the mist droplets into the air. This exposure is difficult to estimate and is
 2224 not considered in this assessment.
 2225

2226 **Table_Apx Q-21. Summary of Exposure Results for Use of TCE in Metalworking Fluids Based on**
 2227 **ESD Estimates**

Scenario	8-hr TWA (ppm) ^a	ADC (ppm)	LADC (ppm)	Data Quality Rating of Associated Air Concentration Data
High-End	0.3	0.1	0.03	N/A – Modeled Data
Central Tendency	0.1	0.02	6.0E-3	

2228 ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

2229 ^a The TCE exposure concentrations are calculated by multiplying the straight oil mist concentrations in Table_Apx Q-20 by
 2230 98% (the concentration of TCE in the metalworking fluid) and converting to ppm.

2231
2232
2233
2234

The monitoring data obtained is two orders of magnitude higher than the modeling data. It is uncertain if the limited monitoring data set (three sample points), or the age of the monitoring data (1976) is representative of exposures to TCE for all sites covered by this condition of use.

2235 **Q.11.2 Water Release Assessment**

2236
2237
2238
2239
2240
2241

The ESD states that water releases from use of straight oil metalworking fluids may come from disposal of container residue and dragout losses from cleaning the part after shaping (OECD, 2011b). Facilities typically treat wastewater onsite due to stringent discharge limits to POTWs (OECD, 2011b). Control technologies used in onsite wastewater treatment in the MP&M industry include ultrafiltration, oil/water separation, and chemical precipitation (OECD, 2011b). Facilities that do not treat wastewater onsite contract waste haulers to collect wastewater for off-site treatment (OECD, 2011b).

2242
2243
2244
2245

EPA assesses water release using TRI and DMR data. However, EPA cannot distinguish between sites using metalworking fluids and sites using TCE in degreasers in TRI and DMR data; therefore, a single set of water release for degreasing and metalworking fluid operations is used for OTVDs.

2246 **Q.12 Adhesives, Sealants, Paints, and Coatings**

2247 **Q.12.1 Exposure Assessment**

2248
2249
2250
2251
2252
2253

EPA identified inhalation exposure monitoring data from a NIOSH a Health Hazard Evaluation report (HHE) (Chrostek, 1981) using TCE in coating applications and from OSHA facility inspections (OSHA, 2017) at three sites using TCE in adhesives and coatings. The following details the results of EPA’s occupational exposure assessment for coating applications based on inhalation exposure monitoring data.

2254
2255
2256
2257
2258
2259

Table_Apx Q-22 summarizes the 8-hr TWA monitoring data for the use of TCE in coatings. The data were obtained from a HHE (Chrostek, 1981) and from OSHA data (OSHA, 2017). EPA assumed this data is applicable to ONU exposure. However, due to the limited data set and the various types of application methods that may be employed, EPA is unsure of the representativeness of these data toward actual exposures to TCE for all sites covered by this condition of use.

2260
2261 **Table_Apx Q-22. Summary of Worker Inhalation Exposure Monitoring Data for**
2262 **Adhesives/Paints/Coatings**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
<i>Workers</i>						
High-End	39.5	13.2	9.0	4.6	22	Medium
Central Tendency	4.6	1.6	1.1	0.4		
<i>Occupational non-users</i>						
High-End	1.0	0.3	0.2	0.1	2	Medium
Central Tendency	0.9	0.3	0.2	0.1		

2263

AC = Acute Concentration, ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

2264 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
 2265 to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the
 2266 primary strengths include the assessment approach, which is the use of monitoring data, the highest of
 2267 the inhalation approach hierarchy. These monitoring data include 22 data points from 2 sources, and the
 2268 data quality ratings from systematic review for these data were medium to high. The primary limitations
 2269 of these data include the uncertainty of the representativeness of these data toward the true distribution
 2270 of inhalation concentrations for the industries and sites covered by this scenario. Based on these
 2271 strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr
 2272 TWA data in this scenario is medium to low.

2273
 2274 For the ONU inhalation air concentration data, the primary strengths include the assessment approach,
 2275 which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring
 2276 data include 2 data points from 1 source, and the data quality ratings from systematic review for the data
 2277 point was high. The primary limitations of this data is the limited dataset (two data points from 1 site),
 2278 and the uncertainty of the representativeness of this data toward the true distribution of inhalation
 2279 concentrations for the industries and sites covered by this scenario. Based on these strengths and
 2280 limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in
 2281 this scenario is medium to low.

2282
 2283 EPA did not find data to provide inhalation exposure estimates for commercial adhesive, sealant, paint
 2284 and coating applications. Therefore, EPA uses the industrial data discussed above as surrogate for
 2285 commercial coatings, as EPA believes the activities and exposures will be similar between industrial and
 2286 commercial sites covered by this condition of use.

2287 **Q.12.2 Water Release Assessment**

2288 In general, potential sources of water releases from adhesive, sealants, and paints/coatings use may
 2289 include the following: equipment cleaning operations, and container cleaning wastes ([OECD, 2011a](#)).
 2290

2291 Water releases for adhesives, sealants, paints and coating sites were assessed using data reported from
 2292 three sites in the 2016 TRI and 2016 DMR. For the sites in the 2014 NEI (where release information is
 2293 not provided), an average release per site was calculated from the total releases of the three
 2294 aforementioned sites reporting water releases to DMR and TRI, and dividing the total release by the
 2295 total number of sites in TRI and DMR (17 sites). This average release per site was used to estimate
 2296 releases from the sites provided in the 2014 NEI. EPA assessed daily releases by assuming 250 days of
 2297 operation per year, as recommended in the 2011 ESD on the Application of Radiation Curable Coatings,
 2298 Inks, and Adhesives via Spray, Vacuum, Roll and Curtain Coating, and averaging the annual releases
 2299 over the operating days ([OECD, 2011a](#)). A summary of the water releases can be found in Table_Apx
 2300 Q-23.
 2301

2302 **Table_Apx Q-23. Reported Water Releases of Trichloroethylene from Sites Using TCE in**
 2303 **Adhesives, Sealants, Paints and Coatings**

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Able Electropolishing Co Inc, Chicago, IL	74.4	250	0.30	Not available	POTW
Garlock Sealing Technologies, Palmyra, NY	0.08	250	3.3E-04	NY0000078	Surface Water
Ls Starrett Co, Athol, MA	9.1E-04	250	3.6E-06	MAR05B615	Surface Water

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Aerojet Rocketdyne, Inc., East Camden, AR	4.4	250	1.8E-02	Not available	Surface Water or POTW
Best One Tire & Service, Nashville, TN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Bridgestone Aircraft Tire (USA), Inc., Mayodan, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Clayton Homes Inc, Oxford, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Cmh Manufacturing, Inc. Dba Schult Homes - Plant 958, Richfield, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Delphi Thermal Systems, Lockport, NY	4.4	250	1.8E-02	Not available	Surface Water or POTW
Green Bay Packaging Inc - Coon Rapids, Coon Rapids, MN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Mastercraft Boat Company, Vonore, TN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Michelin Aircraft Tire Company, Norwood, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
M-Tek, Inc, Manchester, TN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Olin Corp, East Alton, IL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Parker Hannifin Corp - Paraflex Division, Manitowoc, WI	4.4	250	1.8E-02	Not available	Surface Water or POTW
Parrish Tire Company, Yadkinville, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Republic Doors And Frames, Mckenzie, TN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Ro-Lab Rubber Company Inc., Tracy, CA	4.4	250	1.8E-02	Not available	Surface Water or POTW
Royale Comfort Seating, Inc. - Plant No. 1, Taylorsville, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Snider Tire, Inc., Statesville, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Snyder Paper Corporation, Hickory, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Stellana Us, Lake Geneva, WI	4.4	250	1.8E-02	Not available	Surface Water or POTW
Thomas Built Buses - Courtesy Road, High Point, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Unicel Corp, Escondido, CA	4.4	250	1.8E-02	Not available	Surface Water or POTW
Acme Finishing Co Llc, Elk Grove Village, IL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Aerojet Rocketdyne, Inc., Rancho Cordova, CA	4.4	250	1.8E-02	Not available	Surface Water or POTW
Allegheny Cnty Airport Auth/Pgh Intl Airport, Pittsburgh, PA	4.4	250	1.8E-02	Not available	Surface Water or POTW
Amphenol Corp - Aerospace Operations, Sidney, NY	4.4	250	1.8E-02	Not available	Surface Water or POTW
Aprotech Powertrain, Asheville, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Clayton Homes Inc, Oxford, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Coating & Converting Tech Corp/Adhesive Coatings, Philadelphia, PA	4.4	250	1.8E-02	Not available	Surface Water or POTW
Corpus Christi Army Depot, Corpus Christi, TX	4.4	250	1.8E-02	Not available	Surface Water or POTW
Electronic Data Systems Camp Pendleton, Camp Pendleton, CA	4.4	250	1.8E-02	Not available	Surface Water or POTW
Florida Production Engineering, Inc., Ormond Beach, FL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Goodrich Corporation, Jacksonville, FL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Kasai North America Inc, Madison Plant, Madison, MS	4.4	250	1.8E-02	Not available	Surface Water or POTW
Kirtland Air Force Base, Albuquerque, NM	4.4	250	1.8E-02	Not available	Surface Water or POTW
Marvin Windows & Doors, Warroad, MN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Mcneilus Truck & Manufacturing Inc, Dodge Center, MN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Metal Finishing Co. - Wichita (S Mclean Blvd), Wichita, KS	4.4	250	1.8E-02	Not available	Surface Water or POTW

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Michelin Aircraft Tire Company, Norwood, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Murakami Manufacturing Usa Inc, Campbellsville, KY	4.4	250	1.8E-02	Not available	Surface Water or POTW
Peterbilt Motors Denton Facility, Denton, TX	4.4	250	1.8E-02	Not available	Surface Water or POTW
Portsmouth Naval Shipyard, Kittery, ME	4.4	250	1.8E-02	Not available	Surface Water or POTW
R.D. Henry & Co., Wichita, KS	4.4	250	1.8E-02	Not available	Surface Water or POTW
Raytheon Company, Portsmouth, RI	4.4	250	1.8E-02	Not available	Surface Water or POTW
Rehau Inc, Cullman, AL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Rotochopper Inc, Saint Martin, MN	4.4	250	1.8E-02	Not available	Surface Water or POTW
Rubber Applications, Mulberry, FL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Sapa Precision Tubing Rockledge, Llc, Rockledge, FL	4.4	250	1.8E-02	Not available	Surface Water or POTW
Thomas & Betts, Albuquerque, NM	4.4	250	1.8E-02	Not available	Surface Water or POTW
Thomas Built Buses - Fairfield Road, High Point, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Timco, Dba Haeco Americas Airframe Services, Greensboro, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
Trelleborg Coated Systems Us, Inc - Grace Advanced Materials, Rutherfordton, NC	4.4	250	1.8E-02	Not available	Surface Water or POTW
U.S. Coast Guard Yard - Curtis Bay, Curtis Bay, MD	4.4	250	1.8E-02	Not available	Surface Water or POTW
Viracon Inc, Owatonna, MN	4.4	250	1.8E-02	Not available	Surface Water or POTW

2304
2305
2306
2307
2308

POTW = Publicly Owned Treatment Works

Releases of 4.4 kg/site-yr for NEI sites estimated from total releases from TRI and DMR sites and divided by the 3 sites reporting water releases and the 14 sites reporting zero water releases in TRI).

^a Daily releases are back-calculated from the annual release rate and assuming 250 days of operation per year.

Sources: ([U.S. EPA, 2018a](#), [2017c](#), [2016a](#))

2309

Q.13 Other Industrial Uses

2310

Q.13.1 Exposure Assessment

2311 EPA did not identify inhalation exposure monitoring data related to using TCE for other industrial uses.
 2312 Therefore, EPA used monitoring data from loading/unloading TCE during manufacturing as a surrogate.
 2313 See section Q.1.1 for additional information on the data used. EPA assumes the exposure sources,
 2314 routes, and exposure levels are similar to those during loading at a TCE manufacturing facility.
 2315 However, EPA is unsure of the representativeness of these surrogate data toward actual exposures to
 2316 TCE at all sites covered by this condition of use.

2317

2318 EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results
 2319 to determine a level of confidence for the 8-hr TWA inhalation air concentrations. The primary strengths
 2320 include the assessment approach, which is the use of surrogate monitoring data, in the middle of the
 2321 inhalation approach hierarchy. These monitoring data include 50 data points from 2 sources, and the
 2322 data quality ratings from systematic review for these data were medium. The primary limitations of
 2323 these data include the uncertainty of the representativeness of these surrogate data toward the true
 2324 distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on
 2325 these strengths and limitations of the inhalation air concentration data, the overall confidence for these
 2326 8-hr TWA data in this scenario is medium to low.

2327

2328 Table_Apx Q-24 summarizes the 8-hr TWA from monitoring data from TCE manufacturing. The data
 2329 were obtained from obtained from data submitted by Arkema, Inc. ([Arkema, 2020](#)) and the Halogenated
 2330 Solvents Industry Alliance (HSIA) ([Halogenated Solvents Industry Alliance, 2018](#)) via public comment.
 2331 No data were found to estimate ONU exposures during other industrial uses of TCE. EPA estimates that
 2332 ONU exposures are lower than worker exposures, since ONUs do not typically directly handle the
 2333 chemical.

2334

2335 **Table_Apx Q-24. Summary of Occupational Exposure Surrogate Monitoring Data for Unloading**
 2336 **TCE During Other Industrial Uses**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	2.46	0.82	0.56	0.29	50	Medium
Central Tendency	0.12	3.8E ⁻²	2.6E ⁻²	1.0E ⁻²		

2337

AC = Acute Concentration; ADC = Average Daily Concentration; and LADC = Lifetime Average Daily Concentration.

2338

Q.13.2 Water Release Assessment

2339 Specifics of the processes and potential sources of release for other industrial uses are unknown.
 2340 However, general potential sources of water releases in the chemical industry may include the
 2341 following: equipment cleaning operations, aqueous wastes from scrubbers/decanter, reaction water,
 2342 process water from washing intermediate products, and trace water settled in storage tanks ([OECD, 2019](#)).

2343

2344
 2345 EPA assessed water releases using the annual discharge values reported to the 2016 TRI and the 2016
 2346 DMR by the 49 sites using TCE in other industrial uses. In the 2016 TRI, all 28 reported zero discharge
 2347 to water. In the 2016 DMR, twenty-one sites reported a direct discharge to surface water (indirect
 2348 discharges not reported in DMR data).

2349
 2350
 2351
 2352
 2353
 2354

To estimate the daily release, EPA assumed a default of 250 days/yr of operation and averaged the annual release over the operating days. Table_Apx Q-25 summarizes the water releases from the 2016 TRI and DMR for sites with non-zero discharges.

Table_Apx Q-25. Reported Water Releases of Trichloroethylene from Other Industrial Uses

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr) ^a	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Eli Lilly And Company-Lilly Tech Ctr, Indianapolis, IN	388	250	1.6	IN0003310	Surface Water
Oxy Vinyls LP - Deer Park Pvc, Deer Park, TX	37	250	0.15	TX0007412	Surface Water
Solvay - Houston Plant, Houston, TX	8.3	250	0.03	TX0007072	Surface Water
Washington Penn Plastics, Frankfort, KY	8.0	250	0.03	KY0097497	Surface Water
Natrium Plant, New Martinsville, WV	5.5	250	2.2E-02	WV0004359	Surface Water
Leroy Quarry, Leroy, NY	4.8	250	1.9E-02	NY0247189	Surface Water
George C Marshall Space Flight Center, Huntsville, AL	2.6	250	1.0E-02	AL0000221	Surface Water
Whelan Energy Center Power Plant, Hastings, NE	2.4	250	9.4E-03	NE0113506	Surface Water
Akzo Nobel Surface Chemistry LLC, Morris, IL	0.1	250	4.6E-04	IL0026069	Surface Water
Solutia Nitro Site, Nitro, WV	0.1	250	4.4E-04	WV0116181	Surface Water
Amphenol Corporation - Columbia, Columbia, SC	0.1	250	2.8E-04	SC0046264	Surface Water
Army Cold Regions Research & Engineering Lab, Hanover, NH	0.1	250	2.3E-04	NH0001619	Surface Water
Corning - Canton Plant, Canton, NY	0.1	250	2.2E-04	NY0085006	Surface Water
Keeshan And Bost Chemical Co., Inc., Manvel, TX	0.03	250	1.3E-04	TX0072168	Surface Water
Ames Rubber Corp Plant #1, Hamburg Boro, NJ	0.03	250	1. 1E-04	NJG000141	Surface Water
Gorham, Providence, RI	0.02	250	9.2E-05	RIG85E004	Surface Water
Emerson Power Transmission, Ithaca, NY	0.02	250	6.9E-05	NY0002933	Surface Water
Chemtura North and South Plants, Morgantown, WV	8.3E-03	250	3.3E-05	WV0004740	Surface Water
Indorama Ventures Olefins, LLC, Sulphur, LA	5.1E-03	250	2.0E-05	LA0069850	Surface Water
William E. Warne Power Plant, Los Angeles County, CA	3.1E-03	250	1.2E-05	CA0059188	Surface Water
Raytheon Aircraft Co (Was Beech Aircraft), Boulder, CO	2.3E-03	250	9.2E-06	COG315176	Surface Water

^a Annual release amounts are based on the site reported values. Therefore, daily releases are calculated from the annual release rate and assuming 250 days of operation per year.

Sources: ([U.S. EPA, 2017c](#), [2016a](#))

2355
 2356
 2357
 2358

Q.14 Spot Cleaning, Wipe Cleaning and Carpet Cleaning

Q.14.1 Exposure Assessment

EPA identified minimal inhalation exposure monitoring data related to the spot cleaning using TCE. Therefore, EPA supplemented the identified monitoring data using the Near-field/Far-field Exposure Model. The following subsections detail the results of EPA's occupational exposure assessment for spot cleaning based on inhalation exposure monitoring data and modeling.

Table_Apx Q-26 summarizes the 8-hr TWA monitoring data and acute TWAs from the monitoring data for the use of TCE in spot cleaning. No data were found to estimate ONU exposures during spot cleaning. The data were obtained from NIOSH a Health Hazard Evaluation report (HHE) ([Burton and Monesterskey, 1996](#)), as well as a NIOSH Report on Control of Health and Safety Hazards on Commercial Drycleaners document ([NIOSH, 1997](#)). NIOSH HHEs are conducted at the request of employees, employers, or union officials, and provide information on existing and potential hazards present in the workplaces evaluated. NIOSH Health and Safety documents represents NIOSH research in collaboration with industry, labor and other government organizations to protect the health of workers in industry.

For full shift values, sample times ranged from approximately seven to nine hours ([Burton and Monesterskey, 1996](#)). Where sample times were less than eight hours, EPA converted to an 8-hr TWA assuming exposure outside the sample time was zero. For sample times greater than eight hours, EPA left the measured concentration as is. Because of the limited data set, EPA is unsure of the representativeness of these data toward actual exposures to TCE for all sites covered by this condition of use.

Table_Apx Q-26. Summary of Worker Inhalation Exposure Monitoring Data for Spot Cleaning Using TCE

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of 8-hr TWA Data Points	Confidence Rating of Air Concentration Data
High-End	2.8	1.0	0.7	0.3	8	Medium
Central Tendency	0.4	0.1	0.1	0.04		

AC = Acute Concentration; ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 8 data points from 2 sources, and the data quality ratings from systematic review for these data were medium. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 8-hr TWA data in this scenario is medium to low.


EPA also considered the use of modeling, which is in the middle of the inhalation approach hierarchy. A Monte Carlo simulation with 100,000 iterations was used to capture the range of potential input

2399 parameters. Various model parameters were derived from a CARB study. The primary limitations of the
2400 air concentration outputs from the model include the uncertainty of the representativeness of these data
2401 toward the true distribution of inhalation concentrations for the industries and sites covered by this
2402 scenario. Added uncertainties include that the underlying methodologies used to obtain the values in the
2403 CARB study, as well as the assumed TCE concentration in the spot cleaning product. Based on these
2404 strengths and limitations of the air concentrations, the overall confidence for these 8-hr TWA data in this
2405 scenario is medium to low.

2406
2407 Despite these limitation, the modeling and monitoring results match each other very closely. Therefore,
2408 the overall confidence is medium.

2409
2410 Wolf and Morris (IRTA, 2007) estimated 42,000 gal of TCE-based spotting agents are sold in California
2411 annually. Review of SDS's identified TCE-based spotting agents contain 10% to 100% TCE. The study
2412 also estimated approximately 5,000 textile cleaning facilities in California. Results in average of 8.4
2413 gal/site-yr of TCE-based spotting agents used.

2414
2415 Figure_Apx Q-6 illustrates the near-field/far-field modeling approach that EPA applied to spot cleaning
2416 facilities. As the figure shows, chemical vapors evaporate into the near-field (at evaporation rate G),
2417 resulting in near-field exposures to workers at a concentration C_{NF} . The concentration is directly
2418 proportional to the amount of spot cleaner applied by the worker, who is standing in the near-field-zone
2419 (*i.e.*, the working zone). The volume of this zone is denoted by V_{NF} . The ventilation rate for the near-
2420 field zone (Q_{NF}) determines how quickly the chemical of interest dissipates into the far-field (*i.e.*, the
2421 facility space surrounding the near-field), resulting in occupational non-user exposures at a
2422 concentration C_{FF} . V_{FF} denotes the volume of the far-field space into which the chemical of interest
2423 dissipates out of the near-field. The ventilation rate for the surroundings, denoted by Q_{FF} , determines
2424 how quickly the chemical dissipates out of the surrounding space and into the outdoor air.
2425



2426
2427 **Figure_Apx Q-6. Schematic of the Near-Field/Far-Field Model for Spot Cleaning**

2428
2429 EPA performed Monte Carlo simulations, applying one hundred thousand iterations and the Latin
2430 hypercube sampling method. Table_Apx Q-27 presents a statistical summary of the exposure modeling
2431 results. The 50th and 95th percentile near-field exposures are 0.96 ppm and 2.77 ppm 8-hr TWA,

2432 respectively. These results are comparable to the monitoring data. For occupational non-users (far-field),
 2433 model 50th and 95th percentile exposure levels are 0.48 ppm and 1.75 ppm 8-hr TWA, respectively. EPA
 2434 assumes no engineering controls are used at dry cleaning shops, which are typically small, family owned
 2435 businesses.

2436
 2437 The modeling results are comparable to the monitoring data. However, EPA is unsure of the
 2438 representativeness of these data toward actual exposures to TCE for all sites covered by this condition of
 2439 use.

2440
 2441 **Table_Apx Q-27. Summary of Exposure Modeling Results for Spot Cleaning Using TCE**

Scenario	8-hr TWA (ppm)	AC (24-hr) (ppm)	ADC (ppm)	LADC (ppm)	Data Quality Rating of Associated Air Concentration Data
<i>Workers (Near-field)</i>					
High-End	2.8	0.9	0.6	0.3	N/A – Modeled Data
Central Tendency	1.0	0.3	0.2	0.1	
<i>Occupational non-users (Far-Field)</i>					
High-End	1.8	0.6	0.4	0.2	N/A – Modeled Data
Central Tendency	0.5	0.2	0.1	0.04	

2442 AC = Acute Concentration; ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

2443 **Q.14.2 Water Release Assessment**

2444 TCE releases to water from spot cleaning will depend upon whether the stained surface is washed with
 2445 water after spotting. For example, TCE-based cleaners used to pre-spot garments prior to cleaning in
 2446 water or hydrocarbon-based machines would be a source of TCE in wastewater.

2447
 2448 Water releases for spot cleaning were assessed using data reported in the 2016 DMR. No sites
 2449 discharging TCE from spot cleaning activities were found in the 2016 TRI. EPA assessed annual
 2450 releases as reported in the 2016 DMR and assessed daily releases by assuming 300 days of operation per
 2451 year. A summary of the water releases reported to the 2016 DMR can be found in Table_Apx Q-28. The
 2452 annual release for each of the unknown sites is calculated by taking the average annual release of the
 2453 two sites reporting to DMR.

2454
 2455 **Table_Apx Q-28. Reported Water Releases of Trichloroethylene from Sites Using TCE Spot**
 2456 **Cleaning**

Site	Annual Release ^a (kg/site-year)	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	Media of Release
Boise State University, Boise, ID	0.02	300	8.0E-05	Surface Water
Venetian Hotel And Casino, Las Vegas, NV	8.8E-3	300	2.9E-05	Surface Water
63,746 Unknown Sites	0.02	300	5.4E-05	Surface Water or POTW

2457 POTW = Publicly Owned Treatment Works

2458 ^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual
 2459 release rate and assuming 300 days of operation per year.

2460 Sources: 2016 DMR ([U.S. EPA, 2016a](#))

2461

Q.15 Industrial Processing Aid

2462

Q.15.1 Exposure Assessment

2463

EPA did identify inhalation exposure monitoring data related using TCE when used as an industrial processing aid from one site. The following details the results of EPA's occupational exposure assessment for use of TCE as an industrial processing aid based on inhalation exposure monitoring data.

2466

2467

Table_Apx Q-29 summarizes the 12-hr TWA monitoring data and acute TWAs from the monitoring data for the use of TCE as a processing aid for both workers and for ONUs. The data were obtained from a European Commission (EC) Technical Report ([EC, 2014](#)). The data were supplied to the EC as supporting documentation in an application for continued use of TCE under the REACH Regulation. The data indicate a full shift is 12 hours. Therefore, all exposures were calculated using a 12-hr shift. Because of the limited data set, EPA is unsure of the representativeness of these data toward actual exposures to TCE for all sites covered by this condition of use.

2468

2469

2470

2471

2472

2473

2474

2475

Table_Apx Q-29. Summary of Exposure Monitoring Data for Use as a Processing Aid

Scenario	12-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of 12-hr Data Points	Confidence Rating of Air Concentration Data
<i>Workers</i>						
High-End	12.8	6.4	4.4	2.2	30	Medium to High
Central Tendency	4.2	2.1	1.5	0.6		
<i>Occupational non-users</i>						
High-End	2.9	1.4	1.0	0.5	4	Medium
Central Tendency	1.3	0.7	0.4	0.2		

2476

AC = Acute Concentration; ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

2477

2478

EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 12-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 30 data points from 1 source, and the data quality ratings from systematic review for these data were high. The primary limitations of these data include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 12-hr TWA data in this scenario is medium to high.

2487

2488

For the ONU inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 4 data points from 1 source, and the data quality ratings from systematic review for the data point was high. The primary limitations of this single data point include the uncertainty of the representativeness of these data toward the true distribution of inhalation concentrations for the industries and sites covered by this scenario. Based on these strengths and limitations of the inhalation air concentration data, the overall confidence for these 12-hr TWA data in this scenario is medium to low.

2489

2490

2491

2492

2493

2494

2495

Q.15.2 Water Release Assessment

In general, potential sources of water releases in the chemical industry may include the following: equipment cleaning operations, aqueous wastes from scrubbers/decanter, reaction water, process water from washing intermediate products, and trace water settled in storage tanks (OECD, 2019). Based on the use as a processing aid and the amount of TCE used for this condition of use, EPA expects minimal sources of TCE release to water.

Water releases during use as a processing aid were assessed using data reported in the 2016 TRI as well as 2016 DMR. Four of the 16 sites reporting to TRI provided water releases. The remaining 12 sites reported all releases were to off-site land, incineration or recycling. EPA assessed annual releases as reported in the 2016 TRI and assessed daily releases by assuming 300 days of operation per year. A summary of the water releases reported to the 2016 DMR and 2016 TRI can be found in Table_Apx Q-30.

Table_Apx Q-30. Reported Water Releases of Trichloroethylene from Industrial Processing Aid Sites Using TCE

Site Identity	Annual Release (kg/site-yr) ^a	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Entek International LLC, Lebanon, OR	113	300	0.4	Not available	POTW
Occidental Chemical Corp Niagara Plant, Niagara Falls, NY	5.8	300	0.02	NY0003336	Surface Water
National Electrical Carbon Products Db a Morgan Adv Materials, Fostoria, OH	2.3	300	7.6E-03	Not available	POTW
Daramic LLC, Corydon, IN	2.3	300	0.01	Not available	Surface Water
PPG Industries Inc Barberton, Barberton, OH	1.4	300	4.5E-3	OH0123897	POTW
Stepan Co Millsdale Road, Elwood, IL	0.2	300	5.5E-04	IL0002453	Surface Water

^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual release rate and assuming 300 days of operation per year.

POTW = Publicly Owned Treatment Works

Sources: (U.S. EPA, 2017c, 2016a)

Q.16 Commercial Printing and Copying

Q.16.1 Exposure Assessment

EPA identified inhalation exposure monitoring data from a NIOSH a Health Hazard Evaluation report (HHE) (Finely and Page, 2005) using TCE in high speed printing presses. The following details the results of EPA's occupational exposure assessment for printing applications based on inhalation exposure monitoring data. Table_Apx Q-31 summarizes the 8-hr TWA monitoring data for the use of TCE in printing. The data were obtained from a HHE (Finely and Page, 2005).

EPA considered the assessment approach, the quality of the data, and uncertainties in assessment results to determine a level of confidence for the 8-hr TWA data. For the inhalation air concentration data, the primary strengths include the assessment approach, which is the use of monitoring data, the highest of the inhalation approach hierarchy. These monitoring data include 20 data points from 1 source, and the data quality ratings from systematic review for these data were medium. The primary limitations of

2530 these data include a limited dataset, and the uncertainty of the representativeness of these data toward
 2531 the true distribution of inhalation concentrations for the industries and sites covered by this scenario.
 2532 Based on these strengths and limitations of the inhalation air concentration data, the overall confidence
 2533 for these 8-hr TWA data in this scenario is medium to low.

2534
 2535 **Table_Apx Q-31. Summary of Worker Inhalation Exposure Monitoring Data for High Speed**
 2536 **Printing Presses**

Scenario	8-hr TWA (ppm)	AC (ppm)	ADC (ppm)	LADC (ppm)	Number of Data Points	Confidence Rating of Air Concentration Data
High-End	2.1	0.7	0.5	0.2	20	Medium
Central Tendency	0.1	0.03	0.02	8.0E-3		

2537 AC = Acute Concentration, ADC = Average Daily Concentration and LADC = Lifetime Average Daily Concentration.

2538
 2539 No monitoring data were available to estimate ONU exposures. EPA estimates that ONU exposures are
 2540 lower than worker exposures, since ONUs do not typically directly handle the chemical.

2541 **Q.16.2 Water Release Assessment**

2542 A potential source of water releases from Printing/copying use would come from clean-out of printing
 2543 equipment if the ink is water-based ([OECD, 2010](#)). Based on the use in printing/copying and the amount
 2544 of TCE used for this condition of use, EPA expects minimal sources of TCE release to water.

2545
 2546 Water releases during use in printing and copying were assessed using data reported in the 2016 DMR.
 2547 One site provided water releases. EPA assessed annual releases as reported in the 2016 DMR and
 2548 assessed daily releases by assuming 250 days of operation per year. A summary of the water releases
 2549 reported to the 2016 DMR can be found in Table_Apx Q-32.

2550
 2551 **Table_Apx Q-32. Reported Water Releases of Trichloroethylene from Commercial Printing and**
 2552 **Copying**

Site Identity	Annual Release (kg/site-yr) ^a	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Printing and Pub Sys Div, Weatherford, OK	0.05	250	2.0E-4	OK0041785	Surface Water

2553 ^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual
 2554 release rate and assuming 250 days of operation per year.

2555
 2556 As only one site was identified with water releases for this condition of use, EPA acknowledges this site
 2557 does not represent the entirety of commercial printing and copying sites using TCE. However, data is
 2558 not reasonably available to estimate water releases from additional sites. Based on reasonably available
 2559 EPA models releases from containers may be up to: 1) 0.3% to 0.6% for small containers (<20 gal) or
 2560 drums that are emptied via pouring; or 2) 2.5% to 3% for drums emptied via pumping; however, not all
 2561 sites are expected to dispose of container residues to water. Additional water release sources of TCE at
 2562 these sites may exist and will vary depending on the use rate of the TCE-based products.

2564

Q.17 Other Commercial Uses

2565

Q.17.1 Exposure Assessment

2566 EPA did not identify any inhalation exposure monitoring data related to TCE use in other commercial
 2567 uses, including use as a laboratory chemical for research, development, and testing services. See Section
 2568 Q.14.1 for the assessment of worker exposure during spot cleaning activities. EPA assumes that some of
 2569 the other commercial uses may have analogous exposure sources, routes, and exposure levels similar to
 2570 those for spot cleaners.

2571

Q.17.2 Water Release Assessment

2572 Specifics of the processes and potential sources of release for these uses are unknown. Based on the
 2573 volatility of TCE, EPA expects the majority of TCE used for these applications to evaporate and be
 2574 released to air. EPA expects residuals in containers to be disposed of with general site trash that is either
 2575 picked up by local waste management or by a waste handler that disposes wastes as hazardous waste.
 2576

2577 Table_Apx Q-33 summarizes non-zero water releases from sites using TCE in other commercial uses
 2578 reported in the 2016 DMR. To estimate the daily release for the sites in Table_Apx Q-33, EPA assumed
 2579 a default of 250 days/yr of operation and averaged the annual release over the operating days. These data
 2580 are not expected to capture the entirety of water releases from these uses; however, EPA does not have
 2581 information to estimate water releases from sites not reporting to DMR.
 2582

2583 **Table_Apx Q-33. Reported Water Releases of Trichloroethylene from Other Commercial Uses in**
 2584 **the 2016 DMR**

Site Identity	Annual Release (kg/site-yr)	Annual Release Days (days/yr)	Daily Release (kg/site-day)	NPDES Code	Release Media
Corning Hospital, Corning, NY	3.2	250	0.013	NY0246701	Surface Water
Water Street Commercial Bldg, Dayton, OH	0.7	250	2.8E-03	OH0141496	Surface Water
Union Station North Wing Office Building, Denver, CO	1.0E-01	250	4.0E-04	COG315293	Surface Water
Confluence Park Apartments, Denver, CO	7.1E-02	250	2.8E-04	COG315339	Surface Water
Park Place Mixed Use Development, Annapolis, MD	6.7E-02	250	2.7E-04	MD0068861	Surface Water
Tree Top Inc Wenatchee Plant, Wenatchee, WA	9.0E-03	250	3.6E-05	WA0051527	Surface Water
Wynkoop Denver LLC St, Denver, CO	7.8E-03	250	3.1E-05	COG603115	Surface Water
Greer Family LLC, South Burlington, VT	1.3E-03	250	5.0E-06	VT0001376	Surface Water
John Marshall III Site, Mclean, VA	4.7E-04	250	1.9E-06	VA0090093	Surface Water

2585 ^a Annual release amounts are based on the site reported values. Therefore, daily releases are calculated from the annual
 2586 release rate and assuming 250 days of operation per year.

2587 Sources: ([U.S. EPA, 2016a](#))

2588

Q.18 Process Solvent Recycling and Worker Handling of Wastes

Q.18.1 Exposure Assessment

EPA did not identify any inhalation exposure monitoring data related to waste handling/recycling. See Section Q.4.1 for the assessment of worker exposure from chemical unloading activities. EPA assumes the exposure sources, routes, and exposure levels are similar to those at a repackaging facility.

Q.18.2 Water Release Assessment

Potential sources of water releases at disposal/recycling sites may include the following: aqueous wastes from scrubbers/decanter, trace water settled in storage tanks, and process water generated during the disposal/recycling process.

EPA assessed water releases using the values reported to the 2016 TRI and DMR by the 30 disposal/recycling sites. In the 2016 TRI, three of sites reported non-zero indirect discharges to off-site wastewater treatment; one site reported discharges to both off-site wastewater treatment as well as discharge to a POTW. All sites in TRI for this condition of use reported zero direct discharges to surface water.

To estimate the daily release, EPA used a default assumption of 250 days/yr of operation as and averaged the annual release over the operating days. Table_Apx Q-34 summarizes the water releases from the 2016 DMR and 2016 TRI for sites with non-zero discharges.

Table_Apx Q-34. Estimated Water Releases of Trichloroethylene from Disposal/Recycling of TCE

Site Identity	Annual Release (kg/site-yr) ^a	Annual Release Days (days/yr)	Daily Release (kg/site-day) ^a	NPDES Code	Release Media
Veolia Es Technical Solutions LLC, Middlesex, NJ	6035	250	24.1	Not available	POTW WWT (0.02%) and Non-POTW WWT (99.98%)
Clean Harbors Deer Park LLC, La Porte, TX	87.1	250	0.3	TX0005941	Non-POTW WWT
Clean Harbors El Dorado LLC, El Dorado, AR	9.1	250	0.04	AR0037800	Non-POTW WWT
Clean Water Of New York Inc, Staten Island, NY	0.9	250	3.8E-03	NY0200484	Surface Water
Reserve Environmental Services, Ashtabula, OH	3.9E-04	250	1.6E-06	OH0098540	Surface Water

POTW = Publicly-Owned Treatment Works; WWT = Wastewater Treatment

^a Annual release amounts are based on the site reported values. Therefore, daily releases are back-calculated from the annual release rate and assuming 250 days of operation per year.

Sources: ([U.S. EPA, 2017c](#)) and ([U.S. EPA, 2016a](#))

Q.19 Appendix Q References

[AIHA](#) (American Industrial Hygiene Association). (2009). Mathematical models for estimating occupational exposure to chemicals. In CB Keil; CE Simmons; TR Anthony (Eds.), (2nd ed.). Fairfax, VA: AIHA Press.

[Arkema Inc.](#) (2018). Arkema Inc. comments to inform EPAs rulemaking on Problem Formulations for the Risk Evaluations to be conducted under the Toxic Substances Control Act, and general guiding principles to apply systematic review in TSCA Risk Evaluations. (EPA-HQ-OPPT-

2016-0737-0109). Washington, D.C. <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0737-0109>

ATSDR (Agency for Toxic Substances and Disease Registry). (2014). Toxicological profile for tetrachloroethylene (Draft for public comment). Atlanta, GA: US Department of Health and Human Services, Public Health Service.
<http://www.atsdr.cdc.gov/ToxProfiles/tp.asp?id=265&tid=48>

Bakke, B; Stewart, P; Waters, M. (2007). Uses of and exposure to trichloroethylene in U.S. industry: A systematic literature review [Review]. *J Occup Environ Hyg* 4: 375-390.
<http://dx.doi.org/10.1080/15459620701301763>

Baldwin, PE; Maynard, AD. (1998). A survey of wind speed in indoor workplaces. *Ann Occup Hyg* 42: 303-313. [http://dx.doi.org/10.1016/S0003-4878\(98\)00031-3](http://dx.doi.org/10.1016/S0003-4878(98)00031-3)

Barsan, ME. (1991). Health hazard evaluation report no. HETA 90-344-2159, A.W. Cash Valve Manufacturing Corporation, Decatur, Illinois. (HETA 90-344-2159). Cincinnati, OH: National Institute for Occupational Safety and Health.

Burton, NC; Monesterskey, J. (1996). Health hazard evaluation report no. HETA 96-0135-2612, Eagle Knitting Mills, Inc., Shawano, Wisconsin. (HETA 96-0135-2612). Cincinnati, OH: National Institute for Occupational Safety and Health.

CARB (California Air Resources Board). (2000). Initial statement of reasons for the proposed airborne toxic control measure for emissions of chlorinated toxic air contaminants from automotive maintenance and repair activities.

CARB. (2006). California Dry Cleaning Industry Technical Assessment Report. Stationary Source Division, Emissions Assessment Branch.
<https://www.arb.ca.gov/toxics/dryclean/finaldrycleantechreport.pdf>

Cherrie, JW; Semple, S; Brouwer, D. (2004). Gloves and Dermal Exposure to Chemicals: Proposals for Evaluating Workplace Effectiveness. *Ann Occup Hyg* 48: 607-615.
<http://dx.doi.org/10.1093/annhyg/meh060>

Chrostek, WJ, ; Levine, M. S. (1981). Health hazard evaluation report no. HHE 30-153-881, Palmer Industrial Coatings Incorp., Williamsport, Pennsylvania. (HHE 30-153-881). Cincinnati, OH: National Institute for Occupational Safety and Health.

Crandall, MS; Albrecht, WN. (1989). Health Hazard Evaluation Report No. HETA-86-380-1957, York International Corporation, Madisonville, Kentucky (pp. 86-380). (NIOSH/00189611). Crandall, MS; Albrecht, WN.

Dancik, Y; Bigliardi, PL; Bigliardi-Qi, M, ei. (2015). What happens in the skin? Integrating skin permeation kinetics into studies of developmental and reproductive toxicity following topical exposure. *Reprod Toxicol* 58: 252-281. <http://dx.doi.org/10.1016/j.reprotox.2015.10.001>

Daniels, WJ; Orris, P; Kramkowski, R; Almaguer, D. (1988). Health Hazard Evaluation Report No. HETA-86-121-1923, Modern Plating Corporation, Freeport, Illinois (pp. 86-121). (NIOSH/00184446). Daniels, WJ; Orris, P; Kramkowski, R; Almaguer, D.

Demou, E; Hellweg, S; Wilson, MP; Hammond, SK; Mckone, TE. (2009). Evaluating indoor exposure modeling alternatives for LCA: A case study in the vehicle repair industry. *Environ Sci Technol* 43: 5804-5810. <http://dx.doi.org/10.1021/es803551y>

Dow Chemical (Dow Chemical Company). (2014). Product safety assessment: Trichloroethylene.

DOW Deutschland. (2014a). Chemical safety report: Use of trichloroethylene in industrial parts cleaning by vapour degreasing in closed systems where specific requirements (system of use-parameters) exist. Ispra, Italy: European Commission Joint Research Centre, Institute for Health and Consumer Protection, European Chemicals Bureau.
<http://ec.europa.eu/DocsRoom/documents/14369/attachments/1/translations/en/renditions/native>

DOW Deutschland. (2014b). Chemical safety report: Use of trichloroethylene in packaging. Ispra, Italy: European Commission Joint Research Centre, Institute for Health and Consumer Protection,

2671 European Chemicals Bureau.
2672 <http://ec.europa.eu/DocsRoom/documents/14371/attachments/1/translations/en/renditions/native>
2673 Durkee, J. (2014). Cleaning with solvents: Methods and machinery. In Cleaning with solvents: Methods
2674 and machinery. Oxford, UK: Elsevier Inc.
2675 [https://www.sciencedirect.com/book/9780323225205/cleaning-with-solvents-methods-and-](https://www.sciencedirect.com/book/9780323225205/cleaning-with-solvents-methods-and-machinery)
2676 [machinery](https://www.sciencedirect.com/book/9780323225205/cleaning-with-solvents-methods-and-machinery)
2677 EC (European Commission). (2014). Exposure scenario: Use: Trichloroethylene as an extraction solvent
2678 for removal of process oil and formation of the porous structure in polyethylene based separators
2679 used in lead-acid batteries. Ispra, Italy: European Commission Joint Research Centre, Institute
2680 for Health and Consumer Protection, European Chemicals Bureau.
2681 <http://ec.europa.eu/DocsRoom/documents/12344/attachments/1/translations/en/renditions/native>
2682 ECB (European Chemicals Bureau). (2004). European Union risk assessment report: Trichloroethylene
2683 (pp. 1-348). (EUR 21057 EN). European Commission.
2684 <https://echa.europa.eu/documents/10162/83f0c99f-f687-4cdf-a64b-514f1e26fdc0>
2685 Elkin, LM. (1969). Process Economics Program, Chlorinated Solvents, Report No. 48. In Kirk-Othmer
2686 Encyclopedia of Chemical Technology. Menlo Park, CA: Stanford Research Institute.
2687 ENTEK International Limited. (2014). Analysis of alternatives: Use of trichloroethylene as an extraction
2688 solvent for removal of process oil and formation of the porous structure in polyethylene based
2689 separators used in lead-acid batteries. Helsinki, Finland: European Chemicals Agency.
2690 <https://echa.europa.eu/documents/10162/9a728963-e57f-48de-b977-7d05462c43e9>
2691 ESIG. (2012). SPERC fact sheet: Manufacture of substance - industrial (solvent-borne). Brussels,
2692 Belgium: European Solvents Industry Group (ESIG). <https://www.esig.org/reaches/environment/>
2693 [ges/environment/](https://www.esig.org/reaches/environment/)
2694 FH, F. (2012). Dermal Absorption of Finite doses of Volatile Compounds. J Pharm Sci 101: 2616-2619.
2695 <http://dx.doi.org/10.1080/15287394>
2696 Finely, M; Page, E. (2005). Health hazard evaluation report no. HETA 2003-0203-2952, Wallace
2697 Computer Services, Clinton, Illinois. (HETA 2003-0203-2952). Cincinnati, OH: National
2698 Institute for Occupational Safety and Health.
2699 Frasch, HF; Bunge, AL. (2015). The transient dermal exposure II: post-exposure absorption and
2700 evaporation of volatile compounds. J Pharm Sci 104: 1499-1507.
2701 <http://dx.doi.org/10.1002/jps.24334>
2702 Frasch, HF; Dotson, GS; Barbero, AM. (2011). In vitro human epidermal penetration of 1-
2703 bromopropane. J Toxicol Environ Health A 74: 1249-1260.
2704 <http://dx.doi.org/10.1080/15287394.2011.595666>
2705 Garrod, AN; Phillips, AM; Pemberton, JA. (2001). Potential exposure of hands inside protective gloves a
2706 summary of data from non-agricultural pesticide surveys. Ann Occup Hyg 45: 55-60.
2707 [http://dx.doi.org/10.1016/S0003-4878\(00\)00013-2](http://dx.doi.org/10.1016/S0003-4878(00)00013-2)
2708 Gilbert, D; Goyer, M; Lyman, W; Magil, G; Walker, P; Wallace, D; Wechsler, A; Yee, J. (1982). An
2709 exposure and risk assessment for tetrachloroethylene. (EPA-440/4-85-015). Washington, DC:
2710 U.S. Environmental Protection Agency, Office of Water Regulations and Standards.
2711 <http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=2000LLOH.txt>
2712 Gilles, D; Anania, TL; Ilka, R. (1977). Health hazard evaluation report no. HHE 77-12-418, Airtex
2713 Products, Fairfield, Illinois. (HHE 77-12-418). Cincinnati, OH: National Institute for
2714 Occupational Safety and Health.
2715 Gilles, D; Philbin, E. (1976). Health hazard evaluation report no. HHE 76-61-337, TRW Incorporated,
2716 Philadelphia, Pennsylvania. (HHE 76-61-337). Cincinnati, OH: National Institute for
2717 Occupational Safety and Health.
2718 GmbH, WC. (1940). German Patent 901,774. In Kirk-Othmer Encyclopedia of Chemical Technology.
2719 Wacker Chemie GmbH.

2720 [Golsteijn, L; Huizer, D; Hauck, M; van Zelm, R; Huijbregts, MA.](#) (2014). Including exposure variability
2721 in the life cycle impact assessment of indoor chemical emissions: the case of metal degreasing.
2722 Environ Int 71: 36-45. <http://dx.doi.org/10.1016/j.envint.2014.06.003>
2723 [Gorman, R; Rinsky, R; Stein, G; Anderson, K.](#) (1984). Health hazard evaluation report no. HETA 82-
2724 075-1545, Pratt & Whitney Aircraft, West Palm Beach, Florida. (HETA 82-075-1545).
2725 Cincinnati, OH: National Institute for Occupational Safety and Health.
2726 [Halogenated Solvents Industry Alliance, I.](#) (2017). RE: Docket no. EPA-HQ-2016-0737. (EPA-HQ-
2727 OPPT-2016-0737-0027). Washington, D.C. [https://www.regulations.gov/document?D=EPA-
2728 HQ-OPPT-2016-0737-0027](https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0737-0027)
2729 [Halogenated Solvents Industry Alliance, I.](#) (2018). Re: Docket no. EPA-HQ-OPPT-2016-0737. (EPA-
2730 HQ-OPPT-2016-0737-0103). Washington, D.C.
2731 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0737-0103>
2732 [Hellweg, S; Demou, E; Bruzzi, R; Meijer, A; Rosenbaum, RK; Huijbregts, MA; Mckone, TE.](#) (2009).
2733 Integrating human indoor air pollutant exposure within Life Cycle Impact Assessment [Review].
2734 Environ Sci Technol 43: 1670-1679. <http://dx.doi.org/10.1021/es8018176>
2735 [ICF Consulting.](#) (2004). The U.S. solvent cleaning industry and the transition to non ozone depleting
2736 substances. [https://www.epa.gov/sites/production/files/2014-
2737 11/documents/epasolventmarketreport.pdf](https://www.epa.gov/sites/production/files/2014-11/documents/epasolventmarketreport.pdf)
2738 [IRTA](#) (Institute for Research and Technical Assistance). (2007). Spotting chemicals: Alternatives to
2739 perchloroethylene and trichloroethylene in the textile cleaning industry. Prepared for: Cal/EPAs
2740 Department of Toxic Substances Control and U.S. Environmental Protection Agency Region IX.
2741 <http://www.irta.us/reports/DTSC%20Spotting%20Chemical%20for%20Web.pdf>
2742 [Kanegsberg, B; Kanegsberg, E.](#) (2011). Handbook for critical cleaning, cleaning agents and systems
2743 (2nd ed.). Boca Raton, FL: CRC Press.
2744 [Kasting, BG; Miller, MA.](#) (2006). Kinetics of finite dose absorption through skin 2: Volatile
2745 compounds. J Pharm Sci 95: 268-280. <http://dx.doi.org/10.1002/jps.20497>
2746 [Kinnes, GM.](#) (1998). Health hazard evaluation report no. HETA 97-0214-2689, Dorma Door Controls,
2747 Inc., Reamstown Pennsylvania. (HETA 97-0214-2689). Cincinnati, OH: National Institute for
2748 Occupational Safety and Health.
2749 [Klein, P; Kurz, J.](#) (1994). [Reduction of Solvent Concentrations in Surroundings of Dry-Cleaning
2750 Shops]. Bonningheim, Germany: Hohenstein Physiological Institute on Clothing.
2751 [Lewis, FA.](#) (1980). Health hazard evaluation report no. HHE 80-87-708, Harowe Servo Controls Inc.,
2752 West Chester, Pennsylvania. (HHE 80-87-708). Cincinnati, OH: National Institute for
2753 Occupational Safety and Health.
2754 [Marquart, H; Franken, R; Goede, H; Fransman, W; Schinkel, J.](#) (2017). Validation of the dermal
2755 exposure model in ECETOC TRA. Annals of Work Exposures and Health 61: 854-871.
2756 <http://dx.doi.org/10.1093/annweh/wxx059>
2757 [Morford, RG.](#) (2017). Comment submitted by Richard G. Morford, General Counsel, Enviro Tech
2758 International, Inc. Available online at [https://www.regulations.gov/document?D=EPA-HQ-
2759 OPPT-2016-0741-0016](https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0741-0016)
2760 [Morris, M; Wolf, K.](#) (2005). Evaluation of New and Emerging Technologies for Textile Cleaning.
2761 Institute for Research and Technical Assistance (IRTA).
2762 http://wsppn.org/pdf/irta/Emerging_Technologies_Textile_%20Clea.pdf
2763 [Most, CC.](#) (1989). Locating and estimating air emissions from sources of perchloroethylene and
2764 trichloroethylene. (EPA-450/2-89-013). Research Triangle Park, NC: U.S. EPA.
2765 <https://www3.epa.gov/ttn/chief/le/perc.pdf>
2766 [NEWMOA](#) (Northeast Waste Management Officials' Association). (2001). Pollution prevention
2767 technology profile - Closed loop vapor degreasing. Boston, MA.
2768 <http://www.newmoa.org/prevention/p2tech/ProfileVaporDegreasing.pdf>

2769 [NIH](#). (2012). Hazardous Substances Data Bank (HSDB): Trichloroethylene. Bethesda, MD: U.S.
2770 Department of Health & Human Services, National Institutes of Health, U.S. National Library of
2771 Medicine. <https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm>
2772 [NIOSH](#) (National Institute for Occupational Safety and Health). (1997). Control of health and safety
2773 hazards in commercial drycleaners: chemical exposures, fire hazards, and ergonomic risk factors.
2774 In Education and Information Division. (DHHS (NIOSH) Publication Number 97-150). Atlanta,
2775 GA. <http://www.cdc.gov/niosh/docs/97-150/>
2776 [NIOSH](#) (National Institute for Occupational Safety and Health). (2001). Evaluation of Solvent
2777 Exposures from the Degreaser. Trilthic Inc., IN. In Hazard Evaluation Technical Assistance
2778 Branch. (HETA 2000-0233-2845). NIOSH Publishing Office: National Institute of Occupational
2779 Safety and Health. <http://www.cdc.gov/niosh/hhe/reports/pdfs/2000-0233-2845.pdf>
2780 [NIOSH](#). (2002a). In-depth survey report: control of perchloroethylene (PCE) in vapor degreasing
2781 operations, site #1. (EPHB 256-19b). Cincinnati, Ohio: National Institute for Occupational
2782 Safety and Health (NIOSH).
2783 [NIOSH](#) (National Institute for Occupational Safety and Health). (2002b). In-depth survey report:
2784 Control of perchloroethylene (PCE) in vapor degreasing operations, site #2. (EPHB 256-16b).
2785 CDC. <https://www.cdc.gov/niosh/surveyreports/pdfs/256-16b.pdf>
2786 [NIOSH](#). (2002c). In-depth survey report: control of perchloroethylene (PCE) in vapor degreasing
2787 operations, site #4. (EPHB 256-18b). Cincinnati, Ohio: National Institute for Occupational
2788 Safety and Health (NIOSH).
2789 [NIOSH](#) (National Institute for Occupational Safety and Health). (2002d). In-depth survey report:
2790 Control of perchloroethylene exposure (PCE) in vapor degreasing operations, site #3. (EPHB
2791 256-17b). CDC. <https://www.cdc.gov/niosh/surveyreports/pdfs/ECTB-256-17b.pdf>
2792 [OECD](#) (Organisation for Economic Co-operation and Development). (2004). Emission scenario
2793 document on lubricants and lubricant additives. In OECD Series On Emission Scenario
2794 Documents. (JT00174617). Paris, France.
2795 [http://www.oilis.oecd.org/oilis/2004doc.nsf/LinkTo/env-jm-mono\(2004\)21](http://www.oilis.oecd.org/oilis/2004doc.nsf/LinkTo/env-jm-mono(2004)21)
2796 [OECD](#) (Organisation for Economic Co-operation and Development). (2009a). Emission scenario
2797 document on adhesive formulation. (JT03263583). Paris, France.
2798 [OECD](#) (Organisation for Economic Co-operation and Development). (2009b). Emission scenario
2799 documents on coating industry (paints, lacquers and varnishes). (JT03267833). Paris, France.
2800 [OECD](#) (Organisation for Economic Co-operation and Development). (2010). Scoping Document for
2801 Emission Scenario Document on Manufacturing and Use of Printing Inks. OECD Environmental
2802 Health and Safety Publications.
2803 [OECD](#) (Organisation for Economic Co-operation and Development). (2011a). EMISSION SCENARIO
2804 DOCUMENT ON RADIATION CURABLE COATING, INKS AND ADHESIVES. In Series
2805 on Emission Scenario Documents No 27. Paris: OECD Environmental Health and Safety
2806 Publications. [http://www.oecd-](http://www.oecd-ilibrary.org/docserver/download/9714111e.pdf?expires=1497031939&id=id&accname=guest&checksum=C794B2987D98D1D145225EAF9B482280)
2807 [ilibrary.org/docserver/download/9714111e.pdf?expires=1497031939&id=id&accname=guest&c](http://www.oecd-ilibrary.org/docserver/download/9714111e.pdf?expires=1497031939&id=id&accname=guest&checksum=C794B2987D98D1D145225EAF9B482280)
2808 [hecksum=C794B2987D98D1D145225EAF9B482280](http://www.oecd-ilibrary.org/docserver/download/9714111e.pdf?expires=1497031939&id=id&accname=guest&checksum=C794B2987D98D1D145225EAF9B482280)
2809 [OECD](#) (Organisation for Economic Co-operation and Development). (2011b). Emission scenario
2810 document on the use of metalworking fluids. In OECD Environmental health and safety
2811 publications Series on emission scenario documents Emission scenario document on coating and
2812 application via spray painting in the automotive refinishing industry Number 11. (JT03304938).
2813 Organization for Economic Cooperation and Development.
2814 [OECD](#) (Organisation for Economic Co-operation and Development). (2015). Emission scenario
2815 document on use of adhesives. (Number 34). Paris, France.
2816 [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO\(2015](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2015)
2817 [\)4&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2015)

2818 [OECD](#). (2017). Draft ESD on Vapor Degreasing - Internal EPA document. Organization for Economic
2819 Co-operation and Development (OECD).

2820 [OECD](#). (2019). Emission scenario documents. Available online at [http://www.oecd.org/env/ehs/risk-](http://www.oecd.org/env/ehs/risk-assessment/emissionsscenario documents.htm)
2821 [assessment/emissionsscariodocuments.htm](http://www.oecd.org/env/ehs/risk-assessment/emissionsscenario documents.htm) (accessed August 29, 2019).

2822 [Orris, P; Daniels, W](#). (1981). Health Hazard Evaluation Report 80-201-816: Peterson/Puritan Company.
2823 (HE 80-201-816). NIOSH. [https://www.cdc.gov/niosh/hhe/reports/pdfs/80-201-](https://www.cdc.gov/niosh/hhe/reports/pdfs/80-201-816.pdf?id=10.26616/NIOSHHE80201816)
2824 [816.pdf?id=10.26616/NIOSHHE80201816](https://www.cdc.gov/niosh/hhe/reports/pdfs/80-201-816.pdf?id=10.26616/NIOSHHE80201816)

2825 [OSHA](#) (Occupational Safety & Health Administration). (2017). Chemical Exposure Health Data
2826 (CEHD) provided by OSHA to EPA. U.S. Occupational Safety and Health Administration.
2827 [Products, IAfSDaM](#). (2012). AISE SPERC fact sheet - wide dispersive use of cleaning and maintenance
2828 products. International Association for Soaps Detergents and Maintenance Products.
2829 [https://www.aise.eu/our-activities/regulatory-context/reach/environmental-exposure-](https://www.aise.eu/our-activities/regulatory-context/reach/environmental-exposure-assessment.aspx)
2830 [assessment.aspx](https://www.aise.eu/our-activities/regulatory-context/reach/environmental-exposure-assessment.aspx)

2831 [Rosensteel, RE; Lucas, JB](#). (1975). Health hazard evaluation report no. HHE 74-28-212, Westinghouse
2832 Air Brake Company, Wilmerding, Pennsylvania. (HHE 74-28-212). Cincinnati, OH: National
2833 Institute for Occupational Safety and Health.

2834 [Ruhe, RL](#). (1982). Health hazard evaluation report no. HETA 82-040-119, Synthes Ltd. (USA),
2835 Monument, Colorado. (HETA 82-040-119). Cincinnati, OH: National Institute for Occupational
2836 Safety and Health.

2837 [Ruhe, RL; Watanabe, A; Stein, G](#). (1981). Health hazard evaluation report no. HHE 80-49-808, Superior
2838 Tube Company, Collegetown, Pennsylvania. (HHE 80-49-808). Cincinnati, OH: National
2839 Institute for Occupational Safety and Health. [https://www.cdc.gov/niosh/hhe/reports/pdfs/80-49-](https://www.cdc.gov/niosh/hhe/reports/pdfs/80-49-808.pdf)
2840 [808.pdf](https://www.cdc.gov/niosh/hhe/reports/pdfs/80-49-808.pdf)

2841 [Saft America, I](#). (2017). Memorandum: Trichloroethylene, Docket ID number EPA-HQ-OPPT-2016-
2842 0737. (EPA-HQ-OPPT-2016-0737-0007). Washington, D.C.
2843 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0737-0007>

2844 [SCG](#) (Scientific Consulting Group, Inc.). (2013). Final peer review comments for the OPPT
2845 trichloroethylene (TCE) draft risk assessment. Available online at
2846 [https://www.epa.gov/sites/production/files/2017-](https://www.epa.gov/sites/production/files/2017-06/documents/tce_consolidated_peer_review_comments_september_5_2013.pdf)
2847 [06/documents/tce_consolidated_peer_review_comments_september_5_2013.pdf](https://www.epa.gov/sites/production/files/2017-06/documents/tce_consolidated_peer_review_comments_september_5_2013.pdf)

2848 [Seitz, T; Driscoll, R](#). (1989). Health hazard evaluation report no. HETA 88-082-1971, Jostens
2849 Incorporated, Princeton, Illinois. (HETA 88-082-1971). Cincinnati, OH: National Institute for
2850 Occupational Safety and Health. [https://www.cdc.gov/niosh/hhe/reports/pdfs/1988-0082-](https://www.cdc.gov/niosh/hhe/reports/pdfs/1988-0082-1971.pdf)
2851 [1971.pdf](https://www.cdc.gov/niosh/hhe/reports/pdfs/1988-0082-1971.pdf)

2852 [Smart, BE; Fernandez, RE](#). (2000). Fluorinated aliphatic compounds [Encyclopedia]. In Kirk-Othmer
2853 encyclopedia of chemical technology. Hoboken, NJ: John Wiley and Sons, Inc.
2854 <http://dx.doi.org/10.1002/0471238961.0612211519130118.a01>

2855 [Snedecor, G; Hickman, JC; Mertens, JA](#). (2004). Chloroethylenes and chloroethanes.
2856 [Tomer, A; Kane, J](#). (2015). The great port mismatch. U.S. goods trade and international transportation.
2857 The Global Cities Initiative. A joint project of Brookings and JPMorgan Chase.
2858 <https://www.brookings.edu/wp-content/uploads/2015/06/brgkssrvygcifreightnetworks.pdf>

2859 [U.S. BLS](#) (U.S. Bureau of Labor Statistics). (2014). Employee Tenure News Release. Available online
2860 at http://www.bls.gov/news.release/archives/tenure_09182014.htm

2861 [U.S. BLS](#) (U.S. Bureau of Labor Statistics). (2016). May 2016 Occupational Employment and Wage
2862 Estimates: National Industry-Specific Estimates. Available online at
2863 <http://www.bls.gov/oes/tables.htm>

2864 [U.S. Census Bureau](#). (2013). Census 2012 Detailed Industry Code List [Database]. Retrieved from
2865 <https://www.census.gov/topics/employment/industry-occupation/guidance/code-lists.html>

2866 [U.S. Census Bureau](#). (2015). Statistics of U.S. Businesses (SUSB).
2867 <https://www.census.gov/data/tables/2015/econ/susb/2015-susb-annual.html>
2868 [U.S. Census Bureau](#). (2019). Survey of Income and Program Participation: SIPP introduction and
2869 history. Washington, DC. [https://www.census.gov/programs-surveys/sipp/about/sipp-](https://www.census.gov/programs-surveys/sipp/about/sipp-introduction-history.html)
2870 [introduction-history.html](https://www.census.gov/programs-surveys/sipp/about/sipp-introduction-history.html)
2871 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1977). Control of volatile organic emissions from
2872 solvent metal cleaning [EPA Report]. (EPA-450/2-77-022). Research Triangle Park, NC: U.S.
2873 Environmental Protection Agency, Office of Air and Waste Management, Office of Air Quality
2874 Planning and Standards.
2875 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1980). Chapter 4.7: Waste Solvent Reclamation. In
2876 AP-42 Compilation of air pollutant emission factors (5th ed.). Research Triangle Park, NC:
2877 Office of Air and Radiation, Office of Air Quality and Planning Standards.
2878 <https://www3.epa.gov/ttn/chief/ap42/ch04/index.html>
2879 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1981). AP-42. Compilation of air pollutant
2880 emission factors. Chapter 4.6: Solvent degreasing. Washington, DC.
2881 <http://www3.epa.gov/ttn/chief/ap42/ch04/final/c4s06.pdf>
2882 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1985). Occupational exposure and environmental
2883 release assessment of tetrachloroethylene. Office of Pesticides and Toxic Substances.
2884 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1992). Guidelines for exposure assessment. Federal
2885 Register 57(104):22888-22938 [EPA Report]. In Guidelines for exposure assessment.
2886 (EPA/600/Z-92/001). Washington, DC.
2887 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=15263>
2888 [U.S. EPA](#). (1994). Guidelines for Statistical Analysis of Occupational Exposure Data: Final. United
2889 States Environmental Protection Agency :: U.S. EPA.
2890 [U.S. EPA](#) (U.S. Environmental Protection Agency). (1997). Solvent Cleaning. Volume III, Chapter 6.
2891 pp. 6.2.1. Washington, DC. <http://www3.epa.gov/ttnchie1/eiip/techreport/volume03/iii06fin.pdf>
2892 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2001a). Guide to industrial assessments for
2893 pollution prevention and energy efficiency [EPA Report]. (EPA/625/R-99/003). Cincinnati, OH:
2894 Office of Research and Development, National Risk Management Research Laboratory, Center
2895 for Environmental Research Information.
2896 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2001b). Risk assessment guidance for superfund:
2897 Volume III - Part A, Process for conducting probabilistic risk assessment [EPA Report]. (EPA
2898 540-R-02-002). Washington, DC: U.S. Environmental Protection Agency, Office of Emergency
2899 and Remedial Response.
2900 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2006). Risk assessment for the halogenated solvent
2901 cleaning source category [EPA Report]. (EPA Contract No. 68-D-01-052). Research Triangle
2902 Park, NC: U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards.
2903 <https://www.regulations.gov/document?D=EPA-HQ-OAR-2002-0009-0022>
2904 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2011). The 2011 National Emissions Inventory.
2905 Retrieved from [https://www.epa.gov/air-emissions-inventories/2011-national-emissions-](https://www.epa.gov/air-emissions-inventories/2011-national-emissions-inventory-nei-data)
2906 [inventory-nei-data](https://www.epa.gov/air-emissions-inventories/2011-national-emissions-inventory-nei-data)
2907 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2013). ChemSTEER user guide - Chemical
2908 screening tool for exposures and environmental releases. Washington, D.C.
2909 https://www.epa.gov/sites/production/files/2015-05/documents/user_guide.pdf
2910 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014a). Degreasing with TCE in commercial
2911 facilities: Protecting workers [EPA Report]. Washington, DC: U.S. Environmental Protection
2912 Agency, Office of Pollution Prevention and Toxics.
2913 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2014b). TSCA work plan chemical risk
2914 assessment. Trichloroethylene: Degreasing, spot cleaning and arts & crafts uses. (740-R1-4002).

2915 Washington, DC: Environmental Protection Agency, Office of Chemical Safety and Pollution
2916 Prevention. [http://www2.epa.gov/sites/production/files/2015-](http://www2.epa.gov/sites/production/files/2015-09/documents/tce_opptworkplanchemra_final_062414.pdf)
2917 [09/documents/tce_opptworkplanchemra_final_062414.pdf](http://www2.epa.gov/sites/production/files/2015-09/documents/tce_opptworkplanchemra_final_062414.pdf)
2918 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2016a). EPA Discharge Monitoring Report Data.
2919 Retrieved from <https://cfpub.epa.gov/dmr/>
2920 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2016b). Instructions for reporting 2016 TSCA
2921 chemical data reporting. (EPA/600/R-09/052F). Washington, DC: U.S. Environmental Protection
2922 Agency, Office of Pollution Prevention and Toxics. [https://www.epa.gov/chemical-data-](https://www.epa.gov/chemical-data-reporting/instructions-reporting-2016-tsca-chemical-data-reporting)
2923 [reporting/instructions-reporting-2016-tsca-chemical-data-reporting](https://www.epa.gov/chemical-data-reporting/instructions-reporting-2016-tsca-chemical-data-reporting)
2924 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2017a). Chemical data reporting under the Toxic
2925 Substances Control Act. Available online at <https://www.epa.gov/chemical-data-reporting>
2926 (accessed August 29, 2017).
2927 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2017b). Preliminary information on manufacturing,
2928 processing, distribution, use, and disposal: Trichloroethylene [Comment]. (EPA-HQ-OPPT-
2929 2016-0737-003). Washington, DC: Office of Chemical Safety and Pollution Prevention.
2930 <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2016-0737-0003>
2931 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2017c). Toxics Release Inventory (TRI), reporting
2932 year 2016. Retrieved from [https://www.epa.gov/toxics-release-inventory-tri-program/tri-data-](https://www.epa.gov/toxics-release-inventory-tri-program/tri-data-and-tools)
2933 [and-tools](https://www.epa.gov/toxics-release-inventory-tri-program/tri-data-and-tools)
2934 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2017d). Trichloroethylene market and use report.
2935 Washington, DC: U.S. Environmental Protection Agency, Office of Chemical Safety and
2936 Pollution Prevention, Chemistry, Economics, and Sustainable Strategies Division.
2937 [https://www.epa.gov/sites/production/files/2016-](https://www.epa.gov/sites/production/files/2016-05/documents/instructions_for_reporting_2016_tsca_cdr_13may2016.pdf)
2938 [05/documents/instructions_for_reporting_2016_tsca_cdr_13may2016.pdf](https://www.epa.gov/sites/production/files/2016-05/documents/instructions_for_reporting_2016_tsca_cdr_13may2016.pdf)
2939 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2018a). 2014 National Emissions Inventory
2940 Report. [https://www.epa.gov/air-emissions-inventories/2014-national-emissions-inventory-nei-](https://www.epa.gov/air-emissions-inventories/2014-national-emissions-inventory-nei-data)
2941 [data](https://www.epa.gov/air-emissions-inventories/2014-national-emissions-inventory-nei-data)
2942 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2018b). Application of systematic review in TSCA
2943 Risk Evaluations. (740-P1-8001). Washington, DC: U.S. Environmental Protection Agency,
2944 Office of Chemical Safety and Pollution Prevention.
2945 [https://www.epa.gov/sites/production/files/2018-](https://www.epa.gov/sites/production/files/2018-06/documents/final_application_of_sr_in_tsca_05-31-18.pdf)
2946 [06/documents/final_application_of_sr_in_tsca_05-31-18.pdf](https://www.epa.gov/sites/production/files/2018-06/documents/final_application_of_sr_in_tsca_05-31-18.pdf)
2947 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2018c). Problem Formulation of the Risk
2948 Evaluation for trichloroethylene. (EPA-740-R1-7014). Washington, DC: Office of Chemical
2949 Safety and Pollution Prevention, United States Environmental Protection Agency.
2950 [https://www.epa.gov/sites/production/files/2018-06/documents/tce_problem_formulation_05-31-](https://www.epa.gov/sites/production/files/2018-06/documents/tce_problem_formulation_05-31-31.pdf)
2951 [31.pdf](https://www.epa.gov/sites/production/files/2018-06/documents/tce_problem_formulation_05-31-31.pdf)
2952 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2018d). TRI Reporting Forms and Instructions
2953 (RFI) Guidance Document.
2954 https://ofmpub.epa.gov/apex/guideme_ext/f?p=guideme_ext:41:0::NO::
2955 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019a). Aluminum forming point source category.
2956 (40 CFR Part 467). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.467&rgn=div5)
2957 [idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.467&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.467&rgn=div5)
2958 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019b). Coil coating point source category. (40
2959 CFR Part 465). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.465&rgn=div5)
2960 [idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.465&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.465&rgn=div5)
2961 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019c). Electrical and electronic components point
2962 source category. (40 CFR Part 469). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.469&rgn=div5)
2963 [idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.469&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.469&rgn=div5)

2964 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019d). Electroplating Point Source Category. (40
2965 CFR Part 413). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-
2966 idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.413&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.413&rgn=div5)
2967 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019e). Iron and steel manufacturing point source
2968 category. (40 CFR Part 420). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-
2969 idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.420&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.420&rgn=div5)
2970 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019f). Metal finishing point source company. (40
2971 CFR Part 433). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-
2972 idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.433&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=117c2452100f178f42f8141c0887e5f4&mc=true&node=pt40.32.433&rgn=div5)
2973 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019g). Organic chemicals, plastics, and synthetic
2974 fibers. (40 CFR Part 414). Washington, D.C. [https://www.ecfr.gov/cgi-bin/text-
2975 idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.414&rgn=div5](https://www.ecfr.gov/cgi-bin/text-idx?SID=5c5a19d4dd729db1e53fb9ca47e16706&mc=true&node=pt40.31.414&rgn=div5)
2976 [U.S. EPA](#) (U.S. Environmental Protection Agency). (2019h). Risk Evaluation for trichloroethylene.
2977 Washington, D.C.
2978 [Vandervort, R; Polakoff, PL.](#) (1973). Health hazard evaluation report no. HHE 72-84-31, Dunham-Bush,
2979 Incorporated, West Hartford, Connecticut, Part 2. (HHE 72-84-31). Cincinnati, OH: National
2980 Institute for Occupational Safety and Health.
2981 [von Grote, J; Hürlimann, C; Scheringer, M; Hungerbühler, K.](#) (2006). Assessing occupational exposure
2982 to perchloroethylene in dry cleaning. J Occup Environ Hyg 3: 606-619.
2983 <http://dx.doi.org/10.1080/15459620600912173>
2984 [Von Grote, J; Hurlimann, JC; Scheringer, M; Hungerbuhler, K.](#) (2003). Reduction of Occupational
2985 Exposure to Perchloroethylene and Trichloroethylene in Metal Degreasing over the Last 30
2986 years: Influence of Technology Innovation and Legislation. J Expo Anal Environ Epidemiol 13:
2987 325-340. <http://dx.doi.org/10.1038/sj.jea.7500288>
2988 [Whittaker, SG; Johanson, CA.](#) (2011). A profile of the dry cleaning industry in King County,
2989 Washington: Final report. (LHWMP 0048). Seattle, WA: Local Hazardous Waste Management
2990 Program in King County.
2991 [http://www.hazwastehelp.org/publications/publications_
2992 detail.aspx?DocID=Oh73%2fQilg9Q%3d](http://www.hazwastehelp.org/publications/publications_detail.aspx?DocID=Oh73%2fQilg9Q%3d)
2993
2994 [Young, ML.](#) (2012). Pre-spotting step toward better cleaning. Available online at
2995 <https://americandrycleaner.com/articles/pre-spotting-step-toward-better-cleaning>
2996
2997

2998 **Appendix R MASS BALANCE**

2999 EPA developed a mass balance to account for the amount of TCE entering and leaving all facilities in
3000 the United States. EPA quantified the amount of trichloroethylene associated with each of its life cycle
3001 stages from introduction into commerce in the U.S. (from both domestic manufacture and import),
3002 processing, use, release, and disposal using 2016 CDR, 2017 TRI, 2017 NEI and readily available
3003 market data. Due to limitations in the available data (*e.g.*, reporting thresholds, CBI claims, data from
3004 different years), the mass balance may not account for all of the TCE in commerce in the U.S. or could
3005 potentially allocate portions of the production volume inaccurately. The following subsections described
3006 EPA's approach to developing the mass balance and the result of the mass balance.

3007 **R.1 Approach for Developing the Mass Balance**

3008 EPA used the reported aggregated production volume of 171,929,400 lbs from the 2016 CDR data as the
3009 amount of TCE manufactured and imported to the U.S. ([U.S. EPA, 2016c](#)). Starting with this volume,
3010 EPA estimated the portion of the volume used domestically versus or exported. EPA used the reported
3011 aggregated production volume of 171,929,400 lbs from the 2016 CDR data as the amount of TCE
3012 manufactured and imported to the U.S. ([U.S. EPA, 2016d](#)). Starting with this volume, EPA estimated
3013 the portion of the volume used domestically versus or exported. The export volume was estimated to be
3014 10,531,608 lbs in 2015; however, this does not account for export volumes claimed as CBI in the 2016
3015 CDR ([U.S. EPA, 2016d](#)). The domestic use volume was assumed to be anything not reported as
3016 exported in the 2016 CDR plus any volume reported as transferred for off-site recycling in the 2017
3017 TRI. EPA only considered the off-site recycling volume as EPA assumes any volume reported for on-
3018 site recycling is reused at the site with consumption, disposal, and treatment of the recycled volume
3019 accounted for in the facility's other reported TRI values and thus already accounted for in the mass
3020 balance. EPA assumed the volume reported for off-site recycling is reintroduced into commerce similar
3021 to virgin (*i.e.*, unused directly from manufacturer or importer) TCE. This resulted in a total of
3022 161,666,878 lbs, or 94% of the total production volume, being used domestically.

3023 Use volumes were determined based on the 2014 TCE risk assessment, which estimated 83.6% of the
3024 domestic use volume is used as an intermediate, 14.7% is used as a degreasing solvent, and 1.7% is for
3025 miscellaneous uses ([U.S. EPA, 2014b](#)). Accounting for exports and the off-site recycled volume, this
3026 resulted in 135,153,510 lbs for intermediate uses, 23,765,031 lbs for degreasing uses, and 2,748,337 lbs
3027 for miscellaneous uses.

3028 During manufacture, processing, and use, a portion of volume of TCE at a given site may be released to
3029 the environment on-site or end up in waste streams that are ultimately sent off-site for treatment,
3030 disposal, energy recovery, or recycling. EPA used data from the 2017 TRI ([U.S. EPA, 2020b](#)) and 2017
3031 NEI ([U.S. EPA, 2020a](#)) to quantify volumes associated with each end-of-life activities. 2017 TRI data
3032 was grouped into the following categories of end-of-life activities: wastewater discharges, air emissions,
3033 land disposal, off-site recycling, energy recovery, and waste treatment.

3034 In addition to surface water discharges, the volume estimated for wastewater discharges includes the
3035 total volume reported by facilities as transferred to off-site wastewater treatment (non-POTW) and off-
3036 site POTW treatment. It does not account for subsequent removal from wastewater streams into air or
3037 sludge that may occur at such treatment sites. The amount calculated for land disposal includes the
3038 releases from all on-site and off-site underground injection, surface impoundment, land application,
3039 landfills, and any other land disposal reported in the 2017 TRI.

3040 For recycling, TRI includes volumes for both on- and off-site recycling. As stated above, EPA assumed
3041 that any volume reported as recycled on-site is reused at the site with consumption, disposal, and
3042 treatment of the recycled volume accounted for in the facility's other reported TRI values and not further

3043 considered for the mass balance. EPA assumed the volume reported for off-site recycling is reintroduced
3044 into commerce similar to virgin (*i.e.*, unused directly from manufacturer or importer) TCE.

3045 The calculated amount of TCE released as air emissions include data from both 2017 TRI ([U.S. EPA,](#)
3046 [2020b](#)) and 2017 NEI ([U.S. EPA, 2020a](#)). The air emissions include the total reported fugitive air
3047 emissions and stack air emissions from 2017 TRI reporters as well as all nonpoint source emission totals
3048 from NEI. NEI also collects data from point sources which may include sites that also report to TRI. To
3049 avoid double counting any volume reported in both TRI and NEI, EPA excluded a point emission source
3050 if the facility also reported TCE to TRI. Such sites were identified by cross-walking TRIFDs reported in
3051 TRI to those in NEI. EPA also excluded emissions from any point source in NEI reported as being from
3052 landfills, POTW, or wastewater treatment facilities. EPA assumed that emissions from these sources are
3053 already accounted for in the "wastewater treatment" and "land disposal" volumes from TRI. Finally,
3054 EPA excluded air emissions from any point source reported as being from remediation activities. These
3055 volumes are assumed to be from historical uses of TCE such that any volume associated with those
3056 activities are not assumed to be related to the current year's production volume.

3057 Any unused, spent, or waste TCE not accounted for above is expected to be sent for further waste
3058 management. These methods can be reported to TRI specifically as energy recovery or generally as
3059 waste treatment. However, volumes reported as sent for off-site energy recovery or treatment can be
3060 double counted if the site receiving the waste TCE is also required to report to TRI for TCE. This double
3061 count was addressed by comparing the RCRA IDS of reported downstream waste processors with the
3062 RCRA IDs of reporting facilities. For the purpose of the mass balance, the treatment and energy
3063 recovery volumes also assume 100% destruction/removal efficiencies which is likely unrealistic.
3064 Therefore, some portion of these values may also be counted in releases.


3065 The end-of-life stage also accounts for TCE that is consumed in a reaction from intermediate uses. To
3066 estimate the amount that is consumed in reaction, EPA identified in the sites in TRI that report TCE uses
3067 as a reactant and subtracted out the volume reported as released, disposed of, or otherwise managed as
3068 waste at each site from the intermediate use volume and assumed the remainder was consumed. EPA
3069 acknowledges that some portion of the intermediate use volume may remain as unintended impurities in
3070 products from the reaction; however, this volume cannot be quantified.

3071 **R.2 Results and Uncertainties in the Mass Balance**

3072 Figure_Apx R-1 shows the result of the mass balance. The overall percentage of TCE accounted for at
3073 the end-of-life is 101.5% of the 2016 CDR production volume. The 1.5% of the volume that is
3074 overcounted is potentially due to incomplete reporting data and comparison of data from different years.
3075 Other sources of uncertainty include limitations in reporting requirements (*e.g.*, reporting thresholds),
3076 CBI claims on exported volumes, and unknown volumes of unreacted TCE remaining in products.
3077

3078

3079



3080

3081

Figure_Apx R-1. Mass Balance for Trichloroethylene

Appendix S LEVEL III FUGACITY RESULTS

EPA ran the level III fugacity model in EPISuite™ using emissions from a mass balance developed to account for the amount of TCE entering and leaving all facilities in the United States. For the mass balance EPA attempted to quantify the amount of trichloroethylene associated with each of its life cycle stages from introduction into commerce in the U.S. (from both domestic manufacture and import), processing, use, release, and disposal. The mass balance development and uncertainties are detailed in Appendix R. Physical chemical and environmental fate properties used as input to the model were taken from Table 1-1 and Table 2-1 in the Risk Evaluation, respectively. The model was run holding the environmental release steady at 1000 kg/hour but varying the receiving medium. Releases range from 1000 kg/hour simultaneously for air, soil and water to 1000 kg/hour for two of the three media and finally, 1000kg/hour released to a single medium. A total of seven iterations were executed. The model was run using annual emissions to air and water from the mass balance converted to kilograms per hour. Land disposal, energy recovery and treatment, and off-site recycling were not considered as environmental releases. Results are shown below.

Level III Fugacity Model (Full-Output): EQC Default

Chem Name : TRICHLOROETHENE
Molecular Wt: 131.39
Henry's LC : 0.00985 atm-m³/mole (user-entered)
Vapor Press : 69 mm Hg (user-entered)
Log Kow : 2.42 (user-entered)
Soil Koc : 108 (EQC Model Default)

	Mass Amount (percent)	Half-Life (hr)	Emissions (kg/hr)		
Air	99.2	240	614		
Water	0.696	10000	0.567		
Soil	0.132	10000	0		
Sediment	0.00553	10000	0		
	Fugacity (atm)	Reaction (kg/hr)	Advection (kg/hr)	Reaction (percent)	Advection (percent)
Air	8.86e-011	138	477	22.4	77.6
Water	1.25e-010	2.32e-008	0.334	3.77e-009	0.0544
Soil	8.92e-011	4.41e-009	0	7.17e-010	0
Sediment	1.39e-010	1.84e-010	5.31e-005	3e-011	8.65e-006

Persistence Time: 78.2 hr
Reaction Time: 349 hr
Advection Time: 101 hr
Percent Reacted: 22.4
Percent Advected: 77.6

3130 Water Compartment Percents:
 3131 -----
 3132 Mass Amount Half-Life Emissions
 3133 (percent) (hr) (kg/hr)
 3134
 3135 Air 99.2 240 614
 3136 Water 0.696 10000 0.567
 3137 water (0.696)
 3138 biota (9.15e-006)
 3139 suspended
 3140 sediment (0.000113)
 3141 Soil 0.132 10000 0
 3142 Sediment 0.00553 10000 0
 3143
 3144 Half-Lives (hr), (based upon user-entry):
 3145 Air: 240
 3146 Water: 10000
 3147 Soil: 10000
 3148 Sediment: 10000
 3149
 3150 Advection Times (hr):
 3151 Air: 100
 3152 Water: 1000
 3153 Sediment: 50000